<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'><collection><source>PubTator</source><date></date><key>BioC.key</key>
<document><id>37921564</id><passage><infon key="journal">Int J Eat Disord;2023Nov03. doi:10.1002/eat.24085</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Davies MR, Monssen D, Sharpe H, Allen KL, Simms B, Goldsmith KA, Byford S, Lawrence V, Schmidt U, </infon><offset>0</offset><text>Management of fraudulent participants in online research: Practical recommendations from a randomized controlled feasibility trial.</text></passage><passage><infon key="type">abstract</infon><offset>132</offset><text>OBJECTIVE: Fraudulent participation is an escalating concern for online clinical trials and research studies and can have a significant negative impact on findings. We aim to shed light on the risk and to provide practical recommendations for detecting and managing such instances. METHODS: The FREED-Mobile (FREED-M) study is an online, randomized controlled feasibility trial to assess a digital early intervention for young people (aged 16-25) in England or Wales with eating problems. The trial involved baseline (week 0), post-intervention (week 4), and follow-up (week 12) surveys, alongside weekly modules provided over 4 weeks on the study website. Study completers were compensated with $20 shopping vouchers. Despite the complexity of the trial design, two instances of fraudulent sign-ups occurred in January and March 2023. To counter this, we developed a "fraudulent participants protocol" following internal investigations and discussions with collaborators. RESULTS: The implementation of prevention measures such as reCAPTCHA updates, IP address review, and changes in reimbursement effectively halted further fraudulent sign-ups. Our protocol facilitated the systematic identification and withdrawal of suspected or clear fraudsters and was demonstrably robust at distinguishing between fraudsters and genuine responders. DISCUSSION: All remote, online trials or studies are at risk of fraudulent participation. Drawing from our experience and existing literature, we offer practical recommendations for researchers considering online recruitment and data collection. Vigilance and the integration of deterrents, and data quality checks into the study design from the outset are advised to safeguard research integrity. PUBLIC SIGNIFICANCE: Fraudulent participation in digital research can have asignificant impact on research findings, potentially leading to biased resultsand misinformed decisions. We developed an effective protocol for theprevention, identification, and management of fraudulent participants. Bysharing our insights and recommendations, we hope to raise awareness of thisissue and provide other researchers with the knowledge and strategies necessaryto safeguard research integrity moving forward.</text><annotation id="1"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="604" length="15"/><text>eating problems</text></annotation></passage></document>
<document><id>37890330</id><passage><infon key="type">title</infon><offset>0</offset><text>Generation of an induced pluripotent stem cell line (ZJUi013-A) from a Familial cortical myoclonic tremor with epilepsy type 1 patient carrying (TTTCA)n insertion in the SAMD12 gene.</text><annotation id="3"><infon key="identifier">CVCL:ZL90</infon><infon key="type">CellLine</infon><location offset="53" length="9"/><text>ZJUi013-A</text></annotation><annotation id="4"><infon key="identifier">MESH:C563399</infon><infon key="type">Disease</infon><location offset="89" length="37"/><text>myoclonic tremor with epilepsy type 1</text></annotation><annotation id="5"><infon key="identifier">401474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">35979</infon><location offset="170" length="6"/><text>SAMD12</text></annotation></passage><passage><infon key="type">abstract</infon><offset>183</offset><text>FCMTE1 is an autosomal dominant inherited neurodegenerative disorder characterized by myoclonic tremors and epilepsy. The cause of FCMTE1 is an abnormal (TTTCA)n insertion in intron 4 of SAMD12 gene. Fibroblasts obtained from a FCMTE1 patient were successfully transformed into induced pluripotent stem cells (iPSCs) (ZJUi013-A) using the Sendai virus. Our approach provided a resource for further pathogenesis study and drug screening of FCMTE1.</text><annotation id="15"><infon key="identifier">50968</infon><infon key="type">Gene</infon><location offset="183" length="6"/><text>FCMTE1</text></annotation><annotation id="16"><infon key="identifier">MESH:D020271</infon><infon key="type">Disease</infon><location offset="196" length="55"/><text>autosomal dominant inherited neurodegenerative disorder</text></annotation><annotation id="17"><infon key="identifier">MESH:D014202</infon><infon key="type">Disease</infon><location offset="269" length="17"/><text>myoclonic tremors</text></annotation><annotation id="18"><infon key="identifier">MESH:D004827</infon><infon key="type">Disease</infon><location offset="291" length="8"/><text>epilepsy</text></annotation><annotation id="19"><infon key="identifier">50968</infon><infon key="type">Gene</infon><location offset="314" length="6"/><text>FCMTE1</text></annotation><annotation id="20"><infon key="identifier">401474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">35979</infon><location offset="370" length="6"/><text>SAMD12</text></annotation><annotation id="21"><infon key="identifier">50968</infon><infon key="type">Gene</infon><location offset="411" length="6"/><text>FCMTE1</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="501" length="9"/><text>ZJUi013-A</text></annotation><annotation id="23"><infon key="identifier">50968</infon><infon key="type">Gene</infon><location offset="622" length="6"/><text>FCMTE1</text></annotation></passage><relation id="R1"><infon key="score">0.7379</infon><infon key="role1">Disease|MESH:D014202</infon><infon key="role2">Gene|50968</infon><infon key="type">Association</infon><node refid="0" role="5,3"/></relation><relation id="R2"><infon key="score">0.992</infon><infon key="role1">Disease|MESH:C563399</infon><infon key="role2">Gene|401474</infon><infon key="type">Association</infon><node refid="1" role="1,2"/></relation><relation id="R3"><infon key="score">0.9194</infon><infon key="role1">Gene|401474</infon><infon key="role2">Gene|50968</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="9,7"/></relation><relation id="R4"><infon key="score">0.9986</infon><infon key="role1">Disease|MESH:D004827</infon><infon key="role2">Gene|50968</infon><infon key="type">Association</infon><node refid="3" role="6,3"/></relation></document>
<document><id>37890680</id><passage><infon key="type">title</infon><offset>0</offset><text>The Cancer Genome Atlas (TCGA) for Uveal Melanoma is Predictive of Patient Outcomes.</text><annotation id="2"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="4" length="6"/><text>Cancer</text></annotation><annotation id="3"><infon key="identifier">MESH:C536494</infon><infon key="type">Disease</infon><location offset="35" length="14"/><text>Uveal Melanoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>Uveal melanoma (UM) is the most common primary eye malignancy. Despite excellent local tumor rates, UM is still a life-threatening disease with moderate systemic metastatic rates. In the past, certain clinical features were shown to be predictive of patient prognosis, including tumor thickness, tumor diameter, ciliary body involvement, and histopathologic factors. Genetic markers have lately been used to predict patient outcomes. The Cancer Genome Atlas (TCGA) is a worldwide effort developed by the National Cancer Institute and the National Human Genome Research Institute to study numerous mutations in various cancer types. TCGA has explored chromosome copy number alterations in UM, messenger RNA, micro-RNA, and long non-coding RNA expression levels, and established four prognostic classes: Group A (chromosome 3 and 8 disomy), Group B (chromosome 3 disomy and 8q gain), Group C (chromosome 3 monosomy and/or 8q gain), and Group D (chromosome 3 monosomy and multiple 8q gains). Multiple studies have validated TCGA classification and have reported that it has been highly predictive of UM metastasis and patient survival.</text><annotation id="20"><infon key="identifier">MESH:C536494</infon><infon key="type">Disease</infon><location offset="85" length="14"/><text>Uveal melanoma</text></annotation><annotation id="21"><infon key="identifier">MESH:C536494</infon><infon key="type">Disease</infon><location offset="101" length="2"/><text>UM</text></annotation><annotation id="22"><infon key="identifier">MESH:D001932</infon><infon key="type">Disease</infon><location offset="124" length="22"/><text>primary eye malignancy</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="172" length="5"/><text>tumor</text></annotation><annotation id="24"><infon key="identifier">MESH:C536494</infon><infon key="type">Disease</infon><location offset="185" length="2"/><text>UM</text></annotation><annotation id="25"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="364" length="5"/><text>tumor</text></annotation><annotation id="26"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="381" length="5"/><text>tumor</text></annotation><annotation id="27"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="523" length="6"/><text>Cancer</text></annotation><annotation id="28"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="598" length="6"/><text>Cancer</text></annotation><annotation id="29"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="703" length="6"/><text>cancer</text></annotation><annotation id="30"><infon key="identifier">MESH:C536494</infon><infon key="type">Disease</infon><location offset="773" length="2"/><text>UM</text></annotation><annotation id="31"><infon key="identifier">3</infon><infon key="type">Chromosome</infon><location offset="896" length="12"/><text>chromosome 3</text></annotation><annotation id="32"><infon key="identifier">3</infon><infon key="type">Chromosome</infon><location offset="933" length="12"/><text>chromosome 3</text></annotation><annotation id="33"><infon key="identifier">3</infon><infon key="type">Chromosome</infon><location offset="976" length="12"/><text>chromosome 3</text></annotation><annotation id="34"><infon key="identifier">3</infon><infon key="type">Chromosome</infon><location offset="1028" length="12"/><text>chromosome 3</text></annotation><annotation id="35"><infon key="identifier">MESH:C536494</infon><infon key="type">Disease</infon><location offset="1182" length="13"/><text>UM metastasis</text></annotation></passage></document>
<document><id>37891031</id><passage><infon key="journal">Auris Nasus Larynx;2023Oct25. doi:10.1016/j.anl.2023.09.003</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kanai R, Kanemaru SI, Yamaguchi T, Kita SI, Miwa T, Kumazawa A, Okamoto J, Yoshida M, Harada H, Maetani T, </infon><offset>0</offset><text>Outcomes of regenerative treatment for over 200 patients with tympanic membrane perforation.</text><annotation id="1"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="62" length="29"/><text>tympanic membrane perforation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>OBJECTIVE: To evaluate outcomes of a regenerative treatment (RT) for over 200 patients with tympanic membrane perforation (TMP). The RT-TMP method involves a gelatin sponge, basic fibroblast growth factor (bFGF) and fibrin glue. METHODS: The study population included 216 patients and 234 ears (male: female =100:116; age 1-93 years). All enrolled patients were treated with RT-TMP in which TMP edges were disrupted mechanically and a gelatin sponge immersed in bFGF was inserted into the perforation. Fibrin glue was then dripped over the sponge. Patient outcomes including TMP closure rates, change in hearing level, and complications were obtained from retrospective medical chart reviews. The TMP was examined three or more weeks after surgery. The treatment was repeated up to 4 times until complete TMP closure was achieved. RESULTS: After mechanical disruption, the perforation size was Grade I, &lt;=1/3 of entire TM area in 22 ears (9.4 %), Grade II, 1/3-2/3 of entire TM in 77 ears (32.9 %) and Grade III, >=2/3 of entire TM area in 135 ears (57.7 %). The overall TMP closure rates were 97.0 % (227/234). Complete TMP closure was achieved in 68.8 % (161/234), 22.6 % (53/234), 4.7 % (11/234) and 0.9 % (2/234) of ears after 1, 2, 3 and 4 treatments, respectively. In 7 of 234 ears (3.0 %), the TMPs were not closed completely after 4 treatments. There was no correlation between TMP size after mechanical disruption and number of treatments required to achieve complete closure (Fisher's exact test p = 0.70). The mean air-conduction hearing threshold at low frequency improved from 57.3 +- 16.7 dB before treatment to 37.3 +- 16.0 dB (p &lt; 0.0001) after closure of TMPs. For middle and high frequencies, the improvement was 49.0 +- 19.3 dB to 36.9 +- 17.9 dB (p &lt; 0.0001) and 57.7 +- 22.9 dB to 49.2 +- 23.3 dB (p &lt; 0.0001), respectively. The mean air-bone gaps also improved significantly, and were within 10 dB at 250 Hz, 500 Hz and 1 kHz, and 11 dB at 2 kHz. One or more complications occurred in 32 patients (32/216; 14.8 %). The most common complication was formation of an epithelial pearl (16 ears; 6.8 %), followed by severe TM retraction (9 ears; 3.8 %) and otitis media with effusion (6 ears; 2.6 %). There were no serious complications that caused deterioration of the patient's general condition. CONCLUSION: Our results showed that RT-TMP had high success rates for TMP closure and good hearing improvement and produced no severe complications that could affect general health status. This novel therapy is simple, safe and minimally invasive, and could help improve the quality of life in patients with TMP.</text><annotation id="25"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="185" length="29"/><text>tympanic membrane perforation</text></annotation><annotation id="26"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="216" length="3"/><text>TMP</text></annotation><annotation id="27"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="229" length="3"/><text>TMP</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="251" length="14"/><text>gelatin sponge</text></annotation><annotation id="29"><infon key="identifier">2247</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1521</infon><location offset="267" length="30"/><text>basic fibroblast growth factor</text></annotation><annotation id="30"><infon key="identifier">2247</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1521</infon><location offset="299" length="4"/><text>bFGF</text></annotation><annotation id="31"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="471" length="3"/><text>TMP</text></annotation><annotation id="32"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="484" length="3"/><text>TMP</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="528" length="14"/><text>gelatin sponge</text></annotation><annotation id="34"><infon key="identifier">2247</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1521</infon><location offset="555" length="4"/><text>bFGF</text></annotation><annotation id="35"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="668" length="3"/><text>TMP</text></annotation><annotation id="36"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="790" length="3"/><text>TMP</text></annotation><annotation id="37"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="898" length="3"/><text>TMP</text></annotation><annotation id="38"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="1164" length="3"/><text>TMP</text></annotation><annotation id="39"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="1214" length="3"/><text>TMP</text></annotation><annotation id="40"><infon key="identifier">MESH:C047152</infon><infon key="type">Chemical</infon><location offset="1394" length="4"/><text>TMPs</text></annotation><annotation id="41"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="1479" length="3"/><text>TMP</text></annotation><annotation id="42"><infon key="identifier">MESH:C047152</infon><infon key="type">Chemical</infon><location offset="1765" length="4"/><text>TMPs</text></annotation><annotation id="43"><infon key="identifier">MESH:D004370</infon><infon key="type">Disease</infon><location offset="2233" length="13"/><text>TM retraction</text></annotation><annotation id="44"><infon key="identifier">MESH:D010034</infon><infon key="type">Disease</infon><location offset="2267" length="26"/><text>otitis media with effusion</text></annotation><annotation id="45"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="2448" length="3"/><text>TMP</text></annotation><annotation id="46"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="2479" length="3"/><text>TMP</text></annotation><annotation id="47"><infon key="identifier">MESH:D018058</infon><infon key="type">Disease</infon><location offset="2717" length="3"/><text>TMP</text></annotation></passage><relation id="R1"><infon key="score">0.4858</infon><infon key="role1">Disease|MESH:D018058</infon><infon key="role2">Gene|2247</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="3,5"/></relation></document>
<document><id>37891382</id><passage><infon key="journal">J Endocrinol Invest;2023Oct27. doi:10.1007/s40618-023-02223-z</infon><infon key="year">2023</infon><infon key="article-id_pmc">5543750</infon><infon key="type">title</infon><infon key="authors">Sada V, Puliani G, Feola T, Pirchio R, Pofi R, Sesti F, De Alcubierre D, Amodeo ME, D'Aniello F, Vincenzi L, Gianfrilli D, Isidori AM, Grossman AB, Sbardella E, TALENT group, </infon><offset>0</offset><text>Tall stature and gigantism in transition age: clinical and genetic aspects-a literature review and recommendations.</text><annotation id="2"><infon key="identifier">MESH:C537975</infon><infon key="type">Disease</infon><location offset="0" length="12"/><text>Tall stature</text></annotation><annotation id="3"><infon key="identifier">MESH:D005877</infon><infon key="type">Disease</infon><location offset="17" length="9"/><text>gigantism</text></annotation></passage><passage><infon key="type">abstract</infon><offset>116</offset><text>PURPOSE: Tall stature is defined as height greater than the threshold of more than 2 standard deviations above the average population height for age, sex, and ethnicity. Many studies have described the main aspects of this condition during puberty, but an analysis of the characteristics that the physician should consider in the differential diagnosis of gigantism-tall stature secondary to a pituitary tumour-during the transition age (15-25 years) is still lacking. METHODS: A comprehensive search of English-language original articles was conducted in the MEDLINE database (December 2021-March 2022). We selected all studies regarding epidemiology, genetic aspects, and the diagnosis of tall stature and gigantism during the transition age. RESULTS: Generally, referrals for tall stature are not as frequent as expected because most cases are familial and are usually unreported by parents and patients to endocrinologists. For this reason, lacking such experience of tall stature, familiarity with many rarer overgrowth syndromes is essential. In the transition age, it is important but challenging to distinguish adolescents with high constitutional stature from those with gigantism. Pituitary gigantism is a rare disease in the transition age, but its systemic complications are very relevant for future health. Endocrine evaluation is crucial for identifying conditions that require hormonal treatment so that they can be treated early to improve the quality of life and prevent comorbidities of individual patient in this age range. CONCLUSION: The aim of our review is to provide a practical clinical approach to recognise adolescents, potentially affected by gigantism, as early as possible.</text><annotation id="17"><infon key="identifier">MESH:C537975</infon><infon key="type">Disease</infon><location offset="125" length="12"/><text>Tall stature</text></annotation><annotation id="18"><infon key="identifier">MESH:D005877</infon><infon key="type">Disease</infon><location offset="472" length="9"/><text>gigantism</text></annotation><annotation id="19"><infon key="identifier">MESH:C537975</infon><infon key="type">Disease</infon><location offset="482" length="12"/><text>tall stature</text></annotation><annotation id="20"><infon key="identifier">MESH:D010911</infon><infon key="type">Disease</infon><location offset="510" length="16"/><text>pituitary tumour</text></annotation><annotation id="21"><infon key="identifier">MESH:C537975</infon><infon key="type">Disease</infon><location offset="807" length="12"/><text>tall stature</text></annotation><annotation id="22"><infon key="identifier">MESH:D005877</infon><infon key="type">Disease</infon><location offset="824" length="9"/><text>gigantism</text></annotation><annotation id="23"><infon key="identifier">MESH:C537975</infon><infon key="type">Disease</infon><location offset="895" length="12"/><text>tall stature</text></annotation><annotation id="24"><infon key="identifier">MESH:C537975</infon><infon key="type">Disease</infon><location offset="1088" length="12"/><text>tall stature</text></annotation><annotation id="25"><infon key="identifier">MESH:C537340</infon><infon key="type">Disease</infon><location offset="1130" length="20"/><text>overgrowth syndromes</text></annotation><annotation id="26"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="1272" length="7"/><text>stature</text></annotation><annotation id="27"><infon key="identifier">MESH:D005877</infon><infon key="type">Disease</infon><location offset="1296" length="9"/><text>gigantism</text></annotation><annotation id="28"><infon key="identifier">MESH:D005877</infon><infon key="type">Disease</infon><location offset="1307" length="19"/><text>Pituitary gigantism</text></annotation><annotation id="29"><infon key="identifier">MESH:D005877</infon><infon key="type">Disease</infon><location offset="1787" length="9"/><text>gigantism</text></annotation></passage></document>
<document><id>37897341</id><passage><infon key="type">title</infon><offset>0</offset><text>The IUPHAR/BPS Guide to PHARMACOLOGY in 2024.</text></passage><passage><infon key="type">abstract</infon><offset>46</offset><text>The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; https://www.guidetopharmacology.org) is an open-access, expert-curated, online database that provides succinct overviews and key references for pharmacological targets and their recommended experimental ligands. It includes over 3039 protein targets and 12 163 ligand molecules, including approved drugs, small molecules, peptides and antibodies. Here, we report recent developments to the resource and describe expansion in content over the six database releases made during the last two years. The database update section of this paper focuses on two areas relating to important global health challenges. The first, SARS-CoV-2 COVID-19, remains a major concern and we describe our efforts to expand the database to include a new family of coronavirus proteins. The second area is antimicrobial resistance, for which we have extended our coverage of antibacterials in partnership with AntibioticDB, a collaboration that has continued through support from GARDP. We discuss other areas of curation and also focus on our external links to resources such as PubChem that bring important synergies to the resources.</text><annotation id="3"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="710" length="10"/><text>SARS-CoV-2</text></annotation><annotation id="4"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="721" length="8"/><text>COVID-19</text></annotation><annotation id="5"><infon key="identifier">MESH:D018352</infon><infon key="type">Disease</infon><location offset="833" length="11"/><text>coronavirus</text></annotation></passage></document>
<document><id>37897692</id><passage><infon key="type">title</infon><offset>0</offset><text>Investigating tritrophic interactions using bioenergetic demographic models.</text></passage><passage><infon key="type">abstract</infon><offset>77</offset><text>A central debate in ecology has been the long running discussion on the role of apex predators in affecting the abundance and dynamics of their prey. In terrestrial systems, research has primarily relied on correlational approaches, due to the challenge of implementing robust experiments with replication and appropriate controls. A consequence of this is that we largely suffer from a lack of mechanistic understanding of the population dynamics of interacting species that can be surprisingly complex. Mechanistic models offer an opportunity to examine the causes and consequences of some of this complexity. We present a bioenergetic mechanistic model of a tritrophic system where the primary vegetation resource follows a seasonal growth function, and the herbivore and carnivore species are modelled using two integral projection models (IPMs) with body mass as the phenotypic trait. Within each IPM, the demographic functions are structured according to bioenergetic principles, describing how animals acquire and transform resources into body mass, energy reserves and breeding potential. We parameterise this model to reproduce the population dynamics of grass, elk and wolves in northern Yellowstone (USA), and investigate the impact of wolf reintroduction on the system. Our model generated predictions that closely matched the observed population sizes of elk and wolf in Yellowstone prior to and post wolf reintroduction. The introduction of wolves into our basal grass-elk bioenergetic model resulted in a population of 99 wolves, and a reduction in elk numbers by 61% (from 14,948 to 5,823) at equilibrium. In turn, vegetation biomass increased by approximately 25% in the growing season and more than 3-fold in the non-growing season. The addition of wolves to the model caused the elk population to switch from being food-limited to being predator-limited, and had a stabilising effect on elk numbers across different years. Wolf predation also led to a shift in the phenotypic composition of the elk population, via a small increase in elk average body mass. Our model represents a novel approach to the study of predator-prey interactions. Explicitly considering and linking bioenergetics, population demography and body mass phenotypes can provide novel insights into the mechanisms behind complex ecosystem processes.</text></passage></document>
<document><id>37898042</id><passage><infon key="type">title</infon><offset>0</offset><text>Identification and verification of PCDD/Fs indicators from four typical large-scale municipal solid waste incinerations with large sample size in China.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="35" length="7"/><text>PCDD/Fs</text></annotation></passage><passage><infon key="type">abstract</infon><offset>153</offset><text>Monitoring PCDD/Fs emissions from municipal solid waste incinerations (MSWIs) is of paramount importance, yet it can be time-consuming and labor-intensive. Predictive models offer an alternative approach for estimating their levels. However, robust models specific to PCDD/Fs were lacking. In this study, we collected 190 PCDD/Fs samples from 4 large-scale MSWIs in China, with the average PCDD/Fs levels and TEQ levels of 0.987 ng/m3 and 0.030 ng TEQ/m3, respectively. We developed and evaluated predictive models, including traditional statistical methods, e.g., linear regression (LR) as well as machine learning models such as back propagation-artificial neural networks (BP ANN) and random forest (RF). Correlation analysis identified 2,3,4,7,8-PeCDF, 1,2,3,6,7,8-HxCDF, 2,3,4,6,7,8-HxCDF were better indicator congeners for PCDD/Fs estimation (R2 > 0.9, p &lt; 0.001). The predictive results favored the RF model, exhibiting a high R2 value and low root mean square error (RMSE) and mean absolute error (MAE). Additionally, the RF model showed excellent prediction ability during external validation, with low absolute relative error (ARE) of 10.9 %-12.6 % for the three indicator congeners in the normal PCDD/F TEQ levels group (&lt;0.1 ng TEQ/m3) and slightly higher ARE values (13.8 %-17.9 %) for the high PCDD/F TEQ levels group (>0.1 ng TEQ/m3). In conclusion, our findings strongly support the RF model's effectiveness in predicting PCDD/Fs TEQ emission from MSWIs.</text><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="164" length="7"/><text>PCDD/Fs</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="421" length="7"/><text>PCDD/Fs</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="475" length="7"/><text>PCDD/Fs</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="543" length="7"/><text>PCDD/Fs</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="562" length="3"/><text>TEQ</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="601" length="3"/><text>TEQ</text></annotation><annotation id="23"><infon key="identifier">MESH:C038890</infon><infon key="type">Chemical</infon><location offset="893" length="15"/><text>2,3,4,7,8-PeCDF</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="910" length="17"/><text>1,2,3,6,7,8-HxCDF</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="929" length="17"/><text>2,3,4,6,7,8-HxCDF</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="983" length="7"/><text>PCDD/Fs</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1361" length="10"/><text>PCDD/F TEQ</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1394" length="3"/><text>TEQ</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1462" length="10"/><text>PCDD/F TEQ</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1495" length="3"/><text>TEQ</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1592" length="11"/><text>PCDD/Fs TEQ</text></annotation></passage></document>
<document><id>37898395</id><passage><infon key="journal">Exp Neurol;2023Oct26 114591. doi:10.1016/j.expneurol.2023.114591</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yi W, Chen F, Yuan M, Wang C, Wang S, Wen J, Zou Q, Pu Y, Cai Z, </infon><offset>0</offset><text>High-fat diet induces cognitive impairment through repression of SIRT1/AMPK-mediated autophagy.</text><annotation id="3"><infon key="identifier">MESH:D004620</infon><infon key="type">Disease</infon><location offset="5" length="3"/><text>fat</text></annotation><annotation id="4"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="22" length="20"/><text>cognitive impairment</text></annotation><annotation id="5"><infon key="identifier">93759</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56556</infon><location offset="65" length="5"/><text>SIRT1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset><text>AIMS: Recent evidence suggests an association between a high-fat diet (HFD) and cognitive decline. HFD may reduce synaptic plasticity and cause tau hyperphosphorylation, but the mechanisms involved remain unclear. The purpose of this study was to explore whether Sirtuin1 (SIRT1)/AMP-activated protein kinase (AMPK) pathway was involved in this pathogenic effect in the HFD exposed mice. METHODS: C57BL/6 mice at 12 months of age were fed a standard (9% kcal fat) or high-fat (60% kcal fat) diet for 22 weeks, and Neuro-2a (N2a) cells were treated with normal culture medium or a palmitic acid (PA) medium (100uM) for 40 h. After that, cognitive function was tested by Morris water maze (MWM). The levels of proteins involved in SIRT1/AMPK pathway and autophagy were measured using western blotting and immunofluorescence. We also assessed the phosphorylation of tau protein and synapse. RESULTS: The mice presented impaired learning and memory abilities. We further found decreased levels of synaptophysin (Syn) and brain-derived neurotrophic factor (BDNF), increased tau46 and phosphorylated tau protein, and damaged neurons in mice after HFD or in N2a cells treated with PA medium. Moreover, HFD can also reduce the expression of SIRT1, inhibit AMPK phosphorylation, and block autophagic flow in both mice and cells. After treating the cells with the SIRT1 agonist SRT1720, SIRT1/AMPK pathway and autophagy-related proteins were partially reversed and the number of PA-induced positive cells was alleviated in senescence-associated beta-galactosidase (SA-beta-gal) staining. CONCLUSIONS: HFD may inhibit the expression of SIRT1/AMPK pathway and disrupt autophagy flux, and result in tau hyperphosphorylation and synaptic dysfunction during aging, which ultimately lead to cognitive decline.</text><annotation id="36"><infon key="identifier">MESH:D004620</infon><infon key="type">Disease</infon><location offset="157" length="3"/><text>fat</text></annotation><annotation id="37"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="176" length="17"/><text>cognitive decline</text></annotation><annotation id="38"><infon key="identifier">MESH:C536599</infon><infon key="type">Disease</infon><location offset="240" length="24"/><text>tau hyperphosphorylation</text></annotation><annotation id="39"><infon key="identifier">93759</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56556</infon><location offset="359" length="8"/><text>Sirtuin1</text></annotation><annotation id="40"><infon key="identifier">93759</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56556</infon><location offset="369" length="5"/><text>SIRT1</text></annotation><annotation id="41"><infon key="identifier">CVCL:C0MU</infon><infon key="type">CellLine</infon><location offset="493" length="7"/><text>C57BL/6</text></annotation><annotation id="42"><infon key="identifier">MESH:D004620</infon><infon key="type">Disease</infon><location offset="555" length="3"/><text>fat</text></annotation><annotation id="43"><infon key="identifier">MESH:D004620</infon><infon key="type">Disease</infon><location offset="568" length="3"/><text>fat</text></annotation><annotation id="44"><infon key="identifier">MESH:D004620</infon><infon key="type">Disease</infon><location offset="582" length="3"/><text>fat</text></annotation><annotation id="45"><infon key="identifier">CVCL:0470</infon><infon key="type">CellLine</infon><location offset="610" length="8"/><text>Neuro-2a</text></annotation><annotation id="46"><infon key="identifier">CVCL:0470</infon><infon key="type">CellLine</infon><location offset="620" length="3"/><text>N2a</text></annotation><annotation id="47"><infon key="identifier">MESH:D019308</infon><infon key="type">Chemical</infon><location offset="676" length="13"/><text>palmitic acid</text></annotation><annotation id="48"><infon key="identifier">MESH:D019308</infon><infon key="type">Chemical</infon><location offset="691" length="2"/><text>PA</text></annotation><annotation id="49"><infon key="identifier">93759</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56556</infon><location offset="825" length="5"/><text>SIRT1</text></annotation><annotation id="50"><infon key="identifier">MESH:D007859</infon><infon key="type">Disease</infon><location offset="1012" length="28"/><text>impaired learning and memory</text></annotation><annotation id="51"><infon key="identifier">20977</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2391</infon><location offset="1089" length="13"/><text>synaptophysin</text></annotation><annotation id="52"><infon key="identifier">20977</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2391</infon><location offset="1104" length="3"/><text>Syn</text></annotation><annotation id="53"><infon key="identifier">12064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7245</infon><location offset="1113" length="33"/><text>brain-derived neurotrophic factor</text></annotation><annotation id="54"><infon key="identifier">12064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7245</infon><location offset="1148" length="4"/><text>BDNF</text></annotation><annotation id="55"><infon key="identifier">CVCL:0470</infon><infon key="type">CellLine</infon><location offset="1247" length="3"/><text>N2a</text></annotation><annotation id="56"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1270" length="9"/><text>PA medium</text></annotation><annotation id="57"><infon key="identifier">93759</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56556</infon><location offset="1329" length="5"/><text>SIRT1</text></annotation><annotation id="58"><infon key="identifier">93759</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56556</infon><location offset="1450" length="5"/><text>SIRT1</text></annotation><annotation id="59"><infon key="identifier">MESH:C525422</infon><infon key="type">Chemical</infon><location offset="1464" length="7"/><text>SRT1720</text></annotation><annotation id="60"><infon key="identifier">93759</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56556</infon><location offset="1473" length="5"/><text>SIRT1</text></annotation><annotation id="61"><infon key="identifier">MESH:D019308</infon><infon key="type">Chemical</infon><location offset="1565" length="2"/><text>PA</text></annotation><annotation id="62"><infon key="identifier">93759</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56556</infon><location offset="1721" length="5"/><text>SIRT1</text></annotation><annotation id="63"><infon key="identifier">MESH:C536599</infon><infon key="type">Disease</infon><location offset="1782" length="24"/><text>tau hyperphosphorylation</text></annotation><annotation id="64"><infon key="identifier">MESH:C536122</infon><infon key="type">Disease</infon><location offset="1811" length="20"/><text>synaptic dysfunction</text></annotation><annotation id="65"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1871" length="17"/><text>cognitive decline</text></annotation></passage><relation id="R1"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:C525422</infon><infon key="role2">Gene|93759</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="26,25"/></relation><relation id="R2"><infon key="score">0.8934</infon><infon key="role1">Disease|MESH:D004620</infon><infon key="role2">Gene|93759</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,2"/></relation><relation id="R3"><infon key="score">0.9983</infon><infon key="role1">Disease|MESH:D003072</infon><infon key="role2">Gene|93759</infon><infon key="type">Association</infon><node refid="2" role="1,2"/></relation></document>
<document><id>37899095</id><passage><infon key="journal">Ying Yong Sheng Tai Xue Bao;2023Sep; 34 (9) 2314. doi:10.13287/j.1001-9332.202309.004</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yuan SY, Zhang P, Shen HL, </infon><offset>0</offset><text>Response of needle photosynthetic and anatomical characteristics of naturally regenerated Pinus koraiensis seedlings to different canopy densities.</text></passage><passage><infon key="type">abstract</infon><offset>148</offset><text>We took 5-year-old Pinus koraiensis seedlings under natural secondary forests with canopy densities of 0.2-0.3, 0.4-0.6, and 0.7-0.9 at Laoshan Plantation Experimental Station in Maoershan Experimental Forest Farm of Northeast Forestry University as monitor object, and P. koraiensis seedlings under full-light environment as control (CK), to investigate the photosynthetic characteristics and the anatomical structure of P. koraiensis needles in response to the changes of canopy densities. The results showed that the height and diameter of P. koraiensis seedlings tended to decrease while specific leaf area increased with the increases of canopy densities. The total biomass of P. koraiensis seedlings under different canopy densities ranked in an order of 0.4-0.6>CK>0.7-0.9>0.2-0.3. Photosynthetically active radiation (PAR) was significantly and positively correlated with leaf biomass, stem biomass, and root biomass. The net photosynthetic rate, transpiration rate, and intercellular CO2 concentration of P. koraiensis seedlings showed a decreasing trend with the increases of canopy densities, while the stomatal conductance showed an increasing trend. Net photosynthetic rate and chlorophyll a/b showed a significant positive correlation with PAR. Stomatal density showed a gradual decreasing trend with the increases of canopy densities, and the needle cross-sectional area, mesophyll tissue area, xylem area, and phloem area of P. koraiensis seedlings under canopy density 0.4-0.6 were significantly higher than those in other treatments. P. koraiensis seedlings with stronger photosynthetic abilities and higher needle anatomy parameters under canopy density 0.4-0.6, and were able to maintain strong competitiveness in this habitat. Those results indicated that 5-year-old P. koraiensis seedlings need certain shading environment.</text><annotation id="2"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1141" length="3"/><text>CO2</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1339" length="15"/><text>chlorophyll a/b</text></annotation></passage></document>
<document><id>37902248</id><passage><infon key="journal">Macromol Biosci;2023Oct30 2300397. doi:10.1002/mabi.202300397</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Unalan I, Occhipinti I, Miola M, Vern&amp;#xe8; E, Boccaccini AR, </infon><offset>0</offset><text>Development of Super-Paramagnetic Iron Oxide Nanoparticle Coated Melt Electrowritten Scaffolds for Biomedical Applications.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="15" length="29"/><text>Super-Paramagnetic Iron Oxide</text></annotation></passage><passage><infon key="type">abstract</infon><offset>124</offset><text>Polycaprolactone (PCL) is usually the material chosen for melt electrowriting (MEW) due to its biocompatibility, mechanical strength, and melt processability. This work first investigated the effect of different processing parameters to obtain optimum PCL-MEW scaffolds. Secondly, to increase PCL`s hydrophilicity, cell affinity and to enable coating with superparamagnetic iron oxide nanoparticles (SPIONs) and silica-coated SPIONs (Si-SPIONs), the scaffolds were modified with alkaline surface treatment. Finally, SPIONs and Si-SPIONs were successfully coated on MEW scaffolds. Results showed that a reproducible, layered micro-ranged scaffold was fabricated. Additionally, the alkaline treatment did not change the 3D morphology of scaffolds while reducing the fiber diameter. Furthermore, SEM images and ATR-FTIR results confirmed that SPIONs and Si-SPIONs coated on MEW scaffolds. A cytocompatibility assay showed a non-toxic effect on MG-63 osteoblast-like cell viability in all the scaffolds. Additionally, higher MC3T3-E1 pre-osteoblastic cell adhesion efficiency and proliferation were achieved for the alkaline-treated scaffolds and SPIONs/Si-SPIONs-coated scaffolds. Moreover, all the samples demonstrated the ability to generate heat, useful for hyperthermia treatment, when subjected to an alternating magnetic field. Overall, the findings suggested that the strategy of coating MEW PCL scaffolds with SPIONs/Si-SPIONs has the potential to improve scaffolds performance for biomedical applications, especially for producing magnetically responsive MEW scaffolds. This article is protected by copyright. All rights reserved.</text><annotation id="15"><infon key="identifier">MESH:C016240</infon><infon key="type">Chemical</infon><location offset="124" length="16"/><text>Polycaprolactone</text></annotation><annotation id="16"><infon key="identifier">MESH:C016240</infon><infon key="type">Chemical</infon><location offset="142" length="3"/><text>PCL</text></annotation><annotation id="17"><infon key="identifier">MESH:C016240</infon><infon key="type">Chemical</infon><location offset="376" length="3"/><text>PCL</text></annotation><annotation id="18"><infon key="identifier">MESH:C016240</infon><infon key="type">Chemical</infon><location offset="417" length="5"/><text>PCL`s</text></annotation><annotation id="19"><infon key="identifier">MESH:D012822</infon><infon key="type">Chemical</infon><location offset="536" length="6"/><text>silica</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="558" length="9"/><text>Si-SPIONs</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="651" length="9"/><text>Si-SPIONs</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="975" length="9"/><text>Si-SPIONs</text></annotation><annotation id="23"><infon key="identifier">CVCL:0426</infon><infon key="type">CellLine</infon><location offset="1065" length="5"/><text>MG-63</text></annotation><annotation id="24"><infon key="identifier">CVCL:0409</infon><infon key="type">CellLine</infon><location offset="1145" length="8"/><text>MC3T3-E1</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1274" length="9"/><text>Si-SPIONs</text></annotation><annotation id="26"><infon key="identifier">MESH:C016240</infon><infon key="type">Chemical</infon><location offset="1520" length="3"/><text>PCL</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1546" length="9"/><text>Si-SPIONs</text></annotation></passage></document>
<document><id>37902598</id><passage><infon key="journal">Clin Gerontol;2023Oct30 1. doi:10.1080/07317115.2023.2274053</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bergua V, Blanchard C, Amieva H, </infon><offset>0</offset><text>Depression in Older Adults: Do Current DSM Diagnostic Criteria Really Fit?</text><annotation id="1"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="0" length="10"/><text>Depression</text></annotation></passage><passage><infon key="type">abstract</infon><offset>75</offset><text>OBJECTIVES: The great heterogeneity in symptoms and clinical signs of depression in older adults makes the current diagnostic criteria difficult to apply. This scoping review aims to provide an update on the relevance of each of the diagnostic criteria as defined in the DSM-5. METHODS: In order to limit the risk of bias inherent in the study selection process, a priori inclusion and exclusion criteria were defined. Articles meeting these criteria were identified using a combination of search terms entered into PubMed, PsycINFO, PsycARTICLES and SocINDEX. RESULTS: Of the 894 articles identified, 33 articles were selected. This review highlights a different presentation of depression in older adults. Beyond the first two DSM core criteria, some symptoms are more common in older adults: appetite change, sleep disturbance, psychomotor slowing, difficulty concentrating, indecisiveness, and fatigue. CONCLUSIONS: This review provides an updated description of the clinical expression of depressive symptoms in the older population while highlighting current pending issues. CLINICAL IMPLICATIONS: Somatic symptoms should be systematically considered in order to improve the diagnosis of depression in older adults, even if, in some cases, they may reflect symptoms of age-related illnesses.</text><annotation id="12"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="145" length="10"/><text>depression</text></annotation><annotation id="13"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="755" length="10"/><text>depression</text></annotation><annotation id="14"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="870" length="15"/><text>appetite change</text></annotation><annotation id="15"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="887" length="17"/><text>sleep disturbance</text></annotation><annotation id="16"><infon key="identifier">MESH:D011596</infon><infon key="type">Disease</infon><location offset="906" length="19"/><text>psychomotor slowing</text></annotation><annotation id="17"><infon key="identifier">MESH:C567712</infon><infon key="type">Disease</infon><location offset="927" length="24"/><text>difficulty concentrating</text></annotation><annotation id="18"><infon key="type">Disease</infon><location offset="953" length="14"/><text>indecisiveness</text></annotation><annotation id="19"><infon key="identifier">MESH:D005221</infon><infon key="type">Disease</infon><location offset="973" length="7"/><text>fatigue</text></annotation><annotation id="20"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1069" length="19"/><text>depressive symptoms</text></annotation><annotation id="21"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1269" length="10"/><text>depression</text></annotation></passage></document>
<document><id>37902950</id><passage><infon key="journal">Aging Clin Exp Res;2023Oct30. doi:10.1007/s40520-023-02588-4</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Abbasi K, Ali P, Barbour V, Bibbins-Domingo K, Rikkert MGMO, Haines A, Helfand I, Horton R, Mash B, Mitra A, Monteiro C, Naumova EN, Rubin EJ, Ruff T, Sahni P, Tumwine J, Yonga P, Zielinski C, </infon><offset>0</offset><text>Reducing the risks of nuclear war: the role of health professionals.</text><annotation id="1"><infon key="identifier">MESH:D000067398</infon><infon key="type">Disease</infon><location offset="22" length="11"/><text>nuclear war</text></annotation></passage><passage><infon key="type">abstract</infon><offset>69</offset></passage></document>
<document><id>37903326</id><passage><infon key="journal">Plast Reconstr Surg;2023Oct30. doi:10.1097/PRS.0000000000011164</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Pincelli T, Zawawi S, Shapiro S, Heckman MG, Hochwald AP, Desmond C, Arthurs J, Tolaymat L, Forte A, Bruce A, </infon><offset>0</offset><text>A Pilot, Randomized, Single-Blind, Controlled Study Evaluating the Use of Platelet Rich Plasma (PRP) for Hand Skin Rejuvenation.</text><annotation id="1"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="110" length="4"/><text>Skin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>BACKGROUND: The presence of various growth factors in platelets makes platelet rich plasma a powerful tool in the stimulation of collagen regeneration in aging skin. The main objective of this study was to determine efficacy and safety of platelet rich plasma compared to saline solution in women with aging skin of the hands. METHODS: In this prospective, randomized clinical trial, eighteen women with hand aging received PRP injections every 4 weeks into the unilateral dorsal hand for 12 weeks total; with saline injections into the contralateral hand in a randomized, controlled, single-blind fashion. Physician assessment, photographs and quality-of-life questionnaires were used for assessment at baseline; 12- and 24-week follow-up. RESULTS: The majority of patients reported pain and discomfort along with a burning/stinging sensation in both PRP and saline treated hands with no significant differences noted in any patient outcome measures between the two treatments (all P>=0.25). No differences were reliably detected between the treatment hands by a blinded investigator comparing before and after clinical photographs of the hands. CONCLUSION: Three injections of PRP spaced 4 weeks apart did not appear to be effective for treatment of aging skin of the hands in women, with no noted difference as compared with baseline, or saline injection. Although age > 45 years may be a factor accounting for non-response (i.e., subtle skin changes are difficult to appreciate, and possible limited platelet regenerative capacity in advanced age) it appears that PRP is not a reliable cosmetic option for management of hand aging.</text><annotation id="9"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="289" length="4"/><text>skin</text></annotation><annotation id="10"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="437" length="4"/><text>skin</text></annotation><annotation id="11"><infon key="identifier">MESH:D006230</infon><infon key="type">Disease</infon><location offset="533" length="10"/><text>hand aging</text></annotation><annotation id="12"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="913" length="4"/><text>pain</text></annotation><annotation id="13"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="1387" length="4"/><text>skin</text></annotation><annotation id="14"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="1570" length="4"/><text>skin</text></annotation><annotation id="15"><infon key="identifier">MESH:D006230</infon><infon key="type">Disease</infon><location offset="1753" length="10"/><text>hand aging</text></annotation></passage></document>
<document><id>37903677</id><passage><infon key="journal">J Orthop Sci;2023Oct28. doi:10.1016/j.jos.2023.10.010</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nakamoto H, Nakajima K, Miyahara J, Kato S, Doi T, Taniguchi Y, Matsubayashi Y, Nishizawa M, Kawamura N, Kumanomido Y, Higashikawa A, Sasaki K, Takeshita Y, Fukushima M, Iizuka M, Ono T, Yu J, Hara N, Okamoto N, Azuma S, Inanami H, Sakamoto R, Tanaka S, Oshima Y, </infon><offset>0</offset><text>Does surgical site infection affect patient-reported outcomes after spinal surgery? A multicenter cohort study.</text><annotation id="1"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="19" length="9"/><text>infection</text></annotation></passage><passage><infon key="type">abstract</infon><offset>112</offset><text>BACKGROUND: Surgical site infections are common in spinal surgeries. It is uncertain whether outcomes in spine surgery patients with vs. without surgical site infection are equivalent. Therefore, we assessed the effects of surgical site infection on postoperative patient-reported outcomes. METHODS: We enrolled patients who underwent elective spine surgery at 12 hospitals between April 2017 and February 2020. We collected data regarding the patients' backgrounds, operative factors, and incidence of surgical site infection. Data for patient-reported outcomes, namely numerical rating scale, Neck Disability Index/Oswestry Disability Index, EuroQol Five-Dimensional questionnaire, and 12-Item Short-Form Health Survey scores, were obtained preoperatively and 1 year postoperatively. We divided the patients into with and without surgical site infection groups. Multivariate logistic regression analyses were performed to identify the risk factors for surgical site infection. Using propensity score matching, we obtained matched surgical site infection-negative and -positive groups. Student's t-test was used for comparisons of continuous variables, and Pearson's chi-square test was used to compare categorical variables between the two matched groups and two unmatched groups. RESULTS: We enrolled 8861 patients in this study; 74 (0.8 %) developed surgical site infections. Cervical spine surgery and American Society of Anesthesiologists physical status classification >=3 were identified as risk factors; microendoscopy was identified as a protective factor. Using propensity score matching, we compared surgical site infection-positive and -negative groups (74 in each group). No significant difference was found in postoperative pain or dysesthesia of the lower back, buttock, leg, and plantar area between the groups. When comparing preoperative with postoperative pain and dysesthesia, statistically significant improvement was observed for both variables in both groups (p &lt; 0.01 for all variables). No significant differences were observed in postoperative outcomes between the matched surgical site infection-positive and -negative groups. CONCLUSIONS: Patients with surgical site infections had comparable postoperative outcomes to those without surgical site infections.</text><annotation id="18"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="138" length="10"/><text>infections</text></annotation><annotation id="19"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="271" length="9"/><text>infection</text></annotation><annotation id="20"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="349" length="9"/><text>infection</text></annotation><annotation id="21"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="629" length="9"/><text>infection</text></annotation><annotation id="22"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="958" length="9"/><text>infection</text></annotation><annotation id="23"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1080" length="9"/><text>infection</text></annotation><annotation id="24"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1158" length="9"/><text>infection</text></annotation><annotation id="25"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1480" length="10"/><text>infections</text></annotation><annotation id="26"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1738" length="9"/><text>infection</text></annotation><annotation id="27"><infon key="identifier">MESH:D010149</infon><infon key="type">Disease</infon><location offset="1837" length="18"/><text>postoperative pain</text></annotation><annotation id="28"><infon key="identifier">MESH:D010292</infon><infon key="type">Disease</infon><location offset="1859" length="11"/><text>dysesthesia</text></annotation><annotation id="29"><infon key="identifier">MESH:D010149</infon><infon key="type">Disease</infon><location offset="1974" length="18"/><text>postoperative pain</text></annotation><annotation id="30"><infon key="identifier">MESH:D010292</infon><infon key="type">Disease</infon><location offset="1997" length="11"/><text>dysesthesia</text></annotation><annotation id="31"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="2226" length="9"/><text>infection</text></annotation><annotation id="32"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="2308" length="10"/><text>infections</text></annotation><annotation id="33"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="2388" length="10"/><text>infections</text></annotation></passage></document>
<document><id>37904028</id><passage><infon key="journal">J Hum Genet;2023Oct31. doi:10.1038/s10038-023-01204-7</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tanaka T, </infon><offset>0</offset><text>JHG Young Scientist Award 2023.</text></passage><passage><infon key="type">abstract</infon><offset>32</offset></passage></document>
<document><id>37905078</id><passage><infon key="journal">bioRxiv;2023Oct17. doi:10.1101/2023.10.13.561901</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614803</infon><infon key="type">title</infon><infon key="authors">Fazio N, Mersch KN, Hao L, Lohman TM, </infon><offset>0</offset><text>E. coli RecBCD Nuclease Domain Regulates Helicase Activity but not Single Stranded DNA Translocase Activity.</text></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>Much is still unknown about the mechanisms by which helicases unwind duplex DNA. Whereas structure-based models describe DNA unwinding as a consequence of mechanically pulling the DNA duplex across a wedge domain in the helicase by the single stranded (ss)DNA translocase activity of the ATPase motors, biochemical data indicate that processive DNA unwinding by the E. coli RecBCD helicase can occur in the absence of ssDNA translocation of the canonical RecB and RecD motors. Here, we present evidence that dsDNA unwinding is not a simple consequence of ssDNA translocation by the RecBCD motors. Using stopped-flow fluorescence approaches, we show that a RecB nuclease domain deletion variant (RecB DeltaNuc CD) unwinds dsDNA at significantly slower rates than RecBCD, while the rate of ssDNA translocation is unaffected. This effect is primarily due to the absence of the nuclease domain and not the absence of the nuclease activity, since a nuclease-dead mutant (RecB D1080A CD), which retains the nuclease domain, showed no significant change in rates of ssDNA translocation or dsDNA unwinding relative to RecBCD on short DNA substrates (&lt;= 60 base pairs). This indicates that ssDNA translocation is not rate-limiting for DNA unwinding. RecB DeltaNuc CD also initiates unwinding much slower than RecBCD from a blunt-ended DNA, although it binds with higher affinity than RecBCD. RecB DeltaNuc CD also unwinds DNA ~two-fold slower than RecBCD on long DNA (~20 kilo base pair) in single molecule optical tweezer experiments, although the rates for RecB D1080A CD unwinding are intermediate between RecBCD and RecB DeltaNuc CD. Surprisingly, significant pauses occur even in the absence of chi (crossover hotspot instigator) sites. We hypothesize that the nuclease domain influences the rate of DNA base pair melting, rather than DNA translocation, possibly allosterically. Since the rate of DNA unwinding by RecBCD also slows after it recognizes a chi sequence, RecB DeltaNuc CD may mimic a post- chi state of RecBCD.</text><annotation id="3"><infon key="identifier">3654511</infon><infon key="type">Gene</infon><location offset="397" length="6"/><text>ATPase</text></annotation><annotation id="4"><infon key="identifier">tmVar:p|SUB|D|1080|A;HGVS:p.D1080A;VariantGroup:0;CorrespondingGene:3654511</infon><infon key="type">ProteinMutation</infon><location offset="1080" length="6"/><text>D1080A</text></annotation><annotation id="5"><infon key="identifier">tmVar:p|SUB|D|1080|A;HGVS:p.D1080A;VariantGroup:0;CorrespondingGene:3654511</infon><infon key="type">ProteinMutation</infon><location offset="1664" length="6"/><text>D1080A</text></annotation></passage></document>
<document><id>37905428</id><passage><infon key="type">title</infon><offset>0</offset><text>Who consumes ultra-processed food? A systematic review of sociodemographic determinants of ultra-processed food consumption from nationally representative samples.</text></passage><passage><infon key="type">abstract</infon><offset>164</offset><text>Ultra-processed food (UPF) intake is associated with increased non-communicable disease risks. However, systematic reports on sociodemographic predictors of UPF intake are lacking. This review aimed to understand UPF consumption based on sociodemographic factors, using nationally representative cohorts. The systematic review was pre-registered (PROSPERO:CRD42022360199), following PRISMA guidelines. PubMed/MEDLINE searches ('ultra-processed/ultraprocessed' and 'ultra-processing/ultraprocessing') until 07/09/2022 retrieved 1,131 results. Inclusion criteria included: observational, nationally representative adult samples, in English, in peer-reviewed journals, assessing the association between sociodemographics and individual-level UPF intake defined by the NOVA classification. Exclusion criteria included: not nationally representative, no assessment of sociodemographics and individual-level UPF intake defined by NOVA. Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS). 55 papers were included, spanning 32 countries. All 13 sociodemographic variables identified were significantly associated with UPF intake in >=1 studies. Significant differences in UPF intake were seen across age, race/ethnicity, rural/urbanisation, food insecurity, income and region, with up to 10-20% differences in UPF intake (% total energy). Higher UPF intakes were associated with younger age, urbanisation, and being unmarried, single, separated or divorced. Education, income and socioeconomic status showed varying associations, depending on country. Multivariate analyses indicated that associations were independent of other sociodemographics. Household status and gender were generally not associated with UPF intake. NOS averaged 5.7/10. Several characteristics are independently associated with high UPF intake, indicating large sociodemographic variation in non-communicable disease risk. These findings highlight significant public health inequalities associated with UPF intake, and the urgent need for policy action to minimise social injustice-related health inequalities.</text></passage></document>
<document><id>37905779</id><passage><infon key="type">title</infon><offset>0</offset><text>Applications of clinker microscopy for approaching a special case study in cement production.</text></passage><passage><infon key="type">abstract</infon><offset>94</offset><text>Within this article the importance of the optical light microscopy for the investigation of cement clinker is illustrated by three examples: a) Ono's method plays an important role in the case of the production of oil well clinker where the reactivity of alite and additionally the melting phase influences strongly the properties of the later cement; b) the use of secondary fuels can lead to unexpected phenomena in the clinker matrix accompanied by strange changes in color; c) for the interpretation of CSA clinkers, the combination of light and scanning electron microscopy can give important information about the formation of clinker phases depending on the burning conditions which can hardly be detected by other methods. However, in case of CSA clinker there is still little knowledge about the relationship between production and hydraulic properties of the clinker and therefore no systematic documentation is available. This article is protected by copyright. All rights reserved.</text><annotation id="4"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="308" length="3"/><text>oil</text></annotation><annotation id="5"><infon key="identifier">MESH:C506393</infon><infon key="type">Chemical</infon><location offset="349" length="5"/><text>alite</text></annotation><annotation id="6"><infon key="identifier">MESH:D003057</infon><infon key="type">Disease</infon><location offset="601" length="3"/><text>CSA</text></annotation><annotation id="7"><infon key="identifier">MESH:D003057</infon><infon key="type">Disease</infon><location offset="845" length="3"/><text>CSA</text></annotation></passage></document>
<document><id>37906131</id><passage><infon key="type">title</infon><offset>0</offset><text>Comparing outcomes of thulium fiber laser versus high-power Holmium:YAG laser lithotripsy in pediatric patients managed with RIRS for kidney stones. A multicenter retrospective study.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="22" length="19"/><text>thulium fiber laser</text></annotation><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="60" length="11"/><text>Holmium:YAG</text></annotation><annotation id="5"><infon key="identifier">MESH:D007669</infon><infon key="type">Disease</infon><location offset="134" length="13"/><text>kidney stones</text></annotation></passage><passage><infon key="type">abstract</infon><offset>184</offset><text>BACKGROUND: The aim of this study was to evaluate thulium fiber laser (TFL) safety and efficacy compared to high-power (HP) Holmium:YAG laser in pediatric patients who have undergone retrograde intrarenal surgery (RIRS) for kidney stones. METHODS: We retrospectively reviewed data from pediatric patients who underwent RIRS for kidney stones between 2018 and 2020. Complications were assessed 4-6 weeks postoperatively. Stone-free (SF) was defined as the absence of visible fragments or as the presence of a single residual fragment &lt;=2 mm at 3 months postoperative imaging. Student's t-test for continuous variables, and chi2 and Fisher's Exact Test for categorical variables were used to compare outcomes between patients treated with HP Holmium:YAG (group 1) and TFL (group 2). Univariate (UVA) and multivariate (MVA) logistic regression analyses were performed to predict SF-associated factors. RESULTS: Data from 126 pediatric patients were analyzed, 97 in group 1 and 29 in group 2. Preoperative characteristics were similar between cohorts. No major complication occurred in both groups. Group 2 had a shorter operative time (mean time 49.5 vs. 64.3 min, P=0.024). SF rate was 81.4% and 89.7% (P=0.45) and reintervention rate was 14.4% and 6.89% (P=0.046) in group 1 and 2, respectively. At UVA and MVA, the type of laser did not influence SF rate. However, prestenting and single stones were positively associated with SR rate. CONCLUSIONS: Both laser technologies are safe and effective and showed similar SF rates. TFL showed less operative time and lower re-intervention rate compared to HP Holmium:YAG. Further prospective studies are needed to corroborate our findings.</text><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="234" length="19"/><text>thulium fiber laser</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="255" length="3"/><text>TFL</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="308" length="11"/><text>Holmium:YAG</text></annotation><annotation id="19"><infon key="identifier">MESH:D007669</infon><infon key="type">Disease</infon><location offset="408" length="13"/><text>kidney stones</text></annotation><annotation id="20"><infon key="identifier">MESH:D007669</infon><infon key="type">Disease</infon><location offset="512" length="13"/><text>kidney stones</text></annotation><annotation id="21"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="549" length="13"/><text>Complications</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="924" length="11"/><text>Holmium:YAG</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="950" length="3"/><text>TFL</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1709" length="3"/><text>TFL</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1786" length="11"/><text>Holmium:YAG</text></annotation></passage></document>
<document><id>37906481</id><passage><infon key="journal">IEEE Trans Pattern Anal Mach Intell;2023Oct31; PP. doi:10.1109/TPAMI.2023.3328829</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Franchi G, Bursuc A, Aldea E, Dubuisson S, Bloch I, </infon><offset>0</offset><text>Encoding the Latent Posterior of Bayesian Neural Networks for Uncertainty Quantification.</text></passage><passage><infon key="type">abstract</infon><offset>90</offset><text>Bayesian Neural Networks (BNNs) have long been considered an ideal, yet unscalable solution for improving the robustness and the predictive uncertainty of deep neural networks. While they could capture more accurately the posterior distribution of the network parameters, most BNN approaches are either limited to small networks or rely on constraining assumptions, e.g., parameter independence. These drawbacks have enabled prominence of simple, but computationally heavy approaches such as Deep Ensembles, whose training and testing costs increase linearly with the number of networks. In this work we aim for efficient deep BNNs amenable to complex computer vision architectures, e.g., ResNet-50 DeepLabv3+, and tasks, e.g., semantic segmentation and image classification, with fewer assumptions on the parameters. We achieve this by leveraging variational autoencoders (VAEs) to learn the interaction and the latent distribution of the parameters at each network layer. Our approach, called Latent-Posterior BNN (LP-BNN), is compatible with the recent BatchEnsemble method, leading to highly efficient (in terms of computation and memory during both training and testing) ensembles. LP-BNNs attain competitive results across multiple metrics in several challenging benchmarks for image classification, semantic segmentation, and out-of-distribution detection.</text></passage></document>
<document><id>37906855</id><passage><infon key="type">title</infon><offset>0</offset><text>[Tatton-Brown-Rahman Syndrome: Case report and DNMT3A variant not previously reported associated to the syndrome].</text><annotation id="2"><infon key="identifier">OMIM:615879</infon><infon key="type">Disease</infon><location offset="1" length="28"/><text>Tatton-Brown-Rahman Syndrome</text></annotation><annotation id="3"><infon key="identifier">1788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7294</infon><location offset="47" length="6"/><text>DNMT3A</text></annotation></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>Tatton Brown Rahman Syndrome (TBRS) is a recently described overgrowth syndrome caused by variants in the DNMT3A gene. The description of its phenotype and the differences with its main differential diagnoses are still under development, with very few individuals of Latin American origin described to date. OBJECTIVE: To describe a Chilean case of TBRS in order to broaden the phenotypic and genotypic spectrum of this new syndrome. CLINICAL CASE: 9-year-old boy diagno sed with TBRS through whole-exome sequencing (WES), which showed a variant in DNMT3A: c.2311C > T, p. (Arg771*) that has not been previously reported in the literature in individuals with the condition. He presented the main characteristics of this syndrome with overgrowth from the neonatal stage, mild intellectual disability associated with autism spectrum disorder, absen ce of major abnormalities in internal organs, and characteristic dysmorphism with coarse facies, horizontal eyebrows, and prominent upper central incisors. An EEG showed alterations due to frequent interictal epileptiform activity in the left temporal region, with no history of seizures, and normal brain MRI. In addition, he presented advanced bone age, a common finding in other over growth syndromes but not frequently reported in TBRS. A sister showed normal genetic study and the segregation study of the variant identified in the parents could not be performed. CONCLUSIONS: The report of this case broadens the genotypic spectrum of the syndrome and contributes to the characterization of the phenotypic manifestations including individuals of different ethnicities, emphasizing its most common characteristics and others that hinder its differential diagnosis from other overgrowth syndromes.</text><annotation id="21"><infon key="identifier">OMIM:615879</infon><infon key="type">Disease</infon><location offset="115" length="28"/><text>Tatton Brown Rahman Syndrome</text></annotation><annotation id="22"><infon key="identifier">OMIM:615879</infon><infon key="type">Disease</infon><location offset="145" length="4"/><text>TBRS</text></annotation><annotation id="23"><infon key="identifier">MESH:C537340</infon><infon key="type">Disease</infon><location offset="175" length="19"/><text>overgrowth syndrome</text></annotation><annotation id="24"><infon key="identifier">1788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7294</infon><location offset="221" length="6"/><text>DNMT3A</text></annotation><annotation id="25"><infon key="identifier">OMIM:615879</infon><infon key="type">Disease</infon><location offset="464" length="4"/><text>TBRS</text></annotation><annotation id="26"><infon key="identifier">OMIM:615879</infon><infon key="type">Disease</infon><location offset="595" length="4"/><text>TBRS</text></annotation><annotation id="27"><infon key="identifier">1788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7294</infon><location offset="664" length="6"/><text>DNMT3A</text></annotation><annotation id="28"><infon key="identifier">tmVar:c|SUB|C|2311|T;HGVS:c.2311C>T;VariantGroup:0;CorrespondingGene:1788;RS#:779626155;CorrespondingSpecies:9606;CA#:1555658</infon><infon key="type">DNAMutation</infon><location offset="672" length="11"/><text>c.2311C > T</text></annotation><annotation id="29"><infon key="identifier">tmVar:p|Allele|R|771;VariantGroup:1;CorrespondingGene:1788;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="685" length="12"/><text>p. (Arg771*)</text></annotation><annotation id="30"><infon key="identifier">MESH:D008607</infon><infon key="type">Disease</infon><location offset="890" length="23"/><text>intellectual disability</text></annotation><annotation id="31"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="930" length="24"/><text>autism spectrum disorder</text></annotation><annotation id="32"><infon key="identifier">MESH:D000014</infon><infon key="type">Disease</infon><location offset="974" length="16"/><text>abnormalities in</text></annotation><annotation id="33"><infon key="identifier">MESH:D057215</infon><infon key="type">Disease</infon><location offset="1027" length="11"/><text>dysmorphism</text></annotation><annotation id="34"><infon key="identifier">MESH:D014277</infon><infon key="type">Disease</infon><location offset="1171" length="21"/><text>epileptiform activity</text></annotation><annotation id="35"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="1241" length="8"/><text>seizures</text></annotation><annotation id="36"><infon key="identifier">OMIM:615879</infon><infon key="type">Disease</infon><location offset="1397" length="4"/><text>TBRS</text></annotation><annotation id="37"><infon key="identifier">MESH:C537340</infon><infon key="type">Disease</infon><location offset="1842" length="20"/><text>overgrowth syndromes</text></annotation></passage><relation id="R1"><infon key="score">0.7507</infon><infon key="role1">DNAMutation|RS#:779626155;HGVS:c.2311C>T;CorrespondingGene:1788</infon><infon key="role2">Disease|OMIM:615879</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="7,9"/></relation><relation id="R2"><infon key="score">0.8639</infon><infon key="role1">DNAMutation|RS#:779626155;HGVS:c.2311C>T;CorrespondingGene:1788</infon><infon key="role2">Disease|MESH:D000067877</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="12,9"/></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Disease|OMIM:615879</infon><infon key="role2">Gene|1788</infon><infon key="type">Association</infon><node refid="2" role="0,1"/></relation><relation id="R4"><infon key="score">0.9991</infon><infon key="role1">Disease|MESH:C537340</infon><infon key="role2">Gene|1788</infon><infon key="type">Association</infon><node refid="3" role="4,5"/></relation><relation id="R5"><infon key="score">0.7507</infon><infon key="role1">Disease|OMIM:615879</infon><infon key="role2">Gene|1788</infon><infon key="type">Association</infon></relation><relation id="R6"><infon key="score">0.8639</infon><infon key="role1">Disease|MESH:D000067877</infon><infon key="role2">Gene|1788</infon><infon key="type">Association</infon></relation></document>
<document><id>37909324</id><passage><infon key="journal">J Eur Acad Dermatol Venereol;2023Nov01. doi:10.1111/jdv.19612</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kridin K, Zirpel H, Mruwat N, Ludwig RJ, Thaci D, </infon><offset>0</offset><text>Reply to: "Comment on Kridin et al. - Considering Both Relative and Absolute Risk Differences in Infection Risk Between Biologics Classes in Patients With Psoriasis".</text><annotation id="2"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="97" length="9"/><text>Infection</text></annotation><annotation id="3"><infon key="identifier">MESH:D011565</infon><infon key="type">Disease</infon><location offset="155" length="9"/><text>Psoriasis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>167</offset></passage></document>
<document><id>37909679</id><passage><infon key="journal">ACS Nano;2023Nov01. doi:10.1021/acsnano.3c07857</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gu H, Li J, Niu X, Lin J, Chen LW, Zhang Z, Shi Z, Sun Z, Liu Q, Zhang P, Yan W, Wang Y, Zhang L, Li P, Li X, Wang D, Yin P, Chen W, </infon><offset>0</offset><text>Symmetry-Breaking p-Block Antimony Single Atoms Trigger N-Bridged Titanium Sites for Electrocatalytic Nitrogen Reduction with High Efficiency.</text><annotation id="3"><infon key="identifier">MESH:D000965</infon><infon key="type">Chemical</infon><location offset="26" length="8"/><text>Antimony</text></annotation><annotation id="4"><infon key="identifier">MESH:D014025</infon><infon key="type">Chemical</infon><location offset="66" length="8"/><text>Titanium</text></annotation><annotation id="5"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="102" length="8"/><text>Nitrogen</text></annotation></passage><passage><infon key="type">abstract</infon><offset>143</offset><text>The electrochemical nitrogen reduction reaction (eNRR) under mild conditions emerges as a promising approach to produce ammonia (NH3) compared to the typical Haber-Bosch process. Herein, we design an asymmetrically coordinated p-block antimony single-atom catalyst immobilized on nitrogen-doped Ti3C2Tx (Sb SA/N-Ti3C2Tx) for eNRR, which exhibits ultrahigh NH3 yield (108.3 mug h-1 mgcat-1) and excellent Faradaic efficiency (41.2%) at -0.3 V vs RHE. Complementary in situ spectroscopies with theoretical calculations reveal that the nitrogen-bridged two titanium atoms triggered by an adjacent asymmetrical Sb-N1C2 moiety act as the active sites for facilitating the protonation of the rate-determining step from *N2 to *N2H and the kinetic conversion of key intermediates during eNRR. Moreover, the introduction of Sb-N1C2 promotes the formation of oxygen vacancies to expose more titanium sites. This work presents a strategy for single-atom-decorated ultrathin two-dimensional materials with the aim of simultaneously enhancing NH3 yield and Faradaic efficiency for electrocatalytic nitrogen reduction.</text><annotation id="24"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="163" length="8"/><text>nitrogen</text></annotation><annotation id="25"><infon key="identifier">MESH:D000641</infon><infon key="type">Chemical</infon><location offset="263" length="7"/><text>ammonia</text></annotation><annotation id="26"><infon key="identifier">MESH:D000641</infon><infon key="type">Chemical</infon><location offset="272" length="3"/><text>NH3</text></annotation><annotation id="27"><infon key="identifier">MESH:D000965</infon><infon key="type">Chemical</infon><location offset="378" length="8"/><text>antimony</text></annotation><annotation id="28"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="423" length="8"/><text>nitrogen</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="438" length="7"/><text>Ti3C2Tx</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="447" length="5"/><text>Sb SA</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="453" length="9"/><text>N-Ti3C2Tx</text></annotation><annotation id="32"><infon key="identifier">MESH:D000641</infon><infon key="type">Chemical</infon><location offset="499" length="3"/><text>NH3</text></annotation><annotation id="33"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="676" length="8"/><text>nitrogen</text></annotation><annotation id="34"><infon key="identifier">MESH:D014025</infon><infon key="type">Chemical</infon><location offset="697" length="8"/><text>titanium</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="750" length="7"/><text>Sb-N1C2</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="864" length="3"/><text>N2H</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="959" length="7"/><text>Sb-N1C2</text></annotation><annotation id="38"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="993" length="6"/><text>oxygen</text></annotation><annotation id="39"><infon key="identifier">MESH:D014025</infon><infon key="type">Chemical</infon><location offset="1025" length="8"/><text>titanium</text></annotation><annotation id="40"><infon key="identifier">MESH:D000641</infon><infon key="type">Chemical</infon><location offset="1174" length="3"/><text>NH3</text></annotation><annotation id="41"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="1229" length="8"/><text>nitrogen</text></annotation></passage><relation id="R1"><infon key="score">0.5169</infon><infon key="role1">Chemical|MESH:D000641</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="4,3"/></relation><relation id="R2"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D000965</infon><infon key="role2">Chemical|MESH:D014025</infon><infon key="type">Association</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.9976</infon><infon key="role1">Chemical|MESH:D000965</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Association</infon><node refid="2" role="0,2"/></relation><relation id="R4"><infon key="score">0.9674</infon><infon key="role1">Chemical|MESH:D009584</infon><infon key="role2">Chemical|MESH:D014025</infon><infon key="type">Association</infon><node refid="3" role="2,1"/></relation></document>
<document><id>37910034</id><passage><infon key="journal">Eur J Contracept Reprod Health Care;2023Nov01 1. doi:10.1080/13625187.2023.2269455</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Faranna MD, Pesado AC, </infon><offset>0</offset><text>Site necrosis at the insertion place of the single-rod subdermal contraceptive implant: report of five cases.</text><annotation id="1"><infon key="identifier">MESH:D009336</infon><infon key="type">Disease</infon><location offset="5" length="8"/><text>necrosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>110</offset><text>OBJECTIVE: Implant-site necrosis is a rare complication. We present a case-series of a necrosis as an adverse effect after the etonogestrel (ENG)-subdermal contraceptive implant placement. MATERIAL AND METHODS: Five women with site necrosis after the ENG-implant placement and their clinical manifestations and treatments. RESULTS: Local pain was the main symptom, appearing within 35 days of placement. Outpatient multidisciplinary treatment was undertaken. Local debridement and implant removal was performed in four out of the five women. Time to complete healing varied from 45 days to 12 months. CONCLUSION: Early diagnosis and multidisciplinary treatment are essential to avoid severe aesthetic or functional damages and major life-threatening complications.</text><annotation id="9"><infon key="identifier">MESH:D009336</infon><infon key="type">Disease</infon><location offset="134" length="8"/><text>necrosis</text></annotation><annotation id="10"><infon key="identifier">MESH:D009336</infon><infon key="type">Disease</infon><location offset="197" length="8"/><text>necrosis</text></annotation><annotation id="11"><infon key="identifier">MESH:C044815</infon><infon key="type">Chemical</infon><location offset="237" length="12"/><text>etonogestrel</text></annotation><annotation id="12"><infon key="identifier">MESH:C044815</infon><infon key="type">Chemical</infon><location offset="251" length="3"/><text>ENG</text></annotation><annotation id="13"><infon key="identifier">MESH:D009336</infon><infon key="type">Disease</infon><location offset="342" length="8"/><text>necrosis</text></annotation><annotation id="14"><infon key="identifier">MESH:C044815</infon><infon key="type">Chemical</infon><location offset="361" length="3"/><text>ENG</text></annotation><annotation id="15"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="448" length="4"/><text>pain</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C044815</infon><infon key="role2">Disease|MESH:D009336</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="3,2"/></relation></document>
<document><id>37910385</id><passage><infon key="journal">Mol Biol Rep;2023Nov01. doi:10.1007/s11033-023-08840-4</infon><infon key="year">2023</infon><infon key="article-id_pmc">2267168</infon><infon key="type">title</infon><infon key="authors">Lai X, Ji F, Yu F, Chen H, Shen S, Gao H, </infon><offset>0</offset><text>Delta of Exopalaemon carinicauda: molecular characterization, expression in different tissues and developmental stages, and its SNPs association analysis with development.</text></passage><passage><infon key="type">abstract</infon><offset>172</offset><text>BACKGROUND: The Notch signaling pathway plays a significant role in the gene regulatory network of development of vertebrate and invertebrate. However, as a ligand for the Notch signaling pathway, the mechanism of Delta in the development of Exopalaemon carinicauda is still unclear. METHODS AND RESULTS: The Delta's molecular characteristics, tissue distribution and their association with development in E. carinicauda were studied by RACE (rapid amplification of cDNA end), qRT-PCR (quantitative Real-time PCR) and SNP (single nucleotide polymorphism), respectively. The delta in E. carinicauda had a full-length cDNA of 2807 bp and its Delta of 808 amino-acid residue had the highest identity with the Delta of Homarus americanus (identity = 76.63%). Delta had the highest expression in the ovary, and its expression varied with different stages of embryonic, larval, and ovarian development. After delta RNA interference (with a highest interference efficiency of 66% at 24 h), the expression of Notch signaling pathway genes and developmental related genes was significantly reduced, and the ovarian development was significantly delayed. Further study found that there were 4 SNPs (ds1-4) in delta cDNA, of which two (ds2 T1521G caused a mutation Asn422Lys and ds3 G1674A caused a mutation Tyr473Cys in the EGF-like domain) were associated with the development of E. carinicauda. The Gonadosomatic Index (GSI) of the ds2 TT genotypes was 37.28% and 134.60% higher than E. carinicauda of GT and GG genotype respectively (P &lt; 0.05). CONCLUSION: Our research indicated that delta was involved in the development of E. carinicauda and provided new insights for molecular breeding with SNP markers in E. carinicauda.</text><annotation id="7"><infon key="type">Disease</infon><location offset="414" length="23"/><text>Exopalaemon carinicauda</text></annotation><annotation id="8"><infon key="identifier">MESH:D016751</infon><infon key="type">Disease</infon><location offset="578" length="14"/><text>E. carinicauda</text></annotation><annotation id="9"><infon key="identifier">tmVar:c|SUB|T|1521|G;HGVS:c.1521T>G;VariantGroup:0</infon><infon key="type">DNAMutation</infon><location offset="1401" length="6"/><text>T1521G</text></annotation><annotation id="10"><infon key="identifier">tmVar:p|SUB|N|422|K;HGVS:p.N422K;VariantGroup:2</infon><infon key="type">ProteinMutation</infon><location offset="1426" length="9"/><text>Asn422Lys</text></annotation><annotation id="11"><infon key="identifier">tmVar:c|SUB|G|1674|A;HGVS:c.1674G>A;VariantGroup:1</infon><infon key="type">DNAMutation</infon><location offset="1444" length="6"/><text>G1674A</text></annotation><annotation id="12"><infon key="identifier">tmVar:p|SUB|Y|473|C;HGVS:p.Y473C;VariantGroup:3</infon><infon key="type">ProteinMutation</infon><location offset="1469" length="9"/><text>Tyr473Cys</text></annotation><annotation id="13"><infon key="identifier">MESH:D016751</infon><infon key="type">Disease</infon><location offset="1543" length="14"/><text>E. carinicauda</text></annotation></passage><relation id="R1"><infon key="score">0.9994</infon><infon key="role1">DNAMutation|HGVS:c.1674G>A</infon><infon key="role2">Disease|MESH:D016751</infon><infon key="type">Association</infon><node refid="0" role="6,4"/></relation><relation id="R2"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D016751</infon><infon key="role2">ProteinMutation|HGVS:p.Y473C</infon><infon key="type">Association</infon><node refid="1" role="6,5"/></relation><relation id="R3"><infon key="score">0.9992</infon><infon key="role1">DNAMutation|HGVS:c.1521T>G</infon><infon key="role2">Disease|MESH:D016751</infon><infon key="type">Association</infon><node refid="2" role="6,2"/></relation><relation id="R4"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D016751</infon><infon key="role2">ProteinMutation|HGVS:p.N422K</infon><infon key="type">Association</infon><node refid="3" role="6,3"/></relation></document>
<document><id>37910736</id><passage><infon key="journal">Opt Lett;2023Nov01; 48 (21) 5695. doi:10.1364/OL.504531</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zou K, Pang K, Song H, Karpov M, Su X, Zhang R, Song H, Zhou H, Kippenberg TJ, Tur M, Willner AE, </infon><offset>0</offset><text>Space-time wave packets with reduced divergence and tunable group velocity generated in free space after multi-mode fiber propagation.</text></passage><passage><infon key="type">abstract</infon><offset>135</offset><text>Previously, space-time wave packets (STWPs) have been generated in free space with reduced diffraction and a tunable group velocity by combining multiple frequency comb lines each carrying a single Bessel mode with a unique wave number. It might be potentially desirable to propagate the STWP through fiber for reconfigurable positioning. However, fiber mode coupling might degrade the output STWP and distort its propagation characteristics. In this Letter, we experimentally demonstrate STWP generation and propagation over 1-m graded-index multi-mode fiber. Fiber mode coupling is mitigated by pre-distortion according to the inverse matrix of the fiber mode coupling matrix. Measurement of the STWP at the fiber output shows that its group velocity can vary from 1.0042c to 0.9967c by tuning the wave number of the Bessel mode on each frequency. The measured time-averaged intensity profiles show that the beam radius remains similar after 150-mm free-space propagation after exiting the fiber.</text><annotation id="4"><infon key="type">Disease</infon><location offset="423" length="4"/><text>STWP</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="528" length="4"/><text>STWP</text></annotation><annotation id="6"><infon key="type">Disease</infon><location offset="624" length="4"/><text>STWP</text></annotation><annotation id="7"><infon key="type">Disease</infon><location offset="833" length="4"/><text>STWP</text></annotation></passage></document>
<document><id>37911087</id><passage><infon key="journal">Int Dent J (Phila);1893Jul; 14 (7) 501</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109644</infon><infon key="type">title</infon><offset>0</offset><text>New York Odontological Society.</text></passage><passage><infon key="type">abstract</infon><offset>32</offset></passage></document>
<document><id>37911437</id><passage><infon key="journal">Int Dent J (Phila);1890Jul; 11 (7) 436</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110142</infon><infon key="type">title</infon><infon key="authors">Sudduth WX, </infon><offset>0</offset><text>Au Revoir.</text></passage><passage><infon key="type">abstract</infon><offset>11</offset></passage></document>
<document><id>37912137</id><passage><infon key="journal">Int Dent J (Phila);1896Nov; 17 (11) 749</infon><infon key="year">1896</infon><infon key="article-id_pmc">PMC10124533</infon><infon key="type">title</infon><offset>0</offset><text>Examining Boards and Their Selection.</text></passage><passage><infon key="type">abstract</infon><offset>38</offset></passage></document>
<document><id>37912837</id><passage><infon key="journal">Int Dent J (Phila);1901Dec; 22 (12) 896</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153894</infon><infon key="type">title</infon><offset>0</offset><text>The American Dental Society of Europe.</text></passage><passage><infon key="type">abstract</infon><offset>39</offset></passage></document>
<document><id>37913187</id><passage><infon key="journal">Int Dent J (Phila);1903Nov; 24 (11) 825</infon><infon key="year">1903</infon><infon key="article-id_pmc">PMC10162278</infon><infon key="type">title</infon><infon key="authors">Patten CC, </infon><offset>0</offset><text>The Porcelain Art in Dentistry.</text></passage><passage><infon key="type">abstract</infon><offset>32</offset></passage></document>
<document><id>37913538</id><passage><infon key="journal">Neurosurg Focus;2023Nov; 55 (5) 12. doi:10.3171/2023.8.FOCUS23454</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10624113</infon><infon key="type">title</infon><infon key="authors">Ramapriyan R, Ramesh T, Yu H, Richardson LG, Nahed BV, Carter BS, Barker FG, Curry WT, Choi BD, </infon><offset>0</offset><text>County-level disparities in care for patients with glioblastoma.</text><annotation id="1"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="51" length="12"/><text>glioblastoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>65</offset><text>OBJECTIVE: Racial and socioeconomic disparities in neuro-oncological care for patients with brain tumors remain underexplored. This study aimed to analyze county-level disparities in glioblastoma (GBM) care in the United States, focusing on access to surgery and the use of adjuvant temozolomide chemotherapy and radiation therapy. METHODS: Using repeated cross-sectional data from the Surveillance, Epidemiology, and End Results 17 database; the Area Health Resources File; and the American Community Survey, from 2010 to 2019, the authors performed multivariate regression analyses to understand the associations between county-level racial and socioeconomic characteristics, as well as the rates of surgery performed, delays in surgery, and use of adjuvant chemotherapy and radiation therapy for newly diagnosed GBM. RESULTS: In total, 29,609 GBM patients from 602 different US counties over a decade were included in this study. Counties with lower rates of surgery for GBM were associated with a higher percentage of Black residents (coefficient [CE] -0.001, 95% CI -0.002 to 0; p &lt; 0.05) and being located in the Midwest (CE -0.132, 95% CI -0.195 to -0.069; p &lt; 0.001) or West (CE -0.127, 95% CI -0.189 to -0.065; p &lt; 0.001) relative to the Northeast. Counties with delayed surgical treatment were more likely to lack neurosurgeons (adjusted OR [aOR] 2.52, 95% CI 1.77-3.60; p &lt; 0.001), have a higher percentage of Black residents (aOR 1.011, 95% CI 1.00-1.02; p &lt; 0.05), and be located in the Midwest (aOR 3.042, 95% CI 1.12-8.24; p &lt; 0.05) or West (aOR 3.175, 95% CI 1.12-8.97 p &lt; 0.05). Counties with high rates of adjuvant radiation therapy were less likely to have higher percentages of Black residents (aOR 0.987, 95% CI 0.980-0.995; p &lt; 0.01) and uninsured individuals (aOR 0.962, 95% CI 0.937-0.987; p &lt; 0.01). CONCLUSIONS: Counties without neurosurgeons and those with a higher percentage of Black patients have delays in surgical care and demonstrate lower overall rates of surgery and adjuvant therapy for GBM. This study underscores the need for targeted interventions and policies that address structural barriers in healthcare access, improve equitable distribution of the neurosurgery workforce, and ensure timely and comprehensive GBM care to all populations.</text><annotation id="11"><infon key="identifier">MESH:D001932</infon><infon key="type">Disease</infon><location offset="157" length="12"/><text>brain tumors</text></annotation><annotation id="12"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="248" length="12"/><text>glioblastoma</text></annotation><annotation id="13"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="262" length="3"/><text>GBM</text></annotation><annotation id="14"><infon key="identifier">MESH:D000077204</infon><infon key="type">Chemical</infon><location offset="348" length="12"/><text>temozolomide</text></annotation><annotation id="15"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="880" length="3"/><text>GBM</text></annotation><annotation id="16"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="911" length="3"/><text>GBM</text></annotation><annotation id="17"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="1039" length="3"/><text>GBM</text></annotation><annotation id="18"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="2088" length="3"/><text>GBM</text></annotation><annotation id="19"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="2318" length="3"/><text>GBM</text></annotation></passage><relation id="R1"><infon key="score">0.9968</infon><infon key="role1">Chemical|MESH:D000077204</infon><infon key="role2">Disease|MESH:D005909</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="4,2"/></relation></document>
<document><id>37913888</id><passage><infon key="journal">Bone;2023Oct30 116951. doi:10.1016/j.bone.2023.116951</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Savikangas T, Suominen TH, Al&amp;#xe9;n M, Rantalainen T, Sipil&amp;#xe4; S, </infon><offset>0</offset><text>Changes in femoral neck bone mineral density and structural strength during a 12-month multicomponent exercise intervention among older adults - Does accelerometer-measured physical activity matter?</text></passage><passage><infon key="type">abstract</infon><offset>199</offset><text>Age-related bone loss is to some extent unavoidable, but it may be decelerated with regular exercise continued into older age. Daily physical activity alongside structured exercise may be an important stimulus for maintaining bone strength, but the relationships of habitual physical activity with bone strength are sparsely investigated in older adults. Therefore, the main aim was to investigate if accelerometer-derived impact-based and intensity-minute-based measures of physical activity were associated with changes in femoral neck bone traits during a 12-month exercise intervention among community-dwelling older men and women. Data comes from the PASSWORD study (ISRCTN52388040), a year-long multicomponent exercise intervention. Participants were 299 older adults (mean age 74 +- 4 years, 58 % women), who self-reported not to meet the physical activity guidelines for older adults but did not have any contraindications for exercising. The multicomponent training program included both supervised and self-administered exercises aimed at improving muscle strength, postural balance, and aerobic endurance. Physical activity was assessed at baseline and at six months into the intervention, and femoral neck bone properties at baseline and at twelve months. Physical activity measures were accelerometer-measured mean daily osteogenic index score, low, medium, and high intensity impact counts, and sedentary, light, and moderate-to-vigorous intensity activity minutes. Femoral neck bone mineral density (BMD) was measured with DXA and structural strength indicators (cross-sectional area [CSA] and section modulus) were subsequently derived from hip structural analysis. Longitudinal associations of physical activity and bone outcomes were analyzed with generalized estimating equation linear models. Sex was included as a moderating factor, and models were further adjusted by potentially confounding factors (age, height, weight, smoking status, medications, chronic disease conditions, and strength training adherence). Participants increased their physical activity by all measures and decreased their sedentary time from baseline to six months. BMD decreased from baseline to post-intervention, while CSA maintained stable and section modulus slightly increased. Osteogenic index, high impacts, and moderate-to-vigorous intensity physical activity, measured across the first half of the study, were positively associated with changes in BMD over 12 months (time kh physical activity interaction effect: ss = 0.065, 95 % CI [0.004, 0.126]; ss = 0.169, 95 % CI [0.048, 0.289]; and ss = 0.151, 95 % CI [0.016, 0.286], respectively). That is, the higher the physical activity was, the smaller was the decline in BMD. Any physical activity measure was not associated with changes in CSA or section modulus in the full study sample. Sex did not significantly moderate the longitudinal associations, except the association between sedentary time and CSA (sex kh time kh PA interaction effect: ss = -0.017, 95 % CI [-0.033, -0.002]). An inverse association was found between sedentary time and changes in CSA in women, but not in men. In conclusion, BMD decline was less pronounced in individuals who accumulated more accelerometer-measured daily physical activity at the intensity of very brisk walking or light lateral jumping or higher intensities in a sample of relatively healthy, previously physically inactive older adults. Our findings support that accumulating the recommended amount of 150 or more weekly minutes of moderate-to-vigorous physical activity is also beneficial for older adults' bone health when incorporated into a multicomponent exercise program.</text><annotation id="7"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="211" length="9"/><text>bone loss</text></annotation><annotation id="8"><infon key="identifier">1161</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">62</infon><location offset="1799" length="3"/><text>CSA</text></annotation><annotation id="9"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="2172" length="15"/><text>chronic disease</text></annotation><annotation id="10"><infon key="identifier">1161</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">62</infon><location offset="2417" length="3"/><text>CSA</text></annotation><annotation id="11"><infon key="identifier">1161</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">62</infon><location offset="2994" length="3"/><text>CSA</text></annotation><annotation id="12"><infon key="identifier">1161</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">62</infon><location offset="3313" length="3"/><text>CSA</text></annotation><annotation id="13"><infon key="identifier">MESH:D001851</infon><infon key="type">Disease</infon><location offset="3358" length="11"/><text>BMD decline</text></annotation></passage></document>
<document><id>37914238</id><passage><infon key="journal">Rinsho Ketsueki;2023; 64 (10) 1266. doi:10.11406/rinketsu.64.1266</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sato K, Sumi M, Kobayashi M, Kataoka K, Takahashi N, Kobayashi H, </infon><offset>0</offset><text>[Sustaining molecular response with very low dose ponatinib and further response after hemodialysis initiation in a patient with chronic myeloid leukemia].</text><annotation id="2"><infon key="identifier">MESH:C545373</infon><infon key="type">Chemical</infon><location offset="50" length="9"/><text>ponatinib</text></annotation><annotation id="3"><infon key="identifier">MESH:D015464</infon><infon key="type">Disease</infon><location offset="129" length="24"/><text>chronic myeloid leukemia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>156</offset><text>A 46-year-old man was diagnosed with chronic myeloid leukemia (CML) in chronic phase. He was treated with imatinib, nilotinib, and dasatinib, but failed to achieve a complete cytogenetic response (CCyR). After tyrosine kinase inhibitor therapy, F317L BCR-ABL1 kinase domain mutation was detected. At age 66, the patient started ponatinib (PON) at 45 mg/day, and achieved CCyR within three months. Subsequently, PON was tapered to 15 mg once weekly due to arterial-occlusive events. PON was discontinued after a 3-year deep molecular response (>= MR4.5). However, the patient lost MR4.0 within two months, and PON (15 mg once weekly) was restarted. He achieved MR4.0 again within one month, and then a deeper molecular response (MR5.0) after starting dialysis therapy at the same PON dose. The trough value of PON (15 mg once weekly) was 5.8 ng/ml, which suppressed F317L mutation in the CML clone. Currently, the patient is 77 years old and is sustaining MR5.0. Chronic renal failure may cause hyperabsorption and metabolic retardation in patients receiving PON. Initiation of hemodialysis may improve homeostasis resulting in enhanced anti-tumor immunity against CML.</text><annotation id="28"><infon key="identifier">MESH:D015464</infon><infon key="type">Disease</infon><location offset="193" length="24"/><text>chronic myeloid leukemia</text></annotation><annotation id="29"><infon key="identifier">MESH:D015464</infon><infon key="type">Disease</infon><location offset="219" length="3"/><text>CML</text></annotation><annotation id="30"><infon key="identifier">MESH:D000068877</infon><infon key="type">Chemical</infon><location offset="262" length="8"/><text>imatinib</text></annotation><annotation id="31"><infon key="identifier">MESH:C498826</infon><infon key="type">Chemical</infon><location offset="272" length="9"/><text>nilotinib</text></annotation><annotation id="32"><infon key="identifier">MESH:D000069439</infon><infon key="type">Chemical</infon><location offset="287" length="9"/><text>dasatinib</text></annotation><annotation id="33"><infon key="identifier">7294</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2497</infon><location offset="366" length="15"/><text>tyrosine kinase</text></annotation><annotation id="34"><infon key="identifier">tmVar:p|SUB|F|317|L;HGVS:p.F317L;VariantGroup:1;CorrespondingGene:25;RS#:121913451;CorrespondingSpecies:9606;CA#:16602555</infon><infon key="type">ProteinMutation</infon><location offset="401" length="5"/><text>F317L</text></annotation><annotation id="35"><infon key="identifier">613;25</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3192;3783</infon><location offset="407" length="8"/><text>BCR-ABL1</text></annotation><annotation id="36"><infon key="identifier">MESH:C545373</infon><infon key="type">Chemical</infon><location offset="484" length="9"/><text>ponatinib</text></annotation><annotation id="37"><infon key="identifier">MESH:C545373</infon><infon key="type">Chemical</infon><location offset="495" length="3"/><text>PON</text></annotation><annotation id="38"><infon key="identifier">MESH:C545373</infon><infon key="type">Chemical</infon><location offset="567" length="3"/><text>PON</text></annotation><annotation id="39"><infon key="identifier">MESH:D001157</infon><infon key="type">Disease</infon><location offset="611" length="18"/><text>arterial-occlusive</text></annotation><annotation id="40"><infon key="identifier">MESH:C545373</infon><infon key="type">Chemical</infon><location offset="638" length="3"/><text>PON</text></annotation><annotation id="41"><infon key="identifier">MESH:C545373</infon><infon key="type">Chemical</infon><location offset="765" length="3"/><text>PON</text></annotation><annotation id="42"><infon key="identifier">MESH:C545373</infon><infon key="type">Chemical</infon><location offset="935" length="3"/><text>PON</text></annotation><annotation id="43"><infon key="identifier">MESH:C545373</infon><infon key="type">Chemical</infon><location offset="965" length="3"/><text>PON</text></annotation><annotation id="44"><infon key="identifier">tmVar:p|SUB|F|317|L;HGVS:p.F317L;VariantGroup:1;CorrespondingGene:25;RS#:121913451;CorrespondingSpecies:9606;CA#:16602555</infon><infon key="type">ProteinMutation</infon><location offset="1021" length="5"/><text>F317L</text></annotation><annotation id="45"><infon key="identifier">MESH:D015464</infon><infon key="type">Disease</infon><location offset="1043" length="3"/><text>CML</text></annotation><annotation id="46"><infon key="identifier">MESH:D007676</infon><infon key="type">Disease</infon><location offset="1118" length="21"/><text>Chronic renal failure</text></annotation><annotation id="47"><infon key="type">Disease</infon><location offset="1150" length="15"/><text>hyperabsorption</text></annotation><annotation id="48"><infon key="identifier">MESH:D024821</infon><infon key="type">Disease</infon><location offset="1170" length="21"/><text>metabolic retardation</text></annotation><annotation id="49"><infon key="identifier">MESH:C545373</infon><infon key="type">Chemical</infon><location offset="1214" length="3"/><text>PON</text></annotation><annotation id="50"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1297" length="5"/><text>tumor</text></annotation><annotation id="51"><infon key="identifier">MESH:D015464</infon><infon key="type">Disease</infon><location offset="1320" length="3"/><text>CML</text></annotation></passage><relation id="R1"><infon key="score">0.9573</infon><infon key="role1">Disease|MESH:D015464</infon><infon key="role2">ProteinMutation|RS#:121913451;HGVS:p.F317L;CorrespondingGene:25</infon><infon key="type">Association</infon><node refid="0" role="19,18"/></relation><relation id="R2"><infon key="score">0.9662</infon><infon key="role1">Chemical|MESH:C498826</infon><infon key="role2">Disease|MESH:D015464</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="5,2"/></relation><relation id="R3"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:C545373</infon><infon key="role2">ProteinMutation|RS#:121913451;HGVS:p.F317L;CorrespondingGene:25</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="17,18"/></relation><relation id="R4"><infon key="score">0.8795</infon><infon key="role1">Chemical|MESH:C545373</infon><infon key="role2">Disease|MESH:D007676</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="23,20"/></relation><relation id="R5"><infon key="score">0.6439</infon><infon key="role1">Chemical|MESH:D000069439</infon><infon key="role2">Disease|MESH:D015464</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="6,2"/></relation><relation id="R6"><infon key="score">0.9845</infon><infon key="role1">Chemical|MESH:D000068877</infon><infon key="role2">Disease|MESH:D015464</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="4,2"/></relation><relation id="R7"><infon key="score">0.9874</infon><infon key="role1">Chemical|MESH:C545373</infon><infon key="role2">Disease|MESH:D001157</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="12,13"/></relation><relation id="R8"><infon key="score">0.9619</infon><infon key="role1">Chemical|MESH:C545373</infon><infon key="role2">Disease|MESH:D024821</infon><infon key="type">Positive_Correlation</infon><node refid="7" role="23,22"/></relation><relation id="R9"><infon key="score">0.9982</infon><infon key="role1">Chemical|MESH:C545373</infon><infon key="role2">Disease|MESH:D015464</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="0,1"/></relation><relation id="R10"><infon key="score">0.9573</infon><infon key="role1">Disease|MESH:D015464</infon><infon key="role2">Gene|25</infon><infon key="type">Association</infon></relation></document>
<document><id>37914588</id><passage><infon key="journal">Brachytherapy;2023Oct30. doi:10.1016/j.brachy.2023.09.008</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yoder AK, Lakomy DS, Wu J, Andring LM, Corrigan KL, Fellman B, Jhingran A, Klopp AH, Colbert LE, Soliman PT, Frumovitz MM, Peterson SK, Lin LL, </infon><offset>0</offset><text>Comparing long-term sexual dysfunction across different uterine cancer treatment modalities.</text><annotation id="2"><infon key="identifier">MESH:D012735</infon><infon key="type">Disease</infon><location offset="20" length="18"/><text>sexual dysfunction</text></annotation><annotation id="3"><infon key="identifier">MESH:D014594</infon><infon key="type">Disease</infon><location offset="56" length="14"/><text>uterine cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>INTRODUCTION: The objective of this study was to assess differences in long-term sexual and menopausal side effects after uterine cancer treatment among treatment modalities. METHODS AND MATERIALS: This is a cross-sectional study that examined women treated for uterine cancer from 2006-2018. Eligible women included those who underwent a hysterectomy/bilateral salpino-oophorectemy alone (HS), with brachytherapy (BT), or with external beam radiation therapy (EBRT). A noncancer cohort of women who underwent a hysterectomy/BSO for benign indications were also identified (non-CA). To compare outcomes, we utilized a shortened form of the female sexual function index (FSFI) and the menopause survey, which consists of 3 subscales: hot flashes, vaginal symptoms, and urinary symptoms. Demographic, comorbidity, and other treatment variables were collected. Survey totals were compared across cohorts using ANOVA tests and logistic regression. RESULTS: A total of 284 women completed the Menopause Survey (Non-CA 64, HS 60, BT 69, EBRT 91); 116 women reported sexual activity in the last 4 weeks and completed the FSFI (NC 32, HS 21, BT 31, EBRT 32). The mean FSFI score for the entire cohort was 11.4 (SD 4.16), which indicates poor sexual function. There was no significant difference between any cohort in the overall FSFI score (p = 0.708) or in any of the FSFI subscales (all p > 0.05). On univariate analysis, BT was associated with fewer menopausal hot flashes and vaginal symptoms compared to the non-CA cohort (p &lt; 0.05), which did not persist on multivariable analysis. CONCLUSION: There was no significant difference in sexual dysfunction or menopausal symptoms in those treated for uterine cancer with or without adjuvant radiation. Most patients reported poor sexual function.</text><annotation id="19"><infon key="identifier">MESH:D014594</infon><infon key="type">Disease</infon><location offset="215" length="14"/><text>uterine cancer</text></annotation><annotation id="20"><infon key="identifier">MESH:D014594</infon><infon key="type">Disease</infon><location offset="355" length="14"/><text>uterine cancer</text></annotation><annotation id="21"><infon key="type">Disease</infon><location offset="671" length="2"/><text>CA</text></annotation><annotation id="22"><infon key="identifier">MESH:D008594</infon><infon key="type">Disease</infon><location offset="777" length="9"/><text>menopause</text></annotation><annotation id="23"><infon key="identifier">MESH:D019584</infon><infon key="type">Disease</infon><location offset="826" length="11"/><text>hot flashes</text></annotation><annotation id="24"><infon key="identifier">MESH:D014627</infon><infon key="type">Disease</infon><location offset="839" length="16"/><text>vaginal symptoms</text></annotation><annotation id="25"><infon key="identifier">MESH:D059411</infon><infon key="type">Disease</infon><location offset="861" length="16"/><text>urinary symptoms</text></annotation><annotation id="26"><infon key="identifier">MESH:D008594</infon><infon key="type">Disease</infon><location offset="1081" length="9"/><text>Menopause</text></annotation><annotation id="27"><infon key="type">Disease</infon><location offset="1103" length="2"/><text>CA</text></annotation><annotation id="28"><infon key="identifier">MESH:D019584</infon><infon key="type">Disease</infon><location offset="1549" length="11"/><text>hot flashes</text></annotation><annotation id="29"><infon key="identifier">MESH:D014627</infon><infon key="type">Disease</infon><location offset="1565" length="16"/><text>vaginal symptoms</text></annotation><annotation id="30"><infon key="type">Disease</infon><location offset="1602" length="2"/><text>CA</text></annotation><annotation id="31"><infon key="identifier">MESH:D012735</infon><infon key="type">Disease</infon><location offset="1724" length="18"/><text>sexual dysfunction</text></annotation><annotation id="32"><infon key="identifier">MESH:D008594</infon><infon key="type">Disease</infon><location offset="1746" length="19"/><text>menopausal symptoms</text></annotation><annotation id="33"><infon key="identifier">MESH:D014594</infon><infon key="type">Disease</infon><location offset="1787" length="14"/><text>uterine cancer</text></annotation></passage></document>
<document><id>37914938</id><passage><infon key="journal">Nature;2023Nov01. doi:10.1038/s41586-023-06683-4</infon><infon key="year">2023</infon><infon key="article-id_pmc">6889226</infon><infon key="type">title</infon><infon key="authors">Randi F, Sharma AK, Dvali S, Leifer AM, </infon><offset>0</offset><text>Neural signal propagation atlas of Caenorhabditis elegans.</text></passage><passage><infon key="type">abstract</infon><offset>59</offset><text>Establishing how neural function emerges from network properties is a fundamental problem in neuroscience1. Here, to better understand the relationship between the structure and the function of a nervous system, we systematically measure signal propagation in 23,433 pairs of neurons across the head of the nematode Caenorhabditis elegans by direct optogenetic activation and simultaneous whole-brain calcium imaging. We measure the sign (excitatory or inhibitory), strength, temporal properties and causal direction of signal propagation between these neurons to create a functional atlas. We find that signal propagation differs from model predictions that are based on anatomy. Using mutants, we show that extrasynaptic signalling not visible from anatomy contributes to this difference. We identify many instances of dense-core-vesicle-dependent signalling, including on timescales of less than a second, that evoke acute calcium transients-often where no direct wired connection exists but where relevant neuropeptides and receptors are expressed. We propose that, in such cases, extrasynaptically released neuropeptides serve a similar function to that of classical neurotransmitters. Finally, our measured signal propagation atlas better predicts the neural dynamics of spontaneous activity than do models based on anatomy. We conclude that both synaptic and extrasynaptic signalling drive neural dynamics on short timescales, and that measurements of evoked signal propagation are crucial for interpreting neural function.</text><annotation id="2"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="460" length="7"/><text>calcium</text></annotation><annotation id="3"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="985" length="7"/><text>calcium</text></annotation></passage></document>
<document><id>37915290</id><passage><infon key="type">title</infon><offset>0</offset><text>Fracture of the Second Rib: An Indirect Sign of Serious Trauma Like Fracture of the First Rib?</text><annotation id="3"><infon key="identifier">MESH:D012253</infon><infon key="type">Disease</infon><location offset="0" length="26"/><text>Fracture of the Second Rib</text></annotation><annotation id="4"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="56" length="6"/><text>Trauma</text></annotation><annotation id="5"><infon key="identifier">MESH:D012253</infon><infon key="type">Disease</infon><location offset="68" length="25"/><text>Fracture of the First Rib</text></annotation></passage><passage><infon key="type">abstract</infon><offset>95</offset><text>Background: The first 3 ribs are anatomically well-protected, shielded by the large thoracic muscles, the shoulder girdle, and the arm. A significant force is required to fracture these ribs; thus, such fractures suggest a high-energy trauma and are associated with injuries to vital organs of the thorax, such as the aorta, the heart, the lungs and the great vessels. Methods: A retrospective analysis was conducted over a 10-year period at a single hospital. The study assessed patients with fractures of the second rib, including their concurrent injuries and the overall severity of their trauma. Results: Among the 76 patients included in the study, the average age was 47.35 years, 81.5% were men, and 19.5% were women. Thirteen patients (17.1%) survived their injuries. The most common causes of injury were road traffic accidents (63%) and pedestrian injuries (22%). The patients who did not survive sustained injuries to an average of 5 additional organs, while survivors had injuries to an average of 2.07 additional organs. Left rib fractures were the most frequently observed (46%). The most serious concurrent injuries reported were to the aorta (5.26%), heart (10.52%), lung (52.36%), head (57.89%), liver (30.2%), spleen (26.31%), and kidney (17.1%). Conclusion: As indicators of serious injury to vital endothoracic organs, isolated fractures of the second rib should be considered equal to first rib fractures in clinical importance.</text><annotation id="21"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="298" length="9"/><text>fractures</text></annotation><annotation id="22"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="330" length="6"/><text>trauma</text></annotation><annotation id="23"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="361" length="8"/><text>injuries</text></annotation><annotation id="24"><infon key="identifier">MESH:D012253</infon><infon key="type">Disease</infon><location offset="589" length="27"/><text>fractures of the second rib</text></annotation><annotation id="25"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="645" length="8"/><text>injuries</text></annotation><annotation id="26"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="688" length="6"/><text>trauma</text></annotation><annotation id="27"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="862" length="8"/><text>injuries</text></annotation><annotation id="28"><infon key="identifier">MESH:D000081084</infon><infon key="type">Disease</infon><location offset="910" length="22"/><text>road traffic accidents</text></annotation><annotation id="29"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="943" length="19"/><text>pedestrian injuries</text></annotation><annotation id="30"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1013" length="8"/><text>injuries</text></annotation><annotation id="31"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1080" length="8"/><text>injuries</text></annotation><annotation id="32"><infon key="identifier">MESH:D012253</infon><infon key="type">Disease</infon><location offset="1135" length="13"/><text>rib fractures</text></annotation><annotation id="33"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1218" length="8"/><text>injuries</text></annotation><annotation id="34"><infon key="identifier">MESH:D012253</infon><infon key="type">Disease</infon><location offset="1444" length="27"/><text>fractures of the second rib</text></annotation><annotation id="35"><infon key="identifier">MESH:D012253</infon><infon key="type">Disease</infon><location offset="1508" length="13"/><text>rib fractures</text></annotation></passage></document>
<document><id>37916340</id><passage><infon key="type">title</infon><offset>0</offset><text>Sarcopenia and its clinical correlation in elderly chronic obstructive pulmonary disease: a prospective cohort study.</text><annotation id="2"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="0" length="10"/><text>Sarcopenia</text></annotation><annotation id="3"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="51" length="37"/><text>chronic obstructive pulmonary disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>118</offset><text>OBJECTIVE: The aim of this study was to examine the effects of sarcopenia on clinical characteristics and short-term outcomes in elderly chronic obstructive pulmonary disease (COPD) patients. PATIENTS AND METHODS: One hundred twenty elderly COPD patients (age>60) recruited from Beijing Shijingshan Hospital were divided into sarcopenia and non-sarcopenia groups according to the severity of sarcopenia at the first admission. Baseline data, geriatric syndrome, laboratory indicators and body composition analysis were analyzed. One year followed-up by outpatient visits was focused on clinical characteristics and telephone follow-ups for collecting all-cause deaths and acute exacerbations of chronic obstructive pulmonary disease as end-point events. The risk factors for sarcopenia were analyzed by univariate analysis and multivariate logical regression. The proportional hazards model (COX) regression was performed to determine the effect of sarcopenia on COPD patients' prognoses. RESULTS: One hundred twenty patients (76 men and 44 women) with an average age of 76.7+-8.78 years were included, of which 63 patients (52.5%) were diagnosed with sarcopenia. Compared to the non-sarcopenia group, the sarcopenia group exhibited worse lung function and more severe geriatric syndromes with significantly higher incidence ratios of somnipathy and frailty. The sarcopenia group also showed worse muscle indicators and declined body composition. Multivariate analysis showed that the occurrence of sarcopenia in elderly COPD patients was correlated with forced expiratory volume in the first second (FEV1) (OR=0.97, 95% CI: 0.94-1.0, p=0.035), body mass index (BMI) (OR=0.80, 95% CI: 0.71-0.89, p=0.035) and hemoglobin (OR=0.98, 95% CI: 0.96-1.0, p=0.023). Furthermore, the COX regression indicated the association of sarcopenia with acute exacerbations of COPD within the follow-up period (HR=2.4, 95% CI: 1.01-5.72, p=0.048). CONCLUSIONS: Sarcopenia increases the risk of acute exacerbations of chronic obstructive pulmonary disease in the elderly. Sarcopenia incidence in elderly COPD is associated with FEV1, BMI, and hemoglobin and closely monitoring indicators is useful for early diagnosis of sarcopenia.</text><annotation id="33"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="181" length="10"/><text>sarcopenia</text></annotation><annotation id="34"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="255" length="37"/><text>chronic obstructive pulmonary disease</text></annotation><annotation id="35"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="294" length="4"/><text>COPD</text></annotation><annotation id="36"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="359" length="4"/><text>COPD</text></annotation><annotation id="37"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="444" length="10"/><text>sarcopenia</text></annotation><annotation id="38"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="463" length="10"/><text>sarcopenia</text></annotation><annotation id="39"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="510" length="10"/><text>sarcopenia</text></annotation><annotation id="40"><infon key="identifier">MESH:D013577</infon><infon key="type">Disease</infon><location offset="560" length="18"/><text>geriatric syndrome</text></annotation><annotation id="41"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="779" length="6"/><text>deaths</text></annotation><annotation id="42"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="813" length="37"/><text>chronic obstructive pulmonary disease</text></annotation><annotation id="43"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="893" length="10"/><text>sarcopenia</text></annotation><annotation id="44"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="1067" length="10"/><text>sarcopenia</text></annotation><annotation id="45"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="1081" length="4"/><text>COPD</text></annotation><annotation id="46"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="1270" length="10"/><text>sarcopenia</text></annotation><annotation id="47"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="1302" length="10"/><text>sarcopenia</text></annotation><annotation id="48"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="1324" length="10"/><text>sarcopenia</text></annotation><annotation id="49"><infon key="identifier">MESH:D013577</infon><infon key="type">Disease</infon><location offset="1387" length="19"/><text>geriatric syndromes</text></annotation><annotation id="50"><infon key="type">Disease</infon><location offset="1453" length="10"/><text>somnipathy</text></annotation><annotation id="51"><infon key="identifier">MESH:D000073496</infon><infon key="type">Disease</infon><location offset="1468" length="7"/><text>frailty</text></annotation><annotation id="52"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="1481" length="10"/><text>sarcopenia</text></annotation><annotation id="53"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="1617" length="10"/><text>sarcopenia</text></annotation><annotation id="54"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="1639" length="4"/><text>COPD</text></annotation><annotation id="55"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="1937" length="10"/><text>sarcopenia</text></annotation><annotation id="56"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="1976" length="4"/><text>COPD</text></annotation><annotation id="57"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="2060" length="10"/><text>Sarcopenia</text></annotation><annotation id="58"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="2116" length="37"/><text>chronic obstructive pulmonary disease</text></annotation><annotation id="59"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="2170" length="10"/><text>Sarcopenia</text></annotation><annotation id="60"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="2202" length="4"/><text>COPD</text></annotation><annotation id="61"><infon key="identifier">MESH:D055948</infon><infon key="type">Disease</infon><location offset="2319" length="10"/><text>sarcopenia</text></annotation></passage></document>
<document><id>37917048</id><passage><infon key="type">title</infon><offset>0</offset><text>Validating and Improving Adjusted Clinical Group's Future Hospitalization and High-Cost Prediction Models for Dutch Primary Care.</text></passage><passage><infon key="type">abstract</infon><offset>130</offset><text>The rise in health care costs, caused by older and more complex patient populations, requires Population Health Management approaches including risk stratification. With risk stratification, patients are assigned individual risk scores based on medical records. These patient stratifications focus on future high costs and expensive care utilization such as hospitalization, for which different models exist. With this study, the research team validated the accuracy of risk prediction scores for future hospitalization and high health care costs, calculated by the Adjusted Clinical Group (ACG)'s risk stratification models, using Dutch primary health care data registries. In addition, they aimed to adjust the US-based predictive models for Dutch primary care. The statistical validity of the existing models was assessed. In addition, the underlying prediction models were trained on 95,262 patients' data from de Zoetermeer region and externally validated on data of 48,780 patients from Zeist, Nijkerk, and Urk. Information on age, sex, number of general practitioner visits, International Classification of Primary Care coded information on the diagnosis and Anatomical Therapeutic Chemical Classification coded information on the prescribed medications, were incorporated in the model. C-statistics were used to validate the discriminatory ability of the models. Calibrating ability was assessed by visual inspection of calibration plots. Adjustment of the hospitalization model based on Dutch data improved C-statistics from 0.69 to 0.75, whereas adjustment of the high-cost model improved C-statistics from 0.78 to 0.85, indicating good discrimination of the models. The models also showed good calibration. In conclusion, the local adjustments of the ACG prediction models show great potential for use in Dutch primary care.</text></passage></document>
<document><id>37917398</id><passage><infon key="type">title</infon><offset>0</offset><text>Novel Bioinspired Nerve Scaffold with High Synchrony between Biodegradation and Nerve Regeneration for Repair of Peripheral Nerve Injury.</text><annotation id="1"><infon key="identifier">MESH:D059348</infon><infon key="type">Disease</infon><location offset="113" length="23"/><text>Peripheral Nerve Injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>138</offset><text>The morphological structure reconstruction and functional recovery of long-distance peripheral nerve injury (PNI) are global medical challenges. Biodegradable nerve scaffolds that provide mechanical support for the growth and extension of neurites are a desired way to repair long-distance PNI. However, the synchrony of scaffold degradation and nerve regeneration is still challenging. Here, a novel bioinspired multichannel nerve guide conduit (MNGC) with topographical cues based on silk fibroin and epsilon-polylysine modification was constructed. This conduit (SF(A) + PLL MNGC) exhibited sufficient mechanical strength, excellent degradability, and favorable promotion of cell growth. Peripheral nerve repairing was evaluated by an in vivo 10 mm rat sciatic model. In vivo evidence demonstrated that SF(A) + PLL MNGC was completely biodegraded in the body within 4 weeks after providing sufficient physical support and guide for neurite extension, and a 10 mm sciatic nerve defect was effectively repaired without scar formation, indicating a high synchronous effect of scaffold biodegradation and nerve regeneration. More importantly, the regenerated nerve of the SF(A) + PLL MNGC group showed comparable morphological reconstruction and functional recovery to that of autologous nerve transplantation. This work proved that the designed SF(A) + PLL MNGC has potential for application in long-distance PNI repair in the clinic.</text><annotation id="8"><infon key="identifier">MESH:D059348</infon><infon key="type">Disease</infon><location offset="222" length="23"/><text>peripheral nerve injury</text></annotation><annotation id="9"><infon key="identifier">MESH:D059348</infon><infon key="type">Disease</infon><location offset="247" length="3"/><text>PNI</text></annotation><annotation id="10"><infon key="identifier">MESH:D059348</infon><infon key="type">Disease</infon><location offset="428" length="3"/><text>PNI</text></annotation><annotation id="11"><infon key="identifier">MESH:D011107</infon><infon key="type">Chemical</infon><location offset="641" length="18"/><text>epsilon-polylysine</text></annotation><annotation id="12"><infon key="identifier">MESH:D020426</infon><infon key="type">Disease</infon><location offset="1104" length="20"/><text>sciatic nerve defect</text></annotation><annotation id="13"><infon key="identifier">MESH:D059348</infon><infon key="type">Disease</infon><location offset="1547" length="3"/><text>PNI</text></annotation></passage></document>
<document><id>37917749</id><passage><infon key="type">title</infon><offset>0</offset><text>Autoregulatory control of mitochondrial glutathione homeostasis.</text><annotation id="1"><infon key="identifier">MESH:D005978</infon><infon key="type">Chemical</infon><location offset="40" length="11"/><text>glutathione</text></annotation></passage><passage><infon key="type">abstract</infon><offset>65</offset><text>Mitochondria must maintain adequate amounts of metabolites for protective and biosynthetic functions. However, how mitochondria sense the abundance of metabolites and regulate metabolic homeostasis is not well understood. We focused on glutathione (GSH), a critical redox metabolite in mitochondria and identified a feedback mechanism that controls its abundance through the mitochondrial GSH transporter, SLC25A39. Under physiological conditions, SLC25A39 is rapidly degraded by a mitochondrial protease, AFG3L2. Depletion of GSH dissociates AFG3L2 from SLC25A39, causing a compensatory increase in mitochondrial GSH uptake. Genetic and proteomic analysis identified a putative iron-sulfur cluster in the matrix-facing loop of SLC25A39 to be essential for this regulation, coupling mitochondrial iron homeostasis to GSH import. Altogether, our work revealed a paradigm for the autoregulatory control of metabolic homeostasis in organelles.</text><annotation id="15"><infon key="identifier">MESH:D005978</infon><infon key="type">Chemical</infon><location offset="301" length="11"/><text>glutathione</text></annotation><annotation id="16"><infon key="identifier">MESH:D005978</infon><infon key="type">Chemical</infon><location offset="314" length="3"/><text>GSH</text></annotation><annotation id="17"><infon key="identifier">51629</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">69200</infon><location offset="471" length="8"/><text>SLC25A39</text></annotation><annotation id="18"><infon key="identifier">51629</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">69200</infon><location offset="513" length="8"/><text>SLC25A39</text></annotation><annotation id="19"><infon key="identifier">10939</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4947</infon><location offset="571" length="6"/><text>AFG3L2</text></annotation><annotation id="20"><infon key="identifier">MESH:D005978</infon><infon key="type">Chemical</infon><location offset="592" length="3"/><text>GSH</text></annotation><annotation id="21"><infon key="identifier">10939</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4947</infon><location offset="608" length="6"/><text>AFG3L2</text></annotation><annotation id="22"><infon key="identifier">51629</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">69200</infon><location offset="620" length="8"/><text>SLC25A39</text></annotation><annotation id="23"><infon key="identifier">MESH:D005978</infon><infon key="type">Chemical</infon><location offset="679" length="3"/><text>GSH</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="744" length="11"/><text>iron-sulfur</text></annotation><annotation id="25"><infon key="identifier">51629</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">69200</infon><location offset="793" length="8"/><text>SLC25A39</text></annotation><annotation id="26"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="862" length="4"/><text>iron</text></annotation><annotation id="27"><infon key="identifier">MESH:D005978</infon><infon key="type">Chemical</infon><location offset="882" length="3"/><text>GSH</text></annotation></passage><relation id="R1"><infon key="score">0.922</infon><infon key="role1">Chemical|MESH:D005978</infon><infon key="role2">Gene|51629</infon><infon key="type">Association</infon><node refid="0" role="1,3"/></relation><relation id="R2"><infon key="score">0.9959</infon><infon key="role1">Chemical|MESH:D005978</infon><infon key="role2">Gene|10939</infon><infon key="type">Association</infon><node refid="1" role="6,7"/></relation><relation id="R3"><infon key="score">0.9956</infon><infon key="role1">Chemical|MESH:D005978</infon><infon key="role2">Chemical|MESH:D007501</infon><infon key="type">Association</infon><node refid="2" role="13,12"/></relation><relation id="R4"><infon key="score">0.9649</infon><infon key="role1">Gene|10939</infon><infon key="role2">Gene|51629</infon><infon key="type">Association</infon><node refid="3" role="5,4"/></relation></document>
<document><id>37918100</id><passage><infon key="type">title</infon><offset>0</offset><text>Photocatalytic degradation of chlorinated organic pollutants by ZnS@ZIF-8 composite through hydrogen peroxide generation by activating dioxygen under simulated sunlight irradiation.</text><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30" length="30"/><text>chlorinated organic pollutants</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="64" length="9"/><text>ZnS@ZIF-8</text></annotation><annotation id="6"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="92" length="17"/><text>hydrogen peroxide</text></annotation><annotation id="7"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="135" length="8"/><text>dioxygen</text></annotation></passage><passage><infon key="type">abstract</infon><offset>182</offset><text>Photocatalytic hydrogen peroxide (H2O2) production and its application in advanced oxidation processes (AOPs) are regarded as low-cost and environmentally friendly wastewater treatment processes. Herein, by modifying a small amount of sulphide on the zeolitic imidazolate framework-8 (ZIF-8), a ZnS@ZIF-8 composite and used for photocatalytic H2O2 production to degrade chlorinated organic pollutants under simulated sunlight (SSL). ZnS@ZIF-8 composite could enhance the separation of photo-induced charge carriers, promote electron transfer from zinc sulphide (ZnS) to ZIF-8, which exhibited good selectivity for the two-electron oxygen reduction reaction (2e--ORR) and two-electron water oxidation (2e--WOR) pathways. Based on oxygen (O2) activation, the developed ZnS@ZIF-8/O2/SSL system could achieve 6.43 mmol/L H2O2 production within 150 min, which was approximately 8.66 and 10.36 times higher than that of the ZnS/O2/SSL and ZIF-8/O2/SSL systems, respectively. In the ZnS@ZIF-8/O2/SSL system, the ORR, WOR and H2O2 photolysis led to the generation of hydroxyl radical ( OH), while the photochemical behavior of ZnS in ZnS@ZIF-8 composite resulted in the generation of active hydrogen (*H). Benefitting from the high concentration of H2O2 and the coexistence of redox species in the ZnS@ZIF-8/O2/SSL system, various chlorinated organic pollutants could be dechlorinated and mineralized. In addition, a possible mechanism for photocatalytic H2O2 production was also proposed. Importantly, the proposed process did not involve an additional sacrificial agent or Fenton-like catalysts. This work provides insights into the potential application of ZnS@ZIF-8 composite for H2O2 production and wastewater treatment.</text><annotation id="45"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="197" length="17"/><text>hydrogen peroxide</text></annotation><annotation id="46"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="216" length="4"/><text>H2O2</text></annotation><annotation id="47"><infon key="identifier">MESH:D013440</infon><infon key="type">Chemical</infon><location offset="417" length="8"/><text>sulphide</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="433" length="32"/><text>zeolitic imidazolate framework-8</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="467" length="5"/><text>ZIF-8</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="477" length="9"/><text>ZnS@ZIF-8</text></annotation><annotation id="51"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="525" length="4"/><text>H2O2</text></annotation><annotation id="52"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="552" length="30"/><text>chlorinated organic pollutants</text></annotation><annotation id="53"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="615" length="9"/><text>ZnS@ZIF-8</text></annotation><annotation id="54"><infon key="identifier">MESH:C031238</infon><infon key="type">Chemical</infon><location offset="729" length="13"/><text>zinc sulphide</text></annotation><annotation id="55"><infon key="identifier">MESH:C031238</infon><infon key="type">Chemical</infon><location offset="744" length="3"/><text>ZnS</text></annotation><annotation id="56"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="752" length="5"/><text>ZIF-8</text></annotation><annotation id="57"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="813" length="6"/><text>oxygen</text></annotation><annotation id="58"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="866" length="5"/><text>water</text></annotation><annotation id="59"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="911" length="6"/><text>oxygen</text></annotation><annotation id="60"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="919" length="2"/><text>O2</text></annotation><annotation id="61"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="949" length="9"/><text>ZnS@ZIF-8</text></annotation><annotation id="62"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="959" length="2"/><text>O2</text></annotation><annotation id="63"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="999" length="4"/><text>H2O2</text></annotation><annotation id="64"><infon key="identifier">MESH:C031238</infon><infon key="type">Chemical</infon><location offset="1100" length="3"/><text>ZnS</text></annotation><annotation id="65"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1104" length="2"/><text>O2</text></annotation><annotation id="66"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1115" length="5"/><text>ZIF-8</text></annotation><annotation id="67"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1121" length="2"/><text>O2</text></annotation><annotation id="68"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1158" length="9"/><text>ZnS@ZIF-8</text></annotation><annotation id="69"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1168" length="2"/><text>O2</text></annotation><annotation id="70"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="1200" length="4"/><text>H2O2</text></annotation><annotation id="71"><infon key="identifier">MESH:D017665</infon><infon key="type">Chemical</infon><location offset="1241" length="16"/><text>hydroxyl radical</text></annotation><annotation id="72"><infon key="identifier">MESH:C031238</infon><infon key="type">Chemical</infon><location offset="1301" length="3"/><text>ZnS</text></annotation><annotation id="73"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1308" length="9"/><text>ZnS@ZIF-8</text></annotation><annotation id="74"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="1365" length="8"/><text>hydrogen</text></annotation><annotation id="75"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="1423" length="4"/><text>H2O2</text></annotation><annotation id="76"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1472" length="9"/><text>ZnS@ZIF-8</text></annotation><annotation id="77"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1482" length="2"/><text>O2</text></annotation><annotation id="78"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1505" length="30"/><text>chlorinated organic pollutants</text></annotation><annotation id="79"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="1629" length="4"/><text>H2O2</text></annotation><annotation id="80"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1834" length="9"/><text>ZnS@ZIF-8</text></annotation><annotation id="81"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="1858" length="4"/><text>H2O2</text></annotation></passage><relation id="R1"><infon key="score">0.748</infon><infon key="role1">Chemical|MESH:C031238</infon><infon key="role2">Chemical|MESH:D006859</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="32,34"/></relation><relation id="R2"><infon key="score">0.701</infon><infon key="role1">Chemical|MESH:C031238</infon><infon key="role2">Chemical|MESH:D010100</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="13,16"/></relation><relation id="R3"><infon key="score">0.9888</infon><infon key="role1">Chemical|MESH:D006861</infon><infon key="role2">Chemical|MESH:D017665</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="29,30"/></relation><relation id="R4"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D006861</infon><infon key="role2">Chemical|MESH:D010100</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="2,3"/></relation></document>
<document><id>37918450</id><passage><infon key="type">title</infon><offset>0</offset><text>Fish oil-derived n-3 polyunsaturated fatty acids downregulate aquaporin 9 protein expression of liver and white adipose tissues in diabetic KK mice and 3T3-L1 adipocytes.</text><annotation id="6"><infon key="identifier">MESH:D005395</infon><infon key="type">Chemical</infon><location offset="0" length="8"/><text>Fish oil</text></annotation><annotation id="7"><infon key="identifier">MESH:D015525</infon><infon key="type">Chemical</infon><location offset="17" length="31"/><text>n-3 polyunsaturated fatty acids</text></annotation><annotation id="8"><infon key="identifier">64008</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41405</infon><location offset="62" length="11"/><text>aquaporin 9</text></annotation><annotation id="9"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="131" length="8"/><text>diabetic</text></annotation><annotation id="10"><infon key="identifier">CVCL:F844</infon><infon key="type">CellLine</infon><location offset="140" length="2"/><text>KK</text></annotation><annotation id="11"><infon key="identifier">CVCL:0123</infon><infon key="type">CellLine</infon><location offset="152" length="6"/><text>3T3-L1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>171</offset><text>Aquaporin 9 (AQP9) is an integral membrane protein that facilitates glycerol transport in hepatocytes and adipocytes. Glycerol is necessary as a substrate for gluconeogenesis in the physiological fasted state, suggesting that inhibiting AQP9 function may be beneficial for treating type 2 diabetes associated with fasting hyperglycemia. The n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are rich in fish oil and lower the risk of metabolic syndrome; however, the effects of EPA and DHA on AQP9 expression in obese and type 2 diabetes are unclear. The KK mouse is an animal model of obesity and type 2 diabetes because of the polymorphisms on leptin receptor gene, which results in a part of cause for obese and diabetic conditions. In this study, we determined the effect of fish oil-derived n-3 PUFA on AQP9 protein expression in the liver and white adipose tissue (WAT) of KK mice and mouse 3T3-L1 adipocytes. The expression of AQP9 protein in the liver, epididymal WAT, and inguinal WAT were markedly decreased following fish oil administration. We also demonstrated that n-3 PUFAs, such as DHA, and to a lesser extent EPA, downregulated AQP9 protein expression in 3T3-L1 adipocytes. Our results suggest that fish oil-derived n-3 PUFAs may regulate the protein expressions of AQP9 in glycerol metabolism-related organs in KK mice and 3T3-L1 adipocytes.</text><annotation id="55"><infon key="identifier">64008</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41405</infon><location offset="171" length="11"/><text>Aquaporin 9</text></annotation><annotation id="56"><infon key="identifier">64008</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41405</infon><location offset="184" length="4"/><text>AQP9</text></annotation><annotation id="57"><infon key="identifier">MESH:D005990</infon><infon key="type">Chemical</infon><location offset="239" length="8"/><text>glycerol</text></annotation><annotation id="58"><infon key="identifier">MESH:D005990</infon><infon key="type">Chemical</infon><location offset="289" length="8"/><text>Glycerol</text></annotation><annotation id="59"><infon key="identifier">64008</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41405</infon><location offset="408" length="4"/><text>AQP9</text></annotation><annotation id="60"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="453" length="15"/><text>type 2 diabetes</text></annotation><annotation id="61"><infon key="identifier">MESH:D006943</infon><infon key="type">Disease</infon><location offset="493" length="13"/><text>hyperglycemia</text></annotation><annotation id="62"><infon key="identifier">MESH:D015525</infon><infon key="type">Chemical</infon><location offset="512" length="31"/><text>n-3 polyunsaturated fatty acids</text></annotation><annotation id="63"><infon key="identifier">MESH:D005231</infon><infon key="type">Chemical</infon><location offset="545" length="5"/><text>PUFAs</text></annotation><annotation id="64"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="563" length="21"/><text>eicosapentaenoic acid</text></annotation><annotation id="65"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="586" length="3"/><text>EPA</text></annotation><annotation id="66"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="595" length="20"/><text>docosahexaenoic acid</text></annotation><annotation id="67"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="617" length="3"/><text>DHA</text></annotation><annotation id="68"><infon key="identifier">MESH:D005395</infon><infon key="type">Chemical</infon><location offset="635" length="8"/><text>fish oil</text></annotation><annotation id="69"><infon key="identifier">MESH:D024821</infon><infon key="type">Disease</infon><location offset="666" length="18"/><text>metabolic syndrome</text></annotation><annotation id="70"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="710" length="3"/><text>EPA</text></annotation><annotation id="71"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="718" length="3"/><text>DHA</text></annotation><annotation id="72"><infon key="identifier">64008</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41405</infon><location offset="725" length="4"/><text>AQP9</text></annotation><annotation id="73"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="744" length="5"/><text>obese</text></annotation><annotation id="74"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="754" length="15"/><text>type 2 diabetes</text></annotation><annotation id="75"><infon key="identifier">CVCL:F844</infon><infon key="type">CellLine</infon><location offset="787" length="2"/><text>KK</text></annotation><annotation id="76"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="818" length="7"/><text>obesity</text></annotation><annotation id="77"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="830" length="15"/><text>type 2 diabetes</text></annotation><annotation id="78"><infon key="identifier">16847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1731</infon><location offset="878" length="15"/><text>leptin receptor</text></annotation><annotation id="79"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="937" length="5"/><text>obese</text></annotation><annotation id="80"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="947" length="19"/><text>diabetic conditions</text></annotation><annotation id="81"><infon key="identifier">MESH:D005395</infon><infon key="type">Chemical</infon><location offset="1011" length="8"/><text>fish oil</text></annotation><annotation id="82"><infon key="identifier">MESH:D015525</infon><infon key="type">Chemical</infon><location offset="1028" length="8"/><text>n-3 PUFA</text></annotation><annotation id="83"><infon key="identifier">64008</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41405</infon><location offset="1040" length="4"/><text>AQP9</text></annotation><annotation id="84"><infon key="identifier">CVCL:F844</infon><infon key="type">CellLine</infon><location offset="1111" length="2"/><text>KK</text></annotation><annotation id="85"><infon key="identifier">CVCL:0123</infon><infon key="type">CellLine</infon><location offset="1129" length="6"/><text>3T3-L1</text></annotation><annotation id="86"><infon key="identifier">64008</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41405</infon><location offset="1166" length="4"/><text>AQP9</text></annotation><annotation id="87"><infon key="identifier">MESH:D005395</infon><infon key="type">Chemical</infon><location offset="1260" length="8"/><text>fish oil</text></annotation><annotation id="88"><infon key="identifier">MESH:D015525</infon><infon key="type">Chemical</infon><location offset="1311" length="9"/><text>n-3 PUFAs</text></annotation><annotation id="89"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="1330" length="3"/><text>DHA</text></annotation><annotation id="90"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="1358" length="3"/><text>EPA</text></annotation><annotation id="91"><infon key="identifier">64008</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41405</infon><location offset="1377" length="4"/><text>AQP9</text></annotation><annotation id="92"><infon key="identifier">CVCL:0123</infon><infon key="type">CellLine</infon><location offset="1404" length="6"/><text>3T3-L1</text></annotation><annotation id="93"><infon key="identifier">MESH:D015525</infon><infon key="type">Chemical</infon><location offset="1465" length="9"/><text>n-3 PUFAs</text></annotation><annotation id="94"><infon key="identifier">64008</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41405</infon><location offset="1515" length="4"/><text>AQP9</text></annotation><annotation id="95"><infon key="identifier">MESH:D005990</infon><infon key="type">Chemical</infon><location offset="1523" length="8"/><text>glycerol</text></annotation><annotation id="96"><infon key="identifier">CVCL:F844</infon><infon key="type">CellLine</infon><location offset="1561" length="2"/><text>KK</text></annotation><annotation id="97"><infon key="identifier">CVCL:0123</infon><infon key="type">CellLine</infon><location offset="1573" length="6"/><text>3T3-L1</text></annotation></passage><relation id="R1"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:D005395</infon><infon key="role2">Gene|64008</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.8465</infon><infon key="role1">Chemical|MESH:D015525</infon><infon key="role2">Disease|MESH:D003920</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="1,3"/></relation><relation id="R3"><infon key="score">0.8829</infon><infon key="role1">Chemical|MESH:D005395</infon><infon key="role2">Chemical|MESH:D015118</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="19,15"/></relation><relation id="R4"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D015525</infon><infon key="role2">Gene|64008</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="1,2"/></relation><relation id="R5"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D003920</infon><infon key="role2">Gene|16847</infon><infon key="type">Association</infon><node refid="4" role="31,29"/></relation><relation id="R6"><infon key="score">0.3873</infon><infon key="role1">Chemical|MESH:D005395</infon><infon key="role2">Chemical|MESH:D015525</infon><infon key="type">Association</infon><node refid="5" role="0,1"/></relation><relation id="R7"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D006943</infon><infon key="role2">Gene|64008</infon><infon key="type">Association</infon><node refid="6" role="12,10"/></relation><relation id="R8"><infon key="score">0.9779</infon><infon key="role1">Chemical|MESH:D005990</infon><infon key="role2">Disease|MESH:D003924</infon><infon key="type">Association</infon><node refid="7" role="9,11"/></relation><relation id="R9"><infon key="score">0.7565</infon><infon key="role1">Chemical|MESH:D005395</infon><infon key="role2">Disease|MESH:D003920</infon><infon key="type">Association</infon><node refid="8" role="0,3"/></relation><relation id="R10"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D005231</infon><infon key="role2">Disease|MESH:D024821</infon><infon key="type">Negative_Correlation</infon><node refid="9" role="14,20"/></relation><relation id="R11"><infon key="score">0.9988</infon><infon key="role1">Disease|MESH:D003924</infon><infon key="role2">Gene|64008</infon><infon key="type">Association</infon><node refid="10" role="11,10"/></relation><relation id="R12"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D004281</infon><infon key="role2">Gene|64008</infon><infon key="type">Negative_Correlation</infon><node refid="11" role="17,23"/></relation><relation id="R13"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D005990</infon><infon key="role2">Chemical|MESH:D015525</infon><infon key="type">Association</infon><node refid="12" role="46,44"/></relation><relation id="R14"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D015118</infon><infon key="role2">Gene|64008</infon><infon key="type">Negative_Correlation</infon><node refid="13" role="15,23"/></relation><relation id="R15"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D015525</infon><infon key="role2">Disease|MESH:D024821</infon><infon key="type">Negative_Correlation</infon><node refid="14" role="13,20"/></relation><relation id="R16"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D004281</infon><infon key="role2">Disease|MESH:D024821</infon><infon key="type">Negative_Correlation</infon><node refid="15" role="17,20"/></relation><relation id="R17"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D005990</infon><infon key="role2">Gene|64008</infon><infon key="type">Association</infon><node refid="16" role="8,6"/></relation><relation id="R18"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D015118</infon><infon key="role2">Disease|MESH:D024821</infon><infon key="type">Negative_Correlation</infon><node refid="17" role="15,20"/></relation><relation id="R19"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D009765</infon><infon key="role2">Gene|16847</infon><infon key="type">Association</infon><node refid="18" role="27,29"/></relation><relation id="R20"><infon key="score">0.9964</infon><infon key="role1">Disease|MESH:D003924</infon><infon key="role2">Gene|16847</infon><infon key="type">Association</infon><node refid="19" role="28,29"/></relation></document>
<document><id>37918800</id><passage><infon key="journal">Am J Pathol;2023Oct31. doi:10.1016/j.ajpath.2023.10.005</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Negishi Y, Adili A, de Vega S, Momoeda M, Kaneko H, Cilek MZ, Yoshinaga C, Takafuji K, Otsuka Y, Shimoda M, Negishi-Koga T, Ishijima M, Okada Y, </infon><offset>0</offset><text>Interleukin-6 reduces spheroid sizes of osteophytic cells derived from osteoarthritis knee joint via induction of apoptosis.</text><annotation id="2"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="0" length="13"/><text>Interleukin-6</text></annotation><annotation id="3"><infon key="identifier">MESH:D010003</infon><infon key="type">Disease</infon><location offset="71" length="14"/><text>osteoarthritis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>125</offset><text>Osteophyte in osteoarthritis (OA) joints contributes to restriction of joint movement, joint pain, and OA progression, but little is known about regulators of osteophyte. By examining the expression of the genes related to cartilage extracellular matrix (ECM), endochondral ossification and growth factor-signaling in articular cartilage and osteophyte obtained from OA knee joints, we demonstrated that several genes such as COL1A1, VCAN, BGLAP, BMP8B, RUNX2, and SOST are overexpressed in osteophyte compared to articular cartilage. Ratios of mesenchymal stem/progenitor cells (MSPCs), which were characterized by co-expression of CD105 and CD166, were significantly 2.2-fold higher in osteophytic cells than articular cells. Three-dimensional culture method for cartilage and osteophyte cells was developed by modification of cultures of self-assembled spheroid cell organoids (spheroids), and these spheroids cultured in the media for MSCs containing transforming growth factor-beta3 showed characteristic morphologies and gene expression profiles of articular cartilage and osteophyte, respectively. We then studied the effects of interleukin-1beta (IL-1beta), tumor necrosis factor-alpha and IL-6 on the spheroids of articular and osteophytic cells, and provided, to the best of our knowledge, the first evidence that IL-6 suppresses spheroid size of osteophytic cells by inducing apoptosis and reducing ECM molecules. These data demonstrate that IL-6 is the suppressor of osteophyte growth and suggest that IL-6 expression and/or activity are implicated for regulation of osteophyte formation in pathological joints.</text><annotation id="25"><infon key="identifier">MESH:D010003</infon><infon key="type">Disease</infon><location offset="139" length="14"/><text>osteoarthritis</text></annotation><annotation id="26"><infon key="identifier">MESH:D010003</infon><infon key="type">Disease</infon><location offset="155" length="2"/><text>OA</text></annotation><annotation id="27"><infon key="identifier">MESH:D002313</infon><infon key="type">Disease</infon><location offset="181" length="29"/><text>restriction of joint movement</text></annotation><annotation id="28"><infon key="identifier">MESH:D018771</infon><infon key="type">Disease</infon><location offset="212" length="10"/><text>joint pain</text></annotation><annotation id="29"><infon key="identifier">MESH:D010003</infon><infon key="type">Disease</infon><location offset="228" length="2"/><text>OA</text></annotation><annotation id="30"><infon key="identifier">MESH:D010003</infon><infon key="type">Disease</infon><location offset="492" length="2"/><text>OA</text></annotation><annotation id="31"><infon key="identifier">1277</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">73874</infon><location offset="551" length="6"/><text>COL1A1</text></annotation><annotation id="32"><infon key="identifier">1462</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3228</infon><location offset="559" length="4"/><text>VCAN</text></annotation><annotation id="33"><infon key="identifier">632</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">104130</infon><location offset="565" length="5"/><text>BGLAP</text></annotation><annotation id="34"><infon key="identifier">656</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74865</infon><location offset="572" length="5"/><text>BMP8B</text></annotation><annotation id="35"><infon key="identifier">860</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68389</infon><location offset="579" length="5"/><text>RUNX2</text></annotation><annotation id="36"><infon key="identifier">50964</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11542</infon><location offset="590" length="4"/><text>SOST</text></annotation><annotation id="37"><infon key="identifier">214</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1229</infon><location offset="768" length="5"/><text>CD166</text></annotation><annotation id="38"><infon key="identifier">7043</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2433</infon><location offset="1080" length="32"/><text>transforming growth factor-beta3</text></annotation><annotation id="39"><infon key="identifier">3553</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1261" length="17"/><text>interleukin-1beta</text></annotation><annotation id="40"><infon key="identifier">3553</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1280" length="8"/><text>IL-1beta</text></annotation><annotation id="41"><infon key="identifier">7124</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="1291" length="27"/><text>tumor necrosis factor-alpha</text></annotation><annotation id="42"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1323" length="4"/><text>IL-6</text></annotation><annotation id="43"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1449" length="4"/><text>IL-6</text></annotation><annotation id="44"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1578" length="4"/><text>IL-6</text></annotation><annotation id="45"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1639" length="4"/><text>IL-6</text></annotation></passage><relation id="R1"><infon key="score">0.6657</infon><infon key="role1">Disease|MESH:D010003</infon><infon key="role2">Gene|50964</infon><infon key="type">Association</infon><node refid="0" role="7,13"/></relation><relation id="R2"><infon key="score">0.993</infon><infon key="role1">Disease|MESH:D010003</infon><infon key="role2">Gene|3569</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.8244</infon><infon key="role1">Disease|MESH:D010003</infon><infon key="role2">Gene|860</infon><infon key="type">Association</infon><node refid="2" role="7,12"/></relation><relation id="R4"><infon key="score">0.9211</infon><infon key="role1">Disease|MESH:D010003</infon><infon key="role2">Gene|632</infon><infon key="type">Association</infon><node refid="3" role="7,10"/></relation><relation id="R5"><infon key="score">0.8821</infon><infon key="role1">Disease|MESH:D010003</infon><infon key="role2">Gene|1462</infon><infon key="type">Association</infon><node refid="4" role="7,9"/></relation><relation id="R6"><infon key="score">0.809</infon><infon key="role1">Disease|MESH:D010003</infon><infon key="role2">Gene|656</infon><infon key="type">Association</infon><node refid="5" role="7,11"/></relation><relation id="R7"><infon key="score">0.5614</infon><infon key="role1">Disease|MESH:D010003</infon><infon key="role2">Gene|1277</infon><infon key="type">Association</infon><node refid="6" role="7,8"/></relation></document>
<document><id>37919150</id><passage><infon key="journal">J Fr Ophtalmol;2023Oct31. doi:10.1016/j.jfo.2023.04.015</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fitoussi R, Aulanier A, Attia R, Denis D, David T, </infon><offset>0</offset><text>[A case of photic maculopathy].</text><annotation id="1"><infon key="identifier">MESH:D008268</infon><infon key="type">Disease</infon><location offset="11" length="18"/><text>photic maculopathy</text></annotation></passage><passage><infon key="type">abstract</infon><offset>32</offset></passage></document>
<document><id>37919500</id><passage><infon key="journal">Environ Sci Pollut Res Int;2023Nov03. doi:10.1007/s11356-023-30538-0</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">El-Shafie AS, Karamshahi F, El-Azazy M, </infon><offset>0</offset><text>Turning waste avocado stones and montmorillonite into magnetite-supported nanocomposites for the depollution of methylene blue: adsorbent reusability and performance optimization.</text><annotation id="3"><infon key="identifier">MESH:D001546</infon><infon key="type">Chemical</infon><location offset="33" length="15"/><text>montmorillonite</text></annotation><annotation id="4"><infon key="identifier">MESH:D052203</infon><infon key="type">Chemical</infon><location offset="54" length="9"/><text>magnetite</text></annotation><annotation id="5"><infon key="identifier">MESH:D008751</infon><infon key="type">Chemical</infon><location offset="112" length="14"/><text>methylene blue</text></annotation></passage><passage><infon key="type">abstract</infon><offset>180</offset><text>The existence of methylene blue (MB) in wastewater even as traces is raising environmental concerns. In this regard, the performances of four adsorbents, avocado stone biochar (AVS-BC), montmorillonite (MMT), and their magnetite Fe3O4-derived counterparts, were compared. Results showed the superior performance of Fe3O4@AVS-BC and Fe3O4@MMT nanocomposites with removal percentages (%R) of 95.59% and 88%. The morphological features of AVS-BC as revealed by SEM analysis showed a highly porous surface compared to a plane and smooth surface in the case of MMT. Surface analysis using FT-IR and Raman spectroscopies corroborated the existence of the Fe-O peaks upon loading with magnetite. The XRD analysis confirmed the formation of cubic magnetite nanoparticles. The adsorption process in the batch mode was optimized using central composite design (CCD). Equilibrium and kinetic isotherms showed that the adsorption of MB onto Fe3O4@AVS-BC fitted well with the Langmuir isotherm and the pseudo-second-order (PSO) model. The maximum adsorption capacity (qm) was 118.9 mg/g (Fe3O4@AVS-BC) and 72.39 mg/g (Fe3O4@MMT). The Fe3O4@AVS-BC showed a higher selectivity toward MB compared to other organic contaminants. The MB-laden adsorbent was successfully used for the remediation of Cr (III), Ni (II), and Cd (II) with removal efficiencies hitting 100% following thermal activation.</text><annotation id="31"><infon key="identifier">MESH:D008751</infon><infon key="type">Chemical</infon><location offset="197" length="14"/><text>methylene blue</text></annotation><annotation id="32"><infon key="identifier">MESH:D008751</infon><infon key="type">Chemical</infon><location offset="213" length="2"/><text>MB</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="334" length="21"/><text>avocado stone biochar</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="357" length="6"/><text>AVS-BC</text></annotation><annotation id="35"><infon key="identifier">MESH:D001546</infon><infon key="type">Chemical</infon><location offset="366" length="15"/><text>montmorillonite</text></annotation><annotation id="36"><infon key="identifier">MESH:D001546</infon><infon key="type">Chemical</infon><location offset="383" length="3"/><text>MMT</text></annotation><annotation id="37"><infon key="identifier">MESH:D052203</infon><infon key="type">Chemical</infon><location offset="399" length="9"/><text>magnetite</text></annotation><annotation id="38"><infon key="identifier">MESH:D052203</infon><infon key="type">Chemical</infon><location offset="409" length="5"/><text>Fe3O4</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="495" length="12"/><text>Fe3O4@AVS-BC</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="512" length="9"/><text>Fe3O4@MMT</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="616" length="6"/><text>AVS-BC</text></annotation><annotation id="42"><infon key="identifier">MESH:D001546</infon><infon key="type">Chemical</infon><location offset="736" length="3"/><text>MMT</text></annotation><annotation id="43"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="829" length="2"/><text>Fe</text></annotation><annotation id="44"><infon key="identifier">MESH:D052203</infon><infon key="type">Chemical</infon><location offset="858" length="9"/><text>magnetite</text></annotation><annotation id="45"><infon key="identifier">MESH:D052203</infon><infon key="type">Chemical</infon><location offset="919" length="9"/><text>magnetite</text></annotation><annotation id="46"><infon key="identifier">MESH:D008751</infon><infon key="type">Chemical</infon><location offset="1101" length="2"/><text>MB</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1109" length="12"/><text>Fe3O4@AVS-BC</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1255" length="12"/><text>Fe3O4@AVS-BC</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1285" length="9"/><text>Fe3O4@MMT</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1301" length="12"/><text>Fe3O4@AVS-BC</text></annotation><annotation id="51"><infon key="identifier">MESH:D008751</infon><infon key="type">Chemical</infon><location offset="1349" length="2"/><text>MB</text></annotation><annotation id="52"><infon key="identifier">MESH:D008751</infon><infon key="type">Chemical</infon><location offset="1396" length="2"/><text>MB</text></annotation><annotation id="53"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1460" length="8"/><text>Cr (III)</text></annotation><annotation id="54"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1470" length="7"/><text>Ni (II)</text></annotation><annotation id="55"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1483" length="7"/><text>Cd (II)</text></annotation></passage><relation id="R1"><infon key="score">0.8237</infon><infon key="role1">Chemical|MESH:D008751</infon><infon key="role2">Chemical|MESH:D052203</infon><infon key="type">Association</infon><node refid="0" role="2,1"/></relation><relation id="R2"><infon key="score">0.5654</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Chemical|MESH:D052203</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="15,17"/></relation><relation id="R3"><infon key="score">0.9798</infon><infon key="role1">Chemical|MESH:D001546</infon><infon key="role2">Chemical|MESH:D008751</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="0,2"/></relation></document>
<document><id>37919850</id><passage><infon key="journal">Allergy Asthma Proc;2023Nov01; 44 (6) 436. doi:10.2500/aap.2023.44.230054</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Park K, Wang Q, Lee RU, </infon><offset>0</offset><text>Navigating the management complexity in long-term asymptomatic immunodeficiency.</text><annotation id="1"><infon key="identifier">MESH:D007153</infon><infon key="type">Disease</infon><location offset="63" length="16"/><text>immunodeficiency</text></annotation></passage><passage><infon key="type">abstract</infon><offset>81</offset><text>Background: Common variable immunodeficiency disorder (CVID) is a condition associated with recurrent infections and non-infectious outcomes, including lung disease like bronchiectasis and granulomatous and lymphocytic interstitial lung diseases (GLILD), autoimmune disease, enteropathy, and lymphoma. Treatment involves initiation of replacement immunoglobulin (Ig), which is a lifelong commitment. Prior to Ig replacement, life expectancy for patients with CVID was less than 15 years. With replacement Ig, it has improved to over 50 years. In most cases, patients present to a clinician with a history of recurrent infections, and treatment is indicated. However, in patients with asymptomatic disease, the best timing to start treatment can be difficult to determine. Case: We present a case of an otherwise healthy male who had an incidental diagnosis of CVID. Results: Workup revealed hypogammaglobulinemia for over 30 year. Discussion: Though successful in reducing infections, Ig replacement can come with many side effects, as well as a heavy medical burden to the patient and the healthcare system. It is also a big life adjustment, and can greatly affect a patient's quality of life. In the military, a diagnosis of an immunodeficiency, and the need for monthly intravenous immunoglobulin (IVIG) can be detrimental to deployment readiness, and a patient's military career. Risks and benefits need to be weighed prior to initiating Ig therapy.</text><annotation id="18"><infon key="identifier">MESH:D017074</infon><infon key="type">Disease</infon><location offset="93" length="41"/><text>Common variable immunodeficiency disorder</text></annotation><annotation id="19"><infon key="identifier">MESH:D017074</infon><infon key="type">Disease</infon><location offset="136" length="4"/><text>CVID</text></annotation><annotation id="20"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="183" length="10"/><text>infections</text></annotation><annotation id="21"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="233" length="12"/><text>lung disease</text></annotation><annotation id="22"><infon key="identifier">MESH:D001987</infon><infon key="type">Disease</infon><location offset="251" length="14"/><text>bronchiectasis</text></annotation><annotation id="23"><infon key="identifier">MESH:D017563</infon><infon key="type">Disease</infon><location offset="270" length="56"/><text>granulomatous and lymphocytic interstitial lung diseases</text></annotation><annotation id="24"><infon key="identifier">MESH:D017563</infon><infon key="type">Disease</infon><location offset="328" length="5"/><text>GLILD</text></annotation><annotation id="25"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="336" length="18"/><text>autoimmune disease</text></annotation><annotation id="26"><infon key="identifier">MESH:C538273</infon><infon key="type">Disease</infon><location offset="356" length="11"/><text>enteropathy</text></annotation><annotation id="27"><infon key="identifier">MESH:D008223</infon><infon key="type">Disease</infon><location offset="373" length="8"/><text>lymphoma</text></annotation><annotation id="28"><infon key="identifier">MESH:D017074</infon><infon key="type">Disease</infon><location offset="540" length="4"/><text>CVID</text></annotation><annotation id="29"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="699" length="10"/><text>infections</text></annotation><annotation id="30"><infon key="identifier">MESH:D017074</infon><infon key="type">Disease</infon><location offset="941" length="4"/><text>CVID</text></annotation><annotation id="31"><infon key="identifier">MESH:D000361</infon><infon key="type">Disease</infon><location offset="972" length="21"/><text>hypogammaglobulinemia</text></annotation><annotation id="32"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1054" length="10"/><text>infections</text></annotation><annotation id="33"><infon key="identifier">MESH:D007153</infon><infon key="type">Disease</infon><location offset="1311" length="16"/><text>immunodeficiency</text></annotation></passage></document>
<document><id>37920900</id><passage><infon key="journal">J Chem Theory Comput;2023Nov03. doi:10.1021/acs.jctc.3c01055</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hasecke L, Mata RA, </infon><offset>0</offset><text>Nuclear Quantum Effects Made Accessible: Local Density Fitting in Multicomponent Methods.</text></passage><passage><infon key="type">abstract</infon><offset>90</offset><text>The simulation of nuclear quantum effects (NQEs) is crucial for an accurate description of systems and processes involving light nuclei, such as hydrogen atoms. Within the last years, the importance of those effects has been highlighted for a vast range of systems with tremendous implications in chemistry, biology, physics, and materials sciences. However, while electronic structure theory methods have become routine tools for quantum chemical investigations, there is still a lack of approaches to address NQEs that are computationally accessible and straightforward to use. To address this, we present the first combination of the nuclear-electronic orbital Hartree-Fock approach with both local and density fitting approximations (LDF-NEO-HF). This results in a low-order scaling approach that enables the inclusion of NQEs for large systems within a fraction of a day and for small to medium size systems in minutes. Moreover, we demonstrate the qualitative accuracy and robustness of our approach to retrieve NQEs for three real-use cases motivated by chemical, biological, and materials science applications.</text><annotation id="1"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="235" length="8"/><text>hydrogen</text></annotation></passage></document>
<document><id>37921250</id><passage><infon key="journal">J Chem Phys;2023Nov07; 159 (17) . doi:10.1063/5.0169883</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Petersen AC, S&amp;#xf8;lling TI, </infon><offset>0</offset><text>Dissociation processes of ionized freons: CHFCl2+ and CF2Cl2+ in the gas phase.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="42" length="7"/><text>CHFCl2+</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="54" length="7"/><text>CF2Cl2+</text></annotation></passage><passage><infon key="type">abstract</infon><offset>80</offset><text>The present study reveals the effects of symmetry on how the distribution and flow of energy play out on the decomposition of small halocarbons. Unimolecular decay of the freons CHFCl2 and CF2Cl2 when ionized has been investigated. Mass spectrometric results that encompass isotope effects (peak heights) and energy distribution in the exit channel (peak shapes) are interpreted by computational methods. Non-statistical processes of electronic predissociation and isolated state decay are shown to be directly associated with molecular symmetry.</text><annotation id="7"><infon key="identifier">MESH:D006846</infon><infon key="type">Chemical</infon><location offset="212" length="11"/><text>halocarbons</text></annotation><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="258" length="6"/><text>CHFCl2</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="269" length="6"/><text>CF2Cl2</text></annotation></passage></document>
<document><id>37921600</id><passage><infon key="journal">J Gynecol Oncol;2023Oct16. doi:10.3802/jgo.2024.35.e16</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chinnadurai A, Breadner D, Baloush Z, Lohmann AE, Black M, D'Souza D, Welch S, </infon><offset>0</offset><text>Adjuvant carboplatin and paclitaxel with "sandwich" method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution.</text><annotation id="3"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="9" length="11"/><text>carboplatin</text></annotation><annotation id="4"><infon key="identifier">MESH:D017239</infon><infon key="type">Chemical</infon><location offset="25" length="10"/><text>paclitaxel</text></annotation><annotation id="5"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="76" length="34"/><text>stage III or IV endometrial cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>157</offset><text>OBJECTIVE: To evaluate disease-free survival (DFS) and overall survival (OS) associated with adjuvant carboplatin and paclitaxel chemotherapy interposed with radiation for advanced endometrial cancer. METHODS: This is a cohort study of adult women with stage III or IV endometrial cancer treated at a single institution, between April 2002 and October 2017. Tumor and treatment characteristics were recorded. Treatment consisted of 4 cycles of intravenous paclitaxel and carboplatin every 3 weeks, followed by external beam radiotherapy to the pelvis (45-50 Gy), and another 2 cycles of chemotherapy. One cohort of patients were prospectively enrolled from 2002 through 2006 and an additional cohort from 2007 to 2017, which was retrospectively analyzed. Primary endpoints for this study were DFS and OS rates which were calculated using Cox regression models. RESULTS: Eighty-two patients with a median age of 66.5 years (range, 35-83 years) were included. Median follow-up was 46 months (range, 9-196 months). Most patients had stage IIIC disease (62.2%) and serous carcinoma histology (46.3%). Median OS was 146 months and median DFS was 71 months. A 5-year OS and DFS were 64.9% and 55.7%, respectively. Age >60 years subgroup was at a significantly higher risk of DFS event or death. Histological subtype, location of positive nodes, and cancer stage (IIIa vs. higher stage) did not correlate to a higher risk of recurrence or death. CONCLUSION: Long term follow-up and a larger population confirm that the chemoradiotherapy sandwich method yields favorable outcomes in patients with high-risk endometrial cancer.</text><annotation id="19"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="259" length="11"/><text>carboplatin</text></annotation><annotation id="20"><infon key="identifier">MESH:D017239</infon><infon key="type">Chemical</infon><location offset="275" length="10"/><text>paclitaxel</text></annotation><annotation id="21"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="338" length="18"/><text>endometrial cancer</text></annotation><annotation id="22"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="410" length="34"/><text>stage III or IV endometrial cancer</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="515" length="5"/><text>Tumor</text></annotation><annotation id="24"><infon key="identifier">MESH:D017239</infon><infon key="type">Chemical</infon><location offset="613" length="10"/><text>paclitaxel</text></annotation><annotation id="25"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="628" length="11"/><text>carboplatin</text></annotation><annotation id="26"><infon key="identifier">MESH:C566891</infon><infon key="type">Disease</infon><location offset="1187" length="18"/><text>stage IIIC disease</text></annotation><annotation id="27"><infon key="identifier">MESH:D018297</infon><infon key="type">Disease</infon><location offset="1218" length="16"/><text>serous carcinoma</text></annotation><annotation id="28"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1439" length="5"/><text>death</text></annotation><annotation id="29"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1500" length="6"/><text>cancer</text></annotation><annotation id="30"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1589" length="5"/><text>death</text></annotation><annotation id="31"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="1756" length="18"/><text>endometrial cancer</text></annotation></passage><relation id="R1"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:D016190</infon><infon key="role2">Disease|MESH:D016889</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.9978</infon><infon key="role1">Chemical|MESH:D017239</infon><infon key="role2">Disease|MESH:D016889</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="1,2"/></relation></document>
<document><id>37819016</id><passage><infon key="journal">Nucleic Acids Res;2023Oct11. doi:10.1093/nar/gkad795</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kosek DM, Banijamali E, Becker W, Petzold K, Andersson ER, </infon><offset>0</offset><text>Efficient 3'-pairing renders microRNA targeting less sensitive to mRNA seed accessibility.</text></passage><passage><infon key="type">abstract</infon><offset>91</offset><text>MicroRNAs (miRNAs) are short RNAs that post-transcriptionally regulate gene expression by binding to specific sites in mRNAs. Site recognition is primarily mediated by the seed region (nucleotides g2-g8 in the miRNA), but pairing beyond the seed (3'-pairing) is important for some miRNA:target interactions. Here, we use SHAPE, luciferase reporter assays and transcriptomics analyses to study the combined effect of 3'-pairing and secondary structures in mRNAs on repression efficiency. Using the interaction between miR-34a and its SIRT1 binding site as a model, we provide structural and functional evidence that 3'-pairing can compensate for low seed-binding site accessibility, enabling repression of sites that would otherwise be ineffective. We show that miRNA 3'-pairing regions can productively base-pair with nucleotides far upstream of the seed-binding site and that both hairpins and unstructured bulges within the target site are tolerated. We use SHAPE to show that sequences that overcome inaccessible seed-binding sites by strong 3'-pairing adopt the predicted structures and corroborate the model using luciferase assays and high-throughput modelling of 8177 3'-UTR targets for six miRNAs. Finally, we demonstrate that PHB2, a target of miR-141, is an inaccessible target rescued by efficient 3'-pairing. We propose that these results could refine predictions of effective target sites.</text><annotation id="4"><infon key="identifier">407040</infon><infon key="type">Gene</infon><location offset="608" length="7"/><text>miR-34a</text></annotation><annotation id="5"><infon key="identifier">23411</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56556</infon><location offset="624" length="5"/><text>SIRT1</text></annotation><annotation id="6"><infon key="identifier">11331</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">5263</infon><location offset="1326" length="4"/><text>PHB2</text></annotation><annotation id="7"><infon key="identifier">406933</infon><infon key="type">Gene</infon><location offset="1344" length="7"/><text>miR-141</text></annotation></passage><relation id="R1"><infon key="score">0.9988</infon><infon key="role1">Gene|11331</infon><infon key="role2">Gene|406933</infon><infon key="type">Association</infon><node refid="0" role="2,3"/></relation><relation id="R2"><infon key="score">0.9926</infon><infon key="role1">Gene|23411</infon><infon key="role2">Gene|407040</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation></document>
<document><id>37819368</id><passage><infon key="journal">Int Urogynecol J;2023Oct11. doi:10.1007/s00192-023-05653-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">6968909</infon><infon key="type">title</infon><infon key="authors">Szyma&amp;#x144;ski JK, Starzec-Proserpio M, Bartosi&amp;#x144;ska-Raczkiewicz D, Krawczyk A, Kukulski P, Jakiel G, </infon><offset>0</offset><text>Impact of preoperative pelvic floor muscle function on the success of surgical treatment of pelvic organ prolapse.</text><annotation id="1"><infon key="identifier">MESH:D056887</infon><infon key="type">Disease</infon><location offset="92" length="21"/><text>pelvic organ prolapse</text></annotation></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>INTRODUCTION AND HYPOTHESIS: The objective of this study was to identify the potential characteristics of pelvic floor muscles (PFM) in the preoperative assessment that could be associated with post-surgical prolapse severity. We hypothesized that the same variables, if identified, could be addressed in preoperative rehabilitation to improve surgical results. METHODS: This was a single-center prospective observational study that included women who underwent surgical pelvic organ prolapse repair between 2020-2022. Genital prolapse was evaluated according to the Pelvic Organ Prolapse Quantification (POP-Q) system. All the participants underwent a PFM assessment, including a vaginal digital assessment and manometry (Peritron  9300 V) before surgery and at 1-, 3-, and 6-month follow-ups. Several PFM variables were recorded: vaginal resting pressure, vaginal pressure during maximal voluntary contraction (MVC), area under the curve during a 10-second MVC, ability to correctly contract the PFMs, and reflexive activation during cough and relaxation. The primary endpoint of the analysis was objective surgical success defined as POP-Q 0 or 1 at the 6-month follow-up. Additionally, a change in pelvic floor muscle function was recorded during postoperative visits. RESULTS: A total of 106 females were included in the study. Fifty-one were lost during the 6-month follow-up, which is a major limitation of the study. None of the examined parameters evaluating PFM were associated with surgical success. No statistically significant difference was found in MVC and PFM endurance before and after surgery. Post-surgery, a significant change was observed in the vaginal resting pressure and the ability to correct PFM activation and relaxation. CONCLUSIONS: Preoperative PFM function is not associated with surgical success 6 months after surgery.</text><annotation id="9"><infon key="identifier">MESH:D011391</infon><infon key="type">Disease</infon><location offset="323" length="8"/><text>prolapse</text></annotation><annotation id="10"><infon key="identifier">MESH:D056887</infon><infon key="type">Disease</infon><location offset="586" length="21"/><text>pelvic organ prolapse</text></annotation><annotation id="11"><infon key="identifier">MESH:D011391</infon><infon key="type">Disease</infon><location offset="634" length="16"/><text>Genital prolapse</text></annotation><annotation id="12"><infon key="identifier">MESH:D056887</infon><infon key="type">Disease</infon><location offset="682" length="21"/><text>Pelvic Organ Prolapse</text></annotation><annotation id="13"><infon key="type">Disease</infon><location offset="720" length="3"/><text>POP</text></annotation><annotation id="14"><infon key="identifier">MESH:D003371</infon><infon key="type">Disease</infon><location offset="1151" length="5"/><text>cough</text></annotation><annotation id="15"><infon key="type">Disease</infon><location offset="1252" length="4"/><text>POP-</text></annotation></passage></document>
<document><id>37819722</id><passage><infon key="journal">Nicotine Tob Res;2023Oct11. doi:10.1093/ntr/ntad199</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kowitt SD, Goldstein AO, Cornacchione Ross J, Clark SA, Kristen JL, Sheeran P, Thrasher JF, Ranney LM, </infon><offset>0</offset><text>Perceived effectiveness of cigar warnings in discouraging blunt use.</text></passage><passage><infon key="type">abstract</infon><offset>69</offset><text>INTRODUCTION: Many people remove the tobacco leaf from cigars and replace it with cannabis (i.e., blunts), but few studies have examined whether messages about the risks of cigars, like warnings on cigar packages, can affect blunt use. METHODS: Participants were 438 US adults who reported past 30-day cigar use and ever blunt use, recruited from a probability-based national panel to take an online survey. In a 2x2 experiment with a between-subjects design, we manipulated two cigar warning characteristics: 1) warning type: text-only vs. pictorial (i.e., text + image) and 2) warning size: 30% (smaller) vs. 50% (larger) of the product package. Participants then viewed 6 different warnings on a fictious cigarillo package, within their randomly assigned condition. After evaluating all stimuli, participants were asked the extent to which the warnings discouraged them from wanting to use cigars to smoke cannabis (i.e., blunt perceived warning effectiveness). Response options ranged from "not at all" (1) to "a great deal" (5). RESULTS: We observed no main effects of warning type or size on blunt perceived warning effectiveness. However, a significant interaction existed between the two experimental manipulations (p=0.009). Whereas adding images made no difference to blunt perceived warning effectiveness when warnings were smaller (simple effect: -0.22, p=0.28), images mattered for larger warnings. Specifically, adding images increased blunt perceived warning effectiveness when warnings were 50% of the product package (simple effect: 0.52, p=0.008). CONCLUSIONS: This experiment provides preliminary evidence that larger pictorial cigar warnings may discourage blunt use relative to larger but text-only warnings. IMPLICATIONS: Blunts, which are hollowed out cigars with tobacco leaf wrappers that are filled with cannabis leaf, are one of the most common ways in which tobacco and cannabis are used simultaneously, yet few studies have examined whether messages about the risks of cigars can affect blunt use. We conducted an online experiment concerning the perceived effectiveness of cigar warnings among people who use blunts recruited from a probability-based panel. Results provide novel, preliminary evidence that larger pictorial cigar warnings may discourage blunt use, relative to larger but text-only warnings. More research evaluating cigar warnings on blunt use is needed.</text></passage></document>
<document><id>37820082</id><passage><infon key="journal">Am J Ther;2023Oct11. doi:10.1097/MJT.0000000000001644</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fosnight S, Soric MM, Smearman J, Graves E, Vazquez M, Herrington Z, Palladino C, Costello M, Knauss A, </infon><offset>0</offset><text>Investigation Into Potentially Inappropriate Prescribing Patterns of Loop Diuretics in a Nationally Representative Outpatient Population.</text></passage><passage><infon key="type">abstract</infon><offset>138</offset><text>BACKGROUND: Loop diuretic therapy effectively treats edema related to heart failure, chronic kidney disease, and liver impairment; however, evidence supporting other indications is lacking. For indications such as hypertension or dependent edema or treatment of adverse events associated with other medications, the benefits likely do not outweigh the risks, putting patients at an unacceptably high risk of poor outcomes. STUDY QUESTION: What is the proportion of loop diuretic prescribing that occurs in the absence of a diagnosis of heart failure, chronic kidney disease, liver impairment, or other evidence-based indications? STUDY DESIGN: This was a national, retrospective, cross-sectional investigation conducted using the National Ambulatory Care Survey from 2013 to 2016. Outpatient visits for patients aged 18 years or older prescribed with loop diuretics were included. MEASURES AND OUTCOMES: The primary end point was the frequency of potentially inappropriate loop diuretic prescribing. The secondary end point was a multivariable regression model that identified predictors of potentially inappropriate loop diuretic utilization. RESULTS: This analysis identified 5261 outpatient visits conducted during the study period in which loop diuretics were prescribed. Of these, 3648 visits (65.8% of weighted visits) were of patients without a history of heart failure, chronic kidney disease, or liver impairment. Positive predictors included age older than 65 years (odds ratio [OR] 1.71; 95% confidence interval [CI] 1.38-2.13), concomitant calcium channel blocker (OR 1.42; 95% CI, 1.09-1.84), sodium-containing medication use (OR 2.78; 95% CI, 1.23-6.25), and office visit with a cardiology specialist (OR 2.84; 95% CI, 2.31-3.50). CONCLUSIONS: This analysis identified that loop diuretics are prescribed in the absence of evidence-based indications more frequently than they are prescribed for them. This prescribing pattern creates a unique opportunity for clinicians to optimize patient care. Further study of the outcomes associated with this prescribing pattern is warranted.</text><annotation id="13"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="191" length="5"/><text>edema</text></annotation><annotation id="14"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="208" length="13"/><text>heart failure</text></annotation><annotation id="15"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="223" length="22"/><text>chronic kidney disease</text></annotation><annotation id="16"><infon key="identifier">MESH:D017093</infon><infon key="type">Disease</infon><location offset="251" length="16"/><text>liver impairment</text></annotation><annotation id="17"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="352" length="12"/><text>hypertension</text></annotation><annotation id="18"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="378" length="5"/><text>edema</text></annotation><annotation id="19"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="674" length="13"/><text>heart failure</text></annotation><annotation id="20"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="689" length="22"/><text>chronic kidney disease</text></annotation><annotation id="21"><infon key="identifier">MESH:D017093</infon><infon key="type">Disease</infon><location offset="713" length="16"/><text>liver impairment</text></annotation><annotation id="22"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1501" length="13"/><text>heart failure</text></annotation><annotation id="23"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="1516" length="22"/><text>chronic kidney disease</text></annotation><annotation id="24"><infon key="identifier">MESH:D017093</infon><infon key="type">Disease</infon><location offset="1543" length="16"/><text>liver impairment</text></annotation><annotation id="25"><infon key="identifier">MESH:D012964</infon><infon key="type">Chemical</infon><location offset="1744" length="6"/><text>sodium</text></annotation></passage></document>
<document><id>37820453</id><passage><infon key="journal">Biochem Biophys Res Commun;2023Nov19; 682 180. doi:10.1016/j.bbrc.2023.10.019</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chen X, Chen J, Liu S, Li X, </infon><offset>0</offset><text>PECAM-1 mediates temsirolimus-induced increase in neutrophil transendothelial migration that leads to lung injury.</text><annotation id="3"><infon key="identifier">5175</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47925</infon><location offset="0" length="7"/><text>PECAM-1</text></annotation><annotation id="4"><infon key="identifier">MESH:C401859</infon><infon key="type">Chemical</infon><location offset="17" length="12"/><text>temsirolimus</text></annotation><annotation id="5"><infon key="identifier">MESH:D055370</infon><infon key="type">Disease</infon><location offset="102" length="11"/><text>lung injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>Temsirolimus is a first-generation mTOR inhibitor commonly used in the clinical treatment of cancers that is associated with lung injury. However, the mechanism underlying this adverse effect remains elusive. Endothelial barrier dysfunction plays a pivotal role in the infiltration of neutrophils into the pulmonary alveoli, which eventually induces lung injury. The present study demonstrates that temsirolimus induces the aberrant expression of adhesion molecules in endothelial cells, leading to enhanced neutrophil infiltration and subsequent lung injury. Results of a mouse model revealed that temsirolimus disrupted capillary-alveolar barrier function and facilitated neutrophil transmigration across the endothelium within the alveolar space. Consistent with our in vivo observations, temsirolimus impaired intercellular barrier function within monolayers of human lung endothelial cells, resulting in increased neutrophil infiltration. Furthermore, we demonstrated that temsirolimus-induced neutrophil transendothelial migration was mediated by platelet endothelial cell adhesion molecule-1 (PECAM-1) in both in vitro and in vivo experiments. Collectively, these findings highlight that temsirolimus induces endothelial barrier dysfunction via PECAM-1-dependent pathway both in vitro and in vivo, ultimately leading to neutrophil infiltration and subsequent pulmonary injury.</text><annotation id="21"><infon key="identifier">MESH:C401859</infon><infon key="type">Chemical</infon><location offset="115" length="12"/><text>Temsirolimus</text></annotation><annotation id="22"><infon key="identifier">2475</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3637</infon><location offset="150" length="4"/><text>mTOR</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="208" length="7"/><text>cancers</text></annotation><annotation id="24"><infon key="identifier">MESH:D055370</infon><infon key="type">Disease</infon><location offset="240" length="11"/><text>lung injury</text></annotation><annotation id="25"><infon key="identifier">MESH:D055370</infon><infon key="type">Disease</infon><location offset="465" length="11"/><text>lung injury</text></annotation><annotation id="26"><infon key="identifier">MESH:C401859</infon><infon key="type">Chemical</infon><location offset="514" length="12"/><text>temsirolimus</text></annotation><annotation id="27"><infon key="identifier">MESH:D055370</infon><infon key="type">Disease</infon><location offset="662" length="11"/><text>lung injury</text></annotation><annotation id="28"><infon key="identifier">MESH:C401859</infon><infon key="type">Chemical</infon><location offset="714" length="12"/><text>temsirolimus</text></annotation><annotation id="29"><infon key="identifier">MESH:C401859</infon><infon key="type">Chemical</infon><location offset="907" length="12"/><text>temsirolimus</text></annotation><annotation id="30"><infon key="identifier">MESH:C401859</infon><infon key="type">Chemical</infon><location offset="1093" length="12"/><text>temsirolimus</text></annotation><annotation id="31"><infon key="identifier">5175</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47925</infon><location offset="1168" length="45"/><text>platelet endothelial cell adhesion molecule-1</text></annotation><annotation id="32"><infon key="identifier">5175</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47925</infon><location offset="1215" length="7"/><text>PECAM-1</text></annotation><annotation id="33"><infon key="identifier">MESH:C401859</infon><infon key="type">Chemical</infon><location offset="1310" length="12"/><text>temsirolimus</text></annotation><annotation id="34"><infon key="identifier">5175</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47925</infon><location offset="1367" length="7"/><text>PECAM-1</text></annotation><annotation id="35"><infon key="identifier">MESH:D055370</infon><infon key="type">Disease</infon><location offset="1481" length="16"/><text>pulmonary injury</text></annotation></passage><relation id="R1"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:C401859</infon><infon key="role2">Disease|MESH:D055370</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="1,2"/></relation><relation id="R2"><infon key="score">0.9996</infon><infon key="role1">Chemical|MESH:C401859</infon><infon key="role2">Gene|5175</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:C401859</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="3,5"/></relation><relation id="R4"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D055370</infon><infon key="role2">Gene|5175</infon><infon key="type">Association</infon><node refid="3" role="2,0"/></relation><relation id="R5"><infon key="score">0.9978</infon><infon key="role1">Chemical|MESH:C401859</infon><infon key="role2">Gene|2475</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="3,4"/></relation></document>
<document><id>37820806</id><passage><infon key="journal">Sci Total Environ;2023Oct10; 906 167620. doi:10.1016/j.scitotenv.2023.167620</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Omeokachie DN, Laniyan TA, Olawade DB, Abayomi-Agbaje O, Esan DT, Ana GREE, </infon><offset>0</offset><text>Indoor environmental conditions of selected shopping malls in Nigeria: A comparative study of microclimatic conditions, noise levels, and microbial burdens.</text></passage><passage><infon key="type">abstract</infon><offset>157</offset><text>The activities of people and equipment used within shopping malls are major factors that contribute to air pollution and increased sound levels, thereby affecting indoor environmental quality and the well-being of mall operators. This study assessed indoor environmental quality through microbial characterization and measurement of environmental conditions present in selected shopping malls. Investigations were conducted at three shopping malls in Ibadan selected through convenience sampling technique. Environmental parameters such as noise level, relative humidity, temperature, PM2.5 levels, total volatile organic compound (TVOC) levels, microbial characterization, and quantity were determined. Microclimatic parameters (temperature and relative humidity) were measured using a 4-in-1 Precision Gold N09AQ multi-tester. Culturable airborne microbes were collected using the settle plate technique. PM2.5 and TVOC levels were measured using a Thermo Scientific MIE pDR-1500 PM monitor and sf200-TVOC meter respectively. Two bacteria species and five fungi species were isolated across the malls. The noise levels ranged from 61.27 to 81.20 dB. The mean temperatures (highest mean of 33.44 +- 1.42  C), PM2.5 (highest mean of 114.06 +- 25.64 mug/m3), and TVOC (highest mean of 55.21 +- 8.28 ppm) concentrations were higher than the permissible limits stipulated by the WHO guidelines and NESREA standard limit across all the selected malls. A positive correlation was found to exist between particulate matter and TVOC (r = 0.174, p = 0.004). The total bacteria count was generally high with the highest mean of 1965.33 +- 368.56 CFU/m3, while the total fungi count was generally low with the highest mean of 579.82 +- 51.55 CFU/m3. Bacillus spp. and Candida spp. were found to the consistent from all sample points across the three malls. The bacteria isolated are Gram-positive bacteria associated with human skin which suggests a high rate of indoor pollution from humans. In conclusion, this research has demonstrated the necessity to monitor noise levels and indoor air quality in malls. Also, there is need for government policies to improve indoor air quality which must be enforced and regulated, especially within shopping malls.</text><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="742" length="5"/><text>PM2.5</text></annotation><annotation id="10"><infon key="identifier">MESH:D055549</infon><infon key="type">Chemical</infon><location offset="762" length="25"/><text>volatile organic compound</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="789" length="4"/><text>TVOC</text></annotation><annotation id="12"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1064" length="5"/><text>PM2.5</text></annotation><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1074" length="4"/><text>TVOC</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1160" length="4"/><text>TVOC</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1367" length="5"/><text>PM2.5</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1419" length="4"/><text>TVOC</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1678" length="4"/><text>TVOC</text></annotation></passage></document>
<document><id>37821156</id><passage><infon key="journal">J Control Release;2023Oct; 362 778. doi:10.1016/j.jconrel.2023.01.030</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">De Smedt SC, </infon><offset>0</offset><text>High-quality research and innovative ideas are what our readers expect.</text></passage><passage><infon key="type">abstract</infon><offset>72</offset></passage></document>
<document><id>37822210</id><passage><infon key="journal">Expert Rev Gastroenterol Hepatol;2023Jul-Dec; 17 (10) 975. doi:10.1080/17474124.2023.2267441</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Okdahl T, Emmanuel A, Morlion B, Farmer A, Varrassi G, Drewes AM, </infon><offset>0</offset><text>Recommendations for the management of opioid-induced constipation - how to improve usability in clinical practice.</text><annotation id="1"><infon key="identifier">MESH:D003248</infon><infon key="type">Disease</infon><location offset="53" length="12"/><text>constipation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>INTRODUCTION: Opioid-induced constipation remains undertreated despite effective and safe treatment options exists. Previous guidelines have only been partially effective in improving management, possibly due to their complexity, and studies suggest that a simple setup of concise and behaviorally-orientated steps improves usability. AREAS COVERED: This article introduces the concept of opioid-induced constipation and provides an overview of existing guidelines in this field. We also propose simplified recommendations for managing opioid-induced constipation, derived from a synthesis of current guidelines and the principles of optimal guideline design theory. EXPERT OPINION: Despite standard treatment with laxatives and fluid intake in patients with opioid-induced constipation, escalation of treatment is often needed where mu-opioid receptor antagonists or newer medications such as lubiprostone, linaclotide, or prucalopride are used. Previous guidelines have not been used sufficiently and thus management of the condition is often insufficient. We therefore propose simplified recommendations to management, which we believe can come into broader use. It was validated in primary care for credibility, clarity, relevance, usability, and overall benefit. We believe that this initiative can lead to better management of the substantial proportion of patients suffering from side effects of opioids.</text><annotation id="10"><infon key="identifier">MESH:D003248</infon><infon key="type">Disease</infon><location offset="144" length="12"/><text>constipation</text></annotation><annotation id="11"><infon key="identifier">MESH:D003248</infon><infon key="type">Disease</infon><location offset="519" length="12"/><text>constipation</text></annotation><annotation id="12"><infon key="identifier">MESH:D003248</infon><infon key="type">Disease</infon><location offset="666" length="12"/><text>constipation</text></annotation><annotation id="13"><infon key="identifier">MESH:D003248</infon><infon key="type">Disease</infon><location offset="889" length="12"/><text>constipation</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="949" length="30"/><text>mu-opioid receptor antagonists</text></annotation><annotation id="15"><infon key="identifier">MESH:D000068238</infon><infon key="type">Chemical</infon><location offset="1009" length="12"/><text>lubiprostone</text></annotation><annotation id="16"><infon key="identifier">MESH:C523483</infon><infon key="type">Chemical</infon><location offset="1023" length="11"/><text>linaclotide</text></annotation><annotation id="17"><infon key="identifier">MESH:C406662</infon><infon key="type">Chemical</infon><location offset="1039" length="12"/><text>prucalopride</text></annotation></passage><relation id="R1"><infon key="score">0.9935</infon><infon key="role1">Chemical|MESH:D000068238</infon><infon key="role2">Disease|MESH:D003248</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="6,4"/></relation><relation id="R2"><infon key="score">0.9682</infon><infon key="role1">Chemical|MESH:C523483</infon><infon key="role2">Disease|MESH:D003248</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="7,4"/></relation><relation id="R3"><infon key="score">0.9957</infon><infon key="role1">Chemical|MESH:C406662</infon><infon key="role2">Disease|MESH:D003248</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="8,4"/></relation></document>
<document><id>37823261</id><passage><infon key="journal">Lab Chip;2023Oct24; 23 (21) 4701. doi:10.1039/d3lc00687e</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kang BH, Jang KW, Yu ES, Jeong H, Jeong KH, </infon><offset>0</offset><text>Single-shot multi-channel plasmonic real-time polymerase chain reaction for multi-target point-of-care testing.</text></passage><passage><infon key="type">abstract</infon><offset>112</offset><text>Plasmonic nucleic acid amplification tests demand high-throughput and multi-target detection of infectious diseases as well as short turnaround time and small size for point-of-care molecular diagnostics. Here, we report a multi-channel plasmonic real-time reverse-transcription polymerase chain reaction (mpRT-qPCR) assay for ultrafast and on-chip multi-target detection. The mpRT-qPCR system features two pairs of plasmonic thermocyclers for rapid nanostructure-driven amplification and microlens array fluorescence microscopes for in situ multi-color fluorescence quantification. Each channel shows a physical dimension of 32 mm, 75 mm, and 25 mm in width, length, and thickness. The ultrathin microscopes simultaneously capture four different fluorescence images from two PCR chambers of a single cartridge at a single shot exposure per PCR cycle of four different excitation light sources. The experimental results demonstrate a single assay result of high-throughput amplification and multi-target quantification for RNA-dependent RNA polymerase, nucleocapsid, and human ribonuclease P genes in SARS-CoV-2 RNA detection. The mpRT-PCR increases the number of tests four times over the single RT-PCR and exhibits a short detection time of 15 min for the four RT-PCR reactions. This point-of-care molecular diagnostic platform can reduce false negative results in clinical applications of virus detection and decentralize healthcare facilities with limited infrastructure.</text><annotation id="4"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="208" length="19"/><text>infectious diseases</text></annotation><annotation id="5"><infon key="type">Gene</infon><location offset="1135" length="28"/><text>RNA-dependent RNA polymerase</text></annotation><annotation id="6"><infon key="identifier">43740575</infon><infon key="type">Gene</infon><location offset="1165" length="12"/><text>nucleocapsid</text></annotation><annotation id="7"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1213" length="10"/><text>SARS-CoV-2</text></annotation></passage><relation id="R1"><infon key="score">0.9914</infon><infon key="role1">Disease|MESH:D000086382</infon><infon key="role2">Gene|43740575</infon><infon key="type">Association</infon><node refid="0" role="3,2"/></relation></document>
<document><id>37823613</id><passage><infon key="journal">Psychol Health Med;2023Oct12 1. doi:10.1080/13548506.2023.2269497</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">F&amp;#xf6;hner K, Seipp H, Becker A, Maulbecker-Armstrong C, Schneider A, Seifart U, van der Wardt V, </infon><offset>0</offset><text>Factors associated with return-to-work outcomes in inpatient rehabilitation - a systematic scoping review.</text></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>Inpatient rehabilitation is common in Germany to improve return-to-work outcomes. The objective of this systematic scoping review was to identify factors associated with return-to-work outcomes in musculoskeletal, psychological and oncological health conditions to improve tailoring of rehabilitation therapies. A search was completed in Embase, Medline, PsycInfo and AMED until May 2023 for articles investigating inpatient rehabilitation including working-age patients with oncological, musculoskeletal, or psychological diseases using a quantitative design and reporting factors associated with return-to-work outcomes. Screening of all titles and abstracts was completed by one reviewer, full texts were read by two reviewers. Quality appraisal and data extraction was completed by two reviewers. Data was analysed using a narrative synthesis. Eighteen studies of moderate quality were included. The review identified a wide range of return-to-work parameters including employment status, work ability, sickness absence, retirement status and duration of employment since rehabilitation. In addition, 48 psychological, health- and work-related factors associated with return-to-work parameters were identified. Only one RCT investigated the relationship between a depression prevention intervention and a return-to-work outcome (work ability), which showed a significant effect. In addition to the depression prevention intervention, only the factor 'health literacy' could be considered modifiable and be addressed as part of an inpatient rehabilitation programme. Furthermore, gradual work reintegration programs and/or workplace interventions in addition to inpatient rehabilitation should be further explored to improve return-to-work outcomes.</text><annotation id="6"><infon key="identifier">MESH:D000072716</infon><infon key="type">Disease</infon><location offset="339" length="11"/><text>oncological</text></annotation><annotation id="7"><infon key="identifier">MESH:D009140</infon><infon key="type">Disease</infon><location offset="583" length="55"/><text>oncological, musculoskeletal, or psychological diseases</text></annotation><annotation id="8"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1375" length="10"/><text>depression</text></annotation><annotation id="9"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1509" length="10"/><text>depression</text></annotation><annotation id="10"><infon key="type">Disease</infon><location offset="1641" length="9"/><text>inpatient</text></annotation><annotation id="11"><infon key="type">Disease</infon><location offset="1772" length="9"/><text>inpatient</text></annotation></passage></document>
<document><id>37823965</id><passage><infon key="journal">J Neural Transm (Vienna);2023Oct12. doi:10.1007/s00702-023-02706-6</infon><infon key="year">2023</infon><infon key="article-id_pmc">9908935</infon><infon key="type">title</infon><infon key="authors">Swinford-Jackson SE, Pierce RC, </infon><offset>0</offset><text>Deep brain stimulation for psychostimulant use disorders.</text></passage><passage><infon key="type">abstract</infon><offset>58</offset><text>Safe and effective therapeutics for psychostimulant use disorders remain elusive. Deep brain stimulation (DBS), which is FDA-approved for other indications, is a promising candidate for treating severe substance use disorders. We examine the clinical and preclinical evidence for DBS of the nucleus accumbens as a possible therapeutic option for cocaine and methamphetamine use disorders. Limitations of the literature to date, including the lack of females included in studies evaluating the efficacy of DBS, and new strategies to optimize brain stimulation approaches are also discussed.</text><annotation id="3"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="260" length="23"/><text>substance use disorders</text></annotation><annotation id="4"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="404" length="7"/><text>cocaine</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="416" length="29"/><text>methamphetamine use disorders</text></annotation></passage></document>
<document><id>37824316</id><passage><infon key="journal">IEEE Trans Image Process;2023; 32 5721. doi:10.1109/TIP.2023.3321461</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Alexandridis KP, Luo S, Nguyen A, Deng J, Zafeiriou S, </infon><offset>0</offset><text>Inverse Image Frequency for Long-tailed Image Recognition.</text></passage><passage><infon key="type">abstract</infon><offset>59</offset><text>The long-tailed distribution is a common phenomenon in the real world. Extracted large scale image datasets inevitably demonstrate the long-tailed property and models trained with imbalanced data can obtain high performance for the over-represented categories, but struggle for the under-represented categories, leading to biased predictions and performance degradation. To address this challenge, we propose a novel de-biasing method named Inverse Image Frequency (IIF). IIF is a multiplicative margin adjustment transformation of the logits in the classification layer of a convolutional neural network. Our method achieves stronger performance than similar works and it is especially useful for downstream tasks such as long-tailed instance segmentation as it produces fewer false positive detections. Our extensive experiments show that IIF surpasses the state of the art on many long-tailed benchmarks such as ImageNet-LT, CIFAR-LT, Places-LT and LVIS, reaching 55.8% top-1 accuracy with ResNet50 on ImageNet-LT and 26.3% segmentation AP with MaskRCNN ResNet50 on LVIS. Code available at https://github.com/kostas1515/iif.</text></passage></document>
<document><id>37824669</id><passage><infon key="journal">Science;2023Oct13; 382 (6667) 6484. doi:10.1126/science.adf6484</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lee BR, Dalley R, Miller JA, Chartrand T, Close J, Mann R, Mukora A, Ng L, Alfiler L, Baker K, Bertagnolli D, Brouner K, Casper T, Csajbok E, Donadio N, Driessens SLW, Egdorf T, Enstrom R, Galakhova AA, Gary A, Gelfand E, Goldy J, Hadley K, Heistek TS, Hill D, Hou WH, Johansen N, Jorstad N, Kim L, Kocsis AK, Kruse L, Kunst M, Le&amp;#xf3;n G, Long B, Mallory M, Maxwell M, McGraw M, McMillen D, Melief EJ, Molnar G, Mortrud MT, Newman D, Nyhus J, Opitz-Araya X, Ozsv&amp;#xe1;r A, Pham T, Pom A, Potekhina L, Rajanbabu R, Ruiz A, Sunkin SM, Sz&amp;#xf6;ts I, Taskin N, Thyagarajan B, Tieu M, Trinh J, Vargas S, Vumbaco D, Waleboer F, Walling-Bell S, Weed N, Williams G, Wilson J, Yao S, Zhou T, Barz&amp;#xf3; P, Bakken T, Cobbs C, Dee N, Ellenbogen RG, Esposito L, Ferreira M, Gouwens NW, Grannan B, Gwinn RP, Hauptman JS, Hodge R, Jarsky T, Keene CD, Ko AL, Korshoej AR, Levi BP, Meier K, Ojemann JG, Patel A, Ruzevick J, Silbergeld DL, Smith K, S&amp;#xf8;rensen JC, Waters J, Zeng H, Berg J, Capogna M, Goriounova NA, Kalmbach B, de Kock CPJ, Mansvelder HD, Sorensen SA, Tamas G, Lein ES, Ting JT, </infon><offset>0</offset><text>Signature morphoelectric properties of diverse GABAergic interneurons in the human neocortex.</text></passage><passage><infon key="type">abstract</infon><offset>94</offset><text>Human cortex transcriptomic studies have revealed a hierarchical organization of gamma-aminobutyric acid-producing (GABAergic) neurons from subclasses to a high diversity of more granular types. Rapid GABAergic neuron viral genetic labeling plus Patch-seq (patch-clamp electrophysiology plus single-cell RNA sequencing) sampling in human brain slices was used to reliably target and analyze GABAergic neuron subclasses and individual transcriptomic types. This characterization elucidated transitions between PVALB and SST subclasses, revealed morphological heterogeneity within an abundant transcriptomic type, identified multiple spatially distinct types of the primate-specialized double bouquet cells (DBCs), and shed light on cellular differences between homologous mouse and human neocortical GABAergic neuron types. These results highlight the importance of multimodal phenotypic characterization for refinement of emerging transcriptomic cell type taxonomies and for understanding conserved and specialized cellular properties of human brain cell types.</text><annotation id="2"><infon key="identifier">5816</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2137</infon><location offset="603" length="5"/><text>PVALB</text></annotation><annotation id="3"><infon key="identifier">6750</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">819</infon><location offset="613" length="3"/><text>SST</text></annotation></passage><relation id="R1"><infon key="score">0.9361</infon><infon key="role1">Gene|5816</infon><infon key="role2">Gene|6750</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation></document>
<document><id>37827140</id><passage><infon key="journal">Nanotechnology;2023Oct30; 35 (3) . doi:10.1088/1361-6528/ad02a3</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Onishchenko AI, Prokopiuk VY, Chumachenko VA, Virych PA, Tryfonyuk LY, Kutsevol NV, Tkachenko AS, </infon><offset>0</offset><text>Hemocompatibility of dextran-graft-polyacrylamide/zinc oxide nanosystems: Hemolysis or eryptosis?</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="21" length="28"/><text>dextran-graft-polyacrylamide</text></annotation><annotation id="4"><infon key="identifier">MESH:D015034</infon><infon key="type">Chemical</infon><location offset="50" length="10"/><text>zinc oxide</text></annotation><annotation id="5"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="74" length="9"/><text>Hemolysis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>98</offset><text>AIM: In this study, blood compatibility of ZnO nanoparticles-nanocomplex (D-PAA/ZnONPs(SO42-)) synthesized in situ into dextran-graft-polyacrylamide (D-PAA) using zinc oxide nanoparticles produced from zinc sulphate (D-PAA/ZnONPs(SO42-)) as a precursor was tested using hemolysis, osmotic fragility and eryptosis assays.&amp;#xD;Materials and methods. Dose-dependent ability to induce eryptosis was assessed following 24 h incubation at concentrations of 0-800 mg / L analyzing hallmarks of eryptosis (cell shrinkage and phosphatidylserine externalization), as well as reactive oxygen species (ROS) generation. Hemolysis was detected spectrophotometrically based on hemoglobin release following exposure to the D-PAA/ZnONPs(SO42-) nanocomplex. Osmotic fragility test (OFT) involved detection of hemolysis of red blood cells exposed to 0.2% saline solution following incubation with the D-PAA/ZnONPs(SO42-) nanocomplex. Additional incubation of the nanocomplex in the presence or absence of either ascorbic acid or EGTA was used to reveal the implication of oxidative stress- or Ca2+-mediated mechanisms in D-PAA/ZnONPs(SO42-) nanocomplex-induced erythrotoxicity.&amp;#xD;Results. Hemocompatibility assessment of the D-PAA/ZnONPs(SO42-) nanocomplex revealed that it induced hemolysis and reduced resistance of erythrocytes to osmotic stress at concentrations of above 400 and 200 mg / L, respectively. Oxidative stress- or Ca2+-mediated mechanisms were not involved in D-PAA/ZnONPs(SO42-) nanocomplex-induced hemolysis. Strikingly, the D-PAA/ZnONPs(SO42-) nanocomplex did not promote cell membrane scrambling, cell shrinkage and oxidative stress in red blood cells following the direct exposure for 24 h. Thus, the D-PAA/ZnONPs(SO42-) nanocomplex did not induce eryptosis in vitro. Eryptosis is generally considered to occur earlier than hemolysis in response to stress in order to prevent hemolytic cell death. Counterintuitively, our data suggest that hemolysis can be triggered by nanomaterials prior to eryptosis indicating that eryptosis and hemolysis assays should be used in combination for testing blood compatibility of nanomaterials. &amp;#xD;Conclusions. The D-PAA/ZnONPs(SO42-) nanocomplex has a good hemocompatibility profile at low concentrations. Hemocompatibility testing in nanotoxicology should include both eryptosis and hemolysis assays. &amp;#xD;&amp;#xD.</text><annotation id="61"><infon key="identifier">MESH:D015034</infon><infon key="type">Chemical</infon><location offset="141" length="3"/><text>ZnO</text></annotation><annotation id="62"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="172" length="5"/><text>D-PAA</text></annotation><annotation id="63"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="178" length="6"/><text>ZnONPs</text></annotation><annotation id="64"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="185" length="5"/><text>SO42-</text></annotation><annotation id="65"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="218" length="28"/><text>dextran-graft-polyacrylamide</text></annotation><annotation id="66"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="248" length="5"/><text>D-PAA</text></annotation><annotation id="67"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="261" length="24"/><text>zinc oxide nanoparticles</text></annotation><annotation id="68"><infon key="identifier">MESH:D019287</infon><infon key="type">Chemical</infon><location offset="300" length="13"/><text>zinc sulphate</text></annotation><annotation id="69"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="315" length="5"/><text>D-PAA</text></annotation><annotation id="70"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="321" length="6"/><text>ZnONPs</text></annotation><annotation id="71"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="328" length="5"/><text>SO42-</text></annotation><annotation id="72"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="368" length="9"/><text>hemolysis</text></annotation><annotation id="73"><infon key="identifier">MESH:D010718</infon><infon key="type">Chemical</infon><location offset="615" length="18"/><text>phosphatidylserine</text></annotation><annotation id="74"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="663" length="23"/><text>reactive oxygen species</text></annotation><annotation id="75"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="688" length="3"/><text>ROS</text></annotation><annotation id="76"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="705" length="9"/><text>Hemolysis</text></annotation><annotation id="77"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="805" length="5"/><text>D-PAA</text></annotation><annotation id="78"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="811" length="6"/><text>ZnONPs</text></annotation><annotation id="79"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="818" length="5"/><text>SO42-</text></annotation><annotation id="80"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="889" length="9"/><text>hemolysis</text></annotation><annotation id="81"><infon key="identifier">MESH:D012965</infon><infon key="type">Chemical</infon><location offset="934" length="6"/><text>saline</text></annotation><annotation id="82"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="980" length="5"/><text>D-PAA</text></annotation><annotation id="83"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="986" length="6"/><text>ZnONPs</text></annotation><annotation id="84"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="993" length="5"/><text>SO42-</text></annotation><annotation id="85"><infon key="identifier">MESH:D001205</infon><infon key="type">Chemical</infon><location offset="1091" length="13"/><text>ascorbic acid</text></annotation><annotation id="86"><infon key="identifier">MESH:D004533</infon><infon key="type">Chemical</infon><location offset="1108" length="4"/><text>EGTA</text></annotation><annotation id="87"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1172" length="4"/><text>Ca2+</text></annotation><annotation id="88"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1200" length="5"/><text>D-PAA</text></annotation><annotation id="89"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1206" length="6"/><text>ZnONPs</text></annotation><annotation id="90"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1213" length="5"/><text>SO42-</text></annotation><annotation id="91"><infon key="identifier">MESH:C543241</infon><infon key="type">Disease</infon><location offset="1240" length="28"/><text>erythrotoxicity.&amp;#xD;Results</text></annotation><annotation id="92"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1306" length="5"/><text>D-PAA</text></annotation><annotation id="93"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1312" length="6"/><text>ZnONPs</text></annotation><annotation id="94"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1319" length="5"/><text>SO42-</text></annotation><annotation id="95"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="1363" length="9"/><text>hemolysis</text></annotation><annotation id="96"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1512" length="4"/><text>Ca2+</text></annotation><annotation id="97"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1558" length="5"/><text>D-PAA</text></annotation><annotation id="98"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1564" length="6"/><text>ZnONPs</text></annotation><annotation id="99"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1571" length="5"/><text>SO42-</text></annotation><annotation id="100"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="1598" length="9"/><text>hemolysis</text></annotation><annotation id="101"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1625" length="5"/><text>D-PAA</text></annotation><annotation id="102"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1631" length="6"/><text>ZnONPs</text></annotation><annotation id="103"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1638" length="5"/><text>SO42-</text></annotation><annotation id="104"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1804" length="5"/><text>D-PAA</text></annotation><annotation id="105"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1810" length="6"/><text>ZnONPs</text></annotation><annotation id="106"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1817" length="5"/><text>SO42-</text></annotation><annotation id="107"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="1927" length="9"/><text>hemolysis</text></annotation><annotation id="108"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="1979" length="9"/><text>hemolytic</text></annotation><annotation id="109"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="2043" length="9"/><text>hemolysis</text></annotation><annotation id="110"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="2136" length="9"/><text>hemolysis</text></annotation><annotation id="111"><infon key="type">Disease</infon><location offset="2235" length="14"/><text>xD;Conclusions</text></annotation><annotation id="112"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2255" length="5"/><text>D-PAA</text></annotation><annotation id="113"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2261" length="6"/><text>ZnONPs</text></annotation><annotation id="114"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2268" length="5"/><text>SO42-</text></annotation><annotation id="115"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="2425" length="9"/><text>hemolysis</text></annotation></passage><relation id="R1"><infon key="score">0.6289</infon><infon key="role1">Chemical|MESH:D015034</infon><infon key="role2">Disease|MESH:D006461</infon><infon key="type">Association</infon><node refid="0" role="1,2"/></relation></document>
<document><id>37827491</id><passage><infon key="journal">Adv Nutr;2023Oct10. doi:10.1016/j.advnut.2023.10.003</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Schroor MM, Joris PJ, Plat J, Mensink RP, </infon><offset>0</offset><text>Effects of Intermittent Energy Restriction Compared to Those of Continuous Energy Restriction on Body Composition and Cardiometabolic Risk Markers - A Systematic Review and Meta-Analysis of Randomized Controlled Trials in Adults.</text></passage><passage><infon key="type">abstract</infon><offset>230</offset><text>The interest in intermittent energy restriction (IER) diets as weight loss approach is increasing. Different IER protocols exist, including time-restricted eating (TRE), alternate-day fasting (ADF), and the 5:2 diet. This meta-analysis compared the effects of these IER diets to continuous energy restriction (CER) on anthropometrics and cardiometabolic risk markers in healthy adults. Twenty-eight trials were identified that studied TRE (k=7), ADF (k=10), or the 5:2 diet (k=11) for 2 to 52 weeks. Energy intakes between intervention groups within a study were comparable (17 trials), lower in IER (5 trials) or not reported (6 trials). Weighted mean differences (WMD) were calculated using fixed- or random-effects models. Changes in body weight (WMD: -0.42 kg; 95% CI: -0.96 to 0.13; p=0.132) and fat mass (WMD: -0.31 kg; 95% CI: -0.98 to 0.36; p=0.362) were comparable when results of the three IER diets were combined and compared to those of CER. All IER diets combined reduced fat free mass (WMD: -0.20 kg; 95% CI: -0.39 to -0.01; p=0.044) and waist circumference (WMD: -0.91 cm; 95% CI: -1.76 to -0.06; p=0.036) more than CER. Effects on body mass index (BMI), glucose, insulin, homeostatic model assessment for insulin resistance (HOMA-IR), serum lipids and lipoproteins, and blood pressure did not differ. Further, TRE reduced body weight, fat mass, and fat mass more than CER, while ADF improved HOMA-IR more. BMI reduced less in the 5:2 diet compared to CER. In conclusion, the three IER diets combined did not lead to superior improvements in anthropometrics and cardiometabolic risk markers compared to CER diets. Slightly greater reductions were however observed in fat free mass and waist circumference. To what extent differences in energy intakes between groups within studies may have influenced these outcomes should be addressed in future studies. This meta-analysis was registered at PROSPERO as CRD42022350008.</text><annotation id="5"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="293" length="11"/><text>weight loss</text></annotation><annotation id="6"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1400" length="7"/><text>glucose</text></annotation><annotation id="7"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="1409" length="7"/><text>insulin</text></annotation><annotation id="8"><infon key="identifier">MESH:D007333</infon><infon key="type">Disease</infon><location offset="1451" length="18"/><text>insulin resistance</text></annotation><annotation id="9"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1487" length="6"/><text>lipids</text></annotation></passage></document>
<document><id>37827841</id><passage><infon key="journal">J Nucl Med;2023Oct12. doi:10.2967/jnumed.123.266313</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, Ooe K, Toyoshima A, Wang Y, Haba H, Kurimoto K, Kobayashi T, Shimosegawa E, Tomiyama N, Fukase K, Naka T, </infon><offset>0</offset><text>Immuno-PET and Targeted alpha-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.</text><annotation id="4"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="49" length="10"/><text>Glypican-1</text></annotation><annotation id="5"><infon key="identifier">MESH:C000615502</infon><infon key="type">Chemical</infon><location offset="82" length="4"/><text>89Zr</text></annotation><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="90" length="5"/><text>211At</text></annotation><annotation id="7"><infon key="identifier">MESH:D021441</infon><infon key="type">Disease</infon><location offset="124" length="32"/><text>Pancreatic Ductal Adenocarcinoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>158</offset><text>Glypican-1 (GPC1) is overexpressed in several solid cancers and is associated with tumor progression, whereas its expression is low in normal tissues. This study aimed to evaluate the potential of an anti-GPC1 monoclonal antibody (GPC1 mAb) labeled with 89Zr or 211At as a theranostic target in pancreatic ductal adenocarcinoma. Methods: GPC1 mAb clone 01a033 was labeled with 89Zr or 211At with a deferoxamine or decaborane linker, respectively. The internalization ability of GPC1 mAb was evaluated by fluorescence conjugation using a confocal microscope. PANC-1 xenograft mice (n = 6) were intravenously administered [89Zr]GPC1 mAb (0.91 +- 0.10 MBq), and PET/CT scanning was performed for 7 d. Uptake specificity was confirmed through a comparative study using GPC1-positive (BxPC-3) and GPC1-negative (BxPC-3 GPC1-knockout) xenografts (each n = 3) and a blocking study. DNA double-strand breaks were evaluated using the gammaH2AX antibody. The antitumor effect was evaluated by administering [211At]GPC1 mAb (~100 kBq) to PANC-1 xenograft mice (n = 10). Results: GPC1 mAb clone 01a033 showed increased internalization ratios over time. One day after administration, a high accumulation of [89Zr]GPC1 mAb was observed in the PANC-1 xenograft (SUVmax, 3.85 +- 0.10), which gradually decreased until day 7 (SUVmax, 2.16 +- 0.30). The uptake in the BxPC-3 xenograft was significantly higher than in the BxPC-3 GPC1-knockout xenograft (SUVmax, 4.66 +- 0.40 and 2.36 +- 0.36, respectively; P = 0.05). The uptake was significantly inhibited in the blocking group compared with the nonblocking group (percentage injected dose per gram, 7.3 +- 1.3 and 12.4 +- 3.0, respectively; P = 0.05). DNA double-strand breaks were observed by adding 150 kBq of [211At]GPC1 and were significantly suppressed by the internalization inhibitor (dynasore), suggesting a substantial contribution of the internalization ability to the antitumor effect. Tumor growth suppression was observed in PANC-1 mice after the administration of [211At]GPC1 mAb. Internalization inhibitors (prochlorperazine) significantly inhibited the therapeutic effect of [211At]GPC1 mAb, suggesting an essential role in targeted alpha-therapy. Conclusion: [89Zr]GPC1 mAb PET showed high tumoral uptake in the early phase after administration, and targeted alpha-therapy using [211At]GPC1 mAb showed tumor growth suppression. GPC1 is a promising target for future applications for the precise diagnosis of pancreatic ductal adenocarcinoma and GPC1-targeted theranostics.</text><annotation id="51"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="158" length="10"/><text>Glypican-1</text></annotation><annotation id="52"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="170" length="4"/><text>GPC1</text></annotation><annotation id="53"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="204" length="13"/><text>solid cancers</text></annotation><annotation id="54"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="241" length="5"/><text>tumor</text></annotation><annotation id="55"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="363" length="4"/><text>GPC1</text></annotation><annotation id="56"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="389" length="4"/><text>GPC1</text></annotation><annotation id="57"><infon key="identifier">MESH:C000615502</infon><infon key="type">Chemical</infon><location offset="412" length="4"/><text>89Zr</text></annotation><annotation id="58"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="420" length="5"/><text>211At</text></annotation><annotation id="59"><infon key="identifier">MESH:D021441</infon><infon key="type">Disease</infon><location offset="453" length="32"/><text>pancreatic ductal adenocarcinoma</text></annotation><annotation id="60"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="496" length="4"/><text>GPC1</text></annotation><annotation id="61"><infon key="identifier">MESH:C000615502</infon><infon key="type">Chemical</infon><location offset="535" length="4"/><text>89Zr</text></annotation><annotation id="62"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="543" length="5"/><text>211At</text></annotation><annotation id="63"><infon key="identifier">MESH:D003676</infon><infon key="type">Chemical</infon><location offset="556" length="12"/><text>deferoxamine</text></annotation><annotation id="64"><infon key="identifier">MESH:C100070</infon><infon key="type">Chemical</infon><location offset="572" length="10"/><text>decaborane</text></annotation><annotation id="65"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="636" length="4"/><text>GPC1</text></annotation><annotation id="66"><infon key="identifier">CVCL:0480</infon><infon key="type">CellLine</infon><location offset="716" length="6"/><text>PANC-1</text></annotation><annotation id="67"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="784" length="4"/><text>GPC1</text></annotation><annotation id="68"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="923" length="4"/><text>GPC1</text></annotation><annotation id="69"><infon key="identifier">CVCL:0186</infon><infon key="type">CellLine</infon><location offset="938" length="6"/><text>BxPC-3</text></annotation><annotation id="70"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="950" length="4"/><text>GPC1</text></annotation><annotation id="71"><infon key="identifier">CVCL:0186</infon><infon key="type">CellLine</infon><location offset="965" length="6"/><text>BxPC-3</text></annotation><annotation id="72"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="972" length="4"/><text>GPC1</text></annotation><annotation id="73"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="1162" length="4"/><text>GPC1</text></annotation><annotation id="74"><infon key="identifier">CVCL:0480</infon><infon key="type">CellLine</infon><location offset="1185" length="6"/><text>PANC-1</text></annotation><annotation id="75"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="1226" length="4"/><text>GPC1</text></annotation><annotation id="76"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="1358" length="4"/><text>GPC1</text></annotation><annotation id="77"><infon key="identifier">CVCL:0480</infon><infon key="type">CellLine</infon><location offset="1387" length="6"/><text>PANC-1</text></annotation><annotation id="78"><infon key="identifier">CVCL:0186</infon><infon key="type">CellLine</infon><location offset="1508" length="6"/><text>BxPC-3</text></annotation><annotation id="79"><infon key="identifier">CVCL:0186</infon><infon key="type">CellLine</infon><location offset="1562" length="6"/><text>BxPC-3</text></annotation><annotation id="80"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="1569" length="4"/><text>GPC1</text></annotation><annotation id="81"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="1911" length="4"/><text>GPC1</text></annotation><annotation id="82"><infon key="identifier">MESH:C511794</infon><infon key="type">Chemical</infon><location offset="1984" length="8"/><text>dynasore</text></annotation><annotation id="83"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="2089" length="5"/><text>Tumor</text></annotation><annotation id="84"><infon key="identifier">CVCL:0480</infon><infon key="type">CellLine</infon><location offset="2130" length="6"/><text>PANC-1</text></annotation><annotation id="85"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="2177" length="4"/><text>GPC1</text></annotation><annotation id="86"><infon key="identifier">MESH:D011346</infon><infon key="type">Chemical</infon><location offset="2215" length="16"/><text>prochlorperazine</text></annotation><annotation id="87"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="2290" length="4"/><text>GPC1</text></annotation><annotation id="88"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="2374" length="4"/><text>GPC1</text></annotation><annotation id="89"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="2495" length="4"/><text>GPC1</text></annotation><annotation id="90"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="2511" length="5"/><text>tumor</text></annotation><annotation id="91"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="2537" length="4"/><text>GPC1</text></annotation><annotation id="92"><infon key="identifier">MESH:D021441</infon><infon key="type">Disease</infon><location offset="2617" length="32"/><text>pancreatic ductal adenocarcinoma</text></annotation><annotation id="93"><infon key="identifier">14733</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20477</infon><location offset="2654" length="4"/><text>GPC1</text></annotation></passage><relation id="R1"><infon key="score">0.9431</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|14733</infon><infon key="type">Association</infon><node refid="0" role="6,4"/></relation><relation id="R2"><infon key="score">0.9647</infon><infon key="role1">Chemical|MESH:C000615502</infon><infon key="role2">Disease|MESH:D021441</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="1,3"/></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D021441</infon><infon key="role2">Gene|14733</infon><infon key="type">Association</infon><node refid="2" role="3,0"/></relation><relation id="R4"><infon key="score">0.9959</infon><infon key="role1">Chemical|MESH:C511794</infon><infon key="role2">Chemical|MESH:D011346</infon><infon key="type">Association</infon><node refid="3" role="39,44"/></relation><relation id="R5"><infon key="score">0.9895</infon><infon key="role1">Chemical|MESH:C000615502</infon><infon key="role2">Gene|14733</infon><infon key="type">Association</infon><node refid="4" role="1,0"/></relation></document>
<document><id>37830309</id><passage><infon key="journal">Am J Clin Pathol;2023Oct13. doi:10.1093/ajcp/aqad120</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Modi MB, Kiszluk A, Chai JN, Edema U, Ma MY, Sica RA, Wang Y, Shi Y, </infon><offset>0</offset><text>Clinicopathologic characterization of cutaneous adult T-cell leukemia/lymphoma: A single tertiary care center experience in the United States.</text><annotation id="1"><infon key="identifier">MESH:D015459</infon><infon key="type">Disease</infon><location offset="48" length="30"/><text>adult T-cell leukemia/lymphoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>143</offset><text>OBJECTIVES: Adult T-cell leukemia/lymphoma (ATLL) is a rare aggressive T-cell leukemia/lymphoma associated with human T lymphotropic virus type 1 infection. The patients might present with skin rash before, at, or after the diagnosis. The dermatopathologic finding might be diagnostically very challenging. METHODS: We retrospectively identified 110 patients with ATLL at a single institution in a 19-year period, with 19 patients having skin biopsies. Clinical, dermatopathologic, immunophenotypic, and molecular findings were studied. RESULTS: The cohort included 13 skin-first (5 acute, 5 lymphomatous, 2 chronic, 1 smoldering), 6 skin-second (4 acute, 1 lymphomatous, 1 smoldering), and 91 patients without skin biopsy. Some nonphotoprotected areas of body such as the forearm and lower lip were also seen. Skin manifestations included papular (5), erythroderma (1), nodulotumoral (3), plaques (1), patches (1), and a combination of skin rashes (2). Histopathologic findings included large pleomorphic cells, angiocentrism, epidermal infiltration with large Pautrier-like microabscesses, and folliculotropism. Fifteen (78.9%) cases showed CD4+/CD7-/CD25+. Next-generation sequencing study was conducted on 5 patients using either blood or bone marrow samples, revealing multiple genetic mutations across multiple signaling pathways. CONCLUSIONS: Pleomorphic large, atypical cells with CD4+/CD25+/CD7- immunophenotype from a non-"bathing trunk" location, especially in a patient from endemic regions, raise suspicion for ATLL. T-cell receptor gene rearrangement is almost always positive, and the neoplasm usually demonstrates multiple mutations by next-generation sequencing study.</text><annotation id="21"><infon key="identifier">MESH:D015459</infon><infon key="type">Disease</infon><location offset="155" length="30"/><text>Adult T-cell leukemia/lymphoma</text></annotation><annotation id="22"><infon key="identifier">MESH:D015459</infon><infon key="type">Disease</infon><location offset="187" length="4"/><text>ATLL</text></annotation><annotation id="23"><infon key="identifier">MESH:D015459</infon><infon key="type">Disease</infon><location offset="214" length="24"/><text>T-cell leukemia/lymphoma</text></annotation><annotation id="24"><infon key="identifier">MESH:D015490</infon><infon key="type">Disease</infon><location offset="261" length="37"/><text>T lymphotropic virus type 1 infection</text></annotation><annotation id="25"><infon key="identifier">MESH:D005076</infon><infon key="type">Disease</infon><location offset="332" length="9"/><text>skin rash</text></annotation><annotation id="26"><infon key="identifier">MESH:D015459</infon><infon key="type">Disease</infon><location offset="507" length="4"/><text>ATLL</text></annotation><annotation id="27"><infon key="identifier">MESH:D013967</infon><infon key="type">Disease</infon><location offset="735" length="12"/><text>lymphomatous</text></annotation><annotation id="28"><infon key="identifier">MESH:D013967</infon><infon key="type">Disease</infon><location offset="801" length="12"/><text>lymphomatous</text></annotation><annotation id="29"><infon key="identifier">MESH:D003873</infon><infon key="type">Disease</infon><location offset="996" length="12"/><text>erythroderma</text></annotation><annotation id="30"><infon key="type">Disease</infon><location offset="1014" length="13"/><text>nodulotumoral</text></annotation><annotation id="31"><infon key="identifier">MESH:D005076</infon><infon key="type">Disease</infon><location offset="1080" length="11"/><text>skin rashes</text></annotation><annotation id="32"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="1286" length="3"/><text>CD4</text></annotation><annotation id="33"><infon key="identifier">924</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4471</infon><location offset="1291" length="3"/><text>CD7</text></annotation><annotation id="34"><infon key="identifier">3559</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">360</infon><location offset="1296" length="4"/><text>CD25</text></annotation><annotation id="35"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="1532" length="3"/><text>CD4</text></annotation><annotation id="36"><infon key="identifier">3559</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">360</infon><location offset="1537" length="4"/><text>CD25</text></annotation><annotation id="37"><infon key="identifier">924</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4471</infon><location offset="1543" length="3"/><text>CD7</text></annotation><annotation id="38"><infon key="identifier">MESH:D015459</infon><infon key="type">Disease</infon><location offset="1667" length="4"/><text>ATLL</text></annotation><annotation id="39"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1743" length="8"/><text>neoplasm</text></annotation></passage><relation id="R1"><infon key="score">0.6747</infon><infon key="role1">Disease|MESH:D015459</infon><infon key="role2">Gene|3559</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="18,16"/></relation><relation id="R2"><infon key="score">0.9714</infon><infon key="role1">Disease|MESH:D015459</infon><infon key="role2">Gene|924</infon><infon key="type">Association</infon><node refid="1" role="18,17"/></relation><relation id="R3"><infon key="score">0.5158</infon><infon key="role1">Disease|MESH:D015459</infon><infon key="role2">Gene|920</infon><infon key="type">Association</infon><node refid="2" role="18,15"/></relation></document>
<document><id>37831013</id><passage><infon key="journal">Eur J Neurosci;2023Oct13. doi:10.1111/ejn.16160</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yuan WQ, Huang WP, Jiang YC, Xu H, Duan CS, Chen NH, Liu YJ, Fu XM, </infon><offset>0</offset><text>The function of astrocytes and their role in neurological diseases.</text><annotation id="1"><infon key="identifier">MESH:D020271</infon><infon key="type">Disease</infon><location offset="45" length="21"/><text>neurological diseases</text></annotation></passage><passage><infon key="type">abstract</infon><offset>68</offset><text>Astrocytes have countless links with neurons. Previously, astrocytes were only considered a scaffold of neurons; in fact, astrocytes perform a variety of functions, including providing support for neuronal structures and energy metabolism, offering isolation and protection and influencing the formation, function and elimination of synapses. Because of these functions, astrocytes play an critical role in central nervous system (CNS) diseases. The regulation of the secretiory factors, receptors, channels and pathways of astrocytes can effectively inhibit the occurrence and development of CNS diseases, such as neuromyelitis optica (NMO), multiple sclerosis, Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease. The expression of aquaporin 4 in AS is directly related to NMO and indirectly involved in the clearance of Abeta and tau proteins in AD. Connexin 43 has a bidirectional effect on glutamate diffusion at different stages of stroke. Interestingly, astrocytes reduce the occurrence of PD through multiple effects such as secretion of related factors, mitochondrial autophagy and aquaporin 4. Therefore, this review is focused on the structure and function of astrocytes and the correlation between astrocytes and CNS diseases and drug treatment to explore the new functions of astrocytes with the astrocytes as the target. This, in turn, would provide a reference for the development of new drugs to protect neurons and promote the recovery of nerve function.</text><annotation id="23"><infon key="identifier">MESH:D002493</infon><infon key="type">Disease</infon><location offset="475" length="37"/><text>central nervous system (CNS) diseases</text></annotation><annotation id="24"><infon key="identifier">MESH:D002493</infon><infon key="type">Disease</infon><location offset="661" length="12"/><text>CNS diseases</text></annotation><annotation id="25"><infon key="identifier">MESH:D009471</infon><infon key="type">Disease</infon><location offset="683" length="20"/><text>neuromyelitis optica</text></annotation><annotation id="26"><infon key="identifier">MESH:D009471</infon><infon key="type">Disease</infon><location offset="705" length="3"/><text>NMO</text></annotation><annotation id="27"><infon key="identifier">MESH:D009103</infon><infon key="type">Disease</infon><location offset="711" length="18"/><text>multiple sclerosis</text></annotation><annotation id="28"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="731" length="19"/><text>Alzheimer's disease</text></annotation><annotation id="29"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="752" length="2"/><text>AD</text></annotation><annotation id="30"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="757" length="19"/><text>Parkinson's disease</text></annotation><annotation id="31"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="778" length="2"/><text>PD</text></annotation><annotation id="32"><infon key="identifier">MESH:D006816</infon><infon key="type">Disease</infon><location offset="786" length="20"/><text>Huntington's disease</text></annotation><annotation id="33"><infon key="identifier">361</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37507</infon><location offset="826" length="11"/><text>aquaporin 4</text></annotation><annotation id="34"><infon key="identifier">MESH:D009471</infon><infon key="type">Disease</infon><location offset="867" length="3"/><text>NMO</text></annotation><annotation id="35"><infon key="identifier">351</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56379</infon><location offset="915" length="5"/><text>Abeta</text></annotation><annotation id="36"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="925" length="3"/><text>tau</text></annotation><annotation id="37"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="941" length="2"/><text>AD</text></annotation><annotation id="38"><infon key="identifier">2697</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136</infon><location offset="945" length="11"/><text>Connexin 43</text></annotation><annotation id="39"><infon key="identifier">MESH:D018698</infon><infon key="type">Chemical</infon><location offset="987" length="9"/><text>glutamate</text></annotation><annotation id="40"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="1030" length="6"/><text>stroke</text></annotation><annotation id="41"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="1089" length="2"/><text>PD</text></annotation><annotation id="42"><infon key="identifier">361</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37507</infon><location offset="1183" length="11"/><text>aquaporin 4</text></annotation><annotation id="43"><infon key="identifier">MESH:D002493</infon><infon key="type">Disease</infon><location offset="1317" length="12"/><text>CNS diseases</text></annotation></passage><relation id="R1"><infon key="score">0.6113</infon><infon key="role1">Disease|MESH:D000544</infon><infon key="role2">Gene|361</infon><infon key="type">Association</infon><node refid="0" role="16,11"/></relation><relation id="R2"><infon key="score">0.9955</infon><infon key="role1">Disease|MESH:D010300</infon><infon key="role2">Gene|361</infon><infon key="type">Association</infon><node refid="1" role="20,21"/></relation><relation id="R3"><infon key="score">0.9984</infon><infon key="role1">Disease|MESH:D009471</infon><infon key="role2">Gene|361</infon><infon key="type">Association</infon><node refid="2" role="13,11"/></relation><relation id="R4"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D020521</infon><infon key="role2">Gene|2697</infon><infon key="type">Association</infon><node refid="3" role="19,17"/></relation><relation id="R5"><infon key="score">0.9979</infon><infon key="role1">Gene|361</infon><infon key="role2">Gene|4137</infon><infon key="type">Association</infon><node refid="4" role="11,15"/></relation><relation id="R6"><infon key="score">0.9996</infon><infon key="role1">Chemical|MESH:D018698</infon><infon key="role2">Disease|MESH:D020521</infon><infon key="type">Association</infon><node refid="5" role="18,19"/></relation><relation id="R7"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D000544</infon><infon key="role2">Gene|4137</infon><infon key="type">Association</infon><node refid="6" role="16,15"/></relation><relation id="R8"><infon key="score">0.9295</infon><infon key="role1">Gene|351</infon><infon key="role2">Gene|361</infon><infon key="type">Association</infon><node refid="7" role="14,11"/></relation><relation id="R9"><infon key="score">0.9996</infon><infon key="role1">Chemical|MESH:D018698</infon><infon key="role2">Gene|2697</infon><infon key="type">Association</infon><node refid="8" role="18,17"/></relation></document>
<document><id>37831364</id><passage><infon key="journal">J Racial Ethn Health Disparities;2023Oct13. doi:10.1007/s40615-023-01827-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">9628943</infon><infon key="type">title</infon><infon key="authors">Carrico S, Zitta JP, Stevens E, Jenkins R, Mortiboy M, Jenks JD, </infon><offset>0</offset><text>Mpox Vaccination and the Role of Social Vulnerability in Durham County, North Carolina, USA.</text><annotation id="1"><infon key="type">Disease</infon><location offset="0" length="4"/><text>Mpox</text></annotation></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>BACKGROUND: Disparities in vaccine coverage among groups in the USA is common, possibly due to higher vaccine hesitancy in certain populations, difficulty accessing vaccines, and underlying social vulnerability. METHODS: The aim of this study was to investigate the association between mpox vaccine administration, social determinants of health, and social vulnerability index (SVI) in Durham County, North Carolina, USA. Random forest regression (RFE) and min-max scaling preprocessing were used to predict mpox vaccinations in Durham County at the census tract level. The top eleven most influential features and their correlations with mpox vaccination were calculated. RESULTS: Non-Hispanic white individuals, males, and those between the ages of 20 and 40 years were overrepresented in mpox vaccine reception in Durham County. Surprisingly, lacking a high school diploma, lacking health insurance, lacking a household vehicle, and living below the poverty line were all positively associated with receiving the mpox vaccine. Being a Black or African American and Hispanic or Latino individual was also positively associated with receiving the mpox vaccine. DISCUSSION: Vaccine outreach efforts in Durham County, North Carolina, had success in reaching at-risk individuals, including socially vulnerable individuals. Future research should focus more specifically on how social vulnerability relates to vaccine reception for vaccine-preventable diseases.</text><annotation id="8"><infon key="identifier">MESH:C051836</infon><infon key="type">Chemical</infon><location offset="601" length="4"/><text>mpox</text></annotation><annotation id="9"><infon key="identifier">MESH:C051836</infon><infon key="type">Chemical</infon><location offset="732" length="4"/><text>mpox</text></annotation><annotation id="10"><infon key="identifier">MESH:C051836</infon><infon key="type">Chemical</infon><location offset="884" length="4"/><text>mpox</text></annotation><annotation id="11"><infon key="identifier">MESH:C051836</infon><infon key="type">Chemical</infon><location offset="1109" length="4"/><text>mpox</text></annotation><annotation id="12"><infon key="identifier">MESH:C051836</infon><infon key="type">Chemical</infon><location offset="1241" length="4"/><text>mpox</text></annotation><annotation id="13"><infon key="identifier">MESH:D000079263</infon><infon key="type">Disease</infon><location offset="1522" length="28"/><text>vaccine-preventable diseases</text></annotation></passage></document>
<document><id>37832416</id><passage><infon key="journal">Food Chem;2024Mar15; 436 137680. doi:10.1016/j.foodchem.2023.137680</infon><infon key="year">2024</infon><infon key="type">title</infon><infon key="authors">Guo Y, Wang N, Wang D, Luo S, Zhang H, Yu D, Wang L, Elfalleh W, Liao C, </infon><offset>0</offset><text>Preparation of vacuum-assisted conjugated linoleic acid phospholipids under nitrogen: Mechanism of acyl migration of lysophospholipids.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="31" length="38"/><text>conjugated linoleic acid phospholipids</text></annotation><annotation id="4"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="76" length="8"/><text>nitrogen</text></annotation><annotation id="5"><infon key="identifier">MESH:D008246</infon><infon key="type">Chemical</infon><location offset="117" length="17"/><text>lysophospholipids</text></annotation></passage><passage><infon key="type">abstract</infon><offset>136</offset><text>Sn-Glycerol-3-phosphatidylcholine (GPC) was prepared by hydrolysis of phosphatidylcholine (PC) catalyzed by phospholipase A1 (PLA1). Nitrogen flow assisted the esterification of conjugated linoleic acid (CLA) and GPC to produce conjugated linoleic acid lysophosphatidylcholine (LPC - CLA). The effects of different reaction conditions on the PC conversion and acyl migration rates were investigated, and the acyl migration mechanism under acidic and alkaline conditions was studied. In addition, the optimum conditions for the esterification of CLA and GPC were selected. The optimal condition for the hydrolysis of PC was an enzyme loading of 5 %, pH of 5, reaction temperature of 50 C, and reaction time of 3 h. The results also showed that the maximum esterification rate reached 82.37 % at an enzyme loading of 15 %, CLA/GPC molar ratio of 50:1, and vacuum pressure of 13.3 kPa. This study not only improved the bioavailability of PC but also effectively increased the content of LPC - CLA.</text><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="136" length="33"/><text>Sn-Glycerol-3-phosphatidylcholine</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="171" length="3"/><text>GPC</text></annotation><annotation id="29"><infon key="identifier">MESH:D010713</infon><infon key="type">Chemical</infon><location offset="206" length="19"/><text>phosphatidylcholine</text></annotation><annotation id="30"><infon key="identifier">MESH:D010713</infon><infon key="type">Chemical</infon><location offset="227" length="2"/><text>PC</text></annotation><annotation id="31"><infon key="identifier">200879</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">71802</infon><location offset="244" length="16"/><text>phospholipase A1</text></annotation><annotation id="32"><infon key="identifier">200879</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">71802</infon><location offset="262" length="4"/><text>PLA1</text></annotation><annotation id="33"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="269" length="8"/><text>Nitrogen</text></annotation><annotation id="34"><infon key="identifier">MESH:D044243</infon><infon key="type">Chemical</infon><location offset="314" length="24"/><text>conjugated linoleic acid</text></annotation><annotation id="35"><infon key="identifier">MESH:D044243</infon><infon key="type">Chemical</infon><location offset="340" length="3"/><text>CLA</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="349" length="3"/><text>GPC</text></annotation><annotation id="37"><infon key="identifier">MESH:D044243</infon><infon key="type">Chemical</infon><location offset="364" length="24"/><text>conjugated linoleic acid</text></annotation><annotation id="38"><infon key="identifier">MESH:D008244</infon><infon key="type">Chemical</infon><location offset="389" length="23"/><text>lysophosphatidylcholine</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="414" length="9"/><text>LPC - CLA</text></annotation><annotation id="40"><infon key="identifier">MESH:D010713</infon><infon key="type">Chemical</infon><location offset="478" length="2"/><text>PC</text></annotation><annotation id="41"><infon key="identifier">MESH:D044243</infon><infon key="type">Chemical</infon><location offset="681" length="3"/><text>CLA</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="689" length="3"/><text>GPC</text></annotation><annotation id="43"><infon key="identifier">MESH:D010713</infon><infon key="type">Chemical</infon><location offset="752" length="2"/><text>PC</text></annotation><annotation id="44"><infon key="identifier">MESH:D044243</infon><infon key="type">Chemical</infon><location offset="957" length="3"/><text>CLA</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="961" length="3"/><text>GPC</text></annotation><annotation id="46"><infon key="identifier">MESH:D010713</infon><infon key="type">Chemical</infon><location offset="1071" length="2"/><text>PC</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1120" length="9"/><text>LPC - CLA</text></annotation></passage><relation id="R1"><infon key="score">0.9148</infon><infon key="role1">Chemical|MESH:D009584</infon><infon key="role2">Chemical|MESH:D044243</infon><infon key="type">Association</infon><node refid="0" role="9,10"/></relation><relation id="R2"><infon key="score">0.6425</infon><infon key="role1">Chemical|MESH:D008244</infon><infon key="role2">Chemical|MESH:D044243</infon><infon key="type">Association</infon><node refid="1" role="14,10"/></relation><relation id="R3"><infon key="score">0.835</infon><infon key="role1">Chemical|MESH:D008244</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="14,9"/></relation><relation id="R4"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D010713</infon><infon key="role2">Gene|200879</infon><infon key="type">Association</infon><node refid="3" role="5,7"/></relation></document>
<document><id>37832766</id><passage><infon key="journal">Environ Res;2023Oct11; 239 (Pt 2) 117376. doi:10.1016/j.envres.2023.117376</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cantera S, Rodr&amp;#xed;guez E, Santaella Vecchini N, L&amp;#xf3;pez JC, Garc&amp;#xed;a-Encina PA, Sousa DZ, Mu&amp;#xf1;oz R, </infon><offset>0</offset><text>Resilience and robustness of alphaproteobacterial methanotrophs upon methane feast-famine scenarios.</text><annotation id="1"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="69" length="7"/><text>methane</text></annotation></passage><passage><infon key="type">abstract</infon><offset>101</offset><text>Most of methane (CH4) emissions contain low CH4 concentrations and typically occur at irregular intervals, which hinders the implementation and performance of methane abatement processes. This study aimed at understanding the metabolic mechanisms that allow methane oxidizing bacteria (MOB) to survive for long periods of time under methane starvation. To this aim, we used an omics-approach and studied the diversity and metabolism of MOB and non-MOB in bioreactors exposed to low CH4 concentrations under feast-famine cycles of 5 days and supplied with nutrient-rich broth. The 16S rRNA and the pmoA transcripts revealed that the most abundant and active MOB during feast and famine conditions belonged to the alphaproteobacterial genus Methylocystis (91-65%). The closest Methylocystis species were M. parvus and M. echinoides. Nitrifiers and denitrifiers were the most representative non-MOB communities, which likely acted as detoxifiers of the system. During starvation periods, the induced activity of CH4 oxidation was not lost, with the particulate methane monooxygenase of alphaproteobacterial MOB playing a key role in energy production. The polyhydroxyalkanoate and nitrification metabolisms of MOB had also an important role during feast-famine cycles, maintaining cell viability when CH4 concentrations were negligible. This research shows that there is an emergence and resilience of conventional alphaproteobacterial MOB, being the genus Methylocystis a centrepiece in environments exposed to dilute and intermittent methane emissions. This knowledge can be applied to the operation of bioreactors subjected to the treatment of dilute and discontinuous emissions via controlled bioaugmentation.</text><annotation id="13"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="109" length="7"/><text>methane</text></annotation><annotation id="14"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="118" length="3"/><text>CH4</text></annotation><annotation id="15"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="145" length="3"/><text>CH4</text></annotation><annotation id="16"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="260" length="7"/><text>methane</text></annotation><annotation id="17"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="359" length="17"/><text>methane oxidizing</text></annotation><annotation id="18"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="434" length="7"/><text>methane</text></annotation><annotation id="19"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="583" length="3"/><text>CH4</text></annotation><annotation id="20"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="1110" length="3"/><text>CH4</text></annotation><annotation id="21"><infon key="identifier">MESH:D054813</infon><infon key="type">Chemical</infon><location offset="1254" length="20"/><text>polyhydroxyalkanoate</text></annotation><annotation id="22"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="1399" length="3"/><text>CH4</text></annotation><annotation id="23"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="1634" length="7"/><text>methane</text></annotation></passage></document>
<document><id>37833116</id><passage><infon key="journal">Arch Cardiovasc Dis;2023Sep29. doi:10.1016/j.acvd.2023.09.002</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Demina A, Cottin Y, Chagu&amp;#xe9; F, Bentounes SA, Bichat F, Genet T, Vigny P, Zeller M, Fauchier L, </infon><offset>0</offset><text>History of illicit drug use in adults with acute myocardial infarction: Temporal trends from the French national hospital discharge database.</text><annotation id="1"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="43" length="27"/><text>acute myocardial infarction</text></annotation></passage><passage><infon key="type">abstract</infon><offset>142</offset><text>BACKGROUND: Illicit drugs have become more available and diverse in recent decades. There is growing evidence that cannabis, cocaine and non-acute opioid use is associated with cardiovascular risk, including acute coronary events. AIM: In this retrospective study, we aimed to identify and describe the history of illicit drug use in patients with acute myocardial infarction hospitalized between 2011 and 2022 in France. METHODS: We collected data for all adult patients hospitalized for acute myocardial infarction in 1546 healthcare facilities from 01 January 2011 to 31 December 2022. A history of illicit drug use was identified through patient medical records. The rates of illicit drug use history in patients with acute myocardial infarction were analysed across four 3-year time periods in various age groups. RESULTS: Over 12 years, 1,011,706 patients with acute myocardial infarction were identified. Illicit drug use was especially frequent in very young patients with acute myocardial infarction (aged 18-24 years) compared with older patients with acute myocardial infarction. In this very young acute myocardial infarction population there was a 161% increase in illicit drug use over 12 years (9.7 to 14.9%; P=0.0016). In addition, illicit drug use rates increased across all age groups of patients with acute myocardial infarction over time. CONCLUSION: Although this observation is based on a retrospective study of an administrative database, it could contribute to a scientific rationale for implementing systematic toxicology screening for patients with acute myocardial infarction in France.</text><annotation id="14"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="267" length="7"/><text>cocaine</text></annotation><annotation id="15"><infon key="identifier">MESH:D000208</infon><infon key="type">Disease</infon><location offset="283" length="5"/><text>acute</text></annotation><annotation id="16"><infon key="identifier">MESH:D000208</infon><infon key="type">Disease</infon><location offset="350" length="5"/><text>acute</text></annotation><annotation id="17"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="490" length="27"/><text>acute myocardial infarction</text></annotation><annotation id="18"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="631" length="27"/><text>acute myocardial infarction</text></annotation><annotation id="19"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="864" length="27"/><text>acute myocardial infarction</text></annotation><annotation id="20"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="1009" length="27"/><text>acute myocardial infarction</text></annotation><annotation id="21"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="1123" length="27"/><text>acute myocardial infarction</text></annotation><annotation id="22"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="1204" length="27"/><text>acute myocardial infarction</text></annotation><annotation id="23"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="1252" length="27"/><text>acute myocardial infarction</text></annotation><annotation id="24"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="1462" length="27"/><text>acute myocardial infarction</text></annotation><annotation id="25"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="1717" length="27"/><text>acute myocardial infarction</text></annotation></passage><relation id="R1"><infon key="score">0.9096</infon><infon key="role1">Chemical|MESH:D003042</infon><infon key="role2">Disease|MESH:D000208</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="1,2"/></relation></document>
<document><id>37837319</id><passage><infon key="journal">Soc Stud Sci;2023Oct14 3063127231201169. doi:10.1177/03063127231201169</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nafus D, </infon><offset>0</offset><text>Unclearing the air: Data's unexpected limitations for environmental advocacy.</text></passage><passage><infon key="type">abstract</infon><offset>78</offset><text>What makes one dataset powerful for civic advocacy, and another fall flat? Drawing from a citizen science project on environmental health, I argue that there is an underacknowledged quality of datasets-their topology-that shapes the social, cultural, and political possibilities they can sustain or subvert. Data topologies are formal qualities of a dataset that connect data collectors' intentions with the types of calculations that can and cannot be performed. This configures how numerical arguments are made, and the sociotechnical imaginaries those arguments sustain or subvert. The citizen science project's data topology made any easy notion of shared exposure to pollutants, or singular health effects, unravel. The data appeared to tell a story of atypicality at scale, where each person suffers differently from different exposure. Lacking a central tendency, or pockets of tendency disproportionately carried by different subgroups, it became it harder, not easier, for citizen scientists to use data in regulatory contexts, where dominant sociotechnical imaginaries conceive of difference in epidemiological and toxicological terms.</text></passage></document>
<document><id>37837671</id><passage><infon key="journal">Eur J Med Chem;2023Dec05; 261 115858. doi:10.1016/j.ejmech.2023.115858</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gao G, Li J, Cao Y, Li X, Qian Y, Wang X, Li M, Qiu Y, Wu T, Wang L, Fang M, </infon><offset>0</offset><text>Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer.</text><annotation id="4"><infon key="identifier">MESH:C034306</infon><infon key="type">Chemical</infon><location offset="54" length="15"/><text>4,4'-bipyridine</text></annotation><annotation id="5"><infon key="identifier">1025</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55566</infon><location offset="92" length="4"/><text>CDK9</text></annotation><annotation id="6"><infon key="identifier">904</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">947</infon><location offset="97" length="9"/><text>Cyclin T1</text></annotation><annotation id="7"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="154" length="29"/><text>triple-negative breast cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>185</offset><text>Cyclin-dependent kinase 9 (CDK9) is directly related to tumor development in triple-negative breast cancer (TNBC) patients. Increased CDK9 is significantly associated with poor patient prognosis, while inhibiting CDK9-Cyclin T1 protein-protein interaction has recently been demonstrated as a new approach to TNBC treatment. Herein, we synthesized a novel class of 4,4'-bipyridine derivatives as potential CDK9-Cyclin T1 PPI inhibitors against TNBC. The represented compound B19 was found to be an excellent and selective CDK9-Cyclin T1 PPI inhibitor with good potency against TNBC cell lines while exhibiting lower toxicity in normal human cell lines than the positive compound I-CDK9. Notably, compound B19 showed good pharmacokinetic properties and excellent antitumor activity against TNBC (4T1) allografts in mice with a therapeutic index of more than 42 (TGI4T1(12.5 mg/kg,i.p.) = 63.1% vs. LD50 = 537 mg/kg). Moreover, the administration of B19 in combination with the PARP inhibitor Olaparib results in a significant increase of the antitumor activity in MDA-MB-231 cells relative to that of either single agent. To our knowledge, B19 is the first reported non-metal organic compound that acts as a selective CDK9-Cyclin T1 PPI inhibitor with in vivo antitumor activity, and it may be alone and in combination with PARP inhibitor Olaparib for TNBC therapy.</text><annotation id="41"><infon key="identifier">1025</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55566</infon><location offset="185" length="25"/><text>Cyclin-dependent kinase 9</text></annotation><annotation id="42"><infon key="identifier">1025</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55566</infon><location offset="212" length="4"/><text>CDK9</text></annotation><annotation id="43"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="241" length="5"/><text>tumor</text></annotation><annotation id="44"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="262" length="29"/><text>triple-negative breast cancer</text></annotation><annotation id="45"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="293" length="4"/><text>TNBC</text></annotation><annotation id="46"><infon key="identifier">1025</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55566</infon><location offset="319" length="4"/><text>CDK9</text></annotation><annotation id="47"><infon key="identifier">1025</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55566</infon><location offset="398" length="4"/><text>CDK9</text></annotation><annotation id="48"><infon key="identifier">904</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">947</infon><location offset="403" length="9"/><text>Cyclin T1</text></annotation><annotation id="49"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="493" length="4"/><text>TNBC</text></annotation><annotation id="50"><infon key="identifier">MESH:C034306</infon><infon key="type">Chemical</infon><location offset="549" length="15"/><text>4,4'-bipyridine</text></annotation><annotation id="51"><infon key="identifier">1025</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55566</infon><location offset="590" length="4"/><text>CDK9</text></annotation><annotation id="52"><infon key="identifier">904</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">947</infon><location offset="595" length="9"/><text>Cyclin T1</text></annotation><annotation id="53"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="628" length="4"/><text>TNBC</text></annotation><annotation id="54"><infon key="identifier">30811</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8742</infon><location offset="659" length="3"/><text>B19</text></annotation><annotation id="55"><infon key="identifier">1025</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55566</infon><location offset="706" length="4"/><text>CDK9</text></annotation><annotation id="56"><infon key="identifier">904</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">947</infon><location offset="711" length="9"/><text>Cyclin T1</text></annotation><annotation id="57"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="761" length="4"/><text>TNBC</text></annotation><annotation id="58"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="800" length="8"/><text>toxicity</text></annotation><annotation id="59"><infon key="identifier">1025</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55566</infon><location offset="865" length="4"/><text>CDK9</text></annotation><annotation id="60"><infon key="identifier">30811</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8742</infon><location offset="889" length="3"/><text>B19</text></annotation><annotation id="61"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="973" length="4"/><text>TNBC</text></annotation><annotation id="62"><infon key="identifier">CVCL:0125</infon><infon key="type">CellLine</infon><location offset="979" length="3"/><text>4T1</text></annotation><annotation id="63"><infon key="identifier">CVCL:F584</infon><infon key="type">CellLine</infon><location offset="1045" length="6"/><text>TGI4T1</text></annotation><annotation id="64"><infon key="identifier">30811</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8742</infon><location offset="1132" length="3"/><text>B19</text></annotation><annotation id="65"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="1160" length="4"/><text>PARP</text></annotation><annotation id="66"><infon key="identifier">MESH:C531550</infon><infon key="type">Chemical</infon><location offset="1175" length="8"/><text>Olaparib</text></annotation><annotation id="67"><infon key="identifier">CVCL:0062</infon><infon key="type">CellLine</infon><location offset="1247" length="10"/><text>MDA-MB-231</text></annotation><annotation id="68"><infon key="identifier">30811</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8742</infon><location offset="1323" length="3"/><text>B19</text></annotation><annotation id="69"><infon key="identifier">1025</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55566</infon><location offset="1401" length="4"/><text>CDK9</text></annotation><annotation id="70"><infon key="identifier">904</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">947</infon><location offset="1406" length="9"/><text>Cyclin T1</text></annotation><annotation id="71"><infon key="identifier">142</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1222</infon><location offset="1507" length="4"/><text>PARP</text></annotation><annotation id="72"><infon key="identifier">MESH:C531550</infon><infon key="type">Chemical</infon><location offset="1522" length="8"/><text>Olaparib</text></annotation><annotation id="73"><infon key="identifier">MESH:D064726</infon><infon key="type">Disease</infon><location offset="1535" length="4"/><text>TNBC</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Disease|MESH:D064726</infon><infon key="role2">Gene|1025</infon><infon key="type">Association</infon><node refid="0" role="3,1"/></relation><relation id="R2"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|1025</infon><infon key="type">Association</infon><node refid="1" role="6,4"/></relation><relation id="R3"><infon key="score">0.4186</infon><infon key="role1">Chemical|MESH:C531550</infon><infon key="role2">Gene|30811</infon><infon key="type">Cotreatment</infon><node refid="2" role="31,29"/></relation><relation id="R4"><infon key="score">0.925</infon><infon key="role1">Gene|1025</infon><infon key="role2">Gene|904</infon><infon key="type">Association</infon><node refid="3" role="1,2"/></relation><relation id="R5"><infon key="score">0.9982</infon><infon key="role1">Chemical|MESH:C034306</infon><infon key="role2">Disease|MESH:D064726</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="0,3"/></relation><relation id="R6"><infon key="score">0.9976</infon><infon key="role1">Chemical|MESH:C531550</infon><infon key="role2">Disease|MESH:D064726</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="38,39"/></relation><relation id="R7"><infon key="score">0.8262</infon><infon key="role1">Disease|MESH:D064726</infon><infon key="role2">Gene|30811</infon><infon key="type">Association</infon><node refid="6" role="21,17"/></relation><relation id="R8"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D064726</infon><infon key="role2">Gene|904</infon><infon key="type">Association</infon><node refid="7" role="3,2"/></relation><relation id="R9"><infon key="score">0.9937</infon><infon key="role1">Gene|1025</infon><infon key="role2">Gene|30811</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="19,17"/></relation><relation id="R10"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C531550</infon><infon key="role2">Gene|142</infon><infon key="type">Negative_Correlation</infon><node refid="9" role="31,30"/></relation><relation id="R11"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:C034306</infon><infon key="role2">Gene|904</infon><infon key="type">Negative_Correlation</infon><node refid="10" role="0,2"/></relation><relation id="R12"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C034306</infon><infon key="role2">Gene|1025</infon><infon key="type">Negative_Correlation</infon><node refid="11" role="0,1"/></relation><relation id="R13"><infon key="score">0.94</infon><infon key="role1">Gene|30811</infon><infon key="role2">Gene|904</infon><infon key="type">Negative_Correlation</infon><node refid="12" role="17,20"/></relation></document>
<document><id>37838022</id><passage><infon key="journal">Orthop Traumatol Surg Res;2023Oct12 103708. doi:10.1016/j.otsr.2023.103708</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Micicoi L, Rudel A, Ollivier SF, Legr&amp;#xe9; BP, </infon><offset>0</offset><text>Flexor Hallucis Longus Decompression under Ultrasound Guidance: A cadaver study.</text><annotation id="1"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="0" length="22"/><text>Flexor Hallucis Longus</text></annotation></passage><passage><infon key="type">abstract</infon><offset>81</offset><text>INTRODUCTION: The Flexor Hallucis Longus (FHL) is a muscle that can be subject to multiple impingements caused by exaggerated plantar flexion in athletes. The most common impingement is due to inflammation of the tendon at the retrotalar pulley. The constraints exerted on the FHL are responsible for a pathology called functional Hallux Limitus. Surgical treatment consists of tenolysis of the FHL arthroscopically or via open surgery, by opening the pulley. The objective of this study was to evaluate the risk of lesions of the neurovascular pedicle and the posterior tibial tendon after tenolysis of the Flexor Hallucis Longus under ultrasound guidance. HYPOTHESIS: The hypothesis of this study is that tenolysis of the Flexor Hallucis Longus could proceed under ultrasound guidance without associated tendon lesions or neurovascular lesions. MATERIAL AND METHODS: Thirteen cadaveric specimens were studied, resulting in an analysis of 26 feet. Following identification of the Flexor Hallucis Longus, tenolysis with a 19-gauge needle under ultrasound guidance was performed by an orthopedic specialist after hydrodissection to push back the posterior tibial pedicle. The dissection of the cadavers made it possible to verify the positioning of the posterior tibial pedicle, the FHL tendon and the opening of the retrotalar pulley. RESULTS: Five cadaveric subjects, 10 cases, underwent a complete opening of the retrotalar pulley under ultrasound guidance. In 16 cases, the opening was partial, with a section of the pulley of 65.87 +- 18%.The cases of partial openings showed no neurovascular or tendinous lesions. The 10 cases of complete opening resulted in 5 lesions of the tibial nerve, 4 vascular lesions: 1 venous and 3 arterial, and 6 lesions of the FHL tendon. CONCLUSION: Tenolysis of the Flexor Hallucis Longus under ultrasound guidance at the level of its retrotalar pulley was systematically associated with neurovascular lesions in the event of complete release of the pulley by the method studied, unlike a partial release where no lesion was found. LEVEL OF EVIDENCE: III; case-control study.</text><annotation id="25"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="99" length="22"/><text>Flexor Hallucis Longus</text></annotation><annotation id="26"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="123" length="3"/><text>FHL</text></annotation><annotation id="27"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="274" length="26"/><text>inflammation of the tendon</text></annotation><annotation id="28"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="358" length="3"/><text>FHL</text></annotation><annotation id="29"><infon key="identifier">MESH:D020857</infon><infon key="type">Disease</infon><location offset="412" length="14"/><text>Hallux Limitus</text></annotation><annotation id="30"><infon key="type">Disease</infon><location offset="459" length="9"/><text>tenolysis</text></annotation><annotation id="31"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="476" length="3"/><text>FHL</text></annotation><annotation id="32"><infon key="type">Disease</infon><location offset="672" length="9"/><text>tenolysis</text></annotation><annotation id="33"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="689" length="22"/><text>Flexor Hallucis Longus</text></annotation><annotation id="34"><infon key="type">Disease</infon><location offset="788" length="9"/><text>tenolysis</text></annotation><annotation id="35"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="805" length="22"/><text>Flexor Hallucis Longus</text></annotation><annotation id="36"><infon key="identifier">MESH:D052256</infon><infon key="type">Disease</infon><location offset="887" length="14"/><text>tendon lesions</text></annotation><annotation id="37"><infon key="identifier">MESH:D013901</infon><infon key="type">Disease</infon><location offset="905" length="21"/><text>neurovascular lesions</text></annotation><annotation id="38"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="1062" length="22"/><text>Flexor Hallucis Longus</text></annotation><annotation id="39"><infon key="type">Disease</infon><location offset="1086" length="9"/><text>tenolysis</text></annotation><annotation id="40"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="1363" length="3"/><text>FHL</text></annotation><annotation id="41"><infon key="identifier">MESH:D013901</infon><infon key="type">Disease</infon><location offset="1664" length="16"/><text>neurovascular or</text></annotation><annotation id="42"><infon key="identifier">MESH:D052256</infon><infon key="type">Disease</infon><location offset="1681" length="17"/><text>tendinous lesions</text></annotation><annotation id="43"><infon key="identifier">MESH:D014652</infon><infon key="type">Disease</infon><location offset="1778" length="16"/><text>vascular lesions</text></annotation><annotation id="44"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="1842" length="3"/><text>FHL</text></annotation><annotation id="45"><infon key="type">Disease</infon><location offset="1866" length="9"/><text>Tenolysis</text></annotation><annotation id="46"><infon key="identifier">MESH:D052582</infon><infon key="type">Disease</infon><location offset="1883" length="22"/><text>Flexor Hallucis Longus</text></annotation><annotation id="47"><infon key="identifier">MESH:D013901</infon><infon key="type">Disease</infon><location offset="2005" length="21"/><text>neurovascular lesions</text></annotation></passage></document>
<document><id>37838372</id><passage><infon key="journal">Rev Infirm;2023Oct; 72 (294) 42. doi:10.1016/j.revinf.2023.08.012</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Saliot M, Murzot L, </infon><offset>0</offset><text>[CAR-T cells, an innovative therapy].</text></passage><passage><infon key="type">abstract</infon><offset>38</offset><text>CAR-T cell therapy for patients with hematological malignancies has been practiced at the Basse-Normandie Hematology Institute since November 2022. This treatment requires the care pathway to be coordinated by the nurse coordinator. Nurses play a key role in the early diagnosis of side effects induced by this drug. Interdisciplinary collaboration and the value of teamwork are also emphasized.</text><annotation id="1"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="75" length="26"/><text>hematological malignancies</text></annotation></passage></document>
<document><id>37839511</id><passage><infon key="journal">Neuropharmacology;2023Oct13; 242 109757. doi:10.1016/j.neuropharm.2023.109757</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Saito A, Murata H, Niitani K, Nagasaki J, Otoda A, Chujo Y, Yanagida J, Nishitani N, Deyama S, Kaneda K, </infon><offset>0</offset><text>Social defeat stress enhances the rewarding effects of cocaine through alpha1A adrenoceptors in the medial prefrontal cortex of mice.</text><annotation id="1"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="55" length="7"/><text>cocaine</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>Various stressors potentiate the rewarding effects of cocaine and contribute to cocaine cravings. However, it remains unclear whether psychosocial stress enhances the rewarding effects of cocaine. Accordingly, this study employed a cocaine-conditioned place preference (CPP) paradigm combined with social defeat (SD) exposure to investigate the effects of acute SD stress on cocaine reward in male mice. We found that SD stress immediately before the posttest significantly increased cocaine CPP, and systemic blockade of alpha1 adrenoceptors, but not beta adrenoceptors, suppressed this increase. Fiber photometry recordings with GRABNE1m sensors revealed increased noradrenaline (NA) levels in the medial prefrontal cortex (mPFC) in test mice in response to attacks by aggressor mice during SD. Moreover, the SD stress-induced enhancement of CPP was effectively suppressed by intra-mPFC infusion of an alpha1 adrenoceptor antagonist. In vitro whole-cell recordings demonstrated that silodosin, an alpha1A, but not alpha1B or alpha1D, adrenoceptor antagonist, inhibited NA-induced depolarizing currents and facilitation of excitatory synaptic transmissions. Consistently, intra-mPFC silodosin infusion significantly suppressed the SD stress-induced CPP enhancement. Conversely, intra-mPFC infusion of alpha1A adrenoceptor agonist augmented cocaine CPP in the absence of stress exposure. Additionally, intranasal silodosin administration attenuated the SD stress-induced enhancement of CPP, and chemogenetic inhibition of mPFC excitatory neurons also suppressed the SD stress-induced CPP enhancement. Together, these findings suggest that NA stimulation of alpha1A adrenoceptors and the subsequent activation of mPFC pyramidal cells may contribute to SD stress-induced amplification of the rewarding effects of cocaine, and intranasal silodosin administration may hold therapeutic potential for mitigating stress-associated cocaine craving.</text><annotation id="21"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="188" length="7"/><text>cocaine</text></annotation><annotation id="22"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="214" length="7"/><text>cocaine</text></annotation><annotation id="23"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="322" length="7"/><text>cocaine</text></annotation><annotation id="24"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="366" length="7"/><text>cocaine</text></annotation><annotation id="25"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="509" length="7"/><text>cocaine</text></annotation><annotation id="26"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="618" length="7"/><text>cocaine</text></annotation><annotation id="27"><infon key="identifier">MESH:D009638</infon><infon key="type">Chemical</infon><location offset="801" length="13"/><text>noradrenaline</text></annotation><annotation id="28"><infon key="identifier">MESH:C095285</infon><infon key="type">Chemical</infon><location offset="1119" length="9"/><text>silodosin</text></annotation><annotation id="29"><infon key="identifier">12044</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2988</infon><location offset="1133" length="7"/><text>alpha1A</text></annotation><annotation id="30"><infon key="identifier">11548</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55477</infon><location offset="1150" length="7"/><text>alpha1B</text></annotation><annotation id="31"><infon key="identifier">11550</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">551</infon><location offset="1161" length="21"/><text>alpha1D, adrenoceptor</text></annotation><annotation id="32"><infon key="identifier">MESH:C095285</infon><infon key="type">Chemical</infon><location offset="1318" length="9"/><text>silodosin</text></annotation><annotation id="33"><infon key="identifier">11549</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68078</infon><location offset="1436" length="20"/><text>alpha1A adrenoceptor</text></annotation><annotation id="34"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="1475" length="7"/><text>cocaine</text></annotation><annotation id="35"><infon key="identifier">MESH:C095285</infon><infon key="type">Chemical</infon><location offset="1547" length="9"/><text>silodosin</text></annotation><annotation id="36"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="1945" length="7"/><text>cocaine</text></annotation><annotation id="37"><infon key="identifier">MESH:C095285</infon><infon key="type">Chemical</infon><location offset="1969" length="9"/><text>silodosin</text></annotation><annotation id="38"><infon key="identifier">MESH:D003042</infon><infon key="type">Chemical</infon><location offset="2058" length="7"/><text>cocaine</text></annotation><annotation id="39"><infon key="identifier">MESH:C564883</infon><infon key="type">Disease</infon><location offset="2066" length="7"/><text>craving</text></annotation></passage><relation id="R1"><infon key="score">0.9893</infon><infon key="role1">Chemical|MESH:D003042</infon><infon key="role2">Gene|11549</infon><infon key="type">Association</infon><node refid="0" role="16,15"/></relation><relation id="R2"><infon key="score">0.9834</infon><infon key="role1">Chemical|MESH:C095285</infon><infon key="role2">Chemical|MESH:D003042</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="20,19"/></relation><relation id="R3"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C095285</infon><infon key="role2">Disease|MESH:C564883</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="20,22"/></relation></document>
<document><id>37839867</id><passage><infon key="journal">Exp Anim;2023Oct14. doi:10.1538/expanim.23-0070</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chen Y, Zhang C, Zhao L, Chen R, Zhang P, Li J, Zhang X, Zhang X, </infon><offset>0</offset><text>Eriocalyxin B alleviated ischemic cerebral injury via limiting microglia-mediated excessive neuroinflammation in mice.</text><annotation id="3"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="0" length="13"/><text>Eriocalyxin B</text></annotation><annotation id="4"><infon key="identifier">MESH:D017202</infon><infon key="type">Disease</infon><location offset="25" length="24"/><text>ischemic cerebral injury</text></annotation><annotation id="5"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="92" length="17"/><text>neuroinflammation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>119</offset><text>Excessive neuroinflammation mediated by microglia has a detrimental effect on the progression of ischemic stroke. Eriocalyxin B (EriB) was found with a neuroprotective effect in mice with Parkinson's disease by suppressing the microglial overactivation. This study aims to investigate the roles of EriB in permanent middle cerebral artery occlusion (pMCAO) mice. The pMCAO was induced by intraluminal filament method in internal carotidartery of mice, which underwent an immediately intraperitoneal injection of EriB (10 mg/kg) post surgery. The behavior score, 2,3,5-triphenyltetrazole chloride staining, Nissl staining, TUNEL, immunohistochemistry, immunofluorescence, PCR, ELISA and immunoblotting revealed that EriB administration reduced brain infarct and neuron death, ameliorated neuroinflammation and microglia overactivation in pMCAO mice, manifested by alterations of TUNEL-positive cell numbers, ionized calcium binding adaptor molecule 1 (Iba-1)-positive cell numbers, expression of tumor necrosis factor-alpha, interleukin (IL)-6, IL-1beta, inducible nitric oxide synthase and arginase 1. In addition, EriB suppressed ischemia-induced activation of nuclear factor kappa B (NF-kappaB) signaling in brain penumbra, suggesting the involvement of NF-kappaB in EriB function. In conclusions, EriB exerted anti-inflammatory effects in ischemia stroke through regulating NF-kappaB signaling pathway, which may provide insights into the neuroprotective effect of EriB on the treatment of ischemic stroke.</text><annotation id="39"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="129" length="17"/><text>neuroinflammation</text></annotation><annotation id="40"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="216" length="15"/><text>ischemic stroke</text></annotation><annotation id="41"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="233" length="13"/><text>Eriocalyxin B</text></annotation><annotation id="42"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="248" length="4"/><text>EriB</text></annotation><annotation id="43"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="307" length="19"/><text>Parkinson's disease</text></annotation><annotation id="44"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="417" length="4"/><text>EriB</text></annotation><annotation id="45"><infon key="identifier">MESH:D020244</infon><infon key="type">Disease</infon><location offset="425" length="42"/><text>permanent middle cerebral artery occlusion</text></annotation><annotation id="46"><infon key="identifier">MESH:D020244</infon><infon key="type">Disease</infon><location offset="469" length="5"/><text>pMCAO</text></annotation><annotation id="47"><infon key="identifier">MESH:D020244</infon><infon key="type">Disease</infon><location offset="486" length="5"/><text>pMCAO</text></annotation><annotation id="48"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="631" length="4"/><text>EriB</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="681" length="33"/><text>2,3,5-triphenyltetrazole chloride</text></annotation><annotation id="50"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="834" length="4"/><text>EriB</text></annotation><annotation id="51"><infon key="identifier">MESH:D020520</infon><infon key="type">Disease</infon><location offset="862" length="13"/><text>brain infarct</text></annotation><annotation id="52"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="880" length="12"/><text>neuron death</text></annotation><annotation id="53"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="906" length="17"/><text>neuroinflammation</text></annotation><annotation id="54"><infon key="identifier">MESH:D020244</infon><infon key="type">Disease</infon><location offset="956" length="5"/><text>pMCAO</text></annotation><annotation id="55"><infon key="identifier">21926</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="1114" length="27"/><text>tumor necrosis factor-alpha</text></annotation><annotation id="56"><infon key="identifier">16193</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1143" length="18"/><text>interleukin (IL)-6</text></annotation><annotation id="57"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1163" length="8"/><text>IL-1beta</text></annotation><annotation id="58"><infon key="identifier">18126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55473</infon><location offset="1173" length="31"/><text>inducible nitric oxide synthase</text></annotation><annotation id="59"><infon key="identifier">11846</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">29</infon><location offset="1209" length="10"/><text>arginase 1</text></annotation><annotation id="60"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="1234" length="4"/><text>EriB</text></annotation><annotation id="61"><infon key="identifier">MESH:D007511</infon><infon key="type">Disease</infon><location offset="1250" length="8"/><text>ischemia</text></annotation><annotation id="62"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1281" length="22"/><text>nuclear factor kappa B</text></annotation><annotation id="63"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1305" length="9"/><text>NF-kappaB</text></annotation><annotation id="64"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1375" length="9"/><text>NF-kappaB</text></annotation><annotation id="65"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="1388" length="4"/><text>EriB</text></annotation><annotation id="66"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="1419" length="4"/><text>EriB</text></annotation><annotation id="67"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1437" length="12"/><text>inflammatory</text></annotation><annotation id="68"><infon key="identifier">MESH:D007511</infon><infon key="type">Disease</infon><location offset="1461" length="15"/><text>ischemia stroke</text></annotation><annotation id="69"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1496" length="9"/><text>NF-kappaB</text></annotation><annotation id="70"><infon key="identifier">MESH:C516552</infon><infon key="type">Chemical</infon><location offset="1587" length="4"/><text>EriB</text></annotation><annotation id="71"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="1612" length="15"/><text>ischemic stroke</text></annotation></passage><relation id="R1"><infon key="score">0.9988</infon><infon key="role1">Disease|MESH:D020244</infon><infon key="role2">Gene|18126</infon><infon key="type">Association</infon><node refid="0" role="18,22"/></relation><relation id="R2"><infon key="score">0.9903</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Gene|16176</infon><infon key="type">Association</infon><node refid="1" role="14,21"/></relation><relation id="R3"><infon key="score">0.9938</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Gene|21926</infon><infon key="type">Association</infon><node refid="2" role="14,19"/></relation><relation id="R4"><infon key="score">0.9983</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Disease|MESH:D020244</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="8,9"/></relation><relation id="R5"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Disease|MESH:D017202</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="0,1"/></relation><relation id="R6"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Disease|MESH:D007511</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="24,25"/></relation><relation id="R7"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Gene|18126</infon><infon key="type">Association</infon><node refid="6" role="14,22"/></relation><relation id="R8"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Disease|MESH:D009410</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="14,16"/></relation><relation id="R9"><infon key="score">0.9982</infon><infon key="role1">Disease|MESH:D020244</infon><infon key="role2">Gene|11846</infon><infon key="type">Association</infon><node refid="8" role="18,23"/></relation><relation id="R10"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Disease|MESH:D002544</infon><infon key="type">Negative_Correlation</infon><node refid="9" role="30,35"/></relation><relation id="R11"><infon key="score">0.9957</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Gene|16193</infon><infon key="type">Association</infon><node refid="10" role="14,20"/></relation><relation id="R12"><infon key="score">0.9983</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Disease|MESH:D000090862</infon><infon key="type">Negative_Correlation</infon><node refid="11" role="0,2"/></relation><relation id="R13"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Disease|MESH:D020520</infon><infon key="type">Negative_Correlation</infon><node refid="12" role="14,15"/></relation><relation id="R14"><infon key="score">0.9977</infon><infon key="role1">Disease|MESH:D007511</infon><infon key="role2">Gene|18033</infon><infon key="type">Positive_Correlation</infon><node refid="13" role="25,26"/></relation><relation id="R15"><infon key="score">0.9966</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Disease|MESH:D010300</infon><infon key="type">Negative_Correlation</infon><node refid="14" role="5,7"/></relation><relation id="R16"><infon key="score">0.9948</infon><infon key="role1">Disease|MESH:D020244</infon><infon key="role2">Gene|16176</infon><infon key="type">Association</infon><node refid="15" role="18,21"/></relation><relation id="R17"><infon key="score">0.9981</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Gene|11846</infon><infon key="type">Association</infon><node refid="16" role="14,23"/></relation><relation id="R18"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="17" role="30,31"/></relation><relation id="R19"><infon key="score">0.9866</infon><infon key="role1">Chemical|MESH:C516552</infon><infon key="role2">Gene|18033</infon><infon key="type">Negative_Correlation</infon><node refid="18" role="24,26"/></relation><relation id="R20"><infon key="score">0.9887</infon><infon key="role1">Disease|MESH:D020244</infon><infon key="role2">Gene|16193</infon><infon key="type">Association</infon><node refid="19" role="18,20"/></relation><relation id="R21"><infon key="score">0.6736</infon><infon key="role1">Disease|MESH:D020244</infon><infon key="role2">Gene|21926</infon><infon key="type">Association</infon><node refid="20" role="18,19"/></relation></document>
<document><id>37840233</id><passage><infon key="journal">BJOG;2023Oct15. doi:10.1111/1471-0528.17689</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kentros PA, Huang Y, Wylie BJ, Khoury-Collado F, Hou JY, de Meritens AB, St Clair CM, Hershman DL, Wright JD, </infon><offset>0</offset><text>Ambient particulate matter air pollution exposure and ovarian cancer incidence in the USA: An ecological study.</text><annotation id="1"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="54" length="14"/><text>ovarian cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>112</offset><text>OBJECTIVE: To investigate associations between air particulate matter of &lt;=2.5 mum in diameter (PM2.5 ) and ovarian cancer. DESIGN: County-level ecological study. SETTING: Surveillance, epidemiology, and end results from a collection of state-level cancer registries across 744 counties. Data from the Environmental Protection Agency's network for PM2.5 monitoring was used to calculate trailing 5- and 10-year PM2.5 county-level values. County-level data on demographic characteristics were obtained from the American Community Survey. POPULATION: A total of 98 751 patients with histologically confirmed ovarian cancer as a primary malignancy from 2000 to 2016. METHODS: Generalised linear regression models were developed to estimate the association between PM2.5 and PM10 levels, over 5- and 10-year periods of exposure, and ovarian cancer risk, after accounting for county-level covariates. MAIN OUTCOME MEASURES: Risk ratios for associations between ovarian cancer (both overall and specifically epithelial ovarian cancer) and PM2.5 levels. RESULTS: For the 744 counties included, the average PM2.5 level from 1990 through 2018 was 11.75 mug/m3 (SD = 3.7) and the average PM10 level was 22.7 mug/m3 (SD = 5.7). After adjusting for county-level covariates, the overall annualised ovarian cancer incidence was significantly associated with increases in 5-year PM2.5 (RR = 1.11 per 10 units (mug/m3 ) increase, 95% CI 1.06-1.16). Similarly, when the analysis was limited to epithelial cell tumours and adjusted for county-level covariates there was a significant association with trailing 5-year PM2.5 exposure models (RR = 1.12 per 10 units increase, 95% CI 1.08-1.17). Likewise, 10-year PM2.5 exposure was associated with ovarian cancer overall and with epithelial ovarian cancer. CONCLUSIONS: Higher county-level ambient PM2.5 levels are associated with 5- and 10-year incidences of ovarian cancer, as measurable in an ecological study.</text><annotation id="16"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="220" length="14"/><text>ovarian cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="361" length="6"/><text>cancer</text></annotation><annotation id="18"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="718" length="14"/><text>ovarian cancer</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="746" length="10"/><text>malignancy</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="883" length="4"/><text>PM10</text></annotation><annotation id="21"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="941" length="14"/><text>ovarian cancer</text></annotation><annotation id="22"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="1068" length="14"/><text>ovarian cancer</text></annotation><annotation id="23"><infon key="identifier">MESH:D000077216</infon><infon key="type">Disease</infon><location offset="1114" length="25"/><text>epithelial ovarian cancer</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1290" length="4"/><text>PM10</text></annotation><annotation id="25"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="1397" length="14"/><text>ovarian cancer</text></annotation><annotation id="26"><infon key="identifier">MESH:D009375</infon><infon key="type">Disease</infon><location offset="1589" length="23"/><text>epithelial cell tumours</text></annotation><annotation id="27"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="1839" length="14"/><text>ovarian cancer</text></annotation><annotation id="28"><infon key="identifier">MESH:D000077216</infon><infon key="type">Disease</infon><location offset="1871" length="25"/><text>epithelial ovarian cancer</text></annotation><annotation id="29"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="2001" length="14"/><text>ovarian cancer</text></annotation></passage></document>
<document><id>37843065</id><passage><infon key="journal">J Clin Hypertens (Greenwich);2023Oct16. doi:10.1111/jch.14732</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fan K, Cao W, Chang H, Tian F, </infon><offset>0</offset><text>Predicting prognosis in patients with stroke treated with intravenous alteplase through blood pressure changes: A machine learning-based approach.</text><annotation id="1"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="38" length="6"/><text>stroke</text></annotation></passage><passage><infon key="type">abstract</infon><offset>147</offset><text>The use of machine learning (ML) in predicting disease prognosis has increased, and researchers have adopted different methods for variable selection to optimize early screening for AIS to determine its prognosis as soon as possible. We aimed to improve the understanding of the predictors of poor functional outcome at three months after discharge in AIS patients treated with intravenous thrombolysis and to construct a highly effective prognostic model to improve prediction accuracy. And four ML methods (random forest, support vector machine, naive Bayesian, and logistic regression) were used to screen and recombine the features for construction of an ML prognostic model. A total of 352 patients that had experienced AIS and had been treated with intravenous thrombolysis were recruited. The variables included in the model were NIHSS on admission, age, white blood cell count, percentage of neutrophils and triglyceride after thrombolysis, tirofiban, early neurological deterioration, early neurological improvement, and BP at each time point or period. The model's area under the curve for predicting 30-day modified Rankin scale was 0.790 with random forest, 0.542 with support vector machine, 0.411 with naive Bayesian, and 0.661 with logistic regression. The random forest model was shown to accurately evaluate the prognosis of AIS patients treated with intravenous thrombolysis, and therefore they may be helpful for accurate and personalized secondary prevention. The model offers improved prediction accuracy that may reduce rates of misdiagnosis and missed diagnosis in patients with AIS.</text><annotation id="14"><infon key="identifier">MESH:D013734</infon><infon key="type">Disease</infon><location offset="329" length="3"/><text>AIS</text></annotation><annotation id="15"><infon key="identifier">MESH:D013734</infon><infon key="type">Disease</infon><location offset="499" length="3"/><text>AIS</text></annotation><annotation id="16"><infon key="type">Disease</infon><location offset="537" length="12"/><text>thrombolysis</text></annotation><annotation id="17"><infon key="identifier">MESH:D013734</infon><infon key="type">Disease</infon><location offset="872" length="3"/><text>AIS</text></annotation><annotation id="18"><infon key="type">Disease</infon><location offset="914" length="12"/><text>thrombolysis</text></annotation><annotation id="19"><infon key="identifier">MESH:D014280</infon><infon key="type">Chemical</infon><location offset="1063" length="12"/><text>triglyceride</text></annotation><annotation id="20"><infon key="type">Disease</infon><location offset="1082" length="12"/><text>thrombolysis</text></annotation><annotation id="21"><infon key="identifier">MESH:D000077466</infon><infon key="type">Chemical</infon><location offset="1096" length="9"/><text>tirofiban</text></annotation><annotation id="22"><infon key="identifier">MESH:D009422</infon><infon key="type">Disease</infon><location offset="1113" length="26"/><text>neurological deterioration</text></annotation><annotation id="23"><infon key="identifier">MESH:D013734</infon><infon key="type">Disease</infon><location offset="1489" length="3"/><text>AIS</text></annotation><annotation id="24"><infon key="type">Disease</infon><location offset="1527" length="12"/><text>thrombolysis</text></annotation><annotation id="25"><infon key="identifier">MESH:D013734</infon><infon key="type">Disease</infon><location offset="1749" length="3"/><text>AIS</text></annotation></passage></document>
<document><id>37843415</id><passage><infon key="journal">Chem Asian J;2023Oct16 202300836. doi:10.1002/asia.202300836</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Aragoni MC, Podda E, Chaudhary S, Bhasin AKK, Bhasin KK, Coles SJ, Orton JB, Isaia F, Lippolis V, Pintus A, Slawin AMZ, Woollins JD, Arca M, </infon><offset>0</offset><text>An experimental and theoretical insight into I2/Br2 oxidation of bis(pyridin-2-yl)diselane and ditellane.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="45" length="6"/><text>I2/Br2</text></annotation><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="65" length="25"/><text>bis(pyridin-2-yl)diselane</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="95" length="9"/><text>ditellane</text></annotation></passage><passage><infon key="type">abstract</infon><offset>106</offset><text>The reactivity between bis(pyridin-2-yl)diselane oPy2Se2 and ditellane oPy2Te2 (L1 and L2, respectively; oPy = pyridyn-2-yl) and I2/Br2 is discussed. Single-crystal structure analysis revealed that the reaction of L1 with I2 yielded [(HL1+)(I-) 5/2I2]  (1) in which monoprotonated cations HL1+ template a self-assembled infinite pseudo-cubic polyiodide 3D-network, while the reaction with Br2 yielded the dibromide HoPySeIIBr2 (2). The oxidation of L2 with I2 and Br2 yielded the compounds HoPyTeIVI2 (3) and HoPyTeIIBr4 (6), respectively, whose structures were elucidated by X-ray diffraction analysis. FT-Raman spectroscopy measurements are consistent with a 3c-4e description of all the X-Ch-X three-body systems (Ch = Se, Te; X = Br, I) in compounds 2, 3, HoPyTeIIBr2 (5), and 6. The structural and spectroscopic observations are supported by extensive theoretical calculations carried out at the DFT level that were employed to study the electronic structure of the investigated compounds, the thermodynamic aspects of their formation, and the role of noncovalent s-hole halogen and chalcogen bonds in the X   X, X   Ch and Ch   Ch interactions evidenced structurally.</text><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="129" length="25"/><text>bis(pyridin-2-yl)diselane</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="155" length="7"/><text>oPy2Se2</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="167" length="9"/><text>ditellane</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="177" length="7"/><text>oPy2Te2</text></annotation><annotation id="39"><infon key="identifier">MESH:D000077543</infon><infon key="type">Chemical</infon><location offset="186" length="2"/><text>L1</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="193" length="2"/><text>L2</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="211" length="3"/><text>oPy</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="217" length="12"/><text>pyridyn-2-yl</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="235" length="6"/><text>I2/Br2</text></annotation><annotation id="44"><infon key="identifier">MESH:D007455</infon><infon key="type">Chemical</infon><location offset="328" length="2"/><text>I2</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="340" length="16"/><text>(HL1+)(I-) 5/2I2</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="395" length="4"/><text>HL1+</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="448" length="10"/><text>polyiodide</text></annotation><annotation id="48"><infon key="identifier">MESH:D001966</infon><infon key="type">Chemical</infon><location offset="495" length="3"/><text>Br2</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="511" length="9"/><text>dibromide</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="521" length="11"/><text>HoPySeIIBr2</text></annotation><annotation id="51"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="555" length="2"/><text>L2</text></annotation><annotation id="52"><infon key="identifier">MESH:D007455</infon><infon key="type">Chemical</infon><location offset="563" length="2"/><text>I2</text></annotation><annotation id="53"><infon key="identifier">MESH:D001966</infon><infon key="type">Chemical</infon><location offset="570" length="3"/><text>Br2</text></annotation><annotation id="54"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="596" length="14"/><text>HoPyTeIVI2 (3)</text></annotation><annotation id="55"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="615" length="15"/><text>HoPyTeIIBr4 (6)</text></annotation><annotation id="56"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="828" length="2"/><text>Se</text></annotation><annotation id="57"><infon key="identifier">MESH:D013691</infon><infon key="type">Chemical</infon><location offset="832" length="2"/><text>Te</text></annotation><annotation id="58"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="836" length="1"/><text>X</text></annotation><annotation id="59"><infon key="identifier">MESH:D001966</infon><infon key="type">Chemical</infon><location offset="840" length="2"/><text>Br</text></annotation><annotation id="60"><infon key="identifier">MESH:D007455</infon><infon key="type">Chemical</infon><location offset="844" length="1"/><text>I</text></annotation><annotation id="61"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="866" length="11"/><text>HoPyTeIIBr2</text></annotation><annotation id="62"><infon key="identifier">MESH:D006219</infon><infon key="type">Chemical</infon><location offset="1182" length="7"/><text>halogen</text></annotation><annotation id="63"><infon key="identifier">MESH:D018011</infon><infon key="type">Chemical</infon><location offset="1194" length="9"/><text>chalcogen</text></annotation></passage></document>
<document><id>37843765</id><passage><infon key="journal">Breast Cancer;2023Oct16. doi:10.1007/s12282-023-01510-0</infon><infon key="year">2023</infon><infon key="article-id_pmc">5896693</infon><infon key="type">title</infon><infon key="authors">Sakai T, Kutomi G, Shien T, Asaga S, Aruga T, Ishitobi M, Kuba S, Sawaki M, Terata K, Tomita K, Yamauchi C, Yamamoto Y, Iwata H, Saji S, </infon><offset>0</offset><text>The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition.</text><annotation id="2"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="13" length="13"/><text>Breast Cancer</text></annotation><annotation id="3"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="90" length="13"/><text>breast cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>119</offset><text>The 2022 revision of the Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for surgical treatment of breast cancer was updated following a systematic review of the literature using the Medical Information Network Distribution Service (MINDS) procedure, which focuses on the balance of benefits and harms for various clinical questions (CQs). Experts in surgery designated by the JBCS addressed five areas: breast surgery, axillary surgery, breast reconstruction, surgical treatment for recurrent and metastatic breast cancer, and other related topics. The revision of the guidelines encompassed 4 CQs, 7 background questions (BQs), and 14 future research questions (FRQs). A significant revision in the 2022 edition pertained to axillary management after neoadjuvant chemotherapy in CQ2. The primary aim of the 2022 JBCS Clinical Practice Guidelines is to provide evidence-based recommendations to empower patients and healthcare professionals in making informed decisions regarding surgical treatment for breast cancer.</text><annotation id="8"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="153" length="13"/><text>Breast Cancer</text></annotation><annotation id="9"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="237" length="13"/><text>breast cancer</text></annotation><annotation id="10"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="647" length="13"/><text>breast cancer</text></annotation><annotation id="11"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1142" length="13"/><text>breast cancer</text></annotation></passage></document>
<document><id>37844501</id><passage><infon key="journal">J Colloid Interface Sci;2023Oct13; 654 (Pt A) 300. doi:10.1016/j.jcis.2023.10.049</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Si Z, Pei M, Liu Y, Li B, Kang F, </infon><offset>0</offset><text>Boosting the photocatalytic activity of beta-FeOOH catalyst for toluene oxidation by constructing internal electric field at 0D/1D homojunction interfaces.</text><annotation id="2"><infon key="identifier">MESH:C473845</infon><infon key="type">Chemical</infon><location offset="40" length="10"/><text>beta-FeOOH</text></annotation><annotation id="3"><infon key="identifier">MESH:D014050</infon><infon key="type">Chemical</infon><location offset="64" length="7"/><text>toluene</text></annotation></passage><passage><infon key="type">abstract</infon><offset>156</offset><text>Photocatalytic degradation is considered as the most energy-efficient, environmentally benign, and effective method for treating low fraction organic contaminants. However, the photocatalysts still suffer from low utilization efficiency of visible-light and severe carrier recombination. Heterojunctions can resolve these two main problems in some extent but still be restrained by the low quality of hetero-interface. In this study, homojunction was constructed of beta-FeOOH quantum dots and nanorods with the same lattice by a two-step precipitation method, to avoid the heterointerface with too many defects and possess good charge separation as a consequence. The catalysts were characterized by activity test, electron spin resonance, Mott-Schottky plots, photocurrent density tests and open-circuit potential measurements, etc. The results revealed that a strong internal electric fields (IEFs) was created at the interface of catalyst. Beneficently, the electron rearrangement leads to a more rational distribution of oxygen vacancies in the catalyst, resulting in more efficient dissociation of oxygen molecules and formation of active radicals, thus facilitating the efficient degradation of toluene. This study proposes a novel strategy to boosting the photocatalytic activity of low dimensional semiconductors via forming homojunction interfaces to improve their charge transfer.</text><annotation id="8"><infon key="identifier">MESH:C473845</infon><infon key="type">Chemical</infon><location offset="622" length="10"/><text>beta-FeOOH</text></annotation><annotation id="9"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1182" length="6"/><text>oxygen</text></annotation><annotation id="10"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1260" length="6"/><text>oxygen</text></annotation><annotation id="11"><infon key="identifier">MESH:D014050</infon><infon key="type">Chemical</infon><location offset="1358" length="7"/><text>toluene</text></annotation></passage><relation id="R1"><infon key="score">0.7906</infon><infon key="role1">Chemical|MESH:C473845</infon><infon key="role2">Chemical|MESH:D014050</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.9981</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Chemical|MESH:D014050</infon><infon key="type">Association</infon><node refid="1" role="3,5"/></relation></document>
<document><id>37844851</id><passage><infon key="journal">Gene;2023Oct14; 893 147905. doi:10.1016/j.gene.2023.147905</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ma X, Chen Z, Chen W, Chen Z, Meng X, </infon><offset>0</offset><text>Exosome subpopulations: the isolation and the functions in diseases.</text></passage><passage><infon key="type">abstract</infon><offset>69</offset><text>Exosomes are nanoscale extracellular vesicles secreted by cells. Exosomes mediate intercellular communication by releasing their bioactive contents (e.g., DNAs, RNAs, lipids, proteins, and metabolites). The components of exosomes are regulated by the producing cells of exosomes. Due to their diverse origins, exosomes are highly heterogeneous in size, content, and function. Depending on these characteristics, exosomes can be divided into multiple subpopulations which have different functions. Efficient enrichment of specific subpopulations of exosomes helps to investigate their biological functions. Accordingly, numerous techniques have been developed to isolate specific subpopulations of exosomes. This review systematically introduces emerging new technologies for the isolation of different exosome subpopulations and summarizes the critical role of specific exosome subpopulations in diseases, especially in tumor occurrence and progression.</text><annotation id="2"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="236" length="6"/><text>lipids</text></annotation><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="989" length="5"/><text>tumor</text></annotation></passage></document>
<document><id>37845557</id><passage><infon key="journal">Curr Gastroenterol Rep;2023Oct17. doi:10.1007/s11894-023-00885-6</infon><infon key="year">2023</infon><infon key="article-id_pmc">8741287</infon><infon key="type">title</infon><infon key="authors">Shirwaikar Thomas A, Chari ST, </infon><offset>0</offset><text>Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis.</text><annotation id="1"><infon key="identifier">MESH:D000081012</infon><infon key="type">Disease</infon><location offset="36" length="32"/><text>(Type 3) Autoimmune Pancreatitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>70</offset><text>PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICI) have revolutionized cancer care and work primarily by blocking CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), and/or PD-1 (programmed cell death protein 1), and/or PD-L1 (programmed death-ligand 1), thereby providing highly efficacious anti-tumor activity. However, this unmitigated immune response can also trigger immune related adverse events (irAEs) in multiple organs, with pancreatic irAEs (now referred to as type 3 Autoimmune pancreatitis (AIP) being infrequent. RECENT FINDINGS: Type 3 AIP is a drug-induced, immune mediated progressive inflammatory disease of the pancreas that may have variable clinical presentations viz., an asymptomatic pancreatic enzyme elevation, incidental imaging evidence of pancreatitis, painful pancreatitis, or any combination of these subtypes. Management is largely supportive with intravenous fluid hydration, pain control and holding the inciting medication. Steroids have not been shown to demonstrate a clear benefit in acute management. A rapid development pancreatic atrophy is observed on imaging as early as 1 year post initial injury. Type 3 AIP is a chronic inflammatory disease of the pancreas that though predominantly asymptomatic and mild in severity can lead to rapid organ volume loss regardless of type of clinical presentation and despite steroid therapy.</text><annotation id="22"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="144" length="6"/><text>cancer</text></annotation><annotation id="23"><infon key="identifier">397286</infon><infon key="type">Gene</infon><location offset="187" length="6"/><text>CTLA-4</text></annotation><annotation id="24"><infon key="identifier">397286</infon><infon key="type">Gene</infon><location offset="195" length="43"/><text>cytotoxic T-lymphocyte-associated protein 4</text></annotation><annotation id="25"><infon key="identifier">100533201</infon><infon key="type">Gene</infon><location offset="254" length="31"/><text>programmed cell death protein 1</text></annotation><annotation id="26"><infon key="identifier">574058</infon><infon key="type">Gene</infon><location offset="295" length="5"/><text>PD-L1</text></annotation><annotation id="27"><infon key="identifier">574058</infon><infon key="type">Gene</infon><location offset="302" length="25"/><text>programmed death-ligand 1</text></annotation><annotation id="28"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="372" length="5"/><text>tumor</text></annotation><annotation id="29"><infon key="identifier">MESH:D000081012</infon><infon key="type">Disease</infon><location offset="547" length="30"/><text>type 3 Autoimmune pancreatitis</text></annotation><annotation id="30"><infon key="identifier">MESH:D000081012</infon><infon key="type">Disease</infon><location offset="579" length="3"/><text>AIP</text></annotation><annotation id="31"><infon key="identifier">MESH:D000081012</infon><infon key="type">Disease</infon><location offset="619" length="10"/><text>Type 3 AIP</text></annotation><annotation id="32"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="677" length="36"/><text>inflammatory disease of the pancreas</text></annotation><annotation id="33"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="842" length="12"/><text>pancreatitis</text></annotation><annotation id="34"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="864" length="12"/><text>pancreatitis</text></annotation><annotation id="35"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="983" length="4"/><text>pain</text></annotation><annotation id="36"><infon key="identifier">MESH:D013256</infon><infon key="type">Chemical</infon><location offset="1033" length="8"/><text>Steroids</text></annotation><annotation id="37"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="1134" length="18"/><text>pancreatic atrophy</text></annotation><annotation id="38"><infon key="identifier">MESH:D000081012</infon><infon key="type">Disease</infon><location offset="1216" length="10"/><text>Type 3 AIP</text></annotation><annotation id="39"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="1240" length="36"/><text>inflammatory disease of the pancreas</text></annotation><annotation id="40"><infon key="identifier">MESH:D000092124</infon><infon key="type">Disease</infon><location offset="1355" length="17"/><text>organ volume loss</text></annotation><annotation id="41"><infon key="identifier">MESH:D013256</infon><infon key="type">Chemical</infon><location offset="1429" length="7"/><text>steroid</text></annotation></passage><relation id="R1"><infon key="score">0.522</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|574058</infon><infon key="type">Association</infon><node refid="0" role="1,5"/></relation><relation id="R2"><infon key="score">0.5159</infon><infon key="role1">Chemical|MESH:D013256</infon><infon key="role2">Disease|MESH:D010190</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="20,18"/></relation><relation id="R3"><infon key="score">0.4544</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|100533201</infon><infon key="type">Association</infon><node refid="2" role="1,4"/></relation><relation id="R4"><infon key="score">0.9976</infon><infon key="role1">Chemical|MESH:D013256</infon><infon key="role2">Disease|MESH:D000092124</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="20,19"/></relation><relation id="R5"><infon key="score">0.9758</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|397286</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="1,2"/></relation></document>
<document><id>37846083</id><passage><infon key="journal">J Agric Food Chem;2023Oct25; 71 (42) 15692. doi:10.1021/acs.jafc.3c05180</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lee S, Kim S, Kim IK, Kim KJ, </infon><offset>0</offset><text>Structural and Biochemical Studies on Product Inhibition of S-Adenosylmethionine Synthetase from Corynebacterium glutamicum.</text></passage><passage><infon key="type">abstract</infon><offset>125</offset><text>S-Adenosylmethionine (SAM) acts as a methyl donor in living organisms, and S-adenosylmethionine synthetase (MetK) is an essential enzyme for cells, as it synthesizes SAM from methionine and adenosine triphosphate (ATP). This study determined the crystal structures of the apo form and adenosine/triphosphate complex form of MetK from Corynebacterium glutamicum (CgMetK). Results showed that CgMetK has an allosteric inhibitor binding site for the SAM product in the vicinity of the active site and is inhibited by SAM both competitively and noncompetitively. Through structure-guided protein engineering, the CgMetKE68A variant was developed that exhibited an almost complete release of inhibition by SAM with rather enhanced enzyme activity. The crystal structure of the CgMetKE68A variant revealed that the formation of a new hydrogen bond between Tyr66 and Glu102 by the E68A mutation disrupted the allosteric SAM binding site and also improved the protein thermal stability by strengthening the tetramerization of the enzyme.</text><annotation id="12"><infon key="identifier">MESH:D012436</infon><infon key="type">Chemical</infon><location offset="125" length="20"/><text>S-Adenosylmethionine</text></annotation><annotation id="13"><infon key="identifier">MESH:D012436</infon><infon key="type">Chemical</infon><location offset="147" length="3"/><text>SAM</text></annotation><annotation id="14"><infon key="identifier">MESH:D012436</infon><infon key="type">Chemical</infon><location offset="291" length="3"/><text>SAM</text></annotation><annotation id="15"><infon key="identifier">MESH:D008715</infon><infon key="type">Chemical</infon><location offset="300" length="10"/><text>methionine</text></annotation><annotation id="16"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="315" length="22"/><text>adenosine triphosphate</text></annotation><annotation id="17"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="339" length="3"/><text>ATP</text></annotation><annotation id="18"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="410" length="22"/><text>adenosine/triphosphate</text></annotation><annotation id="19"><infon key="identifier">MESH:D012436</infon><infon key="type">Chemical</infon><location offset="572" length="3"/><text>SAM</text></annotation><annotation id="20"><infon key="identifier">MESH:D012436</infon><infon key="type">Chemical</infon><location offset="639" length="3"/><text>SAM</text></annotation><annotation id="21"><infon key="identifier">MESH:D012436</infon><infon key="type">Chemical</infon><location offset="826" length="3"/><text>SAM</text></annotation><annotation id="22"><infon key="identifier">tmVar:p|SUB|E|68|A;HGVS:p.E68A;VariantGroup:0</infon><infon key="type">ProteinMutation</infon><location offset="999" length="4"/><text>E68A</text></annotation><annotation id="23"><infon key="identifier">MESH:D012436</infon><infon key="type">Chemical</infon><location offset="1038" length="3"/><text>SAM</text></annotation></passage><relation id="R1"><infon key="score">0.9923</infon><infon key="role1">Chemical|MESH:D012436</infon><infon key="role2">ProteinMutation|HGVS:p.E68A</infon><infon key="type">Association</infon><node refid="0" role="11,10"/></relation></document>
<document><id>37846433</id><passage><infon key="journal">PM R;2023Oct16. doi:10.1002/pmrj.13081</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tarsney PS, Kondrat A, Watters K, Kirschner KL, Mukherjee D, </infon><offset>0</offset><text>Ethical Aspects of the Disfavored Discharge.</text></passage><passage><infon key="type">abstract</infon><offset>45</offset></passage></document>
<document><id>37847147</id><passage><infon key="journal">Pest Manag Sci;2023Oct17. doi:10.1002/ps.7838</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xiang S, Zhang X, Cao Z, Peng S, Xu J, Huang Q, Huang J, Xu C, Sun X, </infon><offset>0</offset><text>Comparing the antibacterial activity of chitin nanocrystals with chitin: exploring the feasibility of chitin nanocrystals as novel pesticide nanocarriers in agriculture.</text><annotation id="3"><infon key="identifier">MESH:D002686</infon><infon key="type">Chemical</infon><location offset="40" length="6"/><text>chitin</text></annotation><annotation id="4"><infon key="identifier">MESH:D002686</infon><infon key="type">Chemical</infon><location offset="65" length="6"/><text>chitin</text></annotation><annotation id="5"><infon key="identifier">MESH:D002686</infon><infon key="type">Chemical</infon><location offset="102" length="6"/><text>chitin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>170</offset><text>BACKGROUND: In recent years, nanomaterials-based pesticide carriers have garnered significant attention and sparked extensive research. However, most studies have primarily focused on investigating the impact of physical properties of nanomaterials, such as size and modifiable sites, on drug delivery efficiency of nano-pesticides. The limited exploration of biologically active nanomaterials poses a significant obstacle to the advancement and widespread adoption of nano-pesticides. In this study, we prepared chitin nanocrystals (ChNC) based on acid hydrolysis and systematically investigated the differences between nano- and normal chitin against plant bacteria (Pseudomonas syringae pv. tabaci). The primary objective was to seek out nanocarriers with heightened biological activity for the synthesis of nano-pesticides. RESULTS: Zeta potential analysis, Fourier Transform infrared spectrometry (FTIR), X-Ray diffraction (XRD), Atomic force microscopy (AFM) and Transmission electron microscopy (TEM) identified the successful synthesis of ChNC. ChNC showcased remarkable bactericidal activity at comparable concentrations, surpassing that of chitin, particularly in its ability to inhibit bacterial biofilm formation. Furthermore, ChNC displayed heightened effectiveness in disrupting bacterial cell membranes, resulting in the leakage of bacterial cell contents, structural DNA damage, and impairment of DNA replication. Lastly, potting experiments revealed that ChNC is notably more effective in inhibiting the spread and propagation of bacteria on plant leaves. CONCLUSION: ChNC exhibited higher antibacterial activity compared to chitin, enabling efficient control of plant bacterial diseases through enhanced interaction with bacteria. These findings offer compelling evidence of ChNC's superior bacterial inhibition capabilities, underscoring its potential as a promising nanocarrier for nano-pesticide research. This article is protected by copyright. All rights reserved.</text><annotation id="12"><infon key="identifier">MESH:D002686</infon><infon key="type">Chemical</infon><location offset="683" length="6"/><text>chitin</text></annotation><annotation id="13"><infon key="identifier">MESH:D002686</infon><infon key="type">Chemical</infon><location offset="808" length="6"/><text>chitin</text></annotation><annotation id="14"><infon key="type">Disease</infon><location offset="864" length="6"/><text>tabaci</text></annotation><annotation id="15"><infon key="identifier">MESH:D002686</infon><infon key="type">Chemical</infon><location offset="1320" length="6"/><text>chitin</text></annotation><annotation id="16"><infon key="identifier">MESH:D002686</infon><infon key="type">Chemical</infon><location offset="1812" length="6"/><text>chitin</text></annotation><annotation id="17"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="1856" length="18"/><text>bacterial diseases</text></annotation></passage></document>
<document><id>37848218</id><passage><infon key="journal">BMJ;2023Oct17; 383 2406. doi:10.1136/bmj.p2406</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mahase E, </infon><offset>0</offset><text>Long covid: Researchers "extremely angry" at Boris Johnson's "bollocks" comment.</text><annotation id="1"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="0" length="10"/><text>Long covid</text></annotation></passage><passage><infon key="type">abstract</infon><offset>81</offset></passage></document>
<document><id>37848568</id><passage><infon key="journal">J Math Biol;2023Oct17; 87 (5) 72. doi:10.1007/s00285-023-02002-7</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang T, Zhao XQ, </infon><offset>0</offset><text>Threshold dynamics of an almost periodic vector-borne disease model.</text><annotation id="1"><infon key="identifier">MESH:D000079426</infon><infon key="type">Disease</infon><location offset="41" length="20"/><text>vector-borne disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>69</offset><text>Many infectious diseases cannot be transmitted from human to human directly, and the transmission needs to be done via a vector. It is well known that vectors' life cycles are highly dependent on their living environment. In order to investigate dynamics of vector-borne diseases under environment influence, we propose a vector-borne disease model with almost periodic coefficients. We derive the basic reproductive number [Formula: see text] for this model and establish a threshold type result on its global dynamics in terms of [Formula: see text]. As an illustrative example, we consider an almost periodic model of malaria transmission. Our numerical simulation results show that the basic reproductive number may be underestimated if almost periodic coefficients are replaced by their average values . Finally, we use our model to study the dengue fever transmission in Guangdong, China. The parameters are chosen to fit the reported data available for Guangdong. Numerical simulations indicate that the annual dengue fever case in Guangdong will increase steadily in the near future unless more effective control measures are implemented. Sensitivity analysis implies that the parameters with strong impact on the outcome are recovery rate, mosquito recruitment rate, mosquito mortality rate, baseline transmission rates between mosquito and human. This suggests that the effective control strategies may include intensive treatment, mosquito control, decreasing human contact number with mosquitoes (e.g., using bed nets and preventing mosquito bites), and environmental modification.</text><annotation id="8"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="74" length="19"/><text>infectious diseases</text></annotation><annotation id="9"><infon key="identifier">MESH:D000079426</infon><infon key="type">Disease</infon><location offset="327" length="21"/><text>vector-borne diseases</text></annotation><annotation id="10"><infon key="identifier">MESH:D000079426</infon><infon key="type">Disease</infon><location offset="391" length="20"/><text>vector-borne disease</text></annotation><annotation id="11"><infon key="identifier">MESH:D008288</infon><infon key="type">Disease</infon><location offset="690" length="7"/><text>malaria</text></annotation><annotation id="12"><infon key="identifier">MESH:D003715</infon><infon key="type">Disease</infon><location offset="917" length="12"/><text>dengue fever</text></annotation><annotation id="13"><infon key="identifier">MESH:D003715</infon><infon key="type">Disease</infon><location offset="1087" length="12"/><text>dengue fever</text></annotation></passage></document>
<document><id>37849268</id><passage><infon key="journal">Zhonghua Wei Chang Wai Ke Za Zhi;2023Oct25; 26 (10) 968. doi:10.3760/cma.j.cn441530-20230525-00181</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li WJ, Diao DC, Lin JX, Wang JH, Liao WL, Tang X, Xie JX, Ao L, Zhang XY, Yi XJ, Feng XC, Li HM, Lu XQ, </infon><offset>0</offset><text>[Feasibility of a three-sided encapsulation procedure based on fascia anatomy in laparoscopic lateral lymph node dissection for middle and low rectal cancer].</text><annotation id="1"><infon key="identifier">MESH:D012004</infon><infon key="type">Disease</infon><location offset="128" length="28"/><text>middle and low rectal cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>159</offset><text>Objective: To explore the feasibility and value of performing a three-sided encapsulation procedure based on fascia anatomy in laparoscopic lateral lymph node dissection (LLND) for middle and low rectal cancer. Methods: This was a retrospective review. The study cohort comprised patients who met the diagnostic criteria for rectal cancer according to the Chinese Guidelines for the Diagnosis and Treatment of Colorectal Cancer, had a short lymph node diameter of >5 mm on the lateral side within the 15 days before surgery, were evaluated as feasible candidates for laparoscopic total mesorectal excision+LLND surgery, had been diagnosed with low or intermediate level rectal cancer, and whose tumor was less than 8 cm away from the anal verge according to pathological examination of the operative specimen. Patients with a history of other malignant tumors of the abdomen or with incomplete follow-up data were excluded. Forty-two patients with middle and low rectal cancer who had undergone lateral lymph node dissection in diagnosis and treatment center of Gastrointestinal Cancer of Guangdong Hospital of Chinese Medicine from Jan.2018 to Dec.2022 were enrolled. There were 24 men (57.1%) and 18 women (42.9%) aged 58.4+-11.8 years and the median BMI was 22.5 (19.3-24.1) kg/m2. The main point of the three-sided encapsulation procedure is to expand the external side medial to the external iliac artery and vein, narrowing the range of exterior side dissection. The anterior-medial side is designed to expand the vesical fascia to define the range of anterior-medial side extension. The internal side is fully extended to the ureterohypogastric nerve fascia; the distal point of the caudal extension reaches the level of the Alcock canal and the bottom reaches the piriformis, enabling dissection of the obturator nerve and No.283 lymph nodes. No.263D lymph nodes are dissected by exposing the internal iliac artery and its branches, dissecting the group No.263P lymph nodes, and severing the inferior vesical artery. Finally, the lateral lymphatic tissue is completely resected. Relevant variables were recorded, including the number of lateral lymph nodes detected, the rate of lymph node metastasis, operation duration, intraoperative blood loss, postoperative complications, postoperative hospital stay, and 3-year overall survival rate. Results: Laparoscopic surgery was successfully completed in all patients with no conversions to open surgery and no intraoperative complications. Twenty-seven (64.3%) of the study patients underwent left-sided LLND, 10 (23.8%) right-sided LLND, and five (11.9%) bilateral LLND, with lymph nodes cleared on both sides. All patients' lymph nodes were examined pathologically. A median of 17.0 (11.7, 26.0) lymph nodes was detected, the median of lateral lymph nodes being 5.0 (2.0, 10.2). The median operation time was 254.5 (199.0, 325.2) minutes. The median intra-operative blood loss was 50.0 (30.0, 100.0) mL. All patients were diagnosed with adenocarcinoma by pathological examination of the operative specimen. Two patients developed postoperative intestinal obstruction, one lymphatic leakage, and one a perineal incision infection. There were no cases of anastomotic leakage. The median postoperative hospital stay was 6.0 (5.0, 7.0) days and the median follow-up time 23.5 (9.0, 36.7) months. During follow-up, three patients (7.1%) died of tumor recurrence and metastasis. Two (4.8%) experienced mild urinary dysfunction, and one (2.4%) had moderate postoperative erectile dysfunction. One patient (2.4%) was found to have prostate and lung metastases 3 month after surgery. The 3-year overall survival rate was 74.4%. Conclusions: Three sided encapsulation is a safe and feasible procedure for LLND, achieving accurate and complete clearance of lateral lymphatic tissue.</text><annotation id="22"><infon key="identifier">MESH:D012004</infon><infon key="type">Disease</infon><location offset="340" length="28"/><text>middle and low rectal cancer</text></annotation><annotation id="23"><infon key="identifier">MESH:D012004</infon><infon key="type">Disease</infon><location offset="484" length="13"/><text>rectal cancer</text></annotation><annotation id="24"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="569" length="17"/><text>Colorectal Cancer</text></annotation><annotation id="25"><infon key="identifier">MESH:D012004</infon><infon key="type">Disease</infon><location offset="829" length="13"/><text>rectal cancer</text></annotation><annotation id="26"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="854" length="5"/><text>tumor</text></annotation><annotation id="27"><infon key="identifier">MESH:D000006</infon><infon key="type">Disease</infon><location offset="1002" length="31"/><text>malignant tumors of the abdomen</text></annotation><annotation id="28"><infon key="identifier">MESH:D012004</infon><infon key="type">Disease</infon><location offset="1107" length="28"/><text>middle and low rectal cancer</text></annotation><annotation id="29"><infon key="identifier">MESH:D005770</infon><infon key="type">Disease</infon><location offset="1221" length="23"/><text>Gastrointestinal Cancer</text></annotation><annotation id="30"><infon key="identifier">CVCL:B6L0</infon><infon key="type">CellLine</infon><location offset="2010" length="7"/><text>No.263D</text></annotation><annotation id="31"><infon key="identifier">MESH:D008207</infon><infon key="type">Disease</infon><location offset="2346" length="21"/><text>lymph node metastasis</text></annotation><annotation id="32"><infon key="identifier">MESH:D000230</infon><infon key="type">Disease</infon><location offset="3153" length="14"/><text>adenocarcinoma</text></annotation><annotation id="33"><infon key="identifier">MESH:D007415</infon><infon key="type">Disease</infon><location offset="3260" length="22"/><text>intestinal obstruction</text></annotation><annotation id="34"><infon key="identifier">MESH:D008206</infon><infon key="type">Disease</infon><location offset="3288" length="17"/><text>lymphatic leakage</text></annotation><annotation id="35"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="3335" length="9"/><text>infection</text></annotation><annotation id="36"><infon key="identifier">MESH:D057868</infon><infon key="type">Disease</infon><location offset="3369" length="19"/><text>anastomotic leakage</text></annotation><annotation id="37"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="3556" length="5"/><text>tumor</text></annotation><annotation id="38"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="3577" length="10"/><text>metastasis</text></annotation><annotation id="39"><infon key="identifier">MESH:D001745</infon><infon key="type">Disease</infon><location offset="3617" length="19"/><text>urinary dysfunction</text></annotation><annotation id="40"><infon key="identifier">MESH:D007172</infon><infon key="type">Disease</infon><location offset="3680" length="20"/><text>erectile dysfunction</text></annotation><annotation id="41"><infon key="identifier">MESH:D011472</infon><infon key="type">Disease</infon><location offset="3739" length="28"/><text>prostate and lung metastases</text></annotation></passage></document>
<document><id>37850321</id><passage><infon key="journal">Eur J Heart Fail;2023Oct18. doi:10.1002/ejhf.3046</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Molloy CD, Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJS, Dalal H, Rees K, Singh SJ, Taylor RS, </infon><offset>0</offset><text>Exercise-based cardiac rehabilitation for adults with heart failure - 2023 Cochrane systematic review and meta-analysis.</text><annotation id="1"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="54" length="13"/><text>heart failure</text></annotation></passage><passage><infon key="type">abstract</infon><offset>121</offset><text>BACKGROUND AND AIMS: Despite strong evidence, access to exercise-based cardiac rehabilitation (ExCR) remains low across global healthcare systems. We provide a contemporary update of the Cochrane review randomised trial evidence for ExCR for adults with heart failure (HF) and compare different delivery modes: centre-based, home-based (including digital support), and both (hybrid). METHODS: Databases, bibliographies of previous systematic reviews and included trials, and trials registers were searched with no language restrictions. Randomised controlled trials, recruiting adults with HF, assigned to either ExCR or a no-exercise control group, with follow-up >=6-months were included. Two review authors independently screened titles for inclusion, extracted trial and patient characteristics, outcome data, and assessed risk of bias. Outcomes of mortality, hospitalisation, and health-related quality of life (HRQoL) were pooled across trials using meta-analysis at short-term (&lt;=12 months) and long-term follow up (> 12 months) and stratified by delivery mode. RESULTS: 60 trials (8,728 participants) were included. In the short-term, compared to control, ExCR did not impact all-cause mortality (relative risk (RR): 0.93; 95% confidence interval (95% CI): 0.71 to 1.21), reduced all-cause hospitalisation (RR: 0.69; 95% CI: 0.56 to 0.86, number needed to treat: 13, 95% CI: 9 to 22), and was associated with a clinically important improvement in HRQoL measured by the Minnesota Living with Heart Failure Questionnaire (MLWHF) overall score (mean difference: -7.39; 95% CI: -10.30 to -4.47). Improvements in outcomes with ExCR was seen across centre, home (including digitally supported), and hybrid settings. A similar pattern of results was seen in the long-term (mortality: RR 0.87, 95% CI: 0.72 to 1.04; all-cause hospitalisation: RR 0.84, 95% CI: 0.70 to 1.01, MLWHF: -9.59, 95% CI: -17.48 to -1.50). CONCLUSIONS: To improve global suboptimal levels of uptake for HF patients, global healthcare systems need to routinely recommend ExCR and offer a choice of mode of delivery, dependent on an individual patient's level of risk and complexity. This article is protected by copyright. All rights reserved.</text><annotation id="7"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="375" length="13"/><text>heart failure</text></annotation><annotation id="8"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="390" length="2"/><text>HF</text></annotation><annotation id="9"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="711" length="2"/><text>HF</text></annotation><annotation id="10"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1620" length="13"/><text>Heart Failure</text></annotation><annotation id="11"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="2098" length="2"/><text>HF</text></annotation></passage></document>
<document><id>37850679</id><passage><infon key="journal">Anesth Prog;2023Sep01; 70 (3) 134. doi:10.2344/anpr-70-02-10</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Okayasu I, Tachi M, Suzue E, Ito N, Ozaki Y, Mishima G, Kurata S, Ayuse T, </infon><offset>0</offset><text>A Case Report of Burning Mouth Syndrome with Dry Mouth Managed by Kampo Medicine.</text><annotation id="3"><infon key="identifier">MESH:D002054</infon><infon key="type">Disease</infon><location offset="17" length="22"/><text>Burning Mouth Syndrome</text></annotation><annotation id="4"><infon key="identifier">MESH:D014987</infon><infon key="type">Disease</infon><location offset="45" length="9"/><text>Dry Mouth</text></annotation><annotation id="5"><infon key="type">Disease</infon><location offset="66" length="14"/><text>Kampo Medicine</text></annotation></passage><passage><infon key="type">abstract</infon><offset>82</offset><text>The patient was a 56-year-old woman who complained of chronic pain involving her tongue. We diagnosed her with burning mouth syndrome (BMS) based on exclusion of any local factors or systemic conditions. The patient not only had tongue pain but also had other signs and symptoms like scalloped tongue, dry mouth, and headache. To manage these additional issues, we used Goreisan, an herbal Kampo medicine, as a complementary alternative medicine (CAM) approach along with cognitive behavioral therapy (CBT). The patient's BMS was successfully managed with the combination of CAM and CBT, which may suggest that the pathophysiology for BMS might be nociplastic pain rather than purely nociceptive or neuropathic.</text><annotation id="19"><infon key="identifier">MESH:D059350</infon><infon key="type">Disease</infon><location offset="136" length="12"/><text>chronic pain</text></annotation><annotation id="20"><infon key="identifier">MESH:D014060</infon><infon key="type">Disease</infon><location offset="163" length="6"/><text>tongue</text></annotation><annotation id="21"><infon key="identifier">MESH:D002054</infon><infon key="type">Disease</infon><location offset="193" length="22"/><text>burning mouth syndrome</text></annotation><annotation id="22"><infon key="identifier">MESH:D002054</infon><infon key="type">Disease</infon><location offset="217" length="3"/><text>BMS</text></annotation><annotation id="23"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="311" length="11"/><text>tongue pain</text></annotation><annotation id="24"><infon key="identifier">MESH:D014060</infon><infon key="type">Disease</infon><location offset="376" length="6"/><text>tongue</text></annotation><annotation id="25"><infon key="identifier">MESH:D014987</infon><infon key="type">Disease</infon><location offset="384" length="9"/><text>dry mouth</text></annotation><annotation id="26"><infon key="identifier">MESH:D006261</infon><infon key="type">Disease</infon><location offset="399" length="8"/><text>headache</text></annotation><annotation id="27"><infon key="type">Disease</infon><location offset="472" length="14"/><text>Kampo medicine</text></annotation><annotation id="28"><infon key="identifier">MESH:D002054</infon><infon key="type">Disease</infon><location offset="604" length="3"/><text>BMS</text></annotation><annotation id="29"><infon key="identifier">MESH:D002054</infon><infon key="type">Disease</infon><location offset="717" length="3"/><text>BMS</text></annotation><annotation id="30"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="730" length="16"/><text>nociplastic pain</text></annotation><annotation id="31"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="781" length="11"/><text>neuropathic</text></annotation></passage></document>
<document><id>37851034</id><passage><infon key="journal">Continuum (Minneap Minn);2023Oct01; 29 (5) 1357. doi:10.1212/CON.0000000000001290</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gable K, </infon><offset>0</offset><text>Chronic Immune-Mediated Demyelinating Neuropathies.</text><annotation id="1"><infon key="identifier">MESH:D003711</infon><infon key="type">Disease</infon><location offset="24" length="26"/><text>Demyelinating Neuropathies</text></annotation></passage><passage><infon key="type">abstract</infon><offset>52</offset><text>OBJECTIVE: This article is an overview of chronic demyelinating neuropathies and highlights the phenotypic categorization, diagnosis, and treatment of chronic immune-mediated neuropathies. The clinical and diagnostic characteristics of other chronic demyelinating neuropathies that are common mimics of immune-mediated neuropathies are also discussed. LATEST DEVELOPMENTS: The underlying pathophysiology of chronic demyelinating neuropathies is heterogeneous, and components of both humoral and cellular immune responses are thought to play a role in the immune-mediated types of chronic demyelinating neuropathy. The role of the humoral response is highlighted with a specific focus on the relatively recent discovery of antibody-mediated antinodal and paranodal demyelinating neuropathies. Additionally, new diagnostic criteria for some of the chronic demyelinating neuropathies, as well as ways to differentiate chronic inflammatory demyelinating polyradiculoneuropathy from other chronic demyelinating polyneuropathies, are discussed. ESSENTIAL POINTS: Chronic demyelinating neuropathies can present with overlapping clinical characteristics with seemingly subtle variations. It is clinically important to differentiate these types of neuropathies because the treatment and management can vary and affect prognosis.</text><annotation id="15"><infon key="identifier">MESH:D003711</infon><infon key="type">Disease</infon><location offset="94" length="34"/><text>chronic demyelinating neuropathies</text></annotation><annotation id="16"><infon key="identifier">MESH:C567355</infon><infon key="type">Disease</infon><location offset="211" length="28"/><text>immune-mediated neuropathies</text></annotation><annotation id="17"><infon key="identifier">MESH:D003711</infon><infon key="type">Disease</infon><location offset="294" length="34"/><text>chronic demyelinating neuropathies</text></annotation><annotation id="18"><infon key="identifier">MESH:C567355</infon><infon key="type">Disease</infon><location offset="355" length="28"/><text>immune-mediated neuropathies</text></annotation><annotation id="19"><infon key="identifier">MESH:D003711</infon><infon key="type">Disease</infon><location offset="459" length="34"/><text>chronic demyelinating neuropathies</text></annotation><annotation id="20"><infon key="identifier">MESH:D003711</infon><infon key="type">Disease</infon><location offset="640" length="24"/><text>demyelinating neuropathy</text></annotation><annotation id="21"><infon key="identifier">MESH:D003711</infon><infon key="type">Disease</infon><location offset="802" length="40"/><text>and paranodal demyelinating neuropathies</text></annotation><annotation id="22"><infon key="identifier">MESH:D003711</infon><infon key="type">Disease</infon><location offset="898" length="34"/><text>chronic demyelinating neuropathies</text></annotation><annotation id="23"><infon key="identifier">MESH:D020277</infon><infon key="type">Disease</infon><location offset="967" length="57"/><text>chronic inflammatory demyelinating polyradiculoneuropathy</text></annotation><annotation id="24"><infon key="identifier">MESH:D020277</infon><infon key="type">Disease</infon><location offset="1036" length="38"/><text>chronic demyelinating polyneuropathies</text></annotation><annotation id="25"><infon key="identifier">MESH:D020329</infon><infon key="type">Disease</infon><location offset="1091" length="9"/><text>ESSENTIAL</text></annotation><annotation id="26"><infon key="identifier">MESH:D003711</infon><infon key="type">Disease</infon><location offset="1109" length="34"/><text>Chronic demyelinating neuropathies</text></annotation><annotation id="27"><infon key="identifier">MESH:D009422</infon><infon key="type">Disease</infon><location offset="1291" length="12"/><text>neuropathies</text></annotation></passage></document>
<document><id>37851392</id><passage><infon key="journal">Diabetes Care;2023Oct18. doi:10.2337/dc23-0936</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hsieh TYJ, Chang R, Yong SB, Liao PL, Hung YM, Wei JC, </infon><offset>0</offset><text>COVID-19 Vaccination Prior to SARS-CoV-2 Infection Reduced Risk of Subsequent Diabetes Mellitus: A Real-World Investigation Using U.S. Electronic Health Records.</text><annotation id="3"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="0" length="8"/><text>COVID-19</text></annotation><annotation id="4"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="30" length="20"/><text>SARS-CoV-2 Infection</text></annotation><annotation id="5"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="78" length="17"/><text>Diabetes Mellitus</text></annotation></passage><passage><infon key="type">abstract</infon><offset>162</offset><text>OBJECTIVE: Previous studies have indicated a bidirectional correlation between diabetes and SARS-CoV-2 infection. However, no investigation has comprehensively explored the potential of COVID-19 vaccination to reduce the risk of new-onset diabetes mellitus (DM) in infected individuals. RESEARCH DESIGN AND METHODS: In the first of 2 cohorts, we compared the risk of new-onset DM between individuals infected with SARS-CoV-2 and noninfected individuals (N = 1,562,606) using the TriNetX database to validate findings in prior literature. For the second cohort, we identified 83,829 vaccinated and 83,829 unvaccinated COVID-19 survivors from the same period. DM, antihyperglycemic drug use, and a composite of both were defined as outcomes. We conducted Cox proportional hazard regression analysis for the estimation of hazard ratios (HRs) and 95% CIs. Kaplan-Meier analysis was conducted to calculate the incidence of new-onset DM. Subgroup analyses based on age (18-44, 45-64, >=65 years), sex (female, male), race (White, Black or African American, Asian), and BMI categories (&lt;19.9, 20-29, 30-39, >=40), sensitivities analyses, and a dose-response analysis were conducted to validate the findings. RESULTS: The initial cohort of patients infected with SARS-CoV-2 had a 65% increased risk (HR, 1.65; 95% CI, 1.62-1.68) of developing new-onset DM relative to noninfected individuals. In the second cohort, we observed that vaccinated patients had a 21% lower risk of developing new-onset DM in comparison with unvaccinated COVID-19 survivors (HR, 0.79; 95% CI, 0.73-0.86). Subgroup analyses by sex, age, race, and BMI yielded similar results. These findings were consistent in sensitivity analyses and cross-validation with an independent dataset from TriNetX. CONCLUSIONS: In conclusion, this study validates a 65% higher risk of new-onset diabetes in SARS-CoV-2-infected individuals compared to noninfected counterparts. Furthermore, COVID-19 survivors who received COVID-19 vaccinations experienced a reduced risk of new-onset diabetes, with a dose-dependent effect. Notably, the protective impact of COVID-19 vaccination is more pronounced among the Black/African American population than other ethnic groups. These findings emphasize the imperative of widespread vaccination to mitigate diabetes risk and the need for tailored strategies for diverse demographic groups to ensure equitable protection.</text><annotation id="29"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="241" length="8"/><text>diabetes</text></annotation><annotation id="30"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="254" length="20"/><text>SARS-CoV-2 infection</text></annotation><annotation id="31"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="348" length="8"/><text>COVID-19</text></annotation><annotation id="32"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="401" length="17"/><text>diabetes mellitus</text></annotation><annotation id="33"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="420" length="2"/><text>DM</text></annotation><annotation id="34"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="427" length="8"/><text>infected</text></annotation><annotation id="35"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="539" length="2"/><text>DM</text></annotation><annotation id="36"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="562" length="8"/><text>infected</text></annotation><annotation id="37"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="779" length="8"/><text>COVID-19</text></annotation><annotation id="38"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="820" length="2"/><text>DM</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="824" length="22"/><text>antihyperglycemic drug</text></annotation><annotation id="40"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1090" length="2"/><text>DM</text></annotation><annotation id="41"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1403" length="8"/><text>infected</text></annotation><annotation id="42"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1507" length="2"/><text>DM</text></annotation><annotation id="43"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1651" length="2"/><text>DM</text></annotation><annotation id="44"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1686" length="8"/><text>COVID-19</text></annotation><annotation id="45"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="2004" length="8"/><text>diabetes</text></annotation><annotation id="46"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="2027" length="8"/><text>infected</text></annotation><annotation id="47"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="2099" length="8"/><text>COVID-19</text></annotation><annotation id="48"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="2131" length="8"/><text>COVID-19</text></annotation><annotation id="49"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="2193" length="8"/><text>diabetes</text></annotation><annotation id="50"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="2267" length="8"/><text>COVID-19</text></annotation><annotation id="51"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="2455" length="8"/><text>diabetes</text></annotation></passage></document>
<document><id>37851747</id><passage><infon key="journal">An Acad Bras Cienc;2023; 95 (3) 20220801. doi:10.1590/0001-3765202320220801</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Boquett JA, Vianna FSL, Fagundes NJR, Schroeder L, Barbian M, Zagonel-Oliveira M, Andreis TF, P&amp;#xf4;rto LCMS, Chies JAB, Schuler-Faccini L, Ashton-Prolla P, Rosset C, </infon><offset>0</offset><text>HLA haplotypes and differential regional mortality caused by COVID-19 in Brazil: an ecological study based on a large bone marrow donor bank dataset.</text><annotation id="1"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="61" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>150</offset><text>The coronavirus disease 2019 (COVID-19) mortality rates varied among the states of Brazil during the course of the pandemics. The human leukocyte antigen (HLA) is a critical component of the antigen presentation pathway. Individuals with different HLA genotypes may trigger different immune responses against pathogens, which could culminate in different COVID-19 responses. HLA genotypes are variable, especially in the highly admixed Brazilian population. In this ecological study, we aimed to investigate the correlation between HLA haplotypes and the different regional distribution of COVID-19 mortality in Brazil. HLA data was obtained from 4,148,713 individuals registered in The Brazilian Voluntary Bone Marrow Donors Registry. COVID-19 data was retrieved from epidemiological bulletins issued by State Health Secretariats via Brazil's Ministry of Health from February/2020 to July/2022. We found a positive significant correlation between the HLA-A*01~B*08~DRB1*03 haplotype and COVID-19 mortality rates when we analyzed data from 26 states and the Federal District. This result indicates that the HLA-A*01~B*08~DRB1*03 haplotype may represent an additional risk factor for dying due to COVID-19. This haplotype should be further studied in other populations for a better understanding of the variation in COVID-19 outcomes across the world.</text><annotation id="12"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="154" length="24"/><text>coronavirus disease 2019</text></annotation><annotation id="13"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="180" length="8"/><text>COVID-19</text></annotation><annotation id="14"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="505" length="8"/><text>COVID-19</text></annotation><annotation id="15"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="740" length="8"/><text>COVID-19</text></annotation><annotation id="16"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="886" length="8"/><text>COVID-19</text></annotation><annotation id="17"><infon key="identifier">3123</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136635</infon><location offset="1116" length="4"/><text>DRB1</text></annotation><annotation id="18"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1138" length="8"/><text>COVID-19</text></annotation><annotation id="19"><infon key="identifier">3123</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136635</infon><location offset="1271" length="4"/><text>DRB1</text></annotation><annotation id="20"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1346" length="8"/><text>COVID-19</text></annotation><annotation id="21"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1465" length="8"/><text>COVID-19</text></annotation></passage><relation id="R1"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D000086382</infon><infon key="role2">Gene|3123</infon><infon key="type">Association</infon><node refid="0" role="7,6"/></relation></document>
<document><id>37852108</id><passage><infon key="journal">Comput Biol Med;2023Oct11; 166 107577. doi:10.1016/j.compbiomed.2023.107577</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hu W, Jin T, Pan Z, Xu H, Yu L, Chen T, Zhang W, Jiang H, Yang W, Xu J, Zhu F, Dai H, </infon><offset>0</offset><text>An interpretable ensemble learning model facilitates early risk stratification of ischemic stroke in intensive care unit: Development and external validation of ICU-ISPM.</text><annotation id="1"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="82" length="15"/><text>ischemic stroke</text></annotation></passage><passage><infon key="type">abstract</infon><offset>171</offset><text>Ischemic stroke (IS) is a common and severe condition that requires intensive care unit (ICU) admission, with high mortality and variable prognosis. Accurate and reliable predictive tools that enable early risk stratification can facilitate interventions to improve patient outcomes; however, such tools are currently lacking. In this study, we developed and validated novel ensemble learning models based on soft voting and stacking methods to predict in-hospital mortality from IS in the ICU using two public databases: MIMIC-IV and eICU-CRD. Additionally, we identified the key predictors of mortality and developed a user-friendly online prediction tool for clinical use. The soft voting ensemble model, named ICU-ISPM, achieved an AUROC of 0.861 (95% CI: 0.829-0.892) and 0.844 (95% CI: 0.819-0.869) in the internal and external test cohorts, respectively. It significantly outperformed the APACHE scoring system and was more robust than individual models. ICU-ISPM obtained the highest performance compared to other models in similar studies. Using the SHAP method, the model was interpretable, revealing that GCS score, age, and intubation were the most important predictors of mortality. This model also provided a risk stratification system that can effectively distinguish between low-, medium-, and high-risk patients. Therefore, the ICU-ISPM is an accurate, reliable, interpretable, and clinically applicable tool, which is expected to assist clinicians in stratifying IS patients by the risk of mortality and rationally allocating medical resources. Based on ICU-ISPM, an online risk prediction tool was further developed, which was freely available at: http://ispm.idrblab.cn/.</text><annotation id="6"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="171" length="15"/><text>Ischemic stroke</text></annotation><annotation id="7"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="188" length="2"/><text>IS</text></annotation><annotation id="8"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="651" length="2"/><text>IS</text></annotation><annotation id="9"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="1652" length="2"/><text>IS</text></annotation></passage></document>
<document><id>37852458</id><passage><infon key="journal">Environ Res;2023Oct17; 240 (Pt 2) 117351. doi:10.1016/j.envres.2023.117351</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Houweling L, Maitland-Van der Zee AH, Holtjer JCS, Bazdar S, Vermeulen RCH, Downward GS, Bloemsma LD, </infon><offset>0</offset><text>The effect of the urban exposome on COVID-19 health outcomes: A systematic review and meta-analysis.</text><annotation id="1"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="36" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>101</offset><text>BACKGROUND: The global severity of SARS-CoV-2 illness has been associated with various urban characteristics, including exposure to ambient air pollutants. This systematic review and meta-analysis aims to synthesize findings from ecological and non-ecological studies to investigate the impact of multiple urban-related features on a variety of COVID-19 health outcomes. METHODS: On December 5, 2022, PubMed was searched to identify all types of observational studies that examined one or more urban exposome characteristics in relation to various COVID-19 health outcomes such as infection severity, the need for hospitalization, ICU admission, COVID pneumonia, and mortality. RESULTS: A total of 38 non-ecological and 241 ecological studies were included in this review. Non-ecological studies highlighted the significant effects of population density, urbanization, and exposure to ambient air pollutants, particularly PM2.5. The meta-analyses revealed that a 1 mug/m3 increase in PM2.5 was associated with a higher likelihood of COVID-19 hospitalization (pooled OR 1.08 (95% CI:1.02-1.14)) and death (pooled OR 1.06 (95% CI:1.03-1.09)). Ecological studies, in addition to confirming the findings of non-ecological studies, also indicated that higher exposure to nitrogen dioxide (NO2), ozone (O3), sulphur dioxide (SO2), and carbon monoxide (CO), as well as lower ambient temperature, humidity, ultraviolet (UV) radiation, and less green and blue space exposure, were associated with increased COVID-19 morbidity and mortality. CONCLUSION: This systematic review has identified several key vulnerability features related to urban areas in the context of the recent COVID-19 pandemic. The findings underscore the importance of improving policies related to urban exposures and implementing measures to protect individuals from these harmful environmental stressors.</text><annotation id="21"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="136" length="10"/><text>SARS-CoV-2</text></annotation><annotation id="22"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="446" length="8"/><text>COVID-19</text></annotation><annotation id="23"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="649" length="8"/><text>COVID-19</text></annotation><annotation id="24"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="682" length="9"/><text>infection</text></annotation><annotation id="25"><infon key="identifier">MESH:D011014</infon><infon key="type">Disease</infon><location offset="747" length="15"/><text>COVID pneumonia</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1023" length="5"/><text>PM2.5</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1085" length="5"/><text>PM2.5</text></annotation><annotation id="28"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1134" length="8"/><text>COVID-19</text></annotation><annotation id="29"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1199" length="5"/><text>death</text></annotation><annotation id="30"><infon key="identifier">MESH:D009585</infon><infon key="type">Chemical</infon><location offset="1367" length="16"/><text>nitrogen dioxide</text></annotation><annotation id="31"><infon key="identifier">MESH:D009585</infon><infon key="type">Chemical</infon><location offset="1385" length="3"/><text>NO2</text></annotation><annotation id="32"><infon key="identifier">MESH:D010126</infon><infon key="type">Chemical</infon><location offset="1391" length="5"/><text>ozone</text></annotation><annotation id="33"><infon key="identifier">MESH:D010126</infon><infon key="type">Chemical</infon><location offset="1398" length="2"/><text>O3</text></annotation><annotation id="34"><infon key="identifier">MESH:D013458</infon><infon key="type">Chemical</infon><location offset="1403" length="15"/><text>sulphur dioxide</text></annotation><annotation id="35"><infon key="identifier">MESH:D013458</infon><infon key="type">Chemical</infon><location offset="1420" length="3"/><text>SO2</text></annotation><annotation id="36"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1430" length="15"/><text>carbon monoxide</text></annotation><annotation id="37"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1447" length="2"/><text>CO</text></annotation><annotation id="38"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1599" length="8"/><text>COVID-19</text></annotation><annotation id="39"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1770" length="8"/><text>COVID-19</text></annotation></passage><relation id="R1"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:D013458</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="14,18"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D009585</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="10,18"/></relation><relation id="R3"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:D010126</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="12,18"/></relation><relation id="R4"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:D002248</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="16,18"/></relation></document>
<document><id>37852809</id><passage><infon key="journal">Int Dent J;2023Oct16. doi:10.1016/j.identj.2023.09.005</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li Y, Liu W, Zhao R, An Y, Zhang M, Ren X, He H, </infon><offset>0</offset><text>Yunnan Baiyao Inhibits Periodontitis by Suppressing the Autophagic Flux.</text><annotation id="1"><infon key="identifier">MESH:D010518</infon><infon key="type">Disease</infon><location offset="23" length="13"/><text>Periodontitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>73</offset><text>BACKGROUND: Yunnan Baiyao (YNBY), a traditional Chinese medicine, is renowned for its anti-inflammatory properties. Recent studies have suggested that YNBY plays a significant role in inhibiting osteoclast differentiation and autophagy, which are essential processes in inflammation and bone resorption associated with periodontitis. However, the precise relationship between autophagy and the mechanism by which YNBY inhibits osteoclastogenesis remains unexplored.The primary objective of this study was to investigate the inhibitory effects of YNBY on the process of osteoclastogenesis and its potential in preventing inflammatory bone loss. METHODS: The animals were subjected to sacrifice at intervals of 2, 4, and 6 weeks postintervention whilst under deep anaesthesia, and specimens were subsequently collected. The specimens were subjected to hematoxylin and eosin (HE) staining, in addition to tartrate-resistant acid phosphatase (TRAP) staining and subsequently imaged employing a digital scanner. The confirmation of osteoclast (OC) differentiation and autophagic flux was achieved through various techniques, including western blotting, transmission electron microscopy (TEM), TRAP staining, pit formation assay, and immunofluorescence. RESULTS: The microcomputed tomography images provided evidence of the effective inhibition of alveolar bone absorption at 2, 4, and 6 weeks following YNBY treatment. Additionally, the histomorphometric evaluations of tissue segments stained with HE and TRAP, which involved measuring the distance between the alveolar bone crest (ABC) and cementoenamel junction (CEJ) and quantifying TRAP-positive OCs, yielded comparable results to those obtained through computed tomography analysis. YNBY treatment resulted in a decrease in the CEJ-ABC distance and inhibition of OC differentiation. Furthermore, in vitro studies showed that the autophagy modulators rapamycin (RAP) and 3-methyladenine (3-MA) significantly affected OC differentiation and function. YNBY attenuated the impact of RAP on the differentiation of OCs, autophagy-related factor activation, and bone resorption. CONCLUSIONS: We hypothesise that YNBY suppresses the differentiation of OC and bone resorption by blocking autophagy. This study reveals that targeting autophagy might be a new alternative treatment methodology for periodontitis treatment.</text><annotation id="19"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="164" length="12"/><text>inflammatory</text></annotation><annotation id="20"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="343" length="12"/><text>inflammation</text></annotation><annotation id="21"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="360" length="15"/><text>bone resorption</text></annotation><annotation id="22"><infon key="identifier">MESH:D010518</infon><infon key="type">Disease</infon><location offset="392" length="13"/><text>periodontitis</text></annotation><annotation id="23"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="693" length="12"/><text>inflammatory</text></annotation><annotation id="24"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="706" length="9"/><text>bone loss</text></annotation><annotation id="25"><infon key="identifier">MESH:D006416</infon><infon key="type">Chemical</infon><location offset="923" length="11"/><text>hematoxylin</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="1719" length="3"/><text>OCs</text></annotation><annotation id="27"><infon key="identifier">MESH:D020123</infon><infon key="type">Chemical</infon><location offset="1974" length="9"/><text>rapamycin</text></annotation><annotation id="28"><infon key="identifier">MESH:D020123</infon><infon key="type">Chemical</infon><location offset="1985" length="3"/><text>RAP</text></annotation><annotation id="29"><infon key="identifier">MESH:C025946</infon><infon key="type">Chemical</infon><location offset="1994" length="15"/><text>3-methyladenine</text></annotation><annotation id="30"><infon key="identifier">MESH:C025946</infon><infon key="type">Chemical</infon><location offset="2011" length="4"/><text>3-MA</text></annotation><annotation id="31"><infon key="identifier">MESH:D020123</infon><infon key="type">Chemical</infon><location offset="2103" length="3"/><text>RAP</text></annotation><annotation id="32"><infon key="type">Disease</infon><location offset="2133" length="3"/><text>OCs</text></annotation><annotation id="33"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="2179" length="15"/><text>bone resorption</text></annotation><annotation id="34"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="2275" length="15"/><text>bone resorption</text></annotation><annotation id="35"><infon key="identifier">MESH:D010518</infon><infon key="type">Disease</infon><location offset="2411" length="13"/><text>periodontitis</text></annotation></passage><relation id="R1"><infon key="score">0.803</infon><infon key="role1">Chemical|MESH:D020123</infon><infon key="role2">Disease|MESH:D001862</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="13,15"/></relation></document>
<document><id>37853159</id><passage><infon key="journal">Nat Rev Cardiol;2023Oct18. doi:10.1038/s41569-023-00950-7</infon><infon key="year">2023</infon><infon key="article-id_pmc">10154213</infon><infon key="type">title</infon><infon key="authors">Fern&amp;#xe1;ndez-Ruiz I, </infon><offset>0</offset><text>Sirtuin 2 protects against cardiac ageing.</text><annotation id="2"><infon key="identifier">22933</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">40823</infon><location offset="0" length="9"/><text>Sirtuin 2</text></annotation><annotation id="3"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="27" length="14"/><text>cardiac ageing</text></annotation></passage><passage><infon key="type">abstract</infon><offset>43</offset></passage><relation id="R1"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D006331</infon><infon key="role2">Gene|22933</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation></document>
<document><id>37853510</id><passage><infon key="journal">Am Surg;2023Oct18 31348231206582. doi:10.1177/00031348231206582</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Broderick M, Tripodi G, Dwyer K, </infon><offset>0</offset><text>Utility of Repeat Head Computed Tomography in Detecting Delayed Intracranial Hemorrhage in Falls on Direct Oral Anticoagulants.</text><annotation id="3"><infon key="identifier">MESH:D020300</infon><infon key="type">Disease</infon><location offset="64" length="23"/><text>Intracranial Hemorrhage</text></annotation><annotation id="4"><infon key="identifier">MESH:C537863</infon><infon key="type">Disease</infon><location offset="91" length="5"/><text>Falls</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="100" length="26"/><text>Direct Oral Anticoagulants</text></annotation></passage><passage><infon key="type">abstract</infon><offset>128</offset><text>INTRODUCTION: Ground level falls in the elderly often lead to complications due to use of anticoagulants (ACs). Intracranial hemorrhage (ICH), immediate or delayed, is a feared consequence of such falls. The rate of delayed ICH (dICH) in patients taking anticoagulants or antiplatelet (AP) agents ranges from .6% to 6%. Patients on warfarin have a persistent rate of dICH, leading to implementation of routine repeat head CTs at our institution. This policy was extended to direct oral anticoagulants (DOACs). This study aims to determine institutional incidence of DOAC-associated dICH. METHODS: With IRB waiver approval, we conducted a retrospective review of trauma evaluations for falls on DOACs from 2016 to 2018. We reviewed records for neurologic status, DOAC use, and results of initial and delayed head CTs. Exclusion criteria included initial GCS &lt;=14, new neurologic deficits, traumatic findings on initial CT, concurrent use of additional AC/AP, or absence of repeat head CT. RESULTS: Among 632 patients evaluated for falls on AC/AP therapy, 159 (25%) of patients were included in the review. The age range was 19-98 years old, with 99 females and 60 males. Half of the patients were on apixaban, with the rest on dabigatran or rivaroxaban. Ten patients presented with GCS of 14. No delayed hemorrhages were detected in this population. CONCLUSION: The necessity of a repeat head CT in patients taking DOACs is debated in the literature. Our analysis failed to demonstrate any delayed hemorrhage in neurologically intact patients after head strike on DOAC, suggesting no indication for follow-up imaging in this group.</text><annotation id="34"><infon key="identifier">MESH:C537863</infon><infon key="type">Disease</infon><location offset="155" length="5"/><text>falls</text></annotation><annotation id="35"><infon key="identifier">MESH:D020300</infon><infon key="type">Disease</infon><location offset="240" length="23"/><text>Intracranial hemorrhage</text></annotation><annotation id="36"><infon key="identifier">MESH:D020300</infon><infon key="type">Disease</infon><location offset="265" length="3"/><text>ICH</text></annotation><annotation id="37"><infon key="identifier">MESH:C537863</infon><infon key="type">Disease</infon><location offset="325" length="5"/><text>falls</text></annotation><annotation id="38"><infon key="identifier">MESH:D020300</infon><infon key="type">Disease</infon><location offset="352" length="3"/><text>ICH</text></annotation><annotation id="39"><infon key="identifier">MESH:D020300</infon><infon key="type">Disease</infon><location offset="357" length="4"/><text>dICH</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="400" length="16"/><text>antiplatelet (AP</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="418" length="6"/><text>agents</text></annotation><annotation id="42"><infon key="identifier">MESH:D014859</infon><infon key="type">Chemical</infon><location offset="460" length="8"/><text>warfarin</text></annotation><annotation id="43"><infon key="identifier">MESH:D020300</infon><infon key="type">Disease</infon><location offset="495" length="4"/><text>dICH</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="602" length="26"/><text>direct oral anticoagulants</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="630" length="5"/><text>DOACs</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="694" length="4"/><text>DOAC</text></annotation><annotation id="47"><infon key="identifier">MESH:D020300</infon><infon key="type">Disease</infon><location offset="710" length="4"/><text>dICH</text></annotation><annotation id="48"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="790" length="6"/><text>trauma</text></annotation><annotation id="49"><infon key="identifier">MESH:C537863</infon><infon key="type">Disease</infon><location offset="813" length="5"/><text>falls</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="822" length="5"/><text>DOACs</text></annotation><annotation id="51"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="890" length="4"/><text>DOAC</text></annotation><annotation id="52"><infon key="identifier">MESH:D009461</infon><infon key="type">Disease</infon><location offset="995" length="19"/><text>neurologic deficits</text></annotation><annotation id="53"><infon key="identifier">MESH:C537863</infon><infon key="type">Disease</infon><location offset="1158" length="5"/><text>falls</text></annotation><annotation id="54"><infon key="identifier">MESH:C522181</infon><infon key="type">Chemical</infon><location offset="1327" length="8"/><text>apixaban</text></annotation><annotation id="55"><infon key="identifier">MESH:D000069604</infon><infon key="type">Chemical</infon><location offset="1354" length="10"/><text>dabigatran</text></annotation><annotation id="56"><infon key="identifier">MESH:D000069552</infon><infon key="type">Chemical</infon><location offset="1368" length="11"/><text>rivaroxaban</text></annotation><annotation id="57"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="1431" length="11"/><text>hemorrhages</text></annotation><annotation id="58"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1542" length="5"/><text>DOACs</text></annotation><annotation id="59"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="1625" length="10"/><text>hemorrhage</text></annotation><annotation id="60"><infon key="identifier">MESH:D006258</infon><infon key="type">Disease</infon><location offset="1676" length="11"/><text>head strike</text></annotation><annotation id="61"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1691" length="4"/><text>DOAC</text></annotation></passage><relation id="R1"><infon key="score">0.9947</infon><infon key="role1">Chemical|MESH:D014859</infon><infon key="role2">Disease|MESH:D020300</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="11,12"/></relation></document>
<document><id>37890024</id><passage><infon key="journal">J Nerv Ment Dis;2023Nov01; 211 (11) 805. doi:10.1097/NMD.0000000000001722</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Paris J, </infon><offset>0</offset><text>Complex Posttraumatic Stress Disorder and a Biopsychosocial Model of Borderline Personality Disorder.</text><annotation id="2"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="8" length="29"/><text>Posttraumatic Stress Disorder</text></annotation><annotation id="3"><infon key="identifier">MESH:D001883</infon><infon key="type">Disease</infon><location offset="69" length="31"/><text>Borderline Personality Disorder</text></annotation></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>ABSTRACT: This review offers a critique of recent attempts to reconceptualize some cases of borderline personality disorder (BPD) within the newer diagnosis of complex posttraumatic stress disorder (CPTSD). The CPTSD construct focuses on the role of childhood trauma in shaping relational problems in adulthood, difficulties that have been previously seen as features of a personality disorder. The CPTSD model fails to consider the role of heritable personality traits, as well as a broader range of psychosocial risk factors. This review proposes that a biopsychosocial model of BPD is more comprehensive, taking into account a wider range of risk factors, while viewing BPD as rooted in gene-environment interactions. In this model, heritable traits are amplified by an adverse psychosocial environment. One can acknowledge the role of trauma as a risk factor without assuming that it fully accounts for the development of personality pathology.</text><annotation id="15"><infon key="identifier">MESH:D001883</infon><infon key="type">Disease</infon><location offset="194" length="31"/><text>borderline personality disorder</text></annotation><annotation id="16"><infon key="identifier">MESH:D001883</infon><infon key="type">Disease</infon><location offset="227" length="3"/><text>BPD</text></annotation><annotation id="17"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="270" length="29"/><text>posttraumatic stress disorder</text></annotation><annotation id="18"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="301" length="5"/><text>CPTSD</text></annotation><annotation id="19"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="313" length="5"/><text>CPTSD</text></annotation><annotation id="20"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="362" length="6"/><text>trauma</text></annotation><annotation id="21"><infon key="identifier">MESH:D010554</infon><infon key="type">Disease</infon><location offset="475" length="20"/><text>personality disorder</text></annotation><annotation id="22"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="501" length="5"/><text>CPTSD</text></annotation><annotation id="23"><infon key="identifier">MESH:D001883</infon><infon key="type">Disease</infon><location offset="683" length="3"/><text>BPD</text></annotation><annotation id="24"><infon key="identifier">MESH:D001883</infon><infon key="type">Disease</infon><location offset="775" length="3"/><text>BPD</text></annotation><annotation id="25"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="941" length="6"/><text>trauma</text></annotation></passage></document>
<document><id>37890375</id><passage><infon key="journal">J Chromatogr A;2023Oct17; 1711 464455. doi:10.1016/j.chroma.2023.464455</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">&amp;#x160;lampov&amp;#xe1; A, Kub&amp;#xe1;&amp;#x148; P, </infon><offset>0</offset><text>Electromembrane extraction - capillary zone electrophoresis for the quantitative determination of beta-lactam antibiotics in milk samples.</text><annotation id="1"><infon key="identifier">MESH:D008997</infon><infon key="type">Chemical</infon><location offset="98" length="23"/><text>beta-lactam antibiotics</text></annotation></passage><passage><infon key="type">abstract</infon><offset>139</offset><text>Three penicillin-based beta-lactam antibiotics (benzylpenicillin, amoxicillin, and ampicillin) were extracted by electromembrane extraction (EME) and determined in the resulting extracts by capillary zone electrophoresis (CZE) with UV-Vis detection. The EME was optimized for the simultaneous clean-up of complex samples and preconcentration of the three antibiotics and employed 1-octanol as the organic phase interface (impregnated in the pores of a hollow fiber), acidified donor solution (pH 3), and phosphate buffer (pH 5.6) as the acceptor solution. The EMEs were carried out for 20 min at 300 V and constant stirring (750 rpm) of the donor solution. At the optimized EME-CZE conditions, the sensitivity of the analytical method was sufficient for the determination of the three beta-lactam antibiotics in undiluted cow's milk at concentrations below the EU maximum residue limits (4 mug/L) in foodstuffs. The method was simple, rapid, and convenient and offered extraction recoveries of 13.5 - 87.3 %, enrichment factors of 23.6 - 152.8, repeatability (RSD values) better than 7.6 %, linear analytical response in the 1 - 100 mug/L (3 - 100 mug/L for benzylpenicillin) concentration range with correlation coefficients >= 0.9997, and limits of detection from 0.2 to 1.2 mug/L. The proposed analytical concept was used for the rapid control of milk quality (i.e. assessment of excessive use of antibiotics in dairy animals), moreover, it was further extended to the trace determination of beta-lactam antibiotics in other complex samples, such as in wastewater.</text><annotation id="12"><infon key="identifier">MESH:D010406</infon><infon key="type">Chemical</infon><location offset="145" length="10"/><text>penicillin</text></annotation><annotation id="13"><infon key="identifier">MESH:D008997</infon><infon key="type">Chemical</infon><location offset="162" length="23"/><text>beta-lactam antibiotics</text></annotation><annotation id="14"><infon key="identifier">MESH:D010400</infon><infon key="type">Chemical</infon><location offset="187" length="16"/><text>benzylpenicillin</text></annotation><annotation id="15"><infon key="identifier">MESH:D000658</infon><infon key="type">Chemical</infon><location offset="205" length="11"/><text>amoxicillin</text></annotation><annotation id="16"><infon key="identifier">MESH:D000667</infon><infon key="type">Chemical</infon><location offset="222" length="10"/><text>ampicillin</text></annotation><annotation id="17"><infon key="identifier">MESH:D020003</infon><infon key="type">Chemical</infon><location offset="519" length="9"/><text>1-octanol</text></annotation><annotation id="18"><infon key="identifier">MESH:D010710</infon><infon key="type">Chemical</infon><location offset="643" length="9"/><text>phosphate</text></annotation><annotation id="19"><infon key="identifier">MESH:D008997</infon><infon key="type">Chemical</infon><location offset="924" length="23"/><text>beta-lactam antibiotics</text></annotation><annotation id="20"><infon key="identifier">MESH:D010400</infon><infon key="type">Chemical</infon><location offset="1297" length="16"/><text>benzylpenicillin</text></annotation><annotation id="21"><infon key="identifier">MESH:D008997</infon><infon key="type">Chemical</infon><location offset="1634" length="23"/><text>beta-lactam antibiotics</text></annotation></passage></document>
<document><id>37890725</id><passage><infon key="journal">J Hepatol;2023Oct25. doi:10.1016/j.jhep.2023.10.020</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sheehan Y, Grebely J, Lloyd AR, </infon><offset>0</offset><text>'One-stop-shop' does not mean one size fits all.</text></passage><passage><infon key="type">abstract</infon><offset>49</offset></passage></document>
<document><id>37891076</id><passage><infon key="journal">Trends Ecol Evol;2023Oct25. doi:10.1016/j.tree.2023.09.014</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">G&amp;#xf3;mez-Gonz&amp;#xe1;lez S, Miranda A, Hoyos-Santillan J, Lara A, Moraga P, Pausas JG, </infon><offset>0</offset><text>Afforestation and climate mitigation: lessons from Chile.</text></passage><passage><infon key="type">abstract</infon><offset>58</offset><text>The Chilean Climate Change Law excludes tree monocultures as a solution to the climate crisis, offering an opportunity for resilience and climate mitigation in Latin America. The Chilean experience with mega-fires in extensive, homogeneous forest plantations provides important lessons that could inform climate policies in other countries.</text></passage></document>
<document><id>37897386</id><passage><infon key="journal">Ugeskr Laeger;2023Oct16; 185 (42) </infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Willadsen TG, Holm A, Kristensen J, Waldorff FB, Reventlow S, Prior A, </infon><offset>0</offset><text>Definition and delimitation of multimorbidity.</text><annotation id="1"><infon key="type">Disease</infon><location offset="31" length="14"/><text>multimorbidity</text></annotation></passage><passage><infon key="type">abstract</infon><offset>47</offset><text>Multimorbidity is often defined as two or more long-term conditions, the definition may, however, vary. This review summarises various definitions of multimorbidity. The prevalence of multimorbidity in Denmark is between 7% and 29% depending on data sources and definition and is increasing with age; nonetheless most patients with multimorbidity are of working age. Several multimorbidity indices have been developed for research purposes, but with no clinical consensus. The concept of complex multimorbidity adds psychosocial context and health-care patterns to better describe the group of patients with multimorbidity having the highest needs.</text><annotation id="9"><infon key="type">Disease</infon><location offset="47" length="14"/><text>Multimorbidity</text></annotation><annotation id="10"><infon key="type">Disease</infon><location offset="197" length="14"/><text>multimorbidity</text></annotation><annotation id="11"><infon key="type">Disease</infon><location offset="231" length="14"/><text>multimorbidity</text></annotation><annotation id="12"><infon key="type">Disease</infon><location offset="379" length="14"/><text>multimorbidity</text></annotation><annotation id="13"><infon key="type">Disease</infon><location offset="422" length="14"/><text>multimorbidity</text></annotation><annotation id="14"><infon key="type">Disease</infon><location offset="543" length="14"/><text>multimorbidity</text></annotation><annotation id="15"><infon key="type">Disease</infon><location offset="655" length="14"/><text>multimorbidity</text></annotation></passage></document>
<document><id>37897737</id><passage><infon key="journal">ACS Nano;2023Oct28. doi:10.1021/acsnano.3c06510</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Guo Z, Liu G, Sun Y, Zhang Y, Zhao J, Liu P, Wang H, Zhou Z, Zhao Z, Jia X, Sun J, Shao Y, Han X, Zhang Z, Yan X, </infon><offset>0</offset><text>High-Performance Neuromorphic Computing and Logic Operation Based on a Self-Assembled Vertically Aligned Nanocomposite SrTiO3:MgO Film Memristor.</text><annotation id="2"><infon key="identifier">MESH:C119252</infon><infon key="type">Chemical</infon><location offset="119" length="6"/><text>SrTiO3</text></annotation><annotation id="3"><infon key="identifier">MESH:D008277</infon><infon key="type">Chemical</infon><location offset="126" length="3"/><text>MgO</text></annotation></passage><passage><infon key="type">abstract</infon><offset>146</offset><text>Neuromorphic computing based on memristors capable of in-memory computing is promising to break the energy and efficiency bottleneck of well-known von Neumann architectures. However, unstable and nonlinear conductance updates compromise the recognition accuracy and block the integration of neural network hardware. To this end, we present a highly stable memristor with self-assembled vertically aligned nanocomposite (VAN) SrTiO3:MgO films that achieve excellent resistive switching with low set/reset voltage variability (4.7%/-5.6%) and highly linear conductivity variation (nonlinearity = 0.34) by spatially limiting the conductive channels at the vertical interfaces. Various synaptic behaviors are simulated by continuously modulating the conductance. Especially, convolutional image processing using diverse crossbar kernels is demonstrated, and the artificial neural network achieves an overwhelming recognition accuracy of up to 97.50% for handwritten digits. Even under the perturbation of Poisson noise (lambda = 10), 6% Salt and Pepper noise, and 5% Gaussian noise, the high recognition accuracies are retained at 95.43%, 94.56%, and 95.97%, respectively. Importantly, the logic memory function is proven experimentally based on the nonvolatile properties. This work provides a material system and design idea to achieve high-performance neuromorphic computing and logic operation.</text><annotation id="7"><infon key="identifier">MESH:C119252</infon><infon key="type">Chemical</infon><location offset="571" length="6"/><text>SrTiO3</text></annotation><annotation id="8"><infon key="identifier">MESH:D008277</infon><infon key="type">Chemical</infon><location offset="578" length="3"/><text>MgO</text></annotation><annotation id="9"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="1179" length="4"/><text>Salt</text></annotation></passage></document>
<document><id>37898087</id><passage><infon key="journal">J Hazard Mater;2023Oct22; 463 132809. doi:10.1016/j.jhazmat.2023.132809</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wen X, Zhou J, Zheng S, Yang Z, Lu Z, Jiang X, Zhao L, Yan B, Yang X, Chen T, </infon><offset>0</offset><text>Geochemical properties, heavy metals and soil microbial community during revegetation process in a production Pb-Zn tailings.</text><annotation id="2"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="24" length="12"/><text>heavy metals</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="110" length="5"/><text>Pb-Zn</text></annotation></passage><passage><infon key="type">abstract</infon><offset>126</offset><text>Lead-zinc (Pb-Zn) tailings pose a significant environmental threat from heavy metals (HMs) contamination. Revegetation is considered as a green path for HM remediation. However, the interplay between HM transport processes and soil microbial community in Pb-Zn tailings (especially those in production) remain unclear. This study investigated the spatial distribution of HMs as well as the crucial roles of the soil microbial community (i.e., structure, richness, and diversity) during a three-year revegetation of production Pb-Zn tailings in northern Guangdong province, China. Prolonged tailings stockpiling exacerbated Pb contamination, elevating concentrations (from 10.11 to 11.53 g/kg) in long-term weathering. However, revegetation effectively alleviated Pb, reducing its concentrations of 9.81 g/kg. Through 16 S rRNA gene amplicon sequencing, the dominant genera shifted from Weissella (44%) to Thiobacillus (17%) and then to Pseudomonas (comprising 44% of the sequences) during the revegetation process. The structural equation model suggested that Pseudomonas, with its potential to transform bioavailable Pb into a more stable form, emerged as a potential Pb remediator. This study provides essential evidence of HMs contamination and microbial community dynamics during Pb-Zn tailings revegetation, contributing to the development of sustainable microbial technologies for tailings management.</text><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="137" length="5"/><text>Pb-Zn</text></annotation><annotation id="20"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="198" length="12"/><text>heavy metals</text></annotation><annotation id="21"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="212" length="3"/><text>HMs</text></annotation><annotation id="22"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="279" length="2"/><text>HM</text></annotation><annotation id="23"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="326" length="2"/><text>HM</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="381" length="5"/><text>Pb-Zn</text></annotation><annotation id="25"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="497" length="3"/><text>HMs</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="652" length="5"/><text>Pb-Zn</text></annotation><annotation id="27"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="749" length="2"/><text>Pb</text></annotation><annotation id="28"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="889" length="2"/><text>Pb</text></annotation><annotation id="29"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="946" length="1"/><text>S</text></annotation><annotation id="30"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="1244" length="2"/><text>Pb</text></annotation><annotation id="31"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="1295" length="2"/><text>Pb</text></annotation><annotation id="32"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="1352" length="3"/><text>HMs</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1410" length="5"/><text>Pb-Zn</text></annotation></passage></document>
<document><id>37898440</id><passage><infon key="journal">J Ethnopharmacol;2023Oct28; 319 (Pt 3) 117360. doi:10.1016/j.jep.2023.117360</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Du Y, Wang J, Jiang L, Li J, Li J, Ren C, Yan T, Jia Y, He B, </infon><offset>0</offset><text>Screening the components in multi-biological samples and the comparative pharmacokinetic study in healthy and depression model rats of Suan-Zao-Ren decoction combined with a network pharmacology.</text><annotation id="1"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="110" length="10"/><text>depression</text></annotation></passage><passage><infon key="type">abstract</infon><offset>196</offset><text>ETHNOPHARMACOLOGICAL RELEVANCE: Suanzaoren Decoction (SZRD) is a classic traditional Chinese prescription, which has been commonly used for treating insomnia, depression and other nerve system diseases for a long time. AIM OF THIS STUDY: The present study aimed to explore the metabolic profiles in multi-biological samples and pharmacokinetic mechanism between healthy and depression model rats combined with a network pharmacology approach after administration of SZRD. MATERIALS AND METHODS: In our study, an ultra-high performance liquid chromatography (UPLC)-Q-Exactive Orbitrap Mass Spectrometry method was firstly used to study the prototype components and metabolites of SZRD in plasma, brain, urine, and feces between healthy and depressed rats. The possible metabolic pathways were also speculated. Then a network pharmacological study was conducted on the components in the plasma of model rats. According to the above components screened by network pharmacology and the other reported representative active components, the comparative pharmacokinetic study was established for the simultaneous determination of mangiferin, spinosin, ferulic acid, liquiritin, formononetin. magnoflorine and isoliquiritin between healthy and depression model rats. Finally, molecular docking was used to validate the binding affinity between key potential targets and active components in pharmacokinetics. RESULTS: A total of 115 components were identified in healthy rats, and 101 components were identified in model rats. The prototype components and metabolites in plasma, brain, urine, and feces were also distinguished. The main metabolic pathways included phase I and phase II metabolic reactions, such as dehydrogenation, oxidation, hydroxylation, gluconaldehyde conjugation, glutathione conjugation and so on. These results provided a basis for the further study of antidepressive pharmacokinetic and pharmacological action in SZRD. Then, according to the degree value of network pharmacological study, it was predicted that 10 components and 10 core targets, which involved in the critical pathways such as neuroactive ligand-receptor interaction, cyclic adenosine monophosphate (cAMP) signaling pathway, serotonergic synapse, phosphatidylinositol-3 kinase (PI3K)-Akt signaling pathway, etc. Finally, the established pharmacokinetic method was successfully applied to compare the pharmacokinetic behavior of these 7 active components in plasma of healthy and depressed rats after oral administration of SZRD. It showed that except magnoflorine, the pharmacokinetic parameters of each component were different between healthy and depressed rats. Molecular docking analysis also indicated that the active compounds in pharmacokinetics could bind tightly to the key targets of network pharmacological study. CONCLUSION: This study may provide important information for studying the action mechanism of SZRD in treating depression.</text><annotation id="25"><infon key="identifier">MESH:D007319</infon><infon key="type">Disease</infon><location offset="345" length="8"/><text>insomnia</text></annotation><annotation id="26"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="355" length="10"/><text>depression</text></annotation><annotation id="27"><infon key="identifier">MESH:D034721</infon><infon key="type">Disease</infon><location offset="376" length="21"/><text>nerve system diseases</text></annotation><annotation id="28"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="570" length="10"/><text>depression</text></annotation><annotation id="29"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="935" length="9"/><text>depressed</text></annotation><annotation id="30"><infon key="identifier">MESH:C013592</infon><infon key="type">Chemical</infon><location offset="1319" length="10"/><text>mangiferin</text></annotation><annotation id="31"><infon key="identifier">MESH:C055669</infon><infon key="type">Chemical</infon><location offset="1331" length="8"/><text>spinosin</text></annotation><annotation id="32"><infon key="identifier">MESH:C004999</infon><infon key="type">Chemical</infon><location offset="1341" length="12"/><text>ferulic acid</text></annotation><annotation id="33"><infon key="identifier">MESH:C512196</infon><infon key="type">Chemical</infon><location offset="1355" length="10"/><text>liquiritin</text></annotation><annotation id="34"><infon key="identifier">MESH:C007768</infon><infon key="type">Chemical</infon><location offset="1367" length="12"/><text>formononetin</text></annotation><annotation id="35"><infon key="identifier">MESH:C001670</infon><infon key="type">Chemical</infon><location offset="1381" length="12"/><text>magnoflorine</text></annotation><annotation id="36"><infon key="identifier">MESH:C098467</infon><infon key="type">Chemical</infon><location offset="1398" length="13"/><text>isoliquiritin</text></annotation><annotation id="37"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1432" length="10"/><text>depression</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1946" length="14"/><text>gluconaldehyde</text></annotation><annotation id="39"><infon key="identifier">MESH:D005978</infon><infon key="type">Chemical</infon><location offset="1974" length="11"/><text>glutathione</text></annotation><annotation id="40"><infon key="identifier">MESH:D000242</infon><infon key="type">Chemical</infon><location offset="2348" length="30"/><text>cyclic adenosine monophosphate</text></annotation><annotation id="41"><infon key="identifier">MESH:D000242</infon><infon key="type">Chemical</infon><location offset="2380" length="4"/><text>cAMP</text></annotation><annotation id="42"><infon key="identifier">298947</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68269</infon><location offset="2427" length="29"/><text>phosphatidylinositol-3 kinase</text></annotation><annotation id="43"><infon key="identifier">24185</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3785</infon><location offset="2464" length="3"/><text>Akt</text></annotation><annotation id="44"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="2659" length="9"/><text>depressed</text></annotation><annotation id="45"><infon key="identifier">MESH:C001670</infon><infon key="type">Chemical</infon><location offset="2731" length="12"/><text>magnoflorine</text></annotation><annotation id="46"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="2829" length="9"/><text>depressed</text></annotation><annotation id="47"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="3116" length="10"/><text>depression</text></annotation></passage><relation id="R1"><infon key="score">0.9956</infon><infon key="role1">Gene|24185</infon><infon key="role2">Gene|298947</infon><infon key="type">Association</infon><node refid="0" role="20,18"/></relation><relation id="R2"><infon key="score">0.9807</infon><infon key="role1">Chemical|MESH:C098467</infon><infon key="role2">Disease|MESH:D003866</infon><infon key="type">Association</infon><node refid="1" role="12,13"/></relation><relation id="R3"><infon key="score">0.6392</infon><infon key="role1">Disease|MESH:D003866</infon><infon key="role2">Gene|298947</infon><infon key="type">Association</infon><node refid="2" role="21,18"/></relation><relation id="R4"><infon key="score">0.9809</infon><infon key="role1">Chemical|MESH:C001670</infon><infon key="role2">Disease|MESH:D003866</infon><infon key="type">Association</infon><node refid="3" role="11,13"/></relation></document>
<document><id>37899140</id><passage><infon key="journal">Dis Esophagus;2023Oct28. doi:10.1093/dote/doad061</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gordon GSD, Warburton S, Parkes S, Kerridge A, Parra-Blanco A, Ortiz-Fernandez-Sordo J, Fitzgerald RC, </infon><offset>0</offset><text>Cytosponge procedures produce fewer respiratory aerosols and droplets than esophagogastroduodenoscopies.</text></passage><passage><infon key="type">abstract</infon><offset>105</offset><text>Esophagogastroduodenoscopies (EGD) are aerosol-generating procedures that may spread respiratory pathogens. We aim to investigate the production of airborne aerosols and droplets during Cytosponge procedures, which are being evaluated in large-scale research studies and National Health Service (NHS)implementation pilots to reduce endoscopy backlogs. We measured 18 Cytosponge and 37 EGD procedures using a particle counter (diameters = 0.3-25 mum), taking measurements 10 cm from the mouth. Two particle count analyses were performed: whole procedure and event-based. Direct comparison with duration-standardized EGD procedures shows that Cytosponge procedures produce 2.16x reduction (P &lt; 0.001) for aerosols and no significant change for droplets (P = 0.332). Event-based analysis shows that particle production is driven by throat spray (aerosols: 138.1x reference, droplets: 16.2x), which is optional, and removal of Cytosponge (aerosols: 14.6x, droplets: 62.6x). Cytosponge burping produces less aerosols than EGD (2.82x, P &lt; 0.05). Cytosponge procedures produce significantly less aerosols and droplets than EGD procedures and thus reduce two potential transmission routes for respiratory viruses.</text></passage></document>
<document><id>37899491</id><passage><infon key="journal">Pest Manag Sci;2023Oct29. doi:10.1002/ps.7858</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cornelsen JEJ, Ort NWW, Gabert RK, Epp I, Rempel CB, </infon><offset>0</offset><text>Current and Potential Pest Threats for Canola in the Canadian Prairies.</text></passage><passage><infon key="type">abstract</infon><offset>72</offset><text>Canola/oilseed rape (Brassica napus L.) production in Canada has increased to become a foundational crop in the Canadian Prairies and an important economic driver of this region. The increase in seeded area, and by association its reduction in crop rotation frequency, has made it easier for pests to overcome current recommended agronomic management practices. The Canola Council of Canada has been successful in involving the entire commodity value chain in promoting and strengthening the Canadian canola industry, however, because of this production increase it is critically important to understand, evaluate, and mitigate the potential risks of canola yield losses to current and potential pests. This review provides an overview of what are currently the most damaging insects, pathogens and weeds to canola in the Canadian Prairies, potential future threats, and opportunities farmers, agronomists and researchers can take to minimize these risks. This article is protected by copyright. All rights reserved.</text></passage></document>
<document><id>37901943</id><passage><infon key="journal">Phys Chem Chem Phys;2023Oct30. doi:10.1039/d3cp03887d</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Koz&amp;#xe1;kov&amp;#xe1; S, Alharzali N, &amp;#x10c;ernu&amp;#x161;&amp;#xe1;k I, </infon><offset>0</offset><text>Cyclo[n]carbons and catenanes from different perspectives: disentangling the molecular thread.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="15"/><text>Cyclo[n]carbons</text></annotation></passage><passage><infon key="type">abstract</infon><offset>95</offset><text>All-carbon atomic rings, cyclo[n]carbons, have recently attracted vivid attention of experimentalists and theoreticians. Among them, cyclo[18]carbon is the most studied system. In this paper, we summarize and review various properties of cyclo[n]carbons, emphasising the aspects of their aromaticity/antiaromaticity. In the first part, the trends in bonding patterns and selected aromaticity indices with the increasing size of the rings are discussed. In the second part we explore the properties of catenane models based on interlocked cyclo[18]carbon rings from different perspectives and investigate their behaviour under the action of external force using computational experiments.</text><annotation id="7"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="99" length="6"/><text>carbon</text></annotation><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="120" length="15"/><text>cyclo[n]carbons</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="228" length="15"/><text>cyclo[18]carbon</text></annotation><annotation id="10"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="333" length="15"/><text>cyclo[n]carbons</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="633" length="15"/><text>cyclo[18]carbon</text></annotation></passage></document>
<document><id>37902293</id><passage><infon key="journal">Sex Med Rev;2023Oct28. doi:10.1093/sxmrev/qead045</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kraglund R, Durukan E, Giraldi A, Fode M, </infon><offset>0</offset><text>The association between Peyronie's disease and depression: a scoping review.</text><annotation id="2"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="24" length="18"/><text>Peyronie's disease</text></annotation><annotation id="3"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="47" length="10"/><text>depression</text></annotation></passage><passage><infon key="type">abstract</infon><offset>77</offset><text>INTRODUCTION: Peyronie's disease (PD) can have an immense psychological impact, with depression being a reported possible, severe consequence. To date, no literature reviews have systematically and critically assessed the relationship between PD and depression. OBJECTIVES: The study sought to identify and critically appraise the current literature on the association between PD and depression. METHODS: Studies had to address men with PD or probable PD and assess depression or depressive symptoms. Quantitative and qualitative, peer-reviewed, primary, empirical studies written in English or Danish were included. According to the guidelines for scoping reviews and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews) guideline, we performed a systematic review of PubMed, PsycINFO, Embase, CINAHL, the Cochrane Library, and Web of Science. Reference lists of included studies were screened for additional sources. Gray literature was searched for in Google Scholar and Bielefeld Academic Search Engine. Data were charted using a data extraction form, and critical appraisal was performed using the QuADS (quality assessment with diverse studies) tool. RESULTS: Thirteen studies were included. Most studies had a cross-sectional design, and also cohort studies and longitudinal observational studies without a control group were found. Depression was assessed mainly by validated questionnaires or diagnostic codes. Questionnaire studies found a prevalences of moderate to severe depression of 24% to 48%, while studies using diagnostic codes found depression in 4% to 37% of men with PD. The quality of the included studies varied from 38% to 82% of the maximum possible score in the QuADS assessment. CONCLUSION: While most studies describe an association between PD and depression, the evidence is not comprehensive. The current literature is especially at risk of selection bias and the influence of confounding factors, and a direct causality between PD and depression cannot be established. Future research calls for more methodically rigorous studies as well as qualitative studies to understand the relationship.</text><annotation id="23"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="91" length="18"/><text>Peyronie's disease</text></annotation><annotation id="24"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="111" length="2"/><text>PD</text></annotation><annotation id="25"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="162" length="10"/><text>depression</text></annotation><annotation id="26"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="320" length="2"/><text>PD</text></annotation><annotation id="27"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="327" length="10"/><text>depression</text></annotation><annotation id="28"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="454" length="2"/><text>PD</text></annotation><annotation id="29"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="461" length="10"/><text>depression</text></annotation><annotation id="30"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="514" length="2"/><text>PD</text></annotation><annotation id="31"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="529" length="2"/><text>PD</text></annotation><annotation id="32"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="543" length="10"/><text>depression</text></annotation><annotation id="33"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="557" length="10"/><text>depressive</text></annotation><annotation id="34"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1468" length="10"/><text>Depression</text></annotation><annotation id="35"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1612" length="10"/><text>depression</text></annotation><annotation id="36"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1681" length="10"/><text>depression</text></annotation><annotation id="37"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="1717" length="2"/><text>PD</text></annotation><annotation id="38"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="1898" length="2"/><text>PD</text></annotation><annotation id="39"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1905" length="10"/><text>depression</text></annotation><annotation id="40"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="2088" length="2"/><text>PD</text></annotation><annotation id="41"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="2095" length="10"/><text>depression</text></annotation></passage></document>
<document><id>37902643</id><passage><infon key="journal">J Nurses Prof Dev;2023 Nov-Dec 01; 39 (6) 238. doi:10.1097/NND.0000000000001022</infon><infon key="year">2023</infon><infon key="type">title</infon><offset>0</offset><text>Utilizing a Learning Management System to Provide Nursing Professional Development.</text></passage><passage><infon key="type">abstract</infon><offset>84</offset></passage></document>
<document><id>37902995</id><passage><infon key="journal">Photobiomodul Photomed Laser Surg;2023Oct30. doi:10.1089/photob.2023.0033</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Roibu GE, Wu J, Hou W, Delgado-Ruiz R, Romanos GE, </infon><offset>0</offset><text>Thermographic Changes During Soft Tissue Incisions with Diode Infrared Lasers.</text></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Objective: This study aimed to demonstrate temperature changes and heat transfer patterns in soft tissues when using infrared (IR) diode lasers, utilizing thermographic techniques. Methods: Bovine tongue slices (5 mm thick) were placed between two glass slides at 11 cm from a thermographic camera. Twenty-two centimeter-long incisions were made along the soft tissue parallel to the camera capture field. Incisions were performed using the 970 and 980 nm lasers (continuous wave, 2-watt, 320 mum-thick glass initiated, and noninitiated fiber tips, 30-sec irradiation). The maximum temperature changes in oC (DeltaT) and the vertical and lateral heat transfer (in mm) were recorded for 30 sec, using the thermographic images captured using the IR camera. The DeltaT and the amount of lateral and vertical heat distribution were measured in 10-sec intervals for a 30-sec irradiation period. A repeated analysis of variance (ANOVA) (p &lt; 0.05) statistical test was used to analyze the statistical differences between the average DeltaT and heat transfer patterns between the initiated and noninitiated lasers. Results: The maximum DeltaT for the 970 nm diode laser with initiated tips at the 30-sec mark was 17.81 +- 11.48, while the maximum DeltaT for the 980 nm diode laser with initiated tips was 13.24 +- 6.90 (p = 0.041). Statistically significant differences between the vertical and horizontal heat transfer patterns were noted between the initiated and noninitiated diode lasers. The 980 nm diode laser with initiated tips proved to have statistically significant greater vertical and lateral heat transfer when compared to the 970 nm diode laser. The 970 nm diode laser with noninitiated tips proved to have a statistically significant higher heat distribution when compared to the 980 nm laser with noninitiated tips. Conclusions: Different near-IR lasers present differences in lateral heat and tissue penetration, using initiated or noninitiated fibers, and due to these differences, power settings and irradiation period must be considered to avoid risks due to overheating.</text></passage></document>
<document><id>37903371</id><passage><infon key="journal">Mol Cancer Ther;2023Oct30. doi:10.1158/1535-7163.MCT-23-0310</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Doug&amp;#xe9; A, El Ghazzi N, Lemal R, Rouzaire P, </infon><offset>0</offset><text>Adoptive T cells therapy in solid tumors: state-of-the art, current challenges, and upcoming improvements.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="28" length="12"/><text>solid tumors</text></annotation></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>In solid tumors, three main complementary approaches of adoptive T cell therapies were successively developed: tumor infiltrating lymphocytes (TILs), chimeric antigen receptor (CAR) engineered T cells and high-affinity T cell receptor (TCR) engineered T cells. In this review, we summarized rational and main results of these three adoptive T cell therapies in solid tumors field and gave an overview of encouraging data and their limits. Then, we listed the major remaining challenges (including tumor antigen loss, on target/off tumor effect, tumor access difficulties and general / local immunosubversion) and their lines of research. Finally, we gave insight into the ongoing trials in solid tumor.</text><annotation id="13"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="110" length="12"/><text>solid tumors</text></annotation><annotation id="14"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="218" length="5"/><text>tumor</text></annotation><annotation id="15"><infon key="identifier">9970</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="257" length="25"/><text>chimeric antigen receptor</text></annotation><annotation id="16"><infon key="identifier">9970</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="284" length="3"/><text>CAR</text></annotation><annotation id="17"><infon key="identifier">6962</infon><infon key="type">Gene</infon><location offset="326" length="15"/><text>T cell receptor</text></annotation><annotation id="18"><infon key="identifier">6962</infon><infon key="type">Gene</infon><location offset="343" length="3"/><text>TCR</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="468" length="12"/><text>solid tumors</text></annotation><annotation id="20"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="604" length="5"/><text>tumor</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="638" length="5"/><text>tumor</text></annotation><annotation id="22"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="652" length="5"/><text>tumor</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="803" length="5"/><text>tumor</text></annotation></passage></document>
<document><id>37903722</id><passage><infon key="journal">Chempluschem;2023Oct30 202300475. doi:10.1002/cplu.202300475</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gu K, Li P, Yi G, Wu Y, Yang W, Zhang Z, Zhang X, </infon><offset>0</offset><text>N/S Co-Doped Graphene Aerogels as Superior Anode Materials for High-Rate Lithium-Ion Batteries.</text><annotation id="4"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="0" length="3"/><text>N/S</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="4" length="8"/><text>Co-Doped</text></annotation><annotation id="6"><infon key="identifier">MESH:D006108</infon><infon key="type">Chemical</infon><location offset="13" length="8"/><text>Graphene</text></annotation><annotation id="7"><infon key="identifier">MESH:D008094</infon><infon key="type">Chemical</infon><location offset="73" length="7"/><text>Lithium</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset><text>The nitrogen and sulfur co-doped graphene aerogel (SNGA) was synthesized via a one-pot hydrothermal route using graphene oxide as the starting material and thiourea as the S and N source. The obtained SNGA with a three-dimensionally hierarchical structure, providing more available pathways for the transport of lithium ions. The existing form of S and N was regulated by changing the calcination temperature and thiourea doping amount. The results revealed that high temperature could decompose -SOX- functional groups and promote the transformation of C-S-C to C-S, ensuring the cyclic stability of electrode materials, and increasing the thiourea dosage amount introduced more pyridine nitrogen, improving the multiplicative performance of electrode materials. Benefiting from the synergistic effect of sulfur and nitrogen atoms, the prepared SNGA showed superior rate capability (107.8 mAh g-1 at 5 A g-1), twice more than that of GA (52.8 mAh g-1), and excellent stability (232.1 mAh g-1 at 1 A g-1 after 300 cycles), 1.85 times more than that of GA (125.6 mAh g-1). The present study provides a detailed report on thiourea as a dopant to provide a sufficient basis for SNGA and a theoretical guide for further modifying.</text><annotation id="33"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="100" length="8"/><text>nitrogen</text></annotation><annotation id="34"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="113" length="6"/><text>sulfur</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="120" length="8"/><text>co-doped</text></annotation><annotation id="36"><infon key="identifier">MESH:D006108</infon><infon key="type">Chemical</infon><location offset="129" length="8"/><text>graphene</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="147" length="4"/><text>SNGA</text></annotation><annotation id="38"><infon key="identifier">MESH:C000628730</infon><infon key="type">Chemical</infon><location offset="208" length="14"/><text>graphene oxide</text></annotation><annotation id="39"><infon key="identifier">MESH:D013890</infon><infon key="type">Chemical</infon><location offset="252" length="8"/><text>thiourea</text></annotation><annotation id="40"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="268" length="1"/><text>S</text></annotation><annotation id="41"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="274" length="1"/><text>N</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="297" length="4"/><text>SNGA</text></annotation><annotation id="43"><infon key="identifier">MESH:D008094</infon><infon key="type">Chemical</infon><location offset="408" length="7"/><text>lithium</text></annotation><annotation id="44"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="443" length="1"/><text>S</text></annotation><annotation id="45"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="449" length="1"/><text>N</text></annotation><annotation id="46"><infon key="identifier">MESH:D013890</infon><infon key="type">Chemical</infon><location offset="509" length="8"/><text>thiourea</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="650" length="5"/><text>C-S-C</text></annotation><annotation id="48"><infon key="identifier">MESH:D002586</infon><infon key="type">Chemical</infon><location offset="659" length="3"/><text>C-S</text></annotation><annotation id="49"><infon key="identifier">MESH:D013890</infon><infon key="type">Chemical</infon><location offset="737" length="8"/><text>thiourea</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="776" length="17"/><text>pyridine nitrogen</text></annotation><annotation id="51"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="902" length="6"/><text>sulfur</text></annotation><annotation id="52"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="913" length="8"/><text>nitrogen</text></annotation><annotation id="53"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="942" length="4"/><text>SNGA</text></annotation><annotation id="54"><infon key="identifier">MESH:D005708</infon><infon key="type">Chemical</infon><location offset="1031" length="2"/><text>GA</text></annotation><annotation id="55"><infon key="identifier">MESH:D005708</infon><infon key="type">Chemical</infon><location offset="1148" length="2"/><text>GA</text></annotation><annotation id="56"><infon key="identifier">MESH:D013890</infon><infon key="type">Chemical</infon><location offset="1216" length="8"/><text>thiourea</text></annotation><annotation id="57"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1271" length="4"/><text>SNGA</text></annotation></passage><relation id="R1"><infon key="score">0.8046</infon><infon key="role1">Chemical|MESH:D006108</infon><infon key="role2">Chemical|MESH:D013455</infon><infon key="type">Association</infon><node refid="0" role="7,5"/></relation><relation id="R2"><infon key="score">0.6437</infon><infon key="role1">Chemical|MESH:D008094</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="3,0"/></relation><relation id="R3"><infon key="score">0.974</infon><infon key="role1">Chemical|MESH:D009584</infon><infon key="role2">Chemical|MESH:D013890</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="4,10"/></relation><relation id="R4"><infon key="score">0.8815</infon><infon key="role1">Chemical|MESH:D013455</infon><infon key="role2">Chemical|MESH:D013890</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="5,10"/></relation><relation id="R5"><infon key="score">0.9802</infon><infon key="role1">Chemical|MESH:D006108</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Association</infon><node refid="4" role="2,0"/></relation><relation id="R6"><infon key="score">0.6539</infon><infon key="role1">Chemical|MESH:D009584</infon><infon key="role2">Chemical|MESH:D013455</infon><infon key="type">Comparison</infon><node refid="5" role="4,5"/></relation></document>
<document><id>37904073</id><passage><infon key="journal">J Gen Intern Med;2023Oct30. doi:10.1007/s11606-023-08497-6</infon><infon key="year">2023</infon><infon key="article-id_pmc">5758324</infon><infon key="type">title</infon><infon key="authors">Bakdash L, Abid A, Gourisankar A, Henry TL, </infon><offset>0</offset><text>Chatting Beyond ChatGPT: Advancing Equity Through AI-Driven Language Interpretation.</text></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>Medical interpretation is an underutilized resource, despite its legal mandate and proven efficacy in improving health outcomes for populations with low English proficiency. This disconnect can often be attributed to the costs and wait-times associated with traditional means of interpretation, making the service inaccessible and burdensome. Technology has improved access to translation through phone and video interpretation; with the acceleration of artificial intelligence (AI) large language models, we have an opportunity to further improve interpreter access through real-time, automated translation. The impetus to utilize this burgeoning tool for improved health equity must be combined with a critical view of the safety, privacy, and clinical decision-making risks involved. Physicians must be active participants and collaborators in both the mobilization of AI tools to improve clinical care and the development of regulations to mitigate harm.</text></passage></document>
<document><id>37905123</id><passage><infon key="journal">bioRxiv;2023Oct17. doi:10.1101/2023.10.17.562694</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614857</infon><infon key="type">title</infon><infon key="authors">Zierath DK, Davidson S, Manoukian J, White HS, Meeker S, Ericsson A, Barker-Haliski M, </infon><offset>0</offset><text>Diet composition and sterilization modifies intestinal microbiome diversity and burden of Theiler's virus infection-induced acute seizures.</text><annotation id="2"><infon key="identifier">MESH:D014777</infon><infon key="type">Disease</infon><location offset="90" length="25"/><text>Theiler's virus infection</text></annotation><annotation id="3"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="130" length="8"/><text>seizures</text></annotation></passage><passage><infon key="type">abstract</infon><offset>140</offset><text>Objective: Central nervous system infection with Theiler's murine encephalomyelitis virus (TMEV) in C57BL/6J mice can model acquired epileptogenesis. Diet alters the acute seizure incidence in TMEV-infected mice; yet it is unclear whether intestinal dysbiosis may also impact acute or chronic behavioral comorbidities. This study thus assessed the impact of diet sterilization in a specific pathogen-free vivarium on acute seizure presentation, the composition of the gut microbiome, and chronic behavioral comorbidities of epilepsy. Methods: Baseline fecal samples were collected from male C57BL/6J mice (4-5 weeks-old; Jackson Labs) upon arrival. Mice were randomized to either autoclaved (AC) or irradiated (IR) diet (Prolab RMH 3000 - UU diets) or IR (Picolab 5053 - UW IR diet). Mice then underwent intracerebral TMEV or PBS injection three days later. Fecal samples were collected from a subset of mice at infection (Day 0) and Day 7 post-infection. Epilepsy-related working memory deficits and seizure threshold were assessed 6 weeks post-infection. Gut microbiome diversity was determined by 16S rRNA amplicon sequencing of fecal samples. Results: TMEV-infected mice displayed acute handling-induced seizures, regardless of diet: 28/57 UW IR (49.1%), 30/41 UU IR (73.2%), and 47/77 UU AC (61%) mice displayed seizures. The number of observed seizures significantly differed: UW IR mice had 2.2+-2.8 seizures (mean+-standard deviation), UU IR mice had 3.5+-2.9 seizures, and UU AC mice had 4.4+-3.8 seizures during the 7-day monitoring period. The composition of the gut microbiome significantly differed in TMEV-infected mice fed the UU AC diet, with most measured differences occurring in Gram-positive bacteria. TMEV-infected mice fed the UU AC diet displayed worsened chronic working memory. Significance: Intestinal dysbiosis evokes stark differences in acute seizure presentation in the TMEV model and vastly influences the trajectory of post-TMEV infection-induced behavioral comorbidities of epilepsy. Our study reveals a novel disease-modifying contribution of intestinal bacterial species after TMEV-induced acute seizures.</text><annotation id="40"><infon key="identifier">MESH:D002494</infon><infon key="type">Disease</infon><location offset="151" length="32"/><text>Central nervous system infection</text></annotation><annotation id="41"><infon key="identifier">CVCL:C0MW</infon><infon key="type">CellLine</infon><location offset="240" length="8"/><text>C57BL/6J</text></annotation><annotation id="42"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="312" length="7"/><text>seizure</text></annotation><annotation id="43"><infon key="identifier">MESH:D064806</infon><infon key="type">Disease</infon><location offset="379" length="20"/><text>intestinal dysbiosis</text></annotation><annotation id="44"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="563" length="7"/><text>seizure</text></annotation><annotation id="45"><infon key="identifier">MESH:D004827</infon><infon key="type">Disease</infon><location offset="664" length="8"/><text>epilepsy</text></annotation><annotation id="46"><infon key="identifier">CVCL:C0MW</infon><infon key="type">CellLine</infon><location offset="731" length="8"/><text>C57BL/6J</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="868" length="3"/><text>RMH</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="879" length="2"/><text>UU</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="896" length="12"/><text>Picolab 5053</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="911" length="2"/><text>UW</text></annotation><annotation id="51"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="966" length="3"/><text>PBS</text></annotation><annotation id="52"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1052" length="9"/><text>infection</text></annotation><annotation id="53"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1085" length="9"/><text>infection</text></annotation><annotation id="54"><infon key="identifier">MESH:D004827</infon><infon key="type">Disease</infon><location offset="1096" length="8"/><text>Epilepsy</text></annotation><annotation id="55"><infon key="identifier">MESH:D008569</infon><infon key="type">Disease</infon><location offset="1121" length="15"/><text>memory deficits</text></annotation><annotation id="56"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="1141" length="7"/><text>seizure</text></annotation><annotation id="57"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1186" length="9"/><text>infection</text></annotation><annotation id="58"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="1348" length="8"/><text>seizures</text></annotation><annotation id="59"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1384" length="2"/><text>UW</text></annotation><annotation id="60"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1405" length="2"/><text>UU</text></annotation><annotation id="61"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1430" length="2"/><text>UU</text></annotation><annotation id="62"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="1457" length="8"/><text>seizures</text></annotation><annotation id="63"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="1490" length="8"/><text>seizures</text></annotation><annotation id="64"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1523" length="2"/><text>UW</text></annotation><annotation id="65"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="1547" length="8"/><text>seizures</text></annotation><annotation id="66"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1584" length="2"/><text>UU</text></annotation><annotation id="67"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="1608" length="8"/><text>seizures</text></annotation><annotation id="68"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1622" length="2"/><text>UU</text></annotation><annotation id="69"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="1646" length="8"/><text>seizures</text></annotation><annotation id="70"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1782" length="2"/><text>UU</text></annotation><annotation id="71"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1889" length="2"/><text>UU</text></annotation><annotation id="72"><infon key="identifier">MESH:D064806</infon><infon key="type">Disease</infon><location offset="1957" length="20"/><text>Intestinal dysbiosis</text></annotation><annotation id="73"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="2012" length="7"/><text>seizure</text></annotation><annotation id="74"><infon key="identifier">MESH:D004827</infon><infon key="type">Disease</infon><location offset="2147" length="8"/><text>epilepsy</text></annotation><annotation id="75"><infon key="identifier">MESH:D012640</infon><infon key="type">Disease</infon><location offset="2271" length="8"/><text>seizures</text></annotation></passage></document>
<document><id>37905474</id><passage><infon key="journal">Int J Soc Psychiatry;2023Oct31 207640231207571. doi:10.1177/00207640231207571</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Valdes-Sosa M, </infon><offset>0</offset><text>When politics obstructs self-correction in science.</text></passage><passage><infon key="type">abstract</infon><offset>52</offset></passage></document>
<document><id>37905824</id><passage><infon key="journal">Microbiol Resour Announc;2023Oct31 0079323. doi:10.1128/MRA.00793-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Anderson GM, Anderson OE, Bosma CA, Brouwer EE, DeGroot KM, Hede OC, Jonouchi D, Kirkeby DJ, Klinghagen JT, Kralik KJ, Kutz JS, Lott OF, McKenney EJ, Pavik VL, Penner CH, Raymon G, Rozeboom LB, Skrien JL, Slight JK, Stokes MJ, Tiensvold JD, Wajer KJ, Trevino AL, Noordewier B, Tolsma SS, </infon><offset>0</offset><text>Complete genome sequences of microbacterium phages Tedro and BAjuniper.</text></passage><passage><infon key="type">abstract</infon><offset>72</offset><text>We purified two novel bacteriophages from soil collected in Sioux County, Iowa: BAjuniper and Tedro. These bacteriophages were isolated from the host, Microbacterium foliorum. BAjuniper was assigned to cluster EB, and Tedro was assigned to cluster EF. Both phages display genomes typical of other phages in their clusters.</text><annotation id="1"><infon key="type">Disease</infon><location offset="320" length="2"/><text>EF</text></annotation></passage></document>
<document><id>37906176</id><passage><infon key="journal">Child Neuropsychol;2023Oct31 1. doi:10.1080/09297049.2023.2272339</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Horowitz-Kraus T, Fotang J, Niv L, Apter A, Hutton J, Farah R, </infon><offset>0</offset><text>Executive functions abilities in preschool-age children are negatively related to parental EF, screen-time and positively related to home literacy environment: an EEG study.</text></passage><passage><infon key="type">abstract</infon><offset>174</offset><text>Environmental factors such as Home Literacy Environment (HLE), screen time, and parental executive functions (EF) may influence the development of the child's EF. The purpose of this study was to determine the effect of these factors on behavioral and neurobiological measures of EF in 4-year-old children. Electroencephalogram (EEG) data were collected while children performed the Attention Network Task (ANT), showing a smaller difference between incongruent and congruent conditions is related to better EF abilities. Data were analyzed using an Event-Related Potential (ERP) technique focusing on the N200 and P300 components (reflecting executive control and orienting attention, respectively). N200 and P300 differences (delta) between amplitudes and latencies for the incongruent and congruent conditions were computed and correlated with child EF skills, HLE, screen exposure, and parental EF. Screen exposure was associated with lower EF in children and their parents. Additionally, smaller differences between N200 amplitudes and latencies for the incongruent vs. congruent conditions were associated with higher HLE scores. In contrast, greater differences between P300 amplitudes and latencies were related to longer screen time. HLE was positively associated with EF's neurobiological (EEG) and behavioral measures, and screen time was negatively associated with these measures. This study also highlights the important relationship between parental EF (i.e., family predisposition) and EF's neurobiological and behavioral measures in their children.</text><annotation id="1"><infon key="identifier">MESH:D003291</infon><infon key="type">Disease</infon><location offset="1113" length="8"/><text>lower EF</text></annotation></passage></document>
<document><id>37906526</id><passage><infon key="journal">Arch Environ Occup Health;2023Oct31 1. doi:10.1080/19338244.2023.2275155</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sire T, Roy K, Marcel-Millet P, Poirier S, Gendron P, </infon><offset>0</offset><text>Cardiovascular disease risk factors in career firefighters: A 6-year follow-up study.</text><annotation id="1"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="0" length="22"/><text>Cardiovascular disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>86</offset><text>This study sought to investigate the evolution of cardiovascular disease (CVD) risk factors in career firefighters. A questionnaire was sent to a cohort of 233 Quebec career firefighters in 2015 and 2021 to collect demographic and occupational information and the presence of CVD risk factors. Ninety-six (96) firefighters (1 female) responded to the questionnaire in 2015 and 2021. Body weight (2015: 88.3 +- 10.9, 2021: 89.6 +- 10.7 kg, p = 0.01), body mass index (2015: 27.6 +- 3.2, 2021: 28.0 +- 3.0 kg/m2, p = 0.01), number of CVD risk factors (2015: 1.1 +- 1.0, 2021: 1.3 +- 0.9 CVD risk factors, p = 0.05), and proportion of firefighters with at least 1 CVD risk factor (2015: 71, 2021: 82%, p = 0.02) increased. Overall, our results highlight an aggravation of several CVD risk factors in Quebec career firefighters over the years.</text><annotation id="9"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="136" length="22"/><text>cardiovascular disease</text></annotation><annotation id="10"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="160" length="3"/><text>CVD</text></annotation><annotation id="11"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="362" length="3"/><text>CVD</text></annotation><annotation id="12"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="618" length="3"/><text>CVD</text></annotation><annotation id="13"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="671" length="3"/><text>CVD</text></annotation><annotation id="14"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="747" length="3"/><text>CVD</text></annotation><annotation id="15"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="863" length="3"/><text>CVD</text></annotation></passage></document>
<document><id>37906900</id><passage><infon key="journal">Andes Pediatr;2022Oct; 93 (5) 771. doi:10.32641/andespediatr.v93i5.4422</infon><infon key="year">2022</infon><infon key="type">title</infon><infon key="authors">Quiroz Z B, Jauregui U S, Saravia P S C, </infon><offset>0</offset><text>[Vitamin D deficiency and insufficiency in healthy infants receiving standard supplementation].</text><annotation id="1"><infon key="identifier">MESH:D014808</infon><infon key="type">Disease</infon><location offset="1" length="38"/><text>Vitamin D deficiency and insufficiency</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset></passage></document>
<document><id>37907266</id><passage><infon key="journal">Arch Dis Child Fetal Neonatal Ed;2023Oct31. doi:10.1136/archdischild-2023-325871</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Clarke P, Soe A, Nichols A, Harizaj H, Webber MA, Linsell L, Bell JL, Tremlett C, Muthukumar P, Pattnayak S, Partlett C, King A, Juszczak E, Heath PT, </infon><offset>0</offset><text>2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheterisation: the ARCTIC randomised controlled feasibility trial.</text><annotation id="3"><infon key="identifier">MESH:C010882</infon><infon key="type">Chemical</infon><location offset="3" length="23"/><text>chlorhexidine gluconate</text></annotation><annotation id="4"><infon key="identifier">MESH:C010882</infon><infon key="type">Chemical</infon><location offset="45" length="23"/><text>chlorhexidine gluconate</text></annotation><annotation id="5"><infon key="identifier">MESH:D019840</infon><infon key="type">Chemical</infon><location offset="76" length="17"/><text>isopropyl alcohol</text></annotation></passage><passage><infon key="type">abstract</infon><offset>222</offset><text>OBJECTIVE: Catheter-related sepsis (CRS) is a major complication with significant morbidity and mortality. Evidence is lacking regarding the most appropriate antiseptic for skin disinfection before percutaneous central venous catheter (PCVC) insertion in preterm neonates. To inform the feasibility and design of a definitive randomised controlled trial (RCT) of two antiseptic formulations, we conducted the Antiseptic Randomised Controlled Trial for Insertion of Catheters (ARCTIC) feasibility study to assess catheter colonisation, sepsis, and skin morbidity. DESIGN: Feasibility RCT. SETTING: Two UK tertiary-level neonatal intensive care units. PATIENTS: Preterm infants born &lt;34 weeks' gestation scheduled to undergo PCVC insertion. INTERVENTIONS: Skin disinfection with either 2% chlorhexidine gluconate (CHG)-aqueous or 2% CHG-70% isopropyl alcohol (IPA) before PCVC insertion and at removal. PRIMARY OUTCOME: Proportion in the 2% CHG-70% IPA arm with a colonised catheter at removal. MAIN FEASIBILITY OUTCOMES: Rates of: (1) CRS, catheter-associated sepsis (CAS), and CRS/CAS per 1,000 PCVC days; (2) recruitment and retention; (3) data completeness. SAFETY OUTCOMES: Daily skin morbidity scores recorded from catheter insertion until 48 hours post-removal. RESULTS: 116 babies were randomised. Primary outcome incidence was 4.1% (95% confidence interval: 0.9% to 11.5%). Overall catheter colonisation rate was 5.2% (5/97); CRS 2.3/1000 catheter days; CAS 14.8/1000 catheter days. Recruitment, retention and data completeness were good. No major antiseptic-related skin injury was reported. CONCLUSIONS: A definitive comparative efficacy trial is feasible, but the very low catheter colonisation rate would make a large-scale RCT challenging due to the very large sample size required. ARCTIC provides preliminary reassurance supporting potential safe use of 2% CHG-70% IPA and 2% CHG-aqueous in preterm neonates. TRIAL REGISTRATION NUMBER: ISRCTN82571474.</text><annotation id="27"><infon key="identifier">MESH:D018805</infon><infon key="type">Disease</infon><location offset="250" length="6"/><text>sepsis</text></annotation><annotation id="28"><infon key="identifier">MESH:D055499</infon><infon key="type">Disease</infon><location offset="258" length="3"/><text>CRS</text></annotation><annotation id="29"><infon key="identifier">MESH:D018805</infon><infon key="type">Disease</infon><location offset="757" length="6"/><text>sepsis</text></annotation><annotation id="30"><infon key="identifier">MESH:C010882</infon><infon key="type">Chemical</infon><location offset="1009" length="23"/><text>chlorhexidine gluconate</text></annotation><annotation id="31"><infon key="identifier">MESH:C010882</infon><infon key="type">Chemical</infon><location offset="1034" length="3"/><text>CHG</text></annotation><annotation id="32"><infon key="identifier">MESH:C010882</infon><infon key="type">Chemical</infon><location offset="1053" length="3"/><text>CHG</text></annotation><annotation id="33"><infon key="identifier">MESH:D019840</infon><infon key="type">Chemical</infon><location offset="1061" length="17"/><text>isopropyl alcohol</text></annotation><annotation id="34"><infon key="identifier">MESH:D019840</infon><infon key="type">Chemical</infon><location offset="1080" length="3"/><text>IPA</text></annotation><annotation id="35"><infon key="identifier">MESH:C010882</infon><infon key="type">Chemical</infon><location offset="1161" length="3"/><text>CHG</text></annotation><annotation id="36"><infon key="identifier">MESH:D019840</infon><infon key="type">Chemical</infon><location offset="1169" length="3"/><text>IPA</text></annotation><annotation id="37"><infon key="identifier">MESH:D055499</infon><infon key="type">Disease</infon><location offset="1256" length="3"/><text>CRS</text></annotation><annotation id="38"><infon key="identifier">MESH:D018805</infon><infon key="type">Disease</infon><location offset="1281" length="6"/><text>sepsis</text></annotation><annotation id="39"><infon key="identifier">MESH:D055499</infon><infon key="type">Disease</infon><location offset="1289" length="3"/><text>CAS</text></annotation><annotation id="40"><infon key="identifier">MESH:D055499</infon><infon key="type">Disease</infon><location offset="1299" length="3"/><text>CRS</text></annotation><annotation id="41"><infon key="identifier">MESH:D055499</infon><infon key="type">Disease</infon><location offset="1303" length="3"/><text>CAS</text></annotation><annotation id="42"><infon key="identifier">MESH:D055499</infon><infon key="type">Disease</infon><location offset="1655" length="3"/><text>CRS</text></annotation><annotation id="43"><infon key="identifier">MESH:D055499</infon><infon key="type">Disease</infon><location offset="1683" length="3"/><text>CAS</text></annotation><annotation id="44"><infon key="identifier">MESH:D000069836</infon><infon key="type">Disease</infon><location offset="1796" length="11"/><text>skin injury</text></annotation><annotation id="45"><infon key="identifier">MESH:C010882</infon><infon key="type">Chemical</infon><location offset="2093" length="3"/><text>CHG</text></annotation><annotation id="46"><infon key="identifier">MESH:D019840</infon><infon key="type">Chemical</infon><location offset="2101" length="3"/><text>IPA</text></annotation><annotation id="47"><infon key="identifier">MESH:C010882</infon><infon key="type">Chemical</infon><location offset="2112" length="4"/><text>CHG-</text></annotation></passage><relation id="R1"><infon key="score">0.5572</infon><infon key="role1">Chemical|MESH:C010882</infon><infon key="role2">Chemical|MESH:D019840</infon><infon key="type">Cotreatment</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.7243</infon><infon key="role1">Chemical|MESH:D019840</infon><infon key="role2">Disease|MESH:D055499</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="12,13"/></relation></document>
<document><id>37908316</id><passage><infon key="journal">Plasma Process Polym;2015Oct; 12 (10) 1117. doi:10.1002/ppap.201400232</infon><infon key="year">2015</infon><infon key="article-id_pmc">PMC10617645</infon><infon key="type">title</infon><infon key="authors">Lin A, Chernets N, Han J, Alicea Y, Dobrynin D, Fridman G, Freeman TA, Fridman A, Miller V, </infon><offset>0</offset><text>Non-Equilibrium Dielectric Barrier Discharge Treatment of Mesenchymal Stem Cells: Charges and Reactive Oxygen Species Play the Major Role in Cell Death.</text><annotation id="1"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="94" length="23"/><text>Reactive Oxygen Species</text></annotation></passage><passage><infon key="type">abstract</infon><offset>153</offset><text>Atmospheric pressure non-equilibrium plasmas are efficacious in killing both prokaryotic and eukaryotic cells. While the mechanism of plasma induced cell death has been thoroughly studied in prokaryotes, detailed investigation of plasma mediated eukaryotic cell death is still pending. When plasma is generated, four major components that interact with cells are produced: electric fields, radiation, charged particles, and neutral gas species. The goal of this study was to determine which of the plasma components are responsible for plasma-induced cell death by isolating and removing each from treatment. The C3H10T1/2 murine mesenchyme stem cell line was treated in six well plates, stained with Propidium Iodide to determine viability, and analyzed by image cytometry. Our results show that plasma-generated charges and reactive oxygen species are the primary contributors to cell death.</text><annotation id="5"><infon key="identifier">CVCL:0190</infon><infon key="type">CellLine</infon><location offset="766" length="9"/><text>C3H10T1/2</text></annotation><annotation id="6"><infon key="identifier">MESH:D011419</infon><infon key="type">Chemical</infon><location offset="854" length="16"/><text>Propidium Iodide</text></annotation><annotation id="7"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="979" length="23"/><text>reactive oxygen species</text></annotation></passage></document>
<document><id>37909370</id><passage><infon key="journal">Curr Opin Crit Care;2023Dec01; 29 (6) 648. doi:10.1097/MCC.0000000000001103</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Maegele M, </infon><offset>0</offset><text>Editorial: Acute trauma management in a changing environment.</text><annotation id="1"><infon key="identifier">MESH:D000208</infon><infon key="type">Disease</infon><location offset="11" length="12"/><text>Acute trauma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>62</offset></passage></document>
<document><id>37910080</id><passage><infon key="journal">Inorg Chem;2023Nov01. doi:10.1021/acs.inorgchem.3c02708</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mena-Guti&amp;#xe9;rrez S, Pascual-Colino J, Beobide G, Castillo O, Castellanos-Rubio A, Luque A, Maiza-Razkin E, Mentxaka J, P&amp;#xe9;rez-Y&amp;#xe1;&amp;#xf1;ez S, </infon><offset>0</offset><text>Isoreticular Chemistry and Applications of Supramolecularly Assembled Copper-Adenine Porous Materials.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="70" length="14"/><text>Copper-Adenine</text></annotation></passage><passage><infon key="type">abstract</infon><offset>103</offset><text>The useful concepts of reticular chemistry, rigid and predictable metal nodes together with strong and manageable covalent interactions between metal centers and organic linkers, have made the so-called metal-organic frameworks (MOFs) a flourishing area of enormous applicability. In this work, the extension of similar strategies to supramolecularly assembled metal-organic materials has allowed us to obtain a family of isoreticular compounds of the general formula [Cu7(mu-adeninato-kappaN3:kappaN9)6(mu3-OH)6(mu-OH2)6](OOC-R-COO) nH2O (R: ethylene-, acetylene-, naphthalene-, or biphenyl-group) in which the rigid copper-adeninato entities and the organic dicarboxylate anions are held together not by covalent interactions but by a robust and flexible network of synergic hydrogen bonds and pi-pi stacking interactions based on well-known supramolecular synthons (SMOFs). All compounds are isoreticular, highly insoluble, and water-stable and show a porous crystalline structure with a pcu topology containing a two-dimensional (2D) network of channels, whose dimensions and degree of porosity of the supramolecular network are tailored by the length of the dicarboxylate anion. The partial loss of the crystallization water molecules upon removal from the mother liquor produces a shrinkage of the unit cell and porosity, which leads to a color change of the compounds (from blue to olive green) if complete dehydration is achieved by means of gentle heating or vacuuming. However, the supramolecular network of noncovalent interactions is robust and flexible enough to reverse to the expanded unit cell and color after exposure to a humid atmosphere. This humidity-driven breathing behavior has been used to design a sensor in which the electrical resistance varies reversibly with the degree of humidity, very similar to the water vapor adsorption isotherm of the SMOF. The in-solution adsorption properties were explored for the uptake and release of the widely employed 5-fluorouracil, 4-aminosalycilic acid, 5-aminosalycilic acid, and allopurinol drugs. In addition, cytotoxicity activity assays were completed for the pristine and 5-fluorouracil-loaded samples.</text><annotation id="21"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="169" length="5"/><text>metal</text></annotation><annotation id="22"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="247" length="5"/><text>metal</text></annotation><annotation id="23"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="306" length="5"/><text>metal</text></annotation><annotation id="24"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="464" length="5"/><text>metal</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="571" length="70"/><text>[Cu7(mu-adeninato-kappaN3:kappaN9)6(mu3-OH)6(mu-OH2)6](OOC-R-COO) nH2O</text></annotation><annotation id="26"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="721" length="6"/><text>copper</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="728" length="9"/><text>adeninato</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="763" length="13"/><text>dicarboxylate</text></annotation><annotation id="29"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="880" length="8"/><text>hydrogen</text></annotation><annotation id="30"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1034" length="5"/><text>water</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1266" length="19"/><text>dicarboxylate anion</text></annotation><annotation id="32"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1327" length="5"/><text>water</text></annotation><annotation id="33"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1936" length="5"/><text>water</text></annotation><annotation id="34"><infon key="identifier">MESH:D005472</infon><infon key="type">Chemical</infon><location offset="2083" length="14"/><text>5-fluorouracil</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2099" length="21"/><text>4-aminosalycilic acid</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2122" length="21"/><text>5-aminosalycilic acid</text></annotation><annotation id="37"><infon key="identifier">MESH:D000493</infon><infon key="type">Chemical</infon><location offset="2149" length="11"/><text>allopurinol</text></annotation><annotation id="38"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="2181" length="12"/><text>cytotoxicity</text></annotation><annotation id="39"><infon key="identifier">MESH:D005472</infon><infon key="type">Chemical</infon><location offset="2246" length="14"/><text>5-fluorouracil</text></annotation></passage><relation id="R1"><infon key="score">0.8202</infon><infon key="role1">Chemical|MESH:D005472</infon><infon key="role2">Disease|MESH:D064420</infon><infon key="type">Association</infon><node refid="0" role="19,18"/></relation></document>
<document><id>37910781</id><passage><infon key="journal">Ther Hypothermia Temp Manag;2023Nov01. doi:10.1089/ther.2023.0039</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bro-Jeppesen J, Grejs AM, Andersen O, Jeppesen AN, Duez C, Kirkegaard H, </infon><offset>0</offset><text>Soluble Urokinase-Type Plasminogen Activator Receptor in Comatose Survivors After Out-of-Hospital Cardiac Arrest Treated with Targeted Temperature Management.</text><annotation id="2"><infon key="identifier">MESH:D003128</infon><infon key="type">Disease</infon><location offset="57" length="8"/><text>Comatose</text></annotation><annotation id="3"><infon key="identifier">MESH:D006323</infon><infon key="type">Disease</infon><location offset="98" length="14"/><text>Cardiac Arrest</text></annotation></passage><passage><infon key="type">abstract</infon><offset>159</offset><text>Exposure to whole-body ischemia/reperfusion after out-of-hospital cardiac arrest (OHCA) triggers a systemic inflammatory response where soluble urokinase plasminogen activator receptor (suPAR) is released. This study investigated serial levels of suPAR in differentiated target temperature management and the associations with mortality and 6-month neurological outcome. This is a single-center substudy of the randomized Targeted Temperature Management (TTM) for 24-hour versus 48-hour trial. In this analysis, we included 82 patients and measured serial levels of suPAR at 24, 48, and 72 hours after achievement of target temperature (32-34 C). We assessed all-cause mortality and neurological function evaluated by the Cerebral Performance Categories (CPC) at 6 months after OHCA. Levels of suPAR between TTH groups were evaluated in repeated measures mixed models. Mortality was assessed by the Kaplan-Meier method and serial measurements of suPAR (log2 transformed) were investigated by Cox proportional-hazards models. Good neurological outcome at 6 months was assessed by logistic regression analyses. Levels of suPAR were significantly different between TTH groups (pinteraction = 0.04) with the highest difference at 48 hours, 4.7 ng/mL (95% CI: 4.1-5.4 ng/mL) in the TTH24 group compared to 2.8 ng/mL (95% CI: 2.2-3.5 ng/mL) in the TTH48 group, p &lt; 0.0001. Levels of suPAR above the median value were significantly associated with increased all-cause mortality at any time point (plog-rank&lt;0.05). The interaction of suPAR levels and TTH group was not significant (pinteraction = NS). A twofold increase in levels of suPAR was significantly associated with a decreased odds ratio of a good neurological outcome in both unadjusted and adjusted analyses without interaction of TTH group (pinteraction = NS). Prolonged TTM of 48 hours versus 24 hours was associated with lower levels of suPAR. High levels of suPAR were associated with increased mortality and lower odds for good neurological outcome at 6 months with no significant interaction of TTH group.</text><annotation id="16"><infon key="identifier">MESH:D007511</infon><infon key="type">Disease</infon><location offset="182" length="8"/><text>ischemia</text></annotation><annotation id="17"><infon key="identifier">MESH:D006323</infon><infon key="type">Disease</infon><location offset="225" length="14"/><text>cardiac arrest</text></annotation><annotation id="18"><infon key="identifier">MESH:D058687</infon><infon key="type">Disease</infon><location offset="241" length="4"/><text>OHCA</text></annotation><annotation id="19"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="267" length="12"/><text>inflammatory</text></annotation><annotation id="20"><infon key="identifier">5329</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48120</infon><location offset="303" length="40"/><text>urokinase plasminogen activator receptor</text></annotation><annotation id="21"><infon key="identifier">MESH:D058687</infon><infon key="type">Disease</infon><location offset="937" length="4"/><text>OHCA</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="967" length="3"/><text>TTH</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1321" length="3"/><text>TTH</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1436" length="5"/><text>TTH24</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1702" length="3"/><text>TTH</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="1943" length="3"/><text>TTH</text></annotation><annotation id="27"><infon key="type">Disease</infon><location offset="2213" length="3"/><text>TTH</text></annotation></passage><relation id="R1"><infon key="score">0.7666</infon><infon key="role1">Disease|MESH:D058687</infon><infon key="role2">Gene|5329</infon><infon key="type">Association</infon><node refid="0" role="4,6"/></relation></document>
<document><id>37911132</id><passage><infon key="journal">Int Dent J (Phila);1893Nov; 14 (11) 833</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109707</infon><infon key="type">title</infon><infon key="authors">Thompson AH, </infon><offset>0</offset><text>The Pedigree of the Central Incisor.</text></passage><passage><infon key="type">abstract</infon><offset>37</offset></passage></document>
<document><id>37911482</id><passage><infon key="journal">Int Dent J (Phila);1890Mar; 11 (3) 182</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110197</infon><infon key="type">title</infon><offset>0</offset><text>The National Association of Dental Faculties.</text></passage><passage><infon key="type">abstract</infon><offset>46</offset></passage></document>
<document><id>37912182</id><passage><infon key="journal">Int Dent J (Phila);1897Dec; 18 (12) 846</infon><infon key="year">1897</infon><infon key="article-id_pmc">PMC10128689</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37912882</id><passage><infon key="journal">Int Dent J (Phila);1901Oct; 22 (10) 727</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153953</infon><infon key="type">title</infon><offset>0</offset><text>Miscellany.</text></passage><passage><infon key="type">abstract</infon><offset>12</offset></passage></document>
<document><id>37913232</id><passage><infon key="journal">Int Dent J (Phila);1903Apr; 24 (4) 324</infon><infon key="year">1903</infon><infon key="article-id_pmc">PMC10162345</infon><infon key="type">title</infon><offset>0</offset><text>Miscellany.</text></passage><passage><infon key="type">abstract</infon><offset>12</offset></passage></document>
<document><id>37913583</id><passage><infon key="journal">Bioorg Chem;2023Oct25; 142 106937. doi:10.1016/j.bioorg.2023.106937</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hong P, Wu M, Wei X, Xu X, Wu P, Gan L, Wu R, Jin J, Zhang K, Li D, Chen M, Wong W, Liu W, Zheng X, </infon><offset>0</offset><text>Inhibitory effect of liriopesides B in combination with gemcitabine on human pancreatic cancer cells.</text><annotation id="3"><infon key="identifier">MESH:C000624327</infon><infon key="type">Chemical</infon><location offset="21" length="14"/><text>liriopesides B</text></annotation><annotation id="4"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="56" length="11"/><text>gemcitabine</text></annotation><annotation id="5"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="77" length="17"/><text>pancreatic cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>Gemcitabine (GEM) is a standard chemotherapeutic agent for patients with pancreatic cancer; however, GEM-based chemotherapy has a high rate of toxicity. A combination of GEM and active constituents from natural products may enhance its therapeutic efficacy and reduce its toxicity. This study investigated the synergistic effects of the combination of liriopesides B (LirB) from Liriope spicata var. prolifera and GEM on human pancreatic cancer cells. The results of our study showed that the combination of LirB and GEM synergistically decreased the viability of pancreatic cancer cells. The combination also caused a strong increase in apoptosis and a strong decrease in cell migration and invasion. Furthermore, LirB combined with GEM had potent inhibitory effects on pancreatic cancer stem cells (CSCs). Studies on the mechanisms of action showed that the combination more potently inhibited protein kinase B (Akt) and nuclear factor kappa B (NF-kappaB), as well as the downstream antiapoptotic molecules B-cell lymphoma 2 (Bcl-2) and survivin than either agent used alone. The results of this study suggest that the combination of LirB with GEM may improve the efficacy of GEM for the treatment of pancreatic cancer.</text><annotation id="34"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="102" length="11"/><text>Gemcitabine</text></annotation><annotation id="35"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="115" length="3"/><text>GEM</text></annotation><annotation id="36"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="175" length="17"/><text>pancreatic cancer</text></annotation><annotation id="37"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="203" length="3"/><text>GEM</text></annotation><annotation id="38"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="245" length="8"/><text>toxicity</text></annotation><annotation id="39"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="272" length="3"/><text>GEM</text></annotation><annotation id="40"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="374" length="8"/><text>toxicity</text></annotation><annotation id="41"><infon key="identifier">MESH:C000624327</infon><infon key="type">Chemical</infon><location offset="454" length="14"/><text>liriopesides B</text></annotation><annotation id="42"><infon key="identifier">MESH:C000624327</infon><infon key="type">Chemical</infon><location offset="470" length="4"/><text>LirB</text></annotation><annotation id="43"><infon key="type">Disease</infon><location offset="502" length="9"/><text>prolifera</text></annotation><annotation id="44"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="516" length="3"/><text>GEM</text></annotation><annotation id="45"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="529" length="17"/><text>pancreatic cancer</text></annotation><annotation id="46"><infon key="identifier">MESH:C000624327</infon><infon key="type">Chemical</infon><location offset="610" length="4"/><text>LirB</text></annotation><annotation id="47"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="619" length="3"/><text>GEM</text></annotation><annotation id="48"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="666" length="17"/><text>pancreatic cancer</text></annotation><annotation id="49"><infon key="identifier">MESH:C000624327</infon><infon key="type">Chemical</infon><location offset="817" length="4"/><text>LirB</text></annotation><annotation id="50"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="836" length="3"/><text>GEM</text></annotation><annotation id="51"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="873" length="17"/><text>pancreatic cancer</text></annotation><annotation id="52"><infon key="identifier">2185</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">23001</infon><location offset="998" length="16"/><text>protein kinase B</text></annotation><annotation id="53"><infon key="identifier">207</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3785</infon><location offset="1016" length="3"/><text>Akt</text></annotation><annotation id="54"><infon key="identifier">4790</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1025" length="22"/><text>nuclear factor kappa B</text></annotation><annotation id="55"><infon key="identifier">4790</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1049" length="9"/><text>NF-kappaB</text></annotation><annotation id="56"><infon key="identifier">596</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">527</infon><location offset="1111" length="17"/><text>B-cell lymphoma 2</text></annotation><annotation id="57"><infon key="identifier">596</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">527</infon><location offset="1130" length="5"/><text>Bcl-2</text></annotation><annotation id="58"><infon key="identifier">MESH:C000624327</infon><infon key="type">Chemical</infon><location offset="1238" length="4"/><text>LirB</text></annotation><annotation id="59"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="1248" length="3"/><text>GEM</text></annotation><annotation id="60"><infon key="identifier">MESH:D000093542</infon><infon key="type">Chemical</infon><location offset="1280" length="3"/><text>GEM</text></annotation><annotation id="61"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="1305" length="17"/><text>pancreatic cancer</text></annotation></passage><relation id="R1"><infon key="score">0.994</infon><infon key="role1">Chemical|MESH:D000093542</infon><infon key="role2">Disease|MESH:D010190</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="1,2"/></relation><relation id="R2"><infon key="score">0.9106</infon><infon key="role1">Chemical|MESH:C000624327</infon><infon key="role2">Gene|596</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="18,25"/></relation><relation id="R3"><infon key="score">0.8885</infon><infon key="role1">Chemical|MESH:C000624327</infon><infon key="role2">Gene|4790</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="18,23"/></relation><relation id="R4"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:C000624327</infon><infon key="role2">Disease|MESH:D010190</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="0,2"/></relation><relation id="R5"><infon key="score">0.7386</infon><infon key="role1">Chemical|MESH:D000093542</infon><infon key="role2">Disease|MESH:D064420</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="3,7"/></relation><relation id="R6"><infon key="score">0.8499</infon><infon key="role1">Chemical|MESH:C000624327</infon><infon key="role2">Chemical|MESH:D000093542</infon><infon key="type">Cotreatment</infon><node refid="5" role="0,1"/></relation></document>
<document><id>37913933</id><passage><infon key="journal">Curr Probl Cardiol;2023Oct30 102182. doi:10.1016/j.cpcardiol.2023.102182</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Safdar M, Ullah M, Wahab A, Hamayun S, Ur Rehman M, Wazir MA, Khan SU, Ullah A, Awan UA, Naeem M, </infon><offset>0</offset><text>Genomic Insights into Heart Health: Exploring the Genetic Basis of Cardiovascular Disease.</text><annotation id="2"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="28" length="6"/><text>Health</text></annotation><annotation id="3"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="67" length="22"/><text>Cardiovascular Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>91</offset><text>Cardiovascular diseases (CVDs) are considered as the leading cause of death worldwide. CVD continues to be a major cause of death and morbidity despite significant improvements in its detection and treatment. Therefore, it is strategically important to be able to precisely characterize an individual's sensitivity to certain illnesses. The discovery of genes linked to cardiovascular illnesses has benefited from linkage analysis and genome-wide association research. The last 20 years have seen significant advancements in the field of molecular genetics, particularly with the development of new tools like genome-wide association studies. In this article we explore the profound impact of genetic variations on disease development, prognosis, and therapeutic responses. And the significance of genetics in cardiovascular risk assessment and the ever-evolving realm of genetic testing, offering insights into the potential for personalized medicine in this domain. Embracing the future of cardiovascular care, the article explores the implications of pharmacogenomics for tailored treatments, the promise of emerging technologies in cardiovascular genetics and therapies, including the transformative influence of nanotechnology. Furthermore, it delves into the exciting frontiers of gene editing, such as CRISPR/Cas9, as a novel approach to combat cardiovascular diseases. And also explore the potential of stem cell therapy and regenerative medicine, providing a holistic view of the dynamic landscape of cardiovascular genomics and its transformative potential for the field of cardiovascular medicine.</text><annotation id="11"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="91" length="23"/><text>Cardiovascular diseases</text></annotation><annotation id="12"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="116" length="4"/><text>CVDs</text></annotation><annotation id="13"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="161" length="5"/><text>death</text></annotation><annotation id="14"><infon key="type">Disease</infon><location offset="178" length="3"/><text>CVD</text></annotation><annotation id="15"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="215" length="5"/><text>death</text></annotation><annotation id="16"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="461" length="24"/><text>cardiovascular illnesses</text></annotation><annotation id="17"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="1443" length="23"/><text>cardiovascular diseases</text></annotation></passage></document>
<document><id>37914283</id><passage><infon key="journal">Tohoku J Exp Med;2023Nov02. doi:10.1620/tjem.2023.J091</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang L, Zhang S, Han Z, Liu Z, Xu Y, Li X, Miao G, Niu L, </infon><offset>0</offset><text>Serum Cell Division Cycle 42 before and after Programmed Death-1 Inhibitor Therapy in Advanced Melanoma Patients: Correlation with Tumor Features, Clinical Response, and Survival.</text><annotation id="2"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="95" length="8"/><text>Melanoma</text></annotation><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="131" length="5"/><text>Tumor</text></annotation></passage><passage><infon key="type">abstract</infon><offset>180</offset></passage></document>
<document><id>37914633</id><passage><infon key="journal">Sleep Health;2023Oct30. doi:10.1016/j.sleh.2023.09.005</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Boivin DB, Boudreau P, </infon><offset>0</offset><text>Interindividual variability in coherence between self-reported alertness and performance in shift workers.</text></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>OBJECTIVES: Evidence indicates that self-reported measures of alertness do not always reflect performance impairments. The present study aims to explore whether subjective and objective measures of vigilance vary in the same direction in individuals working nights. METHODS: A total of 76 police officers participated to a month-long observational study. They worked either a 2 or 3-shift system during which they self-reported alertness and completed a psychomotor vigilance task several times a day. RESULTS: A reduction in alertness and reaction speed was observed with time awake. At the group level, changes in alertness and reaction speed with time awake were positively correlated during night shifts only. In 63.6% of the officers, changes were coherent between both variables. The other officers reported that their alertness dropped (25.5%) or improved (10.9%) whereas their performance changed in the opposite direction. CONCLUSION: Significant interindividual variability exists in self-appraisal vigilance impairment due to night shift work.</text><annotation id="1"><infon key="identifier">MESH:D000405</infon><infon key="type">Disease</infon><location offset="1116" length="20"/><text>vigilance impairment</text></annotation></passage></document>
<document><id>37914983</id><passage><infon key="journal">Infect Dis Ther;2023Nov02. doi:10.1007/s40121-023-00882-2</infon><infon key="year">2023</infon><infon key="article-id_pmc">9225255</infon><infon key="type">title</infon><infon key="authors">Kijak GH, Ahani B, Arbetter D, Chuecos F, Gopalakrishnan V, Beloor J, Brady T, Nguyen A, Roe TL, Schuko N, Zhang T, Hobbs FDR, Padilla F, Kelly EJ, Montgomery H, Streicher K, </infon><offset>0</offset><text>Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).</text><annotation id="4"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="51" length="7"/><text>AZD7442</text></annotation><annotation id="5"><infon key="identifier">MESH:C000714167</infon><infon key="type">Chemical</infon><location offset="60" length="11"/><text>Tixagevimab</text></annotation><annotation id="6"><infon key="identifier">MESH:C000714149</infon><infon key="type">Chemical</infon><location offset="72" length="10"/><text>Cilgavimab</text></annotation><annotation id="7"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="118" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>143</offset><text>INTRODUCTION: AZD7442 (tixagevimab/cilgavimab) comprises neutralising monoclonal antibodies (mAbs) that bind to distinct non-overlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Viral evolution during mAb therapy can select for variants with reduced neutralisation susceptibility. We examined treatment-emergent SARS-CoV-2 variants during TACKLE (NCT04723394), a phase 3 study of AZD7442 for early outpatient treatment of coronavirus disease 2019 (COVID-19). METHODS: Non-hospitalised adults with mild-to-moderate COVID-19 were randomised and dosed &lt;= 7 days from symptom onset with AZD7442 (n = 452) or placebo (n = 451). Next-generation sequencing of the spike gene was performed on SARS-CoV-2 reverse-transcription polymerase chain reaction-positive nasopharyngeal swabs at baseline and study days 3, 6, and 15 post dosing. SARS-CoV-2 lineages were assigned using spike nucleotide sequences. Amino acid substitutions were analysed at allele fractions (AF; % of sequence reads represented by substitution) >= 25% and 3% to 25%. In vitro susceptibility to tixagevimab, cilgavimab, and AZD7442 was evaluated for all identified treatment-emergent variants using a pseudotyped microneutralisation assay. RESULTS: Longitudinal spike sequences were available for 461 participants (AZD7442, n = 235; placebo, n = 226) and showed that treatment-emergent variants at any time were rare, with 5 (2.1%) AZD7442 participants presenting >= 1 substitution in tixagevimab/cilgavimab binding sites at AF >= 25%. At AF 3% to 25%, treatment-emergent variants were observed in 15 (6.4%) AZD7442 and 12 (5.3%) placebo participants. All treatment-emergent variants showed in vitro susceptibility to AZD7442. CONCLUSION: These data indicate that AZD7442 creates a high genetic barrier for resistance and is a feasible option for COVID-19 treatment.</text><annotation id="31"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="157" length="7"/><text>AZD7442</text></annotation><annotation id="32"><infon key="identifier">MESH:C000714167</infon><infon key="type">Chemical</infon><location offset="166" length="11"/><text>tixagevimab</text></annotation><annotation id="33"><infon key="identifier">MESH:C000714149</infon><infon key="type">Chemical</infon><location offset="178" length="10"/><text>cilgavimab</text></annotation><annotation id="34"><infon key="identifier">43740568</infon><infon key="type">Gene</infon><location offset="357" length="5"/><text>spike</text></annotation><annotation id="35"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="574" length="7"/><text>AZD7442</text></annotation><annotation id="36"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="616" length="24"/><text>coronavirus disease 2019</text></annotation><annotation id="37"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="642" length="8"/><text>COVID-19</text></annotation><annotation id="38"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="708" length="8"/><text>COVID-19</text></annotation><annotation id="39"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="777" length="7"/><text>AZD7442</text></annotation><annotation id="40"><infon key="identifier">43740568</infon><infon key="type">Gene</infon><location offset="851" length="5"/><text>spike</text></annotation><annotation id="41"><infon key="identifier">43740568</infon><infon key="type">Gene</infon><location offset="1061" length="5"/><text>spike</text></annotation><annotation id="42"><infon key="identifier">MESH:C000714167</infon><infon key="type">Chemical</infon><location offset="1251" length="11"/><text>tixagevimab</text></annotation><annotation id="43"><infon key="identifier">MESH:C000714149</infon><infon key="type">Chemical</infon><location offset="1264" length="10"/><text>cilgavimab</text></annotation><annotation id="44"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="1280" length="7"/><text>AZD7442</text></annotation><annotation id="45"><infon key="identifier">43740568</infon><infon key="type">Gene</infon><location offset="1418" length="5"/><text>spike</text></annotation><annotation id="46"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="1471" length="7"/><text>AZD7442</text></annotation><annotation id="47"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="1588" length="7"/><text>AZD7442</text></annotation><annotation id="48"><infon key="identifier">MESH:C000714167</infon><infon key="type">Chemical</infon><location offset="1641" length="11"/><text>tixagevimab</text></annotation><annotation id="49"><infon key="identifier">MESH:C000714149</infon><infon key="type">Chemical</infon><location offset="1653" length="10"/><text>cilgavimab</text></annotation><annotation id="50"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="1764" length="7"/><text>AZD7442</text></annotation><annotation id="51"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="1874" length="7"/><text>AZD7442</text></annotation><annotation id="52"><infon key="identifier">MESH:C000714168</infon><infon key="type">Chemical</infon><location offset="1920" length="7"/><text>AZD7442</text></annotation><annotation id="53"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="2003" length="8"/><text>COVID-19</text></annotation></passage><relation id="R1"><infon key="score">0.8382</infon><infon key="role1">Chemical|MESH:C000714149</infon><infon key="role2">Gene|43740568</infon><infon key="type">Bind</infon><node refid="0" role="6,7"/></relation><relation id="R2"><infon key="score">0.9976</infon><infon key="role1">Chemical|MESH:C000714167</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="1,3"/></relation><relation id="R3"><infon key="score">0.8495</infon><infon key="role1">Chemical|MESH:C000714168</infon><infon key="role2">Gene|43740568</infon><infon key="type">Association</infon><node refid="2" role="4,7"/></relation><relation id="R4"><infon key="score">0.7847</infon><infon key="role1">Chemical|MESH:C000714167</infon><infon key="role2">Gene|43740568</infon><infon key="type">Bind</infon><node refid="3" role="5,7"/></relation><relation id="R5"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:C000714168</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="0,3"/></relation><relation id="R6"><infon key="score">0.9962</infon><infon key="role1">Chemical|MESH:C000714149</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="2,3"/></relation></document>
<document><id>37915335</id><passage><infon key="journal">J Clin Aesthet Dermatol;2023Oct; 16 (10) 48</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10617900</infon><infon key="type">title</infon><infon key="authors">Kaufman-Janette J, Cazzaniga A, Jacobson A, Eaton Jankov LL, Copeland K, Behfar A, Wyles S, </infon><offset>0</offset><text>Effect of Topical Platelet Extract Daily Serum as a Cosmetic Product to Reduce Facial Redness.</text><annotation id="1"><infon key="identifier">MESH:D005153</infon><infon key="type">Disease</infon><location offset="79" length="14"/><text>Facial Redness</text></annotation></passage><passage><infon key="type">abstract</infon><offset>95</offset><text>Objective: The primary objective of this pilot study was to demonstrate the benefits of topical human platelet extract (plated)  serum for the improvement of persistent facial redness. Methods: This single-center, open-label pilot study evaluated six subjects using (plated)  serum containing human platelet extract (HPE) with Renewosome  technology twice daily for six weeks. The primary efficacy endpoint was a reduction in the Clinical Erythema Assessment (CEA) grade, and a reduction in Patient Subjective Assessment grade at six weeks. Secondary endpoints included an improvement in quality of life related to facial redness, and a reduction in redness by Mexameter  spectrometry measurement. Safety data included monitoring for adverse events. Results: Topical HPE serum demonstrated a statistically significant improvement in facial redness at Week 9 when averaging the Mexameter  spectrometry results across nine regions of the face (p=0.0052). The primary and secondary endpoints were achieved. CEA grade at Week 6 demonstrated that all subjects improved by at least one grade, while one subject improved by two grades. One patient reported dryness. No other adverse effects were observed. Limitations: Study limitations included a small sample size and lack of darker skin types (Fitzpatrick IV-VI). Conclusion: This study demonstrates that topical HPE with Renewosome  technology provides statistically significant reduction in facial redness and is safe and well-tolerated.</text><annotation id="9"><infon key="identifier">MESH:D005153</infon><infon key="type">Disease</infon><location offset="264" length="14"/><text>facial redness</text></annotation><annotation id="10"><infon key="identifier">MESH:D004890</infon><infon key="type">Disease</infon><location offset="534" length="8"/><text>Erythema</text></annotation><annotation id="11"><infon key="identifier">MESH:D005153</infon><infon key="type">Disease</infon><location offset="710" length="14"/><text>facial redness</text></annotation><annotation id="12"><infon key="identifier">MESH:D005153</infon><infon key="type">Disease</infon><location offset="928" length="14"/><text>facial redness</text></annotation><annotation id="13"><infon key="identifier">MESH:D014987</infon><infon key="type">Disease</infon><location offset="1245" length="7"/><text>dryness</text></annotation><annotation id="14"><infon key="identifier">MESH:D006011</infon><infon key="type">Disease</infon><location offset="1397" length="3"/><text>IV-</text></annotation><annotation id="15"><infon key="identifier">MESH:D005153</infon><infon key="type">Disease</infon><location offset="1534" length="14"/><text>facial redness</text></annotation></passage></document>
<document><id>37916385</id><passage><infon key="journal">Haematologica;2023Nov02. doi:10.3324/haematol.2023.284104</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Burkhardt B, </infon><offset>0</offset><text>What can we learn from cancer registries?</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="23" length="6"/><text>cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>42</offset><text>Not available.</text></passage></document>
<document><id>37916741</id><passage><infon key="journal">Allergy;2023Nov02. doi:10.1111/all.15940</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jimenez-Rodriguez TW, de Las Vecillas L, Labella M, Lynch DM, Besz KM, Marquis K, Burgos A, Soriano Gomis V, Lozano I, Ant&amp;#xf3;n RAM, de la Calle FM, Gonz&amp;#xe1;lez Delgado MP, Guti&amp;#xe9;rrez A, Montenegro E, Rodr&amp;#xed;guez F, Fern&amp;#xe1;ndez S&amp;#xe1;nchez FJ, Castells M, </infon><offset>0</offset><text>Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization.</text><annotation id="3"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="29" length="16"/><text>hypersensitivity</text></annotation><annotation id="4"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="59" length="11"/><text>carboplatin</text></annotation><annotation id="5"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="75" length="11"/><text>oxaliplatin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>148</offset><text>BACKGROUND: Drug hypersensitivity reactions (DHRs) to platinum-based drugs are heterogenous and restrict their access, and drug desensitization (DD) has provided a ground-breaking procedure for their re-introduction, although the response is heterogeneous. We aimed to identify the phenotypes, endotypes, and biomarkers of reactions to carboplatin and oxaliplatin and their response to DD. METHODS: Seventy-nine patients presenting with DHRs to oxaliplatin (N = 46) and carboplatin (N = 33) were evaluated at the Allergy Departments of two tertiary care hospitals in Spain. Patient symptoms, skin testing, biomarkers, and outcomes of 267 DDs were retrospectively analyzed. RESULTS: Oxaliplatin-reactive patients presented with type I (74%), cytokine release reaction (CRR) (11%), and mixed (Mx) (15%) phenotypes. In contrast, carboplatin reactive patients presented with predominantly type I (85%) and Mx (15%) but no CRRs. Out of 267 DDs, breakthrough reactions (BTRs) to oxaliplatin occurred twice as frequently as carboplatin (32% vs. 15%; p &lt; .05). Phenotype switching from type I to another phenotype was observed in 46% of oxaliplatin DDs compared to 21% of carboplatin DDs. Tryptase was elevated in type I and Mx reactions, and IL-6 in CRR and Mx, indicating different mechanisms and endotypes. CONCLUSION: Carboplatin and oxaliplatin induced three different types of reactions with defined phenotypes and endotypes amendable to DD. Although most of the initial reactions for both were type I, oxaliplatin presented with unique CRR reactions. During DD, carboplatin reactive patients presented mostly type I BTR, while oxaliplatin-reactive patients frequently switched from type I to CRR, providing a critical difference and the need for personalized DD protocols.</text><annotation id="30"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="160" length="31"/><text>Drug hypersensitivity reactions</text></annotation><annotation id="31"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="193" length="4"/><text>DHRs</text></annotation><annotation id="32"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="202" length="8"/><text>platinum</text></annotation><annotation id="33"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="484" length="11"/><text>carboplatin</text></annotation><annotation id="34"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="500" length="11"/><text>oxaliplatin</text></annotation><annotation id="35"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="585" length="4"/><text>DHRs</text></annotation><annotation id="36"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="593" length="11"/><text>oxaliplatin</text></annotation><annotation id="37"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="618" length="11"/><text>carboplatin</text></annotation><annotation id="38"><infon key="type">Disease</infon><location offset="786" length="3"/><text>DDs</text></annotation><annotation id="39"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="830" length="11"/><text>Oxaliplatin</text></annotation><annotation id="40"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="974" length="11"/><text>carboplatin</text></annotation><annotation id="41"><infon key="type">Disease</infon><location offset="1083" length="3"/><text>DDs</text></annotation><annotation id="42"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="1121" length="11"/><text>oxaliplatin</text></annotation><annotation id="43"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="1165" length="11"/><text>carboplatin</text></annotation><annotation id="44"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="1277" length="11"/><text>oxaliplatin</text></annotation><annotation id="45"><infon key="type">Disease</infon><location offset="1289" length="3"/><text>DDs</text></annotation><annotation id="46"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="1312" length="11"/><text>carboplatin</text></annotation><annotation id="47"><infon key="type">Disease</infon><location offset="1324" length="3"/><text>DDs</text></annotation><annotation id="48"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1383" length="4"/><text>IL-6</text></annotation><annotation id="49"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="1462" length="11"/><text>Carboplatin</text></annotation><annotation id="50"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="1478" length="11"/><text>oxaliplatin</text></annotation><annotation id="51"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="1649" length="11"/><text>oxaliplatin</text></annotation><annotation id="52"><infon key="identifier">MESH:D016190</infon><infon key="type">Chemical</infon><location offset="1709" length="11"/><text>carboplatin</text></annotation><annotation id="53"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="1774" length="11"/><text>oxaliplatin</text></annotation></passage><relation id="R1"><infon key="score">0.9418</infon><infon key="role1">Chemical|MESH:D010984</infon><infon key="role2">Disease|MESH:D004342</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="5,3"/></relation><relation id="R2"><infon key="score">0.9974</infon><infon key="role1">Chemical|MESH:D000077150</infon><infon key="role2">Disease|MESH:D004342</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="2,0"/></relation><relation id="R3"><infon key="score">0.9983</infon><infon key="role1">Chemical|MESH:D016190</infon><infon key="role2">Disease|MESH:D004342</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="1,0"/></relation><relation id="R4"><infon key="score">0.8508</infon><infon key="role1">Chemical|MESH:D000077150</infon><infon key="role2">Chemical|MESH:D016190</infon><infon key="type">Comparison</infon><node refid="3" role="2,1"/></relation></document>
<document><id>37917093</id><passage><infon key="journal">Hum Gene Ther;2023Nov02. doi:10.1089/hum.2023.144</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li D, Jiang L, Zhou W, Huang Y, Yang Y, Li J, Yang J, Wang F, Li J, Zhang Y, Yan F, Gao H, Guo X, Xv Q, Tan S, Wei YQ, Wang W, </infon><offset>0</offset><text>CAR-T Cell Therapy Decreases Distant Metastasis and Inhibits Local Recurrence Post-surgery in Mice.</text><annotation id="2"><infon key="identifier">27220</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3169</infon><location offset="0" length="5"/><text>CAR-T</text></annotation><annotation id="3"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="37" length="10"/><text>Metastasis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>Distant metastasis and primary tumor relapse are the two main hurdles to the success of surgical treatment for cancer patients. Circulating tumor cells (CTCs) and incomplete surgical resection are the primary cause of distant metastasis and recurrence of tumors respectively. Chimeric antigen receptor (CAR)-modified T cells targets residual carcinomas and CTCs hold the potential to inhibit primary recurrence and reduce tumor metastasis, but the experimental evidence is lacking. Here, we developed a surgery-induced tumor metastasis model in immunocompetent mice to investigate the efficacy of CAR-T cells therapy in preventing metastasis and local recurrence. We observed that subcutaneous tumor resection has induced a large number of CTCs intravasated into circulation. EpCAM-specific CAR-T was effective in clearing CTCs following surgical removal of the tumor. This resulted in less pulmonary metastasis and longer survival in mice when compared to mice treated with surgery followed by Mock-T cells. In addition, the local relapse was obviously inhibited at the surgical site followed by EpCAM-CAR-T cell treatment. This study demonstrated that CAR-T cell therapy can be an adjuvant treatment following surgery to prevent tumor metastasis and inhibit primary tumor relapse for cancer patients.</text><annotation id="29"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="108" length="10"/><text>metastasis</text></annotation><annotation id="30"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="131" length="5"/><text>tumor</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="211" length="6"/><text>cancer</text></annotation><annotation id="32"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="240" length="5"/><text>tumor</text></annotation><annotation id="33"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="326" length="10"/><text>metastasis</text></annotation><annotation id="34"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="355" length="6"/><text>tumors</text></annotation><annotation id="35"><infon key="identifier">9970</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="376" length="25"/><text>Chimeric antigen receptor</text></annotation><annotation id="36"><infon key="identifier">9970</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="403" length="3"/><text>CAR</text></annotation><annotation id="37"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="442" length="10"/><text>carcinomas</text></annotation><annotation id="38"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="522" length="16"/><text>tumor metastasis</text></annotation><annotation id="39"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="619" length="16"/><text>tumor metastasis</text></annotation><annotation id="40"><infon key="identifier">27220</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3169</infon><location offset="697" length="5"/><text>CAR-T</text></annotation><annotation id="41"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="731" length="10"/><text>metastasis</text></annotation><annotation id="42"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="794" length="5"/><text>tumor</text></annotation><annotation id="43"><infon key="identifier">17075</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1764</infon><location offset="876" length="5"/><text>EpCAM</text></annotation><annotation id="44"><infon key="identifier">27220</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3169</infon><location offset="891" length="5"/><text>CAR-T</text></annotation><annotation id="45"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="962" length="5"/><text>tumor</text></annotation><annotation id="46"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="991" length="20"/><text>pulmonary metastasis</text></annotation><annotation id="47"><infon key="identifier">CVCL:C0UQ</infon><infon key="type">CellLine</infon><location offset="1095" length="6"/><text>Mock-T</text></annotation><annotation id="48"><infon key="identifier">17075</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1764</infon><location offset="1197" length="5"/><text>EpCAM</text></annotation><annotation id="49"><infon key="identifier">27220</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3169</infon><location offset="1203" length="5"/><text>CAR-T</text></annotation><annotation id="50"><infon key="identifier">27220</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3169</infon><location offset="1254" length="5"/><text>CAR-T</text></annotation><annotation id="51"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="1331" length="16"/><text>tumor metastasis</text></annotation><annotation id="52"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1368" length="5"/><text>tumor</text></annotation><annotation id="53"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1386" length="6"/><text>cancer</text></annotation></passage><relation id="R1"><infon key="score">0.9988</infon><infon key="role1">Disease|MESH:D009362</infon><infon key="role2">Gene|27220</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9985</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|9970</infon><infon key="type">Association</infon><node refid="1" role="10,8"/></relation><relation id="R3"><infon key="score">0.9824</infon><infon key="role1">Disease|MESH:D009362</infon><infon key="role2">Gene|9970</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="11,8"/></relation><relation id="R4"><infon key="score">0.9621</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|27220</infon><infon key="type">Association</infon><node refid="3" role="18,17"/></relation><relation id="R5"><infon key="score">0.9894</infon><infon key="role1">Gene|17075</infon><infon key="role2">Gene|27220</infon><infon key="type">Association</infon><node refid="4" role="16,17"/></relation></document>
<document><id>37917443</id><passage><infon key="journal">Psychol Rev;2023Nov02. doi:10.1037/rev0000452</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Feldman J, </infon><offset>0</offset><text>Probabilistic origins of compositional mental representations.</text></passage><passage><infon key="type">abstract</infon><offset>63</offset><text>The representation of complex phenomena via combinations of simple discrete features is a hallmark of human cognition. But it is not clear exactly how (or whether) discrete features can effectively represent the complex probabilistic fabric of the environment. This article introduces information-theoretic tools for quantifying the fidelity and efficiency of a featural representation with respect to a probability model. In this framework, a feature or combination of features is "faithful" to the extent that knowing the value of the features reduces uncertainty about the true state of the world. In a single dimension, a discrete feature is faithful if the values of the feature correspond isomorphically to distinct classes in the probability model. But in multiple dimensions, the situation is more complicated: The fidelity of each feature depends on the direction in multidimensional feature space in which the feature is projected from the underlying distribution. More interestingly, distributions may be more effectively represented by combinations of projected features-that is, compositionality. For any given distribution, a variety of compositional forms (features and combination rules) are possible, which can be quite different from one another, entailing different degrees of fidelity, different numbers of features, and even different induced regularities. This article proposes three specific criteria for a compositional representation: fidelity, simplicity, and robustness. The information-theoretic framework introduces a new and potentially useful way to look at the problem of compositionality in human mental representation. (PsycInfo Database Record (c) 2023 APA, all rights reserved).</text></passage></document>
<document><id>37917794</id><passage><infon key="journal">Proc Natl Acad Sci U S A;2023Nov07; 120 (45) 2306627120. doi:10.1073/pnas.2306627120</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ram S, Erez J, </infon><offset>0</offset><text>Anion elements incorporation into corals skeletons: Experimental approach for biomineralization and paleo-proxies.</text><annotation id="1"><infon key="identifier">MESH:D000838</infon><infon key="type">Chemical</infon><location offset="0" length="5"/><text>Anion</text></annotation></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>The elemental composition of coral skeletons provides important information for palaeoceanographic reconstructions and coral biomineralization. Partition of anions and their stable isotopes in coral skeleton enables the reconstruction of past seawater carbonate chemistry, paleo-CO2, and past climates. Here, we investigated the partition of B, S, As, Br, I, and Mo into the skeletons of two corals, Acropora cervicornis and Pocillopora damicornis, as a function of calcium and carbonate concentrations.* Anion-to-calcium ratio in the corals (An/CaCoral) were correlated with the equivalent ratios in the culturing seawater (An/CO32-SW). Negative intercepts of these relationships suggest a higher CO32- concentration in the coral extracellular calcifying fluid (ECF) relative to seawater, from which the skeleton precipitates. The enrichment factor of CO32- at the ECF was 2.5 for A. cervicornis and 1.9 for P. damicornis, consistent with their relative calcification rates. The CO32-ECF concentrations thus calculated are similar to those proposed by previous studies based on B/Ca coupled with delta11B, as well as by direct measurements using microsensors and fluorescent dyes. Rayleigh fractionation modeling demonstrates a uniform Ca utilization at various CaSW concentrations, providing further evidence that coral calcification occurs directly from a semiclosed seawater reservoir as reported previously. The partition coefficients reported in this study for B, S, As, Br, I, and Mo open up wide possibilities for past ocean chemistry reconstructions based on Br having long residence time (~160 Ma) in the ocean. Other elements like S, Mo, B, as well as pCO2 may also be calculated based on these elements in fossil coral.</text><annotation id="34"><infon key="identifier">MESH:D002254</infon><infon key="type">Chemical</infon><location offset="367" length="9"/><text>carbonate</text></annotation><annotation id="35"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="394" length="3"/><text>CO2</text></annotation><annotation id="36"><infon key="identifier">MESH:D001895</infon><infon key="type">Chemical</infon><location offset="457" length="1"/><text>B</text></annotation><annotation id="37"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="460" length="1"/><text>S</text></annotation><annotation id="38"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="463" length="2"/><text>As</text></annotation><annotation id="39"><infon key="identifier">MESH:D001966</infon><infon key="type">Chemical</infon><location offset="467" length="2"/><text>Br</text></annotation><annotation id="40"><infon key="identifier">MESH:D007455</infon><infon key="type">Chemical</infon><location offset="471" length="1"/><text>I</text></annotation><annotation id="41"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="564" length="2"/><text>as</text></annotation><annotation id="42"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="581" length="7"/><text>calcium</text></annotation><annotation id="43"><infon key="identifier">MESH:D002254</infon><infon key="type">Chemical</infon><location offset="593" length="9"/><text>carbonate</text></annotation><annotation id="44"><infon key="identifier">MESH:D000838</infon><infon key="type">Chemical</infon><location offset="620" length="5"/><text>Anion</text></annotation><annotation id="45"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="629" length="7"/><text>calcium</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="813" length="5"/><text>CO32-</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="968" length="5"/><text>CO32-</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1095" length="8"/><text>CO32-ECF</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1212" length="8"/><text>delta11B</text></annotation><annotation id="50"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1222" length="2"/><text>as</text></annotation><annotation id="51"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1230" length="2"/><text>as</text></annotation><annotation id="52"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1378" length="4"/><text>CaSW</text></annotation><annotation id="53"><infon key="identifier">MESH:D002114</infon><infon key="type">Disease</infon><location offset="1431" length="19"/><text>coral calcification</text></annotation><annotation id="54"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1504" length="2"/><text>as</text></annotation><annotation id="55"><infon key="identifier">MESH:D001895</infon><infon key="type">Chemical</infon><location offset="1582" length="1"/><text>B</text></annotation><annotation id="56"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="1585" length="1"/><text>S</text></annotation><annotation id="57"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1588" length="2"/><text>As</text></annotation><annotation id="58"><infon key="identifier">MESH:D001966</infon><infon key="type">Chemical</infon><location offset="1592" length="2"/><text>Br</text></annotation><annotation id="59"><infon key="identifier">MESH:D007455</infon><infon key="type">Chemical</infon><location offset="1596" length="1"/><text>I</text></annotation><annotation id="60"><infon key="identifier">MESH:D001966</infon><infon key="type">Chemical</infon><location offset="1683" length="2"/><text>Br</text></annotation><annotation id="61"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="1757" length="1"/><text>S</text></annotation><annotation id="62"><infon key="identifier">MESH:D001895</infon><infon key="type">Chemical</infon><location offset="1764" length="1"/><text>B</text></annotation><annotation id="63"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1767" length="2"/><text>as</text></annotation><annotation id="64"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1775" length="2"/><text>as</text></annotation><annotation id="65"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1778" length="4"/><text>pCO2</text></annotation></passage><relation id="R1"><infon key="score">0.4875</infon><infon key="role1">Chemical|MESH:D000838</infon><infon key="role2">Chemical|MESH:D002118</infon><infon key="type">Association</infon><node refid="0" role="12,10"/></relation><relation id="R2"><infon key="score">0.9923</infon><infon key="role1">Chemical|MESH:D001151</infon><infon key="role2">Disease|MESH:D002114</infon><infon key="type">Association</infon><node refid="1" role="24,23"/></relation></document>
<document><id>37918145</id><passage><infon key="journal">Mar Pollut Bull;2023Oct30; 197 115702. doi:10.1016/j.marpolbul.2023.115702</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rashid A, Fang C, Qin D, Zhang Y, Nkinahamira F, Bo J, Sun Q, </infon><offset>0</offset><text>Spatiotemporal profile and ecological impacts of major and trace elements in surface sediments of marginal seas of the Arctic and Northern Pacific Oceans.</text></passage><passage><infon key="type">abstract</infon><offset>155</offset><text>The status and ecological impacts of sedimentary elements of the marginal seas of Arctic and Northern Pacific Oceans was investigated during 2016 to 2018 by using inductively coupled plasma mass spectrometry. Industrial (0.006 mg kg-1-64.6 g kg-1), precious (0.003-43.8 mg kg-1), rare earth (0.006-112.9 mg kg-1), and heavy metal (0.009-398.9 mg kg-1) elements showed spatial variation, and temporal uniformity. The results indicated SigmaREEs and light REEs enrichment compared to chondrite and heavy REEs, respectively, while nonsignificant positive and negative deltaCe and deltaEu anomalies existed, respectively. High contamination and extreme enrichment of priority control, industrial (As, Mo, Re, Sb), precious (Au, Ir, Pd, Pt, and Ru) and RE elements indicated potential moderate to high ecological and biological risks. The study highlighted the ecological importance and fragile nature of these ecosystems and calls for an urgent action to ensure sustainability of these ecosystems.</text><annotation id="10"><infon key="identifier">MESH:D008674</infon><infon key="type">Chemical</infon><location offset="435" length="10"/><text>rare earth</text></annotation><annotation id="11"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="848" length="2"/><text>As</text></annotation><annotation id="12"><infon key="identifier">MESH:D012211</infon><infon key="type">Chemical</infon><location offset="856" length="2"/><text>Re</text></annotation><annotation id="13"><infon key="identifier">MESH:D000965</infon><infon key="type">Chemical</infon><location offset="860" length="2"/><text>Sb</text></annotation><annotation id="14"><infon key="identifier">MESH:D006046</infon><infon key="type">Chemical</infon><location offset="875" length="2"/><text>Au</text></annotation><annotation id="15"><infon key="identifier">MESH:D007495</infon><infon key="type">Chemical</infon><location offset="879" length="2"/><text>Ir</text></annotation><annotation id="16"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="883" length="2"/><text>Pd</text></annotation><annotation id="17"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="887" length="2"/><text>Pt</text></annotation><annotation id="18"><infon key="identifier">MESH:D012428</infon><infon key="type">Chemical</infon><location offset="895" length="2"/><text>Ru</text></annotation><annotation id="19"><infon key="identifier">MESH:D012211</infon><infon key="type">Chemical</infon><location offset="903" length="2"/><text>RE</text></annotation></passage></document>
<document><id>37918495</id><passage><infon key="journal">Int J Pharm;2023Oct31 123567. doi:10.1016/j.ijpharm.2023.123567</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yang C, Yang S, Fang S, Li L, Jing J, Liu W, Wang C, Li R, Lu Y, </infon><offset>0</offset><text>PLGA Nanoparticles Enhanced Cardio-Protection of Scutellarin and Paeoniflorin against Isoproterenol-Induced Myocardial Ischemia in Rats.</text><annotation id="5"><infon key="identifier">MESH:D000077182</infon><infon key="type">Chemical</infon><location offset="0" length="4"/><text>PLGA</text></annotation><annotation id="6"><infon key="identifier">MESH:C484876</infon><infon key="type">Chemical</infon><location offset="49" length="11"/><text>Scutellarin</text></annotation><annotation id="7"><infon key="identifier">MESH:C015423</infon><infon key="type">Chemical</infon><location offset="65" length="12"/><text>Paeoniflorin</text></annotation><annotation id="8"><infon key="identifier">MESH:D007545</infon><infon key="type">Chemical</infon><location offset="86" length="13"/><text>Isoproterenol</text></annotation><annotation id="9"><infon key="identifier">MESH:D017202</infon><infon key="type">Disease</infon><location offset="108" length="19"/><text>Myocardial Ischemia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>137</offset><text>This study aims to examine the impact of the microfluidic preparation process on the quality of poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) co-delivered with scutellarin (SCU) and paeoniflorin (PAE) in comparison to a conventional emulsification method and to evaluatethe potential cardio-protective effect of SCU-PAE PLGA NPs produced through emulsification method. As compared with microfluidics, the nanoparticles prepared by emulsification method exhibited a smaller size, higher encapsulation efficiency, higher drug loading and lower viscosity for injection. Subsequently, a rat myocardial ischemia (MI) was established using male Sprague-Dawley (SD) rats (250 +- 20 g) subcutaneously injected with 85 mg/kg isoproterenol (ISO) for two consecutive days. The pharmacokinetic findings demonstrated that our SCU-PAE PLGA NPs exhibited prolonged blood circulation time in MI rats, leading to increased levels of SCU and PAE in the heart. This resulted in significant improvements in electrocardiogram and cardiac index, as well as reduced serum levels of CK, LDH, AST. Histopathological analysis using H&amp;E and TUNEL staining provided further evidence of improved cardiac function and decreased apoptosis. Additionally, experiments measuring SOD, MDA, GSH, NO, TNF-alpha and IL-6 levels indicated that SCU-PAE PLGA NPs may effectively treat MI through oxidative stress and inflammatory pathways, thereby establishing it as a promising therapeutic intervention.</text><annotation id="33"><infon key="identifier">MESH:D000077182</infon><infon key="type">Chemical</infon><location offset="233" length="30"/><text>poly (lactic-co-glycolic acid)</text></annotation><annotation id="34"><infon key="identifier">MESH:D000077182</infon><infon key="type">Chemical</infon><location offset="265" length="4"/><text>PLGA</text></annotation><annotation id="35"><infon key="identifier">MESH:C484876</infon><infon key="type">Chemical</infon><location offset="309" length="11"/><text>scutellarin</text></annotation><annotation id="36"><infon key="identifier">MESH:C484876</infon><infon key="type">Chemical</infon><location offset="322" length="3"/><text>SCU</text></annotation><annotation id="37"><infon key="identifier">MESH:C015423</infon><infon key="type">Chemical</infon><location offset="331" length="12"/><text>paeoniflorin</text></annotation><annotation id="38"><infon key="identifier">MESH:C015423</infon><infon key="type">Chemical</infon><location offset="345" length="3"/><text>PAE</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="461" length="7"/><text>SCU-PAE</text></annotation><annotation id="40"><infon key="identifier">MESH:D000077182</infon><infon key="type">Chemical</infon><location offset="469" length="4"/><text>PLGA</text></annotation><annotation id="41"><infon key="identifier">MESH:D017202</infon><infon key="type">Disease</infon><location offset="736" length="19"/><text>myocardial ischemia</text></annotation><annotation id="42"><infon key="identifier">MESH:D007545</infon><infon key="type">Chemical</infon><location offset="865" length="13"/><text>isoproterenol</text></annotation><annotation id="43"><infon key="identifier">MESH:D007545</infon><infon key="type">Chemical</infon><location offset="880" length="3"/><text>ISO</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="962" length="7"/><text>SCU-PAE</text></annotation><annotation id="45"><infon key="identifier">MESH:D000077182</infon><infon key="type">Chemical</infon><location offset="970" length="4"/><text>PLGA</text></annotation><annotation id="46"><infon key="identifier">MESH:C484876</infon><infon key="type">Chemical</infon><location offset="1065" length="3"/><text>SCU</text></annotation><annotation id="47"><infon key="identifier">MESH:C015423</infon><infon key="type">Chemical</infon><location offset="1073" length="3"/><text>PAE</text></annotation><annotation id="48"><infon key="identifier">MESH:D006371</infon><infon key="type">Chemical</infon><location offset="1255" length="3"/><text>H&amp;E</text></annotation><annotation id="49"><infon key="identifier">MESH:D015104</infon><infon key="type">Chemical</infon><location offset="1399" length="3"/><text>MDA</text></annotation><annotation id="50"><infon key="identifier">MESH:D005978</infon><infon key="type">Chemical</infon><location offset="1404" length="3"/><text>GSH</text></annotation><annotation id="51"><infon key="identifier">24835</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="1413" length="9"/><text>TNF-alpha</text></annotation><annotation id="52"><infon key="identifier">24498</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1427" length="4"/><text>IL-6</text></annotation><annotation id="53"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1454" length="7"/><text>SCU-PAE</text></annotation><annotation id="54"><infon key="identifier">MESH:D000077182</infon><infon key="type">Chemical</infon><location offset="1462" length="4"/><text>PLGA</text></annotation><annotation id="55"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1525" length="12"/><text>inflammatory</text></annotation></passage><relation id="R1"><infon key="score">0.9889</infon><infon key="role1">Chemical|MESH:D000077182</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Association</infon><node refid="0" role="29,31"/></relation><relation id="R2"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:C484876</infon><infon key="role2">Disease|MESH:D017202</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="1,4"/></relation><relation id="R3"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C015423</infon><infon key="role2">Disease|MESH:D017202</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="2,4"/></relation><relation id="R4"><infon key="score">0.7218</infon><infon key="role1">Chemical|MESH:D000077182</infon><infon key="role2">Chemical|MESH:D007545</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="0,3"/></relation><relation id="R5"><infon key="score">0.8843</infon><infon key="role1">Chemical|MESH:C484876</infon><infon key="role2">Chemical|MESH:D007545</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="1,3"/></relation><relation id="R6"><infon key="score">0.5924</infon><infon key="role1">Chemical|MESH:C015423</infon><infon key="role2">Chemical|MESH:D007545</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="2,3"/></relation><relation id="R7"><infon key="score">0.9955</infon><infon key="role1">Chemical|MESH:D000077182</infon><infon key="role2">Disease|MESH:D017202</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="0,4"/></relation><relation id="R8"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D007545</infon><infon key="role2">Disease|MESH:D017202</infon><infon key="type">Positive_Correlation</infon><node refid="7" role="3,4"/></relation><relation id="R9"><infon key="score">0.9949</infon><infon key="role1">Chemical|MESH:C015423</infon><infon key="role2">Chemical|MESH:D000077182</infon><infon key="type">Positive_Correlation</infon><node refid="8" role="2,0"/></relation><relation id="R10"><infon key="score">0.9705</infon><infon key="role1">Chemical|MESH:C484876</infon><infon key="role2">Chemical|MESH:D000077182</infon><infon key="type">Positive_Correlation</infon><node refid="9" role="1,0"/></relation></document>
<document><id>37918845</id><passage><infon key="journal">J Nucl Med;2023Nov; 64 (Suppl 2) 39. doi:10.2967/jnumed.122.264865</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Thackeray JT, Lavine KJ, Liu Y, </infon><offset>0</offset><text>Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology.</text><annotation id="1"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="8" length="12"/><text>Inflammation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>75</offset><text>Growing evidence implicates the immune system as a critical mediator of cardiovascular disease progression and a viable therapeutic target. Increased inflammatory cell activity is seen in the full spectrum of disorders from early-stage atherosclerosis through myocardial infarction, cardiomyopathy, and chronic heart failure. Although therapeutic strategies to modulate inflammation have shown promise in preclinical animal models, efficacy in patients has been modest owing in part to the variable severity of inflammation across individuals. The diverse leukocyte subpopulations involved in different aspects of heart disease pose a challenge to effective therapy, wherein adverse and beneficial aspects of inflammation require appropriate balance. Noninvasive molecular imaging enables tissue-level interrogation of inflammatory cells in the heart and vasculature to provide mechanistic and temporal insights into disease progression. Although clinical imaging has relied on 18F-FDG as a nonselective and crude marker of inflammatory cell activity, new imaging probes targeting cell surface markers of different leukocyte subpopulations present the opportunity to visualize and quantify distinct phases of cardiac and vessel wall inflammation. Similarly, therapies are evolving to more effectively isolate adverse from beneficial cell populations. This parallel development of immunocardiology and molecular imaging provides the opportunity to refine treatments using imaging guidance, building toward mechanism-based precision medicine. Here, we discuss progress in molecular imaging of immune cells in cardiology from use of 18F-FDG in the past to the present expansion of the radiotracer arsenal and then to a future theranostic paradigm of tracer-therapy compound pairs with shared targets. We then highlight the critical experiments required to advance the field from preclinical concept to clinical reality.</text><annotation id="17"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="147" length="22"/><text>cardiovascular disease</text></annotation><annotation id="18"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="225" length="12"/><text>inflammatory</text></annotation><annotation id="19"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="311" length="15"/><text>atherosclerosis</text></annotation><annotation id="20"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="335" length="21"/><text>myocardial infarction</text></annotation><annotation id="21"><infon key="identifier">MESH:D009202</infon><infon key="type">Disease</infon><location offset="358" length="14"/><text>cardiomyopathy</text></annotation><annotation id="22"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="386" length="13"/><text>heart failure</text></annotation><annotation id="23"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="445" length="12"/><text>inflammation</text></annotation><annotation id="24"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="586" length="12"/><text>inflammation</text></annotation><annotation id="25"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="689" length="13"/><text>heart disease</text></annotation><annotation id="26"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="784" length="12"/><text>inflammation</text></annotation><annotation id="27"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="894" length="12"/><text>inflammatory</text></annotation><annotation id="28"><infon key="identifier">MESH:D019788</infon><infon key="type">Chemical</infon><location offset="1053" length="7"/><text>18F-FDG</text></annotation><annotation id="29"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1099" length="12"/><text>inflammatory</text></annotation><annotation id="30"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1284" length="36"/><text>cardiac and vessel wall inflammation</text></annotation><annotation id="31"><infon key="identifier">MESH:D019788</infon><infon key="type">Chemical</infon><location offset="1705" length="7"/><text>18F-FDG</text></annotation></passage><relation id="R1"><infon key="score">0.9726</infon><infon key="role1">Chemical|MESH:D019788</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Association</infon><node refid="0" role="12,13"/></relation></document>
<document><id>37919195</id><passage><infon key="journal">Asian J Surg;2023Oct31. doi:10.1016/j.asjsur.2023.10.092</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hu Z, Yang Y, Zhang T, Liu L, </infon><offset>0</offset><text>Giant retroperitoneal hematoma complicating minimally invasive lumbar spine surgery: A case report.</text><annotation id="1"><infon key="identifier">MESH:D006406</infon><infon key="type">Disease</infon><location offset="6" length="24"/><text>retroperitoneal hematoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>100</offset></passage></document>
<document><id>37919545</id><passage><infon key="journal">Neurocrit Care;2023Nov02. doi:10.1007/s12028-023-01867-2</infon><infon key="year">2023</infon><infon key="article-id_pmc">3138486</infon><infon key="type">title</infon><infon key="authors">Avadhani R, Ziai WC, Thompson RE, Mould WA, Lane K, Nanni A, Iacobelli M, Sharrock MF, Sansing LH, Van Eldik LJ, Hanley DF, BEACH trial consortium, </infon><offset>0</offset><text>Clinical Trial Protocol for BEACH: A Phase 2a Study of MW189 in Patients with Acute Nontraumatic Intracerebral Hemorrhage.</text><annotation id="3"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="28" length="5"/><text>BEACH</text></annotation><annotation id="4"><infon key="identifier">MESH:C573580</infon><infon key="type">Chemical</infon><location offset="55" length="5"/><text>MW189</text></annotation><annotation id="5"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="97" length="24"/><text>Intracerebral Hemorrhage</text></annotation></passage><passage><infon key="type">abstract</infon><offset>123</offset><text>Patients with acute spontaneous intracerebral hemorrhage (ICH) develop secondary neuroinflammation and cerebral edema that can further damage the brain and lead to increased risk of neurologic complications. Preclinical studies in animal models of acute brain injury have shown that a novel small-molecule drug candidate, MW01-6-189WH (MW189), decreases neuroinflammation and cerebral edema and improves functional outcomes. MW189 was also safe and well tolerated in phase 1 studies in healthy adults. The proof-of-concept phase 2a Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) clinical trial is a first-in-patient, multicenter, randomized, double-blind, placebo-controlled trial. It is designed to determine the safety and tolerability of MW189 in patients with acute ICH, identify trends in potential mitigation of neuroinflammation and cerebral edema, and assess effects on functional outcomes. A total of 120 participants with nontraumatic ICH will be randomly assigned 1:1 to receive intravenous MW189 (0.25 mg/kg) or placebo (saline) within 24 h of symptom onset and every 12 h for up to 5 days or until hospital discharge. The 120-participant sample size (60 per group) will allow testing of the null hypothesis of noninferiority with a tolerance limit of 12% and assuming a "worst-case" safety assumption of 10% rate of death in each arm with 10% significance and 80% power. The primary outcome is all-cause mortality at 7 days post randomization between treatment arms. Secondary end points include all-cause mortality at 30 days, perihematomal edema volume after symptom onset, adverse events, vital signs, pharmacokinetics of MW189, and inflammatory cytokine concentrations in plasma (and cerebrospinal fluid if available). Other exploratory end points are functional outcomes collected on days 30, 90, and 180. BEACH will provide important information about the utility of targeting neuroinflammation in ICH and will inform the design of future larger trials of acute central nervous system injury.</text><annotation id="34"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="155" length="24"/><text>intracerebral hemorrhage</text></annotation><annotation id="35"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="181" length="3"/><text>ICH</text></annotation><annotation id="36"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="204" length="17"/><text>neuroinflammation</text></annotation><annotation id="37"><infon key="identifier">MESH:D001929</infon><infon key="type">Disease</infon><location offset="226" length="14"/><text>cerebral edema</text></annotation><annotation id="38"><infon key="identifier">MESH:D002493</infon><infon key="type">Disease</infon><location offset="305" length="24"/><text>neurologic complications</text></annotation><annotation id="39"><infon key="identifier">MESH:D001930</infon><infon key="type">Disease</infon><location offset="377" length="12"/><text>brain injury</text></annotation><annotation id="40"><infon key="identifier">MESH:C573580</infon><infon key="type">Chemical</infon><location offset="445" length="12"/><text>MW01-6-189WH</text></annotation><annotation id="41"><infon key="identifier">MESH:C573580</infon><infon key="type">Chemical</infon><location offset="459" length="5"/><text>MW189</text></annotation><annotation id="42"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="477" length="17"/><text>neuroinflammation</text></annotation><annotation id="43"><infon key="identifier">MESH:D001929</infon><infon key="type">Disease</infon><location offset="499" length="14"/><text>cerebral edema</text></annotation><annotation id="44"><infon key="identifier">MESH:C573580</infon><infon key="type">Chemical</infon><location offset="548" length="5"/><text>MW189</text></annotation><annotation id="45"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="669" length="5"/><text>Edema</text></annotation><annotation id="46"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="690" length="24"/><text>IntraCerebral Hemorrhage</text></annotation><annotation id="47"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="716" length="5"/><text>BEACH</text></annotation><annotation id="48"><infon key="identifier">MESH:C573580</infon><infon key="type">Chemical</infon><location offset="885" length="5"/><text>MW189</text></annotation><annotation id="49"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="914" length="3"/><text>ICH</text></annotation><annotation id="50"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="962" length="17"/><text>neuroinflammation</text></annotation><annotation id="51"><infon key="identifier">MESH:D001929</infon><infon key="type">Disease</infon><location offset="984" length="14"/><text>cerebral edema</text></annotation><annotation id="52"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="1089" length="3"/><text>ICH</text></annotation><annotation id="53"><infon key="identifier">MESH:C573580</infon><infon key="type">Chemical</infon><location offset="1146" length="5"/><text>MW189</text></annotation><annotation id="54"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1473" length="5"/><text>death</text></annotation><annotation id="55"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="1699" length="5"/><text>edema</text></annotation><annotation id="56"><infon key="identifier">MESH:C573580</infon><infon key="type">Chemical</infon><location offset="1782" length="5"/><text>MW189</text></annotation><annotation id="57"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1793" length="12"/><text>inflammatory</text></annotation><annotation id="58"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="1968" length="5"/><text>BEACH</text></annotation><annotation id="59"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="2040" length="17"/><text>neuroinflammation</text></annotation><annotation id="60"><infon key="identifier">MESH:D002543</infon><infon key="type">Disease</infon><location offset="2061" length="3"/><text>ICH</text></annotation><annotation id="61"><infon key="identifier">MESH:D002493</infon><infon key="type">Disease</infon><location offset="2125" length="29"/><text>central nervous system injury</text></annotation></passage><relation id="R1"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:C573580</infon><infon key="role2">Disease|MESH:D001929</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="9,12"/></relation><relation id="R2"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:C573580</infon><infon key="role2">Disease|MESH:D002543</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:C573580</infon><infon key="role2">Disease|MESH:D000090862</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="9,11"/></relation><relation id="R4"><infon key="score">0.9978</infon><infon key="role1">Chemical|MESH:C573580</infon><infon key="role2">Disease|MESH:D001930</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="9,8"/></relation><relation id="R5"><infon key="score">0.9966</infon><infon key="role1">Chemical|MESH:C573580</infon><infon key="role2">Disease|MESH:D004487</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="25,24"/></relation></document>
<document><id>37919895</id><passage><infon key="journal">Mol Plant;2023Nov02. doi:10.1016/j.molp.2023.11.001</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang N, Gui S, Wang Y, </infon><offset>0</offset><text>LAZing Around: The Intricate Dance of Amyloplast Sedimentation and Gravity Sensing in Plants.</text></passage><passage><infon key="type">abstract</infon><offset>94</offset></passage></document>
<document><id>37920945</id><passage><infon key="journal">Alzheimers Dement;2023Nov03. doi:10.1002/alz.13528</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Woo MS, Tissot C, Lantero-Rodriguez J, Snellman A, Therriault J, Rahmouni N, Macedo AC, Servaes S, Wang YT, Arias JF, Hosseini SA, Chamoun M, Lussier FZ, Benedet AL, Ashton NJ, Karikari TK, Triana-Baltzer G, Kolb HC, Stevenson J, Mayer C, Kobayashi E, Massarweh G, Friese MA, Pascoal TA, Gauthier S, Zetterberg H, Blennow K, Rosa-Neto P, </infon><offset>0</offset><text>Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-beta positive individuals.</text><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="7" length="8"/><text>pTau-217</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="36" length="3"/><text>NTA</text></annotation><annotation id="6"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="73" length="3"/><text>tau</text></annotation><annotation id="7"><infon key="identifier">351</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56379</infon><location offset="95" length="12"/><text>amyloid-beta</text></annotation></passage><passage><infon key="type">abstract</infon><offset>130</offset><text>INTRODUCTION: We set out to identify tau PET-positive (A+T+) individuals among amyloid-beta (Abeta) positive participants using plasma biomarkers. METHODS: In this cross-sectional study we assessed 234 participants across the AD continuum who were evaluated by amyloid PET with [18 F]AZD4694 and tau-PET with [18 F]MK6240 and measured plasma levels of total tau, pTau-181, pTau-217, pTau-231, and N-terminal tau (NTA-tau). We evaluated the performances of plasma biomarkers to predict tau positivity in Abeta+ individuals. RESULTS: Highest associations with tau positivity in Abeta+ individuals were found for plasma pTau-217 (AUC [CI95% ] = 0.89 [0.82, 0.96]) and NTA-tau (AUC [CI95% ] = 0.88 [0.91, 0.95]). Combining pTau-217 and NTA-tau resulted in the strongest agreement (Cohen's Kappa = 0.74, CI95%  = 0.57/0.90, sensitivity = 92%, specificity = 81%) with PET for classifying tau positivity. DISCUSSION: The potential for identifying tau accumulation in later Braak stages will be useful for patient stratification and prognostication in treatment trials and in clinical practice. HIGHLIGHTS: We found that in a cohort without pre-selection pTau-181, pTau-217, and NTA-tau showed the highest association with tau PET positivity. We found that in Abeta+ individuals pTau-217 and NTA-tau showed the highest association with tau PET positivity. Combining pTau-217 and NTA-tau resulted in the strongest agreement with the tau PET-based classification.</text><annotation id="31"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="167" length="3"/><text>tau</text></annotation><annotation id="32"><infon key="identifier">351</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56379</infon><location offset="209" length="12"/><text>amyloid-beta</text></annotation><annotation id="33"><infon key="identifier">351</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56379</infon><location offset="223" length="5"/><text>Abeta</text></annotation><annotation id="34"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="356" length="2"/><text>AD</text></annotation><annotation id="35"><infon key="identifier">MESH:C000718787</infon><infon key="type">Disease</infon><location offset="391" length="7"/><text>amyloid</text></annotation><annotation id="36"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="426" length="3"/><text>tau</text></annotation><annotation id="37"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="488" length="3"/><text>tau</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="503" length="8"/><text>pTau-217</text></annotation><annotation id="39"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="615" length="3"/><text>tau</text></annotation><annotation id="40"><infon key="identifier">351</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56379</infon><location offset="633" length="5"/><text>Abeta</text></annotation><annotation id="41"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="688" length="3"/><text>tau</text></annotation><annotation id="42"><infon key="identifier">351</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56379</infon><location offset="706" length="5"/><text>Abeta</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="747" length="8"/><text>pTau-217</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="849" length="8"/><text>pTau-217</text></annotation><annotation id="45"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="1012" length="3"/><text>tau</text></annotation><annotation id="46"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="1070" length="3"/><text>tau</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1287" length="8"/><text>pTau-217</text></annotation><annotation id="48"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="1345" length="3"/><text>tau</text></annotation><annotation id="49"><infon key="identifier">351</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56379</infon><location offset="1382" length="5"/><text>Abeta</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1401" length="8"/><text>pTau-217</text></annotation><annotation id="51"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="1458" length="3"/><text>tau</text></annotation><annotation id="52"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1488" length="8"/><text>pTau-217</text></annotation><annotation id="53"><infon key="identifier">4137</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">74962</infon><location offset="1554" length="3"/><text>tau</text></annotation></passage><relation id="R1"><infon key="score">0.9995</infon><infon key="role1">Gene|351</infon><infon key="role2">Gene|4137</infon><infon key="type">Association</infon><node refid="0" role="3,2"/></relation></document>
<document><id>37921295</id><passage><infon key="journal">Vet Rec;2023Nov04; 193 (9) 373. doi:10.1002/vetr.3642</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jones T, </infon><offset>0</offset><text>Slurry disposal and seasonal incidence of bovine tuberculosis.</text></passage><passage><infon key="type">abstract</infon><offset>63</offset></passage></document>
<document><id>37921645</id><passage><infon key="journal">Int J Surg;2023Nov03. doi:10.1097/JS9.0000000000000883</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xu B, Radoj&amp;#x10d;i&amp;#x107; MR, Anderson DB, Shi B, Yao L, Chen Y, Feng S, Lee JH, Chen L, </infon><offset>0</offset><text>Trends in prevalence of fractures among adults in the United States, 1999-2020: a population-based study.</text><annotation id="1"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="24" length="9"/><text>fractures</text></annotation></passage><passage><infon key="type">abstract</infon><offset>106</offset><text>BACKGROUND: Population data that examine recent national trends in the prevalence of fractures are lacking in the United States (US). MATERIALS AND METHODS: Analyses were based on 1999-2020 data from National Health and Nutrition Examination Survey (NHANES). Primary outcomes included the prevalence of hip, wrist, and vertebral fractures among adults aged >=50 years. Changes in the prevalence over time were determined by joinpoint regression analysis. We also described the variation by fracture subtypes, sociodemographic characteristics, and their combination. RESULTS: For adults aged >=50 years in NHANES 2017-March 2020, we estimated that there was 2.6 million Americans with hip fractures, 14.6 million Americans with wrist fractures, and 5.2 million Americans with vertebral fractures. The prevalence of wrist fractures significantly increased from 8.7% (7.4% to 9.9%) in 1999-2000 to 12.8% (11.6% to 14.1%) in 2017-March 2020 among adults aged >=50 years (P for trend = 0.04); significant increases were also observed in fractures that occurred at age &lt;50 years, non-Hispanic White, high family income groups, and several combination subgroups (e.g., fractures occurred at age &lt;50 y among women). The prevalence of vertebral fractures increased from 2.2% (1.7% to 2.8%) in 1999-2000 to 4.6% (3.7% to 5.5%) in 2017-March 2020 among adults aged >=50 years (P for trend = 0.02); significant increases were also observed in 50-64 years, women, non-Hispanic White, high family income groups and several combination subgroups (e.g., fractures that occurred at age &lt;50 y among women). We did not observe significant trend changes in the prevalence of hip fractures among adults aged >=50 years between 1999 and 2020. CONCLUSION: The estimated prevalence of wrist and vertebral fractures significantly increased among US adults aged >=50 years from 1999 to 2020, although hip fractures did not significantly change.</text><annotation id="16"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="191" length="9"/><text>fractures</text></annotation><annotation id="17"><infon key="identifier">MESH:D000092503</infon><infon key="type">Disease</infon><location offset="409" length="35"/><text>hip, wrist, and vertebral fractures</text></annotation><annotation id="18"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="596" length="8"/><text>fracture</text></annotation><annotation id="19"><infon key="identifier">MESH:D006620</infon><infon key="type">Disease</infon><location offset="790" length="13"/><text>hip fractures</text></annotation><annotation id="20"><infon key="identifier">MESH:D000092503</infon><infon key="type">Disease</infon><location offset="833" length="15"/><text>wrist fractures</text></annotation><annotation id="21"><infon key="identifier">MESH:C535781</infon><infon key="type">Disease</infon><location offset="881" length="19"/><text>vertebral fractures</text></annotation><annotation id="22"><infon key="identifier">MESH:D000092503</infon><infon key="type">Disease</infon><location offset="920" length="15"/><text>wrist fractures</text></annotation><annotation id="23"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="1138" length="9"/><text>fractures</text></annotation><annotation id="24"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="1268" length="9"/><text>fractures</text></annotation><annotation id="25"><infon key="identifier">MESH:C535781</infon><infon key="type">Disease</infon><location offset="1332" length="19"/><text>vertebral fractures</text></annotation><annotation id="26"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="1644" length="9"/><text>fractures</text></annotation><annotation id="27"><infon key="identifier">MESH:D006620</infon><infon key="type">Disease</infon><location offset="1761" length="13"/><text>hip fractures</text></annotation><annotation id="28"><infon key="identifier">MESH:D000092503</infon><infon key="type">Disease</infon><location offset="1867" length="29"/><text>wrist and vertebral fractures</text></annotation><annotation id="29"><infon key="identifier">MESH:D006620</infon><infon key="type">Disease</infon><location offset="1981" length="13"/><text>hip fractures</text></annotation></passage></document>
<document><id>37889575</id><passage><infon key="type">title</infon><offset>0</offset><text>Dominant mechanism in spinal cord injury-induced immunodeficiency syndrome (SCI-IDS): sympathetic hyperreflexia.</text><annotation id="3"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="22" length="52"/><text>spinal cord injury-induced immunodeficiency syndrome</text></annotation><annotation id="4"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="76" length="7"/><text>SCI-IDS</text></annotation><annotation id="5"><infon key="identifier">MESH:D012021</infon><infon key="type">Disease</infon><location offset="86" length="25"/><text>sympathetic hyperreflexia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>Clinical studies have shown that individuals with spinal cord injury (SCI) are particularly susceptible to infectious diseases, resulting in a syndrome called SCI-induced immunodeficiency syndrome (SCI-IDS), which is the leading cause of death after SCI. It is believed that SCI-IDS is associated with exaggerated activation of sympathetic preganglionic neurons (SPNs). After SCI, disruption of bulbospinal projections from the medulla oblongata C1 neurons to the SPNs results in the loss of sympathetic inhibitory modulation from the brain and brainstem and the occurrence of abnormally high levels of spinal sympathetic reflexes (SSR), named sympathetic hyperreflexia. As the post-injury survival time lengthens, mass recruitment and anomalous sprouting of excitatory interneurons within the spinal cord result in increased SSR excitability, resulting in an excess sympathetic output that disrupts the immune response. Therefore, we first analyze the structural underpinnings of the spinal cord-sympathetic nervous system-immune system after SCI, then demonstrate the progress in highlighting mechanisms of SCI-IDS focusing on norepinephrine (NE)/Beta 2-adrenergic receptor (beta2-AR) signal pathways, and summarize recent preclinical studies examining potential means such as regulating SSR and inhibiting beta2-AR signal pathways to improve immune function after SCI. Finally, we present research perspectives such as to promote the effective regeneration of C1 neurons to rebuild the connection of C1 neurons with SPNs, to regulate excitable or inhibitory interneurons, and specifically to target beta2-AR signal pathways to re-establish neuroimmune balance. These will help us design effective strategies to reverse post-SCI sympathetic hyperreflexia and improve the overall quality of life for individuals with SCI.</text><annotation id="27"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="163" length="18"/><text>spinal cord injury</text></annotation><annotation id="28"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="183" length="3"/><text>SCI</text></annotation><annotation id="29"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="220" length="19"/><text>infectious diseases</text></annotation><annotation id="30"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="272" length="37"/><text>SCI-induced immunodeficiency syndrome</text></annotation><annotation id="31"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="311" length="7"/><text>SCI-IDS</text></annotation><annotation id="32"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="351" length="5"/><text>death</text></annotation><annotation id="33"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="363" length="3"/><text>SCI</text></annotation><annotation id="34"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="388" length="7"/><text>SCI-IDS</text></annotation><annotation id="35"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="489" length="3"/><text>SCI</text></annotation><annotation id="36"><infon key="identifier">MESH:D012021</infon><infon key="type">Disease</infon><location offset="757" length="25"/><text>sympathetic hyperreflexia</text></annotation><annotation id="37"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1157" length="3"/><text>SCI</text></annotation><annotation id="38"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1222" length="7"/><text>SCI-IDS</text></annotation><annotation id="39"><infon key="identifier">MESH:D009638</infon><infon key="type">Chemical</infon><location offset="1242" length="14"/><text>norepinephrine</text></annotation><annotation id="40"><infon key="identifier">154</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30948</infon><location offset="1262" length="26"/><text>Beta 2-adrenergic receptor</text></annotation><annotation id="41"><infon key="identifier">154</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30948</infon><location offset="1290" length="8"/><text>beta2-AR</text></annotation><annotation id="42"><infon key="identifier">154</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30948</infon><location offset="1422" length="8"/><text>beta2-AR</text></annotation><annotation id="43"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1480" length="3"/><text>SCI</text></annotation><annotation id="44"><infon key="identifier">154</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30948</infon><location offset="1715" length="8"/><text>beta2-AR</text></annotation><annotation id="45"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1840" length="3"/><text>SCI</text></annotation><annotation id="46"><infon key="identifier">MESH:D012021</infon><infon key="type">Disease</infon><location offset="1844" length="25"/><text>sympathetic hyperreflexia</text></annotation><annotation id="47"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1931" length="3"/><text>SCI</text></annotation></passage><relation id="R1"><infon key="score">0.9908</infon><infon key="role1">Chemical|MESH:D009638</infon><infon key="role2">Disease|MESH:D013119</infon><infon key="type">Association</infon><node refid="0" role="15,13"/></relation><relation id="R2"><infon key="score">0.7978</infon><infon key="role1">Chemical|MESH:D009638</infon><infon key="role2">Gene|154</infon><infon key="type">Association</infon><node refid="1" role="15,17"/></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D013119</infon><infon key="role2">Gene|154</infon><infon key="type">Association</infon><node refid="2" role="13,17"/></relation></document>
<document><id>37890277</id><passage><infon key="type">title</infon><offset>0</offset><text>Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.</text><annotation id="2"><infon key="identifier">MESH:D000068877</infon><infon key="type">Chemical</infon><location offset="21" length="8"/><text>Imatinib</text></annotation><annotation id="3"><infon key="identifier">MESH:D046152</infon><infon key="type">Disease</infon><location offset="67" length="30"/><text>Gastrointestinal Stromal Tumor</text></annotation></passage><passage><infon key="type">abstract</infon><offset>99</offset><text>PURPOSE: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST. PATIENTS AND METHODS: GISTs from 127 patients enrolled onto a phase II clinical study of imatinib were examined for mutations of KIT or PDGFRA. Mutation types were correlated with clinical outcome. RESULTS: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, respectively. Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85). All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro. In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors containing an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P &lt; .0001), respectively. Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation. CONCLUSION: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib. PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.</text><annotation id="41"><infon key="identifier">MESH:D046152</infon><infon key="type">Disease</infon><location offset="113" length="31"/><text>gastrointestinal stromal tumors</text></annotation><annotation id="42"><infon key="identifier">MESH:D046152</infon><infon key="type">Disease</infon><location offset="146" length="5"/><text>GISTs</text></annotation><annotation id="43"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="205" length="3"/><text>KIT</text></annotation><annotation id="44"><infon key="identifier">5156</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31361</infon><location offset="219" length="45"/><text>platelet-derived growth factor receptor alpha</text></annotation><annotation id="45"><infon key="identifier">5156</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31361</infon><location offset="266" length="6"/><text>PDGFRA</text></annotation><annotation id="46"><infon key="identifier">MESH:D000068877</infon><infon key="type">Chemical</infon><location offset="317" length="17"/><text>imatinib mesylate</text></annotation><annotation id="47"><infon key="identifier">MESH:D000068877</infon><infon key="type">Chemical</infon><location offset="413" length="8"/><text>imatinib</text></annotation><annotation id="48"><infon key="identifier">MESH:D046152</infon><infon key="type">Disease</infon><location offset="472" length="4"/><text>GIST</text></annotation><annotation id="49"><infon key="identifier">MESH:D046152</infon><infon key="type">Disease</infon><location offset="500" length="5"/><text>GISTs</text></annotation><annotation id="50"><infon key="identifier">MESH:D000068877</infon><infon key="type">Chemical</infon><location offset="567" length="8"/><text>imatinib</text></annotation><annotation id="51"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="607" length="3"/><text>KIT</text></annotation><annotation id="52"><infon key="identifier">5156</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31361</infon><location offset="614" length="6"/><text>PDGFRA</text></annotation><annotation id="53"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="709" length="3"/><text>KIT</text></annotation><annotation id="54"><infon key="identifier">5156</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31361</infon><location offset="716" length="6"/><text>PDGFRA</text></annotation><annotation id="55"><infon key="identifier">MESH:D046152</infon><infon key="type">Disease</infon><location offset="764" length="5"/><text>GISTs</text></annotation><annotation id="56"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="790" length="3"/><text>KIT</text></annotation><annotation id="57"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="854" length="3"/><text>KIT</text></annotation><annotation id="58"><infon key="identifier">5156</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31361</infon><location offset="896" length="6"/><text>PDGFRA</text></annotation><annotation id="59"><infon key="identifier">MESH:D000068877</infon><infon key="type">Chemical</infon><location offset="938" length="8"/><text>imatinib</text></annotation><annotation id="60"><infon key="identifier">MESH:D046152</infon><infon key="type">Disease</infon><location offset="975" length="5"/><text>GISTs</text></annotation><annotation id="61"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="999" length="3"/><text>KIT</text></annotation><annotation id="62"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1078" length="6"/><text>tumors</text></annotation><annotation id="63"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="1106" length="3"/><text>KIT</text></annotation><annotation id="64"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="1148" length="3"/><text>KIT</text></annotation><annotation id="65"><infon key="identifier">5156</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31361</infon><location offset="1155" length="6"/><text>PDGFRA</text></annotation><annotation id="66"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1247" length="6"/><text>tumors</text></annotation><annotation id="67"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="1272" length="3"/><text>KIT</text></annotation><annotation id="68"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1348" length="6"/><text>tumors</text></annotation><annotation id="69"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="1379" length="3"/><text>KIT</text></annotation><annotation id="70"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="1467" length="3"/><text>KIT</text></annotation><annotation id="71"><infon key="identifier">5156</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31361</infon><location offset="1474" length="6"/><text>PDGFRA</text></annotation><annotation id="72"><infon key="identifier">MESH:D046152</infon><infon key="type">Disease</infon><location offset="1515" length="5"/><text>GISTs</text></annotation><annotation id="73"><infon key="identifier">MESH:D000068877</infon><infon key="type">Chemical</infon><location offset="1608" length="8"/><text>imatinib</text></annotation><annotation id="74"><infon key="identifier">5156</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31361</infon><location offset="1618" length="6"/><text>PDGFRA</text></annotation><annotation id="75"><infon key="identifier">MESH:D000068877</infon><infon key="type">Chemical</infon><location offset="1675" length="8"/><text>imatinib</text></annotation><annotation id="76"><infon key="identifier">MESH:D046152</infon><infon key="type">Disease</infon><location offset="1692" length="5"/><text>GISTs</text></annotation><annotation id="77"><infon key="identifier">3815</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">187</infon><location offset="1706" length="3"/><text>KIT</text></annotation></passage><relation id="R1"><infon key="score">0.9925</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|3815</infon><infon key="type">Association</infon><node refid="0" role="23,22"/></relation><relation id="R2"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D000068877</infon><infon key="role2">Disease|MESH:D046152</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.978</infon><infon key="role1">Chemical|MESH:D000068877</infon><infon key="role2">Gene|3815</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="7,4"/></relation><relation id="R4"><infon key="score">0.9934</infon><infon key="role1">Chemical|MESH:D000068877</infon><infon key="role2">Gene|5156</infon><infon key="type">Association</infon><node refid="3" role="7,5"/></relation><relation id="R5"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D046152</infon><infon key="role2">Gene|5156</infon><infon key="type">Association</infon><node refid="4" role="2,5"/></relation><relation id="R6"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D046152</infon><infon key="role2">Gene|3815</infon><infon key="type">Association</infon><node refid="5" role="2,4"/></relation></document>
<document><id>37890627</id><passage><infon key="type">title</infon><offset>0</offset><text>Cooking as an organic aerosol source leading to urban air quality degradation.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="14" length="15"/><text>organic aerosol</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Air quality degradation events in the urban environment are often attributed to anthropogenic aerosol sources related to combustion of liquid or solid fuels in various activities. The effects of massive cooking emissions during Greek nationwide traditional festivities were investigated by a combined characterization of particulate matter (PM) levels and organic aerosol (OA) sources. Focus was centered on periods around two major festivities, namely "Fat Thursday" and Easter Sunday along six different years. OA sources were apportioned through Positive Matrix Factorization (PMF) on Aerosol Chemical Speciation Monitor (ACSM) mass spectra, while the spatial characteristics of the episodes were assessed through a low-cost, sensor-based PM2.5 monitoring network operating in Athens and other Greek cities. Contrasts were examined by considering a 15-day period around each event, while the effect of the 2020-2021 mobility restrictions, related to COVID-19, was also assessed. An episode-specific cooking organic aerosol (COA) spectral profile was delineated, and can be considered as a reference for ambient COA from meat grilling. Severe pollution episodes that affected the entire Athens basin were recorded, with PM2.5 concentrations exceeding 300 mug m-3 on occasions. COA contributions dominated primary organic aerosol (POA) and made up almost half of OA concentrations. During "Fat Thursday" COA concentrations and contributions peaked during night-time (23.2 mug m-3 and 46 %, respectively) while for Easter Sunday COA maxima were recorded in the early afternoon (27.4 mug m-3 and 39 %). Analyzing a full-year OA source dataset, revealed a pronounced recreational cooking pattern in central Athens, with COA concentrations rising towards the weekend, reflecting the impact of the food service sector. In view of the upcoming review of the EU air quality directive, foreseeing stricter annual PM2.5 limits as well as 24-h limit values and related alerts, the mitigation of cooking emissions appears as a potent instrument for achieving tangible air quality benefits.</text><annotation id="10"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="435" length="15"/><text>organic aerosol</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="821" length="5"/><text>PM2.5</text></annotation><annotation id="12"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1032" length="8"/><text>COVID-19</text></annotation><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1089" length="15"/><text>organic aerosol</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1301" length="5"/><text>PM2.5</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1394" length="15"/><text>organic aerosol</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1411" length="3"/><text>POA</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1985" length="5"/><text>PM2.5</text></annotation></passage></document>
<document><id>37890977</id><passage><infon key="type">title</infon><offset>0</offset><text>Definition of rheumatoid arthritis flare based on SDAI and CDAI.</text><annotation id="1"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="14" length="26"/><text>rheumatoid arthritis flare</text></annotation></passage><passage><infon key="type">abstract</infon><offset>65</offset><text>OBJECTIVE: To develop and validate definitions for disease flares in rheumatoid arthritis (RA) based on the quantitative Simplified and Clinical Disease Activity Indices (SDAI, CDAI). METHODS: We analysed RA treatment courses from the Norwegian disease-modifying antirheumatic drug registry (NOR-DMARD) and the Vienna RA cohort. In a receiver operating curve analysis, we determined flare definitions for absolute changes in SDAI and CDAI based on a semiquantitative patient anchor. NOR-DMARD was sampled into an 80%-training cohort for cut point derivation and a 20%-test cohort for internal validation. The definitions were then externally validated in the independent Vienna RA cohort and tested regarding their performance on longitudinal, content, face, and construct validity. RESULTS: We analysed 4256 treatment courses from NOR-DMARD and 2557 from the Vienna RA cohort. The preliminary definitions for absolute changes in SDAI and CDAI for flare are an increase of 4.7 and 4.5, respectively. The definitions performed well in the test and external validation cohorts, and showed clinical face and construct validity, as flares significantly impact both functional ( Health Assessment Questionnaire flare vs no-flare +0.43; p&lt;0.001) and structural ( modified Sharp Score 43% higher after flare; p&lt;0.001) disease outcomes, and reflect consistent worsening across all disease core sets, both patient reported and objective. CONCLUSION: We here provide novel definitions for flare in RA based on SDAI and CDAI, validated in two large independent real-world cohorts. In times of highly effective medications for RA, and consideration of their tapering, these definitions will be useful for guiding decision making in clinical practice and designing clinical trials.</text><annotation id="12"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="134" length="20"/><text>rheumatoid arthritis</text></annotation><annotation id="13"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="156" length="2"/><text>RA</text></annotation><annotation id="14"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="270" length="2"/><text>RA</text></annotation><annotation id="15"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="383" length="2"/><text>RA</text></annotation><annotation id="16"><infon key="type">Disease</infon><location offset="548" length="4"/><text>NOR-</text></annotation><annotation id="17"><infon key="type">Disease</infon><location offset="552" length="5"/><text>DMARD</text></annotation><annotation id="18"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="743" length="2"/><text>RA</text></annotation><annotation id="19"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="932" length="2"/><text>RA</text></annotation><annotation id="20"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="1553" length="2"/><text>RA</text></annotation><annotation id="21"><infon key="identifier">MESH:D001172</infon><infon key="type">Disease</infon><location offset="1680" length="2"/><text>RA</text></annotation></passage></document>
<document><id>37891328</id><passage><infon key="journal">Aesthetic Plast Surg;2023Oct27. doi:10.1007/s00266-023-03704-5</infon><infon key="year">2023</infon><infon key="article-id_pmc">9777212</infon><infon key="type">title</infon><infon key="authors">Ciccarelli F, Pieretti G, </infon><offset>0</offset><text>Letter on: "Platelet-Rich Plasma for Treatment of Hair Loss Improves Patient-Reported Quality of Life".</text><annotation id="1"><infon key="identifier">MESH:D000505</infon><infon key="type">Disease</infon><location offset="50" length="9"/><text>Hair Loss</text></annotation></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>Authors comment on the paper "Platelet-Rich Plasma for Treatment of Hair Loss Improves Patient-Reported Quality of Life" written by Abigail Meyers et al in Aesthetic Plastic Surgery. Although the authors present interesting results on the quality of life of patients after platelet-rich plasma, we express some considerations about the proposed composition of PRP and hoping in larger sample study.Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.</text><annotation id="3"><infon key="identifier">MESH:D000505</infon><infon key="type">Disease</infon><location offset="172" length="9"/><text>Hair Loss</text></annotation></passage></document>
<document><id>37897288</id><passage><infon key="type">title</infon><offset>0</offset><text>[Effects of different fertilizer applications on citrus rhizosphere soil quality and arbuscular mycorrhizae colonization].</text></passage><passage><infon key="type">abstract</infon><offset>123</offset><text>To understand the effects of different fertilizer applications on soil quality and arbuscular mycorrhizal colonization, we examined the changes in soil physical and chemical properties, mycorrhizal colonization and propagules, and their relationships in citrus under inorganic fertilization (IF), organic fertilization (OF), combined organic and inorganic fertilization (CF), and no fertilization (CK) treatments. Results showed that all fertilization treatments improved the content of rhizospheric soil organic carbon (SOC), nutrient contents, and electrical conductivity (EC). Both CF and OF significantly increased soil pH, soil aggregate stability, activities of urease, catalase, and sucrase, and the colonization and reproduction of arbuscular mycorrhizae fungi (AMF) in citrus rhizosphere. However, IF treatment significantly decreased soil pH and the colonization and reproduction of AMF in citrus rhizosphere. The number of mycorrhizal colonization and propagation was positively correlated with soil aggregate stability, SOC content, total nitrogen content, total phosphorus content, urease activity, and soil pH. Combined with the principal component analysis, we concluded that application of inorganic fertilizer alone could cause soil acidification and inhibit AMF colonization in citrus orchards. In contrast, organic fertilizer combined with inorganic fertilizer in citrus could improve the soil quality and AMF colonization.</text><annotation id="7"><infon key="identifier">MESH:D003550</infon><infon key="type">Disease</infon><location offset="494" length="2"/><text>CF</text></annotation><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="628" length="14"/><text>organic carbon</text></annotation><annotation id="9"><infon key="identifier">MESH:D003550</infon><infon key="type">Disease</infon><location offset="708" length="2"/><text>CF</text></annotation><annotation id="10"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="799" length="8"/><text>catalase</text></annotation><annotation id="11"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="1174" length="8"/><text>nitrogen</text></annotation><annotation id="12"><infon key="identifier">MESH:D010758</infon><infon key="type">Chemical</infon><location offset="1198" length="10"/><text>phosphorus</text></annotation><annotation id="13"><infon key="identifier">MESH:D005242</infon><infon key="type">Disease</infon><location offset="1368" length="18"/><text>soil acidification</text></annotation></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D003550</infon><infon key="role2">Gene|847</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="2,3"/></relation></document>
<document><id>37897639</id><passage><infon key="journal">Obes Surg;2023Oct28. doi:10.1007/s11695-023-06898-4</infon><infon key="year">2023</infon><infon key="article-id_pmc">5494150</infon><infon key="type">title</infon><infon key="authors">Esparham A, Mehri A, Hadian H, Taheri M, Anari Moghadam H, Kalantari A, Fogli MJ, Khorgami Z, </infon><offset>0</offset><text>The Effect of Bariatric Surgery on Patients with Heart Failure: a Systematic Review and Meta-analysis.</text><annotation id="1"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="49" length="13"/><text>Heart Failure</text></annotation></passage><passage><infon key="type">abstract</infon><offset>103</offset><text>The current study aims to evaluate the effect of bariatric metabolic surgery (BMS) on the New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF) in patients with diagnosed heart failure (HF). Fourteen related articles with 217 patients were included in the final analysis. LVEF significantly improved after BMS in patients with HF with a mean difference of 7.78% (CI 95%: 3.72, 11.84, I2 = 83.75, p-value &lt; 0.001). Also, the NYHA class significantly decreased after BMS with a mean difference of - 0.40 (CI 95%: - 0.62, - 0.19, I2: 47.03, p-value &lt; 0.001). A total of 27 patients with obesity and HF were listed for cardiac transplantation after BMS. Of those, 20 patients successfully underwent heart transplantation after BMS.</text><annotation id="7"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="306" length="13"/><text>heart failure</text></annotation><annotation id="8"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="321" length="2"/><text>HF</text></annotation><annotation id="9"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="462" length="2"/><text>HF</text></annotation><annotation id="10"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="719" length="7"/><text>obesity</text></annotation><annotation id="11"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="731" length="2"/><text>HF</text></annotation></passage></document>
<document><id>37897989</id><passage><infon key="journal">Comput Methods Programs Biomed;2023Oct24; 243 107879. doi:10.1016/j.cmpb.2023.107879</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wani NA, Kumar R, Bedi J, </infon><offset>0</offset><text>DeepXplainer: An interpretable deep learning based approach for lung cancer detection using explainable artificial intelligence.</text><annotation id="1"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="64" length="11"/><text>lung cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>BACKGROUND AND OBJECTIVE: Artificial intelligence (AI) has several uses in the healthcare industry, some of which include healthcare management, medical forecasting, practical making of decisions, and diagnosis. AI technologies have reached human-like performance, but their use is limited since they are still largely viewed as opaque black boxes. This distrust remains the primary factor for their limited real application, particularly in healthcare. As a result, there is a need for interpretable predictors that provide better predictions and also explain their predictions. METHODS: This study introduces "DeepXplainer", a new interpretable hybrid deep learning-based technique for detecting lung cancer and providing explanations of the predictions. This technique is based on a convolutional neural network and XGBoost. XGBoost is used for class label prediction after "DeepXplainer" has automatically learned the features of the input using its many convolutional layers. For providing explanations or explainability of the predictions, an explainable artificial intelligence method known as "SHAP" is implemented. RESULTS: The open-source "Survey Lung Cancer" dataset was processed using this method. On multiple parameters, including accuracy, sensitivity, F1-score, etc., the proposed method outperformed the existing methods. The proposed method obtained an accuracy of 97.43%, a sensitivity of 98.71%, and an F1-score of 98.08. After the model has made predictions with this high degree of accuracy, each prediction is explained by implementing an explainable artificial intelligence method at both the local and global levels. CONCLUSIONS: A deep learning-based classification model for lung cancer is proposed with three primary components: one for feature learning, another for classification, and a third for providing explanations for the predictions made by the proposed hybrid (ConvXGB) model. The proposed "DeepXplainer" has been evaluated using a variety of metrics, and the results demonstrate that it outperforms the current benchmarks. Providing explanations for the predictions, the proposed approach may help doctors in detecting and treating lung cancer patients more effectively.</text><annotation id="6"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="827" length="11"/><text>lung cancer</text></annotation><annotation id="7"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="1286" length="11"/><text>Lung Cancer</text></annotation><annotation id="8"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="1831" length="11"/><text>lung cancer</text></annotation><annotation id="9"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="2300" length="11"/><text>lung cancer</text></annotation></passage></document>
<document><id>37898342</id><passage><infon key="type">title</infon><offset>0</offset><text>Response to Jin and Dobry's "ChatGPT for healthcare providers and patients: Practical implications within dermatology."</text></passage><passage><infon key="type">abstract</infon><offset>120</offset></passage></document>
<document><id>37899042</id><passage><infon key="journal">Blood Purif;2023Oct27. doi:10.1159/000534823</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Vasquez Jimenez E, Campos N&amp;#xfa;&amp;#xf1;ez G, Lerma A, Lerma C, Meave Gonz&amp;#xe1;lez A, P&amp;#xe9;rez-Grovas H, L&amp;#xf3;pez Gil S, Madero M, </infon><offset>0</offset><text>Neurocognitive Function with Conventional Hemodialysis Versus Post-Dilution Hemofiltration as Initial Treatment in ESKD patients. A randomized controlled trial. The DA-VINCI Study.</text><annotation id="1"><infon key="type">Disease</infon><location offset="115" length="4"/><text>ESKD</text></annotation></passage><passage><infon key="type">abstract</infon><offset>181</offset><text>INTRODUCTION: The ideal modality choice and dialysis prescription during the first renal replacement therapy (RRT) session remains unclear. We conducted a pilot study to determine the safety risk for hemodialysis (HD) versus hemofiltration (HF) and its relationship with neurocognitive assessment on incident RRT patients. METHODS: Twenty-four incident RRT patients were included. Patients were randomized to the conventional HD group or post-dilution HF group. Minimental State Examination (MMSE) and Montreal Cognitive Assessment (MOCA) tests were applied in all patients before and after session and brain MRI was performed in 7 patients from the conventional HD group and 8 patients from the post-dilution HF group before and after the intervention. RESULTS: Baseline characteristics were similar between groups. Compared to conventional HD, post-dilution HF had longer treatment time. There were no significant changes in blood pressure after RRT in both groups. The MMSE test showed no significant differences between groups or within groups. The MOCA test showed an increase in the total score for the post dilution HF group with no significant changes between groups. The magnetic resonance image (MRI) evaluation showed no differences between or within groups. CONCLUSION: Post-dilution hemofiltration is a safe alternative for the first hemodialysis session in incident RRT, it allows longer treatment time if ultrafiltration is required and has a similar neurological risk than conventional HD. This is a pilot study and that larger studies are needed to confirm the findings.</text></passage></document>
<document><id>37899392</id><passage><infon key="journal">Pharmacol Rep;2023Oct30. doi:10.1007/s43440-023-00546-5</infon><infon key="year">2023</infon><infon key="article-id_pmc">3181663</infon><infon key="type">title</infon><infon key="authors">Ma&amp;#x107;kowiak M, </infon><offset>0</offset><text>Psychedelics action and schizophrenia.</text><annotation id="1"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="24" length="13"/><text>schizophrenia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>39</offset><text>Psychedelics are compounds acting by serotonin 5-hydroxytryptamine (5-HT)2A receptor activation and induce several behavioral responses. They are of special interest because of their positive effects on neuropsychiatric disorders (depression and posttraumatic stress disorder). However, several findings revealed that some psychedelic actions are similar to symptoms observed in schizophrenia (psychosis, sensorimotor gating impairments, attention, and working memory deficits) which might limit their clinical applications. Psychedelics activate some neurotransmitters, i.e., serotonergic, and glutamatergic, that are also impaired in schizophrenia. Therefore, the neurobiological background of psychedelics and schizophrenia is partially similar. Another important aspect to discuss is the perspective of using psychedelics in schizophrenia therapy. Postmortem studies showed a loss of synapses in schizophrenia, and the positive effects of psychedelics on neuroplasticity (synaptogenesis, neurogenesis, and neuritogenesis) might be essential in the context of schizophrenia therapy. However, because of psychedelics' psychotic action, the recommended doses of psychedelics in schizophrenia treatment are not established, and subpsychedelic dosing or microdosing are considered. Exploratory studies are needed to determine the tolerability of treatment and appropriate dosing regimen. Another therapeutic option is using non-hallucinogenic psychedelic analogs that also induce neuroplastic outcomes but do not have psychotogenic effects. Further preclinical and clinical studies are needed to recognize the potential effectiveness of 5-HT2A agonists in schizophrenia therapy.</text><annotation id="21"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="242" length="26"/><text>neuropsychiatric disorders</text></annotation><annotation id="22"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="270" length="10"/><text>depression</text></annotation><annotation id="23"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="285" length="29"/><text>posttraumatic stress disorder</text></annotation><annotation id="24"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="418" length="13"/><text>schizophrenia</text></annotation><annotation id="25"><infon key="identifier">MESH:D011618</infon><infon key="type">Disease</infon><location offset="433" length="9"/><text>psychosis</text></annotation><annotation id="26"><infon key="identifier">MESH:D020233</infon><infon key="type">Disease</infon><location offset="444" length="31"/><text>sensorimotor gating impairments</text></annotation><annotation id="27"><infon key="identifier">MESH:D008569</infon><infon key="type">Disease</infon><location offset="492" length="23"/><text>working memory deficits</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="616" length="12"/><text>serotonergic</text></annotation><annotation id="29"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="675" length="13"/><text>schizophrenia</text></annotation><annotation id="30"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="752" length="13"/><text>schizophrenia</text></annotation><annotation id="31"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="868" length="13"/><text>schizophrenia</text></annotation><annotation id="32"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="939" length="13"/><text>schizophrenia</text></annotation><annotation id="33"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="1102" length="13"/><text>schizophrenia</text></annotation><annotation id="34"><infon key="identifier">MESH:D011618</infon><infon key="type">Disease</infon><location offset="1159" length="9"/><text>psychotic</text></annotation><annotation id="35"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="1218" length="13"/><text>schizophrenia</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1481" length="19"/><text>psychedelic analogs</text></annotation><annotation id="37"><infon key="type">Disease</infon><location offset="1556" length="13"/><text>psychotogenic</text></annotation><annotation id="38"><infon key="identifier">3356</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68073</infon><location offset="1675" length="6"/><text>5-HT2A</text></annotation><annotation id="39"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="1694" length="13"/><text>schizophrenia</text></annotation></passage><relation id="R1"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D012559</infon><infon key="role2">Gene|3356</infon><infon key="type">Association</infon><node refid="0" role="19,18"/></relation></document>
<document><id>37902195</id><passage><infon key="journal">CNS Neurosci Ther;2023Oct30. doi:10.1111/cns.14494</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kui L, Jiao Y, Jiang H, Wang G, Li Z, Ji X, Zhou C, </infon><offset>0</offset><text>Expression and metabolism profiles of CVT associated with inflammatory responses and oxygen carrier ability in the brain.</text><annotation id="3"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="38" length="3"/><text>CVT</text></annotation><annotation id="4"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="58" length="12"/><text>inflammatory</text></annotation><annotation id="5"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="85" length="6"/><text>oxygen</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>AIM: As the main type of stroke, the incidence of cerebral venous thrombosis (CVT) has been rising. However, the comprehensive mechanisms behind it remain unclear. Thus, the multi-omics study is required to investigate the mechanism after CVT and elucidate the characteristic pathology of venous stroke and arterial stroke. METHODS: Adult rats were subjected to CVT and MCAO models. Whole-transcriptome sequencing (RNA-seq) and untargeted metabolomics analysis were performed to construct the transcriptome and metabolism profiles of rat brains after CVT and also MCAO. The difference analysis, functional annotation, and enrichment analysis were also performed. RESULTS: Through RNA-seq analysis, differentially expressed genes (DEGs) were screened. 174 CVT specific genes including Il1a, Ccl9, Cxxl6, Tnfrsf14, etc., were detected. The hemoglobin genes, including both Hba and Hbb, were significantly downregulated after CVT, compared both to the MCAO and Sham groups. Metabolism analysis showed that CVT had higher heterogeneity of metabolism compared to MCAO. Metabolites including N-stearoyltyrosine, 5-methoxy-3-indoleaceate, Afegostat, pipecolic acid, etc. were specially regulated in CVT. Through the immune infiltration analysis, it was found that CVT had a higher immune response, with the abundance of certain types of immune cells increased, especially T helper cells. It was important to find the prevalence of the activation of inflammatory chemokine, cytokine, NOD-like pathway, and neutrophil extracellular trap. CONCLUSION: We explored and analyzed the gene expression and metabolomic characteristics of CVT, revealed the specific inflammatory reaction mechanism of CVT and found the markers in transcriptome and metabolism levels. It points out the direction for CVT early diagnosis and treatment.</text><annotation id="36"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="147" length="6"/><text>stroke</text></annotation><annotation id="37"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="172" length="26"/><text>cerebral venous thrombosis</text></annotation><annotation id="38"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="200" length="3"/><text>CVT</text></annotation><annotation id="39"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="361" length="3"/><text>CVT</text></annotation><annotation id="40"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="411" length="13"/><text>venous stroke</text></annotation><annotation id="41"><infon key="identifier">MESH:D020243</infon><infon key="type">Disease</infon><location offset="429" length="15"/><text>arterial stroke</text></annotation><annotation id="42"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="484" length="3"/><text>CVT</text></annotation><annotation id="43"><infon key="type">Disease</infon><location offset="492" length="4"/><text>MCAO</text></annotation><annotation id="44"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="673" length="3"/><text>CVT</text></annotation><annotation id="45"><infon key="type">Disease</infon><location offset="686" length="4"/><text>MCAO</text></annotation><annotation id="46"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="877" length="3"/><text>CVT</text></annotation><annotation id="47"><infon key="identifier">24493</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">480</infon><location offset="906" length="4"/><text>Il1a</text></annotation><annotation id="48"><infon key="identifier">360579</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">86734</infon><location offset="912" length="4"/><text>Ccl9</text></annotation><annotation id="49"><infon key="identifier">366518</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2833</infon><location offset="925" length="8"/><text>Tnfrsf14</text></annotation><annotation id="50"><infon key="identifier">24440</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68066</infon><location offset="1001" length="3"/><text>Hbb</text></annotation><annotation id="51"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="1045" length="3"/><text>CVT</text></annotation><annotation id="52"><infon key="type">Disease</infon><location offset="1071" length="4"/><text>MCAO</text></annotation><annotation id="53"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="1125" length="3"/><text>CVT</text></annotation><annotation id="54"><infon key="type">Disease</infon><location offset="1180" length="4"/><text>MCAO</text></annotation><annotation id="55"><infon key="identifier">MESH:C087584</infon><infon key="type">Chemical</infon><location offset="1208" length="18"/><text>N-stearoyltyrosine</text></annotation><annotation id="56"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1228" length="24"/><text>5-methoxy-3-indoleaceate</text></annotation><annotation id="57"><infon key="identifier">MESH:C098432</infon><infon key="type">Chemical</infon><location offset="1254" length="9"/><text>Afegostat</text></annotation><annotation id="58"><infon key="identifier">MESH:C031345</infon><infon key="type">Chemical</infon><location offset="1265" length="14"/><text>pipecolic acid</text></annotation><annotation id="59"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="1314" length="3"/><text>CVT</text></annotation><annotation id="60"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="1379" length="3"/><text>CVT</text></annotation><annotation id="61"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1564" length="12"/><text>inflammatory</text></annotation><annotation id="62"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="1743" length="3"/><text>CVT</text></annotation><annotation id="63"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1770" length="12"/><text>inflammatory</text></annotation><annotation id="64"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="1805" length="3"/><text>CVT</text></annotation><annotation id="65"><infon key="identifier">MESH:D020767</infon><infon key="type">Disease</infon><location offset="1903" length="3"/><text>CVT</text></annotation></passage><relation id="R1"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:C098432</infon><infon key="role2">Disease|MESH:D020767</infon><infon key="type">Association</infon><node refid="0" role="24,26"/></relation><relation id="R2"><infon key="score">0.9991</infon><infon key="role1">Disease|MESH:D020767</infon><infon key="role2">Gene|360579</infon><infon key="type">Association</infon><node refid="1" role="13,15"/></relation><relation id="R3"><infon key="score">0.5986</infon><infon key="role1">Disease|MESH:D020767</infon><infon key="role2">Gene|24440</infon><infon key="type">Association</infon><node refid="2" role="18,17"/></relation><relation id="R4"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D020767</infon><infon key="role2">Gene|24493</infon><infon key="type">Association</infon><node refid="3" role="13,14"/></relation><relation id="R5"><infon key="score">0.9939</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Disease|MESH:D020767</infon><infon key="type">Association</infon><node refid="4" role="2,0"/></relation><relation id="R6"><infon key="score">0.9954</infon><infon key="role1">Chemical|MESH:C087584</infon><infon key="role2">Disease|MESH:D020767</infon><infon key="type">Association</infon><node refid="5" role="22,26"/></relation><relation id="R7"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D020767</infon><infon key="role2">Gene|366518</infon><infon key="type">Association</infon><node refid="6" role="13,16"/></relation><relation id="R8"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:C031345</infon><infon key="role2">Disease|MESH:D020767</infon><infon key="type">Association</infon><node refid="7" role="25,26"/></relation></document>
<document><id>37902545</id><passage><infon key="journal">Recenti Prog Med;2023Nov; 114 (11) 692. doi:10.1701/4133.41274</infon><infon key="year">2023</infon><infon key="type">title</infon><offset>0</offset><text>In ricordo di Giovanni Bissoni.</text></passage><passage><infon key="type">abstract</infon><offset>32</offset></passage></document>
<document><id>37903273</id><passage><infon key="journal">Proc Natl Acad Sci U S A;2023Nov07; 120 (45) 2310924120. doi:10.1073/pnas.2310924120</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li S, Yu Y, Zheng J, Miller-Browne V, Ser Z, Kuang H, Patel DJ, Zhao X, </infon><offset>0</offset><text>Molecular basis for Nse5-6 mediated regulation of Smc5/6 functions.</text><annotation id="2"><infon key="identifier">854985;856760</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">39865;38913</infon><location offset="20" length="6"/><text>Nse5-6</text></annotation><annotation id="3"><infon key="identifier">854123;851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41009;137073</infon><location offset="50" length="6"/><text>Smc5/6</text></annotation></passage><passage><infon key="type">abstract</infon><offset>68</offset><text>The Smc5/6 complex (Smc5/6) is important for genome replication and repair in eukaryotes. Its cellular functions are closely linked to the ATPase activity of the Smc5 and Smc6 subunits. This activity requires the dimerization of the motor domains of the two SMC subunits and is regulated by the six non-SMC subunits (Nse1 to Nse6). Among the NSEs, Nse5 and Nse6 form a stable subcomplex (Nse5-6) that dampens the ATPase activity of the complex. However, the underlying mechanisms and biological significance of this regulation remain unclear. Here, we address these issues using structural and functional studies. We determined cryo-EM structures of the yeast Smc5/6 derived from complexes consisting of either all eight subunits or a subset of five subunits. Both structures reveal that Nse5-6 associates with Smc6's motor domain and the adjacent coiled-coil segment, termed the neck region. Our structural analyses reveal that this binding is compatible with motor domain dimerization but results in dislodging the Nse4 subunit from the Smc6 neck. As the Nse4-Smc6 neck interaction favors motor domain engagement and thus ATPase activity, Nse6's competition with Nse4 can explain how Nse5-6 disfavors ATPase activity. Such regulation could in principle differentially affect Smc5/6-mediated processes depending on their needs of the complex's ATPase activity. Indeed, mutagenesis data in cells provide evidence that the Nse6-Smc6 neck interaction is important for the resolution of DNA repair intermediates but not for replication termination. Our results thus provide a molecular basis for how Nse5-6 modulates the ATPase activity and cellular functions of Smc5/6.</text><annotation id="28"><infon key="identifier">854123;851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41009;137073</infon><location offset="72" length="6"/><text>Smc5/6</text></annotation><annotation id="29"><infon key="identifier">854123;851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41009;137073</infon><location offset="88" length="6"/><text>Smc5/6</text></annotation><annotation id="30"><infon key="identifier">854123</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41009</infon><location offset="230" length="4"/><text>Smc5</text></annotation><annotation id="31"><infon key="identifier">851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">137073</infon><location offset="239" length="4"/><text>Smc6</text></annotation><annotation id="32"><infon key="identifier">850693</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">39646</infon><location offset="385" length="4"/><text>Nse1</text></annotation><annotation id="33"><infon key="identifier">856760</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38913</infon><location offset="393" length="4"/><text>Nse6</text></annotation><annotation id="34"><infon key="identifier">854985</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">39865</infon><location offset="416" length="4"/><text>Nse5</text></annotation><annotation id="35"><infon key="identifier">856760</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38913</infon><location offset="425" length="4"/><text>Nse6</text></annotation><annotation id="36"><infon key="identifier">854985;856760</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">39865;38913</infon><location offset="456" length="6"/><text>Nse5-6</text></annotation><annotation id="37"><infon key="identifier">854123;851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41009;137073</infon><location offset="728" length="6"/><text>Smc5/6</text></annotation><annotation id="38"><infon key="identifier">854985;856760</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">39865;38913</infon><location offset="856" length="6"/><text>Nse5-6</text></annotation><annotation id="39"><infon key="identifier">851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">137073</infon><location offset="879" length="4"/><text>Smc6</text></annotation><annotation id="40"><infon key="identifier">851453</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38597</infon><location offset="1085" length="4"/><text>Nse4</text></annotation><annotation id="41"><infon key="identifier">851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">137073</infon><location offset="1107" length="4"/><text>Smc6</text></annotation><annotation id="42"><infon key="identifier">851453</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38597</infon><location offset="1125" length="4"/><text>Nse4</text></annotation><annotation id="43"><infon key="identifier">851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">137073</infon><location offset="1130" length="4"/><text>Smc6</text></annotation><annotation id="44"><infon key="identifier">856760</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38913</infon><location offset="1209" length="4"/><text>Nse6</text></annotation><annotation id="45"><infon key="identifier">851453</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38597</infon><location offset="1233" length="4"/><text>Nse4</text></annotation><annotation id="46"><infon key="identifier">854985;856760</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">39865;38913</infon><location offset="1254" length="6"/><text>Nse5-6</text></annotation><annotation id="47"><infon key="identifier">854123;851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41009;137073</infon><location offset="1345" length="6"/><text>Smc5/6</text></annotation><annotation id="48"><infon key="identifier">856760</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38913</infon><location offset="1490" length="4"/><text>Nse6</text></annotation><annotation id="49"><infon key="identifier">851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">137073</infon><location offset="1495" length="4"/><text>Smc6</text></annotation><annotation id="50"><infon key="identifier">854985;856760</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">39865;38913</infon><location offset="1665" length="6"/><text>Nse5-6</text></annotation><annotation id="51"><infon key="identifier">854123;851099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41009;137073</infon><location offset="1728" length="6"/><text>Smc5/6</text></annotation></passage><relation id="R1"><infon key="score">0.5179</infon><infon key="role1">Gene|851099</infon><infon key="role2">Gene|854123</infon><infon key="type">Bind</infon><node refid="0" role="2,3"/></relation><relation id="R2"><infon key="score">0.9105</infon><infon key="role1">Gene|854123</infon><infon key="role2">Gene|856760</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.8379</infon><infon key="role1">Gene|851099</infon><infon key="role2">Gene|856760</infon><infon key="type">Bind</infon><node refid="2" role="1,0"/></relation><relation id="R4"><infon key="score">0.7674</infon><infon key="role1">Gene|854985</infon><infon key="role2">Gene|856760</infon><infon key="type">Bind</infon><node refid="3" role="8,9"/></relation><relation id="R5"><infon key="score">0.9331</infon><infon key="role1">Gene|851453</infon><infon key="role2">Gene|856760</infon><infon key="type">Bind</infon><node refid="4" role="16,18"/></relation><relation id="R6"><infon key="score">0.8541</infon><infon key="role1">Gene|851099</infon><infon key="role2">Gene|854985</infon><infon key="type">Association</infon><node refid="5" role="1,0"/></relation><relation id="R7"><infon key="score">0.989</infon><infon key="role1">Gene|854123</infon><infon key="role2">Gene|854985</infon><infon key="type">Association</infon><node refid="6" role="1,0"/></relation></document>
<document><id>37903624</id><passage><infon key="journal">Reg Anesth Pain Med;2023Oct30. doi:10.1136/rapm-2023-105067</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Larson MJ, Ritter G, Adams RS, </infon><offset>0</offset><text>Opioid prescribing to US military members.</text></passage><passage><infon key="type">abstract</infon><offset>43</offset></passage></document>
<document><id>37903975</id><passage><infon key="journal">Bull Environ Contam Toxicol;2023Oct31; 111 (5) 59. doi:10.1007/s00128-023-03801-w</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gan CD, Yang JY, Gou M, </infon><offset>0</offset><text>High-throughput Sequencing Analysis of the Effects of Vanadium on Bacterial Community Structure in Purple Soil.</text><annotation id="1"><infon key="identifier">MESH:D014639</infon><infon key="type">Chemical</infon><location offset="54" length="8"/><text>Vanadium</text></annotation></passage><passage><infon key="type">abstract</infon><offset>112</offset><text>Vanadium (V) contamination in soil has received extensive attention due to its high toxicity. The change of mobility and bioavailability of soil V and the effects of V on the soil microbial community were studied under conditions of different V(V) spiking concentrations (0, 100, 250, and 500 mg kg-1) and aging time (1, 7, 14, 30, 45, and 60 d). The results showed that soil V mainly presented as V(IV) of all treatments throughout the aging process. At high levels of V(V) loading (250 and 500 mg kg-1), soil V(V) showed a downward trend, while bioavailable V did not change significantly within 60 d's aging. The analysis of soil bacterial community showed that Proteobacteria was the most abundant phylum in all soils, and the dominant genera Sphingomonas and Lysobacter can well adapt to high concentration V. These microorganisms exhibited great potential for bioremediation of V-contaminated soils.</text><annotation id="10"><infon key="identifier">MESH:D014639</infon><infon key="type">Chemical</infon><location offset="112" length="8"/><text>Vanadium</text></annotation><annotation id="11"><infon key="identifier">MESH:D014639</infon><infon key="type">Chemical</infon><location offset="122" length="1"/><text>V</text></annotation><annotation id="12"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="196" length="8"/><text>toxicity</text></annotation><annotation id="13"><infon key="identifier">MESH:D014639</infon><infon key="type">Chemical</infon><location offset="257" length="1"/><text>V</text></annotation><annotation id="14"><infon key="identifier">MESH:D014639</infon><infon key="type">Chemical</infon><location offset="278" length="1"/><text>V</text></annotation><annotation id="15"><infon key="identifier">MESH:D014639</infon><infon key="type">Chemical</infon><location offset="672" length="1"/><text>V</text></annotation><annotation id="16"><infon key="identifier">MESH:D014639</infon><infon key="type">Chemical</infon><location offset="924" length="2"/><text>V.</text></annotation><annotation id="17"><infon key="identifier">MESH:D014639</infon><infon key="type">Chemical</infon><location offset="996" length="1"/><text>V</text></annotation></passage></document>
<document><id>37904325</id><passage><infon key="journal">Australas Psychiatry;2023Oct30 10398562231211111. doi:10.1177/10398562231211111</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">O'Connor N, Schuwirth L, Bhatt A, Lyubomirsky A, </infon><offset>0</offset><text>Is workplace-based assessment achievable in practice? Response to Holmes.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="66" length="6"/><text>Holmes</text></annotation></passage><passage><infon key="type">abstract</infon><offset>74</offset></passage></document>
<document><id>37905025</id><passage><infon key="journal">bioRxiv;2023Oct17. doi:10.1101/2023.10.16.562617</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614871</infon><infon key="type">title</infon><infon key="authors">Kim T, Pasupathy A, </infon><offset>0</offset><text>Neural correlates of crowding in macaque area V4.</text><annotation id="1"><infon key="identifier">MESH:D008310</infon><infon key="type">Disease</infon><location offset="21" length="8"/><text>crowding</text></annotation></passage><passage><infon key="type">abstract</infon><offset>50</offset><text>Visual crowding refers to the phenomenon where a target object that is easily identifiable in isolation becomes difficult to recognize when surrounded by other stimuli (distractors). Extensive psychophysical studies support two alternative possibilities for the underlying mechanisms. One hypothesis suggests that crowding results from the loss of visual information due to pooled encoding of multiple nearby stimuli in the mid-level processing stages along the ventral visual pathway. Alternatively, crowding may arise from limited resolution in decoding object information during recognition and the encoded information may remain inaccessible unless it is salient. To rigorously test these alternatives, we studied the responses of single neurons in macaque area V4, an intermediate stage of the ventral, object-processing pathway, to parametrically designed crowded displays and their texture-statistics matched metameric counterparts. Our investigations reveal striking parallels between how crowding parameters, e.g., number, distance, and position of distractors, influence human psychophysical performance and V4 shape selectivity. Importantly, we found that enhancing the salience of a target stimulus could reverse crowding effects even in highly cluttered scenes and such reversals could be protracted reflecting a dynamical process. Overall, we conclude that a pooled encoding of nearby stimuli cannot explain the observed responses and we propose an alternative model where V4 neurons preferentially encode salient stimuli in crowded displays. Significance Statement: Psychophysicists have long studied the phenomena of visual crowding, but the underlying neural mechanisms are unknown. Our results reveal striking correlations between the responses of neurons in mid-level visual cortical area V4 and psychophysical demonstrations, revealing that crowding is influenced not only by the number and spatial arrangement of distractors but also by the similarity of features between target and distractors, as well as among the distractors themselves. Overall, our studies provide strong evidence that the visual system uses strategies to preferentially encode salient features in a visual scene presumably to process visual information efficiently. When multiple nearby stimuli are equally salient, the phenomenon of crowding ensues.</text><annotation id="10"><infon key="identifier">MESH:D008310</infon><infon key="type">Disease</infon><location offset="50" length="15"/><text>Visual crowding</text></annotation><annotation id="11"><infon key="identifier">MESH:D008310</infon><infon key="type">Disease</infon><location offset="364" length="8"/><text>crowding</text></annotation><annotation id="12"><infon key="identifier">MESH:D008310</infon><infon key="type">Disease</infon><location offset="551" length="8"/><text>crowding</text></annotation><annotation id="13"><infon key="identifier">MESH:D008310</infon><infon key="type">Disease</infon><location offset="1047" length="8"/><text>crowding</text></annotation><annotation id="14"><infon key="identifier">MESH:D008310</infon><infon key="type">Disease</infon><location offset="1275" length="8"/><text>crowding</text></annotation><annotation id="15"><infon key="identifier">MESH:D008310</infon><infon key="type">Disease</infon><location offset="1683" length="15"/><text>visual crowding</text></annotation><annotation id="16"><infon key="identifier">MESH:D008310</infon><infon key="type">Disease</infon><location offset="1911" length="8"/><text>crowding</text></annotation><annotation id="17"><infon key="identifier">MESH:D008310</infon><infon key="type">Disease</infon><location offset="2378" length="8"/><text>crowding</text></annotation></passage></document>
<document><id>37905375</id><passage><infon key="journal">Nanoscale;2023Oct31. doi:10.1039/d3nr03655c</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Shen K, Li L, Tan F, Wu S, Jin T, You J, Chee MY, Yan Y, Lew WS, </infon><offset>0</offset><text>Hollow spherical Mn0.5Zn0.5Fe2O4 nanoparticles with a magnetic vortex configuration for enhanced magnetic hyperthermia efficacy.</text></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>Conventional magnetic nanoagents in cancer hyperthermia therapy suffer from a low magnetic heating efficiency. To address this issue, researchers have pursued magnetic nanoparticles with topological magnetic domain structures, such as the vortex-domain structure, to enhance the magnetic heating performance of conventional nanoparticles while maintaining excellent biocompatibility. In this study, we synthesized hollow spherical Mn0.5Zn0.5Fe2O4 (MZF-HS) nanoparticles using a straightforward solvothermal method, yielding samples with an average outer diameter of approximately 350 nm and an average inner diameter of about 220 nm. The heating efficiency of the nanoparticles was experimentally verified, and the specific absorption rate (SAR) value of the hollow MZF was found to be approximately 1.5 times that of solid MZF. The enhanced heating performance is attributed to the vortex states in the hollow MZF structure as validated with micromagnetic simulation studies. In vitro studies demonstrated the lower cell viability of breast cancer cells (MCF-7, BT549, and 4T1) after MHT in the presence of MZF-HS. The synthesized MZF caused 51% cell death after MHT, while samples of MZF-HS resulted in 77% cell death. Our findings reveal that magnetic particles with a vortex state demonstrate superior heating efficiency, highlighting the potential of hollow spherical particles as effective heat generators for MHT applications.</text><annotation id="12"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="165" length="6"/><text>cancer</text></annotation><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="577" length="6"/><text>MZF-HS</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="895" length="3"/><text>MZF</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="953" length="3"/><text>MZF</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1040" length="3"/><text>MZF</text></annotation><annotation id="17"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1164" length="13"/><text>breast cancer</text></annotation><annotation id="18"><infon key="identifier">CVCL:0031</infon><infon key="type">CellLine</infon><location offset="1185" length="5"/><text>MCF-7</text></annotation><annotation id="19"><infon key="identifier">CVCL:1092</infon><infon key="type">CellLine</infon><location offset="1192" length="5"/><text>BT549</text></annotation><annotation id="20"><infon key="identifier">CVCL:0125</infon><infon key="type">CellLine</infon><location offset="1203" length="3"/><text>4T1</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1237" length="6"/><text>MZF-HS</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1261" length="3"/><text>MZF</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1315" length="6"/><text>MZF-HS</text></annotation></passage></document>
<document><id>37905726</id><passage><infon key="journal">Rhinology;2023Oct31. doi:10.4193/Rhin23.220</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Alanzi OA, AlBlaies WF, Elnadif IA, Riga MG, </infon><offset>0</offset><text>Biases related to periostin levels in chronic rhinosinusitis with nasal polyposis: a systematic review.</text><annotation id="2"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="18" length="9"/><text>periostin</text></annotation><annotation id="3"><infon key="identifier">MESH:D000092562</infon><infon key="type">Disease</infon><location offset="38" length="43"/><text>chronic rhinosinusitis with nasal polyposis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>BACKGROUND: The role of periostin in the pathophysiology of chronic rhinosinusitis with nasal polyposis (CRSwNP) has been debated in the literature, with several authors proposing periostin as a potential biomarker or theurapeutical target. However, the mechanisms regulating the systematic or local periostin production in both CRSwNP patients and controls remain elusive. METHODOLOGY: Any factors reported to affect periostin expression in polyp tissue samples, nasal mucosa samples, serum and nasal secretions were considered as primary outcomes in this systematic review. Interactions or synergistic effects between bias factors were considered as secondary outcomes. RESULTS: Eosinophilic CRSwNP, large polyp size and radiological severity were found to be high-risk, positive bias factors for periostin levels in polyp tissue samples, while the role of atopy and asthma has been debated. Immunotherapy and eosinophilic endotype were identified as biases for serum periostin measurements, while steroids and non-steroidal anti-inflammatory drug exacerbated respiratory disease remain of unclear risk. Bronchal asthma, eosinophilic endotype and immunotherapy have been reported to bias periostin measurements in nasal secretions. CONCLUSIONS: The relevant literature is extremely limited and little is actually known about the intrinsic or extrinsic factors affecting periostin measurements. The synthesis of the existing literature should be done with cautiousness.</text><annotation id="29"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="128" length="9"/><text>periostin</text></annotation><annotation id="30"><infon key="identifier">MESH:D000092562</infon><infon key="type">Disease</infon><location offset="164" length="43"/><text>chronic rhinosinusitis with nasal polyposis</text></annotation><annotation id="31"><infon key="identifier">MESH:D000092562</infon><infon key="type">Disease</infon><location offset="209" length="6"/><text>CRSwNP</text></annotation><annotation id="32"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="284" length="9"/><text>periostin</text></annotation><annotation id="33"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="404" length="9"/><text>periostin</text></annotation><annotation id="34"><infon key="identifier">MESH:D000092562</infon><infon key="type">Disease</infon><location offset="433" length="6"/><text>CRSwNP</text></annotation><annotation id="35"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="522" length="9"/><text>periostin</text></annotation><annotation id="36"><infon key="identifier">MESH:D011127</infon><infon key="type">Disease</infon><location offset="546" length="5"/><text>polyp</text></annotation><annotation id="37"><infon key="identifier">MESH:D017681</infon><infon key="type">Disease</infon><location offset="785" length="12"/><text>Eosinophilic</text></annotation><annotation id="38"><infon key="identifier">MESH:D000092562</infon><infon key="type">Disease</infon><location offset="798" length="6"/><text>CRSwNP</text></annotation><annotation id="39"><infon key="identifier">MESH:D011127</infon><infon key="type">Disease</infon><location offset="812" length="5"/><text>polyp</text></annotation><annotation id="40"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="903" length="9"/><text>periostin</text></annotation><annotation id="41"><infon key="identifier">MESH:D011127</infon><infon key="type">Disease</infon><location offset="923" length="5"/><text>polyp</text></annotation><annotation id="42"><infon key="identifier">MESH:C564133</infon><infon key="type">Disease</infon><location offset="963" length="5"/><text>atopy</text></annotation><annotation id="43"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="973" length="6"/><text>asthma</text></annotation><annotation id="44"><infon key="identifier">MESH:D017681</infon><infon key="type">Disease</infon><location offset="1016" length="12"/><text>eosinophilic</text></annotation><annotation id="45"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="1074" length="9"/><text>periostin</text></annotation><annotation id="46"><infon key="identifier">MESH:D013256</infon><infon key="type">Chemical</infon><location offset="1104" length="8"/><text>steroids</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1121" length="14"/><text>steroidal anti</text></annotation><annotation id="48"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1136" length="12"/><text>inflammatory</text></annotation><annotation id="49"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="1166" length="19"/><text>respiratory disease</text></annotation><annotation id="50"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="1210" length="15"/><text>Bronchal asthma</text></annotation><annotation id="51"><infon key="identifier">MESH:D017681</infon><infon key="type">Disease</infon><location offset="1227" length="12"/><text>eosinophilic</text></annotation><annotation id="52"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="1294" length="9"/><text>periostin</text></annotation><annotation id="53"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="1476" length="9"/><text>periostin</text></annotation></passage><relation id="R1"><infon key="score">0.9991</infon><infon key="role1">Disease|MESH:D001249</infon><infon key="role2">Gene|10631</infon><infon key="type">Association</infon><node refid="0" role="16,13"/></relation><relation id="R2"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D000092562</infon><infon key="role2">Gene|10631</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.9991</infon><infon key="role1">Disease|MESH:D011127</infon><infon key="role2">Gene|10631</infon><infon key="type">Association</infon><node refid="2" role="9,8"/></relation><relation id="R4"><infon key="score">0.9961</infon><infon key="role1">Chemical|MESH:D013256</infon><infon key="role2">Disease|MESH:D012140</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="19,22"/></relation><relation id="R5"><infon key="score">0.9715</infon><infon key="role1">Disease|MESH:D017681</infon><infon key="role2">Gene|10631</infon><infon key="type">Association</infon><node refid="4" role="10,13"/></relation></document>
<document><id>37906077</id><passage><infon key="journal">J Contin Educ Nurs;2023Nov; 54 (11) 497. doi:10.3928/00220124-20231011-04</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Embree JL, Liebig D, </infon><offset>0</offset><text>Nurse as Leader, A Pillar of Professional Identity.</text></passage><passage><infon key="type">abstract</infon><offset>52</offset><text>The nurse as leader is a critical pillar of nursing professional identity to support ongoing development of nurses in a safe, effective, and healthy work environment. Defined as "inspiring self and others to transform a shared vision into reality" (University of Kansas School of Nursing, 2023), the Nurse as Leader Pillar is developed throughout a nurse's career. Starting with nursing school, students must learn nursing leadership skills and develop and integrate leadership characteristics into their practice. Professional development specialists must embed these characteristics into nursing education, as all nurses are leaders. Current nurses in practice must set the stage and model leadership in their environment as new nurses are introduced into the profession. [J Contin Educ Nurs. 2023;54(11):497-500.].</text></passage></document>
<document><id>37906428</id><passage><infon key="journal">J Agric Food Chem;2023Oct31. doi:10.1021/acs.jafc.3c03952</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Shao WB, Luo RS, Meng J, Lv XK, Xiang HM, Xiao WL, Zhou X, Liu LW, Wu ZB, Yang S, </infon><offset>0</offset><text>Engineering Phenothiazine-Based Functional Mimics of Host Defense Peptides as New Agrochemical Candidates: Design, Synthesis, and Antibacterial Evaluation.</text><annotation id="2"><infon key="identifier">MESH:C031637</infon><infon key="type">Chemical</infon><location offset="12" length="13"/><text>Phenothiazine</text></annotation><annotation id="3"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="66" length="8"/><text>Peptides</text></annotation></passage><passage><infon key="type">abstract</infon><offset>156</offset><text>In the protracted "arms race" between host and plant pathogenic bacteria, host organisms have evolved powerful weapons known as host defense peptides (HDPs). However, natural HDPs are not suitable for large-scale applications; therefore, researchers have chosen to develop bespoke small-molecule functional mimics. Phenothiazine derivatives were developed as functional HDPs mimics, owing to their broad biological activity and high lipophilicity. The phenothiazine analogues designed in this study exhibited excellent in vitro bioactivity against the three Gram-negative bacteria Xanthomonas oryzae pv oryzae, Xanthomonas axonopodis pv citri, and Pseudomonas syringae pv actinidiae, with optimal EC50 values of 0.80, 0.31, and 1.91 mug/mL, respectively. Preliminary evidence suggests that compound C2 may act on bacterial cell membranes and interact with bacterial Deoxyribonucleic acid in the groove binding mode. In vivo trials showed that compound C2 was highly effective against rice leaf blight (51.97-56.69%), with activity superior to those of bismerthiazol (40.7-43.4%) and thiodiazole copper (30.2-37.1%). Our study provides strong evidence to support the development of phenothiazine derivatives into pesticide candidates.</text><annotation id="12"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="297" length="8"/><text>peptides</text></annotation><annotation id="13"><infon key="identifier">MESH:C031637</infon><infon key="type">Chemical</infon><location offset="471" length="13"/><text>Phenothiazine</text></annotation><annotation id="14"><infon key="identifier">MESH:C031637</infon><infon key="type">Chemical</infon><location offset="608" length="13"/><text>phenothiazine</text></annotation><annotation id="15"><infon key="identifier">MESH:C023714</infon><infon key="type">Chemical</infon><location offset="955" length="2"/><text>C2</text></annotation><annotation id="16"><infon key="identifier">MESH:C023714</infon><infon key="type">Chemical</infon><location offset="1108" length="2"/><text>C2</text></annotation><annotation id="17"><infon key="identifier">MESH:C000608952</infon><infon key="type">Chemical</infon><location offset="1208" length="13"/><text>bismerthiazol</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1239" length="18"/><text>thiodiazole copper</text></annotation><annotation id="19"><infon key="identifier">MESH:C031637</infon><infon key="type">Chemical</infon><location offset="1337" length="13"/><text>phenothiazine</text></annotation></passage><relation id="R1"><infon key="score">0.4701</infon><infon key="role1">Chemical|MESH:C000608952</infon><infon key="role2">Chemical|MESH:C023714</infon><infon key="type">Comparison</infon><node refid="0" role="7,6"/></relation></document>
<document><id>37906802</id><passage><infon key="journal">Andes Pediatr;2022Dec; 93 (6) 851. doi:10.32641/andespediatr.v93i6.3903</infon><infon key="year">2022</infon><infon key="type">title</infon><infon key="authors">Saravia S, D&amp;#xed;az-Castrill&amp;#xf3;n F, Cruzat-Mandich C, Lizana-Calder&amp;#xf3;n P, G&amp;#xf3;mez D, Corona F, </infon><offset>0</offset><text>[Parental feeding strategies in children with Avoidant/Restrictive Food Intake Disorder (ARFID): Association with food refusal behavior].</text><annotation id="3"><infon key="identifier">MESH:D000080146</infon><infon key="type">Disease</infon><location offset="46" length="41"/><text>Avoidant/Restrictive Food Intake Disorder</text></annotation><annotation id="4"><infon key="identifier">MESH:D000080146</infon><infon key="type">Disease</infon><location offset="89" length="5"/><text>ARFID</text></annotation><annotation id="5"><infon key="type">Disease</infon><location offset="119" length="7"/><text>refusal</text></annotation></passage><passage><infon key="type">abstract</infon><offset>138</offset><text>Avoidance/Restriction of Food Intake Disorder (ARFID) is characterized by persistent avoidance and/or restriction of food intake, with three clinical presentations: lack of interest in food, selectivity based on sensory sensitivity, and fear of aversive consequences. The strategies used by parents during mealtimes may predispose or maintain the child's food refusal. OBJECTIVE: to determine the associa tion between parental strategies used during mealtimes and food refusal behavior in ARFID children. PATIENTS AND METHOD: Cross-sectional research. Non-probabilistic sampling was used for the selec tion of participants. Twenty-four parents whose children had been diagnosed with ARFID participa ted. ARFID subtypes were considered according to DSM-5 criteria: limited appetite, selective eating and fear of eating. Exclusion criteria were ARFID of organic cause and/or pervasive developmental disorders. The Child Eating Behaviors Questionnaire and the Child Feeding Questionnaire were used for data collection. RESULTS: An association was evidenced between the parental eating strategy of pressure to eat with food refusal behavior, and with child eating behaviors of emotional underfeeding (p = 0.046), slowness to eat (p = 0.016), refusal in front of food (p = 0.019) and satiety response (p = 0.003). CONCLUSION: Eating behaviors frequently perceived by parents with children diagnosed with ARFID are related to the dimension of negative approach towards food, such as satiety response, food refusal, slowness to eat and emotional underfeeding.</text><annotation id="22"><infon key="identifier">MESH:D000080146</infon><infon key="type">Disease</infon><location offset="138" length="45"/><text>Avoidance/Restriction of Food Intake Disorder</text></annotation><annotation id="23"><infon key="identifier">MESH:D000080146</infon><infon key="type">Disease</infon><location offset="185" length="5"/><text>ARFID</text></annotation><annotation id="24"><infon key="type">Disease</infon><location offset="498" length="7"/><text>refusal</text></annotation><annotation id="25"><infon key="type">Disease</infon><location offset="607" length="7"/><text>refusal</text></annotation><annotation id="26"><infon key="identifier">MESH:D000080146</infon><infon key="type">Disease</infon><location offset="627" length="5"/><text>ARFID</text></annotation><annotation id="27"><infon key="identifier">MESH:D000080146</infon><infon key="type">Disease</infon><location offset="821" length="5"/><text>ARFID</text></annotation><annotation id="28"><infon key="identifier">MESH:D000080146</infon><infon key="type">Disease</infon><location offset="842" length="5"/><text>ARFID</text></annotation><annotation id="29"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="902" length="16"/><text>limited appetite</text></annotation><annotation id="30"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="920" length="16"/><text>selective eating</text></annotation><annotation id="31"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="941" length="14"/><text>fear of eating</text></annotation><annotation id="32"><infon key="identifier">MESH:D000080146</infon><infon key="type">Disease</infon><location offset="981" length="5"/><text>ARFID</text></annotation><annotation id="33"><infon key="identifier">MESH:D002659</infon><infon key="type">Disease</infon><location offset="1011" length="33"/><text>pervasive developmental disorders</text></annotation><annotation id="34"><infon key="type">Disease</infon><location offset="1258" length="7"/><text>refusal</text></annotation><annotation id="35"><infon key="type">Disease</infon><location offset="1376" length="7"/><text>refusal</text></annotation><annotation id="36"><infon key="identifier">MESH:D000080146</infon><infon key="type">Disease</infon><location offset="1537" length="5"/><text>ARFID</text></annotation><annotation id="37"><infon key="type">Disease</infon><location offset="1638" length="7"/><text>refusal</text></annotation></passage></document>
<document><id>37907168</id><passage><infon key="journal">Chemosphere;2023Oct29 140528. doi:10.1016/j.chemosphere.2023.140528</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Egbadon EO, Wigley K, Nwoba ST, Carere CR, Weaver L, Baronian K, Burbery L, Gostomski PA, </infon><offset>0</offset><text>Microaerobic methane-driven denitrification in a biotrickle bed - Investigating the active microbial biofilm community composition using RNA-stable isotope probing.</text><annotation id="1"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="13" length="7"/><text>methane</text></annotation></passage><passage><infon key="type">abstract</infon><offset>165</offset><text>A microaerobic (2% O2 v/v) biotrickle bed reactor supplied continuously with 2% methane to drive nitrate removal (MAME-D) was investigated using 16S rDNA and rRNA amplicon sequencing in combination with RNA-stable isotope probing (RNA-SIP) to identify the active microorganisms. Methane removal rates varied from 500 to 1000 mmol m-3h-1 and nitrate removal rates from 25 to 58 mmol m-3h-1 over 55 days of operation. Biofilm samples from the column were incubated in serum bottles supplemented with 13CH4. 16S rDNA analysis indicated a simple community structure in which four taxa accounted for 45% of the total relative abundance (RA). Dominant genera included the methanotroph Methylosinus and known denitrifiers Nubsella and Pseudoxanthomonas; along with a probable denitrifier assigned to the order Obscuribacterales. The 16S rRNA results revealed the methanotrophs Methylocystis (15% RA) and Methylosinus (10% RA) and the denitrifiers Arenimonas (10% RA) and Pseudoxanthomonas (7% RA) were the most active genera. Obscuribacterales was the most active taxa in the community at 22% RA. Activity was confirmed by the Delta buoyant density changes with time for the taxa, indicating most of the community activity was associated with methane oxidation and subsequent consumption of methanotrophic metabolic intermediates by the denitrifiers. This is the first report of RNA stable isotope probing within a microaerobic methane driven denitrification system and the active community was markedly different from the full community identified via 16S-rDNA analysis.</text><annotation id="10"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="184" length="2"/><text>O2</text></annotation><annotation id="11"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="245" length="7"/><text>methane</text></annotation><annotation id="12"><infon key="identifier">MESH:D009566</infon><infon key="type">Chemical</infon><location offset="262" length="7"/><text>nitrate</text></annotation><annotation id="13"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="444" length="7"/><text>Methane</text></annotation><annotation id="14"><infon key="identifier">MESH:D009566</infon><infon key="type">Chemical</infon><location offset="506" length="7"/><text>nitrate</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="663" length="5"/><text>13CH4</text></annotation><annotation id="16"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="1401" length="7"/><text>methane</text></annotation><annotation id="17"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="1586" length="7"/><text>methane</text></annotation></passage><relation id="R1"><infon key="score">0.8144</infon><infon key="role1">Chemical|MESH:D008697</infon><infon key="role2">Chemical|MESH:D009566</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="2,3"/></relation></document>
<document><id>37908218</id><passage><infon key="journal">JCEM Case Rep;2023Sep; 1 (5) 100. doi:10.1210/jcemcr/luad100</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10580440</infon><infon key="type">title</infon><infon key="authors">Cutrone L, Subauste J, Gomez-Sanchez C, Joiner S, </infon><offset>0</offset><text>Metastatic Merkel Cell Carcinoma Within a Cortisol-producing Adrenal Adenoma.</text><annotation id="3"><infon key="identifier">MESH:D015266</infon><infon key="type">Disease</infon><location offset="11" length="21"/><text>Merkel Cell Carcinoma</text></annotation><annotation id="4"><infon key="identifier">MESH:D006854</infon><infon key="type">Chemical</infon><location offset="42" length="8"/><text>Cortisol</text></annotation><annotation id="5"><infon key="identifier">MESH:D018246</infon><infon key="type">Disease</infon><location offset="61" length="15"/><text>Adrenal Adenoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>78</offset><text>A 54-year-old man with hypertension, type 2 diabetes mellitus, and a history of Merkel cell carcinoma (MCC) of the right thigh presented to the emergency department with a 4-day history of right lower-quadrant abdominal pain associated with constipation and decreased appetite. Workup showed a heterogenous 6-cm right adrenal mass with macroscopic fat. Imaging was suggestive of benign pathology. Hormonal workup for the adrenal nodule led to the diagnosis of Cushing syndrome. The patient underwent a right adrenalectomy for Cushing syndrome with pathology revealing a 6.5-cm adrenocortical adenoma harboring a 2-cm, well-circumscribed neuroendocrine tumor consistent with metastatic MCC. Adrenal collision tumors are exceedingly rare. This case describes a collision tumor that has not previously been identified-a cortisol-producing adrenal adenoma and metastatic MCC.</text><annotation id="24"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="101" length="12"/><text>hypertension</text></annotation><annotation id="25"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="115" length="24"/><text>type 2 diabetes mellitus</text></annotation><annotation id="26"><infon key="identifier">MESH:D015266</infon><infon key="type">Disease</infon><location offset="158" length="21"/><text>Merkel cell carcinoma</text></annotation><annotation id="27"><infon key="identifier">MESH:D015266</infon><infon key="type">Disease</infon><location offset="181" length="3"/><text>MCC</text></annotation><annotation id="28"><infon key="identifier">MESH:D015746</infon><infon key="type">Disease</infon><location offset="288" length="14"/><text>abdominal pain</text></annotation><annotation id="29"><infon key="identifier">MESH:D003248</infon><infon key="type">Disease</infon><location offset="319" length="12"/><text>constipation</text></annotation><annotation id="30"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="336" length="18"/><text>decreased appetite</text></annotation><annotation id="31"><infon key="identifier">MESH:D016606</infon><infon key="type">Disease</infon><location offset="499" length="14"/><text>adrenal nodule</text></annotation><annotation id="32"><infon key="identifier">MESH:D003480</infon><infon key="type">Disease</infon><location offset="538" length="16"/><text>Cushing syndrome</text></annotation><annotation id="33"><infon key="identifier">MESH:D003480</infon><infon key="type">Disease</infon><location offset="604" length="16"/><text>Cushing syndrome</text></annotation><annotation id="34"><infon key="identifier">MESH:D018246</infon><infon key="type">Disease</infon><location offset="655" length="22"/><text>adrenocortical adenoma</text></annotation><annotation id="35"><infon key="identifier">MESH:D018358</infon><infon key="type">Disease</infon><location offset="715" length="20"/><text>neuroendocrine tumor</text></annotation><annotation id="36"><infon key="identifier">MESH:D015266</infon><infon key="type">Disease</infon><location offset="763" length="3"/><text>MCC</text></annotation><annotation id="37"><infon key="identifier">MESH:D000310</infon><infon key="type">Disease</infon><location offset="768" length="24"/><text>Adrenal collision tumors</text></annotation><annotation id="38"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="837" length="15"/><text>collision tumor</text></annotation><annotation id="39"><infon key="identifier">MESH:D006854</infon><infon key="type">Chemical</infon><location offset="895" length="8"/><text>cortisol</text></annotation><annotation id="40"><infon key="identifier">MESH:D018246</infon><infon key="type">Disease</infon><location offset="914" length="15"/><text>adrenal adenoma</text></annotation><annotation id="41"><infon key="identifier">MESH:D015266</infon><infon key="type">Disease</infon><location offset="945" length="3"/><text>MCC</text></annotation></passage><relation id="R1"><infon key="score">0.9598</infon><infon key="role1">Chemical|MESH:D006854</infon><infon key="role2">Disease|MESH:D018246</infon><infon key="type">Association</infon><node refid="0" role="1,2"/></relation></document>
<document><id>37909271</id><passage><infon key="journal">Phys Chem Chem Phys;2023Nov01. doi:10.1039/d3cp03604a</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Omezzine Gnioua M, Spesyvyi A, &amp;#x160;pan&amp;#x11b;l P, </infon><offset>0</offset><text>Gas phase H+, H3O+ and NH4+ affinities of oxygen-bearing volatile organic compounds; DFT calculations for soft chemical ionisation mass spectrometry.</text><annotation id="4"><infon key="identifier">MESH:C027727</infon><infon key="type">Chemical</infon><location offset="14" length="4"/><text>H3O+</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="23" length="4"/><text>NH4+</text></annotation><annotation id="6"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="42" length="6"/><text>oxygen</text></annotation><annotation id="7"><infon key="identifier">MESH:D055549</infon><infon key="type">Chemical</infon><location offset="57" length="26"/><text>volatile organic compounds</text></annotation></passage><passage><infon key="type">abstract</infon><offset>150</offset><text>Quantum chemistry calculations were performed using the density functional theory, DFT, to understand the structures and energetics of organic ions relevant to gas phase ion chemistry in soft chemical ionisation mass spectrometry analytical methods. Geometries of a range of neutral volatile organic compound molecules and ions resulting from protonation, the addition of H3O+ and the addition of NH4+ were optimised using the B3LYP hybrid DFT method. Then, the total energies and the normal mode vibrational frequencies were determined, and the total enthalpies of the neutral molecules and ions were calculated for the standard temperature and pressure. The calculations were performed for several feasible structures of each of the ions. The proton affinities of several benchmark molecules agree with the accepted values within +-4 kJ mol-1, indicating that B3LYP/6-311++G(d,p) provides chemical accuracy for oxygen-containing volatile organic compounds. It was also found that the binding energies of H3O+ and NH4+ to molecules correlate with their proton affinities. The results contribute to the understanding of ligand switching ion-molecule reactions important for secondary electrospray ionisation, SESI, and selected ion flow tube, SIFT, mass spectrometries.</text><annotation id="14"><infon key="identifier">MESH:C027727</infon><infon key="type">Chemical</infon><location offset="522" length="4"/><text>H3O+</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="547" length="4"/><text>NH4+</text></annotation><annotation id="16"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1063" length="6"/><text>oxygen</text></annotation><annotation id="17"><infon key="identifier">MESH:D055549</infon><infon key="type">Chemical</infon><location offset="1081" length="26"/><text>volatile organic compounds</text></annotation><annotation id="18"><infon key="identifier">MESH:C027727</infon><infon key="type">Chemical</infon><location offset="1156" length="4"/><text>H3O+</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1165" length="4"/><text>NH4+</text></annotation></passage><relation id="R1"><infon key="score">0.9911</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Chemical|MESH:D055549</infon><infon key="type">Association</infon><node refid="0" role="3,4"/></relation></document>
<document><id>37909981</id><passage><infon key="type">title</infon><offset>0</offset><text>Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.</text><annotation id="3"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="60" length="5"/><text>PD-L1</text></annotation><annotation id="4"><infon key="identifier">MESH:D000077192</infon><infon key="type">Disease</infon><location offset="92" length="19"/><text>Lung Adenocarcinoma</text></annotation><annotation id="5"><infon key="identifier">MESH:D002294</infon><infon key="type">Disease</infon><location offset="116" length="23"/><text>Squamous Cell Carcinoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>141</offset><text>BACKGROUND/AIM: Lung adenocarcinoma and lung squamous cell carcinoma represent the most prevalent subtypes of non-small cell lung cancer eligible for surgery in the early stages. The emergence of immune checkpoint inhibitors as adjuvant therapy has shown promising potential in improving the postoperative prognosis of patients with lung cancer. Hence, a comprehensive understanding of the clinicopathological and molecular features of programmed cell death ligand-1 (PD-L1) expression in lung adenocarcinoma and squamous cell carcinoma is crucial. PATIENTS AND METHODS: In this retrospective study, we conducted a comparative analysis of clinicopathological features associated with the expression of PD-L1, stratifying patients who underwent surgical resection into two distinct groups: 289 patients with lung adenocarcinoma and 66 with lung squamous cell carcinoma. Furthermore, we investigated the associations between the expression of PD-L1 and genetic alterations in well-established oncogenic driver mutations. RESULTS: Among the cases, 52.9% exhibited negative PD-L1 expression, 32.9% had low PD-L1 expression, and 12.3% had high PD-L1 expression in adenocarcinoma, while the PD-L1 expression in squamous cell carcinoma showed a near-even distribution. Notably, male sex, smoking history, the presence of invasive pathological factors, and disease progression significantly influenced PD-L1 expression in adenocarcinoma, whereas none of these factors were associated with PD-L1 expression in squamous cell carcinoma. Additionally, the distribution of PD-L1 expression varied based on the type of specific driver gene mutation in adenocarcinoma. CONCLUSION: The present study revealed clinicopathological and molecular differences between lung adenocarcinoma and squamous cell carcinoma patients promoting the expression of PD-L1.</text><annotation id="33"><infon key="identifier">MESH:D000077192</infon><infon key="type">Disease</infon><location offset="157" length="19"/><text>Lung adenocarcinoma</text></annotation><annotation id="34"><infon key="identifier">MESH:D002294</infon><infon key="type">Disease</infon><location offset="181" length="28"/><text>lung squamous cell carcinoma</text></annotation><annotation id="35"><infon key="identifier">MESH:D002289</infon><infon key="type">Disease</infon><location offset="251" length="26"/><text>non-small cell lung cancer</text></annotation><annotation id="36"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="474" length="11"/><text>lung cancer</text></annotation><annotation id="37"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="577" length="30"/><text>programmed cell death ligand-1</text></annotation><annotation id="38"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="609" length="5"/><text>PD-L1</text></annotation><annotation id="39"><infon key="identifier">MESH:D000077192</infon><infon key="type">Disease</infon><location offset="630" length="19"/><text>lung adenocarcinoma</text></annotation><annotation id="40"><infon key="identifier">MESH:D002294</infon><infon key="type">Disease</infon><location offset="654" length="23"/><text>squamous cell carcinoma</text></annotation><annotation id="41"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="843" length="5"/><text>PD-L1</text></annotation><annotation id="42"><infon key="identifier">MESH:D000077192</infon><infon key="type">Disease</infon><location offset="948" length="19"/><text>lung adenocarcinoma</text></annotation><annotation id="43"><infon key="identifier">MESH:D002294</infon><infon key="type">Disease</infon><location offset="980" length="28"/><text>lung squamous cell carcinoma</text></annotation><annotation id="44"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1082" length="5"/><text>PD-L1</text></annotation><annotation id="45"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1211" length="5"/><text>PD-L1</text></annotation><annotation id="46"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1243" length="5"/><text>PD-L1</text></annotation><annotation id="47"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1280" length="5"/><text>PD-L1</text></annotation><annotation id="48"><infon key="identifier">MESH:D000230</infon><infon key="type">Disease</infon><location offset="1300" length="14"/><text>adenocarcinoma</text></annotation><annotation id="49"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1326" length="5"/><text>PD-L1</text></annotation><annotation id="50"><infon key="identifier">MESH:D002294</infon><infon key="type">Disease</infon><location offset="1346" length="23"/><text>squamous cell carcinoma</text></annotation><annotation id="51"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1535" length="5"/><text>PD-L1</text></annotation><annotation id="52"><infon key="identifier">MESH:D000230</infon><infon key="type">Disease</infon><location offset="1555" length="14"/><text>adenocarcinoma</text></annotation><annotation id="53"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1622" length="5"/><text>PD-L1</text></annotation><annotation id="54"><infon key="identifier">MESH:D002294</infon><infon key="type">Disease</infon><location offset="1642" length="23"/><text>squamous cell carcinoma</text></annotation><annotation id="55"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1701" length="5"/><text>PD-L1</text></annotation><annotation id="56"><infon key="identifier">MESH:D000230</infon><infon key="type">Disease</infon><location offset="1779" length="14"/><text>adenocarcinoma</text></annotation><annotation id="57"><infon key="identifier">MESH:D000077192</infon><infon key="type">Disease</infon><location offset="1888" length="19"/><text>lung adenocarcinoma</text></annotation><annotation id="58"><infon key="identifier">MESH:D002294</infon><infon key="type">Disease</infon><location offset="1912" length="23"/><text>squamous cell carcinoma</text></annotation><annotation id="59"><infon key="identifier">29126</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1973" length="5"/><text>PD-L1</text></annotation></passage><relation id="R1"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D000230</infon><infon key="role2">Gene|29126</infon><infon key="type">Association</infon><node refid="0" role="18,15"/></relation><relation id="R2"><infon key="score">0.9961</infon><infon key="role1">Disease|MESH:D002294</infon><infon key="role2">Gene|29126</infon><infon key="type">Association</infon><node refid="1" role="2,0"/></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D000077192</infon><infon key="role2">Gene|29126</infon><infon key="type">Association</infon><node refid="2" role="1,0"/></relation></document>
<document><id>37910332</id><passage><infon key="journal">Probiotics Antimicrob Proteins;2023Nov01. doi:10.1007/s12602-023-10176-1</infon><infon key="year">2023</infon><infon key="article-id_pmc">7168299</infon><infon key="type">title</infon><infon key="authors">Barman P, Sharma C, Joshi S, Sharma S, Maan M, Rishi P, Singla N, Saini A, </infon><offset>0</offset><text>In Vivo Acute Toxicity and Therapeutic Potential of a Synthetic Peptide, DP1 in a Staphylococcus aureus Infected Murine Wound Excision Model.</text><annotation id="4"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="14" length="8"/><text>Toxicity</text></annotation><annotation id="5"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="64" length="7"/><text>Peptide</text></annotation><annotation id="6"><infon key="identifier">21781</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38276</infon><location offset="73" length="3"/><text>DP1</text></annotation><annotation id="7"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="104" length="8"/><text>Infected</text></annotation></passage><passage><infon key="type">abstract</infon><offset>142</offset><text>Bacterial infections at the surgical sites are one of the most prevalent skin infections that impair the healing mechanism. They account for about 20% of all types of infections and lead to approximately 75% of surgical-site infection-associated mortality. Several antibiotics, such as cephalosporins, fluoroquinolones, quinolones, penicillin, sulfonamides, etc., that are used to treat such wound infections not only counter infections but also disrupt the normal flora. Moreover, antibiotics, when used for a prolonged duration, may impair the formation of new blood vessels, delay collagen production, or inhibit the migration of certain cells involved in wound repair, leading to an impaired healing process. Therefore, there is a dire need for alternate therapeutic approaches against such infections. Antimicrobial peptides have gained considerable attention as a promising strategy to counter these pathogens and prevent the spread of infection. Recently, we have reported a designed peptide, DP1, and its broad-spectrum in vitro antimicrobial activity against Gram-positive and Gram-negative bacteria. In the present study, in vivo acute toxicity of DP1 was evaluated and even at a high dose (20 mg/kg body weight) of DP1, a 100% survival of mice was observed. Subsequently, a Staphylococcus aureus-infected murine wound excision model was established to assess the wound healing efficacy of DP1. The study revealed significant wound healing vis-a-vis attenuated S. aureus bioburden at the wound site and also controlled the oxidative stress depicting anti-oxidant activity as well. Healing of the infected wounds was also verified by histopathological examination. Based on the results of this study, it can be concluded that DP1 improves wound resolution despite infections and promotes the healing mechanism. Hence, DP1 holds compelling potential as a novel antimicrobial drug that requires further explorations in clinical platforms.</text><annotation id="32"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="142" length="20"/><text>Bacterial infections</text></annotation><annotation id="33"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="215" length="15"/><text>skin infections</text></annotation><annotation id="34"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="309" length="10"/><text>infections</text></annotation><annotation id="35"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="367" length="9"/><text>infection</text></annotation><annotation id="36"><infon key="identifier">MESH:D002511</infon><infon key="type">Chemical</infon><location offset="428" length="14"/><text>cephalosporins</text></annotation><annotation id="37"><infon key="identifier">MESH:D024841</infon><infon key="type">Chemical</infon><location offset="444" length="16"/><text>fluoroquinolones</text></annotation><annotation id="38"><infon key="identifier">MESH:D015363</infon><infon key="type">Chemical</infon><location offset="462" length="10"/><text>quinolones</text></annotation><annotation id="39"><infon key="identifier">MESH:D010406</infon><infon key="type">Chemical</infon><location offset="474" length="10"/><text>penicillin</text></annotation><annotation id="40"><infon key="identifier">MESH:D013449</infon><infon key="type">Chemical</infon><location offset="486" length="12"/><text>sulfonamides</text></annotation><annotation id="41"><infon key="identifier">MESH:D014946</infon><infon key="type">Disease</infon><location offset="534" length="16"/><text>wound infections</text></annotation><annotation id="42"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="568" length="10"/><text>infections</text></annotation><annotation id="43"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="937" length="10"/><text>infections</text></annotation><annotation id="44"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1084" length="9"/><text>infection</text></annotation><annotation id="45"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="1133" length="7"/><text>peptide</text></annotation><annotation id="46"><infon key="identifier">21781</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38276</infon><location offset="1142" length="3"/><text>DP1</text></annotation><annotation id="47"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1288" length="8"/><text>toxicity</text></annotation><annotation id="48"><infon key="identifier">21781</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38276</infon><location offset="1300" length="3"/><text>DP1</text></annotation><annotation id="49"><infon key="identifier">21781</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38276</infon><location offset="1368" length="3"/><text>DP1</text></annotation><annotation id="50"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1449" length="8"/><text>infected</text></annotation><annotation id="51"><infon key="identifier">21781</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38276</infon><location offset="1542" length="3"/><text>DP1</text></annotation><annotation id="52"><infon key="identifier">MESH:D014946</infon><infon key="type">Disease</infon><location offset="1748" length="15"/><text>infected wounds</text></annotation><annotation id="53"><infon key="identifier">21781</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38276</infon><location offset="1877" length="3"/><text>DP1</text></annotation><annotation id="54"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1915" length="10"/><text>infections</text></annotation><annotation id="55"><infon key="identifier">21781</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38276</infon><location offset="1969" length="3"/><text>DP1</text></annotation></passage><relation id="R1"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D013449</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="13,15"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D002511</infon><infon key="role2">Disease|MESH:D014946</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="9,14"/></relation><relation id="R3"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D010406</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="12,15"/></relation><relation id="R4"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D013449</infon><infon key="role2">Disease|MESH:D014946</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="13,14"/></relation><relation id="R5"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D015363</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="11,15"/></relation><relation id="R6"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D010406</infon><infon key="role2">Disease|MESH:D014946</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="12,14"/></relation><relation id="R7"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D015363</infon><infon key="role2">Disease|MESH:D014946</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="11,14"/></relation><relation id="R8"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D024841</infon><infon key="role2">Disease|MESH:D014946</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="10,14"/></relation><relation id="R9"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D002511</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="9,15"/></relation><relation id="R10"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D024841</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Negative_Correlation</infon><node refid="9" role="10,15"/></relation></document>
<document><id>37910683</id><passage><infon key="journal">Opt Lett;2023Nov01; 48 (21) 5483. doi:10.1364/OL.501921</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yu S, Qin M, Zhang Z, </infon><offset>0</offset><text>Phase-mismatched optical parametric oscillators based on aperiodic quasi-phase-matched crystals.</text></passage><passage><infon key="type">abstract</infon><offset>97</offset><text>We present that femtosecond optical parametric oscillators (OPOs) based on aperiodic quasi-phase-matched (AQPM) crystals can be configured to operate in the "phase-mismatched" region. The phase-mismatch-induced frequency chirp is mainly introduced by the subcrystal that first interacts with pump pulses. By optimizing the intracavity group velocity dispersion and by selecting the direction of crystals, OPOs based on AQPM crystals could support the generation of wavelength-tunable, transform-limited pulses in an all-normal-dispersion cavity. In a preliminary experiment, transform-limited optical pulses with a tuning range over 1520-1660 nm were obtained by simply altering the cavity length. This scheme represents a unique and concise scheme of producing widely tunable, chirp-free femtosecond optical pulses.</text></passage></document>
<document><id>37911034</id><passage><infon key="journal">Int Dent J (Phila);1893Jan; 14 (1) 15</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109571</infon><infon key="type">title</infon><infon key="authors">Lord B, </infon><offset>0</offset><text>A Brief Review.</text></passage><passage><infon key="type">abstract</infon><offset>16</offset></passage></document>
<document><id>37911384</id><passage><infon key="journal">Int Dent J (Phila);1890May; 11 (5) 310</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110066</infon><infon key="type">title</infon><offset>0</offset><text>Dental Societies.</text></passage><passage><infon key="type">abstract</infon><offset>18</offset></passage></document>
<document><id>37912084</id><passage><infon key="journal">Int Dent J (Phila);1896Sep; 17 (9) 566</infon><infon key="year">1896</infon><infon key="article-id_pmc">PMC10124448</infon><infon key="type">title</infon><infon key="authors">De Terra P, </infon><offset>0</offset><text>Salubrol, a Substitute for Iodoform.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="8"/><text>Salubrol</text></annotation><annotation id="3"><infon key="identifier">MESH:C010473</infon><infon key="type">Chemical</infon><location offset="27" length="8"/><text>Iodoform</text></annotation></passage><passage><infon key="type">abstract</infon><offset>37</offset></passage></document>
<document><id>37912784</id><passage><infon key="journal">Int Dent J (Phila);1901Mar; 22 (3) 150</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153832</infon><infon key="type">title</infon><infon key="authors">Danforth GR, </infon><offset>0</offset><text>The Duty of Young Men to the Profession.</text></passage><passage><infon key="type">abstract</infon><offset>41</offset></passage></document>
<document><id>37913134</id><passage><infon key="journal">Int Dent J (Phila);1903Sep; 24 (9) 666</infon><infon key="year">1903</infon><infon key="article-id_pmc">PMC10162210</infon><infon key="type">title</infon><infon key="authors">Stanley NA, </infon><offset>0</offset><text>Points of Interest in a Twenty Years' Practice.</text></passage><passage><infon key="type">abstract</infon><offset>48</offset></passage></document>
<document><id>37913485</id><passage><infon key="journal">Int Dent J (Phila);1904Jul; 25 (7) 505</infon><infon key="year">1904</infon><infon key="article-id_pmc">PMC10169069</infon><infon key="type">title</infon><infon key="authors">Wedelstaedt EK, </infon><offset>0</offset><text>A Reply to Dr. Rhein's Answer.</text></passage><passage><infon key="type">abstract</infon><offset>31</offset></passage></document>
<document><id>37913835</id><passage><infon key="journal">Biochim Biophys Acta Mol Basis Dis;2023Oct30 166920. doi:10.1016/j.bbadis.2023.166920</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ciubuc-Batcu MT, Stapelberg NJC, Headrick JP, Renshaw GMC, </infon><offset>0</offset><text>A mitochondrial nexus in major depressive disorder: Integration with the psycho-immune-neuroendocrine network.</text><annotation id="2"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="2" length="13"/><text>mitochondrial</text></annotation><annotation id="3"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="25" length="25"/><text>major depressive disorder</text></annotation></passage><passage><infon key="type">abstract</infon><offset>111</offset><text>Nervous system processes, including cognition and affective state, fundamentally rely on mitochondria. Impaired mitochondrial function is evident in major depressive disorder (MDD), reflecting cumulative detrimental influences of both extrinsic and intrinsic stressors, genetic predisposition, and mutation. Glucocorticoid 'stress' pathways converge on mitochondria; oxidative and nitrosative stresses in MDD are largely mitochondrial in origin; both initiate cascades promoting mitochondrial DNA (mtDNA) damage with disruptions to mitochondrial biogenesis and tryptophan catabolism. Mitochondrial dysfunction facilitates proinflammatory dysbiosis while directly triggering immuno-inflammatory activation via released mtDNA, mitochondrial lipids and mitochondria associated membranes (MAMs), further disrupting mitochondrial function and mitochondrial quality control, promoting the accumulation of abnormal mitochondria (confirmed in autopsy studies). Established and putative mechanisms highlight a mitochondrial nexus within the psycho-immune neuroendocrine (PINE) network implicated in MDD. Whether lowering neuronal resilience and thresholds for disease, or linking mechanistic nodes within the MDD pathogenic network, impaired mitochondrial function emerges as an important risk, a functional biomarker, providing a therapeutic target in MDD. Several treatment modalities have been demonstrated to reset mitochondrial function, which could benefit those with MDD.</text><annotation id="26"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="223" length="13"/><text>mitochondrial</text></annotation><annotation id="27"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="260" length="25"/><text>major depressive disorder</text></annotation><annotation id="28"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="287" length="3"/><text>MDD</text></annotation><annotation id="29"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="516" length="3"/><text>MDD</text></annotation><annotation id="30"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="532" length="13"/><text>mitochondrial</text></annotation><annotation id="31"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="590" length="13"/><text>mitochondrial</text></annotation><annotation id="32"><infon key="identifier">MESH:D004266</infon><infon key="type">Disease</infon><location offset="604" length="3"/><text>DNA</text></annotation><annotation id="33"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="643" length="13"/><text>mitochondrial</text></annotation><annotation id="34"><infon key="identifier">MESH:D014364</infon><infon key="type">Chemical</infon><location offset="672" length="10"/><text>tryptophan</text></annotation><annotation id="35"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="695" length="25"/><text>Mitochondrial dysfunction</text></annotation><annotation id="36"><infon key="identifier">MESH:D000163</infon><infon key="type">Disease</infon><location offset="785" length="19"/><text>immuno-inflammatory</text></annotation><annotation id="37"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="836" length="13"/><text>mitochondrial</text></annotation><annotation id="38"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="850" length="6"/><text>lipids</text></annotation><annotation id="39"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="922" length="13"/><text>mitochondrial</text></annotation><annotation id="40"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="949" length="13"/><text>mitochondrial</text></annotation><annotation id="41"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="1112" length="13"/><text>mitochondrial</text></annotation><annotation id="42"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="1201" length="3"/><text>MDD</text></annotation><annotation id="43"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="1311" length="3"/><text>MDD</text></annotation><annotation id="44"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="1344" length="13"/><text>mitochondrial</text></annotation><annotation id="45"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="1455" length="3"/><text>MDD</text></annotation><annotation id="46"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="1521" length="13"/><text>mitochondrial</text></annotation><annotation id="47"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="1576" length="3"/><text>MDD</text></annotation></passage><relation id="R1"><infon key="score">0.7019</infon><infon key="role1">Chemical|MESH:D008055</infon><infon key="role2">Disease|MESH:D028361</infon><infon key="type">Association</infon><node refid="0" role="14,11"/></relation><relation id="R2"><infon key="score">0.9615</infon><infon key="role1">Chemical|MESH:D014364</infon><infon key="role2">Disease|MESH:D003865</infon><infon key="type">Association</infon><node refid="1" role="10,5"/></relation><relation id="R3"><infon key="score">0.9912</infon><infon key="role1">Chemical|MESH:D008055</infon><infon key="role2">Disease|MESH:D000163</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="14,12"/></relation><relation id="R4"><infon key="score">0.9239</infon><infon key="role1">Chemical|MESH:D014364</infon><infon key="role2">Disease|MESH:D004266</infon><infon key="type">Association</infon><node refid="3" role="10,8"/></relation><relation id="R5"><infon key="score">0.9934</infon><infon key="role1">Chemical|MESH:D014364</infon><infon key="role2">Disease|MESH:D028361</infon><infon key="type">Association</infon><node refid="4" role="10,6"/></relation></document>
<document><id>37914535</id><passage><infon key="journal">Clin Exp Optom;2023Nov; 106 (8) 930. doi:10.1080/08164622.2022.2131376</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Pinheiro-Costa J, Ribeiro M, Moura R, Madeira D, Falc&amp;#xe3;o-Reis F, Carneiro &amp;#xc2;, </infon><offset>0</offset><text>Macular parameters with and without scleral contact lens in keratoconus using Spectralis optical coherence tomography.</text><annotation id="1"><infon key="identifier">MESH:D007640</infon><infon key="type">Disease</infon><location offset="60" length="11"/><text>keratoconus</text></annotation></passage><passage><infon key="type">abstract</infon><offset>119</offset></passage></document>
<document><id>37914885</id><passage><infon key="journal">Obes Surg;2023Nov02. doi:10.1007/s11695-023-06549-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">1664601</infon><infon key="type">title</infon><infon key="authors">Maria CR, Rodriguez CM, Ines P, Helder V, Mafalda S, Ricardo V, Concei&amp;#xe7;&amp;#xe3;o MM, </infon><offset>0</offset><text>Bismuth-Based Therapy: The New Therapy for Obese Patients Undergoing Gastric Bypass Surgery?</text><annotation id="2"><infon key="identifier">MESH:D001729</infon><infon key="type">Chemical</infon><location offset="0" length="7"/><text>Bismuth</text></annotation><annotation id="3"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="43" length="5"/><text>Obese</text></annotation></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>AIMS: Our aim was to assess, in obese patients undergoing Roux-en Y gastric bypass surgery, the bismuth quadruple therapy (BQT) eradication rates at the first-line Helicobacter pylori (Hp) treatment as proposed by the Maastricht V/Florence consensus in areas with high clarithromycin (CLT) resistance rates-10 days proton pump inhibitor bid and three-in-one single capsule bismuth therapy containing bismuth, metronidazole, and tetracycline, marketed as Pylera four times a day. METHODS: This is a single-center prospective study over a 3-year period. Endoscopy and Hp assessment by histology was performed at baseline, and posttreatment Hp status was assessed by C13 urea breath test 4-6 weeks after the end of therapy. Data analysis was performed using the IBM  SPSS  Statistics 28.0 (IBM Corp. 2021, Armonk, NY) using mostly nonparametric comparisons (alpha = 0.05). RESULTS: The study cohort consisted of 598 adult obese Hp-positive patients [476, 78.6% female, age 43.2 (+- 10.4) years] consecutively scheduled for Hp eradication therapy. Hp was eradicated in 500 patients [83.6.3% (95% CI: 80.4%-86.5%)], and the eradication was independent of gender, age, endoscopic diagnosis, and smoking status (p > 0.05). CONCLUSION: Ten days of BQT did achieve Maastricht V/Florence recommended first-line eradication rates (at least 80%) in obese Portuguese patients undergoing Roux-en Y gastric bypass, being by now the most reliable choice for Hp eradication.</text><annotation id="15"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="125" length="5"/><text>obese</text></annotation><annotation id="16"><infon key="identifier">MESH:D001729</infon><infon key="type">Chemical</infon><location offset="189" length="7"/><text>bismuth</text></annotation><annotation id="17"><infon key="identifier">MESH:D017291</infon><infon key="type">Chemical</infon><location offset="362" length="14"/><text>clarithromycin</text></annotation><annotation id="18"><infon key="identifier">MESH:D017291</infon><infon key="type">Chemical</infon><location offset="378" length="3"/><text>CLT</text></annotation><annotation id="19"><infon key="identifier">MESH:D001729</infon><infon key="type">Chemical</infon><location offset="466" length="7"/><text>bismuth</text></annotation><annotation id="20"><infon key="identifier">MESH:D001729</infon><infon key="type">Chemical</infon><location offset="493" length="7"/><text>bismuth</text></annotation><annotation id="21"><infon key="identifier">MESH:D008795</infon><infon key="type">Chemical</infon><location offset="502" length="13"/><text>metronidazole</text></annotation><annotation id="22"><infon key="identifier">MESH:D013752</infon><infon key="type">Chemical</infon><location offset="521" length="12"/><text>tetracycline</text></annotation><annotation id="23"><infon key="identifier">MESH:D014508</infon><infon key="type">Chemical</infon><location offset="761" length="4"/><text>urea</text></annotation><annotation id="24"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="1012" length="5"/><text>obese</text></annotation><annotation id="25"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="1430" length="5"/><text>obese</text></annotation></passage><relation id="R1"><infon key="score">0.8771</infon><infon key="role1">Chemical|MESH:D001729</infon><infon key="role2">Chemical|MESH:D013752</infon><infon key="type">Cotreatment</infon><node refid="0" role="3,9"/></relation><relation id="R2"><infon key="score">0.8682</infon><infon key="role1">Chemical|MESH:D001729</infon><infon key="role2">Chemical|MESH:D008795</infon><infon key="type">Cotreatment</infon><node refid="1" role="3,8"/></relation><relation id="R3"><infon key="score">0.972</infon><infon key="role1">Chemical|MESH:D001729</infon><infon key="role2">Disease|MESH:D009765</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="0,1"/></relation></document>
<document><id>37915237</id><passage><infon key="journal">J Child Sex Abus;2023Nov02 1. doi:10.1080/10538712.2023.2274889</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Guastaferro K, Melchior M, Murphy-Costanzo AS, Anderson A, Melamed N, Madden S, </infon><offset>0</offset><text>Preventive Education Outreach on Social Media: The Quest to Enroll Community Members in a Child Sexual Prevention Workshop.</text></passage><passage><infon key="type">abstract</infon><offset>124</offset><text>Social media is a frequently used tool in health promotion efforts although less so for the prevention of child sexual abuse (CSA). This is due, in part, to the lack of standardized branding guides for community-based efforts in how to craft messages related to CSA prevention. This study examined the use of Twitter (now "X") as a means of promoting participation in the adult-focused Stewards of Children CSA prevention workshop, prior to and following the implementation of a standardized branding guide. The exposure, reach, and engagement of the top tweets and top media tweets were examined over 24-months pre- and post-implementation of a five-point branding guide. Engagement was descriptively compared to the number of adults who enrolled in the Stewards of Children workshop. As evidenced by the increase in tweet impressions and the number of adults trained, it is likely the implementation of the branding guide was beneficial in promoting participation in the Stewards of Children workshop. Though participation in a program does not inherently suggest behavior change, getting participants to enroll is a crucial first step. The findings emphasize the potential of using social media to ultimately promote behavior change in the field of CSA prevention and beyond.</text><annotation id="5"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="230" length="18"/><text>child sexual abuse</text></annotation><annotation id="6"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="250" length="3"/><text>CSA</text></annotation><annotation id="7"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="386" length="3"/><text>CSA</text></annotation><annotation id="8"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="531" length="3"/><text>CSA</text></annotation><annotation id="9"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="1376" length="3"/><text>CSA</text></annotation></passage></document>
<document><id>37916287</id><passage><infon key="journal">Am J Physiol Renal Physiol;2023Nov02. doi:10.1152/ajprenal.00229.2023</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Dayton A, Almutlaq RN, Guntipally S, Ross J, Evans LC, </infon><offset>0</offset><text>T-cells regulate albuminuria but not hypertension, renal histology, or the medullary transcriptome in the Dahl SSCD247+/+ rat.</text><annotation id="3"><infon key="identifier">MESH:D000419</infon><infon key="type">Disease</infon><location offset="17" length="11"/><text>albuminuria</text></annotation><annotation id="4"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="37" length="12"/><text>hypertension</text></annotation><annotation id="5"><infon key="identifier">25300</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12818</infon><location offset="111" length="7"/><text>SSCD247</text></annotation></passage><passage><infon key="type">abstract</infon><offset>127</offset><text>In the current study we took advantage of the loss of protection from hypertension in SSCD247-/- rats to characterize the pathological effects of renal T-cells in isolation from the confounding effects of elevated renal perfusion pressure. Male SSCD247-/- and SSCD247+/+ littermates were fed 4.0% NaCl (high salt) diet to induce hypertension. Blood pressure was assessed continuously throughout the time course with radiotelemetry. Urine albumin and protein excretion were assessed on the final day of high salt. Renal injury and medullary transcriptome were assessed after completion of the high salt protocol.In contrast to previous studies, mean arterial pressure was not significantly different between SSCD247-/- and SSCD247+/+ rats. Despite this lack of pressure difference, urinary albumin was significantly lower in SSCD247-/- rats than their wild-type littermates. In the outer medulla substantially more transcriptomic changes were found to correlate with end point blood pressure than the absence of presence of renal T-cells. We also demonstrated that renal histological damage was driven by elevated renal perfusion pressure rather than the presence of renal T-cells. In conclusion, using the loss of protection from hypertension in SSCD247-/- rats we demonstrated that renal perfusion pressure has more profound pathological effects on the kidney than renal T-cells. However, renal T-cells, independently of blood pressure, modulate the progression of albuminuria.</text><annotation id="25"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="197" length="12"/><text>hypertension</text></annotation><annotation id="26"><infon key="identifier">25300</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12818</infon><location offset="213" length="7"/><text>SSCD247</text></annotation><annotation id="27"><infon key="identifier">25300</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12818</infon><location offset="372" length="7"/><text>SSCD247</text></annotation><annotation id="28"><infon key="identifier">25300</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12818</infon><location offset="387" length="7"/><text>SSCD247</text></annotation><annotation id="29"><infon key="identifier">MESH:D012965</infon><infon key="type">Chemical</infon><location offset="424" length="4"/><text>NaCl</text></annotation><annotation id="30"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="435" length="4"/><text>salt</text></annotation><annotation id="31"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="456" length="12"/><text>hypertension</text></annotation><annotation id="32"><infon key="identifier">24186</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">405</infon><location offset="565" length="7"/><text>albumin</text></annotation><annotation id="33"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="634" length="4"/><text>salt</text></annotation><annotation id="34"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="640" length="12"/><text>Renal injury</text></annotation><annotation id="35"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="724" length="4"/><text>salt</text></annotation><annotation id="36"><infon key="identifier">25300</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12818</infon><location offset="834" length="7"/><text>SSCD247</text></annotation><annotation id="37"><infon key="identifier">25300</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12818</infon><location offset="849" length="7"/><text>SSCD247</text></annotation><annotation id="38"><infon key="identifier">24186</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">405</infon><location offset="916" length="7"/><text>albumin</text></annotation><annotation id="39"><infon key="identifier">25300</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12818</infon><location offset="951" length="7"/><text>SSCD247</text></annotation><annotation id="40"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="1191" length="25"/><text>renal histological damage</text></annotation><annotation id="41"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="1357" length="12"/><text>hypertension</text></annotation><annotation id="42"><infon key="identifier">25300</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12818</infon><location offset="1373" length="7"/><text>SSCD247</text></annotation><annotation id="43"><infon key="identifier">MESH:D000419</infon><infon key="type">Disease</infon><location offset="1593" length="11"/><text>albuminuria</text></annotation></passage><relation id="R1"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:D012492</infon><infon key="role2">Disease|MESH:D006973</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="8,9"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D012965</infon><infon key="role2">Disease|MESH:D006973</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="7,9"/></relation></document>
<document><id>37916641</id><passage><infon key="journal">Ultrasound Obstet Gynecol;2023Nov02. doi:10.1002/uog.27527</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hernandez-Andrade E, Huntley ES, Sibai B, Blackwell SC, Soto-Torres EE, </infon><offset>0</offset><text>A reduction in cervical length after starting vaginal progesterone in women with short cervix is significantly associated with preterm delivery &lt;=34 weeks and &lt;37 weeks of gestation.</text><annotation id="3"><infon key="identifier">MESH:D011374</infon><infon key="type">Chemical</infon><location offset="54" length="12"/><text>progesterone</text></annotation><annotation id="4"><infon key="identifier">MESH:D002577</infon><infon key="type">Disease</infon><location offset="81" length="12"/><text>short cervix</text></annotation><annotation id="5"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="127" length="16"/><text>preterm delivery</text></annotation></passage><passage><infon key="type">abstract</infon><offset>183</offset><text>OBJECTIVE: To associate changes in cervical length (CL) after vaginal progesterone treatment with preterm delivery (PTD) METHODS: This is a retrospective cohort study that included 197 singleton pregnancies without (n=178) and with (n=19) history of PTD who were found to have a short cervix (&lt;=25mm) between 18+0 and 23+6 weeks/days of gestation and subsequently had a follow up transvaginal cervical length at least one-week after vaginal progesterone treatment started. ROC analysis was performed and three CL shortening patterns evaluated: 1) >=10% reduction, 2) >=20% reduction, and 3) >=5 mm reduction in relation to the first measurement. Predictive performance for each CL reduction and associations with PTD &lt;=34 weeks and PTD &lt;37 weeks were evaluated. RESULTS: Overall, prevalence of PTD &lt;=34 weeks was 16.7% (n=33/197), and PTD &lt;37 weeks was 36.5% (n=72/197). The area under the ROC curve for cervical shortening and PTD &lt;=34 weeks was 0.703, and for PTD &lt;37 weeks was 0.608. Prediction analysis showed sensitivity/specificity for PTD &lt;=34 weeks: &lt;=10% reduction, 48.4% and 79.8%; for &lt;=20% reduction, 36.4% and 87.8%; and for &lt;=5mm reduction, 27.3% and 83.2%, respectively; and sensitivity/specificity for PTD &lt;37 weeks: &lt;=10% reduction, 36.1% and 81.6%; for &lt;=20% reduction, 27.8% and 90.4%; and for &lt;=5mm reduction, 20.8% 90.4%, respectively. The best positive likelihood ratios for PTD &lt;=34 and &lt;37 weeks were for >=20% reduction (2.98 [95% CI 1.62-5.49] and 2.89 [1.5-5.7], respectively. Despite significant differences in sensitivity among different cut-off values, a reduction of >=20% in cervical length showed the higher positive likelihood ratio and the highest association with PTD &lt;=34 weeks (OR 95% CI, 4.8 (2.01-11.47)) and &lt;37 weeks (3.63 (1.68-7.85)), as compared to lesser reduction in cervical length. CONCLUSION: A reduction in cervical length in women with a short cervix treated with vaginal progesterone in a subsequent scan, can predict PTD &lt;=34 and &lt;37 weeks. A >=20% reduction had the highest positive likelihood ratio and association with preterm delivery PTD &lt;=34 and &lt;37 weeks as compared to &lt;=10% or &lt;=5 mm reduction. This article is protected by copyright. All rights reserved.</text><annotation id="30"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="235" length="2"/><text>CL</text></annotation><annotation id="31"><infon key="identifier">MESH:D011374</infon><infon key="type">Chemical</infon><location offset="253" length="12"/><text>progesterone</text></annotation><annotation id="32"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="281" length="16"/><text>preterm delivery</text></annotation><annotation id="33"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="299" length="3"/><text>PTD</text></annotation><annotation id="34"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="433" length="3"/><text>PTD</text></annotation><annotation id="35"><infon key="identifier">MESH:D002577</infon><infon key="type">Disease</infon><location offset="462" length="12"/><text>short cervix</text></annotation><annotation id="36"><infon key="identifier">MESH:D011374</infon><infon key="type">Chemical</infon><location offset="624" length="12"/><text>progesterone</text></annotation><annotation id="37"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="693" length="2"/><text>CL</text></annotation><annotation id="38"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="861" length="12"/><text>CL reduction</text></annotation><annotation id="39"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="896" length="3"/><text>PTD</text></annotation><annotation id="40"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="915" length="3"/><text>PTD</text></annotation><annotation id="41"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="977" length="3"/><text>PTD</text></annotation><annotation id="42"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="1018" length="3"/><text>PTD</text></annotation><annotation id="43"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="1111" length="3"/><text>PTD</text></annotation><annotation id="44"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="1145" length="3"/><text>PTD</text></annotation><annotation id="45"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="1225" length="3"/><text>PTD</text></annotation><annotation id="46"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="1401" length="3"/><text>PTD</text></annotation><annotation id="47"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="1580" length="3"/><text>PTD</text></annotation><annotation id="48"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="1883" length="3"/><text>PTD</text></annotation><annotation id="49"><infon key="identifier">MESH:D002577</infon><infon key="type">Disease</infon><location offset="2073" length="12"/><text>short cervix</text></annotation><annotation id="50"><infon key="identifier">MESH:D011374</infon><infon key="type">Chemical</infon><location offset="2107" length="12"/><text>progesterone</text></annotation><annotation id="51"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="2154" length="3"/><text>PTD</text></annotation><annotation id="52"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="2259" length="16"/><text>preterm delivery</text></annotation><annotation id="53"><infon key="identifier">MESH:D047928</infon><infon key="type">Disease</infon><location offset="2276" length="3"/><text>PTD</text></annotation></passage><relation id="R1"><infon key="score">0.7951</infon><infon key="role1">Chemical|MESH:D011374</infon><infon key="role2">Disease|MESH:D047928</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D011374</infon><infon key="role2">Disease|MESH:D002577</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.8973</infon><infon key="role1">Chemical|MESH:D011374</infon><infon key="role2">Disease|MESH:D002575</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="4,3"/></relation></document>
<document><id>37916995</id><passage><infon key="journal">Aging (Albany NY);2023Nov01; 15. doi:10.18632/aging.205138</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang L, Liu Y, Li S, Zha Z, Chen Y, Wang Q, Zhou S, Huang X, Xu M, </infon><offset>0</offset><text>Capsaicin alleviates doxorubicin-induced acute myocardial injury by regulating iron homeostasis and PI3K-Akt signaling pathway.</text><annotation id="5"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="0" length="9"/><text>Capsaicin</text></annotation><annotation id="6"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="21" length="11"/><text>doxorubicin</text></annotation><annotation id="7"><infon key="identifier">MESH:D009202</infon><infon key="type">Disease</infon><location offset="47" length="17"/><text>myocardial injury</text></annotation><annotation id="8"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="79" length="4"/><text>iron</text></annotation><annotation id="9"><infon key="identifier">11651</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3785</infon><location offset="105" length="3"/><text>Akt</text></annotation></passage><passage><infon key="type">abstract</infon><offset>128</offset><text>BACKGROUND: Capsaicin (CAP), a frequently occurring alkaloid component found in spicy peppers, has demonstrated therapeutic potential against tumors, metabolic disease, and cardiovascular disorders. Doxorubicin (DOX), a widely used anthracycline drug in chemotherapy, is notorious for its cardiotoxicity. This study aimed to investigate the potential of CAP in mitigating DOX toxicity in mouse hearts and H9C2 cells, as well as to explore the underlying mechanisms. METHODS: In our study, we conducted experiments on both mice and H9C2 cells. The mice were divided into four groups and treated with different substances: normal saline, CAP, DOX and CAP+DOX. We evaluated the induction of ferroptosis by DOX and the remission of ferroptosis by CAP using various methods, including echocardiography, Hematoxylin and Eosin (H&amp;E) staining, Masson's trichrome staining, and determination of ferroptosis metabolites, genes and proteins. Additionally, we employed RNA-seq to identify the inhibitory effect of CAP on DOX-induced myocardial apoptosis, which was further confirmed through western blotting. Similar approaches were applied to H9C2 cells, yielding reliable results. RESULTS: Our study demonstrated that treatment with CAP improved the survival rate of DOX-treated mice and reduced myocardial injury. Mechanistically, CAP downregulated transferrin (Trf) and upregulated solute carrier family 40 member 1 (SLC40A1), which helped maintain iron levels in the cells and prevent ferroptosis. Furthermore, CAP inhibited DOX-induced apoptosis by modulating the phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt) signaling pathway. Specifically, CAP activated the PI3K-Akt pathway and regulated downstream BCL2 and BAX to mitigate DOX-induced apoptosis. Therefore, our results suggest that CAP effectively alleviates acute myocardial injury induced by DOX. CONCLUSION: Our findings demonstrate that CAP has the potential to alleviate DOX-induced ferroptosis by regulating iron homeostasis. Additionally, it can inhibit DOX-induced apoptosis by activating PI3K-Akt signaling pathway.</text><annotation id="65"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="140" length="9"/><text>Capsaicin</text></annotation><annotation id="66"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="151" length="3"/><text>CAP</text></annotation><annotation id="67"><infon key="identifier">MESH:D000470</infon><infon key="type">Chemical</infon><location offset="180" length="8"/><text>alkaloid</text></annotation><annotation id="68"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="208" length="13"/><text>spicy peppers</text></annotation><annotation id="69"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="270" length="6"/><text>tumors</text></annotation><annotation id="70"><infon key="identifier">MESH:D008659</infon><infon key="type">Disease</infon><location offset="278" length="17"/><text>metabolic disease</text></annotation><annotation id="71"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="301" length="24"/><text>cardiovascular disorders</text></annotation><annotation id="72"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="327" length="11"/><text>Doxorubicin</text></annotation><annotation id="73"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="340" length="3"/><text>DOX</text></annotation><annotation id="74"><infon key="identifier">MESH:D018943</infon><infon key="type">Chemical</infon><location offset="360" length="13"/><text>anthracycline</text></annotation><annotation id="75"><infon key="identifier">MESH:D066126</infon><infon key="type">Disease</infon><location offset="417" length="14"/><text>cardiotoxicity</text></annotation><annotation id="76"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="482" length="3"/><text>CAP</text></annotation><annotation id="77"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="500" length="3"/><text>DOX</text></annotation><annotation id="78"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="504" length="8"/><text>toxicity</text></annotation><annotation id="79"><infon key="identifier">CVCL:0286</infon><infon key="type">CellLine</infon><location offset="533" length="4"/><text>H9C2</text></annotation><annotation id="80"><infon key="identifier">CVCL:0286</infon><infon key="type">CellLine</infon><location offset="659" length="4"/><text>H9C2</text></annotation><annotation id="81"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="764" length="3"/><text>CAP</text></annotation><annotation id="82"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="769" length="3"/><text>DOX</text></annotation><annotation id="83"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="777" length="3"/><text>CAP</text></annotation><annotation id="84"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="781" length="3"/><text>DOX</text></annotation><annotation id="85"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="831" length="3"/><text>DOX</text></annotation><annotation id="86"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="871" length="3"/><text>CAP</text></annotation><annotation id="87"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="926" length="21"/><text>Hematoxylin and Eosin</text></annotation><annotation id="88"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="949" length="3"/><text>H&amp;E</text></annotation><annotation id="89"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="964" length="18"/><text>Masson's trichrome</text></annotation><annotation id="90"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="1130" length="3"/><text>CAP</text></annotation><annotation id="91"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1137" length="3"/><text>DOX</text></annotation><annotation id="92"><infon key="identifier">MESH:D065703</infon><infon key="type">Disease</infon><location offset="1149" length="20"/><text>myocardial apoptosis</text></annotation><annotation id="93"><infon key="identifier">CVCL:0286</infon><infon key="type">CellLine</infon><location offset="1260" length="4"/><text>H9C2</text></annotation><annotation id="94"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="1351" length="3"/><text>CAP</text></annotation><annotation id="95"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1385" length="3"/><text>DOX</text></annotation><annotation id="96"><infon key="identifier">MESH:D009202</infon><infon key="type">Disease</infon><location offset="1414" length="17"/><text>myocardial injury</text></annotation><annotation id="97"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="1450" length="3"/><text>CAP</text></annotation><annotation id="98"><infon key="identifier">22041</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68153</infon><location offset="1468" length="11"/><text>transferrin</text></annotation><annotation id="99"><infon key="identifier">22041</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68153</infon><location offset="1481" length="3"/><text>Trf</text></annotation><annotation id="100"><infon key="identifier">53945</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">40959</infon><location offset="1502" length="33"/><text>solute carrier family 40 member 1</text></annotation><annotation id="101"><infon key="identifier">53945</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">40959</infon><location offset="1537" length="7"/><text>SLC40A1</text></annotation><annotation id="102"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1569" length="4"/><text>iron</text></annotation><annotation id="103"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="1632" length="3"/><text>CAP</text></annotation><annotation id="104"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1646" length="3"/><text>DOX</text></annotation><annotation id="105"><infon key="identifier">18708</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7889</infon><location offset="1686" length="25"/><text>phosphoinositide 3-kinase</text></annotation><annotation id="106"><infon key="identifier">11651</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3785</infon><location offset="1738" length="3"/><text>Akt</text></annotation><annotation id="107"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="1776" length="3"/><text>CAP</text></annotation><annotation id="108"><infon key="identifier">11651</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3785</infon><location offset="1799" length="3"/><text>Akt</text></annotation><annotation id="109"><infon key="identifier">12043</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">527</infon><location offset="1836" length="4"/><text>BCL2</text></annotation><annotation id="110"><infon key="identifier">12028</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7242</infon><location offset="1845" length="3"/><text>BAX</text></annotation><annotation id="111"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1861" length="3"/><text>DOX</text></annotation><annotation id="112"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="1920" length="3"/><text>CAP</text></annotation><annotation id="113"><infon key="identifier">MESH:D009202</infon><infon key="type">Disease</infon><location offset="1953" length="17"/><text>myocardial injury</text></annotation><annotation id="114"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1982" length="3"/><text>DOX</text></annotation><annotation id="115"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="2029" length="3"/><text>CAP</text></annotation><annotation id="116"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="2064" length="3"/><text>DOX</text></annotation><annotation id="117"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="2102" length="4"/><text>iron</text></annotation><annotation id="118"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="2149" length="3"/><text>DOX</text></annotation><annotation id="119"><infon key="identifier">11651</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3785</infon><location offset="2190" length="3"/><text>Akt</text></annotation></passage><relation id="R1"><infon key="score">0.9965</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|22041</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="38,39"/></relation><relation id="R2"><infon key="score">0.9655</infon><infon key="role1">Disease|MESH:D009202</infon><infon key="role2">Gene|11651</infon><infon key="type">Association</infon><node refid="1" role="2,5"/></relation><relation id="R3"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="6,10"/></relation><relation id="R4"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Disease|MESH:D008659</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="6,11"/></relation><relation id="R5"><infon key="score">0.7401</infon><infon key="role1">Chemical|MESH:D004317</infon><infon key="role2">Gene|18708</infon><infon key="type">Association</infon><node refid="4" role="45,46"/></relation><relation id="R6"><infon key="score">0.9943</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Chemical|MESH:D004317</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="0,1"/></relation><relation id="R7"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D004317</infon><infon key="role2">Disease|MESH:D009202</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="1,2"/></relation><relation id="R8"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Disease|MESH:D065703</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="31,33"/></relation><relation id="R9"><infon key="score">0.9983</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|12043</infon><infon key="type">Positive_Correlation</infon><node refid="8" role="49,52"/></relation><relation id="R10"><infon key="score">0.9721</infon><infon key="role1">Chemical|MESH:D004317</infon><infon key="role2">Disease|MESH:D065703</infon><infon key="type">Positive_Correlation</infon><node refid="9" role="32,33"/></relation><relation id="R11"><infon key="score">0.9958</infon><infon key="role1">Chemical|MESH:D004317</infon><infon key="role2">Gene|11651</infon><infon key="type">Association</infon><node refid="10" role="1,5"/></relation><relation id="R12"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|53945</infon><infon key="type">Positive_Correlation</infon><node refid="11" role="38,41"/></relation><relation id="R13"><infon key="score">0.9298</infon><infon key="role1">Chemical|MESH:D004317</infon><infon key="role2">Disease|MESH:D066126</infon><infon key="type">Positive_Correlation</infon><node refid="12" role="13,16"/></relation><relation id="R14"><infon key="score">0.9737</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Chemical|MESH:D007501</infon><infon key="type">Association</infon><node refid="13" role="0,3"/></relation><relation id="R15"><infon key="score">0.9704</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|11651</infon><infon key="type">Positive_Correlation</infon><node refid="14" role="0,5"/></relation><relation id="R16"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Disease|MESH:D002318</infon><infon key="type">Negative_Correlation</infon><node refid="15" role="6,12"/></relation><relation id="R17"><infon key="score">0.9976</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Disease|MESH:D009202</infon><infon key="type">Negative_Correlation</infon><node refid="16" role="0,2"/></relation><relation id="R18"><infon key="score">0.9949</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Gene|53945</infon><infon key="type">Association</infon><node refid="17" role="43,41"/></relation><relation id="R19"><infon key="score">0.9994</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|18708</infon><infon key="type">Association</infon><node refid="18" role="44,46"/></relation><relation id="R20"><infon key="score">0.9966</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|12028</infon><infon key="type">Positive_Correlation</infon><node refid="19" role="49,53"/></relation></document>
<document><id>37917345</id><passage><infon key="journal">Nurs Leadersh (Tor Ont);2023Jul; 36 (2) 58. doi:10.12927/cjnl.2023.27203</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Moody E, Jamieson HS, Bradbury K, Rothfus M, Khanna I, Weeks LE, Belliveau A, Bilski T, Adisaputri G, </infon><offset>0</offset><text>Interventions to Improve the Nursing Care of People with Dementia in Canadian Hospitals: An Environmental Scan.</text><annotation id="1"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="57" length="8"/><text>Dementia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>112</offset><text>As the number of people with dementia admitted to hospitals is expected to grow, now is the time to identify methods to improve nursing care of this population. We conducted an environmental scan to identify and describe interventions in Canadian hospitals to improve the nursing care of people with dementia, how they are being evaluated and what issues influence the success of interventions. Methods included a search of published and unpublished literature and key stakeholder interviews. Interventions are described under three categories: (1) interventions to improve nurses' knowledge, attitudes and skills; (2) interventions to address responsive behaviours; and (3) interventions to help nurses individualize care. The evaluation of interventions rarely included an evaluation of effectiveness and more often included a qualitative evaluation of nurses' experiences with interventions. We summarize the factors affecting the implementation of interventions following the Consolidated Framework for Implementation Research (Damschroder et al. 2009) and suggest strategies for supporting the success of interventions to improve patient care and the experiences of nurses working with people with dementia.</text><annotation id="5"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="141" length="8"/><text>dementia</text></annotation><annotation id="6"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="412" length="8"/><text>dementia</text></annotation><annotation id="7"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="1315" length="8"/><text>dementia</text></annotation></passage></document>
<document><id>37917695</id><passage><infon key="journal">Science;2023Nov03; 382 (6670) 508. doi:10.1126/science.adl6581</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fraser B, </infon><offset>0</offset><text>Amazon observatory.</text></passage><passage><infon key="type">abstract</infon><offset>20</offset><text>In Peru, a lowlands-to-peak study has revealed how climate change is affecting forests-and helped nurture young scientists.</text></passage></document>
<document><id>37918047</id><passage><infon key="journal">Biosens Bioelectron;2023Oct28; 244 115799. doi:10.1016/j.bios.2023.115799</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chen CA, Ho NY, Hsiao HY, Lin SS, Lai PL, Tsai TT, </infon><offset>0</offset><text>Smartphone-assisted fluorescence-based detection of sunrise-type smart amplification process and a 3D-printed ultraviolet light-emitting diode device for the diagnosis of tuberculosis.</text><annotation id="1"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="171" length="12"/><text>tuberculosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>185</offset><text>Accurate and rapid diagnosis of infectious diseases plays a key role in clinical practice, especially in resource-limited countries. In this study, we integrated sunrise-type smart amplification process (s-SmartAmp), a convenient and sensitive isothermal amplification method for nucleic acid, into a portable 3D-printed device equipped with smartphone-assisted image analysis capabilities to develop a novel fluorescence-based sensing system for the on-site diagnosis of tuberculosis (TB). To increase the efficiency of fluorescence (or Forster) resonance energy transfer, two types of sunrise probe systems were compared to detect the IS6110 DNA sequence of TB. Subsequently, linear regression was conducted to compare the performance of s-SmartAmp and loop-mediated isothermal amplification (LAMP). The results indicated that, compared with LAMP, s-SmartAmp yielded more stable and precise results with lower background interference and high linear correlation coefficients (R2 = 0.9994 and 1, respectively) for the FAM-TAMRA and FITC-BHQ-1 probe system. The detection time was 45 min with a detection limit of 10 fg/muL. To evaluate the performance of our proposed on-site sensing system, we used s-SmartAmp 3D-printed ultraviolet light-emitting diode device to test multiple clinical samples of TB. Our findings suggest that the proposed system has the potential to achieve accurate and rapid on-site diagnosis of TB.</text><annotation id="10"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="217" length="19"/><text>infectious diseases</text></annotation><annotation id="11"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="657" length="12"/><text>tuberculosis</text></annotation><annotation id="12"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="671" length="2"/><text>TB</text></annotation><annotation id="13"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="845" length="2"/><text>TB</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1204" length="9"/><text>FAM-TAMRA</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1218" length="10"/><text>FITC-BHQ-1</text></annotation><annotation id="16"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="1485" length="2"/><text>TB</text></annotation><annotation id="17"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="1604" length="2"/><text>TB</text></annotation></passage></document>
<document><id>37918397</id><passage><infon key="journal">Curr Biol;2023Oct25. doi:10.1016/j.cub.2023.10.010</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Heitmann C, Zhan M, Linke M, H&amp;#xf6;lig C, Kekunnaya R, van Hoof R, Goebel R, R&amp;#xf6;der B, </infon><offset>0</offset><text>Early visual experience refines the retinotopic organization within and across visual cortical regions.</text></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>Early visual areas are retinotopically organized in human and non-human primates. Population receptive field (pRF) size increases with eccentricity and from lower- to higher-level visual areas. Furthermore, the cortical magnification factor (CMF), a measure of how much cortical space is devoted to each degree of visual angle, is typically larger for foveal as opposed to peripheral regions of the visual field. Whether this fine-scale organization within and across visual areas depends on early visual experience has yet been unknown. Here, we employed 7T functional magnetic resonance imaging pRF mapping to assess the retinotopic organization of early visual regions (i.e., V1, V2, and V3) in eight sight recovery individuals with a history of congenital blindness until a maximum of 4 years of age. Compared with sighted controls, foveal pRF sizes in these individuals were larger, and pRF sizes did not show the typical increase with eccentricity and down the visual cortical processing stream (V1-V2-V3). Cortical magnification was overall diminished and decreased less from foveal to parafoveal visual field locations. Furthermore, cortical magnification correlated with visual acuity in sight recovery individuals. The results of this study suggest that early visual experience is essential for refining a presumably innate prototypical retinotopic organization in humans within and across visual areas, which seems to be crucial for acquiring full visual capabilities.</text><annotation id="1"><infon key="identifier">MESH:D057130</infon><infon key="type">Disease</infon><location offset="853" length="20"/><text>congenital blindness</text></annotation></passage></document>
<document><id>37918747</id><passage><infon key="journal">Sci Total Environ;2023Oct31 168060. doi:10.1016/j.scitotenv.2023.168060</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tullio SCMC, McCoy K, Chalcraft DR, </infon><offset>0</offset><text>Chronic toxicity and liver histopathology of mosquito fish (Gambusia holbrooki) exposed to natural and modified nanoclays.</text><annotation id="2"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="0" length="16"/><text>Chronic toxicity</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="112" length="9"/><text>nanoclays</text></annotation></passage><passage><infon key="type">abstract</infon><offset>123</offset><text>Nanoclays are found in the air, water, and soil, and modified nanoclays are being developed and used in several consumer products. For example, modified nanoclays are used to remove pollutants from wastewater. Ironically, however, nanoclays are now considered emerging contaminants. Indeed, release of modified nanoclays in aquatic systems, even as remediating agents, could adversely affect associated wildlife. However, aquatic organisms have interacted with natural nanoclays for millennia, and it is unclear if modified nanoclays induce stronger effects than the nanoclays that occur naturally. The concentrations over which nanoclays occur and illicit negative effects are not well studied. This study investigated the dose response of a natural nanoclay (Na+montmorillonite) relative to two modified nanoclays (Cloisite 30B and Novaclay ) on survival, body condition, and liver pathomorphology of Gambusia holbrooki after 14 days of exposure. Although none of the nanoclays affected survival and body condition of G. holbrooki over 14 days, each nanoclay induced histopathological changes in liver tissues at very low concentrations (LOAEL: 0.01 mgL-1). The effects of nanoclays on hepatic cell circulatory (blood cell aggregation with increased number of Kupffer cells and hemosiderin deposits), regressive (hepatocyte vacuolization), and degenerative (cell death) changes of mosquito fish varied among nanoclay types. Novaclay  at low concentrations caused circulatory changes on hepatic tissues of G. holbrooki, whereas both natural nanoclays and Cloisite 30B showed little effect on circulatory endpoints. In contrast, all of the nanoclays induced regressive and degenerative changes on liver tissues of mosquito fish across all concentrations tested. This study clearly reveals that natural and modified nanoclays have important health implications for fish and other aquatic organisms. Consequently, the widespread use of modified nanoclays in several applications and increased release of natural nanoclays through erosion or other processes needs to be evaluated in more detail especially in the context of their safety for aquatic systems.</text><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="123" length="9"/><text>Nanoclays</text></annotation><annotation id="28"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="155" length="5"/><text>water</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="185" length="9"/><text>nanoclays</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="276" length="9"/><text>nanoclays</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="354" length="9"/><text>nanoclays</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="434" length="9"/><text>nanoclays</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="592" length="9"/><text>nanoclays</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="647" length="9"/><text>nanoclays</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="690" length="9"/><text>nanoclays</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="752" length="9"/><text>nanoclays</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="884" length="18"/><text>Na+montmorillonite</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="929" length="9"/><text>nanoclays</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="940" length="12"/><text>Cloisite 30B</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="957" length="8"/><text>Novaclay</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1093" length="9"/><text>nanoclays</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1298" length="9"/><text>nanoclays</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1549" length="8"/><text>Novaclay</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1665" length="9"/><text>nanoclays</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1679" length="12"/><text>Cloisite 30B</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1763" length="9"/><text>nanoclays</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1938" length="9"/><text>nanoclays</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2066" length="9"/><text>nanoclays</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2133" length="9"/><text>nanoclays</text></annotation></passage></document>
<document><id>37919097</id><passage><infon key="journal">Small;2023Nov02 2305767. doi:10.1002/smll.202305767</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ma F, Wen Y, Fu P, Zhang J, Tang Q, Chen T, Luo W, Zhou Y, Wang J, </infon><offset>0</offset><text>Engineering 0D/2D Architecture of Ni(OH)2 Nanoparticles on Covalent Organic Framework Nanosheets for Selective Visible-Light-Driven CO2 Reduction.</text><annotation id="2"><infon key="identifier">MESH:C037473</infon><infon key="type">Chemical</infon><location offset="34" length="7"/><text>Ni(OH)2</text></annotation><annotation id="3"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="132" length="3"/><text>CO2</text></annotation></passage><passage><infon key="type">abstract</infon><offset>147</offset><text>Low-dimensional materials serving as photocatalysts favor providing abundant unsaturated active sites and shortening the charge transport distance, but the high surface energy readily causes the aggregation that limits their application. Herein, it is demonstrated that 2D covalent organic framework (COF) TpBD nanosheets are effective in the dispersion and stabilization of 0D Ni(OH)2 . The COF precursor TpBD is synthesized from the Schiff base condensation of 1,3,5-triformylphloroglucinol (Tp) and benzidine (BD) and exfoliated into 2D nanosheets named BDNs via ultrasonication. The formation of highly dispersive 0D Ni(OH)2 on BDNs is reached under a mild weak basic condition, enabling robust active sites for CO2 adsorption/activation and rapid interface cascaded electron transport channels for the accumulation of long-lived photo-generated charges. The champion catalyst 30%Ni-BDNs effectively catalyze the CO2 to CO conversion under visible-light irradiation, offering a high CO evolution rate of 158.4 mmol g-1 h-1 and turnover frequency of 51 h-1 . By contrast, the counterpart photocatalyst, the bulk TpBD stabilized Ni(OH)2 , affords a much lower CO evolution rate and selectivity. This work demonstrates a new avenue to simultaneously construct efficient active sites and electron transport channels by coupling 0D metal hydroxides and 2D COF nanosheets for CO2 photoreduction.</text><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="453" length="4"/><text>TpBD</text></annotation><annotation id="25"><infon key="identifier">MESH:C037473</infon><infon key="type">Chemical</infon><location offset="525" length="7"/><text>Ni(OH)2</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="553" length="4"/><text>TpBD</text></annotation><annotation id="27"><infon key="identifier">MESH:D012545</infon><infon key="type">Chemical</infon><location offset="582" length="11"/><text>Schiff base</text></annotation><annotation id="28"><infon key="identifier">MESH:C000607859</infon><infon key="type">Chemical</infon><location offset="610" length="29"/><text>1,3,5-triformylphloroglucinol</text></annotation><annotation id="29"><infon key="identifier">MESH:C000607859</infon><infon key="type">Chemical</infon><location offset="641" length="2"/><text>Tp</text></annotation><annotation id="30"><infon key="identifier">MESH:C029876</infon><infon key="type">Chemical</infon><location offset="649" length="9"/><text>benzidine</text></annotation><annotation id="31"><infon key="type">Disease</infon><location offset="704" length="4"/><text>BDNs</text></annotation><annotation id="32"><infon key="identifier">MESH:C037473</infon><infon key="type">Chemical</infon><location offset="768" length="7"/><text>Ni(OH)2</text></annotation><annotation id="33"><infon key="type">Disease</infon><location offset="779" length="4"/><text>BDNs</text></annotation><annotation id="34"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="863" length="3"/><text>CO2</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1034" length="4"/><text>BDNs</text></annotation><annotation id="36"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1064" length="3"/><text>CO2</text></annotation><annotation id="37"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1071" length="2"/><text>CO</text></annotation><annotation id="38"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1134" length="2"/><text>CO</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1262" length="4"/><text>TpBD</text></annotation><annotation id="40"><infon key="identifier">MESH:C037473</infon><infon key="type">Chemical</infon><location offset="1278" length="7"/><text>Ni(OH)2</text></annotation><annotation id="41"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1309" length="2"/><text>CO</text></annotation><annotation id="42"><infon key="identifier">MESH:D006878</infon><infon key="type">Chemical</infon><location offset="1484" length="10"/><text>hydroxides</text></annotation><annotation id="43"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1521" length="3"/><text>CO2</text></annotation></passage><relation id="R1"><infon key="score">0.5647</infon><infon key="role1">Chemical|MESH:C037473</infon><infon key="role2">Chemical|MESH:D002245</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,1"/></relation></document>
<document><id>37919447</id><passage><infon key="journal">NPJ Precis Oncol;2023Nov02; 7 (1) 113. doi:10.1038/s41698-023-00469-7</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S, Walker S, Graff JN, Robinson B, Mosquera JM, Sboner A, Elemento O, Robine N, Beltran H, </infon><offset>0</offset><text>Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.</text><annotation id="2"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="61" length="15"/><text>prostate cancer</text></annotation><annotation id="3"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="77" length="23"/><text>intracranial metastases</text></annotation></passage><passage><infon key="type">abstract</infon><offset>102</offset></passage></document>
<document><id>37919797</id><passage><infon key="journal">Part Fibre Toxicol;2023Nov02; 20 (1) 41. doi:10.1186/s12989-023-00552-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">7768640</infon><infon key="type">title</infon><infon key="authors">Mo Y, Mo L, Zhang Y, Zhang Y, Yuan J, Zhang Q, </infon><offset>0</offset><text>High glucose enhances the activation of NLRP3 inflammasome by ambient fine particulate matter in alveolar macrophages.</text><annotation id="2"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="5" length="7"/><text>glucose</text></annotation><annotation id="3"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="40" length="5"/><text>NLRP3</text></annotation></passage><passage><infon key="type">abstract</infon><offset>119</offset><text>BACKGROUND: Epidemiological studies have demonstrated that individuals with preexisting conditions, including diabetes mellitus (DM), are more susceptible to air pollution. However, the underlying mechanisms remain unclear. In this study, we proposed that a high glucose setting enhances ambient fine particulate matter (PM2.5)-induced macrophage activation and secretion of the proinflammatory cytokine, IL-1beta, through activation of the NLRP3 inflammasome, altering the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs). RESULTS: Exposure of mouse alveolar macrophages to non-cytotoxic doses of PM2.5 led to upregulation of IL-1beta, activation of the NLRP3 inflammasome, increased nuclear translocation of the transcription factor NF-kappaB, increased generation of reactive oxygen species (ROS), and increased expression and enzymatic activity of MMP-9; these effects were enhanced when cells were pretreated with high glucose. However, pretreatment in a high glucose setting alone did not induce significant changes. ROS generation following PM2.5 exposure was abolished when cells were pretreated with ROS scavengers such as Trolox and superoxide dismutase (SOD), or with an NADPH oxidase inhibitor, DPI. Pretreatment of cells with DPI attenuated the effects of a high glucose setting on PM2.5-induced upregulation of IL-1beta, activation of the NLRP3 inflammasome, and nuclear translocation of NF-kappaB. In addition, enhancement of PM2.5-induced expression and enzymatic activity of MMP-9 following high glucose pretreatment was not observed in primary alveolar macrophages obtained from NLRP3 or IL-1R1 knockout (KO) mice, where pro-IL-1beta cannot be cleaved to IL-1beta or cells are insensitive to IL-1beta, respectively. CONCLUSIONS: This study demonstrated that exposure of mouse alveolar macrophages to PM2.5 in a high glucose setting enhanced PM2.5-induced production of IL-1beta through activation of the NLRP3 inflammasome and nuclear translocation of NF-kappaB due to PM2.5-induced oxidative stress, leading to MMP-9 upregulation. The key role of NADPH oxidase in PM2.5-induced ROS generation and activation of the IL-1beta secretion pathway and the importance of IL-1beta secretion and signaling in PM2.5-induced increases in MMP-9 enzymatic activity were also demonstrated. This study provides a further understanding of the potential mechanisms underlying the susceptibility of individuals with DM to air pollution and suggests potential therapeutic targets.</text><annotation id="53"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="229" length="17"/><text>diabetes mellitus</text></annotation><annotation id="54"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="248" length="2"/><text>DM</text></annotation><annotation id="55"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="382" length="7"/><text>glucose</text></annotation><annotation id="56"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="440" length="5"/><text>PM2.5</text></annotation><annotation id="57"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="524" length="8"/><text>IL-1beta</text></annotation><annotation id="58"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="560" length="5"/><text>NLRP3</text></annotation><annotation id="59"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="755" length="5"/><text>PM2.5</text></annotation><annotation id="60"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="784" length="8"/><text>IL-1beta</text></annotation><annotation id="61"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="812" length="5"/><text>NLRP3</text></annotation><annotation id="62"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="892" length="9"/><text>NF-kappaB</text></annotation><annotation id="63"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="927" length="23"/><text>reactive oxygen species</text></annotation><annotation id="64"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="952" length="3"/><text>ROS</text></annotation><annotation id="65"><infon key="identifier">17395</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="1009" length="5"/><text>MMP-9</text></annotation><annotation id="66"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1081" length="7"/><text>glucose</text></annotation><annotation id="67"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1122" length="7"/><text>glucose</text></annotation><annotation id="68"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="1180" length="3"/><text>ROS</text></annotation><annotation id="69"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1205" length="5"/><text>PM2.5</text></annotation><annotation id="70"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="1266" length="3"/><text>ROS</text></annotation><annotation id="71"><infon key="identifier">MESH:C010643</infon><infon key="type">Chemical</infon><location offset="1289" length="6"/><text>Trolox</text></annotation><annotation id="72"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1364" length="3"/><text>DPI</text></annotation><annotation id="73"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1396" length="3"/><text>DPI</text></annotation><annotation id="74"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1433" length="7"/><text>glucose</text></annotation><annotation id="75"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1452" length="5"/><text>PM2.5</text></annotation><annotation id="76"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1482" length="8"/><text>IL-1beta</text></annotation><annotation id="77"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="1510" length="5"/><text>NLRP3</text></annotation><annotation id="78"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1559" length="10"/><text>NF-kappaB.</text></annotation><annotation id="79"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1598" length="5"/><text>PM2.5</text></annotation><annotation id="80"><infon key="identifier">17395</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="1649" length="5"/><text>MMP-9</text></annotation><annotation id="81"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1670" length="7"/><text>glucose</text></annotation><annotation id="82"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="1754" length="5"/><text>NLRP3</text></annotation><annotation id="83"><infon key="identifier">16177</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">677</infon><location offset="1763" length="6"/><text>IL-1R1</text></annotation><annotation id="84"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1800" length="8"/><text>IL-1beta</text></annotation><annotation id="85"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1830" length="8"/><text>IL-1beta</text></annotation><annotation id="86"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1867" length="8"/><text>IL-1beta</text></annotation><annotation id="87"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1975" length="5"/><text>PM2.5</text></annotation><annotation id="88"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1991" length="7"/><text>glucose</text></annotation><annotation id="89"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2016" length="5"/><text>PM2.5</text></annotation><annotation id="90"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="2044" length="8"/><text>IL-1beta</text></annotation><annotation id="91"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="2079" length="5"/><text>NLRP3</text></annotation><annotation id="92"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="2127" length="9"/><text>NF-kappaB</text></annotation><annotation id="93"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2144" length="5"/><text>PM2.5</text></annotation><annotation id="94"><infon key="identifier">17395</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="2187" length="5"/><text>MMP-9</text></annotation><annotation id="95"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2240" length="5"/><text>PM2.5</text></annotation><annotation id="96"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="2254" length="3"/><text>ROS</text></annotation><annotation id="97"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="2291" length="8"/><text>IL-1beta</text></annotation><annotation id="98"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="2340" length="8"/><text>IL-1beta</text></annotation><annotation id="99"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2376" length="5"/><text>PM2.5</text></annotation><annotation id="100"><infon key="identifier">17395</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="2403" length="5"/><text>MMP-9</text></annotation><annotation id="101"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="2574" length="2"/><text>DM</text></annotation></passage><relation id="R1"><infon key="score">0.5082</infon><infon key="role1">Chemical|MESH:D005947</infon><infon key="role2">Gene|18033</infon><infon key="type">Association</infon><node refid="0" role="15,11"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D005947</infon><infon key="role2">Gene|216799</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D005947</infon><infon key="role2">Gene|17395</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="15,14"/></relation><relation id="R4"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D005947</infon><infon key="role2">Gene|16176</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="4,6"/></relation><relation id="R5"><infon key="score">0.9976</infon><infon key="role1">Chemical|MESH:C010643</infon><infon key="role2">Chemical|MESH:D017382</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="20,17"/></relation></document>
<document><id>37920147</id><passage><infon key="journal">Drug Alcohol Rev;2023Nov03. doi:10.1111/dar.13771</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Dietze P, Stewart A, Hill P, Draper B, Curtis M, Kirwan A, National Naloxone Reference Group, </infon><offset>0</offset><text>The National Naloxone Reference Group: A collective voice on take-home naloxone policy and practice in Australia.</text><annotation id="2"><infon key="identifier">MESH:D009270</infon><infon key="type">Chemical</infon><location offset="13" length="8"/><text>Naloxone</text></annotation><annotation id="3"><infon key="identifier">MESH:D009270</infon><infon key="type">Chemical</infon><location offset="71" length="8"/><text>naloxone</text></annotation></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>The National Naloxone Reference Group has played a key role in the development of take-home naloxone programs, policy and practice in Australia. In this commentary we detail the origins of the group, some of its main achievements since its inception and its future directions in light of the major policy changes around naloxone that have recently occurred in Australia.</text><annotation id="7"><infon key="identifier">MESH:D009270</infon><infon key="type">Chemical</infon><location offset="127" length="8"/><text>Naloxone</text></annotation><annotation id="8"><infon key="identifier">MESH:D009270</infon><infon key="type">Chemical</infon><location offset="206" length="8"/><text>naloxone</text></annotation><annotation id="9"><infon key="identifier">MESH:D009270</infon><infon key="type">Chemical</infon><location offset="434" length="8"/><text>naloxone</text></annotation></passage></document>
<document><id>37921197</id><passage><infon key="journal">Minerva Anestesiol;2023Nov; 89 (11) 957. doi:10.23736/S0375-9393.23.17668-1</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Richa FC, Harb SK, </infon><offset>0</offset><text>Fight against postoperative pulmonary complications: ways to anticipate.</text><annotation id="1"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="14" length="37"/><text>postoperative pulmonary complications</text></annotation></passage><passage><infon key="type">abstract</infon><offset>73</offset></passage></document>
<document><id>37921547</id><passage><infon key="journal">Mol Carcinog;2023Nov03. doi:10.1002/mc.23653</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hahm ER, Kim SH, Pore SK, Mathan SV, Singh RP, Singh SV, </infon><offset>0</offset><text>Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation.</text><annotation id="4"><infon key="identifier">MESH:C031403</infon><infon key="type">Chemical</infon><location offset="46" length="21"/><text>benzyl isothiocyanate</text></annotation><annotation id="5"><infon key="identifier">MESH:D000077211</infon><infon key="type">Chemical</infon><location offset="72" length="15"/><text>zoledronic acid</text></annotation><annotation id="6"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="103" length="13"/><text>breast cancer</text></annotation><annotation id="7"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="130" length="10"/><text>osteoclast</text></annotation></passage><passage><infon key="type">abstract</infon><offset>158</offset><text>Bone is the most favored site for metastasis for each major subtype of breast cancer. Therapeutic modalities for alleviation of clinical symptoms associated with bone metastasis include surgical resection, radiation, and bone-targeted therapies, including bisphosphonates (e.g., zoledronic acid; ZA) and a humanized antibody against receptor activator of nuclear factor-kappaB ligand (denosumab). However, the bone-targeted therapies are expensive, and have poor pharmacokinetic attributes and/or serious adverse effects. Therefore, novel strategies are needed for treatment of bone metastasis or to increase effectiveness of existing bone-targeted therapies. We have shown previously that benzyl isothiocyanate (BITC) is a novel inhibitor of osteoclast differentiation in vitro and bone metastasis in vivo. The present study shows that BITC + ZA combination synergistically inhibits osteoclast differentiation induced by addition of conditioned media from breast cancer cells. These effects were associated with a significant increase in levels of several antiosteoclastogenic cytokines, including interferons, interleukin (IL)-3, IL-4, and IL-27. Kyoto Encyclopedia of Genes and Genomes pathway analysis of RNA-seq data from BITC and/or ZA-treated cells revealed downregulation of genes of many pathways (e.g., actin cytoskeleton, Hippo signaling, etc.) by treatment with BITC + ZA combination, but not by BITC alone or ZA alone. Confocal microscopy confirmed severe disruption of actin cytoskeleton upon treatment of MCF-7 and MDA-MB-231 cells with the BITC + ZA combination. This combination also decreased the nuclear level of yes-associated protein, a core component of Hippo signaling. In conclusion, the present study offers a novel combination for prevention or treatment of bone metastasis of breast cancer.</text><annotation id="33"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="192" length="10"/><text>metastasis</text></annotation><annotation id="34"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="229" length="13"/><text>breast cancer</text></annotation><annotation id="35"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="320" length="15"/><text>bone metastasis</text></annotation><annotation id="36"><infon key="identifier">MESH:D004164</infon><infon key="type">Chemical</infon><location offset="414" length="15"/><text>bisphosphonates</text></annotation><annotation id="37"><infon key="identifier">MESH:D000077211</infon><infon key="type">Chemical</infon><location offset="437" length="15"/><text>zoledronic acid</text></annotation><annotation id="38"><infon key="identifier">8600</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2744</infon><location offset="491" length="50"/><text>receptor activator of nuclear factor-kappaB ligand</text></annotation><annotation id="39"><infon key="identifier">MESH:D000069448</infon><infon key="type">Chemical</infon><location offset="543" length="9"/><text>denosumab</text></annotation><annotation id="40"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="736" length="15"/><text>bone metastasis</text></annotation><annotation id="41"><infon key="identifier">MESH:C031403</infon><infon key="type">Chemical</infon><location offset="848" length="21"/><text>benzyl isothiocyanate</text></annotation><annotation id="42"><infon key="identifier">MESH:C031403</infon><infon key="type">Chemical</infon><location offset="871" length="4"/><text>BITC</text></annotation><annotation id="43"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="901" length="10"/><text>osteoclast</text></annotation><annotation id="44"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="941" length="15"/><text>bone metastasis</text></annotation><annotation id="45"><infon key="identifier">MESH:C031403</infon><infon key="type">Chemical</infon><location offset="995" length="4"/><text>BITC</text></annotation><annotation id="46"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="1042" length="10"/><text>osteoclast</text></annotation><annotation id="47"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1115" length="13"/><text>breast cancer</text></annotation><annotation id="48"><infon key="identifier">3562</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47938</infon><location offset="1270" length="18"/><text>interleukin (IL)-3</text></annotation><annotation id="49"><infon key="identifier">3565</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">491</infon><location offset="1290" length="4"/><text>IL-4</text></annotation><annotation id="50"><infon key="identifier">246778</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17087</infon><location offset="1300" length="5"/><text>IL-27</text></annotation><annotation id="51"><infon key="identifier">MESH:C031403</infon><infon key="type">Chemical</infon><location offset="1385" length="4"/><text>BITC</text></annotation><annotation id="52"><infon key="identifier">MESH:C031403</infon><infon key="type">Chemical</infon><location offset="1532" length="4"/><text>BITC</text></annotation><annotation id="53"><infon key="identifier">MESH:C031403</infon><infon key="type">Chemical</infon><location offset="1566" length="4"/><text>BITC</text></annotation><annotation id="54"><infon key="identifier">CVCL:0031</infon><infon key="type">CellLine</infon><location offset="1678" length="5"/><text>MCF-7</text></annotation><annotation id="55"><infon key="identifier">CVCL:0062</infon><infon key="type">CellLine</infon><location offset="1688" length="10"/><text>MDA-MB-231</text></annotation><annotation id="56"><infon key="identifier">MESH:C031403</infon><infon key="type">Chemical</infon><location offset="1714" length="4"/><text>BITC</text></annotation><annotation id="57"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1942" length="32"/><text>bone metastasis of breast cancer</text></annotation></passage><relation id="R1"><infon key="score">0.4527</infon><infon key="role1">Chemical|MESH:C031403</infon><infon key="role2">Chemical|MESH:D000077211</infon><infon key="type">Cotreatment</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C031403</infon><infon key="role2">Disease|MESH:D001862</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,3"/></relation><relation id="R3"><infon key="score">0.9947</infon><infon key="role1">Chemical|MESH:C031403</infon><infon key="role2">Gene|3565</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="16,20"/></relation><relation id="R4"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:C031403</infon><infon key="role2">Gene|246778</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="16,21"/></relation><relation id="R5"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D000077211</infon><infon key="role2">Disease|MESH:D001862</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="1,3"/></relation><relation id="R6"><infon key="score">0.9903</infon><infon key="role1">Chemical|MESH:D004164</infon><infon key="role2">Disease|MESH:D009362</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="7,6"/></relation><relation id="R7"><infon key="score">0.9259</infon><infon key="role1">Chemical|MESH:D000069448</infon><infon key="role2">Gene|8600</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="10,9"/></relation><relation id="R8"><infon key="score">0.9854</infon><infon key="role1">Chemical|MESH:C031403</infon><infon key="role2">Gene|3562</infon><infon key="type">Positive_Correlation</infon><node refid="7" role="16,19"/></relation><relation id="R9"><infon key="score">0.6567</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|3565</infon><infon key="type">Positive_Correlation</infon><node refid="8" role="18,20"/></relation><relation id="R10"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D000077211</infon><infon key="role2">Disease|MESH:D001943</infon><infon key="type">Negative_Correlation</infon><node refid="9" role="1,2"/></relation><relation id="R11"><infon key="score">0.9777</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|246778</infon><infon key="type">Positive_Correlation</infon><node refid="10" role="18,21"/></relation><relation id="R12"><infon key="score">0.6481</infon><infon key="role1">Chemical|MESH:D000069448</infon><infon key="role2">Disease|MESH:D009362</infon><infon key="type">Negative_Correlation</infon><node refid="11" role="10,6"/></relation><relation id="R13"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C031403</infon><infon key="role2">Disease|MESH:D009362</infon><infon key="type">Negative_Correlation</infon><node refid="12" role="12,15"/></relation><relation id="R14"><infon key="score">0.9943</infon><infon key="role1">Chemical|MESH:C031403</infon><infon key="role2">Disease|MESH:D001943</infon><infon key="type">Negative_Correlation</infon><node refid="13" role="0,2"/></relation></document>
<document><id>37889583</id><passage><infon key="journal">Curr Opin Infect Dis;2023Oct30. doi:10.1097/QCO.0000000000000985</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ron R, Moreno E, Cancio-Su&amp;#xe1;rez MR, Serrano-Villar S, </infon><offset>0</offset><text>The microbiome as a biomarker of anal precancerous lesions in people with HIV.</text><annotation id="1"><infon key="identifier">MESH:D011230</infon><infon key="type">Disease</infon><location offset="33" length="25"/><text>anal precancerous lesions</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>PURPOSE OF REVIEW: Early detection and treatment of human papillomavirus (HPV)-related anal dysplasia in some high-risk groups can help anal cancer prevention, but new tools to improve diagnostic and risk assessment are needed. Here, we aim to discuss the evidence on the role of the microbiome as a potential biomarker for anal high-grade squamous intraepithelial lesions (HSILs) in people with HIV (PWH). RECENT FINDINGS: This review covers relevant studies on the links between the microbiome and HPV infection, cervical dysplasia/cancer, and anal HPV disease. It focuses on anal samples and precancerous lesions. SUMMARY: The review highlights the promising potential of the anal microbiome as a novel biomarker for precancerous lesions in people with HIV, while also discussing limitations and future research needs.</text><annotation id="11"><infon key="identifier">MESH:C538254</infon><infon key="type">Disease</infon><location offset="166" length="14"/><text>anal dysplasia</text></annotation><annotation id="12"><infon key="identifier">MESH:D001005</infon><infon key="type">Disease</infon><location offset="215" length="11"/><text>anal cancer</text></annotation><annotation id="13"><infon key="identifier">MESH:D000081483</infon><infon key="type">Disease</infon><location offset="419" length="32"/><text>squamous intraepithelial lesions</text></annotation><annotation id="14"><infon key="identifier">MESH:D000081483</infon><infon key="type">Disease</infon><location offset="453" length="5"/><text>HSILs</text></annotation><annotation id="15"><infon key="identifier">MESH:D030361</infon><infon key="type">Disease</infon><location offset="579" length="13"/><text>HPV infection</text></annotation><annotation id="16"><infon key="identifier">MESH:D002583</infon><infon key="type">Disease</infon><location offset="594" length="25"/><text>cervical dysplasia/cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D030361</infon><infon key="type">Disease</infon><location offset="630" length="11"/><text>HPV disease</text></annotation><annotation id="18"><infon key="identifier">MESH:D011230</infon><infon key="type">Disease</infon><location offset="674" length="20"/><text>precancerous lesions</text></annotation><annotation id="19"><infon key="identifier">MESH:D011230</infon><infon key="type">Disease</infon><location offset="799" length="20"/><text>precancerous lesions</text></annotation></passage></document>
<document><id>37889933</id><passage><infon key="journal">Otol Neurotol;2023Oct25. doi:10.1097/MAO.0000000000004041</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Carlson ML, Lohse CM, Marinelli JP, Sydlowski SA, Collaborative Hearing Health, </infon><offset>0</offset><text>Perceptions Surrounding Cochlear Implants Among At-Risk and Qualifying Older Adults in the United States.</text></passage><passage><infon key="type">abstract</infon><offset>106</offset><text>OBJECTIVE: Limited evidence to date has examined public perceptions of cochlear implants among adult hearing aid users with moderate to profound hearing loss. The current work was conceived with the chief objective of characterizing the perceptions surrounding cochlear implants among the prospective candidate pool. STUDY DESIGN: National cross-sectional survey study. SETTING: United States. PATIENTS: Adults between 50 and 80 years of age with self-reported moderate to moderately severe (n = 200) or moderately severe to profound (n = 200) hearing loss currently using hearing aids. RESULTS: The overall survey response rate was 12%. Median age at time of survey for the 400 respondents was 66 years (interquartile range, 60-71 yr) and included 215 (54%) men. In total, 26% did not think of hearing loss as a medical condition, and another 23% were unsure. Overall, 63% of respondents had heard of cochlear implants, but only 2% indicated they were very familiar with them. Despite 52% of respondents reporting "very positive" or "somewhat positive" feelings about cochlear implants, only 9% indicated they were "very likely" to get a cochlear implant in the future, including 7% of those with estimated moderately severe to profound hearing loss at time of survey. CONCLUSIONS: Even among people with presumed qualifying levels of hearing loss, there exists a widespread lack of familiarity with cochlear implantation as a viable treatment option. This limited awareness seems influenced by a generally poor appreciation for hearing loss as a chronic disease state that warrants treatment. However, among those familiar with cochlear implants, they are generally viewed favorably.</text><annotation id="6"><infon key="identifier">MESH:D034381</infon><infon key="type">Disease</infon><location offset="251" length="12"/><text>hearing loss</text></annotation><annotation id="7"><infon key="identifier">MESH:D034381</infon><infon key="type">Disease</infon><location offset="650" length="12"/><text>hearing loss</text></annotation><annotation id="8"><infon key="identifier">MESH:D034381</infon><infon key="type">Disease</infon><location offset="901" length="12"/><text>hearing loss</text></annotation><annotation id="9"><infon key="identifier">MESH:D034381</infon><infon key="type">Disease</infon><location offset="1344" length="12"/><text>hearing loss</text></annotation><annotation id="10"><infon key="identifier">MESH:D034381</infon><infon key="type">Disease</infon><location offset="1442" length="12"/><text>hearing loss</text></annotation><annotation id="11"><infon key="identifier">MESH:D034381</infon><infon key="type">Disease</infon><location offset="1636" length="12"/><text>hearing loss</text></annotation></passage></document>
<document><id>37890285</id><passage><infon key="journal">Eur J Cell Biol;2023Oct20; 102 (4) 151367. doi:10.1016/j.ejcb.2023.151367</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Suarez C, Winkelman JD, Harker AJ, Ye HJ, McCall PM, Morganthaler AN, Gardel ML, Kovar DR, </infon><offset>0</offset><text>Reconstitution of the transition from a lamellipodia- to filopodia-like actin network with purified proteins.</text></passage><passage><infon key="type">abstract</infon><offset>110</offset><text>How cells utilize complex mixtures of actin binding proteins to assemble and maintain functionally diverse actin filament networks with distinct architectures and dynamics within a common cytoplasm is a longstanding question in cell biology. A compelling example of complex and specialized actin structures in cells are filopodia which sense extracellular chemical and mechanical signals to help steer motile cells. Filopodia have distinct actin architecture, composed of long, parallel actin filaments bundled by fascin, which form finger-like membrane protrusions. Elongation of the parallel actin filaments in filopodia can be mediated by two processive actin filament elongation factors, formin and Ena/VASP, which localize to the tips of filopodia. There remains debate as to how the architecture of filopodia are generated, with one hypothesis proposing that filopodia are generated from the lamellipodia, which consists of densely packed, branched actin filaments nucleated by Arp2/3 complex and kept short by capping protein. It remains unclear if different actin filament elongation factors are necessary and sufficient to facilitate the emergence of filopodia with diverse characteristics from a highly dense network of short-branched capped filaments. To address this question, we combined bead motility and micropatterning biomimetic assays with multi-color Total Internal Reflection Fluorescence microscopy imaging, to successfully reconstitute the formation of filopodia-like networks (FLN) from densely-branched lamellipodia-like networks (LLN) with eight purified proteins (actin, profilin, Arp2/3 complex, Wasp pWA, fascin, capping protein, VASP and formin mDia2). Saturating capping protein concentrations inhibit FLN assembly, but the addition of either formin or Ena/VASP differentially rescues the formation of FLN from LLN. Specifically, we found that formin/mDia2-generated FLNs are relatively long and lack capping protein, whereas VASP-generated FLNs are comparatively short and contain capping protein, indicating that the actin elongation factor can affect the architecture and composition of FLN emerging from LLN. Our biomimetic reconstitution systems reveal that formin or VASP are necessary and sufficient to induce the transition from a LLN to a FLN, and establish robust in vitro platforms to investigate FLN assembly mechanisms.</text><annotation id="11"><infon key="identifier">6624</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48164</infon><location offset="624" length="6"/><text>fascin</text></annotation><annotation id="12"><infon key="identifier">7408</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7592</infon><location offset="817" length="4"/><text>VASP</text></annotation><annotation id="13"><infon key="identifier">10097;10096</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4181;68483</infon><location offset="1094" length="6"/><text>Arp2/3</text></annotation><annotation id="14"><infon key="identifier">10097;10096</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4181;68483</infon><location offset="1717" length="6"/><text>Arp2/3</text></annotation><annotation id="15"><infon key="identifier">6624</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48164</infon><location offset="1743" length="6"/><text>fascin</text></annotation><annotation id="16"><infon key="identifier">7408</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7592</infon><location offset="1768" length="4"/><text>VASP</text></annotation><annotation id="17"><infon key="identifier">81624</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">84829</infon><location offset="1784" length="5"/><text>mDia2</text></annotation><annotation id="18"><infon key="identifier">7408</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7592</infon><location offset="1897" length="4"/><text>VASP</text></annotation><annotation id="19"><infon key="identifier">81624</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">84829</infon><location offset="1991" length="5"/><text>mDia2</text></annotation><annotation id="20"><infon key="identifier">7408</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7592</infon><location offset="2066" length="4"/><text>VASP</text></annotation><annotation id="21"><infon key="identifier">7408</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7592</infon><location offset="2313" length="4"/><text>VASP</text></annotation></passage></document>
<document><id>37890635</id><passage><infon key="type">title</infon><offset>0</offset><text>Harnessing the composition of dissolved organic matter in lagoon sediment in association with rare earth elements using fluorescence and UV-visible absorption spectroscopy.</text><annotation id="1"><infon key="identifier">MESH:D008674</infon><infon key="type">Chemical</infon><location offset="94" length="19"/><text>rare earth elements</text></annotation></passage><passage><infon key="type">abstract</infon><offset>173</offset><text>Dissolved Organic Matter (DOM) plays a pivotal role in influencing metal binding and mobility within lagoon sediments. However, there exists a gap in understanding the compositional alterations of DOM concerning Rare Earth Elements (REEs) across varying pollution gradients. This study aimed to characterize DOM and examine its relationship with REEs in sediment cores from different pollution levels in Yundang Lagoon, China using excitation-emission matrix-parallel factor analysis (EEM-PARAFAC). The results raveled four distinct fluorescent components. Among these, two correspond to humic-like substances, while the remaining two are attributed to protein-like substances. Remarkably, the prevalence of protein-like compounds was observed to exceed 58 % of the total fluorescence intensity across all the investigated sites. Furthermore, a substantial discrepancy in total fluorescence intensity was detected between the Songbai Lake and the Inner and Outer Lagoon, indicating a variance in DOM content. In terms of REEs, the average concentration of total REEs was notably elevated within the Songbai Lake sediments (318.36 mg/kg) as compared to the Inner and Outer Lagoon sediments (296.36 and 278.05 mg/kg, respectively). Of significance is the enrichment of Light Rare Earth Elements (LREEs), particularly Ce, La, Pr, and Nd, over Heavy REEs (HREEs) across all surveyed locations. Intriguingly, a coherent trend emerged wherein the fluorescence intensity and LREE concentrations exhibited a synchronized increase from Outer to Inner to Songbai Lake core sediments. This observation substantiates a strong correlation between DOM content and pollution levels (p &lt; 0.05). By shedding light on the intricate interplay between DOM and REEs within urban aquatic sediments, this study imparts novel insights which enrich our comprehension of urban environmental dynamics.</text><annotation id="7"><infon key="identifier">MESH:D008674</infon><infon key="type">Chemical</infon><location offset="385" length="19"/><text>Rare Earth Elements</text></annotation><annotation id="8"><infon key="identifier">MESH:D008674</infon><infon key="type">Chemical</infon><location offset="1446" length="19"/><text>Rare Earth Elements</text></annotation><annotation id="9"><infon key="identifier">MESH:D011221</infon><infon key="type">Chemical</infon><location offset="1496" length="2"/><text>Pr</text></annotation><annotation id="10"><infon key="identifier">MESH:D009354</infon><infon key="type">Chemical</infon><location offset="1504" length="2"/><text>Nd</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1641" length="4"/><text>LREE</text></annotation></passage></document>
<document><id>37890985</id><passage><infon key="journal">J Neurol Neurosurg Psychiatry;2023Oct27. doi:10.1136/jnnp-2023-332539</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ciron J, Biotti D, Bost C, Bonneville F, Marignier R, </infon><offset>0</offset><text>Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease.</text><annotation id="2"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="0" length="21"/><text>Haemorrhagic myelitis</text></annotation><annotation id="3"><infon key="identifier">MESH:D007153</infon><infon key="type">Disease</infon><location offset="44" length="31"/><text>MOG antibody-associated disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>77</offset></passage></document>
<document><id>37897296</id><passage><infon key="journal">Ying Yong Sheng Tai Xue Bao;2023Oct; 34 (10) 2871. doi:10.13287/j.1001-9332.202310.020</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Pan L, Zheng XN, Luo S, Mao HJ, Meng QL, Chen JR, </infon><offset>0</offset><text>[Review on building energy saving and outdoor cooling effect of vertical greenery systems].</text></passage><passage><infon key="type">abstract</infon><offset>92</offset><text>Vertical greenery system (VGS) is a sustainable solution to promote building energy saving and emission reduction, mitigate the urban heat island effect, as well as a crucial component of urban ecological construction. We summarized four main mechanisms of the thermal effects of VGSs, including shading effect, evapotranspiration effect, thermal insulation effect, and wind control effect. We elucidated the effects of VGSs on building cooling and energy saving, and analyzed the cooling effects of VGSs on plant canopy and outdoor ambient air, as well as their influence on mitigating the urban heat island effect. Based on available research on the thermal effects of VGSs, we identified key directions for future research, aiming to expedite the development of green cities and achieve carbon neutrality.</text><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="372" length="4"/><text>VGSs</text></annotation><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="512" length="4"/><text>VGSs</text></annotation><annotation id="7"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="592" length="4"/><text>VGSs</text></annotation><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="763" length="4"/><text>VGSs</text></annotation><annotation id="9"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="882" length="6"/><text>carbon</text></annotation></passage></document>
<document><id>37897647</id><passage><infon key="journal">Breast Cancer Res Treat;2023Oct28. doi:10.1007/s10549-023-07140-6</infon><infon key="year">2023</infon><infon key="article-id_pmc">7890613</infon><infon key="type">title</infon><infon key="authors">Huang HC, Guadamuz JS, Hoskins KF, Ko NY, Calip GS, </infon><offset>0</offset><text>Risk of contralateral breast cancer among Asian/Pacific Islander women in the United States.</text><annotation id="1"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="8" length="27"/><text>contralateral breast cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>PURPOSE: While breast cancer studies often aggregate Asian/Pacific Islander (API) women, as a single group or exclude them, this population is heterogeneous in terms of genetic background, environmental exposures, and health-related behaviors, potentially resulting in different cancer outcomes. Our purpose was to evaluate risks of contralateral breast cancer (CBC) among subgroups of API women with breast cancer. METHODS: We conducted a retrospective cohort study of women ages 18 + years diagnosed with stage I-III breast cancer between 2000 and 2016 in the Surveillance, Epidemiology and End Results registries. API subgroups included Chinese, Japanese, Filipina, Native Hawaiian, Korean, Vietnamese, Indian/Pakistani, and other API women. Asynchronous CBC was defined as breast cancer diagnosed in the opposite breast 12 + months after first primary unilateral breast cancer. Multivariable-adjusted subdistribution hazard ratios (SHR) and 95% confidence intervals (CI) were estimated and stratified by API subgroups. RESULTS: From a cohort of 44,362 API women with breast cancer, 25% were Filipina, 18% were Chinese, 14% were Japanese, and 8% were Indian/Pakistani. API women as an aggregate group had increased risk of CBC (SHR 1.15, 95% CI 1.08-1.22) compared to NHW women, among whom Chinese (SHR 1.23, 95% CI 1.08-1.40), Filipina (SHR 1.37, 95% CI 1.23-1.52), and Native Hawaiian (SHR 1.69, 95% CI 1.37-2.08) women had greater risks. CONCLUSION: Aggregating or excluding API patients from breast cancer studies ignores their heterogeneous health outcomes. To advance cancer health equity among API women, future research should examine inequities within the API population to design interventions that can adequately address their unique differences.</text><annotation id="15"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="108" length="13"/><text>breast cancer</text></annotation><annotation id="16"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="372" length="6"/><text>cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="426" length="27"/><text>contralateral breast cancer</text></annotation><annotation id="18"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="455" length="3"/><text>CBC</text></annotation><annotation id="19"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="494" length="13"/><text>breast cancer</text></annotation><annotation id="20"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="600" length="25"/><text>stage I-III breast cancer</text></annotation><annotation id="21"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="851" length="3"/><text>CBC</text></annotation><annotation id="22"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="870" length="13"/><text>breast cancer</text></annotation><annotation id="23"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="960" length="13"/><text>breast cancer</text></annotation><annotation id="24"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1164" length="13"/><text>breast cancer</text></annotation><annotation id="25"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1319" length="3"/><text>CBC</text></annotation><annotation id="26"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1592" length="13"/><text>breast cancer</text></annotation><annotation id="27"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1670" length="6"/><text>cancer</text></annotation></passage></document>
<document><id>37897997</id><passage><infon key="type">title</infon><offset>0</offset><text>Successive exposure to traditional disinfectants and quaternary ammonium compounds enhances resistance genes expression and co-selection in biofilm-based partial nitrification-anammox systems.</text><annotation id="1"><infon key="identifier">MESH:D000644</infon><infon key="type">Chemical</infon><location offset="53" length="29"/><text>quaternary ammonium compounds</text></annotation></passage><passage><infon key="type">abstract</infon><offset>193</offset><text>Quaternary ammonium compounds (QACs) are recommended disinfectants with surfactant properties, surpassing triclosan (TCS) and chloroxylenol (PCMX). Given the transition from traditional disinfectants, it is essential to investigate their impacts on biological nitrogen removal systems and the fate of resistance genes (RGs). In this study, three biofilm-based partial nitrification-anammox (PN/A) systems were established. A reactor named PD was successively exposed to 1 mg/L PCMX and 3 mg/L dioctadecyldimethylammonium chloride (DODMAC, a common QACs). A reactor named TD was successively exposed to 1 mg/L TCS and 3 mg/L DODMAC. A reactor named CD served as a control with only 3 mg/L DODMAC exposure. Results indicated that the total nitrogen removal performance of CD deteriorated markedly with DODMAC exposure compared to that of PD and TD. This phenomenon correlated closely with variations in RGs and their co-selection patterns. Pre-exposure to PCMX or TCS increased the abundance of RGs in the extracellular DNA of the PN/A biofilm, but reduced RGs abundances in the extracellular DNA of water. The tolerance of the PN/A system to successive exposure to the two disinfectants may be strengthened through co-selection of QACs RGs (qacEdelta1-01, qacEdelta1-02, qacH-01 and qacH-02) and mobile genetic elements (intI1 and tnpA-04). Furthermore, potential hosts of RGs are crucial for maintaining PN/A performance. Accumulation of extracellular polymeric substances, reactive oxygen species, and lactate dehydrogenase plays vital roles in the accumulation and transmission of RGs within the PN/A system.</text><annotation id="28"><infon key="identifier">MESH:D000644</infon><infon key="type">Chemical</infon><location offset="193" length="29"/><text>Quaternary ammonium compounds</text></annotation><annotation id="29"><infon key="identifier">MESH:D000644</infon><infon key="type">Chemical</infon><location offset="224" length="4"/><text>QACs</text></annotation><annotation id="30"><infon key="identifier">MESH:D014260</infon><infon key="type">Chemical</infon><location offset="299" length="9"/><text>triclosan</text></annotation><annotation id="31"><infon key="identifier">MESH:D014260</infon><infon key="type">Chemical</infon><location offset="310" length="3"/><text>TCS</text></annotation><annotation id="32"><infon key="identifier">MESH:C007027</infon><infon key="type">Chemical</infon><location offset="319" length="13"/><text>chloroxylenol</text></annotation><annotation id="33"><infon key="identifier">MESH:C007027</infon><infon key="type">Chemical</infon><location offset="334" length="4"/><text>PCMX</text></annotation><annotation id="34"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="453" length="8"/><text>nitrogen</text></annotation><annotation id="35"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="632" length="2"/><text>PD</text></annotation><annotation id="36"><infon key="identifier">MESH:C007027</infon><infon key="type">Chemical</infon><location offset="670" length="4"/><text>PCMX</text></annotation><annotation id="37"><infon key="identifier">MESH:C015831</infon><infon key="type">Chemical</infon><location offset="686" length="36"/><text>dioctadecyldimethylammonium chloride</text></annotation><annotation id="38"><infon key="identifier">MESH:C015831</infon><infon key="type">Chemical</infon><location offset="724" length="6"/><text>DODMAC</text></annotation><annotation id="39"><infon key="identifier">MESH:D000644</infon><infon key="type">Chemical</infon><location offset="741" length="4"/><text>QACs</text></annotation><annotation id="40"><infon key="identifier">MESH:D004409</infon><infon key="type">Disease</infon><location offset="764" length="2"/><text>TD</text></annotation><annotation id="41"><infon key="identifier">MESH:D014260</infon><infon key="type">Chemical</infon><location offset="802" length="3"/><text>TCS</text></annotation><annotation id="42"><infon key="identifier">MESH:C015831</infon><infon key="type">Chemical</infon><location offset="817" length="6"/><text>DODMAC</text></annotation><annotation id="43"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="841" length="2"/><text>CD</text></annotation><annotation id="44"><infon key="identifier">MESH:C015831</infon><infon key="type">Chemical</infon><location offset="881" length="6"/><text>DODMAC</text></annotation><annotation id="45"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="931" length="8"/><text>nitrogen</text></annotation><annotation id="46"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="963" length="2"/><text>CD</text></annotation><annotation id="47"><infon key="identifier">MESH:C015831</infon><infon key="type">Chemical</infon><location offset="993" length="6"/><text>DODMAC</text></annotation><annotation id="48"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="1029" length="2"/><text>PD</text></annotation><annotation id="49"><infon key="identifier">MESH:C076628</infon><infon key="type">Chemical</infon><location offset="1036" length="2"/><text>TD</text></annotation><annotation id="50"><infon key="identifier">MESH:C007027</infon><infon key="type">Chemical</infon><location offset="1147" length="4"/><text>PCMX</text></annotation><annotation id="51"><infon key="identifier">MESH:D014260</infon><infon key="type">Chemical</infon><location offset="1155" length="3"/><text>TCS</text></annotation><annotation id="52"><infon key="identifier">MESH:D000644</infon><infon key="type">Chemical</infon><location offset="1423" length="4"/><text>QACs</text></annotation><annotation id="53"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="1667" length="23"/><text>reactive oxygen species</text></annotation></passage><relation id="R1"><infon key="score">0.9934</infon><infon key="role1">Chemical|MESH:C015831</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="20,18"/></relation><relation id="R2"><infon key="score">0.9948</infon><infon key="role1">Chemical|MESH:D002104</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="19,18"/></relation><relation id="R3"><infon key="score">0.4597</infon><infon key="role1">Chemical|MESH:C015831</infon><infon key="role2">Chemical|MESH:D002104</infon><infon key="type">Association</infon><node refid="2" role="17,16"/></relation><relation id="R4"><infon key="score">0.4713</infon><infon key="role1">Chemical|MESH:D000644</infon><infon key="role2">Chemical|MESH:D014260</infon><infon key="type">Comparison</infon><node refid="3" role="1,3"/></relation><relation id="R5"><infon key="score">0.824</infon><infon key="role1">Chemical|MESH:D014260</infon><infon key="role2">Disease|MESH:D004409</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="14,13"/></relation></document>
<document><id>37898350</id><passage><infon key="journal">Behav Brain Res;2023Oct26 114731. doi:10.1016/j.bbr.2023.114731</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lutfy RH, Salam SA, Mohammed HS, Shakweer MM, Essawy AE, </infon><offset>0</offset><text>Photomodulatory effects in the hypothalamus of sleep-deprived young and aged rats.</text></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>Insufficient sleep is associated with impaired hypothalamic activity and declined attentional performance. In this study, alterations in the hypothalamus of REM sleep-deprived (SD) young and aged rats, and the modulatory effect of near-infrared (NIR) laser were investigated. Forty-eight male Wistar rats (24 young at 2 months and 24 senile at 14 months) were divided into three groups: the control, the SD group subjected to 72hr of sleep deprivation, and the transcranial-NIR laser-treated (TLT) group subjected to SD for 72hr and irradiated with 830nm laser. The hypothalamic levels of oxidative stress, inflammatory biomarkers, antioxidant enzymes, mitochondrial cytochrome C oxidase (CCO), apoptotic markers (BAX, BCL-2), and neuronal survival-associated genes (BDNF, GLP-1) were evaluated. Furthermore, the hypothalamic tissue alterations were analyzed via histological examination. The results revealed that TLT treatment has enhanced the antioxidant status, prevented oxidative insults, suppressed neuroinflammation, regulated CCO activity, reduced apoptotic markers, and tuned the survival genes (BDNF &amp; GLP-1) in hypothalamic tissue of SD young and aged rats. Microscopically, TLT treatment has ameliorated the SD-induced alterations and restored the normal histological features of hypothalamus tissue. Moreover, the obtained data showed that SD and NIR laser therapy are age-dependent. Altogether, our findings emphasize the age-dependent adverse effects of SD on the hypothalamus and suggest the use of low-laser NIR radiation as a potential non-invasive and therapeutic approach against SD-induced adverse effects in young and aged animals.</text><annotation id="11"><infon key="identifier">MESH:D012892</infon><infon key="type">Disease</infon><location offset="83" length="18"/><text>Insufficient sleep</text></annotation><annotation id="12"><infon key="identifier">MESH:D007027</infon><infon key="type">Disease</infon><location offset="121" length="30"/><text>impaired hypothalamic activity</text></annotation><annotation id="13"><infon key="identifier">MESH:D012892</infon><infon key="type">Disease</infon><location offset="517" length="17"/><text>sleep deprivation</text></annotation><annotation id="14"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="690" length="12"/><text>inflammatory</text></annotation><annotation id="15"><infon key="identifier">24887</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7242</infon><location offset="797" length="3"/><text>BAX</text></annotation><annotation id="16"><infon key="identifier">24224</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">527</infon><location offset="802" length="5"/><text>BCL-2</text></annotation><annotation id="17"><infon key="identifier">24225</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7245</infon><location offset="850" length="4"/><text>BDNF</text></annotation><annotation id="18"><infon key="identifier">24952</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1553</infon><location offset="856" length="5"/><text>GLP-1</text></annotation><annotation id="19"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="1089" length="17"/><text>neuroinflammation</text></annotation><annotation id="20"><infon key="identifier">24225</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7245</infon><location offset="1189" length="4"/><text>BDNF</text></annotation><annotation id="21"><infon key="identifier">24952</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1553</infon><location offset="1196" length="5"/><text>GLP-1</text></annotation></passage></document>
<document><id>37899050</id><passage><infon key="journal">Arq Neuropsiquiatr;2023Oct29. doi:10.1055/s-0043-1775834</infon><infon key="year">2023</infon><infon key="type">title</infon><offset>0</offset><text>Erratum.</text></passage><passage><infon key="type">abstract</infon><offset>9</offset></passage></document>
<document><id>37899400</id><passage><infon key="journal">Zhejiang Da Xue Xue Bao Yi Xue Ban;2023Oct03; 52 (5) 605. doi:10.3724/zdxbyxb-2022-0716</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xian X, Chen Y, Qiao S, Shao J, Wang M, Sun L, Ye Z, </infon><offset>0</offset><text>Influencing factors of self-management behavior in cancer patients based on a theoretical domain framework.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="51" length="6"/><text>cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>108</offset><text>OBJECTIVES: To explore the factors that influence self-management behavior in cancer patients based on the theoretical domain framework. METHODS: Studies in Chinese and English about factors influencing self-management behavior in cancer patients were searched from Wanfang database, CNKI, VIP, SinoMed, PubMed, Embase, CINAHL, Web of Science Core Collection, Cochrane library and Medline from inception to June 2022. Two investigators independently identified, extracted data, and collected characteristics and methodology of the studies. Factors were analyzed with Nvivo12, and the theoretical domain framework was mapped to the theoretical domain. Then the secondary node was generalized by theme analysis. Finally, the specific influencing factors were summarized and analyzed. RESULTS: Thirty-four studies were included for analysis. A total of 194 factors were mapped to 13 theoretical domains, and 31 secondary nodes were summarized. Theoretical domains environmental context and resources, social/professional role and identity, and beliefs about consequences were the most common factors. Knowledge, age, self-efficacy, disease stage, social support, gender, economic status and physical status were the most influential factors for self-management in cancer patients. CONCLUSIONS: The influencing factors of self-management of cancer patients involve most of the theoretical domains, are intersectional, multi-source and complex.</text><annotation id="6"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="186" length="6"/><text>cancer</text></annotation><annotation id="7"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="339" length="6"/><text>cancer</text></annotation><annotation id="8"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1369" length="6"/><text>cancer</text></annotation><annotation id="9"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1445" length="6"/><text>cancer</text></annotation></passage></document>
<document><id>37899753</id><passage><infon key="journal">Am J Physiol Regul Integr Comp Physiol;2023Oct30. doi:10.1152/ajpregu.00152.2023</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kano R, Tabuchi A, Tanaka Y, Shirakawa H, Hoshino D, Poole DC, Kano Y, </infon><offset>0</offset><text>In vivo cytosolic H2O2 changes and Ca2+ homeostasis in mouse skeletal muscle.</text><annotation id="2"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="18" length="4"/><text>H2O2</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="35" length="4"/><text>Ca2+</text></annotation></passage><passage><infon key="type">abstract</infon><offset>78</offset><text>Hydrogen peroxide (H2O2) and calcium ions (Ca2+) are functional regulators of skeletal muscle contraction and metabolism. Although H2O2 is one of the activators of the type-1 ryanodine receptor (RyR1) in the Ca2+ release channel, the interdependence between H2O2 and Ca2+ dynamics remains unclear. This study tested the following hypotheses using an in vivo model of mouse tibialis anterior (TA) skeletal muscle. 1. Under resting conditions, elevated cytosolic H2O2 concentration ([H2O2]cyto) leads to a concentration-dependent increase in cytosolic Ca2+concentration ([Ca2+]cyto) through its effect on RyR1. 2. In hypoxia (cardiac arrest) and muscle contractions (electrical stimulation), increased [H2O2]cyto induce Ca2+ accumulation. Cytosolic H2O2 (HyPer7) and Ca2+ (Fura-2) dynamics were resolved by TA bioimaging in C57BL/6J male mice under four conditions: Elevated exogenous H2O2, Cardiac arrest, Twitch and Tetanic contractions. Exogenous H2O2 (0.1-100mM) induced a concentration-dependent increase in [H2O2]cyto (+55%,0.1mM; +280%,100mM) and an increase in [Ca2+]cyto (+3%,1.0mM; +8%,10mM). This increase in [Ca2+]cyto was inhibited by pharmacological inhibition of RyR1 by dantrolene. Cardiac arrest-induced hypoxia increased [H2O2]cyto (+33%) and [Ca2+]cyto (+20%) 50min post-cardiac arrest. Compared to exogenous 1.0mM H2O2 condition, [H2O2]cyto after tetanic contractions rose less than one-tenth as much, while [Ca2+]cyto was 4.7-fold higher. In conclusion, substantial increases in [H2O2]cyto levels evoke only modest Ca2+ accumulation via their effect on the sarcoplasmic reticulum RyR1. On the other hand, contrary to hypoxia secondary to cardiac arrest, increases in [H2O2]cyto from contractions are small, indicating that H2O2 generation is unlikely to be a primary factor driving the significant Ca2+ accumulation after, especially tetanic, muscle contractions.</text><annotation id="56"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="78" length="17"/><text>Hydrogen peroxide</text></annotation><annotation id="57"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="97" length="4"/><text>H2O2</text></annotation><annotation id="58"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="107" length="12"/><text>calcium ions</text></annotation><annotation id="59"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="121" length="4"/><text>Ca2+</text></annotation><annotation id="60"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="209" length="4"/><text>H2O2</text></annotation><annotation id="61"><infon key="identifier">20190</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68069</infon><location offset="246" length="25"/><text>type-1 ryanodine receptor</text></annotation><annotation id="62"><infon key="identifier">20190</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68069</infon><location offset="273" length="4"/><text>RyR1</text></annotation><annotation id="63"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="286" length="4"/><text>Ca2+</text></annotation><annotation id="64"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="336" length="4"/><text>H2O2</text></annotation><annotation id="65"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="345" length="4"/><text>Ca2+</text></annotation><annotation id="66"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="539" length="4"/><text>H2O2</text></annotation><annotation id="67"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="560" length="9"/><text>H2O2]cyto</text></annotation><annotation id="68"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="628" length="4"/><text>Ca2+</text></annotation><annotation id="69"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="648" length="4"/><text>Ca2+</text></annotation><annotation id="70"><infon key="identifier">20190</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68069</infon><location offset="681" length="4"/><text>RyR1</text></annotation><annotation id="71"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="693" length="7"/><text>hypoxia</text></annotation><annotation id="72"><infon key="identifier">MESH:D006323</infon><infon key="type">Disease</infon><location offset="702" length="14"/><text>cardiac arrest</text></annotation><annotation id="73"><infon key="identifier">MESH:C536214</infon><infon key="type">Disease</infon><location offset="722" length="19"/><text>muscle contractions</text></annotation><annotation id="74"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="779" length="9"/><text>H2O2]cyto</text></annotation><annotation id="75"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="796" length="4"/><text>Ca2+</text></annotation><annotation id="76"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="825" length="4"/><text>H2O2</text></annotation><annotation id="77"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="843" length="4"/><text>Ca2+</text></annotation><annotation id="78"><infon key="identifier">MESH:D016257</infon><infon key="type">Chemical</infon><location offset="849" length="6"/><text>Fura-2</text></annotation><annotation id="79"><infon key="identifier">CVCL:C0MW</infon><infon key="type">CellLine</infon><location offset="900" length="8"/><text>C57BL/6J</text></annotation><annotation id="80"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="961" length="4"/><text>H2O2</text></annotation><annotation id="81"><infon key="identifier">MESH:D006323</infon><infon key="type">Disease</infon><location offset="967" length="14"/><text>Cardiac arrest</text></annotation><annotation id="82"><infon key="identifier">MESH:C536214</infon><infon key="type">Disease</infon><location offset="994" length="20"/><text>Tetanic contractions</text></annotation><annotation id="83"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="1026" length="4"/><text>H2O2</text></annotation><annotation id="84"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1090" length="9"/><text>H2O2]cyto</text></annotation><annotation id="85"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1146" length="4"/><text>Ca2+</text></annotation><annotation id="86"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1197" length="4"/><text>Ca2+</text></annotation><annotation id="87"><infon key="identifier">20190</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68069</infon><location offset="1254" length="4"/><text>RyR1</text></annotation><annotation id="88"><infon key="identifier">MESH:D003620</infon><infon key="type">Chemical</infon><location offset="1262" length="10"/><text>dantrolene</text></annotation><annotation id="89"><infon key="identifier">MESH:D006323</infon><infon key="type">Disease</infon><location offset="1274" length="14"/><text>Cardiac arrest</text></annotation><annotation id="90"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="1297" length="7"/><text>hypoxia</text></annotation><annotation id="91"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1316" length="9"/><text>H2O2]cyto</text></annotation><annotation id="92"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1338" length="4"/><text>Ca2+</text></annotation><annotation id="93"><infon key="identifier">MESH:D006323</infon><infon key="type">Disease</infon><location offset="1366" length="14"/><text>cardiac arrest</text></annotation><annotation id="94"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="1410" length="4"/><text>H2O2</text></annotation><annotation id="95"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1427" length="9"/><text>H2O2]cyto</text></annotation><annotation id="96"><infon key="identifier">MESH:C536214</infon><infon key="type">Disease</infon><location offset="1443" length="20"/><text>tetanic contractions</text></annotation><annotation id="97"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1505" length="4"/><text>Ca2+</text></annotation><annotation id="98"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1577" length="9"/><text>H2O2]cyto</text></annotation><annotation id="99"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1612" length="4"/><text>Ca2+</text></annotation><annotation id="100"><infon key="identifier">20190</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68069</infon><location offset="1677" length="4"/><text>RyR1</text></annotation><annotation id="101"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="1714" length="7"/><text>hypoxia</text></annotation><annotation id="102"><infon key="identifier">MESH:D006323</infon><infon key="type">Disease</infon><location offset="1735" length="14"/><text>cardiac arrest</text></annotation><annotation id="103"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1765" length="9"/><text>H2O2]cyto</text></annotation><annotation id="104"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="1820" length="4"/><text>H2O2</text></annotation><annotation id="105"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1895" length="4"/><text>Ca2+</text></annotation><annotation id="106"><infon key="type">Disease</infon><location offset="1931" length="7"/><text>tetanic</text></annotation><annotation id="107"><infon key="identifier">MESH:C536214</infon><infon key="type">Disease</infon><location offset="1940" length="19"/><text>muscle contractions</text></annotation></passage><relation id="R1"><infon key="score">0.9954</infon><infon key="role1">Chemical|MESH:D006861</infon><infon key="role2">Disease|MESH:D006323</infon><infon key="type">Association</infon><node refid="0" role="22,27"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D003620</infon><infon key="role2">Gene|20190</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="34,33"/></relation><relation id="R3"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D006861</infon><infon key="role2">Gene|20190</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="6,7"/></relation></document>
<document><id>37902203</id><passage><infon key="journal">J Water Health;2023Oct; 21 (10) 1470. doi:10.2166/wh.2023.132</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Adewumi AJ, Laniyan TA, </infon><offset>0</offset><text>Contamination, ecological, and human health risks of heavy metals in water from a Pb-Zn-F mining area, North Eastern Nigeria.</text><annotation id="3"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="53" length="12"/><text>heavy metals</text></annotation><annotation id="4"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="69" length="5"/><text>water</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="82" length="7"/><text>Pb-Zn-F</text></annotation></passage><passage><infon key="type">abstract</infon><offset>126</offset><text>In Nigeria, artisanal mining has become a serious issue. In the Nigerian mining region of Arufu Pb-Zn-F, this study assessed the level of pollution, ecological hazards, and health risks related to the presence of metals in the water. In the dry and rainy seasons, 36 water samples (20 from the ground, 10 from the surface, and six from the mine) were gathered. Samples were examined for the presence of heavy metals such as Cr, Co, Ni, Cu, Zn, As, Cd, and Pb. Other than Cu, Zn, As, Cd, Sb, and Cd (surface water, dry season), which were below the acceptable norm, all water samples had metals over the suggested limits. Heavy metals from nearby mining activities polluted the water, according to contamination evaluations utilizing the contamination factor (CF). Metals in the water may pose very significant ecological dangers, according to ecological risk assessments. The evaluation of human health risks revealed that both adults and children in the region are susceptible to carcinogenic and non-carcinogenic health hazards since the hazard index (HI) values for both indices were above 1 x 10-5 and above 1, respectively. This report emphasizes the need for monitoring mining operations in the nation to safeguard public health.</text><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="222" length="7"/><text>Pb-Zn-F</text></annotation><annotation id="35"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="339" length="6"/><text>metals</text></annotation><annotation id="36"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="353" length="5"/><text>water</text></annotation><annotation id="37"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="393" length="5"/><text>water</text></annotation><annotation id="38"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="529" length="12"/><text>heavy metals</text></annotation><annotation id="39"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="547" length="2"/><text>as</text></annotation><annotation id="40"><infon key="identifier">MESH:D002857</infon><infon key="type">Chemical</infon><location offset="550" length="2"/><text>Cr</text></annotation><annotation id="41"><infon key="identifier">MESH:D003035</infon><infon key="type">Chemical</infon><location offset="554" length="2"/><text>Co</text></annotation><annotation id="42"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="562" length="2"/><text>Cu</text></annotation><annotation id="43"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="566" length="2"/><text>Zn</text></annotation><annotation id="44"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="570" length="2"/><text>As</text></annotation><annotation id="45"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="574" length="2"/><text>Cd</text></annotation><annotation id="46"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="582" length="2"/><text>Pb</text></annotation><annotation id="47"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="597" length="2"/><text>Cu</text></annotation><annotation id="48"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="601" length="2"/><text>Zn</text></annotation><annotation id="49"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="605" length="2"/><text>As</text></annotation><annotation id="50"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="609" length="2"/><text>Cd</text></annotation><annotation id="51"><infon key="identifier">MESH:D000965</infon><infon key="type">Chemical</infon><location offset="613" length="2"/><text>Sb</text></annotation><annotation id="52"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="621" length="2"/><text>Cd</text></annotation><annotation id="53"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="633" length="5"/><text>water</text></annotation><annotation id="54"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="695" length="5"/><text>water</text></annotation><annotation id="55"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="713" length="6"/><text>metals</text></annotation><annotation id="56"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="747" length="12"/><text>Heavy metals</text></annotation><annotation id="57"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="803" length="5"/><text>water</text></annotation><annotation id="58"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="890" length="6"/><text>Metals</text></annotation><annotation id="59"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="904" length="5"/><text>water</text></annotation><annotation id="60"><infon key="identifier">MESH:D011230</infon><infon key="type">Disease</infon><location offset="1107" length="12"/><text>carcinogenic</text></annotation><annotation id="61"><infon key="identifier">MESH:D011230</infon><infon key="type">Disease</infon><location offset="1128" length="12"/><text>carcinogenic</text></annotation></passage><relation id="R1"><infon key="score">0.9918</infon><infon key="role1">Chemical|MESH:D014867</infon><infon key="role2">Chemical|MESH:D019216</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9848</infon><infon key="role1">Chemical|MESH:D008670</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="1" role="4,5"/></relation></document>
<document><id>37902903</id><passage><infon key="journal">J Immigr Minor Health;2023Oct30. doi:10.1007/s10903-023-01557-3</infon><infon key="year">2023</infon><infon key="article-id_pmc">4289337</infon><infon key="type">title</infon><infon key="authors">Alkhaifi S, Padela AI, </infon><offset>0</offset><text>"I'm not Alone; He will be There for Me": A Mixed-Method Approach Exploring the Impact of Spousal Support on Mammogram Utilization and Health Beliefs.</text></passage><passage><infon key="type">abstract</infon><offset>151</offset><text>Regular mammogram screenings are effective for early breast cancer (BC) detection and decreased mortality rate. However, immigrant Muslim Arab women (IMAW) are less likely to adhere to these screenings although the rate of BC among IMAW is high. Recent studies have explored low mammogram screening rates among immigrant Muslim and/or Arab women from a limited perspective, overlooking the fact that husbands have an influence in IMAW's health behaviors toward cancer screenings. Thus, this mixed-method approaches were employed to (a) explore the association between spousal support and IMAW's health beliefs toward mammograms and their utilization, (b) to understand IMAW's experiences of spousal influence related to their mammogram use and health beliefs. The quantitative portion of the study, recruitment and data collection were conducted via online surveys in Arabic and English. Logistic regressions were used to explore relationships between perceived spousal support and IMAW's mammogram utilization and health beliefs. The qualitative portion of the study was conducted on a purposive sample of IMAW. A semi-structured interview guide in Arabic and English was used during one-on-one interviews. Arabic interviews were translated into English and transcribed by professionals. Interviews were analyzed by thematic analysis according to Braun and Clarke (2008). A total of 184 IMAW completed the survey with mean age of 50.4 (SD = 5.58, range = 45-60). Results revealed low mammogram screening rate among IMAW. Only 32.6% adhered to mammograms. Spousal support was positively associated with ever having obtained a mammogram and IMAW's adherence to mammogram. The 20 qualitative interviews, 16 in Arabic and four in English, produced rich description supporting results from the survey which includes, (a) types of spousal support, (b) impact of spousal support on participants' mammogram utilization and experience, and (3) impact of spousal support on participants' health beliefs toward mammograms. Findings from surveys and interviews show that a husband's support is positively associated with IMAW's mammogram utilization and health beliefs. Suggesting a new approach to integrate husbands in culturally appropriate interventions to increase mammogram screening rates among IMAW.</text><annotation id="4"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="204" length="13"/><text>breast cancer</text></annotation><annotation id="5"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="219" length="2"/><text>BC</text></annotation><annotation id="6"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="374" length="2"/><text>BC</text></annotation><annotation id="7"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="612" length="6"/><text>cancer</text></annotation></passage></document>
<document><id>37903281</id><passage><infon key="journal">J Gen Physiol;2023Dec04; 155 (12) . doi:10.1085/jgp.202313450</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10616507</infon><infon key="type">title</infon><infon key="authors">Wisedchaisri G, Gamal El-Din TM, Powell NM, Zheng N, Catterall WA, </infon><offset>0</offset><text>Structural basis for severe pain caused by mutations in the voltage sensors of sodium channel NaV1.7.</text><annotation id="2"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="28" length="4"/><text>pain</text></annotation><annotation id="3"><infon key="identifier">6335</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2237</infon><location offset="94" length="6"/><text>NaV1.7</text></annotation></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>Voltage-gated sodium channels in peripheral nerves conduct nociceptive signals from nerve endings to the spinal cord. Mutations in voltage-gated sodium channel NaV1.7 are responsible for a number of severe inherited pain syndromes, including inherited erythromelalgia (IEM). Here, we describe the negative shifts in the voltage dependence of activation in the bacterial sodium channel NaVAb as a result of the incorporation of four different IEM mutations in the voltage sensor, which recapitulate the gain-of-function effects observed with these mutations in human NaV1.7. Crystal structures of NaVAb with these IEM mutations revealed that a mutation in the S1 segment of the voltage sensor facilitated the outward movement of S4 gating charges by widening the pathway for gating charge translocation. In contrast, mutations in the S4 segments modified hydrophobic interactions with surrounding amino acid side chains or membrane phospholipids that would enhance the outward movement of the gating charges. These results provide key structural insights into the mechanisms by which these IEM mutations in the voltage sensors can facilitate outward movements of the gating charges in the S4 segment and cause hyperexcitability and severe pain in IEM. Our work gives new insights into IEM pathogenesis at the near-atomic level and provides a molecular model for mutation-specific therapy of this debilitating disease.</text><annotation id="16"><infon key="identifier">6335</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2237</infon><location offset="262" length="6"/><text>NaV1.7</text></annotation><annotation id="17"><infon key="identifier">MESH:C538101</infon><infon key="type">Disease</infon><location offset="308" length="24"/><text>inherited pain syndromes</text></annotation><annotation id="18"><infon key="identifier">MESH:D004916</infon><infon key="type">Disease</infon><location offset="344" length="25"/><text>inherited erythromelalgia</text></annotation><annotation id="19"><infon key="identifier">MESH:D004916</infon><infon key="type">Disease</infon><location offset="371" length="3"/><text>IEM</text></annotation><annotation id="20"><infon key="identifier">MESH:D004916</infon><infon key="type">Disease</infon><location offset="544" length="3"/><text>IEM</text></annotation><annotation id="21"><infon key="identifier">6335</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2237</infon><location offset="668" length="6"/><text>NaV1.7</text></annotation><annotation id="22"><infon key="identifier">MESH:D004916</infon><infon key="type">Disease</infon><location offset="715" length="3"/><text>IEM</text></annotation><annotation id="23"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="1033" length="13"/><text>phospholipids</text></annotation><annotation id="24"><infon key="identifier">MESH:D004916</infon><infon key="type">Disease</infon><location offset="1191" length="3"/><text>IEM</text></annotation><annotation id="25"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1340" length="4"/><text>pain</text></annotation><annotation id="26"><infon key="identifier">MESH:D004916</infon><infon key="type">Disease</infon><location offset="1348" length="3"/><text>IEM</text></annotation><annotation id="27"><infon key="identifier">MESH:D004916</infon><infon key="type">Disease</infon><location offset="1386" length="3"/><text>IEM</text></annotation></passage><relation id="R1"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:C538101</infon><infon key="role2">Gene|6335</infon><infon key="type">Association</infon><node refid="0" role="3,2"/></relation><relation id="R2"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D010146</infon><infon key="role2">Gene|6335</infon><infon key="type">Association</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D004916</infon><infon key="role2">Gene|6335</infon><infon key="type">Association</infon><node refid="2" role="4,2"/></relation></document>
<document><id>37903632</id><passage><infon key="journal">Arch Dis Child;2023Oct30. doi:10.1136/archdischild-2023-325637</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Prasad V, Rezel-Potts E, White P, Downs J, Boddy N, Sayal K, Sonuga-Barke E, </infon><offset>0</offset><text>Use of healthcare services before diagnosis of attention-deficit/hyperactivity disorder: a population-based matched case-control study.</text><annotation id="1"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="47" length="40"/><text>attention-deficit/hyperactivity disorder</text></annotation></passage><passage><infon key="type">abstract</infon><offset>136</offset><text>OBJECTIVE: To compare use of healthcare services and reasons for attendance by children and young people (CYP) with attention-deficit/hyperactivity disorder (ADHD) versus non-ADHD controls. DESIGN: Population-based matched case-control study. SETTING: English primary care electronic health records with linked hospital records from the Clinical Practice Research Datalink, 1998-2015. PARTICIPANTS: 8127 CYP with an ADHD diagnosis aged 4-17 years at the time of diagnosis and 40 136 non-ADHD controls matched by age, sex and general practitioner (GP) practice. MAIN OUTCOME MEASURES: Medical diagnoses, prescriptions, hospital admissions and hospital procedures in the 2 years before diagnosis (or the index date for controls). RESULTS: CYP with ADHD attended healthcare services twice as often as controls (rate ratios: GP: 2.0, 95% CI=2.0, 2.1; hospital 1.8, 95% CI=1.8, 1.9). CYP with ADHD attended their GP, received prescriptions and were admitted to hospital for a wide range of reasons. The strongest association for GP attendances, comparing CYP with versus without ADHD, was for 'mental and behavioural disorders' (OR=25.2, 95% CI=23.3, 27.2). Common reasons for GP attendance included eye, ear, nose, throat, oral (OR=1.5, 95% CI=1.4, 1.5) and conditions such as asthma (OR=1.3, 95% CI=1.3, 1.4) or eczema (OR=1.2, 95% CI=1.0, 1.3). CONCLUSIONS: Two years before diagnosis, CYP with ADHD attended healthcare services twice as often as CYP without. CYP with ADHD had increased rates of physical conditions, such as asthma and eczema. These contacts may be an opportunity for earlier recognition and diagnosis of ADHD.</text><annotation id="18"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="252" length="40"/><text>attention-deficit/hyperactivity disorder</text></annotation><annotation id="19"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="294" length="4"/><text>ADHD</text></annotation><annotation id="20"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="311" length="4"/><text>ADHD</text></annotation><annotation id="21"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="552" length="4"/><text>ADHD</text></annotation><annotation id="22"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="623" length="4"/><text>ADHD</text></annotation><annotation id="23"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="882" length="4"/><text>ADHD</text></annotation><annotation id="24"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="1024" length="4"/><text>ADHD</text></annotation><annotation id="25"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="1210" length="4"/><text>ADHD</text></annotation><annotation id="26"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1225" length="32"/><text>mental and behavioural disorders</text></annotation><annotation id="27"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="1409" length="6"/><text>asthma</text></annotation><annotation id="28"><infon key="identifier">MESH:D004485</infon><infon key="type">Disease</infon><location offset="1445" length="6"/><text>eczema</text></annotation><annotation id="29"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="1529" length="4"/><text>ADHD</text></annotation><annotation id="30"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="1603" length="4"/><text>ADHD</text></annotation><annotation id="31"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="1660" length="6"/><text>asthma</text></annotation><annotation id="32"><infon key="identifier">MESH:D004485</infon><infon key="type">Disease</infon><location offset="1671" length="6"/><text>eczema</text></annotation><annotation id="33"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="1757" length="4"/><text>ADHD</text></annotation></passage></document>
<document><id>37904333</id><passage><infon key="journal">Addiction;2023Oct30. doi:10.1111/add.16380</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Back S, Kroon E, Colyer-Patel K, Cousijn J, </infon><offset>0</offset><text>Does nitrous oxide addiction exist? An evaluation of the evidence for the presence and prevalence of substance use disorder symptoms in recreational nitrous oxide users.</text><annotation id="3"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="5" length="13"/><text>nitrous oxide</text></annotation><annotation id="4"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="101" length="22"/><text>substance use disorder</text></annotation><annotation id="5"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="149" length="13"/><text>nitrous oxide</text></annotation></passage><passage><infon key="type">abstract</infon><offset>170</offset><text>BACKGROUND: Prevalence of nitrous oxide (N2 O) use appears to be increasing in numerous countries worldwide, and excessive use has been associated with physical and mental problems. Because there currently is no consensus whether N2 O has addictive potential, we aimed to evaluate the evidence for the presence and prevalence of DSM-5 substance use disorder (SUD) symptoms in N2 O users. ANALYSIS: A literature search was conducted to assess the evidence for the presence of any of the 11 DSM-5 SUD symptoms in N2 O users and the prevalence experiencing those symptoms. A substantial part of the studied N2 O users use more than intended (i.e. 46% to 98%) and spend a substantial amount of time using N2 O. At least some of the studied N2 O users experience interpersonal problems (i.e. 13% to 80%) and use N2 O in risky situations, such as driving under the influence. Evidence for the other criteria is either insufficient or inconclusive. CONCLUSIONS: The literature base for the presence and prevalence of DSM-5 substance use disorder (SUD) symptoms in nitrous oxide (N2 O) users is limited and largely consists of qualitative studies and case studies, but it provides consistent evidence for the presence of at least four SUD criteria in heavy N2 O users. N2 O could well be addictive and should be treated as a potentially addictive substance until systematic assessments can provide evidence-based guidance to users, healthcare professionals and legislators.</text><annotation id="29"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="196" length="13"/><text>nitrous oxide</text></annotation><annotation id="30"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="211" length="4"/><text>N2 O</text></annotation><annotation id="31"><infon key="identifier">MESH:D059445</infon><infon key="type">Disease</infon><location offset="322" length="8"/><text>physical</text></annotation><annotation id="32"><infon key="identifier">MESH:D008607</infon><infon key="type">Disease</infon><location offset="335" length="15"/><text>mental problems</text></annotation><annotation id="33"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="400" length="4"/><text>N2 O</text></annotation><annotation id="34"><infon key="identifier">MESH:D008232</infon><infon key="type">Disease</infon><location offset="499" length="5"/><text>DSM-5</text></annotation><annotation id="35"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="505" length="22"/><text>substance use disorder</text></annotation><annotation id="36"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="529" length="3"/><text>SUD</text></annotation><annotation id="37"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="546" length="4"/><text>N2 O</text></annotation><annotation id="38"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="659" length="9"/><text>DSM-5 SUD</text></annotation><annotation id="39"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="681" length="4"/><text>N2 O</text></annotation><annotation id="40"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="774" length="4"/><text>N2 O</text></annotation><annotation id="41"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="871" length="5"/><text>N2 O.</text></annotation><annotation id="42"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="906" length="4"/><text>N2 O</text></annotation><annotation id="43"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="977" length="4"/><text>N2 O</text></annotation><annotation id="44"><infon key="identifier">MESH:D008232</infon><infon key="type">Disease</infon><location offset="1180" length="5"/><text>DSM-5</text></annotation><annotation id="45"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="1186" length="22"/><text>substance use disorder</text></annotation><annotation id="46"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="1210" length="3"/><text>SUD</text></annotation><annotation id="47"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="1227" length="13"/><text>nitrous oxide</text></annotation><annotation id="48"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="1242" length="4"/><text>N2 O</text></annotation><annotation id="49"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="1397" length="3"/><text>SUD</text></annotation><annotation id="50"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="1419" length="4"/><text>N2 O</text></annotation><annotation id="51"><infon key="identifier">MESH:D009609</infon><infon key="type">Chemical</infon><location offset="1431" length="4"/><text>N2 O</text></annotation></passage><relation id="R1"><infon key="score">0.5953</infon><infon key="role1">Chemical|MESH:D009609</infon><infon key="role2">Disease|MESH:D019966</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="2,1"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D009609</infon><infon key="role2">Disease|MESH:D008607</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="3,6"/></relation><relation id="R3"><infon key="score">0.7359</infon><infon key="role1">Chemical|MESH:D009609</infon><infon key="role2">Disease|MESH:D008232</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="7,8"/></relation><relation id="R4"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D009609</infon><infon key="role2">Disease|MESH:D059445</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="3,5"/></relation></document>
<document><id>37905033</id><passage><infon key="journal">bioRxiv;2023Oct16. doi:10.1101/2023.10.13.562298</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614799</infon><infon key="type">title</infon><infon key="authors">Derry A, Altman RB, </infon><offset>0</offset><text>Explainable protein function annotation using local structure embeddings.</text></passage><passage><infon key="type">abstract</infon><offset>74</offset><text>The rapid expansion of protein sequence and structure databases has resulted in a significant number of proteins with ambiguous or unknown function. While advances in machine learning techniques hold great potential to fill this annotation gap, current methods for function prediction are unable to associate global function reliably to the specific residues responsible for that function. We address this issue by introducing PARSE (Protein Annotation by Residue-Specific Enrichment), a knowledge-based method which combines pre-trained embeddings of local structural environments with traditional statistical techniques to identify enriched functions with residue-level explainability. For the task of predicting the catalytic function of enzymes, PARSE achieves comparable or superior global performance to state-of-the-art machine learning methods (F1 score > 85%) while simultaneously annotating the specific residues involved in each function with much greater precision. Since it does not require supervised training, our method can make one-shot predictions for very rare functions and is not limited to a particular type of functional label (e.g. Enzyme Commission numbers or Gene Ontology codes). Finally, we leverage the AlphaFold Structure Database to perform functional annotation at a proteome scale. By applying PARSE to the dark proteome-predicted structures which cannot be classified into known structural families-we predict several novel bacterial metalloproteases. Each of these proteins shares a strongly conserved catalytic site despite highly divergent sequences and global folds, illustrating the value of local structure representations for new function discovery.</text></passage></document>
<document><id>37905383</id><passage><infon key="journal">Nurs Crit Care;2023Oct31. doi:10.1111/nicc.12982</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang Y, Diao D, Zhang H, Gao Y, </infon><offset>0</offset><text>Validity and predictability of the confusion assessment method for the intensive care unit for delirium among critically ill patients in the intensive care unit: A systematic review and meta-analysis.</text><annotation id="2"><infon key="identifier">MESH:D003693</infon><infon key="type">Disease</infon><location offset="95" length="8"/><text>delirium</text></annotation><annotation id="3"><infon key="identifier">MESH:D016638</infon><infon key="type">Disease</infon><location offset="110" length="14"/><text>critically ill</text></annotation></passage><passage><infon key="type">abstract</infon><offset>201</offset><text>OBJECTIVE: To identify the validity and predictability of the confusion assessment method for the intensive care unit (CAM-ICU) for delirium in critically ill patients in the ICU. METHODS: In this systematic review, PubMed, Embase, Cochrane Central Register of Controlled Trials, and MEDLINE databases were searched for observational studies investigating delirium screening tools for ICU patients. In the meta-analysis, we combined the sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve (AUC) of SROC to analysis the predictive value of CAM-ICU. RESULTS: Twenty-nine articles met the inclusion criteria. The pooled sensitivity and specificity values were 0.82 (95% confidence interval [CI]: 0.75-0.87) and 0.95 (95% CI: 0.93-0.97), respectively. The AUC point estimate of the SROC curve was 0.96 (95% CI: 0.94-0.97). Race (Asian or Others) could affect the pooled sensitivity and specificity, and the analysis method (Patient- or Scan-based) and study design were not sources of heterogeneity for pooled sensitivity and specificity. CONCLUSIONS: The CAM-ICU is a valid and reliable tool for delirium prediction among ICU patients. When introducing CAM-ICU to assess delirium, it is necessary to localize its language and content to improve its predictive efficacy in different countries and different ethnic groups. RELEVANCE TO CLINICAL PRACTICE: In clinical practice, nurses can use CAM-ICU to evaluate delirium in critically ill patients in ICU. However, it is necessary to debug the language and content according to the application population.</text><annotation id="16"><infon key="identifier">MESH:D020786</infon><infon key="type">Disease</infon><location offset="320" length="3"/><text>CAM</text></annotation><annotation id="17"><infon key="identifier">MESH:D003693</infon><infon key="type">Disease</infon><location offset="333" length="8"/><text>delirium</text></annotation><annotation id="18"><infon key="identifier">MESH:D016638</infon><infon key="type">Disease</infon><location offset="345" length="14"/><text>critically ill</text></annotation><annotation id="19"><infon key="identifier">MESH:D003693</infon><infon key="type">Disease</infon><location offset="557" length="8"/><text>delirium</text></annotation><annotation id="20"><infon key="identifier">MESH:D020786</infon><infon key="type">Disease</infon><location offset="816" length="3"/><text>CAM</text></annotation><annotation id="21"><infon key="identifier">MESH:D020786</infon><infon key="type">Disease</infon><location offset="1329" length="3"/><text>CAM</text></annotation><annotation id="22"><infon key="identifier">MESH:D003693</infon><infon key="type">Disease</infon><location offset="1370" length="8"/><text>delirium</text></annotation><annotation id="23"><infon key="identifier">MESH:D020786</infon><infon key="type">Disease</infon><location offset="1427" length="3"/><text>CAM</text></annotation><annotation id="24"><infon key="identifier">MESH:D003693</infon><infon key="type">Disease</infon><location offset="1445" length="8"/><text>delirium</text></annotation><annotation id="25"><infon key="identifier">MESH:D020786</infon><infon key="type">Disease</infon><location offset="1664" length="3"/><text>CAM</text></annotation><annotation id="26"><infon key="identifier">MESH:D003693</infon><infon key="type">Disease</infon><location offset="1684" length="8"/><text>delirium</text></annotation><annotation id="27"><infon key="identifier">MESH:D016638</infon><infon key="type">Disease</infon><location offset="1696" length="14"/><text>critically ill</text></annotation></passage></document>
<document><id>37905734</id><passage><infon key="journal">Br J Haematol;2023Oct31. doi:10.1111/bjh.19170</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mart&amp;#xed;nez-Cibri&amp;#xe1;n N, Ortiz-Maldonado V, Espa&amp;#xf1;ol-Rego M, Bl&amp;#xe1;zquez A, Cid J, Lozano M, Magnano L, Gin&amp;#xe9; E, Correa JG, Mozas P, Rodr&amp;#xed;guez-Lobato LG, Rivero A, Montoro-Lorite M, Ayora P, Navarro S, Alserawan L, Gonz&amp;#xe1;lez-Navarro EA, Castell&amp;#xe0; M, S&amp;#xe1;nchez-Casta&amp;#xf1;&amp;#xf3;n M, Cabez&amp;#xf3;n R, Ben&amp;#xed;tez-Ribas D, Setoa&amp;#xed;n X, Rodr&amp;#xed;guez S, Brillembourg H, Varea S, Olesti E, Guill&amp;#xe9;n E, S&amp;#xe1;ez-Pe&amp;#xf1;ataro J, de Larrea CF, L&amp;#xf3;pez-Guillermo A, Pascal M, Urbano-Ispizua &amp;#xc1;, Juan M, Delgado J, </infon><offset>0</offset><text>The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.</text><annotation id="5"><infon key="identifier">930</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1341</infon><location offset="32" length="4"/><text>CD19</text></annotation><annotation id="6"><infon key="identifier">9970</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="37" length="25"/><text>chimeric antigen receptor</text></annotation><annotation id="7"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="78" length="26"/><text>varnimcabtagene autoleucel</text></annotation><annotation id="8"><infon key="identifier">CVCL:8Y24</infon><infon key="type">CellLine</infon><location offset="106" length="8"/><text>ARI-0001</text></annotation><annotation id="9"><infon key="identifier">MESH:D016393</infon><infon key="type">Disease</infon><location offset="188" length="27"/><text>B-cell non-Hodgkin lymphoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>217</offset><text>Varnimcabtagene autoleucel (var-cel) is an academic anti-CD19 chimeric antigen receptor (CAR) product used for the treatment of non-Hodgkin lymphoma (NHL) in the CART19-BE-01 trial. Here we report updated outcomes of patients with NHL treated with var-cel. B-cell recovery was compared with patients with acute lymphoblastic leukaemia (ALL). Forty-five patients with NHL were treated. Cytokine release syndrome (any grade) occurred in 84% of patients (4% grade >=3) and neurotoxicity in 7% (2% grade >=3). The objective response rate was 73% at Day +100, and the 3-year duration of response was 56%. The 3-year progression-free and overall survival were 40% and 52% respectively. High lactate dehydrogenase was the only covariate with an impact on progression-free survival. The 3-year incidence of B-cell recovery was lower in patients with NHL compared to ALL (25% vs. 60%). In conclusion, in patients with NHL, the toxicity of var-cel was manageable, while B-cell recovery was significantly prolonged compared to ALL. This trial was registered as NCT03144583.</text><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="217" length="26"/><text>Varnimcabtagene autoleucel</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="245" length="7"/><text>var-cel</text></annotation><annotation id="29"><infon key="identifier">930</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1341</infon><location offset="274" length="4"/><text>CD19</text></annotation><annotation id="30"><infon key="identifier">9970</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="279" length="25"/><text>chimeric antigen receptor</text></annotation><annotation id="31"><infon key="identifier">9970</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="306" length="3"/><text>CAR</text></annotation><annotation id="32"><infon key="identifier">MESH:D008228</infon><infon key="type">Disease</infon><location offset="345" length="20"/><text>non-Hodgkin lymphoma</text></annotation><annotation id="33"><infon key="identifier">MESH:D008228</infon><infon key="type">Disease</infon><location offset="367" length="3"/><text>NHL</text></annotation><annotation id="34"><infon key="identifier">MESH:D008228</infon><infon key="type">Disease</infon><location offset="448" length="3"/><text>NHL</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="465" length="7"/><text>var-cel</text></annotation><annotation id="36"><infon key="identifier">MESH:D054218</infon><infon key="type">Disease</infon><location offset="522" length="29"/><text>acute lymphoblastic leukaemia</text></annotation><annotation id="37"><infon key="identifier">MESH:D008228</infon><infon key="type">Disease</infon><location offset="584" length="3"/><text>NHL</text></annotation><annotation id="38"><infon key="identifier">MESH:D000080424</infon><infon key="type">Disease</infon><location offset="602" length="25"/><text>Cytokine release syndrome</text></annotation><annotation id="39"><infon key="identifier">MESH:D020258</infon><infon key="type">Disease</infon><location offset="687" length="13"/><text>neurotoxicity</text></annotation><annotation id="40"><infon key="identifier">MESH:D008228</infon><infon key="type">Disease</infon><location offset="1059" length="3"/><text>NHL</text></annotation><annotation id="41"><infon key="identifier">MESH:D008228</infon><infon key="type">Disease</infon><location offset="1126" length="3"/><text>NHL</text></annotation><annotation id="42"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1135" length="8"/><text>toxicity</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1147" length="7"/><text>var-cel</text></annotation></passage></document>
<document><id>37906085</id><passage><infon key="journal">Int J Eat Disord;2023Oct31. doi:10.1002/eat.24074</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Simons EI, Noteboom F, van Furth EF, </infon><offset>0</offset><text>Pro-anorexia coaches prey on individuals with eating disorders.</text><annotation id="2"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="4" length="8"/><text>anorexia</text></annotation><annotation id="3"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="46" length="16"/><text>eating disorders</text></annotation></passage><passage><infon key="type">abstract</infon><offset>64</offset><text>OBJECTIVE: While studies have focused on pro-ana communities and pro-anorexia websites, no research has been conducted on the presence of pro-anorexia coaches within these communities. This study aimed to gain insight into the modus operandi of pro-anorexia coaches. METHOD: First, three fake profiles were used to attempt interaction with pro-anorexia coaches (n = 31). Second, an online questionnaire on experiences with pro-anorexia coaches was completed by 79 respondents. Third, a follow-up in-depth interview was conducted with 14 of these respondents. RESULTS: The results show that pro-anorexia coaches' behavior fits a five-staged model which has similarities to stages of online grooming. They focus on (1) building trust and developing a dependency relationship with the aim of (2) obtaining sexually explicit materials. Subsequently, they (3) increase pressure, (4) utilize blackmail methods with acquired content, and (5) groom respondents to meet in person. DISCUSSION: Pro-anorexia coaches deliberately abuse vulnerable young people who suffer from eating disorders to receive sexually explicit material or to meet face-to-face with a sexual intention. This study shows that the modus operandi of pro-ana coaches is similar to online grooming. Clinical professionals need to be aware of this practice to detect victims and potential victims in order to support and treat them. Prevention is invaluable to further combat pro-anorexia coaches and protect potential victims. PUBLIC SIGNIFICANCE: Individuals with an eating disorder are avid internet users. A minority frequent pro-anorexia websites and fora seeking help in losing weight. This study showed that pro-anorexia coaches prey on these individuals, often to obtain sexually explicit content. The modus operandi of pro-anorexia coaches shows similarities to online grooming. Awareness of this phenomenon and the way in which pro-anorexia coaches operate is valuable for clinicians, parents, and teachers.</text><annotation id="20"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="133" length="8"/><text>anorexia</text></annotation><annotation id="21"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="206" length="8"/><text>anorexia</text></annotation><annotation id="22"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="313" length="8"/><text>anorexia</text></annotation><annotation id="23"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="408" length="8"/><text>anorexia</text></annotation><annotation id="24"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="491" length="8"/><text>anorexia</text></annotation><annotation id="25"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="658" length="8"/><text>anorexia</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="950" length="9"/><text>blackmail</text></annotation><annotation id="27"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="1052" length="8"/><text>anorexia</text></annotation><annotation id="28"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="1128" length="16"/><text>eating disorders</text></annotation><annotation id="29"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="1503" length="8"/><text>anorexia</text></annotation><annotation id="30"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="1592" length="15"/><text>eating disorder</text></annotation><annotation id="31"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="1657" length="8"/><text>anorexia</text></annotation><annotation id="32"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="1700" length="13"/><text>losing weight</text></annotation><annotation id="33"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="1742" length="8"/><text>anorexia</text></annotation><annotation id="34"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="1855" length="8"/><text>anorexia</text></annotation><annotation id="35"><infon key="identifier">MESH:D000855</infon><infon key="type">Disease</infon><location offset="1965" length="8"/><text>anorexia</text></annotation></passage></document>
<document><id>37906436</id><passage><infon key="journal">Mol Biol Cell;2023Nov01; 34 (12) 6. doi:10.1091/mbc.E22-08-0358</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fritz-Laylin LK, Titus MA, </infon><offset>0</offset><text>The evolution and diversity of actin-dependent cell migration.</text></passage><passage><infon key="type">abstract</infon><offset>63</offset><text>Many eukaryotic cells, including animal cells and unicellular amoebae, use dynamic-actin networks to crawl across solid surfaces. Recent discoveries of actin-dependent crawling in additional lineages have sparked interest in understanding how and when this type of motility evolved. Tracing the evolution of cell crawling requires understanding the molecular mechanisms underlying motility. Here we outline what is known about the diversity and evolution of the molecular mechanisms that drive cell motility, with a focus on actin-dependent crawling. Classic studies and recent work have revealed a surprising number of distinct mechanical modes of actin-dependent crawling used by different cell types and species to navigate different environments. The overlap in actin network regulators driving multiple types of actin-dependent crawling, along with cortical-actin networks that support the plasma membrane in these cells, suggest that actin motility and cortical actin networks might have a common evolutionary origin. The rapid development of additional evolutionarily diverse model systems, advanced imaging technologies, and CRISPR-based genetic tools, is opening the door to testing these and other new ideas about the evolution of actin-dependent cell crawling.</text></passage></document>
<document><id>37906810</id><passage><infon key="journal">Andes Pediatr;2022Dec; 93 (6) 920. doi:10.32641/andespediatr.v93i6.4569</infon><infon key="year">2022</infon><infon key="type">title</infon><infon key="authors">Toro MC, </infon><offset>0</offset><text>[Response to the letter of editor entitled: Other difficulties in exclusive breastfeeding, leading to early weaning in young infants].</text></passage><passage><infon key="type">abstract</infon><offset>135</offset></passage></document>
<document><id>37907176</id><passage><infon key="journal">Int J Biol Macromol;2023Oct29 127660. doi:10.1016/j.ijbiomac.2023.127660</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gupta P, Sharma S, Jabin S, Jadoun S, </infon><offset>0</offset><text>Chitosan nanocomposite for tissue engineering and regenerative medicine: A review.</text><annotation id="1"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="0" length="8"/><text>Chitosan</text></annotation></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>Regenerative medicine and tissue engineering have emerged as a multidisciplinary promising field in the quest to address the limitations of traditional medical approaches. One of the key aspects of these fields is the development of such types of biomaterials that can mimic the extracellular matrix and provide a conducive environment for tissue regeneration. In this regard, chitosan has played a vital role which is a naturally derived linear bi-poly-aminosaccharide, and has gained significant attention due to its biocompatibility and unique properties. Chitosan possesses many unique physicochemical properties, making it a significant polysaccharide for different applications such as agriculture, nutraceutical, biomedical, food, nutraceutical, packaging, etc. as well as significant material for developing next-generation hydrogel and bio-scaffolds for regenerative medicinal applications. Moreover, chitosan can be easily modified to incorporate desirable properties, such as improved mechanical strength, enhanced biodegradability, and controlled release of bioactive molecules. Blending chitosan with other polymers or incorporating nanoparticles into its matrix further expands its potential in tissue engineering applications. This review summarizes the most recent studies of the last 10 years based on chitosan, blends, and nanocomposites and their application in bone tissue engineering, hard tissue engineering, dental implants, dental tissue engineering, dental fillers, and cartilage tissue engineering.</text><annotation id="9"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="460" length="8"/><text>chitosan</text></annotation><annotation id="10"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="529" length="23"/><text>bi-poly-aminosaccharide</text></annotation><annotation id="11"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="642" length="8"/><text>Chitosan</text></annotation><annotation id="12"><infon key="identifier">MESH:D011134</infon><infon key="type">Chemical</infon><location offset="725" length="14"/><text>polysaccharide</text></annotation><annotation id="13"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="993" length="8"/><text>chitosan</text></annotation><annotation id="14"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="1183" length="8"/><text>chitosan</text></annotation><annotation id="15"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="1203" length="8"/><text>polymers</text></annotation></passage></document>
<document><id>37909279</id><passage><infon key="journal">Int J Syst Evol Microbiol;2023Nov; 73 (11) . doi:10.1099/ijsem.0.006115</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Freese HM, Giner-P&amp;#xe9;rez L, Oren A, G&amp;#xf6;ker M, Arahal DR, </infon><offset>0</offset><text>The gender gap in names of prokaryotes honouring persons.</text></passage><passage><infon key="type">abstract</infon><offset>58</offset><text>The aim of this study is to analyse prokaryotic names which honour persons, eponyms, from a gender perspective. Data were retrieved from the List of Prokaryotic names with Standing in Nomenclature. Excluding new combinations, the etymologies of 23 315 unique names at the rank of genus, species and subspecies were analysed. A total of 2018 (8.7 %) names honour persons (eponyms), for which the development of the female share over time was further investigated. Women started to be honoured very recently (1947) compared to men (1823). Moreover, only 14.8 % of all prokaryotic eponyms refer to females. This ratio has hardly improved since 1947, although the number of women whose contributions to microbiology could have been recognized has increased over time. In contrast, about 50 % of prokaryotic names derived from mythological characters refer to females. To reduce this gender gap, we encourage authors proposing new taxon names to honour female scientists who can serve as role models for new generations.</text></passage></document>
<document><id>37909633</id><passage><infon key="journal">Braz Dent J;2023Jul-Aug; 34 (4) 107. doi:10.1590/0103-6440202305357</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Pejon LS, Oliveira VC, Amorim AA, Raffaini JC, Arruda CNF, Pires-de-Souza FCP, </infon><offset>0</offset><text>Antimicrobial effect of phytosphingosine in acrylic resin.</text><annotation id="2"><infon key="identifier">MESH:C012491</infon><infon key="type">Chemical</infon><location offset="24" length="16"/><text>phytosphingosine</text></annotation><annotation id="3"><infon key="identifier">MESH:D000180</infon><infon key="type">Chemical</infon><location offset="44" length="13"/><text>acrylic resin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>59</offset><text>This study evaluated color stability (CS), anti-adherence effect (AAE), and cell viability of microorganisms on acrylic resin (AR) surface, treated associated or not with sodium percarbonate (SP). AR specimens were prepared, and color analysis was performed before and after the treatments and the CS was calculated. For analysis of AAE, the samples were sterilized by radiation in a microwave oven. Then samples were randomly distributed: phosphate-buffered saline (PBS - control), 0.5% sodium hypochlorite (SH), phytosphingosine (PHS), and phytosphingosine + SP (PHS+Na2CO3). The specimens remained in contact with solutions for 30 minutes and were later contaminated by Candida albicans. Aliquots were seeded in Petri dishes with Sabouraud Dextrose agar and incubated at 37 C for 24 hours. After the incubation, the number of colonies was counted. The cell viability of adhered microorganisms on the AR was evaluated and 20 fields were observed under an epifluorescence microscope, and the percentage of adhered viable cells was calculated. Data were compared (One-way ANOVA, Tukey, p&lt;.05). As for CS, PHS+ Na2CO3 (0.4+-0.1) resulted in less change than PBS (0.9+-0.2), similar to the other groups (SH [1.0+-0.3)]; PHS [0.9+-0.2)]). There was no difference for all tested solutions regarding the ability to avoid microorganism adherence (p>0.05), but PHS (11.2+-4.1) resulted in a smaller area of adhered viable cells, statistically different from SH (18.2+-7.6) and PBS (26.4+-10.8). It was concluded that PHS resulted in lower adhered viable cells and when associated with Na2CO3, also shows a lower effect on the CS of AR.</text><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="97" length="2"/><text>CS</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="125" length="3"/><text>AAE</text></annotation><annotation id="38"><infon key="identifier">MESH:D000180</infon><infon key="type">Chemical</infon><location offset="171" length="13"/><text>acrylic resin</text></annotation><annotation id="39"><infon key="identifier">MESH:D000180</infon><infon key="type">Chemical</infon><location offset="186" length="2"/><text>AR</text></annotation><annotation id="40"><infon key="identifier">MESH:C034738</infon><infon key="type">Chemical</infon><location offset="230" length="19"/><text>sodium percarbonate</text></annotation><annotation id="41"><infon key="identifier">MESH:C034738</infon><infon key="type">Chemical</infon><location offset="251" length="2"/><text>SP</text></annotation><annotation id="42"><infon key="type">Disease</infon><location offset="256" length="2"/><text>AR</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="357" length="2"/><text>CS</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="392" length="3"/><text>AAE</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="499" length="25"/><text>phosphate-buffered saline</text></annotation><annotation id="46"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="526" length="3"/><text>PBS</text></annotation><annotation id="47"><infon key="identifier">MESH:D012973</infon><infon key="type">Chemical</infon><location offset="547" length="19"/><text>sodium hypochlorite</text></annotation><annotation id="48"><infon key="identifier">MESH:D012973</infon><infon key="type">Chemical</infon><location offset="568" length="2"/><text>SH</text></annotation><annotation id="49"><infon key="identifier">MESH:C012491</infon><infon key="type">Chemical</infon><location offset="573" length="16"/><text>phytosphingosine</text></annotation><annotation id="50"><infon key="identifier">MESH:C012491</infon><infon key="type">Chemical</infon><location offset="591" length="3"/><text>PHS</text></annotation><annotation id="51"><infon key="identifier">MESH:C012491</infon><infon key="type">Chemical</infon><location offset="601" length="16"/><text>phytosphingosine</text></annotation><annotation id="52"><infon key="identifier">MESH:C034738</infon><infon key="type">Chemical</infon><location offset="620" length="2"/><text>SP</text></annotation><annotation id="53"><infon key="identifier">MESH:C012491</infon><infon key="type">Chemical</infon><location offset="624" length="3"/><text>PHS</text></annotation><annotation id="54"><infon key="identifier">MESH:C005686</infon><infon key="type">Chemical</infon><location offset="628" length="6"/><text>Na2CO3</text></annotation><annotation id="55"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="792" length="23"/><text>Sabouraud Dextrose agar</text></annotation><annotation id="56"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1160" length="2"/><text>CS</text></annotation><annotation id="57"><infon key="identifier">MESH:C012491</infon><infon key="type">Chemical</infon><location offset="1164" length="3"/><text>PHS</text></annotation><annotation id="58"><infon key="identifier">MESH:C005686</infon><infon key="type">Chemical</infon><location offset="1169" length="6"/><text>Na2CO3</text></annotation><annotation id="59"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="1216" length="3"/><text>PBS</text></annotation><annotation id="60"><infon key="identifier">MESH:D012973</infon><infon key="type">Chemical</infon><location offset="1261" length="2"/><text>SH</text></annotation><annotation id="61"><infon key="identifier">MESH:C012491</infon><infon key="type">Chemical</infon><location offset="1277" length="3"/><text>PHS</text></annotation><annotation id="62"><infon key="identifier">MESH:C012491</infon><infon key="type">Chemical</infon><location offset="1413" length="3"/><text>PHS</text></annotation><annotation id="63"><infon key="identifier">MESH:D012973</infon><infon key="type">Chemical</infon><location offset="1510" length="2"/><text>SH</text></annotation><annotation id="64"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="1529" length="3"/><text>PBS</text></annotation><annotation id="65"><infon key="identifier">MESH:C012491</infon><infon key="type">Chemical</infon><location offset="1569" length="3"/><text>PHS</text></annotation><annotation id="66"><infon key="identifier">MESH:C005686</infon><infon key="type">Chemical</infon><location offset="1637" length="6"/><text>Na2CO3</text></annotation><annotation id="67"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1678" length="2"/><text>CS</text></annotation></passage><relation id="R1"><infon key="score">0.7538</infon><infon key="role1">Chemical|MESH:C034738</infon><infon key="role2">Chemical|MESH:D000180</infon><infon key="type">Association</infon><node refid="0" role="6,4"/></relation><relation id="R2"><infon key="score">0.6979</infon><infon key="role1">Chemical|MESH:C012491</infon><infon key="role2">Chemical|MESH:D007854</infon><infon key="type">Comparison</infon><node refid="1" role="15,12"/></relation><relation id="R3"><infon key="score">0.8382</infon><infon key="role1">Chemical|MESH:C005686</infon><infon key="role2">Chemical|MESH:D000180</infon><infon key="type">Association</infon><node refid="2" role="20,4"/></relation><relation id="R4"><infon key="score">0.8592</infon><infon key="role1">Chemical|MESH:C005686</infon><infon key="role2">Chemical|MESH:C012491</infon><infon key="type">Cotreatment</infon><node refid="3" role="20,15"/></relation><relation id="R5"><infon key="score">0.8663</infon><infon key="role1">Chemical|MESH:C012491</infon><infon key="role2">Chemical|MESH:D000180</infon><infon key="type">Association</infon><node refid="4" role="0,1"/></relation></document>
<document><id>37909989</id><passage><infon key="journal">Anticancer Res;2023Nov; 43 (11) 4793. doi:10.21873/anticanres.16676</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yoo SS, Katsarakes P, Gashi J, Kim E, Kim HC, B&amp;#xf6;hlke M, </infon><offset>0</offset><text>Non-thermal Acoustic Enhancement of Chemotherapeutic Effects of Cisplatin on Xenografted Cervical Cancer in Mice.</text><annotation id="2"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="64" length="9"/><text>Cisplatin</text></annotation><annotation id="3"><infon key="identifier">MESH:D002583</infon><infon key="type">Disease</infon><location offset="89" length="15"/><text>Cervical Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>BACKGROUND/AIM: We examined the effect of low-intensity focused ultrasound (FUS) on unbinding cisplatin from plasma proteins and enhancing its chemotherapeutic efficacy using a mouse model of xenograft human cervical cancer. MATERIALS AND METHODS: FUS, operating in a pulsed mode, was applied to a dialysis cassette immersed in a normal saline bath containing both bovine serum albumin (BSA) and cisplatin, and the unbound level of cisplatin diffused into the cassette was measured. To assess the in vivo efficacy of the technique, athymic nu/nu mice were inoculated with human cervical cancer cells under four different combinatory conditions, with and without the administration of cisplatin and FUS. FUS was delivered to the tumor mass for 1 h across four separate sessions spanning a period of 10 days, following the intraperitoneal injection of cisplatin. RESULTS: In vitro equilibrium dialysis revealed that non-thermal application of FUS increased the concentration of unbound cisplatin compared to cassettes that were not exposed to sonication, suggesting successful unbinding. Assessment of tumor growth in vivo showed that FUS following cisplatin administration resulted in a significant reduction in tumor growth, whereas the administration of cisplatin alone exhibited plateau growth. Without administration of cisplatin, equivalent rates of aggressive tumor growth were observed regardless of the application of FUS. CONCLUSION: Pulsed application of FUS can unbind cisplatin from albumin and enhance its tumoricidal effects in cervical cancer. Further assessment of intratumoral/systemic cisplatin concentration is required to quantify its selective delivery to the tumor.</text><annotation id="25"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="208" length="9"/><text>cisplatin</text></annotation><annotation id="26"><infon key="identifier">MESH:D002583</infon><infon key="type">Disease</infon><location offset="322" length="15"/><text>cervical cancer</text></annotation><annotation id="27"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="510" length="9"/><text>cisplatin</text></annotation><annotation id="28"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="546" length="9"/><text>cisplatin</text></annotation><annotation id="29"><infon key="identifier">MESH:D002583</infon><infon key="type">Disease</infon><location offset="692" length="15"/><text>cervical cancer</text></annotation><annotation id="30"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="798" length="9"/><text>cisplatin</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="842" length="5"/><text>tumor</text></annotation><annotation id="32"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="964" length="9"/><text>cisplatin</text></annotation><annotation id="33"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="1098" length="9"/><text>cisplatin</text></annotation><annotation id="34"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1214" length="5"/><text>tumor</text></annotation><annotation id="35"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="1261" length="9"/><text>cisplatin</text></annotation><annotation id="36"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1325" length="5"/><text>tumor</text></annotation><annotation id="37"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="1369" length="9"/><text>cisplatin</text></annotation><annotation id="38"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="1437" length="9"/><text>cisplatin</text></annotation><annotation id="39"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1479" length="5"/><text>tumor</text></annotation><annotation id="40"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="1593" length="9"/><text>cisplatin</text></annotation><annotation id="41"><infon key="identifier">213</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">405</infon><location offset="1608" length="7"/><text>albumin</text></annotation><annotation id="42"><infon key="type">Disease</infon><location offset="1632" length="11"/><text>tumoricidal</text></annotation><annotation id="43"><infon key="identifier">MESH:D002583</infon><infon key="type">Disease</infon><location offset="1655" length="15"/><text>cervical cancer</text></annotation><annotation id="44"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="1716" length="9"/><text>cisplatin</text></annotation><annotation id="45"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1794" length="5"/><text>tumor</text></annotation></passage><relation id="R1"><infon key="score">0.9964</infon><infon key="role1">Chemical|MESH:D002945</infon><infon key="role2">Disease|MESH:D002583</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.9965</infon><infon key="role1">Chemical|MESH:D002945</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="9,8"/></relation></document>
<document><id>37910340</id><passage><infon key="journal">Pharm Res;2023Nov01. doi:10.1007/s11095-023-03624-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">4788714</infon><infon key="type">title</infon><infon key="authors">Lakio S, Smith DJ, Andrade G, Sandler N, Evans P, McDermott J, Roe C, H&amp;#x4d5;ggstr&amp;#xf6;m E, </infon><offset>0</offset><text>Small is Powerful: Demonstration of the Impact of Nanoformed Piroxicam in a Controlled Clinical Study.</text><annotation id="1"><infon key="identifier">MESH:D010894</infon><infon key="type">Chemical</infon><location offset="61" length="9"/><text>Piroxicam</text></annotation></passage><passage><infon key="type">abstract</infon><offset>103</offset><text>PURPOSE: New solutions are needed to enable the efficient use of poorly water-soluble drugs. Therefore, we aimed to demonstrate that decreasing particle size with a solution-to-particle method known as nanoforming can improve dissolution and thus bioavailability. METHODS: Piroxicam, a poorly water-soluble non-steroidal anti-inflammatory drug (NSAID), was used as a model compound. A Quality-by-Design (QbD) approach was used to nanoform piroxicam and a design space was established. The pharmacokinetics of piroxicam nanoparticles were compared to two marketed products in a clinical trial. RESULTS: Nanoformed tablets showed a 33% increase in exposure during the first hour after dosing (AUC0-1 h) compared with an immediate release tablet and was similar to a fast absorbing tablet incorporating complexation of piroxicam with beta-cyclodextrin. CONCLUSIONS: The results show that nanoforming enabled more rapid absorption in comparison to a typical marketed tablet and indicate that nanoforming is an alternative to complex formulation such as cyclodextrins based products. The study outcomes support the potential of nanoforming for producing fast-acting dosage forms of poorly soluble drugs.</text><annotation id="10"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="175" length="5"/><text>water</text></annotation><annotation id="11"><infon key="identifier">MESH:D010894</infon><infon key="type">Chemical</infon><location offset="376" length="9"/><text>Piroxicam</text></annotation><annotation id="12"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="396" length="5"/><text>water</text></annotation><annotation id="13"><infon key="identifier">MESH:D010894</infon><infon key="type">Chemical</infon><location offset="542" length="9"/><text>piroxicam</text></annotation><annotation id="14"><infon key="identifier">MESH:D010894</infon><infon key="type">Chemical</infon><location offset="612" length="9"/><text>piroxicam</text></annotation><annotation id="15"><infon key="identifier">MESH:D010894</infon><infon key="type">Chemical</infon><location offset="919" length="9"/><text>piroxicam</text></annotation><annotation id="16"><infon key="identifier">MESH:C031215</infon><infon key="type">Chemical</infon><location offset="934" length="17"/><text>beta-cyclodextrin</text></annotation><annotation id="17"><infon key="identifier">MESH:D003505</infon><infon key="type">Chemical</infon><location offset="1152" length="13"/><text>cyclodextrins</text></annotation></passage><relation id="R1"><infon key="score">0.9385</infon><infon key="role1">Chemical|MESH:C031215</infon><infon key="role2">Chemical|MESH:D010894</infon><infon key="type">Association</infon><node refid="0" role="7,6"/></relation></document>
<document><id>37910691</id><passage><infon key="journal">Opt Lett;2023Nov01; 48 (21) 5515. doi:10.1364/OL.496279</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jenkins EL, Burrell DJ, </infon><offset>0</offset><text>Improved active-tracking performance through Hadamard speckle contrast reduction.</text></passage><passage><infon key="type">abstract</infon><offset>82</offset><text>We report wave-optics simulation results and benchtop experimental findings that demonstrate reduced centroiding error through a Hadamard speckle contrast reduction (HSCR). The method involves projecting multiple orthogonal phase patterns onto an actively imaged object within a single camera resolution cell and integration time. Ideally, performance improves in proportion to the square root of the number of such phase realizations applied. Using 16 subpixels per camera pixel, our simulated track performance consistently meets this expectation with a decent experimental agreement, particularly at smaller object sizes. This outcome has promising implications for active tracking and wavefront sensing, extending the utility of HSCR beyond its known benefits to coherent image quality.</text></passage></document>
<document><id>37911042</id><passage><infon key="journal">Int Dent J (Phila);1893Jan; 14 (1) 31</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109581</infon><infon key="type">title</infon><offset>0</offset><text>New York Odontological Society.</text></passage><passage><infon key="type">abstract</infon><offset>32</offset></passage></document>
<document><id>37911392</id><passage><infon key="journal">Int Dent J (Phila);1890May; 11 (5) 301</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110077</infon><infon key="type">title</infon><offset>0</offset><text>Union Meeting of the Connecticut Valley Dental Society, the New England Dental Society, and the Connecticut State Dental Association, at Springfield, Mass., October 23, 24, and 25, 1889.</text></passage><passage><infon key="type">abstract</infon><offset>187</offset></passage></document>
<document><id>37912092</id><passage><infon key="journal">Int Dent J (Phila);1896Feb; 17 (2) 122</infon><infon key="year">1896</infon><infon key="article-id_pmc">PMC10124465</infon><infon key="type">title</infon><offset>0</offset><text>The War on the Dental Colleges.</text></passage><passage><infon key="type">abstract</infon><offset>32</offset></passage></document>
<document><id>37912792</id><passage><infon key="journal">Int Dent J (Phila);1901Mar; 22 (3) 185</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153842</infon><infon key="type">title</infon><offset>0</offset><text>American Academy of Dental Science.</text></passage><passage><infon key="type">abstract</infon><offset>36</offset></passage></document>
<document><id>37913142</id><passage><infon key="journal">Int Dent J (Phila);1903May; 24 (5) 371</infon><infon key="year">1903</infon><infon key="article-id_pmc">PMC10162219</infon><infon key="type">title</infon><offset>0</offset><text>International Dental Federation and International Commission of Education: Meeting Held in Stockholm, Sweden, August, 1902.</text></passage><passage><infon key="type">abstract</infon><offset>124</offset></passage></document>
<document><id>37913493</id><passage><infon key="journal">Int Dent J (Phila);1904Jan; 25 (1) 65</infon><infon key="year">1904</infon><infon key="article-id_pmc">PMC10169081</infon><infon key="type">title</infon><offset>0</offset><text>Will Gold Foil Cease to Be Chief of Filling-Materials?</text></passage><passage><infon key="type">abstract</infon><offset>55</offset></passage></document>
<document><id>37913843</id><passage><infon key="journal">Acta Biomater;2023Oct30. doi:10.1016/j.actbio.2023.10.029</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhong C, He S, Huang Y, Yan J, Wang J, Liu W, Fang J, Ren F, </infon><offset>0</offset><text>Scaffold-based non-viral CRISPR delivery platform for efficient and prolonged gene activation to accelerate tissue regeneration.</text></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>Clustered regularly interspaced short palindromic repeat activation (CRISPRa) technology has emerged as a precise genome editing tool for activating endogenous transgene expression. While it holds promise for precise cell modification, its translation into tissue engineering has been hampered by biosafety concerns and suboptimal delivery methods. To address these challenges, we have developed a CRISPRa non-viral gene delivery platform by immobilizing non-viral CRISPRa complexes into a biocompatible hydrogel/nanofiber (Gel/NF) composite scaffold. The Gel/NF scaffold facilitates the controlled and sustained release of CRISPRa complexes and also promotes cell recruitment to the scaffold for efficient and localized transfection. As a proof of concept, we employed this CRISPRa delivery platform to activate the vascular endothelial growth factor (VEGF) gene in a rat model with full-thickness skin defects. Our results demonstrate sustained upregulation of VEGF expression even at 21 days post-implantation, resulting in enhanced angiogenesis and improved skin regeneration. These findings underscore the potential of the Gel/NF scaffold-based CRISPRa delivery platform as an efficient and durable strategy for gene activation, offering promising prospects for tissue regeneration. STATEMENT OF SIGNIFICANCE: Translation of clustered regularly interspaced short palindromic repeat activation (CRISPRa) therapy to tissue engineering is limited by biosafety concerns and unsatisfactory delivery strategy. To solve this issue, we have developed a CRISPRa non-viral gene delivery platform by immobilizing non-viral CRISPRa complexes into a biocompatible hydrogel/nanofiber (Gel/NF) composite scaffold. This scaffold enables controlled and sustained release of CRISPRa and can induce cell recruitment for localized transfection. As a proof of concept, we activated vascular endothelial growth factor (VEGF) in a rat model with full-thickness skin defects, leading to sustained upregulation of VEGF expression, enhanced angiogenesis and improved skin regeneration in vivo. These findings demonstrate the potential of this platform for gene activation, thereby offering promising prospects for tissue regeneration.</text><annotation id="8"><infon key="identifier">83785</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2534</infon><location offset="946" length="34"/><text>vascular endothelial growth factor</text></annotation><annotation id="9"><infon key="identifier">83785</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2534</infon><location offset="982" length="4"/><text>VEGF</text></annotation><annotation id="10"><infon key="identifier">MESH:D012868</infon><infon key="type">Disease</infon><location offset="1028" length="12"/><text>skin defects</text></annotation><annotation id="11"><infon key="identifier">83785</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2534</infon><location offset="1092" length="4"/><text>VEGF</text></annotation><annotation id="12"><infon key="identifier">83785</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2534</infon><location offset="1995" length="34"/><text>vascular endothelial growth factor</text></annotation><annotation id="13"><infon key="identifier">83785</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2534</infon><location offset="2031" length="4"/><text>VEGF</text></annotation><annotation id="14"><infon key="identifier">MESH:D012868</infon><infon key="type">Disease</infon><location offset="2072" length="12"/><text>skin defects</text></annotation><annotation id="15"><infon key="identifier">83785</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2534</infon><location offset="2123" length="4"/><text>VEGF</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Disease|MESH:D012868</infon><infon key="role2">Gene|83785</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="2,0"/></relation></document>
<document><id>37914543</id><passage><infon key="journal">Oral Surg Oral Med Oral Pathol Oral Radiol;2023Sep11. doi:10.1016/j.oooo.2023.09.002</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Dorsey AK, Mol A, Green P, Ludlow J, Johnson B, </infon><offset>0</offset><text>Radiation doses in extraoral bitewing radiography compared with intraoral bitewing and panoramic radiography.</text></passage><passage><infon key="type">abstract</infon><offset>110</offset><text>OBJECTIVES: We compared the effective dose (E) and thyroid equivalent dose of 2 extraoral bitewing (EOBW) units and compared E with their respective panoramic (PAN) modes and with intraoral bitewing radiography (IOBW). STUDY DESIGN: Child and adult anthropomorphic phantoms with dosimeters were used to evaluate Orthophos SL, Rayscan alpha+, and 1 intraoral unit using rectangular and circular collimation. Extraoral bitewing thyroid equivalent dose was assessed without and with thyroid shielding. RESULTS: Child and adult E values of EOBW were lower with Orthophos (3.6 and 8.6 muSv) than with Rayscan (28.1 and 30.2 muSv). For IOBW, E was lower with rectangular vs circular collimation for child (7.0 vs 11.8 muSv) and adult (4.6 vs 14.2 muSv). E values of EOBW were lower than PAN for Orthophos. The IOBW E was lower than Rayscan EOBW for child (&lt;=11.8 vs 28.1 muSv) and adult (&lt;=14.2 vs 30.2 muSv). Adult E for rectangular IOBW (4.6 muSv) was lower than EOBW with Orthophos (8.6 muSv) and Rayscan (30.2 muSv). Thyroid shielding reduced EOBW thyroid equivalent dose with Rayscan in the adult from 190.7 to 89.0 muSv. CONCLUSION: Orthophos provides significantly lower EOBW E than Rayscan, thus EOBW recommendations must be unit specific. For children, Orthophos EOBW could be an alternative to IOBW, for which rectangular collimation is recommended. Thyroid shielding reduced adult Rayscan equivalent dose but added imaging artifacts.</text></passage></document>
<document><id>37914893</id><passage><infon key="journal">Neuropsychopharmacology;2023Nov01. doi:10.1038/s41386-023-01762-6</infon><infon key="year">2023</infon><infon key="article-id_pmc">6135092</infon><infon key="type">title</infon><infon key="authors">Luo Q, Kanen JW, Bari A, Skandali N, Langley C, Knudsen GM, Alsi&amp;#xf6; J, Phillips BU, Sahakian BJ, Cardinal RN, Robbins TW, </infon><offset>0</offset><text>Comparable roles for serotonin in rats and humans for computations underlying flexible decision-making.</text><annotation id="1"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="21" length="9"/><text>serotonin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>Serotonin is critical for adapting behavior flexibly to meet changing environmental demands. Cognitive flexibility is important for successful attainment of goals, as well as for social interactions, and is frequently impaired in neuropsychiatric disorders, including obsessive-compulsive disorder. However, a unifying mechanistic framework accounting for the role of serotonin in behavioral flexibility has remained elusive. Here, we demonstrate common effects of manipulating serotonin function across two species (rats and humans) on latent processes supporting choice behavior during probabilistic reversal learning, using computational modelling. The findings support a role of serotonin in behavioral flexibility and plasticity, indicated, respectively, by increases or decreases in choice repetition ('stickiness') or reinforcement learning rates following manipulations intended to increase or decrease serotonin function. More specifically, the rate at which expected value increased following reward and decreased following punishment (reward and punishment 'learning rates') was greatest after sub-chronic administration of the selective serotonin reuptake inhibitor (SSRI) citalopram (5 mg/kg for 7 days followed by 10 mg/kg twice a day for 5 days) in rats. Conversely, humans given a single dose of an SSRI (20 mg escitalopram), which can decrease post-synaptic serotonin signalling, and rats that received the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT), which destroys forebrain serotonergic neurons, exhibited decreased reward learning rates. A basic perseverative tendency ('stickiness'), or choice repetition irrespective of the outcome produced, was likewise increased in rats after the 12-day SSRI regimen and decreased after single dose SSRI in humans and 5,7-DHT in rats. These common effects of serotonergic manipulations on rats and humans-identified via computational modelling-suggest an evolutionarily conserved role for serotonin in plasticity and behavioral flexibility and have clinical relevance transdiagnostically for neuropsychiatric disorders.</text><annotation id="20"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="104" length="9"/><text>Serotonin</text></annotation><annotation id="21"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="334" length="26"/><text>neuropsychiatric disorders</text></annotation><annotation id="22"><infon key="identifier">MESH:D009771</infon><infon key="type">Disease</infon><location offset="372" length="29"/><text>obsessive-compulsive disorder</text></annotation><annotation id="23"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="472" length="9"/><text>serotonin</text></annotation><annotation id="24"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="582" length="9"/><text>serotonin</text></annotation><annotation id="25"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="787" length="9"/><text>serotonin</text></annotation><annotation id="26"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="1015" length="9"/><text>serotonin</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1243" length="28"/><text>selective serotonin reuptake</text></annotation><annotation id="28"><infon key="identifier">MESH:D015283</infon><infon key="type">Chemical</infon><location offset="1289" length="10"/><text>citalopram</text></annotation><annotation id="29"><infon key="identifier">MESH:D000089983</infon><infon key="type">Chemical</infon><location offset="1431" length="12"/><text>escitalopram</text></annotation><annotation id="30"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="1479" length="9"/><text>serotonin</text></annotation><annotation id="31"><infon key="identifier">MESH:D015116</infon><infon key="type">Chemical</infon><location offset="1539" length="23"/><text>5,7-dihydroxytryptamine</text></annotation><annotation id="32"><infon key="identifier">MESH:D015116</infon><infon key="type">Chemical</infon><location offset="1564" length="7"/><text>5,7-DHT</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1599" length="12"/><text>serotonergic</text></annotation><annotation id="34"><infon key="identifier">MESH:D015116</infon><infon key="type">Chemical</infon><location offset="1882" length="7"/><text>5,7-DHT</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1923" length="12"/><text>serotonergic</text></annotation><annotation id="36"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="2053" length="9"/><text>serotonin</text></annotation><annotation id="37"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="2156" length="26"/><text>neuropsychiatric disorders</text></annotation></passage><relation id="R1"><infon key="score">0.8855</infon><infon key="role1">Chemical|MESH:D012701</infon><infon key="role2">Disease|MESH:D001523</infon><infon key="type">Association</infon><node refid="0" role="17,18"/></relation><relation id="R2"><infon key="score">0.9478</infon><infon key="role1">Chemical|MESH:D000089983</infon><infon key="role2">Chemical|MESH:D012701</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="10,11"/></relation></document>
<document><id>37915245</id><passage><infon key="journal">J Magn Reson Imaging;2023Nov02. doi:10.1002/jmri.29073</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ariz M, Mart&amp;#xed;nez M, Alvarez I, Fern&amp;#xe1;ndez-Seara MA, Castellanos G, Catalonian Neuroimaging Parkinson's Disease Consortium, Pastor P, Pastor MA, Ortiz de Sol&amp;#xf3;rzano C, </infon><offset>0</offset><text>Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease.</text><annotation id="3"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="57" length="12"/><text>Neuromelanin</text></annotation><annotation id="4"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="74" length="4"/><text>Iron</text></annotation><annotation id="5"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="113" length="19"/><text>Parkinson's Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>BACKGROUND: There is a lack of automated tools for the segmentation and quantification of neuromelanin (NM) and iron in the nigrosome-1 (N1). Existing tools evaluate the N1 sign, i.e., the presence or absence of the "swallow-tail" in iron-sensitive MRI, or globally analyze the MRI signal in an area containing the N1, without providing a volumetric delineation. PURPOSE: Present an automated method to segment the N1 and quantify differences in N1's NM and iron content between Parkinson's disease (PD) patients and healthy controls (HCs). Study whether N1 degeneration is clinically related to PD and could be used as a biomarker of the disease. STUDY TYPE: Prospective. SUBJECTS: Seventy-one PD (65.3 +- 10.3 years old, 34 female/37 male); 30 HC (62.7 +- 7.8 years old, 17 female/13 male). FIELD STRENGTH/SEQUENCE: 3 T Anatomical T1-weighted MPRAGE, NM-MRI T1-weighted gradient with magnetization transfer, susceptibility-weighted imaging (SWI). ASSESSMENT: N1 was automatically segmented in SWI images using a multi-image atlas, populated with healthy N1 structures manually annotated by a neurologist. Relative NM and iron content were quantified and their diagnostic performance assessed and compared with the substantia nigra pars compacta (SNc). The association between image parameters and clinically relevant variables was studied. STATISTICAL TESTS: Nonparametric tests were used (Mann-Whitney's U, chi-square, and Friedman tests) at P = 0.05. RESULTS: N1's relative NM content decreased and relative iron content increased in PD patients compared with HCs (NM-CRHC  = 22.55 +- 1.49; NM-CRPD  = 19.79 +- 1.92; NM-nVolHC  = 2.69 x 10-5  +- 1.02 x 10-5 ; NM-nVolPD  = 1.18 x 10-5  +- 0.96 x 10-5 ; Iron-CRHC  = 10.51 +- 2.64; Iron-CRPD  = 19.35 +- 7.88; Iron-nVolHC  = 0.72 x 10-5  +- 0.81 x 10-5 ; Iron-nVolPD  = 2.82 x 10-5  +- 2.04 x 10-5 ). Binary logistic regression analyses combining N1 and SNc image parameters yielded a top AUC = 0.955. Significant correlation was found between most N1 parameters and both disease duration (rhoNM-CR  = -0.31; rhoiron-CR  = 0.43; rhoiron-nVol  = 0.46) and the motor status (rhoNM-nVol  = -0.27; rhoiron-CR  = 0.33; rhoiron-nVol  = 0.28), suggesting NM reduction along with iron accumulation in N1 as the disease progresses. DATA CONCLUSION: This method provides a fully automatic N1 segmentation, and the analyses performed reveal that N1 relative NM and iron quantification improves diagnostic performance and suggest a relative NM reduction along with a relative iron accumulation in N1 as the disease progresses. EVIDENCE LEVEL: 1 TECHNICAL EFFICACY: Stage 1.</text><annotation id="37"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="224" length="12"/><text>neuromelanin</text></annotation><annotation id="38"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="238" length="2"/><text>NM</text></annotation><annotation id="39"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="246" length="4"/><text>iron</text></annotation><annotation id="40"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="368" length="4"/><text>iron</text></annotation><annotation id="41"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="585" length="2"/><text>NM</text></annotation><annotation id="42"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="592" length="4"/><text>iron</text></annotation><annotation id="43"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="613" length="19"/><text>Parkinson's disease</text></annotation><annotation id="44"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="634" length="2"/><text>PD</text></annotation><annotation id="45"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="689" length="15"/><text>N1 degeneration</text></annotation><annotation id="46"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="730" length="2"/><text>PD</text></annotation><annotation id="47"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="829" length="2"/><text>PD</text></annotation><annotation id="48"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="987" length="2"/><text>NM</text></annotation><annotation id="49"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="1250" length="2"/><text>NM</text></annotation><annotation id="50"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1257" length="4"/><text>iron</text></annotation><annotation id="51"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="1612" length="2"/><text>NM</text></annotation><annotation id="52"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1646" length="4"/><text>iron</text></annotation><annotation id="53"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="1672" length="2"/><text>PD</text></annotation><annotation id="54"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="1703" length="2"/><text>NM</text></annotation><annotation id="55"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="1729" length="2"/><text>NM</text></annotation><annotation id="56"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="1755" length="2"/><text>NM</text></annotation><annotation id="57"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="1798" length="2"/><text>NM</text></annotation><annotation id="58"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1841" length="4"/><text>Iron</text></annotation><annotation id="59"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1869" length="4"/><text>Iron</text></annotation><annotation id="60"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1897" length="4"/><text>Iron</text></annotation><annotation id="61"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1942" length="4"/><text>Iron</text></annotation><annotation id="62"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="2335" length="2"/><text>NM</text></annotation><annotation id="63"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="2359" length="4"/><text>iron</text></annotation><annotation id="64"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="2534" length="2"/><text>NM</text></annotation><annotation id="65"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="2541" length="4"/><text>iron</text></annotation><annotation id="66"><infon key="identifier">MESH:C014121</infon><infon key="type">Chemical</infon><location offset="2616" length="2"/><text>NM</text></annotation><annotation id="67"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="2651" length="4"/><text>iron</text></annotation></passage><relation id="R1"><infon key="score">0.9572</infon><infon key="role1">Chemical|MESH:C014121</infon><infon key="role2">Disease|MESH:D010300</infon><infon key="type">Association</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.6922</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Disease|MESH:D010300</infon><infon key="type">Association</infon><node refid="1" role="1,2"/></relation></document>
<document><id>37916295</id><passage><infon key="journal">J Med Econ;2023Nov02 1. doi:10.1080/13696998.2023.2277058</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ponomareva E, Schmerold L, Sss S, Preblick R, Park S, Wilson L, Revel A, </infon><offset>0</offset><text>The economic value of insulin glargine 300 U/mL (Gla-300) in people >=18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective.</text><annotation id="2"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="22" length="7"/><text>insulin</text></annotation><annotation id="3"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="91" length="24"/><text>type 2 diabetes mellitus</text></annotation></passage><passage><infon key="type">abstract</infon><offset>177</offset><text>AIMS: This study aimed to evaluate the value and affordability of insulin glargine 300 U/mL (Gla-300) in a budget impact model from a United States (U.S.) payer perspective by leveraging recent real-world evidence (RWE) studies and incorporating the recent insulin price caps where applicable. MATERIALS &amp; METHODS: An economic model for a hypothetical one million U.S. health-plan population was developed to assess the budgetary impact of therapeutic interchanges in either direction between the two long- and longer-acting basal insulins (BIs) for patients with type 2 diabetes over a three-year model horizon. The utilization of long-acting BIs, longer-acting BIs, biosimilar BIs, and insulin degludec (IDeg-100) were informed by IQVIA data and internal forecasting at Sanofi. The DELIVER-2 and DELIVER-naive studies provided healthcare resource utilization (HCRU) parameters. In the model base case, 24% of patients switched from long-acting BIs to insulin glargine biosimilars, IDeg-100, and other longer-acting BIs (Gla-300) by projected year 3. RESULTS: The base case total costs were $10,145 per patient per year (PPPY) in year 3 for the cumulative population. When all patients switched to Gla-300, the total costs in year 3 were $8,799, reflecting a net savings of -$660 PPPY compared to the budget increase of $686 PPPY in the base case. However, the longer-acting to long-acting BIs reversal scenario demonstrated a budgetary decrease of $676 PPPY over the model horizon. The reduction in incremental PPPY cost of $93 was observed using net drug costs rather than wholesale acquisition costs (WAC). LIMITATIONS: The market shares for years 1-3 were based on expectations supported by the clinicians' expert opinions and were not obtained from real-world data. CONCLUSIONS: The economic value of increased utilization of Gla-300 was driven by the reduction in HCRU, costs and market shares assumptions. Budgetary reductions were achieved by switching patients from long-acting BIs to Gla-300.</text><annotation id="11"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="243" length="7"/><text>insulin</text></annotation><annotation id="12"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="434" length="7"/><text>insulin</text></annotation><annotation id="13"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="741" length="15"/><text>type 2 diabetes</text></annotation><annotation id="14"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="865" length="7"/><text>insulin</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="883" length="8"/><text>IDeg-100</text></annotation><annotation id="16"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="1130" length="7"/><text>insulin</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1160" length="8"/><text>IDeg-100</text></annotation></passage><relation id="R1"><infon key="score">0.9896</infon><infon key="role1">Disease|MESH:D003924</infon><infon key="role2">Gene|3630</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="2,0"/></relation></document>
<document><id>37916649</id><passage><infon key="journal">HLA;2023Nov02. doi:10.1111/tan.15277</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">de Oliveira AML, Massi FP, Pinto LDB, Zacarias JMV, Visentainer JEL, </infon><offset>0</offset><text>Description of four new HLA-B alleles in Brazilian bone marrow donors.</text><annotation id="1"><infon key="identifier">3106</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">134029</infon><location offset="24" length="5"/><text>HLA-B</text></annotation></passage><passage><infon key="type">abstract</infon><offset>71</offset><text>Four new HLA-B alleles were identified in Brazilian individuals using next generation sequencing.</text><annotation id="3"><infon key="identifier">3106</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">134029</infon><location offset="80" length="5"/><text>HLA-B</text></annotation></passage></document>
<document><id>37917003</id><passage><infon key="journal">Aging (Albany NY);2023Nov01; 15. doi:10.18632/aging.205098</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lenzi C, Piat A, Schlich P, Ducau J, Bregliano JC, Aguilaniu H, Lauren&amp;#xe7;on A, </infon><offset>0</offset><text>Parental age effect on the longevity and healthspan in Drosophila melanogaster and Caenorhabditis elegans.</text></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>Several studies have investigated the effect of parental age on biological parameters such as reproduction, lifespan, and health; however, the results have been inconclusive, largely due to inter-species variation and/or modest effect sizes. Here, we examined the effect of parental age on the lifespan, reproductive capacity, and locomotor activity of genetic isogenic lines of the nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster. We found that the progeny of successive generations of old parents had significantly shorter lifespans than the progeny of young parents in both species. Moreover, we investigated the fertility, fecundity, and locomotor activity of C. elegans. Interestingly, both the shorter lifespan and deteriorated healthspan of the progeny were significantly improved by switching to only one generation of younger parents. Collectively, these data demonstrate that the detrimental effect of older parental age on the longevity of the progeny can be reversed, suggesting the existence of a beneficial non-genetic mechanism.</text></passage></document>
<document><id>37917353</id><passage><infon key="journal">Mikrochim Acta;2023Nov02; 190 (11) 458. doi:10.1007/s00604-023-06038-w</infon><infon key="year">2023</infon><infon key="article-id_pmc">4835027</infon><infon key="type">title</infon><infon key="authors">Zhang X, Li H, Zhao W, Xu J, Wang S, Yu R, </infon><offset>0</offset><text>Development of a separation platform comprising magnetic beads combined with the CRISPR/Cas12a system enabling ultrasensitive and rapid detection of miRNA-21.</text><annotation id="1"><infon key="identifier">406991</infon><infon key="type">Gene</infon><location offset="149" length="8"/><text>miRNA-21</text></annotation></passage><passage><infon key="type">abstract</infon><offset>159</offset><text>A separation platform has been developed mediated by a combination of magnetic beads and the CRISPR/Cas12a system to achieve ultrasensitive and rapid detection of miRNA-21 at a low level. In this system, with the assistance of an auxiliary probe, the target miRNA-21 can be specifically combined with three-stranded probes to initiate the SDR reaction. Abundant aptamer A3 was added to the solution that can activate the CRISPR/Cas12a system and initiate the trans-cleavage reaction to recover the fluorescence signal. Using magnetic beads to mediate the separation considerably greatly improves the signal conversion efficiency and detection sensitivity. At the 492 nm excitation wavelength, and 502-650 nm scan range, through analyzing the fluorescence peak intensity at 520 nm, the biosensor's determination range and limit of detection is 8 fM-250 nM and 2.42 fM, respectively, and the RSD is 19.03-37.80. Compared with other biosensors, the biosensor developed exhibited superior performance and the signal recovered excellently in 1% human serum and the LOD is 12.12 fM. This method provides a novel highly sensitive scheme for detecting miRNA .</text><annotation id="4"><infon key="identifier">406991</infon><infon key="type">Gene</infon><location offset="322" length="8"/><text>miRNA-21</text></annotation><annotation id="5"><infon key="identifier">406991</infon><infon key="type">Gene</infon><location offset="417" length="8"/><text>miRNA-21</text></annotation></passage></document>
<document><id>37917703</id><passage><infon key="journal">Science;2023Nov03; 382 (6670) 525. doi:10.1126/science.adl3202</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tessnow-von Wysocki I, Wang M, Morales-Caselles C, Woodall LC, Syberg K, Carney Almroth B, Fernandez M, Moncl&amp;#xfa;s L, Wilson SP, Warren M, Knoblauch D, Helm RR, </infon><offset>0</offset><text>Plastics treaty text must center ecosystems.</text></passage><passage><infon key="type">abstract</infon><offset>45</offset></passage></document>
<document><id>37918055</id><passage><infon key="journal">Reprod Biomed Online;2023Aug25; 47 (6) 103369. doi:10.1016/j.rbmo.2023.103369</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">La Marca A, Longo M, Sighinolfi G, Grisendi V, Imbrogno MG, Giulini S, </infon><offset>0</offset><text>New insights into the role of LH in early ovarian follicular growth: a possible tool to optimize follicular recruitment.</text></passage><passage><infon key="type">abstract</infon><offset>121</offset><text>Evidence shows that LH participates in enhancing transition from the early stage to the antral stage of folliculogenesis. It has been demonstrated that functional LH receptors are expressed, albeit at a very low level and even in smaller follicles, during the phase that was traditionally considered to be gonadotrophin independent, suggesting a role for LH in accelerating the rate of progression of non-growing and primary follicles to the preantral/antral stage. Hypogonadotropic hypogonadism, together with other clinical conditions of pituitary suppression, has been associated with reduced functional ovarian reserve. The reduction in LH serum concentration is associated with a low concentration of anti-Mullerian hormone. This is the case in hypothalamic amenorrhoea, pregnancy, long-term GnRH-analogue therapy and hormonal contraception. The effect seems to be reversible, such that after pregnancy and after discontinuation of drugs, the functional ovarian reserve returns to the baseline level. Evidence suggests that women with similar primordial follicle reserves could present with different numbers of antral follicles, and that gonadotrophins may play a fundamental role in permitting a normal rate of progression of follicles through non-cyclic folliculogenesis. The precise role of gonadotrophins in early folliculogenesis, as well as their use to modify the functional ovarian reserve, must be investigated.</text><annotation id="4"><infon key="identifier">MESH:D007006</infon><infon key="type">Disease</infon><location offset="587" length="29"/><text>Hypogonadotropic hypogonadism</text></annotation><annotation id="5"><infon key="identifier">MESH:D010900</infon><infon key="type">Disease</infon><location offset="661" length="21"/><text>pituitary suppression</text></annotation><annotation id="6"><infon key="identifier">268</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68060</infon><location offset="827" length="22"/><text>anti-Mullerian hormone</text></annotation><annotation id="7"><infon key="identifier">MESH:D007027</infon><infon key="type">Disease</infon><location offset="871" length="24"/><text>hypothalamic amenorrhoea</text></annotation></passage></document>
<document><id>37918405</id><passage><infon key="journal">Cell Rep Med;2023Oct27 101253. doi:10.1016/j.xcrm.2023.101253</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Deal CE, Richards AF, Yeung T, Maron MJ, Wang Z, Lai YT, Fritz BR, Himansu S, Narayanan E, Liu D, Koleva R, Licht S, Hsiao CJ, Rajlic IL, Koch H, Kleyman M, Pulse ME, Weiss WJ, Doering JE, Lindberg SK, Mantis NJ, Carfi A, Plante OJ, </infon><offset>0</offset><text>An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions.</text><annotation id="1"><infon key="identifier">12518</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31053</infon><location offset="61" length="3"/><text>IgA</text></annotation></passage><passage><infon key="type">abstract</infon><offset>90</offset><text>Colonization of the gut and airways by pathogenic bacteria can lead to local tissue destruction and life-threatening systemic infections, especially in immunologically compromised individuals. Here, we describe an mRNA-based platform enabling delivery of pathogen-specific immunoglobulin A (IgA) monoclonal antibodies into mucosal secretions. The platform consists of synthetic mRNA encoding IgA heavy, light, and joining (J) chains, packaged in lipid nanoparticles (LNPs) that express glycosylated, dimeric IgA with functional activity in vitro and in vivo. Importantly, mRNA-derived IgA had a significantly greater serum half-life and a more native glycosylation profile in mice than did a recombinantly produced IgA. Expression of an mRNA encoded Salmonella-specific IgA in mice resulted in intestinal localization and limited Peyer's patch invasion. The same mRNA-LNP technology was used to express a Pseudomonas-specific IgA that protected from a lung challenge. Leveraging the mRNA antibody technology as a means to intercept bacterial pathogens at mucosal surfaces opens up avenues for prophylactic and therapeutic interventions.</text><annotation id="12"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="216" length="10"/><text>infections</text></annotation><annotation id="13"><infon key="identifier">12518</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31053</infon><location offset="363" length="16"/><text>immunoglobulin A</text></annotation><annotation id="14"><infon key="identifier">12518</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31053</infon><location offset="381" length="3"/><text>IgA</text></annotation><annotation id="15"><infon key="identifier">12518</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31053</infon><location offset="482" length="3"/><text>IgA</text></annotation><annotation id="16"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="536" length="5"/><text>lipid</text></annotation><annotation id="17"><infon key="identifier">12518</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31053</infon><location offset="598" length="3"/><text>IgA</text></annotation><annotation id="18"><infon key="identifier">12518</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31053</infon><location offset="675" length="3"/><text>IgA</text></annotation><annotation id="19"><infon key="identifier">238447</infon><infon key="type">Gene</infon><location offset="805" length="4"/><text>IgA.</text></annotation><annotation id="20"><infon key="identifier">12518</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31053</infon><location offset="860" length="3"/><text>IgA</text></annotation><annotation id="21"><infon key="identifier">12518</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31053</infon><location offset="1016" length="3"/><text>IgA</text></annotation></passage></document>
<document><id>37918755</id><passage><infon key="journal">Sci Total Environ;2023Oct31 168246. doi:10.1016/j.scitotenv.2023.168246</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Morais TA, Fleming NA, Attalage D, Mayer B, Mayer KU, Ryan MC, </infon><offset>0</offset><text>Field investigation of the transport and attenuation of fugitive methane in shallow groundwater around an oil and gas well with gas migration.</text><annotation id="2"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="65" length="7"/><text>methane</text></annotation><annotation id="3"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="106" length="3"/><text>oil</text></annotation></passage><passage><infon key="type">abstract</infon><offset>143</offset><text>'Fugitive' or 'stray' gas migration from deeper formations due to well bore integrity failure has prompted concern regarding environmental impacts. Unintended methane (CH4) migration can increase greenhouse gas emissions and affect groundwater quality in the critical zone. Although the CH4 transport in shallow aquifers has been investigated at experimental injection sites, no intensive groundwater studies have been published around an oil and gas well that has been leaking for a significant period of time. In this field study, groundwater samples were collected from sixteen groundwater monitoring wells (1.25 m below ground surface) installed around a suspended oil and gas well with decadal scale gas migration (estimated ~0.2 m3/day). Stray CH4 distribution and preferential pathways in the shallow groundwater zone were evaluated though high-resolution profiling of equivalent concentrations of hydrocarbon gases (C1-C6; >85 % CH4 at the study site) and bulk formation electrical conductivity to 6.0 m below ground surface. The highest dissolved CH4 concentration (0.074 mmol/L or 1.18 mg/L) in groundwater (1.25 m bgs) was observed immediately downgradient (1.25 m) of the oil and gas well head. Similarly, high-resolution profiling data also revealed the occurrence of relatively high CH4 concentrations in shallow groundwater along the groundwater flow direction and below fine-grained layers up to 10 m distance from the well head. Microbial DNA analysis from groundwater showed significant community shifts, with the highest relative abundance and diversity of methanotrophs observed in the vicinity of the oil and gas well. This study supports findings from experimental injection and laboratory studies, which also found that significant CH4 transport i) dominantly occurs in the groundwater flow direction, and ii) laterally as free phase below fine-grained layers. The occurrence of CH4 concentrations below saturation after more than two decades of gas migration suggests limited impacts have occurred in the shallow subsurface investigated.</text><annotation id="20"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="302" length="7"/><text>methane</text></annotation><annotation id="21"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="311" length="3"/><text>CH4</text></annotation><annotation id="22"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="430" length="3"/><text>CH4</text></annotation><annotation id="23"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="582" length="3"/><text>oil</text></annotation><annotation id="24"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="812" length="3"/><text>oil</text></annotation><annotation id="25"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="893" length="3"/><text>CH4</text></annotation><annotation id="26"><infon key="identifier">MESH:D006838</infon><infon key="type">Chemical</infon><location offset="1048" length="11"/><text>hydrocarbon</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1067" length="5"/><text>C1-C6</text></annotation><annotation id="28"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="1080" length="3"/><text>CH4</text></annotation><annotation id="29"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="1199" length="3"/><text>CH4</text></annotation><annotation id="30"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="1327" length="3"/><text>oil</text></annotation><annotation id="31"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="1440" length="3"/><text>CH4</text></annotation><annotation id="32"><infon key="type">Disease</infon><location offset="1719" length="13"/><text>methanotrophs</text></annotation><annotation id="33"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="1765" length="3"/><text>oil</text></annotation><annotation id="34"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="1898" length="3"/><text>CH4</text></annotation><annotation id="35"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="2045" length="3"/><text>CH4</text></annotation></passage><relation id="R1"><infon key="score">0.9905</infon><infon key="role1">Chemical|MESH:D008697</infon><infon key="role2">Chemical|MESH:D009821</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation></document>
<document><id>37919105</id><passage><infon key="journal">Pathology;2023Oct12. doi:10.1016/j.pathol.2023.07.017</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ruiz H, Westley-Wise V, Mayne DJ, Keighley C, Newton P, Miyakis S, Seale H, </infon><offset>0</offset><text>Experience with COVID-19: swab technique shows no association with willingness to retest.</text><annotation id="1"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="16" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>90</offset></passage></document>
<document><id>37919455</id><passage><infon key="journal">Cancer Causes Control;2023Nov03. doi:10.1007/s10552-023-01821-9</infon><infon key="year">2023</infon><infon key="article-id_pmc">5577755</infon><infon key="type">title</infon><infon key="authors">Khan S, Fuzzell L, Langston M, Han Y, Moore JX, Gilbert K, Sutcliffe S, Bensen JT, Mohler JL, Fontham ETH, Song L, Lewis-Thames MW, </infon><offset>0</offset><text>The impact of marital status on tumor aggressiveness, treatment, and screening among black and white men diagnosed with prostate cancer.</text><annotation id="2"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="32" length="20"/><text>tumor aggressiveness</text></annotation><annotation id="3"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="120" length="15"/><text>prostate cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>137</offset><text>PURPOSE: To examine the association of marital status with prostate cancer outcomes in a racially-diverse cohort. METHODS: The study population consisted of men (1010 Black; 1070 White) with incident prostate cancer from the baseline North Carolina-Louisiana Prostate Cancer (PCaP) cohort. Marital status at time of diagnosis and screening history were determined by self-report. The binary measure of marital status was defined as married (including living as married) vs. not married (never married, divorced/separated, or widowed). High-aggressive tumors were defined using a composite measure of PSA, Gleason Score, and stage. Definitive treatment was defined as receipt of radical prostatectomy or radiation. Multivariable logistic regression was used to examine the association of marital status with (1) high-aggressive tumors, (2) receipt of definitive treatment, and (3) screening history among Black and White men with prostate cancer. RESULTS: Black men were less likely to be married than White men (68.1% vs. 83.6%). Not being married (vs. married) was associated with increased odds of high-aggressive tumors in the overall study population (adjusted Odds Ratio (aOR): 1.56; 95% Confidence Interval (CI): 1.20-2.02) and both Black and White men in race-stratified analyses. Unmarried men were less likely to receive definitive treatment in the overall study population (aOR: 0.68; 95% CI: 0.54-0.85). In race-stratified analyses, unmarried Black men were less likely to receive definitive treatment. Both unmarried Black and White men were less likely to have a history of prostate cancer screening than married men. CONCLUSION: Lower rates of marriage among Black men might signal decreased support for treatment decision-making, symptom management, and caregiver support which could potentially contribute to prostate cancer disparities.</text><annotation id="15"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="196" length="15"/><text>prostate cancer</text></annotation><annotation id="16"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="337" length="15"/><text>prostate cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="396" length="15"/><text>Prostate Cancer</text></annotation><annotation id="18"><infon key="type">Disease</infon><location offset="413" length="4"/><text>PCaP</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="688" length="6"/><text>tumors</text></annotation><annotation id="20"><infon key="identifier">9520</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">36199</infon><location offset="737" length="3"/><text>PSA</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="964" length="6"/><text>tumors</text></annotation><annotation id="22"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="1066" length="15"/><text>prostate cancer</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1253" length="6"/><text>tumors</text></annotation><annotation id="24"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="1724" length="15"/><text>prostate cancer</text></annotation><annotation id="25"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="1962" length="15"/><text>prostate cancer</text></annotation></passage></document>
<document><id>37919805</id><passage><infon key="journal">J Cheminform;2023Nov02; 15 (1) 103. doi:10.1186/s13321-023-00771-3</infon><infon key="year">2023</infon><infon key="article-id_pmc">8431528</infon><infon key="type">title</infon><infon key="authors">Wang S, Wang L, Li F, Bai F, </infon><offset>0</offset><text>DeepSA: a deep-learning driven predictor of compound synthesis accessibility.</text></passage><passage><infon key="type">abstract</infon><offset>78</offset><text>With the continuous development of artificial intelligence technology, more and more computational models for generating new molecules are being developed. However, we are often confronted with the question of whether these compounds are easy or difficult to synthesize, which refers to synthetic accessibility of compounds. In this study, a deep learning based computational model called DeepSA, was proposed to predict the synthesis accessibility of compounds, which provides a useful tool to choose molecules. DeepSA is a chemical language model that was developed by training on a dataset of 3,593,053 molecules using various natural language processing (NLP) algorithms, offering advantages over state-of-the-art methods and having a much higher area under the receiver operating characteristic curve (AUROC), i.e., 89.6%, in discriminating those molecules that are difficult to synthesize. This helps users select less expensive molecules for synthesis, reducing the time and cost required for drug discovery and development. Interestingly, a comparison of DeepSA with a Graph Attention-based method shows that using SMILES alone can also efficiently visualize and extract compound's informative features. DeepSA is available online on the below web server ( https://bailab.siais.shanghaitech.edu.cn/services/deepsa/ ) of our group, and the code is available at https://github.com/Shihang-Wang-58/DeepSA .</text></passage></document>
<document><id>37921205</id><passage><infon key="journal">Int J Lab Hematol;2023Nov03. doi:10.1111/ijlh.14197</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bla&amp;#x17e;ek M, Vrback&amp;#xfd; F, F&amp;#xe1;torov&amp;#xe1; I, Mirsk&amp;#xe1; K, &amp;#x17d;&amp;#xe1;k P, </infon><offset>0</offset><text>Sysmex-derived COVID-19 prognostic score as an early prognostic marker for severity of the COVID-19 disease.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="6"/><text>Sysmex</text></annotation><annotation id="4"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="15" length="8"/><text>COVID-19</text></annotation><annotation id="5"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="91" length="16"/><text>COVID-19 disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>BACKGROUND: Coronavirus disease 2019 (COVID-19) is a life-threatening disease with a heterogeneous course. Even some young patients are at increased risk of severe course or death, as they can face severe complications. It would be very useful to have a cheap and easily available marker to predict COVID-19 course in the early stages of the disease. The COVID-19 prognostic score could be a very useful clinical indicator available at the time of primary contact with the patient. METHODS: The COVID-19 prognostic score and the clinical condition together with selected laboratory parameters were evaluated in patients with respiratory tract infection and a positive PCR test for the SARS-CoV-2 during the first contact with the patient. Prognostic significance was evaluated using receiver operating characteristic curves (ROC) and area under the curve (AUC). Selected parameters of the blood count and hemostasis, as well as selected biochemical indicators, were examined too. RESULTS: Thirty-seven of 164 patients developed serious symptoms. The COVID-19 score had one of the highest AUC values (0.855) of all markers. The highest combination of sensitivity (91.9%) and specificity (71.7%) for identifying patients with a subsequent moderate and severe course of the disease was achieved at the threshold 1.5. The predictive value of a negative test is beneficial too (0.968). CONCLUSIONS: The COVID-19 prognostic score is a promising indicator stratifying patients with COVID-19 into prognostic groups at the time of the first contact, thus allowing the timely provision of increased care in patients at high risk of severe development.</text><annotation id="16"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="121" length="24"/><text>Coronavirus disease 2019</text></annotation><annotation id="17"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="147" length="8"/><text>COVID-19</text></annotation><annotation id="18"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="283" length="5"/><text>death</text></annotation><annotation id="19"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="408" length="8"/><text>COVID-19</text></annotation><annotation id="20"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="464" length="8"/><text>COVID-19</text></annotation><annotation id="21"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="604" length="8"/><text>COVID-19</text></annotation><annotation id="22"><infon key="identifier">MESH:D012141</infon><infon key="type">Disease</infon><location offset="734" length="27"/><text>respiratory tract infection</text></annotation><annotation id="23"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1159" length="8"/><text>COVID-19</text></annotation><annotation id="24"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1507" length="8"/><text>COVID-19</text></annotation><annotation id="25"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1584" length="8"/><text>COVID-19</text></annotation></passage></document>
<document><id>37921555</id><passage><infon key="journal">Radiol Imaging Cancer;2023Nov; 5 (6) 220153. doi:10.1148/rycan.220153</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mendes Serr&amp;#xe3;o E, Klug M, Moloney BM, Jhaveri A, Lo Gullo R, Pinker K, Luker G, Haider MA, Shinagare AB, Liu X, </infon><offset>0</offset><text>Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="18" length="6"/><text>Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>90</offset><text>Ongoing discoveries in cancer genomics and epigenomics have revolutionized clinical oncology and precision health care. This knowledge provides unprecedented insights into tumor biology and heterogeneity within a single tumor, among primary and metastatic lesions, and among patients with the same histologic type of cancer. Large-scale genomic sequencing studies also sparked the development of new tumor classifications, biomarkers, and targeted therapies. Because of the central role of imaging in cancer diagnosis and therapy, radiologists need to be familiar with the basic concepts of genomics, which are now becoming the new norm in oncologic clinical practice. By incorporating these concepts into clinical practice, radiologists can make their imaging interpretations more meaningful and specific, facilitate multidisciplinary clinical dialogue and interventions, and provide better patient-centric care. This review article highlights basic concepts of genomics and epigenomics, reviews the most common genetic alterations in cancer, and discusses the implications of these concepts on imaging by organ system in a case-based manner. This information will help stimulate new innovations in imaging research, accelerate the development and validation of new imaging biomarkers, and motivate efforts to bring new molecular and functional imaging methods to clinical radiology. Keywords: Oncology, Cancer Genomics, Epignomics, Radiogenomics, Imaging Markers Supplemental material is available for this article.   RSNA, 2023.</text><annotation id="10"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="113" length="6"/><text>cancer</text></annotation><annotation id="11"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="262" length="5"/><text>tumor</text></annotation><annotation id="12"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="310" length="5"/><text>tumor</text></annotation><annotation id="13"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="407" length="6"/><text>cancer</text></annotation><annotation id="14"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="490" length="5"/><text>tumor</text></annotation><annotation id="15"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="591" length="6"/><text>cancer</text></annotation><annotation id="16"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1126" length="6"/><text>cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1495" length="6"/><text>Cancer</text></annotation></passage></document>
<document><id>37890078</id><passage><infon key="journal">Health Syst Reform;2023Dec31; 9 (1) 2267255. doi:10.1080/23288604.2023.2267255</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Anjur KI, Darmstadt GL, </infon><offset>0</offset><text>Separation of Maternal and Newborn Care in US Hospitals: A Systemic Threat to Survival, Health and Well-Being.</text></passage><passage><infon key="type">abstract</infon><offset>111</offset><text>Through greater understanding of past social, cultural, economic, political, scientific and technological forces which shaped our current health systems to separate mothers and newborn infants, we can begin to devise effective approaches to reshape these systems to meet the needs of mothers and newborn infants today. Medical science and technology have evolved vastly in the last century; however, effects of historical factors persist in our current health care systems, reflected in separate maternal and neonatal care in different departments with distinct guidelines, providers, and treatment locations. This separation prevents maternal-infant skin-to-skin contact and bonding, which significantly affects infant development, well-being, and that of their caregivers. We explore historical precedents for the separation of maternal-newborn care, including the transition from midwifery home care to hospital obstetric care, reasons for the increase in hospital births and hospital nursery development, and the effects of world wars, federal acts, health insurance, rooming-in practices, and the development of medical advances such as antibiotics, on hospital infrastructure. This information is evaluated in the context of modern scientific advancements to show that the conditions which shaped health systems to separate mothers and newborns in the past no longer hold. The insights gained will help to identify strategic actions to reshape health care systems to enable more integrated maternal-newborn care and the practice of Kangaroo Mother Care, and to improve survival outcomes and well-being for mothers, families, and their newborn infants.</text></passage></document>
<document><id>37890428</id><passage><infon key="journal">Ann Phys Rehabil Med;2023Oct25; 66 (8) 101778. doi:10.1016/j.rehab.2023.101778</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chen P, Hreha K, </infon><offset>0</offset><text>Spatial neglect not only occurs after stroke but also after traumatic brain injury.</text><annotation id="3"><infon key="identifier">MESH:D058069</infon><infon key="type">Disease</infon><location offset="0" length="15"/><text>Spatial neglect</text></annotation><annotation id="4"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="38" length="6"/><text>stroke</text></annotation><annotation id="5"><infon key="identifier">MESH:D000070642</infon><infon key="type">Disease</infon><location offset="60" length="22"/><text>traumatic brain injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>84</offset></passage></document>
<document><id>37890778</id><passage><infon key="journal">J Biol Chem;2023Oct25 105392. doi:10.1016/j.jbc.2023.105392</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Balasubramanian S, Maharana S, Srivastava A, </infon><offset>0</offset><text>"Boundary residues" between the folded RNA Recognition Motif and disordered RGG domains are critical for FUS-RNA binding.</text><annotation id="1"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="105" length="3"/><text>FUS</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>Fused in Sarcoma (FUS) is an abundant RNA binding protein, which drives phase separation of cellular condensates and plays multiple roles in RNA regulation. The RNA binding ability of FUS protein is crucial to its cellular function. Here, our molecular simulation study on the FUS-RNA complex provides atomic resolution insights into the observations from biochemical studies and also illuminates our understanding of molecular driving forces that mediate the structure, stability and interaction of the RNA recognition motif (RRM) and RGG domains of FUS with a stem-loop junction RNA. We observe clear cooperativity and division of labor among the ordered (RRM) and disordered domains (RGG1 and RGG2 domain) of FUS that leads to an organized and tighter RNA binding. Irrespective of the length of RGG2, the RGG2-RNA interaction is confined to the stem-loop junction and the proximal stem regions. On the other hand, the RGG1 interactions are primarily with the longer RNA stem. We find that the C-terminus of RRM, which make up the "boundary residues" that connect the folded RRM with the long disordered RGG2 stretch of the protein, plays a critical role in FUS-RNA binding. Our study provides high-resolution molecular insights into the FUS-RNA interactions and forms the basis for understanding the molecular origins of full-length FUS interaction with RNA.</text><annotation id="12"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="122" length="16"/><text>Fused in Sarcoma</text></annotation><annotation id="13"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="140" length="3"/><text>FUS</text></annotation><annotation id="14"><infon key="identifier">27303</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49388</infon><location offset="160" length="19"/><text>RNA binding protein</text></annotation><annotation id="15"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="306" length="3"/><text>FUS</text></annotation><annotation id="16"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="399" length="3"/><text>FUS</text></annotation><annotation id="17"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="673" length="3"/><text>FUS</text></annotation><annotation id="18"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="834" length="3"/><text>FUS</text></annotation><annotation id="19"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="1282" length="3"/><text>FUS</text></annotation><annotation id="20"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="1362" length="3"/><text>FUS</text></annotation><annotation id="21"><infon key="identifier">2521</infon><infon key="type">Gene</infon><location offset="1458" length="3"/><text>FUS</text></annotation></passage></document>
<document><id>37891129</id><passage><infon key="journal">J Voice;2023Oct25. doi:10.1016/j.jvoice.2023.09.024</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xie X, Cai H, Li C, Wu Y, Ding F, </infon><offset>0</offset><text>A Voice Disease Detection Method Based on MFCCs and Shallow CNN.</text><annotation id="1"><infon key="identifier">MESH:D014832</infon><infon key="type">Disease</infon><location offset="2" length="13"/><text>Voice Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>65</offset><text>The incidence rate of voice diseases is increasing year by year. The use of software for remote diagnosis is a technical development trend and has important practical value. Among voice diseases, common diseases that cause hoarseness include spasmodic dysphonia, vocal cord paralysis, vocal nodule, and vocal cord polyp. This paper presents a voice disease detection method that can be applied in a wide range of clinical. We cooperated with Xiangya Hospital of Central South University to collect voice samples from 352 different patients. The Mel Frequency Cepstrum Coefficient (MFCC) parameters are extracted as input features to describe the voice in the form of data. An innovative model combining MFCC parameters and single convolution layer CNN is proposed for fast calculation and classification. The highest accuracy we achieved was 92%, it is fully ahead of the original research results and internationally advanced. And we use advanced voice function assessment databases (AVFAD) to evaluate the generalization ability of the method we proposed, which achieved an accuracy rate of 98%. Experiments on clinical and standard datasets show that for the pathological detection of voice diseases, our method has greatly improved in accuracy and computational efficiency.</text><annotation id="11"><infon key="identifier">MESH:D014832</infon><infon key="type">Disease</infon><location offset="87" length="14"/><text>voice diseases</text></annotation><annotation id="12"><infon key="identifier">MESH:D014832</infon><infon key="type">Disease</infon><location offset="245" length="14"/><text>voice diseases</text></annotation><annotation id="13"><infon key="identifier">MESH:D006685</infon><infon key="type">Disease</infon><location offset="288" length="10"/><text>hoarseness</text></annotation><annotation id="14"><infon key="identifier">MESH:D055154</infon><infon key="type">Disease</infon><location offset="307" length="19"/><text>spasmodic dysphonia</text></annotation><annotation id="15"><infon key="identifier">MESH:D014826</infon><infon key="type">Disease</infon><location offset="328" length="20"/><text>vocal cord paralysis</text></annotation><annotation id="16"><infon key="identifier">MESH:D016606</infon><infon key="type">Disease</infon><location offset="350" length="12"/><text>vocal nodule</text></annotation><annotation id="17"><infon key="identifier">MESH:D014826</infon><infon key="type">Disease</infon><location offset="368" length="16"/><text>vocal cord polyp</text></annotation><annotation id="18"><infon key="identifier">MESH:D014832</infon><infon key="type">Disease</infon><location offset="408" length="13"/><text>voice disease</text></annotation><annotation id="19"><infon key="identifier">MESH:D014832</infon><infon key="type">Disease</infon><location offset="1253" length="14"/><text>voice diseases</text></annotation></passage></document>
<document><id>37897089</id><passage><infon key="journal">Thyroid;2023Oct28. doi:10.1089/thy.2023.0360</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Uysal M, Akgun E, Sarioglu AG, Berber E, </infon><offset>0</offset><text>Comparison of Perioperative Outcomes in Patients with Graves' Disease Undergoing Total Thyroidectomy with or without Near Infrared Auto-Fluorescence Imaging.</text><annotation id="1"><infon key="identifier">MESH:D006111</infon><infon key="type">Disease</infon><location offset="54" length="15"/><text>Graves' Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>158</offset><text>BACKGROUND: The impact of near-infrared autofluorescence (NIRAF) imaging on post-thyroidectomy hypocalcemia is controversial. As patients with Graves' disease are at increased risk, our aim was to compare postoperative parathyroid function in these patients undergoing total thyroidectomy with or without NIRAF imaging. METHODS: This was a retrospective "before and after" study, comparing outcomes of patients who underwent total thyroidectomy without or with NIRAF imaging at a single center. Primary outcome was the incidence of temporary hypocalcemia and secondary outcomes, rates of incidental parathyroidectomy on final specimens and permanent hypocalcemia. Analyses were performed using Mann-Whitney-U and Chi-Square tests. Continuous data are expressed as median (interquartile range). RESULTS: There were 85 patients in NIRAF and 100 patients in non-NIRAF group. Groups were comparable regarding age, gender, body-mass-index, and thyroid weight. Number of parathyroid glands identified intraoperatively was 3 in both groups (p=0.47). Intraoperative parathyroid implantation rate was 16.5% in NIRAF and 6% in non-NIRAF group (p=0.02). Incidental parathyroidectomy rate on final pathology was 12.9% in NIRAF and 32% in non-NIRAF group (p=0.002). The rates of temporary (11.7% vs 16%) and permanent hypocalcemia (2.4% vs 2%) were similar between the two groups, respectively (p=0.66). CONCLUSION: To our knowledge, this is the first comparative study investigating the impact of NIRAF on postoperative parathyroid function after thyroidectomy for Graves' disease. The rate of incidental parathyroidectomy on final pathology was lower with use of NIRAF, without an impact on temporary or permanent hypocalcemia rates compared to conventional technique.</text><annotation id="9"><infon key="identifier">MESH:D006996</infon><infon key="type">Disease</infon><location offset="253" length="12"/><text>hypocalcemia</text></annotation><annotation id="10"><infon key="identifier">MESH:D006111</infon><infon key="type">Disease</infon><location offset="301" length="15"/><text>Graves' disease</text></annotation><annotation id="11"><infon key="identifier">MESH:D006996</infon><infon key="type">Disease</infon><location offset="700" length="12"/><text>hypocalcemia</text></annotation><annotation id="12"><infon key="identifier">MESH:D006996</infon><infon key="type">Disease</infon><location offset="808" length="12"/><text>hypocalcemia</text></annotation><annotation id="13"><infon key="identifier">MESH:D006996</infon><infon key="type">Disease</infon><location offset="1463" length="12"/><text>hypocalcemia</text></annotation><annotation id="14"><infon key="identifier">MESH:D006111</infon><infon key="type">Disease</infon><location offset="1711" length="15"/><text>Graves' disease</text></annotation><annotation id="15"><infon key="identifier">MESH:D006996</infon><infon key="type">Disease</infon><location offset="1861" length="12"/><text>hypocalcemia</text></annotation></passage></document>
<document><id>37897440</id><passage><infon key="journal">J Am Soc Mass Spectrom;2023Oct28. doi:10.1021/jasms.3c00295</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chua AE, Pfeifer LD, Sekera ER, Hummon AB, Desaire H, </infon><offset>0</offset><text>Workflow for Evaluating Normalization Tools for Omics Data Using Supervised and Unsupervised Machine Learning.</text></passage><passage><infon key="type">abstract</infon><offset>111</offset><text>To achieve high quality omics results, systematic variability in mass spectrometry (MS) data must be adequately addressed. Effective data normalization is essential for minimizing this variability. The abundance of approaches and the data-dependent nature of normalization have led some researchers to develop open-source academic software for choosing the best approach. While these tools are certainly beneficial to the community, none of them meet all of the needs of all users, particularly users who want to test new strategies that are not available in these products. Herein, we present a simple and straightforward workflow that facilitates the identification of optimal normalization strategies using straightforward evaluation metrics, employing both supervised and unsupervised machine learning. The workflow offers a "DIY" aspect, where the performance of any normalization strategy can be evaluated for any type of MS data. As a demonstration of its utility, we apply this workflow on two distinct datasets, an ESI-MS dataset of extracted lipids from latent fingerprints and a cancer spheroid dataset of metabolites ionized by MALDI-MSI, for which we identified the best-performing normalization strategies.</text><annotation id="2"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1163" length="6"/><text>lipids</text></annotation><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1201" length="6"/><text>cancer</text></annotation></passage></document>
<document><id>37897790</id><passage><infon key="journal">Phys Rev Lett;2023Oct13; 131 (15) 151602. doi:10.1103/PhysRevLett.131.151602</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Choi S, Kim S, Song J, </infon><offset>0</offset><text>Supersymmetric Spectral Form Factor and Euclidean Black Holes.</text></passage><passage><infon key="type">abstract</infon><offset>63</offset><text>The late-time behavior of spectral form factor (SFF) encodes the inherent discreteness of a quantum system, which should be generically nonvanishing. We study an index analog of the microcanonical spectrum form factor in four-dimensional N=4 super Yang-Mills theory. In the large N limit and at large enough energy, the most dominant saddle corresponds to the black hole in the AdS bulk. This gives rise to the slope that decreases exponentially for a small imaginary chemical potential, which is a natural analog of an early time. We find that the "late-time" behavior is governed by the multicut saddles that arise in the index matrix model, which are nonperturbatively subdominant at early times. These saddles become dominant at late times, preventing the SFF from decaying. These multicut saddles correspond to the orbifolded Euclidean black holes in the AdS bulk, therefore giving the geometrical interpretation of the "ramp". Our analysis is done in the standard AdS/CFT setting without ensemble average or wormholes.</text><annotation id="4"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="343" length="1"/><text>N</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="441" length="3"/><text>AdS</text></annotation><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="923" length="3"/><text>AdS</text></annotation><annotation id="7"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1033" length="3"/><text>AdS</text></annotation></passage></document>
<document><id>37898143</id><passage><infon key="journal">Lancet Glob Health;2023Oct25. doi:10.1016/S2214-109X(23)00496-5</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Villavicencio F, Perin J, Eilerts-Spinelli H, Yeung D, Prieto-Merino D, Hug L, Sharrow D, You D, Strong KL, Black RE, Liu L, </infon><offset>0</offset><text>Global, regional, and national causes of death in children and adolescents younger than 20 years: an open data portal with estimates for 2000-21.</text><annotation id="1"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="41" length="5"/><text>death</text></annotation></passage><passage><infon key="type">abstract</infon><offset>146</offset></passage></document>
<document><id>37898493</id><passage><infon key="journal">Acta Chir Orthop Traumatol Cech;2023; 90 (5) 301</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang L, Alkentar R, Man&amp;#xf3; S, Szab&amp;#xf3; J, Mankovits T, Csern&amp;#xe1;tony Z, </infon><offset>0</offset><text>Biomechanical Comparison of the Roof Step Cut Technique with the Bulk Bone Graft Technique During Total Hip Arthroplasty for Hip Dysplasia: a Finite Element Analysis.</text><annotation id="2"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="104" length="3"/><text>Hip</text></annotation><annotation id="3"><infon key="identifier">MESH:D006617</infon><infon key="type">Disease</infon><location offset="125" length="13"/><text>Hip Dysplasia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>167</offset><text>PURPOSE OF THE STUDY Different techniques have been reported to reconstruct the defi cient acetabulum during total hip arthroplasty (THA). The purpose of this study was to compare the biomechanical features of the bulk bone graft (BBG) technique (Harris acetabular plasty) and the Roof Step Cut (RSC) technique using fi nite element analysis. MATERIAL AND METHODS Based on a female patient's dysplastic hip CT scan, 3D models were assembled according to the two techniques. For the Harris technique, an irregular BBG was sculpted from a solid sphere, while for the RSC technique, the graft was sculpted into a step-cut shape with a similar size. Each graft was fi xed with two compression screws at two different angles (0  and 45 ). Four fi nite element models were used to compare the von Mises stress distribution and total deformation of the grafts and the screws. The pressure and sliding distances of the contacts between the bone graft, metal cup and acetabular host bone were also analyzed. RESULTS For both of the bone grafts and the screws, compared to the Harris models, the maximum stress of the RSC models was signifi cantly lower (16.56 MPa, 25.50 MPa vs 97.13 MPa, 112.72 MPa) and the total deformation was signifi cantly smaller (0.0096 mm, 0.0089 mm vs 0.022 mm, 0.018 mm). 45  inserted screws generated higher stress at the end of the screws and on the outside of the bone graft. In case of 0  inserted screws, the maximum value was mainly located in the middle of the screws, inside the screw channel as well as at the contact area between the graft and the host bone. At all analyzed contacts, the RSC technique shows signifi cantly lower pressure and sliding distances, irrelevant to the screw's insertion angle. In comparison, the model of BBG with 45  screws showed a signifi cant sliding effect and higher contact pressure. CONCLUSIONS Compared with the BBG technique, the step-shaped graft of the RSC technique could signifi cantly reduce the maximum stress and deformation of the graft and the screws, and decrease the pressure and sliding distance between the bone graft, metal cup and the acetabular host bone. The angle of screw placement affects the location of stress and deformation. Key words: developmental dysplasia of the hip, total hip arthroplasty, acetabular reconstruction, bone graft, fi nite element analysis.</text><annotation id="8"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="282" length="3"/><text>hip</text></annotation><annotation id="9"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="559" length="14"/><text>dysplastic hip</text></annotation><annotation id="10"><infon key="identifier">MESH:D000082602</infon><infon key="type">Disease</infon><location offset="2394" length="34"/><text>developmental dysplasia of the hip</text></annotation><annotation id="11"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="2436" length="3"/><text>hip</text></annotation></passage></document>
<document><id>37898843</id><passage><infon key="journal">Asian Pac J Cancer Prev;2023Oct01; 24 (10) 3397. doi:10.31557/APJCP.2023.24.10.3397</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nugroho ST, Ahsan A, Kusuma D, Adani N, Irawaty DK, Amalia N, Hati SRH, </infon><offset>0</offset><text>Income Disparity and Healthcare Utilization: Lessons from Indonesia's National Health Insurance Claim Data.</text></passage><passage><infon key="type">abstract</infon><offset>108</offset><text>BACKGROUND: Indonesia's National Health Insurance Program, known as Jaminan Kesehatan Nasional (JKN), has a variety of membership pathways for those wishing to gain access. Claim data from JKN offers a cost-effective way of observing who is accessing healthcare services and what types of services are being used. This study is a novel attempt to measure disparities amongst JKN users in their engagement with services, providing an opportunity to reflect on patterns of use. METHODS: Using claims data collected from JKN users between 2015-2016, we used the Ordinary Least Square estimation model to compare health services utilization among subsidized and non-subsidized users. We focused primarily on the individual use of the hospital for outpatient and inpatient treatment. RESULTS: Analysis reveals that subsidized users access primary healthcare services more frequently than non-subsidized users. Conversely, non-subsidized users access secondary and tertiary health care services more frequently than other users. Subsidized users who utilize secondary and tertiary health care tend to suffer more severe health illnesses than non-subsidized members. CONCLUSIONS: This study concludes that income disparity affects healthcare utilization. Non-subsidized members are more likely than subsidized members to access secondary and tertiary health care services. Our study offers evidence of the potential underutilization of secondary and tertiary healthcare (STHC) by subsidized members, which could lead to inefficiency since subsidized members seeking STHC treatment had severe health conditions, thus needing to be treated longer and requiring higher healthcare expenditures.</text><annotation id="1"><infon key="identifier">MESH:D000071069</infon><infon key="type">Disease</infon><location offset="1222" length="16"/><text>health illnesses</text></annotation></passage></document>
<document><id>37899193</id><passage><infon key="journal">Rinsho Ketsueki;2023; 64 (9) 1137. doi:10.11406/rinketsu.64.1137</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ikezoe T, </infon><offset>0</offset><text>[Prophylaxis and treatment of hematological malignancy-associated thrombosis].</text><annotation id="2"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="30" length="24"/><text>hematological malignancy</text></annotation><annotation id="3"><infon key="identifier">MESH:D013927</infon><infon key="type">Disease</infon><location offset="66" length="10"/><text>thrombosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Hematologic malignancies, particularly acute myeloid leukemia, are associated with thrombocytopenia as well as hyperfibrinolytic disseminated intravascular coagulation, which increases the risk of death due to bleeding. Conversely, thromboembolism is known to complicate certain proportions of patients and lead to a poor prognosis; however, prophylaxis and treatment with anticoagulants received little attention. This article discusses the risk factors for thromboembolism in hematologic malignancies, such as acute leukemia, malignant lymphoma, and multiple myeloma, as well as thromboembolism prevention and treatment. Meta-analyses have revealed that second- and third-generation BCR-ABL tyrosine kinase inhibitors increase the risk of cardiovascular events in patients with chronic myeloid leukemia, and this article discusses strategies to prevent these events, which are regarded as a major clinical issue.</text><annotation id="17"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="79" length="24"/><text>Hematologic malignancies</text></annotation><annotation id="18"><infon key="identifier">MESH:D015470</infon><infon key="type">Disease</infon><location offset="118" length="22"/><text>acute myeloid leukemia</text></annotation><annotation id="19"><infon key="identifier">MESH:D013921</infon><infon key="type">Disease</infon><location offset="162" length="16"/><text>thrombocytopenia</text></annotation><annotation id="20"><infon key="identifier">MESH:D004211</infon><infon key="type">Disease</infon><location offset="208" length="38"/><text>disseminated intravascular coagulation</text></annotation><annotation id="21"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="289" length="8"/><text>bleeding</text></annotation><annotation id="22"><infon key="identifier">MESH:D013923</infon><infon key="type">Disease</infon><location offset="311" length="15"/><text>thromboembolism</text></annotation><annotation id="23"><infon key="identifier">MESH:D013923</infon><infon key="type">Disease</infon><location offset="538" length="15"/><text>thromboembolism</text></annotation><annotation id="24"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="557" length="24"/><text>hematologic malignancies</text></annotation><annotation id="25"><infon key="identifier">MESH:D015470</infon><infon key="type">Disease</infon><location offset="591" length="14"/><text>acute leukemia</text></annotation><annotation id="26"><infon key="identifier">MESH:D008223</infon><infon key="type">Disease</infon><location offset="607" length="18"/><text>malignant lymphoma</text></annotation><annotation id="27"><infon key="identifier">MESH:D009101</infon><infon key="type">Disease</infon><location offset="631" length="16"/><text>multiple myeloma</text></annotation><annotation id="28"><infon key="identifier">MESH:D013923</infon><infon key="type">Disease</infon><location offset="660" length="15"/><text>thromboembolism</text></annotation><annotation id="29"><infon key="identifier">MESH:D015464</infon><infon key="type">Disease</infon><location offset="859" length="24"/><text>chronic myeloid leukemia</text></annotation></passage></document>
<document><id>37902346</id><passage><infon key="journal">Crit Care Med;2023Nov01; 51 (11) 1600. doi:10.1097/CCM.0000000000006024</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Grecu L, </infon><offset>0</offset><text>ICU Analgesia and Sedation: Is It Time to Change Our Practice?</text></passage><passage><infon key="type">abstract</infon><offset>63</offset></passage></document>
<document><id>37902696</id><passage><infon key="journal">J Exp Psychol Appl;2023Oct30. doi:10.1037/xap0000500</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zarzeczna N, Hanel PHP, Rutjens BT, Bono SA, Chen YH, Haddock G, </infon><offset>0</offset><text>Scientists, speak up! Source impacts trust in health advice across five countries.</text></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>We examined how different types of communication influence people's responses to health advice. We tested whether presenting COVID-19 prevention advice (e.g., washing hands/distancing) as either originating from a government or scientific source would affect people's trust in and intentions to comply with the advice. We also manipulated uncertainty in communicating the advice effectiveness. To achieve this, we conducted an experiment using large samples of participants (N = 4,561) from the United Kingdom, the United States, Canada, Malaysia, and Taiwan. Across countries, participants found messages more trustworthy when the purported source was science rather than the government. This effect was moderated by political orientation in all countries except for Canada, while religiosity moderated the source effect in the United States. Although source did not directly affect intentions to act upon the advice, we found an indirect effect via trust, such that a more trusted source (i.e., science) was predictive of higher intentions to comply. However, the uncertainty manipulation was not effective. Together, our findings suggest that despite prominence of science skepticism in public discourse, people trust scientists more than governments when it comes to practical health advice. It is therefore beneficial to communicate health messages by stressing their scientific bases. (PsycInfo Database Record (c) 2023 APA, all rights reserved).</text><annotation id="1"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="208" length="8"/><text>COVID-19</text></annotation></passage></document>
<document><id>37903048</id><passage><infon key="journal">IEEE Trans Image Process;2023; 32 5933. doi:10.1109/TIP.2023.3327003</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang Y, Ding K, Li N, Wang H, Huang X, Kuo CJ, </infon><offset>0</offset><text>Perceptually Weighted Rate Distortion Optimization for Video-Based Point Cloud Compression.</text></passage><passage><infon key="type">abstract</infon><offset>92</offset><text>Dynamic point cloud is a volumetric visual data representing realistic 3D scenes for virtual reality and augmented reality applications. However, its large data volume has been the bottleneck of data processing, transmission, and storage, which requires effective compression. In this paper, we propose a Perceptually Weighted Rate-Distortion Optimization (PWRDO) scheme for Video-based Point Cloud Compression (V-PCC), which aims to minimize the perceptual distortion of reconstructed point cloud at the given bit rate. Firstly, we propose a general framework of perceptually optimized V-PCC to exploit visual redundancies in point clouds. Secondly, a multi-scale Projection based Point Cloud quality Metric (PPCM) is proposed to measure the perceptual quality of 3D point cloud. The PPCM model comprises 3D-to-2D patch projection, multi-scale structural distortion measurement, and fusion model. Approximations and simplifications of the proposed PPCM are also presented for both V-PCC integration and low complexity. Thirdly, based on the simplified PPCM model, we propose a PWRDO scheme with Lagrange multiplier adaptation, which is incorporated into the V-PCC to enhance the coding efficiency. Experimental results show that the proposed PPCM models can be used as standalone quality metrics, and they are able to achieve higher consistency with the human subjective scores than the state-of-the-art objective visual quality metrics. Also, compared with the latest V-PCC reference model, the proposed PWRDO-based V-PCC scheme achieves an average bit rate reduction of 13.52%, 8.16%, 10.56% and 9.54%, respectively, in terms of four objective visual quality metrics for point clouds. It is significantly superior to the state-of-the-art coding algorithms. The computational complexity of the proposed PWRDO increases by 1.71% and 0.05% on average to the V-PCC encoder and decoder, respectively, which is negligible. The source codes of the PPCM and PWRDO schemes are available at https://github.com/VVCodec/PPCM-PWRDO.</text></passage></document>
<document><id>37905527</id><passage><infon key="journal">Int J Syst Evol Microbiol;2023Oct; 73 (10) . doi:10.1099/ijsem.0.006125</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Santos ARO, Barros KO, Batista TM, Souza GFL, Alvarenga FBM, Abegg MA, Sato TK, Hittinger CT, Lachance MA, Rosa CA, </infon><offset>0</offset><text>Saccharomycopsis praedatoria sp. nov., a predacious yeast isolated from soil and rotten wood in an Amazonian rainforest biome.</text></passage><passage><infon key="type">abstract</infon><offset>127</offset><text>Three yeast isolates were obtained from soil and rotting wood samples collected in an Amazonian rainforest biome in Brazil. Comparison of the intergenic spacer 5.8S region and the D1/D2 domains of the large subunit rRNA gene showed that the isolates represent a novel species of the genus Saccharomycopsis. A tree inferred from the D1/D2 sequences placed the novel species near a subclade containing Saccharomycopsis lassenensis, Saccharomycopsis fermentans, Saccharomycopsis javanensis, Saccharomycopsis babjevae, Saccharomycopsis schoenii and Saccharomycopsis oosterbeekiorum, but with low bootstrap support. In terms of sequence divergence, the novel species had the highest identity in the D1/D2 domains with Saccharomycopsis capsularis, from which it differed by 36 substitutions. In contrast, a phylogenomic analysis based on 1061 single-copy orthologs for a smaller set of Saccharomycopsis species whose whole genome sequences are available indicated that the novel species represented by strain UFMG-CM-Y6991 is phylogenetically closer to Saccharomycopsis fodiens and Saccharomycopsis sp. TF2021a (=Saccharomycopsis phalluae). The novel yeast is homothallic and produces asci with one spheroidal ascospore with an equatorial or subequatorial ledge. The name Saccharomycopsis praedatoria sp. nov. is proposed to accommodate the novel species. The holotype of Saccharomycopsis praedatoria is CBS 16589T. The MycoBank number is MB849369. S. praedatoria was able to kill cells of Saccharomyces cerevisiae by means of penetration with infection pegs, a trait common to most species of Saccharomycopsis.</text><annotation id="1"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1665" length="9"/><text>infection</text></annotation></passage></document>
<document><id>37905877</id><passage><infon key="journal">Neural Regen Res;2024Jun01; 19 (6) 1284. doi:10.4103/1673-5374.385854</infon><infon key="year">2024</infon><infon key="type">title</infon><infon key="authors">Huo A, Wang J, Li Q, Li M, Qi Y, Yin Q, Luo W, Shi J, Cong Q, </infon><offset>0</offset><text>Molecular mechanisms underlying microglial sensing and phagocytosis in synaptic pruning.</text></passage><passage><infon key="type">abstract</infon><offset>89</offset><text>ABSTRACT: Microglia are the main non-neuronal cells in the central nervous system that have important roles in brain development and functional connectivity of neural circuits. In brain physiology, highly dynamic microglial processes are facilitated to sense the surrounding environment and stimuli. Once the brain switches its functional states, microglia are recruited to specific sites to exert their immune functions, including the release of cytokines and phagocytosis of cellular debris. The crosstalk of microglia between neurons, neural stem cells, endothelial cells, oligodendrocytes, and astrocytes contributes to their functions in synapse pruning, neurogenesis, vascularization, myelination, and blood-brain barrier permeability. In this review, we highlight the neuron-derived "find-me," "eat-me," and "don't eat-me" molecular signals that drive microglia in response to changes in neuronal activity for synapse refinement during brain development. This review reveals the molecular mechanism of neuron-microglia interaction in synaptic pruning and presents novel ideas for the synaptic pruning of microglia in disease, thereby providing important clues for discovery of target drugs and development of nervous system disease treatment methods targeting synaptic dysfunction.</text><annotation id="2"><infon key="identifier">MESH:D009422</infon><infon key="type">Disease</infon><location offset="1305" length="22"/><text>nervous system disease</text></annotation><annotation id="3"><infon key="identifier">MESH:C536122</infon><infon key="type">Disease</infon><location offset="1356" length="20"/><text>synaptic dysfunction</text></annotation></passage></document>
<document><id>37906229</id><passage><infon key="journal">JMIR Public Health Surveill;2023Oct31; 9 50147. doi:10.2196/50147</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xu RH, Ng SSM, Luo N, Dong D, Zhang S, </infon><offset>0</offset><text>Measurement of Health-Related Quality of Life in Individuals With Rare Diseases in China: Nation-Wide Online Survey.</text><annotation id="1"><infon key="identifier">MESH:D035583</infon><infon key="type">Disease</infon><location offset="66" length="13"/><text>Rare Diseases</text></annotation></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>BACKGROUND: Rare diseases (RDs) affect millions of people worldwide, and these diseases can severely impact the health-related quality of life (HRQoL) of those affected. Despite this, there is a lack of research measuring HRQoL using the EQ-5D-5L, which is one of the most widely used generic preference-based instruments to measure HRQoL in populations living with RDs. OBJECTIVE: This study aimed to measure HRQoL using the EQ-5D-5L in a large number of patients with various types of RDs in China, and to examine the relationship between respondents' socioeconomic characteristics and preference-based health utility scores. METHODS: The data used in this study were obtained from a web-based survey conducted in China. The survey aimed to explore and understand the health and socioeconomic status of patients with RDs in China. We recruited registered and eligible members, including patients or their primary caregivers, from 33 RD patient associations to complete the questionnaires via their internal social networks. HRQoL was measured using the EQ-5D-5L utility score, which was calculated based on an established Chinese value set. Utility scores have been presented based on demographics and disease-related information. Univariate linear regression analysis was used to assess the differences in the EQ-5D-5L utility scores between subgroups. RESULTS: A total of 12,502 respondents completed the questionnaire and provided valid responses, including 6919 self-completed respondents and 5583 proxy-completed respondents. Data from 10,102 participants over the age of 12 years were elicited for analysis. Among patients with RDs, 65.3% (6599/10,102), 47.5% (4799/10,102), 47.0% (4746/10,102), 24.8% (2506/10,102), and 18.4% (1855/10,102) reported no problems for "self-care," "usual activities," "mobility," "pain/discomfort," and "anxiety/depression," respectively. A full health state was reported by 6.0% (413/6902) and 9.2% (295/3200) of self- and proxy-completed patients, respectively. Among self-completed patients, 69.9% (4826/6902) and 50.4% (3478/6902) reported no problems for "self-care" and "usual activities," respectively, whereas only 17.7% (1223/6902) reported problems for "anxiety/depression." Proxy-completed respondents showed a higher proportion of reporting extreme problems than self-completed respondents in all 5 dimensions. The mean utility scores reported by self- and proxy-completed respondents were 0.691 and 0.590, respectively. Different types of caregivers reported different utility scores, and among them, proxy-completed (mother) respondents reported the highest mean utility score. CONCLUSIONS: The establishment of a normative profile for RD patients can facilitate patients' adaptation and assess the effectiveness of interventions to improve the HRQoL and well-being of this population. Differences between self- and proxy-completed HRQoL assessed by the EQ-5D-5L have been identified in this study. This finding highlights the importance of incorporating perspectives from both patients and their proxies in clinical practice. Further development of the patient cohort is necessary to assess long-term changes in HRQoL in the RD population.</text><annotation id="16"><infon key="identifier">MESH:D035583</infon><infon key="type">Disease</infon><location offset="129" length="13"/><text>Rare diseases</text></annotation><annotation id="17"><infon key="identifier">MESH:D035583</infon><infon key="type">Disease</infon><location offset="144" length="3"/><text>RDs</text></annotation><annotation id="18"><infon key="identifier">MESH:D035583</infon><infon key="type">Disease</infon><location offset="483" length="3"/><text>RDs</text></annotation><annotation id="19"><infon key="identifier">MESH:D035583</infon><infon key="type">Disease</infon><location offset="604" length="3"/><text>RDs</text></annotation><annotation id="20"><infon key="identifier">MESH:D035583</infon><infon key="type">Disease</infon><location offset="936" length="3"/><text>RDs</text></annotation><annotation id="21"><infon key="identifier">MESH:D000077733</infon><infon key="type">Disease</infon><location offset="1052" length="2"/><text>RD</text></annotation><annotation id="22"><infon key="identifier">MESH:D035583</infon><infon key="type">Disease</infon><location offset="1753" length="3"/><text>RDs</text></annotation><annotation id="23"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1937" length="15"/><text>pain/discomfort</text></annotation><annotation id="24"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="1960" length="7"/><text>anxiety</text></annotation><annotation id="25"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1968" length="10"/><text>depression</text></annotation><annotation id="26"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="2320" length="7"/><text>anxiety</text></annotation><annotation id="27"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="2328" length="10"/><text>depression</text></annotation><annotation id="28"><infon key="identifier">MESH:D000077733</infon><infon key="type">Disease</infon><location offset="2806" length="2"/><text>RD</text></annotation><annotation id="29"><infon key="identifier">MESH:D000077733</infon><infon key="type">Disease</infon><location offset="3296" length="2"/><text>RD</text></annotation></passage></document>
<document><id>37906969</id><passage><infon key="journal">J Neural Eng;2023Oct31. doi:10.1088/1741-2552/ad085a</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Peng D, Zheng WL, Liu L, Jiang WB, Li Z, Lu Y, Lu BL, </infon><offset>0</offset><text>Identifying sex differences in EEG-based emotion recognition using graph convolutional network with attention mechanism.</text></passage><passage><infon key="type">abstract</infon><offset>121</offset><text>OBJECTIVE: Sex differences in emotions have been widely perceived via self-reports, peripheral physiological signals and brain imaging techniques. However, how sex differences are reflected in the EEG neural patterns of emotions remains unresolved. In this paper, we detect sex differences in emotional EEG patterns, investigate the consistency of such differences in various emotion datasets across cultures, and study how sex as a factor affects the performance of EEG-based emotion recognition models. APPROACH: We thoroughly assess sex differences in emotional EEG patterns on five public datasets, including SEED, SEED-IV, SEED-V, DEAP and DREAMER, systematically examine the sex-specific EEG patterns for happy, sad, fearful, disgusted and neutral emotions, and implement deep learning models for sex-specific emotion recognition. MAIN RESULTS: (1) Sex differences exist in various emotion types and both Western and Eastern cultures; (2) The emotion patterns of females are more stable than those of males, and the patterns of happiness from females are in sharp contrast with the patterns of sadness, fear and disgust, while the energy levels are more balanced for males; (3) The key features for emotion recognition are mainly located at the frontal and temporal sites for females and distributed more evenly over the whole brain for males, and (4) The same-sex emotion recognition models outperform the corresponding cross-sex models. SIGNIFICANCE: These findings extend efforts to characterize sex differences in emotional brain activation, provide new physiological evidence for sex-specific emotion processing, and reinforce the message that sex differences should be carefully considered in affective research and precision medicine.</text></passage></document>
<document><id>37907319</id><passage><infon key="journal">BMJ Case Rep;2023Oct31; 16 (10) . doi:10.1136/bcr-2023-254566</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10619083</infon><infon key="type">title</infon><infon key="authors">Chong A, Lewin J, Goh IY, Liu C, </infon><offset>0</offset><text>Brunner's gland adenoma: a robotic approach.</text><annotation id="1"><infon key="identifier">MESH:C563156</infon><infon key="type">Disease</infon><location offset="0" length="23"/><text>Brunner's gland adenoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>45</offset><text>This report describes an unusual case of a symptomatic Brunner's gland adenoma arising in a man in his 40s that underwent robotic transduodenal resection. Initial investigations revealed a polypoidal, submucosal lesion that was found in the first part of the duodenum. Microscopically, there was neither dysplasia nor evidence of adenocarcinoma, suggesting differentials of gastrointestinal stroma tumour and duodenal adenoma. Given the size of the lesion, he underwent a surgical resection. Symptomatic Brunner's gland adenoma is uncommon and should be considered as a differential diagnosis in patients presenting with obstructive symptoms.</text><annotation id="9"><infon key="identifier">MESH:C563156</infon><infon key="type">Disease</infon><location offset="100" length="23"/><text>Brunner's gland adenoma</text></annotation><annotation id="10"><infon key="identifier">MESH:D015792</infon><infon key="type">Disease</infon><location offset="349" length="9"/><text>dysplasia</text></annotation><annotation id="11"><infon key="identifier">MESH:D000230</infon><infon key="type">Disease</infon><location offset="375" length="14"/><text>adenocarcinoma</text></annotation><annotation id="12"><infon key="identifier">MESH:D005770</infon><infon key="type">Disease</infon><location offset="419" length="30"/><text>gastrointestinal stroma tumour</text></annotation><annotation id="13"><infon key="identifier">MESH:D004382</infon><infon key="type">Disease</infon><location offset="454" length="16"/><text>duodenal adenoma</text></annotation><annotation id="14"><infon key="identifier">MESH:C563156</infon><infon key="type">Disease</infon><location offset="549" length="23"/><text>Brunner's gland adenoma</text></annotation><annotation id="15"><infon key="identifier">MESH:D000402</infon><infon key="type">Disease</infon><location offset="666" length="11"/><text>obstructive</text></annotation></passage></document>
<document><id>37907669</id><passage><infon key="journal">Int J Impot Res;2023Oct31. doi:10.1038/s41443-023-00784-4</infon><infon key="year">2023</infon><infon key="article-id_pmc">5715186</infon><infon key="type">title</infon><infon key="authors">Preto M, Falcone M, Plamadeala N, Schifano N, Bettocchi C, Colombo F, Fiordelise S, Vitarelli A, Silvani M, Mondaini N, Paradiso M, Ceruti C, Varvello F, Palumbo F, Avolio A, Antonini G, Corvasce A, Pozza D, Franco G, Bitelli M, Boezio F, Conti E, Caraceni E, Negro C, Carrino M, Vicini P, Ghidini N, Alei G, Italiano E, Timpano M, Polito M, Natali A, Tamai A, Pescatori E, Deh&amp;#xf2; F, Gideon B, Gontero P, Palmieri A, Capogrosso P, </infon><offset>0</offset><text>Risk of unfavorable outcomes after penile prosthesis implantation - results from a national registry (INSIST-ED).</text><annotation id="1"><infon key="identifier">MESH:D007172</infon><infon key="type">Disease</infon><location offset="109" length="2"/><text>ED</text></annotation></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>Like all surgeries, penile prosthesis implantation (PPI) has the potential for both postoperative complications and suboptimal patient satisfaction. In order to assess risk factors for poor satisfaction, we reviewed patients who had been prospectively recruited in a national multi-institutional registry of penile prostheses procedures (INSIST-ED) from 2014 to 20121. Patient baseline characteristics and postoperative complications were recorded. The primary endpoint of this study was unfavorable outcomes after inflatable PPI, defined as significant postoperative complications (Clavien-Dindo >=2) and/or Sexuality with Quality of Life and Sexuality with Penile Prosthesis (QoLSPP) scores below the 10th percentile. A total of 256 patients were included in the study. The median age was 60 years (IQR 56-67). The most common cause of erectile dysfunction (ED) was organic (42.2%), followed by pelvic surgery/radiotherapy (39.8%) and Peyronie's disease (18.0%). Postoperative complications were recorded in 9.6%. High-grade complications (Clavien >=2) occurred in 4.7%. At 1-year follow-up, the median QoLSPP total score was 71 (IQR 65-76). In all, 14.8% of patients were classified as having experienced unfavorable outcomes because of significant postoperative complications and/or QoLSPP scores below the 10th percentile. Logistic regression analysis demonstrated patient age to be non-linearly associated with the risk of experiencing unfavorable outcomes. A U-shaped correlation showed a lower risk for younger and older patients and a higher risk for middle-aged men. ED etiology and surgical volume were not associated with PPI outcomes. Physicians should, therefore, be aware that middle-aged men may be at higher risk of being unsatisfied following PPI compared to both younger and older patients.</text><annotation id="14"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="198" length="27"/><text>postoperative complications</text></annotation><annotation id="15"><infon key="identifier">MESH:D007172</infon><infon key="type">Disease</infon><location offset="459" length="2"/><text>ED</text></annotation><annotation id="16"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="520" length="27"/><text>postoperative complications</text></annotation><annotation id="17"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="668" length="27"/><text>postoperative complications</text></annotation><annotation id="18"><infon key="type">Disease</infon><location offset="697" length="7"/><text>Clavien</text></annotation><annotation id="19"><infon key="identifier">MESH:D007172</infon><infon key="type">Disease</infon><location offset="952" length="20"/><text>erectile dysfunction</text></annotation><annotation id="20"><infon key="identifier">MESH:D007172</infon><infon key="type">Disease</infon><location offset="974" length="2"/><text>ED</text></annotation><annotation id="21"><infon key="identifier">MESH:D010411</infon><infon key="type">Disease</infon><location offset="1051" length="18"/><text>Peyronie's disease</text></annotation><annotation id="22"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="1079" length="27"/><text>Postoperative complications</text></annotation><annotation id="23"><infon key="type">Disease</infon><location offset="1156" length="7"/><text>Clavien</text></annotation><annotation id="24"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="1366" length="27"/><text>postoperative complications</text></annotation><annotation id="25"><infon key="identifier">MESH:D007172</infon><infon key="type">Disease</infon><location offset="1691" length="2"/><text>ED</text></annotation></passage></document>
<document><id>37909069</id><passage><infon key="journal">Creat Nurs;2023Nov01 10784535231211682. doi:10.1177/10784535231211682</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Shaw RJ, </infon><offset>0</offset><text>Access to Technology and Digital Literacy as Determinants of Health and Health Care.</text></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>Access to and the skills to use technology provide the digital equity necessary for civic and cultural participation, employment, lifelong learning, and access to essential services. However, existing digital disparities and the resultant 'digital divide' risk exacerbating health and health-care inequalities. The COVID-19 pandemic amplified these disparities and accelerated the adoption of technology-driven health care such as telehealth, electronic health records, and digital health technologies. Unfortunately, pre-existing disparities influence the adoption and utilization of these technologies, often leaving disadvantaged groups further behind. Efforts toward digital inclusion, access to technology, and digital literacy are necessary to ensure universal access to and meaningful engagement with digital resources. Nurses play a vital role in promoting digital equity, serving as educators, advocates, and digital navigators, guiding patients through the complexities of the digital health landscape.</text><annotation id="1"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="400" length="8"/><text>COVID-19</text></annotation></passage></document>
<document><id>37909425</id><passage><infon key="journal">Crit Rev Clin Lab Sci;2023Nov01 1. doi:10.1080/10408363.2023.2274325</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">He H, Wang L, Wang X, Zhang M, </infon><offset>0</offset><text>Artificial intelligence in serum protein electrophoresis: history, state of the art, and perspective.</text></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>Serum protein electrophoresis (SPEP) is a valuable laboratory test that separates proteins from the blood based on their electrical charge and size. The test can detect and analyze various protein abnormalities, and the interpretation of graphic SPEP features plays a crucial role in the diagnosis and monitoring of conditions, such as myeloma. Furthermore, the advancement of artificial intelligence (AI) technology presents an opportunity to enhance the organization and optimization of analytical procedures by streamlining the process and reducing the potential for human error in SPEP analysis, thereby making the process more efficient and reliable. For instance, AI can assist in the identification of protein peaks, the calculation of their relative proportions, and the detection of abnormalities or inconsistencies. This review explores the characteristics and limitations of AI in SPEP, and the role of standardization in improving its clinical utility. It also offers guidance on the rational ordering and interpreting of SPEP results in conjunction with AI. Such integration can effectively reduce the time and resources required for manual analysis while improving the accuracy and consistency of the results.</text><annotation id="1"><infon key="identifier">MESH:D009101</infon><infon key="type">Disease</infon><location offset="438" length="7"/><text>myeloma</text></annotation></passage></document>
<document><id>37909778</id><passage><infon key="journal">mSystems;2023Nov01 0082623. doi:10.1128/msystems.00826-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xia X, Wang Q, Gurr GM, Vasseur L, Han S, You M, </infon><offset>0</offset><text>Gut bacteria mediated adaptation of diamondback moth, Plutella xylostella, to secondary metabolites of host plants.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="78" length="21"/><text>secondary metabolites</text></annotation></passage><passage><infon key="type">abstract</infon><offset>116</offset><text>The diamondback moth (DBM), Plutella xylostella, has successfully adapted to the potent chemical defenses of Brassicaceae plants that deter most other herbivores. Gut bacteria are increasingly recognized as key to the biology of many species but their role in DBM adaptation to plant defense compounds is not well known. In this study, the secondary metabolites of radish seedlings, rich in flavonoids, were identified by liquid chromatography-mass spectrometry. These secondary metabolites reduced the larval growth of DBM lacking gut bacteria. The effect was rapidly eclipsed by the re-introduction of gut microbiota, which was dominated by Enterobacter (Proteobacteria). Similarly, while treatment with the flavonoid kaempferol adversely affected growth and extended the development time, these were alleviated by the re-introduction of Enterobacter sp. EbPXG5 (EbPXG5) to the DBM gut. EbPXG5 not only degrades kaempferol both in vitro and DBM gut, but is also shown to colonize the gut epithelium, forming a protective biofilm. Genomic sequencing of EbPXG5 showed that metabolic genes were the most abundant, especially those involved in xenobiotic degradation, and the metabolism of terpenoids and polyketides, which could participate in the degradation of plant secondary metabolites such as kaempferol. Overall, our results showed that EbPXG5 is a bacterium common in the gut of DBM larvae and has the in vitro and in vivo capacity to detoxify a major secondary metabolite that is produced in brassica plants as a defense against herbivores. This insect-bacterial association may be an important contributor to the status of DBM as a major pest of brassica crops worldwide.IMPORTANCEIn this study, we identify an important role of gut bacteria in mediating the adaptation of diamondback moth (DBM) to plant secondary metabolites. We demonstrate that kaempferol's presence in radish seedlings greatly reduces the fitness of DBM with depleted gut biota. Reinstatement of gut biota, particularly Enterobacter sp. EbPXG5, improved insect performance by degrading kaempferol. This bacterium was common in the larval gut of DBM, lining the epithelium as a protective film. Our work highlights the role of symbiotic bacteria in insect herbivore adaptation to plant defenses and provides a practical and mechanistic framework for developing a more comprehensive understanding of insect-gut microbe-host plant co-evolution.</text><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="456" length="21"/><text>secondary metabolites</text></annotation><annotation id="17"><infon key="identifier">MESH:D005419</infon><infon key="type">Chemical</infon><location offset="507" length="10"/><text>flavonoids</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="585" length="21"/><text>secondary metabolites</text></annotation><annotation id="19"><infon key="identifier">MESH:D005419</infon><infon key="type">Chemical</infon><location offset="826" length="9"/><text>flavonoid</text></annotation><annotation id="20"><infon key="identifier">MESH:C006552</infon><infon key="type">Chemical</infon><location offset="836" length="10"/><text>kaempferol</text></annotation><annotation id="21"><infon key="identifier">MESH:C006552</infon><infon key="type">Chemical</infon><location offset="1030" length="10"/><text>kaempferol</text></annotation><annotation id="22"><infon key="identifier">MESH:D013729</infon><infon key="type">Chemical</infon><location offset="1304" length="10"/><text>terpenoids</text></annotation><annotation id="23"><infon key="identifier">MESH:D061065</infon><infon key="type">Chemical</infon><location offset="1319" length="11"/><text>polyketides</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1384" length="21"/><text>secondary metabolites</text></annotation><annotation id="25"><infon key="identifier">MESH:C006552</infon><infon key="type">Chemical</infon><location offset="1414" length="10"/><text>kaempferol</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="1771" length="8"/><text>brassica</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1930" length="21"/><text>secondary metabolites</text></annotation><annotation id="28"><infon key="identifier">MESH:C006552</infon><infon key="type">Chemical</infon><location offset="1973" length="10"/><text>kaempferol</text></annotation><annotation id="29"><infon key="identifier">MESH:C006552</infon><infon key="type">Chemical</infon><location offset="2182" length="10"/><text>kaempferol</text></annotation></passage></document>
<document><id>37910133</id><passage><infon key="journal">Psychosom Med;2023Oct24. doi:10.1097/PSY.0000000000001257</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Syed SU, Cortez JI, Wilson SJ, </infon><offset>0</offset><text>Depression, Inflammation, and the Moderating Role of Metformin: Results from the Midlife in the United States (MIDUS) Study and Sacramento Area Latino Study on Aging (SALSA).</text><annotation id="3"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="0" length="10"/><text>Depression</text></annotation><annotation id="4"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="12" length="12"/><text>Inflammation</text></annotation><annotation id="5"><infon key="identifier">MESH:D008687</infon><infon key="type">Chemical</infon><location offset="53" length="9"/><text>Metformin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>175</offset><text>OBJECTIVE: Depression can promote inflammation and accelerate aging. Metformin, a widely prescribed antidiabetic, has shown promising preclinical evidence of aging-related health benefits, including decreased inflammation. The current study examined whether metformin usage buffers the association between depressive symptoms and inflammatory markers in two large samples of middle-aged and older, primarily white adults, and older Latino adults. METHODS: Data from the Midlife in the United States Study (MIDUS; N = 1255) and the Sacramento Area Latino Study on Aging (SALSA; N = 1786) included information on medication use, depressive symptoms, and inflammatory markers, namely IL-6, TNF-alpha, and CRP. These data were merged into a harmonized sample, and the sample group variable was included in a three-way interaction for analysis. RESULTS: Specifically, in the MIDUS sample, metformin buffered the association between depressive symptoms and CRP (b = -0.029, SE = 0.013, p = .007) and IL-6 (b = 0.21, SE = 0.010, p = .046), while no significant association was found with TNF-alpha. Metformin non-users displayed higher depressive symptoms associated with elevated CRP (b = 0.01, SE = 0.003, p &lt; .001) and IL-6 (b = 0.011, SE = 0.003, p &lt; .001), whereas this association was not present among metformin users (ps > .068). Conversely, in the SALSA sample, metformin use did not show a significant protective link. CONCLUSION: Results from mostly white, highly educated adults supported a mitigating role of metformin in ties between depression, a well-known behavioral risk factor, and inflammation, a key source of biological aging. However, the benefits did not extend to a large sample of older Mexican Americans. The findings reveal a hidden potential benefit of this therapeutic agent and raise important questions around its health equity.Trial Registration: The study was pre-registered on OSF (https://osf.io/c92vw/).</text><annotation id="32"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="186" length="10"/><text>Depression</text></annotation><annotation id="33"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="209" length="12"/><text>inflammation</text></annotation><annotation id="34"><infon key="identifier">MESH:D008687</infon><infon key="type">Chemical</infon><location offset="244" length="9"/><text>Metformin</text></annotation><annotation id="35"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="384" length="12"/><text>inflammation</text></annotation><annotation id="36"><infon key="identifier">MESH:D008687</infon><infon key="type">Chemical</infon><location offset="433" length="9"/><text>metformin</text></annotation><annotation id="37"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="481" length="19"/><text>depressive symptoms</text></annotation><annotation id="38"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="505" length="12"/><text>inflammatory</text></annotation><annotation id="39"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="802" length="19"/><text>depressive symptoms</text></annotation><annotation id="40"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="827" length="12"/><text>inflammatory</text></annotation><annotation id="41"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="856" length="4"/><text>IL-6</text></annotation><annotation id="42"><infon key="identifier">7124</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="862" length="9"/><text>TNF-alpha</text></annotation><annotation id="43"><infon key="identifier">1401</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">128039</infon><location offset="877" length="3"/><text>CRP</text></annotation><annotation id="44"><infon key="identifier">MESH:D008687</infon><infon key="type">Chemical</infon><location offset="1059" length="9"/><text>metformin</text></annotation><annotation id="45"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1102" length="19"/><text>depressive symptoms</text></annotation><annotation id="46"><infon key="identifier">1401</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">128039</infon><location offset="1126" length="3"/><text>CRP</text></annotation><annotation id="47"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1169" length="4"/><text>IL-6</text></annotation><annotation id="48"><infon key="identifier">7124</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="1256" length="9"/><text>TNF-alpha</text></annotation><annotation id="49"><infon key="identifier">MESH:D008687</infon><infon key="type">Chemical</infon><location offset="1267" length="9"/><text>Metformin</text></annotation><annotation id="50"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1304" length="19"/><text>depressive symptoms</text></annotation><annotation id="51"><infon key="identifier">1401</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">128039</infon><location offset="1349" length="3"/><text>CRP</text></annotation><annotation id="52"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1390" length="4"/><text>IL-6</text></annotation><annotation id="53"><infon key="identifier">MESH:D008687</infon><infon key="type">Chemical</infon><location offset="1477" length="9"/><text>metformin</text></annotation><annotation id="54"><infon key="identifier">MESH:D008687</infon><infon key="type">Chemical</infon><location offset="1539" length="9"/><text>metformin</text></annotation><annotation id="55"><infon key="identifier">MESH:D008687</infon><infon key="type">Chemical</infon><location offset="1690" length="9"/><text>metformin</text></annotation><annotation id="56"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1716" length="10"/><text>depression</text></annotation><annotation id="57"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1769" length="12"/><text>inflammation</text></annotation></passage><relation id="R1"><infon key="score">0.9965</infon><infon key="role1">Disease|MESH:D003866</infon><infon key="role2">Gene|3569</infon><infon key="type">Association</infon><node refid="0" role="10,12"/></relation><relation id="R2"><infon key="score">0.9607</infon><infon key="role1">Disease|MESH:D003866</infon><infon key="role2">Gene|1401</infon><infon key="type">Association</infon><node refid="1" role="10,14"/></relation><relation id="R3"><infon key="score">0.9825</infon><infon key="role1">Chemical|MESH:D008687</infon><infon key="role2">Gene|3569</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="15,18"/></relation><relation id="R4"><infon key="score">0.8866</infon><infon key="role1">Chemical|MESH:D008687</infon><infon key="role2">Disease|MESH:D003866</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="2,0"/></relation><relation id="R5"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D008687</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="2,1"/></relation><relation id="R6"><infon key="score">0.9752</infon><infon key="role1">Chemical|MESH:D008687</infon><infon key="role2">Gene|1401</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="15,17"/></relation><relation id="R7"><infon key="score">0.9922</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|1401</infon><infon key="type">Association</infon><node refid="6" role="11,14"/></relation></document>
<document><id>37910834</id><passage><infon key="journal">Int J Oral Maxillofac Implants;2023Nov01; 0 (0) 1. doi:10.11607/jomi.10427</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Elshafey MM, Tarek ZM, Fahmy RA, </infon><offset>0</offset><text>Piezosurgical buccal plate repositioning technique: A modified surgical approach for horizontal augmentation of atrophied mandible.</text><annotation id="1"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="112" length="18"/><text>atrophied mandible</text></annotation></passage><passage><infon key="type">abstract</infon><offset>132</offset><text>PURPOSE: Reconstruction of atrophied mandible using ridge splitting technique is a challenging procedure. In the present study we demonstrate a modified surgical approach for horizontal ridge augmentation. The technique allows safe manipulation and predictable management of the buccal plate, and avoids secondary surgical site. MATERIALS AND METHODS: This pilot randomized controlled clinical trial included 24 patients requiring horizontal alveolar ridge augmentation. Patients were assigned to one of the three groups. Group A was treated with the buccal plate repositioning technique (BPR) technique and grafted with silica-calcium-phosphate nanocomposite (SCPC) graft. Group B was similarly managed and grafted using freeze-dried bone-allograft (FDBA). While group C was augmented using mandibular ramus autogenous bone block graft (ABBG). The primary outcome was the coronal crest width measured at 6 months using CBCT. RESULTS: BRT resulted in horizontal augmentation of a mean (4.30mm +- 0.94) for the SCPC group, showing no significant difference to either of the allograft group (4.98mm +- 1.13), or the ABBG group (3.68mm +- 0.27). All augmented ridges allowed for successful implant placement with good primary stability. CONCLUSION: The BPR technique resulted in horizontal bone gain in extremely narrow alveolar ridge. It allowed implant placement in a vascular cancellous bed protected by intact cortical plate. Different types of bone grafts whether alloplast or allograft, resulted in successful augmentation comparable to that gained from autogenous block grafting.</text><annotation id="7"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="159" length="18"/><text>atrophied mandible</text></annotation><annotation id="8"><infon key="identifier">MESH:D012822</infon><infon key="type">Chemical</infon><location offset="753" length="6"/><text>silica</text></annotation><annotation id="9"><infon key="identifier">MESH:C020243</infon><infon key="type">Chemical</infon><location offset="760" length="17"/><text>calcium-phosphate</text></annotation><annotation id="10"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="941" length="10"/><text>autogenous</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1689" length="10"/><text>autogenous</text></annotation></passage></document>
<document><id>37911185</id><passage><infon key="journal">Int Dent J (Phila);1891Feb; 12 (2) 138</infon><infon key="year">1891</infon><infon key="article-id_pmc">PMC10109775</infon><infon key="type">title</infon><offset>0</offset><text>Domestic Correspondence.</text></passage><passage><infon key="type">abstract</infon><offset>25</offset></passage></document>
<document><id>37912235</id><passage><infon key="journal">Int Dent J (Phila);1897Jan; 18 (1) 1</infon><infon key="year">1897</infon><infon key="article-id_pmc">PMC10128770</infon><infon key="type">title</infon><infon key="authors">Burchard HH, </infon><offset>0</offset><text>Hypersensitivity of Dentine and Its Treatment.</text><annotation id="1"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="0" length="16"/><text>Hypersensitivity</text></annotation></passage><passage><infon key="type">abstract</infon><offset>47</offset></passage></document>
<document><id>37912935</id><passage><infon key="journal">Int Dent J (Phila);1902Jun; 23 (6) 451</infon><infon key="year">1902</infon><infon key="article-id_pmc">PMC10156214</infon><infon key="type">title</infon><offset>0</offset><text>Miscellany.</text></passage><passage><infon key="type">abstract</infon><offset>12</offset></passage></document>
<document><id>37913286</id><passage><infon key="journal">Int Dent J (Phila);1905Nov; 26 (11) 706</infon><infon key="year">1905</infon><infon key="article-id_pmc">PMC10168793</infon><infon key="type">title</infon><infon key="authors">Miller WD, </infon><offset>0</offset><text>Inaugural Address.</text></passage><passage><infon key="type">abstract</infon><offset>19</offset></passage></document>
<document><id>37913636</id><passage><infon key="journal">Cognition;2023Oct30; 242 105650. doi:10.1016/j.cognition.2023.105650</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yanaoka K, Van't Wout F, Saito S, Jarrold C, </infon><offset>0</offset><text>Evidence for positive and negative transfer of abstract task knowledge in adults and school-aged children.</text></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>Engaging cognitive control is essential to flexibly adapt to constantly changing environments. However, relatively little is known about how prior task experience impacts on the engagement of cognitive control in novel task environments. We aimed to clarify how individuals learn and transfer the engagement of cognitive control with a focus on the hierarchical and temporal aspects of task knowledge. Highlighting two distinct cognitive control processes, the engagement of cognitive control in advance (proactive control) and in response to conflicts (reactive control), we conducted six preregistered online experiments with both adults (Experiment 1, 3, and 5: N = 71, N = 108, and N = 70) and 9- to 10-year-olds (Experiment 2, 4, 6: N = 69, N = 108, and N = 70). Using two different experimental paradigms, we demonstrated that prior task experience of engaging reactive control makes adults and 9-to 10-year-olds respond in a reactive way in a subsequent similar-structured condition with different stimuli in which proactive control could have been engaged. This indicates that individuals do learn knowledge about the temporal structure of task goal activation and, on occasion, negatively transfer this knowledge. Furthermore, individuals exhibited these negative transfer effects in a similar-structured condition with different task goals and stimuli, indicating that they learn hierarchically-structured task knowledge. The collective findings suggest a new way of understanding how hierarchical and temporal task knowledge influences the engagement of cognitive control and highlight potential mechanisms underlying the near transfer effects observed in cognitive control training.</text></passage></document>
<document><id>37913986</id><passage><infon key="journal">J Genet Genomics;2023Oct30. doi:10.1016/j.jgg.2023.10.007</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ma B, Cao X, Li X, Bian Z, Zhang QQ, Fang Z, Liu J, Li Q, Liu Q, Zhang L, He Z, </infon><offset>0</offset><text>Two ABCI family transporters, OsABCI15 and OsABCI16, are involved in grain-filling in rice.</text></passage><passage><infon key="type">abstract</infon><offset>92</offset><text>Seed development is critical for plant reproduction and crop yield, with panicle seed-setting rate, grain-filling, and grain weight being key seed characteristics for yield improvement. However, few genes are known to regulate grain-filling. Here, we identify two ABCI-type transporter genes, OsABCI15 and OsABCI16, involved in rice grain-filling. Both genes are highly expressed in developing seeds, and their proteins are localized to the plasma membrane and cytosol. Interestingly, knockout of OsABCI15 and OsABCI16 results in a significant reduction in seed-setting rate, caused predominantly by the severe empty pericarp phenotype, which differs from the previously reported low seed-setting phenotype resulting from failed pollination. Further analysis indicates that OsABCI15 and OsABCI16 participate in ion homeostasis and likely export ions between filial tissues and maternal tissues during grain-filling. Importantly, overexpression of OsABCI15 and OsABCI16 enhances seed-setting rate and grain yield in transgenic plants and decreases ion accumulation in brown rice. Moreover, the OsABCI15/16 orthologues in maize exhibit a similar role in kernel development, as demonstrated by their disruption in transgenic maize. Therefore, our findings reveal the important roles of two ABC transporters in cereal grain-filling, highlighting their value in crop yield improvement.</text></passage></document>
<document><id>37914336</id><passage><infon key="journal">Yakugaku Zasshi;2023; 143 (11) 897. doi:10.1248/yakushi.23-00115</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Okada K, </infon><offset>0</offset><text>[Time-Domain NMR Study to Evaluate Physical Properties of Pharmaceutical Dosage Forms for Process Analysis].</text></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>Here, we sought to investigate the usefulness of time-domain NMR (TD-NMR) for evaluating the physical properties of drug formulations. TD-NMR measures NMR relaxation and is mainly performed using a bench-top low-field NMR system (e.g., 20 MHz); thus, it does not require any specific sample shape for measurement if the sample is not gas. Taking advantage of these features, TD-NMR has been widely used for quality control in food science. However, it has rarely been used in the pharmaceutical field. The T1 and T2 relaxations are not spectra like those obtained by a high-field NMR system (e.g., 300-600 MHz) but only curves in which the NMR signal recovers or decays according to a specific rule. Therefore, selecting the equation used in the fitting analysis is crucial to estimate the time constants, T1 and T2 relaxation times. As the result of a series of studies, the T1 relaxation measurement by TD-NMR was shown to help evaluate the crystallinity of drugs in solid dosage forms and the miscibility of a drug and excipient in a binary mixture. The T2 relaxation measurement was also helpful for quantitatively evaluating the solid form of drugs in a physical mixture with or without moisture adsorption. TD-NMR is an excellent technique widely applied to evaluating the physical properties of various formulations, whether solid or liquid, and is expected to be applied to process analysis and quality control in the pharmaceutical field.</text></passage></document>
<document><id>37916439</id><passage><infon key="journal">Thorac Cancer;2023Nov02. doi:10.1111/1759-7714.15139</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li L, Zhao J, Zhang Y, Pan Z, Zhang J, </infon><offset>0</offset><text>Nomogram based on multiparametric analysis of early-stage breast cancer: Prediction of high burden metastatic axillary lymph nodes.</text><annotation id="1"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="58" length="13"/><text>breast cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>132</offset><text>BACKGROUND: The Z0011 and AMAROS trials found that axillary lymph node dissection (ALND) was no longer mandatory for early-stage breast cancer patients who had one or two metastatic axillary lymph nodes (mALNs). The aim of our study was to establish a nomogram which could be used to quantitatively predict the individual likelihood of high burden mALN (>=3 mALN). METHODS: We retrospectively analyzed 564 women with early breast cancer who had all undergone both ultrasound (US) and magnetic resonance imaging (MRI) to examine axillary lymph nodes before radical surgery. All the patients were divided into training (n = 452) and validation (n = 112) cohorts by computer-generated random numbers. Their clinicopathological features and preoperative imaging associated with high burden mALNs were evaluated by logistic regression analysis to develop a nomogram for predicting the probability of high burden mALNs. RESULTS: Multivariate analysis showed that high burden mALNs were significantly associated with replaced hilum and the shortest diameter >10 mm on MRI, with cortex thickness >3 mm on US (p &lt; 0.05 each). These imaging criteria plus higher grade (grades II and III) and quadrant of breast tumor were used to develop a nomogram calculating the probability of high burden mALNs. The AUC of the nomogram was 0.853 (95% CI: 0.790-0.908) for the training set and 0.783 (95% CI: 0.638-0.929) for the validation set. Both internal and external validation evaluated the accuracy of nomogram to be good. CONCLUSION: A well-discriminated nomogram was developed to predict the high burden mALN in early-stage breast patients, which may assist the breast surgeon in choosing the appropriate surgical approach.</text><annotation id="6"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="261" length="13"/><text>breast cancer</text></annotation><annotation id="7"><infon key="type">Disease</infon><location offset="480" length="4"/><text>mALN</text></annotation><annotation id="8"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="555" length="13"/><text>breast cancer</text></annotation><annotation id="9"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1326" length="12"/><text>breast tumor</text></annotation></passage></document>
<document><id>37916794</id><passage><infon key="journal">Ann N Y Acad Sci;2023Nov02. doi:10.1111/nyas.15074</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Trautwein U, Golle J, Jaggy AK, Hasselhorn M, Nagengast B, </infon><offset>0</offset><text>Mutual benefits for research and practice: Randomized controlled trials in the Hector Children's Academy Program.</text></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>This article describes how a series of randomized controlled trials (RCTs) were implemented in the Hector Children's Academy Talent Development Program with the goal of generating mutual benefits for research and practice. The Hector Children's Academy Program, founded in 2010 and located in one of the largest states in Germany, Baden-Wurttemberg, is a statewide enrichment program for talented primary school students, with a focus on STEMM topics. The program is financed by a private foundation, supervised by the Ministry of Education, and offered by 69 local sites that are hosted by local schools. About 15,000 primary school students (Grades 1-4) attend enrichment courses (more than 23,000 course participations) offered by the Hector Children's Academy Program every year. A unique element of the Hector Children's Academy Program is the role of empirical research in course development. The Hector Core Courses-offered by all local sites-undergo a strict quality assurance process in which RCTs are used to test their effectiveness with regard to central outcomes. After describing the Hector Children's Academy Program, we explain how the Hector Core Courses were developed and incorporated into the program, summarize key findings from the RCTs, and discuss mutual benefits for research and practice.</text></passage></document>
<document><id>37917146</id><passage><infon key="journal">JMIR Form Res;2023Nov02; 7 50833. doi:10.2196/50833</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gilmore AK, Fortson K, Mullican KN, Garc&amp;#xed;a-Ram&amp;#xed;rez G, Hutchins A, Bartlett AM, Gooding HC, Wallis E, Levy S, Ruggiero KJ, Kaysen D, Danielson CK, Platner R, Hartman A, Self-Brown S, </infon><offset>0</offset><text>An eHealth Prevention Program for Substance Use, Sexual Assault, and Sexual Risk Behaviors for Adolescents in Primary Care: Pilot Feasibility Randomized Controlled Trial of Teen Well Check.</text><annotation id="3"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="34" length="13"/><text>Substance Use</text></annotation><annotation id="4"><infon key="identifier">MESH:D050035</infon><infon key="type">Disease</infon><location offset="49" length="14"/><text>Sexual Assault</text></annotation><annotation id="5"><infon key="identifier">MESH:D050035</infon><infon key="type">Disease</infon><location offset="69" length="21"/><text>Sexual Risk Behaviors</text></annotation></passage><passage><infon key="type">abstract</infon><offset>190</offset><text>BACKGROUND: Substance use, sexual assault, and sexual risk behaviors are common among adolescents and are interrelated. Nearly 1 in 5 adolescents use substances before sexual encounters, placing these young people at risk for both sexual assault and sexual risk behaviors. Primary care visits present a unique opportunity to address multiple health risk behaviors. OBJECTIVE: Teen Well Check is a web-based integrated prevention program for substance use, sexual assault, and sexual risk behaviors with demonstrated usability and acceptability among patients and providers. The aim of this study was to conduct a pilot randomized controlled trial to assess feasibility. METHODS: Adolescents (n=123) aged 14 to 18 years from diverse backgrounds were recruited from primarily Medicaid-serving pediatric primary care clinics. Participants completed a baseline survey; were randomized to receive Teen Well Check or an assessment-only control; and completed 1-, 3-, and 6-month follow-up surveys. Feasibility was assessed in terms of recruitment and retention rates. Preliminary changes from baseline to follow-up periods were examined separately in the Teen Well Check and control conditions. RESULTS: We recruited 123 participants (Teen Well Check: n=61, 49.6%; control: n=62, 50.4%). Of the 61 participants assigned to the Teen Well Check condition, 55 (90%) completed the full program and viewed all intervention content. Of the 123 participants, 105 (85.4%) were retained across at least 1 follow-up period, and there was no difference in follow-up rates between the conditions (chi21=0.6; P=.43). The completion of Teen Well Check took an average of 6.2 (SD 5.8) minutes. Preliminary analyses revealed that there were significant reductions in perceived peer norms (descriptive norms) for substance use before sex across follow-ups among participants in the Teen Well Check condition (P=.001 from baseline to 6 months), whereas there were significant increases among participants in the control condition (P=.003 from baseline to 6 months). In addition, there were nonsignificant reductions in substance misuse risk from baseline to the 6-month follow-up among participants in the Teen Well Check condition (P=.16). CONCLUSIONS: These findings support the feasibility of Teen Well Check delivery within pediatric primary care clinics. A randomized clinical trial is needed to assess efficacy. TRIAL REGISTRATION: ClinicalTrials.gov NCT3489434; https://www.clinicaltrials.gov/study/NCT03489434.</text><annotation id="19"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="202" length="13"/><text>Substance use</text></annotation><annotation id="20"><infon key="identifier">MESH:D050035</infon><infon key="type">Disease</infon><location offset="217" length="14"/><text>sexual assault</text></annotation><annotation id="21"><infon key="identifier">MESH:D050035</infon><infon key="type">Disease</infon><location offset="237" length="21"/><text>sexual risk behaviors</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="407" length="4"/><text>risk</text></annotation><annotation id="23"><infon key="identifier">MESH:D050035</infon><infon key="type">Disease</infon><location offset="421" length="14"/><text>sexual assault</text></annotation><annotation id="24"><infon key="identifier">MESH:D050035</infon><infon key="type">Disease</infon><location offset="440" length="21"/><text>sexual risk behaviors</text></annotation><annotation id="25"><infon key="type">Disease</infon><location offset="539" length="4"/><text>risk</text></annotation><annotation id="26"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="631" length="13"/><text>substance use</text></annotation><annotation id="27"><infon key="identifier">MESH:D050035</infon><infon key="type">Disease</infon><location offset="646" length="14"/><text>sexual assault</text></annotation><annotation id="28"><infon key="identifier">MESH:D050035</infon><infon key="type">Disease</infon><location offset="666" length="21"/><text>sexual risk behaviors</text></annotation><annotation id="29"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="1980" length="13"/><text>substance use</text></annotation><annotation id="30"><infon key="identifier">MESH:D009293</infon><infon key="type">Disease</infon><location offset="2285" length="16"/><text>substance misuse</text></annotation><annotation id="31"><infon key="type">Disease</infon><location offset="2302" length="4"/><text>risk</text></annotation></passage></document>
<document><id>37917496</id><passage><infon key="journal">Psychol Assess;2023Nov02. doi:10.1037/pas0001289</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li X, Ng TK, Lee TH, Li CN, </infon><offset>0</offset><text>Peer victimization among Chinese adolescents: A longitudinal validation study.</text><annotation id="1"><infon key="type">Disease</infon><location offset="0" length="18"/><text>Peer victimization</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Peer victimization is a social problem for children and adolescents worldwide. This study examined the factor structure of peer victimization in relation to school life among Chinese adolescent students. The Multidimensional Peer-Victimization Scale (MPVS) was used to measure this phenomenon. We examined psychometric properties such as factor structure, factorial invariance across genders, area types (urban vs. rural), and time (Time 1 vs. Time 2), nomological network validity in relation to the symptoms of depression and anxiety, and internal consistency reliability of the MPVS in Chinese culture. We analyzed the results of a survey of 2,764 adolescents from six public secondary schools in Fujian Province, China; 50.8% of these participants were female, and their mean age was 13.967 years (SD = .843). Of these participants, 2,217 (51.2% female), with a mean age of 13.839 years (SD = .802), also completed the survey at Time 2. Four-factor models were tested: a null model, a one-factor model, the hypothesized four-factor model, and a hierarchical model. The results revealed that the four-factor model exhibited the best fit and demonstrated factorial invariance across genders, area types, and time points. Future directions for research among Chinese adolescents were also discussed. (PsycInfo Database Record (c) 2023 APA, all rights reserved).</text><annotation id="6"><infon key="type">Disease</infon><location offset="79" length="18"/><text>Peer victimization</text></annotation><annotation id="7"><infon key="type">Disease</infon><location offset="202" length="18"/><text>peer victimization</text></annotation><annotation id="8"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="592" length="10"/><text>depression</text></annotation><annotation id="9"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="607" length="7"/><text>anxiety</text></annotation></passage></document>
<document><id>37917848</id><passage><infon key="journal">Psychiatr Danub;2023Fall; 35 (3) 433. doi:10.24869/psyd.2023.433</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kok Kendirlioglu B, Corekli Kaymakci E, Kucukgoncu S, Cetin B, Ece Arat Celik H, </infon><offset>0</offset><text>DELIRIOUS MANIA OR HYPERACTIVE DELIRIUM? A CASE REPORT.</text><annotation id="2"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="0" length="15"/><text>DELIRIOUS MANIA</text></annotation><annotation id="3"><infon key="identifier">MESH:D003693</infon><infon key="type">Disease</infon><location offset="19" length="20"/><text>HYPERACTIVE DELIRIUM</text></annotation></passage><passage><infon key="type">abstract</infon><offset>56</offset></passage></document>
<document><id>37918198</id><passage><infon key="journal">Water Res;2023Oct28; 247 120796. doi:10.1016/j.watres.2023.120796</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fan X, Zhang L, Lan S, Wang B, Qi W, Wu Y, Peng Y, </infon><offset>0</offset><text>A pilot study of situ sludge fermentation-driven multiple biological nitrogen removal pathways (SFBNR): Revealing microbial synergy mechanism based on co-occurrence network analysis.</text><annotation id="1"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="69" length="8"/><text>nitrogen</text></annotation></passage><passage><infon key="type">abstract</infon><offset>183</offset><text>The sludge fermentation-driven biological nitrogen removal (SFBNR) has garnered increasing attention due to its efficient carbon resource utilization from waste activated sludge (WAS). This study successfully extended the application of this technique to a 38 m3 reactor, facilitating a daily ultra-low carbon to nitrogen ratio (&lt;1) wastewater treatment capacity of 16 tons and a WAS capacity of 500 L. After 185-days operation, the system demonstrated commendable performance with a denitrification efficiency (DNE) of 93.22 % and a sludge reduction efficiency (SRE) of 72.07 %. To better understand the potential mechanisms, various functional bacteria interactions were revealed by co-occurrence network analysis. The results unveiled module hubs (e.g., Anaerolineaceae, Denitratisoma, and Candidatus Brocadia) and connectors (e.g., Tuaera and Candidatus Alysiosphaera) in the network exhibited synergistic relationships facilitated by carbon metabolism and nitrogen cycling. Furthermore, the interaction between biofilm sludge (BS) and suspended sludge (SS) contributed to the in-situ enrichment of anaerobic ammonium oxidizing bacteria (AnAOB), whose abundance in BS reached 1.8 % (200-times higher than in SS) after six months, and the suspend-biofilm interface served as a hotspot for anammox activity.</text><annotation id="11"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="225" length="8"/><text>nitrogen</text></annotation><annotation id="12"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="305" length="6"/><text>carbon</text></annotation><annotation id="13"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="486" length="6"/><text>carbon</text></annotation><annotation id="14"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="496" length="8"/><text>nitrogen</text></annotation><annotation id="15"><infon key="type">Disease</infon><location offset="717" length="6"/><text>sludge</text></annotation><annotation id="16"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1122" length="6"/><text>carbon</text></annotation><annotation id="17"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="1144" length="8"/><text>nitrogen</text></annotation><annotation id="18"><infon key="identifier">MESH:C000719206</infon><infon key="type">Disease</infon><location offset="1296" length="27"/><text>ammonium oxidizing bacteria</text></annotation><annotation id="19"><infon key="identifier">MESH:C000719206</infon><infon key="type">Disease</infon><location offset="1325" length="5"/><text>AnAOB</text></annotation></passage><relation id="R1"><infon key="score">0.9028</infon><infon key="role1">Chemical|MESH:D002244</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Association</infon><node refid="0" role="2,1"/></relation></document>
<document><id>37918548</id><passage><infon key="journal">Gene;2023Oct31 147951. doi:10.1016/j.gene.2023.147951</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Williams RP, Lesseur C, Cheng H, Li Q, Deyssenroth M, Molteno CD, Meintjes EM, Jacobson SW, Jacobson JL, Wainwright H, Hao K, Chen J, Colin Carter R, </infon><offset>0</offset><text>RNA-seq analysis reveals prenatal alcohol exposure is associated with placental inflammatory cells and gene expression.</text><annotation id="2"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="34" length="7"/><text>alcohol</text></annotation><annotation id="3"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="80" length="12"/><text>inflammatory</text></annotation></passage><passage><infon key="type">abstract</infon><offset>120</offset><text>BACKGROUND: Fetal alcohol spectrum disorders (FASD) are the most common preventable cause of birth defects and neurodevelopmental disorders worldwide. The placenta is the crucial interface between mother and fetus. Prenatal alcohol exposure (PAE) has been shown to alter placental structure and expression of genes in bulk placental tissue samples, but few studies have examined effects on placental cell-type composition or take cell-type into consideration in transcriptome analyses. METHODS: We leveraged an existent placenta single-cell RNA-seq dataset to perform cell-type deconvolution of bulk placental RNA-seq data from 35 heavy drinking pregnant women and 33 controls in a prospective birth cohort in Cape Town, South Africa. We used bivariate analyses and multivariable adjusted linear regression models to assess the relation of PAE on inferred placental cell-type proportions. We also examined differential expression of inflammatory response genes and PAE, using multivariable adjusted linear models. RESULTS: Deconvolution analyses showed heterogeneous placenta cell-type composition in which stromal (27%), endothelial (26%) and cytotrophoblasts (18%) were the predominant cell-types. PAE around conception was associated with a higher proportion of Hofbauer cells (B= 0.51, p=0.035) in linear models adjusted for maternal age, infant sex, and gestational age. Among the 652 inflammatory genes examined, 35 were differential expressed in alcohol exposed placentas (FDR p&lt;0.05). CONCLUSIONS: Our findings suggest that heavy alcohol exposure during pregnancy can influence the proportion of fetal placental villi macrophages (Hofbauer cells) and increased expression of inflammatory genes. Future studies are needed to further characterize these effects and to assess the potential functional roles of placental inflammation in FASD.</text><annotation id="16"><infon key="identifier">MESH:D063647</infon><infon key="type">Disease</infon><location offset="132" length="32"/><text>Fetal alcohol spectrum disorders</text></annotation><annotation id="17"><infon key="identifier">MESH:D063647</infon><infon key="type">Disease</infon><location offset="166" length="4"/><text>FASD</text></annotation><annotation id="18"><infon key="identifier">MESH:D000014</infon><infon key="type">Disease</infon><location offset="213" length="13"/><text>birth defects</text></annotation><annotation id="19"><infon key="identifier">MESH:D002658</infon><infon key="type">Disease</infon><location offset="231" length="28"/><text>neurodevelopmental disorders</text></annotation><annotation id="20"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="344" length="7"/><text>alcohol</text></annotation><annotation id="21"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1053" length="12"/><text>inflammatory</text></annotation><annotation id="22"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1510" length="12"/><text>inflammatory</text></annotation><annotation id="23"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1573" length="7"/><text>alcohol</text></annotation><annotation id="24"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1658" length="7"/><text>alcohol</text></annotation><annotation id="25"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1803" length="12"/><text>inflammatory</text></annotation><annotation id="26"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1945" length="12"/><text>inflammation</text></annotation><annotation id="27"><infon key="identifier">MESH:D063647</infon><infon key="type">Disease</infon><location offset="1961" length="4"/><text>FASD</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D000438</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="0,1"/></relation></document>
<document><id>37918898</id><passage><infon key="journal">Arch Dis Child;2023Nov02. doi:10.1136/archdischild-2023-325703</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Connett G, Harper S, Raut B, James D, </infon><offset>0</offset><text>Hospital discharge using salbutamol as required after acute attacks of wheeze in children: a service evaluation.</text><annotation id="3"><infon key="identifier">MESH:D000420</infon><infon key="type">Chemical</infon><location offset="25" length="10"/><text>salbutamol</text></annotation><annotation id="4"><infon key="identifier">MESH:D000208</infon><infon key="type">Disease</infon><location offset="54" length="5"/><text>acute</text></annotation><annotation id="5"><infon key="identifier">MESH:D012135</infon><infon key="type">Disease</infon><location offset="71" length="6"/><text>wheeze</text></annotation></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>OBJECTIVE: Most UK hospitals discharge children after acute wheeze with advice to give regular salbutamol using a fixed dose weaning regime. We have introduced and evaluated the safety and efficacy of changing practice to using bronchodilators only as needed after 4 hourly assessments. DESIGN: A multidisciplinary team of healthcare professionals worked with eight families of children who had needed hospital treatment with acute wheeze to develop guidance for the use of salbutamol on an as required basis after 4 hourly assessments. Data on salbutamol used with this approach were compared with a similar period in the previous year. RESULTS: Data from 103 families showed a 73% reduction in salbutamol on day 1, 69% on day 2 and 50% on day 3 compared with what would have been used according to previous advice. Families found the advice easy to follow. There was a trend towards lower reattendance rates within 1 week compared with those recorded in the previous year. Those who had previously attended preferred this change in practice. CONCLUSIONS: These data suggest that with information to support the use of salbutamol on an as required basis after hospital attendance, children can be safely managed by their parents/guardians with much lower doses of salbutamol than those recommended in commonly used fixed dose weaning regimes.</text><annotation id="16"><infon key="identifier">MESH:D000208</infon><infon key="type">Disease</infon><location offset="167" length="5"/><text>acute</text></annotation><annotation id="17"><infon key="identifier">MESH:D012135</infon><infon key="type">Disease</infon><location offset="173" length="6"/><text>wheeze</text></annotation><annotation id="18"><infon key="identifier">MESH:D000420</infon><infon key="type">Chemical</infon><location offset="208" length="10"/><text>salbutamol</text></annotation><annotation id="19"><infon key="identifier">MESH:D000208</infon><infon key="type">Disease</infon><location offset="539" length="5"/><text>acute</text></annotation><annotation id="20"><infon key="identifier">MESH:D012135</infon><infon key="type">Disease</infon><location offset="545" length="6"/><text>wheeze</text></annotation><annotation id="21"><infon key="identifier">MESH:D000420</infon><infon key="type">Chemical</infon><location offset="587" length="10"/><text>salbutamol</text></annotation><annotation id="22"><infon key="identifier">MESH:D000420</infon><infon key="type">Chemical</infon><location offset="658" length="10"/><text>salbutamol</text></annotation><annotation id="23"><infon key="identifier">MESH:D000420</infon><infon key="type">Chemical</infon><location offset="809" length="10"/><text>salbutamol</text></annotation><annotation id="24"><infon key="identifier">MESH:D000420</infon><infon key="type">Chemical</infon><location offset="1233" length="10"/><text>salbutamol</text></annotation><annotation id="25"><infon key="identifier">MESH:D000420</infon><infon key="type">Chemical</infon><location offset="1378" length="10"/><text>salbutamol</text></annotation></passage><relation id="R1"><infon key="score">0.9956</infon><infon key="role1">Chemical|MESH:D000420</infon><infon key="role2">Disease|MESH:D012135</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.9902</infon><infon key="role1">Chemical|MESH:D000420</infon><infon key="role2">Disease|MESH:D000208</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,1"/></relation></document>
<document><id>37919248</id><passage><infon key="journal">Inorg Chem;2023Nov02. doi:10.1021/acs.inorgchem.3c03245</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liu J, Ji X, Wang C, Wang L, Jian P, </infon><offset>0</offset><text>Beneficial Synergistic Intermetallic Effect in ZnCo2O4 for Enhancing the Limonene Oxidation Catalysis.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="47" length="7"/><text>ZnCo2O4</text></annotation><annotation id="3"><infon key="identifier">MESH:D000077222</infon><infon key="type">Chemical</infon><location offset="73" length="8"/><text>Limonene</text></annotation></passage><passage><infon key="type">abstract</infon><offset>103</offset><text>Utilization of naturally occurring limonene from renewable biomass as a key starting material for the synthesis of valuable chemicals is a promising avenue to reduce both the dependence on nonrenewable fossil fuels and global CO2 emission. Herein, we report a highly active tremella-like ZnCo2O4 catalyst for the selective oxidation of limonene with molecular oxygen under mild reaction conditions. The developed ZnCo2O4 catalyst exhibits an appealing reaction performance with a limonene conversion of 93.5% (reaction rate of 0.0823 mmol gcat-1 h-1) and selectivity of 75.8% for 1,2-limonene oxide (LO), far outperforming the monometallic oxides of ZnO and Co3O4. Detained experimental characterizations and analyses manifest that the substitution of Zn into the Co3O4 framework can facilitate the formation of more unsaturated coordination sites and oxygen vacancies due to the modified chemical environment of Co atoms, inducing a beneficial synergistic intermetallic effect for the limonene oxidation catalysis.</text><annotation id="20"><infon key="identifier">MESH:D000077222</infon><infon key="type">Chemical</infon><location offset="138" length="8"/><text>limonene</text></annotation><annotation id="21"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="329" length="3"/><text>CO2</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="391" length="7"/><text>ZnCo2O4</text></annotation><annotation id="23"><infon key="identifier">MESH:D000077222</infon><infon key="type">Chemical</infon><location offset="439" length="8"/><text>limonene</text></annotation><annotation id="24"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="463" length="6"/><text>oxygen</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="516" length="7"/><text>ZnCo2O4</text></annotation><annotation id="26"><infon key="identifier">MESH:D000077222</infon><infon key="type">Chemical</infon><location offset="583" length="8"/><text>limonene</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="683" length="18"/><text>1,2-limonene oxide</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="703" length="2"/><text>LO</text></annotation><annotation id="29"><infon key="identifier">MESH:D015034</infon><infon key="type">Chemical</infon><location offset="753" length="3"/><text>ZnO</text></annotation><annotation id="30"><infon key="identifier">MESH:C000711807</infon><infon key="type">Chemical</infon><location offset="761" length="5"/><text>Co3O4</text></annotation><annotation id="31"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="855" length="2"/><text>Zn</text></annotation><annotation id="32"><infon key="identifier">MESH:C000711807</infon><infon key="type">Chemical</infon><location offset="867" length="5"/><text>Co3O4</text></annotation><annotation id="33"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="955" length="6"/><text>oxygen</text></annotation><annotation id="34"><infon key="identifier">MESH:D003035</infon><infon key="type">Chemical</infon><location offset="1016" length="2"/><text>Co</text></annotation><annotation id="35"><infon key="identifier">MESH:D000077222</infon><infon key="type">Chemical</infon><location offset="1089" length="8"/><text>limonene</text></annotation></passage><relation id="R1"><infon key="score">0.9952</infon><infon key="role1">Chemical|MESH:D000077222</infon><infon key="role2">Chemical|MESH:D010100</infon><infon key="type">Association</infon><node refid="0" role="5,6"/></relation></document>
<document><id>37919598</id><passage><infon key="journal">MMW Fortschr Med;2023Nov; 165 (19) 66. doi:10.1007/s15006-023-3119-1</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Klein F, </infon><offset>0</offset><text>IL-5-Antikorper bei Vaskulitis.</text><annotation id="2"><infon key="identifier">3567</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">679</infon><location offset="0" length="4"/><text>IL-5</text></annotation><annotation id="3"><infon key="type">Disease</infon><location offset="20" length="10"/><text>Vaskulitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>32</offset></passage></document>
<document><id>37919948</id><passage><infon key="journal">Women Health;2023Nov02 1. doi:10.1080/03630242.2023.2277890</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bokek-Cohen Y, </infon><offset>0</offset><text>The impact of relationship status on IVF patients' quality of life.</text><annotation id="1"><infon key="identifier">MESH:C537182</infon><infon key="type">Disease</infon><location offset="37" length="3"/><text>IVF</text></annotation></passage><passage><infon key="type">abstract</infon><offset>68</offset><text>Infertility treatments are emotionally taxing and include invasive and time-consuming procedures over extended periods of time. In light of the growing numbers of single mothers by choice, the objective of this study was to apply the Conservation of Resources Theory in the context of infertility care and examine whether relationship status constitutes a psychological resource that buffers the decline in quality of life during IVF treatments. We used the FertiQol questionnaire to compare the quality of life of IVF patients between 422 patients who are involved in a couple relationship ("attached") and 117 patients who are not ("unattached"). Results show that the total FertiQol was significantly higher among the attached participants; the Core FertiQol and the Treatment FertiQol were rated higher by the "attached." No significant differences were found between the attached and unattached for the Emotional and Social subscales. "unattached" participants report significantly lower levels of quality of life in the "mind-body" and "treatment tolerability" subscales than the "attached" participants. It is concluded that being involved in a long-term couple relationship is to be seen as a resource that buffers the decline in quality of life of infertile women undergoing IVF treatments.</text><annotation id="11"><infon key="identifier">MESH:D007246</infon><infon key="type">Disease</infon><location offset="68" length="11"/><text>Infertility</text></annotation><annotation id="12"><infon key="identifier">MESH:D007246</infon><infon key="type">Disease</infon><location offset="353" length="11"/><text>infertility</text></annotation><annotation id="13"><infon key="identifier">MESH:C537182</infon><infon key="type">Disease</infon><location offset="498" length="3"/><text>IVF</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="526" length="8"/><text>FertiQol</text></annotation><annotation id="15"><infon key="identifier">MESH:C537182</infon><infon key="type">Disease</infon><location offset="583" length="3"/><text>IVF</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="745" length="8"/><text>FertiQol</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="821" length="8"/><text>FertiQol</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="848" length="8"/><text>FertiQol</text></annotation><annotation id="19"><infon key="identifier">MESH:C537182</infon><infon key="type">Disease</infon><location offset="1352" length="3"/><text>IVF</text></annotation></passage></document>
<document><id>37920998</id><passage><infon key="journal">Arch Physiol Biochem;2023Nov03 1. doi:10.1080/13813455.2023.2274279</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liu J, Wang H, Huang C, </infon><offset>0</offset><text>Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy in vivo and in vitro.</text><annotation id="3"><infon key="identifier">MESH:D000077270</infon><infon key="type">Chemical</infon><location offset="0" length="9"/><text>Exendin-4</text></annotation><annotation id="4"><infon key="identifier">2740</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1558</infon><location offset="13" length="14"/><text>GLP-1 receptor</text></annotation><annotation id="5"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="48" length="20"/><text>diabetic retinopathy</text></annotation></passage><passage><infon key="type">abstract</infon><offset>91</offset><text>Diabetic retinopathy (DR) is a complication of diabetes and a leading cause of blindness in adults. Studies have shown that glucagon-like peptide-1 (GLP-1) exerts a protective effect on patients with DR. Here, we investigated the protective effects of Exendin-4, a GLP-1 analogue, on DR. We established a high-glucose-induced HREC cell model and an STZ-induced rat DR Model to study the effect of Exendin-4 in DR in vitro and in vivo. The qRT-PCR, CCK-8, TUNEL, western blotting, tube formation assays, and ELISA were performed. In addition, we overexpressed TGFB2 to observe whether the protective effect of Exendin-4 was reversed. Our results showed that Exendin-4 inhibited the progression of DR. Furthermore, the protective effect of Exendin-4 was suppressed in cells overexpressing TGFB2. Our findings suggest that Exendin-4 may be involved in the regulation of TGFB2 expression levels to inhibit DR. These results indicate that Exendin-4 could be an effective therapy for DR.</text><annotation id="32"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="91" length="20"/><text>Diabetic retinopathy</text></annotation><annotation id="33"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="113" length="2"/><text>DR</text></annotation><annotation id="34"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="138" length="8"/><text>diabetes</text></annotation><annotation id="35"><infon key="identifier">MESH:D001766</infon><infon key="type">Disease</infon><location offset="170" length="9"/><text>blindness</text></annotation><annotation id="36"><infon key="identifier">2641</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136497</infon><location offset="215" length="23"/><text>glucagon-like peptide-1</text></annotation><annotation id="37"><infon key="identifier">2641</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136497</infon><location offset="240" length="5"/><text>GLP-1</text></annotation><annotation id="38"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="291" length="2"/><text>DR</text></annotation><annotation id="39"><infon key="identifier">MESH:D000077270</infon><infon key="type">Chemical</infon><location offset="343" length="9"/><text>Exendin-4</text></annotation><annotation id="40"><infon key="identifier">2641</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136497</infon><location offset="356" length="5"/><text>GLP-1</text></annotation><annotation id="41"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="375" length="2"/><text>DR</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="396" length="12"/><text>high-glucose</text></annotation><annotation id="43"><infon key="identifier">MESH:D013311</infon><infon key="type">Chemical</infon><location offset="440" length="3"/><text>STZ</text></annotation><annotation id="44"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="456" length="2"/><text>DR</text></annotation><annotation id="45"><infon key="identifier">MESH:D000077270</infon><infon key="type">Chemical</infon><location offset="488" length="9"/><text>Exendin-4</text></annotation><annotation id="46"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="501" length="2"/><text>DR</text></annotation><annotation id="47"><infon key="identifier">81809</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2432</infon><location offset="650" length="5"/><text>TGFB2</text></annotation><annotation id="48"><infon key="identifier">MESH:D000077270</infon><infon key="type">Chemical</infon><location offset="700" length="9"/><text>Exendin-4</text></annotation><annotation id="49"><infon key="identifier">MESH:D000077270</infon><infon key="type">Chemical</infon><location offset="748" length="9"/><text>Exendin-4</text></annotation><annotation id="50"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="787" length="2"/><text>DR</text></annotation><annotation id="51"><infon key="identifier">MESH:D000077270</infon><infon key="type">Chemical</infon><location offset="829" length="9"/><text>Exendin-4</text></annotation><annotation id="52"><infon key="identifier">81809</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2432</infon><location offset="878" length="5"/><text>TGFB2</text></annotation><annotation id="53"><infon key="identifier">MESH:D000077270</infon><infon key="type">Chemical</infon><location offset="911" length="9"/><text>Exendin-4</text></annotation><annotation id="54"><infon key="identifier">81809</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2432</infon><location offset="958" length="5"/><text>TGFB2</text></annotation><annotation id="55"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="993" length="2"/><text>DR</text></annotation><annotation id="56"><infon key="identifier">MESH:D000077270</infon><infon key="type">Chemical</infon><location offset="1025" length="9"/><text>Exendin-4</text></annotation><annotation id="57"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="1069" length="2"/><text>DR</text></annotation></passage><relation id="R1"><infon key="score">0.9741</infon><infon key="role1">Disease|MESH:D003930</infon><infon key="role2">Gene|2641</infon><infon key="type">Association</infon><node refid="0" role="9,7"/></relation><relation id="R2"><infon key="score">0.9759</infon><infon key="role1">Disease|MESH:D003930</infon><infon key="role2">Gene|81809</infon><infon key="type">Association</infon><node refid="1" role="26,25"/></relation><relation id="R3"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:D000077270</infon><infon key="role2">Gene|2740</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="0,1"/></relation><relation id="R4"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:D000077270</infon><infon key="role2">Disease|MESH:D003930</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="0,2"/></relation><relation id="R5"><infon key="score">0.996</infon><infon key="role1">Chemical|MESH:D000077270</infon><infon key="role2">Gene|81809</infon><infon key="type">Association</infon><node refid="4" role="19,18"/></relation><relation id="R6"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D013311</infon><infon key="role2">Disease|MESH:D003930</infon><infon key="type">Positive_Correlation</infon><node refid="5" role="14,15"/></relation></document>
<document><id>37921348</id><passage><infon key="journal">Vet Rec;2023Nov; 193 Suppl 1 7. doi:10.1002/vetr.3611</infon><infon key="year">2023</infon><infon key="type">title</infon><offset>0</offset><text>Charities consider their castration policies.</text></passage><passage><infon key="type">abstract</infon><offset>46</offset><text>While population control remains a key priority for the UK's leading dog welfare charities, it must increasingly be balanced with concerns about the possible health impact of castration.</text></passage></document>
<document><id>37921698</id><passage><infon key="journal">J Biomol Struct Dyn;2023Nov03 1. doi:10.1080/07391102.2023.2274976</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Saeed M, Alshammari N, Saeed A, Ayyed Al-Shammary A, Alabdallah NM, Ahmad I, Aqil F, </infon><offset>0</offset><text>Molecular interactions of cucurbitacins A and B with anaplastic lymphoma kinase for lung cancer treatment.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="26" length="21"/><text>cucurbitacins A and B</text></annotation><annotation id="4"><infon key="identifier">238</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68387</infon><location offset="53" length="26"/><text>anaplastic lymphoma kinase</text></annotation><annotation id="5"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="84" length="11"/><text>lung cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>Lung cancer is a major global public health issue and the leading cause of cancer-related deaths. Several medications are commonly used to treat lung cancer, either alone or in combination with other treatments. The anaplastic lymphoma kinase (ALK) protein is one of several target proteins that are thought to be potential therapeutic targets in the context of lung cancer. Several ALK inhibitors have been identified, but many of these have been associated with side effects and toxicity concerns. In this study, we intend to computationally predict the binding potential of cucurbitacins (CBNs), A and B to the active pockets of ALK, in order to estimate their potential ALK inhibitors. Compared to CBN-A, which has a binding energy of -7.9 kcal/mol, CBN B exhibits significantly better binding efficacy with a binding energy of -8.1 kcal/mol. This is closely comparable to the binding energy of Crizotinib, which is -8.2 kcal/mol. The results of the molecular dynamics simulation indicated that the docked complexes remained stable for the duration of the 100 ns simulation period. CBN inhibited the proliferation of both non-small cell lung cancer cell lines, H1299 and A549, in a dose-dependent manner. CBN-B inhibited the proliferation of lung cancer cells, showing IC50 values of 0.08 microM for H1299 cells and 0.10 microM for A549 cells. The computational analyses provide strong evidence that CBN-B has the potential to act as a potent natural inhibitor against ALK, and could prove to be a valuable treatment option for lung cancer.Communicated by Ramaswamy H. Sarma.</text><annotation id="30"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="107" length="11"/><text>Lung cancer</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="182" length="6"/><text>cancer</text></annotation><annotation id="32"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="252" length="11"/><text>lung cancer</text></annotation><annotation id="33"><infon key="identifier">238</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68387</infon><location offset="323" length="26"/><text>anaplastic lymphoma kinase</text></annotation><annotation id="34"><infon key="identifier">238</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68387</infon><location offset="351" length="3"/><text>ALK</text></annotation><annotation id="35"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="469" length="11"/><text>lung cancer</text></annotation><annotation id="36"><infon key="identifier">238</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68387</infon><location offset="490" length="3"/><text>ALK</text></annotation><annotation id="37"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="588" length="8"/><text>toxicity</text></annotation><annotation id="38"><infon key="identifier">MESH:D054728</infon><infon key="type">Chemical</infon><location offset="684" length="13"/><text>cucurbitacins</text></annotation><annotation id="39"><infon key="identifier">MESH:D054728</infon><infon key="type">Chemical</infon><location offset="699" length="4"/><text>CBNs</text></annotation><annotation id="40"><infon key="identifier">238</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68387</infon><location offset="739" length="3"/><text>ALK</text></annotation><annotation id="41"><infon key="identifier">238</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68387</infon><location offset="781" length="3"/><text>ALK</text></annotation><annotation id="42"><infon key="identifier">MESH:D000077547</infon><infon key="type">Chemical</infon><location offset="1006" length="10"/><text>Crizotinib</text></annotation><annotation id="43"><infon key="identifier">MESH:D054728</infon><infon key="type">Chemical</infon><location offset="1193" length="3"/><text>CBN</text></annotation><annotation id="44"><infon key="identifier">MESH:D002289</infon><infon key="type">Disease</infon><location offset="1233" length="26"/><text>non-small cell lung cancer</text></annotation><annotation id="45"><infon key="identifier">CVCL:0060</infon><infon key="type">CellLine</infon><location offset="1272" length="5"/><text>H1299</text></annotation><annotation id="46"><infon key="identifier">CVCL:0023</infon><infon key="type">CellLine</infon><location offset="1282" length="4"/><text>A549</text></annotation><annotation id="47"><infon key="identifier">MESH:C041246</infon><infon key="type">Chemical</infon><location offset="1316" length="5"/><text>CBN-B</text></annotation><annotation id="48"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="1353" length="11"/><text>lung cancer</text></annotation><annotation id="49"><infon key="identifier">CVCL:0060</infon><infon key="type">CellLine</infon><location offset="1411" length="5"/><text>H1299</text></annotation><annotation id="50"><infon key="identifier">CVCL:0023</infon><infon key="type">CellLine</infon><location offset="1443" length="4"/><text>A549</text></annotation><annotation id="51"><infon key="identifier">MESH:C041246</infon><infon key="type">Chemical</infon><location offset="1511" length="5"/><text>CBN-B</text></annotation><annotation id="52"><infon key="identifier">238</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68387</infon><location offset="1580" length="3"/><text>ALK</text></annotation><annotation id="53"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="1639" length="11"/><text>lung cancer</text></annotation></passage><relation id="R1"><infon key="score">0.9977</infon><infon key="role1">Chemical|MESH:D054728</infon><infon key="role2">Gene|238</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="11,13"/></relation><relation id="R2"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D008175</infon><infon key="role2">Gene|238</infon><infon key="type">Association</infon><node refid="1" role="2,1"/></relation><relation id="R3"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D054728</infon><infon key="role2">Disease|MESH:D002289</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="16,17"/></relation><relation id="R4"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:C041246</infon><infon key="role2">Gene|238</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="24,25"/></relation><relation id="R5"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C041246</infon><infon key="role2">Disease|MESH:D008175</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="20,21"/></relation></document>
<document><id>37890028</id><passage><infon key="journal">ChemSusChem;2023Oct27 202300948. doi:10.1002/cssc.202300948</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tian N, Comer BM, Medford A, </infon><offset>0</offset><text>Screening and discovery of metal compound active sites for strong and selective adsorption of N2 in air.</text><annotation id="1"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="94" length="2"/><text>N2</text></annotation></passage><passage><infon key="type">abstract</infon><offset>105</offset><text>Photocatalytic nitrogen fixation has the potential to provide a greener route for producing nitrogen-based fertilizers under ambient conditions. Computational screening is a promising route to discover new materials for the nitrogen fixation process, but requires identifying "descriptors" that can be efficiently computed. In this work, we argue that selectivity toward the adsorption of molecular nitrogen and oxygen can act as a key descriptor. A catalyst that can selectively adsorb nitrogen and resist poisoning of oxygen and other molecules present in air has the potential to facilitate the nitrogen fixation process under ambient conditions. We provide a framework for active site screening based on multifidelity density functional theory (DFT) calculations for a range of metal oxides, (oxy)borides, and (oxy)phosphides. The screening methodology consists of initial low-fidelity fixed geometry calculations and a second screening in which more expensive geometry optimizations were performed. The approach identifies promising active sites on several TiO2 polymorph surfaces and a VBO4 surface, and the full nitrogen reduction pathway is studied with the BEEF-vdW and HSE06 functionals on two active sites. The findings suggest that meta-stable TiO2 polymorphs may play a role in photocatalytic nitrogen fixation, and that VBO4 may be an interesting material for further studies.</text><annotation id="19"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="120" length="8"/><text>nitrogen</text></annotation><annotation id="20"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="197" length="8"/><text>nitrogen</text></annotation><annotation id="21"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="329" length="8"/><text>nitrogen</text></annotation><annotation id="22"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="504" length="8"/><text>nitrogen</text></annotation><annotation id="23"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="517" length="6"/><text>oxygen</text></annotation><annotation id="24"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="592" length="8"/><text>nitrogen</text></annotation><annotation id="25"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="625" length="6"/><text>oxygen</text></annotation><annotation id="26"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="703" length="8"/><text>nitrogen</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="887" length="12"/><text>metal oxides</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="901" length="12"/><text>(oxy)borides</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="919" length="15"/><text>(oxy)phosphides</text></annotation><annotation id="30"><infon key="identifier">MESH:C009495</infon><infon key="type">Chemical</infon><location offset="1167" length="4"/><text>TiO2</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1197" length="4"/><text>VBO4</text></annotation><annotation id="32"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="1224" length="8"/><text>nitrogen</text></annotation><annotation id="33"><infon key="identifier">MESH:C009495</infon><infon key="type">Chemical</infon><location offset="1361" length="4"/><text>TiO2</text></annotation><annotation id="34"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="1411" length="8"/><text>nitrogen</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1439" length="4"/><text>VBO4</text></annotation></passage><relation id="R1"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:C009495</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Association</infon><node refid="0" role="12,14"/></relation></document>
<document><id>37890379</id><passage><infon key="journal">Int Immunopharmacol;2023Oct25; 125 (Pt A) 111054. doi:10.1016/j.intimp.2023.111054</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kandekar S, Punatar S, Khattry N, Gokarn A, Jindal N, Mirgh S, Chichra A, Tembhare P, Rane P, Gawde J, Mathew L, Patil A, Chiplunkar S, Kode J, </infon><offset>0</offset><text>Low levels of CD26 on certain cellular subtypes of donor harvest is associated with better clinical outcomes post allogeneic stem cell transplantation through regulation of NF-kappaB pathway and pro-inflammatory cytokines.</text><annotation id="4"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="14" length="4"/><text>CD26</text></annotation><annotation id="5"><infon key="identifier">4790</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="173" length="9"/><text>NF-kappaB</text></annotation><annotation id="6"><infon key="type">Disease</infon><location offset="195" length="3"/><text>pro</text></annotation><annotation id="7"><infon key="identifier">MESH:D000080424</infon><infon key="type">Disease</infon><location offset="199" length="22"/><text>inflammatory cytokines</text></annotation></passage><passage><infon key="type">abstract</infon><offset>223</offset><text>BACKGROUND: We had previously reported significant association of immunoectoenzyme CD26 expression on donor harvest with acute Graft-versus-Host-Disease (aGVHD) in allogeneic stem cell transplantation (ASCT) patients. The current study was aimed at analysing CD26 signaling pathway molecules and understanding their impact on immune reconstitution and clinical outcomes post-ASCT. SUBJECTS AND METHODOLOGY: The study cohort included 26 transplant donors/patients who underwent reduced intensity (n = 21), myeloablative (n = 4) and non-myeloablative (n = 1) ASCT for hematological malignancies. Donors were matched related donors (n = 19) and haploidentical donors (n = 7). Surface expression of CD26, CD73 and ADA, and various immune cell subtypes were assessed by multicolour-flow cytometry. Soluble CD26 (sCD26) and cytokine levels were measured in plasma samples by ELISA and Multiplex Luminex assay, respectively. Immune cells from healthy individuals were stimulated with phytohemagglutinin (PHA) in the presence or absence of CD26 inhibitor. Effect of CD26 inhibition on NF-kappaB localization in PHA stimulated cells was analysed by immunofluorescence and confocal microscopy. Pro-inflammatory cytokines from the culture supernatants were detected with Cytometric bead array flow cytometry. Association of all measured markers with clinical outcomes was evaluated using appropriate statistical tests. RESULTS: CD26 surface expression on PBSC donor harvest cells showed increased risk of chronic GVHD (cGVHD, p = 0.055). Amongst the various immune cell subtypes, decreased B cells in harvest showed significant association with aGVHD (p = 0.022) whereas increased myeloid dendritic cells and CD3+T cells at Day100 in peripheral blood of transplant recipients correlated with cGVHD (p = 0.046) and aGVHD (p = 0.035), respectively. Further, high sCD26 in transplant recipients at Day100 exhibited association with reduced event-free survival (EFS) (p = 0.011). Higher CD26 expression on more &amp; less mature NK cells, naive &amp; post-switched memory B cells and Treg cells in the donor harvest (p &lt; 0.05) led to lower EFS in transplant recipients. Mechanistically, CD26 inhibitor caused dose-dependent reduction in CD26 enzyme activity and in pro-inflammatory cytokine production in post mitogen-stimulated T cell cultures. CONCLUSION: Our study has implicated that lower CD26 expression on immune cell subtypes of the donor stem cell harvest is associated with reduced risk of GVHD and better survival. The underlying mechanism was found to be through NF-kappaB pathway and pro-inflammatory cytokines. Based on these observations, chemically designed or natural resources-based CD26 inhibitors can be explored further in clinical trials for improving ASCT outcomes.</text><annotation id="39"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="306" length="4"/><text>CD26</text></annotation><annotation id="40"><infon key="identifier">MESH:D006086</infon><infon key="type">Disease</infon><location offset="350" length="25"/><text>Graft-versus-Host-Disease</text></annotation><annotation id="41"><infon key="identifier">MESH:D006086</infon><infon key="type">Disease</infon><location offset="377" length="5"/><text>aGVHD</text></annotation><annotation id="42"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="482" length="4"/><text>CD26</text></annotation><annotation id="43"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="789" length="26"/><text>hematological malignancies</text></annotation><annotation id="44"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="918" length="4"/><text>CD26</text></annotation><annotation id="45"><infon key="identifier">4907</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1895</infon><location offset="924" length="4"/><text>CD73</text></annotation><annotation id="46"><infon key="identifier">100</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37249</infon><location offset="933" length="3"/><text>ADA</text></annotation><annotation id="47"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="1024" length="4"/><text>CD26</text></annotation><annotation id="48"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="1255" length="4"/><text>CD26</text></annotation><annotation id="49"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="1281" length="4"/><text>CD26</text></annotation><annotation id="50"><infon key="identifier">4790</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1300" length="9"/><text>NF-kappaB</text></annotation><annotation id="51"><infon key="type">Disease</infon><location offset="1407" length="3"/><text>Pro</text></annotation><annotation id="52"><infon key="identifier">MESH:D000080424</infon><infon key="type">Disease</infon><location offset="1411" length="22"/><text>inflammatory cytokines</text></annotation><annotation id="53"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="1640" length="4"/><text>CD26</text></annotation><annotation id="54"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="1717" length="12"/><text>chronic GVHD</text></annotation><annotation id="55"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="1731" length="5"/><text>cGVHD</text></annotation><annotation id="56"><infon key="identifier">MESH:D006086</infon><infon key="type">Disease</infon><location offset="1857" length="5"/><text>aGVHD</text></annotation><annotation id="57"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="2004" length="5"/><text>cGVHD</text></annotation><annotation id="58"><infon key="identifier">MESH:D006086</infon><infon key="type">Disease</infon><location offset="2026" length="5"/><text>aGVHD</text></annotation><annotation id="59"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="2195" length="4"/><text>CD26</text></annotation><annotation id="60"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="2387" length="4"/><text>CD26</text></annotation><annotation id="61"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="2437" length="4"/><text>CD26</text></annotation><annotation id="62"><infon key="type">Disease</infon><location offset="2465" length="3"/><text>pro</text></annotation><annotation id="63"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="2469" length="12"/><text>inflammatory</text></annotation><annotation id="64"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="2594" length="4"/><text>CD26</text></annotation><annotation id="65"><infon key="type">Disease</infon><location offset="2700" length="4"/><text>GVHD</text></annotation><annotation id="66"><infon key="identifier">4790</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="2775" length="9"/><text>NF-kappaB</text></annotation><annotation id="67"><infon key="type">Disease</infon><location offset="2797" length="3"/><text>pro</text></annotation><annotation id="68"><infon key="identifier">MESH:D000080424</infon><infon key="type">Disease</infon><location offset="2801" length="22"/><text>inflammatory cytokines</text></annotation><annotation id="69"><infon key="identifier">1803</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3279</infon><location offset="2901" length="4"/><text>CD26</text></annotation></passage><relation id="R1"><infon key="score">0.8287</infon><infon key="role1">Gene|1803</infon><infon key="role2">Gene|4790</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.9985</infon><infon key="role1">Disease|MESH:D000080424</infon><infon key="role2">Gene|1803</infon><infon key="type">Association</infon><node refid="1" role="3,0"/></relation><relation id="R3"><infon key="score">0.9978</infon><infon key="role1">Disease|MESH:D002908</infon><infon key="role2">Gene|1803</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="19,18"/></relation><relation id="R4"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D006086</infon><infon key="role2">Gene|1803</infon><infon key="type">Association</infon><node refid="3" role="5,4"/></relation></document>
<document><id>37890729</id><passage><infon key="journal">J Virol Methods;2023Oct25 114836. doi:10.1016/j.jviromet.2023.114836</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Therrien C, Pr&amp;#xe9;vost J, Blais AC, Turcotte S, Gendron-Lepage G, Finzi A, Fafard J, </infon><offset>0</offset><text>Development and Validation of a Highly Specific In-house Chemiluminescent-based Serological Assay for the Detection of Antibodies Directed against the Human Monkeypox Virus.</text></passage><passage><infon key="type">abstract</infon><offset>174</offset></passage></document>
<document><id>37891080</id><passage><infon key="journal">Curr Probl Diagn Radiol;2023Oct22. doi:10.1067/j.cpradiol.2023.10.011</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ladumor H, Vilanilam GK, Ameli S, Pandey I, Vattoth S, </infon><offset>0</offset><text>CT perfusion in stroke: Comparing conventional and RAPID automated software.</text><annotation id="1"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="16" length="6"/><text>stroke</text></annotation></passage><passage><infon key="type">abstract</infon><offset>77</offset><text>CT perfusion (CTP) imaging is increasingly used for routine evaluation of acute ischemic stroke. Knowledge about the different types of CTP software, imaging acquisition and post-processing, and interpretation is crucial for appropriate patient selection for reperfusion therapy. Conventional vendor-provided CTP software differentiates between ischemic penumbra and core infarct using the tiebreaker of critically reduced cerebral blood volume (CBV) values within brain regions showing abnormally elevated time parameters like mean transit time (MTT) or time to peak (TTP). On the other hand, RAPID automated software differentiates between ischemic penumbra and core infarct using the tiebreaker of critically reduced cerebral blood flow (CBF) values within brain regions showing abnormally elevated time to maximum (Tmax). Additionally, RAPID calculates certain indices that confer prognostic value, such as the hypoperfusion and CBV index. In this review, we aim to familiarize the reader with the technical principles of CTP imaging, compare CTP maps generated by conventional and RAPID software, and discuss important thresholds for reperfusion and prognostic indices. Lastly, we discuss common pitfalls to help with the accurate interpretation of CTP imaging.</text><annotation id="7"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="157" length="15"/><text>ischemic stroke</text></annotation><annotation id="8"><infon key="identifier">MESH:D002545</infon><infon key="type">Disease</infon><location offset="422" length="8"/><text>ischemic</text></annotation><annotation id="9"><infon key="identifier">MESH:D007238</infon><infon key="type">Disease</infon><location offset="449" length="7"/><text>infarct</text></annotation><annotation id="10"><infon key="identifier">MESH:D002545</infon><infon key="type">Disease</infon><location offset="719" length="8"/><text>ischemic</text></annotation><annotation id="11"><infon key="identifier">MESH:D007238</infon><infon key="type">Disease</infon><location offset="746" length="7"/><text>infarct</text></annotation></passage></document>
<document><id>37891432</id><passage><infon key="journal">Ann Biomed Eng;2023Oct27. doi:10.1007/s10439-023-03388-7</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ortiz-Paparoni M, Morino C, Bercaw J, Eynde JO', Nightingale R, Bass C', </infon><offset>0</offset><text>Translating Cadaveric Injury Risk to Dummy Injury Risk at Iso-energy.</text><annotation id="1"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="12" length="16"/><text>Cadaveric Injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>70</offset><text>Injury risk assessment based on cadaver data is essential for informing safety standards. The common 'matched-pair' method matches energy-based inputs to translate human response to anthropometric test devices (ATDs). However, this method can result in less conservative human injury risk curves due to intrinsic differences between human and ATDs. Generally, dummies are stiffer than cadavers, so force and displacement cannot be matched simultaneously. Differences in fracture tolerance further influence the dummy risk curve to be less conservative under matched-pair. For example, translating a human lumbar injury risk curve to a dummy of equivalent stiffness using matched-pair resulted in a dummy injury risk over 80% greater than the cadaver at 50% fracture risk. This inevitable increase arises because the dummy continues loading without fracture to attenuate energy beyond the 'matched' cadaver input selected. Human injury response should be translated using an iso-energy approach, as strain energy is well associated with failure in biological tissues. Until cadaver failure, dummy force is related to cadaver force at iso-energy. Beyond cadaver failure, dummy force is related to cadaver force through failure energy. This method does not require perfect cadaver/dummy biofidelity and ensures that energy beyond cadaver failure does not influence the injury risk function.</text><annotation id="6"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="540" length="8"/><text>fracture</text></annotation><annotation id="7"><infon key="identifier">MESH:D055013</infon><infon key="type">Disease</infon><location offset="675" length="13"/><text>lumbar injury</text></annotation><annotation id="8"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="827" length="8"/><text>fracture</text></annotation><annotation id="9"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="918" length="8"/><text>fracture</text></annotation></passage></document>
<document><id>37897040</id><passage><infon key="journal">Plant Commun;2023Oct26 100739. doi:10.1016/j.xplc.2023.100739</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tai L, Wu J, Jing Y, Liu H, Zeng Q, Xu X, Shi S, Wang H, Liu W, Sun J, Han DJ, Chen KM, </infon><offset>0</offset><text>A genome-wide association study uncovers that TaPI4K-2A regulates pre-harvest sprouting in wheat.</text></passage><passage><infon key="type">abstract</infon><offset>98</offset></passage></document>
<document><id>37897390</id><passage><infon key="journal">Dan Med J;2023Sep19; 70 (10) </infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tolstrup JS, Bramming M, Davidsen M, Schramm S, </infon><offset>0</offset><text>Time trends in body mass index distribution in the general population in Denmark from 1987 to 2021.</text></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>INTRODUCTION: The epidemic increase in obesity is well documented and of intensive public health interest. Attention has almost entirely focused on a dichotomous measure of obesity such as how the prevalence of BMI >= 30 kg/m2 has changed over time. Less consideration has been given to how the general distribution of BMI has evolved. METHODS: We used data from the National Health and Morbidity Surveys, which are surveys of the adult Danish population (16 years or above) conducted in 1987, 2000, 2005, 2010, 2013, 2017 and 2021. Participants reported height and weight from which BMI was calculated following correction for systematic bias in self-reported data and non-response. RESULTS: The prevalence of obesity in Denmark increased from 6.1% in 1987 to 18.4% in 2021. A right shift in BMI distribution was observed with positive linear slopes for high and low BMI percentiles and for all socioeconomic groups, although with steeper slopes for high BMI percentiles and for short education. CONCLUSIONS: The right shift in the distribution curve of BMI from 1987 to 2021 with gradually higher values in all BMI percentiles and in all socioeconomic strata show that the increasing obesity prevalence may, to some extent, be attributed to a generally higher BMI in the entire Danish population. FUNDING: None. TRIAL REGISTRATION: Not relevant.</text><annotation id="4"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="139" length="7"/><text>obesity</text></annotation><annotation id="5"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="273" length="7"/><text>obesity</text></annotation><annotation id="6"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="811" length="7"/><text>obesity</text></annotation><annotation id="7"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="1286" length="7"/><text>obesity</text></annotation></passage></document>
<document><id>37897741</id><passage><infon key="journal">J Intellect Disabil;2023Oct28 17446295231208399. doi:10.1177/17446295231208399</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Song X, Ma M, Ma X, Zhao K, Gao L, Wang T, </infon><offset>0</offset><text>Application of the positive and negative affect scale in Chinese children with intellectual disability.</text><annotation id="1"><infon key="identifier">MESH:D008607</infon><infon key="type">Disease</infon><location offset="79" length="23"/><text>intellectual disability</text></annotation></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>The purpose is to test the applicability of the Positive and Negative Affect Scale (PANAS) to Chinese children with intellectual disabilities. The study was done by distributing the questionnaire to the parents through teachers online. Asked the parents to fill out the scale based on their observations of their children's daily life. The correlation coefficients between each item and the total score of the corresponding dimension ranged from 0.52 to 0.77. Factor analysis confirmed the establishment of the PA-NA two-factor structure of affect. A significant positive correlation existed between the NA and the challenging behavior. The Cronbach's alpha coefficient and split-half reliability of the PA scale were 0.87 and 0.85, and the Cronbach's alpha coefficient and split-half reliability of the NA scale were 0.85 and 0.83, respectively, higher than 0.80. It was concluded that PANAS has good applicability in Chinese children with intellectual disabilities.</text><annotation id="5"><infon key="identifier">MESH:D008607</infon><infon key="type">Disease</infon><location offset="220" length="25"/><text>intellectual disabilities</text></annotation><annotation id="6"><infon key="identifier">MESH:C535387</infon><infon key="type">Disease</infon><location offset="808" length="2"/><text>PA</text></annotation><annotation id="7"><infon key="identifier">MESH:D008607</infon><infon key="type">Disease</infon><location offset="1045" length="25"/><text>intellectual disabilities</text></annotation></passage></document>
<document><id>37898091</id><passage><infon key="journal">J Hazard Mater;2023Oct16; 463 132790. doi:10.1016/j.jhazmat.2023.132790</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fu B, Chen G, Cao Y, Hower JC, Huang Y, Huang Y, Chen L, Luo G, Dong L, Yao H, </infon><offset>0</offset><text>Partitioning of selenium from coal to fly ash: The key roles of Fe-bearing minerals and implications for Se potential recovery.</text><annotation id="3"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="16" length="8"/><text>selenium</text></annotation><annotation id="4"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="64" length="2"/><text>Fe</text></annotation><annotation id="5"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="105" length="2"/><text>Se</text></annotation></passage><passage><infon key="type">abstract</infon><offset>128</offset><text>The roles of Ca/Fe phases on selenium (Se) enrichment behavior in fly ash during coal combustion were investigated by examining the Ca/Fe mineralogy of various ash samples, exploring the binding forms of Se in fly ashes, and performing bench-scale adsorption experiments (150-1000 C). The results indicated that Se capture by fly ash is a function of flue gas temperature, particle size, and more importantly, the contents and form of Ca/Fe in combustion ash. Physical condensation/adsorption was mainly determined by temperature and particle size, contributing to less than 25% of total Se in fly ash. The remaining Se in fly ash was captured by chemical reactions of Se with ash components. Calcium in ash mostly was present as Ca-aluminosilicates, Ca-silicates, gypsum, or complex Ca-Al-Si-Fe-O mixed phases. Iron mainly occurred as Fe-silicates and some crystalline minerals including hematite, magnetite, and maghemite. Although adsorption experiments found that only CaO was able to capture SeO2 (g) at high temperature (> 900 C), the roles of lime as well as Fe2+-/Fe3+-silicates (conclusion from previous literature) can be excluded, as inferred from the small amount of CaO in ash and the lack of correlation between Fe-silicate and Se. Sequential extraction experiments and electron microscopy analysis revealed that Fe-bound Se was dominant and iron oxides might be the critical phase for Se retention. Simulated adsorption experiments demonstrated that magnetite had the best Se capture ability among the iron minerals. The extraction of Fe-bound Se from coal fly ash required more stringent conditions than that of physiosorbed-Se and Ca-bound Se. Therefore, pretreatment methods including magnetic separation, flotation, size segregation, etc. were suggested to be used prior to acid leaching. This study can provide scientific basis for developing high-efficiency Se recovery methods or Se emission control techniques for high-Se coal utilization in thermal power stations.</text><annotation id="50"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="144" length="2"/><text>Fe</text></annotation><annotation id="51"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="157" length="8"/><text>selenium</text></annotation><annotation id="52"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="167" length="2"/><text>Se</text></annotation><annotation id="53"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="263" length="2"/><text>Fe</text></annotation><annotation id="54"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="332" length="2"/><text>Se</text></annotation><annotation id="55"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="440" length="2"/><text>Se</text></annotation><annotation id="56"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="566" length="2"/><text>Fe</text></annotation><annotation id="57"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="716" length="2"/><text>Se</text></annotation><annotation id="58"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="745" length="2"/><text>Se</text></annotation><annotation id="59"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="797" length="2"/><text>Se</text></annotation><annotation id="60"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="821" length="7"/><text>Calcium</text></annotation><annotation id="61"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="858" length="19"/><text>Ca-aluminosilicates</text></annotation><annotation id="62"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="879" length="12"/><text>Ca-silicates</text></annotation><annotation id="63"><infon key="identifier">MESH:D002133</infon><infon key="type">Chemical</infon><location offset="893" length="6"/><text>gypsum</text></annotation><annotation id="64"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="912" length="5"/><text>Ca-Al</text></annotation><annotation id="65"><infon key="identifier">MESH:D012825</infon><infon key="type">Chemical</infon><location offset="918" length="2"/><text>Si</text></annotation><annotation id="66"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="921" length="3"/><text>Fe-</text></annotation><annotation id="67"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="940" length="4"/><text>Iron</text></annotation><annotation id="68"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="964" length="12"/><text>Fe-silicates</text></annotation><annotation id="69"><infon key="identifier">MESH:C000499</infon><infon key="type">Chemical</infon><location offset="1017" length="8"/><text>hematite</text></annotation><annotation id="70"><infon key="identifier">MESH:D052203</infon><infon key="type">Chemical</infon><location offset="1027" length="9"/><text>magnetite</text></annotation><annotation id="71"><infon key="identifier">MESH:C000499</infon><infon key="type">Chemical</infon><location offset="1042" length="9"/><text>maghemite</text></annotation><annotation id="72"><infon key="identifier">MESH:C016538</infon><infon key="type">Chemical</infon><location offset="1101" length="3"/><text>CaO</text></annotation><annotation id="73"><infon key="identifier">MESH:D064588</infon><infon key="type">Chemical</infon><location offset="1125" length="4"/><text>SeO2</text></annotation><annotation id="74"><infon key="identifier">MESH:C016538</infon><infon key="type">Chemical</infon><location offset="1178" length="4"/><text>lime</text></annotation><annotation id="75"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1194" length="4"/><text>Fe2+</text></annotation><annotation id="76"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1200" length="14"/><text>Fe3+-silicates</text></annotation><annotation id="77"><infon key="identifier">MESH:C016538</infon><infon key="type">Chemical</infon><location offset="1307" length="3"/><text>CaO</text></annotation><annotation id="78"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1354" length="11"/><text>Fe-silicate</text></annotation><annotation id="79"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="1370" length="2"/><text>Se</text></annotation><annotation id="80"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1455" length="2"/><text>Fe</text></annotation><annotation id="81"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="1464" length="2"/><text>Se</text></annotation><annotation id="82"><infon key="identifier">MESH:C000499</infon><infon key="type">Chemical</infon><location offset="1484" length="11"/><text>iron oxides</text></annotation><annotation id="83"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="1528" length="2"/><text>Se</text></annotation><annotation id="84"><infon key="identifier">MESH:D052203</infon><infon key="type">Chemical</infon><location offset="1593" length="9"/><text>magnetite</text></annotation><annotation id="85"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="1616" length="2"/><text>Se</text></annotation><annotation id="86"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1645" length="4"/><text>iron</text></annotation><annotation id="87"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1678" length="2"/><text>Fe</text></annotation><annotation id="88"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="1687" length="2"/><text>Se</text></annotation><annotation id="89"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="1769" length="2"/><text>Se</text></annotation><annotation id="90"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="1785" length="2"/><text>Se</text></annotation><annotation id="91"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="2007" length="2"/><text>Se</text></annotation><annotation id="92"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="2030" length="2"/><text>Se</text></annotation><annotation id="93"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="2070" length="2"/><text>Se</text></annotation></passage><relation id="R1"><infon key="score">0.6874</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Chemical|MESH:D012643</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9838</infon><infon key="role1">Chemical|MESH:D012643</infon><infon key="role2">Chemical|MESH:D052203</infon><infon key="type">Association</infon><node refid="1" role="42,41"/></relation><relation id="R3"><infon key="score">0.6261</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Chemical|MESH:D052203</infon><infon key="type">Association</infon><node refid="2" role="24,27"/></relation><relation id="R4"><infon key="score">0.9071</infon><infon key="role1">Chemical|MESH:C016538</infon><infon key="role2">Chemical|MESH:D064588</infon><infon key="type">Association</infon><node refid="3" role="29,30"/></relation><relation id="R5"><infon key="score">0.9901</infon><infon key="role1">Chemical|MESH:C000499</infon><infon key="role2">Chemical|MESH:D012643</infon><infon key="type">Association</infon><node refid="4" role="39,38"/></relation></document>
<document><id>37898444</id><passage><infon key="journal">Neurosci Biobehav Rev;2023Oct26 105431. doi:10.1016/j.neubiorev.2023.105431</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hoy N, Lynch SJ, Waszczuk MA, Reppermund S, Mewton L, </infon><offset>0</offset><text>Transdiagnostic Biomarkers of Mental Illness Across the Lifespan: A Systematic Review Examining the Genetic and Neural Correlates of Latent Transdiagnostic Dimensions of Psychopathology in the General Population.</text><annotation id="1"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="30" length="14"/><text>Mental Illness</text></annotation></passage><passage><infon key="type">abstract</infon><offset>213</offset><text>This systematic review synthesizes evidence from research investigating the biological correlates of latent transdiagnostic dimensions of psychopathology (e.g., the p-factor, internalizing, externalizing) across the lifespan. Eligibility criteria captured genomic and neuroimaging studies investigating general and/or specific dimensions in general population samples across all age groups. MEDLINE, Embase, and PsycINFO were searched for relevant studies published up to March 2023 and 46 studies were selected for inclusion. The results revealed several biological correlates consistently associated with transdiagnostic dimensions of psychopathology, including polygenic scores for ADHD and neuroticism, global surface area and global gray matter volume. Shared and unique associations between symptom dimensions are highlighted, as are potential age-specific differences in biological associations. Findings are interpreted with reference to key methodological differences across studies. The included studies provide compelling evidence that the general dimension of psychopathology reflects common underlying genetic and neurobiological vulnerabilities that are shared across diverse manifestations of mental illness. Substantive interpretations of general psychopathology in the context of genetic and neurobiological evidence are discussed.</text><annotation id="5"><infon key="identifier">MESH:D001289</infon><infon key="type">Disease</infon><location offset="898" length="4"/><text>ADHD</text></annotation><annotation id="6"><infon key="type">Disease</infon><location offset="907" length="11"/><text>neuroticism</text></annotation><annotation id="7"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1421" length="14"/><text>mental illness</text></annotation></passage></document>
<document><id>37899495</id><passage><infon key="journal">Pest Manag Sci;2023Oct29. doi:10.1002/ps.7860</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Coston DJ, Clark SJ, Breeze TD, Field LM, Potts SG, Cook SM, </infon><offset>0</offset><text>Quantifying the impact of Psylliodes chrysocephala injury on the productivity of oilseed rape.</text></passage><passage><infon key="type">abstract</infon><offset>95</offset><text>BACKGROUND: Current European Union and UK legislation prohibits the use of neonicotinoid insecticidal seed treatments in oilseed rape (OSR, Brassica napus). This ban, and the reduction in efficacy of pyrethroid insecticide sprays due to resistance, has exacerbated pest pressure from the cabbage stem flea beetle (Psylliodes chrysocephala) in winter OSR. We quantified the direct impact of P. chrysocephala injury on the productivity of OSR. Leaf area was removed from young plants to simulate differing intensities of adult feeding injury alone or in combination with varying larval infestation levels. RESULTS: OSR can compensate for up to 90% leaf area loss at early growth stages, with no meaningful effect on yield. Significant impacts were observed with high infestations of more than five larvae per plant; plants were shorter, producing fewer flowers and pods, with less seeds per pod which had lower oil content and higher glucosinolate content. Such effects were not recorded when five larvae or fewer were present. CONCLUSION: These data confirm the yield-limiting potential of the larval stages of P. chrysocephala yet suggest that the current action thresholds which trigger insecticide application for both adult and larval stages (25% leaf area loss and five larvae/plant, respectively) are potentially too low as they are below the physiological injury level where plants can fully compensate for damage. Further research in field conditions is needed to define physiological thresholds more accurately as disparity may result in insecticide applications that are unnecessary to protect yield and may in turn exacerbate the development and spread of insecticide resistance in P. chrysocephala. This article is protected by copyright. All rights reserved.</text><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="170" length="26"/><text>neonicotinoid insecticidal</text></annotation><annotation id="5"><infon key="identifier">MESH:D011722</infon><infon key="type">Chemical</infon><location offset="295" length="10"/><text>pyrethroid</text></annotation><annotation id="6"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="1004" length="3"/><text>oil</text></annotation><annotation id="7"><infon key="identifier">MESH:D005961</infon><infon key="type">Chemical</infon><location offset="1027" length="13"/><text>glucosinolate</text></annotation></passage></document>
<document><id>37901947</id><passage><infon key="journal">Stroke;2023Oct30. doi:10.1161/STROKEAHA.123.044297</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">de Kort FAS, Coenen M, Weaver NA, Kuijf HJ, Aben HP, Bae HJ, Bordet R, Camm&amp;#xe0; G, Chen CPLH, Dewenter A, Duering M, Fang R, van der Giessen RS, Hamilton OKL, Hilal S, Huenges Wajer IMC, Kan CN, Kim J, Kim BJ, K&amp;#xf6;hler S, de Kort PLM, Koudstaal PJ, Lim JS, Lopes R, Mok VCT, Staals J, Venketasubramanian N, Verhagen CM, Verhey FRJ, Wardlaw JM, Xu X, Yu KH, Biesbroek JM, Biessels GJ, </infon><offset>0</offset><text>White Matter Hyperintensity Volume and Poststroke Cognition: An Individual Patient Data Pooled Analysis of 9 Ischemic Stroke Cohort Studies.</text><annotation id="1"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="109" length="15"/><text>Ischemic Stroke</text></annotation></passage><passage><infon key="type">abstract</infon><offset>141</offset><text>BACKGROUND: White matter hyperintensities (WMH) are associated with cognitive dysfunction after ischemic stroke. Yet, uncertainty remains about affected domains, the role of other preexisting brain injury, and infarct types in the relation between WMH burden and poststroke cognition. We aimed to disentangle these factors in a large sample of patients with ischemic stroke from different cohorts. METHODS: We pooled and harmonized individual patient data (n=1568) from 9 cohorts, through the Meta VCI Map consortium (www.metavcimap.org). Included cohorts comprised patients with available magnetic resonance imaging and multidomain cognitive assessment &lt;15 months poststroke. In this individual patient data meta-analysis, linear mixed models were used to determine the association between WMH volume and domain-specific cognitive functioning (Z scores; attention and executive functioning, processing speed, language and verbal memory) for the total sample and stratified by infarct type. Preexisting brain injury was accounted for in the multivariable models and all analyses were corrected for the study site as a random effect. RESULTS: In the total sample (67 years [SD, 11.5], 40% female), we found a dose-dependent inverse relationship between WMH volume and poststroke cognitive functioning across all 4 cognitive domains (coefficients ranging from -0.09 [SE, 0.04, P=0.01] for verbal memory to -0.19 [SE, 0.03, P&lt;0.001] for attention and executive functioning). This relation was independent of acute infarct volume and the presence of lacunes and old infarcts. In stratified analyses, the relation between WMH volume and domain-specific functioning was also largely independent of infarct type. CONCLUSIONS: In patients with ischemic stroke, increasing WMH volume is independently associated with worse cognitive functioning across all major domains, regardless of old ischemic lesions and infarct type.</text><annotation id="23"><infon key="identifier">MESH:D056784</infon><infon key="type">Disease</infon><location offset="153" length="29"/><text>White matter hyperintensities</text></annotation><annotation id="24"><infon key="identifier">MESH:D056784</infon><infon key="type">Disease</infon><location offset="184" length="3"/><text>WMH</text></annotation><annotation id="25"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="209" length="21"/><text>cognitive dysfunction</text></annotation><annotation id="26"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="237" length="15"/><text>ischemic stroke</text></annotation><annotation id="27"><infon key="identifier">MESH:D001930</infon><infon key="type">Disease</infon><location offset="333" length="12"/><text>brain injury</text></annotation><annotation id="28"><infon key="identifier">MESH:D007238</infon><infon key="type">Disease</infon><location offset="351" length="7"/><text>infarct</text></annotation><annotation id="29"><infon key="identifier">MESH:D056784</infon><infon key="type">Disease</infon><location offset="389" length="3"/><text>WMH</text></annotation><annotation id="30"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="499" length="15"/><text>ischemic stroke</text></annotation><annotation id="31"><infon key="identifier">MESH:D056784</infon><infon key="type">Disease</infon><location offset="932" length="3"/><text>WMH</text></annotation><annotation id="32"><infon key="identifier">MESH:D007238</infon><infon key="type">Disease</infon><location offset="1118" length="7"/><text>infarct</text></annotation><annotation id="33"><infon key="identifier">MESH:D001930</infon><infon key="type">Disease</infon><location offset="1144" length="12"/><text>brain injury</text></annotation><annotation id="34"><infon key="identifier">MESH:D056784</infon><infon key="type">Disease</infon><location offset="1393" length="3"/><text>WMH</text></annotation><annotation id="35"><infon key="identifier">MESH:D056989</infon><infon key="type">Disease</infon><location offset="1646" length="13"/><text>acute infarct</text></annotation><annotation id="36"><infon key="type">Disease</infon><location offset="1687" length="7"/><text>lacunes</text></annotation><annotation id="37"><infon key="identifier">MESH:D007238</infon><infon key="type">Disease</infon><location offset="1703" length="8"/><text>infarcts</text></annotation><annotation id="38"><infon key="identifier">MESH:D056784</infon><infon key="type">Disease</infon><location offset="1758" length="3"/><text>WMH</text></annotation><annotation id="39"><infon key="identifier">MESH:D007238</infon><infon key="type">Disease</infon><location offset="1833" length="7"/><text>infarct</text></annotation><annotation id="40"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="1877" length="15"/><text>ischemic stroke</text></annotation><annotation id="41"><infon key="identifier">MESH:D056784</infon><infon key="type">Disease</infon><location offset="1905" length="3"/><text>WMH</text></annotation><annotation id="42"><infon key="identifier">MESH:D017202</infon><infon key="type">Disease</infon><location offset="2021" length="16"/><text>ischemic lesions</text></annotation><annotation id="43"><infon key="identifier">MESH:D007238</infon><infon key="type">Disease</infon><location offset="2042" length="7"/><text>infarct</text></annotation></passage></document>
<document><id>37902297</id><passage><infon key="journal">Chem Commun (Camb);2023Oct30. doi:10.1039/d3cc03066k</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Morais AF, Silva IGN, Ferreira BJ, Teixeira AC, Sree SP, Terraschke H, Garcia FA, Breynaert E, Mustafa D, </infon><offset>0</offset><text>Eu3+ doped ZnAl layered double hydroxides as calibrationless, fluorescent sensors for carbonate.</text><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="4"/><text>Eu3+</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="11" length="4"/><text>ZnAl</text></annotation><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="16" length="25"/><text>layered double hydroxides</text></annotation><annotation id="7"><infon key="identifier">MESH:D002254</infon><infon key="type">Chemical</infon><location offset="86" length="9"/><text>carbonate</text></annotation></passage><passage><infon key="type">abstract</infon><offset>97</offset><text>The photoluminescence properties (PL) of Eu3+ hosted in the hydroxide layers of layered double hydroxides (LDHs) enables calibrationless quantification of anions in the interlayers. The concept is demonstrated during the nitrate-to-carbonate ion exchange in Zn2+/Al3+/Eu3+ LDHs and can be implemented as a remote optical sensor to detect intrusion of anions such as Cl- or CO32-.</text><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="138" length="4"/><text>Eu3+</text></annotation><annotation id="20"><infon key="identifier">MESH:C031356</infon><infon key="type">Chemical</infon><location offset="157" length="9"/><text>hydroxide</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="177" length="25"/><text>layered double hydroxides</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="204" length="4"/><text>LDHs</text></annotation><annotation id="23"><infon key="identifier">MESH:D009566</infon><infon key="type">Chemical</infon><location offset="318" length="7"/><text>nitrate</text></annotation><annotation id="24"><infon key="identifier">MESH:D002254</infon><infon key="type">Chemical</infon><location offset="329" length="9"/><text>carbonate</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="355" length="4"/><text>Zn2+</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="360" length="4"/><text>Al3+</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="365" length="4"/><text>Eu3+</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="370" length="4"/><text>LDHs</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="470" length="5"/><text>CO32-</text></annotation></passage><relation id="R1"><infon key="score">0.4552</infon><infon key="role1">Chemical|MESH:D002254</infon><infon key="role2">Chemical|MESH:D009566</infon><infon key="type">Association</infon><node refid="0" role="9,8"/></relation></document>
<document><id>37902647</id><passage><infon key="journal">Chemistry;2023Oct30 202302848. doi:10.1002/chem.202302848</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Maiti A, Elvers BJ, Bera S, Lindl F, Krummenacher I, Ghosh P, Braunschweig H, Yildiz CB, Schulzke C, Korth HG, Jana A, </infon><offset>0</offset><text>Comment on "Disclosing Cyclic(Alkyl)(Amino)Carbenes as a One-Electron Reductant: Synthesis of Acyclic(Amino)(Aryl)Carbene-Based Kekule Diradicaloids".</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="23" length="28"/><text>Cyclic(Alkyl)(Amino)Carbenes</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="101" length="20"/><text>(Amino)(Aryl)Carbene</text></annotation></passage><passage><infon key="type">abstract</infon><offset>151</offset><text>This correspondence addresses a misassignment of an EPR spectrum of 2 in a recent publication (Chem. Eur. J. 2022, 28, e202104567) by Dr. Jana and co-workers. The original authors have prepared this correspondence together with Dr. Korth.</text></passage></document>
<document><id>37902999</id><passage><infon key="journal">Acta Oncol;2023Oct30 1. doi:10.1080/0284186X.2023.2272293</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gram SB, Alosi D, Bagger FO, &amp;#xd8;strup O, von Buchwald C, Friborg J, Wessel I, Vogelius IR, Rohrberg K, Rasmussen JH, </infon><offset>0</offset><text>Clinical implication of genetic intratumor heterogeneity for targeted therapy in head and neck cancer.</text><annotation id="1"><infon key="identifier">MESH:D006258</infon><infon key="type">Disease</infon><location offset="81" length="20"/><text>head and neck cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>103</offset><text>Background: Genomic profiling is increasingly used both in therapeutic decision-making and as inclusion criteria for trials testing targeted therapies. However, the mutational landscape may vary across different areas of a tumor and intratumor heterogeneity will challenge treatments or clinical decisions based on single tumor biopsies. The purpose of this study was to assess the clinical relevance of genetic intratumor heterogeneity in head and neck squamous cell carcinomas (HNSCC) using the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).Materials and methods: This prospective study included 33 whole tumor specimens from 28 patients with primary or recurrent HNSCC referred for surgery. Three tumor blocks were selected from central, semi-peripheral, and peripheral positions, mimicking biopsies in three different locations. Genetic analysis of somatic copy number alterations (SCNAs) was performed on the three biopsies using Oncoscan, focusing on 45 preselected HNSCC genes of interest. Clinical relevance was assessed using the ESCAT score to investigate whether and how treatment decisions would change based on the three biopsies from the same tumor.Results: The SCNAs identified among 45 preselected genes within the three tumor biopsies derived from the same tumor revealed distinct variations. The detected discrepancies could potentially influence treatment approaches or clinical decisions in 36% of the patients if only one tumor biopsy was used. Recurrent tumors exhibited significantly higher variation in SCNAs than primary tumors (p = .024). No significant correlation between tumor size and heterogeneity (p = .7) was observed.Conclusion: In 36% of patients diagnosed with HNSCC, clinically significant intratumor heterogeneity was observed which may have implications for patient management. This finding substantiates the need for future studies that specifically investigate the clinical implications associated with intratumor heterogeneity.</text><annotation id="18"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="326" length="5"/><text>tumor</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="425" length="5"/><text>tumor</text></annotation><annotation id="20"><infon key="identifier">MESH:D000077195</infon><infon key="type">Disease</infon><location offset="543" length="38"/><text>head and neck squamous cell carcinomas</text></annotation><annotation id="21"><infon key="identifier">MESH:D000077195</infon><infon key="type">Disease</infon><location offset="583" length="5"/><text>HNSCC</text></annotation><annotation id="22"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="731" length="5"/><text>tumor</text></annotation><annotation id="23"><infon key="identifier">MESH:D000077195</infon><infon key="type">Disease</infon><location offset="790" length="5"/><text>HNSCC</text></annotation><annotation id="24"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="824" length="5"/><text>tumor</text></annotation><annotation id="25"><infon key="identifier">MESH:D000077195</infon><infon key="type">Disease</infon><location offset="1096" length="5"/><text>HNSCC</text></annotation><annotation id="26"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1281" length="5"/><text>tumor</text></annotation><annotation id="27"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1361" length="5"/><text>tumor</text></annotation><annotation id="28"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1398" length="5"/><text>tumor</text></annotation><annotation id="29"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1567" length="5"/><text>tumor</text></annotation><annotation id="30"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1600" length="6"/><text>tumors</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1670" length="6"/><text>tumors</text></annotation><annotation id="32"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1724" length="5"/><text>tumor</text></annotation><annotation id="33"><infon key="identifier">MESH:D000077195</infon><infon key="type">Disease</infon><location offset="1821" length="5"/><text>HNSCC</text></annotation></passage></document>
<document><id>37903375</id><passage><infon key="journal">J Am Med Inform Assoc;2023Oct31. doi:10.1093/jamia/ocad209</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jeffery AD, Reale C, Faiman J, Borkowski V, Beebe R, Matheny ME, Anders S, </infon><offset>0</offset><text>Inpatient nurses' preferences and decisions with risk information visualization.</text></passage><passage><infon key="type">abstract</infon><offset>81</offset><text>OBJECTIVE: We examined the influence of 4 different risk information formats on inpatient nurses' preferences and decisions with an acute clinical deterioration decision-support system. MATERIALS AND METHODS: We conducted a comparative usability evaluation in which participants provided responses to multiple user interface options in a simulated setting. We collected qualitative data using think aloud methods. We collected quantitative data by asking participants which action they would perform after each time point in 3 different patient scenarios. RESULTS: More participants (n = 6) preferred the probability format over relative risk ratios (n = 2), absolute differences (n = 2), and number of persons out of 100 (n = 0). Participants liked average lines, having a trend graph to supplement the risk estimate, and consistent colors between trend graphs and possible actions. Participants did not like too much text information or the presence of confidence intervals. From a decision-making perspective, use of the probability format was associated with greater concordance in actions taken by participants compared to the other 3 risk information formats. DISCUSSION: By focusing on nurses' preferences and decisions with several risk information display formats and collecting both qualitative and quantitative data, we have provided meaningful insights for the design of clinical decision-support systems containing complex quantitative information. CONCLUSION: This study adds to our knowledge of presenting risk information to nurses within clinical decision-support systems. We encourage those developing risk-based systems for inpatient nurses to consider expressing risk in a probability format and include a graph (with average line) to display the patient's recent trends.</text></passage></document>
<document><id>37903726</id><passage><infon key="journal">Histopathology;2023Oct30. doi:10.1111/his.15081</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Na HY, Kim JH, Kim H, Cho JY, Han HS, Jang ES, Kim JW, Jeong SH, Heo J, Kim JW, Kim JW, Ahn S, </infon><offset>0</offset><text>Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.</text><annotation id="1"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="26" length="42"/><text>combined hepatocellular-cholangiocarcinoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>123</offset><text>Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare type of liver tumour that exhibits both hepatocytic and biliary differentiation within the same tumour. The histology and genomic alterations of recurrent/metastatic cHCC-CC are poorly understood. We selected six patients with cHCC-CC whose recurrent or metastatic tumours were histologically confirmed. Four patients with classic cHCC-CCs and two with intermediate cell carcinomas (ICs) were included. The clinicopathological features were evaluated, and next-generation sequencing was performed in 17 multiregional and longitudinal tumour samples. The histology of recurrent/metastatic lesions of classic cHCC-CCs was variable: hepatocellular carcinoma (HCC) was observed in one (25.0%) patient, cHCC-CC in one (25.0%) patient, and cholangiocarcinoma (CC) in two (50.0%) patients. Among 13 samples from four classic cHCC-CC patients, the most frequent pathological variants were TP53 (46.2%), TERT promoter (38.5%), ARID1A mutations (23.1%), and MET amplification (30.8%). In the sequencing analysis of each HCC and CC component, three (75.0%) of the four classic cHCC-CCs shared pathogenic variants. A large proportion of mutations, both pathogenic and those of undetermined significance, were shared by each HCC and CC component. Regarding ICs, the ATM mutation was detected in one patient. In conclusion, the histology of recurrent/metastatic cHCC-CCs was heterogeneous. Genomic profiling of classic cHCC-CCs revealed similar genomic alterations to those of HCC. Considerable overlapping genomic alterations in each HCC and CC component were observed, suggesting a monoclonal origin. Genetic alterations in ICs were different from those in either HCC or CC, suggesting the distinct nature of this tumour.</text><annotation id="44"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="123" length="42"/><text>Combined hepatocellular-cholangiocarcinoma</text></annotation><annotation id="45"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="167" length="7"/><text>cHCC-CC</text></annotation><annotation id="46"><infon key="identifier">MESH:D008113</infon><infon key="type">Disease</infon><location offset="194" length="12"/><text>liver tumour</text></annotation><annotation id="47"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="282" length="6"/><text>tumour</text></annotation><annotation id="48"><infon key="identifier">MESH:D000092182</infon><infon key="type">Disease</infon><location offset="341" length="10"/><text>metastatic</text></annotation><annotation id="49"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="352" length="7"/><text>cHCC-CC</text></annotation><annotation id="50"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="413" length="7"/><text>cHCC-CC</text></annotation><annotation id="51"><infon key="identifier">MESH:D000092182</infon><infon key="type">Disease</infon><location offset="440" length="10"/><text>metastatic</text></annotation><annotation id="52"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="451" length="7"/><text>tumours</text></annotation><annotation id="53"><infon key="type">Disease</infon><location offset="517" length="8"/><text>cHCC-CCs</text></annotation><annotation id="54"><infon key="identifier">MESH:D002280</infon><infon key="type">Disease</infon><location offset="539" length="28"/><text>intermediate cell carcinomas</text></annotation><annotation id="55"><infon key="identifier">MESH:D002280</infon><infon key="type">Disease</infon><location offset="569" length="3"/><text>ICs</text></annotation><annotation id="56"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="720" length="6"/><text>tumour</text></annotation><annotation id="57"><infon key="identifier">MESH:D000092182</infon><infon key="type">Disease</infon><location offset="763" length="10"/><text>metastatic</text></annotation><annotation id="58"><infon key="type">Disease</infon><location offset="793" length="8"/><text>cHCC-CCs</text></annotation><annotation id="59"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="816" length="24"/><text>hepatocellular carcinoma</text></annotation><annotation id="60"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="842" length="3"/><text>HCC</text></annotation><annotation id="61"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="884" length="7"/><text>cHCC-CC</text></annotation><annotation id="62"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="920" length="18"/><text>cholangiocarcinoma</text></annotation><annotation id="63"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="940" length="2"/><text>CC</text></annotation><annotation id="64"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="1004" length="7"/><text>cHCC-CC</text></annotation><annotation id="65"><infon key="identifier">7157</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">460</infon><location offset="1067" length="4"/><text>TP53</text></annotation><annotation id="66"><infon key="identifier">7015</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31141</infon><location offset="1081" length="4"/><text>TERT</text></annotation><annotation id="67"><infon key="identifier">8289</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21216</infon><location offset="1104" length="6"/><text>ARID1A</text></annotation><annotation id="68"><infon key="identifier">79811</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11696</infon><location offset="1134" length="3"/><text>MET</text></annotation><annotation id="69"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="1196" length="3"/><text>HCC</text></annotation><annotation id="70"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="1204" length="2"/><text>CC</text></annotation><annotation id="71"><infon key="type">Disease</infon><location offset="1252" length="8"/><text>cHCC-CCs</text></annotation><annotation id="72"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="1398" length="3"/><text>HCC</text></annotation><annotation id="73"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="1406" length="2"/><text>CC</text></annotation><annotation id="74"><infon key="identifier">MESH:D002280</infon><infon key="type">Disease</infon><location offset="1430" length="3"/><text>ICs</text></annotation><annotation id="75"><infon key="identifier">472</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30952</infon><location offset="1439" length="3"/><text>ATM</text></annotation><annotation id="76"><infon key="identifier">MESH:D000092182</infon><infon key="type">Disease</infon><location offset="1523" length="10"/><text>metastatic</text></annotation><annotation id="77"><infon key="type">Disease</infon><location offset="1534" length="8"/><text>cHCC-CCs</text></annotation><annotation id="78"><infon key="type">Disease</infon><location offset="1591" length="8"/><text>cHCC-CCs</text></annotation><annotation id="79"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="1649" length="3"/><text>HCC</text></annotation><annotation id="80"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="1707" length="3"/><text>HCC</text></annotation><annotation id="81"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="1715" length="2"/><text>CC</text></annotation><annotation id="82"><infon key="identifier">MESH:D002280</infon><infon key="type">Disease</infon><location offset="1798" length="3"/><text>ICs</text></annotation><annotation id="83"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="1838" length="3"/><text>HCC</text></annotation><annotation id="84"><infon key="identifier">MESH:D018281</infon><infon key="type">Disease</infon><location offset="1845" length="2"/><text>CC</text></annotation><annotation id="85"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1888" length="6"/><text>tumour</text></annotation></passage><relation id="R1"><infon key="score">0.6721</infon><infon key="role1">Disease|MESH:D018281</infon><infon key="role2">Gene|7015</infon><infon key="type">Association</infon><node refid="0" role="21,23"/></relation><relation id="R2"><infon key="score">0.9987</infon><infon key="role1">Disease|MESH:D018281</infon><infon key="role2">Gene|7157</infon><infon key="type">Association</infon><node refid="1" role="21,22"/></relation><relation id="R3"><infon key="score">0.9982</infon><infon key="role1">Disease|MESH:D018281</infon><infon key="role2">Gene|8289</infon><infon key="type">Association</infon><node refid="2" role="21,24"/></relation><relation id="R4"><infon key="score">0.9983</infon><infon key="role1">Disease|MESH:D002280</infon><infon key="role2">Gene|472</infon><infon key="type">Association</infon><node refid="3" role="31,32"/></relation><relation id="R5"><infon key="score">0.9976</infon><infon key="role1">Disease|MESH:D018281</infon><infon key="role2">Gene|79811</infon><infon key="type">Association</infon><node refid="4" role="21,25"/></relation></document>
<document><id>37904077</id><passage><infon key="journal">Acta Neurol Belg;2023Oct30. doi:10.1007/s13760-023-02412-w</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ers&amp;#xf6;z AS, Ya&amp;#x15f;arg&amp;#xfc;n D&amp;#xd6;, M&amp;#x131;s&amp;#x131;rl&amp;#x131; CH, </infon><offset>0</offset><text>Development of RISS in two patients with NMOSD undergoing rituximab treatment: a case report.</text><annotation id="3"><infon key="type">Disease</infon><location offset="15" length="4"/><text>RISS</text></annotation><annotation id="4"><infon key="type">Disease</infon><location offset="41" length="5"/><text>NMOSD</text></annotation><annotation id="5"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="58" length="9"/><text>rituximab</text></annotation></passage><passage><infon key="type">abstract</infon><offset>94</offset></passage></document>
<document><id>37905127</id><passage><infon key="journal">bioRxiv;2023Oct17. doi:10.1101/2023.10.17.562754</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614930</infon><infon key="type">title</infon><infon key="authors">Safa BN, Fraticelli Guzm&amp;#xe1;n NS, Li G, Stamer WD, Feola AJ, Ethier CR, </infon><offset>0</offset><text>A Histomorphometric and Computational Investigation of the Stabilizing Role of Pectinate Ligaments in the Aqueous Outflow Pathway.</text></passage><passage><infon key="type">abstract</infon><offset>131</offset><text>Murine models are commonly used to study glaucoma, the leading cause of irreversible blindness in humans. Blindness in glaucoma is associated with intraocular pressure (IOP), which is generated and regulated by the tissues of the aqueous outflow pathway. One of the main components of the aqueous humor pathway are the pectinate ligaments (PLs) that connect iris and trabecular meshwork at the anterior chamber angle. However, their role in helping maintain the biomechanical stability of murine aqueous outflow pathway is unknown, thus motivating this study. In this work, we conducted histomorphometric analysis and optical coherence tomographic-imaging-based finite element (FE) modeling on three age cohorts of C57BL/6 mice: 'young' (2-6 months), 'middle-aged' (11-16 months), and 'elderly' (29-32 months). We also evaluated the age-specific morphometric characteristics of the outflow pathway tissues, specifically the trabecular meshwork (TM) and Schlemm's canal (SC). Further, because of the known pressure-dependent narrowing of the SC lumen in humans and mice, we assessed the sensitivity of the SC lumen area (SCLA) to varying IOPs in age-specific FE models in a physiological range of TM and PL stiffness values. We found age-dependent changes in morphological characteristics of outflow tissues; notably, the PLs were more developed in older compared to younger mice. In addition, our FE analysis demonstrated that the patency of SC in the mouse is highly dependent on the presence of PLs, and that increased IOP caused SC collapse only when TM/PL stiffness was sufficiently low. In particular, young and middle-aged mice showed a lower susceptibility to SC collapse under elevated IOP compared to elderly mice. In conclusion, our study has elucidated the previously unexplored role of PLs in the aqueous outflow pathway, indicating their function in biomechanically supporting TM and SC under elevated IOP.</text><annotation id="9"><infon key="identifier">MESH:D005901</infon><infon key="type">Disease</infon><location offset="172" length="8"/><text>glaucoma</text></annotation><annotation id="10"><infon key="identifier">MESH:D001766</infon><infon key="type">Disease</infon><location offset="216" length="9"/><text>blindness</text></annotation><annotation id="11"><infon key="identifier">MESH:D001766</infon><infon key="type">Disease</infon><location offset="237" length="9"/><text>Blindness</text></annotation><annotation id="12"><infon key="identifier">MESH:D005901</infon><infon key="type">Disease</infon><location offset="250" length="8"/><text>glaucoma</text></annotation><annotation id="13"><infon key="identifier">CVCL:C0MU</infon><infon key="type">CellLine</infon><location offset="846" length="7"/><text>C57BL/6</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1334" length="2"/><text>PL</text></annotation><annotation id="15"><infon key="identifier">MESH:D001261</infon><infon key="type">Disease</infon><location offset="1663" length="11"/><text>SC collapse</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1688" length="2"/><text>PL</text></annotation><annotation id="17"><infon key="identifier">MESH:D001261</infon><infon key="type">Disease</infon><location offset="1798" length="11"/><text>SC collapse</text></annotation></passage></document>
<document><id>37905478</id><passage><infon key="journal">Ecol Food Nutr;2023Oct31 1. doi:10.1080/03670244.2023.2276982</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Abbasi K, Ali P, Barbour V, Benfield T, Bibbins-Domingo K, Erhabor GE, Hancocks S, Horton R, Laybourn-Langton L, Mash R, Sahni P, Sharief WM, Yonga P, Zielinski C, </infon><offset>0</offset><text>Time to Treat the Climate and Nature Crisis as One Indivisible Global Health Emergency.</text><annotation id="1"><infon key="identifier">MESH:D001752</infon><infon key="type">Disease</infon><location offset="37" length="6"/><text>Crisis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>88</offset></passage></document>
<document><id>37905828</id><passage><infon key="journal">Oper Neurosurg (Hagerstown);2023Oct31. doi:10.1227/ons.0000000000000973</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Scagnet M, Agushi R, Mussa F, Genitori L, </infon><offset>0</offset><text>In Reply: Endoscopic Transseptal Approach for Removal of Colloid Cysts: 2-Dimensional Operative Video.</text><annotation id="1"><infon key="identifier">MESH:D056364</infon><infon key="type">Disease</infon><location offset="57" length="13"/><text>Colloid Cysts</text></annotation></passage><passage><infon key="type">abstract</infon><offset>103</offset></passage></document>
<document><id>37906180</id><passage><infon key="journal">J Feline Med Surg;2023Oct; 25 (10) 1098612. doi:10.1177/1098612X231200375</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Enright D, Cole G, Hatfield J, </infon><offset>0</offset><text>Evaluation of endoscopic-assisted feline lateral bulla osteotomy: a cadaveric study.</text></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>OBJECTIVES: The aims of the study were to investigate if feline middle ear anatomy can be visualized using endoscopy via a lateral bulla approach and to determine if scope-assistance increases rates of successful entry into the hypotympanum during feline total ear canal ablation and lateral bulla osteotomy (TECA-LBO). METHODS: A total of 13 feline cadaver heads underwent CT to confirm the absence of pre-existing middle ear disease. For each head, an electronic coin toss was used to determine which ear would undergo endoscope-assisted TECA-LBO; a traditional TECA-LBO without the use of the scope was performed on the contralateral side. In endoscope-assisted procedures, a 1.9 mm scope was intermittently inserted into the tympanic bulla via a lateral bulla approach and used to identify middle ear structures, visualize the bony septum and confirm entry into the hypotympanum. After the bilateral TECA-LBO, the cadaver heads were imaged again and assessed for evidence of entry through the septum. RESULTS: Soft tissue and osseus structures of the middle ear were readily visualized with a 1.9 mm scope. Success rates for entry into the hypotympanum were high between both endoscope-assisted and traditional procedures, with entry confirmed for 12/13 ears in each group. CONCLUSIONS AND RELEVANCE: Endoscope assistance can facilitate the identification and examination of middle ear structures but does not appear to increase the success rate of entry into the hypotympanum during feline TECA-LBO, as entry through the bony septum was consistently accomplished even without scope-assisted visualization. Alternative benefits to scope assistance may exist, and future studies to elucidate its impact on rates of intraoperative trauma to middle ear structures are indicated.</text><annotation id="7"><infon key="type">Disease</infon><location offset="399" length="3"/><text>LBO</text></annotation><annotation id="8"><infon key="identifier">MESH:D010033</infon><infon key="type">Disease</infon><location offset="501" length="18"/><text>middle ear disease</text></annotation><annotation id="9"><infon key="type">Disease</infon><location offset="630" length="3"/><text>LBO</text></annotation><annotation id="10"><infon key="type">Disease</infon><location offset="654" length="3"/><text>LBO</text></annotation><annotation id="11"><infon key="type">Disease</infon><location offset="994" length="3"/><text>LBO</text></annotation><annotation id="12"><infon key="type">Disease</infon><location offset="1585" length="3"/><text>LBO</text></annotation><annotation id="13"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1818" length="9"/><text>trauma to</text></annotation></passage></document>
<document><id>37906530</id><passage><infon key="journal">Psychol Health Med;2023Oct31 1. doi:10.1080/13548506.2023.2277152</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tung WC, Chen Y, Yang X, Lam C, </infon><offset>0</offset><text>Human papillomavirus vaccination: a quantitative cross-sectional study of perceived barriers, influential advisors, and acculturation among Chinese college students aged 18-26 in the USA.</text></passage><passage><infon key="type">abstract</infon><offset>188</offset><text>HPV vaccines are highly effective in preventing HPV-associated cancers; however, HPV vaccination uptake is low among Chinese students studying at U.S. colleges. The purposes of this study were to evaluate (a) perceived barriers and influential others trusted for advice regarding HPV vaccination and (b) factors (i.e. HPV vaccination, acculturation) related to barriers and influential advisors among 18- to 26-year-old Chinese students attending U.S. colleges. We used a cross-sectional design to obtain self-reported data in 2019 from a chain-referral sample of 213 Chinese students. Among 125 respondents who were unvaccinated or partially vaccinated, the reported barriers to receiving the HPV vaccine included: (a) lack of recommendations from a healthcare provider, (b) lack of risk perception for HPV infection, and (c) limited knowledge about HPV vaccination locations. The influential advisors for receiving HPV vaccination were doctors, parents, self, nurses, and same-sex friends. Multivariate analysis revealed that unvaccinated respondents were more likely to report the following barriers to HPV vaccination: (a) lack of recommendations from a healthcare provider, (b) lack of risk perception for HPV infection, (c) limited knowledge about vaccination locations, and (d) uncertainty about effectiveness. High Asian identified respondents were more likely to perceive barriers related to limited knowledge about vaccination locations and uncertainty about effectiveness, while they were less likely to state nurses as influential advisors. Individuals who received one or more HPV vaccine doses were more inclined to view same-sex friends and nurses as influential advisors for HPV vaccination. The influence of culture on preferences for information sources, such as specific providers and provider gender, needs to be addressed. Programs designed to decrease barriers and improve HPV vaccination among Chinese students should also focus on acculturation status.</text><annotation id="4"><infon key="identifier">MESH:D030361</infon><infon key="type">Disease</infon><location offset="236" length="14"/><text>HPV-associated</text></annotation><annotation id="5"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="251" length="7"/><text>cancers</text></annotation><annotation id="6"><infon key="identifier">MESH:D030361</infon><infon key="type">Disease</infon><location offset="992" length="13"/><text>HPV infection</text></annotation><annotation id="7"><infon key="identifier">MESH:D030361</infon><infon key="type">Disease</infon><location offset="1399" length="13"/><text>HPV infection</text></annotation></passage></document>
<document><id>37906904</id><passage><infon key="journal">Rev Med Chil;2022Jun; 150 (6) 705. doi:10.4067/S0034-98872022000600705</infon><infon key="year">2022</infon><infon key="type">title</infon><infon key="authors">Cu&amp;#xe9;llar MC, Guti&amp;#xe9;rrez M, Herrera A, Elgueta F, Wurmann P, Badilla N, Mansilla B, Basualdo J, Vega J, Erlij D, Labarca C, Vergara C, Mezzano V, M&amp;#xe9;ndez I, Stange L, Michalland S, Silva F, Jara A, Goecke A, </infon><offset>0</offset><text>[IGG4-related disease. Report of 52 patients].</text><annotation id="1"><infon key="identifier">MESH:D000077733</infon><infon key="type">Disease</infon><location offset="1" length="20"/><text>IGG4-related disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>47</offset><text>BACKGROUND: IgG4-related disease (IgG4 RD) is an immune-mediated fibro-inflammatory disorder, with tissue infiltration of IgG4+ plasma cells. It causes pseudotumors, tumors, and a wide spectrum of clinical manifestations. AIM: To report the clinical, laboratory, histopathological and treatment characteristics of a group of Chilean patients with IgG4 RD. MATERIAL AND METHODS: Review of medical records of 52 patients aged 18 to 76 years with IgG4 RD seen at six medical centers. RESULTS: Elevated IgG4 serum levels (> 135 mg/dl) were found in 18 of 44 (41%) patients. There was histological confirmation of the disease in 46 patients. The most common sites of involvement were lungs, eyes and kidneys. Eighteen (35%) patients had only one organ involved, 34 (65%) patients had two organs and 13 (25%) patients had three or more organs. The involvement of two organs was significantly more common in men (p &lt; 0.05). In patients with only one organ involvement, the most frequent location was orbital and meningeal. All patients with kidney or lung disease had multiorgan involvement. All patients received corticosteroid therapy, 67% synthetic immunosuppressants, and 16% rituximab. CONCLUSIONS: ER-IgG4 can affect any tissue. Multiorgan involvement was more common in this series, with preference for lungs, eyes and kidneys. An excellent response to steroids is characteristic of the disease, but with a high relapse rate that requires additional immunosuppression.</text><annotation id="13"><infon key="identifier">MESH:D000077733</infon><infon key="type">Disease</infon><location offset="59" length="20"/><text>IgG4-related disease</text></annotation><annotation id="14"><infon key="identifier">MESH:D000077733</infon><infon key="type">Disease</infon><location offset="81" length="7"/><text>IgG4 RD</text></annotation><annotation id="15"><infon key="identifier">MESH:D009810</infon><infon key="type">Disease</infon><location offset="112" length="27"/><text>fibro-inflammatory disorder</text></annotation><annotation id="16"><infon key="identifier">MESH:D006104</infon><infon key="type">Disease</infon><location offset="199" length="12"/><text>pseudotumors</text></annotation><annotation id="17"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="213" length="6"/><text>tumors</text></annotation><annotation id="18"><infon key="identifier">MESH:D000077733</infon><infon key="type">Disease</infon><location offset="394" length="7"/><text>IgG4 RD</text></annotation><annotation id="19"><infon key="identifier">MESH:D000077733</infon><infon key="type">Disease</infon><location offset="491" length="7"/><text>IgG4 RD</text></annotation><annotation id="20"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="1081" length="22"/><text>kidney or lung disease</text></annotation><annotation id="21"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="1220" length="9"/><text>rituximab</text></annotation><annotation id="22"><infon key="identifier">2069</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1097</infon><location offset="1244" length="2"/><text>ER</text></annotation><annotation id="23"><infon key="identifier">MESH:D013256</infon><infon key="type">Chemical</infon><location offset="1400" length="8"/><text>steroids</text></annotation></passage><relation id="R1"><infon key="score">0.8407</infon><infon key="role1">Chemical|MESH:D013256</infon><infon key="role2">Disease|MESH:D000077733</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="11,7"/></relation><relation id="R2"><infon key="score">0.9681</infon><infon key="role1">Chemical|MESH:D000069283</infon><infon key="role2">Disease|MESH:D000077733</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="9,7"/></relation><relation id="R3"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:D000069283</infon><infon key="role2">Disease|MESH:D007674</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="9,8"/></relation></document>
<document><id>37907270</id><passage><infon key="journal">Evid Based Nurs;2023Oct31. doi:10.1136/ebnurs-2023-103788</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mazaheri M, </infon><offset>0</offset><text>Cultivating rapport in telehealth: insights from palliative care.</text></passage><passage><infon key="type">abstract</infon><offset>66</offset></passage></document>
<document><id>37907620</id><passage><infon key="journal">Nat Rev Cancer;2023Oct31. doi:10.1038/s41568-023-00632-z</infon><infon key="year">2023</infon><infon key="article-id_pmc">4715268</infon><infon key="type">title</infon><infon key="authors">Bartman CR, Faubert B, Rabinowitz JD, DeBerardinis RJ, </infon><offset>0</offset><text>Metabolic pathway analysis using stable isotopes in patients with cancer.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="66" length="6"/><text>cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>74</offset><text>Metabolic reprogramming is central to malignant transformation and cancer cell growth. How tumours use nutrients and the relative rates of reprogrammed pathways are areas of intense investigation. Tumour metabolism is determined by a complex and incompletely defined combination of factors intrinsic and extrinsic to cancer cells. This complexity increases the value of assessing cancer metabolism in disease-relevant microenvironments, including in patients with cancer. Stable-isotope tracing is an informative, versatile method for probing tumour metabolism in vivo. It has been used extensively in preclinical models of cancer and, with increasing frequency, in patients with cancer. In this Review, we describe approaches for using in vivo isotope tracing to define fuel preferences and pathway engagement in tumours, along with some of the principles that have emerged from this work. Stable-isotope infusions reported so far have revealed that in humans, tumours use a diverse set of nutrients to supply central metabolic pathways, including the tricarboxylic acid cycle and amino acid synthesis. Emerging data suggest that some activities detected by stable-isotope tracing correlate with poor clinical outcomes and may drive cancer progression. We also discuss current challenges in isotope tracing, including comparisons of in vivo and in vitro models, and opportunities for future discovery in tumour metabolism.</text><annotation id="16"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="141" length="6"/><text>cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="165" length="7"/><text>tumours</text></annotation><annotation id="18"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="271" length="6"/><text>Tumour</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="391" length="6"/><text>cancer</text></annotation><annotation id="20"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="454" length="6"/><text>cancer</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="538" length="6"/><text>cancer</text></annotation><annotation id="22"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="617" length="6"/><text>tumour</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="698" length="6"/><text>cancer</text></annotation><annotation id="24"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="754" length="6"/><text>cancer</text></annotation><annotation id="25"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="888" length="7"/><text>tumours</text></annotation><annotation id="26"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1036" length="7"/><text>tumours</text></annotation><annotation id="27"><infon key="identifier">MESH:D014233</infon><infon key="type">Chemical</infon><location offset="1127" length="18"/><text>tricarboxylic acid</text></annotation><annotation id="28"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1308" length="6"/><text>cancer</text></annotation><annotation id="29"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1479" length="6"/><text>tumour</text></annotation></passage><relation id="R1"><infon key="score">0.9994</infon><infon key="role1">Chemical|MESH:D014233</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Association</infon><node refid="0" role="12,11"/></relation></document>
<document><id>37909374</id><passage><infon key="journal">Phys Chem Chem Phys;2023Nov01. doi:10.1039/d3cp02984k</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Datar SD, Kumar N, Sawant V, Shaikh N, Jha N, </infon><offset>0</offset><text>Solar reduced graphene oxide decorated with manganese dioxide nanostructures for brackish water desalination using asymmetric capacitive deionization.</text><annotation id="3"><infon key="identifier">MESH:C000628730</infon><infon key="type">Chemical</infon><location offset="14" length="14"/><text>graphene oxide</text></annotation><annotation id="4"><infon key="identifier">MESH:C016552</infon><infon key="type">Chemical</infon><location offset="44" length="17"/><text>manganese dioxide</text></annotation><annotation id="5"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="90" length="5"/><text>water</text></annotation></passage><passage><infon key="type">abstract</infon><offset>151</offset><text>Capacitive deionization (CDI) has emerged as a low-cost, reagent-free technique for the desalination of water. This technique is based on the immobilization of dissolved ions on the electrically charged electrodes, by the electrosorption phenomenon. The electrosorption of dissolved ions by using CDI is limited for feed water having a low concentration of salts. To address this problem, we employ an asymmetric capacitive deionization (Asy-CDI) architecture having solar reduced graphene oxide decorated with manganese dioxide nanostructures (SRGO-MnO2 composite). The Asy-CDI possesses an SRGO-MnO2 composite as the cathode and SRGO as the anode with an anion exchange membrane. The cathode formed from the SRGO-MnO2 composite serves the purpose of immobilization of cations, whereas the anode formed from SRGO is responsible for anion removal. The crystal structure, chemical composition and morphology of the as-synthesized SRGO-MnO2 composite electrode materials are characterized by several techniques, confirming that the surface of SRGO is successfully loaded with alpha-MnO2 nanostructures. The electrochemical characterization reveals a high specific capacitance of the as-synthesized SRGO-MnO2 composite (419.9 F g-1) at 100 mV s-1. The Asy-CDI provides a higher salt adsorption capacity (40.2 mg g-1) compared to Sy-CDI (28.3 mg g-1) with feed water containing a salt concentration of 2000 mg L-1. These results indicate that the Asy-CDI may be employed as an efficient technique for the desalination of high concentration salt water.</text><annotation id="27"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="255" length="5"/><text>water</text></annotation><annotation id="28"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="472" length="5"/><text>water</text></annotation><annotation id="29"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="508" length="5"/><text>salts</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="589" length="3"/><text>Asy</text></annotation><annotation id="31"><infon key="identifier">MESH:C000628730</infon><infon key="type">Chemical</infon><location offset="632" length="14"/><text>graphene oxide</text></annotation><annotation id="32"><infon key="identifier">MESH:C016552</infon><infon key="type">Chemical</infon><location offset="662" length="17"/><text>manganese dioxide</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="696" length="4"/><text>SRGO</text></annotation><annotation id="34"><infon key="identifier">MESH:C016552</infon><infon key="type">Chemical</infon><location offset="701" length="4"/><text>MnO2</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="722" length="3"/><text>Asy</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="743" length="4"/><text>SRGO</text></annotation><annotation id="37"><infon key="identifier">MESH:C016552</infon><infon key="type">Chemical</infon><location offset="748" length="4"/><text>MnO2</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="782" length="4"/><text>SRGO</text></annotation><annotation id="39"><infon key="identifier">MESH:C016552</infon><infon key="type">Chemical</infon><location offset="1085" length="4"/><text>MnO2</text></annotation><annotation id="40"><infon key="identifier">MESH:C016552</infon><infon key="type">Chemical</infon><location offset="1352" length="4"/><text>MnO2</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1400" length="3"/><text>Asy</text></annotation><annotation id="42"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="1426" length="4"/><text>salt</text></annotation><annotation id="43"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1508" length="5"/><text>water</text></annotation><annotation id="44"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="1527" length="4"/><text>salt</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1594" length="3"/><text>Asy</text></annotation><annotation id="46"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="1687" length="4"/><text>salt</text></annotation><annotation id="47"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1692" length="5"/><text>water</text></annotation></passage><relation id="R1"><infon key="score">0.9735</infon><infon key="role1">Chemical|MESH:C000628730</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.5653</infon><infon key="role1">Chemical|MESH:C016552</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="1,2"/></relation><relation id="R3"><infon key="score">0.8113</infon><infon key="role1">Chemical|MESH:D012492</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="2" role="5,4"/></relation><relation id="R4"><infon key="score">0.6154</infon><infon key="role1">Chemical|MESH:C000628730</infon><infon key="role2">Chemical|MESH:C016552</infon><infon key="type">Association</infon><node refid="3" role="0,1"/></relation></document>
<document><id>37909729</id><passage><infon key="journal">J Virol;2023Nov01 0093723. doi:10.1128/jvi.00937-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xue J, Zhou D, Zhou J, Du X, Zhang X, Liu X, Ding L, Cheng Z, </infon><offset>0</offset><text>miR-155 facilitates the synergistic replication between avian leukosis virus subgroup J and reticuloendotheliosis virus by targeting a dual pathway.</text><annotation id="1"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="0" length="7"/><text>miR-155</text></annotation></passage><passage><infon key="type">abstract</infon><offset>149</offset><text>Co-infection of avian leukosis virus subgroup J (ALV-J) and reticuloendotheliosis virus (REV) in poultry flocks induces synergistic replication, which worsens immunosuppression, growth inhibition, and increased mortality. However, the synergistic replication mechanism between ALV-J and REV is still not fully understood. We showed that microRNA-155 (miR-155) targets a dual pathway, PRKCI-MAPK8 and TIMP3-MMP2, which interacts with the U3 region of ALV-J and REV to promote synergistic replication between ALV-J and REV. Initially, we found that the RNA levels of ALV-J and REV increased significantly in ALV-J and REV co-infected cells and tissues compared with mono-infected cells and tissues. Next, miRNAomics showed that ALV-J and REV synergistically increased miR-155 levels. In co-infected cells, miR-155 promoted synergistic replication of ALV-J and REV. All structural proteins of the two viruses activated the expression of miR-155, especially gag proteins, rather than insertional activation. Proteomic study of cells co-infected with ALV-J and REV and transfected with miR-155 indicated that miR-155 directly suppressed PRKCI and TIMP3 and that PRKCI directly prevented MAPK8 expression, while TIMP3 directly interfered MMP2 expression. We also found that MAPK8 and MMP2 co-interacted with ALV-J and REV's U3 to enhance synergistic replication. In conclusion, ALV-J and REV synergistically activate miR-155, facilitating the synergistic replication of ALV-J and REV by PRKCI-MAPK8 and TIMP3-MMP2 dual-pathway interaction with the U3 region of ALV-J and REV. This discovery will assist in explaining how two retroviruses replicate synergistically. IMPORTANCE The synergy of two oncogenic retroviruses is an essential phenomenon in nature. The synergistic replication of ALV-J and REV in poultry flocks increases immunosuppression and pathogenicity, extends the tumor spectrum, and accelerates viral evolution, causing substantial economic losses to the poultry industry. However, the mechanism of synergistic replication between ALV-J and REV is still incompletely elusive. We observed that microRNA-155 targets a dual pathway, PRKCI-MAPK8 and TIMP3-MMP2, interacting with the U3 region of ALV-J and REV, enabling synergistic replication. This work gives us new targets to modulate ALV-J and REV's synergistic replication, guiding future research on the mechanism.</text><annotation id="37"><infon key="identifier">MESH:D060085</infon><infon key="type">Disease</infon><location offset="149" length="15"/><text>Co-infection of</text></annotation><annotation id="38"><infon key="type">Disease</infon><location offset="308" length="17"/><text>immunosuppression</text></annotation><annotation id="39"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="486" length="12"/><text>microRNA-155</text></annotation><annotation id="40"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="500" length="7"/><text>miR-155</text></annotation><annotation id="41"><infon key="identifier">5584</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37667</infon><location offset="533" length="5"/><text>PRKCI</text></annotation><annotation id="42"><infon key="identifier">5599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56760</infon><location offset="539" length="5"/><text>MAPK8</text></annotation><annotation id="43"><infon key="identifier">7078</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">36322</infon><location offset="549" length="5"/><text>TIMP3</text></annotation><annotation id="44"><infon key="identifier">4313</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3329</infon><location offset="555" length="4"/><text>MMP2</text></annotation><annotation id="45"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="915" length="7"/><text>miR-155</text></annotation><annotation id="46"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="953" length="7"/><text>miR-155</text></annotation><annotation id="47"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="1083" length="7"/><text>miR-155</text></annotation><annotation id="48"><infon key="identifier">CVCL:0541</infon><infon key="type">CellLine</infon><location offset="1205" length="3"/><text>REV</text></annotation><annotation id="49"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="1230" length="7"/><text>miR-155</text></annotation><annotation id="50"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="1253" length="7"/><text>miR-155</text></annotation><annotation id="51"><infon key="identifier">5584</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37667</infon><location offset="1281" length="5"/><text>PRKCI</text></annotation><annotation id="52"><infon key="identifier">7078</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">36322</infon><location offset="1291" length="5"/><text>TIMP3</text></annotation><annotation id="53"><infon key="identifier">5584</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37667</infon><location offset="1306" length="5"/><text>PRKCI</text></annotation><annotation id="54"><infon key="identifier">5599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56760</infon><location offset="1331" length="5"/><text>MAPK8</text></annotation><annotation id="55"><infon key="identifier">7078</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">36322</infon><location offset="1355" length="5"/><text>TIMP3</text></annotation><annotation id="56"><infon key="identifier">4313</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3329</infon><location offset="1381" length="4"/><text>MMP2</text></annotation><annotation id="57"><infon key="identifier">5599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56760</infon><location offset="1417" length="5"/><text>MAPK8</text></annotation><annotation id="58"><infon key="identifier">4313</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3329</infon><location offset="1427" length="4"/><text>MMP2</text></annotation><annotation id="59"><infon key="type">Gene</infon><location offset="1461" length="8"/><text>REV's U3</text></annotation><annotation id="60"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="1560" length="7"/><text>miR-155</text></annotation><annotation id="61"><infon key="identifier">5584</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37667</infon><location offset="1630" length="5"/><text>PRKCI</text></annotation><annotation id="62"><infon key="identifier">5599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56760</infon><location offset="1636" length="5"/><text>MAPK8</text></annotation><annotation id="63"><infon key="identifier">7078</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">36322</infon><location offset="1646" length="5"/><text>TIMP3</text></annotation><annotation id="64"><infon key="identifier">4313</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3329</infon><location offset="1652" length="4"/><text>MMP2</text></annotation><annotation id="65"><infon key="type">Disease</infon><location offset="1972" length="17"/><text>immunosuppression</text></annotation><annotation id="66"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="2021" length="5"/><text>tumor</text></annotation><annotation id="67"><infon key="identifier">406947</infon><infon key="type">Gene</infon><location offset="2251" length="12"/><text>microRNA-155</text></annotation><annotation id="68"><infon key="identifier">5584</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37667</infon><location offset="2288" length="5"/><text>PRKCI</text></annotation><annotation id="69"><infon key="identifier">5599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56760</infon><location offset="2294" length="5"/><text>MAPK8</text></annotation><annotation id="70"><infon key="identifier">7078</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">36322</infon><location offset="2304" length="5"/><text>TIMP3</text></annotation><annotation id="71"><infon key="identifier">4313</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3329</infon><location offset="2310" length="4"/><text>MMP2</text></annotation></passage><relation id="R1"><infon key="score">0.995</infon><infon key="role1">Gene|406947</infon><infon key="role2">Gene|5584</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="3,5"/></relation><relation id="R2"><infon key="score">0.828</infon><infon key="role1">Gene|406947</infon><infon key="role2">Gene|4313</infon><infon key="type">Association</infon><node refid="1" role="3,8"/></relation><relation id="R3"><infon key="score">0.9984</infon><infon key="role1">Gene|406947</infon><infon key="role2">Gene|7078</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="3,7"/></relation><relation id="R4"><infon key="score">0.9945</infon><infon key="role1">Gene|4313</infon><infon key="role2">Gene|7078</infon><infon key="type">Association</infon><node refid="3" role="8,7"/></relation><relation id="R5"><infon key="score">0.9965</infon><infon key="role1">Gene|5584</infon><infon key="role2">Gene|5599</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="5,6"/></relation></document>
<document><id>37910084</id><passage><infon key="journal">JAMA Psychiatry;2023Nov01. doi:10.1001/jamapsychiatry.2023.3564</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mart&amp;#xed;nez-Gonz&amp;#xe1;lez KG, Morou-Berm&amp;#xfa;dez E, Bux&amp;#xf3; CJ, </infon><offset>0</offset><text>Perinatal Mental Health Outcomes Following Natural Disasters.</text><annotation id="1"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="10" length="13"/><text>Mental Health</text></annotation></passage><passage><infon key="type">abstract</infon><offset>62</offset></passage></document>
<document><id>37910434</id><passage><infon key="journal">Drug Alcohol Rev;2023Nov01. doi:10.1111/dar.13756</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Patsouras M, Riordan BC, Room R, Kuntsche E, </infon><offset>0</offset><text>Support for policies restricting alcohol exposure in films: Does feeding back the amount of alcohol in films increase support?</text><annotation id="2"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="33" length="7"/><text>alcohol</text></annotation><annotation id="3"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="92" length="7"/><text>alcohol</text></annotation></passage><passage><infon key="type">abstract</infon><offset>127</offset><text>INTRODUCTION: Alcohol exposure is common in popular films, and research has demonstrated a link between alcohol exposure and use. The likelihood of implementing specific policies to reduce the amount of film exposure is dependent on the level of public support; however, evidence is currently lacking. This study investigated how supportive people are of film-related alcohol policies and whether providing information about the amount of film exposure increased support. METHODS: Australian adults (N = 252) first provided estimates of how much alcohol they thought were in popular films and then were randomised to either see an infographic about the amount of alcohol in films or not. All participants rated how supportive they were of eight policies. RESULTS: The items 'alcoholic beverages and consumption should not be shown in G or PG rated films' (M = 3.54) and 'alcohol should not be glorified in films' (M = 3.49) were rated significantly higher than the scale's midpoint of 3 (p &lt; 0.001). Participants who were older, female or reported lower alcohol use were more supportive of the policies. Only one policy item, 'information about alcohol sponsorship should be provided' received higher support from those who received the infographic compared to those who did not (M = 3.53 vs. M = 3.05; t(250) = -3.09, p = 0.002). DISCUSSION AND CONCLUSION: Participants were relatively supportive of film alcohol policies. However, providing information about the amount of alcohol in films did not make a difference on the level of support for most film alcohol policies.</text><annotation id="15"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="141" length="7"/><text>Alcohol</text></annotation><annotation id="16"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="231" length="7"/><text>alcohol</text></annotation><annotation id="17"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="495" length="7"/><text>alcohol</text></annotation><annotation id="18"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="673" length="7"/><text>alcohol</text></annotation><annotation id="19"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="790" length="7"/><text>alcohol</text></annotation><annotation id="20"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="998" length="7"/><text>alcohol</text></annotation><annotation id="21"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1181" length="7"/><text>alcohol</text></annotation><annotation id="22"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1272" length="7"/><text>alcohol</text></annotation><annotation id="23"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1533" length="7"/><text>alcohol</text></annotation><annotation id="24"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1602" length="7"/><text>alcohol</text></annotation><annotation id="25"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1683" length="7"/><text>alcohol</text></annotation></passage></document>
<document><id>37910785</id><passage><infon key="journal">ACS Appl Mater Interfaces;2023Nov01. doi:10.1021/acsami.3c09386</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Meijs ZC, Yun HS, Fandre P, Park G, Yoon DK, Isa L, </infon><offset>0</offset><text>Pixelated Physical Unclonable Functions through Capillarity-Assisted Particle Assembly.</text></passage><passage><infon key="type">abstract</infon><offset>88</offset><text>Recent years have shown the need for trustworthy, unclonable, and durable tokens as proof of authenticity for a large variety of products to combat the economic cost of counterfeits. An excellent solution is physical unclonable functions (PUFs), which are intrinsically random objects that cannot be recreated, even if illegitimate manufacturers have access to the same methods. We propose a robust and simple way to make pixelated PUFs through the deposition of a random mixture of fluorescent colloids in a predetermined lattice using capillarity-assisted particle assembly. As the encoding capacity scales exponentially with the number of deposited particles, we can easily achieve encoding capacities above 10700 for sub millimeter scale samples, where the pixelated nature of the PUFs allows for easy and trustworthy readout. Our method allows for the PUFs to be transferred to, and embedded in, a range of transparent materials to protect them from environmental challenges, leading to improved stability and robustness and allowing their implementation for a large number of different applications.</text></passage></document>
<document><id>37911136</id><passage><infon key="journal">Int Dent J (Phila);1893Sep; 14 (9) 655</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109713</infon><infon key="type">title</infon><infon key="authors">Mills GA, </infon><offset>0</offset><text>Riggs's Disease-What Is It, and Can It Be Cured?</text><annotation id="1"><infon key="identifier">MESH:C535623</infon><infon key="type">Disease</infon><location offset="0" length="15"/><text>Riggs's Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>49</offset></passage></document>
<document><id>37911486</id><passage><infon key="journal">Int Dent J (Phila);1890Mar; 11 (3) 191</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110201</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37912186</id><passage><infon key="journal">Int Dent J (Phila);1897Dec; 18 (12) 812</infon><infon key="year">1897</infon><infon key="article-id_pmc">PMC10128695</infon><infon key="type">title</infon><infon key="authors">Bogue EA, </infon><offset>0</offset><text>Dr. G. V. Black's Conclusions Reviewed.</text></passage><passage><infon key="type">abstract</infon><offset>40</offset></passage></document>
<document><id>37912886</id><passage><infon key="journal">Int Dent J (Phila);1901Oct; 22 (10) 732</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153959</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37913236</id><passage><infon key="journal">Int Dent J (Phila);1905Jan; 26 (1) 24</infon><infon key="year">1905</infon><infon key="article-id_pmc">PMC10168723</infon><infon key="type">title</infon><infon key="authors">Smith HC, </infon><offset>0</offset><text>Should the Dental Practitioner Concern Himself with the Chemical Examination of Saliva or Urine?</text></passage><passage><infon key="type">abstract</infon><offset>97</offset></passage></document>
<document><id>37913587</id><passage><infon key="journal">Biochem Biophys Res Commun;2023Oct24; 684 149145. doi:10.1016/j.bbrc.2023.149145</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ogura H, Nakamura T, Ishii T, Saito A, Onodera S, Yamaguchi A, Nishii Y, Azuma T, </infon><offset>0</offset><text>Mechanical stress-induced FGF-2 promotes proliferation and consequently induces osteoblast differentiation in mesenchymal stem cells.</text><annotation id="1"><infon key="identifier">2247</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1521</infon><location offset="26" length="5"/><text>FGF-2</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>Mechanical stimuli serve as crucial regulators of bone mass, promoting bone formation. However, the molecular mechanisms governing how mesenchymal stem cells (MSCs) respond to mechanical cues during their differentiation into osteogenic cells remain elusive. In this study, we found that cyclic stretching enhances MSC proliferation but does not increase the expression of osteoblast-related genes. We further revealed that this proliferative effect is mediated by fibroblast growth factor 2 (FGF-2), synthesized by MSCs in response to mechanical stress. Cell proliferation induced by cyclic stretching was inhibited upon the addition of either U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK), or early growth response 1 (EGR1)-targeting small-hairpin RNA (shRNA), indicating the involvement of the extracellular signal-regulated kinase (ERK)/EGR1 signaling pathway. Osteoblast differentiation, evaluated through ALP activity, osteoblast-related gene expression, and mineralization, was stimulated by recombinant human FGF-2 (rhFGF-2) when applied during the proliferation phase, but not when applied during the differentiation stage alone. Our results suggest that FGF-2 indirectly promotes osteoblast differentiation as a downstream effect of stimulating cell proliferation. For the first time, we demonstrate that cyclic stretching induces MSCs to produce FGF-2, which in turn encourages cell proliferation through an autocrine/paracrine mechanism, consequently leading to osteoblast differentiation.</text><annotation id="16"><infon key="identifier">2247</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1521</infon><location offset="599" length="26"/><text>fibroblast growth factor 2</text></annotation><annotation id="17"><infon key="identifier">2247</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1521</infon><location offset="627" length="5"/><text>FGF-2</text></annotation><annotation id="18"><infon key="identifier">MESH:C113580</infon><infon key="type">Chemical</infon><location offset="779" length="5"/><text>U0126</text></annotation><annotation id="19"><infon key="identifier">5609</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56548</infon><location offset="802" length="39"/><text>mitogen-activated protein kinase kinase</text></annotation><annotation id="20"><infon key="identifier">5609</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56548</infon><location offset="843" length="3"/><text>MEK</text></annotation><annotation id="21"><infon key="identifier">1958</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56394</infon><location offset="852" length="23"/><text>early growth response 1</text></annotation><annotation id="22"><infon key="identifier">1958</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56394</infon><location offset="877" length="4"/><text>EGR1</text></annotation><annotation id="23"><infon key="identifier">5594</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37670</infon><location offset="954" length="37"/><text>extracellular signal-regulated kinase</text></annotation><annotation id="24"><infon key="identifier">5594</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37670</infon><location offset="993" length="3"/><text>ERK</text></annotation><annotation id="25"><infon key="identifier">1958</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56394</infon><location offset="998" length="4"/><text>EGR1</text></annotation><annotation id="26"><infon key="identifier">470</infon><infon key="type">Gene</infon><location offset="1068" length="3"/><text>ALP</text></annotation><annotation id="27"><infon key="identifier">2247</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1521</infon><location offset="1174" length="5"/><text>FGF-2</text></annotation><annotation id="28"><infon key="identifier">2247</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1521</infon><location offset="1321" length="5"/><text>FGF-2</text></annotation><annotation id="29"><infon key="identifier">2247</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1521</infon><location offset="1514" length="5"/><text>FGF-2</text></annotation></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:C113580</infon><infon key="role2">Gene|5609</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="3,4"/></relation><relation id="R2"><infon key="score">0.922</infon><infon key="role1">Gene|1958</infon><infon key="role2">Gene|5594</infon><infon key="type">Association</infon><node refid="1" role="6,8"/></relation><relation id="R3"><infon key="score">0.9753</infon><infon key="role1">Gene|2247</infon><infon key="role2">Gene|470</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="12,11"/></relation></document>
<document><id>37913937</id><passage><infon key="journal">Clin Gastroenterol Hepatol;2023Oct30. doi:10.1016/j.cgh.2023.10.013</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">M&amp;#xe5;rild K, S&amp;#xf6;derling J, Axelrad J, Halfvarson J, Forss A, Ol&amp;#xe9;n O, Ludvigsson JF, SWIBREG Study Group, Olsson M, Myrelid P, Hjortswang H, Bengtsson J, Strid H, Andersson M, J&amp;#xe4;ghult S, Eberhardson M, Nordenvall C, Bj&amp;#xf6;rk J, Rejler M, Grip O, Fagerberg UL, Karling P, </infon><offset>0</offset><text>Histological activity in inflammatory bowel disease and risk of serious infections: A nationwide study.</text><annotation id="2"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="25" length="26"/><text>inflammatory bowel disease</text></annotation><annotation id="3"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="64" length="18"/><text>serious infections</text></annotation></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>BACKGROUND AND AIMS: Individuals with inflammatory bowel disease (IBD) are at increased risk of serious infections, but whether this risk varies by histological disease activity is unclear. METHODS: A national population-based study of 55,626 individuals diagnosed with IBD in 1990-2016 with longitudinal data on ileo-colorectal biopsies followed through 2016. Serious infections were defined as having an inpatient infectious disease diagnosis in the Swedish National Patient Register. We used Cox regression to estimate hazard ratios (HRs) for serious infections in the 12 months following documentation of histologic inflammation (vs. histological remission), adjusting for social and demographic factors, chronic comorbidities, prior IBD-related surgery and hospitalization. We also adjusted for IBD-related medications in sensitivity analyses. RESULTS: With histological inflammation vs. remission, there was 4.62 (95%CI=4.46-4.78) and 2.53 (95%CI=2.36-2.70) serious infections per 100 person-years of follow-up, respectively (adjusted [a]HR=1.59; 95%CI=1.48-1.72). Histological inflammation (vs. remission) were associated with an increased risk of serious infections in ulcerative colitis (UC, aHR=1.68; 95%CI=1.51-1.87) and Crohn's disease (CD, aHR=1.59; 95%CI=1.40-1.80). The aHRs of sepsis and opportunistic infections were 1.66 (95%CI=1.28-2.15) and 1.71 (95%CI=1.22-2.41), respectively. Overall, results were consistent across age groups, sex and education level and remained largely unchanged after adjustment for IBD-related medications (aHR=1.47; 95%CI=1.34-1.61). CONCLUSION: Histological inflammation of IBD was an independent risk factor of serious infections, including sepsis, suggesting that achieving histological remission may reduce infections in IBD.</text><annotation id="31"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="142" length="26"/><text>inflammatory bowel disease</text></annotation><annotation id="32"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="170" length="3"/><text>IBD</text></annotation><annotation id="33"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="200" length="18"/><text>serious infections</text></annotation><annotation id="34"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="374" length="3"/><text>IBD</text></annotation><annotation id="35"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="465" length="18"/><text>Serious infections</text></annotation><annotation id="36"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="520" length="18"/><text>infectious disease</text></annotation><annotation id="37"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="650" length="18"/><text>serious infections</text></annotation><annotation id="38"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="724" length="12"/><text>inflammation</text></annotation><annotation id="39"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="842" length="3"/><text>IBD</text></annotation><annotation id="40"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="904" length="3"/><text>IBD</text></annotation><annotation id="41"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="980" length="12"/><text>inflammation</text></annotation><annotation id="42"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1068" length="18"/><text>serious infections</text></annotation><annotation id="43"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1188" length="12"/><text>inflammation</text></annotation><annotation id="44"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1259" length="18"/><text>serious infections</text></annotation><annotation id="45"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="1281" length="18"/><text>ulcerative colitis</text></annotation><annotation id="46"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="1301" length="2"/><text>UC</text></annotation><annotation id="47"><infon key="identifier">MESH:D003424</infon><infon key="type">Disease</infon><location offset="1336" length="15"/><text>Crohn's disease</text></annotation><annotation id="48"><infon key="identifier">MESH:D003424</infon><infon key="type">Disease</infon><location offset="1353" length="2"/><text>CD</text></annotation><annotation id="49"><infon key="identifier">MESH:D018805</infon><infon key="type">Disease</infon><location offset="1397" length="6"/><text>sepsis</text></annotation><annotation id="50"><infon key="identifier">MESH:D009894</infon><infon key="type">Disease</infon><location offset="1408" length="24"/><text>opportunistic infections</text></annotation><annotation id="51"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="1631" length="3"/><text>IBD</text></annotation><annotation id="52"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1709" length="12"/><text>inflammation</text></annotation><annotation id="53"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="1725" length="3"/><text>IBD</text></annotation><annotation id="54"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1763" length="18"/><text>serious infections</text></annotation><annotation id="55"><infon key="identifier">MESH:D018805</infon><infon key="type">Disease</infon><location offset="1793" length="6"/><text>sepsis</text></annotation><annotation id="56"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1861" length="10"/><text>infections</text></annotation><annotation id="57"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="1875" length="3"/><text>IBD</text></annotation></passage></document>
<document><id>37914287</id><passage><infon key="journal">J Toxicol Sci;2023; 48 (11) 597. doi:10.2131/jts.48.597</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sano R, Ryu K, Sasase T, Shinozaki Y, Teoh SH, Yamaguchi A, Uno K, Maekawa T, Ohta T, Miyajima K, </infon><offset>0</offset><text>Effects of salt supplementation in uninephrectomized KK-Ay mice: Examining the potential of a diabetic kidney disease model.</text><annotation id="3"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="11" length="4"/><text>salt</text></annotation><annotation id="4"><infon key="identifier">CVCL:F844</infon><infon key="type">CellLine</infon><location offset="53" length="5"/><text>KK-Ay</text></annotation><annotation id="5"><infon key="identifier">MESH:D003928</infon><infon key="type">Disease</infon><location offset="94" length="23"/><text>diabetic kidney disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>125</offset><text>Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD). Although current therapeutic strategies for DKD, including sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists, have shown some degree of efficacy, they have failed to completely halt the progression of DKD to ESRD owing to the complexity of DKD pathogenesis. Elucidating the pathophysiological mechanism of DKD is essential for the development of novel therapeutic strategies. In this study, we investigated the pathophysiological characteristics of uninephrectomized (UNx) KK-Ay mice and examined the effects of salt supplementation on the acceleration of renal injury in these mice. UNx KK-Ay mice exhibited pathophysiological renal abnormalities with glomerular and tubulointerstitial fibrosis. Additionally, salt supplementation exacerbated renal injury, particularly tubular injury. These results suggest that UNx KK-Ay mice are useful models for advanced DKD and that salt exacerbates tubular damage in DKD.</text><annotation id="30"><infon key="identifier">MESH:D003928</infon><infon key="type">Disease</infon><location offset="125" length="23"/><text>Diabetic kidney disease</text></annotation><annotation id="31"><infon key="identifier">MESH:D003928</infon><infon key="type">Disease</infon><location offset="150" length="3"/><text>DKD</text></annotation><annotation id="32"><infon key="identifier">MESH:D007676</infon><infon key="type">Disease</infon><location offset="179" length="23"/><text>end-stage renal disease</text></annotation><annotation id="33"><infon key="identifier">MESH:D007676</infon><infon key="type">Disease</infon><location offset="204" length="4"/><text>ESRD</text></annotation><annotation id="34"><infon key="identifier">MESH:D003928</infon><infon key="type">Disease</infon><location offset="255" length="3"/><text>DKD</text></annotation><annotation id="35"><infon key="identifier">246787</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="270" length="30"/><text>sodium-glucose cotransporter-2</text></annotation><annotation id="36"><infon key="identifier">MESH:D003928</infon><infon key="type">Disease</infon><location offset="447" length="3"/><text>DKD</text></annotation><annotation id="37"><infon key="identifier">MESH:D007676</infon><infon key="type">Disease</infon><location offset="454" length="4"/><text>ESRD</text></annotation><annotation id="38"><infon key="identifier">MESH:D003928</infon><infon key="type">Disease</infon><location offset="486" length="3"/><text>DKD</text></annotation><annotation id="39"><infon key="identifier">MESH:D003928</infon><infon key="type">Disease</infon><location offset="552" length="3"/><text>DKD</text></annotation><annotation id="40"><infon key="identifier">CVCL:F844</infon><infon key="type">CellLine</infon><location offset="719" length="5"/><text>KK-Ay</text></annotation><annotation id="41"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="758" length="4"/><text>salt</text></annotation><annotation id="42"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="802" length="12"/><text>renal injury</text></annotation><annotation id="43"><infon key="identifier">CVCL:F844</infon><infon key="type">CellLine</infon><location offset="834" length="5"/><text>KK-Ay</text></annotation><annotation id="44"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="874" length="19"/><text>renal abnormalities</text></annotation><annotation id="45"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="910" length="31"/><text>and tubulointerstitial fibrosis</text></annotation><annotation id="46"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="957" length="4"/><text>salt</text></annotation><annotation id="47"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="990" length="12"/><text>renal injury</text></annotation><annotation id="48"><infon key="identifier">MESH:D000230</infon><infon key="type">Disease</infon><location offset="1017" length="14"/><text>tubular injury</text></annotation><annotation id="49"><infon key="identifier">CVCL:F844</infon><infon key="type">CellLine</infon><location offset="1064" length="5"/><text>KK-Ay</text></annotation><annotation id="50"><infon key="identifier">MESH:D003928</infon><infon key="type">Disease</infon><location offset="1106" length="3"/><text>DKD</text></annotation><annotation id="51"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="1119" length="4"/><text>salt</text></annotation><annotation id="52"><infon key="identifier">MESH:D000230</infon><infon key="type">Disease</infon><location offset="1136" length="14"/><text>tubular damage</text></annotation><annotation id="53"><infon key="identifier">MESH:D003928</infon><infon key="type">Disease</infon><location offset="1154" length="3"/><text>DKD</text></annotation></passage><relation id="R1"><infon key="score">0.7611</infon><infon key="role1">Chemical|MESH:D012492</infon><infon key="role2">Disease|MESH:D003928</infon><infon key="type">Association</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D012492</infon><infon key="role2">Disease|MESH:D000230</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="19,21"/></relation><relation id="R3"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D012492</infon><infon key="role2">Disease|MESH:D007674</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="14,15"/></relation><relation id="R4"><infon key="score">0.9963</infon><infon key="role1">Disease|MESH:D003928</infon><infon key="role2">Gene|246787</infon><infon key="type">Association</infon><node refid="3" role="7,8"/></relation></document>
<document><id>37914637</id><passage><infon key="journal">Nefrologia (Engl Ed);2023Oct30. doi:10.1016/j.nefroe.2023.10.003</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Arriola MT, </infon><offset>0</offset><text>Persistent macroscopic hematuria as presentation of IgA nephropathy.</text><annotation id="2"><infon key="identifier">MESH:D006417</infon><infon key="type">Disease</infon><location offset="23" length="9"/><text>hematuria</text></annotation><annotation id="3"><infon key="identifier">MESH:D005922</infon><infon key="type">Disease</infon><location offset="52" length="15"/><text>IgA nephropathy</text></annotation></passage><passage><infon key="type">abstract</infon><offset>69</offset></passage></document>
<document><id>37916389</id><passage><infon key="journal">Nanoscale;2023Nov02. doi:10.1039/d3nr03267a</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Vanneste F, Faure A, Varache M, Menendez-Miranda M, Dyon-Tafani V, Dussurgey S, Errazuriz-Cerda E, La Padula V, Alcouffe P, Carri&amp;#xe8;re M, Gref R, Laurent F, Josse J, Ladavi&amp;#xe8;re C, </infon><offset>0</offset><text>LipoParticles: a lipid membrane coating onto polymer particles to enhance the internalization in osteoblast cells.</text><annotation id="2"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="17" length="5"/><text>lipid</text></annotation><annotation id="3"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="45" length="7"/><text>polymer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>LipoParticles, core-shell assemblies consisting of a polymer core coated by a lipid membrane, are promising carriers for drug delivery applications with intracellular targets. This is of great interest since it is actually challenging to treat infections involving intracellular bacteria such as bone and joint infections where the bacteria are hidden in osteoblast cells. The present work reports for the first time to the best of our knowledge the proof of enhanced internalization of particles in osteoblast cells thanks to a lipid coating of particles (= LipoParticles). The ca. 300 nm-sized assemblies were elaborated by reorganization of liposomes (composed of DPPC/DPTAP 10/90 mol/mol) onto the surface of poly(lactic-co-glycolic acid) (PLGA) particles, and were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and zetametry. Optimization of these assemblies was also performed by adding poly(ethylene glycol) (PEG) chains on their surface (corresponding to a final formulation of DPPC/DPTAP/DPPE-PEG5000 8/90/2 mol/mol/mol). Interestingly, this provided them colloidal stability after their 20-fold dilution in PBS or cell culture medium, and made possible their freeze-drying without forming aggregates after their re-hydration. Their non-cytotoxicity towards a human osteoblast cell line (MG63) was also demonstrated. The enhanced internalization of LipoParticles in this MG63 cell line, in comparison with PLGA particles, was proven by observations with a confocal laser scanning microscope, as well as by flow cytometry assays. Finally, this efficient internalization of LipoParticles in MG63 cells was confirmed by TEM on ultrathin sections, which also revealed localization close to intracellular Staphylococcus aureus.</text><annotation id="25"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="168" length="7"/><text>polymer</text></annotation><annotation id="26"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="193" length="5"/><text>lipid</text></annotation><annotation id="27"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="359" length="10"/><text>infections</text></annotation><annotation id="28"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="411" length="4"/><text>bone</text></annotation><annotation id="29"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="420" length="16"/><text>joint infections</text></annotation><annotation id="30"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="644" length="5"/><text>lipid</text></annotation><annotation id="31"><infon key="identifier">MESH:D015060</infon><infon key="type">Chemical</infon><location offset="782" length="4"/><text>DPPC</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="787" length="5"/><text>DPTAP</text></annotation><annotation id="33"><infon key="identifier">MESH:D000077182</infon><infon key="type">Chemical</infon><location offset="828" length="29"/><text>poly(lactic-co-glycolic acid)</text></annotation><annotation id="34"><infon key="identifier">MESH:D000077182</infon><infon key="type">Chemical</infon><location offset="859" length="4"/><text>PLGA</text></annotation><annotation id="35"><infon key="identifier">MESH:D011092</infon><infon key="type">Chemical</infon><location offset="1051" length="21"/><text>poly(ethylene glycol)</text></annotation><annotation id="36"><infon key="identifier">MESH:D011092</infon><infon key="type">Chemical</infon><location offset="1074" length="3"/><text>PEG</text></annotation><annotation id="37"><infon key="identifier">MESH:D015060</infon><infon key="type">Chemical</infon><location offset="1144" length="4"/><text>DPPC</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1149" length="5"/><text>DPTAP</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1155" length="12"/><text>DPPE-PEG5000</text></annotation><annotation id="40"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="1275" length="3"/><text>PBS</text></annotation><annotation id="41"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1404" length="12"/><text>cytotoxicity</text></annotation><annotation id="42"><infon key="identifier">CVCL:0426</infon><infon key="type">CellLine</infon><location offset="1455" length="4"/><text>MG63</text></annotation><annotation id="43"><infon key="identifier">CVCL:0426</infon><infon key="type">CellLine</infon><location offset="1538" length="4"/><text>MG63</text></annotation><annotation id="44"><infon key="identifier">MESH:D000077182</infon><infon key="type">Chemical</infon><location offset="1573" length="4"/><text>PLGA</text></annotation><annotation id="45"><infon key="identifier">CVCL:0426</infon><infon key="type">CellLine</infon><location offset="1756" length="4"/><text>MG63</text></annotation></passage><relation id="R1"><infon key="score">0.9797</infon><infon key="role1">Chemical|MESH:D000077182</infon><infon key="role2">Chemical|MESH:D015060</infon><infon key="type">Association</infon><node refid="0" role="10,8"/></relation><relation id="R2"><infon key="score">0.4131</infon><infon key="role1">Chemical|MESH:D008055</infon><infon key="role2">Chemical|MESH:D011108</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,1"/></relation></document>
<document><id>37916745</id><passage><infon key="journal">Cochrane Database Syst Rev;2023Nov02; 11 (11) 008176. doi:10.1002/14651858.CD008176.pub3</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10621004</infon><infon key="type">title</infon><infon key="authors">Colombijn JM, Hooft L, Jun M, Webster AC, Bots ML, Verhaar MC, Vernooij RW, </infon><offset>0</offset><text>Antioxidants for adults with chronic kidney disease.</text><annotation id="1"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="29" length="22"/><text>chronic kidney disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>53</offset><text>BACKGROUND: Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease (CVD) and death. Increased oxidative stress in people with CKD has been implicated as a potential causative factor. Antioxidant therapy decreases oxidative stress and may consequently reduce cardiovascular morbidity and death in people with CKD. This is an update of a Cochrane review first published in 2012. OBJECTIVES: To examine the benefits and harms of antioxidant therapy on death and cardiovascular and kidney endpoints in adults with CKD stages 3 to 5, patients undergoing dialysis, and kidney transplant recipients. SEARCH METHODS: We searched the Cochrane Kidney and Transplant Register of Studies until 15 November 2022 using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal, and ClinicalTrials.gov. SELECTION CRITERIA: We included all randomised controlled trials investigating the use of antioxidants, compared with placebo, usual or standard care, no treatment, or other antioxidants, for adults with CKD on cardiovascular and kidney endpoints. DATA COLLECTION AND ANALYSIS: Titles and abstracts were screened independently by two authors who also performed data extraction using standardised forms. Results were pooled using random effects models and expressed as risk ratios (RR) or mean difference (MD) with 95% confidence intervals (CI). Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. MAIN RESULTS: We included 95 studies (10,468 randomised patients) that evaluated antioxidant therapy in adults with non-dialysis-dependent CKD (31 studies, 5342 patients), dialysis-dependent CKD (41 studies, 3444 patients) and kidney transplant recipients (21 studies, 1529 patients). Two studies enrolled dialysis and non-dialysis patients (153 patients). Twenty-one studies assessed the effects of vitamin antioxidants, and 74 assessed the effects of non-vitamin antioxidants. Overall, the quality of included studies was moderate to low or very low due to unclear or high risk of bias for randomisation, allocation concealment, blinding, and loss to follow-up. Compared with placebo, usual care, or no treatment, antioxidant therapy may have little or no effect on cardiovascular death (8 studies, 3813 patients: RR 0.94, 95% CI 0.64 to 1.40; I2 = 33%; low certainty of evidence) and probably has little to no effect on death (any cause) (45 studies, 7530 patients: RR 0.95, 95% CI 0.82 to 1.11; I2 = 0%; moderate certainty of evidence), CVD (16 studies, 4768 patients: RR 0.79, 95% CI 0.63 to 0.99; I2 = 23%; moderate certainty of evidence), or loss of kidney transplant (graft loss) (11 studies, 1053 patients: RR 0.88, 95% CI 0.67 to 1.17; I2 = 0%; moderate certainty of evidence). Compared with placebo, usual care, or no treatment, antioxidants had little to no effect on the slope of urinary albumin/creatinine ratio (change in UACR) (7 studies, 1286 patients: MD -0.04 mg/mmol, 95% CI -0.55 to 0.47; I2 = 37%; very low certainty of evidence) but the evidence is very uncertain. Antioxidants probably reduced the progression to kidney failure (10 studies, 3201 patients: RR 0.65, 95% CI 0.41 to 1.02; I2 = 41%; moderate certainty of evidence), may improve the slope of estimated glomerular filtration rate (change in eGFR) (28 studies, 4128 patients: MD 3.65 mL/min/1.73 m2, 95% CI 2.81 to 4.50; I2 = 99%; low certainty of evidence), but had uncertain effects on the slope of serum creatinine (change in SCr) (16 studies, 3180 patients: MD -13.35 micromol/L, 95% CI -23.49 to -3.23; I2 = 98%; very low certainty of evidence). Possible safety concerns are an observed increase in the risk of infection (14 studies, 3697 patients: RR 1.30, 95% CI 1.14 to 1.50; I2 = 3%; moderate certainty of evidence) and heart failure (6 studies, 3733 patients: RR 1.40, 95% CI 1.11 to 1.75; I2 = 0; moderate certainty of evidence) among antioxidant users. Results of studies with a low risk of bias or longer follow-ups generally were comparable to the main analyses. AUTHORS' CONCLUSIONS: We found no evidence that antioxidants reduced death or improved kidney transplant outcomes or proteinuria in patients with CKD. Antioxidants likely reduce cardiovascular events and progression to kidney failure and may improve kidney function. Possible concerns are an increased risk of infections and heart failure among antioxidant users. However, most studies were of suboptimal quality and had limited follow-up, and few included people undergoing dialysis or kidney transplant recipients. Furthermore, the large heterogeneity in interventions hampers drawing conclusions on the efficacy and safety of individual agents.</text><annotation id="34"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="65" length="22"/><text>Chronic kidney disease</text></annotation><annotation id="35"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="89" length="3"/><text>CKD</text></annotation><annotation id="36"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="127" length="22"/><text>cardiovascular disease</text></annotation><annotation id="37"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="151" length="3"/><text>CVD</text></annotation><annotation id="38"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="160" length="5"/><text>death</text></annotation><annotation id="39"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="209" length="3"/><text>CKD</text></annotation><annotation id="40"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="370" length="5"/><text>death</text></annotation><annotation id="41"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="391" length="3"/><text>CKD</text></annotation><annotation id="42"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="532" length="5"/><text>death</text></annotation><annotation id="43"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="593" length="3"/><text>CKD</text></annotation><annotation id="44"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="646" length="17"/><text>kidney transplant</text></annotation><annotation id="45"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="1242" length="3"/><text>CKD</text></annotation><annotation id="46"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="1856" length="3"/><text>CKD</text></annotation><annotation id="47"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="1908" length="3"/><text>CKD</text></annotation><annotation id="48"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="1944" length="17"/><text>kidney transplant</text></annotation><annotation id="49"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="2485" length="20"/><text>cardiovascular death</text></annotation><annotation id="50"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="2640" length="5"/><text>death</text></annotation><annotation id="51"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="2758" length="3"/><text>CVD</text></annotation><annotation id="52"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="2874" length="17"/><text>kidney transplant</text></annotation><annotation id="53"><infon key="identifier">MESH:D003404</infon><infon key="type">Chemical</infon><location offset="3126" length="10"/><text>creatinine</text></annotation><annotation id="54"><infon key="identifier">MESH:D051437</infon><infon key="type">Disease</infon><location offset="3354" length="14"/><text>kidney failure</text></annotation><annotation id="55"><infon key="identifier">MESH:D003404</infon><infon key="type">Chemical</infon><location offset="3708" length="10"/><text>creatinine</text></annotation><annotation id="56"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="3917" length="9"/><text>infection</text></annotation><annotation id="57"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="4030" length="13"/><text>heart failure</text></annotation><annotation id="58"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="4347" length="5"/><text>death</text></annotation><annotation id="59"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="4365" length="17"/><text>kidney transplant</text></annotation><annotation id="60"><infon key="identifier">MESH:D011507</infon><infon key="type">Disease</infon><location offset="4395" length="11"/><text>proteinuria</text></annotation><annotation id="61"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="4424" length="3"/><text>CKD</text></annotation><annotation id="62"><infon key="identifier">MESH:D051437</infon><infon key="type">Disease</infon><location offset="4497" length="14"/><text>kidney failure</text></annotation><annotation id="63"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="4588" length="10"/><text>infections</text></annotation><annotation id="64"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="4603" length="13"/><text>heart failure</text></annotation><annotation id="65"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="4765" length="17"/><text>kidney transplant</text></annotation></passage><relation id="R1"><infon key="score">0.903</infon><infon key="role1">Chemical|MESH:D003404</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Association</infon><node refid="0" role="22,23"/></relation><relation id="R2"><infon key="score">0.9818</infon><infon key="role1">Chemical|MESH:D003404</infon><infon key="role2">Disease|MESH:D011507</infon><infon key="type">Association</infon><node refid="1" role="22,27"/></relation><relation id="R3"><infon key="score">0.9974</infon><infon key="role1">Chemical|MESH:D003404</infon><infon key="role2">Disease|MESH:D006333</infon><infon key="type">Association</infon><node refid="2" role="22,24"/></relation><relation id="R4"><infon key="score">0.9886</infon><infon key="role1">Chemical|MESH:D003404</infon><infon key="role2">Disease|MESH:D051437</infon><infon key="type">Association</infon><node refid="3" role="22,21"/></relation></document>
<document><id>37917097</id><passage><infon key="journal">Scand J Occup Ther;2023Nov02 1. doi:10.1080/11038128.2023.2271050</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Loudoun FM, Boyle B, Larsson-Lund M, </infon><offset>0</offset><text>Making choices in digital play spaces: Children's experiences.</text></passage><passage><infon key="type">abstract</infon><offset>63</offset><text>BACKGROUND: Digital spaces are rapidly emerging as a space for children to engage in autotelic play. AIM: To explore and describe children's experiences of choice-making in their play in digital spaces from the perspective of children themselves. METHODS: Focus groups were conducted with a total of eight children aged six years of age within their school, in a large city in Ireland. A Mosaic Approach with drawing, cutting, and colouring in was used to elicit the children's voices to ensure their active engagement throughout the data collection. Data was analyzed using focus group analysis. RESULTS: Data analysis revealed three main themes; children enjoy the ability to make choices in their play, that they are often constrained in their ability to make choices, and that they negotiate ways in which they can select options for play in digital spaces. CONCLUSIONS: Findings indicate that children are agentic individuals who are capable of making decisions in their play in digital spaces. This knowledge provides implications for Occupational Therapists to enhance play as an occupation in digital spaces.</text></passage></document>
<document><id>37917447</id><passage><infon key="journal">Psychol Trauma;2023Nov02. doi:10.1037/tra0001608</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liddell BJ, Das P, Malhi GS, Felmingham KL, Outhred T, Cheung J, Den M, Nickerson A, Askovic M, Aroche J, Coello M, Bryant RA, </infon><offset>0</offset><text>Opponent intrinsic brain network connectivity profiles associated with posttraumatic fear and dysphoria symptoms in trauma-exposed refugees.</text><annotation id="2"><infon key="identifier">MESH:C000719212</infon><infon key="type">Disease</infon><location offset="71" length="41"/><text>posttraumatic fear and dysphoria symptoms</text></annotation><annotation id="3"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="116" length="6"/><text>trauma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>141</offset><text>OBJECTIVE: Resting-state functional magnetic resonance imaging (rsfMRI) studies report functional alterations in the connectivity between intrinsic brain networks in posttraumatic stress disorder (PTSD), but PTSD heterogeneity is rarely considered. Evidence points to fear (e.g., reexperiencing) and dysphoria (e.g., withdrawal) symptom factors as important in PTSD presentations, including relating to variable emotion dysregulation patterns. This study, therefore, tested how fear and dysphoria posttraumatic symptoms were differentially associated with core network connectivity and emotion dysregulation behaviors in a large group of trauma-exposed refugees. METHOD: A final sample of 77 trauma-exposed participants completed a rsfMRI scan. Independent component analysis identified active networks and functional network connectivity (FNC) between networks was assessed. Fear and dysphoria posttraumatic symptoms were partially correlated with FNCs, and linear regression models examined relationships with self-reported difficulties in emotion regulation. RESULTS: Twenty-three active networks were identified, eight being in the networks of interest (p &lt; .05 false discovery rate-corrected). Fear and dysphoria symptoms were specifically related to connectivity patterns between two subnetworks of the default mode network (DMN). Fear symptoms were negatively associated with anterior dorsomedial DMN (admDMN) and temporoparietal DMN (tpDMN) connectivity; whereas dysphoria symptoms were positively associated with admDMN-tpDMN connectivity. Additionally, admDMN-tpDMN connectivity was positively predicted by goal-directed emotion dysregulation but negatively predicted by poor emotional clarity. CONCLUSIONS: Fear and dysphoria posttraumatic symptoms showed opponent associations with admDMN and tpDMN connectivity, potentially reflecting patterns of under- and overemotion dysregulation associated with these symptom profiles respectively. Findings highlight the importance of considering posttraumatic heterogeneity when constructing neural models of PTSD. (PsycInfo Database Record (c) 2023 APA, all rights reserved).</text><annotation id="26"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="307" length="29"/><text>posttraumatic stress disorder</text></annotation><annotation id="27"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="338" length="4"/><text>PTSD</text></annotation><annotation id="28"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="349" length="4"/><text>PTSD</text></annotation><annotation id="29"><infon key="identifier">MESH:C000719212</infon><infon key="type">Disease</infon><location offset="409" length="4"/><text>fear</text></annotation><annotation id="30"><infon key="identifier">MESH:D019052</infon><infon key="type">Disease</infon><location offset="441" length="9"/><text>dysphoria</text></annotation><annotation id="31"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="502" length="4"/><text>PTSD</text></annotation><annotation id="32"><infon key="identifier">MESH:D021081</infon><infon key="type">Disease</infon><location offset="553" length="21"/><text>emotion dysregulation</text></annotation><annotation id="33"><infon key="identifier">MESH:C000719212</infon><infon key="type">Disease</infon><location offset="619" length="4"/><text>fear</text></annotation><annotation id="34"><infon key="identifier">MESH:D019052</infon><infon key="type">Disease</infon><location offset="628" length="32"/><text>dysphoria posttraumatic symptoms</text></annotation><annotation id="35"><infon key="identifier">MESH:D021081</infon><infon key="type">Disease</infon><location offset="727" length="31"/><text>emotion dysregulation behaviors</text></annotation><annotation id="36"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="779" length="6"/><text>trauma</text></annotation><annotation id="37"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="833" length="6"/><text>trauma</text></annotation><annotation id="38"><infon key="identifier">MESH:C000719212</infon><infon key="type">Disease</infon><location offset="1017" length="4"/><text>Fear</text></annotation><annotation id="39"><infon key="identifier">MESH:D019052</infon><infon key="type">Disease</infon><location offset="1026" length="32"/><text>dysphoria posttraumatic symptoms</text></annotation><annotation id="40"><infon key="identifier">MESH:C000719212</infon><infon key="type">Disease</infon><location offset="1340" length="4"/><text>Fear</text></annotation><annotation id="41"><infon key="identifier">MESH:D019052</infon><infon key="type">Disease</infon><location offset="1349" length="18"/><text>dysphoria symptoms</text></annotation><annotation id="42"><infon key="identifier">MESH:C000719212</infon><infon key="type">Disease</infon><location offset="1478" length="13"/><text>Fear symptoms</text></annotation><annotation id="43"><infon key="identifier">MESH:D019052</infon><infon key="type">Disease</infon><location offset="1612" length="18"/><text>dysphoria symptoms</text></annotation><annotation id="44"><infon key="identifier">MESH:D021081</infon><infon key="type">Disease</infon><location offset="1772" length="21"/><text>emotion dysregulation</text></annotation><annotation id="45"><infon key="identifier">MESH:C000719212</infon><infon key="type">Disease</infon><location offset="1859" length="4"/><text>Fear</text></annotation><annotation id="46"><infon key="identifier">MESH:D019052</infon><infon key="type">Disease</infon><location offset="1868" length="32"/><text>dysphoria posttraumatic symptoms</text></annotation><annotation id="47"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="2203" length="4"/><text>PTSD</text></annotation></passage></document>
<document><id>37917798</id><passage><infon key="journal">Ocul Immunol Inflamm;2023Nov02 1. doi:10.1080/09273948.2023.2272171</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Watane A, Patel M, Yannuzzi NA, Kombo N, Sridhar J, </infon><offset>0</offset><text>Trends in Immunosuppressive Agent Use for Non-Infectious Uveitis by US Ophthalmologists in Medicare Beneficiaries and Association with Physician-Industry Interactions.</text><annotation id="1"><infon key="identifier">MESH:D014605</infon><infon key="type">Disease</infon><location offset="57" length="7"/><text>Uveitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>168</offset><text>PURPOSE: To report the trends of immunosuppressive drug use for non-infectious uveitis and explore their relationship with industry payments. METHODS: A retrospective review of ophthalmologists reimbursed by Medicare for the administration of adalimumab (ADA), repository corticotropin (RCI), methotrexate (MTX), and mycophenolate mofetil (MMF) between 2014 and 2018. RESULTS: A total of 316 ophthalmologists were reimbursed by Medicare for 1567 ADA, 465 RCI, 1752 MTX, and 12 333 MMF administrations. The number and dollar amount of industry payments were positively associated with ADA and RCI use (P &lt; 0.001). From 2014 to 2018, there was a positive trend in the proportion of ADA (P = 0.007) and RCI (P = 0.007) used and negative trend in the proportion of MMF (P = 0.025) used. CONCLUSION: From 2014 to 2018, the use of ADA and RCI increased while MMF decreased and MTX remained stable. There was a positive association between ADA and RCI use and physician-industry interactions. A causal relationship is not determined.</text><annotation id="25"><infon key="identifier">MESH:D014605</infon><infon key="type">Disease</infon><location offset="247" length="7"/><text>uveitis</text></annotation><annotation id="26"><infon key="identifier">MESH:D000068879</infon><infon key="type">Chemical</infon><location offset="411" length="10"/><text>adalimumab</text></annotation><annotation id="27"><infon key="identifier">MESH:D000068879</infon><infon key="type">Chemical</infon><location offset="423" length="3"/><text>ADA</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="455" length="3"/><text>RCI</text></annotation><annotation id="29"><infon key="identifier">MESH:D008727</infon><infon key="type">Chemical</infon><location offset="461" length="12"/><text>methotrexate</text></annotation><annotation id="30"><infon key="identifier">MESH:D008727</infon><infon key="type">Chemical</infon><location offset="475" length="3"/><text>MTX</text></annotation><annotation id="31"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="485" length="21"/><text>mycophenolate mofetil</text></annotation><annotation id="32"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="508" length="3"/><text>MMF</text></annotation><annotation id="33"><infon key="identifier">MESH:D000068879</infon><infon key="type">Chemical</infon><location offset="614" length="3"/><text>ADA</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="623" length="3"/><text>RCI</text></annotation><annotation id="35"><infon key="identifier">MESH:D008727</infon><infon key="type">Chemical</infon><location offset="633" length="3"/><text>MTX</text></annotation><annotation id="36"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="649" length="3"/><text>MMF</text></annotation><annotation id="37"><infon key="identifier">MESH:D000068879</infon><infon key="type">Chemical</infon><location offset="752" length="3"/><text>ADA</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="760" length="3"/><text>RCI</text></annotation><annotation id="39"><infon key="identifier">MESH:D000068879</infon><infon key="type">Chemical</infon><location offset="848" length="3"/><text>ADA</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="868" length="3"/><text>RCI</text></annotation><annotation id="41"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="929" length="3"/><text>MMF</text></annotation><annotation id="42"><infon key="identifier">MESH:D000068879</infon><infon key="type">Chemical</infon><location offset="993" length="3"/><text>ADA</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1001" length="3"/><text>RCI</text></annotation><annotation id="44"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="1021" length="3"/><text>MMF</text></annotation><annotation id="45"><infon key="identifier">MESH:D008727</infon><infon key="type">Chemical</infon><location offset="1039" length="3"/><text>MTX</text></annotation><annotation id="46"><infon key="identifier">MESH:D000068879</infon><infon key="type">Chemical</infon><location offset="1101" length="3"/><text>ADA</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1109" length="3"/><text>RCI</text></annotation></passage><relation id="R1"><infon key="score">0.9945</infon><infon key="role1">Chemical|MESH:D009173</infon><infon key="role2">Disease|MESH:D014605</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="7,1"/></relation><relation id="R2"><infon key="score">0.6905</infon><infon key="role1">Chemical|MESH:D008727</infon><infon key="role2">Disease|MESH:D014605</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="5,1"/></relation><relation id="R3"><infon key="score">0.9911</infon><infon key="role1">Chemical|MESH:D000068879</infon><infon key="role2">Disease|MESH:D014605</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="2,1"/></relation></document>
<document><id>37918149</id><passage><infon key="journal">Bioorg Chem;2023Oct30; 142 106949. doi:10.1016/j.bioorg.2023.106949</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liu S, Liu X, Xian J, Feng Z, Tian Y, Wang W, Tian X, </infon><offset>0</offset><text>Visualizing intracellular membrane interactions and cell type-specific differentiation in ferroptosis and apoptosis with Boranil-Carbazole derivative.</text><annotation id="2"><infon key="type">Disease</infon><location offset="90" length="11"/><text>ferroptosis</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="121" length="17"/><text>Boranil-Carbazole</text></annotation></passage><passage><infon key="type">abstract</infon><offset>151</offset><text>Intracellular lipid systems play essential roles in various physiological functions and cell growth processes. However, our understanding of the intricate interactions within this system, especially between mitochondria and lipid droplets, is limited, particularly in the context of cancer cells' altered lipid metabolism. To address this, our study introduces an N-B-O BODIPY-hexylcarbazole derivative, named Cz-Boranil, that sets a new benchmark in visualizing these critical interactions. Cz-Boranil's unique capability lies in its ability to display distinct intracellular distribution patterns in both normal and cancer cells, offering nuanced cell type-specific differentiation. More impressively, this probe tracks the coordinated interactions of lipid droplets and mitochondria during the critical processes of ferroptosis and apoptosis. We believe that the innovative capabilities of Cz-Boranil will revolutionize our understanding of intracellular lipid interactions and prove pivotal in identifying and studying cancerous cells.</text><annotation id="17"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="165" length="5"/><text>lipid</text></annotation><annotation id="18"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="375" length="5"/><text>lipid</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="434" length="6"/><text>cancer</text></annotation><annotation id="20"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="456" length="5"/><text>lipid</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="515" length="27"/><text>N-B-O BODIPY-hexylcarbazole</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="561" length="10"/><text>Cz-Boranil</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="643" length="10"/><text>Cz-Boranil</text></annotation><annotation id="24"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="769" length="6"/><text>cancer</text></annotation><annotation id="25"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="905" length="5"/><text>lipid</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="970" length="11"/><text>ferroptosis</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1044" length="10"/><text>Cz-Boranil</text></annotation><annotation id="28"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1109" length="5"/><text>lipid</text></annotation><annotation id="29"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1174" length="9"/><text>cancerous</text></annotation></passage><relation id="R1"><infon key="score">0.9975</infon><infon key="role1">Chemical|MESH:D008055</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Association</infon><node refid="0" role="3,4"/></relation></document>
<document><id>37918499</id><passage><infon key="journal">Eur J Pharmacol;2023Oct31 176173. doi:10.1016/j.ejphar.2023.176173</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gei L, Yan Y, Xing W, Li Q, Chen X, Yan F, Wang Y, Cao Y, Jiang W, RiQi E, Luo D, Zhang Y, Zeng W, Chen D, </infon><offset>0</offset><text>Amiloride alleviates morphine tolerance by suppressing ASIC3-dependent neuroinflammation in the spinal cord.</text><annotation id="4"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="0" length="9"/><text>Amiloride</text></annotation><annotation id="5"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="21" length="8"/><text>morphine</text></annotation><annotation id="6"><infon key="identifier">171209</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20999</infon><location offset="55" length="5"/><text>ASIC3</text></annotation><annotation id="7"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="71" length="17"/><text>neuroinflammation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>BACKGROUND: The use of morphine in clinical medicine is severely constrained by tolerance. Therefore, it is essential to examine pharmacological therapies that suppress the development of morphine tolerance. Amiloride suppressed the expression of inflammatory cytokines by inhibiting microglial activation. Microglia play a crucial role in the establishment of morphine tolerance. Thus, we anticipated that amiloride might suppress the development of morphine tolerance. During this investigation, we assessed the impact of amiloride on mouse morphine tolerance. METHODS: Mice received morphine (10 mg/kg, s.c.) twice daily with intrathecally injected amiloride (0.3 mug/5 mul, 1 mug/5 mul, and 3 mug/5 mul) for nine continuous days. To assess morphine tolerance, mice underwent the tail-flick and hot plate tests. BV-2 cells were used to investigate the mechanism of amiloride. By using Western blotting, real-time PCR, and immunofluorescence labeling methods, the levels of acid-sensing ion channels (ASICs), nuclear factor kappa B (NF-kB) p65, p38 mitogen-activated protein kinase (MAPK) proteins, and neuroinflammation-related cytokines were determined. RESULTS: The levels of ASIC3 in the spinal cord were considerably increased after long-term morphine administration. Amiloride was found to delay the development of tolerance to chronic morphine assessed via tail-flick and hot plate tests. Amiloride reduced microglial activation and downregulated the cytokines IL-1beta and TNF-a by inhibiting ASIC3 in response to morphine. Furthermore, amiloride reduced p38 MAPK phosphorylation and inhibited NF-kappaB expression. CONCLUSIONS: Amiloride effectively reduces chronic morphine tolerance by suppressing microglial activation caused by morphine by inhibiting ASIC3.</text><annotation id="39"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="132" length="8"/><text>morphine</text></annotation><annotation id="40"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="297" length="8"/><text>morphine</text></annotation><annotation id="41"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="317" length="9"/><text>Amiloride</text></annotation><annotation id="42"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="356" length="12"/><text>inflammatory</text></annotation><annotation id="43"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="470" length="8"/><text>morphine</text></annotation><annotation id="44"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="516" length="9"/><text>amiloride</text></annotation><annotation id="45"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="560" length="8"/><text>morphine</text></annotation><annotation id="46"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="633" length="9"/><text>amiloride</text></annotation><annotation id="47"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="652" length="8"/><text>morphine</text></annotation><annotation id="48"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="695" length="8"/><text>morphine</text></annotation><annotation id="49"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="761" length="9"/><text>amiloride</text></annotation><annotation id="50"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="853" length="8"/><text>morphine</text></annotation><annotation id="51"><infon key="identifier">CVCL:0182</infon><infon key="type">CellLine</infon><location offset="924" length="4"/><text>BV-2</text></annotation><annotation id="52"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="977" length="9"/><text>amiloride</text></annotation><annotation id="53"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="1214" length="17"/><text>neuroinflammation</text></annotation><annotation id="54"><infon key="identifier">171209</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20999</infon><location offset="1290" length="5"/><text>ASIC3</text></annotation><annotation id="55"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="1359" length="8"/><text>morphine</text></annotation><annotation id="56"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="1384" length="9"/><text>Amiloride</text></annotation><annotation id="57"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="1453" length="8"/><text>morphine</text></annotation><annotation id="58"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="1507" length="9"/><text>Amiloride</text></annotation><annotation id="59"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1579" length="8"/><text>IL-1beta</text></annotation><annotation id="60"><infon key="identifier">21926</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="1592" length="5"/><text>TNF-a</text></annotation><annotation id="61"><infon key="identifier">171209</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20999</infon><location offset="1612" length="5"/><text>ASIC3</text></annotation><annotation id="62"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="1633" length="8"/><text>morphine</text></annotation><annotation id="63"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="1656" length="9"/><text>amiloride</text></annotation><annotation id="64"><infon key="identifier">26416</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31777</infon><location offset="1674" length="8"/><text>p38 MAPK</text></annotation><annotation id="65"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1713" length="9"/><text>NF-kappaB</text></annotation><annotation id="66"><infon key="identifier">MESH:D000584</infon><infon key="type">Chemical</infon><location offset="1748" length="9"/><text>Amiloride</text></annotation><annotation id="67"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="1786" length="8"/><text>morphine</text></annotation><annotation id="68"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="1852" length="8"/><text>morphine</text></annotation><annotation id="69"><infon key="identifier">171209</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20999</infon><location offset="1875" length="5"/><text>ASIC3</text></annotation></passage><relation id="R1"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D000090862</infon><infon key="role2">Gene|171209</infon><infon key="type">Association</infon><node refid="0" role="3,2"/></relation><relation id="R2"><infon key="score">0.9972</infon><infon key="role1">Chemical|MESH:D000584</infon><infon key="role2">Chemical|MESH:D009020</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:D000584</infon><infon key="role2">Disease|MESH:D000090862</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="0,3"/></relation><relation id="R4"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D000584</infon><infon key="role2">Gene|16176</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="23,24"/></relation><relation id="R5"><infon key="score">0.9624</infon><infon key="role1">Chemical|MESH:D009020</infon><infon key="role2">Gene|21926</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="27,25"/></relation><relation id="R6"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D000584</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="6,7"/></relation><relation id="R7"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D009020</infon><infon key="role2">Gene|171209</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="1,2"/></relation><relation id="R8"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D000584</infon><infon key="role2">Gene|18033</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="28,30"/></relation><relation id="R9"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D000584</infon><infon key="role2">Gene|26416</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="28,29"/></relation><relation id="R10"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D000584</infon><infon key="role2">Gene|21926</infon><infon key="type">Negative_Correlation</infon><node refid="9" role="23,25"/></relation><relation id="R11"><infon key="score">0.768</infon><infon key="role1">Chemical|MESH:D009020</infon><infon key="role2">Gene|16176</infon><infon key="type">Positive_Correlation</infon><node refid="10" role="27,24"/></relation><relation id="R12"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D000584</infon><infon key="role2">Gene|171209</infon><infon key="type">Negative_Correlation</infon><node refid="11" role="0,2"/></relation></document>
<document><id>37918849</id><passage><infon key="journal">BMJ;2023Nov02; 383 2537. doi:10.1136/bmj.p2537</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mahase E, </infon><offset>0</offset><text>NHS must hire more diverse talking therapists to reduce inequalities, says report.</text></passage><passage><infon key="type">abstract</infon><offset>83</offset></passage></document>
<document><id>37919199</id><passage><infon key="journal">Enferm Infecc Microbiol Clin (Engl Ed);2023Oct31. doi:10.1016/j.eimce.2023.05.009</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mart&amp;#xed;nez-Sanz J, Losa-Garc&amp;#xed;a JE, Orozco N, Alastru&amp;#xe9; I, Mascort J, P&amp;#xe9;rez-El&amp;#xed;as MJ, Grupo de Trabajo de Atenci&amp;#xf3;n Compartida en VIH (Sociedad Espa&amp;#xf1;ola de Medicina de Familia y Comunitaria &amp;#x2013; semFYC &amp;#x2013; y Grupo de estudio del SIDA de la Sociedad Espa&amp;#xf1;ola de Enfermedades Infecciosas y Microbiolog&amp;#xed;a Cl&amp;#xed;nica &amp;#x2013; GeSIDA SEIMC), </infon><offset>0</offset><text>Executive summary of the consensus document on the shared care of patients with HIV infection between primary and hospital care.</text><annotation id="1"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="80" length="13"/><text>HIV infection</text></annotation></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>The current reality of the diagnosis and treatment of HIV infection justifies a multidisciplinary and coordinated approach between Primary Care and Hospital Care, contemplating bidirectionality and communication between the two care settings. The consensus document, coordinated by the AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC-GeSIDA) and the Spanish Society of Family and Community Medicine (semFYC), was born out of this need. Here, the recommendations of the four sections that comprise it are summarized: the first deals with aspects of prevention and diagnosis of HIV infection; the second contemplates the clinical care of people living with HIV; the third deals with social factors, including legal and confidentiality issues, quality of life, and the role of NGOs; finally, the fourth block addresses bidirectional and shared training/teaching and research.</text><annotation id="7"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="183" length="13"/><text>HIV infection</text></annotation><annotation id="8"><infon key="identifier">MESH:D000163</infon><infon key="type">Disease</infon><location offset="415" length="4"/><text>AIDS</text></annotation><annotation id="9"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="458" length="19"/><text>Infectious Diseases</text></annotation><annotation id="10"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="753" length="13"/><text>HIV infection</text></annotation><annotation id="11"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="832" length="3"/><text>HIV</text></annotation></passage></document>
<document><id>37919549</id><passage><infon key="journal">Nat Chem Biol;2023Nov02. doi:10.1038/s41589-023-01458-4</infon><infon key="year">2023</infon><infon key="article-id_pmc">4423819</infon><infon key="type">title</infon><infon key="authors">Mason JW, Chow YT, Hudson L, Tutter A, Michaud G, Westphal MV, Shu W, Ma X, Tan ZY, Coley CW, Clemons PA, Bonazzi S, Berst F, Briner K, Liu S, Z&amp;#xe9;cri FJ, Schreiber SL, </infon><offset>0</offset><text>DNA-encoded library-enabled discovery of proximity-inducing small molecules.</text></passage><passage><infon key="type">abstract</infon><offset>77</offset><text>Small molecules that induce protein-protein associations represent powerful tools to modulate cell circuitry. We sought to develop a platform for the direct discovery of compounds able to induce association of any two preselected proteins, using the E3 ligase von Hippel-Lindau (VHL) and bromodomains as test systems. Leveraging the screening power of DNA-encoded libraries (DELs), we synthesized ~1 million DNA-encoded compounds that possess a VHL-targeting ligand, a variety of connectors and a diversity element generated by split-and-pool combinatorial chemistry. By screening our DEL against bromodomains in the presence and absence of VHL, we could identify VHL-bound molecules that simultaneously bind bromodomains. For highly barcode-enriched library members, ternary complex formation leading to bromodomain degradation was confirmed in cells. Furthermore, a ternary complex crystal structure was obtained for our most enriched library member with BRD4BD1 and a VHL complex. Our work provides a foundation for adapting DEL screening to the discovery of proximity-inducing small molecules.</text><annotation id="8"><infon key="identifier">7428</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">465</infon><location offset="337" length="17"/><text>von Hippel-Lindau</text></annotation><annotation id="9"><infon key="identifier">7428</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">465</infon><location offset="356" length="3"/><text>VHL</text></annotation><annotation id="10"><infon key="identifier">7428</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">465</infon><location offset="522" length="3"/><text>VHL</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="662" length="3"/><text>DEL</text></annotation><annotation id="12"><infon key="identifier">7428</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">465</infon><location offset="718" length="3"/><text>VHL</text></annotation><annotation id="13"><infon key="identifier">7428</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">465</infon><location offset="741" length="3"/><text>VHL</text></annotation><annotation id="14"><infon key="identifier">7428</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">465</infon><location offset="1048" length="3"/><text>VHL</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1105" length="3"/><text>DEL</text></annotation></passage></document>
<document><id>37919899</id><passage><infon key="journal">Mol Ther;2023Nov01. doi:10.1016/j.ymthe.2023.10.023</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yao J, Atasheva S, Wagner N, Di Paolo NC, Stewart PL, Shayakhmetov DM, </infon><offset>0</offset><text>Targeted, safe, and efficient gene delivery to human hematopoietic stem and progenitor cells in vivo using the engineered AVID adenovirus vector platform.</text></passage><passage><infon key="type">abstract</infon><offset>155</offset><text>Targeted delivery and cell-type-specific expression of gene editing proteins in various cell types in vivo represent major challenges for all viral and non-viral delivery platforms developed to date. Here, we describe the development and analysis of AVIDs, an engineered adenovirus-based gene delivery platform, that allows for highly targeted, safe, and efficient gene delivery to human hematopoietic stem and progenitor cells (HSPCs) in vivo after intravenous vector administration. Due to a set of refined structural modifications, intravenous administration of AVIDs did not trigger cytokine storm, hepatotoxicity, or thrombocytopenia. Single intravenous administration of AVIDs to humanized mice, grafted with human CD34+ cells, led to up to 20% transduction of CD34+CD38-CD45RA- HSPC subsets in the bone marrow. Importantly, targeted in vivo transduction of CD34+CD38-CD45RA-CD90-CD49f+ subsets, highly enriched for human HSCs, reached up to 19%, which represented a 1900-fold selectivity in gene delivery to HSC-enriched over lineage committed CD34-negative cell populations. Because the AVID platform allows for regulated, cell type-specific expression of gene editing technologies as well as expression of immunomodulatory proteins to ensure persistence of corrected HSCs in vivo, the HSC-targeted AVID platform may enable development of curative therapies through in vivo gene correction in human HSCs after a single intravenous administration.</text><annotation id="15"><infon key="type">Disease</infon><location offset="405" length="5"/><text>AVIDs</text></annotation><annotation id="16"><infon key="type">Disease</infon><location offset="720" length="5"/><text>AVIDs</text></annotation><annotation id="17"><infon key="type">Disease</infon><location offset="758" length="14"/><text>hepatotoxicity</text></annotation><annotation id="18"><infon key="identifier">MESH:D013921</infon><infon key="type">Disease</infon><location offset="777" length="16"/><text>thrombocytopenia</text></annotation><annotation id="19"><infon key="type">Disease</infon><location offset="832" length="5"/><text>AVIDs</text></annotation><annotation id="20"><infon key="identifier">947</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1343</infon><location offset="876" length="4"/><text>CD34</text></annotation><annotation id="21"><infon key="identifier">947</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1343</infon><location offset="922" length="4"/><text>CD34</text></annotation><annotation id="22"><infon key="identifier">952</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1345</infon><location offset="927" length="4"/><text>CD38</text></annotation><annotation id="23"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="932" length="6"/><text>CD45RA</text></annotation><annotation id="24"><infon key="identifier">947</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1343</infon><location offset="1019" length="4"/><text>CD34</text></annotation><annotation id="25"><infon key="identifier">952</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1345</infon><location offset="1024" length="4"/><text>CD38</text></annotation><annotation id="26"><infon key="identifier">5788</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2126</infon><location offset="1029" length="6"/><text>CD45RA</text></annotation><annotation id="27"><infon key="identifier">7070</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4580</infon><location offset="1036" length="4"/><text>CD90</text></annotation><annotation id="28"><infon key="identifier">3655</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20091</infon><location offset="1041" length="5"/><text>CD49f</text></annotation><annotation id="29"><infon key="identifier">947</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1343</infon><location offset="1206" length="4"/><text>CD34</text></annotation></passage><relation id="R1"><infon key="score">0.9937</infon><infon key="role1">Gene|3655</infon><infon key="role2">Gene|7070</infon><infon key="type">Association</infon><node refid="0" role="13,12"/></relation></document>
<document><id>37920249</id><passage><infon key="journal">Ann LGBTQ Public Popul Health;2021Dec; 2 (4) 317. doi:10.1891/lgbtq-2020-0030</infon><infon key="year">2021</infon><infon key="article-id_pmc">PMC10621598</infon><infon key="type">title</infon><infon key="authors">Paschen-Wolff MM, Putney JM, Corbeil T, Tse-Hwei C, Hughes TL, </infon><offset>0</offset><text>The Association between Hazardous Drinking Indicators and Drinking Problem Concerns among Sexual Minority Women.</text><annotation id="2"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="24" length="18"/><text>Hazardous Drinking</text></annotation><annotation id="3"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="58" length="25"/><text>Drinking Problem Concerns</text></annotation></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>Sexual minority women (SMW) report high rates of hazardous drinking (HD), treatment utilization that is not commensurate with need, and low perceived alcohol use severity. This study examined SMW's drinking problem concerns by sexual identity and other demographic characteristics, and the strength of associations between endorsement of unique HD indicators and drinking problem concerns. Data were from a supplemental sample of SMW added in Wave 3 of the longitudinal, community-based Chicago Health and Life Experiences of Women (CHLEW) study. HD was measured using a validated 13-item HD Index (HDI). Multivariable logistic regression models examined independent associations between past-five-year drinking problem concerns and each HD indicator. Twelve HD indicators were significantly associated with past-five-year drinking problem concerns, adjusting for age and sexual identity. Adjusted odds ratios varied from 2.44 for driving drunk to 15.52 for drinking first thing in the morning. After adjusting for number of HD indicators endorsed, associations were no longer significant, indicating that number of endorsed indicators was a more important predictor of drinking problem concerns than were individual HD indicators. Early intervention and harm reduction strategies could support SMW in addressing salient aspects of HD before progression to alcohol use disorder.</text><annotation id="21"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="162" length="18"/><text>hazardous drinking</text></annotation><annotation id="22"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="182" length="2"/><text>HD</text></annotation><annotation id="23"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="311" length="25"/><text>drinking problem concerns</text></annotation><annotation id="24"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="458" length="2"/><text>HD</text></annotation><annotation id="25"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="476" length="25"/><text>drinking problem concerns</text></annotation><annotation id="26"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="660" length="2"/><text>HD</text></annotation><annotation id="27"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="702" length="2"/><text>HD</text></annotation><annotation id="28"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="816" length="25"/><text>drinking problem concerns</text></annotation><annotation id="29"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="851" length="2"/><text>HD</text></annotation><annotation id="30"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="872" length="2"/><text>HD</text></annotation><annotation id="31"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="936" length="25"/><text>drinking problem concerns</text></annotation><annotation id="32"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="1071" length="8"/><text>drinking</text></annotation><annotation id="33"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="1138" length="2"/><text>HD</text></annotation><annotation id="34"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="1283" length="25"/><text>drinking problem concerns</text></annotation><annotation id="35"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="1330" length="2"/><text>HD</text></annotation><annotation id="36"><infon key="identifier">MESH:D063425</infon><infon key="type">Disease</infon><location offset="1445" length="2"/><text>HD</text></annotation><annotation id="37"><infon key="identifier">MESH:D000437</infon><infon key="type">Disease</infon><location offset="1470" length="20"/><text>alcohol use disorder</text></annotation></passage></document>
<document><id>37920949</id><passage><infon key="journal">Hosp Pediatr;2023Nov03. doi:10.1542/hpeds.2023-007348</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Porter AS, Gouda SR, Broden EG, Snaman JM, </infon><offset>0</offset><text>"Palliative Intensive Care" at the End of a Child's Life.</text></passage><passage><infon key="type">abstract</infon><offset>58</offset></passage></document>
<document><id>37921299</id><passage><infon key="journal">Vet Rec;2023Nov04; 193 (9) 374. doi:10.1002/vetr.3644</infon><infon key="year">2023</infon><infon key="type">title</infon><offset>0</offset><text>Death Notices.</text><annotation id="1"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="0" length="5"/><text>Death</text></annotation></passage><passage><infon key="type">abstract</infon><offset>15</offset></passage></document>
<document><id>37921649</id><passage><infon key="journal">J Phys Chem B;2023Nov03. doi:10.1021/acs.jpcb.3c03473</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jacobsen L, Lydersen L, Khandelia H, </infon><offset>0</offset><text>ATP-Bound State of the Uncoupling Protein 1 (UCP1) from Molecular Simulations.</text><annotation id="3"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="0" length="3"/><text>ATP</text></annotation><annotation id="4"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="23" length="20"/><text>Uncoupling Protein 1</text></annotation><annotation id="5"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="45" length="4"/><text>UCP1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>The uncoupling protein 1 (UCP1) dissipates the transmembrane (TM) proton gradient in the inner mitochondrial membrane (IMM) by leaking protons across the membrane and producing heat in the process. Such a nonshivering production of heat in the brown adipose tissue can combat obesity-related diseases. UCP1-associated proton leak is activated by free fatty acids and inhibited by purine nucleotides. The mechanism of proton leak and the binding sites of the activators (fatty acids) remain unknown, while the binding site of the inhibitors (nucleotides) was described recently. Using molecular dynamics simulations, we generated a conformational ensemble of UCP1. Using metadynamics-based free energy calculations, we obtained the most likely ATP-bound conformation of UCP1. Our conformational ensemble provides a molecular basis for a breadth of prior biochemical data available for UCP1. Based on the simulations, we make the following testable predictions about the mechanisms of activation of proton leak and proton leak inhibition by ATP: (1) R277 plays the dual role of stabilizing ATP at the binding site for inhibition and acting as a proton surrogate for D28 in the absence of a proton during proton transport, (2) the binding of ATP to UCP1 is mediated by residues R84, R92, R183, and S88, (3) R92 shuttles ATP from the E191-R92 gate in the intermembrane space to the nucleotide binding site and serves to increase ATP affinity, (4) ATP can inhibit proton leak by controlling the ionization states of matrix facing lysine residues such as K269 and K56, and (5) fatty acids can bind to UCP1 from the IMM either via the cavity between TM1 and TM2 or between TM5 and TM6. Our simulations set the platform for future investigations into the proton transport and inhibition mechanisms of UCP1.</text><annotation id="28"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="83" length="20"/><text>uncoupling protein 1</text></annotation><annotation id="29"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="105" length="4"/><text>UCP1</text></annotation><annotation id="30"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="355" length="24"/><text>obesity-related diseases</text></annotation><annotation id="31"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="381" length="4"/><text>UCP1</text></annotation><annotation id="32"><infon key="identifier">MESH:D005230</infon><infon key="type">Chemical</infon><location offset="425" length="16"/><text>free fatty acids</text></annotation><annotation id="33"><infon key="identifier">MESH:D011685</infon><infon key="type">Chemical</infon><location offset="459" length="18"/><text>purine nucleotides</text></annotation><annotation id="34"><infon key="identifier">MESH:D005227</infon><infon key="type">Chemical</infon><location offset="549" length="11"/><text>fatty acids</text></annotation><annotation id="35"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="737" length="4"/><text>UCP1</text></annotation><annotation id="36"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="822" length="3"/><text>ATP</text></annotation><annotation id="37"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="848" length="4"/><text>UCP1</text></annotation><annotation id="38"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="963" length="4"/><text>UCP1</text></annotation><annotation id="39"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="1118" length="3"/><text>ATP</text></annotation><annotation id="40"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="1167" length="3"/><text>ATP</text></annotation><annotation id="41"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="1318" length="3"/><text>ATP</text></annotation><annotation id="42"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1325" length="4"/><text>UCP1</text></annotation><annotation id="43"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="1396" length="3"/><text>ATP</text></annotation><annotation id="44"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="1504" length="3"/><text>ATP</text></annotation><annotation id="45"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="1522" length="3"/><text>ATP</text></annotation><annotation id="46"><infon key="identifier">MESH:D008239</infon><infon key="type">Chemical</infon><location offset="1604" length="6"/><text>lysine</text></annotation><annotation id="47"><infon key="identifier">MESH:D005227</infon><infon key="type">Chemical</infon><location offset="1650" length="11"/><text>fatty acids</text></annotation><annotation id="48"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1674" length="4"/><text>UCP1</text></annotation><annotation id="49"><infon key="identifier">7350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1872" length="4"/><text>UCP1</text></annotation></passage><relation id="R1"><infon key="score">0.5056</infon><infon key="role1">Chemical|MESH:D000255</infon><infon key="role2">Gene|7350</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.9971</infon><infon key="role1">Chemical|MESH:D000255</infon><infon key="role2">Chemical|MESH:D008239</infon><infon key="type">Association</infon><node refid="1" role="15,23"/></relation><relation id="R3"><infon key="score">0.9902</infon><infon key="role1">Disease|MESH:D009765</infon><infon key="role2">Gene|7350</infon><infon key="type">Association</infon><node refid="2" role="5,3"/></relation><relation id="R4"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D005230</infon><infon key="role2">Gene|7350</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="7,6"/></relation><relation id="R5"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D011685</infon><infon key="role2">Gene|7350</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="8,6"/></relation><relation id="R6"><infon key="score">0.8559</infon><infon key="role1">Chemical|MESH:D005227</infon><infon key="role2">Gene|7350</infon><infon key="type">Positive_Correlation</infon><node refid="5" role="24,18"/></relation></document>
<document><id>37890127</id><passage><infon key="journal">J Am Chem Soc;2023Oct27. doi:10.1021/jacs.3c08541</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xu X, Cui Q, Chen H, Huang N, </infon><offset>0</offset><text>Carborane-Based Three-Dimensional Covalent Organic Frameworks.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="9"/><text>Carborane</text></annotation></passage><passage><infon key="type">abstract</infon><offset>63</offset><text>The predesignable porous structure and high structural flexibility of covalent organic frameworks (COFs) render this material desirable as a platform for addressing various cutting-edge issues. Precise control over their composition, topological structure, porosity, and stability to realize tailor-made functionality still remains a great challenge. In this work, we developed a new kind of three-dimensional (3D) carborane-based COF with a 7-fold interpenetrating dia topological diagram. The resulting COFs exhibited high crystallinity, exceptional porosity, and strong robustness. The slightly lower electronegativity of boron (2.04) than that of hydrogen (2.20) can lead to the polarization of the B-H bond into a Bdelta+-Hdelta- mode, which renders these COFs as high-performance materials for the adsorption and separation of hexane isomers through the B-Hdelta-   Hdelta+-C interaction. Significantly, the carborane content of obtained COFs reached up to 54.2 wt %, which gets the highest rank among all the reported porous materials. Combining high surface area, strong robustness, and high content of carborane, the obtained COFs can work as efficient adsorbents for the separation of the five hexane isomers with high separation factors. This work not only enhances the diversity of 3D functional COFs but also constitutes a further step toward the efficient separation of alkane isomers.</text><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="478" length="9"/><text>carborane</text></annotation><annotation id="12"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="494" length="3"/><text>COF</text></annotation><annotation id="13"><infon key="identifier">MESH:D001895</infon><infon key="type">Chemical</infon><location offset="688" length="5"/><text>boron</text></annotation><annotation id="14"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="714" length="8"/><text>hydrogen</text></annotation><annotation id="15"><infon key="identifier">MESH:D006586</infon><infon key="type">Chemical</infon><location offset="896" length="6"/><text>hexane</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="977" length="9"/><text>carborane</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1174" length="9"/><text>carborane</text></annotation><annotation id="18"><infon key="identifier">MESH:D006586</infon><infon key="type">Chemical</infon><location offset="1267" length="6"/><text>hexane</text></annotation><annotation id="19"><infon key="identifier">MESH:D000473</infon><infon key="type">Chemical</infon><location offset="1447" length="6"/><text>alkane</text></annotation></passage></document>
<document><id>37890477</id><passage><infon key="journal">Nanotechnology;2023Oct27. doi:10.1088/1361-6528/ad07a0</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang K, Zhou Y, Hu Z, Tai Y, Cheng L, Ge B, Wu C, </infon><offset>0</offset><text>Controlled synthesis of transition metal oxide multi-shell structures and in situ study of the energy storage mechanism.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="24" length="22"/><text>transition metal oxide</text></annotation></passage><passage><infon key="type">abstract</infon><offset>121</offset><text>Multi-shell transition metal oxide hollow spheres show great potential for applications in energy storage because of their unique multilayered hollow structure with large specific surface area, short electron and charge transport paths, and structural stability. In this paper, the controlled synthesis of NiCo2O4, MnCo2O4, NiMn2O4 multi-shell layer structures was achieved by using the solvothermal method. As the anode materials for Li-ion batteries, the three multi-shell structures maintained good stability after 650 long cycles in the cyclic charge/discharge test. The in-situ transmisssion electron microscope characterization combined with cyclic voltammetry tests demonstrated that the three anode materials NiCo2O4, MnCo2O4 and NiMn2O4 have similar charge/discharge transition mechanisms, and the multi-shell structure can effectively buffer the volume expansion and structural collapse during lithium embedding/delithiation to ensure the stability of the electrode structure and cycling performance. The research results can provide effective guidance for the synathesis and charging/discharging mechanism of multi-shell metal oxide lithium-ion battery anode materials.</text><annotation id="12"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="133" length="22"/><text>transition metal oxide</text></annotation><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="427" length="7"/><text>NiCo2O4</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="436" length="7"/><text>MnCo2O4</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="445" length="7"/><text>NiMn2O4</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="838" length="7"/><text>NiCo2O4</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="847" length="7"/><text>MnCo2O4</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="859" length="7"/><text>NiMn2O4</text></annotation><annotation id="19"><infon key="identifier">MESH:D008094</infon><infon key="type">Chemical</infon><location offset="1025" length="7"/><text>lithium</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1253" length="11"/><text>metal oxide</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1265" length="11"/><text>lithium-ion</text></annotation></passage></document>
<document><id>37890827</id><passage><infon key="journal">Environ Res;2023Oct25 117508. doi:10.1016/j.envres.2023.117508</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gong X, Zhou Z, Su D, Dong H, Yan L, Ding S, Wang X, Zhang Y, </infon><offset>0</offset><text>Sulfur-oxygen isotope analysis of SO42- sources in cave dripwater and their influence on the karst carbon cycle.</text><annotation id="4"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="0" length="6"/><text>Sulfur</text></annotation><annotation id="5"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="7" length="6"/><text>oxygen</text></annotation><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="34" length="4"/><text>SO42</text></annotation><annotation id="7"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="99" length="6"/><text>carbon</text></annotation></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>Sulfuric acid is involved in carbonate rock dissolution in karst areas and affects regional hydrogeochemical and carbon cycling processes. Sulfate sources and carbonate weathering at dripwater points of different hydrological types also differ significantly. Therefore, in this paper, three dripwater points (SQ2#, PB and MH6#) of different hydrological types in Dafeng Cave and Mahuang Cave were selected and systematically analyzed. The results show that: (1) ions in the cave dripwater mainly originated from rock weathering, and the water chemistry types were HCO3 Ca-Mg and HCO3-SO4 Ca-Mg. (2) Sulfur and oxygen isotopes reveal that sulfate in the cave water of Shuanghe Cave mainly came from a mixture of soil sulfate and chemical fertilizers. (3) The Simmr model shows that the main sources of sulfate at each dripwater point were natural sources, such as soil sulfate and gypsum dissolution. The natural sources contributed more than 80% of the sulfate in the cave water and were less affected by anthropogenic activities. (4) Carbonate weathering by sulfuric acid (CSW) can accelerate rock weathering and the prior calcite precipitation effect, involving regional CO2 exchange through fissure pipes. The forward model results show that CSW reduced the karst carbon sinks at SQ2#, PB and MH6# by about 19.44%, 23.88% and 12.74%, respectively. Therefore, the impact cannot be ignored in assessing carbon source and sink processes in karst areas.</text><annotation id="31"><infon key="identifier">MESH:C033158</infon><infon key="type">Chemical</infon><location offset="113" length="13"/><text>Sulfuric acid</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="142" length="14"/><text>carbonate rock</text></annotation><annotation id="33"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="226" length="6"/><text>carbon</text></annotation><annotation id="34"><infon key="identifier">MESH:D013431</infon><infon key="type">Chemical</infon><location offset="252" length="7"/><text>Sulfate</text></annotation><annotation id="35"><infon key="identifier">MESH:D002254</infon><infon key="type">Chemical</infon><location offset="272" length="9"/><text>carbonate</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="677" length="10"/><text>HCO3 Ca-Mg</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="692" length="14"/><text>HCO3-SO4 Ca-Mg</text></annotation><annotation id="38"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="712" length="6"/><text>Sulfur</text></annotation><annotation id="39"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="723" length="6"/><text>oxygen</text></annotation><annotation id="40"><infon key="identifier">MESH:D013431</infon><infon key="type">Chemical</infon><location offset="751" length="7"/><text>sulfate</text></annotation><annotation id="41"><infon key="identifier">MESH:D013431</infon><infon key="type">Chemical</infon><location offset="829" length="7"/><text>sulfate</text></annotation><annotation id="42"><infon key="identifier">MESH:D013431</infon><infon key="type">Chemical</infon><location offset="914" length="7"/><text>sulfate</text></annotation><annotation id="43"><infon key="identifier">MESH:D013431</infon><infon key="type">Chemical</infon><location offset="981" length="7"/><text>sulfate</text></annotation><annotation id="44"><infon key="identifier">MESH:D002133</infon><infon key="type">Chemical</infon><location offset="993" length="6"/><text>gypsum</text></annotation><annotation id="45"><infon key="identifier">MESH:D013431</infon><infon key="type">Chemical</infon><location offset="1066" length="7"/><text>sulfate</text></annotation><annotation id="46"><infon key="identifier">MESH:D002254</infon><infon key="type">Chemical</infon><location offset="1148" length="9"/><text>Carbonate</text></annotation><annotation id="47"><infon key="identifier">MESH:C033158</infon><infon key="type">Chemical</infon><location offset="1172" length="13"/><text>sulfuric acid</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1187" length="3"/><text>CSW</text></annotation><annotation id="49"><infon key="identifier">MESH:D002119</infon><infon key="type">Chemical</infon><location offset="1237" length="7"/><text>calcite</text></annotation><annotation id="50"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1286" length="3"/><text>CO2</text></annotation><annotation id="51"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1358" length="3"/><text>CSW</text></annotation><annotation id="52"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1380" length="6"/><text>carbon</text></annotation><annotation id="53"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1517" length="6"/><text>carbon</text></annotation></passage><relation id="R1"><infon key="score">0.9624</infon><infon key="role1">Chemical|MESH:D002245</infon><infon key="role2">Chemical|MESH:D002254</infon><infon key="type">Association</infon><node refid="0" role="23,19"/></relation><relation id="R2"><infon key="score">0.9734</infon><infon key="role1">Chemical|MESH:D002133</infon><infon key="role2">Chemical|MESH:D013431</infon><infon key="type">Association</infon><node refid="1" role="17,15"/></relation><relation id="R3"><infon key="score">0.9972</infon><infon key="role1">Chemical|MESH:C033158</infon><infon key="role2">Chemical|MESH:D002119</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="20,22"/></relation><relation id="R4"><infon key="score">0.9524</infon><infon key="role1">Chemical|MESH:C033158</infon><infon key="role2">Chemical|MESH:D002254</infon><infon key="type">Association</infon><node refid="3" role="20,19"/></relation><relation id="R5"><infon key="score">0.9982</infon><infon key="role1">Chemical|MESH:C033158</infon><infon key="role2">Chemical|MESH:D002244</infon><infon key="type">Association</infon><node refid="4" role="4,6"/></relation></document>
<document><id>37897138</id><passage><infon key="journal">Neurogastroenterol Motil;2023Oct27 14698. doi:10.1111/nmo.14698</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Veraza DI, Calderon G, Jansson-Knodell C, Aljaras R, Foster ED, Xu H, Biruete A, Shin A, </infon><offset>0</offset><text>A systematic review and meta-analysis of diet and nutrient intake in adults with irritable bowel syndrome.</text><annotation id="1"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="81" length="24"/><text>irritable bowel syndrome</text></annotation></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>BACKGROUND: Numerous individual and environmental factors including diet may play an important role in the pathophysiology of irritable bowel syndrome (IBS). It is unclear to what degree dietary intake is affected in individuals with IBS. We aimed to perform a systematic review and meta-analysis to summarize dietary intake of adults with IBS and to compare dietary intake between adults with IBS and non-IBS controls. METHODS: Ovid MEDLINE, Embase, Cochrane, CINAHL, and Scopus were searched through February 2023 for clinical trials and observational studies measuring usual diet in adults with IBS. Pooled weighted averages were estimated for total energy, macronutrient, and micronutrient data. Mean differences (MD) in nutrient intake were estimated for adults with IBS versus non-IBS controls using a random effects model. Heterogeneity was assessed by the inconsistency index (I2). KEY RESULTS: Sixty-three full-text articles were included in the review of which 29 studies included both IBS and control subjects. Nutrients not meeting the recommended intake level for any dietary reference values in the IBS population were fiber and vitamin D. Meta-regression by female proportion was positively correlated with total fat intake and negatively correlated with carbohydrate intake. Comparisons between participants with IBS and controls showed significantly lower fiber intake in participants with IBS with high heterogeneity (MD: -1.8; 95% CI: -3.0, -0.6; I2 = 85%). CONCLUSIONS AND INFERENCES: This review suggests that fiber and vitamin D intake is suboptimal in IBS; however, overall dietary intake does not appear to be comprised. Causes and consequences of reduced fiber in IBS deserve further study. Results of this systematic review and meta-analysis suggest that fiber and vitamin D intake is suboptimal in IBS. However, overall intake of other macro- and micronutrients does not appear to be compromised. Causes and consequences of reduced fiber and Vitamin D intake in IBS deserve further study.</text><annotation id="30"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="233" length="24"/><text>irritable bowel syndrome</text></annotation><annotation id="31"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="259" length="3"/><text>IBS</text></annotation><annotation id="32"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="341" length="3"/><text>IBS</text></annotation><annotation id="33"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="447" length="3"/><text>IBS</text></annotation><annotation id="34"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="501" length="3"/><text>IBS</text></annotation><annotation id="35"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="513" length="3"/><text>IBS</text></annotation><annotation id="36"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="705" length="3"/><text>IBS</text></annotation><annotation id="37"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="879" length="3"/><text>IBS</text></annotation><annotation id="38"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="894" length="3"/><text>IBS</text></annotation><annotation id="39"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="1103" length="3"/><text>IBS</text></annotation><annotation id="40"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="1220" length="3"/><text>IBS</text></annotation><annotation id="41"><infon key="identifier">MESH:D004043</infon><infon key="type">Chemical</infon><location offset="1240" length="5"/><text>fiber</text></annotation><annotation id="42"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="1250" length="10"/><text>vitamin D.</text></annotation><annotation id="43"><infon key="identifier">MESH:D002241</infon><infon key="type">Chemical</infon><location offset="1377" length="12"/><text>carbohydrate</text></annotation><annotation id="44"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="1436" length="3"/><text>IBS</text></annotation><annotation id="45"><infon key="identifier">MESH:D004043</infon><infon key="type">Chemical</infon><location offset="1480" length="5"/><text>fiber</text></annotation><annotation id="46"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="1514" length="3"/><text>IBS</text></annotation><annotation id="47"><infon key="identifier">MESH:D004043</infon><infon key="type">Chemical</infon><location offset="1638" length="5"/><text>fiber</text></annotation><annotation id="48"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="1648" length="9"/><text>vitamin D</text></annotation><annotation id="49"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="1682" length="3"/><text>IBS</text></annotation><annotation id="50"><infon key="identifier">MESH:D004043</infon><infon key="type">Chemical</infon><location offset="1787" length="5"/><text>fiber</text></annotation><annotation id="51"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="1796" length="3"/><text>IBS</text></annotation><annotation id="52"><infon key="identifier">MESH:D004043</infon><infon key="type">Chemical</infon><location offset="1888" length="5"/><text>fiber</text></annotation><annotation id="53"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="1898" length="9"/><text>vitamin D</text></annotation><annotation id="54"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="1932" length="3"/><text>IBS</text></annotation><annotation id="55"><infon key="identifier">MESH:D004043</infon><infon key="type">Chemical</infon><location offset="2066" length="5"/><text>fiber</text></annotation><annotation id="56"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="2076" length="9"/><text>Vitamin D</text></annotation><annotation id="57"><infon key="identifier">MESH:D043183</infon><infon key="type">Disease</infon><location offset="2096" length="3"/><text>IBS</text></annotation></passage><relation id="R1"><infon key="score">0.97</infon><infon key="role1">Chemical|MESH:D004043</infon><infon key="role2">Disease|MESH:D043183</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="12,11"/></relation></document>
<document><id>37897489</id><passage><infon key="journal">Endocrinology;2023Sep23; 164 (11) . doi:10.1210/endocr/bqad151</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Huang J, Siyar S, Sharma R, Herrig I, Wise L, Aidt S, List E, Kopchick JJ, Puri V, Lee KY, </infon><offset>0</offset><text>Adipocyte Subpopulations Mediate Growth Hormone Induced Lipolysis and Glucose Tolerance in Male Mice.</text><annotation id="2"><infon key="identifier">2688</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">128036</infon><location offset="33" length="14"/><text>Growth Hormone</text></annotation><annotation id="3"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="70" length="7"/><text>Glucose</text></annotation></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>In adipose tissue, growth hormone (GH) stimulates lipolysis, leading to an increase in plasma free fatty acid levels and a reduction in insulin sensitivity. In our previous studies, we have found that GH increases lipolysis by reducing peroxisome proliferator-activated receptor gamma (PPARgamma) transcription activity, leading to a reduction of Fat-specific protein 27 (FSP27, also known as CIDEC) expression. In previous studies, our lab uncovered three developmentally distinct subpopulations of white adipocytes. In this manuscript, we show that one of the subpopulations, termed Type 2 adipocytes, has increased GH-induced signaling and lipolysis compared to other adipocyte subtypes. To assess the physiological role of GH-mediated lipolysis mediated by this adipocyte subpopulation, we specifically expressed human FSP27 (hFSP27) transgene in Type 2 adipocytes (Type2Ad-hFSP27tg mice). Systemically, male Type2Ad-hFSP27tg mice displayed reduced serum glycerol release and non-esterified fatty acids levels after acute GH treatment, and improvement in acute, but not chronic, GH-induced glucose intolerance. Furthermore, we demonstrate that Type2Ad-hFSP27tg mice displayed improved hepatic insulin signaling. Taken together, these results indicate that this adipocyte subpopulation is a critical regulator of the GH-mediated lipolytic and metabolic response. Thus, further investigation of adipocyte subpopulations may provide novel treatment strategies to regulate GH-induced glucose intolerance in patients with growth and metabolic disorders.</text><annotation id="28"><infon key="identifier">2688</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">128036</infon><location offset="121" length="14"/><text>growth hormone</text></annotation><annotation id="29"><infon key="identifier">2688</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">128036</infon><location offset="137" length="2"/><text>GH</text></annotation><annotation id="30"><infon key="identifier">MESH:D005230</infon><infon key="type">Chemical</infon><location offset="196" length="15"/><text>free fatty acid</text></annotation><annotation id="31"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="238" length="7"/><text>insulin</text></annotation><annotation id="32"><infon key="identifier">14599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47932</infon><location offset="303" length="2"/><text>GH</text></annotation><annotation id="33"><infon key="identifier">5468</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7899</infon><location offset="338" length="48"/><text>peroxisome proliferator-activated receptor gamma</text></annotation><annotation id="34"><infon key="identifier">5468</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7899</infon><location offset="388" length="9"/><text>PPARgamma</text></annotation><annotation id="35"><infon key="identifier">63924</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11128</infon><location offset="449" length="23"/><text>Fat-specific protein 27</text></annotation><annotation id="36"><infon key="identifier">63924</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11128</infon><location offset="474" length="5"/><text>FSP27</text></annotation><annotation id="37"><infon key="identifier">63924</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11128</infon><location offset="495" length="5"/><text>CIDEC</text></annotation><annotation id="38"><infon key="identifier">14599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47932</infon><location offset="720" length="2"/><text>GH</text></annotation><annotation id="39"><infon key="identifier">14599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47932</infon><location offset="829" length="2"/><text>GH</text></annotation><annotation id="40"><infon key="identifier">63924</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11128</infon><location offset="925" length="5"/><text>FSP27</text></annotation><annotation id="41"><infon key="identifier">CVCL:C5HZ</infon><infon key="type">CellLine</infon><location offset="1023" length="8"/><text>hFSP27tg</text></annotation><annotation id="42"><infon key="identifier">MESH:D005990</infon><infon key="type">Chemical</infon><location offset="1061" length="8"/><text>glycerol</text></annotation><annotation id="43"><infon key="identifier">MESH:D005230</infon><infon key="type">Chemical</infon><location offset="1082" length="26"/><text>non-esterified fatty acids</text></annotation><annotation id="44"><infon key="identifier">14599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47932</infon><location offset="1128" length="2"/><text>GH</text></annotation><annotation id="45"><infon key="identifier">14599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47932</infon><location offset="1185" length="2"/><text>GH</text></annotation><annotation id="46"><infon key="identifier">MESH:D018149</infon><infon key="type">Disease</infon><location offset="1196" length="19"/><text>glucose intolerance</text></annotation><annotation id="47"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="1299" length="7"/><text>insulin</text></annotation><annotation id="48"><infon key="identifier">14599</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47932</infon><location offset="1422" length="2"/><text>GH</text></annotation><annotation id="49"><infon key="identifier">2688</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">128036</infon><location offset="1575" length="2"/><text>GH</text></annotation><annotation id="50"><infon key="identifier">MESH:D018149</infon><infon key="type">Disease</infon><location offset="1586" length="19"/><text>glucose intolerance</text></annotation><annotation id="51"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="1623" length="30"/><text>growth and metabolic disorders</text></annotation></passage><relation id="R1"><infon key="score">0.9934</infon><infon key="role1">Disease|MESH:D018149</infon><infon key="role2">Gene|14599</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="21,19"/></relation><relation id="R2"><infon key="score">0.9989</infon><infon key="role1">Gene|2688</infon><infon key="role2">Gene|3630</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="3,6"/></relation><relation id="R3"><infon key="score">0.9993</infon><infon key="role1">Gene|14599</infon><infon key="role2">Gene|63924</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="7,10"/></relation><relation id="R4"><infon key="score">0.999</infon><infon key="role1">Disease|MESH:D006130</infon><infon key="role2">Gene|2688</infon><infon key="type">Association</infon><node refid="3" role="26,24"/></relation><relation id="R5"><infon key="score">0.6156</infon><infon key="role1">Disease|MESH:D018149</infon><infon key="role2">Gene|2688</infon><infon key="type">Association</infon><node refid="4" role="25,24"/></relation><relation id="R6"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:D005990</infon><infon key="role2">Gene|14599</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="17,19"/></relation><relation id="R7"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D005230</infon><infon key="role2">Gene|2688</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="5,3"/></relation><relation id="R8"><infon key="score">0.9993</infon><infon key="role1">Gene|14599</infon><infon key="role2">Gene|5468</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="7,8"/></relation><relation id="R9"><infon key="score">0.9847</infon><infon key="role1">Chemical|MESH:D005230</infon><infon key="role2">Gene|14599</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="18,19"/></relation></document>
<document><id>37897839</id><passage><infon key="journal">J Psychiatr Res;2023Oct17; 168 71. doi:10.1016/j.jpsychires.2023.10.024</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kavanaugh BC, Fukuda AM, Gemelli ZT, Thorpe R, Tirrell E, Vigne M, Jones SR, Carpenter LL, </infon><offset>0</offset><text>Pre-treatment frontal beta events are associated with executive dysfunction improvement after repetitive transcranial magnetic stimulation for depression: A preliminary report.</text><annotation id="2"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="54" length="21"/><text>executive dysfunction</text></annotation><annotation id="3"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="143" length="10"/><text>depression</text></annotation></passage><passage><infon key="type">abstract</infon><offset>177</offset><text>Repetitive transcranial magnetic stimulation (rTMS) is an established clinical treatment for major depressive disorder (MDD) that has also been found to improve aspects of executive functioning. The objective of this study was to examine whether oscillatory burst-like events within the beta band (15-29 Hz) prior to treatment could predict subsequent change in self-reported executive dysfunction (EDF) across a clinical course of rTMS for MDD. Twenty-eight adults (64% female) with MDD completed the self-report Frontal Systems Behavior Scale (FrSBe) and provided eyes-closed resting-state electroencephalography (EEG) before and after a clinical course of rTMS therapy for primary MDD. The rate, power, duration, and frequency span of transient EEG measured oscillatory beta events were calculated. Events within delta/theta and alpha bands were examined to assess for beta specificity. After controlling for improvement in primary depressive symptoms, a lower rate of beta events at F3, Fz, F4, and Cz prior to rTMS treatment was associated with a larger improvement in EDF after rTMS treatment. In addition, a decrease in beta event rate at Fz pre-to-post treatment was associated with a larger improvement in EDF after treatment. Results were largely specific to the beta band. In this study, the rate of frontrocentral beta events prior to treatment significantly predicted the likelihood of subsequent improvement in EDF symptoms following a clinical course of rTMS for MDD. These preliminary findings suggest the potential utility of EEG measured beta events and rTMS for targeting EDF across an array of neuropsychiatric disorders.</text><annotation id="18"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="270" length="25"/><text>major depressive disorder</text></annotation><annotation id="19"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="297" length="3"/><text>MDD</text></annotation><annotation id="20"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="553" length="21"/><text>executive dysfunction</text></annotation><annotation id="21"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="576" length="3"/><text>EDF</text></annotation><annotation id="22"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="618" length="3"/><text>MDD</text></annotation><annotation id="23"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="661" length="3"/><text>MDD</text></annotation><annotation id="24"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="861" length="3"/><text>MDD</text></annotation><annotation id="25"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1112" length="19"/><text>depressive symptoms</text></annotation><annotation id="26"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="1251" length="3"/><text>EDF</text></annotation><annotation id="27"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="1392" length="3"/><text>EDF</text></annotation><annotation id="28"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="1602" length="3"/><text>EDF</text></annotation><annotation id="29"><infon key="identifier">MESH:D003865</infon><infon key="type">Disease</infon><location offset="1655" length="3"/><text>MDD</text></annotation><annotation id="30"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="1768" length="3"/><text>EDF</text></annotation><annotation id="31"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1791" length="26"/><text>neuropsychiatric disorders</text></annotation></passage></document>
<document><id>37898192</id><passage><infon key="journal">Sci Total Environ;2023Oct26 168049. doi:10.1016/j.scitotenv.2023.168049</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hu X, Gu H, Liu J, Wei D, Zhu P, Cui X, Zhou B, Chen X, Jin J, Wang G, </infon><offset>0</offset><text>Different long-term fertilization regimes affect soil protists and their top-down control on bacterial and fungal communities in Mollisols.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="129" length="9"/><text>Mollisols</text></annotation></passage><passage><infon key="type">abstract</infon><offset>140</offset><text>Soil protists represent a vastly diverse component of soil microbial communities and significantly contribute to biogeochemical cycling. However, how different fertilization regimes impact the protistan communities and their top-down control on bacteria and fungi remain largely unknown. Here, using high-throughput sequencing, we investigated the differences in protist communities and their relationships with bacterial and fungal communities in Mollisols of Northeast China that were subjected to chemical and organic fertilization over 30 years. The results showed that manure addition rather than chemical fertilization significantly increased protistan alpha diversity and changed protistan community structure. Manure amendments markedly increased the relative abundances of protistan consumers (such as Cercozoa) and reduced the proportion of phototrophic protists (such as Chlorophyta). Soil pH was the most influential factor driving microbial communities, and protists were less sensitive to environmental disturbances than bacteria and fungi. Protistan communities exhibited more stronger relationships with bacterial communities than fungal communities, and Chlorococcum was the most important contributor in regulation of microbial taxa and functional genes. Furthermore, manure addition slightly simplified the microbial network, and chemical plus manure fertilization improved network stability with the highest robustness. Manure addition specifically mitigated the negative interactions between protists and bacteria while reinforced the positive interactions between protists and fungi. This study advanced our knowledge about the roles of protistan groups in regulating microbial communities and ecosystem functions associated with chemical and organic fertilization.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="588" length="9"/><text>Mollisols</text></annotation></passage></document>
<document><id>37898542</id><passage><infon key="journal">Adv Food Nutr Res;2023; 107 41. doi:10.1016/bs.afnr.2023.06.001</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Soares Mateus AR, Barros S, Pena A, Sanches-Silva A, </infon><offset>0</offset><text>The potential of citrus by-products in the development of functional food and active packaging.</text></passage><passage><infon key="type">abstract</infon><offset>96</offset><text>Food by-product valorization has become an important research area for promoting the sustainability of the food chain. Citrus fruits are among the most widely cultivated fruit crops worldwide. Citrus by-products, including pomace, seeds, and peels (flavedo and albedo), are produced in large amounts each year. Those by-products have an important economic value due to the high content on bioactive compounds, namely phenolic compounds and carotenoids, and are considered a valuable bio-resource for potential applications in the food industry. However, green extraction techniques are required to ensure their sustainability. This chapter addresses the main components of citrus by-products and their recent applications in food products and active food packaging, towards a circular economy. In addition, the concern regarding citrus by-products contamination (e.g. with pesticides residues and mycotoxins) is also discussed.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="289" length="10"/><text>Citrus by-</text></annotation><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="513" length="18"/><text>phenolic compounds</text></annotation><annotation id="5"><infon key="identifier">MESH:D002338</infon><infon key="type">Chemical</infon><location offset="536" length="11"/><text>carotenoids</text></annotation></passage></document>
<document><id>37898892</id><passage><infon key="journal">Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med;2023Sep; 31 (5) 1011. doi:10.32687/0869-866X-2023-31-5-1011-1016</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rostovskaya TK, Vasilyeva EN, Afzali M, </infon><offset>0</offset><text>MAIN PROBLEMS AFFECTING THE FORMATION OF THE WELL-BEING OF YOUNG RUSSIAN FAMILIES: ACCORDING TO THE RESULTS OF THE ALL-RUSSIAN SOCIOLOGICAL RESEARCH.</text></passage><passage><infon key="type">abstract</infon><offset>150</offset><text>The paper presents the findings of a study conducted using a mass questionnaire survey of members of young families (n = 893). The purpose of the study is to identify what problems affecting well-being are faced by members of young families. In the sample, young families are represented by two groups - families with children and families without children. It was revealed that the assessment of the significance of problems in family life is different in families with children and childless families, including the number of children in the family that affects the situation. Ratings of family problems were built according to the following criteria - self-assessment of men and women and parenting experience. It is concluded that, according to a number of criteria (both material and non-material), well-being is formed.</text><annotation id="1"><infon key="identifier">MESH:D019973</infon><infon key="type">Disease</infon><location offset="740" length="15"/><text>family problems</text></annotation></passage></document>
<document><id>37899242</id><passage><infon key="journal">Intern Med;2023Oct27. doi:10.2169/internalmedicine.2742-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Takahashi K, Iwamura T, Hiratsuka Y, Sasaki D, Yamamura N, Ueda M, Morioka H, Yoshino M, Enomoto D, Uemura S, Okura T, Sakaue T, Ikeda S, </infon><offset>0</offset><text>A Gluteus Medius Muscle Biopsy to Confirm Amyloid Transthyretin Deposition in Wild-type Transthyretin Cardiac Amyloidosis: A Report of Two Cases.</text><annotation id="2"><infon key="identifier">7276</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">317</infon><location offset="88" length="13"/><text>Transthyretin</text></annotation><annotation id="3"><infon key="identifier">MESH:D000686</infon><infon key="type">Disease</infon><location offset="102" length="19"/><text>Cardiac Amyloidosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>146</offset><text>In patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), the uptake of the tracer on technetium-99m-labeled pyrophosphate (99mTc-PYP) scintigraphy, which indicates amyloid transthyretin (ATTR) per se, is often observed in skeletal muscles, such as the abdominal oblique and gluteal muscles. Among extracardiac biopsies for confirming ATTR deposition in ATTRwt-CA, a 99mTc-PYP imaging-based computed tomography (CT)-guided core needle biopsy of the internal oblique muscle has relatively high sensitivity. In some patients, the 99mTc-PYP uptake is more pronounced in the gluteal muscles than in oblique muscles. We herein report two cases of ATTRwt-CA in which a CT-guided biopsy of the gluteus medius muscle with 99mTc-PYP uptake confirmed the presence of ATTR deposits.</text><annotation id="18"><infon key="identifier">7276</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">317</infon><location offset="173" length="13"/><text>transthyretin</text></annotation><annotation id="19"><infon key="identifier">MESH:D000686</infon><infon key="type">Disease</infon><location offset="187" length="19"/><text>cardiac amyloidosis</text></annotation><annotation id="20"><infon key="type">Disease</infon><location offset="208" length="9"/><text>ATTRwt-CA</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="248" length="36"/><text>technetium-99m-labeled pyrophosphate</text></annotation><annotation id="22"><infon key="identifier">MESH:D016698</infon><infon key="type">Chemical</infon><location offset="286" length="9"/><text>99mTc-PYP</text></annotation><annotation id="23"><infon key="identifier">7276</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">317</infon><location offset="327" length="21"/><text>amyloid transthyretin</text></annotation><annotation id="24"><infon key="identifier">7276</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">317</infon><location offset="350" length="4"/><text>ATTR</text></annotation><annotation id="25"><infon key="identifier">7276</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">317</infon><location offset="497" length="4"/><text>ATTR</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="516" length="9"/><text>ATTRwt-CA</text></annotation><annotation id="27"><infon key="identifier">MESH:D016698</infon><infon key="type">Chemical</infon><location offset="529" length="9"/><text>99mTc-PYP</text></annotation><annotation id="28"><infon key="identifier">MESH:D016698</infon><infon key="type">Chemical</infon><location offset="690" length="9"/><text>99mTc-PYP</text></annotation><annotation id="29"><infon key="type">Disease</infon><location offset="804" length="9"/><text>ATTRwt-CA</text></annotation><annotation id="30"><infon key="identifier">MESH:D016698</infon><infon key="type">Chemical</infon><location offset="876" length="9"/><text>99mTc-PYP</text></annotation><annotation id="31"><infon key="identifier">7276</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">317</infon><location offset="919" length="4"/><text>ATTR</text></annotation></passage><relation id="R1"><infon key="score">0.9679</infon><infon key="role1">Chemical|MESH:D016698</infon><infon key="role2">Gene|7276</infon><infon key="type">Association</infon><node refid="0" role="6,2"/></relation><relation id="R2"><infon key="score">0.9985</infon><infon key="role1">Disease|MESH:D000686</infon><infon key="role2">Gene|7276</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation></document>
<document><id>37899593</id><passage><infon key="journal">Anal Chem;2023Oct30. doi:10.1021/acs.analchem.3c02952</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang M, He S, Han X, Cui J, Wang H, Huo X, Yan F, Feng L, Wang C, Ma X, </infon><offset>0</offset><text>Discovery of Potential Antituberculosis Agents Targeted Methionine Aminopeptidase 1 of Mycobacterium tuberculosis by the Developed Fluorescent Probe.</text></passage><passage><infon key="type">abstract</infon><offset>150</offset><text>Tuberculosis (TB) is a chronic systemic infectious disease caused by Mycobacterium tuberculosis (M. tuberculosis). Methionine aminopeptidase 1 (MtMET-AP1) is a hydrolase that mediates the necessary post-translational N-terminal methionine excision (NME) of peptides during protein synthesis, which is necessary for bacterial proliferation and is a potential target for the treatment of tuberculosis. Based on the functional characteristics of MtMET-AP1, we developed an enzymatic activated near-infrared fluorescent probe DDAN-MT for rapid, highly selective, and real-time monitoring of endogenous MtMET-AP1 activity in M. tuberculosis. Using the probe DDAN-MT, a visually high-throughput screening technique was established, which obtained three potential inhibitors (GSK-J4 hydrochchloride, JX06, and lavendustin C) against MtMET-AP1 from a 2560 compounds library. More importantly, these inhibitors could inhibit the growth of M. tuberculosis H37Ra especially (MICs &lt; 5 muM), with low toxicities on intestinal bacteria strains and human cells. Therefore, the visual sensing of MtMET-AP1 was successfully performed by DDAN-MT, and MtMET-AP1 inhibitors were discovered as potential antituberculosis agents.</text><annotation id="11"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="150" length="12"/><text>Tuberculosis</text></annotation><annotation id="12"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="164" length="2"/><text>TB</text></annotation><annotation id="13"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="190" length="18"/><text>infectious disease</text></annotation><annotation id="14"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="536" length="12"/><text>tuberculosis</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="672" length="7"/><text>DDAN-MT</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="803" length="7"/><text>DDAN-MT</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="919" length="22"/><text>GSK-J4 hydrochchloride</text></annotation><annotation id="18"><infon key="identifier">MESH:C000720167</infon><infon key="type">Chemical</infon><location offset="943" length="4"/><text>JX06</text></annotation><annotation id="19"><infon key="identifier">MESH:C080022</infon><infon key="type">Chemical</infon><location offset="953" length="13"/><text>lavendustin C</text></annotation><annotation id="20"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1138" length="10"/><text>toxicities</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1270" length="7"/><text>DDAN-MT</text></annotation></passage></document>
<document><id>37900645</id><passage><infon key="journal">Indian J Surg Oncol;2023Sep; 14 (3) 752. doi:10.1007/s13193-023-01793-x</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10611654</infon><infon key="type">title</infon><infon key="authors">Das S, Mishra SS, Rakshit K, Agarwal R, </infon><offset>0</offset><text>Case Report: Primary Ewing Sarcoma of the Penis.</text><annotation id="1"><infon key="identifier">MESH:D012512</infon><infon key="type">Disease</infon><location offset="21" length="13"/><text>Ewing Sarcoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>49</offset><text>Background: Ewing sarcoma is a malignancy that commonly affects the skeletal system and primary extraskeletal involvement is rare. Extraskeletal Ewing sarcoma (EES) arises in soft tissue anywhere in the body. These are very rarely seen aggressive tumours. There have been only 7 reported cases of EES of penis. Case Presentation: We report a 22-year-young patient who presented to our hospital with a ulcero-proliferative growth in the shaft of penis. There were no other complaints indicating any metastasis. Incisional biopsy was suggestive of invasive malignancy. He was scheduled for a partial penectomy. Final HPE and IHC were suggestive of EES. Conclusion: EES as a subtype of Ewing sarcoma is rare and it can occur in any soft tissue site. Hence, clinicians need to differentiate this entity from other soft tissue sarcomas. Early diagnosis and timely treatment of EES are pivotal for a favourable prognosis due to its aggressive nature. Supplementary Information: The online version contains supplementary material available at 10.1007/s13193-023-01793-x.</text><annotation id="15"><infon key="identifier">MESH:D012512</infon><infon key="type">Disease</infon><location offset="61" length="13"/><text>Ewing sarcoma</text></annotation><annotation id="16"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="80" length="10"/><text>malignancy</text></annotation><annotation id="17"><infon key="identifier">MESH:D012512</infon><infon key="type">Disease</infon><location offset="180" length="27"/><text>Extraskeletal Ewing sarcoma</text></annotation><annotation id="18"><infon key="identifier">MESH:D012512</infon><infon key="type">Disease</infon><location offset="209" length="3"/><text>EES</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="296" length="7"/><text>tumours</text></annotation><annotation id="20"><infon key="identifier">MESH:D012512</infon><infon key="type">Disease</infon><location offset="346" length="3"/><text>EES</text></annotation><annotation id="21"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="547" length="10"/><text>metastasis</text></annotation><annotation id="22"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="604" length="10"/><text>malignancy</text></annotation><annotation id="23"><infon key="identifier">MESH:D012512</infon><infon key="type">Disease</infon><location offset="695" length="3"/><text>EES</text></annotation><annotation id="24"><infon key="identifier">MESH:D012512</infon><infon key="type">Disease</infon><location offset="712" length="3"/><text>EES</text></annotation><annotation id="25"><infon key="identifier">MESH:D012512</infon><infon key="type">Disease</infon><location offset="732" length="13"/><text>Ewing sarcoma</text></annotation><annotation id="26"><infon key="identifier">MESH:D012509</infon><infon key="type">Disease</infon><location offset="859" length="20"/><text>soft tissue sarcomas</text></annotation><annotation id="27"><infon key="identifier">MESH:D012512</infon><infon key="type">Disease</infon><location offset="921" length="3"/><text>EES</text></annotation></passage></document>
<document><id>37902045</id><passage><infon key="journal">Pak J Biol Sci;2023May; 26 (6) 311. doi:10.3923/pjbs.2023.311.320</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Alotaibi MA, </infon><offset>0</offset><text>Empirical Study on Exploring the Role of CD180 and MD-1 Prognostic Indicators for the Chronic Lymphocytic Leukaemia (CLL) Disease.</text><annotation id="3"><infon key="identifier">4064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4077</infon><location offset="41" length="5"/><text>CD180</text></annotation><annotation id="4"><infon key="identifier">4095</infon><infon key="type">Gene</infon><location offset="51" length="4"/><text>MD-1</text></annotation><annotation id="5"><infon key="identifier">MESH:D015461</infon><infon key="type">Disease</infon><location offset="86" length="43"/><text>Chronic Lymphocytic Leukaemia (CLL) Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>131</offset><text>&amp;amp;lt;b&amp;amp;gt;Background and Objective:&amp;amp;lt;/b&amp;amp;gt; Chronic Lymphocytic Leukaemia (CLL) is a frequent type of leukaemia disease. This study was focused on investigating the role of prognostic indicators, such as CD180 and MD-1 for Chronic Lymphocytic Leukaemia (CLL) pathogenesis because they involve cell signalling and proliferation. &amp;amp;lt;b&amp;amp;gt;Materials and Methods:&amp;amp;lt;/b&amp;amp;gt; A total of 12 normal controls and 52 patients were taken to determine the expressions of CD180 and MD-1 with different variations in comparison with the IgVH (Immunoglobulin Heavy Chain variable region gene) mutational status, FISH (fluorescence &amp;amp;lt;i&amp;amp;gt;in situ&amp;amp;lt;/i&amp;amp;gt; hybridization) and Rai staging. &amp;amp;lt;b&amp;amp;gt;Results:&amp;amp;lt;/b&amp;amp;gt; The quantitative data findings were evident that CD180 and MD-1 expressions showed insignificant differences among CLL patients at the protein level based on SPSS results. On the contrary, they resulted in significant differences for subgroups of established biomarkers like Rai staging (stages 0, I, II and III), FISH (13q and non-13q deletions) and IgVH (mutated and unmutated). &amp;amp;lt;b&amp;amp;gt;Conclusion:&amp;amp;lt;/b&amp;amp;gt; The CD180 and MD-1 have been used as prognostic indicators to evaluate the outcomes relevant to the cell cycle and survival rate of CLL cells.</text><annotation id="25"><infon key="identifier">MESH:D015461</infon><infon key="type">Disease</infon><location offset="192" length="29"/><text>Chronic Lymphocytic Leukaemia</text></annotation><annotation id="26"><infon key="identifier">MESH:D015461</infon><infon key="type">Disease</infon><location offset="223" length="3"/><text>CLL</text></annotation><annotation id="27"><infon key="identifier">MESH:D015458</infon><infon key="type">Disease</infon><location offset="250" length="17"/><text>leukaemia disease</text></annotation><annotation id="28"><infon key="identifier">4064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4077</infon><location offset="352" length="5"/><text>CD180</text></annotation><annotation id="29"><infon key="identifier">4095</infon><infon key="type">Gene</infon><location offset="362" length="4"/><text>MD-1</text></annotation><annotation id="30"><infon key="identifier">MESH:D015461</infon><infon key="type">Disease</infon><location offset="371" length="29"/><text>Chronic Lymphocytic Leukaemia</text></annotation><annotation id="31"><infon key="identifier">MESH:D015461</infon><infon key="type">Disease</infon><location offset="402" length="3"/><text>CLL</text></annotation><annotation id="32"><infon key="identifier">4064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4077</infon><location offset="623" length="5"/><text>CD180</text></annotation><annotation id="33"><infon key="identifier">4095</infon><infon key="type">Gene</infon><location offset="633" length="4"/><text>MD-1</text></annotation><annotation id="34"><infon key="identifier">28402</infon><infon key="type">Gene</infon><location offset="687" length="4"/><text>IgVH</text></annotation><annotation id="35"><infon key="identifier">MESH:C564523</infon><infon key="type">Disease</infon><location offset="842" length="3"/><text>Rai</text></annotation><annotation id="36"><infon key="identifier">4064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4077</infon><location offset="948" length="5"/><text>CD180</text></annotation><annotation id="37"><infon key="identifier">4095</infon><infon key="type">Gene</infon><location offset="958" length="4"/><text>MD-1</text></annotation><annotation id="38"><infon key="identifier">MESH:D015461</infon><infon key="type">Disease</infon><location offset="1014" length="3"/><text>CLL</text></annotation><annotation id="39"><infon key="identifier">MESH:C564523</infon><infon key="type">Disease</infon><location offset="1174" length="3"/><text>Rai</text></annotation><annotation id="40"><infon key="identifier">28402</infon><infon key="type">Gene</infon><location offset="1250" length="4"/><text>IgVH</text></annotation><annotation id="41"><infon key="identifier">4064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4077</infon><location offset="1331" length="5"/><text>CD180</text></annotation><annotation id="42"><infon key="identifier">4095</infon><infon key="type">Gene</infon><location offset="1341" length="4"/><text>MD-1</text></annotation><annotation id="43"><infon key="identifier">MESH:D015461</infon><infon key="type">Disease</infon><location offset="1459" length="3"/><text>CLL</text></annotation></passage><relation id="R1"><infon key="score">0.9902</infon><infon key="role1">Disease|MESH:C564523</infon><infon key="role2">Gene|4095</infon><infon key="type">Association</infon><node refid="0" role="13,11"/></relation><relation id="R2"><infon key="score">0.9871</infon><infon key="role1">Disease|MESH:D015461</infon><infon key="role2">Gene|4095</infon><infon key="type">Association</infon><node refid="1" role="2,1"/></relation><relation id="R3"><infon key="score">0.9799</infon><infon key="role1">Disease|MESH:D015461</infon><infon key="role2">Gene|4064</infon><infon key="type">Association</infon><node refid="2" role="2,0"/></relation><relation id="R4"><infon key="score">0.924</infon><infon key="role1">Disease|MESH:C564523</infon><infon key="role2">Gene|4064</infon><infon key="type">Association</infon><node refid="3" role="13,10"/></relation></document>
<document><id>37902395</id><passage><infon key="journal">Haemophilia;2023Oct30. doi:10.1111/hae.14894</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Escobar MA, Kavakli K, </infon><offset>0</offset><text>Plasma-derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency.</text><annotation id="1"><infon key="identifier">MESH:D009386</infon><infon key="type">Disease</infon><location offset="77" length="30"/><text>hereditary factor X deficiency</text></annotation></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>INTRODUCTION: Hereditary factor X (FX) deficiency (HFXD) is an autosomal recessive rare bleeding disorder that leads to defects in the FX protein. Depending on the degree of deficiency, patients may be at risk of life-threatening bleeding episodes. Historical treatments for FX deficiency include prothrombin complex concentrates, which can increase the risk of thrombosis, and fresh frozen plasma, which can cause volume overload and transfusion reactions. Plasma-derived FX (pdFX), a single-factor, high-purity, high-potency human FX treatment, was approved in 2015 in the United States and in 2016 in Europe for on-demand treatment and prophylaxis of bleeding episodes and perioperative management of patients with HFXD. METHODS: Five studies that examined the use of pdFX in patients with mild (plasma FX activity [FX:C] >=5 IU/dL), moderate (FX:C >=1 and &lt;5 IU/dL), or severe (FX:C &lt; 1 IU/dL) HFXD were reviewed: TEN01, TEN02 and TEN03 were prospective, open-label, multicentre, nonrandomised studies, and TEN05 and TEN06 were multicentre retrospective studies. RESULTS: When used as an on-demand treatment, pdFX was judged by investigators to be successful in treating 41/42 (97.6%), 2/3 (66.6%) and 79/79 (100%) bleeds in TEN01, TEN02 and TEN05, respectively. When used prophylactically, pdFX was judged 'excellent' for the prevention of bleeds in nine (100%) and eight (100%) patients in TEN02 and TEN05, respectively. Perioperative treatment and pharmacokinetics were also assessed. pdFX was safe and well tolerated. CONCLUSIONS: Together, these studies support the use of pdFX for on-demand treatment of bleeding, routine prophylaxis, and perioperative management of bleeding in patients with HFXD.</text><annotation id="17"><infon key="identifier">MESH:D009386</infon><infon key="type">Disease</infon><location offset="123" length="35"/><text>Hereditary factor X (FX) deficiency</text></annotation><annotation id="18"><infon key="type">Disease</infon><location offset="160" length="4"/><text>HFXD</text></annotation><annotation id="19"><infon key="type">Disease</infon><location offset="172" length="42"/><text>autosomal recessive rare bleeding disorder</text></annotation><annotation id="20"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="339" length="8"/><text>bleeding</text></annotation><annotation id="21"><infon key="identifier">MESH:D005171</infon><infon key="type">Disease</infon><location offset="384" length="13"/><text>FX deficiency</text></annotation><annotation id="22"><infon key="identifier">MESH:D013927</infon><infon key="type">Disease</infon><location offset="471" length="10"/><text>thrombosis</text></annotation><annotation id="23"><infon key="identifier">MESH:D019190</infon><infon key="type">Disease</infon><location offset="524" length="15"/><text>volume overload</text></annotation><annotation id="24"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="763" length="8"/><text>bleeding</text></annotation><annotation id="25"><infon key="type">Disease</infon><location offset="827" length="4"/><text>HFXD</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="1007" length="4"/><text>HFXD</text></annotation><annotation id="27"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="1328" length="6"/><text>bleeds</text></annotation><annotation id="28"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="1454" length="6"/><text>bleeds</text></annotation><annotation id="29"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="1723" length="8"/><text>bleeding</text></annotation><annotation id="30"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="1786" length="8"/><text>bleeding</text></annotation><annotation id="31"><infon key="type">Disease</infon><location offset="1812" length="4"/><text>HFXD</text></annotation></passage></document>
<document><id>37902745</id><passage><infon key="journal">JAMA Intern Med;2023Oct30. doi:10.1001/jamainternmed.2023.5712</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Incze MA, Azari S, Finnell DS, </infon><offset>0</offset><text>Amplifying the Strength and Leadership of Nurses in Opioid Use Disorder Care-Loud and PROUD.</text><annotation id="2"><infon key="identifier">MESH:D009293</infon><infon key="type">Disease</infon><location offset="52" length="19"/><text>Opioid Use Disorder</text></annotation><annotation id="3"><infon key="identifier">MESH:C563110</infon><infon key="type">Disease</infon><location offset="86" length="5"/><text>PROUD</text></annotation></passage><passage><infon key="type">abstract</infon><offset>93</offset></passage></document>
<document><id>37903098</id><passage><infon key="journal">Global Spine J;2023Oct30 21925682231209869. doi:10.1177/21925682231209869</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jiang Z, Davies B, Zipser C, Margetis K, Martin A, Matsoukas S, Zipser-Mohammadzada F, Kheram N, Boraschi A, Zakin E, Obadaseraye OR, Fehlings MG, Wilson J, Yurac R, Cook CE, Milligan J, Tabrah J, Widdop S, Wood L, Roberts EA, Rujeedawa T, Tetreault L, AO Spine RECODE-DCM Diagnostic Criteria Incubator, </infon><offset>0</offset><text>The value of Clinical signs in the diagnosis of Degenerative Cervical Myelopathy - A Systematic review and Meta-analysis.</text><annotation id="1"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="48" length="32"/><text>Degenerative Cervical Myelopathy</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>STUDY DESIGN: Delayed diagnosis of degenerative cervical myelopathy (DCM) is likely due to a combination of its subtle symptoms, incomplete neurological assessments by clinicians and a lack of public and professional awareness. Diagnostic criteria for DCM will likely facilitate earlier referral for definitive management. OBJECTIVES: This systematic review aims to determine (i) the diagnostic accuracy of various clinical signs and (ii) the association between clinical signs and disease severity in DCM? METHODS: A search was performed to identify studies on adult patients that evaluated the diagnostic accuracy of a clinical sign used for diagnosing DCM. Studies were also included if they assessed the association between the presence of a clinical sign and disease severity. The QUADAS-2 tool was used to evaluate the risk of bias of individual studies. RESULTS: This review identified eleven studies that used a control group to evaluate the diagnostic accuracy of various signs. An additional 61 articles reported on the frequency of clinical signs in a cohort of DCM patients. The most sensitive clinical tests for diagnosing DCM were the Tromner and hyperreflexia, whereas the most specific tests were the Babinski, Tromner, clonus and inverted supinator sign. Five studies evaluated the association between the presence of various clinical signs and disease severity. There was no definite association between Hoffmann sign, Babinski sign or hyperreflexia and disease severity. CONCLUSION: The presence of clinical signs suggesting spinal cord compression should encourage health care professionals to pursue further investigation, such as neuroimaging to either confirm or refute a diagnosis of DCM.</text><annotation id="13"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="157" length="32"/><text>degenerative cervical myelopathy</text></annotation><annotation id="14"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="191" length="3"/><text>DCM</text></annotation><annotation id="15"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="374" length="3"/><text>DCM</text></annotation><annotation id="16"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="624" length="3"/><text>DCM</text></annotation><annotation id="17"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="777" length="3"/><text>DCM</text></annotation><annotation id="18"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="1195" length="3"/><text>DCM</text></annotation><annotation id="19"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="1258" length="3"/><text>DCM</text></annotation><annotation id="20"><infon key="identifier">MESH:D012021</infon><infon key="type">Disease</infon><location offset="1283" length="13"/><text>hyperreflexia</text></annotation><annotation id="21"><infon key="identifier">MESH:D012021</infon><infon key="type">Disease</infon><location offset="1576" length="13"/><text>hyperreflexia</text></annotation><annotation id="22"><infon key="identifier">MESH:D013117</infon><infon key="type">Disease</infon><location offset="1666" length="23"/><text>spinal cord compression</text></annotation><annotation id="23"><infon key="identifier">MESH:D002575</infon><infon key="type">Disease</infon><location offset="1830" length="3"/><text>DCM</text></annotation></passage></document>
<document><id>37903473</id><passage><infon key="journal">J Innate Immun;2023Oct30. doi:10.1159/000534704</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhou M, Liu Y, Xu H, Chen X, Zheng N, Duan Z, Ge Y, Li D, Lin T, Zeng R, Chen Q, Li M, </infon><offset>0</offset><text>YTHDC1-modified m6A methylation of hsa_circ_0102678 promotes keratinocyte inflammation induced by Cutibacterium acnes biofilm through regulating miR-146a/TRAF6 and IRAK1 axis.</text><annotation id="6"><infon key="identifier">91746</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">15796</infon><location offset="0" length="6"/><text>YTHDC1</text></annotation><annotation id="7"><infon key="identifier">MESH:C005955</infon><infon key="type">Chemical</infon><location offset="16" length="3"/><text>m6A</text></annotation><annotation id="8"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="74" length="12"/><text>inflammation</text></annotation><annotation id="9"><infon key="identifier">406938</infon><infon key="type">Gene</infon><location offset="145" length="8"/><text>miR-146a</text></annotation><annotation id="10"><infon key="identifier">7189</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3395</infon><location offset="154" length="5"/><text>TRAF6</text></annotation><annotation id="11"><infon key="identifier">3654</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37496</infon><location offset="164" length="5"/><text>IRAK1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>176</offset><text>INTRODUCTION: CircRNAs are closely related to many human diseases, however, their role in acne remains unclear. This study aimed to determine the role of hsa-circ_0102678 in regulating inflammation of acne. METHODS: Firstly, microarray analysis was performed to study the expression of circRNAs in acne. Subsequently, RNase R digestion assay and FISH assay were utilized to confirm the characteristics of hsa-circ_0102678. Finally, qRT-PCR, Western blotting analysis, Immunoprecipitation, Luciferase reporter assay, circRNA probe pull-down assay, Biotin-labeled miRNA pull-down assay, RNA immunoprecipitation (RIP) assay and m6A dot blot assay were utilized to reveal the functional roles of hsa-circ_0102678 on inflammation induced by C. acnes biofilm in human primary keratinocytes. RESULTS: Our investigations showed that the expression of hsa-circ_0102678 was significantly decreased in acne tissues and hsa-circ_0102678 was a type of circRNAs, which was mainly localized in the cytoplasm of primary human keratinocytes. Moreover, hsa-circ_0102678 remarkably affected the expression of IL-8, IL-6, and TNF-alpha, which induced by C. acnes biofilm. Importantly, mechanistic studies indicated that the YTHDC1 could bind directly to hsa-circ_0102678 and promote the export of N6-methyladenosine modified hsa-circ_0102678 to the cytoplasm. Besides, hsa-circ_0102678 could bind to miR-146a and sponge miR-146a to promote the expression of IRAK1 and TRAF6. CONCLUSION: Our findings revealed a previously unknown process by which hsa_circ_0102678 promoted keratinocyte inflammation induced by C. acnes biofilm via regulating miR-146a/TRAF6 and IRAK1 axis.</text><annotation id="33"><infon key="identifier">MESH:D000152</infon><infon key="type">Disease</infon><location offset="266" length="4"/><text>acne</text></annotation><annotation id="34"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="361" length="15"/><text>inflammation of</text></annotation><annotation id="35"><infon key="identifier">MESH:D000152</infon><infon key="type">Disease</infon><location offset="377" length="4"/><text>acne</text></annotation><annotation id="36"><infon key="identifier">MESH:D000152</infon><infon key="type">Disease</infon><location offset="474" length="4"/><text>acne</text></annotation><annotation id="37"><infon key="identifier">MESH:D001710</infon><infon key="type">Chemical</infon><location offset="723" length="6"/><text>Biotin</text></annotation><annotation id="38"><infon key="identifier">MESH:C005955</infon><infon key="type">Chemical</infon><location offset="801" length="3"/><text>m6A</text></annotation><annotation id="39"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="888" length="12"/><text>inflammation</text></annotation><annotation id="40"><infon key="identifier">MESH:D000152</infon><infon key="type">Disease</infon><location offset="1067" length="4"/><text>acne</text></annotation><annotation id="41"><infon key="identifier">3576</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47937</infon><location offset="1266" length="4"/><text>IL-8</text></annotation><annotation id="42"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1272" length="4"/><text>IL-6</text></annotation><annotation id="43"><infon key="identifier">7124</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="1282" length="9"/><text>TNF-alpha</text></annotation><annotation id="44"><infon key="identifier">91746</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">15796</infon><location offset="1380" length="6"/><text>YTHDC1</text></annotation><annotation id="45"><infon key="identifier">MESH:C010223</infon><infon key="type">Chemical</infon><location offset="1453" length="18"/><text>N6-methyladenosine</text></annotation><annotation id="46"><infon key="identifier">406938</infon><infon key="type">Gene</infon><location offset="1556" length="8"/><text>miR-146a</text></annotation><annotation id="47"><infon key="identifier">406938</infon><infon key="type">Gene</infon><location offset="1576" length="8"/><text>miR-146a</text></annotation><annotation id="48"><infon key="identifier">3654</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37496</infon><location offset="1614" length="5"/><text>IRAK1</text></annotation><annotation id="49"><infon key="identifier">7189</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3395</infon><location offset="1624" length="5"/><text>TRAF6</text></annotation><annotation id="50"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1742" length="12"/><text>inflammation</text></annotation><annotation id="51"><infon key="identifier">406938</infon><infon key="type">Gene</infon><location offset="1798" length="8"/><text>miR-146a</text></annotation><annotation id="52"><infon key="identifier">7189</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3395</infon><location offset="1807" length="5"/><text>TRAF6</text></annotation><annotation id="53"><infon key="identifier">3654</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37496</infon><location offset="1817" length="5"/><text>IRAK1</text></annotation></passage><relation id="R1"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|406938</infon><infon key="type">Association</infon><node refid="0" role="2,3"/></relation><relation id="R2"><infon key="score">0.7241</infon><infon key="role1">Gene|406938</infon><infon key="role2">Gene|91746</infon><infon key="type">Association</infon><node refid="1" role="3,0"/></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|3654</infon><infon key="type">Association</infon><node refid="2" role="2,5"/></relation><relation id="R4"><infon key="score">0.5973</infon><infon key="role1">Chemical|MESH:C005955</infon><infon key="role2">Gene|3654</infon><infon key="type">Association</infon><node refid="3" role="1,5"/></relation><relation id="R5"><infon key="score">0.9995</infon><infon key="role1">Chemical|MESH:C005955</infon><infon key="role2">Gene|91746</infon><infon key="type">Association</infon><node refid="4" role="1,0"/></relation><relation id="R6"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:C010223</infon><infon key="role2">Gene|91746</infon><infon key="type">Association</infon><node refid="5" role="18,17"/></relation><relation id="R7"><infon key="score">0.9445</infon><infon key="role1">Gene|7189</infon><infon key="role2">Gene|91746</infon><infon key="type">Association</infon><node refid="6" role="4,0"/></relation><relation id="R8"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|7189</infon><infon key="type">Association</infon><node refid="7" role="2,4"/></relation><relation id="R9"><infon key="score">0.9946</infon><infon key="role1">Chemical|MESH:C005955</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Association</infon><node refid="8" role="1,2"/></relation><relation id="R10"><infon key="score">0.9967</infon><infon key="role1">Gene|3654</infon><infon key="role2">Gene|91746</infon><infon key="type">Association</infon><node refid="9" role="5,0"/></relation><relation id="R11"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|91746</infon><infon key="type">Association</infon><node refid="10" role="2,0"/></relation></document>
<document><id>37904525</id><passage><infon key="journal">Nat Prod Res;2023Oct30 1. doi:10.1080/14786419.2023.2275738</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Frezza C, Sciubba F, Giampaoli O, De Salvador FR, Lucarini M, Engel P, Patriarca A, Spagnoli M, Gianferri R, Delfini M, Di Cocco ME, De Vita D, </infon><offset>0</offset><text>Comparison of the metabolic profile of pecan nuts cultivars [Carya illinoinensis (Wangenh.) K. Koch] by NMR spectroscopy.</text></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>Pecan nuts (Carya illinoinensis (Wangenh.) K. Koch) contain the highest number of phytochemicals of all nuts, are a natural source of unsaturated fatty acids and other nutrients and can be considered an important addition to the Mediterranean diet al.though several studies have been carried out on pecans, employing several analytical techniques, no systematic study of the metabolic profile is available in literature. In this study, the metabolic profile of pecan nuts of three different cultivars was analysed by Nuclear Magnetic Resonance Spectroscopy. The cultivars compared were Wichita, Stuart, and Sioux, all grown in Italy in the same pedoclimatic conditions. 31 metabolites were identified and 28 were quantified and the three species were differentiated based on multivariate PCA analysis. The differences among them, and the levels of scutellarein and GABA, in particular, were attributed to the adaptation of the plants to the climate in their original areas.</text><annotation id="3"><infon key="identifier">MESH:D005231</infon><infon key="type">Chemical</infon><location offset="256" length="23"/><text>unsaturated fatty acids</text></annotation><annotation id="4"><infon key="identifier">MESH:C458179</infon><infon key="type">Chemical</infon><location offset="970" length="12"/><text>scutellarein</text></annotation><annotation id="5"><infon key="identifier">MESH:D005680</infon><infon key="type">Chemical</infon><location offset="987" length="4"/><text>GABA</text></annotation></passage></document>
<document><id>37905576</id><passage><infon key="journal">J Liposome Res;2023Oct31 1. doi:10.1080/08982104.2023.2274424</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Aizawa H, </infon><offset>0</offset><text>Impact of micelle characteristics on cholesterol absorption and ezetimibe inhibition: Insights from Niemann-Pick C1-like 1 binding and molecular structure.</text><annotation id="3"><infon key="identifier">MESH:D002784</infon><infon key="type">Chemical</infon><location offset="37" length="11"/><text>cholesterol</text></annotation><annotation id="4"><infon key="identifier">MESH:D000069438</infon><infon key="type">Chemical</infon><location offset="64" length="9"/><text>ezetimibe</text></annotation><annotation id="5"><infon key="identifier">29881</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56585</infon><location offset="100" length="22"/><text>Niemann-Pick C1-like 1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>156</offset><text>Yamanashi et al., conducted a study on the absorption of cholesterol and beta-sitosterol, as well as the inhibitory effect of ezetimibe (EZE). They used CaCo-2 cells to simulate the intestines and investigated how different mixed micelles, acting as carriers, were absorbed into these cells through the Niemann-Pick C1-like 1 (NPC1L1) protein. The study focused on the impact of micelle shape, size, and zeta potential on absorption and the inhibitory effect of EZE. I utilized small-angle X-ray scattering and a zeta potential measuring device to measure these characteristics. The findings revealed a two-step mechanism: NPC1L1 selectively bound micelles based on their shape and size, and once bound, the absorption was regulated by the molecular structure of the micelle components. EZE's inhibitory effect changed with micelle composition, influencing micelle size and shape. EZE initially acted on the micelle's shape and size, and then NPC1L1 selectively bound micelles based on their shape and size, allowing EZE to directly inhibit absorption by interacting with NPC1L1. This groundbreaking discovery challenges existing concepts and holds significant implications for researchers in drug development, as well as physicians and pharmacists.</text><annotation id="20"><infon key="identifier">MESH:D002784</infon><infon key="type">Chemical</infon><location offset="213" length="11"/><text>cholesterol</text></annotation><annotation id="21"><infon key="identifier">MESH:C025473</infon><infon key="type">Chemical</infon><location offset="229" length="15"/><text>beta-sitosterol</text></annotation><annotation id="22"><infon key="identifier">MESH:D000069438</infon><infon key="type">Chemical</infon><location offset="282" length="9"/><text>ezetimibe</text></annotation><annotation id="23"><infon key="identifier">MESH:D000069438</infon><infon key="type">Chemical</infon><location offset="293" length="3"/><text>EZE</text></annotation><annotation id="24"><infon key="identifier">CVCL:0025</infon><infon key="type">CellLine</infon><location offset="309" length="6"/><text>CaCo-2</text></annotation><annotation id="25"><infon key="identifier">29881</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56585</infon><location offset="459" length="22"/><text>Niemann-Pick C1-like 1</text></annotation><annotation id="26"><infon key="identifier">29881</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56585</infon><location offset="483" length="6"/><text>NPC1L1</text></annotation><annotation id="27"><infon key="identifier">MESH:D000069438</infon><infon key="type">Chemical</infon><location offset="618" length="3"/><text>EZE</text></annotation><annotation id="28"><infon key="identifier">29881</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56585</infon><location offset="779" length="6"/><text>NPC1L1</text></annotation><annotation id="29"><infon key="identifier">MESH:D000069438</infon><infon key="type">Chemical</infon><location offset="943" length="3"/><text>EZE</text></annotation><annotation id="30"><infon key="identifier">MESH:D000069438</infon><infon key="type">Chemical</infon><location offset="1037" length="3"/><text>EZE</text></annotation><annotation id="31"><infon key="identifier">29881</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56585</infon><location offset="1099" length="6"/><text>NPC1L1</text></annotation><annotation id="32"><infon key="identifier">MESH:D000069438</infon><infon key="type">Chemical</infon><location offset="1173" length="3"/><text>EZE</text></annotation><annotation id="33"><infon key="identifier">29881</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56585</infon><location offset="1228" length="6"/><text>NPC1L1</text></annotation></passage><relation id="R1"><infon key="score">0.8217</infon><infon key="role1">Chemical|MESH:D000069438</infon><infon key="role2">Gene|29881</infon><infon key="type">Association</infon><node refid="0" role="1,2"/></relation></document>
<document><id>37905926</id><passage><infon key="journal">Appl Environ Microbiol;2023Oct31 0116823. doi:10.1128/aem.01168-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mittal P, Sipani R, Pandiyan A, Sulthana S, Sinha AK, Hussain A, Ray MK, Pavankumar TL, </infon><offset>0</offset><text>Exoribonuclease RNase R protects Antarctic Pseudomonas syringae Lz4W from DNA damage and oxidative stress.</text></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>RNase R is a highly processive, 3'-5' exoribonuclease involved in RNA degradation, maturation, and processing in bacteria. In Pseudomonas syringae Lz4W, RNase R interacts with RNase E to form the RNA degradosome complex and is essential for growth at low temperature. RNase R is also implicated in general stress response in many bacteria. We show here that the deletion mutant of rnr gene (encoding RNase R) of P. syringae is highly sensitive to various DNA damaging agents and oxidative stress. RNase R is a multidomain protein comprised of cold shock domain, RNB, and S1 domains. We investigated the role of each domain of RNase R and its exoribonuclease activity in nucleic acid damage and oxidative stress response. Our results revealed that the RNB domain alone without its exoribonuclease activity is sufficient to protect against DNA damage and oxidative stress. We also show that the association of RNase R with the degradosome complex is not required for this function. Our study has discovered for the first time a hitherto unknown role of RNase R in protecting P. syringae Lz4W against DNA damage and oxidative stress. IMPORTANCE Bacterial exoribonucleases play a crucial role in RNA maturation, degradation, quality control, and turnover. In this study, we have uncovered a previously unknown role of 3'-5' exoribonuclease RNase R of Pseudomonas syringae Lz4W in DNA damage and oxidative stress response. Here, we show that neither the exoribonuclease function of RNase R nor its association with the RNA degradosome complex is essential for this function. Interestingly, in P. syringae Lz4W, hydrolytic RNase R exhibits physiological roles similar to phosphorolytic 3'-5' exoribonuclease PNPase of E. coli. Our data suggest that during the course of evolution, mesophilic E. coli and psychrotrophic P. syringae have apparently swapped these exoribonucleases to adapt to their respective environmental growth conditions.</text></passage></document>
<document><id>37906278</id><passage><infon key="journal">Appl Microbiol Biotechnol;2023Oct31. doi:10.1007/s00253-023-12803-x</infon><infon key="year">2023</infon><infon key="article-id_pmc">7326054</infon><infon key="type">title</infon><infon key="authors">Fan Y, Li J, Ren X, Wang D, Liu Y, </infon><offset>0</offset><text>Preparation, characterization, bacteriostatic efficacy, and mechanism of zinc/selenium-loaded sodium humate.</text><annotation id="2"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="78" length="8"/><text>selenium</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="94" length="13"/><text>sodium humate</text></annotation></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>In recent years, metal-based complexes including selenium (Se) and zinc (Zn)-containing compounds have been widely explored for their therapeutic properties due to their roles in biological processes and modulation of diverse molecular targets. Humic acid, as a metal complexing agent, is also widely used in biomedical field. In this work, three kinds of modified sodium humate (HNa), including Zn-HNA, Se-HNa, and Zn/Se-HNa, were prepared by ion exchange reaction method. The modified HNa was characterized by X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and elemental mapping. The bacteriostatic activity and mechanism of modified HNa against gram-positive and gram-negative bacteria were investigated by testing bacterial inhibition zone, minimum inhibitory concentration, and capacity to destroy integrity of the bacterial membrane, promoting ROS generation level and prevention of biofilms. FTIR results showed that HNa could combine with zinc ions and selenite ions. The main XRD peaks did not change significantly. In the modified HNa, the particle shape was irregular. Compared to HNa, Zn-HNA, and Se-HNa, Zn/Se-HNa showed the strongest bacteriostatic activity. Zn/Se-HNa exhibited high bacteriostatic activity against gram-negative bacteria (Escherichia coli, Salmonella typhimurium, Klebsiella pneumoniae) and gram-positive bacteria (Staphylococcus aureus), but showed weak antibacterial activity against another gram-positive bacteria, Bacillus subtilis. The bacteriostasis was achieved by altering the permeability of bacterial cell membranes, generating ROS, and preventing the formation of biofilms. In conclusion, Zn/Se-HNa has high bacteriostatic activity, making it a suitable alternative to antibiotics in fields like the treatment of trauma infections and animal husbandry. KEY POINTS:   Preparate and characterize zinc- and selenium-loaded sodium humate (Zn/Se-HNa).   The combination of Zn and Se enhanced the bacteriostatic activity of HNa.   Zn/Se-HNa alters the permeability of bacterial cell membranes and promotes generation of ROS.</text><annotation id="36"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="126" length="5"/><text>metal</text></annotation><annotation id="37"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="158" length="8"/><text>selenium</text></annotation><annotation id="38"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="168" length="2"/><text>Se</text></annotation><annotation id="39"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="182" length="2"/><text>Zn</text></annotation><annotation id="40"><infon key="identifier">MESH:D006812</infon><infon key="type">Chemical</infon><location offset="354" length="10"/><text>Humic acid</text></annotation><annotation id="41"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="371" length="5"/><text>metal</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="474" length="13"/><text>sodium humate</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="505" length="6"/><text>Zn-HNA</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="513" length="6"/><text>Se-HNa</text></annotation><annotation id="45"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="525" length="2"/><text>Zn</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="528" length="6"/><text>Se-HNa</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1021" length="3"/><text>ROS</text></annotation><annotation id="48"><infon key="identifier">MESH:D020887</infon><infon key="type">Chemical</infon><location offset="1132" length="8"/><text>selenite</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1268" length="6"/><text>Zn-HNA</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1280" length="6"/><text>Se-HNa</text></annotation><annotation id="51"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="1288" length="2"/><text>Zn</text></annotation><annotation id="52"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1291" length="6"/><text>Se-HNa</text></annotation><annotation id="53"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="1344" length="2"/><text>Zn</text></annotation><annotation id="54"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1347" length="6"/><text>Se-HNa</text></annotation><annotation id="55"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1741" length="3"/><text>ROS</text></annotation><annotation id="56"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="1803" length="3"/><text>Zn/</text></annotation><annotation id="57"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1806" length="6"/><text>Se-HNa</text></annotation><annotation id="58"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1927" length="17"/><text>trauma infections</text></annotation><annotation id="59"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="2018" length="8"/><text>selenium</text></annotation><annotation id="60"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2034" length="13"/><text>sodium humate</text></annotation><annotation id="61"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="2049" length="2"/><text>Zn</text></annotation><annotation id="62"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2052" length="6"/><text>Se-HNa</text></annotation><annotation id="63"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="2082" length="2"/><text>Zn</text></annotation><annotation id="64"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="2089" length="2"/><text>Se</text></annotation><annotation id="65"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="2139" length="2"/><text>Zn</text></annotation><annotation id="66"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2142" length="6"/><text>Se-HNa</text></annotation><annotation id="67"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2228" length="3"/><text>ROS</text></annotation></passage><relation id="R1"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D015032</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="25,27"/></relation><relation id="R2"><infon key="score">0.9707</infon><infon key="role1">Chemical|MESH:D006812</infon><infon key="role2">Chemical|MESH:D008670</infon><infon key="type">Association</infon><node refid="1" role="8,9"/></relation></document>
<document><id>37906628</id><passage><infon key="journal">Sci Signal;2023Oct31; 16 (809) 5171. doi:10.1126/scisignal.adg5171</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Loh JT, Teo JKH, Kannan S, Verma CS, Andiappan AK, Lim HH, Lam KP, </infon><offset>0</offset><text>DOK3 promotes atopic dermatitis by enabling the phosphatase PP4C to inhibit the T cell signaling mediator CARD11.</text><annotation id="4"><infon key="identifier">79930</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8448</infon><location offset="0" length="4"/><text>DOK3</text></annotation><annotation id="5"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="14" length="17"/><text>atopic dermatitis</text></annotation><annotation id="6"><infon key="identifier">5531</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2038</infon><location offset="60" length="4"/><text>PP4C</text></annotation><annotation id="7"><infon key="identifier">84433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">13024</infon><location offset="106" length="6"/><text>CARD11</text></annotation></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>The scaffolding protein CARD11 is a critical mediator of antigen receptor signaling in lymphocytes. Hypomorphic (partial loss-of-function) mutations in CARD11 are associated with the development of severe atopic dermatitis, in which T cell receptor signaling is reduced and helper T cell differentiation is skewed to an allergy-associated type 2 phenotype. Here, we found that the docking protein DOK3 plays a key role in the pathogenesis of atopic dermatitis by suppressing CARD11 activity. DOK3 interacted with CARD11 and decreased its phosphorylation in T cells by recruiting the catalytic subunit of protein phosphatase 4, thereby dampening downstream signaling. Knocking out Dok3 enhanced the production of the cytokine IFN-gamma by T cells, which conferred protection against experimental atopic dermatitis-like skin inflammation in mice. The expression of DOK3 was increased in T cells isolated from patients with atopic dermatitis and inversely correlated with IFNG expression. A subset of hypomorphic CARD11 variants found in patients with atopic dermatitis bound more strongly than wild-type CARD11 to DOK3. Our findings suggest that the strength of the interaction of DOK3 with CARD11 may predispose individuals to developing atopic dermatitis.</text><annotation id="31"><infon key="identifier">84433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">13024</infon><location offset="138" length="6"/><text>CARD11</text></annotation><annotation id="32"><infon key="identifier">84433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">13024</infon><location offset="266" length="6"/><text>CARD11</text></annotation><annotation id="33"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="319" length="17"/><text>atopic dermatitis</text></annotation><annotation id="34"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="434" length="25"/><text>allergy-associated type 2</text></annotation><annotation id="35"><infon key="identifier">79930</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8448</infon><location offset="511" length="4"/><text>DOK3</text></annotation><annotation id="36"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="556" length="17"/><text>atopic dermatitis</text></annotation><annotation id="37"><infon key="identifier">84433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">13024</infon><location offset="589" length="6"/><text>CARD11</text></annotation><annotation id="38"><infon key="identifier">79930</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8448</infon><location offset="606" length="4"/><text>DOK3</text></annotation><annotation id="39"><infon key="identifier">84433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">13024</infon><location offset="627" length="6"/><text>CARD11</text></annotation><annotation id="40"><infon key="identifier">27261</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8448</infon><location offset="794" length="4"/><text>Dok3</text></annotation><annotation id="41"><infon key="identifier">15978</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55526</infon><location offset="839" length="9"/><text>IFN-gamma</text></annotation><annotation id="42"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="909" length="17"/><text>atopic dermatitis</text></annotation><annotation id="43"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="932" length="17"/><text>skin inflammation</text></annotation><annotation id="44"><infon key="identifier">79930</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8448</infon><location offset="977" length="4"/><text>DOK3</text></annotation><annotation id="45"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="1035" length="17"/><text>atopic dermatitis</text></annotation><annotation id="46"><infon key="identifier">3458</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55526</infon><location offset="1083" length="4"/><text>IFNG</text></annotation><annotation id="47"><infon key="identifier">84433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">13024</infon><location offset="1124" length="6"/><text>CARD11</text></annotation><annotation id="48"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="1163" length="17"/><text>atopic dermatitis</text></annotation><annotation id="49"><infon key="identifier">84433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">13024</infon><location offset="1216" length="6"/><text>CARD11</text></annotation><annotation id="50"><infon key="identifier">79930</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8448</infon><location offset="1226" length="4"/><text>DOK3</text></annotation><annotation id="51"><infon key="identifier">79930</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8448</infon><location offset="1293" length="4"/><text>DOK3</text></annotation><annotation id="52"><infon key="identifier">84433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">13024</infon><location offset="1303" length="6"/><text>CARD11</text></annotation><annotation id="53"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="1351" length="17"/><text>atopic dermatitis</text></annotation></passage><relation id="R1"><infon key="score">0.8756</infon><infon key="role1">Disease|MESH:D003876</infon><infon key="role2">Gene|79930</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9879</infon><infon key="role1">Gene|5531</infon><infon key="role2">Gene|79930</infon><infon key="type">Association</infon><node refid="1" role="2,0"/></relation><relation id="R3"><infon key="score">0.6988</infon><infon key="role1">Gene|15978</infon><infon key="role2">Gene|27261</infon><infon key="type">Association</infon><node refid="2" role="14,13"/></relation><relation id="R4"><infon key="score">0.9934</infon><infon key="role1">Gene|79930</infon><infon key="role2">Gene|84433</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="0,3"/></relation><relation id="R5"><infon key="score">0.7684</infon><infon key="role1">Gene|5531</infon><infon key="role2">Gene|84433</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="2,3"/></relation><relation id="R6"><infon key="score">0.9988</infon><infon key="role1">Disease|MESH:D004342</infon><infon key="role2">Gene|84433</infon><infon key="type">Association</infon><node refid="5" role="7,5"/></relation><relation id="R7"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D003876</infon><infon key="role2">Gene|84433</infon><infon key="type">Association</infon><node refid="6" role="1,3"/></relation><relation id="R8"><infon key="score">0.96</infon><infon key="role1">Gene|3458</infon><infon key="role2">Gene|79930</infon><infon key="type">Association</infon><node refid="7" role="19,17"/></relation><relation id="R9"><infon key="score">0.9973</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|27261</infon><infon key="type">Association</infon><node refid="8" role="16,13"/></relation></document>
<document><id>37907018</id><passage><infon key="journal">Eur J Surg Oncol;2023Oct27; 49 (12) 107116. doi:10.1016/j.ejso.2023.107116</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Reuvers JRD, Gaikhorst E, Ben &amp;#xc2;J, Scholten J, van Egmond M, Bosmans JE, Stockmann HBAC, Kazemier G, Tuynman JB, Abis GSA, Oosterling SJ, SELECT-trial group, </infon><offset>0</offset><text>Cost-effectiveness of selective decontamination of the digestive tract to decrease infectious complications in colorectal cancer surgery: An analysis of the SELECT trial.</text><annotation id="2"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="83" length="24"/><text>infectious complications</text></annotation><annotation id="3"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="111" length="17"/><text>colorectal cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>171</offset><text>INTRODUCTION: Selective decontamination of the digestive tract (SDD) is effective in reducing infectious complications in elective colorectal cancer (CRC) surgery. However, it is unclear whether SDD is cost-effective compared to standard antibiotic prophylaxis. MATERIAL &amp; METHODS: Economic evaluation alongside multicenter randomized controlled trial, the SELECT-trial, from a healthcare perspective. Patients included underwent elective surgery for non-metastatic CRC. The intervention group received oral non-absorbable colistin, tobramycin and amphotericin B (SDD) next to standard antibiotic prophylaxis. Both groups received a single shot intravenous cefazolin and metronidazole preoperatively as standard prophylaxis. Occurrence of postoperative infectious complication in the first 30 postoperative days was extracted from medical records, Quality-Adjusted Life-Years (QALYs) based on the ED-5D-3L, and healthcare costs collected from the hospital's financial administration. RESULTS: Of the 455 patients, 228 were randomly assigned to intervention group and 227 patients to the control group. SDD significantly reduced the number of infectious complications compared to control (difference = -0.13, 95 % CI -0.05 to -0.20). No difference was found for QALYs (difference = 0.002, 95 % CI -0.002 to 0.005). Healthcare costs were statistically significantly lower in the intervention group (difference = -$1258, 95 % CI -2751 to -166). The ICER was -9872 $/infectious complication prevented and -820,380 $/QALY gained. For all willingness-to-pay thresholds, the probability that prophylactic SDD was cost-effective compared to standard prophylactic practice alone was 1.0. CONCLUSION: The addition of SDD to the standard preoperative intravenous antibiotic prophylaxis is cost-effective compared to standard prophylactic practice from a healthcare perspective and should be considered as the standard of care.</text><annotation id="15"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="265" length="24"/><text>infectious complications</text></annotation><annotation id="16"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="302" length="17"/><text>colorectal cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="321" length="3"/><text>CRC</text></annotation><annotation id="18"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="637" length="3"/><text>CRC</text></annotation><annotation id="19"><infon key="identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location offset="704" length="10"/><text>tobramycin</text></annotation><annotation id="20"><infon key="identifier">MESH:D000666</infon><infon key="type">Chemical</infon><location offset="719" length="14"/><text>amphotericin B</text></annotation><annotation id="21"><infon key="identifier">MESH:D002437</infon><infon key="type">Chemical</infon><location offset="828" length="9"/><text>cefazolin</text></annotation><annotation id="22"><infon key="identifier">MESH:D008795</infon><infon key="type">Chemical</infon><location offset="842" length="13"/><text>metronidazole</text></annotation><annotation id="23"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="910" length="37"/><text>postoperative infectious complication</text></annotation><annotation id="24"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="1313" length="24"/><text>infectious complications</text></annotation><annotation id="25"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="1634" length="23"/><text>infectious complication</text></annotation></passage><relation id="R1"><infon key="score">0.9888</infon><infon key="role1">Chemical|MESH:D000666</infon><infon key="role2">Disease|MESH:D015179</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="7,5"/></relation><relation id="R2"><infon key="score">0.995</infon><infon key="role1">Chemical|MESH:D014031</infon><infon key="role2">Disease|MESH:D015179</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="6,5"/></relation></document>
<document><id>37907368</id><passage><infon key="journal">Am J Crit Care;2023Nov01; 32 (6) 459. doi:10.4037/ajcc2023292</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Halm MA, </infon><offset>0</offset><text>Skin Pigmentation and Accuracy of Pulse Oximetry Values.</text><annotation id="1"><infon key="identifier">MESH:D010859</infon><infon key="type">Disease</infon><location offset="5" length="12"/><text>Pigmentation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>57</offset></passage></document>
<document><id>37907718</id><passage><infon key="journal">Transpl Infect Dis;2023Oct31 14187. doi:10.1111/tid.14187</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Palacio DM, Kates OS, Baddley JW, </infon><offset>0</offset><text>Tools to improve donor utilization by infectious diseases clinicians.</text><annotation id="1"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="38" length="19"/><text>infectious diseases</text></annotation></passage><passage><infon key="type">abstract</infon><offset>70</offset></passage></document>
<document><id>37908068</id><passage><infon key="journal">ACS Appl Mater Interfaces;2023Oct31. doi:10.1021/acsami.3c12921</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liu J, Liu J, Zhang X, Liu X, Zhang C, </infon><offset>0</offset><text>Customizing Three-Dimensional Elastic Barium Titanate Sponge for Intelligent Piezoelectric Sensing.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="38" length="22"/><text>Barium Titanate Sponge</text></annotation></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>Piezoelectric energy harvesters (PEHs) with porous structures, such as piezoelectric elastic sponges, exhibit high force-to-electricity conversion efficiencies owing to their excellent compression recovery properties. However, conventional preparation methods are limited to producing bulk-form sponge-like PEHs and fail to create more elaborate three-dimensional (3D) structures that could enhance conversion efficiency. Herein, we invent a composite ink consisting of waterborne polyurethane (WPU), barium titanate (BTO), and cellulose nanofibers (CNFs) that is suitable for direct ink writing (DIW) 3D printing. This ink, when coupled with freeze-drying, allows the customization of piezoelectric sponges with functional 3D structures. The printed lattice sponge exhibits remarkable compression recovery of 70% and a notably high relative sensitivity of 9.83 mV/kPa*wt % (where *wt % denotes the BTO content) across a wide pressure range of 2.98-37 kPa, which is approximately three times broader than those of other composite piezoelectric pressure sensors based on BTO or piezoceramic (PZT) materials. Furthermore, a customized 3D piezoelectric sponge with a "boomerang" configuration is utilized as an anisotropic bending sensor on the wrist for intelligently monitoring the stroke posture and programming scientific training for table tennis players. This study highlights a versatile strategy for constructing elastic sponges with high piezoelectricity and designing 3D PEH functional structures that can be applied to flexible self-powered intelligent sensing systems.</text><annotation id="12"><infon key="identifier">MESH:D011140</infon><infon key="type">Chemical</infon><location offset="581" length="12"/><text>polyurethane</text></annotation><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="595" length="3"/><text>WPU</text></annotation><annotation id="14"><infon key="identifier">MESH:C024547</infon><infon key="type">Chemical</infon><location offset="601" length="15"/><text>barium titanate</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="618" length="3"/><text>BTO</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="628" length="20"/><text>cellulose nanofibers</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="650" length="4"/><text>CNFs</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="999" length="3"/><text>BTO</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1170" length="3"/><text>BTO</text></annotation><annotation id="20"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="1381" length="6"/><text>stroke</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1578" length="3"/><text>PEH</text></annotation></passage></document>
<document><id>37909119</id><passage><infon key="journal">Int J Geriatr Psychiatry;2023Nov; 38 (11) 6021. doi:10.1002/gps.6021</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xiong F, Wang Y, Zhu J, Li S, Guan Q, Jing Z, </infon><offset>0</offset><text>Association of multimorbidity patterns with motoric cognitive risk syndrome among older adults: Evidence from a China longitudinal study.</text><annotation id="2"><infon key="type">Disease</infon><location offset="15" length="14"/><text>multimorbidity</text></annotation><annotation id="3"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="44" length="31"/><text>motoric cognitive risk syndrome</text></annotation></passage><passage><infon key="type">abstract</infon><offset>138</offset><text>OBJECTIVES: Motoric cognitive risk syndrome (MCR), a pre-dementia syndrome, is characterized by slow gait and subjective cognitive complaints among older adults. This study assessed the relationship between multimorbidity, its patterns, and MCR. METHODS: Data for this study were obtained from three waves (2011, 2013, and 2015) of the China Health and Retirement Longitudinal Study. Participants who were aged 60 years and older and had complete data at baseline as well as complete data about MCR at follow-up were selected. Patients without MCR at baseline were selected for further analyses. Longitudinal associations between multimorbidity, its patterns, and MCR were examined using a Cox proportional hazards model. Multimorbidity patterns were classified using latent class analysis. RESULTS: A total of 4923 respondents were included at baseline, 43.47% of whom had multimorbidity. Additionally, the prevalence of MCR at baseline was 12.61%. After adjusting for covariates, multimorbidity was positively associated with MCR (hazard ratio [HR] = 1.33, 95% confidence interval [CI] = 1.06-1.68). A higher number of multimorbidity was also significantly associated with an increased risk of developing MCR (HR = 1.10, 95% CI = 1.02-1.19). Three multimorbidity patterns were selected: relatively healthy pattern, respiratory pattern, and cardiovascular pattern. Older adults with the cardiovascular pattern were 1.57 times more likely to develop MCR than those with the relatively healthy pattern (HR = 1.57, 95% CI = 1.16-2.13). There was no significant difference between the relatively healthy pattern and the respiratory pattern (HR = 1.31, 95% CI = 0.91-1.92). CONCLUSIONS: MCR is highly prevalent among older Chinese adults. MCR may be exacerbated by multimorbidity. For older adults with multimorbidity (especially cardiovascular multimorbidity), attention should be paid to MCR to achieve early detection, diagnosis, and treatment.</text><annotation id="30"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="150" length="31"/><text>Motoric cognitive risk syndrome</text></annotation><annotation id="31"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="183" length="3"/><text>MCR</text></annotation><annotation id="32"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="195" length="17"/><text>dementia syndrome</text></annotation><annotation id="33"><infon key="identifier">MESH:D020234</infon><infon key="type">Disease</infon><location offset="234" length="9"/><text>slow gait</text></annotation><annotation id="34"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="259" length="20"/><text>cognitive complaints</text></annotation><annotation id="35"><infon key="type">Disease</infon><location offset="345" length="14"/><text>multimorbidity</text></annotation><annotation id="36"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="379" length="3"/><text>MCR</text></annotation><annotation id="37"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="633" length="3"/><text>MCR</text></annotation><annotation id="38"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="682" length="3"/><text>MCR</text></annotation><annotation id="39"><infon key="type">Disease</infon><location offset="768" length="14"/><text>multimorbidity</text></annotation><annotation id="40"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="802" length="3"/><text>MCR</text></annotation><annotation id="41"><infon key="type">Disease</infon><location offset="860" length="14"/><text>Multimorbidity</text></annotation><annotation id="42"><infon key="type">Disease</infon><location offset="1012" length="14"/><text>multimorbidity</text></annotation><annotation id="43"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1060" length="3"/><text>MCR</text></annotation><annotation id="44"><infon key="type">Disease</infon><location offset="1120" length="14"/><text>multimorbidity</text></annotation><annotation id="45"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1166" length="3"/><text>MCR</text></annotation><annotation id="46"><infon key="type">Disease</infon><location offset="1259" length="14"/><text>multimorbidity</text></annotation><annotation id="47"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1345" length="3"/><text>MCR</text></annotation><annotation id="48"><infon key="type">Disease</infon><location offset="1388" length="14"/><text>multimorbidity</text></annotation><annotation id="49"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1588" length="3"/><text>MCR</text></annotation><annotation id="50"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1821" length="3"/><text>MCR</text></annotation><annotation id="51"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1873" length="3"/><text>MCR</text></annotation><annotation id="52"><infon key="type">Disease</infon><location offset="1899" length="14"/><text>multimorbidity</text></annotation><annotation id="53"><infon key="type">Disease</infon><location offset="1937" length="14"/><text>multimorbidity</text></annotation><annotation id="54"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="1964" length="29"/><text>cardiovascular multimorbidity</text></annotation><annotation id="55"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="2024" length="3"/><text>MCR</text></annotation></passage></document>
<document><id>37909474</id><passage><infon key="journal">Chemistry;2023Nov01 202302464. doi:10.1002/chem.202302464</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Pr&amp;#xfc;&amp;#xdf;ner T, Meinderink D, Zhu S, Orive AG, Kielar C, Huck M, Steinr&amp;#xfc;ck HG, Keller A, Grundmeier G, </infon><offset>0</offset><text>Molecular Adhesion of a Pilus-derived Peptide Involved in Pseudomonas aeruginosa Biofilm Formation on non-polar ZnO Surfaces.</text><annotation id="2"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="38" length="7"/><text>Peptide</text></annotation><annotation id="3"><infon key="identifier">MESH:D015034</infon><infon key="type">Chemical</infon><location offset="112" length="3"/><text>ZnO</text></annotation></passage><passage><infon key="type">abstract</infon><offset>126</offset><text>Bacterial colonization and biofilm formation on abiotic surfaces are initiated by the adhesion of peptides and proteins. Understanding the adhesion of such peptides and proteins at a molecular level thus represents an important step toward controlling and suppressing biofilm formation on technological and medical materials. This study investigates the molecular adhesion of a pilus-derived peptide that facilitates biofilm formation of Pseudomonas aeruginosa, a multidrug-resistant opportunistic pathogen frequently encountered in healthcare settings. Single-molecule force spectroscopy (SMFS) was performed on chemically etched ZnO surfaces to gather insights about peptide adsorption force and its kinetics. Metal-free click chemistry for the fabrication of peptide-terminated SMFS cantilevers was performed on amine-terminated gold cantilevers and verified by X-ray photoelectron spectroscopy (XPS) and polarization-modulated infrared reflection absorption spectroscopy (PM-IRRAS). Atomic force microscopy (AFM) and XPS analyses reveal stable topographies and surface chemistries of the substrates that are not affected by SMFS. Rupture events described by the worm-like chain model (WLC) up to 600 pN were detected for the non-polar ZnO(11-20) surfaces. The dissociation barrier energy at zero force DeltaG(0), the transition state distance xb and bound-unbound dissociation rate at zero force koff(0) for the single crystalline substrate indicate that coordination and hydrogen bonds dominate the peptide/surface interaction.</text><annotation id="12"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="518" length="7"/><text>peptide</text></annotation><annotation id="13"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="795" length="7"/><text>peptide</text></annotation><annotation id="14"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="838" length="5"/><text>Metal</text></annotation><annotation id="15"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="888" length="7"/><text>peptide</text></annotation><annotation id="16"><infon key="identifier">MESH:D000588</infon><infon key="type">Chemical</infon><location offset="941" length="5"/><text>amine</text></annotation><annotation id="17"><infon key="identifier">MESH:D015034</infon><infon key="type">Chemical</infon><location offset="1365" length="3"/><text>ZnO</text></annotation><annotation id="18"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="1602" length="8"/><text>hydrogen</text></annotation><annotation id="19"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="1630" length="7"/><text>peptide</text></annotation></passage><relation id="R1"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D006859</infon><infon key="role2">Chemical|MESH:D010455</infon><infon key="type">Association</infon><node refid="0" role="9,10"/></relation><relation id="R2"><infon key="score">0.6094</infon><infon key="role1">Chemical|MESH:D010455</infon><infon key="role2">Chemical|MESH:D015034</infon><infon key="type">Association</infon><node refid="1" role="0,1"/></relation></document>
<document><id>37909829</id><passage><infon key="journal">Thorac Res Pract;2023Nov; 24 (6) 304. doi:10.5152/ThoracResPract.2023.23032</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">K&amp;#xf6;pr&amp;#xfc;l&amp;#xfc;o&amp;#x11f;lu M, Naz &amp;#x130;, Akta&amp;#x15f; B, K&amp;#xf6;m&amp;#xfc;rc&amp;#xfc;o&amp;#x11f;lu B, &amp;#xd6;zer Kaya D, </infon><offset>0</offset><text>Comparison of Self-Efficacy and Problem-Solving Skills Between Women with Asthma and Healthy Controls: A Cross-Sectional Study.</text><annotation id="1"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="74" length="6"/><text>Asthma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>128</offset><text>OBJECTIVE: Problem-solving skills and self-efficacy are among the topics that are frequently investigated in people with various chronic conditions. However, there are limited studies on asthma patients. Our study aims to compare self-efficacy and problem-solving skills in asthma patients and healthy controls. MATERIAL AND METHODS: We included 23 women with asthma [age: 39 (34-56) years] and 23 healthy controls [age: 42 (30-55) years] in the study. Participants' sociodemographic and disease-related characteristics, Asthma Control Test, and the Modified Medical Research Council Dyspnea Scale scores were recorded. We examined problem-solving skills with the Problem-Solving Inventory and self-efficacy with General Self-Efficacy Scale. We compared groups with the chi-square test, Mann-Whitney U-test, and Independent Sample t-test. RESULTS: Age, body mass index, educational status, marital status, and occupational status were similar among the groups (P > .05). However, smoking was significantly higher in healthy controls (P &lt; .05). It was found that women with asthma had worse self-efficacy and problem-solving skills compared to healthy controls (P &lt; .05). CONCLUSION: These results showed that there may be problems in socio-cognitive skills associated with the disease. Our study focused on the possibility that female asthma patients may have low levels of self-efficacy and problem-solving skills. Therefore, health professionals designing the rehabilitation program should take these skills into account while conducting the assessment as they may be useful in developing an efficient rehabilitation program.</text><annotation id="9"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="315" length="6"/><text>asthma</text></annotation><annotation id="10"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="402" length="6"/><text>asthma</text></annotation><annotation id="11"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="488" length="6"/><text>asthma</text></annotation><annotation id="12"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="649" length="6"/><text>Asthma</text></annotation><annotation id="13"><infon key="identifier">MESH:D004417</infon><infon key="type">Disease</infon><location offset="712" length="7"/><text>Dyspnea</text></annotation><annotation id="14"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="1201" length="6"/><text>asthma</text></annotation><annotation id="15"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="1463" length="6"/><text>asthma</text></annotation></passage></document>
<document><id>37910182</id><passage><infon key="journal">Eur Stroke J;2023Nov01 23969873231209819. doi:10.1177/23969873231209819</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tokareva B, Meyer L, Heitkamp C, Wentz R, Faizy TD, Meyer HS, Bester M, Fiehler J, Thaler C, </infon><offset>0</offset><text>Early and recurrent cerebral vasospasms after aneurysmal subarachnoid hemorrhage: The impact of age.</text><annotation id="2"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="20" length="19"/><text>cerebral vasospasms</text></annotation><annotation id="3"><infon key="identifier">MESH:D013345</infon><infon key="type">Disease</infon><location offset="46" length="34"/><text>aneurysmal subarachnoid hemorrhage</text></annotation></passage><passage><infon key="type">abstract</infon><offset>101</offset><text>INTRODUCTION: Cerebral vasospasms remain a strong predictor of poor outcome after aneurysmal SAH. The aim of this study was to describe the time course of relevant vasospasms after aneurysmal SAH and to determine the variables associated with early-onset or prolonged and recurrent vasospasms. PATIENTS AND METHODS: We conducted a retrospective, single-center study of consecutive adult patients with aneurysmal SAH admitted between 2016 and 2022 at our tertiary stroke center. Relevant vasospasms, defined as vessel narrowing detected in DSA in combination with clinical deterioration or new perfusion deficit, were detected according to our in-house algorithm and eventually treated endovascularly. The primary endpoint was the diagnosis of relevant vasospasms. As secondary endpoints, the time from hemorrhage to the onset of vasospasms and the time from the first to the last endovascular intervention were measured. RESULTS: Of 368 patients with aneurysmal SAH, 135 (41.0%) developed relevant vasospasms. The median time between ictus and detection of vasospasms was 8 days (IQR: 6-10). Patients with early-onset vasospasms were significantly younger (mean 52.7 +- 11.2 years vs 58.7 +- 11.5 years, p = 0.003) and presented more frequently vasospasm-related infarctions at discharge (58.8% vs 38.7%, p = 0.03). In 74 patients (54.8%), recurrent relevant vasospasms were observed despite endovascular treatment. Younger age and early onset were significantly associated with longer duration of relevant vasospasms (both p &lt; 0.05). DISCUSSION AND CONCLUSION: Younger age was associated with early-onset and longer duration of relevant vasospasms in this study. More frequent clinical and diagnostic follow-up should be considered in this subgroup of patients that are at risk for poor outcomes.</text><annotation id="24"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="115" length="19"/><text>Cerebral vasospasms</text></annotation><annotation id="25"><infon key="identifier">MESH:D013345</infon><infon key="type">Disease</infon><location offset="183" length="14"/><text>aneurysmal SAH</text></annotation><annotation id="26"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="265" length="10"/><text>vasospasms</text></annotation><annotation id="27"><infon key="identifier">MESH:D013345</infon><infon key="type">Disease</infon><location offset="282" length="14"/><text>aneurysmal SAH</text></annotation><annotation id="28"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="383" length="10"/><text>vasospasms</text></annotation><annotation id="29"><infon key="identifier">MESH:D013345</infon><infon key="type">Disease</infon><location offset="502" length="14"/><text>aneurysmal SAH</text></annotation><annotation id="30"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="564" length="6"/><text>stroke</text></annotation><annotation id="31"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="588" length="10"/><text>vasospasms</text></annotation><annotation id="32"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="853" length="10"/><text>vasospasms</text></annotation><annotation id="33"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="903" length="10"/><text>hemorrhage</text></annotation><annotation id="34"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="930" length="10"/><text>vasospasms</text></annotation><annotation id="35"><infon key="identifier">MESH:D013345</infon><infon key="type">Disease</infon><location offset="1052" length="14"/><text>aneurysmal SAH</text></annotation><annotation id="36"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="1099" length="10"/><text>vasospasms</text></annotation><annotation id="37"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="1158" length="10"/><text>vasospasms</text></annotation><annotation id="38"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="1219" length="10"/><text>vasospasms</text></annotation><annotation id="39"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="1346" length="9"/><text>vasospasm</text></annotation><annotation id="40"><infon key="identifier">MESH:D007238</infon><infon key="type">Disease</infon><location offset="1364" length="11"/><text>infarctions</text></annotation><annotation id="41"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="1460" length="10"/><text>vasospasms</text></annotation><annotation id="42"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="1608" length="10"/><text>vasospasms</text></annotation><annotation id="43"><infon key="identifier">MESH:D020301</infon><infon key="type">Disease</infon><location offset="1739" length="10"/><text>vasospasms</text></annotation></passage></document>
<document><id>37910532</id><passage><infon key="journal">J Neurophysiol;2023Nov01. doi:10.1152/jn.00290.2023</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Thrower L, Dang W, Jaffe RG, Sun JD, Constantinidis C, </infon><offset>0</offset><text>Decoding working memory information from neurons with and without persistent activity in the primate prefrontal cortex.</text></passage><passage><infon key="type">abstract</infon><offset>120</offset><text>Persistent activity of neurons in the prefrontal cortex has been thought to represent the information maintained in working memory, though alternative models have challenged this idea. Theories that depend on the dynamic representation of information posit that stimulus information may be maintained by the activity pattern of neurons whose firing rate is not significantly elevated above their baseline during the delay period of working memory tasks. We thus tested the ability of neurons that do and do not generate persistent activity in the prefrontal cortex of monkeys to represent spatial and object information in working memory. Neurons that generated persistent activity represented more information about the stimuli in both spatial and object working memory tasks. The amount of information that could be decoded from neural activity depended on the choice of decoder and parameters used but neurons with persistent activity outperformed non-persistent neurons consistently. Although averaged across all neurons and stimuli, firing rate did not appear clearly elevated above baseline during the maintenance of neural activity particularly for object working memory, this grand average masked neurons that generated persistent activity selective for their preferred stimuli, which carried the majority of stimulus information. These results reveal that prefrontal neurons that generate persistent activity maintain information more reliably during working memory.</text></passage></document>
<document><id>37911234</id><passage><infon key="journal">Int Dent J (Phila);1891Mar; 12 (3) 201</infon><infon key="year">1891</infon><infon key="article-id_pmc">PMC10109853</infon><infon key="type">title</infon><offset>0</offset><text>Annual Meeting of the Dental Protective Association.</text></passage><passage><infon key="type">abstract</infon><offset>53</offset></passage></document>
<document><id>37912284</id><passage><infon key="journal">Int Dent J (Phila);1897Apr; 18 (4) 240</infon><infon key="year">1897</infon><infon key="article-id_pmc">PMC10128832</infon><infon key="type">title</infon><infon key="authors">Davenport SE, </infon><offset>0</offset><text>The Restoration of Badly Broken Teeth without Crowning.</text></passage><passage><infon key="type">abstract</infon><offset>56</offset></passage></document>
<document><id>37912984</id><passage><infon key="journal">Int Dent J (Phila);1902Oct; 23 (10) 778</infon><infon key="year">1902</infon><infon key="article-id_pmc">PMC10156283</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37913335</id><passage><infon key="journal">Int Dent J (Phila);1905Aug; 26 (8) 565</infon><infon key="year">1905</infon><infon key="article-id_pmc">PMC10168855</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37913685</id><passage><infon key="journal">Aquat Toxicol;2023Oct22; 264 106734. doi:10.1016/j.aquatox.2023.106734</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gasque-Belz L, Colville C, Kurukulasuriya S, Siciliano SD, Hogan N, Weber L, Campbell P, Peters R, Hanson M, Hecker M, </infon><offset>0</offset><text>Characterization of molecular and apical effects of legacy-contaminated groundwater on early life stages of fathead minnows.</text></passage><passage><infon key="type">abstract</infon><offset>125</offset><text>Mechanistic toxicology approaches represent a promising alternative to traditional live animal testing; however, the often-noted uncertainties concerning the linkages between effects observed at molecular and apical levels curtails the adoption of such approaches. The objective of this study was to apply a novel transcriptomics tool, EcoToxChips, to characterize the effects of complex mixtures of contaminants in fish and to compare molecular response patterns to higher-level biological responses including swimming behavior, deformities, and mortality. Fathead minnow (FHM) embryos were exposed for seven days to increasing concentrations of groundwater collected from moderate (MIAZ) and high (HIAZ) industrial activity zones of a legacy contaminated site. There was a concentration-dependent disruption of photo-dependent swimming responses associated with avoidance behavior patterns and spinal deformities (HIAZ and MIAZ), and an induction of pericardial edema and mortality (HIAZ-10%). Parallel EcoToxChip analyses showed a shift from a majority of upregulated genes at lower concentrations to a majority of downregulated genes at higher concentrations for both treatment conditions. Many of the significantly differentially regulated genes were involved in biological pathways including induction of oxidative stress, activating of several metabolic processes and growth, cell death, and inhibition of signal transduction signaling processes. Several contaminants present in the groundwater mixtures could have contributed to an exceedance of antioxidant system capacities that possibly led to the deformities, altered swimming behaviours, and mortality observed in FHMs. Therefore, molecular response patterns could be linked to apical outcomes observed in this study. Overall, the results observed in this study demonstrate that transcriptomics approaches such as the EcoToxChip system could be supportive of risk assessment of complex contaminated sites.</text><annotation id="4"><infon key="type">Disease</infon><location offset="809" length="4"/><text>MIAZ</text></annotation><annotation id="5"><infon key="identifier">MESH:D013122</infon><infon key="type">Disease</infon><location offset="1021" length="18"/><text>spinal deformities</text></annotation><annotation id="6"><infon key="type">Disease</infon><location offset="1050" length="4"/><text>MIAZ</text></annotation><annotation id="7"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="1077" length="17"/><text>pericardial edema</text></annotation></passage></document>
<document><id>37914035</id><passage><infon key="journal">J Arthroplasty;2023Oct30. doi:10.1016/j.arth.2023.10.044</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Warwick H, Kwong JW, Namiri NK, Kayupov E, Maher P, Hansen EN, </infon><offset>0</offset><text>Revision Dual Mobility Constructs with Unmatched Acetabular and Femoral Components Do Not Increase Failure Rate.</text></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>INTRODUCTION: Dual mobility (DM) constructs for revision total hip arthroplasty (THA) have continued to grow in popularity to mitigate instability. This benefit comes at the cost of potential unique modes of failure, and there are theoretical concerns that combining femoral and acetabular components from different manufacturers could lead to increased failure rates. We aimed to investigate rates of reoperation between matched and unmatched DM implants used in revision THA. METHODS: We retrospectively reviewed 217 revision THAs performed with DM constructs between July 2012 and September 2021 at a single institution. DM constructs were classified as "matched" if the acetabular and femoral components were manufactured by the same company. They were classified as "unmatched" if the acetabular and femoral components were manufactured by different companies. The primary outcome was reoperation for any reason. RESULTS: There were 136 matched DM constructs and 81 unmatched constructs. Average follow-up was 4.6 years (range, 2.0 to 9.6 years). There was no difference in reoperation rate between matched and unmatched groups (11.0 versus 13.6%, P=0.576). The most common reasons for reoperation in both groups were instability and periprosthetic joint infection. There was one revision for intra-prosthetic dislocation in the matched group. CONCLUSION: The use of unmatched DM components in revision THA was common and did not increase the risk of reoperation at an average of 4.6 year follow up. This information can be helpful in operative planning, but further research on long-term survival will be necessary.</text><annotation id="5"><infon key="identifier">MESH:D043171</infon><infon key="type">Disease</infon><location offset="248" length="11"/><text>instability</text></annotation><annotation id="6"><infon key="identifier">MESH:D043171</infon><infon key="type">Disease</infon><location offset="1336" length="11"/><text>instability</text></annotation><annotation id="7"><infon key="identifier">MESH:D057068</infon><infon key="type">Disease</infon><location offset="1352" length="30"/><text>periprosthetic joint infection</text></annotation><annotation id="8"><infon key="identifier">MESH:D057072</infon><infon key="type">Disease</infon><location offset="1411" length="16"/><text>intra-prosthetic</text></annotation><annotation id="9"><infon key="identifier">MESH:D004204</infon><infon key="type">Disease</infon><location offset="1428" length="11"/><text>dislocation</text></annotation></passage></document>
<document><id>37914385</id><passage><infon key="journal">J Immunother Cancer;2023Nov; 11 (11) . doi:10.1136/jitc-2023-007870</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Usaite I, Biswas D, Dijkstra K, Watkins TB, Pich O, Puttick C, Angelova M, Thakkar K, Hiley C, Birkbak N, Kok M, Zaccaria S, Wu Y, Litchfield K, Swanton C, Kanu N, </infon><offset>0</offset><text>Quantifying the impact of immunotherapy on RNA dynamics in cancer.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="59" length="6"/><text>cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>67</offset><text>BACKGROUND: Checkpoint inhibitor (CPI) immunotherapies have provided durable clinical responses across a range of solid tumor types for some patients with cancer. Nonetheless, response rates to CPI vary greatly between cancer types. Resolving intratumor transcriptomic changes induced by CPI may improve our understanding of the mechanisms of sensitivity and resistance. METHODS: We assembled a cohort of longitudinal pre-therapy and on-therapy samples from 174 patients treated with CPI across six cancer types by leveraging transcriptomic sequencing data from five studies. RESULTS: Meta-analyses of published RNA markers revealed an on-therapy pattern of immune reinvigoration in patients with breast cancer, which was not discernible pre-therapy, providing biological insight into the impact of CPI on the breast cancer immune microenvironment. We identified 98 breast cancer-specific correlates of CPI response, including 13 genes which are known IO targets, such as toll-like receptors TLR1, TLR4, and TLR8, that could hold potential as combination targets for patients with breast cancer receiving CPI treatment. Furthermore, we demonstrate that a subset of response genes identified in breast cancer are already highly expressed pre-therapy in melanoma, and additionally we establish divergent RNA dynamics between breast cancer and melanoma following CPI treatment, which may suggest distinct immune microenvironments between the two cancer types. CONCLUSIONS: Overall, delineating longitudinal RNA dynamics following CPI therapy sheds light on the mechanisms underlying diverging response trajectories, and identifies putative targets for combination therapy.</text><annotation id="18"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="187" length="5"/><text>tumor</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="222" length="6"/><text>cancer</text></annotation><annotation id="20"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="286" length="6"/><text>cancer</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="566" length="6"/><text>cancer</text></annotation><annotation id="22"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="764" length="13"/><text>breast cancer</text></annotation><annotation id="23"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="877" length="13"/><text>breast cancer</text></annotation><annotation id="24"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="933" length="13"/><text>breast cancer</text></annotation><annotation id="25"><infon key="identifier">7096</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20694</infon><location offset="1059" length="4"/><text>TLR1</text></annotation><annotation id="26"><infon key="identifier">7099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41317</infon><location offset="1065" length="4"/><text>TLR4</text></annotation><annotation id="27"><infon key="identifier">51311</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">44054</infon><location offset="1075" length="4"/><text>TLR8</text></annotation><annotation id="28"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1148" length="13"/><text>breast cancer</text></annotation><annotation id="29"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1261" length="13"/><text>breast cancer</text></annotation><annotation id="30"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="1319" length="8"/><text>melanoma</text></annotation><annotation id="31"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1390" length="13"/><text>breast cancer</text></annotation><annotation id="32"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="1408" length="8"/><text>melanoma</text></annotation><annotation id="33"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1510" length="6"/><text>cancer</text></annotation></passage><relation id="R1"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|51311</infon><infon key="type">Association</infon><node refid="0" role="7,10"/></relation><relation id="R2"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|7096</infon><infon key="type">Association</infon><node refid="1" role="7,8"/></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|7099</infon><infon key="type">Association</infon><node refid="2" role="7,9"/></relation></document>
<document><id>37915787</id><passage><infon key="journal">Can Vet J;2023Nov; 64 (11) 1009</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10581360</infon><infon key="type">title</infon><infon key="authors">Recchi L, Merch&amp;#xe1;n A, Ducrocq M, Koenig J, Dubois MS, Brisson BA, </infon><offset>0</offset><text>Anoplasty and rectovaginal fistula repair in a gilt with atresia ani: A case report.</text><annotation id="2"><infon key="identifier">MESH:D012006</infon><infon key="type">Disease</infon><location offset="14" length="20"/><text>rectovaginal fistula</text></annotation><annotation id="3"><infon key="identifier">MESH:D011538</infon><infon key="type">Disease</infon><location offset="57" length="11"/><text>atresia ani</text></annotation></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>A 2-year-old female Vietnamese potbellied pig was referred to the Large Animal Teaching Hospital at the Ontario Veterinary College for anoplasty and rectovaginal fistula repair. The presence of atresia ani and rectovaginal fistula had been previously diagnosed. Contrast radiography was used to confirm the diagnosis and determine the position of the fistula and terminal rectum. Under general anesthesia, the urethra was catheterized. An incision was made at the anatomic location of the anus, the rectovaginal fistula was isolated through deep dissection, and a Penrose drain was placed around it for caudal retraction. Transvaginal catheter placement through the fistula and into the rectum assisted with anatomic location. Once the urogenital and gastrointestinal tracts were clearly identified, the fistula was transected as close to the vaginal cavity as possible. The vaginal defect was sutured, and the fistula tract was mobilized 90  and sutured to the skin, creating the anal canal. Postoperative complications included constipation and cystitis. The gilt passed feces 5 d after surgery and was discharged on Day 11 of hospitalization. Normal urination and defecation were observed at the time, and fecal incontinence was resolved. Six months after surgical intervention, the gilt remained continent and no complications were reported. Key clinical message: Anoplasty and rectovaginal fistula repair were completed successfully in a gilt. Preservation of the fistula and its use during anal reconstruction may provide an internal anal sphincter and may be associated with improved continence.</text><annotation id="18"><infon key="identifier">MESH:D012006</infon><infon key="type">Disease</infon><location offset="234" length="20"/><text>rectovaginal fistula</text></annotation><annotation id="19"><infon key="identifier">MESH:D011538</infon><infon key="type">Disease</infon><location offset="279" length="11"/><text>atresia ani</text></annotation><annotation id="20"><infon key="identifier">MESH:D012006</infon><infon key="type">Disease</infon><location offset="295" length="20"/><text>rectovaginal fistula</text></annotation><annotation id="21"><infon key="identifier">MESH:D005402</infon><infon key="type">Disease</infon><location offset="436" length="7"/><text>fistula</text></annotation><annotation id="22"><infon key="identifier">MESH:D012006</infon><infon key="type">Disease</infon><location offset="584" length="20"/><text>rectovaginal fistula</text></annotation><annotation id="23"><infon key="identifier">MESH:D005402</infon><infon key="type">Disease</infon><location offset="751" length="7"/><text>fistula</text></annotation><annotation id="24"><infon key="identifier">MESH:D005402</infon><infon key="type">Disease</infon><location offset="889" length="7"/><text>fistula</text></annotation><annotation id="25"><infon key="identifier">MESH:D005402</infon><infon key="type">Disease</infon><location offset="996" length="7"/><text>fistula</text></annotation><annotation id="26"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="1078" length="27"/><text>Postoperative complications</text></annotation><annotation id="27"><infon key="identifier">MESH:D003248</infon><infon key="type">Disease</infon><location offset="1115" length="12"/><text>constipation</text></annotation><annotation id="28"><infon key="identifier">MESH:D003556</infon><infon key="type">Disease</infon><location offset="1132" length="8"/><text>cystitis</text></annotation><annotation id="29"><infon key="identifier">MESH:D005242</infon><infon key="type">Disease</infon><location offset="1294" length="18"/><text>fecal incontinence</text></annotation><annotation id="30"><infon key="identifier">MESH:D012006</infon><infon key="type">Disease</infon><location offset="1467" length="20"/><text>rectovaginal fistula</text></annotation><annotation id="31"><infon key="identifier">MESH:D005402</infon><infon key="type">Disease</infon><location offset="1554" length="7"/><text>fistula</text></annotation></passage></document>
<document><id>37916490</id><passage><infon key="journal">Curr Pharm Des;2023Nov01. doi:10.2174/0113816128259795231023193419</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Singh MP, Singh N, Mishra D, Ehsan S, Chaturvedi VK, Chaudhary A, Singh V, Vamanu E, </infon><offset>0</offset><text>Computational Approaches to Designing Antiviral Drugs against COVID-19: A Comprehensive Review.</text><annotation id="1"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="62" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset><text>The global impact of the COVID-19 pandemic caused by SARS-CoV-2 necessitates innovative strategies for the rapid development of effective treatments. Computational methodologies, such as molecular modelling, molecular dynamics simulations, and artificial intelligence, have emerged as indispensable tools in the drug discovery process. This review aimed to provide a comprehensive overview of these computational approaches and their application in the design of antiviral agents for COVID-19. Starting with an examination of ligand-based and structure-based drug discovery, the review has delved into the intricate ways through which molecular modelling can accelerate the identification of potential therapies. Additionally, the investigation extends to phytochemicals sourced from nature, which have shown promise as potential antiviral agents. Noteworthy compounds, including gallic acid, naringin, hesperidin, Tinospora cordifolia, curcumin, nimbin, azadironic acid, nimbionone, nimbionol, and nimocinol, have exhibited high affinity for COVID-19 Mpro and favourable binding energy profiles compared to current drugs. Although these compounds hold potential, their further validation through in vitro and in vivo experimentation is imperative. Throughout this exploration, the review has emphasized the pivotal role of computational biologists, bioinformaticians, and biotechnologists in driving rapid advancements in clinical research and therapeutic development. By combining state-of-the-art computational techniques with insights from structural and molecular biology, the search for potent antiviral agents has been accelerated. The collaboration between these disciplines holds immense promise in addressing the transmissibility and virulence of SARS-CoV-2.</text><annotation id="16"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="121" length="8"/><text>COVID-19</text></annotation><annotation id="17"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="580" length="8"/><text>COVID-19</text></annotation><annotation id="18"><infon key="identifier">MESH:D005707</infon><infon key="type">Chemical</infon><location offset="976" length="11"/><text>gallic acid</text></annotation><annotation id="19"><infon key="identifier">MESH:C005274</infon><infon key="type">Chemical</infon><location offset="989" length="8"/><text>naringin</text></annotation><annotation id="20"><infon key="identifier">MESH:D006569</infon><infon key="type">Chemical</infon><location offset="999" length="10"/><text>hesperidin</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1011" length="20"/><text>Tinospora cordifolia</text></annotation><annotation id="22"><infon key="identifier">MESH:D003474</infon><infon key="type">Chemical</infon><location offset="1033" length="8"/><text>curcumin</text></annotation><annotation id="23"><infon key="identifier">MESH:C008621</infon><infon key="type">Chemical</infon><location offset="1043" length="6"/><text>nimbin</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1051" length="15"/><text>azadironic acid</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1068" length="10"/><text>nimbionone</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1080" length="9"/><text>nimbionol</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1095" length="9"/><text>nimocinol</text></annotation><annotation id="28"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1139" length="8"/><text>COVID-19</text></annotation><annotation id="29"><infon key="identifier">8673700</infon><infon key="type">Gene</infon><location offset="1148" length="4"/><text>Mpro</text></annotation></passage><relation id="R1"><infon key="score">0.9454</infon><infon key="role1">Chemical|MESH:D003474</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Association</infon><node refid="0" role="7,13"/></relation><relation id="R2"><infon key="score">0.9509</infon><infon key="role1">Chemical|MESH:D006569</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Association</infon><node refid="1" role="5,13"/></relation><relation id="R3"><infon key="score">0.9248</infon><infon key="role1">Chemical|MESH:C008621</infon><infon key="role2">Gene|8673700</infon><infon key="type">Association</infon><node refid="2" role="8,14"/></relation><relation id="R4"><infon key="score">0.9416</infon><infon key="role1">Chemical|MESH:D003474</infon><infon key="role2">Gene|8673700</infon><infon key="type">Association</infon><node refid="3" role="7,14"/></relation><relation id="R5"><infon key="score">0.9023</infon><infon key="role1">Chemical|MESH:C005274</infon><infon key="role2">Gene|8673700</infon><infon key="type">Association</infon><node refid="4" role="4,14"/></relation><relation id="R6"><infon key="score">0.8195</infon><infon key="role1">Chemical|MESH:D005707</infon><infon key="role2">Gene|8673700</infon><infon key="type">Association</infon><node refid="5" role="3,14"/></relation><relation id="R7"><infon key="score">0.8883</infon><infon key="role1">Chemical|MESH:C008621</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Association</infon><node refid="6" role="8,13"/></relation><relation id="R8"><infon key="score">0.8991</infon><infon key="role1">Chemical|MESH:D006569</infon><infon key="role2">Gene|8673700</infon><infon key="type">Association</infon><node refid="7" role="5,14"/></relation><relation id="R9"><infon key="score">0.9586</infon><infon key="role1">Chemical|MESH:C005274</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Association</infon><node refid="8" role="4,13"/></relation><relation id="R10"><infon key="score">0.952</infon><infon key="role1">Chemical|MESH:D005707</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Association</infon><node refid="9" role="3,13"/></relation></document>
<document><id>37916843</id><passage><infon key="journal">Nurs Res;2023Nov01. doi:10.1097/NNR.0000000000000702</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chao AM, Wadden TA, Cao W, Zhou Y, Maldonado D, Cardel MI, Foster GD, Loughead J, </infon><offset>0</offset><text>Randomized Controlled Trial of Effects of Behavioral Weight Loss Treatment on Food Cue Reactivity.</text><annotation id="1"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="53" length="11"/><text>Weight Loss</text></annotation></passage><passage><infon key="type">abstract</infon><offset>99</offset><text>BACKGROUND: It is not known whether behavioral weight loss can attenuate blood oxygen level-dependent responses to food stimuli. OBJECTIVES: This randomized controlled trial assessed the effects of a commercially available behavioral weight loss program (WeightWatchers) compared to a wait-list control on blood-oxygen-level-dependent response to food cues. METHODS: Females with obesity (N = 61) were randomized to behavioral weight loss or wait-list control. At baseline and follow-up, participants completed assessments that included functional magnetic resonance imaging scans to assess response to images of high-calorie foods (HCF) or low-calorie foods (LCF), and neutral objects. RESULTS: There were no significant between-group differences in change from baseline to follow-up in any regions of the brain in response to viewing HCF or LCF. From baseline to follow-up, participants in behavioral weight loss, compared with wait-list control, reported significantly greater increases in desire for LCF. Changes in liking and palatability of LCF and liking, palatability, and desire for HCF did not differ between groups. DISCUSSION: Behavioral weight loss was associated with increased desire for LCF without changes in neural reactivity to food cues. These results suggest that alteration of neurological processes underlying responsiveness to food is difficult to achieve through behavioral weight management alone.</text><annotation id="10"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="146" length="11"/><text>weight loss</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="172" length="12"/><text>blood oxygen</text></annotation><annotation id="12"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="333" length="11"/><text>weight loss</text></annotation><annotation id="13"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="411" length="6"/><text>oxygen</text></annotation><annotation id="14"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="479" length="7"/><text>obesity</text></annotation><annotation id="15"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="526" length="11"/><text>weight loss</text></annotation><annotation id="16"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="1002" length="11"/><text>weight loss</text></annotation><annotation id="17"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="1249" length="11"/><text>weight loss</text></annotation></passage></document>
<document><id>37917195</id><passage><infon key="journal">J Clin Invest;2023Nov02. doi:10.1172/JCI171468</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Matrongolo MJ, Ang PS, Wu J, Jain A, Thackray JK, Reddy AG, Sung CC, Barbet G, Hong YK, Tischfield MA, </infon><offset>0</offset><text>Piezo1 agonist restores meningeal lymphatic vessels, drainage, and brain-CSF perfusion in craniosynostosis and aged mice.</text><annotation id="2"><infon key="identifier">234839</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">124356</infon><location offset="0" length="6"/><text>Piezo1</text></annotation><annotation id="3"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="90" length="16"/><text>craniosynostosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>Skull development coincides with the onset of cerebrospinal fluid (CSF) circulation, brain-CSF perfusion, and meningeal lymphangiogenesis, processes essential for brain waste clearance. How these processes are affected by craniofacial disorders such as craniosynostosis are poorly understood. We report that raised intracranial pressure and diminished CSF flow in craniosynostosis mouse models associates with pathological changes to meningeal lymphatic vessels that affect their sprouting, expansion, and long-term maintenance. We also show that craniosynostosis affects CSF circulatory pathways and perfusion into the brain. Further, craniosynostosis exacerbates amyloid pathology and plaque buildup in Twist1+/-:5xFAD transgenic Alzheimer's disease models. Treating craniosynostosis mice with Yoda1, a small molecule agonist for Piezo1, reduces intracranial pressure and improves CSF flow, in addition to restoring meningeal lymphangiogenesis, drainage to the deep cervical lymph nodes, and brain-CSF perfusion. Leveraging these findings, we show Yoda1 treatments in aged mice with reduced CSF flow and turnover improve lymphatic networks, drainage, and brain-CSF perfusion. Our results suggest CSF provides mechanical force to facilitate meningeal lymphatic growth and maintenance. Additionally, applying Yoda1 agonist in conditions with raised intracranial pressure and/or diminished CSF flow, as seen in craniosynostosis or with ageing, is a possible therapeutic option to help restore meningeal lymphatic networks and brain-CSF perfusion.</text><annotation id="17"><infon key="identifier">MESH:D019465</infon><infon key="type">Disease</infon><location offset="344" length="22"/><text>craniofacial disorders</text></annotation><annotation id="18"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="375" length="16"/><text>craniosynostosis</text></annotation><annotation id="19"><infon key="identifier">MESH:D019586</infon><infon key="type">Disease</infon><location offset="430" length="28"/><text>raised intracranial pressure</text></annotation><annotation id="20"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="486" length="16"/><text>craniosynostosis</text></annotation><annotation id="21"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="669" length="16"/><text>craniosynostosis</text></annotation><annotation id="22"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="758" length="16"/><text>craniosynostosis</text></annotation><annotation id="23"><infon key="identifier">MESH:C000718787</infon><infon key="type">Disease</infon><location offset="787" length="7"/><text>amyloid</text></annotation><annotation id="24"><infon key="identifier">22160</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">402</infon><location offset="827" length="6"/><text>Twist1</text></annotation><annotation id="25"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="854" length="19"/><text>Alzheimer's disease</text></annotation><annotation id="26"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="891" length="16"/><text>craniosynostosis</text></annotation><annotation id="27"><infon key="identifier">234839</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">124356</infon><location offset="954" length="6"/><text>Piezo1</text></annotation><annotation id="28"><infon key="identifier">MESH:D019586</infon><infon key="type">Disease</infon><location offset="1464" length="28"/><text>raised intracranial pressure</text></annotation><annotation id="29"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="1532" length="16"/><text>craniosynostosis</text></annotation></passage><relation id="R1"><infon key="score">0.9981</infon><infon key="role1">Disease|MESH:D003398</infon><infon key="role2">Gene|234839</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation></document>
<document><id>37917545</id><passage><infon key="journal">J Agric Food Chem;2023Nov02. doi:10.1021/acs.jafc.3c05383</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Weidner L, Cannas JV, Rychlik M, Schmitt-Kopplin P, </infon><offset>0</offset><text>Molecular Characterization of Cooking Processes: A Metabolomics Decoding of Vaporous Emissions for Food Markers and Thermal Reaction Indicators.</text></passage><passage><infon key="type">abstract</infon><offset>145</offset><text>Thermal processing of food plays a fundamental role in everyday life. Whereas most researchers study thermal processes directly in the matrix, molecular information in the form of non- and semivolatile compounds conveyed by vaporous emissions is often neglected. We performed a metabolomics study of processing emissions from 96 different food items to define the interaction between the processed matrix and released metabolites. Untargeted profiling of vapor samples revealed matrix-dependent molecular spaces that were characterized by Fourier-transform ion cyclotron resonance-mass spectrometry and ultra-performance liquid chromatography-mass spectrometry. Thermal degradation products of peptides and amino acids can be used for the differentiation of animal-based food from plant-based food, which generally is characterized by secondary plant metabolites or carbohydrates. Further, heat-sensitive processing indicators were characterized and discussed in the background of the Maillard reaction. These reveal that processing emissions contain a dense layer of information suitable for deep insights into food composition and control of cooking processes based on processing emissions.</text><annotation id="1"><infon key="identifier">MESH:D002241</infon><infon key="type">Chemical</infon><location offset="1011" length="13"/><text>carbohydrates</text></annotation></passage></document>
<document><id>37917897</id><passage><infon key="journal">Altern Ther Health Med;2023Nov03</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xia J, Zhou Z, Wu Z, Zhu S, Li L, </infon><offset>0</offset><text>The Initial Efficacy of Comprehensive Treatment of External Treatment of Traditional Chinese Medicine on Acute Mastitis During Lactation and its Influence on Patients' Symptoms.</text><annotation id="1"><infon key="identifier">MESH:D008413</infon><infon key="type">Disease</infon><location offset="105" length="14"/><text>Acute Mastitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>178</offset><text>Objective: To evaluate the initial efficacy of comprehensive treatment of external treatment of traditional Chinese medicine in the therapy of acute mastitis during lactation and its influence on sufferers' symptoms. Methods: From January 2021 to January 2023, a retrospective analysis was performed on 100 sufferers with acute mastitis during lactation who were received in our hospital as the study objects. Divided them into a control group (n = 50) and an observation group (n = 50). Among them, the control one was received in 50% magnesium sulfate for moist heat compress, and the observation one was treated with comprehensive external therapy of traditional Chinese medicine. After different treatment measures were carried out in the 2 groups, the total effective ratio of clinical therapy, excellent and good rates of lactation, quality of life measurements, pain scores before and after treatment, and TCM symptom points at pre-therapy and post-therapy, negative emotion scores at pre-therapy and post-therapy related to patients were analyzed. Results: (1) In the data comparison of the total effective ratio of clinical therapy between the 2 groups of sufferers after therapy, the data in the observation one were greater than the control one, and the distinction was obvious, with P &lt; .05. (2) In the data comparison of the excellent and good lactation rate between the 2 groups of sufferers at post-therapy, the data in observation one were greater than the control one, and the distinction was obvious, with P &lt; .05. (3) In the data comparison of quality of life measurements between the 2 groups of sufferers at post-therapy, the data in the observation one were greater than the control one, and the distinction was obvious, with P &lt; .05. (4) Before treatment, it had no obvious distinction in the pain scores between the 2 groups, with P > .05; in the data comparison of the pain points between the 2 groups after therapy, the data in observation one were less than the control one, and the distinction was obvious, with P &lt; .05. (5) Before therapy, it had no obvious distinction in TCM symptom points between the 2 groups, with P > .05; in the data comparison of TCM symptom points between the 2 groups after therapy, the data in the observation one were less than the control one, and the distinction was obvious, with P &lt; .05. (6) Before therapy, it had no obvious distinction in negative emotion points between the 2 groups, with P > .05; in the data comparison of negative emotion scores between the 2 groups of sufferers at post-therapy, the data in the observation one were less than those in the control one, and the distinction was obvious, with P &lt; .05. Conclusion: The comprehensive therapy of TCM external treatment for acute mastitis during lactation has a significant therapeutic effect, which is conducive to improving the clinical symptoms of sufferers as soon as possible and at the same time, greatly improving the life quality of sufferers and improving their negative emotions, which can relieve the pain of sufferers and promote the recovery of the sufferers.</text><annotation id="14"><infon key="identifier">MESH:D008413</infon><infon key="type">Disease</infon><location offset="321" length="14"/><text>acute mastitis</text></annotation><annotation id="15"><infon key="identifier">MESH:D008413</infon><infon key="type">Disease</infon><location offset="500" length="14"/><text>acute mastitis</text></annotation><annotation id="16"><infon key="identifier">MESH:D008278</infon><infon key="type">Chemical</infon><location offset="714" length="17"/><text>magnesium sulfate</text></annotation><annotation id="17"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1047" length="4"/><text>pain</text></annotation><annotation id="18"><infon key="type">Disease</infon><location offset="1091" length="3"/><text>TCM</text></annotation><annotation id="19"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1994" length="4"/><text>pain</text></annotation><annotation id="20"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="2072" length="4"/><text>pain</text></annotation><annotation id="21"><infon key="type">Disease</infon><location offset="2280" length="3"/><text>TCM</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="2361" length="3"/><text>TCM</text></annotation><annotation id="23"><infon key="type">Disease</infon><location offset="2902" length="3"/><text>TCM</text></annotation><annotation id="24"><infon key="identifier">MESH:D008413</infon><infon key="type">Disease</infon><location offset="2929" length="14"/><text>acute mastitis</text></annotation><annotation id="25"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="3217" length="4"/><text>pain</text></annotation></passage></document>
<document><id>37918247</id><passage><infon key="journal">Talanta;2023Oct17; 268 (Pt 1) 125322. doi:10.1016/j.talanta.2023.125322</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Qu J, Zhang X, Zhou W, Yao R, Zhang X, Jing S, </infon><offset>0</offset><text>Carbon dots/Ruthenium(III) nanocomposites for FRET fluorescence detection and removal of mercury (II) via assembling into nanofibers.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="11"/><text>Carbon dots</text></annotation><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="12" length="14"/><text>Ruthenium(III)</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="89" length="12"/><text>mercury (II)</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>The determination and removal of mercury(II) (Hg2+) are essential for human health and environmental ecosystems. Herein, an ingenious carbon dots (CDs)-based Forster resonance energy transfer (FRET) system (N, S-CDs/Ru) was fabricated employing CDs and Ru3+ units as energy-transfer doner/acceptor pairs for visual detection and efficient removal of Hg2+. The treatment of Hg2+ induced a remarkable linear enhancement of the ratiometric fluorescence (F613 nm/F478 nm) with a detection limit (LOD) of 95 nM, along with continuous fluorescence color variations from blue to red. Given that the fluorescence color recognition and processing realized the real-time and rapid quantitation of Hg2+ by paper-based smartphone sensing platform. The mechanistic study revealed that the N/S/O-rich surface of the system enabled the Hg2+-triggered self-assembly from dots to nanofibers, combing with the active FRET process. Also, the efficient removal of Hg2+ with a removal efficiency of ~98 % and an adsorption capacity of ~372 mg/g was obtained. Furthermore, it was found that N, S-CDs/Ru loaded commercialized SiO2 or SBA-15 could facilitate the removal of Hg2+ with a removal efficiency over 99 % and an adsorption capacity up to ~562 mg/g. This study provides a potential strategy for environmental monitoring and remediation.</text><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="167" length="11"/><text>mercury(II)</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="180" length="4"/><text>Hg2+</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="268" length="11"/><text>carbon dots</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="281" length="3"/><text>CDs</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="341" length="8"/><text>N, S-CDs</text></annotation><annotation id="29"><infon key="identifier">MESH:D012428</infon><infon key="type">Chemical</infon><location offset="350" length="2"/><text>Ru</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="379" length="3"/><text>CDs</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="387" length="4"/><text>Ru3+</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="484" length="4"/><text>Hg2+</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="507" length="4"/><text>Hg2+</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="821" length="4"/><text>Hg2+</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="955" length="4"/><text>Hg2+</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1078" length="4"/><text>Hg2+</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1203" length="8"/><text>N, S-CDs</text></annotation><annotation id="38"><infon key="identifier">MESH:D012428</infon><infon key="type">Chemical</infon><location offset="1212" length="2"/><text>Ru</text></annotation><annotation id="39"><infon key="identifier">MESH:D012822</infon><infon key="type">Chemical</infon><location offset="1237" length="4"/><text>SiO2</text></annotation><annotation id="40"><infon key="identifier">MESH:C509969</infon><infon key="type">Chemical</infon><location offset="1245" length="6"/><text>SBA-15</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1284" length="4"/><text>Hg2+</text></annotation></passage><relation id="R1"><infon key="score">0.9555</infon><infon key="role1">Chemical|MESH:D012428</infon><infon key="role2">Chemical|MESH:D012822</infon><infon key="type">Association</infon><node refid="0" role="18,19"/></relation><relation id="R2"><infon key="score">0.5043</infon><infon key="role1">Chemical|MESH:C509969</infon><infon key="role2">Chemical|MESH:D012428</infon><infon key="type">Association</infon><node refid="1" role="20,18"/></relation></document>
<document><id>37918597</id><passage><infon key="journal">Int J Biol Macromol;2023Oct31 127653. doi:10.1016/j.ijbiomac.2023.127653</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang Y, Man J, Wang J, Liu J, Song X, Yu X, Li J, Li R, Qiu Y, Li J, Chen Y, </infon><offset>0</offset><text>Surface modification of polyvinyl chloride with sodium alginate/carboxymethyl chitosan and heparin for realizing the anticoagulation.</text><annotation id="4"><infon key="identifier">MESH:D011143</infon><infon key="type">Chemical</infon><location offset="24" length="18"/><text>polyvinyl chloride</text></annotation><annotation id="5"><infon key="identifier">MESH:D000464</infon><infon key="type">Chemical</infon><location offset="48" length="15"/><text>sodium alginate</text></annotation><annotation id="6"><infon key="identifier">MESH:C514968</infon><infon key="type">Chemical</infon><location offset="64" length="22"/><text>carboxymethyl chitosan</text></annotation><annotation id="7"><infon key="identifier">MESH:D006493</infon><infon key="type">Chemical</infon><location offset="91" length="7"/><text>heparin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>Thrombosis of extracorporeal circuits causes significant morbidity and mortality worldwide. In this study, plasma treatment technology and chemical grafting method were used to construct heparinized surfaces on the PVC substrate, which could not only reduce thrombosis but also decrease the side effects of the direct injection of anticoagulants. The PVC substrate was modified by plasma treatment technology firstly to obtain the active surface with the hydroxyl groups used for grafting. Then, heparin was grafted onto the modified PVC surface using different grafting strategies to prepare different heparinized surfaces. The experimental results indicated that the sodium alginate (SA) and carboxymethyl chitosan (CCS) used as interlayers could significantly increase the graft density of heparin to improve the anticoagulant effects and hemocompatibility of heparinized surfaces. In addition, the modification of heparin can further improve the anticoagulant effects. The CCS/low-molecular-weight heparin (LWMH) surface has the best anticoagulant properties, which can prolong the activated partial thromboplastin time (APTT) values of human plasma for about 35 s, reduce the hemolysis rates to &lt;0.3 %, and perform well in the in-vitro blood circulation test. The heparinized surfaces prepared in this work have great application potential in anticoagulant treatment for medical devices.</text><annotation id="24"><infon key="identifier">MESH:D013927</infon><infon key="type">Disease</infon><location offset="134" length="10"/><text>Thrombosis</text></annotation><annotation id="25"><infon key="identifier">MESH:D011143</infon><infon key="type">Chemical</infon><location offset="349" length="3"/><text>PVC</text></annotation><annotation id="26"><infon key="identifier">MESH:D013927</infon><infon key="type">Disease</infon><location offset="392" length="10"/><text>thrombosis</text></annotation><annotation id="27"><infon key="identifier">MESH:D011143</infon><infon key="type">Chemical</infon><location offset="485" length="3"/><text>PVC</text></annotation><annotation id="28"><infon key="identifier">MESH:D006493</infon><infon key="type">Chemical</infon><location offset="630" length="7"/><text>heparin</text></annotation><annotation id="29"><infon key="identifier">MESH:D011143</infon><infon key="type">Chemical</infon><location offset="668" length="3"/><text>PVC</text></annotation><annotation id="30"><infon key="identifier">MESH:D000464</infon><infon key="type">Chemical</infon><location offset="803" length="15"/><text>sodium alginate</text></annotation><annotation id="31"><infon key="identifier">MESH:D000464</infon><infon key="type">Chemical</infon><location offset="820" length="2"/><text>SA</text></annotation><annotation id="32"><infon key="identifier">MESH:C514968</infon><infon key="type">Chemical</infon><location offset="828" length="22"/><text>carboxymethyl chitosan</text></annotation><annotation id="33"><infon key="identifier">MESH:C514968</infon><infon key="type">Chemical</infon><location offset="852" length="3"/><text>CCS</text></annotation><annotation id="34"><infon key="identifier">MESH:D006493</infon><infon key="type">Chemical</infon><location offset="927" length="7"/><text>heparin</text></annotation><annotation id="35"><infon key="identifier">MESH:D006493</infon><infon key="type">Chemical</infon><location offset="1052" length="7"/><text>heparin</text></annotation><annotation id="36"><infon key="identifier">MESH:C514968</infon><infon key="type">Chemical</infon><location offset="1111" length="3"/><text>CCS</text></annotation><annotation id="37"><infon key="identifier">MESH:D006495</infon><infon key="type">Chemical</infon><location offset="1115" length="28"/><text>low-molecular-weight heparin</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1145" length="4"/><text>LWMH</text></annotation><annotation id="39"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="1315" length="9"/><text>hemolysis</text></annotation></passage><relation id="R1"><infon key="score">0.9995</infon><infon key="role1">Chemical|MESH:D006493</infon><infon key="role2">Chemical|MESH:D011143</infon><infon key="type">Association</infon><node refid="0" role="3,0"/></relation><relation id="R2"><infon key="score">0.4553</infon><infon key="role1">Chemical|MESH:C514968</infon><infon key="role2">Chemical|MESH:D006493</infon><infon key="type">Cotreatment</infon><node refid="1" role="2,3"/></relation><relation id="R3"><infon key="score">0.9609</infon><infon key="role1">Chemical|MESH:C514968</infon><infon key="role2">Disease|MESH:D006461</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="16,19"/></relation><relation id="R4"><infon key="score">0.9697</infon><infon key="role1">Chemical|MESH:D000464</infon><infon key="role2">Chemical|MESH:D011143</infon><infon key="type">Association</infon><node refid="3" role="1,0"/></relation><relation id="R5"><infon key="score">0.9966</infon><infon key="role1">Chemical|MESH:C514968</infon><infon key="role2">Chemical|MESH:D011143</infon><infon key="type">Association</infon><node refid="4" role="2,0"/></relation><relation id="R6"><infon key="score">0.4375</infon><infon key="role1">Chemical|MESH:D000464</infon><infon key="role2">Chemical|MESH:D006493</infon><infon key="type">Cotreatment</infon><node refid="5" role="1,3"/></relation><relation id="R7"><infon key="score">0.9817</infon><infon key="role1">Chemical|MESH:C514968</infon><infon key="role2">Chemical|MESH:D006495</infon><infon key="type">Association</infon><node refid="6" role="16,17"/></relation><relation id="R8"><infon key="score">0.9983</infon><infon key="role1">Chemical|MESH:D006495</infon><infon key="role2">Disease|MESH:D006461</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="17,19"/></relation></document>
<document><id>37918947</id><passage><infon key="journal">BMJ Case Rep;2023Nov02; 16 (11) . doi:10.1136/bcr-2023-258361</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Anand M, Kumar A, Yadav J, Goel A, </infon><offset>0</offset><text>Utilising anterolateral bladder flap to create a continent cutaneous diversion in a patient with pelvic fracture urethral injury.</text><annotation id="2"><infon key="identifier">MESH:D034161</infon><infon key="type">Disease</infon><location offset="97" length="15"/><text>pelvic fracture</text></annotation><annotation id="3"><infon key="identifier">MESH:D014526</infon><infon key="type">Disease</infon><location offset="113" length="15"/><text>urethral injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>130</offset><text>A male child in the first decade of life presented to us with a history of a pelvic fracture and urethral injury resulting from a road traffic accident 4 months prior. He had previously undergone an exploratory laparotomy and suprapubic cystostomy at another medical centre. He was circumcised and exhibited a substantial urethral defect on the retrograde urethrogram, as well as on the micturating cystourethrogram. Following a careful assessment of the patient's and caregivers' expectations, a continent cutaneous catheterisable channel was planned. This procedure involved the use of an anterolateral bladder flap, and continence was achieved through the creation of a Nissen-type seromuscular invagination. Three months postoperatively, the child remains continent, can easily catheterise the stoma and has resumed his education.</text><annotation id="8"><infon key="identifier">MESH:D034161</infon><infon key="type">Disease</infon><location offset="207" length="15"/><text>pelvic fracture</text></annotation><annotation id="9"><infon key="identifier">MESH:D014526</infon><infon key="type">Disease</infon><location offset="227" length="15"/><text>urethral injury</text></annotation><annotation id="10"><infon key="identifier">MESH:D000081084</infon><infon key="type">Disease</infon><location offset="260" length="21"/><text>road traffic accident</text></annotation><annotation id="11"><infon key="identifier">MESH:D014526</infon><infon key="type">Disease</infon><location offset="452" length="15"/><text>urethral defect</text></annotation></passage></document>
<document><id>37919297</id><passage><infon key="journal">Nat Commun;2023Nov02; 14 (1) 7004. doi:10.1038/s41467-023-42778-2</infon><infon key="year">2023</infon><infon key="article-id_pmc">5349499</infon><infon key="type">title</infon><infon key="authors">Stanley LJ, Lin PV, Jaroszy&amp;#x144;ski J, Popovi&amp;#x107; D, </infon><offset>0</offset><text>Screening the Coulomb interaction leads to a prethermal regime in two-dimensional bad conductors.</text></passage><passage><infon key="type">abstract</infon><offset>98</offset><text>The absence of thermalization in certain isolated many-body systems is of great fundamental interest. Many-body localization (MBL) is a widely studied mechanism for thermalization to fail in strongly disordered quantum systems, but it is still not understood precisely how the range of interactions affects the dynamical behavior and the existence of MBL, especially in dimensions D > 1. By investigating nonequilibrium dynamics in strongly disordered D = 2 electron systems with power-law interactions   1/ralpha and poor coupling to a thermal bath, here we observe MBL-like, prethermal dynamics for alpha = 3. In contrast, for alpha = 1, the system thermalizes, although the dynamics is glassy. Our results provide important insights for theory, especially since we obtained them on systems that are much closer to the thermodynamic limit than synthetic quantum systems employed in previous studies of MBL. Thus, our work is a key step towards further studies of ergodicity breaking and quantum entanglement in real materials.</text></passage></document>
<document><id>37919997</id><passage><infon key="journal">Math Biosci Eng;2023Aug03; 20 (9) 15962. doi:10.3934/mbe.2023711</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nia ZM, Ahmadi A, Mellado B, Wu J, Orbinski J, Asgary A, Kong JD, </infon><offset>0</offset><text>Twitter-based gender recognition using transformers.</text></passage><passage><infon key="type">abstract</infon><offset>53</offset><text>Social media contains useful information about people and society that could help advance research in many different areas of health (e.g. by applying opinion mining, emotion/sentiment analysis and statistical analysis) such as mental health, health surveillance, socio-economic inequality and gender vulnerability. User demographics provide rich information that could help study the subject further. However, user demographics such as gender are considered private and are not freely available. In this study, we propose a model based on transformers to predict the user's gender from their images and tweets. The image-based classification model is trained in two different methods: using the profile image of the user and using various image contents posted by the user on Twitter. For the first method a Twitter gender recognition dataset, publicly available on Kaggle and for the second method the PAN-18 dataset is used. Several transformer models, i.e. vision transformers (ViT), LeViT and Swin Transformer are fine-tuned for both of the image datasets and then compared. Next, different transformer models, namely, bidirectional encoders representations from transformers (BERT), RoBERTa and ELECTRA are fine-tuned to recognize the user's gender by their tweets. This is highly beneficial, because not all users provide an image that indicates their gender. The gender of such users could be detected from their tweets. The significance of the image and text classification models were evaluated using the Mann-Whitney U test. Finally, the combination model improved the accuracy of image and text classification models by 11.73 and 5.26% for the Kaggle dataset and by 8.55 and 9.8% for the PAN-18 dataset, respectively. This shows that the image and text classification models are capable of complementing each other by providing additional information to one another. Our overall multimodal method has an accuracy of 88.11% for the Kaggle and 89.24% for the PAN-18 dataset and outperforms state-of-the-art models. Our work benefits research that critically require user demographic information such as gender to further analyze and study social media content for health-related issues.</text><annotation id="1"><infon key="identifier">CVCL:XR32</infon><infon key="type">CellLine</infon><location offset="1753" length="6"/><text>PAN-18</text></annotation></passage></document>
<document><id>37921047</id><passage><infon key="journal">Protein Sci;2023Nov03 4829. doi:10.1002/pro.4829</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jin Z, Song D, Wang WW, Feng L, Li ZX, Chen HF, Xiao X, Liu XP, </infon><offset>0</offset><text>Synthesis and degradation of the cyclic dinucleotide messenger c-di-AMP in the hyperthermophilic archaeon Pyrococcus yayanosii.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="33" length="19"/><text>cyclic dinucleotide</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="63" length="8"/><text>c-di-AMP</text></annotation></passage><passage><infon key="type">abstract</infon><offset>128</offset><text>Cyclic di-adenosine monophosphate (c-di-AMP) is a newly identified prokaryotic cyclic dinucleotide second messenger well elucidated in bacteria, while less studied in archaea. Here, we describe the enzymes involved in c-di-AMP metabolism in hyperthermophilic archaeon Pyrococcus yayanosii. Our results demonstrate that c-di-AMP is synthesized from two molecules of ATP by diadenylate cyclase (DAC) and degraded into pApA and then to AMP by a DHH family phosphodiesterase (PDE). DAC can be activated by a wider variety of ions, using two conserved residues, D188 and E244, to coordinate divalent metal ions, which is different from bacterial CdaA and DisA. PDE possesses a broad substrate spectrum like bacterial DHH family PDEs, but shows a stricter base selection between A and G in cyclic dinucleotides hydrolysis. PDE shows differences in substrate binding patch from bacterial counterparts. C-di-AMP was confirmed to exist in Thermococcus kodakarensis cells, and the deletion of the dac or pde gene supports that the synthesis and degradation of c-di-AMP is catalysed by DAC and PDE, respectively. Our results provide further understanding of the metabolism of c-di-AMP in archaea. This article is protected by copyright. All rights reserved.</text><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="128" length="33"/><text>Cyclic di-adenosine monophosphate</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="163" length="8"/><text>c-di-AMP</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="207" length="19"/><text>cyclic dinucleotide</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="346" length="8"/><text>c-di-AMP</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="447" length="8"/><text>c-di-AMP</text></annotation><annotation id="20"><infon key="identifier">MESH:D000255</infon><infon key="type">Chemical</infon><location offset="493" length="3"/><text>ATP</text></annotation><annotation id="21"><infon key="identifier">MESH:D000249</infon><infon key="type">Chemical</infon><location offset="561" length="3"/><text>AMP</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="912" length="20"/><text>cyclic dinucleotides</text></annotation><annotation id="23"><infon key="identifier">MESH:C528998</infon><infon key="type">Chemical</infon><location offset="1023" length="8"/><text>C-di-AMP</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1178" length="8"/><text>c-di-AMP</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1293" length="8"/><text>c-di-AMP</text></annotation></passage></document>
<document><id>37921397</id><passage><infon key="journal">ACS Appl Mater Interfaces;2023Nov03. doi:10.1021/acsami.3c11882</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Feng J, Ding Y, Wang Z, Bao C, Xiao Y, </infon><offset>0</offset><text>Facile Preparation of a Multifunctional Hydrogel Composite Dressing via Dual Self-Redox Mechanism for Accelerated Infected Wound Healing.</text><annotation id="1"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="114" length="8"/><text>Infected</text></annotation></passage><passage><infon key="type">abstract</infon><offset>138</offset><text>The management of infected wound healing remains a formidable challenge primarily due to the absence of an ideal wound dressing that can not only effectively inhibit persistent bacterial infection and mitigate excessive inflammation but also possess appropriate mechanical strength, moderate adhesiveness, and favorable self-healability to maintain its protective function and facilitate easy change. In this study, we present an effective strategy for the preparation of a novel composite hydrogel under mild conditions, without the need for additives. This is achieved by incorporating resveratrol (RSV)-loaded alkali lignin nanoparticles (ARNPs) into an advanced polyacrylamide-based hydrogel matrix. The utilization of ARNPs facilitated the sustained release of RSV, thereby enhancing its bioavailability. The polymerization of acrylamide was gently triggered by free radicals generated through a novel dual self-redox mechanism involving silver ions (Ag+), catechols, and ammonium persulfate in neutral and at room temperature, without the requirement of cross-linkers. The dual self-redox reactions played a dominant role in facilitating the gelation process and imparting the desired properties to the resulting hydrogels. The obtained product exhibited exceptional antibacterial properties, favorable anti-inflammatory activity, superior tensile strength, moderate adhesiveness, and reliable self-healability, thereby accelerating the closure of infected wounds. Collectively, this study synergistically integrated RSV-sustained release nanoparticles and a specially designed multifunctional hydrogel into a single system in a conveniently manipulable manner. This composite wound dressing material holds promise for promoting the healing of infected wounds and has potential applications in other complex wound treatments.</text><annotation id="20"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="156" length="8"/><text>infected</text></annotation><annotation id="21"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="315" length="19"/><text>bacterial infection</text></annotation><annotation id="22"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="358" length="12"/><text>inflammation</text></annotation><annotation id="23"><infon key="identifier">MESH:D000077185</infon><infon key="type">Chemical</infon><location offset="726" length="11"/><text>resveratrol</text></annotation><annotation id="24"><infon key="identifier">MESH:D000077185</infon><infon key="type">Chemical</infon><location offset="739" length="3"/><text>RSV</text></annotation><annotation id="25"><infon key="identifier">MESH:D008031</infon><infon key="type">Chemical</infon><location offset="758" length="6"/><text>lignin</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="780" length="5"/><text>ARNPs</text></annotation><annotation id="27"><infon key="identifier">MESH:C016679</infon><infon key="type">Chemical</infon><location offset="804" length="14"/><text>polyacrylamide</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="861" length="5"/><text>ARNPs</text></annotation><annotation id="29"><infon key="identifier">MESH:D000077185</infon><infon key="type">Chemical</infon><location offset="904" length="3"/><text>RSV</text></annotation><annotation id="30"><infon key="identifier">MESH:D020106</infon><infon key="type">Chemical</infon><location offset="970" length="10"/><text>acrylamide</text></annotation><annotation id="31"><infon key="identifier">MESH:D012834</infon><infon key="type">Chemical</infon><location offset="1081" length="6"/><text>silver</text></annotation><annotation id="32"><infon key="identifier">MESH:D002396</infon><infon key="type">Chemical</infon><location offset="1100" length="9"/><text>catechols</text></annotation><annotation id="33"><infon key="identifier">MESH:C031276</infon><infon key="type">Chemical</infon><location offset="1115" length="19"/><text>ammonium persulfate</text></annotation><annotation id="34"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1452" length="12"/><text>inflammatory</text></annotation><annotation id="35"><infon key="identifier">MESH:D014946</infon><infon key="type">Disease</infon><location offset="1592" length="15"/><text>infected wounds</text></annotation><annotation id="36"><infon key="identifier">MESH:D000077185</infon><infon key="type">Chemical</infon><location offset="1661" length="3"/><text>RSV</text></annotation><annotation id="37"><infon key="identifier">MESH:D014946</infon><infon key="type">Disease</infon><location offset="1888" length="15"/><text>infected wounds</text></annotation></passage><relation id="R1"><infon key="score">0.4855</infon><infon key="role1">Chemical|MESH:C031276</infon><infon key="role2">Chemical|MESH:D020106</infon><infon key="type">Association</infon><node refid="0" role="15,11"/></relation><relation id="R2"><infon key="score">0.5178</infon><infon key="role1">Chemical|MESH:D000077185</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="18,16"/></relation><relation id="R3"><infon key="score">0.9966</infon><infon key="role1">Chemical|MESH:D000077185</infon><infon key="role2">Disease|MESH:D014946</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="18,17"/></relation><relation id="R4"><infon key="score">0.7279</infon><infon key="role1">Chemical|MESH:C016679</infon><infon key="role2">Chemical|MESH:D008031</infon><infon key="type">Association</infon><node refid="3" role="8,6"/></relation></document>
<document><id>37921747</id><passage><infon key="journal">JAMA Health Forum;2023Nov03; 4 (11) 233667. doi:10.1001/jamahealthforum.2023.3667</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Adams D, Wolfe AJ, Warren J, Laberge A, Richards AC, Herzer K, Fleisher LA, </infon><offset>0</offset><text>Initial Findings From an Acute Hospital Care at Home Waiver Initiative.</text></passage><passage><infon key="type">abstract</infon><offset>72</offset></passage></document>
<document><id>37889600</id><passage><infon key="journal">Pain;2023Oct27. doi:10.1097/j.pain.0000000000003100</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Han S, Ren J, Li Z, Wen J, Jiang B, Wei X, </infon><offset>0</offset><text>Deactivation of dorsal CA1 pyramidal neurons projecting to medial prefrontal cortex contributes to neuropathic pain and short-term memory impairment.</text><annotation id="2"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="99" length="16"/><text>neuropathic pain</text></annotation><annotation id="3"><infon key="identifier">MESH:D008569</infon><infon key="type">Disease</infon><location offset="131" length="17"/><text>memory impairment</text></annotation></passage><passage><infon key="type">abstract</infon><offset>150</offset><text>ABSTRACT: Neuropathic pain after peripheral nerve injury is a multidimensional experience that includes sensory, affective, and cognitive components that interact with one another. Hypoexcitation of the medial prefrontal cortex (mPFC) was observed in mice with peripheral nerve injury, but the changes in neural inputs onto the mPFC have not been completely explored. Here, we report that the neural terminals from the dorsal hippocampus CA1 (dCA1) form excitatory connection with layer 5 pyramidal neurons in the prelimbic area (PrL) of the mPFC. Spared nerve injury (SNI) induced a reduction in the intrinsic excitability of dCA1 pyramidal neurons innervating the PrL and impairment in excitatory synaptic transmission onto dCA1 pyramidal cells. Specifically, activating the neural circuit from dCA1 to mPFC alleviated neuropathic pain behaviors and improved novel object recognition ability in SNI mice, whereas deactivating this pathway in naive animals recapitulated tactile allodynia and memory deficits. These results indicated that hypoactivity in dCA1 pyramidal cells after SNI in turn deactivated layer 5 pyramidal neurons in PrL and ultimately caused pain hypersensitivity and memory deficits.</text><annotation id="16"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="160" length="16"/><text>Neuropathic pain</text></annotation><annotation id="17"><infon key="identifier">MESH:D059348</infon><infon key="type">Disease</infon><location offset="183" length="23"/><text>peripheral nerve injury</text></annotation><annotation id="18"><infon key="identifier">MESH:D059348</infon><infon key="type">Disease</infon><location offset="411" length="23"/><text>peripheral nerve injury</text></annotation><annotation id="19"><infon key="identifier">MESH:D000080902</infon><infon key="type">Disease</infon><location offset="698" length="19"/><text>Spared nerve injury</text></annotation><annotation id="20"><infon key="identifier">MESH:D000080902</infon><infon key="type">Disease</infon><location offset="719" length="3"/><text>SNI</text></annotation><annotation id="21"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="971" length="16"/><text>neuropathic pain</text></annotation><annotation id="22"><infon key="identifier">MESH:D000080902</infon><infon key="type">Disease</infon><location offset="1047" length="3"/><text>SNI</text></annotation><annotation id="23"><infon key="identifier">MESH:D006930</infon><infon key="type">Disease</infon><location offset="1122" length="17"/><text>tactile allodynia</text></annotation><annotation id="24"><infon key="identifier">MESH:D008569</infon><infon key="type">Disease</infon><location offset="1144" length="15"/><text>memory deficits</text></annotation><annotation id="25"><infon key="identifier">MESH:D000080902</infon><infon key="type">Disease</infon><location offset="1233" length="3"/><text>SNI</text></annotation><annotation id="26"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1312" length="21"/><text>pain hypersensitivity</text></annotation><annotation id="27"><infon key="identifier">MESH:D008569</infon><infon key="type">Disease</infon><location offset="1338" length="15"/><text>memory deficits</text></annotation></passage></document>
<document><id>37889951</id><passage><infon key="journal">Epidemiology;2023Oct25. doi:10.1097/EDE.0000000000001684</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Post RAJ, Petkovic M, van den Heuvel IL, van den Heuvel ER, </infon><offset>0</offset><text>Flexible Machine Learning Estimation of Conditional Average Treatment Effects: A Blessing and a Curse.</text></passage><passage><infon key="type">abstract</infon><offset>103</offset><text>Causal inference from observational data requires untestable identification assumptions. If these assumptions apply, machine learning methods can be used to study complex forms of causal effect heterogeneity. Recently, several machine learning methods were developed to estimate the conditional average treatment effect (ATE). If the features at hand cannot explain all heterogeneity, the individual treatment effects can seriously deviate from the conditional ATE. In this work, we demonstrate how the distributions of the individual treatment effect and the conditional ATE can differ when a causal random forest is applied. We extend the causal random forest to estimate the difference in conditional variance between treated and controls. If the distribution of the individual treatment effect equals that of the conditional ATE, this estimated difference in variance should be small. If they differ, an additional causal assumption is necessary to quantify the heterogeneity not captured by the distribution of the conditional ATE. The conditional variance of the individual treatment effect can be identified when the individual effect is independent of the outcome under no treatment given the measured features. Then, in the cases where the individual treatment effect and conditional ATE distributions differ, the extended causal random forest can appropriately estimate the variance of the individual treatment effect distribution, whereas the causal random forest fails to do so.</text></passage></document>
<document><id>37890302</id><passage><infon key="journal">J Environ Manage;2023Oct25; 349 119406. doi:10.1016/j.jenvman.2023.119406</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chang Y, Zhiyun Z, Dengfeng Z, Di Z, Liguo X, </infon><offset>0</offset><text>Co-treatment of steel slag and oil shale waste in cemented paste backfill: Evaluation of fresh properties, microstructure, and heavy metals immobilization.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="16" length="10"/><text>steel slag</text></annotation><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="31" length="15"/><text>oil shale waste</text></annotation><annotation id="5"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="127" length="12"/><text>heavy metals</text></annotation></passage><passage><infon key="type">abstract</infon><offset>156</offset><text>The environmentally sustainable treatment of steel slag (SS) and oil shale waste (OSW) is a significant concern in the field of industrial development. The mining industry also faces challenges related to the high costs and carbon emissions associated with ordinary Portland cement (OPC), leading to environmental pollution. To address these challenges, this study aimed to develop a cost-effective and environmentally friendly binder for cemented paste backfill (CPB) by utilizing SS and calcined oil shale waste (COSW) as primary precursors. Extensive investigations were conducted to evaluate the properties of the CPB sample with varying COSW content, including rheological properties, mechanical strength, and microstructure. The binder sample was comprehensively characterized using isothermal calorimetric analysis, X-ray diffraction (XRD), thermogravimetry (TG), and scanning electron microscopy (SEM). Based on systematic experimentation, an optimal blend ratio for the binder was determined, consisting of 60 wt% SS, 15 wt% COSW, 15 wt% phosphogypsum (PG), and 10 wt% OPC. The exceptional performance of the binder was attributed to the substantial formation of precipitated ettringite (AFt), resulting in a more compact structure and improved mechanical strength. Additionally, a sequential extraction test revealed that the heavy metals in the CPB sample were mainly present in the residual fraction, demonstrating the effective immobilization of heavy metals by the binder.</text><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="201" length="10"/><text>steel slag</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="213" length="2"/><text>SS</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="221" length="15"/><text>oil shale waste</text></annotation><annotation id="29"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="380" length="6"/><text>carbon</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="422" length="15"/><text>Portland cement</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="439" length="3"/><text>OPC</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="638" length="2"/><text>SS</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="645" length="8"/><text>calcined</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="654" length="15"/><text>oil shale waste</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="671" length="4"/><text>COSW</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="798" length="4"/><text>COSW</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1179" length="2"/><text>SS</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1190" length="4"/><text>COSW</text></annotation><annotation id="39"><infon key="identifier">MESH:C077769</infon><infon key="type">Chemical</infon><location offset="1203" length="13"/><text>phosphogypsum</text></annotation><annotation id="40"><infon key="identifier">MESH:C077769</infon><infon key="type">Chemical</infon><location offset="1218" length="2"/><text>PG</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1234" length="3"/><text>OPC</text></annotation><annotation id="42"><infon key="identifier">MESH:C501337</infon><infon key="type">Chemical</infon><location offset="1341" length="10"/><text>ettringite</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1353" length="3"/><text>AFt</text></annotation><annotation id="44"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="1492" length="12"/><text>heavy metals</text></annotation><annotation id="45"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="1615" length="12"/><text>heavy metals</text></annotation></passage></document>
<document><id>37890652</id><passage><infon key="journal">Mol Cell Endocrinol;2023Oct25 112090. doi:10.1016/j.mce.2023.112090</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li Z, Zhou G, Li Q, Jiang L, He J, Ye C, </infon><offset>0</offset><text>USP7 promotes decidualization of ESCs by STAT3/PR axis during early pregnancy.</text><annotation id="3"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="0" length="4"/><text>USP7</text></annotation><annotation id="4"><infon key="identifier">6774</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="41" length="5"/><text>STAT3</text></annotation><annotation id="5"><infon key="identifier">5241</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">713</infon><location offset="47" length="2"/><text>PR</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Decidualization is an essential process for embryo implantation during early pregnancy. Defective decidualization is a critical leading cause of early pregnancy loss (EPL). Ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that is involved in uterine function. This study aimed to explore the underlying mechanism by which USP7 regulates decidualization in EPL. We found that USP7 was downregulated in the decidual tissue of EPL patients. Upregulation of USP7 enhanced decidualization in endometrial stromal cells (ESCs), with increased decidualized biomarkers IGFBP1 and PRL and progesterone receptor A/B (PR-A/B) expression. Moreover, we found that signal transducer and activator of transcription 3 (STAT3) is a direct target of USP7 in ESCs. USP7 bound to STAT3 by deubiquitination and increased STAT3 levels in ESCs. Suppression of STAT3 impeded the USP7-promoted cell viability, decidualization, and PR-A/B expression of ESCs. USP7 promoted the decidualization of ESCs through the STAT3/PR signaling pathway during early pregnancy, which provides new insight into the pathological mechanism of EPL and may contribute to the clinical treatment of EPL.</text><annotation id="32"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="224" length="20"/><text>early pregnancy loss</text></annotation><annotation id="33"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="246" length="3"/><text>EPL</text></annotation><annotation id="34"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="252" length="29"/><text>Ubiquitin-specific protease 7</text></annotation><annotation id="35"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="283" length="4"/><text>USP7</text></annotation><annotation id="36"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="418" length="4"/><text>USP7</text></annotation><annotation id="37"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="452" length="3"/><text>EPL</text></annotation><annotation id="38"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="471" length="4"/><text>USP7</text></annotation><annotation id="39"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="520" length="3"/><text>EPL</text></annotation><annotation id="40"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="550" length="4"/><text>USP7</text></annotation><annotation id="41"><infon key="identifier">3484</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">498</infon><location offset="656" length="6"/><text>IGFBP1</text></annotation><annotation id="42"><infon key="identifier">5617</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">732</infon><location offset="667" length="3"/><text>PRL</text></annotation><annotation id="43"><infon key="identifier">6277;5925</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7925;272</infon><location offset="702" length="6"/><text>PR-A/B</text></annotation><annotation id="44"><infon key="identifier">6774</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="746" length="50"/><text>signal transducer and activator of transcription 3</text></annotation><annotation id="45"><infon key="identifier">6774</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="798" length="5"/><text>STAT3</text></annotation><annotation id="46"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="827" length="4"/><text>USP7</text></annotation><annotation id="47"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="841" length="4"/><text>USP7</text></annotation><annotation id="48"><infon key="identifier">6774</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="855" length="5"/><text>STAT3</text></annotation><annotation id="49"><infon key="identifier">6774</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="895" length="5"/><text>STAT3</text></annotation><annotation id="50"><infon key="identifier">6774</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="932" length="5"/><text>STAT3</text></annotation><annotation id="51"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="950" length="4"/><text>USP7</text></annotation><annotation id="52"><infon key="identifier">6277;5925</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7925;272</infon><location offset="1001" length="6"/><text>PR-A/B</text></annotation><annotation id="53"><infon key="identifier">7874</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2592</infon><location offset="1028" length="4"/><text>USP7</text></annotation><annotation id="54"><infon key="identifier">6774</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="1082" length="5"/><text>STAT3</text></annotation><annotation id="55"><infon key="identifier">5241</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">713</infon><location offset="1088" length="2"/><text>PR</text></annotation><annotation id="56"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="1195" length="3"/><text>EPL</text></annotation><annotation id="57"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="1247" length="3"/><text>EPL</text></annotation></passage><relation id="R1"><infon key="score">0.9964</infon><infon key="role1">Gene|5241</infon><infon key="role2">Gene|7874</infon><infon key="type">Association</infon><node refid="0" role="2,0"/></relation><relation id="R2"><infon key="score">0.8813</infon><infon key="role1">Disease|MESH:D000022</infon><infon key="role2">Gene|7874</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="8,7"/></relation><relation id="R3"><infon key="score">0.9992</infon><infon key="role1">Gene|3484</infon><infon key="role2">Gene|7874</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="12,11"/></relation><relation id="R4"><infon key="score">0.9988</infon><infon key="role1">Gene|6277</infon><infon key="role2">Gene|7874</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="14,11"/></relation><relation id="R5"><infon key="score">0.9955</infon><infon key="role1">Gene|5925</infon><infon key="role2">Gene|6774</infon><infon key="type">Association</infon><node refid="4" role="23,21"/></relation><relation id="R6"><infon key="score">0.5848</infon><infon key="role1">Disease|MESH:D000022</infon><infon key="role2">Gene|5241</infon><infon key="type">Association</infon><node refid="5" role="27,26"/></relation><relation id="R7"><infon key="score">0.6006</infon><infon key="role1">Disease|MESH:D000022</infon><infon key="role2">Gene|6774</infon><infon key="type">Association</infon><node refid="6" role="27,25"/></relation><relation id="R8"><infon key="score">0.9992</infon><infon key="role1">Gene|5617</infon><infon key="role2">Gene|7874</infon><infon key="type">Positive_Correlation</infon><node refid="7" role="13,11"/></relation><relation id="R9"><infon key="score">0.908</infon><infon key="role1">Gene|6774</infon><infon key="role2">Gene|7874</infon><infon key="type">Association</infon><node refid="8" role="1,0"/></relation><relation id="R10"><infon key="score">0.9955</infon><infon key="role1">Gene|6277</infon><infon key="role2">Gene|6774</infon><infon key="type">Association</infon><node refid="9" role="23,21"/></relation><relation id="R11"><infon key="score">0.9988</infon><infon key="role1">Gene|5925</infon><infon key="role2">Gene|7874</infon><infon key="type">Positive_Correlation</infon><node refid="10" role="14,11"/></relation></document>
<document><id>37891354</id><passage><infon key="journal">J Public Health Policy;2023Oct27. doi:10.1057/s41271-023-00446-1</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gulma K, </infon><offset>0</offset><text>Enhancing public health programs with performance-based memorandum of understanding.</text></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>This Viewpoint presents a case study that explored the effects of using a performance-based Memorandum of Understanding (MoU) in public health donor programs to enhance health metrics, program efficiency, and accountability. The MoU between Kebbi State Government in Nigeria and the United States Agency for International Development (USAID) focused on strengthening primary healthcare. It covered Health Systems Strengthening (HSS) indicators, overseen by an Operations Committee (OC) and a high-level Steering Committee (SC). Quarterly and biannual reviews tracked indicators through a dashboard developed by the Integrated Health Program (IHP). Results suggest that the MoU led to better monitoring of primary healthcare (PHC) revitalization, health sector work plan harmonization, and data quality. Dashboard tracking showed improved health facility financing, immunization, antenatal care, and skilled attendants at births. The use of the MoU demonstrated potential for boosting program efficiency, cost-effectiveness, and political commitment for resource mobilization in public health initiatives. Results support recommending MoUs as valuable tools for effective outcome-driven public health funding.</text></passage></document>
<document><id>37891705</id><passage><infon key="journal">Mol Microbiol;2023Oct27. doi:10.1111/mmi.15183</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Neuber J, Lang C, Aurass P, Flieger A, </infon><offset>0</offset><text>Tools and mechanisms of vacuolar escape leading to host egress in Legionella pneumophila infection: Emphasis on bacterial phospholipases.</text></passage><passage><infon key="type">abstract</infon><offset>138</offset><text>The phenomenon of host cell escape exhibited by intracellular pathogens is a remarkably versatile occurrence, capable of unfolding through lytic or non-lytic pathways. Among these pathogens, the bacterium Legionella pneumophila stands out, having adopted a diverse spectrum of strategies to disengage from their host cells. A pivotal juncture that predates most of these host cell escape modalities is the initial escape from the intracellular compartment. This critical step is increasingly supported by evidence suggesting the involvement of several secreted pathogen effectors, including lytic proteins. In this intricate landscape, L. pneumophila emerges as a focal point for research, particularly concerning secreted phospholipases. While nestled within its replicative vacuole, the bacterium deftly employs both its type II (Lsp) and type IVB (Dot/Icm) secretion systems to convey phospholipases into either the phagosomal lumen or the host cell cytoplasm. Its repertoire encompasses numerous phospholipases A (PLA), including three enzymes-PlaA, PlaC, and PlaD-bearing the GDSL motif. Additionally, there are 11 patatin-like phospholipases A as well as PlaB. Furthermore, the bacterium harbors three extracellular phospholipases C (PLCs) and one phospholipase D. Within this comprehensive review, we undertake an exploration of the pivotal role played by phospholipases in the broader context of phagosomal and host cell egress. Moreover, we embark on a detailed journey to unravel the established and potential functions of the secreted phospholipases of L. pneumophila in orchestrating this indispensable process.</text></passage></document>
<document><id>37897313</id><passage><infon key="journal">Adv Sci (Weinh);2023Oct28 2303946. doi:10.1002/advs.202303946</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xu R, Xie H, Shen X, Huang J, Zhang H, Fu Y, Zhang P, Guo S, Wang D, Li S, Zheng K, Sun W, Liu L, Cheng J, Jiang H, </infon><offset>0</offset><text>Impaired Efferocytosis Enables Apoptotic Osteoblasts to Escape Osteoimmune Surveillance During Aging.</text></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>Macrophage efferocytosis of apoptotic osteoblasts (apoOBs) is a key osteoimmune process for bone homeostasis. However, apoOBs frequently accumulate in aged bone marrow, where they may mount proinflammatory responses and progressive bone loss. The reason why apoOBs are not cleared during aging remains unclear. In this study, it is demonstrated that aged apoOBs upregulate the immune checkpoint molecule CD47, which is controlled by SIRT6-regulated transcriptional pausing, to evade clearance by macrophages. Using osteoblast- and myeloid-specific gene knockout mice, SIRT6 is further revealed to be a critical modulator for apoOBs clearance via targeting CD47-SIRPalpha checkpoint. Moreover, apoOBs activate SIRT6-mediated chemotaxis to recruit macrophages by releasing apoptotic vesicles. Two targeting delivery strategies are developed to enhance SIRT6 activity, resulting in rejuvenated apoOBs clearance and delayed age-related bone loss. Collectively, the findings reveal a previously unknown linkage between immune surveillance and bone homeostasis and targeting the SIRT6-regulated mechanism can be a promising therapeutic strategy for age-related bone diseases.</text><annotation id="12"><infon key="type">Disease</infon><location offset="292" length="15"/><text>proinflammatory</text></annotation><annotation id="13"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="334" length="9"/><text>bone loss</text></annotation><annotation id="14"><infon key="identifier">16423</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1346</infon><location offset="506" length="4"/><text>CD47</text></annotation><annotation id="15"><infon key="identifier">50721</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">6924</infon><location offset="535" length="5"/><text>SIRT6</text></annotation><annotation id="16"><infon key="identifier">50721</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">6924</infon><location offset="670" length="5"/><text>SIRT6</text></annotation><annotation id="17"><infon key="identifier">16423</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1346</infon><location offset="758" length="4"/><text>CD47</text></annotation><annotation id="18"><infon key="identifier">19261</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7246</infon><location offset="763" length="9"/><text>SIRPalpha</text></annotation><annotation id="19"><infon key="identifier">50721</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">6924</infon><location offset="811" length="5"/><text>SIRT6</text></annotation><annotation id="20"><infon key="identifier">50721</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">6924</infon><location offset="952" length="5"/><text>SIRT6</text></annotation><annotation id="21"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="1034" length="9"/><text>bone loss</text></annotation><annotation id="22"><infon key="identifier">50721</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">6924</infon><location offset="1175" length="5"/><text>SIRT6</text></annotation><annotation id="23"><infon key="identifier">MESH:D010024</infon><infon key="type">Disease</infon><location offset="1245" length="25"/><text>age-related bone diseases</text></annotation></passage><relation id="R1"><infon key="score">0.9974</infon><infon key="role1">Gene|19261</infon><infon key="role2">Gene|50721</infon><infon key="type">Association</infon><node refid="0" role="6,4"/></relation><relation id="R2"><infon key="score">0.9985</infon><infon key="role1">Gene|16423</infon><infon key="role2">Gene|50721</infon><infon key="type">Association</infon><node refid="1" role="2,3"/></relation><relation id="R3"><infon key="score">0.975</infon><infon key="role1">Gene|16423</infon><infon key="role2">Gene|19261</infon><infon key="type">Association</infon><node refid="2" role="5,6"/></relation><relation id="R4"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D010024</infon><infon key="role2">Gene|50721</infon><infon key="type">Association</infon><node refid="3" role="11,10"/></relation><relation id="R5"><infon key="score">0.9929</infon><infon key="role1">Disease|MESH:D001847</infon><infon key="role2">Gene|50721</infon><infon key="type">Association</infon><node refid="4" role="9,8"/></relation></document>
<document><id>37897664</id><passage><infon key="journal">Biomol Biomed;2023Oct26. doi:10.17305/bb.2023.9760</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tian Z, Zhu L, Xie Y, Hu H, Ren Q, Liu J, Wang Q, </infon><offset>0</offset><text>The mechanism of high mobility group box-1 protein and its bidirectional regulation in tumors.</text><annotation id="2"><infon key="identifier">3146</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">110676</infon><location offset="17" length="25"/><text>high mobility group box-1</text></annotation><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="87" length="6"/><text>tumors</text></annotation></passage><passage><infon key="type">abstract</infon><offset>95</offset><text>High mobility group protein box-1 (HMGB1) is a nonhistone chromatin-related protein widely found in eukaryotic cells. It is involved in the transcription, replication and repair of DNA to maintain nuclear homeostasis. It participates in cell growth, differentiation and signal transduction. Recent studies showed that HMGB1 has a bidirectional regulatory effect on tumors by regulating TLR4/MYD88/NF-kappaB and RAGE/AMPK/mTOR signaling pathways. On one hand, it is highly expressed in a variety of tumors, promoting tumor proliferation and invasion, whilst on the other hand, it induces autophagy and apoptosis of tumor cells and stimulates tumor-infiltrating lymphocytes to produce anti-tumor immune response. At present, HMGB1 could be used as a target to regulate the drug-resistance and prognostication in cancer. Clinical applications of HMGB1 in cancer need further in-depth studies.</text><annotation id="22"><infon key="identifier">3146</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">110676</infon><location offset="130" length="5"/><text>HMGB1</text></annotation><annotation id="23"><infon key="identifier">3146</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">110676</infon><location offset="413" length="5"/><text>HMGB1</text></annotation><annotation id="24"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="460" length="6"/><text>tumors</text></annotation><annotation id="25"><infon key="identifier">7099</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41317</infon><location offset="481" length="4"/><text>TLR4</text></annotation><annotation id="26"><infon key="identifier">4615</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1849</infon><location offset="486" length="5"/><text>MYD88</text></annotation><annotation id="27"><infon key="identifier">4790</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="492" length="9"/><text>NF-kappaB</text></annotation><annotation id="28"><infon key="identifier">177</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">883</infon><location offset="506" length="4"/><text>RAGE</text></annotation><annotation id="29"><infon key="identifier">5562</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49590</infon><location offset="511" length="4"/><text>AMPK</text></annotation><annotation id="30"><infon key="identifier">2475</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3637</infon><location offset="516" length="4"/><text>mTOR</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="593" length="6"/><text>tumors</text></annotation><annotation id="32"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="611" length="5"/><text>tumor</text></annotation><annotation id="33"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="709" length="5"/><text>tumor</text></annotation><annotation id="34"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="736" length="5"/><text>tumor</text></annotation><annotation id="35"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="783" length="5"/><text>tumor</text></annotation><annotation id="36"><infon key="identifier">3146</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">110676</infon><location offset="818" length="5"/><text>HMGB1</text></annotation><annotation id="37"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="905" length="6"/><text>cancer</text></annotation><annotation id="38"><infon key="identifier">3146</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">110676</infon><location offset="938" length="5"/><text>HMGB1</text></annotation><annotation id="39"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="947" length="6"/><text>cancer</text></annotation></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|177</infon><infon key="type">Association</infon><node refid="0" role="4,8"/></relation><relation id="R2"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|7099</infon><infon key="type">Association</infon><node refid="1" role="4,5"/></relation><relation id="R3"><infon key="score">0.9975</infon><infon key="role1">Gene|2475</infon><infon key="role2">Gene|3146</infon><infon key="type">Association</infon><node refid="2" role="10,3"/></relation><relation id="R4"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|3146</infon><infon key="type">Association</infon><node refid="3" role="1,0"/></relation><relation id="R5"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|4615</infon><infon key="type">Association</infon><node refid="4" role="4,6"/></relation><relation id="R6"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|4790</infon><infon key="type">Association</infon><node refid="5" role="4,7"/></relation><relation id="R7"><infon key="score">0.9792</infon><infon key="role1">Gene|3146</infon><infon key="role2">Gene|7099</infon><infon key="type">Association</infon><node refid="6" role="3,5"/></relation><relation id="R8"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|5562</infon><infon key="type">Association</infon><node refid="7" role="4,9"/></relation><relation id="R9"><infon key="score">0.9916</infon><infon key="role1">Gene|3146</infon><infon key="role2">Gene|4790</infon><infon key="type">Association</infon><node refid="8" role="3,7"/></relation><relation id="R10"><infon key="score">0.9965</infon><infon key="role1">Gene|177</infon><infon key="role2">Gene|3146</infon><infon key="type">Association</infon><node refid="9" role="8,3"/></relation><relation id="R11"><infon key="score">0.9899</infon><infon key="role1">Gene|3146</infon><infon key="role2">Gene|4615</infon><infon key="type">Association</infon><node refid="10" role="3,6"/></relation><relation id="R12"><infon key="score">0.9911</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|2475</infon><infon key="type">Association</infon><node refid="11" role="4,10"/></relation><relation id="R13"><infon key="score">0.9954</infon><infon key="role1">Gene|3146</infon><infon key="role2">Gene|5562</infon><infon key="type">Association</infon><node refid="12" role="3,9"/></relation></document>
<document><id>37898014</id><passage><infon key="journal">Meat Sci;2023Oct21; 207 109371. doi:10.1016/j.meatsci.2023.109371</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Elhadef K, Chaari M, Akermi S, Ennouri K, Ben Hlima H, Fourati M, Chakchouk Mtibaa A, Ennouri M, Sarkar T, Shariati MA, G&amp;#xf6;k&amp;#x15f;en G, Pateiro M, Mellouli L, Lorenzo JM, Smaoui S, </infon><offset>0</offset><text>Gelatin-sodium alginate packaging film with date pits extract: An eco-friendly packaging for extending raw minced beef shelf life.</text><annotation id="1"><infon key="identifier">MESH:D000464</infon><infon key="type">Chemical</infon><location offset="8" length="15"/><text>sodium alginate</text></annotation></passage><passage><infon key="type">abstract</infon><offset>131</offset><text>Gelatin-sodium alginate-based active packaging films were formulated by including date pits extracts (DPE), as bioactive compound, in raw minced beef meat packaging. The DPE effects at 0.37, 0.75 and 1.5% (w/w, DPE/ gelatin-sodium alginate) on physical, optical, antioxidant and antibacterial properties of established films were assessed. Findings showed that film lightness decreased with the incorporation of DPE. Physical, antioxidant and anti-food-borne pathogens capacities were enhanced by increasing DPE concentration in the films. For 2,2-Diphenyl-1-picrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), the films with 1.5% DPE had the greatest levels (94 and 88%, respectively). DPE films (1.5%) also exhibited the highest anti-Listeria moncytogenes activity, with an inhibition zone of 25 mm. Moreover, during 14 days at 4  C, the bio-preservative impact of gelatin-sodium alginate film impregnated with DPE at three levels on microbial, chemical, and sensory characteristics of meat beef samples was evaluated. By the end of the storage, DPE at 1.5% enhanced the instrumental color, delayed chemical oxidation and improved sensory traits. By chemometric techniques (principal component analysis (PCA) and heat maps), all data allowed to obtain helpful information by segregating all the samples at each storage time. PCA and heat maps could connect oxidative chemical changes, instrumental color parameters, and microbiological properties to sensory attributes. These data offer an approach to well interpreting the sensory quality and how they are affected by chemical and microbiological changes in the studied meat samples. Our findings indicated the potential of the gelatin-sodium alginate film incorporated with DPE for enhancing meat safety and quality.</text><annotation id="22"><infon key="identifier">MESH:D000464</infon><infon key="type">Chemical</infon><location offset="139" length="15"/><text>sodium alginate</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="213" length="18"/><text>date pits extracts</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="233" length="3"/><text>DPE</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="301" length="3"/><text>DPE</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="342" length="3"/><text>DPE</text></annotation><annotation id="27"><infon key="identifier">MESH:D000464</infon><infon key="type">Chemical</infon><location offset="355" length="15"/><text>sodium alginate</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="543" length="3"/><text>DPE</text></annotation><annotation id="29"><infon key="identifier">MESH:D017282</infon><infon key="type">Disease</infon><location offset="583" length="16"/><text>-borne pathogens</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="639" length="3"/><text>DPE</text></annotation><annotation id="31"><infon key="identifier">MESH:C004931</infon><infon key="type">Chemical</infon><location offset="675" length="29"/><text>2,2-Diphenyl-1-picrylhydrazyl</text></annotation><annotation id="32"><infon key="identifier">MESH:C004931</infon><infon key="type">Chemical</infon><location offset="706" length="4"/><text>DPPH</text></annotation><annotation id="33"><infon key="identifier">MESH:C002502</infon><infon key="type">Chemical</infon><location offset="716" length="54"/><text>2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)</text></annotation><annotation id="34"><infon key="identifier">MESH:C002502</infon><infon key="type">Chemical</infon><location offset="772" length="4"/><text>ABTS</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="799" length="3"/><text>DPE</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="855" length="3"/><text>DPE</text></annotation><annotation id="37"><infon key="identifier">MESH:D000464</infon><infon key="type">Chemical</infon><location offset="1043" length="15"/><text>sodium alginate</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1081" length="3"/><text>DPE</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1216" length="3"/><text>DPE</text></annotation><annotation id="40"><infon key="identifier">MESH:D000464</infon><infon key="type">Chemical</infon><location offset="1857" length="15"/><text>sodium alginate</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1896" length="3"/><text>DPE</text></annotation></passage></document>
<document><id>37898367</id><passage><infon key="journal">Bioresour Technol;2023Oct26 129932. doi:10.1016/j.biortech.2023.129932</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cao Y, Chen Z, Boukhir M, Dong B, Zhang J, Gu S, Zhang S, </infon><offset>0</offset><text>Insight into the pyrolysis of bamboo flour, polylactic acid and their composite: Pyrolysis behavior, kinetic triplets, and thermodynamic parameters based on Fraser-Suzuki deconvolution procedure.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30" length="12"/><text>bamboo flour</text></annotation><annotation id="3"><infon key="identifier">MESH:C033616</infon><infon key="type">Chemical</infon><location offset="44" length="15"/><text>polylactic acid</text></annotation></passage><passage><infon key="type">abstract</infon><offset>196</offset><text>Kinetic triplets and thermodynamics are important in the design of pyrolysis processing. In this study, the non-isothermal kinetics and thermodynamics of pseudo components of bamboo flour (BF), Polylactic acid (PLA), and the resulting BF/PLA composite were investigated using Fraser-Suzuki deconvolution. Fourier-transform infrared spectra (FTIR) was used to characterize the gaseous products. Results showed the Fraser-Suzuki deconvolution curves fitted well to the experimental data. For pseudo hemicellulose and pseudo components in PLA, common kinetic models were applied. The pyrolysis of pseudo cellulose met the random scission model and pseudo lignin need to be described with empirical model. The Kinetic models were verified and shown to be in good agreement with the experimental results FTIR results indicated that more radical reactions occur in PLA during co-pyrolysis with BF.Thermodynamic results indicated the pyrolysis of pseudo components were non-spontaneous reactions except lignin. These results will contribute to reactor design and scale-up in future.</text><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="371" length="12"/><text>bamboo flour</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="385" length="2"/><text>BF</text></annotation><annotation id="19"><infon key="identifier">MESH:C033616</infon><infon key="type">Chemical</infon><location offset="390" length="15"/><text>Polylactic acid</text></annotation><annotation id="20"><infon key="identifier">MESH:C033616</infon><infon key="type">Chemical</infon><location offset="407" length="3"/><text>PLA</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="431" length="2"/><text>BF</text></annotation><annotation id="22"><infon key="identifier">MESH:C033616</infon><infon key="type">Chemical</infon><location offset="434" length="3"/><text>PLA</text></annotation><annotation id="23"><infon key="identifier">MESH:C007916</infon><infon key="type">Chemical</infon><location offset="693" length="13"/><text>hemicellulose</text></annotation><annotation id="24"><infon key="identifier">MESH:C033616</infon><infon key="type">Chemical</infon><location offset="732" length="3"/><text>PLA</text></annotation><annotation id="25"><infon key="identifier">MESH:D002482</infon><infon key="type">Chemical</infon><location offset="797" length="9"/><text>cellulose</text></annotation><annotation id="26"><infon key="identifier">MESH:D008031</infon><infon key="type">Chemical</infon><location offset="848" length="6"/><text>lignin</text></annotation><annotation id="27"><infon key="identifier">MESH:C033616</infon><infon key="type">Chemical</infon><location offset="1055" length="3"/><text>PLA</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1084" length="16"/><text>BF.Thermodynamic</text></annotation><annotation id="29"><infon key="identifier">MESH:D008031</infon><infon key="type">Chemical</infon><location offset="1192" length="6"/><text>lignin</text></annotation></passage></document>
<document><id>37898717</id><passage><infon key="journal">Eye (Lond);2023Oct28. doi:10.1038/s41433-023-02806-3</infon><infon key="year">2023</infon><infon key="article-id_pmc">1856963</infon><infon key="type">title</infon><infon key="authors">Fujita A, Konishi T, Sakata R, Hashimoto Y, Yasunaga H, Aihara M, </infon><offset>0</offset><text>Cost-effectiveness analysis of prophylactic laser peripheral iridotomy for primary angle-closure suspect in Japan.</text><annotation id="1"><infon key="identifier">MESH:D015812</infon><infon key="type">Disease</infon><location offset="75" length="21"/><text>primary angle-closure</text></annotation></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>BACKGROUND/OBJECTIVES: This study aimed to compare the cost-effectiveness of prophylactic laser peripheral iridotomy (LPI) with that of observation for primary angle-closure suspect (PACS) in Japan. SUBJECTS/METHODS: A Markov model was developed to compare the costs and utilities of prophylactic LPI with those of observation of 40-year-old patients with PACS. In the model with a yearly cycle over a 20-year time horizon, the disease was postulated to irreversibly progress from PACS to primary angle closure, followed by primary angle-closure glaucoma, unilateral blindness, and bilateral blindness. The parameters were estimated mainly based on a recent randomised controlled trial and analyses of Japanese claims data. The incremental cost-effectiveness ratio was estimated from the healthcare payer's perspective and evaluated at the willingness-to-pay 5 million Japanese Yen per quality-adjusted life-year. The observation period and the age at entry into the cohort was changed to account for a variety of clinical courses in sensitivity analyses. We conducted one-way deterministic sensitivity analysis and probabilistic sensitivity analysis with Monte Carlo simulations with 10 000 iterations. RESULTS: The incremental cost-effectiveness ratio of LPI was 2,287,662 Japanese Yen (14,298 pounds sterling) per quality-adjusted life-year, which was below the willingness-to-pay threshold. The ratios were approximately 4 and 8 million in the 15-year and 10-year time horizons, respectively. Increasing the age at entry had little influence on the incremental cost-effectiveness ratio. The deterministic and probabilistic sensitivity analyses indicated that the results were robust. CONCLUSIONS: Our results indicate that prophylactic LPI for middle-aged patients with PACS is cost-effective in Japan.</text><annotation id="6"><infon key="identifier">MESH:D015812</infon><infon key="type">Disease</infon><location offset="267" length="21"/><text>primary angle-closure</text></annotation><annotation id="7"><infon key="identifier">MESH:D015812</infon><infon key="type">Disease</infon><location offset="639" length="30"/><text>primary angle-closure glaucoma</text></annotation><annotation id="8"><infon key="identifier">MESH:D001766</infon><infon key="type">Disease</infon><location offset="671" length="20"/><text>unilateral blindness</text></annotation><annotation id="9"><infon key="identifier">MESH:D001766</infon><infon key="type">Disease</infon><location offset="697" length="19"/><text>bilateral blindness</text></annotation></passage></document>
<document><id>37899067</id><passage><infon key="journal">Technol Health Care;2023Oct19. doi:10.3233/THC-220686</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Deng LH, Yao TT, Jin HY, Li Y, Zong Y, Chen MG, Chen P, </infon><offset>0</offset><text>Establishment and evaluation of the impact of a supervisory group for chemotherapy safety management in an oncology department.</text></passage><passage><infon key="type">abstract</infon><offset>128</offset><text>BACKGROUND: The nursing model of establishing a chemotherapy safety management supervisory group has guaranteed the safety and effectiveness of intravenous chemotherapy while reducing the adverse effects of chemotherapy and improving patient satisfaction and quality of life. OBJECTIVE: To explore the impact of establishing a nursing supervision group on improving the safety management of patients receiving chemotherapy in the oncology department. METHODS: We selected a total of 60 patients who underwent chemotherapy at the oncology department between January and June 2021 and assigned them to the control group. They received conventional chemotherapy safety management nursing care. We selected another 60 patients undergoing chemotherapy in the oncology department between July and December 2021 and assigned them to the observation group. They received a nursing intervention model facilitated by the chemotherapy safety supervision team. We compared the intervention effects in the two groups. RESULTS: Patient satisfaction was significantly higher in the observation group than in the control group (P&lt; 0.05); the incidence of post-chemotherapy nausea and vomiting was significantly lower in the observation group than in the control group (P&lt; 0.05); and the self-rating depression scale (SDS) and self-rating anxiety scale (SAS) scores of patients in the observation group were reduced (P&lt; 0.05) and significantly lower than in the control group (P&lt; 0.05). We used the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC-QLQ-C30) and found a statistically significant difference in the quality of life of patients before the nursing intervention and on the day of discharge (P&lt; 0.05). CONCLUSION: The establishment of a chemotherapy safety management supervisory group was effective in reducing the incidence of post-chemotherapy nausea and vomiting as well as the patient's psychological burden; it could also improve the quality of life of patients and their satisfaction with nursing care.</text><annotation id="5"><infon key="identifier">MESH:D020250</infon><infon key="type">Disease</infon><location offset="1285" length="19"/><text>nausea and vomiting</text></annotation><annotation id="6"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1411" length="10"/><text>depression</text></annotation><annotation id="7"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="1450" length="7"/><text>anxiety</text></annotation><annotation id="8"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1662" length="6"/><text>Cancer</text></annotation><annotation id="9"><infon key="identifier">MESH:D020250</infon><infon key="type">Disease</infon><location offset="2023" length="19"/><text>nausea and vomiting</text></annotation></passage></document>
<document><id>37899417</id><passage><infon key="journal">Ann Surg Oncol;2023Oct29. doi:10.1245/s10434-023-14485-1</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ong C, Blue CM, Khan J, Deng X, Bandyopadhyay D, Louie RJ, McGuire KP, </infon><offset>0</offset><text>ASO Visual Abstract: Luminal A Versus B After Choosing Wisely: Does Lymph Node Surgery Affect Oncologic Outcomes?</text></passage><passage><infon key="type">abstract</infon><offset>114</offset></passage></document>
<document><id>37902220</id><passage><infon key="journal">Cancer Med;2023Oct30. doi:10.1002/cam4.6646</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wooten SV, Wang F, Roth ME, Liu G, Livingston JA, Amini B, Gilchrist SC, Hildebrandt M, Kleinerman ES, </infon><offset>0</offset><text>Early skeletal muscle loss in adolescent and young adult cancer patients treated with anthracycline chemotherapy.</text><annotation id="3"><infon key="identifier">MESH:D005207</infon><infon key="type">Disease</infon><location offset="6" length="20"/><text>skeletal muscle loss</text></annotation><annotation id="4"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="57" length="6"/><text>cancer</text></annotation><annotation id="5"><infon key="identifier">MESH:D018943</infon><infon key="type">Chemical</infon><location offset="86" length="13"/><text>anthracycline</text></annotation></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>BACKGROUND: Early skeletal muscle loss has been observed in adolescent and young adult (AYA) sarcoma patients undergoing treatment. Identification of individuals within the AYA populace that are at greatest risk of anthracycline-induced skeletal muscle loss is unknown. Moreover, investigations which seek out underlying causes of skeletal muscle degradation during chemotherapy are critical for understanding, preventing, and reducing chronic health conditions associated with poor skeletal muscle status. METHODS: Computed tomography (CT) scans were used to investigate changes in skeletal muscle of 153 AYA sarcoma and Hodgkin lymphoma patients at thoracic vertebra 4 after anthracycline treatment. Images were examined at three time points during the first year of treatment. In parallel, we used translational juvenile mouse models to assess the impact of doxorubicin (DOX) in the soleus and gastrocnemius on muscle wasting. RESULTS: Significant reductions in total skeletal muscle index and density were seen after chemotherapy in AYA cancer patients (p &lt; 0.01 &amp; p = 0.04, respectively). The severity of skeletal muscle loss varied by subgroup (i.e., cancer type, sex, and treatment). Murine models demonstrated a reduction in skeletal muscle fiber cross-sectional area, increased apoptosis and collagen volume for both the soleus and gastrocnemius after DOX treatment (all p &lt; 0.05). After DOX, hindlimb skeletal muscle blood flow was significantly reduced (p &lt; 0.01). CONCLUSION: Significant skeletal muscle loss is experienced early during treatment in AYA cancer patients. Reductions in skeletal muscle blood flow may be a key contributing factor to anthracycline doxorubicin induced skeletal muscle loss.</text><annotation id="34"><infon key="identifier">MESH:D005207</infon><infon key="type">Disease</infon><location offset="132" length="20"/><text>skeletal muscle loss</text></annotation><annotation id="35"><infon key="identifier">MESH:D012509</infon><infon key="type">Disease</infon><location offset="207" length="7"/><text>sarcoma</text></annotation><annotation id="36"><infon key="identifier">MESH:D018943</infon><infon key="type">Chemical</infon><location offset="329" length="13"/><text>anthracycline</text></annotation><annotation id="37"><infon key="identifier">MESH:D005207</infon><infon key="type">Disease</infon><location offset="351" length="20"/><text>skeletal muscle loss</text></annotation><annotation id="38"><infon key="identifier">MESH:C564967</infon><infon key="type">Disease</infon><location offset="445" length="8"/><text>skeletal</text></annotation><annotation id="39"><infon key="identifier">MESH:D055959</infon><infon key="type">Disease</infon><location offset="454" length="18"/><text>muscle degradation</text></annotation><annotation id="40"><infon key="identifier">MESH:C564967</infon><infon key="type">Disease</infon><location offset="597" length="8"/><text>skeletal</text></annotation><annotation id="41"><infon key="identifier">MESH:C564967</infon><infon key="type">Disease</infon><location offset="697" length="8"/><text>skeletal</text></annotation><annotation id="42"><infon key="identifier">MESH:D012509</infon><infon key="type">Disease</infon><location offset="724" length="7"/><text>sarcoma</text></annotation><annotation id="43"><infon key="identifier">MESH:D006689</infon><infon key="type">Disease</infon><location offset="736" length="16"/><text>Hodgkin lymphoma</text></annotation><annotation id="44"><infon key="identifier">MESH:D018943</infon><infon key="type">Chemical</infon><location offset="791" length="13"/><text>anthracycline</text></annotation><annotation id="45"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="975" length="11"/><text>doxorubicin</text></annotation><annotation id="46"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="988" length="3"/><text>DOX</text></annotation><annotation id="47"><infon key="identifier">MESH:D009133</infon><infon key="type">Disease</infon><location offset="1028" length="14"/><text>muscle wasting</text></annotation><annotation id="48"><infon key="identifier">MESH:C564967</infon><infon key="type">Disease</infon><location offset="1085" length="8"/><text>skeletal</text></annotation><annotation id="49"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1155" length="6"/><text>cancer</text></annotation><annotation id="50"><infon key="identifier">MESH:D005207</infon><infon key="type">Disease</infon><location offset="1224" length="20"/><text>skeletal muscle loss</text></annotation><annotation id="51"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1271" length="6"/><text>cancer</text></annotation><annotation id="52"><infon key="identifier">MESH:C564967</infon><infon key="type">Disease</infon><location offset="1347" length="8"/><text>skeletal</text></annotation><annotation id="53"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1475" length="3"/><text>DOX</text></annotation><annotation id="54"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1511" length="3"/><text>DOX</text></annotation><annotation id="55"><infon key="identifier">MESH:C564967</infon><infon key="type">Disease</infon><location offset="1525" length="8"/><text>skeletal</text></annotation><annotation id="56"><infon key="identifier">MESH:D005207</infon><infon key="type">Disease</infon><location offset="1614" length="20"/><text>skeletal muscle loss</text></annotation><annotation id="57"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1680" length="6"/><text>cancer</text></annotation><annotation id="58"><infon key="identifier">MESH:C564967</infon><infon key="type">Disease</infon><location offset="1711" length="8"/><text>skeletal</text></annotation><annotation id="59"><infon key="identifier">MESH:D018943</infon><infon key="type">Chemical</infon><location offset="1774" length="13"/><text>anthracycline</text></annotation><annotation id="60"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1788" length="11"/><text>doxorubicin</text></annotation><annotation id="61"><infon key="identifier">MESH:D005207</infon><infon key="type">Disease</infon><location offset="1808" length="20"/><text>skeletal muscle loss</text></annotation></passage><relation id="R1"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D018943</infon><infon key="role2">Disease|MESH:D005207</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="2,0"/></relation><relation id="R2"><infon key="score">0.9967</infon><infon key="role1">Chemical|MESH:D018943</infon><infon key="role2">Disease|MESH:D006689</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="13,12"/></relation><relation id="R3"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D004317</infon><infon key="role2">Disease|MESH:C564967</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="22,21"/></relation><relation id="R4"><infon key="score">0.8697</infon><infon key="role1">Chemical|MESH:D018943</infon><infon key="role2">Disease|MESH:D012509</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="13,11"/></relation><relation id="R5"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D004317</infon><infon key="role2">Disease|MESH:D005207</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="29,30"/></relation><relation id="R6"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D018943</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="2,1"/></relation><relation id="R7"><infon key="score">0.9127</infon><infon key="role1">Chemical|MESH:D004317</infon><infon key="role2">Disease|MESH:D009133</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="14,16"/></relation></document>
<document><id>37902570</id><passage><infon key="journal">Med Decis Making;2023Oct30 272989. doi:10.1177/0272989X231205858</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bossen JKJ, Wesselink JA, Heyligers IC, Jansen J, </infon><offset>0</offset><text>Implementation of a Decision Aid for Hip and Knee Osteoarthritis in Orthopedics: A Mixed-Methods Process Evaluation.</text><annotation id="1"><infon key="identifier">MESH:D020370</infon><infon key="type">Disease</infon><location offset="37" length="27"/><text>Hip and Knee Osteoarthritis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>BACKGROUND: In orthopedics, the use of patient decision aids (ptDAs) is limited. With a mixed-method process evaluation, we investigated patient factors associated with accepting versus declining the use of the ptDA, patients' reasons for declining the ptDA, and clinicians' perceived barriers and facilitators for its use. METHODS: Patients with an indication for joint replacement surgery (N = 153) completed questionnaires measuring demographics, physical functioning, quality of life (EQ-5D-3L), and a visual analog scale (VAS) pain score at 1 time point. Subsequently, their clinician offered them the relevant ptDA. Using a retrospective design, we compared patients who used the ptDA (59%) with patients who declined (41%) on all these measures as well as the chosen treatment. If the use of the ptDA was declined, patients' reasons were recorded by their clinician and analysed (n = 46). To evaluate the experiences of clinicians (n = 5), semistructured interviews were conducted and thematically analyzed. Clinicians who did not use the ptDA substantially (&lt;10 times) were also interviewed (n = 3). RESULTS: Compared with patients who used the ptDA, patients who declined use had higher VAS pain scores (7.2 v. 6.2, P &lt; .001), reported significantly worse quality of life (on 4 of 6 EQ-5D-3L subscales), and were less likely to receive nonsurgical treatment (4% v. 28%, P &lt; .001). Of the patients who declined to use the ptDA, 46% said they had enough information and felt ready to make a decision without the ptDA. The interviews revealed that clinicians considered the ptDAs most useful for newly diagnosed patients who had not received previous treatment. CONCLUSION: These results suggest that the uptake of a ptDA may be improved if it is introduced in the early disease stages of hip and knee osteoarthritis. HIGHLIGHTS: Patients who declined the use of a patient decision aid (ptDA) for hip and knee osteoarthritis reported more pain and worse quality of life.Most patients who declined to use a ptDA felt sufficiently well informed to make a treatment decision.Patients who declined the ptDA were more likely to have received prior treatment in primary care.Clinicians found the ptDA to be a helpful addition to the consultation, particularly for newly diagnosed patients.</text><annotation id="7"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="649" length="4"/><text>pain</text></annotation><annotation id="8"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1317" length="4"/><text>pain</text></annotation><annotation id="9"><infon key="identifier">MESH:D020370</infon><infon key="type">Disease</infon><location offset="1912" length="27"/><text>hip and knee osteoarthritis</text></annotation><annotation id="10"><infon key="identifier">MESH:D020370</infon><infon key="type">Disease</infon><location offset="2020" length="27"/><text>hip and knee osteoarthritis</text></annotation><annotation id="11"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="2062" length="4"/><text>pain</text></annotation></passage></document>
<document><id>37902920</id><passage><infon key="journal">Matern Child Health J;2023Oct30. doi:10.1007/s10995-023-03797-z</infon><infon key="year">2023</infon><infon key="article-id_pmc">6381630</infon><infon key="type">title</infon><infon key="authors">Iqbal H, West J, McEachan RRC, Haith-Cooper M, </infon><offset>0</offset><text>Identifying the Health Concerns of Pregnant British Pakistani Women Living in Deprived Areas: A Qualitative Study.</text></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>INTRODUCTION: Pregnant British Pakistani women have disproportionately poorer health than the wider population. Bradford has a strong Pakistani presence and a wide range of public health problems including high levels of gestational diabetes, high obesity rates and a high infant mortality rate, which is highest for babies of Pakistani origin. For women to be healthy, we need to know what concerns they have about their health so they can be addressed appropriately. The aim of this study, therefore, was to explore the health concerns of pregnant British Pakistani women living in deprived areas. METHODS: Semi-structured qualitative interviews were conducted with 21 pregnant Pakistani women in a hospital setting. Data were analysed using thematic analysis. RESULTS: Pakistani women identified safety issues, barriers to undertaking physical activity in the areas where they live, concerns surrounding exercising during pregnancy and cultural and religious constraints that prevented them from engaging in physical activity. They reported issues around food, concerns around a lack of culturally appropriate diet information, the cost of unhealthy food locally, and the lack of healthy food options in their residences. Women were unsure on where to obtain health promotion information and reported a lack of access in obtaining that information. Language barriers in accessing health promotion information were further reported as a concern. DISCUSSION: Researchers, midwives, health providers, local authority and policy makers interested in improving the health of pregnant Pakistani women may use these findings to develop further research and interventions to improve the poor health of this population.</text><annotation id="2"><infon key="identifier">MESH:D016640</infon><infon key="type">Disease</infon><location offset="336" length="20"/><text>gestational diabetes</text></annotation><annotation id="3"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="363" length="7"/><text>obesity</text></annotation></passage></document>
<document><id>37903298</id><passage><infon key="journal">Pain;2023Oct30. doi:10.1097/j.pain.0000000000003029</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Erdogan O, Michot B, Xia J, Alabdulaaly L, Yesares Rubi P, Ha V, Chiu IM, Gibbs JL, </infon><offset>0</offset><text>Neuronal-immune axis alters pain and sensory afferent damage during dental pulp injury.</text><annotation id="2"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="28" length="4"/><text>pain</text></annotation><annotation id="3"><infon key="identifier">MESH:D003788</infon><infon key="type">Disease</infon><location offset="68" length="18"/><text>dental pulp injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>88</offset><text>ABSTRACT: Dental pulp tissue is densely innervated by afferent fibers of the trigeminal ganglion. When bacteria cause dental decay near the pulpal tissue, a strong neuronal and immune response occurs, creating pulpitis, which is associated with severe pain and pulp tissue damage. Neuroimmune interactions have the potential to modulate both the pain and pathological outcome of pulpitis. We first investigated the role of the neuropeptide calcitonin gene-related peptide (CGRP), released from peptidergic sensory afferents, in dental pain and immune responses by using Calca knockout (Calca-/-) and wild-type (Calca+/+) mice, in a model of pulpitis by creating a mechanical exposure of the dental pulp horn. We found that the neuropeptide CGRP, facilitated the recruitment of myeloid cells into the pulp while also increasing spontaneous pain-like behavior 20% to 25% at an early time point. Moreover, when we depleted neutrophils and monocytes, we found that there was 20% to 30% more sensory afferent loss and increased presence of bacteria in deeper parts of the tissue, whereas there was a significant reduction in mechanical pain response scores compared with the control group at a later time point. Overall, we showed that there is a crosstalk between peptidergic neurons and neutrophils in the pulp, modulating the pain and inflammatory outcomes of the disease.</text><annotation id="22"><infon key="identifier">MESH:D003731</infon><infon key="type">Disease</infon><location offset="206" length="12"/><text>dental decay</text></annotation><annotation id="23"><infon key="identifier">MESH:D011671</infon><infon key="type">Disease</infon><location offset="298" length="8"/><text>pulpitis</text></annotation><annotation id="24"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="340" length="4"/><text>pain</text></annotation><annotation id="25"><infon key="identifier">MESH:D017695</infon><infon key="type">Disease</infon><location offset="349" length="18"/><text>pulp tissue damage</text></annotation><annotation id="26"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="434" length="4"/><text>pain</text></annotation><annotation id="27"><infon key="identifier">MESH:D011671</infon><infon key="type">Disease</infon><location offset="467" length="8"/><text>pulpitis</text></annotation><annotation id="28"><infon key="identifier">12310</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">88337</infon><location offset="528" length="31"/><text>calcitonin gene-related peptide</text></annotation><annotation id="29"><infon key="identifier">12310</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">88337</infon><location offset="561" length="4"/><text>CGRP</text></annotation><annotation id="30"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="616" length="11"/><text>dental pain</text></annotation><annotation id="31"><infon key="identifier">12310</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">88337</infon><location offset="658" length="5"/><text>Calca</text></annotation><annotation id="32"><infon key="identifier">12310</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">88337</infon><location offset="674" length="5"/><text>Calca</text></annotation><annotation id="33"><infon key="identifier">12310</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">88337</infon><location offset="699" length="5"/><text>Calca</text></annotation><annotation id="34"><infon key="identifier">MESH:D011671</infon><infon key="type">Disease</infon><location offset="729" length="8"/><text>pulpitis</text></annotation><annotation id="35"><infon key="identifier">12310</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">88337</infon><location offset="828" length="4"/><text>CGRP</text></annotation><annotation id="36"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="927" length="4"/><text>pain</text></annotation><annotation id="37"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1219" length="4"/><text>pain</text></annotation><annotation id="38"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1412" length="4"/><text>pain</text></annotation><annotation id="39"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1421" length="12"/><text>inflammatory</text></annotation></passage><relation id="R1"><infon key="score">0.905</infon><infon key="role1">Disease|MESH:D010146</infon><infon key="role2">Gene|12310</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="10,8"/></relation></document>
<document><id>37903649</id><passage><infon key="journal">Histopathology;2023Oct30. doi:10.1111/his.15086</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Beaufr&amp;#xe8;re A, Paisley S, Ba I, Laouirem S, Priori V, Cazier H, Favre L, Cauchy F, Lesurtel M, Calderaro J, Kannengiesser C, Paradis V, </infon><offset>0</offset><text>Differential diagnosis of small hepatocellular nodules in cirrhosis: surrogate histological criteria of TERT promoter mutations.</text><annotation id="3"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="32" length="22"/><text>hepatocellular nodules</text></annotation><annotation id="4"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="58" length="9"/><text>cirrhosis</text></annotation><annotation id="5"><infon key="identifier">7015</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31141</infon><location offset="104" length="4"/><text>TERT</text></annotation></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>AIMS: The differential diagnosis of small hepatocellular nodules in cirrhosis between dysplastic nodules and hepatocellular carcinoma (HCC) remains challenging on biopsy. As TERT promoter (pTERT) mutations may indicate the nodules already engaged in the malignant process, the aim of this study was to identify histological criteria associated with pTERT mutations by detecting these mutations by ddPCR in small formalin-fixed paraffin-embedded (FFPE) hepatocellular nodules arising in cirrhosis. METHODS AND RESULTS: We built a bicentric cohort data set of 339 hepatocellular nodules &lt; 2 cm from cirrhotic samples, divided into a test cohort of 299 resected samples and a validation cohort of 40 biopsies. Pathological review, based on the evaluation of 14 histological criteria, classified all nodules. pTERT mutations were identified by ddPCR in FFPE samples. Among the 339 nodules, ddPCR revealed pTERT mutations in 105 cases (31%), including 90 and 15 cases in the test and validation cohorts, respectively. On multivariate analysis, three histological criteria were associated with pTERT mutations in the test cohort: increased cell density (P = 0.003), stromal invasion (P = 0.036) and plate-thickening anomalies (P &lt; 0.001). With the combination of at least two of these major criteria, the AUC for predicting pTERT mutations was 0.84 in the test cohort (sensitivity: 86%, specificity: 83%) and 0.81 in the validation cohort (sensitivity: 87%, specificity: 76%). CONCLUSIONS: We identified three histological criteria as surrogate markers of pTERT mutations that may be used in routine biopsy to more clearly classify small hepatocellular nodules arising in cirrhosis.</text><annotation id="23"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="171" length="22"/><text>hepatocellular nodules</text></annotation><annotation id="24"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="197" length="9"/><text>cirrhosis</text></annotation><annotation id="25"><infon key="identifier">MESH:D016606</infon><infon key="type">Disease</infon><location offset="215" length="18"/><text>dysplastic nodules</text></annotation><annotation id="26"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="238" length="24"/><text>hepatocellular carcinoma</text></annotation><annotation id="27"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="264" length="3"/><text>HCC</text></annotation><annotation id="28"><infon key="identifier">7015</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31141</infon><location offset="303" length="4"/><text>TERT</text></annotation><annotation id="29"><infon key="identifier">MESH:D016606</infon><infon key="type">Disease</infon><location offset="352" length="7"/><text>nodules</text></annotation><annotation id="30"><infon key="identifier">MESH:D005557</infon><infon key="type">Chemical</infon><location offset="541" length="8"/><text>formalin</text></annotation><annotation id="31"><infon key="identifier">MESH:D010232</infon><infon key="type">Chemical</infon><location offset="556" length="8"/><text>paraffin</text></annotation><annotation id="32"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="581" length="22"/><text>hepatocellular nodules</text></annotation><annotation id="33"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="615" length="9"/><text>cirrhosis</text></annotation><annotation id="34"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="691" length="22"/><text>hepatocellular nodules</text></annotation><annotation id="35"><infon key="identifier">MESH:D000094724</infon><infon key="type">Disease</infon><location offset="726" length="9"/><text>cirrhotic</text></annotation><annotation id="36"><infon key="identifier">MESH:D016606</infon><infon key="type">Disease</infon><location offset="925" length="7"/><text>nodules</text></annotation><annotation id="37"><infon key="identifier">MESH:D016606</infon><infon key="type">Disease</infon><location offset="1006" length="7"/><text>nodules</text></annotation><annotation id="38"><infon key="identifier">MESH:D006528</infon><infon key="type">Disease</infon><location offset="1761" length="22"/><text>hepatocellular nodules</text></annotation><annotation id="39"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="1795" length="9"/><text>cirrhosis</text></annotation></passage><relation id="R1"><infon key="score">0.9752</infon><infon key="role1">Disease|MESH:D005355</infon><infon key="role2">Gene|7015</infon><infon key="type">Association</infon><node refid="0" role="1,2"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Disease|MESH:D006528</infon><infon key="role2">Gene|7015</infon><infon key="type">Association</infon><node refid="1" role="0,2"/></relation><relation id="R3"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D016606</infon><infon key="role2">Gene|7015</infon><infon key="type">Association</infon><node refid="2" role="9,8"/></relation></document>
<document><id>37904000</id><passage><infon key="journal">Eye (Lond);2023Oct30. doi:10.1038/s41433-023-02807-2</infon><infon key="year">2023</infon><infon key="article-id_pmc">9267454</infon><infon key="type">title</infon><infon key="authors">Jiao X, Qi Y, Gao N, Zhang C, Zhao S, Yang R, </infon><offset>0</offset><text>Exploration of efficacy and mechanism of 0.05% cyclosporine eye drops (II) monotherapy in allergic conjunctivitis-associated dry eye.</text><annotation id="3"><infon key="identifier">MESH:D016572</infon><infon key="type">Chemical</infon><location offset="47" length="12"/><text>cyclosporine</text></annotation><annotation id="4"><infon key="identifier">MESH:D003233</infon><infon key="type">Disease</infon><location offset="90" length="23"/><text>allergic conjunctivitis</text></annotation><annotation id="5"><infon key="identifier">MESH:D015352</infon><infon key="type">Disease</infon><location offset="125" length="7"/><text>dry eye</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>PURPOSE: To explore the efficacy and relevant mechanism of 0.05% cyclosporine A (CsA) eye drops (II) monotherapy in patients with allergic conjunctivitis-associated dry eye (ACDE). METHODS: Prospective, randomized, controlled study. Fifty-three patients with mild-to-moderate ACDE were randomly assigned to two groups. The CsA group received 0.05% CsA eye drops (II) monotherapy four times daily. The control group received 0.1% olopatadine twice daily combined with 0.1% preservative-free artificial tears four times daily. Clinical symptoms and signs, tear total IgE, and lymphotoxin-alpha (LT-alpha) concentrations were assessed at pre- and post-treatment days 7, 30, and 60. And we further measured six tear cytokines levels using a microsphere-based immunoassay. RESULTS: The CsA group showed significant improvement in symptoms (Ocular Surface Disease Index and itching scores) and signs (conjunctival hyperaemia, conjunctival oedema, conjunctival papillae, tear break-up time (TBUT), corneal fluorescein staining, and goblet cell density) at each follow-up period compared to pre-treatment (all P &lt; 0.050). And its improvement in itching scores (P7th &lt; 0.001, P30th = 0.039, and P60th = 0.031) and TBUT (P7th = 0.009, P30th = 0.003, and P60th = 0.005) was more significant than the control group at all follow-up periods. The tear total IgE, interleukin (IL)-5, IL-6, periostin, eotaxin-3, and MMP-9 levels significantly decreased in the CsA group at day 60 after treatment (all P &lt; 0.050). And the changed values in tear total IgE were positively correlated with the change in itching scores. CONCLUSIONS: 0.05% CsA eye drops (II) monotherapy can rapidly improve the symptoms and signs, especially in ocular itching and TBUT, in patients with ACDE. And its efficacy is superior to 0.1% olopatadine combined with artificial tears. Moreover, CsA downregulates the expression levels of tear inflammatory cytokines, including tear total IgE, IL-5, IL-6, periostin, eotaxin-3, and MMP-9. Among that, the reduction in tear total IgE levels may reflect the improvement of ocular itching.</text><annotation id="50"><infon key="identifier">MESH:D016572</infon><infon key="type">Chemical</infon><location offset="199" length="14"/><text>cyclosporine A</text></annotation><annotation id="51"><infon key="identifier">MESH:D016572</infon><infon key="type">Chemical</infon><location offset="215" length="3"/><text>CsA</text></annotation><annotation id="52"><infon key="identifier">MESH:D003233</infon><infon key="type">Disease</infon><location offset="264" length="24"/><text>allergic conjunctivitis-</text></annotation><annotation id="53"><infon key="identifier">MESH:D015352</infon><infon key="type">Disease</infon><location offset="299" length="7"/><text>dry eye</text></annotation><annotation id="54"><infon key="identifier">MESH:D003233</infon><infon key="type">Disease</infon><location offset="308" length="4"/><text>ACDE</text></annotation><annotation id="55"><infon key="identifier">MESH:D003233</infon><infon key="type">Disease</infon><location offset="410" length="4"/><text>ACDE</text></annotation><annotation id="56"><infon key="identifier">MESH:D016572</infon><infon key="type">Chemical</infon><location offset="457" length="3"/><text>CsA</text></annotation><annotation id="57"><infon key="identifier">MESH:D016572</infon><infon key="type">Chemical</infon><location offset="482" length="3"/><text>CsA</text></annotation><annotation id="58"><infon key="identifier">MESH:D000069605</infon><infon key="type">Chemical</infon><location offset="563" length="11"/><text>olopatadine</text></annotation><annotation id="59"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="699" length="3"/><text>IgE</text></annotation><annotation id="60"><infon key="identifier">4049</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">497</infon><location offset="708" length="17"/><text>lymphotoxin-alpha</text></annotation><annotation id="61"><infon key="identifier">4049</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">497</infon><location offset="727" length="8"/><text>LT-alpha</text></annotation><annotation id="62"><infon key="identifier">MESH:D016572</infon><infon key="type">Chemical</infon><location offset="915" length="3"/><text>CsA</text></annotation><annotation id="63"><infon key="identifier">MESH:D010534</infon><infon key="type">Disease</infon><location offset="969" length="22"/><text>Ocular Surface Disease</text></annotation><annotation id="64"><infon key="identifier">MESH:D011537</infon><infon key="type">Disease</infon><location offset="1002" length="7"/><text>itching</text></annotation><annotation id="65"><infon key="identifier">MESH:D003229</infon><infon key="type">Disease</infon><location offset="1029" length="23"/><text>conjunctival hyperaemia</text></annotation><annotation id="66"><infon key="identifier">MESH:D003229</infon><infon key="type">Disease</infon><location offset="1054" length="19"/><text>conjunctival oedema</text></annotation><annotation id="67"><infon key="type">Disease</infon><location offset="1118" length="4"/><text>TBUT</text></annotation><annotation id="68"><infon key="identifier">MESH:D019793</infon><infon key="type">Chemical</infon><location offset="1133" length="11"/><text>fluorescein</text></annotation><annotation id="69"><infon key="identifier">MESH:D011537</infon><infon key="type">Disease</infon><location offset="1271" length="7"/><text>itching</text></annotation><annotation id="70"><infon key="type">Disease</infon><location offset="1339" length="4"/><text>TBUT</text></annotation><annotation id="71"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="1478" length="3"/><text>IgE</text></annotation><annotation id="72"><infon key="identifier">3567</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">679</infon><location offset="1483" length="18"/><text>interleukin (IL)-5</text></annotation><annotation id="73"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1503" length="4"/><text>IL-6</text></annotation><annotation id="74"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="1509" length="9"/><text>periostin</text></annotation><annotation id="75"><infon key="identifier">10344</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48398</infon><location offset="1520" length="9"/><text>eotaxin-3</text></annotation><annotation id="76"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="1535" length="5"/><text>MMP-9</text></annotation><annotation id="77"><infon key="identifier">MESH:D016572</infon><infon key="type">Chemical</infon><location offset="1579" length="3"/><text>CsA</text></annotation><annotation id="78"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="1669" length="3"/><text>IgE</text></annotation><annotation id="79"><infon key="identifier">MESH:D011537</infon><infon key="type">Disease</infon><location offset="1719" length="7"/><text>itching</text></annotation><annotation id="80"><infon key="identifier">MESH:D016572</infon><infon key="type">Chemical</infon><location offset="1754" length="3"/><text>CsA</text></annotation><annotation id="81"><infon key="identifier">MESH:D011537</infon><infon key="type">Disease</infon><location offset="1843" length="14"/><text>ocular itching</text></annotation><annotation id="82"><infon key="type">Disease</infon><location offset="1862" length="4"/><text>TBUT</text></annotation><annotation id="83"><infon key="identifier">MESH:D003233</infon><infon key="type">Disease</infon><location offset="1885" length="4"/><text>ACDE</text></annotation><annotation id="84"><infon key="identifier">MESH:D000069605</infon><infon key="type">Chemical</infon><location offset="1928" length="11"/><text>olopatadine</text></annotation><annotation id="85"><infon key="identifier">MESH:D016572</infon><infon key="type">Chemical</infon><location offset="1982" length="3"/><text>CsA</text></annotation><annotation id="86"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="2075" length="3"/><text>IgE</text></annotation><annotation id="87"><infon key="identifier">3567</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">679</infon><location offset="2080" length="4"/><text>IL-5</text></annotation><annotation id="88"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="2086" length="4"/><text>IL-6</text></annotation><annotation id="89"><infon key="identifier">10631</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4730</infon><location offset="2092" length="9"/><text>periostin</text></annotation><annotation id="90"><infon key="identifier">10344</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48398</infon><location offset="2103" length="9"/><text>eotaxin-3</text></annotation><annotation id="91"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="2118" length="5"/><text>MMP-9</text></annotation><annotation id="92"><infon key="identifier">3497</infon><infon key="type">Gene</infon><location offset="2165" length="3"/><text>IgE</text></annotation><annotation id="93"><infon key="identifier">MESH:D011537</infon><infon key="type">Disease</infon><location offset="2207" length="14"/><text>ocular itching</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Gene|3567</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="30,25"/></relation><relation id="R2"><infon key="score">0.9955</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Disease|MESH:D003229</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="15,18"/></relation><relation id="R3"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Gene|3497</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="30,24"/></relation><relation id="R4"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Gene|10631</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="30,27"/></relation><relation id="R5"><infon key="score">0.6514</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Disease|MESH:D011537</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="15,17"/></relation><relation id="R6"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Disease|MESH:D015352</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="0,2"/></relation><relation id="R7"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Disease|MESH:D003233</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="0,1"/></relation><relation id="R8"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Gene|10344</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="30,28"/></relation><relation id="R9"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Disease|MESH:D010534</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="15,16"/></relation><relation id="R10"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Gene|3569</infon><infon key="type">Negative_Correlation</infon><node refid="9" role="30,26"/></relation><relation id="R11"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D016572</infon><infon key="role2">Gene|4318</infon><infon key="type">Negative_Correlation</infon><node refid="10" role="30,29"/></relation><relation id="R12"><infon key="score">0.9976</infon><infon key="role1">Disease|MESH:D011537</infon><infon key="role2">Gene|3497</infon><infon key="type">Association</infon><node refid="11" role="32,31"/></relation></document>
<document><id>37905050</id><passage><infon key="journal">bioRxiv;2023Oct17. doi:10.1101/2023.10.15.562396</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614790</infon><infon key="type">title</infon><infon key="authors">Norrie JL, Lupo M, Shirinifard A, Djekidel N, Ramirez C, Xu B, Dundee JM, Dyer MA, </infon><offset>0</offset><text>Latent Epigenetic Programs in Muller Glia Contribute to Stress, Injury, and Disease Response in the Retina.</text><annotation id="1"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="64" length="6"/><text>Injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>108</offset><text>Previous studies have demonstrated the dynamic changes in chromatin structure during retinal development that correlate with changes in gene expression. However, a major limitation of those prior studies was the lack of cellular resolution. Here, we integrate single-cell (sc) RNA-seq and scATAC-seq with bulk retinal data sets to identify cell type-specific changes in the chromatin structure during development. Although most genes' promoter activity is strongly correlated with chromatin accessibility, we discovered several hundred genes that were transcriptionally silent but had accessible chromatin at their promoters. Most of those silent/accessible gene promoters were in the Muller glial cells. The Muller cells are radial glia of the retina and perform a variety of essential functions to maintain retinal homeostasis and respond to stress, injury, or disease. The silent/accessible genes in Muller glia are enriched in pathways related to inflammation, angiogenesis, and other types of cell-cell signaling and were rapidly activated when we tested 15 different physiologically relevant conditions to mimic retinal stress, injury, or disease in human and murine retinae. We refer to these as "pliancy genes" because they allow the Muller glia to rapidly change their gene expression and cellular state in response to different types of retinal insults. The Muller glial cell pliancy program is established during development, and we demonstrate that pliancy genes are necessary and sufficient for regulating inflammation in the murine retina in vivo. In zebrafish, Muller glia can de-differentiate and form retinal progenitor cells that replace lost neurons. The pro-inflammatory pliancy gene cascade is not activated in zebrafish Muller glia following injury, and we propose a model in which species-specific pliancy programs underly the differential response to retinal damage in species that can regenerate retinal neurons (zebrafish) versus those that cannot (humans and mice).</text><annotation id="16"><infon key="identifier">MESH:D012173</infon><infon key="type">Disease</infon><location offset="193" length="7"/><text>retinal</text></annotation><annotation id="17"><infon key="identifier">MESH:D012173</infon><infon key="type">Disease</infon><location offset="418" length="7"/><text>retinal</text></annotation><annotation id="18"><infon key="identifier">MESH:D012173</infon><infon key="type">Disease</infon><location offset="917" length="7"/><text>retinal</text></annotation><annotation id="19"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="960" length="6"/><text>injury</text></annotation><annotation id="20"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1059" length="12"/><text>inflammation</text></annotation><annotation id="21"><infon key="identifier">MESH:D012173</infon><infon key="type">Disease</infon><location offset="1226" length="7"/><text>retinal</text></annotation><annotation id="22"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1242" length="6"/><text>injury</text></annotation><annotation id="23"><infon key="identifier">MESH:D012173</infon><infon key="type">Disease</infon><location offset="1455" length="7"/><text>retinal</text></annotation><annotation id="24"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1627" length="12"/><text>inflammation</text></annotation><annotation id="25"><infon key="identifier">MESH:D012173</infon><infon key="type">Disease</infon><location offset="1726" length="7"/><text>retinal</text></annotation><annotation id="26"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1786" length="12"/><text>inflammatory</text></annotation><annotation id="27"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1872" length="6"/><text>injury</text></annotation><annotation id="28"><infon key="identifier">MESH:D012164</infon><infon key="type">Disease</infon><location offset="1983" length="14"/><text>retinal damage</text></annotation><annotation id="29"><infon key="identifier">MESH:D012173</infon><infon key="type">Disease</infon><location offset="2029" length="7"/><text>retinal</text></annotation></passage></document>
<document><id>37905751</id><passage><infon key="journal">Br J Soc Psychol;2023Oct31. doi:10.1111/bjso.12694</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">La Rue CJ, Steffens NK, Werth B&amp;#xc1;, Bentley SV, Haslam C, </infon><offset>0</offset><text>A latent profile analysis of the nature of social group memberships and their contribution to retirement outcomes.</text></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>Positive experiences of groups (e.g., the extent to which groups are important and supportive) tend to be associated with better retirement adjustment outcomes. However, group experiences are not always positive, and we know little about their varied contribution to adjustment outcomes. We addressed this gap by exploring the nature of social group memberships - in terms of varying positive and negative experiences of groups - to better understand how social group memberships shape retirement adjustment, life satisfaction and mental health. A latent profile analysis (using data from 489 retirees and their membership of 1887 groups) identified four profiles of social group memberships: optimal (63%), slightly straining (13%), low-supportive (18%) and ambivalent (6%). Subsequent regression analysis showed that these different profiles of group membership were differentially associated with retirement adjustment outcomes: belonging to more optimal groups was associated with better perceived adjustment, higher life satisfaction and better mental health, while belonging to slightly straining and ambivalent groups contributed to poorer adjustment, lower life satisfaction and greater depression. These findings have implications for theory and practice, not least because they advance our understanding of the diversity of people's group memberships and their contribution to retirement and health outcomes.</text><annotation id="1"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1310" length="10"/><text>depression</text></annotation></passage></document>
<document><id>37906102</id><passage><infon key="journal">J Gen Psychol;2023Oct31 1. doi:10.1080/00221309.2023.2275304</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rod&amp;#xe1;n A, Romero M, Casadevante C, Santacreu J, Montoro PR, Contreras MJ, </infon><offset>0</offset><text>Getting it right takes time: response time and performance in secondary school students.</text></passage><passage><infon key="type">abstract</infon><offset>89</offset><text>The relation between response time and performance in cognitive tasks is increasingly evident. In the present study, we analyzed the effect of participants' spontaneous speed when responding to a mental rotation task. We carried out a data reanalysis from a previous study where a training of 3 practice sessions of 100 trials each was applied. The procedure was applied to a sample of 21 high school students (11 boys, 10 girls). The relation between response time and performance (hits) across the training trials was analyzed. In addition, we carried out a regression analysis of performance on the learning task as a function of response time on that same task, as well as with the score on two previously applied tests of spatial intelligence and fluid intelligence. Results showed, (a) a significant relationship (r = 0.624) between response time and hits, (b) that the group of participants with longer response times performed better; (c) that participants' response time explained most of the variance of their score on the training task in the regression analysis, although spatial and fluid intelligence scores improved the prediction of performance. Our results suggest that the reflective style achieves greater performance in solving spatial tasks, which could have important practical implications to promote a slower and more reflective style when solving school tasks with spatial components.</text></passage></document>
<document><id>37906453</id><passage><infon key="journal">Water Sci Technol;2023Oct; 88 (8) 1974. doi:10.2166/wst.2023.328</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Montes CA, Ortiz NV, Arias CA, Chaparro TR, </infon><offset>0</offset><text>Vertical flow wetlands as the core for the sustainable treatment of coffee wastewater in small communities in Colombia: preliminary results of the treatment of coffee wastewater in rural areas by vertical flow wetlands.</text></passage><passage><infon key="type">abstract</infon><offset>220</offset><text>Coffee is one of the most important agricultural products in Colombia. To date, small-scale Colombian coffee growers have developed this activity with a simple infrastructure and random use of water that generates harmful by-products to the water resource mainly in the stage of separation of the mucilage. The coffee mucilage wastewater (CMW) is composed of high organic loads and its impact on water sources is due to its high load of nutrients such as nitrogen (N), phosphorus (P), and chemical oxygen demand (COD) values of over 25,000 mg/L. However, there is no consensus on what treatment can be used, especially whether it is accessible to coffee producers. Thus , the aim of this study consisted of assessing the performance of the combination of a carbon filter (CF) as pretreatment and vertical flow wetland (VFW) as a Natural-based Solution (NbS). The results show a reduction of more than 85% of COD, 96% of total solids, and UV254 close to 94%. It was remarkable that both treatments are appropriate for waters with a high concentration of solids. Finally, it can be concluded that CF + VFW is a feasible technology to treat the coffee wastewater from small communities of coffee producers.</text><annotation id="9"><infon key="type">Disease</infon><location offset="517" length="8"/><text>mucilage</text></annotation><annotation id="10"><infon key="type">Disease</infon><location offset="538" length="8"/><text>mucilage</text></annotation><annotation id="11"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="675" length="8"/><text>nitrogen</text></annotation><annotation id="12"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="685" length="1"/><text>N</text></annotation><annotation id="13"><infon key="identifier">MESH:D010758</infon><infon key="type">Chemical</infon><location offset="689" length="10"/><text>phosphorus</text></annotation><annotation id="14"><infon key="identifier">MESH:D010758</infon><infon key="type">Chemical</infon><location offset="701" length="1"/><text>P</text></annotation><annotation id="15"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="977" length="6"/><text>carbon</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1146" length="6"/><text>solids</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1273" length="6"/><text>solids</text></annotation></passage></document>
<document><id>37906827</id><passage><infon key="journal">Rev Med Chil;2022Jul; 150 (7) 924. doi:10.4067/s0034-98872022000700924</infon><infon key="year">2022</infon><infon key="type">title</infon><infon key="authors">Rojas LE, Huidobro E JP, </infon><offset>0</offset><text>[Estimation of kidney function to adjust drug dosing].</text></passage><passage><infon key="type">abstract</infon><offset>55</offset><text>Drug dosing according to renal function is a globally accepted practice whose main purpose is to avoid drug associated toxicity when renal clearance is decreased. Renal function is usually estimated based on creatinine clearance or an estimated glomerular filtration rate (GFR) obtained from one of the available equations based on serum biomarkers. In this review we will analyze the different available methods to adjust the dose of drugs based on GFR, with emphasis on their comparative performance for this objective. Based on this, we will provide some recommendations for drug dosing in chronic and acute renal dysfunction.</text><annotation id="3"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="174" length="8"/><text>toxicity</text></annotation><annotation id="4"><infon key="identifier">MESH:D003404</infon><infon key="type">Chemical</infon><location offset="263" length="10"/><text>creatinine</text></annotation><annotation id="5"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="660" length="23"/><text>acute renal dysfunction</text></annotation></passage></document>
<document><id>37907193</id><passage><infon key="journal">Environ Pollut;2023Oct29 122804. doi:10.1016/j.envpol.2023.122804</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rahmatinia M, Mohseni-Bandpei A, Khodagholi F, Abdollahifar MA, Amouei Torkmahalleh M, Hassani Moghaddam M, Hopke PK, Ghavimehr E, Bazzazpour S, Shahsavani A, </infon><offset>0</offset><text>Exposure to different PM2.5 extracts induces gliosis and changes behavior in male rats similar to autism spectrum disorders features.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="22" length="5"/><text>PM2.5</text></annotation><annotation id="4"><infon key="identifier">MESH:D005911</infon><infon key="type">Disease</infon><location offset="45" length="7"/><text>gliosis</text></annotation><annotation id="5"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="98" length="25"/><text>autism spectrum disorders</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>Epidemiological studies have documented that exposure to fine particulate matter (PM2.5) could affect neurodevelopment, thereby leading to autism spectrum disorders (ASD). Nevertheless, there is little laboratory data to support this epidemiological evidence. In the current study, we carried out a series of experiments to assess whether developmental exposures to different extracts of PM2.5 can result in ASD-like behavioral, biochemical, and immunohistochemical characteristics in male rat offspring. PM2.5 samples were collected daily for a year, and monthly composites were extracted with an acetone-hexane mixture. The extracts were analyzed for their chemical constituents. Three groups of rats were exposed to the different PM2.5 extracts during pre- and postnatal periods. All exposed groups of rats exhibited typical behavioral features of ASD, including increased repetitive and depression-related behaviors. We also found microglia and astrocytes activation and decreased concentrations of oxytocin (OXT) in the brain regions of exposed rats compared with control rats. Comparing the current results with a prior study, the induced biological effects followed a sequence of whole particles of PM2.5 > organic extract > inorganic extract. These findings indicated that exposure to PM2.5 can elicit ASD-like features in rats and raise concerns about particulate matter as a possible trigger for the induction of ASD in humans; therefore, mitigating the contents of the PAHs and metals could reduce the PM2.5 neurotoxicity.</text><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="216" length="5"/><text>PM2.5</text></annotation><annotation id="27"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="273" length="25"/><text>autism spectrum disorders</text></annotation><annotation id="28"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="300" length="3"/><text>ASD</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="522" length="5"/><text>PM2.5</text></annotation><annotation id="30"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="542" length="3"/><text>ASD</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="639" length="5"/><text>PM2.5</text></annotation><annotation id="32"><infon key="identifier">MESH:D000096</infon><infon key="type">Chemical</infon><location offset="732" length="7"/><text>acetone</text></annotation><annotation id="33"><infon key="identifier">MESH:D006586</infon><infon key="type">Chemical</infon><location offset="740" length="6"/><text>hexane</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="867" length="5"/><text>PM2.5</text></annotation><annotation id="35"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="985" length="3"/><text>ASD</text></annotation><annotation id="36"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1025" length="10"/><text>depression</text></annotation><annotation id="37"><infon key="identifier">25504</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55494</infon><location offset="1137" length="8"/><text>oxytocin</text></annotation><annotation id="38"><infon key="identifier">25504</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55494</infon><location offset="1147" length="3"/><text>OXT</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1340" length="5"/><text>PM2.5</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1427" length="5"/><text>PM2.5</text></annotation><annotation id="41"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="1444" length="3"/><text>ASD</text></annotation><annotation id="42"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="1557" length="3"/><text>ASD</text></annotation><annotation id="43"><infon key="identifier">MESH:D011084</infon><infon key="type">Chemical</infon><location offset="1614" length="4"/><text>PAHs</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1647" length="5"/><text>PM2.5</text></annotation><annotation id="45"><infon key="identifier">MESH:D020258</infon><infon key="type">Disease</infon><location offset="1653" length="13"/><text>neurotoxicity</text></annotation></passage><relation id="R1"><infon key="score">0.4678</infon><infon key="role1">Chemical|MESH:D011084</infon><infon key="role2">Disease|MESH:D020258</infon><infon key="type">Association</infon><node refid="0" role="20,22"/></relation><relation id="R2"><infon key="score">0.5099</infon><infon key="role1">Chemical|MESH:D000096</infon><infon key="role2">Chemical|MESH:D006586</infon><infon key="type">Cotreatment</infon><node refid="1" role="9,10"/></relation></document>
<document><id>37909296</id><passage><infon key="journal">Disabil Rehabil;2023Nov01 1. doi:10.1080/09638288.2023.2272714</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kuiper H, Leeuwen CMCV, Stolwijk-Sw&amp;#xfc;ste JM, Post MWM, </infon><offset>0</offset><text>Does the disposition of passive coping mediate the association between illness perception and symptoms of anxiety and depression in patients with spinal cord injury during first inpatient rehabilitation?</text><annotation id="2"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="106" length="22"/><text>anxiety and depression</text></annotation><annotation id="3"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="146" length="18"/><text>spinal cord injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>204</offset><text>PURPOSE: To examine associations between illness perception, also called illness cognitions or appraisals, disposition of passive coping, and symptoms of anxiety and depression, and to test whether passive coping mediates the associations between illness perception and symptoms of anxiety and depression. MATERIALS AND METHODS: Longitudinal, multicentre study. Participants were inpatients of spinal cord injury (SCI) rehabilitation. Measures included the Brief Illness Perception Questionnaire (B-IPQ), the Utrecht Coping List passive coping subscale (UCL-P), and the Hospital Anxiety and Depression Scale (HADS). Mediation was tested with the PROCESS tool. RESULTS: The questionnaires were completed by 121 participants at admission and at discharge. Of them, 70% were male, 58% had a paraplegia, and 82% an incomplete lesion. Weak to strong (0.294-0.650) significant associations were found between each pair of study variables. The use of passive coping strategies mediated the associations between illness perception and symptoms of anxiety and depression. CONCLUSION: Symptoms of anxiety and depression were more frequent in people who have a threatening illness perception combined with a lower use of passive coping strategies. Therefore, it is advised that patients are screened and treated for threatening illness perception and high use of passive coping strategies during rehabilitation after SCI.</text><annotation id="13"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="358" length="22"/><text>anxiety and depression</text></annotation><annotation id="14"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="486" length="22"/><text>anxiety and depression</text></annotation><annotation id="15"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="598" length="18"/><text>spinal cord injury</text></annotation><annotation id="16"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="618" length="3"/><text>SCI</text></annotation><annotation id="17"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="783" length="22"/><text>Anxiety and Depression</text></annotation><annotation id="18"><infon key="identifier">MESH:D010264</infon><infon key="type">Disease</infon><location offset="992" length="10"/><text>paraplegia</text></annotation><annotation id="19"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="1243" length="22"/><text>anxiety and depression</text></annotation><annotation id="20"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="1291" length="22"/><text>anxiety and depression</text></annotation><annotation id="21"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1610" length="3"/><text>SCI</text></annotation></passage></document>
<document><id>37910006</id><passage><infon key="journal">J Med Microbiol;2023Nov; 72 (11) . doi:10.1099/jmm.0.001763</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sun Q, Liao X, Yan J, Jiang G, Huo F, Wang G, Li H, </infon><offset>0</offset><text>In vitro activity of tubercidin against Mycobacterium tuberculosis and nontuberculosis Mycobacteria.</text><annotation id="1"><infon key="identifier">MESH:D014372</infon><infon key="type">Chemical</infon><location offset="21" length="10"/><text>tubercidin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>101</offset><text>Tubercidin is an adenosine analogue that has been shown to exhibit good activity against some tumours and parasites. In this study, the in vitro activity of tubercidin was evaluated against Mycobacterium tuberculosis (Mtb) and nontuberculosis Mycobacteria (NTM). For determining the MICs of tubercidin, 23 fully drug-sensitive (DS) Mtb strains, 33 multi-drug resistance tuberculosis (MDR-TB) strains, 29 pre-extensively drug-resistant tuberculosis (pre-XDR-TB) strains, 21 extensively drug-resistant tuberculosis (XDR-TB) strains, 17 rapidly growing mycobacteria (RGM) and nine slowly growing mycobacteria (SGM) references strains were tested by microplate-based Alamar Blue assay (MABA) method. The results indicate that tubercidin has high in vitro activity against some drug-resistance Mtb strains and NTM reference strains, which warrants further investigation on the actions of tubercidin and its derivatives as potential drugs for mycobacterial infections.</text><annotation id="20"><infon key="identifier">MESH:D014372</infon><infon key="type">Chemical</infon><location offset="101" length="10"/><text>Tubercidin</text></annotation><annotation id="21"><infon key="identifier">MESH:D000241</infon><infon key="type">Chemical</infon><location offset="118" length="9"/><text>adenosine</text></annotation><annotation id="22"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="195" length="7"/><text>tumours</text></annotation><annotation id="23"><infon key="identifier">MESH:D014372</infon><infon key="type">Chemical</infon><location offset="258" length="10"/><text>tubercidin</text></annotation><annotation id="24"><infon key="identifier">MESH:D014372</infon><infon key="type">Chemical</infon><location offset="392" length="10"/><text>tubercidin</text></annotation><annotation id="25"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="471" length="12"/><text>tuberculosis</text></annotation><annotation id="26"><infon key="identifier">MESH:D018088</infon><infon key="type">Disease</infon><location offset="485" length="6"/><text>MDR-TB</text></annotation><annotation id="27"><infon key="identifier">MESH:D000079822</infon><infon key="type">Disease</infon><location offset="509" length="11"/><text>extensively</text></annotation><annotation id="28"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="536" length="12"/><text>tuberculosis</text></annotation><annotation id="29"><infon key="identifier">MESH:D054908</infon><infon key="type">Disease</infon><location offset="554" length="6"/><text>XDR-TB</text></annotation><annotation id="30"><infon key="identifier">MESH:D000079822</infon><infon key="type">Disease</infon><location offset="574" length="11"/><text>extensively</text></annotation><annotation id="31"><infon key="identifier">MESH:D018088</infon><infon key="type">Disease</infon><location offset="590" length="23"/><text>-resistant tuberculosis</text></annotation><annotation id="32"><infon key="identifier">MESH:D054908</infon><infon key="type">Disease</infon><location offset="615" length="6"/><text>XDR-TB</text></annotation><annotation id="33"><infon key="type">Disease</infon><location offset="651" length="12"/><text>mycobacteria</text></annotation><annotation id="34"><infon key="identifier">MESH:C005843</infon><infon key="type">Chemical</infon><location offset="764" length="11"/><text>Alamar Blue</text></annotation><annotation id="35"><infon key="identifier">MESH:D014372</infon><infon key="type">Chemical</infon><location offset="823" length="10"/><text>tubercidin</text></annotation><annotation id="36"><infon key="identifier">MESH:D014372</infon><infon key="type">Chemical</infon><location offset="984" length="10"/><text>tubercidin</text></annotation><annotation id="37"><infon key="identifier">MESH:D009165</infon><infon key="type">Disease</infon><location offset="1038" length="24"/><text>mycobacterial infections</text></annotation></passage><relation id="R1"><infon key="score">0.9622</infon><infon key="role1">Chemical|MESH:D014372</infon><infon key="role2">Disease|MESH:D018088</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="5,7"/></relation><relation id="R2"><infon key="score">0.9959</infon><infon key="role1">Chemical|MESH:D014372</infon><infon key="role2">Disease|MESH:D009165</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="16,18"/></relation><relation id="R3"><infon key="score">0.9973</infon><infon key="role1">Chemical|MESH:D014372</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="1,3"/></relation><relation id="R4"><infon key="score">0.9676</infon><infon key="role1">Chemical|MESH:D014372</infon><infon key="role2">Disease|MESH:D054908</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="5,10"/></relation></document>
<document><id>37910357</id><passage><infon key="journal">Environ Sci Pollut Res Int;2023Nov01. doi:10.1007/s11356-023-30693-4</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Petrovi&amp;#x107; P, </infon><offset>0</offset><text>Innovations effect on CO2 emissions: asymmetric panel data approach.</text><annotation id="1"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="22" length="3"/><text>CO2</text></annotation></passage><passage><infon key="type">abstract</infon><offset>69</offset><text>The objective of this study is to uncover the nature and strength of the effect that innovations have on CO2 emissions. The main motivation of this research is to offer reliable and credible findings by eliminating some methodical and conceptual shortcomings of the existing papers. The scope of the analysis is examining the innovations-CO2 emissions relationship in a sample of 43 countries in the period from 1991 to 2018. The research is based on the application of hidden panel cointegration theory and the concept of a partially asymmetric cointegration equation. The main findings of the study demonstrate that when innovations grow by 1%, the pattern of their change leads to an increase in CO2 emissions by an average of 0.006%. At the same time, when innovations decline by 1%, their change leads to a reduction in CO2 emissions by an average of 0.001%. Strictly speaking, in the phase of innovations growth, they have environmentally hostile average influence, while in the phase of innovations reduction, their impact is on average environmentally friendly. The average effect of innovations is very asymmetric, because negative environmental impact is about six times stronger than the positive one. Analysis by countries demonstrates that innovations influence varies significantly from country to country. The impact is environmentally friendly in only 32.6% of countries, regardless of whether innovations increase or decrease. In the remaining cases, the influence on the environment is hostile either when innovations grow, when they decline, or in both situations. The main conclusion of this study is that nature of the impact of innovations on CO2 emissions is quite unfavorable, which points to the need for much greater support for green innovations.</text><annotation id="7"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="174" length="3"/><text>CO2</text></annotation><annotation id="8"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="407" length="3"/><text>CO2</text></annotation><annotation id="9"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="768" length="3"/><text>CO2</text></annotation><annotation id="10"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="894" length="3"/><text>CO2</text></annotation><annotation id="11"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1734" length="3"/><text>CO2</text></annotation></passage></document>
<document><id>37910708</id><passage><infon key="journal">Opt Lett;2023Nov01; 48 (21) 5583. doi:10.1364/OL.503909</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Angulo AM, Heine J, Duran Gomez JSS, Mahmudlu H, Haldar R, Klitis C, Sorel M, Kues M, </infon><offset>0</offset><text>Shaping the spectral correlation of bi-photon quantum frequency combs by multi-frequency excitation of an SOI integrated nonlinear resonator.</text></passage><passage><infon key="type">abstract</infon><offset>142</offset><text>We reveal the generation of a broadband (> 1.9 THz) bi-photon quantum frequency comb (QFC) in a silicon-on-insulator (SOI) Fabry-Perot micro-cavity and the control of its spectral correlation properties. Correlated photon pairs are generated through three spontaneous four-wave mixing (SFWM) processes by using a co-polarized bi-chromatic coherent input with power P1 and P2 on adjacent resonances of the nonlinear cavity. Adjusting the spectral power ratio r = P1/(P1 + P2) allows control over the influence of each process leading to an enhancement of the overall photon pair generation rate (PGR) mu(r) by a maximal factor of mu(r = 0.5)/mu(r = 0)   1.5, compared to the overall PGR provided by a single-pump configuration with the same power budget. We demonstrate that the efficiency aND of the non-degenerate excitation SFWM process (NDP) doubles the efficiency a1   a2 of the degenerate excitation SFWM processes (DP), showing a good agreement with the provided model.</text><annotation id="1"><infon key="identifier">MESH:D012825</infon><infon key="type">Chemical</infon><location offset="238" length="7"/><text>silicon</text></annotation></passage></document>
<document><id>37911059</id><passage><infon key="journal">Int Dent J (Phila);1893Feb; 14 (2) 148</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109606</infon><infon key="type">title</infon><infon key="authors">Hunt AO, </infon><offset>0</offset><text>The World's Columbian Dental Congress-Change of Time.</text></passage><passage><infon key="type">abstract</infon><offset>54</offset></passage></document>
<document><id>37911409</id><passage><infon key="journal">Int Dent J (Phila);1891Jul; 12 (7) 451</infon><infon key="year">1891</infon><infon key="article-id_pmc">PMC10110104</infon><infon key="type">title</infon><infon key="authors">Palmer SB, </infon><offset>0</offset><text>Secret Preparations.</text></passage><passage><infon key="type">abstract</infon><offset>21</offset></passage></document>
<document><id>37912109</id><passage><infon key="journal">Int Dent J (Phila);1896May; 17 (5) 327</infon><infon key="year">1896</infon><infon key="article-id_pmc">PMC10124491</infon><infon key="type">title</infon><offset>0</offset><text>Delayed Matter.</text></passage><passage><infon key="type">abstract</infon><offset>16</offset></passage></document>
<document><id>37912809</id><passage><infon key="journal">Int Dent J (Phila);1901Jul; 22 (7) 516</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153862</infon><infon key="type">title</infon><offset>0</offset><text>Miscellany.</text></passage><passage><infon key="type">abstract</infon><offset>12</offset></passage></document>
<document><id>37913159</id><passage><infon key="journal">Int Dent J (Phila);1903Jun; 24 (6) 478</infon><infon key="year">1903</infon><infon key="article-id_pmc">PMC10162244</infon><infon key="type">title</infon><infon key="authors">Peirce CN, </infon><offset>0</offset><text>The Older Methods of Filling Teeth.</text></passage><passage><infon key="type">abstract</infon><offset>36</offset></passage></document>
<document><id>37913510</id><passage><infon key="journal">N Engl J Med;2023Nov02; 389 (18) 1718. doi:10.1056/NEJMe2310338</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Laine L, </infon><offset>0</offset><text>Management of Bleeding Due to Small-Intestinal Angiodysplasias.</text><annotation id="2"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="14" length="8"/><text>Bleeding</text></annotation><annotation id="3"><infon key="identifier">MESH:D016888</infon><infon key="type">Disease</infon><location offset="30" length="32"/><text>Small-Intestinal Angiodysplasias</text></annotation></passage><passage><infon key="type">abstract</infon><offset>64</offset></passage></document>
<document><id>37913860</id><passage><infon key="journal">Neuroscience;2023Oct30. doi:10.1016/j.neuroscience.2023.10.021</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zheng A, Chen X, Xiang G, Li Q, Du X, Liu X, Xiao M, Chen H, </infon><offset>0</offset><text>Association between negative affect and perceived mortality threat during the COVID-19 pandemic: the role of brain activity and connectivity.</text><annotation id="3"><infon key="identifier">MESH:D019964</infon><infon key="type">Disease</infon><location offset="20" length="15"/><text>negative affect</text></annotation><annotation id="4"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="50" length="9"/><text>mortality</text></annotation><annotation id="5"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="78" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>142</offset><text>The prevalence of the novel coronavirus (COVID-19) has been considered a major threat to physical and mental health around the world, causing great pressure and mortality threat to most people. The current study aimed to investigate the neurological markers underlying the relationship between perceived mortality threat (PMT) and negative affect (NA). We examined whether the regional amplitude of low-frequency fluctuations (ALFF) and resting-state functional connectivity (RSFC) before the COVID-19 outbreak (October 2019 to December 2019, wave 1) were predictive for NA and PMT during the mid-term of the COVID-19 pandemic (February 22 to 28, 2020, wave 2) among 603 young adults (age range 17-22, 70.8% females). Results indicated that PMT was associated with spontaneous activity in several regions (e.g., inferior temporal gyrus, medial occipital gyrus, medial frontal gyrus, angular gyrus, and cerebellum) and their RSFC with the distributed regions of the default mode network and cognitive control network. Furthermore, longitudinal mediation models showed that ALFF in the cerebellum, medial occipital gyrus, medial frontal gyrus, and angular gyrus (wave 1) predicted PMT (wave 2) through NA (wave 2). These findings revealed functional neural markers of PMT and suggest candidate mechanisms for explaining the complex relationship between NA and mental/neural processing related to PMT in the circumstance of a major crisis.</text><annotation id="17"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="164" length="17"/><text>novel coronavirus</text></annotation><annotation id="18"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="183" length="8"/><text>COVID-19</text></annotation><annotation id="19"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="303" length="9"/><text>mortality</text></annotation><annotation id="20"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="446" length="9"/><text>mortality</text></annotation><annotation id="21"><infon key="identifier">MESH:D019964</infon><infon key="type">Disease</infon><location offset="473" length="15"/><text>negative affect</text></annotation><annotation id="22"><infon key="identifier">MESH:D019964</infon><infon key="type">Disease</infon><location offset="490" length="2"/><text>NA</text></annotation><annotation id="23"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="635" length="8"/><text>COVID-19</text></annotation><annotation id="24"><infon key="identifier">MESH:D019964</infon><infon key="type">Disease</infon><location offset="713" length="2"/><text>NA</text></annotation><annotation id="25"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="751" length="8"/><text>COVID-19</text></annotation><annotation id="26"><infon key="identifier">MESH:D019964</infon><infon key="type">Disease</infon><location offset="1342" length="2"/><text>NA</text></annotation><annotation id="27"><infon key="identifier">MESH:D019964</infon><infon key="type">Disease</infon><location offset="1493" length="2"/><text>NA</text></annotation></passage></document>
<document><id>37914560</id><passage><infon key="journal">Gait Posture;2023Oct26. doi:10.1016/j.gaitpost.2023.10.020</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jafarnezhadgero A, Givi AM, Hamlabadi MP, Sajedi H, Zago M, </infon><offset>0</offset><text>Muscle activation while running on the ground compared to artificial turf in males with pronated and supinated feet.</text></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>BACKGROUND: Running on different surfaces, including natural and artificial surfaces, requires different gait mechanics, especially in individuals with foot deformity. RESEARCH QUESTION: How muscle activity change during running on the ground and artificial turf in males with pronated and supinated feet? METHODS: In this quasi-experimental study, we assessed a cohort of young male subjects, classified as healthy (n = 10), and with pronated (n = 10) or supinated (n = 10) feet. An electromyographic system was used to record lower limb muscle activity while running on the ground and artificial turf at constant speed (3.2 m/s). RESULTS: Results demonstrated significant main effects of the "surface" factor for vastus medialis activity during the loading phase (p = 0.040, eta2 =0.147). Paired comparison revealed significantly greater vastus medialis activity while running on artificial grass with respect to the ground. A significant effect of the "group" factor was found for medial gastrocnemius during loading phase (p = 0.020, eta2 =0.250). Paired-wise comparison revealed significantly lower medial gastrocnemius activity in the pronated and supinated feet groups than in the healthy group. SIGNIFICANCE: The healthy group may possess better neuromuscular control, allowing them to effectively coordinate the activation of the medial gastrocnemius with other muscles involved in running. Based on these findings, running on artificial turf is useful when the runner would like to strengthen vastus medialis muscle. The runner should carefully choose the running surface according to his/her state and training session goal.</text><annotation id="1"><infon key="identifier">MESH:D005530</infon><infon key="type">Disease</infon><location offset="269" length="14"/><text>foot deformity</text></annotation></passage></document>
<document><id>37914910</id><passage><infon key="journal">Nat Rev Genet;2023Nov01. doi:10.1038/s41576-023-00673-y</infon><infon key="year">2023</infon><infon key="article-id_pmc">10567551</infon><infon key="type">title</infon><infon key="authors">Attwaters M, </infon><offset>0</offset><text>A genetic atlas of the human blood proteome.</text></passage><passage><infon key="type">abstract</infon><offset>45</offset></passage></document>
<document><id>37915262</id><passage><infon key="journal">ESC Heart Fail;2023Nov01. doi:10.1002/ehf2.14441</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lim HS, </infon><offset>0</offset><text>A novel 'shunt fraction' method to derive native cardiac output during liberation from central VA ECMO.</text></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>The Fick principle is an established method to quantify intracardiac shunts. The Fick principle has also found utility in the practice of extracorporeal membrane oxygenation (ECMO). This report describes a novel 'shunt fraction' method to calculate intrinsic cardiac output in central (right atrial-to-aorta) ECMO. The physiological basis of this 'shunt fraction' method is described, followed by the case presentation that details the clinical application of this method of quantifying intrinsic cardiac output to guide weaning and liberation from central VA ECMO.</text><annotation id="1"><infon key="identifier">MESH:C562451</infon><infon key="type">Disease</infon><location offset="160" length="19"/><text>intracardiac shunts</text></annotation></passage></document>
<document><id>37916312</id><passage><infon key="journal">Haematologica;2023Nov02. doi:10.3324/haematol.2022.282099</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Alcedo Andrade PE, Mannucci PM, Kessler CM, </infon><offset>0</offset><text>Emicizumab: the hemophilia A game changer.</text><annotation id="2"><infon key="identifier">MESH:C000608208</infon><infon key="type">Chemical</infon><location offset="0" length="10"/><text>Emicizumab</text></annotation><annotation id="3"><infon key="identifier">MESH:D006467</infon><infon key="type">Disease</infon><location offset="16" length="12"/><text>hemophilia A</text></annotation></passage><passage><infon key="type">abstract</infon><offset>43</offset><text>In hemophilia, the unmet needs regarding adherence to prophylaxis and lack of effective longterm prophylaxis regimens, especially in patients with inhibitors, led to the production of emicizumab, the first non-factor medicine for subcutaneous administration in patients with severe and moderate hemophilia A with or without factor VIII inhibitors. This article describes the research steps behind the development of this game-changer medication, its success for the prophylaxis of bleeding episodes as witnessed by the results of pivotal clinical trial but also by real life use in the frame of a still expanding global market. We shall also discuss potential and actual adverse events and the nuances related to clinical use such as laboratory monitoring, development of neutralizing anti-drug-antibodies, risk of thrombosis/hypercoagulability and use in the management of surgical operations. The potential of using emicizumab to prevent bleeding in other congenital and acquired coagulation disorders will also be sketched.</text><annotation id="14"><infon key="identifier">MESH:D006467</infon><infon key="type">Disease</infon><location offset="46" length="10"/><text>hemophilia</text></annotation><annotation id="15"><infon key="identifier">MESH:C000608208</infon><infon key="type">Chemical</infon><location offset="227" length="10"/><text>emicizumab</text></annotation><annotation id="16"><infon key="identifier">MESH:D006467</infon><infon key="type">Disease</infon><location offset="338" length="12"/><text>hemophilia A</text></annotation><annotation id="17"><infon key="identifier">MESH:D006467</infon><infon key="type">Disease</infon><location offset="367" length="22"/><text>factor VIII inhibitors</text></annotation><annotation id="18"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="524" length="8"/><text>bleeding</text></annotation><annotation id="19"><infon key="identifier">MESH:D013927</infon><infon key="type">Disease</infon><location offset="858" length="10"/><text>thrombosis</text></annotation><annotation id="20"><infon key="identifier">MESH:D019851</infon><infon key="type">Disease</infon><location offset="869" length="18"/><text>hypercoagulability</text></annotation><annotation id="21"><infon key="identifier">MESH:C000608208</infon><infon key="type">Chemical</infon><location offset="961" length="10"/><text>emicizumab</text></annotation><annotation id="22"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="983" length="8"/><text>bleeding</text></annotation><annotation id="23"><infon key="identifier">MESH:D025861</infon><infon key="type">Disease</infon><location offset="1001" length="45"/><text>congenital and acquired coagulation disorders</text></annotation></passage><relation id="R1"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:C000608208</infon><infon key="role2">Disease|MESH:D006470</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="9,10"/></relation><relation id="R2"><infon key="score">0.9959</infon><infon key="role1">Chemical|MESH:C000608208</infon><infon key="role2">Disease|MESH:D006467</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.9967</infon><infon key="role1">Chemical|MESH:C000608208</infon><infon key="role2">Disease|MESH:D025861</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="9,11"/></relation></document>
<document><id>37917020</id><passage><infon key="journal">J Stud Alcohol Drugs;2023Oct30. doi:10.15288/jsad.22-00372</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Clifford PR, Davis CM, Maisto SA, Stout RL, </infon><offset>0</offset><text>FRAMES Elements Associated with Alcohol Treatment Research Assessments and Related Behavior Change.</text><annotation id="1"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="32" length="7"/><text>Alcohol</text></annotation></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>OBJECTIVE: Assessment reactivity research has contributed substantially to our understanding of alcohol treatment research protocols influencing clinical outcomes. The state of the science is such that relatively little is known about how alcohol treatment research participation influences behavior. The purpose of this study was twofold: 1) to determine the distribution of FRAMES elements (i.e., Feedback, personal Responsibility, Advice, a Menu of options, Empathic style of interaction, and support for Self-efficacy) contained in alcohol treatment research assessment interviews; and 2) to examine their association with subsequent alcohol use among a sample of clients presenting for alcohol use disorder (AUD) treatment. METHODS: Audiotaped recordings of participant (N=189) research assessment interviews were converted to digital recordings and reviewed for FRAMES elements using the FRAMES Checklist Instrument (FCI). RESULTS: Feedback, personal Responsibility, Empathic style of interaction, and support for Self-efficacy were the more frequently occurring elements across follow-up periods. Alternatively, Menu of options and Advice occurred infrequently. Feedback and support for Self-efficacy predicted subsequent alcohol use, although the association between Feedback and alcohol use was unexpectedly positive. CONCLUSIONS: As part of the assessment interview process, alcohol treatment research participants receive multiple instances of Feedback and support for Self-efficacy specific to their alcohol use that are predictive of changes in alcohol use.</text><annotation id="13"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="196" length="7"/><text>alcohol</text></annotation><annotation id="14"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="339" length="7"/><text>alcohol</text></annotation><annotation id="15"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="636" length="7"/><text>alcohol</text></annotation><annotation id="16"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="738" length="7"/><text>alcohol</text></annotation><annotation id="17"><infon key="identifier">MESH:D000437</infon><infon key="type">Disease</infon><location offset="791" length="20"/><text>alcohol use disorder</text></annotation><annotation id="18"><infon key="identifier">MESH:D000437</infon><infon key="type">Disease</infon><location offset="813" length="3"/><text>AUD</text></annotation><annotation id="19"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1329" length="7"/><text>alcohol</text></annotation><annotation id="20"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1388" length="7"/><text>alcohol</text></annotation><annotation id="21"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1485" length="7"/><text>alcohol</text></annotation><annotation id="22"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1612" length="7"/><text>alcohol</text></annotation><annotation id="23"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1658" length="7"/><text>alcohol</text></annotation></passage></document>
<document><id>37917370</id><passage><infon key="journal">Naunyn Schmiedebergs Arch Pharmacol;2023Nov02. doi:10.1007/s00210-023-02809-7</infon><infon key="year">2023</infon><infon key="article-id_pmc">9467421</infon><infon key="type">title</infon><infon key="authors">Bhat AA, Gupta G, Goyal A, Thapa R, Almalki WH, Kazmi I, Alzarea SI, Kukreti N, Sekar M, Meenakshi DU, Singh SK, MacLoughlin R, Dua K, </infon><offset>0</offset><text>Unwinding circular RNA's role in inflammatory pulmonary diseases.</text><annotation id="1"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="33" length="31"/><text>inflammatory pulmonary diseases</text></annotation></passage><passage><infon key="type">abstract</infon><offset>66</offset><text>Circular RNAs (circRNAs) have emerged as pivotal regulators of gene expression and cellular processes in various physiological and pathological conditions. In recent years, there has been a growing interest in investigating the role of circRNAs in inflammatory lung diseases, owing to their potential to modulate inflammation-associated pathways and contribute to disease pathogenesis. Inflammatory lung diseases, like asthma, chronic obstructive pulmonary disease (COPD), and COVID-19, pose significant global health challenges. The dysregulation of inflammatory responses demonstrates a pivotal function in advancing these diseases. CircRNAs have been identified as important players in regulating inflammation by functioning as miRNA sponges, engaging with RNA-binding proteins, and participating in intricate ceRNA networks. These interactions enable circRNAs to regulate the manifestation of key inflammatory genes and signaling pathways. Furthermore, emerging evidence suggests that specific circRNAs are differentially expressed in response to inflammatory stimuli and exhibit distinct patterns in various lung diseases. Their involvement in immune cell activation, cytokine production, and tissue remodeling processes underscores their possible capabilities as therapeutic targets and diagnostic biomarkers. Harnessing the knowledge of circRNA-mediated regulation in inflammatory lung diseases could lead to the development of innovative strategies for disease management and intervention. This review summarizes the current understanding of the role of circRNAs in inflammatory lung diseases, focusing on their regulatory mechanisms and functional implications.</text><annotation id="16"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="314" length="26"/><text>inflammatory lung diseases</text></annotation><annotation id="17"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="379" length="12"/><text>inflammation</text></annotation><annotation id="18"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="452" length="26"/><text>Inflammatory lung diseases</text></annotation><annotation id="19"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="485" length="6"/><text>asthma</text></annotation><annotation id="20"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="493" length="37"/><text>chronic obstructive pulmonary disease</text></annotation><annotation id="21"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="532" length="4"/><text>COPD</text></annotation><annotation id="22"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="543" length="8"/><text>COVID-19</text></annotation><annotation id="23"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="617" length="12"/><text>inflammatory</text></annotation><annotation id="24"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="766" length="12"/><text>inflammation</text></annotation><annotation id="25"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="967" length="12"/><text>inflammatory</text></annotation><annotation id="26"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1117" length="12"/><text>inflammatory</text></annotation><annotation id="27"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="1179" length="13"/><text>lung diseases</text></annotation><annotation id="28"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="1441" length="26"/><text>inflammatory lung diseases</text></annotation><annotation id="29"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="1640" length="26"/><text>inflammatory lung diseases</text></annotation></passage></document>
<document><id>37917721</id><passage><infon key="journal">PLoS One;2023; 18 (11) 0287894. doi:10.1371/journal.pone.0287894</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tang W, Chen Y, Guo F, </infon><offset>0</offset><text>Effects of topping on rhizome, and analysis of chemical composition, antioxidant activity and alpha-amylase and alpha-glucosidase inhibition of the aerial parts in Polygonatum cyrtonema.</text></passage><passage><infon key="type">abstract</infon><offset>187</offset><text>Polygonatum cyrtonema is a perennial plant, and it has long been used in traditional Chinese medicine for food and medicine. The medicinal part of P.cyrtonema is the rhizome; however, the aerial part has not been studied. To understand the effect of the topping of aerial parts on the yield and chemical components of rhizomes, as well as the chemical constituents, antioxidant, and in vitro hypoglycemic activities of the aerial stem, leave, and flower parts of P.cyrtonema, the present study was conducted. The results showed that compared to the control (CK) treatment, the topping of the aerial part increased rhizome weight gain coefficient (3.43) and the total saponin content (37.60 mg/g) significantly (P&lt;0.01) than the CK treatment. The contents of total phenols and total flavonoids in PCL and PCF were significantly (P&lt;0.01) higher than those in rhizomes; however, the polysaccharide content (10.47%) in PCR (whole rhizome) was higher than that in PCS (3.65%), PCL (5.99%), and PCF (4.76%) content. The protein and amino acid contents in PCS, PCL, and PCF were higher than those in rhizomes. The protein and amino acid contents in PCS, PCL, and PCF were higher than those in rhizomes. PCS, PCL, and PCF showed strong antioxidant activity (DPPH,  OH, ABTS, and FRAP), which were better than traditional medicinal parts (the rhizome).In vitro hypoglycemic results showed that PCS, PCL, and PCF had certain inhibitory activities on alpha-amylase and alpha-glucosidase (66.25% and 52.81%), which were close to the hypoglycemic activity of rhizomes (67.96% and 52.22%). The leaf extracts also showed better inhibitory activity. To sum up, the topping measures can improve yield and total saponin content of the rhizomes from P.cyrtonema, which can be applied to improve production. The stems, leaves, and flowers had a much stronger antioxidant and hypoglycemic activities and higher the total polyphenols, flavonoids, proteins, and amino acid content. Therefore, stems, leaves, and flowers of Polygonatum can be fully developed according to different needs. they are typically used in animal feed, food storage and cosmetics.</text><annotation id="19"><infon key="identifier">MESH:C000721848</infon><infon key="type">Disease</infon><location offset="579" length="12"/><text>hypoglycemic</text></annotation><annotation id="20"><infon key="identifier">MESH:D012503</infon><infon key="type">Chemical</infon><location offset="854" length="7"/><text>saponin</text></annotation><annotation id="21"><infon key="identifier">MESH:D010636</infon><infon key="type">Chemical</infon><location offset="951" length="7"/><text>phenols</text></annotation><annotation id="22"><infon key="identifier">MESH:D005419</infon><infon key="type">Chemical</infon><location offset="969" length="10"/><text>flavonoids</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="991" length="3"/><text>PCF</text></annotation><annotation id="24"><infon key="identifier">MESH:D011134</infon><infon key="type">Chemical</infon><location offset="1067" length="14"/><text>polysaccharide</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1176" length="3"/><text>PCF</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1250" length="3"/><text>PCF</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1343" length="3"/><text>PCF</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1397" length="3"/><text>PCF</text></annotation><annotation id="29"><infon key="identifier">MESH:C004931</infon><infon key="type">Chemical</infon><location offset="1437" length="4"/><text>DPPH</text></annotation><annotation id="30"><infon key="identifier">MESH:C002502</infon><infon key="type">Chemical</infon><location offset="1448" length="4"/><text>ABTS</text></annotation><annotation id="31"><infon key="identifier">MESH:C000721848</infon><infon key="type">Disease</infon><location offset="1539" length="12"/><text>hypoglycemic</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1586" length="3"/><text>PCF</text></annotation><annotation id="33"><infon key="identifier">MESH:C000721848</infon><infon key="type">Disease</infon><location offset="1708" length="12"/><text>hypoglycemic</text></annotation><annotation id="34"><infon key="identifier">MESH:D012503</infon><infon key="type">Chemical</infon><location offset="1881" length="7"/><text>saponin</text></annotation><annotation id="35"><infon key="identifier">MESH:C000721848</infon><infon key="type">Disease</infon><location offset="2042" length="12"/><text>hypoglycemic</text></annotation><annotation id="36"><infon key="identifier">MESH:D059808</infon><infon key="type">Chemical</infon><location offset="2087" length="11"/><text>polyphenols</text></annotation><annotation id="37"><infon key="identifier">MESH:D005419</infon><infon key="type">Chemical</infon><location offset="2100" length="10"/><text>flavonoids</text></annotation></passage><relation id="R1"><infon key="score">0.9009</infon><infon key="role1">Chemical|MESH:D059808</infon><infon key="role2">Disease|MESH:C000721848</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="20,19"/></relation></document>
<document><id>37918072</id><passage><infon key="journal">J Hazard Mater;2023Oct28; 463 132885. doi:10.1016/j.jhazmat.2023.132885</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yang Y, Zhong Z, Du H, Li Q, Zheng X, Qi R, Ren P, </infon><offset>0</offset><text>Experimental and theoretical study to control the heavy metals in solid waste and sludge during pyrolysis using modified expanded vermiculite.</text><annotation id="2"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="50" length="12"/><text>heavy metals</text></annotation><annotation id="3"><infon key="identifier">MESH:C003760</infon><infon key="type">Chemical</infon><location offset="130" length="11"/><text>vermiculite</text></annotation></passage><passage><infon key="type">abstract</infon><offset>143</offset><text>Na+/K+/Mg2+/Ca2+ expansion-modified vermiculite and calcination expansion (700  C, 800  C and 900  C)-modified vermiculite (700-Mg-V, 800-Mg-V and 900-Mg-V) were prepared as additives to control the emission of five heavy metals (Zn, Cr, Cu, Pb, and Cd) during the pyrolysis of municipal sewage sludge, paper mill sludge, municipal domestic waste, and aged refuse. Mg2+-Modified vermiculite obtained via thermally activated calcination at 800  C retained 65% of heavy metals from all raw materials at 450  C. Zn, Cr, and Cu retained nearly 90%. Although modified vermiculite could reduce the ecological risk, Cd had an ecological risk level higher than Zn, Cr, Cu, and Pb. The fine textural properties, laminated morphology, and expansion capacity of modified vermiculite were positively correlated with its retention of heavy metals. Heavy metals interacted with the (002) surface of vermiculite, and the reactions were mainly concentrated near the 17-O and surrounding atoms. The heavy-metal monomers were less capable of binding to the (002) surface of vermiculite than the oxides and chlorides of heavy metals. The effect of heavy-metal oxides and chlorides binding to the (002) surface of vermiculite was related to heavy metals.</text><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="150" length="4"/><text>Mg2+</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="155" length="4"/><text>Ca2+</text></annotation><annotation id="45"><infon key="identifier">MESH:C003760</infon><infon key="type">Chemical</infon><location offset="179" length="11"/><text>vermiculite</text></annotation><annotation id="46"><infon key="identifier">MESH:C003760</infon><infon key="type">Chemical</infon><location offset="254" length="11"/><text>vermiculite</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="271" length="4"/><text>Mg-V</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="281" length="4"/><text>Mg-V</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="294" length="4"/><text>Mg-V</text></annotation><annotation id="50"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="359" length="12"/><text>heavy metals</text></annotation><annotation id="51"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="373" length="2"/><text>Zn</text></annotation><annotation id="52"><infon key="identifier">MESH:D002857</infon><infon key="type">Chemical</infon><location offset="377" length="2"/><text>Cr</text></annotation><annotation id="53"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="381" length="2"/><text>Cu</text></annotation><annotation id="54"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="385" length="2"/><text>Pb</text></annotation><annotation id="55"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="393" length="2"/><text>Cd</text></annotation><annotation id="56"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="446" length="10"/><text>paper mill</text></annotation><annotation id="57"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="508" length="4"/><text>Mg2+</text></annotation><annotation id="58"><infon key="identifier">MESH:C003760</infon><infon key="type">Chemical</infon><location offset="522" length="11"/><text>vermiculite</text></annotation><annotation id="59"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="605" length="12"/><text>heavy metals</text></annotation><annotation id="60"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="652" length="2"/><text>Zn</text></annotation><annotation id="61"><infon key="identifier">MESH:D002857</infon><infon key="type">Chemical</infon><location offset="656" length="2"/><text>Cr</text></annotation><annotation id="62"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="664" length="2"/><text>Cu</text></annotation><annotation id="63"><infon key="identifier">MESH:C003760</infon><infon key="type">Chemical</infon><location offset="706" length="11"/><text>vermiculite</text></annotation><annotation id="64"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="752" length="2"/><text>Cd</text></annotation><annotation id="65"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="796" length="2"/><text>Zn</text></annotation><annotation id="66"><infon key="identifier">MESH:D002857</infon><infon key="type">Chemical</infon><location offset="800" length="2"/><text>Cr</text></annotation><annotation id="67"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="804" length="2"/><text>Cu</text></annotation><annotation id="68"><infon key="identifier">MESH:D007854</infon><infon key="type">Chemical</infon><location offset="812" length="2"/><text>Pb</text></annotation><annotation id="69"><infon key="identifier">MESH:C003760</infon><infon key="type">Chemical</infon><location offset="903" length="11"/><text>vermiculite</text></annotation><annotation id="70"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="964" length="12"/><text>heavy metals</text></annotation><annotation id="71"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="978" length="12"/><text>Heavy metals</text></annotation><annotation id="72"><infon key="identifier">MESH:C003760</infon><infon key="type">Chemical</infon><location offset="1028" length="11"/><text>vermiculite</text></annotation><annotation id="73"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="1125" length="11"/><text>heavy-metal</text></annotation><annotation id="74"><infon key="identifier">MESH:C003760</infon><infon key="type">Chemical</infon><location offset="1199" length="11"/><text>vermiculite</text></annotation><annotation id="75"><infon key="identifier">MESH:D010087</infon><infon key="type">Chemical</infon><location offset="1220" length="6"/><text>oxides</text></annotation><annotation id="76"><infon key="identifier">MESH:D002712</infon><infon key="type">Chemical</infon><location offset="1231" length="9"/><text>chlorides</text></annotation><annotation id="77"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="1244" length="12"/><text>heavy metals</text></annotation><annotation id="78"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1272" length="18"/><text>heavy-metal oxides</text></annotation><annotation id="79"><infon key="identifier">MESH:D002712</infon><infon key="type">Chemical</infon><location offset="1295" length="9"/><text>chlorides</text></annotation><annotation id="80"><infon key="identifier">MESH:C003760</infon><infon key="type">Chemical</infon><location offset="1337" length="11"/><text>vermiculite</text></annotation><annotation id="81"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="1364" length="12"/><text>heavy metals</text></annotation></passage><relation id="R1"><infon key="score">0.8138</infon><infon key="role1">Chemical|MESH:C003760</infon><infon key="role2">Chemical|MESH:D002104</infon><infon key="type">Association</infon><node refid="0" role="6,16"/></relation><relation id="R2"><infon key="score">0.8755</infon><infon key="role1">Chemical|MESH:C003760</infon><infon key="role2">Chemical|MESH:D007854</infon><infon key="type">Association</infon><node refid="1" role="6,15"/></relation><relation id="R3"><infon key="score">0.5594</infon><infon key="role1">Chemical|MESH:C003760</infon><infon key="role2">Chemical|MESH:D002857</infon><infon key="type">Association</infon><node refid="2" role="6,13"/></relation><relation id="R4"><infon key="score">0.9821</infon><infon key="role1">Chemical|MESH:C003760</infon><infon key="role2">Chemical|MESH:D019216</infon><infon key="type">Association</infon><node refid="3" role="1,0"/></relation><relation id="R5"><infon key="score">0.6575</infon><infon key="role1">Chemical|MESH:C003760</infon><infon key="role2">Chemical|MESH:D015032</infon><infon key="type">Association</infon><node refid="4" role="6,12"/></relation></document>
<document><id>37918422</id><passage><infon key="journal">J Biomater Appl;2023Nov02 8853282231209653. doi:10.1177/08853282231209653</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhao Q, Yue X, Miaomiao L, Yanming W, Wu G, </infon><offset>0</offset><text>Nano-injectable pH/NIR-responsive hydrogel for chemo-photothermal synergistic drug delivery.</text></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>Conventional cancer treatments are highly toxic and ineffective; therefore, it is essential to develop less toxic and minimally invasive treatment methods. A pH/Near Infra-red (NIR) dual-responsive, nano-injectable smart hydrogel was fabricated by incorporating CuS nanoparticles into the hydrogel networks formed by a random copolymer of N-isopropylacrylamide (NIPAM) and double-bond functionalized uracil. Microstructural characterizations of synthesized polymer and hydrogels were carried out using transmission electron microscope (TEM), scanning electron microscope (SEM), nuclear magnetic resonance (NMR) and fourier transform infrared spectroscopy (FT-IR). Multiple hydrogen bonding interactions between uracils function as physical cross-linking points to construct the network structure of the polymeric nanogel without the addition of additional cross-linking agents, ensuring the material's safety. The amino group on the structure of uracil gives the uracil-modified polymeric hydrogel excellent pH responsiveness. Notably, as a temperature-responsive material, poly (N-isopropylacrylamide) (PNIPAM) nanogel solution can achieve in situ gel formation (within 100 s at 37 C) above its lower critical solution temperature (LCST), granting injectability to polymeric solutions. Moreover, using a hierarchical construction strategy, the variable loading of DOX and CuS was achieved. First, a heterogeneous system was created by encapsulating doxorubicin (DOX) inside the nanogel via hydrophobic and pi-pi stacking interactions, followed by the introduction of CuS nanoparticles as photosensitizers outside of the nanogels. Due to the presence of CuS nanoparticles, the gel is able to convert NIR light into local heat to enhance the destruction of tumor cells while simultaneously achieving rapid in situ gel formation. The in situ-forming hydrogel showed promising tissue biocompatibility. The in vitro antitumor test demonstrated the capacity of the nanocomposite hydrogel for chemo-photothermal synergistic therapy. Therefore, this prepared platform has the potential to become a safe and effective, smart-responsive drug carrier for chemotherapy and PTT synergy, a minimally invasive material for tumor treatment.</text><annotation id="20"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="106" length="6"/><text>cancer</text></annotation><annotation id="21"><infon key="identifier">MESH:C017846</infon><infon key="type">Chemical</infon><location offset="355" length="3"/><text>CuS</text></annotation><annotation id="22"><infon key="identifier">MESH:C067295</infon><infon key="type">Chemical</infon><location offset="432" length="21"/><text>N-isopropylacrylamide</text></annotation><annotation id="23"><infon key="identifier">MESH:C067295</infon><infon key="type">Chemical</infon><location offset="455" length="5"/><text>NIPAM</text></annotation><annotation id="24"><infon key="identifier">MESH:D014498</infon><infon key="type">Chemical</infon><location offset="493" length="6"/><text>uracil</text></annotation><annotation id="25"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="550" length="7"/><text>polymer</text></annotation><annotation id="26"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="766" length="8"/><text>hydrogen</text></annotation><annotation id="27"><infon key="identifier">MESH:D014498</infon><infon key="type">Chemical</infon><location offset="804" length="7"/><text>uracils</text></annotation><annotation id="28"><infon key="identifier">MESH:D014498</infon><infon key="type">Chemical</infon><location offset="1039" length="6"/><text>uracil</text></annotation><annotation id="29"><infon key="identifier">MESH:D014498</infon><infon key="type">Chemical</infon><location offset="1056" length="6"/><text>uracil</text></annotation><annotation id="30"><infon key="identifier">MESH:C052970</infon><infon key="type">Chemical</infon><location offset="1167" length="28"/><text>poly (N-isopropylacrylamide)</text></annotation><annotation id="31"><infon key="identifier">MESH:C052970</infon><infon key="type">Chemical</infon><location offset="1197" length="6"/><text>PNIPAM</text></annotation><annotation id="32"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1458" length="3"/><text>DOX</text></annotation><annotation id="33"><infon key="identifier">MESH:C017846</infon><infon key="type">Chemical</infon><location offset="1466" length="3"/><text>CuS</text></annotation><annotation id="34"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1543" length="11"/><text>doxorubicin</text></annotation><annotation id="35"><infon key="identifier">MESH:D004317</infon><infon key="type">Chemical</infon><location offset="1556" length="3"/><text>DOX</text></annotation><annotation id="36"><infon key="identifier">MESH:C017846</infon><infon key="type">Chemical</infon><location offset="1661" length="3"/><text>CuS</text></annotation><annotation id="37"><infon key="identifier">MESH:C017846</infon><infon key="type">Chemical</infon><location offset="1747" length="3"/><text>CuS</text></annotation><annotation id="38"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1849" length="5"/><text>tumor</text></annotation><annotation id="39"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="2302" length="5"/><text>tumor</text></annotation></passage><relation id="R1"><infon key="score">0.9981</infon><infon key="role1">Chemical|MESH:C017846</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="17,18"/></relation></document>
<document><id>37918772</id><passage><infon key="journal">Environ Pollut;2023Oct31 122844. doi:10.1016/j.envpol.2023.122844</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zheng X, Tang J, Song A, Zhou Y, Miao J, Li Z, Pan L, </infon><offset>0</offset><text>Study on reproductive endocrine disturbance and DNA damage mechanism of female Ruditapes philippinarum under Benzo[a]pyrene stress.</text><annotation id="2"><infon key="identifier">MESH:D004700</infon><infon key="type">Disease</infon><location offset="9" length="34"/><text>reproductive endocrine disturbance</text></annotation><annotation id="3"><infon key="identifier">MESH:D001564</infon><infon key="type">Chemical</infon><location offset="109" length="14"/><text>Benzo[a]pyrene</text></annotation></passage><passage><infon key="type">abstract</infon><offset>132</offset><text>The reproductive toxicity of polycyclic aromatic hydrocarbons (PAHs) in aquatic organisms has attracted increasing attention from scholars. Currently, research in this field primarily focuses on vertebrates such as zebrafish and other model species. However, there is still a significant knowledge gap in the toxicity of PAHs to invertebrates and its potential mechanisms. Benzo[a]pyrene (B[a]P) is one of the most representative PAHs. In this study, female Ruditapes philippinarum (R. philippinarum) was treated with B[a]P concentrations of 0, 0.8, 4, and 20 mug/L to investigate reproductive indicators in the proliferative, growth, mature, and spawn stages. Transcriptomics was used to investigate the expression of genes associated with the reproductive endocrine system, DNA repair, autophagy, apoptosis, and ovarian development at different reproductive stages. Our results suggested that B[a]P disrupted the endocrine system by interfering with the production of steroid hormones and the transmission of estrogen signals in female R. philippinarum. The structure of the ovarian DNA duplex is severely damaged under the stress of B[a]P, and a series of cellular responses caused by DNA damage are also interfered. Additionally, we observed a reduction in the gonadosomatic index (GSI) and mature oocytes numbers after B[a]P exposed. Tissue section indicated that severe damage to the ovarian structure at mature and spawn stages. In conclusion, this study combined transcriptomic and toxicological to explore the negative effects on ovarian development induced by B[a]P, focusing on reproductive endocrine disturbance and DNA damage.</text><annotation id="19"><infon key="identifier">MESH:D060737</infon><infon key="type">Disease</infon><location offset="136" length="21"/><text>reproductive toxicity</text></annotation><annotation id="20"><infon key="identifier">MESH:D011084</infon><infon key="type">Chemical</infon><location offset="161" length="32"/><text>polycyclic aromatic hydrocarbons</text></annotation><annotation id="21"><infon key="identifier">MESH:D011084</infon><infon key="type">Chemical</infon><location offset="195" length="4"/><text>PAHs</text></annotation><annotation id="22"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="441" length="8"/><text>toxicity</text></annotation><annotation id="23"><infon key="identifier">MESH:D011084</infon><infon key="type">Chemical</infon><location offset="453" length="4"/><text>PAHs</text></annotation><annotation id="24"><infon key="identifier">MESH:D001564</infon><infon key="type">Chemical</infon><location offset="505" length="14"/><text>Benzo[a]pyrene</text></annotation><annotation id="25"><infon key="identifier">MESH:D001564</infon><infon key="type">Chemical</infon><location offset="521" length="5"/><text>B[a]P</text></annotation><annotation id="26"><infon key="identifier">MESH:D011084</infon><infon key="type">Chemical</infon><location offset="562" length="4"/><text>PAHs</text></annotation><annotation id="27"><infon key="identifier">MESH:D001564</infon><infon key="type">Chemical</infon><location offset="650" length="5"/><text>B[a]P</text></annotation><annotation id="28"><infon key="identifier">MESH:D001564</infon><infon key="type">Chemical</infon><location offset="1027" length="5"/><text>B[a]P</text></annotation><annotation id="29"><infon key="identifier">MESH:D013256</infon><infon key="type">Chemical</infon><location offset="1102" length="16"/><text>steroid hormones</text></annotation><annotation id="30"><infon key="identifier">MESH:D001564</infon><infon key="type">Chemical</infon><location offset="1268" length="5"/><text>B[a]P</text></annotation><annotation id="31"><infon key="identifier">MESH:D001564</infon><infon key="type">Chemical</infon><location offset="1456" length="5"/><text>B[a]P</text></annotation><annotation id="32"><infon key="identifier">MESH:D001564</infon><infon key="type">Chemical</infon><location offset="1702" length="5"/><text>B[a]P</text></annotation><annotation id="33"><infon key="identifier">MESH:D004700</infon><infon key="type">Disease</infon><location offset="1721" length="34"/><text>reproductive endocrine disturbance</text></annotation></passage><relation id="R1"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D001564</infon><infon key="role2">Disease|MESH:D004700</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9956</infon><infon key="role1">Chemical|MESH:D001564</infon><infon key="role2">Chemical|MESH:D013256</infon><infon key="type">Association</infon><node refid="1" role="11,12"/></relation></document>
<document><id>37919122</id><passage><infon key="journal">Eur J Intern Med;2023Oct31. doi:10.1016/j.ejim.2023.10.029</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Guarino D, Ballerini A, Manes A, </infon><offset>0</offset><text>What changed after the 2022 guidelines for pulmonary hypertension?</text><annotation id="1"><infon key="identifier">MESH:D006976</infon><infon key="type">Disease</infon><location offset="43" length="22"/><text>pulmonary hypertension</text></annotation></passage><passage><infon key="type">abstract</infon><offset>67</offset></passage></document>
<document><id>37919472</id><passage><infon key="journal">Sci Rep;2023Nov02; 13 (1) 18942. doi:10.1038/s41598-023-46412-5</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nakazawa T, Kishi S, </infon><offset>0</offset><text>Author Correction: Pollinator sex matters in competition and coexistence of co-flowering plants.</text></passage><passage><infon key="type">abstract</infon><offset>97</offset></passage></document>
<document><id>37921222</id><passage><infon key="journal">J Child Sex Abus;2023Jul-Dec; 32 (7) 860. doi:10.1080/10538712.2023.2273311</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Young JA, Mann-Williams A, </infon><offset>0</offset><text>Evaluating the Effectiveness of a Live Musical Theater-Based Approach to Child Sexual Abuse Prevention in Elementary Schools.</text><annotation id="1"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="73" length="18"/><text>Child Sexual Abuse</text></annotation></passage><passage><infon key="type">abstract</infon><offset>126</offset><text>Hugs and Kisses is a theater-based child sexual abuse (CSA) prevention program designed for children in kindergarten through fifth grades. The purpose of this cross-sectional case study is to evaluate how a comprehensive live musical theater program can prepare teachers to discuss and identify the signs of CSA, help children increase their knowledge, and learn prevention strategies to stop CSA in the future. A total of 154 teachers and 2,700 children from 31 schools participated in this program during 2016. Findings show this program increases children's awareness of touch and action knowledge through five primary safety lessons taught during the program and reinforced by a teacher led in-person discussion after the play. Nearly 85% of the students across all grade levels in this sample understood the lessons taught in the play, and students whose teachers held an in-class discussion after the play scored better than those students whose teachers did not hold a discussion. Teachers who were prepared with training resources also held longer in-class discussions compared to those who were not prepared. The Hugs play has the potential to be a national model for evidence-based CSA programs.</text><annotation id="7"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="161" length="18"/><text>child sexual abuse</text></annotation><annotation id="8"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="181" length="3"/><text>CSA</text></annotation><annotation id="9"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="434" length="3"/><text>CSA</text></annotation><annotation id="10"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="519" length="3"/><text>CSA</text></annotation><annotation id="11"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="1318" length="3"/><text>CSA</text></annotation></passage></document>
<document><id>37921572</id><passage><infon key="journal">New Phytol;2023Nov03. doi:10.1111/nph.19361</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Stubbs RL, Theodoridis S, Mora-Carrera E, Keller B, Potente G, Yousefi N, Jay P, L&amp;#xe9;veill&amp;#xe9;-Bourret &amp;#xc9;, Choudhury RR, Celep F, Kochjarov&amp;#xe1; J, Conti E, </infon><offset>0</offset><text>The genomes of Darwin's primroses reveal chromosome-scale adaptive introgression and differential permeability of species boundaries.</text></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>Introgression is an important source of genetic variation that can determine species adaptation to environmental conditions. Yet, definitive evidence of the genomic and adaptive implications of introgression in nature remains scarce. The widespread hybrid zones of Darwin's primroses (Primula elatior, Primula veris, and Primula vulgaris) provide a unique natural laboratory for studying introgression in flowering plants and the varying permeability of species boundaries. Through analysis of 650 genomes, we provide evidence of an introgressed genomic region likely to confer adaptive advantage in conditions of soil toxicity. We also document unequivocal evidence of chloroplast introgression, an important precursor to species-wide chloroplast capture. Finally, we provide the first evidence that the S-locus supergene, which controls heterostyly in primroses, does not introgress in this clade. Our results contribute novel insights into the adaptive role of introgression and demonstrate the importance of extensive genomic and geographical sampling for illuminating the complex nature of species boundaries.</text><annotation id="1"><infon key="identifier">MESH:D005242</infon><infon key="type">Disease</infon><location offset="748" length="13"/><text>soil toxicity</text></annotation></passage></document>
<document><id>37813479</id><passage><infon key="journal">Int J Gynecol Cancer;2023Oct09. doi:10.1136/ijgc-2023-004939</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Loukovaara M, B&amp;#xfc;tzow R, Staff S, M&amp;#xe4;enp&amp;#xe4;&amp;#xe4; M, Faltinov&amp;#xe1; M, Lassus H, Veijalainen O, Gr&amp;#xf6;nvall M, Vaalavirta L, Kuikka E, Haataja M, Urpilainen E, Simojoki M, Anttila M, Auranen A, </infon><offset>0</offset><text>PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.</text><annotation id="1"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="27" length="21"/><text>Endometrial Carcinoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>128</offset><text>BACKGROUND: Endometrial carcinomas can be classified into four molecular subgroups - mismatch repair deficient (MMRd), p53 abnormal (p53abn), polymerase-epsilon (POLE) ultramutated, and 'no specific molecular profile' (NSMP). Retrospective data imply that the response to adjuvant therapies may depend on the molecular subgroup. These findings emphasize the need for adjuvant therapy trials where patients are randomized to treatment arms separately within each molecular subgroup. PRIMARY OBJECTIVE: The PErsonalized TReatment for Endometrial Carcinoma (PETREC) trial clarifies the value of molecular classification in the determination of adjuvant therapies of high-intermediate risk and early-stage high-risk endometrial carcinoma. STUDY HYPOTHESIS: Compared with vaginal brachytherapy, the utilization of whole pelvic radiotherapy may result in improved outcomes for either MMRd or NSMP high-intermediate risk carcinomas. Early-stage high-risk p53abn and nonendometrioid carcinomas are postulated to gain benefits from chemoradiotherapy, as opposed to chemotherapy alone. POLE ultramutated carcinomas harboring high-intermediate or high-risk clinicopathologic features are speculated to have favorable prognosis without any adjuvant therapy. TRIAL DESIGN: This prospective, multicenter, phase 3 trial compares the efficacy of vaginal brachytherapy vs whole pelvic radiotherapy in high-intermediate risk MMRd and NSMP molecular subgroups, and chemotherapy vs chemoradiotherapy in early-stage high-risk p53abn subtype and nonendometrioid carcinomas. Eligible women who consent to participation in the trial are randomly allocated (1:1) to treatment arms. MAJOR INCLUSION/EXCLUSION CRITERIA: Women with stages I-II molecular integrated high-intermediate risk or high-risk endometrial carcinoma will be included. PRIMARY ENDPOINT: The primary endpoint is the 5 year cumulative incidence of disease recurrence. SAMPLE SIZE: A total sample size of 294 patients (49 subjects in each treatment arm of the three subgroups intended for randomization) was estimated to be sufficient. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: Patient recruitment will be completed in 2025, and follow-up will be completed in 2030. TRIAL REGISTRATION: NCT05655260.</text><annotation id="16"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="140" length="22"/><text>Endometrial carcinomas</text></annotation><annotation id="17"><infon key="identifier">MESH:C536928</infon><infon key="type">Disease</infon><location offset="213" length="8"/><text>mismatch</text></annotation><annotation id="18"><infon key="identifier">7157</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">460</infon><location offset="247" length="3"/><text>p53</text></annotation><annotation id="19"><infon key="identifier">MESH:D000080888</infon><infon key="type">Disease</infon><location offset="347" length="4"/><text>NSMP</text></annotation><annotation id="20"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="660" length="21"/><text>Endometrial Carcinoma</text></annotation><annotation id="21"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="840" length="21"/><text>endometrial carcinoma</text></annotation><annotation id="22"><infon key="identifier">MESH:D000080888</infon><infon key="type">Disease</infon><location offset="1014" length="4"/><text>NSMP</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1042" length="10"/><text>carcinomas</text></annotation><annotation id="24"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1087" length="26"/><text>nonendometrioid carcinomas</text></annotation><annotation id="25"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1222" length="10"/><text>carcinomas</text></annotation><annotation id="26"><infon key="identifier">MESH:D000080888</infon><infon key="type">Disease</infon><location offset="1544" length="4"/><text>NSMP</text></annotation><annotation id="27"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1652" length="26"/><text>nonendometrioid carcinomas</text></annotation><annotation id="28"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="1901" length="21"/><text>endometrial carcinoma</text></annotation><annotation id="29"><infon key="type">Disease</infon><location offset="2236" length="7"/><text>ACCRUAL</text></annotation></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D016889</infon><infon key="role2">Gene|7157</infon><infon key="type">Association</infon><node refid="0" role="1,3"/></relation></document>
<document><id>37818967</id><passage><infon key="journal">Environ Toxicol;2023Oct11. doi:10.1002/tox.23944</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang Q, Lu F, Zhang C, Yu X, Yang X, Yan H, </infon><offset>0</offset><text>Blocking exosomal secretion aggravated 1,4-benzoquinone-induced cytotoxicity.</text><annotation id="2"><infon key="identifier">MESH:C004532</infon><infon key="type">Chemical</infon><location offset="39" length="16"/><text>1,4-benzoquinone</text></annotation><annotation id="3"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="64" length="12"/><text>cytotoxicity</text></annotation></passage><passage><infon key="type">abstract</infon><offset>78</offset><text>Benzene exposure inhibits the hematopoietic system and leads to the occurrence of various types of leukemia. However, the mechanism underlying the hematotoxicity of benzene is still largely unclear. Emerging evidence has shown that exosomes are involved in toxic mechanisms of benzene. To understand the effect of 1,4-benzoquinone (PBQ; an active metabolite of benzene in bone marrow) on the exosomal release characteristics and role of exosomal secretion in PBQ-induced cytotoxicity. Exosomes were isolated from PBQ-treated HL-60 cells, purified by ultracentrifugation, and verified by transmission electron microscopy, nanoparticle tracking analysis and the presence of specific biomarkers. Our results showed that PBQ increased exosomal secretion in a dose-dependent manner, reaching a peak in 3 h at 10 muM PBQ treatment and then slowly decreasing in HL-60 cells. The exosomes contained miRNAs, which have been reported to be associated with benzene exposure or benzene poisoning. In particular, mir-34a-3p and mir-34A-5p were enriched in exosomes derived from PBQ-treated cells. In addition, the inhibition of exosomal release by GW4869 (an inhibitor of exosomal release) exacerbated PBQ-induced cytotoxicity, including increased intracellular reactive oxygen species levels, decreased mitochondrial membrane potential, and increased the apoptosis rate. Our findings illustrated that exosomes secretion plays an important role in antagonizing PBQ-induced cytotoxicity and maintaining cell homeostasis.</text><annotation id="29"><infon key="identifier">MESH:D001554</infon><infon key="type">Chemical</infon><location offset="78" length="7"/><text>Benzene</text></annotation><annotation id="30"><infon key="identifier">MESH:D007938</infon><infon key="type">Disease</infon><location offset="177" length="8"/><text>leukemia</text></annotation><annotation id="31"><infon key="type">Disease</infon><location offset="225" length="14"/><text>hematotoxicity</text></annotation><annotation id="32"><infon key="identifier">MESH:D001554</infon><infon key="type">Chemical</infon><location offset="243" length="7"/><text>benzene</text></annotation><annotation id="33"><infon key="identifier">MESH:D001554</infon><infon key="type">Chemical</infon><location offset="355" length="7"/><text>benzene</text></annotation><annotation id="34"><infon key="identifier">MESH:C004532</infon><infon key="type">Chemical</infon><location offset="392" length="16"/><text>1,4-benzoquinone</text></annotation><annotation id="35"><infon key="identifier">MESH:C056194</infon><infon key="type">Chemical</infon><location offset="410" length="3"/><text>PBQ</text></annotation><annotation id="36"><infon key="identifier">MESH:D001554</infon><infon key="type">Chemical</infon><location offset="439" length="7"/><text>benzene</text></annotation><annotation id="37"><infon key="identifier">MESH:C056194</infon><infon key="type">Chemical</infon><location offset="537" length="3"/><text>PBQ</text></annotation><annotation id="38"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="549" length="12"/><text>cytotoxicity</text></annotation><annotation id="39"><infon key="identifier">MESH:C056194</infon><infon key="type">Chemical</infon><location offset="591" length="3"/><text>PBQ</text></annotation><annotation id="40"><infon key="identifier">CVCL:0002</infon><infon key="type">CellLine</infon><location offset="603" length="5"/><text>HL-60</text></annotation><annotation id="41"><infon key="identifier">MESH:C056194</infon><infon key="type">Chemical</infon><location offset="795" length="3"/><text>PBQ</text></annotation><annotation id="42"><infon key="identifier">MESH:C056194</infon><infon key="type">Chemical</infon><location offset="889" length="3"/><text>PBQ</text></annotation><annotation id="43"><infon key="identifier">CVCL:0002</infon><infon key="type">CellLine</infon><location offset="933" length="5"/><text>HL-60</text></annotation><annotation id="44"><infon key="identifier">MESH:D001554</infon><infon key="type">Chemical</infon><location offset="1024" length="7"/><text>benzene</text></annotation><annotation id="45"><infon key="identifier">MESH:D001554</infon><infon key="type">Chemical</infon><location offset="1044" length="7"/><text>benzene</text></annotation><annotation id="46"><infon key="identifier">MESH:D011041</infon><infon key="type">Disease</infon><location offset="1052" length="9"/><text>poisoning</text></annotation><annotation id="47"><infon key="identifier">MESH:C056194</infon><infon key="type">Chemical</infon><location offset="1143" length="3"/><text>PBQ</text></annotation><annotation id="48"><infon key="identifier">MESH:C468773</infon><infon key="type">Chemical</infon><location offset="1213" length="6"/><text>GW4869</text></annotation><annotation id="49"><infon key="identifier">MESH:C056194</infon><infon key="type">Chemical</infon><location offset="1267" length="3"/><text>PBQ</text></annotation><annotation id="50"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1279" length="12"/><text>cytotoxicity</text></annotation><annotation id="51"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="1327" length="23"/><text>reactive oxygen species</text></annotation><annotation id="52"><infon key="identifier">MESH:C056194</infon><infon key="type">Chemical</infon><location offset="1526" length="3"/><text>PBQ</text></annotation><annotation id="53"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1538" length="12"/><text>cytotoxicity</text></annotation></passage><relation id="R1"><infon key="score">0.9738</infon><infon key="role1">Chemical|MESH:C056194</infon><infon key="role2">Chemical|MESH:C468773</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="22,21"/></relation><relation id="R2"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:C004532</infon><infon key="role2">Disease|MESH:D064420</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D001554</infon><infon key="role2">Disease|MESH:D007938</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="2,3"/></relation><relation id="R4"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:C468773</infon><infon key="role2">Chemical|MESH:D017382</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="21,24"/></relation><relation id="R5"><infon key="score">0.5344</infon><infon key="role1">Chemical|MESH:C056194</infon><infon key="role2">Chemical|MESH:D017382</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="22,24"/></relation><relation id="R6"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D001554</infon><infon key="role2">Disease|MESH:D011041</infon><infon key="type">Positive_Correlation</infon><node refid="5" role="17,19"/></relation><relation id="R7"><infon key="score">0.9462</infon><infon key="role1">Chemical|MESH:C468773</infon><infon key="role2">Disease|MESH:D064420</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="21,23"/></relation><relation id="R8"><infon key="score">0.9983</infon><infon key="role1">Chemical|MESH:C056194</infon><infon key="role2">Disease|MESH:D064420</infon><infon key="type">Positive_Correlation</infon><node refid="7" role="8,11"/></relation></document>
<document><id>37819673</id><passage><infon key="journal">JAMA Surg;2023Oct11. doi:10.1001/jamasurg.2023.4995</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10568437</infon><infon key="type">title</infon><infon key="authors">Garcia Whitlock AE, Gill BP, Richardson JB, Patton DU, Strong B, Nwakanma CC, Kaufman EJ, </infon><offset>0</offset><text>Analysis of Social Media Involvement in Violent Injury.</text><annotation id="1"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="40" length="14"/><text>Violent Injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>56</offset></passage></document>
<document><id>37820031</id><passage><infon key="journal">Clin Infect Dis;2023Oct11. doi:10.1093/cid/ciad615</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kolberg L, Khanijau A, van der Velden FJS, Herberg J, De T, Galassini R, Cunnington AJ, Wright V, Shah P, Kaforou M, Wilson C, Kuijpers T, Martin&amp;#xf3;n-Torres F, Rivero-Calle I, Moll H, Vermont C, Pokorn M, Kolnik M, Pollard AJ, Agyeman PKA, Schlapbach LJ, Tsolia MN, Yeung S, Zavadska D, Zenz W, Schweintzger NA, van der Flier M, de Groot R, Usuf E, Voice M, Calvo-Bado L, Mallet F, Fidler K, Levin M, Carrol ED, Emonts M, von Both U, PERFORM Consortium, </infon><offset>0</offset><text>Raising AWaRe-ness of antimicrobial stewardship challenges in pediatric emergency care: results from the PERFORM study assessing consistency and appropriateness of antibiotic prescribing across Europe.</text></passage><passage><infon key="type">abstract</infon><offset>202</offset><text>OBJECTIVES: Optimization of antimicrobial stewardship (AMS) is key to tackling antimicrobial resistance (AMR), which is exacerbated by over-prescription of antibiotics in pediatric Emergency Departments (EDs). We described patterns of empiric antibiotic use in European EDs, and characterized appropriateness and consistency of prescribing. METHODS: Between August 2016 and December 2019 febrile children attending the ED in nine European countries with suspected infection were recruited into the PERFORM (Personalised Risk assessment in Febrile illness to Optimise Real-life Management) study. Empiric systemic antibiotic use was determined in view of assigned final 'bacterial' or 'viral' phenotype. Antibiotics were classified according to WHO AWaRe. RESULTS: Of 2130 febrile episodes (excluding children with non-bacterial/non-viral phenotypes), 1549 (72.7%) were assigned a 'bacterial' and 581 (27.3%) a 'viral' phenotype. A total of 1318/1549 (85.1%) episodes with a 'bacterial' and 269/581 (46.3%) with a 'viral' phenotype received empiric systemic antibiotics (first two days of admission). Of those, the majority (87.8% in 'bacterial' and 87.0% in 'viral' group) received parenteral antibiotics. The top three antibiotics prescribed were third-generation cephalosporins, penicillins and penicillin/beta-lactamase inhibitor combinations. Of those treated with empiric systemic antibiotics in the 'viral' group 216/269 (80.3%) received >= one Watch antibiotic. CONCLUSIONS: Differentiating bacterial from viral etiology in febrile illness on initial ED presentation remains challenging, resulting in a substantial over-prescription of antibiotics. A significant proportion of patients with a 'viral' phenotype received systemic antibiotics, predominantly classified as WHO Watch. Rapid and accurate point-of-care tests in the ED differentiating between bacterial and viral etiology, could significantly improve AMS.</text><annotation id="15"><infon key="identifier">MESH:D000071072</infon><infon key="type">Disease</infon><location offset="590" length="7"/><text>febrile</text></annotation><annotation id="16"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="666" length="9"/><text>infection</text></annotation><annotation id="17"><infon key="identifier">MESH:D005334</infon><infon key="type">Disease</infon><location offset="741" length="15"/><text>Febrile illness</text></annotation><annotation id="18"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="872" length="9"/><text>bacterial</text></annotation><annotation id="19"><infon key="identifier">MESH:C580065</infon><infon key="type">Disease</infon><location offset="974" length="16"/><text>febrile episodes</text></annotation><annotation id="20"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="1020" length="9"/><text>bacterial</text></annotation><annotation id="21"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="1083" length="9"/><text>bacterial</text></annotation><annotation id="22"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="1177" length="9"/><text>bacterial</text></annotation><annotation id="23"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="1336" length="9"/><text>bacterial</text></annotation><annotation id="24"><infon key="identifier">MESH:D002511</infon><infon key="type">Chemical</infon><location offset="1467" length="14"/><text>cephalosporins</text></annotation><annotation id="25"><infon key="identifier">MESH:D010406</infon><infon key="type">Chemical</infon><location offset="1483" length="11"/><text>penicillins</text></annotation><annotation id="26"><infon key="identifier">MESH:D010406</infon><infon key="type">Chemical</infon><location offset="1499" length="10"/><text>penicillin</text></annotation><annotation id="27"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="1700" length="9"/><text>bacterial</text></annotation><annotation id="28"><infon key="identifier">MESH:D005334</infon><infon key="type">Disease</infon><location offset="1733" length="15"/><text>febrile illness</text></annotation><annotation id="29"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="2063" length="9"/><text>bacterial</text></annotation></passage></document>
<document><id>37820404</id><passage><infon key="journal">Animal;2023Sep18; 17 (11) 100996. doi:10.1016/j.animal.2023.100996</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Berry DP, Spangler ML, </infon><offset>0</offset><text>Animal board invited review: Practical applications of genomic information in livestock.</text></passage><passage><infon key="type">abstract</infon><offset>89</offset><text>Access to high-dimensional genomic information in many livestock species is accelerating. This has been greatly aided not only by continual reductions in genotyping costs but also an expansion in the services available that leverage genomic information to create a greater return-on-investment. Genomic information on individual animals has many uses including (1) parentage verification and discovery, (2) traceability, (3) karyotyping, (4) sex determination, (5) reporting and monitoring of mutations conferring major effects or congenital defects, (6) better estimating inbreeding of individuals and coancestry among individuals, (7) mating advice, (8) determining breed composition, (9) enabling precision management, and (10) genomic evaluations; genomic evaluations exploit genome-wide genotype information to improve the accuracy of predicting an animal's (and by extension its progeny's) genetic merit. Genomic data also provide a huge resource for research, albeit the outcome from this research, if successful, should eventually be realised through one of the ten applications already mentioned. The process for generating a genotype all the way from sample procurement to identifying erroneous genotypes is described, as are the steps that should be considered when developing a bespoke genotyping panel for practical application.</text><annotation id="1"><infon key="identifier">MESH:D000013</infon><infon key="type">Disease</infon><location offset="620" length="18"/><text>congenital defects</text></annotation></passage></document>
<document><id>37820757</id><passage><infon key="journal">Arch Biochem Biophys;2023Oct15; 748 109772. doi:10.1016/j.abb.2023.109772</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Alt TB, Hoag MR, Moran GR, </infon><offset>0</offset><text>Dihydropyrmidine dehydrogenase from Escherichia coli: Transient state analysis reveals both reductive activation prior to turnover and diminished substrate effector roles relative to the mammalian form.</text></passage><passage><infon key="type">abstract</infon><offset>203</offset><text>Dihydropyrimidine dehydrogenase (DPD) is an enzyme that uses an elaborate architecture to catalyze a simple net reaction: the reduction of the vinylic bond of uracil and thymine. Known DPDs have two active sites separated by approximately 60 A. One active site has an FAD cofactor and binds NAD(P) and the other has an FMN cofactor and binds pyrimidines. The intervening distance is spanned by four Fe4S4 centers that act as an electron conduit. Recent advancements with porcine DPD have revealed unexpected chemical sequences where the enzyme undergoes reductive activation by transferring two electrons from NADPH to the FMN via the FAD such that the active form has the cofactor set FAD Fe4S4 FMNH2. Here we describe the first comprehensive kinetic investigation of a bacterial form of DPD. Using primarily transient state methods, DPD from E. coli (EcDPD) was shown to have a similar mechanism to that observed with the mammalian form in that EcDPD is observed to undergo reductive activation before pyrimidine reduction and displays half-of-sites activity. However, two distinct aspects of the EcDPD reaction relative to the mammalian enzyme were observed that relate to the effector roles for substrates: (i) the enzyme will rapidly take up electrons from NADH, reducing a flavin in the absence of pyrimidine substrate, and (ii) the activated form of the enzyme can become fully oxidized by transferring electrons to pyrimidine substrates in the absence of NADH.</text><annotation id="25"><infon key="identifier">1806</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">85</infon><location offset="203" length="31"/><text>Dihydropyrimidine dehydrogenase</text></annotation><annotation id="26"><infon key="identifier">1806</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">85</infon><location offset="236" length="3"/><text>DPD</text></annotation><annotation id="27"><infon key="identifier">MESH:D014498</infon><infon key="type">Chemical</infon><location offset="362" length="6"/><text>uracil</text></annotation><annotation id="28"><infon key="identifier">MESH:D013941</infon><infon key="type">Chemical</infon><location offset="373" length="7"/><text>thymine</text></annotation><annotation id="29"><infon key="identifier">MESH:C036020</infon><infon key="type">Chemical</infon><location offset="388" length="4"/><text>DPDs</text></annotation><annotation id="30"><infon key="identifier">MESH:D005182</infon><infon key="type">Chemical</infon><location offset="471" length="3"/><text>FAD</text></annotation><annotation id="31"><infon key="identifier">MESH:D009249</infon><infon key="type">Chemical</infon><location offset="494" length="6"/><text>NAD(P)</text></annotation><annotation id="32"><infon key="identifier">MESH:D005486</infon><infon key="type">Chemical</infon><location offset="522" length="3"/><text>FMN</text></annotation><annotation id="33"><infon key="identifier">MESH:D011743</infon><infon key="type">Chemical</infon><location offset="545" length="11"/><text>pyrimidines</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="602" length="5"/><text>Fe4S4</text></annotation><annotation id="35"><infon key="identifier">1806</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">85</infon><location offset="682" length="3"/><text>DPD</text></annotation><annotation id="36"><infon key="identifier">MESH:D009249</infon><infon key="type">Chemical</infon><location offset="813" length="5"/><text>NADPH</text></annotation><annotation id="37"><infon key="identifier">MESH:D005486</infon><infon key="type">Chemical</infon><location offset="826" length="3"/><text>FMN</text></annotation><annotation id="38"><infon key="identifier">MESH:D005182</infon><infon key="type">Chemical</infon><location offset="838" length="3"/><text>FAD</text></annotation><annotation id="39"><infon key="identifier">MESH:D005182</infon><infon key="type">Chemical</infon><location offset="889" length="3"/><text>FAD</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="893" length="5"/><text>Fe4S4</text></annotation><annotation id="41"><infon key="identifier">MESH:C540087</infon><infon key="type">Chemical</infon><location offset="899" length="5"/><text>FMNH2</text></annotation><annotation id="42"><infon key="identifier">1806</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">85</infon><location offset="992" length="3"/><text>DPD</text></annotation><annotation id="43"><infon key="identifier">1806</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">85</infon><location offset="1038" length="3"/><text>DPD</text></annotation><annotation id="44"><infon key="identifier">MESH:C030986</infon><infon key="type">Chemical</infon><location offset="1207" length="10"/><text>pyrimidine</text></annotation><annotation id="45"><infon key="identifier">MESH:D009243</infon><infon key="type">Chemical</infon><location offset="1465" length="4"/><text>NADH</text></annotation><annotation id="46"><infon key="identifier">MESH:C024132</infon><infon key="type">Chemical</infon><location offset="1482" length="6"/><text>flavin</text></annotation><annotation id="47"><infon key="identifier">MESH:C030986</infon><infon key="type">Chemical</infon><location offset="1507" length="10"/><text>pyrimidine</text></annotation><annotation id="48"><infon key="identifier">MESH:C030986</infon><infon key="type">Chemical</infon><location offset="1626" length="10"/><text>pyrimidine</text></annotation><annotation id="49"><infon key="identifier">MESH:D009243</infon><infon key="type">Chemical</infon><location offset="1666" length="4"/><text>NADH</text></annotation></passage><relation id="R1"><infon key="score">0.7751</infon><infon key="role1">Chemical|MESH:D005182</infon><infon key="role2">Chemical|MESH:D009249</infon><infon key="type">Association</infon><node refid="0" role="5,6"/></relation><relation id="R2"><infon key="score">0.8852</infon><infon key="role1">Chemical|MESH:D013941</infon><infon key="role2">Gene|1806</infon><infon key="type">Association</infon><node refid="1" role="3,0"/></relation><relation id="R3"><infon key="score">0.9721</infon><infon key="role1">Chemical|MESH:D005486</infon><infon key="role2">Chemical|MESH:D011743</infon><infon key="type">Association</infon><node refid="2" role="7,8"/></relation><relation id="R4"><infon key="score">0.7118</infon><infon key="role1">Chemical|MESH:D005182</infon><infon key="role2">Chemical|MESH:D005486</infon><infon key="type">Association</infon><node refid="3" role="5,7"/></relation><relation id="R5"><infon key="score">0.8602</infon><infon key="role1">Chemical|MESH:D005486</infon><infon key="role2">Chemical|MESH:D009249</infon><infon key="type">Association</infon><node refid="4" role="7,6"/></relation></document>
<document><id>37821107</id><passage><infon key="journal">Genes Dev;2023Sep01; 37 (17-18) 829. doi:10.1101/gad.350896.123</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10620047</infon><infon key="type">title</infon><infon key="authors">Loftus D, Bae B, Whilden CM, Whipple AJ, </infon><offset>0</offset><text>Allelic chromatin structure precedes imprinted expression of Kcnk9 during neurogenesis.</text><annotation id="1"><infon key="identifier">223604</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56758</infon><location offset="61" length="5"/><text>Kcnk9</text></annotation></passage><passage><infon key="type">abstract</infon><offset>88</offset><text>Differences in chromatin state inherited from the parental gametes influence the regulation of maternal and paternal alleles in offspring. This phenomenon, known as genomic imprinting, results in genes preferentially transcribed from one parental allele. While local epigenetic factors such as DNA methylation are known to be important for the establishment of imprinted gene expression, less is known about the mechanisms by which differentially methylated regions (DMRs) lead to differences in allelic expression across broad stretches of chromatin. Allele-specific higher-order chromatin structure has been observed at multiple imprinted loci, consistent with the observation of allelic binding of the chromatin-organizing factor CTCF at multiple DMRs. However, whether allelic chromatin structure impacts allelic gene expression is not known for most imprinted loci. Here we characterize the mechanisms underlying brain-specific imprinted expression of the Peg13-Kcnk9 locus, an imprinted region associated with intellectual disability. We performed region capture Hi-C on mouse brains from reciprocal hybrid crosses and found imprinted higher-order chromatin structure caused by the allelic binding of CTCF to the Peg13 DMR. Using an in vitro neuron differentiation system, we showed that imprinted chromatin structure precedes imprinted expression at the locus. Additionally, activation of a distal enhancer induced imprinted expression of Kcnk9 in an allelic chromatin structure-dependent manner. This work provides a high-resolution map of imprinted chromatin structure and demonstrates that chromatin state established in early development can promote imprinted expression upon differentiation.</text><annotation id="9"><infon key="identifier">13018</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4786</infon><location offset="821" length="4"/><text>CTCF</text></annotation><annotation id="10"><infon key="identifier">353342</infon><infon key="type">Gene</infon><location offset="1049" length="5"/><text>Peg13</text></annotation><annotation id="11"><infon key="identifier">223604</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56758</infon><location offset="1055" length="5"/><text>Kcnk9</text></annotation><annotation id="12"><infon key="identifier">MESH:D008607</infon><infon key="type">Disease</infon><location offset="1104" length="23"/><text>intellectual disability</text></annotation><annotation id="13"><infon key="identifier">13018</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4786</infon><location offset="1295" length="4"/><text>CTCF</text></annotation><annotation id="14"><infon key="identifier">353342</infon><infon key="type">Gene</infon><location offset="1307" length="5"/><text>Peg13</text></annotation><annotation id="15"><infon key="identifier">223604</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56758</infon><location offset="1534" length="5"/><text>Kcnk9</text></annotation></passage><relation id="R1"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D008607</infon><infon key="role2">Gene|353342</infon><infon key="type">Association</infon><node refid="0" role="4,2"/></relation><relation id="R2"><infon key="score">0.3975</infon><infon key="role1">Gene|13018</infon><infon key="role2">Gene|353342</infon><infon key="type">Association</infon><node refid="1" role="5,6"/></relation><relation id="R3"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D008607</infon><infon key="role2">Gene|223604</infon><infon key="type">Association</infon><node refid="2" role="4,3"/></relation><relation id="R4"><infon key="score">0.9908</infon><infon key="role1">Gene|223604</infon><infon key="role2">Gene|353342</infon><infon key="type">Association</infon><node refid="3" role="3,2"/></relation></document>
<document><id>37821458</id><passage><infon key="journal">J Agric Food Chem;2023Oct11. doi:10.1021/acs.jafc.3c03950</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang N, Feng S, Ma X, Chen Q, Liu C, Qi Z, </infon><offset>0</offset><text>Meta-Analysis and Multiomics of a Chromosome Segment Substitution Line Reveal Candidate Genes Associated with Seed Hardness in Soybean.</text></passage><passage><infon key="type">abstract</infon><offset>136</offset><text>Soybean seed hardness is a key trait that influences planting, nutritional quality, and postharvest processing, but its genetic and molecular mechanisms remain to be clarified. We used meta-analysis to detect 17 meta-quantitative trait locus (QTLs) for soybean seed hardness. We then identified a hard-seeded chromosome segment substitution line, R75, with fragments introduced from hard-seeded wild germplasm in four of the meta-QTL intervals. Observations of the seed coat ultrastructure revealed thicker palisade tissue in R75 than in its soft-seeded recurrent parent. Transcriptomics and proteomics of R75 and its recurrent parent revealed multiple candidate genes associated with seed hardness. Fifty-seven were located on homozygous introduced fragments, 26 in meta-QTL intervals, and one in both (Glyma.02G268600). Five initial candidates were selected for KASP marker development on the basis of their predicted functions and nonsynonymous SNPs. The selection efficiency of the markers was as high as 90% for nonhard lines and 43% for hard lines in the chromosome segment substitution line (CSSL) population.</text></passage></document>
<document><id>37822159</id><passage><infon key="journal">J Org Chem;2023Oct20; 88 (20) 14753. doi:10.1021/acs.joc.3c00949</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li J, Yuan L, Yang Q, Zhang N, Sun T, Bao X, </infon><offset>0</offset><text>A Carbazole-1,8-Disulfonamide-Derived Cryptand Receptor for Anion Recognition.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2" length="27"/><text>Carbazole-1,8-Disulfonamide</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>A novel cryptand-like anion receptor 1 was synthesized in reasonable yield by a one-step condensation reaction. The UV-vis spectroscopic titrations indicated that cryptand 1 bound AcO- in preference to other monovalent anions (including its competing F- and H2PO4-) in CH3CN, generating a 1:1 binding complex with Ka = 51,000 M-1. Moreover, the crystal structures revealed that the acetate ion was encapsulated inside the cryptand's cavity in a 1:1 manner, through multiple N-H   O hydrogen bonds (although having two different crystal forms).</text><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="242" length="10"/><text>cryptand 1</text></annotation><annotation id="9"><infon key="identifier">MESH:C034482</infon><infon key="type">Chemical</infon><location offset="259" length="4"/><text>AcO-</text></annotation><annotation id="10"><infon key="identifier">MESH:D005461</infon><infon key="type">Chemical</infon><location offset="330" length="2"/><text>F-</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="337" length="6"/><text>H2PO4-</text></annotation><annotation id="12"><infon key="identifier">MESH:C032159</infon><infon key="type">Chemical</infon><location offset="348" length="5"/><text>CH3CN</text></annotation><annotation id="13"><infon key="identifier">MESH:D000085</infon><infon key="type">Chemical</infon><location offset="461" length="7"/><text>acetate</text></annotation></passage></document>
<document><id>37823212</id><passage><infon key="journal">J Neurophysiol;2023Nov01; 130 (5) 1252. doi:10.1152/jn.00514.2022</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Khazali MF, Daddaoua N, Thier P, </infon><offset>0</offset><text>Nonhuman primates exploit the prior assumption that the visual world is vertical.</text></passage><passage><infon key="type">abstract</infon><offset>82</offset><text>When human subjects tilt their heads in dark surroundings, the noisiness of vestibular information impedes precise reports on objects' orientation with respect to Earth's vertical axis. This difficulty is mitigated if a vertical visual background is available. Tilted visual backgrounds induce feelings of head tilt in subjects who are in fact upright. This is often explained as a result of the brain resorting to the prior assumption that natural visual backgrounds are vertical. Here, we tested whether monkeys show comparable perceptual mechanisms. To this end we trained two monkeys to align a visual arrow to a vertical reference line that had variable luminance across trials, while including a large, clearly visible background square whose orientation changed from trial to trial. On ~20% of all trials, the vertical reference line was left out to measure the subjective visual vertical (SVV). When the frame was upright, the monkeys' SVV was aligned with the gravitational vertical. In accordance with the perceptual reports of humans, however, when the frame was tilted it induced an illusion of head tilt as indicated by a bias in SVV toward the frame orientation. Thus all primates exploit the prior assumption that the visual world is vertical.NEW &amp; NOTEWORTHY Here we show that the principles that characterize the human perception of the vertical are shared by another old world primate species, the rhesus monkey, suggesting phylogenetic continuity. In both species the integration of visual and vestibular information on the orientation of the head relative to the world is similarly constrained by the prior assumption that the visual world is vertical in the sense of having an orientation that is congruent with the gravity vector.</text><annotation id="3"><infon key="type">Disease</infon><location offset="102" length="4"/><text>tilt</text></annotation><annotation id="4"><infon key="identifier">MESH:D006258</infon><infon key="type">Disease</infon><location offset="388" length="9"/><text>head tilt</text></annotation><annotation id="5"><infon key="identifier">MESH:D006258</infon><infon key="type">Disease</infon><location offset="1189" length="9"/><text>head tilt</text></annotation></passage></document>
<document><id>37823564</id><passage><infon key="journal">J Histotechnol;2023Oct12 1. doi:10.1080/01478885.2023.2261093</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tao J, Zhang Y, Huang Y, Xu M, </infon><offset>0</offset><text>The role of iron and ferroptosis in the pathogenesis of acute pancreatitis.</text><annotation id="3"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="12" length="4"/><text>iron</text></annotation><annotation id="4"><infon key="type">Disease</infon><location offset="21" length="11"/><text>ferroptosis</text></annotation><annotation id="5"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="56" length="18"/><text>acute pancreatitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>76</offset><text>Acute pancreatitis (AP) is an inflammatory disease of the pancreas. Iron is an essential element for life and is involved in many metabolic processes. Ferroptosis is a type of regulated cell death that is triggered by iron and oxidative stress. A well-established mouse AP model was adopted to study the role of iron and ferroptosis in the pathogenesis of pancreatitis. Mice were injected with cerulein to induce AP, and pancreatic tissue samples were analyzed to determine the pathology, cell death, iron deposition, expression of iron transporters, and lipid peroxidation. The role of iron was studied by giving mice extra iron or iron chelator. In vitro studies with acinar cells with ferroptosis activator and inhibitor were also performed to assess the inflammatory response. Iron was found accumulated in the pancreatic tissue of mice who suffered cerulein-induced pancreatitis. Cell death and lipid peroxidation increased in these tissues and could be further modulated by iron dextran or iron chelator. Mice given Hemin through gavage had reduced levels of GSH in pancreatic tissue and increased inflammatory response. Studies with acinar cells showed increased levels of lipid peroxidation and ferroptosis-specific mitochondrial damage when treated with ferroptosis inducer and inflammatory cytokines.</text><annotation id="39"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="76" length="18"/><text>Acute pancreatitis</text></annotation><annotation id="40"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="96" length="2"/><text>AP</text></annotation><annotation id="41"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="106" length="36"/><text>inflammatory disease of the pancreas</text></annotation><annotation id="42"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="144" length="4"/><text>Iron</text></annotation><annotation id="43"><infon key="type">Disease</infon><location offset="227" length="11"/><text>Ferroptosis</text></annotation><annotation id="44"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="294" length="4"/><text>iron</text></annotation><annotation id="45"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="346" length="2"/><text>AP</text></annotation><annotation id="46"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="388" length="4"/><text>iron</text></annotation><annotation id="47"><infon key="type">Disease</infon><location offset="397" length="11"/><text>ferroptosis</text></annotation><annotation id="48"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="432" length="12"/><text>pancreatitis</text></annotation><annotation id="49"><infon key="identifier">MESH:D002108</infon><infon key="type">Chemical</infon><location offset="470" length="8"/><text>cerulein</text></annotation><annotation id="50"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="489" length="2"/><text>AP</text></annotation><annotation id="51"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="577" length="4"/><text>iron</text></annotation><annotation id="52"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="631" length="5"/><text>lipid</text></annotation><annotation id="53"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="663" length="4"/><text>iron</text></annotation><annotation id="54"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="701" length="4"/><text>iron</text></annotation><annotation id="55"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="709" length="4"/><text>iron</text></annotation><annotation id="56"><infon key="type">Disease</infon><location offset="764" length="11"/><text>ferroptosis</text></annotation><annotation id="57"><infon key="identifier">MESH:D018746</infon><infon key="type">Disease</infon><location offset="834" length="21"/><text>inflammatory response</text></annotation><annotation id="58"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="857" length="4"/><text>Iron</text></annotation><annotation id="59"><infon key="identifier">MESH:D002108</infon><infon key="type">Chemical</infon><location offset="930" length="8"/><text>cerulein</text></annotation><annotation id="60"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="947" length="12"/><text>pancreatitis</text></annotation><annotation id="61"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="976" length="5"/><text>lipid</text></annotation><annotation id="62"><infon key="identifier">MESH:D007505</infon><infon key="type">Chemical</infon><location offset="1056" length="12"/><text>iron dextran</text></annotation><annotation id="63"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1072" length="4"/><text>iron</text></annotation><annotation id="64"><infon key="identifier">MESH:D006427</infon><infon key="type">Chemical</infon><location offset="1098" length="5"/><text>Hemin</text></annotation><annotation id="65"><infon key="identifier">MESH:D005978</infon><infon key="type">Chemical</infon><location offset="1141" length="3"/><text>GSH</text></annotation><annotation id="66"><infon key="identifier">MESH:D018746</infon><infon key="type">Disease</infon><location offset="1180" length="21"/><text>inflammatory response</text></annotation><annotation id="67"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1256" length="5"/><text>lipid</text></annotation><annotation id="68"><infon key="type">Disease</infon><location offset="1279" length="11"/><text>ferroptosis</text></annotation><annotation id="69"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="1300" length="20"/><text>mitochondrial damage</text></annotation><annotation id="70"><infon key="type">Disease</infon><location offset="1339" length="11"/><text>ferroptosis</text></annotation><annotation id="71"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1363" length="12"/><text>inflammatory</text></annotation></passage><relation id="R1"><infon key="score">0.9746</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Disease|MESH:D010195</infon><infon key="type">Association</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.9982</infon><infon key="role1">Chemical|MESH:D007505</infon><infon key="role2">Chemical|MESH:D008055</infon><infon key="type">Association</infon><node refid="1" role="26,25"/></relation><relation id="R3"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D006427</infon><infon key="role2">Disease|MESH:D018746</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="28,30"/></relation><relation id="R4"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D002108</infon><infon key="role2">Disease|MESH:D010195</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="13,14"/></relation><relation id="R5"><infon key="score">0.9208</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Chemical|MESH:D008055</infon><infon key="type">Association</infon><node refid="4" role="15,16"/></relation><relation id="R6"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D005978</infon><infon key="role2">Chemical|MESH:D006427</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="29,28"/></relation></document>
<document><id>37823916</id><passage><infon key="journal">Dermatologie (Heidelb);2023Nov; 74 (11) 864. doi:10.1007/s00105-023-05232-4</infon><infon key="year">2023</infon><infon key="article-id_pmc">1168638</infon><infon key="type">title</infon><infon key="authors">Nenoff P, Stahl M, Schaller M, Burmester A, Monod M, Ebert A, Uhrla&amp;#xdf; S, </infon><offset>0</offset><text>[Recurrent tinea corporis generalisata due to Terbinafine-resistant Trichophyton rubrum strain : Long-term treatment with super bioavailability itraconazole].</text><annotation id="3"><infon key="identifier">MESH:D014005</infon><infon key="type">Disease</infon><location offset="11" length="27"/><text>tinea corporis generalisata</text></annotation><annotation id="4"><infon key="identifier">MESH:D000077291</infon><infon key="type">Chemical</infon><location offset="46" length="11"/><text>Terbinafine</text></annotation><annotation id="5"><infon key="identifier">MESH:D017964</infon><infon key="type">Chemical</infon><location offset="144" length="12"/><text>itraconazole</text></annotation></passage><passage><infon key="type">abstract</infon><offset>159</offset><text>For more than 30 years, an 82-year-old man has been suffering from tinea corporis generalisata in the sense of Trichophyton rubrum syndrome. The patient received long-term treatment with terbinafine. Fluconazole had no effect. There was an increase in liver enzymes with itraconazole. Super bioavailability (SUBA) itraconazole was initially not tolerated. A therapy attempt with voriconazole was successful, but was stopped due to side effects. The Trichophyton (T.) rubrum strain isolated from skin scales was tested for terbinafine resistance using the breakpoint method and found to be (still) sensitive. Sequencing of the squalene epoxidase (SQLE) gene revealed a previously unknown point mutation of the codon for isoleucine ATC ACC with amino acid substitution I479T (isoleucine479 threonine). Long-term therapy with terbinafine 250 mg had been given every 3 days since 2018. In addition, bifonazole cream, ciclopirox solution, and occasionally terbinafine cream were used. The skin condition was stable until an exacerbation of the dermatophytosis in 2021. There were erythematosquamous, partly atrophic, centrifugal, scaly, confluent plaques on the integument and the extremities. Fingernails and toenails had white to yellow-brown discoloration, and were hyperkeratotic and totally dystrophic. T. rubrum was cultured from skin scales from the integument, from the feet, from nail shavings from the fingernails and also toenails and detected by PCR. In the breakpoint test, the T. rubrum isolates from tinea corporis and nail samples showed a minimum inhibitory concentration (MIC) of 0.5 microg ml-1 (terbinafine resistance in vitro). Sequencing of the SQLE gene of the T. rubrum isolate revealed evidence of a further point mutation that led to amino acid substitution I479V (isoleucine 479 valine). Long-term therapy was started with SUBA itraconazole: 14 days 2 x 1 capsule daily, then twice weekly administration of 2 x 50 mg. During breaks in therapy, the mycosis regularly flared up again. Finally, 50 mg SUBA itraconazole was given 5 days a week, which completely suppressed the dermatophytosis. Topically, ciclopirox and miconazole cream were used alternately. In conclusion, in the case of recurrent and therapy-refractory dermatophytoses caused by T. rubrum, terbinafine resistance must also be considered in individual cases. An in vitro resistance test and point mutation analysis of the squalene epoxidase gene confirms the diagnosis. Itraconazole, also in the form of SUBA itraconazole, is the drug of choice for the oral antifungal treatment of these patients.</text><annotation id="35"><infon key="identifier">MESH:D014005</infon><infon key="type">Disease</infon><location offset="226" length="27"/><text>tinea corporis generalisata</text></annotation><annotation id="36"><infon key="identifier">MESH:C569516</infon><infon key="type">Disease</infon><location offset="270" length="28"/><text>Trichophyton rubrum syndrome</text></annotation><annotation id="37"><infon key="identifier">MESH:D000077291</infon><infon key="type">Chemical</infon><location offset="346" length="11"/><text>terbinafine</text></annotation><annotation id="38"><infon key="identifier">MESH:D015725</infon><infon key="type">Chemical</infon><location offset="359" length="11"/><text>Fluconazole</text></annotation><annotation id="39"><infon key="identifier">MESH:D017964</infon><infon key="type">Chemical</infon><location offset="430" length="12"/><text>itraconazole</text></annotation><annotation id="40"><infon key="identifier">MESH:D017964</infon><infon key="type">Chemical</infon><location offset="473" length="12"/><text>itraconazole</text></annotation><annotation id="41"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="538" length="12"/><text>voriconazole</text></annotation><annotation id="42"><infon key="identifier">MESH:D000077291</infon><infon key="type">Chemical</infon><location offset="681" length="11"/><text>terbinafine</text></annotation><annotation id="43"><infon key="identifier">tmVar:p|SUB|I|479|T;HGVS:p.I479T;VariantGroup:0</infon><infon key="type">ProteinMutation</infon><location offset="926" length="5"/><text>I479T</text></annotation><annotation id="44"><infon key="identifier">tmVar:p|SUB|I|479|T;HGVS:p.I479T;VariantGroup:0</infon><infon key="type">ProteinMutation</infon><location offset="933" length="23"/><text>isoleucine479 threonine</text></annotation><annotation id="45"><infon key="identifier">MESH:D000077291</infon><infon key="type">Chemical</infon><location offset="982" length="11"/><text>terbinafine</text></annotation><annotation id="46"><infon key="identifier">MESH:C036596</infon><infon key="type">Chemical</infon><location offset="1054" length="10"/><text>bifonazole</text></annotation><annotation id="47"><infon key="identifier">MESH:D000077768</infon><infon key="type">Chemical</infon><location offset="1072" length="10"/><text>ciclopirox</text></annotation><annotation id="48"><infon key="identifier">MESH:D000077291</infon><infon key="type">Chemical</infon><location offset="1110" length="11"/><text>terbinafine</text></annotation><annotation id="49"><infon key="identifier">MESH:D014005</infon><infon key="type">Disease</infon><location offset="1198" length="15"/><text>dermatophytosis</text></annotation><annotation id="50"><infon key="identifier">MESH:D014005</infon><infon key="type">Disease</infon><location offset="1669" length="14"/><text>tinea corporis</text></annotation><annotation id="51"><infon key="identifier">MESH:D000077291</infon><infon key="type">Chemical</infon><location offset="1769" length="11"/><text>terbinafine</text></annotation><annotation id="52"><infon key="identifier">tmVar:p|SUB|I|479|V;HGVS:p.I479V;VariantGroup:0</infon><infon key="type">ProteinMutation</infon><location offset="1938" length="5"/><text>I479V</text></annotation><annotation id="53"><infon key="identifier">tmVar:p|SUB|I|479|V;HGVS:p.I479V;VariantGroup:0</infon><infon key="type">ProteinMutation</infon><location offset="1945" length="21"/><text>isoleucine 479 valine</text></annotation><annotation id="54"><infon key="identifier">MESH:D017964</infon><infon key="type">Chemical</infon><location offset="2009" length="12"/><text>itraconazole</text></annotation><annotation id="55"><infon key="identifier">MESH:D015821</infon><infon key="type">Disease</infon><location offset="2129" length="7"/><text>mycosis</text></annotation><annotation id="56"><infon key="identifier">MESH:D017964</infon><infon key="type">Chemical</infon><location offset="2184" length="12"/><text>itraconazole</text></annotation><annotation id="57"><infon key="identifier">MESH:D014005</infon><infon key="type">Disease</infon><location offset="2254" length="15"/><text>dermatophytosis</text></annotation><annotation id="58"><infon key="identifier">MESH:D000077768</infon><infon key="type">Chemical</infon><location offset="2282" length="10"/><text>ciclopirox</text></annotation><annotation id="59"><infon key="identifier">MESH:D008825</infon><infon key="type">Chemical</infon><location offset="2297" length="10"/><text>miconazole</text></annotation><annotation id="60"><infon key="identifier">MESH:D014005</infon><infon key="type">Disease</infon><location offset="2400" length="15"/><text>dermatophytoses</text></annotation><annotation id="61"><infon key="identifier">MESH:D000077291</infon><infon key="type">Chemical</infon><location offset="2437" length="11"/><text>terbinafine</text></annotation><annotation id="62"><infon key="identifier">MESH:D017964</infon><infon key="type">Chemical</infon><location offset="2616" length="12"/><text>Itraconazole</text></annotation><annotation id="63"><infon key="identifier">MESH:D017964</infon><infon key="type">Chemical</infon><location offset="2655" length="12"/><text>itraconazole</text></annotation></passage><relation id="R1"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:D000077291</infon><infon key="role2">Disease|MESH:C569516</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="5,4"/></relation><relation id="R2"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:D017964</infon><infon key="role2">Disease|MESH:D014005</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="2,0"/></relation><relation id="R3"><infon key="score">0.8613</infon><infon key="role1">Chemical|MESH:D017964</infon><infon key="role2">Disease|MESH:C569516</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="7,4"/></relation><relation id="R4"><infon key="score">0.8343</infon><infon key="role1">Chemical|MESH:D017964</infon><infon key="role2">Disease|MESH:D015821</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="22,23"/></relation><relation id="R5"><infon key="score">0.8826</infon><infon key="role1">Chemical|MESH:D065819</infon><infon key="role2">Disease|MESH:C569516</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="9,4"/></relation><relation id="R6"><infon key="score">0.9978</infon><infon key="role1">Chemical|MESH:D000077291</infon><infon key="role2">Disease|MESH:D014005</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="1,0"/></relation></document>
<document><id>37824267</id><passage><infon key="journal">J Appl Psychol;2023Oct12. doi:10.1037/apl0001138</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ma A, Ponce de Leon R, Rosette AS, </infon><offset>0</offset><text>Asking for less (but receiving more): Women avoid impasses and outperform men when negotiators have weak alternatives.</text></passage><passage><infon key="type">abstract</infon><offset>119</offset><text>Both research and conventional wisdom suggest that, due to their relational orientation, women are less likely than men to engage in agentic and assertive behaviors, leading them to underperform in zero-sum, distributive negotiations where one party's gain is equivalent to the other party's loss. However, past research tends to neglect the costs of reaching impasse by excluding impasses from measures of negotiation performance. Departing from this convention, we incorporate the economic costs of impasses into measures of negotiation performance to provide a more holistic examination of negotiation outcomes. In so doing, we reveal a reversal of the oft-cited male performance advantage when obtaining an impasse is especially economically costly (as is the case when negotiators have weak negotiation alternatives). Specifically, we predicted that female negotiators would make less assertive first offers than men due to their more relational orientation and that these gender differences in offer assertiveness should result in women avoiding impasse more often than men. Since avoiding impasses should improve negotiation performance when negotiators are able to obtain a deal that is more valuable than their negotiation alternative, women's tendency to avoid impasses should improve their performance when negotiators have weak (vs. strong) alternatives. These predictions were supported in eight studies (three preregistered) across various negotiation contexts, comprising data from the television show Shark Tank (Study 1), four incentive-compatible negotiation simulations (Studies 2 and 3, Supplemental Studies), and a multistudy causal experimental chain (Supplemental Studies 4a-c). (PsycInfo Database Record (c) 2023 APA, all rights reserved).</text></passage></document>
<document><id>37827091</id><passage><infon key="journal">Vet Immunol Immunopathol;2023Oct06; 264 110661. doi:10.1016/j.vetimm.2023.110661</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Taylor C, Belin E, Brodbelt D, Klaasen HLBM, Catchpole B, </infon><offset>0</offset><text>Exploration of the potential utility of the luciferase immunoprecipitation system (LIPS) assay for the detection of anti-leptospira antibodies in dogs.</text></passage><passage><infon key="type">abstract</infon><offset>152</offset><text>Canine leptospirosis represents a diagnostic challenge to veterinarians, due to the variability in presenting clinical signs and interpretation of serology test results in dogs that have been vaccinated previously. None of the commercially available serological assays, including the microscopic agglutination test (MAT), have been verified to be capable of differentiating infected from vaccinated animals (DIVA). Recent work identified that half of primary practice attending dogs were up to date with their leptospirosis vaccination and would be expected to have circulating anti-leptospira antibodies (Taylor et al., 2022), indicating that this is a relevant issue for suspected leptospirosis cases in dogs in the UK. This study aimed to explore the utility of three leptospiral outer membrane proteins (OMPs: LipL32, LipL21 and LipL41) as potential DIVA targets in the luciferase immunoprecipitation system (LIPS) assay. N and C terminal nanoluciferase tagged recombinant proteins were generated for each OMP. Differences in reactivity between serum samples from MAT positive dogs (n = 29) and paired samples (n = 6 dogs) taken pre and 21 days post leptospirosis vaccination were assessed against these six constructs. Reactivity was greater towards the N terminal than the C terminal recombinant proteins for all three OMPs. None of the constructs appeared to demonstrate DIVA capability, although two (pNLF1-N-FLAG/LipL32 and pNLF1-N-FLAG/LipL21) were able to detect vaccine seroconversion. The findings of this work suggest that these particular OMP targets do not offer DIVA ability, however LipL32 and LipL21 may be suitable for use in immunoassays for vaccine trials or for detection of infections in humans, where there is no requirement for DIVA capability.</text><annotation id="4"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="526" length="8"/><text>infected</text></annotation><annotation id="5"><infon key="identifier">MESH:D007922</infon><infon key="type">Disease</infon><location offset="662" length="13"/><text>leptospirosis</text></annotation><annotation id="6"><infon key="identifier">MESH:D007922</infon><infon key="type">Disease</infon><location offset="835" length="13"/><text>leptospirosis</text></annotation><annotation id="7"><infon key="identifier">MESH:D007922</infon><infon key="type">Disease</infon><location offset="1306" length="13"/><text>leptospirosis</text></annotation></passage></document>
<document><id>37827442</id><passage><infon key="journal">Exp Eye Res;2023Oct10; 236 109676. doi:10.1016/j.exer.2023.109676</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bai Y, Zhang K, Cao X, Chen P, </infon><offset>0</offset><text>Aquaporins in lacrimal glands and their role in dry eye disease.</text><annotation id="1"><infon key="identifier">MESH:D015352</infon><infon key="type">Disease</infon><location offset="48" length="15"/><text>dry eye disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>65</offset><text>Aging is the most important known risk factor for dry eye is aging, which is associated with changes in the structure and function of the lacrimal gland (LG) and characterized by atrophy, duct blocking lymphocyte infiltration, and reduced protein secretion. Aquaporins (AQP) have been proposed as a potential producer of exocrine gland fluids since exocrine secretion depends on the mobility of water. Therefore, the main topics of this review will be the expression, localization, and function of AQPs in LG. In addition, we review the mechanisms of fluid transport in exocrine gland fluid secretion and discuss the potential role of AQPs in dry eye.</text><annotation id="6"><infon key="identifier">MESH:D015352</infon><infon key="type">Disease</infon><location offset="115" length="7"/><text>dry eye</text></annotation><annotation id="7"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="244" length="7"/><text>atrophy</text></annotation><annotation id="8"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="460" length="5"/><text>water</text></annotation><annotation id="9"><infon key="identifier">MESH:D015352</infon><infon key="type">Disease</infon><location offset="708" length="7"/><text>dry eye</text></annotation></passage></document>
<document><id>37827792</id><passage><infon key="journal">Huan Jing Ke Xue;2023Oct08; 44 (10) 5769. doi:10.13227/j.hjkx.202212028</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lin XB, He SL, Wu DJ, Zhou LJ, Wu L, Peng J, Huang SS, Wang BQ, Huang QR, Wu JF, </infon><offset>0</offset><text>[Characteristics of Cadmium Concentration and Transport of Pueraria thornsonii in Farmland with Different Cadmium Pollution Degrees].</text><annotation id="2"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="20" length="7"/><text>Cadmium</text></annotation><annotation id="3"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="106" length="7"/><text>Cadmium</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>This study aimed to elucidate the cadmium (Cd) concentration and transport characteristics of Pueraria thornsonii in farmland with different Cd pollution degrees, so as to provide a reference basis for phytoremediation of Cd-contaminated farmland. The multi-point experiments in farmland with different Cd pollution degrees[omega(Cd) 0.32-38.08 mg kg-1] were conducted, and the biomass (dry weight), Cd content, accumulation, concentration, and transport of Cd in P. thornsonii tissues under the main growing period were assessed. According to the results, for P. thornsonii, the tuber dry weight ranged from 5.04 to 11.98 t hm-2, biomass ranged from 13.21 to 29.07 t hm-2, and Cd accumulation ranged from 15.74 to 106.03 g hm-2in the study area. The pattern of Cd uptake by P. thornsonii showed that the main vine>leaf>lateral branches>basal part of sti>tuber. The Cd content in P. thornsonii tissues considerably increased with soil Cd content (P&lt;0.05), whereas the biomass decreased significantly (P&lt;0.05). The Cd concentration and transport factor of aboveground parts in P. thornsonii showed a trend of initially falling, then increasing and decreasing again, whereas the Cd enrichment and transport coefficient of tubers gradually decreased. Correlation analysis revealed that the amount of Cd in the soil was a major predictor of Cd accumulation in P. thornsonii. Under light to moderate Cd contamination, the commercial portion of P. thornsonii (arrowroot)[omega(Cd) 0.03-0.22 mg kg-1] was less than the standard limit for medicinal plants (&lt;= 0.30 mg kg-1). In P. thornsonii from moderately contaminated areas, the Cd concentration and transport factor of aboveground parts were 2.43-7.97 and 3.02-9.81, respectively. This indicates that P. thornsonii is a prospective plant ideal for remediating Cd-contaminated soil because of its high capacity to transfer and enrich Cd.</text><annotation id="25"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="168" length="7"/><text>cadmium</text></annotation><annotation id="26"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="177" length="2"/><text>Cd</text></annotation><annotation id="27"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="275" length="2"/><text>Cd</text></annotation><annotation id="28"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="356" length="2"/><text>Cd</text></annotation><annotation id="29"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="437" length="2"/><text>Cd</text></annotation><annotation id="30"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="464" length="2"/><text>Cd</text></annotation><annotation id="31"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="534" length="2"/><text>Cd</text></annotation><annotation id="32"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="592" length="2"/><text>Cd</text></annotation><annotation id="33"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="812" length="2"/><text>Cd</text></annotation><annotation id="34"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="896" length="2"/><text>Cd</text></annotation><annotation id="35"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1000" length="2"/><text>Cd</text></annotation><annotation id="36"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1069" length="2"/><text>Cd</text></annotation><annotation id="37"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1148" length="2"/><text>Cd</text></annotation><annotation id="38"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1311" length="2"/><text>Cd</text></annotation><annotation id="39"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1431" length="2"/><text>Cd</text></annotation><annotation id="40"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1471" length="2"/><text>Cd</text></annotation><annotation id="41"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1529" length="2"/><text>Cd</text></annotation><annotation id="42"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1605" length="2"/><text>Cd</text></annotation><annotation id="43"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1758" length="2"/><text>Cd</text></annotation><annotation id="44"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1940" length="2"/><text>Cd</text></annotation><annotation id="45"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="2013" length="2"/><text>Cd</text></annotation></passage></document>
<document><id>37828859</id><passage><infon key="journal">Cancer Res;2023Oct13; 83 (20) 3324. doi:10.1158/0008-5472.CAN-23-2769</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Shirnekhi HK, Chandra B, Kriwacki RW, </infon><offset>0</offset><text>Dissolving Fusion Oncoprotein Condensates to Reverse Aberrant Gene Expression.</text></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>In a recent study, Wang and colleagues reported that a significant fraction of cancer-associated fusion proteins display a common structural topology, including an N-terminal phase separation-prone region (PS) from one parent protein and a C-terminal DNA-binding domain (DBD) from the other. This is reminiscent of the structural topology of transcription factors and led to the hypothesis that the PS-DBD fusions form aberrant transcriptional condensates through phase separation, which was supported through transcriptomic data analysis and cellular condensate assays. The authors developed a high-throughput screen based upon time-lapse, high-content imaging to identify 114 compounds that dissolved condensates formed by a chromatin-dissociated mutant of FUS::ERG (FUS::ERGmut). One of these compounds, LY2835219, was shown to dissolve FUS::ERGmut condensates by promoting lysosome formation and was also active against condensates formed by other PS-DBD fusions, including EWS::FLI1. Finally, condensate dissolution by LY2835219 was shown to reverse aberrant gene expression driven by EWS::FLI1, although how this compound specifically marshals lysosomes to target some PS-DBD fusions and not other condensate-forming proteins remains elusive. This work not only highlights likely roles for aberrant condensate formation in the oncogenic function of PS-DBD fusions, but also provides proof of principle for mechanistically unbiased screening to identify compounds that modulate fusion protein-driven condensates and their oncogenic functions.</text><annotation id="11"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="158" length="6"/><text>cancer</text></annotation><annotation id="12"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="285" length="2"/><text>PS</text></annotation><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="478" length="2"/><text>PS</text></annotation><annotation id="14"><infon key="identifier">2521;2078</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">15848</infon><location offset="838" length="8"/><text>FUS::ERG</text></annotation><annotation id="15"><infon key="identifier">MESH:C000590451</infon><infon key="type">Chemical</infon><location offset="886" length="9"/><text>LY2835219</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1031" length="2"/><text>PS</text></annotation><annotation id="17"><infon key="identifier">2130;2313</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136069;55624</infon><location offset="1057" length="9"/><text>EWS::FLI1</text></annotation><annotation id="18"><infon key="identifier">MESH:C000590451</infon><infon key="type">Chemical</infon><location offset="1103" length="9"/><text>LY2835219</text></annotation><annotation id="19"><infon key="identifier">2130;2313</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136069;55624</infon><location offset="1169" length="9"/><text>EWS::FLI1</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1254" length="2"/><text>PS</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1434" length="2"/><text>PS</text></annotation></passage><relation id="R1"><infon key="score">0.9886</infon><infon key="role1">Chemical|MESH:C000590451</infon><infon key="role2">Gene|2130</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="4,6"/></relation><relation id="R2"><infon key="score">0.8442</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|2521</infon><infon key="type">Association</infon><node refid="1" role="0,3"/></relation><relation id="R3"><infon key="score">0.9886</infon><infon key="role1">Chemical|MESH:C000590451</infon><infon key="role2">Gene|2313</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="4,6"/></relation><relation id="R4"><infon key="score">0.8442</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|2078</infon><infon key="type">Association</infon><node refid="3" role="0,3"/></relation></document>
<document><id>37829209</id><passage><infon key="journal">Proc (Bayl Univ Med Cent);2023; 36 (6) 706. doi:10.1080/08998280.2023.2254185</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10566428</infon><infon key="type">title</infon><infon key="authors">Collinsworth AW, Kouznetsova M, Hall L, Robinson C, Ogola GO, Turner A, Priest EL, Hart C, B&amp;#xf6;ing EA, Wan GJ, Peters WR, Masica AL, </infon><offset>0</offset><text>Impact of an enhanced recovery after surgery program with a multimodal analgesia care pathway on opioid prescribing and clinical outcomes for patients undergoing colorectal surgery.</text></passage><passage><infon key="type">abstract</infon><offset>182</offset><text>Background: Opioids are a mainstay for acute pain management, but their side effects can adversely impact patient recovery. Multimodal analgesia (MMA) is recommended for treatment of postoperative pain and has been incorporated in enhanced recovery after surgery (ERAS) protocols. The objective of this quality improvement study was to implement an MMA care pathway as part of an ERAS program for colorectal surgery and to measure the effect of this intervention on patient outcomes and costs. Methods: This pre-post study included 856 adult inpatients who underwent an elective colorectal surgery at three hospitals within an integrated healthcare system. The impact of ERAS program implementation on opioid prescribing practices, outcomes, and costs was examined after adjusting for clinical and demographic confounders. Results: Improvements were seen in MMA compliance (34.0% vs 65.5%, P &lt; 0.0001) and ERAS compliance (50.4% vs 57.6%, P &lt; 0.0001). Reductions in mean days on opioids (4.2 vs 3.2), daily (51.6 vs 33.4 mg) and total (228.8 vs 112.7 mg) morphine milligram equivalents given during hospitalization, and risk-adjusted length of stay (4.3 vs 3.6 days, P &lt; 0.05) were also observed. Conclusions: Implementing ERAS programs that include MMA care pathways as standard of care may result in more judicious use of opioids and reduce patient recovery time.</text><annotation id="3"><infon key="identifier">MESH:D059787</infon><infon key="type">Disease</infon><location offset="221" length="10"/><text>acute pain</text></annotation><annotation id="4"><infon key="identifier">MESH:D010149</infon><infon key="type">Disease</infon><location offset="365" length="18"/><text>postoperative pain</text></annotation><annotation id="5"><infon key="identifier">MESH:D009020</infon><infon key="type">Chemical</infon><location offset="1237" length="8"/><text>morphine</text></annotation></passage></document>
<document><id>37830260</id><passage><infon key="journal">Dalton Trans;2023Oct13. doi:10.1039/d3dt02717a</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Franc M, Vos&amp;#xe1;hlo P, Schulz J, C&amp;#xed;sa&amp;#x159;ov&amp;#xe1; I, &amp;#x160;t&amp;#x11b;pni&amp;#x10d;ka P, </infon><offset>0</offset><text>Synthesis and reactivity of Pd(II) imidoyl complexes obtained by insertion of isocyanoferrocene into the Pd-C bonds of orthopalladated precursors.</text><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="28" length="24"/><text>Pd(II) imidoyl complexes</text></annotation><annotation id="6"><infon key="identifier">MESH:C470605</infon><infon key="type">Chemical</infon><location offset="78" length="17"/><text>isocyanoferrocene</text></annotation><annotation id="7"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="105" length="2"/><text>Pd</text></annotation><annotation id="8"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="108" length="1"/><text>C</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="119" length="15"/><text>orthopalladated</text></annotation></passage><passage><infon key="type">abstract</infon><offset>147</offset><text>While the multifaceted reactivity of organic isocyanides has been extensively demonstrated, that of their organometallic analogue, isocyanoferrocene (FcNC; Fc = ferrocenyl), has not yet been adequately explored. This contribution describes the syntheses of novel chelating Pd(II) imidoyl complexes, [(YCH2C6H4C(NFc)-kappa2Y,C)PdCl(PR3)], by insertion of FcNC into the Pd-C bond of cyclopalladated precursors [(YCH2C6H4-kappa2Y,C)PdCl(PR3)] (Y = Me2N, MeS, R = Ph, Me). The imidoyl complexes underwent facile alkylation with [Me3O][BF4] to produce the cationic aminocarbene complexes [{YCH2C6H4C(N(Me)Fc)-kappa2Y,C}PdCl(PR3)][BF4]. All compounds were fully characterised using a combination of spectroscopic methods (NMR, FTIR and ESI MS), cyclic voltammetry and single-crystal X-ray crystallography. In addition, DFT calculations were used to describe the bonding in the two compound families. Analyses with intrinsic bond orbitals (IBOs) and the quantum theory of atoms in molecules (QTAIM) consistently pointed to the transformation of an X-type imidoyl C-ligand (sigma-organyl) into an L-type carbene donor upon alkylation, which has only a minor structural consequence. Also reported is the unexpected conversion of the imidoyl complex [(Me2NCH2C6H4C(NFc)-kappa2N,C)PdCl(PPh3)] into (Z)-2,2-dimethyl-1-(ferrocenylimino)isoindolin-2-ium tetrafluoroborate as a reductive elimination product, which was induced by Lewis and Bronsted acids.</text><annotation id="29"><infon key="identifier">MESH:D003486</infon><infon key="type">Chemical</infon><location offset="192" length="11"/><text>isocyanides</text></annotation><annotation id="30"><infon key="identifier">MESH:C470605</infon><infon key="type">Chemical</infon><location offset="278" length="17"/><text>isocyanoferrocene</text></annotation><annotation id="31"><infon key="identifier">MESH:C095424</infon><infon key="type">Chemical</infon><location offset="303" length="2"/><text>Fc</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="308" length="10"/><text>ferrocenyl</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="420" length="24"/><text>Pd(II) imidoyl complexes</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="447" length="35"/><text>(YCH2C6H4C(NFc)-kappa2Y,C)PdCl(PR3)</text></annotation><annotation id="35"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="515" length="2"/><text>Pd</text></annotation><annotation id="36"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="518" length="1"/><text>C</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="556" length="29"/><text>(YCH2C6H4-kappa2Y,C)PdCl(PR3)</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="592" length="4"/><text>Me2N</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="671" length="10"/><text>[Me3O][BF4</text></annotation><annotation id="40"><infon key="identifier">MESH:C504703</infon><infon key="type">Chemical</infon><location offset="707" length="12"/><text>aminocarbene</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="730" length="41"/><text>[{YCH2C6H4C(N(Me)Fc)-kappa2Y,C}PdCl(PR3)]</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="772" length="3"/><text>BF4</text></annotation><annotation id="43"><infon key="identifier">MESH:C030011</infon><infon key="type">Chemical</infon><location offset="1243" length="7"/><text>carbene</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1371" length="15"/><text>imidoyl complex</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1388" length="39"/><text>(Me2NCH2C6H4C(NFc)-kappa2N,C)PdCl(PPh3)</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1434" length="70"/><text>(Z)-2,2-dimethyl-1-(ferrocenylimino)isoindolin-2-ium tetrafluoroborate</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1572" length="14"/><text>Bronsted acids</text></annotation></passage><relation id="R1"><infon key="score">0.948</infon><infon key="role1">Chemical|MESH:C470605</infon><infon key="role2">Chemical|MESH:D010165</infon><infon key="type">Association</infon><node refid="0" role="1,2"/></relation></document>
<document><id>37830964</id><passage><infon key="journal">Tidsskr Nor Laegeforen;2023Oct10; 143 (14) . doi:10.4045/tidsskr.23.0630</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cooper JG, Julsrud-Berg T, </infon><offset>0</offset><text>God erfaring med strukturerte helsedata.</text></passage><passage><infon key="type">abstract</infon><offset>41</offset></passage></document>
<document><id>37831315</id><passage><infon key="journal">Arch Osteoporos;2023Oct13; 18 (1) 126. doi:10.1007/s11657-023-01336-5</infon><infon key="year">2023</infon><infon key="article-id_pmc">9908666</infon><infon key="type">title</infon><infon key="authors">Tan CW, Arlachov Y, Czernicki M, Bishop S, Pasku D, Drummond A, Podlasek A, Sahota O, </infon><offset>0</offset><text>Spinal medial branch nerve root block (MBNB) intervention compared to standard care-vertebroplasty (VP) for the treatment of painful osteoporotic vertebral fractures in frail, older hospitalised patients: a feasibility study.</text><annotation id="1"><infon key="identifier">MESH:D058866</infon><infon key="type">Disease</infon><location offset="133" length="32"/><text>osteoporotic vertebral fractures</text></annotation></passage><passage><infon key="type">abstract</infon><offset>226</offset><text>Our study aimed to assess the feasibility outcomes comparing spinal medial branch nerve root block intervention to standard care vertebroplasty for the treatment of painful osteoporotic vertebral fractures in frail, hospitalised older patients. We found the study to be feasible and now propose a clinical effectiveness, cost effectiveness and safety evaluation. INTRODUCTION: Vertebroplasty (VP) is a key-hole procedure involving injection of bone cement into a fractured vertebral body, to reduce pain and increase vertebral body stability, although it is associated with a small risk of complications, particularly in frail, older hospitalised patients. Medial branch spinal nerve block (MBNB) may be an alternative treatment to alleviate pain symptoms, with less complications; however, no study has prospectively compared the clinical effectiveness, cost-effectiveness and safety of MBNB to VP, in frail, older hospitalised patients. The aim of our study was to conduct a 1st stage feasibility study, exploring recruitment, retention and several outcomes measures (means and SDs), together with qualitative interviews to assess participant and clinician views, to inform a definitive larger study. METHODS: We conducted a two-arm feasibility randomised controlled trial with participants allocated to continue with routine surgical care-VP or MBNB treatment, with an embedded qualitative study. Data was collected at baseline, week 1, 4, and week 8. RESULTS: Out of 40 eligible patients, 30 (75%) consented to take part in the study. The overall median time from randomisation to intervention was 3 days, IQR 1-7 days, 5 (1-7) days for VP and 2 (1-3) days for MBNB. Median (IQR) length of hospital stay for the VP group was 20 (8) days and for the MBNB 15(22) days. The proportion of completeness of outcome data collection at weeks 1, 4 and 8 was at least 77%: 14 (100%), 12 (85.7%) and 11(78.9%) for VP and 13 (100%), 12 (92.3%) and 10 (76.8%) for MBNB, respectively. There were no significant difference in the clinical outcomes or adverse events between the two groups. DISCUSSION: Our study was feasible in achieving is target recruitment, participants adhered to the randomisation and at least 77% completeness of data at the 8 week end-point (target 75%). We now plan to conduct a definitive clinical effectiveness, cost effectiveness and safety outcome study, comparing VP to MBNB in frail, older patients hospitalised with an acute vertebral osteoporotic fracture.</text><annotation id="7"><infon key="identifier">MESH:D058866</infon><infon key="type">Disease</infon><location offset="399" length="32"/><text>osteoporotic vertebral fractures</text></annotation><annotation id="8"><infon key="identifier">MESH:C536543</infon><infon key="type">Disease</infon><location offset="689" length="24"/><text>fractured vertebral body</text></annotation><annotation id="9"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="725" length="4"/><text>pain</text></annotation><annotation id="10"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="968" length="4"/><text>pain</text></annotation><annotation id="11"><infon key="identifier">MESH:D058866</infon><infon key="type">Disease</infon><location offset="2672" length="31"/><text>vertebral osteoporotic fracture</text></annotation></passage></document>
<document><id>37832017</id><passage><infon key="journal">Phys Rev Lett;2023Sep29; 131 (13) 136502. doi:10.1103/PhysRevLett.131.136502</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Dong J, Wang J, Ledwith PJ, Vishwanath A, Parker DE, </infon><offset>0</offset><text>Composite Fermi Liquid at Zero Magnetic Field in Twisted MoTe_{2}.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="57" length="8"/><text>MoTe_{2}</text></annotation></passage><passage><infon key="type">abstract</infon><offset>67</offset><text>The pursuit of exotic phases of matter outside of the extreme conditions of a quantizing magnetic field is a long-standing quest of solid state physics. Recent experiments have observed spontaneous valley polarization and fractional Chern insulators in zero magnetic field in twisted bilayers of MoTe_{2}, at partial filling of the topological valence band (nu=-2/3 and -3/5). We study the topological valence band at half filling, using exact diagonalization and density matrix renormalization group calculations. We discover a composite Fermi liquid (CFL) phase even at zero magnetic field that covers a large portion of the phase diagram near twist angle ~3.6 . The CFL is a non-Fermi liquid phase with metallic behavior despite the absence of Landau quasiparticles. We discuss experimental implications including the competition between the CFL and a Fermi liquid, which can be tuned with a displacement field. The topological valence band has excellent quantum geometry over a wide range of twist angles and a small bandwidth that is, remarkably, reduced by interactions. These key properties stabilize the exotic zero field quantum Hall phases. Finally, we present an optical signature involving "extinguished" optical responses that detects Chern bands with ideal quantum geometry.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="363" length="8"/><text>MoTe_{2}</text></annotation></passage></document>
<document><id>37832367</id><passage><infon key="journal">Plant Physiol Biochem;2023Oct; 203 108074. doi:10.1016/j.plaphy.2023.108074</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rivero-Montejo SJ, Rivera-Bustamante RF, Saavedra-Trejo DL, Vargas-Hernandez M, Palos-Barba V, Macias-Bobadilla I, Guevara-Gonzalez RG, Rivera-Mu&amp;#xf1;oz EM, Torres-Pacheco I, </infon><offset>0</offset><text>Inhibition of pepper huasteco yellow veins virus by foliar application of ZnO nanoparticles in Capsicum annuum L.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="74" length="17"/><text>ZnO nanoparticles</text></annotation></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>The Pepper huasteco yellow vein virus (PHYVV) is an endemic geminivirus in Mexico causing partial or total losses in the pepper crop since the damage caused by the virus has not been fully controlled. In this work, we evaluated the effect of ZnO NPs (0, 50, 100, 150, and 200 mM) as a preventive (72 h before) and curative (72 h after) treatment of PHYVV infection in two jalapeno pepper varieties. In this study, we observed a decrease in symptoms, and it could be caused by an induction of the defense system in pepper plants and a direct action on PHYVV by foliar application of ZnO NPs. Our findings suggest that ZnO NP application significantly decreased the viral titer for both varieties at 200 mM by 15.11-fold. However, this effect was different depending on the timing of application and the variety of pepper. The greatest decrease in the viral titer in the preventive treatment in both varieties was at the concentration of 200 mM (1781.17 and 274.5 times, respectively). For curative treatment in cv. Don Pancho at the concentration of 200 mM (333.33 times) and cv. Don Benito at 100 mM (43.10 folds). compared to control. Furthermore, virus mobility was generally restricted for both varieties at 100 mM (15.13-fold) compared to the control. The results possibly delineated that ZnO NPs increased plant resistance possibly by increasing POD (2.08 and 0.25 times) and SOD (0.998 and 1.38) in cv. Don Pancho and cv. Don Benito, respectively. On the other hand, in cv. Don Pancho and cv. Don Benito presented a decrease in CAT (0.61 and 0.058) and PAL (0.78 and 0.77), respectively. Taken together, we provide the first evidence to demonstrate the effect of ZnO NPs on viral symptoms depending on the plan-virus-ZnO NP interaction.</text><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="356" length="7"/><text>ZnO NPs</text></annotation><annotation id="12"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="696" length="7"/><text>ZnO NPs</text></annotation><annotation id="13"><infon key="identifier">MESH:D015034</infon><infon key="type">Chemical</infon><location offset="731" length="3"/><text>ZnO</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1407" length="7"/><text>ZnO NPs</text></annotation><annotation id="15"><infon key="identifier">107871140</infon><infon key="type">Gene</infon><location offset="1465" length="3"/><text>POD</text></annotation><annotation id="16"><infon key="identifier">107871142</infon><infon key="type">Gene</infon><location offset="1495" length="3"/><text>SOD</text></annotation><annotation id="17"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="1648" length="3"/><text>CAT</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1783" length="7"/><text>ZnO NPs</text></annotation><annotation id="19"><infon key="identifier">MESH:D015034</infon><infon key="type">Chemical</infon><location offset="1837" length="3"/><text>ZnO</text></annotation></passage></document>
<document><id>37832717</id><passage><infon key="journal">Transplant Cell Ther;2023Oct11. doi:10.1016/j.jtct.2023.10.011</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">LeMaistre FI, Tsai HL, Varadhan R, Al-Talib T, Jones R, Ambinder A, </infon><offset>0</offset><text>Allogeneic Hematopoietic Cell Transplantation with Non-Myeloablative Conditioning and Post-Transplant Cyclophosphamide Prophylaxis in Patients with Reduced Systolic Function.</text><annotation id="2"><infon key="identifier">MESH:D003520</infon><infon key="type">Chemical</infon><location offset="102" length="16"/><text>Cyclophosphamide</text></annotation><annotation id="3"><infon key="type">Disease</infon><location offset="131" length="2"/><text>in</text></annotation></passage><passage><infon key="type">abstract</infon><offset>175</offset><text>BACKGROUND: Post-transplant cyclophosphamide (PTCy) has become standard-of-care for graft-vs-host disease (GVHD) prophylaxis, including allowing expanded donor options. However, there is little literature examining outcomes of patients with reduced systolic function receiving PTCy. OBJECTIVES: This study aims to describe our experience in transplanting patients with reduced systolic function, including their non-relapse related mortality (NRM), overall survival (OS), and cumulative incidence of early cardiac events (ECE). STUDY DESIGN: This study is a retrospective descriptive analysis using the Johns Hopkins Hematologic Malignancy database. From 2017 through 2021, 1118 consecutive patients underwent allogeneic transplantation with a non-myeloablative (NMA) conditioning and PTCy. A total of 43 of those patients were found to have a pretransplant left ventricular ejection fraction (LVEF) &lt;= 45% measured by transthoracic echocardiography. Patients whose LVEF improved on treatment prior to transplant were also included. These two cohorts were stratified into heart failure with reduced ejection fraction (HFrEF) and heart failure with recovered ejection fraction (HFrecEF), and subgroup analysis compared NRM, OS, and cumulative incidence of ECE. ECE was defined as arrhythmia, coronary artery disease, reduction in LVEF, or pericardial effusion within 100 days post-transplant. RESULTS: The median LVEF for 31 patients undergoing transplant with HFrEF was 40-45% (range 30-45%) and 35-40% (range 20-45%) for the 12 patients with HFrecEF. The NRM for all 43 patients was 16% (5-27%) at 100 days and 23% (11-36%) at 2 years. The NRM was 23% (8-38%) and 26% (10-42%) at 100 days and 2 years for the HFrEF cohort and 0 and 18% (0-41%) at 100 days and 2 years for the HFrecEf cohort. The OS at 3 years was 41% (26-62%), 40% (25-65%) and 38% (14-100%) in combined, HFrEF, and HFrecEF cohorts, respectively. The cumulative incidence of any ECE was 37.2% (22-51.9%), including 39% of HFrEF subjects and 33% of HFrecEF subjects. Grade 3 or higher toxicities were seen in 56% of patients. A reduction in ejection fraction was the most common ECE. One death was attributable to a cardiac etiology. CONCLUSIONS: Cardiac toxicities seemed to frequent and severe in patients with a history of systolic dysfunction, but these do not lead to worse survival outcomes. This study adds to and extends existing literature supporting NMA conditioning and PTCy in patients with systolic dysfunction.</text><annotation id="29"><infon key="identifier">MESH:D003520</infon><infon key="type">Chemical</infon><location offset="203" length="16"/><text>cyclophosphamide</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="221" length="4"/><text>PTCy</text></annotation><annotation id="31"><infon key="identifier">MESH:D006086</infon><infon key="type">Disease</infon><location offset="259" length="21"/><text>graft-vs-host disease</text></annotation><annotation id="32"><infon key="identifier">MESH:D006086</infon><infon key="type">Disease</infon><location offset="282" length="4"/><text>GVHD</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="452" length="4"/><text>PTCy</text></annotation><annotation id="34"><infon key="type">Disease</infon><location offset="513" length="2"/><text>in</text></annotation><annotation id="35"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="792" length="22"/><text>Hematologic Malignancy</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="960" length="4"/><text>PTCy</text></annotation><annotation id="37"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1247" length="18"/><text>heart failure with</text></annotation><annotation id="38"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1304" length="18"/><text>heart failure with</text></annotation><annotation id="39"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="1454" length="10"/><text>arrhythmia</text></annotation><annotation id="40"><infon key="identifier">MESH:D003324</infon><infon key="type">Disease</infon><location offset="1466" length="23"/><text>coronary artery disease</text></annotation><annotation id="41"><infon key="type">Disease</infon><location offset="1501" length="2"/><text>in</text></annotation><annotation id="42"><infon key="identifier">MESH:D010490</infon><infon key="type">Disease</infon><location offset="1513" length="20"/><text>pericardial effusion</text></annotation><annotation id="43"><infon key="type">Disease</infon><location offset="2035" length="2"/><text>in</text></annotation><annotation id="44"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="2227" length="10"/><text>toxicities</text></annotation><annotation id="45"><infon key="type">Disease</infon><location offset="2248" length="2"/><text>in</text></annotation><annotation id="46"><infon key="type">Disease</infon><location offset="2280" length="2"/><text>in</text></annotation><annotation id="47"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="2330" length="5"/><text>death</text></annotation><annotation id="48"><infon key="identifier">MESH:D066126</infon><infon key="type">Disease</infon><location offset="2389" length="18"/><text>Cardiac toxicities</text></annotation><annotation id="49"><infon key="type">Disease</infon><location offset="2438" length="2"/><text>in</text></annotation><annotation id="50"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="2468" length="20"/><text>systolic dysfunction</text></annotation><annotation id="51"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2623" length="4"/><text>PTCy</text></annotation><annotation id="52"><infon key="type">Disease</infon><location offset="2628" length="2"/><text>in</text></annotation><annotation id="53"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="2645" length="20"/><text>systolic dysfunction</text></annotation></passage><relation id="R1"><infon key="score">0.6306</infon><infon key="role1">Chemical|MESH:D003520</infon><infon key="role2">Disease|MESH:D006333</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="2,10"/></relation><relation id="R2"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D003520</infon><infon key="role2">Disease|MESH:D006086</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="2,4"/></relation><relation id="R3"><infon key="score">0.5103</infon><infon key="role1">Chemical|MESH:D003520</infon><infon key="role2">Disease|MESH:D006331</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="2,23"/></relation></document>
<document><id>37833067</id><passage><infon key="journal">J Neurosci;2023Oct13. doi:10.1523/JNEUROSCI.0529-23.2023</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rahamim N, Slovik M, Mevorach T, Linkovski O, Bergman H, Rosin B, Eitan R, </infon><offset>0</offset><text>Tuned to Tremor: Increased Sensitivity of Cortico-Basal Ganglia Neurons to Tremor Frequency in the MPTP Non-Human Primate Model of Parkinson's Disease.</text><annotation id="2"><infon key="identifier">MESH:D015632</infon><infon key="type">Chemical</infon><location offset="99" length="4"/><text>MPTP</text></annotation><annotation id="3"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="131" length="19"/><text>Parkinson's Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>152</offset><text>Rest tremor is one of the most prominent clinical features of Parkinson's disease (PD). Here, we hypothesized that cortico-basal ganglia (CBG) neurons tend to fire in a pattern that matches PD tremor frequency, suggesting a resonance phenomenon. We recorded spiking activity in the primary motor cortex (M1) and Globus Pallidus external segment (GPe) of two female non-human primates (NHPs), before and after parkinsonian state induction with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The NHP's arm was passively rotated at seven different frequencies surrounding and overlapping PD tremor frequency. We found entrainment of the spiking activity to arm rotation and a significant sharpening of the tuning curves in the MPTP state, with a peak response at frequencies that matched the frequency of PD tremor. These results reveal increased sensitivity of the CBG network to tremor frequency and could indicate that this network acts not only as a tremor switch but is involved in setting its frequency.Significance StatementTremor is a prominent clinical feature of Parkinson's disease (PD); however, its underlying pathophysiology is still poorly understood. Using electrophysiological recordings of single cortico-basal ganglia (CBG) neurons before and after the induction of a parkinsonian state, and in response to passive arm rotation, this study reports increased sensitivity to tremor frequency in PD. We found sharpening of the population tuning to the midrange of the tested frequencies (1-13.3Hz) in the healthy state that further increased in the parkinsonian state. These results hint at the increased frequency-tuned sensitivity of CBG neurons and suggest that they tend to resonate with the tremor.</text><annotation id="23"><infon key="identifier">MESH:D014202</infon><infon key="type">Disease</infon><location offset="157" length="6"/><text>tremor</text></annotation><annotation id="24"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="214" length="19"/><text>Parkinson's disease</text></annotation><annotation id="25"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="235" length="2"/><text>PD</text></annotation><annotation id="26"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="342" length="9"/><text>PD tremor</text></annotation><annotation id="27"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="561" length="12"/><text>parkinsonian</text></annotation><annotation id="28"><infon key="identifier">MESH:D015632</infon><infon key="type">Chemical</infon><location offset="595" length="44"/><text>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</text></annotation><annotation id="29"><infon key="identifier">MESH:D015632</infon><infon key="type">Chemical</infon><location offset="641" length="4"/><text>MPTP</text></annotation><annotation id="30"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="743" length="9"/><text>PD tremor</text></annotation><annotation id="31"><infon key="identifier">MESH:D015632</infon><infon key="type">Chemical</infon><location offset="882" length="4"/><text>MPTP</text></annotation><annotation id="32"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="960" length="9"/><text>PD tremor</text></annotation><annotation id="33"><infon key="identifier">MESH:D014202</infon><infon key="type">Disease</infon><location offset="1036" length="6"/><text>tremor</text></annotation><annotation id="34"><infon key="identifier">MESH:D014202</infon><infon key="type">Disease</infon><location offset="1109" length="6"/><text>tremor</text></annotation><annotation id="35"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="1228" length="19"/><text>Parkinson's disease</text></annotation><annotation id="36"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="1249" length="2"/><text>PD</text></annotation><annotation id="37"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="1442" length="12"/><text>parkinsonian</text></annotation><annotation id="38"><infon key="identifier">MESH:D014202</infon><infon key="type">Disease</infon><location offset="1547" length="6"/><text>tremor</text></annotation><annotation id="39"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="1567" length="2"/><text>PD</text></annotation><annotation id="40"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="1720" length="12"/><text>parkinsonian</text></annotation><annotation id="41"><infon key="identifier">MESH:D014202</infon><infon key="type">Disease</infon><location offset="1867" length="6"/><text>tremor</text></annotation></passage><relation id="R1"><infon key="score">0.7972</infon><infon key="role1">Chemical|MESH:D015632</infon><infon key="role2">Disease|MESH:D010300</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="0,1"/></relation></document>
<document><id>37833417</id><passage><infon key="journal">J Comp Physiol B;2023Dec; 193 (6) 615. doi:10.1007/s00360-023-01518-0</infon><infon key="year">2023</infon><infon key="article-id_pmc">5604330</infon><infon key="type">title</infon><infon key="authors">Yang Y, Tian J, Xu W, Ping C, Du X, Ye Y, Zhu B, Huang Y, Li Y, Jiang Q, Zhao Y, </infon><offset>0</offset><text>Comparative metabolomics analysis investigating the impact of melatonin-enriched diet on energy metabolism in the crayfish, Cherax destructor.</text><annotation id="1"><infon key="identifier">MESH:D008550</infon><infon key="type">Chemical</infon><location offset="62" length="9"/><text>melatonin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>143</offset><text>Melatonin is a multifunctional bioactive molecule present in almost all organisms and has been gradually used in the aquaculture industry in recent years. Energy metabolism is an essential process for individuals to maintain their life activities; however, the process through which melatonin regulates energy metabolism in aquatic animals remains unclear. The present study aimed to conduct a comprehensive analysis of the regulatory mechanism of melatonin for energy metabolism in Cherax destructor by combining metabolomics analysis with the detection of the key substance content, enzymatic activity, and gene expression levels in the energy metabolism process after culturing with dietary melatonin supplementation for 8 weeks. Our results showed that dietary melatonin increased the content of glycogen, triglycerides, and free fatty acids; decreased lactate levels; and promoted the enzymatic activity of pyruvate kinase (PK), malate dehydrogenase (MDH), and acetyl-CoA carboxylase. The results of gene expression analysis showed that dietary melatonin also increased the expression levels of hexokinase, PK, MDH, lactate dehydrogenase, lipase, and fatty acid synthase genes. The results of metabolomics analysis showed that differentially expressed metabolites were significantly enriched in lysine degradation and glycerophospholipid metabolism. In conclusion, our study demonstrates that dietary melatonin increased oxidative phosphorylation, improved glucose utilization, and promoted storage of glycogen and lipids in C. destructor. These lipids are used not only for energy storage but also to maintain the structure and function of cell membranes. Our results further add to the understanding of the mechanisms of energy regulation by melatonin in crustaceans.</text><annotation id="20"><infon key="identifier">MESH:D008550</infon><infon key="type">Chemical</infon><location offset="143" length="9"/><text>Melatonin</text></annotation><annotation id="21"><infon key="identifier">MESH:D008550</infon><infon key="type">Chemical</infon><location offset="426" length="9"/><text>melatonin</text></annotation><annotation id="22"><infon key="identifier">MESH:D008550</infon><infon key="type">Chemical</infon><location offset="591" length="9"/><text>melatonin</text></annotation><annotation id="23"><infon key="identifier">MESH:D008550</infon><infon key="type">Chemical</infon><location offset="837" length="9"/><text>melatonin</text></annotation><annotation id="24"><infon key="identifier">MESH:D008550</infon><infon key="type">Chemical</infon><location offset="908" length="9"/><text>melatonin</text></annotation><annotation id="25"><infon key="identifier">MESH:D006003</infon><infon key="type">Chemical</infon><location offset="943" length="8"/><text>glycogen</text></annotation><annotation id="26"><infon key="identifier">MESH:D014280</infon><infon key="type">Chemical</infon><location offset="953" length="13"/><text>triglycerides</text></annotation><annotation id="27"><infon key="identifier">MESH:D005230</infon><infon key="type">Chemical</infon><location offset="972" length="16"/><text>free fatty acids</text></annotation><annotation id="28"><infon key="identifier">MESH:D019344</infon><infon key="type">Chemical</infon><location offset="1000" length="7"/><text>lactate</text></annotation><annotation id="29"><infon key="identifier">MESH:D008550</infon><infon key="type">Chemical</infon><location offset="1193" length="9"/><text>melatonin</text></annotation><annotation id="30"><infon key="identifier">MESH:D008239</infon><infon key="type">Chemical</infon><location offset="1443" length="6"/><text>lysine</text></annotation><annotation id="31"><infon key="identifier">MESH:D020404</infon><infon key="type">Chemical</infon><location offset="1466" length="19"/><text>glycerophospholipid</text></annotation><annotation id="32"><infon key="identifier">MESH:D008550</infon><infon key="type">Chemical</infon><location offset="1549" length="9"/><text>melatonin</text></annotation><annotation id="33"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1605" length="7"/><text>glucose</text></annotation><annotation id="34"><infon key="identifier">MESH:D006003</infon><infon key="type">Chemical</infon><location offset="1650" length="8"/><text>glycogen</text></annotation><annotation id="35"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1663" length="6"/><text>lipids</text></annotation><annotation id="36"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1694" length="6"/><text>lipids</text></annotation><annotation id="37"><infon key="identifier">MESH:D008550</infon><infon key="type">Chemical</infon><location offset="1892" length="9"/><text>melatonin</text></annotation></passage><relation id="R1"><infon key="score">0.5305</infon><infon key="role1">Chemical|MESH:D008239</infon><infon key="role2">Chemical|MESH:D008550</infon><infon key="type">Association</infon><node refid="0" role="11,10"/></relation><relation id="R2"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:D008550</infon><infon key="role2">Chemical|MESH:D014280</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="5,7"/></relation><relation id="R3"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D008055</infon><infon key="role2">Chemical|MESH:D008550</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="16,13"/></relation><relation id="R4"><infon key="score">0.9977</infon><infon key="role1">Chemical|MESH:D005947</infon><infon key="role2">Chemical|MESH:D008550</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="14,13"/></relation><relation id="R5"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:D006003</infon><infon key="role2">Chemical|MESH:D008550</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="6,5"/></relation><relation id="R6"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D008550</infon><infon key="role2">Chemical|MESH:D019344</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="5,9"/></relation><relation id="R7"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D005230</infon><infon key="role2">Chemical|MESH:D008550</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="8,5"/></relation></document>
<document><id>37837270</id><passage><infon key="journal">Expert Rev Clin Immunol;2023Oct14. doi:10.1080/1744666X.2023.2271666</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Marko M, Pawliczak R, </infon><offset>0</offset><text>Skin infections during dupilumab monotherapy in moderate-to-severe atopic dermatitis - a meta-analysis of randomized clinical trials.</text><annotation id="3"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="0" length="15"/><text>Skin infections</text></annotation><annotation id="4"><infon key="identifier">MESH:C582203</infon><infon key="type">Chemical</infon><location offset="23" length="9"/><text>dupilumab</text></annotation><annotation id="5"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="67" length="17"/><text>atopic dermatitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>OBJECTIVE: Atopic dermatitis (AD) increases the risk of bacterial and viral cutaneous infections. This study assesses the risk of skin infections related to dupilumab monotherapy in moderate-to-severe AD. METHODS: We searched PubMed/Medline, Embase, Web of Science, ClinicalTrials.gov, and Cochrane Library. For gray literature, Google Scholar was searched. A meta-analysis of randomized clinical trials (RCTs) for overall skin infections, eczema herpeticum, nonherpetic skin infections and subgroup meta-analysis based on overall herpetic infection type was performed. RESULTS: We observed a statistically significant (p &lt; 0.005) lower incidence rate in the dupilumab group compared to placebo for overall skin infections (Risk Ratio [RR] = 0.59, 95% confidence interval [CI]: [0.47, 0.75], P &lt; 0.0001) and nonherpetic skin infections (RR = 0.42, 95% CI: [0.27, 0.66], P = 0.0001). For herpetic infections in 2b phase studies a meta-analysis demonstrated significantly higher events in dupilumab group compared to placebo (RR = 3.38, 95% CI: [1.98, 5.76], P &lt; 0.00001, test for subgroup differences: P = 0.02, I2 = 65.6%). CONCLUSIONS: In moderate-to-severe AD, dupilumab in monotherapy may be an effective and safe therapeutic approach, not associated with an increased risk of overall skin infections and nonherpetic skin infections. Due to the lack of statistical significance in heterogeneity associated with potential confounders in some cases, results should be interpreted cautiously. REGISTRATION: The meta-analysis was registered in PROSPERO, ID: CRD42023441346.</text><annotation id="27"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="145" length="17"/><text>Atopic dermatitis</text></annotation><annotation id="28"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="164" length="2"/><text>AD</text></annotation><annotation id="29"><infon key="identifier">MESH:D001424</infon><infon key="type">Disease</infon><location offset="190" length="9"/><text>bacterial</text></annotation><annotation id="30"><infon key="identifier">MESH:D014777</infon><infon key="type">Disease</infon><location offset="204" length="5"/><text>viral</text></annotation><annotation id="31"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="210" length="20"/><text>cutaneous infections</text></annotation><annotation id="32"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="264" length="15"/><text>skin infections</text></annotation><annotation id="33"><infon key="identifier">MESH:C582203</infon><infon key="type">Chemical</infon><location offset="291" length="9"/><text>dupilumab</text></annotation><annotation id="34"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="335" length="2"/><text>AD</text></annotation><annotation id="35"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="557" length="15"/><text>skin infections</text></annotation><annotation id="36"><infon key="identifier">MESH:D007617</infon><infon key="type">Disease</infon><location offset="574" length="17"/><text>eczema herpeticum</text></annotation><annotation id="37"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="605" length="15"/><text>skin infections</text></annotation><annotation id="38"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="665" length="18"/><text>herpetic infection</text></annotation><annotation id="39"><infon key="identifier">MESH:C582203</infon><infon key="type">Chemical</infon><location offset="793" length="9"/><text>dupilumab</text></annotation><annotation id="40"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="841" length="15"/><text>skin infections</text></annotation><annotation id="41"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="954" length="15"/><text>skin infections</text></annotation><annotation id="42"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1021" length="19"/><text>herpetic infections</text></annotation><annotation id="43"><infon key="identifier">MESH:C582203</infon><infon key="type">Chemical</infon><location offset="1121" length="9"/><text>dupilumab</text></annotation><annotation id="44"><infon key="identifier">MESH:D003876</infon><infon key="type">Disease</infon><location offset="1293" length="2"/><text>AD</text></annotation><annotation id="45"><infon key="identifier">MESH:C582203</infon><infon key="type">Chemical</infon><location offset="1297" length="9"/><text>dupilumab</text></annotation><annotation id="46"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1422" length="15"/><text>skin infections</text></annotation><annotation id="47"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1454" length="15"/><text>skin infections</text></annotation></passage><relation id="R1"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:C582203</infon><infon key="role2">Disease|MESH:D003876</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="1,2"/></relation><relation id="R2"><infon key="score">0.9913</infon><infon key="role1">Chemical|MESH:C582203</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="1,0"/></relation></document>
<document><id>37837622</id><passage><infon key="journal">Cell Rep;2023Oct31; 42 (10) 113245. doi:10.1016/j.celrep.2023.113245</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Pranoto IKA, Lee J, Kwon YV, </infon><offset>0</offset><text>The roles of the native cell differentiation program aberrantly recapitulated in Drosophila intestinal tumors.</text><annotation id="1"><infon key="identifier">MESH:D007414</infon><infon key="type">Disease</infon><location offset="92" length="17"/><text>intestinal tumors</text></annotation></passage><passage><infon key="type">abstract</infon><offset>111</offset><text>Many tumors recapitulate the developmental and differentiation program of their tissue of origin, a basis for tumor cell heterogeneity. Although stem-cell-like tumor cells are well studied, the roles of tumor cells undergoing differentiation remain to be elucidated. We employ Drosophila genetics to demonstrate that the differentiation program of intestinal stem cells is crucial for enabling intestinal tumors to invade and induce non-tumor-autonomous phenotypes. The differentiation program that generates absorptive cells is aberrantly recapitulated in the intestinal tumors generated by activation of the Yap1 ortholog Yorkie. Inhibiting it allows stem-cell-like tumor cells to grow but suppresses invasiveness and reshapes various phenotypes associated with cachexia-like wasting by altering the expression of tumor-derived factors. Our study provides insight into how a native differentiation program determines a tumor's capacity to induce advanced cancer phenotypes and suggests that manipulating the differentiation programs co-opted in tumors might alleviate complications of cancer, including cachexia.</text><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="116" length="6"/><text>tumors</text></annotation><annotation id="20"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="221" length="5"/><text>tumor</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="271" length="5"/><text>tumor</text></annotation><annotation id="22"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="314" length="5"/><text>tumor</text></annotation><annotation id="23"><infon key="identifier">MESH:D007414</infon><infon key="type">Disease</infon><location offset="505" length="17"/><text>intestinal tumors</text></annotation><annotation id="24"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="548" length="5"/><text>tumor</text></annotation><annotation id="25"><infon key="identifier">MESH:D007414</infon><infon key="type">Disease</infon><location offset="672" length="17"/><text>intestinal tumors</text></annotation><annotation id="26"><infon key="identifier">37851</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">121770</infon><location offset="735" length="6"/><text>Yorkie</text></annotation><annotation id="27"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="779" length="5"/><text>tumor</text></annotation><annotation id="28"><infon key="identifier">MESH:D002100</infon><infon key="type">Disease</infon><location offset="875" length="8"/><text>cachexia</text></annotation><annotation id="29"><infon key="identifier">MESH:D019282</infon><infon key="type">Disease</infon><location offset="889" length="7"/><text>wasting</text></annotation><annotation id="30"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="927" length="5"/><text>tumor</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1032" length="5"/><text>tumor</text></annotation><annotation id="32"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1068" length="6"/><text>cancer</text></annotation><annotation id="33"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1158" length="6"/><text>tumors</text></annotation><annotation id="34"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1198" length="6"/><text>cancer</text></annotation><annotation id="35"><infon key="identifier">MESH:D002100</infon><infon key="type">Disease</infon><location offset="1216" length="8"/><text>cachexia</text></annotation></passage><relation id="R1"><infon key="score">0.7736</infon><infon key="role1">Disease|MESH:D007414</infon><infon key="role2">Gene|37851</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="7,8"/></relation><relation id="R2"><infon key="score">0.9181</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|37851</infon><infon key="type">Association</infon><node refid="1" role="6,8"/></relation></document>
<document><id>37837972</id><passage><infon key="journal">Lancet Gastroenterol Hepatol;2023Nov; 8 (11) 969. doi:10.1016/S2468-1253(23)00312-6</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Prasad M, Sarin SK, Chauhan V, </infon><offset>0</offset><text>Expanding public health responses to non-communicable diseases: the NAFLD model of India.</text><annotation id="1"><infon key="identifier">MESH:D065626</infon><infon key="type">Disease</infon><location offset="68" length="5"/><text>NAFLD</text></annotation></passage><passage><infon key="type">abstract</infon><offset>90</offset></passage></document>
<document><id>37838323</id><passage><infon key="journal">Gastrointest Endosc;2023Oct12. doi:10.1016/j.gie.2023.08.024</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tang D, Lim R, Korman L, Forbes J, Ellsbury K, Auh S, Trivedi A, Chen CC, Hughes M, Wank S, </infon><offset>0</offset><text>Performance of capsule endoscopy for the detection of small intestinal neuroendocrine tumor in familial carcinoid: a prospective single site study.</text><annotation id="2"><infon key="identifier">MESH:D018358</infon><infon key="type">Disease</infon><location offset="60" length="31"/><text>intestinal neuroendocrine tumor</text></annotation><annotation id="3"><infon key="identifier">MESH:D002276</infon><infon key="type">Disease</infon><location offset="104" length="9"/><text>carcinoid</text></annotation></passage><passage><infon key="type">abstract</infon><offset>148</offset><text>BACKGROUND AND AIMS: Small bowel neuroendocrine tumors are slow growing, clinically silent tumors whose prognosis depends on disease stage. Members of kindreds with a familial form of small intestine neuroendocrine tumors (SI-NET) represent a high-risk population for whom early detection improves disease outcome. The aim was to determine the utility of small bowel capsule endoscopy (SB-CE) for screening high-risk asymptomatic relatives from kindreds with familial carcinoid. METHODS: 174 asymptomatic subjects with a family history (>= 2 family members) of SI-NET were screened under Protocol NCT00646022, Natural History of Familial Carcinoid Tumor at the National Institutes of Health. All patients were imaged with SB-CE and 18F-DOPA PET/CT and results were independently analyzed. Patients with a positive imaging study underwent surgical exploration. RESULTS: Thirty-five of 174 asymptomatic subjects screened for SI-NET were positive on either SB-CE or 18F-DOPA PET. Thirty-two of 35 patients with a positive study were confirmed at surgery. SB-CE was positive in 28 of 32 patients with confirmed tumors for a per patient sensitivity of 87.5%. SB-CE had a specificity of 97.3% and a negative predictive value (NPV) of 96.5%. The average tumor number and size was 7.7 and 5.0 mm, respectively, and 81.2% of patients had multiple tumors. 18F-DOPA PET/CT imaging had a similar sensitivity of 84% versus surgery. CONCLUSIONS: SB-CE is a sensitive and specific method comparable to 18F-DOPA PET/CT for screening high-risk patients with familial SI-NET.</text><annotation id="20"><infon key="identifier">MESH:D018358</infon><infon key="type">Disease</infon><location offset="169" length="33"/><text>Small bowel neuroendocrine tumors</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="239" length="6"/><text>tumors</text></annotation><annotation id="22"><infon key="identifier">MESH:D018358</infon><infon key="type">Disease</infon><location offset="332" length="37"/><text>small intestine neuroendocrine tumors</text></annotation><annotation id="23"><infon key="identifier">MESH:D018358</infon><infon key="type">Disease</infon><location offset="371" length="6"/><text>SI-NET</text></annotation><annotation id="24"><infon key="identifier">MESH:D002276</infon><infon key="type">Disease</infon><location offset="616" length="9"/><text>carcinoid</text></annotation><annotation id="25"><infon key="identifier">MESH:D018358</infon><infon key="type">Disease</infon><location offset="709" length="6"/><text>SI-NET</text></annotation><annotation id="26"><infon key="identifier">MESH:D002276</infon><infon key="type">Disease</infon><location offset="777" length="24"/><text>Familial Carcinoid Tumor</text></annotation><annotation id="27"><infon key="identifier">MESH:C043437</infon><infon key="type">Chemical</infon><location offset="880" length="8"/><text>18F-DOPA</text></annotation><annotation id="28"><infon key="identifier">MESH:D018358</infon><infon key="type">Disease</infon><location offset="1071" length="6"/><text>SI-NET</text></annotation><annotation id="29"><infon key="identifier">MESH:C043437</infon><infon key="type">Chemical</infon><location offset="1111" length="8"/><text>18F-DOPA</text></annotation><annotation id="30"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1255" length="6"/><text>tumors</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1395" length="5"/><text>tumor</text></annotation><annotation id="32"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1486" length="6"/><text>tumors</text></annotation><annotation id="33"><infon key="identifier">MESH:C043437</infon><infon key="type">Chemical</infon><location offset="1494" length="8"/><text>18F-DOPA</text></annotation><annotation id="34"><infon key="identifier">MESH:C043437</infon><infon key="type">Chemical</infon><location offset="1635" length="8"/><text>18F-DOPA</text></annotation><annotation id="35"><infon key="identifier">MESH:D018358</infon><infon key="type">Disease</infon><location offset="1698" length="6"/><text>SI-NET</text></annotation></passage><relation id="R1"><infon key="score">0.8635</infon><infon key="role1">Chemical|MESH:C043437</infon><infon key="role2">Disease|MESH:D018358</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="11,10"/></relation></document>
<document><id>37839111</id><passage><infon key="journal">Biomed Pharmacother;2023Oct13; 168 115643. doi:10.1016/j.biopha.2023.115643</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ren H, Dai R, Nik Nabil WN, Xi Z, Wang F, Xu H, </infon><offset>0</offset><text>Unveiling the dual role of autophagy in vascular remodelling and its related diseases.</text><annotation id="1"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="40" length="20"/><text>vascular remodelling</text></annotation></passage><passage><infon key="type">abstract</infon><offset>87</offset><text>Vascular remodelling is an adaptive response to physiological and pathological stimuli that leads to structural and functional changes in the vascular intima, media, and adventitia. Pathological vascular remodelling is a hallmark feature of numerous vascular diseases, including atherosclerosis, hypertension, abdominal aortic aneurysm, pulmonary hypertension and preeclampsia. Autophagy is critical in maintaining cellular homeostasis, and its dysregulation has been implicated in the pathogenesis of various diseases, including vascular diseases. However, despite emerging evidence, the role of autophagy and its dual effects on vascular remodelling has garnered limited attention. Autophagy can exert protective and detrimental effects on the vascular intima, media and adventitia, thereby substantially influencing the course of vascular remodelling and its related vascular diseases. Currently, there has not been a review that thoroughly describes the regulation of autophagy in vascular remodelling and its impact on related diseases. Therefore, this review aimed to bridge this gap by focusing on the regulatory roles of autophagy in diseases related to vascular remodelling. This review also summarizes recent advancements in therapeutic agents targeting autophagy to regulate vascular remodelling. Additionally, this review offers an overview of recent breakthroughs in therapeutic agents targeting autophagy to regulate vascular remodelling. A deeper understanding of how autophagy orchestrates vascular remodelling can drive the development of targeted therapies for vascular diseases.</text><annotation id="20"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="87" length="20"/><text>Vascular remodelling</text></annotation><annotation id="21"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="282" length="20"/><text>vascular remodelling</text></annotation><annotation id="22"><infon key="identifier">MESH:D014652</infon><infon key="type">Disease</infon><location offset="337" length="17"/><text>vascular diseases</text></annotation><annotation id="23"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="366" length="15"/><text>atherosclerosis</text></annotation><annotation id="24"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="383" length="12"/><text>hypertension</text></annotation><annotation id="25"><infon key="identifier">MESH:D017544</infon><infon key="type">Disease</infon><location offset="397" length="25"/><text>abdominal aortic aneurysm</text></annotation><annotation id="26"><infon key="identifier">MESH:D006976</infon><infon key="type">Disease</infon><location offset="424" length="22"/><text>pulmonary hypertension</text></annotation><annotation id="27"><infon key="identifier">MESH:D011225</infon><infon key="type">Disease</infon><location offset="451" length="12"/><text>preeclampsia</text></annotation><annotation id="28"><infon key="identifier">MESH:D014652</infon><infon key="type">Disease</infon><location offset="617" length="17"/><text>vascular diseases</text></annotation><annotation id="29"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="718" length="20"/><text>vascular remodelling</text></annotation><annotation id="30"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="920" length="20"/><text>vascular remodelling</text></annotation><annotation id="31"><infon key="identifier">MESH:D014652</infon><infon key="type">Disease</infon><location offset="957" length="17"/><text>vascular diseases</text></annotation><annotation id="32"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="1072" length="20"/><text>vascular remodelling</text></annotation><annotation id="33"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="1249" length="20"/><text>vascular remodelling</text></annotation><annotation id="34"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="1373" length="20"/><text>vascular remodelling</text></annotation><annotation id="35"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="1518" length="20"/><text>vascular remodelling</text></annotation><annotation id="36"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="1593" length="20"/><text>vascular remodelling</text></annotation><annotation id="37"><infon key="identifier">MESH:D014652</infon><infon key="type">Disease</infon><location offset="1666" length="17"/><text>vascular diseases</text></annotation></passage></document>
<document><id>37839462</id><passage><infon key="journal">Am J Cardiol;2023Oct12; 209 29. doi:10.1016/j.amjcard.2023.08.141</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zou Z, Ren T, Li Y, Zeng Q, Wang X, Teng J, Xu J, Jia P, Ding X, </infon><offset>0</offset><text>The Association Between Serum Glutathione Peroxidase-3 Concentration and Risk of Acute Kidney Injury After Cardiac Surgery: A Nested Case-Control Study.</text><annotation id="2"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="30" length="24"/><text>Glutathione Peroxidase-3</text></annotation><annotation id="3"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="81" length="19"/><text>Acute Kidney Injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>153</offset><text>Oxidative stress has an integral role in the pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Glutathione peroxidase 3 (GPx3) is an important antioxidant enzyme in circulation and is mainly secreted by the kidney. This study aimed to evaluate the relation between GPx3 protein and CSA-AKI. This study is a nested case-control study in Zhongshan Hospital affiliated with Fudan University. We examined serum samples from 80 CSA-AKI patients and 80 age-and gender-matched non-AKI patients who underwent cardiac surgery. AKI was defined according to Kidney Disease: Improving Global Outcomes (KDIGO) 2012 criteria. We measured serum GPx3 concentration using the enzyme-linked immunosorbent assay. GPx3 ratio is the ratio of preoperative and 6 hours postoperative of GPx3 protein concentration. We applied dose-response relation analyses to odds ratio in different GPx3 ratio levels and integrated it into the logistic model to predict the risk of AKI. The receiver operating characteristic curve and area under the curve (AUC) was used to assess the prediction models. Postoperative serum GPx3 concentrations were significantly lower in the AKI group compared with the non-AKI group (1.78 +- 0.33 vs 2.03 +- 0.27, p &lt;0.001). Malondialdehyde was higher in the AKI than in the non-AKI group (17.74 +- 8.65 vs 7.48 +- 4.59, p &lt;0.001). The AKI risk increased in a dose-dependent manner, which was flat in the first half of the GPx3 ratio and then tended to be faster. The peaking odds ratio of CSA-AKI was 2.615 at the GPx3 ratio of 1.21 to 1.40. The AUC value to predict CSA-AKI only included the GPx3 ratio was 72.3%. After gradually integrating other covariates (body mass index, aortic crossclamp time, and cardiopulmonary bypass), the model showed an AUC of 82.6%. The serum GPx3 concentration was significantly lower in the CSA-AKI group. GPx3 ratio has a good predictive value for CSA-AKI, which may be a potential early diagnostic marker for AKI.</text><annotation id="36"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="217" length="46"/><text>cardiac surgery-associated acute kidney injury</text></annotation><annotation id="37"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="265" length="7"/><text>CSA-AKI</text></annotation><annotation id="38"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="275" length="24"/><text>Glutathione peroxidase 3</text></annotation><annotation id="39"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="301" length="4"/><text>GPx3</text></annotation><annotation id="40"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="445" length="4"/><text>GPx3</text></annotation><annotation id="41"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="462" length="7"/><text>CSA-AKI</text></annotation><annotation id="42"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="603" length="7"/><text>CSA-AKI</text></annotation><annotation id="43"><infon key="type">Disease</infon><location offset="654" length="3"/><text>AKI</text></annotation><annotation id="44"><infon key="type">Disease</infon><location offset="698" length="3"/><text>AKI</text></annotation><annotation id="45"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="727" length="15"/><text>Kidney Disease:</text></annotation><annotation id="46"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="810" length="4"/><text>GPx3</text></annotation><annotation id="47"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="874" length="4"/><text>GPx3</text></annotation><annotation id="48"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="943" length="4"/><text>GPx3</text></annotation><annotation id="49"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="1041" length="4"/><text>GPx3</text></annotation><annotation id="50"><infon key="type">Disease</infon><location offset="1124" length="3"/><text>AKI</text></annotation><annotation id="51"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="1266" length="4"/><text>GPx3</text></annotation><annotation id="52"><infon key="type">Disease</infon><location offset="1318" length="3"/><text>AKI</text></annotation><annotation id="53"><infon key="type">Disease</infon><location offset="1350" length="3"/><text>AKI</text></annotation><annotation id="54"><infon key="identifier">MESH:D008315</infon><infon key="type">Chemical</infon><location offset="1402" length="15"/><text>Malondialdehyde</text></annotation><annotation id="55"><infon key="type">Disease</infon><location offset="1436" length="3"/><text>AKI</text></annotation><annotation id="56"><infon key="type">Disease</infon><location offset="1456" length="3"/><text>AKI</text></annotation><annotation id="57"><infon key="type">Disease</infon><location offset="1513" length="3"/><text>AKI</text></annotation><annotation id="58"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="1600" length="4"/><text>GPx3</text></annotation><annotation id="59"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="1667" length="7"/><text>CSA-AKI</text></annotation><annotation id="60"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="1692" length="4"/><text>GPx3</text></annotation><annotation id="61"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="1745" length="7"/><text>CSA-AKI</text></annotation><annotation id="62"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="1771" length="4"/><text>GPx3</text></annotation><annotation id="63"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="1953" length="4"/><text>GPx3</text></annotation><annotation id="64"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="2003" length="7"/><text>CSA-AKI</text></annotation><annotation id="65"><infon key="identifier">2878</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20480</infon><location offset="2018" length="4"/><text>GPx3</text></annotation><annotation id="66"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="2061" length="7"/><text>CSA-AKI</text></annotation><annotation id="67"><infon key="type">Disease</infon><location offset="2123" length="3"/><text>AKI</text></annotation></passage><relation id="R1"><infon key="score">0.9004</infon><infon key="role1">Disease|MESH:D058186</infon><infon key="role2">Gene|2878</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation></document>
<document><id>37839812</id><passage><infon key="journal">J Rheumatol;2023Oct15. doi:10.3899/jrheum.2023-0742</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kawano Y, Wang X, Patel NJ, Qian G, Kowalski E, Bade KJ, Vanni KMM, Jonsson AH, Williams ZK, Srivatsan S, Cook CE, Wallace ZS, Sparks JA, </infon><offset>0</offset><text>Breakthrough COVID-19 after tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases.</text><annotation id="4"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="13" length="8"/><text>COVID-19</text></annotation><annotation id="5"><infon key="identifier">MESH:C000714167</infon><infon key="type">Chemical</infon><location offset="28" length="11"/><text>tixagevimab</text></annotation><annotation id="6"><infon key="identifier">MESH:C000714149</infon><infon key="type">Chemical</infon><location offset="40" length="10"/><text>cilgavimab</text></annotation><annotation id="7"><infon key="identifier">MESH:D012216</infon><infon key="type">Disease</infon><location offset="71" length="38"/><text>systemic autoimmune rheumatic diseases</text></annotation></passage><passage><infon key="type">abstract</infon><offset>111</offset><text>OBJECTIVE: To determine the incidence and baseline factors associated with breakthrough COVID-19 after pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs). METHODS: We performed a retrospective cohort study among patients with SARDs who received tixagevimab/cilgavimab between January 2, 2022 and November 16, 2022. The primary outcome was breakthrough COVID-19 after tixagevimab/cilgavimab. We performed multivariable Cox regression models adjusted for baseline factors to identify risk factors for breakthrough COVID-19. RESULTS: We identified 444 SARD patients who received tixagevimab/cilgavimab (mean age 62.0 years, 78.2% female). There were 83 (18.7%) breakthrough COVID-19 cases (incidence rate 31.5 per 1000 person-months [95% CI 24.7 - 38.2]), 7 (1.6%) hospitalizations and 1 (0.2%) death. Older age was inversely associated with breakthrough COVID-19 (adjusted hazard ratio [aHR] 0.86 per 10 years, 95% CI 0.75 - 0.99). Higher baseline spike antibody levels were associated with lower risk of breakthrough COVID-19 (aHR 0.42, 95% CI 0.18 - 0.99 for spike antibody levels >200 vs. &lt;0.4 units). CD20 inhibitor users had a similar risk of breakthrough COVID-19 (aHR 1.05, 95% CI 0.44 - 2.49) compared to conventional synthetic DMARD users. CONCLUSION: We found that SARD patients had frequent breakthrough COVID-19, but the proportion experiencing severe COVID-19 was low. DMARD type, including CD20 inhibitors, did not significantly affect risk of breakthrough COVID-19. Evidence of prior humoral immunity was protective against breakthrough infection, highlighting the continued need for a multimodal approach to prevent severe COVID-19 as novel PrEP therapies are being developed.</text><annotation id="36"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="199" length="8"/><text>COVID-19</text></annotation><annotation id="37"><infon key="identifier">MESH:C000714167</infon><infon key="type">Chemical</infon><location offset="251" length="11"/><text>tixagevimab</text></annotation><annotation id="38"><infon key="identifier">MESH:C000714149</infon><infon key="type">Chemical</infon><location offset="263" length="10"/><text>cilgavimab</text></annotation><annotation id="39"><infon key="identifier">MESH:D012216</infon><infon key="type">Disease</infon><location offset="294" length="38"/><text>systemic autoimmune rheumatic diseases</text></annotation><annotation id="40"><infon key="identifier">MESH:D012216</infon><infon key="type">Disease</infon><location offset="334" length="5"/><text>SARDs</text></annotation><annotation id="41"><infon key="identifier">MESH:D012216</infon><infon key="type">Disease</infon><location offset="413" length="5"/><text>SARDs</text></annotation><annotation id="42"><infon key="identifier">MESH:C000714167</infon><infon key="type">Chemical</infon><location offset="432" length="11"/><text>tixagevimab</text></annotation><annotation id="43"><infon key="identifier">MESH:C000714149</infon><infon key="type">Chemical</infon><location offset="444" length="10"/><text>cilgavimab</text></annotation><annotation id="44"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="539" length="8"/><text>COVID-19</text></annotation><annotation id="45"><infon key="identifier">MESH:C000714167</infon><infon key="type">Chemical</infon><location offset="554" length="11"/><text>tixagevimab</text></annotation><annotation id="46"><infon key="identifier">MESH:C000714149</infon><infon key="type">Chemical</infon><location offset="566" length="10"/><text>cilgavimab</text></annotation><annotation id="47"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="699" length="8"/><text>COVID-19</text></annotation><annotation id="48"><infon key="identifier">MESH:C537236</infon><infon key="type">Disease</infon><location offset="736" length="4"/><text>SARD</text></annotation><annotation id="49"><infon key="identifier">MESH:C000714167</infon><infon key="type">Chemical</infon><location offset="763" length="11"/><text>tixagevimab</text></annotation><annotation id="50"><infon key="identifier">MESH:C000714149</infon><infon key="type">Chemical</infon><location offset="775" length="10"/><text>cilgavimab</text></annotation><annotation id="51"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="858" length="8"/><text>COVID-19</text></annotation><annotation id="52"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="979" length="5"/><text>death</text></annotation><annotation id="53"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1039" length="8"/><text>COVID-19</text></annotation><annotation id="54"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1203" length="8"/><text>COVID-19</text></annotation><annotation id="55"><infon key="identifier">54474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56837</infon><location offset="1290" length="4"/><text>CD20</text></annotation><annotation id="56"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1346" length="8"/><text>COVID-19</text></annotation><annotation id="57"><infon key="identifier">MESH:C537236</infon><infon key="type">Disease</infon><location offset="1460" length="4"/><text>SARD</text></annotation><annotation id="58"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1500" length="8"/><text>COVID-19</text></annotation><annotation id="59"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1549" length="8"/><text>COVID-19</text></annotation><annotation id="60"><infon key="identifier">54474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56837</infon><location offset="1589" length="4"/><text>CD20</text></annotation><annotation id="61"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1656" length="8"/><text>COVID-19</text></annotation><annotation id="62"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1737" length="9"/><text>infection</text></annotation><annotation id="63"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1824" length="8"/><text>COVID-19</text></annotation></passage><relation id="R1"><infon key="score">0.9955</infon><infon key="role1">Chemical|MESH:C000714167</infon><infon key="role2">Disease|MESH:D012216</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="1,3"/></relation><relation id="R2"><infon key="score">0.9962</infon><infon key="role1">Chemical|MESH:C000714149</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="2,0"/></relation><relation id="R3"><infon key="score">0.996</infon><infon key="role1">Chemical|MESH:C000714167</infon><infon key="role2">Disease|MESH:D000086382</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="1,0"/></relation><relation id="R4"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:C000714167</infon><infon key="role2">Disease|MESH:C537236</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="17,16"/></relation><relation id="R5"><infon key="score">0.5618</infon><infon key="role1">Chemical|MESH:C000714149</infon><infon key="role2">Chemical|MESH:C000714167</infon><infon key="type">Comparison</infon><node refid="4" role="2,1"/></relation><relation id="R6"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:C000714149</infon><infon key="role2">Disease|MESH:C537236</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="18,16"/></relation><relation id="R7"><infon key="score">0.9972</infon><infon key="role1">Chemical|MESH:C000714149</infon><infon key="role2">Disease|MESH:D012216</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="2,3"/></relation></document>
<document><id>37840183</id><passage><infon key="journal">Zhonghua Yi Xue Za Zhi;2023Oct24; 103 (39) 3119. doi:10.3760/cma.j.cn112137-20230513-00780</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tang XJ, Li MY, Zhao XD, Chen L, Lu XJ, Shi RH, </infon><offset>0</offset><text>[Construction of a prediction model for predicting rebleeding in patients with obscure gastrointestinal bleeding after capsule endoscopy].</text><annotation id="1"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="79" length="33"/><text>obscure gastrointestinal bleeding</text></annotation></passage><passage><infon key="type">abstract</infon><offset>139</offset><text>Objective: To explore the risk factors of rebleeding in patients with obscure gastrointestinal bleeding (OGIB) after capsule endoscopy (CE), and construct a model to predict rebleeding. Methods: The data of patients with OGIB who underwent CE in Zhongda Hospital Affiliated to Southeast University from July 2018 to September 2021 were retrospectively analyzed. Follow-up data were obtained via electronic medical records or telephone interviews. Univariate and multivariate Cox regression models were performed to figure out the risk factors of rebleeding in OGIB patients. Then the optimal prediction model was determined and presented as a nomogram. The model was evaluated by C statistic, calibration curve and decision curve analysis. Results: One hundred and thirty patients with OGIB were included, including 64 females and 66 males, aged (55.8+-17.2) years (18-87 years), and 39 (30.0%) cases developed rebleeding during follow-up. Univariate and multivariate Cox regression model analysis showed the duration of more than 2 weeks OGIB (HR=3.70, 95%CI: 1.85-7.42, P&lt;0.001), a history of previous gastrointestinal bleeding (HR=5.25, 95%CI: 2.00-13.81, P&lt;0.001), positive CE findings (HR=3.72, 95%CI: 1.66-8.33, P=0.001), and the lowest hemoglobin level before CE&lt;80 g/L (HR=2.00, 95%CI: 1.02-3.84, P=0.044) were risk factors for rebleeding, while specific treatment (HR=0.25, 95%CI: 0.11-0.54, P&lt;0.001) was a protective factor. The corresponding scores of the above five predictive factors were: OGIB duration>2 weeks: 79 points; Previous history of gastrointestinal bleeding: 100 points; The result of CE was positive: 79 points; Specific treatment:-85 points; Minimum hemoglobin before CE&lt;80 g/L: 41 points. The prediction model constructed from the above five variables had good discriminative capability (concordance index=0.798, 95%CI: 0.732-0.865). The calibration curves showed high consistency between nomogram-predicted probabilities and actual observations. The decision curves showed that when the threshold probability was above 0.04, the use of the nomogram to predict rebleeding provided a greater net benefit than the assumption of "all patients rebleeding or no patients rebleeding". Conclusion: The prediction model established in this study has a good ability to predic rebleeding in patients with OGIB after CE examination.</text><annotation id="12"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="209" length="33"/><text>obscure gastrointestinal bleeding</text></annotation><annotation id="13"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="244" length="4"/><text>OGIB</text></annotation><annotation id="14"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="360" length="4"/><text>OGIB</text></annotation><annotation id="15"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="699" length="4"/><text>OGIB</text></annotation><annotation id="16"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="925" length="4"/><text>OGIB</text></annotation><annotation id="17"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="1178" length="4"/><text>OGIB</text></annotation><annotation id="18"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="1243" length="25"/><text>gastrointestinal bleeding</text></annotation><annotation id="19"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="1642" length="4"/><text>OGIB</text></annotation><annotation id="20"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="1696" length="25"/><text>gastrointestinal bleeding</text></annotation><annotation id="21"><infon key="identifier">MESH:D006471</infon><infon key="type">Disease</infon><location offset="2462" length="4"/><text>OGIB</text></annotation></passage></document>
<document><id>37843016</id><passage><infon key="journal">ALTEX;2023Oct12. doi:10.14573/altex.2305311</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Staal YCM, Geraets L, Rothen-Rutishauser B, Clift MJD, Braakhuis H, Kienhuis AS, Bos PMJ, </infon><offset>0</offset><text>The importance of variations in in vitro dosimetry to support risk assessment of inhaled toxicants.</text></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>In vitro methods provide a key opportunity to consider human-relevant exposure scenarios for hazard identification of inhaled toxicants. Compared to in vivo tests, in vitro methods have the advantage of assessing effects of inhaled toxicants expressed by differences in dosimetry, e.g. variations in concentration (exposure intensity), exposure duration and exposure frequency, in an easier way. Variations in dosimetry can be used to obtain information on adverse effects in human relevant exposure scenarios that can be used for risk assessment. Based on the published literature of exposure approaches using Air-Liquid-Interface models of the respiratory tract, supplemented with additional experimental data from the EU H2020 project 'PATROLS' and research funded by the Dutch Ministry of Agriculture, Nature and Food Quality, the advantages and disadvantages of different exposure methods and considerations to design an experimental setup have been summarized and discussed. As the cell models used are models for the respiratory epithelium, our focus is on the local effects in the airways. In conclusion, in order to generate data from in vitro methods for the risk assessment of inhaled toxicants it is recommended that (1) it is considered what information really is needed for hazard or risk assessment; (2) the exposure system that is most suitable for the chemical to be assessed is chosen; (3) a deposited dose that mimics human deposition in the respiratory tract is used and (4) the post-exposure sampling methodology should be carefully considered and relevant to the testing strategy used.</text></passage></document>
<document><id>37843366</id><passage><infon key="journal">J Virol;2023Oct16 0120923. doi:10.1128/jvi.01209-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Suo X, Wang J, Wang D, Fan G, Zhu M, Fan B, Yang X, Li B, </infon><offset>0</offset><text>DHA and EPA inhibit porcine coronavirus replication by alleviating ER stress.</text><annotation id="2"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="0" length="3"/><text>DHA</text></annotation><annotation id="3"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="8" length="3"/><text>EPA</text></annotation></passage><passage><infon key="type">abstract</infon><offset>78</offset><text>The 2019 coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlighted significant gaps in our mechanisms to prevent and control cross-species transmission of animal coronaviruses. Porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV), and porcine delta coronavirus (PDCoV) are common porcine coronaviruses with similar clinical features. In the absence of effective drugs and methods of prevention and control, outbreaks of these viruses have led to significant economic losses in the global pig industry. Here, we report the effect of five fatty acids against porcine coronaviruses: sodium butyrate, lauric acid, palmitic acid, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). DHA and EPA reduced viral replication by attenuating the endoplasmic reticulum stress and inhibiting PEDV, TGEV, and PDCoV infections in vero cells, PK-15 cells, and LLC-PK1 cells in vitro, respectively. Additionally, DHA and EPA increased the host antioxidant levels and reduced inflammation. In conclusion, we report here for the first time the antiviral effects of DHA and EPA on porcine coronaviruses and provide a molecular basis for the development of new fatty acid-based therapies to control porcine coronavirus infection and transmission. IMPORTANCE Porcine epidemic diarrhea caused by porcine coronaviruses remains a major threat to the global swine industry. Fatty acids are extensively involved in the whole life of the virus. In this study, we found that docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) significantly reduced the viral load of porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV), and porcine delta coronavirus (PDCoV) and acted on the replication of the viruses rather than attachment and entry. We further confirmed that DHA and EPA inhibited PEDV replication by alleviating the endoplasmic reticulum stress. Meanwhile, DHA and EPA alleviate PEDV-induced inflammation and reactive oxygen species (ROS) levels and enhance the cellular antioxidant capacity. These data indicate that DHA and EPA have antiviral effects on porcine coronaviruses and provide a molecular basis for the development of new fatty acid-based therapies to control porcine coronavirus infection and transmission.</text><annotation id="43"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="82" length="24"/><text>2019 coronavirus disease</text></annotation><annotation id="44"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="108" length="8"/><text>COVID-19</text></annotation><annotation id="45"><infon key="identifier">MESH:D005227</infon><infon key="type">Chemical</infon><location offset="710" length="11"/><text>fatty acids</text></annotation><annotation id="46"><infon key="identifier">MESH:D020148</infon><infon key="type">Chemical</infon><location offset="753" length="15"/><text>sodium butyrate</text></annotation><annotation id="47"><infon key="identifier">MESH:C030358</infon><infon key="type">Chemical</infon><location offset="770" length="11"/><text>lauric acid</text></annotation><annotation id="48"><infon key="identifier">MESH:D019308</infon><infon key="type">Chemical</infon><location offset="783" length="13"/><text>palmitic acid</text></annotation><annotation id="49"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="798" length="20"/><text>docosahexaenoic acid</text></annotation><annotation id="50"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="820" length="3"/><text>DHA</text></annotation><annotation id="51"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="830" length="21"/><text>eicosapentaenoic acid</text></annotation><annotation id="52"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="853" length="3"/><text>EPA</text></annotation><annotation id="53"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="859" length="3"/><text>DHA</text></annotation><annotation id="54"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="867" length="3"/><text>EPA</text></annotation><annotation id="55"><infon key="identifier">CVCL:0059</infon><infon key="type">CellLine</infon><location offset="996" length="4"/><text>vero</text></annotation><annotation id="56"><infon key="identifier">CVCL:2160</infon><infon key="type">CellLine</infon><location offset="1008" length="5"/><text>PK-15</text></annotation><annotation id="57"><infon key="identifier">CVCL:0391</infon><infon key="type">CellLine</infon><location offset="1025" length="7"/><text>LLC-PK1</text></annotation><annotation id="58"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="1077" length="3"/><text>DHA</text></annotation><annotation id="59"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="1085" length="3"/><text>EPA</text></annotation><annotation id="60"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1139" length="12"/><text>inflammation</text></annotation><annotation id="61"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="1227" length="3"/><text>DHA</text></annotation><annotation id="62"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="1235" length="3"/><text>EPA</text></annotation><annotation id="63"><infon key="identifier">MESH:D005227</infon><infon key="type">Chemical</infon><location offset="1321" length="10"/><text>fatty acid</text></annotation><annotation id="64"><infon key="identifier">MESH:D018352</infon><infon key="type">Disease</infon><location offset="1359" length="29"/><text>porcine coronavirus infection</text></annotation><annotation id="65"><infon key="identifier">MESH:D019318</infon><infon key="type">Disease</infon><location offset="1418" length="25"/><text>Porcine epidemic diarrhea</text></annotation><annotation id="66"><infon key="identifier">MESH:D005227</infon><infon key="type">Chemical</infon><location offset="1529" length="11"/><text>Fatty acids</text></annotation><annotation id="67"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="1627" length="20"/><text>docosahexaenoic acid</text></annotation><annotation id="68"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="1649" length="3"/><text>DHA</text></annotation><annotation id="69"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="1658" length="21"/><text>eicosapentaenoic acid</text></annotation><annotation id="70"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="1681" length="3"/><text>EPA</text></annotation><annotation id="71"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="1952" length="3"/><text>DHA</text></annotation><annotation id="72"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="1960" length="3"/><text>EPA</text></annotation><annotation id="73"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="2051" length="3"/><text>DHA</text></annotation><annotation id="74"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="2059" length="3"/><text>EPA</text></annotation><annotation id="75"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="2086" length="12"/><text>inflammation</text></annotation><annotation id="76"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="2103" length="23"/><text>reactive oxygen species</text></annotation><annotation id="77"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="2128" length="3"/><text>ROS</text></annotation><annotation id="78"><infon key="identifier">MESH:D004281</infon><infon key="type">Chemical</infon><location offset="2212" length="3"/><text>DHA</text></annotation><annotation id="79"><infon key="identifier">MESH:D015118</infon><infon key="type">Chemical</infon><location offset="2220" length="3"/><text>EPA</text></annotation><annotation id="80"><infon key="identifier">MESH:D005227</infon><infon key="type">Chemical</infon><location offset="2329" length="10"/><text>fatty acid</text></annotation><annotation id="81"><infon key="identifier">MESH:D018352</infon><infon key="type">Disease</infon><location offset="2367" length="29"/><text>porcine coronavirus infection</text></annotation></passage><relation id="R1"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:D004281</infon><infon key="role2">Disease|MESH:D018352</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="20,23"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D005227</infon><infon key="role2">Disease|MESH:D018352</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="22,23"/></relation><relation id="R3"><infon key="score">0.7693</infon><infon key="role1">Chemical|MESH:D004281</infon><infon key="role2">Chemical|MESH:D015118</infon><infon key="type">Comparison</infon><node refid="2" role="0,1"/></relation><relation id="R4"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D015118</infon><infon key="role2">Disease|MESH:D018352</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="21,23"/></relation><relation id="R5"><infon key="score">0.9958</infon><infon key="role1">Chemical|MESH:D004281</infon><infon key="role2">Chemical|MESH:D017382</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="32,35"/></relation><relation id="R6"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D015118</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="18,19"/></relation><relation id="R7"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D004281</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="17,19"/></relation><relation id="R8"><infon key="score">0.9939</infon><infon key="role1">Chemical|MESH:D015118</infon><infon key="role2">Chemical|MESH:D017382</infon><infon key="type">Positive_Correlation</infon><node refid="7" role="33,35"/></relation></document>
<document><id>37843716</id><passage><infon key="journal">Fish Physiol Biochem;2023Oct16. doi:10.1007/s10695-023-01253-x</infon><infon key="year">2023</infon><infon key="article-id_pmc">6539070</infon><infon key="type">title</infon><infon key="authors">Tian Z, Wei M, Xue R, Song L, Li H, Ji H, Sun J, </infon><offset>0</offset><text>lpla (lipoprotein lipase a) is a marker of early adipogenesis rather than late adipogenesis in grass carp (Ctenopharyngodon idellus).</text></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>Lipoprotein lipase (LPL) functions as a marker of adipocyte differentiation in mammals, but little is known about its role in fish adipogenesis. The aim of this research is to investigate the function of Lpl in adipocyte differentiation in fish. In this paper, we isolated and characterized lipoprotein lipase a (lpla) and lipoprotein lipase b (lplb) from grass carp (Ctenopharyngodon idellus). The complete coding sequence of lpla and lplb was 1587 bp and 1437 bp in length, coding for 507 amino acids and 500 amino acids, respectively. Both lpla and lplb mRNA were expressed in a great number of tissues. During adipogenesis, the level of lpla mRNA reached its maximum at day 2 and then dropped gradually, while the level of lplb mRNA had no significant changes, indicating that lpla and lplb may have different function in the differentiation of grass carp adipocyte. Furthermore, inhibition of lpla by inhibitor of LPL(GSK264220A) at early time points most clearly reduced adipogenesis, whereas these effects were less pronounced at later stages, suggesting that lpla predominantly affects early adipogenesis rather than late adipogenesis. Based on these findings, it can be inferred that lpla and lplb in grass carp may have distinct roles in the differentiation of grass carp adipocyte, and lpla may play an important role in the early adipogenesis rather than late adipogenesis in grass carp.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1057" length="10"/><text>GSK264220A</text></annotation></passage></document>
<document><id>37844071</id><passage><infon key="journal">Vector Borne Zoonotic Dis;2023Oct16. doi:10.1089/vbz.2023.0066</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Russo TP, Borrelli L, Minichino A, Fioretti A, Dipineto L, </infon><offset>0</offset><text>Occurrence and Antimicrobial Resistance of Staphylococcus aureus Isolated from Healthy Pet Rabbits.</text></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>Background: Staphylococcus aureus is a ubiquitous microorganism and an opportunistic pathogen responsible for numerous diseases in humans and animals, characterized by different clinical pictures with acute or subacute course. S. aureus, due to its great adaptability and versatility in terms of infections and hosts, can be considered a relevant pathogen because of the harmful effects on animal health and its potential for transmission from animals to humans and vice versa. In recent years, a marked increase in multidrug-resistant S. aureus has been reported, posing a serious threat for disease management, food safety, and animal and human health as they limit available therapeutic options. In light of a growing interest of the scientific community for this micro- organism and considering the limited data availability on the prevalence of this pathogen in pet rabbits, the purpose of this research was to evaluate the presence of S. aureus in pet rabbits. Materials and Methods: From November 2021 to December 2022, nasal swabs were collected from 50 pet rabbits from private households in the Campania Region, southern Italy, and underwent analysis for S. aureus detection. Samples were enriched in broth, then inoculated onto nutrient and selective media, including Blood agar base supplemented with 7% sheep blood and Baird-Parker Agar Base, following standard laboratory protocols. Incubations in aerobic conditions at 37 C were performed for 24/48h for colony identification. Antimicrobial susceptibility testing for all S. aureus isolates was conducted using the disc diffusion method. Results: Our results reported the presence of S. aureus in 16/50 (32%) rabbits examined, showing high levels of phenotypic resistance to different antibiotics, in particular penicillin 10U (81.2%) and erythromycin 15 mug (62.5%). Conclusion: The study demonstrated that pet rabbits represent a significant reservoir of S. aureus and contributes to the knowledge on the phenotypic antimicrobial resistance of these bacteria in rabbits raised in a domestic environment.</text><annotation id="2"><infon key="identifier">MESH:D010406</infon><infon key="type">Chemical</infon><location offset="1877" length="10"/><text>penicillin</text></annotation><annotation id="3"><infon key="identifier">MESH:D004917</infon><infon key="type">Chemical</infon><location offset="1904" length="12"/><text>erythromycin</text></annotation></passage></document>
<document><id>37844452</id><passage><infon key="journal">Spectrochim Acta A Mol Biomol Spectrosc;2023Oct13; 305 123492. doi:10.1016/j.saa.2023.123492</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li F, Tang R, Kang Y, Cui X, Wang Y, Yang X, </infon><offset>0</offset><text>Fluorescent composite based on peptide nanotubes activating coumarin 6 for sensitive detection of new coccine in food samples.</text><annotation id="3"><infon key="identifier">MESH:D045333</infon><infon key="type">Chemical</infon><location offset="31" length="17"/><text>peptide nanotubes</text></annotation><annotation id="4"><infon key="identifier">MESH:C517282</infon><infon key="type">Chemical</infon><location offset="60" length="10"/><text>coumarin 6</text></annotation><annotation id="5"><infon key="identifier">MESH:C576297</infon><infon key="type">Chemical</infon><location offset="98" length="11"/><text>new coccine</text></annotation></passage><passage><infon key="type">abstract</infon><offset>127</offset><text>New coccine (NC), as a kind of common colorant, has been frequently used in our daily life. Herein, the fluorescent composite (PNTs@C6) prepared by the hydrophobic non-covalent interaction between peptide nanotubes and coumarin 6 (C6) was designed for the determination of NC. Due to the activation of C6 by peptide nanotubes, the composite exhibits strong green fluorescence emission, which can be selectively quenched by NC through the inner filter effect. Therefore, a new fluorescent method based on the PNTs@C6 composite for NC detection was constructed. Under optimal conditions, the fluorescence quenching of the sensor exhibits a good linear relationship with the concentration of NC in the range of 0.01-10 muM and the limit of detection is 3.6 nM. Furthermore, the strategy shows simplicity, rapid response and high selectivity and has been successfully applied to the detection of NC in food samples.</text><annotation id="21"><infon key="identifier">MESH:C576297</infon><infon key="type">Chemical</infon><location offset="127" length="11"/><text>New coccine</text></annotation><annotation id="22"><infon key="identifier">MESH:C576297</infon><infon key="type">Chemical</infon><location offset="140" length="2"/><text>NC</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="165" length="8"/><text>colorant</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="254" length="7"/><text>PNTs@C6</text></annotation><annotation id="25"><infon key="identifier">MESH:D045333</infon><infon key="type">Chemical</infon><location offset="324" length="17"/><text>peptide nanotubes</text></annotation><annotation id="26"><infon key="identifier">MESH:C517282</infon><infon key="type">Chemical</infon><location offset="346" length="10"/><text>coumarin 6</text></annotation><annotation id="27"><infon key="identifier">MESH:C517282</infon><infon key="type">Chemical</infon><location offset="358" length="2"/><text>C6</text></annotation><annotation id="28"><infon key="identifier">MESH:C576297</infon><infon key="type">Chemical</infon><location offset="400" length="2"/><text>NC</text></annotation><annotation id="29"><infon key="identifier">MESH:C517282</infon><infon key="type">Chemical</infon><location offset="429" length="2"/><text>C6</text></annotation><annotation id="30"><infon key="identifier">MESH:D045333</infon><infon key="type">Chemical</infon><location offset="435" length="17"/><text>peptide nanotubes</text></annotation><annotation id="31"><infon key="identifier">MESH:C576297</infon><infon key="type">Chemical</infon><location offset="550" length="2"/><text>NC</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="635" length="7"/><text>PNTs@C6</text></annotation><annotation id="33"><infon key="identifier">MESH:C576297</infon><infon key="type">Chemical</infon><location offset="657" length="2"/><text>NC</text></annotation><annotation id="34"><infon key="identifier">MESH:C576297</infon><infon key="type">Chemical</infon><location offset="816" length="2"/><text>NC</text></annotation><annotation id="35"><infon key="identifier">MESH:C576297</infon><infon key="type">Chemical</infon><location offset="1019" length="2"/><text>NC</text></annotation></passage><relation id="R1"><infon key="score">0.9001</infon><infon key="role1">Chemical|MESH:C517282</infon><infon key="role2">Chemical|MESH:C576297</infon><infon key="type">Association</infon><node refid="0" role="1,2"/></relation><relation id="R2"><infon key="score">0.9622</infon><infon key="role1">Chemical|MESH:C576297</infon><infon key="role2">Chemical|MESH:D045333</infon><infon key="type">Association</infon><node refid="1" role="2,0"/></relation><relation id="R3"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C517282</infon><infon key="role2">Chemical|MESH:D045333</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="1,0"/></relation></document>
<document><id>37844802</id><passage><infon key="journal">J Glob Antimicrob Resist;2023Oct14. doi:10.1016/j.jgar.2023.10.007</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Alzayer M, Alkhulaifi MM, Alyami A, Aldosary M, Alageel A, Garaween G, Shibl A, Al-Hamad AM, Doumith M, </infon><offset>0</offset><text>Molecular Typing and Antimicrobial Resistance of Group B Streptococcus Clinical Isolates in Saudi Arabia.</text></passage><passage><infon key="type">abstract</infon><offset>106</offset><text>OBJECTIVES: Group B Streptococcus (GBS) has emerged as an important cause of severe infections in adults. However, limited data are available regarding the epidemiology of GBS in Saudi Arabia. METHODS: Isolates were collected over a period of eight months from colonized (n=104) and infected adults (n=95). Serotypes and virulence determinants were detected by polymerase chain reactions (PCRs). Genetic relatedness was assessed using Multiple Locus Variable Number Tandem Repeat Analysis (MLVA). Antimicrobial susceptibilities were determined by disk diffusion. RESULTS: Serotypes III and V (25% each) were the most prevalent, followed by serotypes II (16.18%), Ia (13.24%), VI (9.31%), and Ib (8.82%), while five isolates remained non-typeable (2.45%). Hypervirulent serotype III/CC17 clone (n=21) accounted for 41.18% of the serotype III isolates. Majority of isolates (53.92%) harboured pilus island (PI) 1 and 2a types, while PI-2b was predominantly detected in the hypervirulent clone. Isolates were variably resistant to tetracycline (76.47%), erythromycin (36.76%), clindamycin (25.49%), and levofloxacin (6.37%), but remained susceptible to penicillin. Macrolide resistant isolates exhibited constitutive (55.42%) and inducible macrolide-lincosamide-streptogramin B resistance phenotypes (33.74%), while a few had L (9.64%) or M (1.2%) phenotypes. MLVA patterns of dominant serotypes III and V revealed 40 different types divided into 12 clusters and 28 singletons. Interestingly, macrolide resistance was significantly associated with two major MLVA types. CONCLUSION: GBS isolates belonged predominantly to serotypes III and V, but there were no clear associations between serotypes and patient groups. The studied isolates exhibited high levels of resistance to erythromycin and clindamycin that needs further surveillance.</text><annotation id="15"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="190" length="10"/><text>infections</text></annotation><annotation id="16"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="389" length="8"/><text>infected</text></annotation><annotation id="17"><infon key="identifier">5265</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20103</infon><location offset="1011" length="12"/><text>PI) 1 and 2a</text></annotation><annotation id="18"><infon key="identifier">MESH:D013752</infon><infon key="type">Chemical</infon><location offset="1134" length="12"/><text>tetracycline</text></annotation><annotation id="19"><infon key="identifier">MESH:D004917</infon><infon key="type">Chemical</infon><location offset="1157" length="12"/><text>erythromycin</text></annotation><annotation id="20"><infon key="identifier">MESH:D002981</infon><infon key="type">Chemical</infon><location offset="1180" length="11"/><text>clindamycin</text></annotation><annotation id="21"><infon key="identifier">MESH:D064704</infon><infon key="type">Chemical</infon><location offset="1206" length="12"/><text>levofloxacin</text></annotation><annotation id="22"><infon key="identifier">MESH:D010406</infon><infon key="type">Chemical</infon><location offset="1256" length="10"/><text>penicillin</text></annotation><annotation id="23"><infon key="identifier">MESH:D018942</infon><infon key="type">Chemical</infon><location offset="1268" length="9"/><text>Macrolide</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1343" length="37"/><text>macrolide-lincosamide-streptogramin B</text></annotation><annotation id="25"><infon key="identifier">MESH:D007926</infon><infon key="type">Disease</infon><location offset="1429" length="1"/><text>L</text></annotation><annotation id="26"><infon key="identifier">MESH:C566367</infon><infon key="type">Disease</infon><location offset="1442" length="1"/><text>M</text></annotation><annotation id="27"><infon key="identifier">MESH:D018942</infon><infon key="type">Chemical</infon><location offset="1596" length="9"/><text>macrolide</text></annotation><annotation id="28"><infon key="identifier">MESH:D004917</infon><infon key="type">Chemical</infon><location offset="1880" length="12"/><text>erythromycin</text></annotation><annotation id="29"><infon key="identifier">MESH:D002981</infon><infon key="type">Chemical</infon><location offset="1897" length="11"/><text>clindamycin</text></annotation></passage></document>
<document><id>37845157</id><passage><infon key="journal">Int J Biol Macromol;2023Oct14 126676. doi:10.1016/j.ijbiomac.2023.126676</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">He Y, Tian Y, Zhang W, Wang X, Yang X, Li B, Ge L, Bai D, Li D, </infon><offset>0</offset><text>Corrigendum to "Fabrication of oxidized sodium alginate-collagen heterogeneous bilayer barrier membrane with osteogenesis-promoting ability" [International Journal of Biological Macromolecules 202 (2022) 55-67].</text><annotation id="1"><infon key="identifier">MESH:D000464</infon><infon key="type">Chemical</infon><location offset="40" length="15"/><text>sodium alginate</text></annotation></passage><passage><infon key="type">abstract</infon><offset>212</offset></passage></document>
<document><id>37845508</id><passage><infon key="journal">Nat Aging;2023Oct16. doi:10.1038/s43587-023-00498-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">8911062</infon><infon key="type">title</infon><infon key="authors">Zhang Y, Bai J, Cui Z, Li Y, Gao Q, Miao Y, Xiong B, </infon><offset>0</offset><text>Polyamine metabolite spermidine rejuvenates oocyte quality by enhancing mitophagy during female reproductive aging.</text><annotation id="2"><infon key="identifier">MESH:D011073</infon><infon key="type">Chemical</infon><location offset="0" length="9"/><text>Polyamine</text></annotation><annotation id="3"><infon key="identifier">MESH:D013095</infon><infon key="type">Chemical</infon><location offset="21" length="10"/><text>spermidine</text></annotation></passage><passage><infon key="type">abstract</infon><offset>116</offset><text>Advanced age is a primary risk factor for female infertility due to reduced ovarian reserve and declining oocyte quality. However, as an important contributing factor, the role of metabolic regulation during reproductive aging is poorly understood. Here, we applied untargeted metabolomics to identify spermidine as a critical metabolite in ovaries to protect oocytes against aging. In particular, we found that the spermidine level was reduced in ovaries of aged mice and that supplementation with spermidine promoted follicle development, oocyte maturation, early embryonic development and female fertility of aged mice. By microtranscriptomic analysis, we further discovered that spermidine-induced recovery of oocyte quality was mediated by enhancement of mitophagy activity and mitochondrial function in aged mice, and this mechanism of action was conserved in porcine oocytes under oxidative stress. Altogether, our findings suggest that spermidine supplementation could represent a therapeutic strategy to ameliorate oocyte quality and reproductive outcome in cis-gender women and other persons trying to conceive at an advanced age. Future work is needed to test whether this approach can be safely and effectively translated to humans.</text><annotation id="10"><infon key="identifier">MESH:D007247</infon><infon key="type">Disease</infon><location offset="158" length="18"/><text>female infertility</text></annotation><annotation id="11"><infon key="identifier">MESH:D013095</infon><infon key="type">Chemical</infon><location offset="418" length="10"/><text>spermidine</text></annotation><annotation id="12"><infon key="identifier">MESH:D013095</infon><infon key="type">Chemical</infon><location offset="532" length="10"/><text>spermidine</text></annotation><annotation id="13"><infon key="identifier">MESH:D013095</infon><infon key="type">Chemical</infon><location offset="615" length="10"/><text>spermidine</text></annotation><annotation id="14"><infon key="identifier">MESH:D013095</infon><infon key="type">Chemical</infon><location offset="799" length="10"/><text>spermidine</text></annotation><annotation id="15"><infon key="identifier">MESH:D013095</infon><infon key="type">Chemical</infon><location offset="1060" length="10"/><text>spermidine</text></annotation></passage></document>
<document><id>37846034</id><passage><infon key="journal">Bioinformatics;2023Oct16. doi:10.1093/bioinformatics/btad629</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Genz LR, Mulvaney T, Nair S, Topf M, </infon><offset>0</offset><text>PICKLUSTER: A protein-interface clustering and analysis plug-in for UCSF ChimeraX.</text></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>MOTIVATION: The identification and characterization of interfaces in protein complexes is crucial for understanding the mechanisms of molecular recognition. These interfaces are also attractive targets for protein inhibition. However, targeting protein interfaces can be challenging for large interfaces that consist of multiple interacting regions. We present PICKLUSTER - a program for identifying "sub-interfaces" in protein-protein complexes using distance clustering. The division of the interface into smaller "sub-interfaces" offers a more focused approach for targeting protein-protein interfaces. AVAILABILITY AND IMPLEMENTATION: PICKLUSTER is implemented as a plug-in for the molecular visualization program UCSF ChimeraX 1.4 and subsequent versions. It is freely available for download in the ChimeraX Toolshed and https://gitlab.com/topf-lab/pickluster.git. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.</text></passage></document>
<document><id>37846742</id><passage><infon key="journal">Health Promot Pract;2023Oct17 15248399231201131. doi:10.1177/15248399231201131</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zoschke IN, Betancur A, Ehsan S, TenHaken JD, Rahman JR, King-Tezino K, Kramer-Najjar M, Bravo CA, Wilkerson JM, </infon><offset>0</offset><text>SWOT Analysis and Recommendations for Community Health Workers and Stakeholders Responding to COVID-19 Health Inequities.</text><annotation id="1"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="94" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>Background. By 2023, 1,080,000 cases of COVID-19 have been reported in Harris County. Systemic inequity and vaccine hesitancy have contributed to COVID-19 disparities. Community Health Workers provide health education and instrumental support to alleviate health disparities among vulnerable communities. We conducted an analysis of Strengths, Weaknesses, Opportunities, and Threats (SWOT) analysis in June 2022 among a broad coalition of Community Health Work stakeholders to better understand the local landscape in the context of the COVID-19 pandemic. Methods. We recruited 33 community health workers and industry stakeholders in Harris County, Texas, to participate in the SWOT analysis. Participants were asked to describe their opinions on the SWOT facing the Community Health Work landscape and then rank the outcomes of the analysis to prioritize action. Results. A total of 19 themes were identified. Weaknesses included lack of respect and resources for Community Health Workers and poor coordination and capacity among the workforce infrastructure. Limited funding and lack of appreciation for Community Health Workers were deemed important threats. Diversity and community connection were critical strengths, and strong education, training, and raising awareness for community health work were considered opportunities to overcome identified weaknesses and threats. Discussion. Increased funding, greater coordination, greater respect, and amplified training can improve capacity for Community Health Workers and, therefore, improve public health outcomes for respiratory illness and viral infections such as COVID-19. This analysis helps fill an important research gap on the topic Community Health Workers responding to public health crises with racially disparate outcomes.</text><annotation id="8"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="162" length="8"/><text>COVID-19</text></annotation><annotation id="9"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="268" length="8"/><text>COVID-19</text></annotation><annotation id="10"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="659" length="8"/><text>COVID-19</text></annotation><annotation id="11"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="1696" length="19"/><text>respiratory illness</text></annotation><annotation id="12"><infon key="identifier">MESH:D014777</infon><infon key="type">Disease</infon><location offset="1720" length="16"/><text>viral infections</text></annotation><annotation id="13"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1745" length="8"/><text>COVID-19</text></annotation></passage></document>
<document><id>37847097</id><passage><infon key="journal">J Acoust Soc Am;2023Oct01; 154 (4) 2337. doi:10.1121/10.0021332</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fabre F, Le Carrou JL, Chomette B, </infon><offset>0</offset><text>Physical modelling of a harp from Central Africa.</text><annotation id="1"><infon key="identifier">MESH:C564603</infon><infon key="type">Disease</infon><location offset="24" length="4"/><text>harp</text></annotation></passage><passage><infon key="type">abstract</infon><offset>50</offset><text>Central Africa harps are string instruments, often anthropomorphic, serving an essential cultural role. Compared to pedal harps, their body is small in size with a soundboard mainly made of animal skin and a neck made of a wood beam. In this paper, a physical model is developed as a tool for assessing the specificities of these musical instruments, from a vibro-acoustic perspective. The modeling strategy is based on the modal Udwadia-Kalaba formalism which is a multibody substructuring technique. Input modal parameters of the body and the strings are experimentally identified and the main steps of the estimation procedures are detailed. The reliability of the physical model is investigated via the comparison between simulated and experimental data for several plucking configurations. Different hypotheses are assessed such as the string/neck coupling which proves to strongly influence the dynamic response of the body when there is a coincidence between string and neck modal frequencies. The inclusion of geometrical nonlinearities proves to be of major importance, even for a weak plucking, as it allows qualitative representation of double frequency terms in the simulations. Overall, physical simulations of the soundboard motion are in good agreement with measurements indicating characteristic features of the instrument are captured.</text><annotation id="4"><infon key="identifier">MESH:C564603</infon><infon key="type">Disease</infon><location offset="65" length="5"/><text>harps</text></annotation><annotation id="5"><infon key="identifier">MESH:C564603</infon><infon key="type">Disease</infon><location offset="172" length="5"/><text>harps</text></annotation></passage></document>
<document><id>37847452</id><passage><infon key="journal">Antonie Van Leeuwenhoek;2023Oct17. doi:10.1007/s10482-023-01869-2</infon><infon key="year">2023</infon><infon key="article-id_pmc">3414457</infon><infon key="type">title</infon><infon key="authors">Wang X, Gao K, Chen C, Zhang C, Zhou C, Song Y, Guo W, </infon><offset>0</offset><text>Prevalence of the virulence genes and their correlation with carbapenem resistance amongst the Pseudomonas aeruginosa strains isolated from a tertiary hospital in China.</text><annotation id="1"><infon key="identifier">MESH:D015780</infon><infon key="type">Chemical</infon><location offset="61" length="10"/><text>carbapenem</text></annotation></passage><passage><infon key="type">abstract</infon><offset>170</offset><text>Pseudomonas aeruginosa is one of the top-listed pathogens in nosocomial infection. It is notorious for its complicated virulence system and rapid adaptability to drugs or antimicrobials. In this study, we aimed to evaluate the prevalence of sixteen virulence genes in four groups including type III secretion system, biofilm formation, extracellular toxin biosynthesis and enzymes amongst 209 clinical Pseudomonas aeruginosa strains. We investigated the different distribution patterns of virulence genotypes based on carbapenem-resistant phenotype or the carriage of carbapenemase genes. The detection rate of each virulence gene varied greatly. phzM and plcN were detected in all collected strains, while pilB and exoU were only carried by a small portion of isolates (6.7% and 16.3%). Additionally, the number of genotypes observed in each group of examined virulence genes ranged from 4 to 8. Only the distribution of genotypes of type III secretion system showed statistical difference between carbapenem-mediated or carbapenem-resistant and carbapenem-sensitive strains. The virulence genotype of Pseudomonas aeruginosa was possibly interrelated to its resistance mechanism. Further research suggested that one particular TTSS genotype exhibited higher ratio in carbapenemase-producing strains and exoS was less frequently detected in CRPA strains carrying carbapenemase gene. Generally, the significant genetic diversity of virulence genes amongst Pseudomonas aeruginosa strains was highlighted in this study. Specific TTSS genotypes were associated with carbapenem-resistance. In particular, certain incompatibility might exist between exoS and carbapenemase genes, which provided valuable information for further understanding the relationship between carbapenem resistance and virulence.</text><annotation id="11"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="231" length="20"/><text>nosocomial infection</text></annotation><annotation id="12"><infon key="identifier">MESH:D015780</infon><infon key="type">Chemical</infon><location offset="688" length="10"/><text>carbapenem</text></annotation><annotation id="13"><infon key="identifier">MESH:D015780</infon><infon key="type">Chemical</infon><location offset="1169" length="10"/><text>carbapenem</text></annotation><annotation id="14"><infon key="identifier">MESH:D015780</infon><infon key="type">Chemical</infon><location offset="1192" length="10"/><text>carbapenem</text></annotation><annotation id="15"><infon key="identifier">MESH:D015780</infon><infon key="type">Chemical</infon><location offset="1217" length="10"/><text>carbapenem</text></annotation><annotation id="16"><infon key="type">Disease</infon><location offset="1398" length="4"/><text>TTSS</text></annotation><annotation id="17"><infon key="type">Disease</infon><location offset="1696" length="4"/><text>TTSS</text></annotation><annotation id="18"><infon key="identifier">MESH:D015780</infon><infon key="type">Chemical</infon><location offset="1732" length="10"/><text>carbapenem</text></annotation><annotation id="19"><infon key="identifier">MESH:D015780</infon><infon key="type">Chemical</infon><location offset="1931" length="10"/><text>carbapenem</text></annotation></passage></document>
<document><id>37847811</id><passage><infon key="journal">J Cogn Neurosci;2023Oct12 1. doi:10.1162/jocn_a_02068</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Takashima A, Carota F, Schoots V, Redmann A, Jehee J, Indefrey P, </infon><offset>0</offset><text>Tomatoes Are Red: The Perception of Achromatic Objects Elicits Retrieval of Associated Color Knowledge.</text></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>When preparing to name an object, semantic knowledge about the object and its attributes is activated, including perceptual properties. It is unclear, however, whether semantic attribute activation contributes to lexical access or is a consequence of activating a concept irrespective of whether that concept is to be named or not. In this study, we measured neural responses using fMRI while participants named objects that are typically green or red, presented in black line drawings. Furthermore, participants underwent two other tasks with the same objects, color naming and semantic judgment, to see if the activation pattern we observe during picture naming is (a) similar to that of a task that requires accessing the color attribute and (b) distinct from that of a task that requires accessing the concept but not its name or color. We used representational similarity analysis to detect brain areas that show similar patterns within the same color category, but show different patterns across the two color categories. In all three tasks, activation in the bilateral fusiform gyri ("Human V4") correlated with a representational model encoding the red-green distinction weighted by the importance of color feature for the different objects. This result suggests that when seeing objects whose color attribute is highly diagnostic, color knowledge about the objects is retrieved irrespective of whether the color or the object itself have to be named.</text></passage></document>
<document><id>37848168</id><passage><infon key="journal">Obstet Gynecol Sci;2023Oct17. doi:10.5468/ogs.23143</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Okoro CC, Ikpeze OC, Eleje GU, Udigwe GO, Ezeama CO, Ugboaja JO, Enechukwu CI, Umeononihu OS, Ogabido CA, Oguejiofor C, Njoku T, Egeonu RO, Okafor C, Obiagwu HI, Onyejiaka CC, Obidike AB, Onah CE, Uzukwu I, Okoro AD, Ezema EC, Ibekwe A, Ikechebelu JI, </infon><offset>0</offset><text>Association between serum vitamin D status and uterine leiomyomas: a case-control study.</text><annotation id="2"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="26" length="9"/><text>vitamin D</text></annotation><annotation id="3"><infon key="identifier">OMIM:150699</infon><infon key="type">Disease</infon><location offset="47" length="18"/><text>uterine leiomyomas</text></annotation></passage><passage><infon key="type">abstract</infon><offset>89</offset><text>Objective: Uterine leiomyoma is a common gynecological condition that negatively affects women's quality of life. Vitamin D plays an important role in tumor development and progression. However, clinical studies comparing serum vitamin D levels between women with and without uterine leiomyomas are limited and inconclusive. This study aimed to compare serum vitamin D levels in women with and without uterine leiomyomas. Methods: This hospital-based case-control study included 150 women who visited a gynecological clinic. The cases included 75 women with uterine leiomyoma, whereas the controls included 75 age-and parity-matched participants without uterine leiomyoma. Serum vitamin D levels were measured in each participant and volumes of the uterine leiomyomas were determined using the water displacement method following myomectomy. The statistical significance was inferred at P-value &lt;=0.05. Results: The mean serum vitamin D level was 15.26+-4.96 ng/mL and 22.45+-6.93 ng/mL for the case and control groups, respectively. The difference was statistically significant (t-value -7.302 and P-value &lt;0.001). Within the fibroid group, 9 (12.0%), 49 (65.33%), and 17 (22.67%) participants had vitamin D deficiency, insufficiency, and sufficiency, respectively; and in the control group, 2 (2.67%), 24 (45.33%), and 39 (52.0%) participants had vitamin D deficiency, insufficiency, and sufficiency, respectively. There was significant negative correlation between the fibroid volume and the serum vitamin D level (r=-0.591, P&lt;0.001). Conclusion: Women with uterine leiomyoma had lower vitamin D levels than women in the control group. Lower vitamin D levels were associated with larger fibroid masses. Therefore, vitamin D supplementation reduces fibroid growth and development.</text><annotation id="28"><infon key="identifier">OMIM:150699</infon><infon key="type">Disease</infon><location offset="100" length="17"/><text>Uterine leiomyoma</text></annotation><annotation id="29"><infon key="identifier">MESH:D005831</infon><infon key="type">Disease</infon><location offset="130" length="23"/><text>gynecological condition</text></annotation><annotation id="30"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="203" length="9"/><text>Vitamin D</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="240" length="5"/><text>tumor</text></annotation><annotation id="32"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="317" length="9"/><text>vitamin D</text></annotation><annotation id="33"><infon key="identifier">OMIM:150699</infon><infon key="type">Disease</infon><location offset="365" length="18"/><text>uterine leiomyomas</text></annotation><annotation id="34"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="448" length="9"/><text>vitamin D</text></annotation><annotation id="35"><infon key="identifier">OMIM:150699</infon><infon key="type">Disease</infon><location offset="491" length="18"/><text>uterine leiomyomas</text></annotation><annotation id="36"><infon key="identifier">OMIM:150699</infon><infon key="type">Disease</infon><location offset="647" length="17"/><text>uterine leiomyoma</text></annotation><annotation id="37"><infon key="identifier">OMIM:150699</infon><infon key="type">Disease</infon><location offset="743" length="17"/><text>uterine leiomyoma</text></annotation><annotation id="38"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="768" length="9"/><text>vitamin D</text></annotation><annotation id="39"><infon key="identifier">OMIM:150699</infon><infon key="type">Disease</infon><location offset="838" length="18"/><text>uterine leiomyomas</text></annotation><annotation id="40"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="1016" length="9"/><text>vitamin D</text></annotation><annotation id="41"><infon key="identifier">MESH:D007889</infon><infon key="type">Disease</infon><location offset="1216" length="7"/><text>fibroid</text></annotation><annotation id="42"><infon key="identifier">MESH:D014808</infon><infon key="type">Disease</infon><location offset="1288" length="35"/><text>vitamin D deficiency, insufficiency</text></annotation><annotation id="43"><infon key="identifier">MESH:D014808</infon><infon key="type">Disease</infon><location offset="1438" length="35"/><text>vitamin D deficiency, insufficiency</text></annotation><annotation id="44"><infon key="identifier">MESH:D007889</infon><infon key="type">Disease</infon><location offset="1561" length="7"/><text>fibroid</text></annotation><annotation id="45"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="1590" length="9"/><text>vitamin D</text></annotation><annotation id="46"><infon key="identifier">OMIM:150699</infon><infon key="type">Disease</infon><location offset="1650" length="17"/><text>uterine leiomyoma</text></annotation><annotation id="47"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="1678" length="9"/><text>vitamin D</text></annotation><annotation id="48"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="1734" length="9"/><text>vitamin D</text></annotation><annotation id="49"><infon key="identifier">MESH:D007889</infon><infon key="type">Disease</infon><location offset="1779" length="14"/><text>fibroid masses</text></annotation><annotation id="50"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="1806" length="9"/><text>vitamin D</text></annotation><annotation id="51"><infon key="identifier">MESH:D007889</infon><infon key="type">Disease</infon><location offset="1840" length="7"/><text>fibroid</text></annotation></passage><relation id="R1"><infon key="score">0.6955</infon><infon key="role1">Chemical|MESH:D014807</infon><infon key="role2">Disease|OMIM:150699</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.7196</infon><infon key="role1">Chemical|MESH:D014807</infon><infon key="role2">Disease|MESH:D007889</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="19,18"/></relation><relation id="R3"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D014807</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Association</infon><node refid="2" role="4,5"/></relation></document>
<document><id>37848519</id><passage><infon key="journal">Nature;2023Oct; 622 (7983) 461. doi:10.1038/d41586-023-03233-w</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kuemmerle T, Meyfroidt P, Pendrill F, </infon><offset>0</offset><text>Making conventional farming more biodiversity friendly.</text></passage><passage><infon key="type">abstract</infon><offset>56</offset></passage></document>
<document><id>37849219</id><passage><infon key="journal">Angew Chem Int Ed Engl;2023Oct17 202312632. doi:10.1002/anie.202312632</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li J, Wang J, Xu L, Chi H, Liang X, Yoon J, Lin W, </infon><offset>0</offset><text>A Class of Activatable NIR-II Photoacoustic Dyes for High-Contrast Bioimaging.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="23" length="6"/><text>NIR-II</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Photoacoustic (PA) imaging is emerging as one of the important non-invasive imaging techniques in biomedical research. Small molecule- second near-infrared window (NIR-II) PA dyes combined with imaging data can provide comprehensive and in-depth in vivo physiological and pathological information. However, the NIR-II PA dyes usually exhibit "always-on" properties due to the lack of a readily optically tunable group, which hinders the further applications in vivo. Herein, a novel class of dyes GX have been designed and synthesized as the activatable NIR-II PA platform, in which the absorption/emission wavelength of GX-5 extends up to 1082/1360 nm. Importantly, dyes GX have a strong tissue penetration depth and high-resolution for the mouse vasculature structures in NIR-II PA 3D imaging and high signal-to-noise ratio in NIR-II fluorescence (FL) imaging. Furthermore, to demonstrate the applicability of GX dyes, the first NIR-II PA probe GX-5-CO activated by carbon monoxide (CO) was engineered and employed to reveal the enhancement of the CO levels in the hypertensive mice by high-contrast NIR-II PA and FL imaging. We expect that many derivatives of dyes GX will be developed to afford versatile NIR-II PA platforms for designing a wide variety activatable NIR-II PA probes as biomedical tools.</text><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="243" length="6"/><text>NIR-II</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="390" length="6"/><text>NIR-II</text></annotation><annotation id="24"><infon key="identifier">MESH:C001306</infon><infon key="type">Chemical</infon><location offset="576" length="2"/><text>GX</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="633" length="6"/><text>NIR-II</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="700" length="4"/><text>GX-5</text></annotation><annotation id="27"><infon key="identifier">MESH:C001306</infon><infon key="type">Chemical</infon><location offset="751" length="2"/><text>GX</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="853" length="6"/><text>NIR-II</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="908" length="6"/><text>NIR-II</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="991" length="7"/><text>GX dyes</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1010" length="6"/><text>NIR-II</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1026" length="5"/><text>GX-5-</text></annotation><annotation id="33"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1031" length="2"/><text>CO</text></annotation><annotation id="34"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1047" length="15"/><text>carbon monoxide</text></annotation><annotation id="35"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1064" length="2"/><text>CO</text></annotation><annotation id="36"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1129" length="2"/><text>CO</text></annotation><annotation id="37"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="1146" length="12"/><text>hypertensive</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1181" length="6"/><text>NIR-II</text></annotation><annotation id="39"><infon key="identifier">MESH:C001306</infon><infon key="type">Chemical</infon><location offset="1247" length="2"/><text>GX</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1288" length="6"/><text>NIR-II</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1349" length="6"/><text>NIR-II</text></annotation></passage><relation id="R1"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:C001306</infon><infon key="role2">Chemical|MESH:D002248</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="6,12"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D002248</infon><infon key="role2">Disease|MESH:D006973</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="12,16"/></relation></document>
<document><id>37850272</id><passage><infon key="journal">Nurs Older People;2023Oct18. doi:10.7748/nop.2023.e1448</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Duffy A, Lawler F, Dalton C, Connolly M, </infon><offset>0</offset><text>Setting up a journal club for healthcare professionals in an older people's residential care setting.</text></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>With the rise in the number of older people in the population and new developments in older people's services such as integrated care hubs, there is a need for healthcare professionals working with older people to keep up to date with the latest research. This article describes the process of establishing a multidisciplinary journal club in a residential care setting and recognising the potential of such clubs to develop staff members' critical thinking, presentation and communication skills. The authors emphasise the importance of fostering a culture of learning in older people's services and describe how a journal club can support healthcare professionals to maintain their knowledge and improve care.</text></passage></document>
<document><id>37850628</id><passage><infon key="journal">Ned Tijdschr Geneeskd;2023Oct11; 167</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fijen LM, Petersen RS, Cohn DM, </infon><offset>0</offset><text>[Facial swelling due to angioedema: often mast cell mediated, but not always].</text><annotation id="2"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="1" length="15"/><text>Facial swelling</text></annotation><annotation id="3"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="24" length="10"/><text>angioedema</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Most cases of angioedema are mast cell mediated. We present three patients with angioedema, who were admitted to our emergency room or outpatient clinic. One of them did have mast cell mediated angioedema, despite insufficient response to initial antihistamine treatment. The other patients had more rare cases of angioedema, i.e. hereditary angioedema with C1-inhibitor deficiency and angiotensin converting enzyme inhibitor associated angioedema. We discuss similarities and differences in symptoms, diagnosis and treatment between these causes of angioedema. We recommend keeping the differential diagnosis of angioedema in mind when a patient with angioedema is presented, including rarer pathophysiological explanations.</text><annotation id="14"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="93" length="10"/><text>angioedema</text></annotation><annotation id="15"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="159" length="10"/><text>angioedema</text></annotation><annotation id="16"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="273" length="10"/><text>angioedema</text></annotation><annotation id="17"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="393" length="10"/><text>angioedema</text></annotation><annotation id="18"><infon key="identifier">MESH:D054179</infon><infon key="type">Disease</infon><location offset="410" length="21"/><text>hereditary angioedema</text></annotation><annotation id="19"><infon key="identifier">MESH:D054179</infon><infon key="type">Disease</infon><location offset="437" length="23"/><text>C1-inhibitor deficiency</text></annotation><annotation id="20"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="516" length="10"/><text>angioedema</text></annotation><annotation id="21"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="629" length="10"/><text>angioedema</text></annotation><annotation id="22"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="692" length="10"/><text>angioedema</text></annotation><annotation id="23"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="731" length="10"/><text>angioedema</text></annotation></passage></document>
<document><id>37850982</id><passage><infon key="journal">J Acquir Immune Defic Syndr;2023Nov01; 94 (3) 244. doi:10.1097/QAI.0000000000003250</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10593489</infon><infon key="type">title</infon><infon key="authors">McLaughlin A, Lin N, Jiang W, Lodi S, Lioznov D, Patts G, Gnatienko N, Blokhina E, Bendiks S, Freiberg MS, Tindle HA, Krupitsky E, Hahn JA, Samet JH, So-Armah K, </infon><offset>0</offset><text>Association of Alcohol Consumption With CD4 Recovery After Antiretroviral Therapy Initiation in St. Petersburg, Russia.</text><annotation id="2"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="15" length="7"/><text>Alcohol</text></annotation><annotation id="3"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="40" length="3"/><text>CD4</text></annotation></passage><passage><infon key="type">abstract</infon><offset>120</offset><text>BACKGROUND: Delayed CD4 recovery after initiating antiretroviral therapy (ART) is a novel potential mechanism by which alcohol consumption leads to increased morbidity and mortality in people with HIV. We hypothesized that alcohol consumption at ART initiation is associated with slower CD4 recovery. METHODS: We retrospectively analyzed 2 pooled longitudinal alcohol/HIV cohorts (2014-2019) in St. Petersburg, Russia. Eligible participants initiated the first ART during parent studies; had alcohol consumption assessed by the blood biomarker, phosphatidylethanol (PEth), at the last research visit before ART initiation; and had >=1 CD4 count measurement before and after initiating ART. Participants were stratified by low, moderate, and high PEth (&lt;8, 8-80, and >80 ng/mL, respectively). We used random-effects piecewise linear regression models to estimate CD4 recovery, defined as CD4 count change per 30 days after ART initiation, by the alcohol group. RESULTS: Of 60 eligible participants, median age was 34 years and 28% were female. The median pre-ART PEth in the low, moderate, and high PEth groups were &lt;8, 23, and 232 ng/mL, respectively. After starting ART, the CD4 count increased by 13.60 cells/mm3/mo (95% CI: 0.33 to 26.87) with low PEth, 0.93 cells/mm3/mo (95% CI: -6.18 to 8.04) with moderate PEth, and 2.33 cells/mm3/mo (95% CI: -3.44 to 8.09) with high PEth. CONCLUSIONS: Among Russians with HIV, we observed faster CD4 recovery after ART initiation in those with low alcohol consumption compared with those with moderate and high alcohol consumption, as assessed by PEth. This analysis provides further evidence for the possible value of alcohol reduction interventions for people with HIV who are initiating ART.</text><annotation id="32"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="140" length="3"/><text>CD4</text></annotation><annotation id="33"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="239" length="7"/><text>alcohol</text></annotation><annotation id="34"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="317" length="3"/><text>HIV</text></annotation><annotation id="35"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="343" length="7"/><text>alcohol</text></annotation><annotation id="36"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="407" length="3"/><text>CD4</text></annotation><annotation id="37"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="480" length="7"/><text>alcohol</text></annotation><annotation id="38"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="488" length="3"/><text>HIV</text></annotation><annotation id="39"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="612" length="7"/><text>alcohol</text></annotation><annotation id="40"><infon key="identifier">MESH:C051521</infon><infon key="type">Chemical</infon><location offset="665" length="19"/><text>phosphatidylethanol</text></annotation><annotation id="41"><infon key="identifier">MESH:C051521</infon><infon key="type">Chemical</infon><location offset="686" length="4"/><text>PEth</text></annotation><annotation id="42"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="755" length="3"/><text>CD4</text></annotation><annotation id="43"><infon key="identifier">MESH:C051521</infon><infon key="type">Chemical</infon><location offset="866" length="4"/><text>PEth</text></annotation><annotation id="44"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="982" length="3"/><text>CD4</text></annotation><annotation id="45"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="1007" length="3"/><text>CD4</text></annotation><annotation id="46"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1065" length="7"/><text>alcohol</text></annotation><annotation id="47"><infon key="identifier">MESH:C051521</infon><infon key="type">Chemical</infon><location offset="1182" length="4"/><text>PEth</text></annotation><annotation id="48"><infon key="identifier">MESH:C051521</infon><infon key="type">Chemical</infon><location offset="1218" length="4"/><text>PEth</text></annotation><annotation id="49"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="1296" length="3"/><text>CD4</text></annotation><annotation id="50"><infon key="identifier">MESH:C051521</infon><infon key="type">Chemical</infon><location offset="1371" length="4"/><text>PEth</text></annotation><annotation id="51"><infon key="identifier">MESH:C051521</infon><infon key="type">Chemical</infon><location offset="1433" length="4"/><text>PEth</text></annotation><annotation id="52"><infon key="identifier">MESH:C051521</infon><infon key="type">Chemical</infon><location offset="1495" length="4"/><text>PEth</text></annotation><annotation id="53"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="1534" length="3"/><text>HIV</text></annotation><annotation id="54"><infon key="identifier">920</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="1558" length="3"/><text>CD4</text></annotation><annotation id="55"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1610" length="7"/><text>alcohol</text></annotation><annotation id="56"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1673" length="7"/><text>alcohol</text></annotation><annotation id="57"><infon key="identifier">MESH:C051521</infon><infon key="type">Chemical</infon><location offset="1709" length="4"/><text>PEth</text></annotation><annotation id="58"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1781" length="7"/><text>alcohol</text></annotation><annotation id="59"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="1829" length="3"/><text>HIV</text></annotation></passage><relation id="R1"><infon key="score">0.8791</infon><infon key="role1">Chemical|MESH:C051521</infon><infon key="role2">Gene|920</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="10,12"/></relation><relation id="R2"><infon key="score">0.6581</infon><infon key="role1">Chemical|MESH:D000438</infon><infon key="role2">Gene|920</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.9976</infon><infon key="role1">Chemical|MESH:C051521</infon><infon key="role2">Chemical|MESH:D000438</infon><infon key="type">Association</infon><node refid="2" role="10,9"/></relation><relation id="R4"><infon key="score">0.978</infon><infon key="role1">Chemical|MESH:D000438</infon><infon key="role2">Disease|MESH:D015658</infon><infon key="type">Association</infon><node refid="3" role="3,4"/></relation></document>
<document><id>37851343</id><passage><infon key="journal">Pain;2023Oct17. doi:10.1097/j.pain.0000000000003052</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">van der Miesen MM, Joosten EA, Kaas AL, Linden DEJ, Peters JC, Vossen CJ, </infon><offset>0</offset><text>Habituation to pain: self-report, electroencephalography, and functional magnetic resonance imaging in healthy individuals. A scoping review and future recommendations.</text><annotation id="1"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="15" length="4"/><text>pain</text></annotation></passage><passage><infon key="type">abstract</infon><offset>169</offset><text>ABSTRACT: Habituation to pain is a fundamental learning process and important adaption. Yet, a comprehensive review of the current state of the field is lacking. Through a systematic search, 63 studies were included. Results address habituation to pain in healthy individuals based on self-report, electroencephalography, or functional magnetic resonance imaging. Our findings indicate a large variety in methods, experimental settings, and contexts, making habituation a ubiquitous phenomenon. Habituation to pain based on self-report studies shows a large influence of expectations, as well as the presence of individual differences. Furthermore, widespread neural effects, with sometimes opposing effects in self-report measures, are noted. Electroencephalography studies showed habituation of the N2-P2 amplitude, whereas functional magnetic resonance imaging studies showed decreasing activity during painful repeated stimulation in several identified brain areas (cingulate cortex and somatosensory cortices). Important considerations for the use of terminology, methodology, statistics, and individual differences are discussed. This review will aid our understanding of habituation to pain in healthy individuals and may lead the way to improving methods and designs for personalized treatment approaches in chronic pain patients.</text><annotation id="7"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="194" length="4"/><text>pain</text></annotation><annotation id="8"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="417" length="4"/><text>pain</text></annotation><annotation id="9"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="679" length="4"/><text>pain</text></annotation><annotation id="10"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1362" length="4"/><text>pain</text></annotation><annotation id="11"><infon key="identifier">MESH:D059350</infon><infon key="type">Disease</infon><location offset="1485" length="12"/><text>chronic pain</text></annotation></passage></document>
<document><id>37851698</id><passage><infon key="journal">PLoS Genet;2023Oct18; 19 (10) 1011006. doi:10.1371/journal.pgen.1011006</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hu Y, Hao T, Yu H, Miao W, Zheng Y, Tao W, Zhuang J, Wang J, Fan Y, Jia S, </infon><offset>0</offset><text>lhCLIP reveals the in vivo RNA-RNA interactions recognized by hnRNPK.</text><annotation id="1"><infon key="identifier">3190</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">81909</infon><location offset="62" length="6"/><text>hnRNPK</text></annotation></passage><passage><infon key="type">abstract</infon><offset>70</offset><text>RNA-RNA interactions play a crucial role in regulating gene expression and various biological processes, but identifying these interactions on a transcriptomic scale remains a challenge. To address this, we have developed a new biochemical technique called pCp-biotin labelled RNA hybrid and ultraviolet crosslinking and immunoprecipitation (lhCLIP) that enables the transcriptome-wide identification of intra- and intermolecular RNA-RNA interactions mediated by a specific RNA-binding protein (RBP). Using lhCLIP, we have uncovered a diverse landscape of intermolecular RNA interactions recognized by hnRNPK in human cells, involving all major classes of noncoding RNAs (ncRNAs) and mRNA. Notably, hnRNPK selectively binds with snRNA U4, U11, and U12, and shapes the secondary structure of these snRNAs, which may impact RNA splicing. Our study demonstrates the potential of lhCLIP as a user-friendly and widely applicable method for discovering RNA-RNA interactions mediated by a particular protein of interest and provides a valuable tool for further investigating the role of RBPs in gene expression and biological processes.</text><annotation id="9"><infon key="identifier">MESH:D001710</infon><infon key="type">Chemical</infon><location offset="331" length="6"/><text>biotin</text></annotation><annotation id="10"><infon key="identifier">27303</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49388</infon><location offset="544" length="19"/><text>RNA-binding protein</text></annotation><annotation id="11"><infon key="identifier">27303</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49388</infon><location offset="565" length="3"/><text>RBP</text></annotation><annotation id="12"><infon key="identifier">3190</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">81909</infon><location offset="672" length="6"/><text>hnRNPK</text></annotation><annotation id="13"><infon key="identifier">3190</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">81909</infon><location offset="769" length="6"/><text>hnRNPK</text></annotation><annotation id="14"><infon key="identifier">26824</infon><infon key="type">Gene</infon><location offset="809" length="3"/><text>U11</text></annotation><annotation id="15"><infon key="identifier">26823</infon><infon key="type">Gene</infon><location offset="818" length="3"/><text>U12</text></annotation></passage><relation id="R1"><infon key="score">0.9787</infon><infon key="role1">Gene|26824</infon><infon key="role2">Gene|3190</infon><infon key="type">Association</infon><node refid="0" role="6,5"/></relation><relation id="R2"><infon key="score">0.9805</infon><infon key="role1">Gene|26823</infon><infon key="role2">Gene|3190</infon><infon key="type">Association</infon><node refid="1" role="7,5"/></relation></document>
<document><id>37852059</id><passage><infon key="journal">Int Emerg Nurs;2023Oct16; 71 101366. doi:10.1016/j.ienj.2023.101366</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xu HG, Ullman AJ, Rickard CM, Johnston A, </infon><offset>0</offset><text>Factors impacting emergency department clinicians' peripheral intravenous catheter practice: A qualitative analysis.</text></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>BACKGROUND: Peripheral intravenous catheters (PIVCs) are commonly used devices in emergency departments (EDs), and yet relatively little is known about factors influencing Australian clinicians' adherence to the national PIVC quality and safety Standard. AIMS: To explore attitudes and experiences of ED clinicians around PIVC insertion and care processes. METHODS: This study used an exploratory qualitative approach to analyse written responses to open-ended questions included in an online national (mixed data) survey. Snowballing methods were used to gather responses. Deductive analysis was used to analyse open-ended questions regarding practice and Standard adherence. RESULTS: There were 340 written responses, mainly from nurses in public EDs, who reported suboptimal practices regarding idle catheters, lack of patient participation in care, antecubital fossa insertion, multiple insertion attempts, inadequate site preparation, poor documentation and insufficient review of PIVC. The main factors inhibiting ED clinicians from adhering to the Standard includes inadequate knowledge, perceptions of infeasibility, disbelief in evidence, ambiguous responsibilities, habitual practice, insufficient training, lack of recognition of good practice and inadequate engagement. CONCLUSION: The factors that impact ED clinicians' PIVC Standard adherence are complex and multifactorial. Strategies and interventions are needed to facilitate the implementation of the Standard into daily practice and achieve sustainable behaviour change.</text></passage></document>
<document><id>37852409</id><passage><infon key="journal">Biosystems;2023Oct16; 234 105043. doi:10.1016/j.biosystems.2023.105043</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Spirov A, </infon><offset>0</offset><text>Evolution of the RNA world: From signals to codes.</text></passage><passage><infon key="type">abstract</infon><offset>51</offset><text>The accumulated material in evolutionary biology, greatly enhanced by the achievements of modern synthetic biology, allows us to envision certain key hypothetical stages of prebiotic (chemical) evolution. This is often understood as the further evolution in the RNA World towards the RNA-protein World. It is a path towards the emergence of translation and the genetic code (I), signaling pathways with signaling molecules (II), and the appearance of RNA-based components of future gene regulatory networks (III). We believe that these evolutionary paths can be constructively viewed from the perspective of the concept of biological codes (Barbieri, 2003). Crucial evolutionary events in these directions would involve the emergence of RNA-based adaptors. Such adaptors connect two families of functionally and chemically distinct molecules into one functional entity. The emergence of primitive translation processes is undoubtedly the major milestone in the evolutionary path towards modern life. The key aspect here is the appearance of adaptors between amino acids and their cognate triplet codons. The initial steps are believed to involve the emergence of proto-transfer RNAs capable of self-aminoacylation. The second significant evolutionary breakthrough is the development of biochemical regulatory networks based on signaling molecules of the RNA World (ribonucleotides and their derivatives), as well as receptors and effectors (riboswitches) for these messengers. Some authors refer to this as the "lost language of the RNA World." The third evolutionary step is the emergence of signal sequences for ribozymes on the molecules of their RNA targets. This level of regulation in the RNA World is comparable to the gene regulatory networks of modern organisms. We believe that the signal sequences on target molecules have been rediscovered and developed by evolution into the gene regulatory networks of modern cells. In conclusion, the immense diversity of modern biological codes, in some of its key characteristics, can be traced back to the achievements of prebiotic evolution.</text></passage></document>
<document><id>37853820</id><passage><infon key="journal">Dalton Trans;2023Oct18. doi:10.1039/d3dt02769d</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang Y, Liu X, Jin Q, Han F, Zhang Z, Zhang X, Wu L, </infon><offset>0</offset><text>CoS2@C catalyzes polysulfide conversion to promote the rate and cycling performances of lithium-sulfur batteries.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="6"/><text>CoS2@C</text></annotation><annotation id="4"><infon key="identifier">MESH:C032915</infon><infon key="type">Chemical</infon><location offset="17" length="11"/><text>polysulfide</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="88" length="14"/><text>lithium-sulfur</text></annotation></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>Lithium-sulfur (Li-S) batteries have been considered one of the most promising candidates for next-generation energy storage devices due to their high theoretical energy density and low cost. Nonetheless, the practical application of Li-S batteries is still inhibited by their lithium polysulfide (LiPS) shuttling and sluggish redox kinetics, which cause rapid capacity decay and inferior rate performance. Hence, anchoring LiPSs and catalyzing their conversion reactions are imperative to enhance the performance of Li-S batteries. In this work, one-dimensional (1D) porous carbon-encapsulated CoS2 (CoS2@C) fiber structures were prepared through a simple two-step hydrothermal reaction and they exhibited a robust LiPS trapping ability and rapid catalytic conversion of LiPSs. The formed three-dimensional (3D) architecture (CoS2@C/MWCNT) facilitates the physical adsorption of LiPSs and rapid ion transport. The electrode exhibited a high initial capacity of 1329.5 mA h g-1 at a current density of 0.1 C and a reversible capacity of 1060.6 mA h g-1 after 100 cycles, with an 80% capacity retention rate. Meanwhile, the decay rate of the electrode is 0.048% per cycle at 1 C and after 500 cycles. With a sulfur loading of 3 mg cm-2, the capacity retention rate is approximately 83.7% after 80 cycles.</text><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="114" length="14"/><text>Lithium-sulfur</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="130" length="4"/><text>Li-S</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="348" length="4"/><text>Li-S</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="391" length="19"/><text>lithium polysulfide</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="412" length="4"/><text>LiPS</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="538" length="5"/><text>LiPSs</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="631" length="4"/><text>Li-S</text></annotation><annotation id="29"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="689" length="6"/><text>carbon</text></annotation><annotation id="30"><infon key="identifier">MESH:C027875</infon><infon key="type">Chemical</infon><location offset="709" length="4"/><text>CoS2</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="715" length="6"/><text>CoS2@C</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="830" length="4"/><text>LiPS</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="886" length="5"/><text>LiPSs</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="941" length="6"/><text>CoS2@C</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="948" length="5"/><text>MWCNT</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="994" length="5"/><text>LiPSs</text></annotation><annotation id="37"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="1321" length="6"/><text>sulfur</text></annotation></passage><relation id="R1"><infon key="score">0.9887</infon><infon key="role1">Chemical|MESH:C027875</infon><infon key="role2">Chemical|MESH:D002244</infon><infon key="type">Association</infon><node refid="0" role="11,10"/></relation></document>
<document><id>37890044</id><passage><infon key="type">title</infon><offset>0</offset><text>Black therapists' experiences with their Black clients: A systematic review.</text></passage><passage><infon key="type">abstract</infon><offset>77</offset><text>This systematic review explores Black therapists' experiences with their Black clients. The search initially identified 459 possible articles. Through the study selection process, following the Cochrane Collaboration's guidelines, the 459 studies were narrowed down to 11 studies. A total of eight qualitative studies and three quantitative studies were identified. The analytic process of this review mirrored that of a thematic analysis due to the proportion of qualitative articles. Five themes emerged: Understanding the Black Experience, Connection to Clients, Working with Black Clients, Working While Black, and Training Black Therapists. Implications for training and supervision are discussed.</text></passage></document>
<document><id>37890394</id><passage><infon key="type">title</infon><offset>0</offset><text>Exploring trauma and wellbeing of people who use drugs after witnessing overdose: A qualitative study.</text><annotation id="2"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="10" length="6"/><text>trauma</text></annotation><annotation id="3"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="72" length="8"/><text>overdose</text></annotation></passage><passage><infon key="type">abstract</infon><offset>103</offset><text>BACKGROUND: The national overdose crisis is often quantified by overdose deaths, but understanding the traumatic impact for those who witness and respond to overdoses can help elucidate mental health needs and opportunities for intervention for this population. Many who respond to overdoses are people who use drugs. This study adds to the literature on how people who use drugs qualitatively experience trauma resulting from witnessing and responding to overdose, through the lens of the Trauma-Informed Theory of Individual Health Behavior. METHODS: We conducted 60-min semi-structured, in-depth phone interviews. Participants were recruited from six states and Washington, DC in March-April 2022. Participants included 17 individuals who witnessed overdose(s) during the COVID-19 pandemic. The interview guide was shaped by theories of trauma. The codebook was developed using a priori codes from the interview guide; inductive codes were added during content analysis. Transcripts were coded using ATLAS.ti. RESULTS: A vast majority reported trauma from witnessing overdoses. Participants reported that the severity of trauma varied by contextual factors such as the closeness of the relationship to the person overdosing or whether the event was their first experience witnessing an overdose. Participants often described symptoms of trauma including rumination, guilt, and hypervigilance. Some reported normalization of witnessing overdoses due to how common overdoses were, while some acknowledged overdoses will never be "normal." The impacts of witnessing overdose on drug use behaviors varied from riskier substance use to increased motivation for treatment and safer drug use practices. CONCLUSION: Recognizing the traumatic impact of witnessed overdoses is key to effectively addressing the full range of sequelae of the overdose crisis. Trauma-informed approaches should be central for service providers when they approach this subject with clients, with awareness of how normalization can reduce help-seeking behaviors and the need for psychological aftercare. We found increased motivation for behavior change after witnessing, which presents opportunity for intervention.</text><annotation id="28"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="128" length="8"/><text>overdose</text></annotation><annotation id="29"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="167" length="8"/><text>overdose</text></annotation><annotation id="30"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="260" length="9"/><text>overdoses</text></annotation><annotation id="31"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="385" length="9"/><text>overdoses</text></annotation><annotation id="32"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="508" length="6"/><text>trauma</text></annotation><annotation id="33"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="559" length="8"/><text>overdose</text></annotation><annotation id="34"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="593" length="6"/><text>Trauma</text></annotation><annotation id="35"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="855" length="8"/><text>overdose</text></annotation><annotation id="36"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="878" length="8"/><text>COVID-19</text></annotation><annotation id="37"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="943" length="6"/><text>trauma</text></annotation><annotation id="38"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1150" length="6"/><text>trauma</text></annotation><annotation id="39"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="1173" length="9"/><text>overdoses</text></annotation><annotation id="40"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1227" length="6"/><text>trauma</text></annotation><annotation id="41"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="1392" length="8"/><text>overdose</text></annotation><annotation id="42"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1443" length="6"/><text>trauma</text></annotation><annotation id="43"><infon key="identifier">MESH:D000079562</infon><infon key="type">Disease</infon><location offset="1460" length="10"/><text>rumination</text></annotation><annotation id="44"><infon key="type">Disease</infon><location offset="1472" length="5"/><text>guilt</text></annotation><annotation id="45"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="1541" length="9"/><text>overdoses</text></annotation><annotation id="46"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="1569" length="9"/><text>overdoses</text></annotation><annotation id="47"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="1609" length="9"/><text>overdoses</text></annotation><annotation id="48"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="1669" length="8"/><text>overdose</text></annotation><annotation id="49"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="1860" length="9"/><text>overdoses</text></annotation><annotation id="50"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="1937" length="8"/><text>overdose</text></annotation><annotation id="51"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1954" length="6"/><text>Trauma</text></annotation></passage></document>
<document><id>37890744</id><passage><infon key="journal">Int J Biol Macromol;2023Oct25 127680. doi:10.1016/j.ijbiomac.2023.127680</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tao Y, Xu L, Liu X, Wang P, Wei S, Huang Y, Gu W, Bo R, Liu M, Yu J, Li J, </infon><offset>0</offset><text>Chitosan-coated artesunate protects against ulcerative colitis via STAT6-mediated macrophage M2 polarization and intestinal barrier protection.</text><annotation id="4"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="0" length="8"/><text>Chitosan</text></annotation><annotation id="5"><infon key="identifier">MESH:D000077332</infon><infon key="type">Chemical</infon><location offset="16" length="10"/><text>artesunate</text></annotation><annotation id="6"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="44" length="18"/><text>ulcerative colitis</text></annotation><annotation id="7"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="67" length="5"/><text>STAT6</text></annotation></passage><passage><infon key="type">abstract</infon><offset>144</offset><text>Oral delivery of chitosan-coated artesunate (CPA) has been proven to be effective at preventing ulcerative colitis (UC) in mice. However, the anti-inflammatory mechanism is not fully understood. STAT6 is a key transcription factor that promotes anti-inflammatory effects by inducing M2 and Th2 dominant phenotypes, therefore we hypothesized STAT6 might play a key role in the process. To prove it, a STAT6 gene knockout macrophage cell line (STAT6-/- RAW264.7, by CRISPR/Cas9 method), and its corresponding Caco-2/RAW264.7 co-culture system combined with the STAT6 inhibitor (AS1517499, AS) in a mouse UC model were established and studied. The results showed that CPA remarkably suppressed the activation of TLR-4/NF-kappaB pathway and the mRNA levels of proinflammatory cytokines, while increased the IL-10 levels in RAW264.7. This effect of CPA contributed to the protection of the ZO-1 in Caco-2 which was disrupted upon the stimulation to macrophages. Simultaneously, CPA reduced the expression of CD86 but increase the expression of CD206 and p-STAT6 in LPS-stimulated RAW264.7 cells. However, above alterations were not obvious as in STAT6-/- RAW264.7 and its co-culture system, suggesting STAT6 plays a key role. Furthermore, CPA treatment significantly inhibited TLR-4/NF-kappaB activation, intestinal macrophage M1 polarization and mucosal barrier injury induced by DSS while promoted STAT6 phosphorylation in the UC mouse model, but this effect was also prominently counteracted by AS. Therefore, our data indicate that STAT6 is a major regulator in the balance of M1/M2 polarization, intestinal barrier integrity and then anti-colitis effects of CPA. These findings broaden our understanding of how CPA fights against UC and imply an alternative treatment strategy for UC via this pathway.</text><annotation id="49"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="161" length="8"/><text>chitosan</text></annotation><annotation id="50"><infon key="identifier">MESH:D000077332</infon><infon key="type">Chemical</infon><location offset="177" length="10"/><text>artesunate</text></annotation><annotation id="51"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="240" length="18"/><text>ulcerative colitis</text></annotation><annotation id="52"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="260" length="2"/><text>UC</text></annotation><annotation id="53"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="291" length="12"/><text>inflammatory</text></annotation><annotation id="54"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="339" length="5"/><text>STAT6</text></annotation><annotation id="55"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="394" length="12"/><text>inflammatory</text></annotation><annotation id="56"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="485" length="5"/><text>STAT6</text></annotation><annotation id="57"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="544" length="5"/><text>STAT6</text></annotation><annotation id="58"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="586" length="5"/><text>STAT6</text></annotation><annotation id="59"><infon key="identifier">CVCL:0493</infon><infon key="type">CellLine</infon><location offset="595" length="8"/><text>RAW264.7</text></annotation><annotation id="60"><infon key="identifier">CVCL:0025</infon><infon key="type">CellLine</infon><location offset="651" length="6"/><text>Caco-2</text></annotation><annotation id="61"><infon key="identifier">CVCL:0493</infon><infon key="type">CellLine</infon><location offset="658" length="8"/><text>RAW264.7</text></annotation><annotation id="62"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="703" length="5"/><text>STAT6</text></annotation><annotation id="63"><infon key="identifier">MESH:C544923</infon><infon key="type">Chemical</infon><location offset="720" length="9"/><text>AS1517499</text></annotation><annotation id="64"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="731" length="2"/><text>AS</text></annotation><annotation id="65"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="746" length="2"/><text>UC</text></annotation><annotation id="66"><infon key="identifier">21898</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41317</infon><location offset="853" length="5"/><text>TLR-4</text></annotation><annotation id="67"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="859" length="9"/><text>NF-kappaB</text></annotation><annotation id="68"><infon key="identifier">16153</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">478</infon><location offset="947" length="5"/><text>IL-10</text></annotation><annotation id="69"><infon key="identifier">CVCL:0493</infon><infon key="type">CellLine</infon><location offset="963" length="8"/><text>RAW264.7</text></annotation><annotation id="70"><infon key="identifier">21872</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2445</infon><location offset="1029" length="4"/><text>ZO-1</text></annotation><annotation id="71"><infon key="identifier">CVCL:0025</infon><infon key="type">CellLine</infon><location offset="1037" length="6"/><text>Caco-2</text></annotation><annotation id="72"><infon key="identifier">12524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">10443</infon><location offset="1147" length="4"/><text>CD86</text></annotation><annotation id="73"><infon key="identifier">17533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37622</infon><location offset="1183" length="5"/><text>CD206</text></annotation><annotation id="74"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="1195" length="5"/><text>STAT6</text></annotation><annotation id="75"><infon key="identifier">MESH:D008070</infon><infon key="type">Chemical</infon><location offset="1204" length="3"/><text>LPS</text></annotation><annotation id="76"><infon key="identifier">CVCL:0493</infon><infon key="type">CellLine</infon><location offset="1219" length="8"/><text>RAW264.7</text></annotation><annotation id="77"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="1285" length="5"/><text>STAT6</text></annotation><annotation id="78"><infon key="identifier">CVCL:0493</infon><infon key="type">CellLine</infon><location offset="1294" length="8"/><text>RAW264.7</text></annotation><annotation id="79"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="1341" length="5"/><text>STAT6</text></annotation><annotation id="80"><infon key="identifier">21898</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">41317</infon><location offset="1416" length="5"/><text>TLR-4</text></annotation><annotation id="81"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1422" length="9"/><text>NF-kappaB</text></annotation><annotation id="82"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1502" length="6"/><text>injury</text></annotation><annotation id="83"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="1539" length="5"/><text>STAT6</text></annotation><annotation id="84"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="1568" length="2"/><text>UC</text></annotation><annotation id="85"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1637" length="2"/><text>AS</text></annotation><annotation id="86"><infon key="identifier">20852</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2373</infon><location offset="1675" length="5"/><text>STAT6</text></annotation><annotation id="87"><infon key="identifier">MESH:D003092</infon><infon key="type">Disease</infon><location offset="1783" length="7"/><text>colitis</text></annotation><annotation id="88"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="1874" length="2"/><text>UC</text></annotation><annotation id="89"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="1925" length="2"/><text>UC</text></annotation></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D000077332</infon><infon key="role2">Disease|MESH:D003093</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="1,2"/></relation><relation id="R2"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:D001151</infon><infon key="role2">Gene|20852</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="19,12"/></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D003093</infon><infon key="role2">Gene|20852</infon><infon key="type">Association</infon><node refid="2" role="2,3"/></relation><relation id="R4"><infon key="score">0.9997</infon><infon key="role1">Chemical|MESH:D000077332</infon><infon key="role2">Gene|20852</infon><infon key="type">Association</infon><node refid="3" role="1,3"/></relation><relation id="R5"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D048271</infon><infon key="role2">Gene|20852</infon><infon key="type">Association</infon><node refid="4" role="0,3"/></relation><relation id="R6"><infon key="score">0.6929</infon><infon key="role1">Chemical|MESH:D000077332</infon><infon key="role2">Chemical|MESH:D048271</infon><infon key="type">Association</infon><node refid="5" role="1,0"/></relation><relation id="R7"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D003092</infon><infon key="role2">Gene|20852</infon><infon key="type">Association</infon><node refid="6" role="42,41"/></relation><relation id="R8"><infon key="score">0.9987</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|20852</infon><infon key="type">Association</infon><node refid="7" role="10,9"/></relation><relation id="R9"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:D048271</infon><infon key="role2">Disease|MESH:D003093</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="0,2"/></relation><relation id="R10"><infon key="score">0.5805</infon><infon key="role1">Gene|18033</infon><infon key="role2">Gene|20852</infon><infon key="type">Association</infon><node refid="9" role="36,38"/></relation><relation id="R11"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:C544923</infon><infon key="role2">Gene|20852</infon><infon key="type">Negative_Correlation</infon><node refid="10" role="18,12"/></relation></document>
<document><id>37891095</id><passage><infon key="type">title</infon><offset>0</offset><text>[Validation of a questionnaire to assess patient safety culture in healthcare managers: Psychometric properties and usability].</text></passage><passage><infon key="type">abstract</infon><offset>128</offset><text>AIM: To validate a reduced and applicable to distinct location version of the only validated questionnaire of patient safety culture in managers in Spanish language. METHOD: Questionnaire validation study. Community of Madrid 2022. Reduction/adaptation of the original questionnaire: Gimenez-Aibar-Gutierrez, 2013 Questionnaire was reduced from 85 items to 25; those local or not applicable were removed. Pre-test: Semi-structured survey on comprehension and response scale. There was no need to modify the questionnaire. VALIDATION: It was tested in 39 primary care managers without care activity. Internal consistency (alpha Cronbach), content validity (experts) and construct validity (factor analysis) were analysed. Usability analysis: Survey on time spent and non-response rate. RESULTS: alpha Cronbach=0.894. Content validity: Experts deemed questionnaire was complete. Factor analysis: five factors explain 68% of variance. The factors corresponded to the dimensions of the theoretical construct. Factors, internal consistency of each and correlation with global score were: commitment with patient safety: alpha Cronbach=0.793, r=0.778; P&lt;.001; procedures/reporting: alpha Cronbach=0.83, r=0.806; P&lt;.001; attitudes with patient safety: alpha Cronbach=0.766, r=0.596; P&lt;.001; clinicians involving: alpha Cronbach=0.773, r=0.798; P&lt;.001; patient safety communication: alpha Cronbach=0.615, r=0.518; P=.001; usability survey: 95% thought spent time was adequate. Non-response rate was 0%, except one item. CONCLUSION: In this work, a reduced and adapted version of questionnaire of Gimenez-Aibar-Gutierrez was validated at distinct location (Madrid region). Psychometric properties and usability, which were found, suggest that the reduced questionnaire is a reliable, valid and usable instrument to assess patient safety culture in managers of any place.</text></passage></document>
<document><id>37891447</id><passage><infon key="type">title</infon><offset>0</offset><text>Discovery of a second-site nia2 mutation in the background of multiple Arabidopsis PIF-related mutants containing the pif3-3 allele.</text><annotation id="2"><infon key="identifier">840630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">135055</infon><location offset="27" length="4"/><text>nia2</text></annotation><annotation id="3"><infon key="identifier">837479</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">116227</infon><location offset="118" length="6"/><text>pif3-3</text></annotation></passage><passage><infon key="type">abstract</infon><offset>133</offset></passage></document>
<document><id>37897055</id><passage><infon key="journal">Br J Clin Pharmacol;2023Oct27. doi:10.1111/bcp.15946</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Udomkarnjananun S, Eiamsitrakoon T, de Winter BCM, van Gelder T, Hesselink DA, </infon><offset>0</offset><text>SHOULD WE ABANDON THERAPEUTIC DRUG MONITORING OF TACROLIMUS IN WHOLE BLOOD AND MOVE TO INTRACELLULAR CONCENTRATION MEASUREMENTS?</text><annotation id="2"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="49" length="10"/><text>TACROLIMUS</text></annotation><annotation id="3"><infon key="identifier">MESH:C531766</infon><infon key="type">Disease</infon><location offset="63" length="5"/><text>WHOLE</text></annotation></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>The measurement of whole blood (WB) concentrations has been the primary method for therapeutic drug monitoring (TDM) of tacrolimus since its introduction in the field of organ transplantation. However, more than 99% of tacrolimus measured in WB is bound to erythrocytes and plasma proteins, which are the pharmacologically inactive fractions. The pharmacologically active fractions, the free (or unbound) tacrolimus in plasma and the intracellular tacrolimus, make up 1% or less of the WB concentration. The mechanism of action of tacrolimus is to inhibit the enzyme calcineurin within T lymphocytes, and therefore, measuring the intra-lymphocytic tacrolimus concentration may better reflect its pharmacodynamic effects and better correlate with clinical outcomes. However, studies on intracellular tacrolimus concentrations have shown conflicting results. In this review, we argue that we need to overcome the analytical limitations of current assays for the measurement of intracellular tacrolimus before moving this technique into the clinical setting. The validity and standardization of the cell isolation process before the measurement of the intracellular tacrolimus concentration is as important as the measurement itself but has received little attention in our view. Recent evidence suggests that the addition of an inhibitor of P-glycoprotein, an efflux transporter expressed on lymphocytes, prevents the expulsion of tacrolimus during the cell isolation process. Refining the technique for the intracellular tacrolimus concentration measurement should be the focus followed by clinical evaluation of its association with rejection risk.</text><annotation id="16"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="249" length="10"/><text>tacrolimus</text></annotation><annotation id="17"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="348" length="10"/><text>tacrolimus</text></annotation><annotation id="18"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="534" length="10"/><text>tacrolimus</text></annotation><annotation id="19"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="577" length="10"/><text>tacrolimus</text></annotation><annotation id="20"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="660" length="10"/><text>tacrolimus</text></annotation><annotation id="21"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="777" length="10"/><text>tacrolimus</text></annotation><annotation id="22"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="928" length="10"/><text>tacrolimus</text></annotation><annotation id="23"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="1118" length="10"/><text>tacrolimus</text></annotation><annotation id="24"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="1292" length="10"/><text>tacrolimus</text></annotation><annotation id="25"><infon key="identifier">5243</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55496</infon><location offset="1468" length="14"/><text>P-glycoprotein</text></annotation><annotation id="26"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="1558" length="10"/><text>tacrolimus</text></annotation><annotation id="27"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="1649" length="10"/><text>tacrolimus</text></annotation></passage><relation id="R1"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:D016559</infon><infon key="role2">Disease|MESH:C531766</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.9925</infon><infon key="role1">Chemical|MESH:D016559</infon><infon key="role2">Gene|5243</infon><infon key="type">Association</infon><node refid="1" role="12,11"/></relation></document>
<document><id>37897406</id><passage><infon key="type">title</infon><offset>0</offset><text>Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda.</text><annotation id="2"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="10" length="8"/><text>Toxicity</text></annotation><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="44" length="6"/><text>Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>INTRODUCTION: Cancer is a major public health problem in Rwanda and other low- and middle-income countries (LMICs). While there have been some improvements in access to cancer treatment, the cost of care has increased, leading to financial toxicity and treatment barriers for many patients. This study explores the financial toxicity of cancer care in Rwanda. METHODS: This prospective cross-sectional study was conducted at 3 referral hospitals in Rwanda, which deliver most of the country's cancer care. Data were collected over 6 months from June 1 to December 1, 2022 by trained research assistants (RAs) using a modified validated data collection tool. RAs interviewed consecutive eligible patients with breast cancer, cervical cancer, colorectal cancer, Hodgkin's and non-Hodgkin's lymphoma who were on active systemic therapy. The study aimed to identify sources of financial burden. Data were analyzed using descriptive statistics. RESULTS: 239 patients were included; 75% (n = 180/239) were female and mean age was 51 years. Breast, cervix, and colorectal cancers were the most common diagnoses (42%, 100/239; 24%, 58/239; and 24%, 57/239, respectively) and 54% (n = 129/239) were diagnosed with advanced stage (stages III-IV). Financial burden was high; 44% (n = 106/239) of respondents sold property, 29% (n = 70/239) asked for charity from public, family, or friends, and 16% (n = 37/239) took loans with interest to fund cancer treatment. CONCLUSION: Despite health insurance which covers many elements of cancer care, a substantial proportion of patients on anti-cancer treatment in Rwanda experience major financial toxicity. Novel health financing solutions are needed to ensure accessible and affordable cancer care.</text><annotation id="20"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="93" length="6"/><text>Cancer</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="248" length="6"/><text>cancer</text></annotation><annotation id="22"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="319" length="8"/><text>toxicity</text></annotation><annotation id="23"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="404" length="8"/><text>toxicity</text></annotation><annotation id="24"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="416" length="6"/><text>cancer</text></annotation><annotation id="25"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="572" length="6"/><text>cancer</text></annotation><annotation id="26"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="788" length="13"/><text>breast cancer</text></annotation><annotation id="27"><infon key="identifier">MESH:D002583</infon><infon key="type">Disease</infon><location offset="803" length="15"/><text>cervical cancer</text></annotation><annotation id="28"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="820" length="17"/><text>colorectal cancer</text></annotation><annotation id="29"><infon key="identifier">MESH:D008228</infon><infon key="type">Disease</infon><location offset="839" length="36"/><text>Hodgkin's and non-Hodgkin's lymphoma</text></annotation><annotation id="30"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1113" length="38"/><text>Breast, cervix, and colorectal cancers</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1513" length="6"/><text>cancer</text></annotation><annotation id="32"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1598" length="6"/><text>cancer</text></annotation><annotation id="33"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1656" length="6"/><text>cancer</text></annotation><annotation id="34"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1710" length="8"/><text>toxicity</text></annotation><annotation id="35"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1800" length="6"/><text>cancer</text></annotation></passage></document>
<document><id>37897756</id><passage><infon key="journal">Phys Rev Lett;2023Oct13; 131 (15) 151002. doi:10.1103/PhysRevLett.131.151002</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Aguilar M, Ambrosi G, Anderson H, Arruda L, Attig N, Bagwell C, Barao F, Barbanera M, Barrin L, Bartoloni A, Battiston R, Belyaev N, Berdugo J, Bertucci B, Bindi V, Bollweg K, Bolster J, Borchiellini M, Borgia B, Boschini MJ, Bourquin M, Burger J, Burger WJ, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen H, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, D'Angelo F, Dass A, Delgado C, Della Torre S, Demirk&amp;#xf6;z MB, Derome L, Di Falco S, Di Felice V, D&amp;#xed;az C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Faldi F, Feng J, Fiandrini E, Fisher P, Formato V, G&amp;#xe1;mez C, Garc&amp;#xed;a-L&amp;#xf3;pez RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, G&amp;#xf3;mez-Coral DM, Gong J, Goy C, Grandi D, Graziani M, Guracho AN, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Huang BW, Ionica M, Incagli M, Jia Y, Jinchi H, Karag&amp;#xf6;z G, Khan S, Khiali B, Kirn T, Klipfel AP, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, LaVecchia G, Lazzizzera I, Lee HT, Lee SC, Li HL, Li JQ, Li M, Li M, Li Q, Li Q, Li QY, Li S, Li SL, Li JH, Li ZH, Liang J, Liang MJ, Lin CH, Lippert T, Liu JH, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo SD, Luo X, Ma&amp;#xf1;&amp;#xe1; C, Mar&amp;#xed;n J, Marquardt J, Martin T, Mart&amp;#xed;nez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Molero M, Mott P, Mussolin L, Jozani YN, Negrete J, Nicolaidis R, Nikonov N, Nozzoli F, Ocampo-Peleteiro J, Oliva A, Orcinha M, Ottupara MA, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Plyaskin V, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rodr&amp;#xed;guez-Garc&amp;#xed;a I, Romaneehsen L, Rossi F, Rozhkov A, Rozza D, Sagdeev R, Savin E, Schael S, von Dratzig AS, Schwering G, Seo ES, Shan BS, Siedenburg T, Silvestre G, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Tian Y, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, V&amp;#xe1;zquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Wu Y, Xiao JN, Xiong RQ, Xiong XZ, Xu W, Yan Q, Yang HT, Yang Y, Yelland A, Yi H, You YH, Yu YM, Yu ZQ, Zhang C, Zhang F, Zhang FZ, Zhang J, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P, AMS Collaboration, </infon><offset>0</offset><text>Temporal Structures in Positron Spectra and Charge-Sign Effects in Galactic Cosmic Rays.</text></passage><passage><infon key="type">abstract</infon><offset>89</offset><text>We present the precision measurements of 11 years of daily cosmic positron fluxes in the rigidity range from 1.00 to 41.9 GV based on 3.4x10^{6} positrons collected with the Alpha Magnetic Spectrometer (AMS) aboard the International Space Station. The positron fluxes show distinctly different time variations from the electron fluxes at short and long timescales. A hysteresis between the electron fluxes and the positron fluxes is observed with a significance greater than 5sigma at rigidities below 8.5 GV. On the contrary, the positron fluxes and the proton fluxes show similar time variation. Remarkably, we found that positron fluxes are modulated more than proton fluxes with a significance greater than 5sigma for rigidities below 7 GV. These continuous daily positron fluxes, together with AMS daily electron, proton, and helium fluxes over an 11-year solar cycle, provide unique input to the understanding of both the charge-sign and mass dependencies of cosmic rays in the heliosphere.</text><annotation id="1"><infon key="identifier">MESH:D006371</infon><infon key="type">Chemical</infon><location offset="920" length="6"/><text>helium</text></annotation></passage></document>
<document><id>37898106</id><passage><infon key="journal">J Cereb Blood Flow Metab;2023Oct28 271678. doi:10.1177/0271678X231211726</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chen X, Xu S, Li M, Wu D, Ji X, </infon><offset>0</offset><text>Transnasal cooling: New prospect of selective hypothermia in acute ischemic stroke.</text><annotation id="2"><infon key="identifier">MESH:D007035</infon><infon key="type">Disease</infon><location offset="46" length="11"/><text>hypothermia</text></annotation><annotation id="3"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="67" length="15"/><text>ischemic stroke</text></annotation></passage><passage><infon key="type">abstract</infon><offset>84</offset><text>Rapid and selective therapeutic hypothermia is a promising neuroprotective method for acute ischemic stroke. A recent study developed a simple but efficient technique of transnasal cooling, in which air at ambient temperature was passed through standard nasal cannula to induce evaporative cooling of the brain. Selective brain temperature decrease was achieved within 25 minutes in piglets. It is a major step forward to initiate early brain cooling. However, it is still necessary to devise a more comprehensive strategy to enhance the benefits of selective brain cooling in the era of effective reperfusion.</text><annotation id="6"><infon key="identifier">MESH:D007035</infon><infon key="type">Disease</infon><location offset="116" length="11"/><text>hypothermia</text></annotation><annotation id="7"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="176" length="15"/><text>ischemic stroke</text></annotation></passage></document>
<document><id>37898459</id><passage><infon key="type">title</infon><offset>0</offset><text>A novel free-moving rat model of transcranial direct current stimulation.</text></passage><passage><infon key="type">abstract</infon><offset>74</offset></passage></document>
<document><id>37899510</id><passage><infon key="journal">J Cataract Refract Surg;2023Oct30. doi:10.1097/j.jcrs.0000000000001353</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kumar DA, Narang P, Holladay J, Sivagnanam S, Narang R, Agarwal A, Agarwal A, </infon><offset>0</offset><text>OPTIMUM PINHOLE SIZE DETERMINATION IN PINHOLE PUPILLOPLASTY FOR HIGHER ORDER ABERRATIONS.</text><annotation id="2"><infon key="identifier">MESH:C537550</infon><infon key="type">Disease</infon><location offset="0" length="34"/><text>OPTIMUM PINHOLE SIZE DETERMINATION</text></annotation><annotation id="3"><infon key="identifier">MESH:D002869</infon><infon key="type">Disease</infon><location offset="77" length="11"/><text>ABERRATIONS</text></annotation></passage><passage><infon key="type">abstract</infon><offset>90</offset><text>PURPOSE: To determine optimal pinhole size (OPS) and establish relationship with visual acuity (VA) and RMS (root-mean-square) values in cases with higher-order-aberrations (HOAs) undergoing pinhole pupilloplasty (PPP). SETTING: Private practice, India. DESIGN: Prospective, interventional study. METHODS: RMS value for 6 millimetres (mm) diameter optical zone was determined by Scheimpflug imaging (Pentacam). Patients with RMS value >0.3microm were included. Preoperatively, a hand-held pinhole gauge with varied apertures determined the OPS and Single-pass-four-throw technique was employed to perform pupilloplasty with Purkinke-1 reflex as a marker for centration. MAINOUTCOME MEASURES: VA with OPS; corelation of RMS values with OPS and pupil size; Strehl ratio. RESULTS: 29 eyes with HOAs were analyzed; all patients chose a 1.0mm or 1.5mm as OPS. The mean preoperative and postoperative pupil-size was 3.25+-0.81mm and 1.8+-0.54mm (p=0.000) respectively. Postoperative mean pupil-size when compared to OPS denoted that 14 eyes had a difference of &lt;0.1mm, 8 eyes ranged from 0.2 to 0.45mm and 7 eyes had >= 0.6mm (range from 0.6-1.8mm) difference from OPS. Eyes with higher RMS values needed smaller pupil gauge size to achieve better VA. Preoperatively, the vision with OPS correlated well with preoperative 6mm RMS HOA (r=0.728; p=0.00). Post-operative UCVA correlated well with VA measured with OPS (r= 0.847; p=0.00). The preoperative and postoperative mean Strehl-ratio was 0.109+-0.07 and 0.195 +-0.11 (p=0.001) respectively. CONCLUSIONS: Higher RMS values required a smaller pupil size to achieve optimum VA. PPP can be help achieve pinhole size in accordance with patient's optimum pinhole requirement.</text><annotation id="7"><infon key="identifier">MESH:D002869</infon><infon key="type">Disease</infon><location offset="244" length="18"/><text>-order-aberrations</text></annotation><annotation id="8"><infon key="identifier">MESH:D002869</infon><infon key="type">Disease</infon><location offset="264" length="4"/><text>HOAs</text></annotation><annotation id="9"><infon key="identifier">MESH:D002869</infon><infon key="type">Disease</infon><location offset="881" length="4"/><text>HOAs</text></annotation></passage></document>
<document><id>37901962</id><passage><infon key="type">title</infon><offset>0</offset><text>Pd-Catalyzed Stereoselective Construction of Benzo-Fused Decalines with a Quaternary Carbon.</text><annotation id="3"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="0" length="2"/><text>Pd</text></annotation><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="45" length="21"/><text>Benzo-Fused Decalines</text></annotation><annotation id="5"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="85" length="6"/><text>Carbon</text></annotation></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>The Pd-catalyzed stereoselective construction of decalins with one-carbon units bearing heteroatoms at the ring junction is described. The Pd-catalyzed cyclization of silyl enol ether resulted in exclusive formation of the cis isomer (89%, >100/1 cis/trans). On the contrary, Pd-catalyzed carboiodination and carboborylation (with oxidative workup) provided products in 56% yield (1/>100 cis/trans) and 69% yield (1/11 cis/trans), respectively.</text><annotation id="12"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="97" length="2"/><text>Pd</text></annotation><annotation id="13"><infon key="identifier">MESH:C007229</infon><infon key="type">Chemical</infon><location offset="142" length="8"/><text>decalins</text></annotation><annotation id="14"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="160" length="6"/><text>carbon</text></annotation><annotation id="15"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="232" length="2"/><text>Pd</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="260" length="16"/><text>silyl enol ether</text></annotation><annotation id="17"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="369" length="2"/><text>Pd</text></annotation></passage></document>
<document><id>37902312</id><passage><infon key="journal">J Vis Exp;2023Oct13 (200) . doi:10.3791/65778</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bonaldo B, Casile A, Montarolo F, Bertolotto A, </infon><offset>0</offset><text>Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis.</text><annotation id="2"><infon key="identifier">MESH:D009103</infon><infon key="type">Disease</infon><location offset="9" length="18"/><text>Multiple Sclerosis</text></annotation><annotation id="3"><infon key="identifier">MESH:D004681</infon><infon key="type">Disease</infon><location offset="63" length="41"/><text>Experimental Autoimmune Encephalomyelitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>106</offset><text>Multiple Sclerosis (MS) is a chronic autoimmune inflammatory disease affecting the central nervous system (CNS). It is characterized by different prevalence in the sexes, affecting more women than men, and different outcomes, showing more aggressive forms in men than in women. Furthermore, MS is highly heterogeneous in terms of clinical aspects, radiological, and pathological features. Thus, it is necessary to take advantage of experimental animal models that allow the investigation of as many aspects of the pathology as possible. Experimental autoimmune encephalomyelitis (EAE) represents one of the most used models of MS in mice, modeling different disease features, from the activation of the immune system to CNS damage. Here we describe a protocol for the induction of EAE in both male and female C57BL/6J mice using myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35-55) immunization, which leads to the development of a chronic form of the disease. We also report the evaluation of the daily clinical score and motor performance of these mice for 28 days post immunization (28 dpi). Lastly, we illustrate some basic histological analysis at the CNS level, focusing on the spinal cord as the primary site of disease-induced damage.</text><annotation id="13"><infon key="identifier">MESH:D009103</infon><infon key="type">Disease</infon><location offset="106" length="18"/><text>Multiple Sclerosis</text></annotation><annotation id="14"><infon key="identifier">MESH:D009103</infon><infon key="type">Disease</infon><location offset="126" length="2"/><text>MS</text></annotation><annotation id="15"><infon key="identifier">MESH:D001327</infon><infon key="type">Disease</infon><location offset="143" length="31"/><text>autoimmune inflammatory disease</text></annotation><annotation id="16"><infon key="identifier">MESH:D009103</infon><infon key="type">Disease</infon><location offset="397" length="2"/><text>MS</text></annotation><annotation id="17"><infon key="identifier">MESH:D004681</infon><infon key="type">Disease</infon><location offset="643" length="41"/><text>Experimental autoimmune encephalomyelitis</text></annotation><annotation id="18"><infon key="identifier">MESH:D004681</infon><infon key="type">Disease</infon><location offset="686" length="3"/><text>EAE</text></annotation><annotation id="19"><infon key="identifier">MESH:D009103</infon><infon key="type">Disease</infon><location offset="733" length="2"/><text>MS</text></annotation><annotation id="20"><infon key="identifier">MESH:D002493</infon><infon key="type">Disease</infon><location offset="826" length="10"/><text>CNS damage</text></annotation><annotation id="21"><infon key="identifier">MESH:D004681</infon><infon key="type">Disease</infon><location offset="887" length="3"/><text>EAE</text></annotation></passage></document>
<document><id>37902662</id><passage><infon key="type">title</infon><offset>0</offset><text>Contrasting MMPI-3 validity scale effectiveness differences across in-person and telehealth administration procedures.</text></passage><passage><infon key="type">abstract</infon><offset>119</offset><text>Psychological assessment underwent substantive challenges and changes when the COVID-19 pandemic began, and these changes are likely to endure given the rapid growth of telehealth clinical practice and assessment research using virtual procedures. COVID-19-related changes to assessment practices have impacted accordingly how we study overreporting scale functioning, including the modality through which we administer measures. No available research provides direct comparisons of overreporting scale effectiveness within simulation research across in-person and telehealth modalities, despite early support for novel instruments relying on remote procedures within the historic context of the pandemic. We used simulated feigning conditions collected using best telehealth practices to examine if, and how, overreporting scales differed in effectiveness by evaluating mean scores, elevation rates, and classification accuracy statistics, relative to parallel in-person conditions. Results indicate no meaningful differences in scale effectiveness, particularly when exclusion procedures included a posttest questionnaire. Our findings support telehealth assessment practice and the integration of research collected virtually into the traditional, in-person feigning literature. Limitations and future directions are discussed. (PsycInfo Database Record (c) 2023 APA, all rights reserved).</text><annotation id="2"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="198" length="8"/><text>COVID-19</text></annotation><annotation id="3"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="367" length="8"/><text>COVID-19</text></annotation></passage></document>
<document><id>37903014</id><passage><infon key="journal">Surg Infect (Larchmt);2023Oct30. doi:10.1089/sur.2023.154</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gillies GS, Munley JA, Kelly LS, Pons EE, Kannan KB, Bible LE, Efron PA, Mohr AM, </infon><offset>0</offset><text>Anemia Recovery After Lung Contusion, Hemorrhagic Shock, and Chronic Stress Is Gender-Specific in a Rat Model.</text><annotation id="3"><infon key="identifier">MESH:D000740</infon><infon key="type">Disease</infon><location offset="0" length="6"/><text>Anemia</text></annotation><annotation id="4"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="22" length="14"/><text>Lung Contusion</text></annotation><annotation id="5"><infon key="identifier">MESH:D012771</infon><infon key="type">Disease</infon><location offset="38" length="17"/><text>Hemorrhagic Shock</text></annotation></passage><passage><infon key="type">abstract</infon><offset>111</offset><text>Background: Severe trauma and hemorrhagic shock lead to persistent anemia. Although biologic gender is known to modulate inflammatory responses after critical illness, the impact of gender on anemia recovery after injury remains unknown. The aim of this study was to identify gender-specific differences in anemia recovery after critical illness. Materials and Methods: Male and proestrus female Sprague-Dawley rats (n = 8-9 per group) were subjected to lung contusion and hemorrhagic shock (LCHS) or LCHS with daily chronic stress (LCHS/CS) compared with naive. Hematologic data, bone marrow progenitor growth, and bone marrow and liver gene transcription were analyzed on day seven. Significance was defined as p &lt; 0.05. Results: Males lost substantial weight after LCHS and LCHS/CS compared with naive males, while female LCHS rats did not compared with naive counterparts. Male LCHS rats had a drastic decrease in hemoglobin from naive males. Male LCHS/CS rats had reduced colony-forming units-granulocyte, -erythrocyte, -monocyte, -megakaryocyte (CFU-GEMM) and burst-forming unit-erythroid (BFU-E) when compared with female counterparts. Naive, LCHS, and LCHS/CS males had lower serum iron than their respective female counterparts. Liver transcription of BMP4 and BMP6 was elevated after LCHS and LCHS/CS in males compared with females. The LCHS/CS males had decreased expression of bone marrow pro-erythroid factors compared with LCHS/CS females. Conclusions: After trauma with or without chronic stress, male rats demonstrated increased weight loss, substantial decrease in hemoglobin level, dysregulated iron metabolism, substantial suppression of bone marrow erythroid progenitor growth, and no change in transcription of pro-erythroid factors. These findings confirm that gender is an important variable that impacts anemia recovery and bone marrow dysfunction after traumatic injury and shock in this rat model.</text><annotation id="47"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="130" length="6"/><text>trauma</text></annotation><annotation id="48"><infon key="identifier">MESH:D012771</infon><infon key="type">Disease</infon><location offset="141" length="17"/><text>hemorrhagic shock</text></annotation><annotation id="49"><infon key="identifier">MESH:D000740</infon><infon key="type">Disease</infon><location offset="178" length="6"/><text>anemia</text></annotation><annotation id="50"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="232" length="12"/><text>inflammatory</text></annotation><annotation id="51"><infon key="identifier">MESH:D016638</infon><infon key="type">Disease</infon><location offset="261" length="16"/><text>critical illness</text></annotation><annotation id="52"><infon key="identifier">MESH:D000740</infon><infon key="type">Disease</infon><location offset="303" length="6"/><text>anemia</text></annotation><annotation id="53"><infon key="identifier">MESH:D000740</infon><infon key="type">Disease</infon><location offset="418" length="6"/><text>anemia</text></annotation><annotation id="54"><infon key="identifier">MESH:D016638</infon><infon key="type">Disease</infon><location offset="440" length="16"/><text>critical illness</text></annotation><annotation id="55"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="565" length="14"/><text>lung contusion</text></annotation><annotation id="56"><infon key="identifier">MESH:D012771</infon><infon key="type">Disease</infon><location offset="584" length="17"/><text>hemorrhagic shock</text></annotation><annotation id="57"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="603" length="4"/><text>LCHS</text></annotation><annotation id="58"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="612" length="4"/><text>LCHS</text></annotation><annotation id="59"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="644" length="4"/><text>LCHS</text></annotation><annotation id="60"><infon key="identifier">MESH:D006223</infon><infon key="type">Disease</infon><location offset="649" length="2"/><text>CS</text></annotation><annotation id="61"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="879" length="4"/><text>LCHS</text></annotation><annotation id="62"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="888" length="4"/><text>LCHS</text></annotation><annotation id="63"><infon key="identifier">MESH:D006223</infon><infon key="type">Disease</infon><location offset="893" length="2"/><text>CS</text></annotation><annotation id="64"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="936" length="4"/><text>LCHS</text></annotation><annotation id="65"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="993" length="4"/><text>LCHS</text></annotation><annotation id="66"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1063" length="4"/><text>LCHS</text></annotation><annotation id="67"><infon key="identifier">MESH:D006223</infon><infon key="type">Disease</infon><location offset="1068" length="2"/><text>CS</text></annotation><annotation id="68"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1261" length="4"/><text>LCHS</text></annotation><annotation id="69"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1271" length="4"/><text>LCHS</text></annotation><annotation id="70"><infon key="identifier">MESH:D006223</infon><infon key="type">Disease</infon><location offset="1276" length="2"/><text>CS</text></annotation><annotation id="71"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1301" length="4"/><text>iron</text></annotation><annotation id="72"><infon key="identifier">25296</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7247</infon><location offset="1372" length="4"/><text>BMP4</text></annotation><annotation id="73"><infon key="identifier">25644</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1300</infon><location offset="1381" length="4"/><text>BMP6</text></annotation><annotation id="74"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1405" length="4"/><text>LCHS</text></annotation><annotation id="75"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1414" length="4"/><text>LCHS</text></annotation><annotation id="76"><infon key="identifier">MESH:D006223</infon><infon key="type">Disease</infon><location offset="1419" length="2"/><text>CS</text></annotation><annotation id="77"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1458" length="4"/><text>LCHS</text></annotation><annotation id="78"><infon key="identifier">MESH:D006223</infon><infon key="type">Disease</infon><location offset="1463" length="2"/><text>CS</text></annotation><annotation id="79"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1548" length="4"/><text>LCHS</text></annotation><annotation id="80"><infon key="identifier">MESH:D006223</infon><infon key="type">Disease</infon><location offset="1553" length="2"/><text>CS</text></annotation><annotation id="81"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1584" length="6"/><text>trauma</text></annotation><annotation id="82"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="1656" length="11"/><text>weight loss</text></annotation><annotation id="83"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1724" length="4"/><text>iron</text></annotation><annotation id="84"><infon key="identifier">MESH:D000740</infon><infon key="type">Disease</infon><location offset="1939" length="6"/><text>anemia</text></annotation><annotation id="85"><infon key="identifier">MESH:D001855</infon><infon key="type">Disease</infon><location offset="1959" length="23"/><text>bone marrow dysfunction</text></annotation><annotation id="86"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1989" length="16"/><text>traumatic injury</text></annotation><annotation id="87"><infon key="identifier">MESH:D012769</infon><infon key="type">Disease</infon><location offset="2010" length="5"/><text>shock</text></annotation></passage><relation id="R1"><infon key="score">0.9843</infon><infon key="role1">Disease|MESH:D012128</infon><infon key="role2">Gene|25296</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="30,28"/></relation><relation id="R2"><infon key="score">0.9477</infon><infon key="role1">Disease|MESH:D012128</infon><infon key="role2">Gene|25644</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="30,29"/></relation><relation id="R3"><infon key="score">0.5089</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Disease|MESH:D014947</infon><infon key="type">Association</infon><node refid="2" role="39,37"/></relation><relation id="R4"><infon key="score">0.9829</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Disease|MESH:D012128</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="27,24"/></relation><relation id="R5"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D006223</infon><infon key="role2">Gene|25296</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="32,28"/></relation><relation id="R6"><infon key="score">0.9978</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Disease|MESH:D006223</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="27,26"/></relation><relation id="R7"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D006223</infon><infon key="role2">Gene|25644</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="32,29"/></relation></document>
<document><id>37903390</id><passage><infon key="type">title</infon><offset>0</offset><text>Hypotrichosis and Hair Loss on the Occipital Scalp.</text><annotation id="2"><infon key="identifier">MESH:D007039</infon><infon key="type">Disease</infon><location offset="0" length="13"/><text>Hypotrichosis</text></annotation><annotation id="3"><infon key="identifier">MESH:D000505</infon><infon key="type">Disease</infon><location offset="18" length="9"/><text>Hair Loss</text></annotation></passage><passage><infon key="type">abstract</infon><offset>52</offset></passage></document>
<document><id>37903742</id><passage><infon key="journal">Urol Pract;2023Oct30 101097. doi:10.1097/UPJ.0000000000000471</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL, </infon><offset>0</offset><text>Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors.</text><annotation id="3"><infon key="identifier">MESH:D000092182</infon><infon key="type">Disease</infon><location offset="28" length="18"/><text>Metastatic Disease</text></annotation><annotation id="4"><infon key="identifier">MESH:D064129</infon><infon key="type">Disease</infon><location offset="103" length="36"/><text>Castration-Resistant Prostate Cancer</text></annotation><annotation id="5"><infon key="identifier">367</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">28</infon><location offset="153" length="17"/><text>Androgen Receptor</text></annotation></passage><passage><infon key="type">abstract</infon><offset>191</offset><text>INTRODUCTION: Patients with synchronous (de novo) metastatic castration-sensitive prostate cancer appear to have worse survival outcomes and shorter time to develop castration resistance than patients with metachronous disease. However, the impact of synchronous metastasis on outcomes in metastatic castration-resistant prostate cancer (mCRPC) setting is unknown in patients without prior exposure to androgen receptor pathway inhibitors (ARPIs). In this study, we assessed the impact of initial timing of metastasis (synchronous vs metachronous) on survival outcomes of patients with new-onset mCRPC in a real-world population treated with first-line abiraterone or enzalutamide. METHODS: Data were collected retrospectively from 323 patients with a confirmed diagnosis of mCRPC who received ARPIs as first-line therapy and had no prior exposure to ARPIs. The study endpoints were progression-free survival and overall survival (OS). RESULTS: The results showed that median OS was significantly shorter in patients with synchronous disease than those with metachronous disease (26 vs 38.7 months, HR 1.42, 95% CI 1.09-1.86, P = .011). However, there was no difference in median progression-free survival. CONCLUSIONS: The initial timing of metastasis remained an independent factor associated with shorter OS in the multivariable analysis. These hypothesis-generating data, after external validation, may have implications in patient counseling, prognostication, and design of future clinical trials in the new-onset mCRPC setting.</text><annotation id="18"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="252" length="36"/><text>castration-sensitive prostate cancer</text></annotation><annotation id="19"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="454" length="10"/><text>metastasis</text></annotation><annotation id="20"><infon key="identifier">MESH:D064129</infon><infon key="type">Disease</infon><location offset="491" length="36"/><text>castration-resistant prostate cancer</text></annotation><annotation id="21"><infon key="identifier">MESH:D064129</infon><infon key="type">Disease</infon><location offset="529" length="5"/><text>mCRPC</text></annotation><annotation id="22"><infon key="identifier">367</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">28</infon><location offset="593" length="17"/><text>androgen receptor</text></annotation><annotation id="23"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="698" length="10"/><text>metastasis</text></annotation><annotation id="24"><infon key="identifier">MESH:D064129</infon><infon key="type">Disease</infon><location offset="787" length="5"/><text>mCRPC</text></annotation><annotation id="25"><infon key="identifier">MESH:C089740</infon><infon key="type">Chemical</infon><location offset="844" length="11"/><text>abiraterone</text></annotation><annotation id="26"><infon key="identifier">MESH:C540278</infon><infon key="type">Chemical</infon><location offset="859" length="12"/><text>enzalutamide</text></annotation><annotation id="27"><infon key="identifier">MESH:D064129</infon><infon key="type">Disease</infon><location offset="966" length="5"/><text>mCRPC</text></annotation><annotation id="28"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="1433" length="10"/><text>metastasis</text></annotation><annotation id="29"><infon key="identifier">MESH:D064129</infon><infon key="type">Disease</infon><location offset="1710" length="5"/><text>mCRPC</text></annotation></passage><relation id="R1"><infon key="score">0.9929</infon><infon key="role1">Chemical|MESH:C540278</infon><infon key="role2">Disease|MESH:D064129</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="11,9"/></relation><relation id="R2"><infon key="score">0.9952</infon><infon key="role1">Chemical|MESH:C089740</infon><infon key="role2">Disease|MESH:D064129</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="10,9"/></relation></document>
<document><id>37904792</id><passage><infon key="journal">Hand Ther;2022Mar; 27 (1) 32. doi:10.1177/17589983221074934</infon><infon key="year">2022</infon><infon key="article-id_pmc">PMC10584059</infon><infon key="type">title</infon><offset>0</offset><text>Corrigendum to The reliability and validity of novel clinical strength measures of the upper body in older adults.</text></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>[This corrects the article DOI: 10.1177/1758998320957373.].</text></passage></document>
<document><id>37905142</id><passage><infon key="journal">bioRxiv;2023Oct20. doi:10.1101/2023.10.17.562670</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614845</infon><infon key="type">title</infon><infon key="authors">Nowicka Z, Rentzeperis F, Beck R, Tagal V, Pinto AF, Scanu E, Veith T, Cole J, Ilter D, Viqueira WD, Teer JK, Maksin K, Pasetto S, Abdalah MA, Fiandaca G, Prabhakaran S, Schultz A, Ojwang M, Barnholtz-Sloan JS, Farinhas JM, Gomes AP, Katira P, Andor N, </infon><offset>0</offset><text>Interactions between ploidy and resource availability shape clonal interference at initiation and recurrence of glioblastoma.</text><annotation id="1"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="112" length="12"/><text>glioblastoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>126</offset><text>Glioblastoma (GBM) is the most aggressive form of primary brain tumor. Complete surgical resection of GBM is almost impossible due to the infiltrative nature of the cancer. While no evidence for recent selection events have been found after diagnosis, the selective forces that govern gliomagenesis are strong, shaping the tumor's cell composition during the initial progression to malignancy with late consequences for invasiveness and therapy response. We present a mathematical model that simulates the growth and invasion of a glioma, given its ploidy level and the nature of its brain tissue micro-environment (TME), and use it to make inferences about GBM initiation and response to standard-of-care treatment. We approximate the spatial distribution of resource access in the TME through integration of in-silico modelling, multi-omics data and image analysis of primary and recurrent GBM. In the pre-malignant setting, our in-silico results suggest that low ploidy cancer cells are more resistant to starvation-induced cell death. In the malignant setting, between first and second surgery, simulated tumors with different ploidy compositions progressed at different rates. Whether higher ploidy predicted fast recurrence, however, depended on the TME. Historical data supports this dependence on TME resources, as shown by a significant correlation between the median glucose uptake rates in human tissues and the median ploidy of cancer types that arise in the respective tissues (Spearman r = -0.70; P = 0.026). Taken together our findings suggest that availability of metabolic substrates in the TME drives different cell fate decisions for cancer cells with different ploidy and shapes GBM disease initiation and relapse characteristics.</text><annotation id="19"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="126" length="12"/><text>Glioblastoma</text></annotation><annotation id="20"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="140" length="3"/><text>GBM</text></annotation><annotation id="21"><infon key="identifier">MESH:D001932</infon><infon key="type">Disease</infon><location offset="184" length="11"/><text>brain tumor</text></annotation><annotation id="22"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="228" length="3"/><text>GBM</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="291" length="6"/><text>cancer</text></annotation><annotation id="24"><infon key="type">Disease</infon><location offset="411" length="13"/><text>gliomagenesis</text></annotation><annotation id="25"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="449" length="5"/><text>tumor</text></annotation><annotation id="26"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="508" length="10"/><text>malignancy</text></annotation><annotation id="27"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="657" length="6"/><text>glioma</text></annotation><annotation id="28"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="784" length="3"/><text>GBM</text></annotation><annotation id="29"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="1018" length="3"/><text>GBM</text></annotation><annotation id="30"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1099" length="6"/><text>cancer</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1235" length="6"/><text>tumors</text></annotation><annotation id="32"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1503" length="7"/><text>glucose</text></annotation><annotation id="33"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1566" length="6"/><text>cancer</text></annotation><annotation id="34"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1779" length="6"/><text>cancer</text></annotation><annotation id="35"><infon key="identifier">MESH:D005909</infon><infon key="type">Disease</infon><location offset="1825" length="3"/><text>GBM</text></annotation></passage><relation id="R1"><infon key="score">0.9907</infon><infon key="role1">Chemical|MESH:D005947</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Association</infon><node refid="0" role="14,15"/></relation></document>
<document><id>37905493</id><passage><infon key="type">title</infon><offset>0</offset><text>Beyond government accountability: the role of medical schools in addressing the NHS workforce crisis.</text></passage><passage><infon key="type">abstract</infon><offset>102</offset></passage></document>
<document><id>37905843</id><passage><infon key="journal">Microbiol Spectr;2023Oct31 0246823. doi:10.1128/spectrum.02468-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hu Y-F, Liu J-W, Luo X-X, Xu Z-H, Xia J-W, Zhang X-G, Casta&amp;#xf1;eda-Ru&amp;#xed;z RF, Ma J, </infon><offset>0</offset><text>Multi-locus phylogenetic analyses reveal eight novel species of Distoseptispora from southern China.</text></passage><passage><infon key="type">abstract</infon><offset>101</offset><text>Plant debris are habitat favoring the growth of various microbial species. Over the course of our mycological surveys in Jiangxi and Yunnan Provinces, China, eight new Distoseptispora species, viz. D. gasaensis, D. guanshanensis, D. jinghongensis, D. longnanensis, D. menghaiensis, D. menglunensis, D. nanchangensis, and D. yichunensis collected on dead branches of unidentified plants, were introduced by morphological and molecular phylogenetic analyses. Multi-locus (LSU, ITS, TEF1, and RPB2) phylogenetic analyses were performed using maximum-likelihood and Bayesian inference to infer their taxonomic positions within Distoseptispora. Both molecular phylogenetic analyses and morphological characters supported them as eight independent taxa within Distoseptispora. This work improves our understanding of the diversity of Distoseptispora in southern China.IMPORTANCEDistoseptispora as a single genus in Distoseptisporaceae was introduced by morphological and phylogenetic analyses. Members of this genus occur mainly as asexual morphs, forming effuse, hairy colonies on decaying wood, plant stems, bamboo culms, and fallen leaves and shafts in terrestrial and freshwater habitats. In the present study, saprobic hyphomycetes from plant debris were investigated, and eight new Distoseptispora species were introduced based on morphology and phylogenetic analyses of LSU, ITS, TEF1, and RPB2 sequence data. This study provides important data on the species diversity, ecological environment, and geographical area of Distoseptispora, greatly updates the classification of Distoseptispora, and improves our understanding of the taxonomy of Distoseptispora.</text><annotation id="4"><infon key="identifier">7003</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2418</infon><location offset="581" length="4"/><text>TEF1</text></annotation><annotation id="5"><infon key="identifier">5431</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">722</infon><location offset="591" length="4"/><text>RPB2</text></annotation><annotation id="6"><infon key="identifier">7003</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2418</infon><location offset="1482" length="4"/><text>TEF1</text></annotation><annotation id="7"><infon key="identifier">5431</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">722</infon><location offset="1492" length="4"/><text>RPB2</text></annotation></passage></document>
<document><id>37906919</id><passage><infon key="type">title</infon><offset>0</offset><text>[Non-alcoholic fatty liver disease and COVID-19: Pathologies that add their risks and effects].</text><annotation id="2"><infon key="identifier">MESH:D065626</infon><infon key="type">Disease</infon><location offset="1" length="33"/><text>Non-alcoholic fatty liver disease</text></annotation><annotation id="3"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="39" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset></passage></document>
<document><id>37907285</id><passage><infon key="journal">Facial Plast Surg;2023Oct31. doi:10.1055/a-2201-8156</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Speranzini MM, Souza SEG, </infon><offset>0</offset><text>Advancements in Graft Placement Techniques.</text></passage><passage><infon key="type">abstract</infon><offset>44</offset><text>For decades, the placement of follicular units (FUs) into incisions in the recipient area was exclusively carried out using forceps. In 1992, Dr. Choi introduced an instrument known as the "implanter," which had the advantage of simultaneously creating incisions and placing FUs without damaging sensitive parts. Its initial popularity was greater in the East, primarily due to the characteristics of Asian hair. Asian hair typically has straight and thick hair, with FUs mostly consisting of just one or two hairs. With the description of the FUE technique in 2002 and its widespread adoption nearly a decade later, the advantages of using the implanter also gained popularity in the West. The uniformity in the size of FUs provided by the FUE technique and the possibility of delegating the placement were key attractions in the use of this placement tool. In addition to the traditional Korean implanter with a sharp needle, other implanters and inserters have been described. The choice of implantation technique depends on individual adaptation and the advantages and disadvantages offered by each instrument. Although forceps allow for safe placement in the hands of well-trained teams, the increased fragility of FUs obtained with the FUE technique has.</text></passage></document>
<document><id>37907635</id><passage><infon key="journal">Nature;2023Nov; 623 (7985) 32. doi:10.1038/d41586-023-03349-z</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rimawi R, Madani N, </infon><offset>0</offset><text>Gaza's broken health-care system is compounding the risk of disease.</text></passage><passage><infon key="type">abstract</infon><offset>69</offset></passage></document>
<document><id>37909035</id><passage><infon key="journal">Cell Chem Biol;2023Sep07. doi:10.1016/j.chembiol.2023.08.010</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sahayasheela VJ, Sugiyama H, </infon><offset>0</offset><text>RNA G-quadruplex in functional regulation of noncoding RNA: Challenges and emerging opportunities.</text></passage><passage><infon key="type">abstract</infon><offset>99</offset><text>G-quadruplexes (G4s) are stable, noncanonical structures formed in guanine (G)-rich sequences of DNA/RNA. G4 structures are reported to play a regulatory role in various cellular processes and, recently, a considerable number of studies have attributed new biological functions to these structures, especially in RNA. Noncoding RNA (ncRNA), which does not translate into a functional protein, is widely expressed and has been shown to play a key role in shaping cellular activity. There has been growing evidence of G4 formation in several ncRNA classes, and it has been identified as a key part for diverse biological functions and physio-pathological contexts in neurodegenerative diseases and cancer. This review discusses RNA G4s (rG4s) in ncRNA, focusing on the molecular mechanism underlying its function. This review also aims to highlight potential and emerging opportunities to identify and target the rG4s in ncRNA to understand its function and, ultimately, treat many diseases.</text><annotation id="3"><infon key="identifier">MESH:D006147</infon><infon key="type">Chemical</infon><location offset="166" length="7"/><text>guanine</text></annotation><annotation id="4"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="764" length="26"/><text>neurodegenerative diseases</text></annotation><annotation id="5"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="795" length="6"/><text>cancer</text></annotation></passage></document>
<document><id>37909389</id><passage><infon key="journal">Mol Omics;2023Nov01. doi:10.1039/d3mo00127j</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sahu B, Pani S, Swalsingh G, Senapati U, Pani P, Pati B, Rout S, Trivedi R, Raj R, Dey S, Jeet A, Kumar D, Bal NC, </infon><offset>0</offset><text>Long-term physical inactivity induces significant changes in biochemical pathways related to metabolism of proteins and glycerophospholipids in mice.</text><annotation id="2"><infon key="identifier">MESH:C564765</infon><infon key="type">Disease</infon><location offset="19" length="10"/><text>inactivity</text></annotation><annotation id="3"><infon key="identifier">MESH:D020404</infon><infon key="type">Chemical</infon><location offset="120" length="20"/><text>glycerophospholipids</text></annotation></passage><passage><infon key="type">abstract</infon><offset>150</offset><text>Physical inactivity affects multiple organ systems, including the musculoskeletal system, which upsets the delicate balance of several secretory factors leading to metabolic derailment. This reduces contractile recruitment of the skeletal muscle with dampening of its oxidative capacity resulting in impaired intramuscular lipid metabolism and substrate utilization. We hypothesized that this altered phenotype would also have an indispensable effect on circulatory cytokines and the level of metabolic intermediates. In this study, comparison between sedentary (SED) and exercised (EXER) animal models showed that organismal metabolic parameters (body mass, oxygen utilization and glucose tolerance) are altered based on physical activity. Our data suggest that cytokines linked to glycemic excursions (insulin, c-peptide, glucagon) and their passive regulators (leptin, BDNF, active ghrelin, and GIP) exhibit changes in the SED group. Furthermore, some of the proinflammatory cytokines and myokines were upregulated in SED. Interestingly, serum metabolite analysis showed that the levels of glucogenic amino acids (alanine, glycine, tryptophan, proline and valine), nitrogenous amino acids (ornithine, asparagine, and glutamine) and myogenic metabolites (taurine, creatine) were altered due to the level of physical activity. A pyrimidine nucleoside (uridine), lipid metabolite (glycerol) and ketone bodies (acetoacetate and acetate) were found to be altered in SED. A Spearman rank correlation study between SED and CTRL showed that cytokines build a deformed network with metabolites in SED, indicating significant modifications in amino acids, phosphatidylinositol phosphate and glycerophospholipid metabolic pathways. Overall, long-term physical inactivity reorganizes the profile of proinflammatory cytokines, glucose sensing hormones, and protein and glycerophospholipid metabolism, which might be the initial factors of metabolic diseases due to SED.</text><annotation id="39"><infon key="identifier">MESH:C564765</infon><infon key="type">Disease</infon><location offset="159" length="10"/><text>inactivity</text></annotation><annotation id="40"><infon key="identifier">MESH:D008659</infon><infon key="type">Disease</infon><location offset="314" length="20"/><text>metabolic derailment</text></annotation><annotation id="41"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="473" length="5"/><text>lipid</text></annotation><annotation id="42"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="809" length="6"/><text>oxygen</text></annotation><annotation id="43"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="832" length="7"/><text>glucose</text></annotation><annotation id="44"><infon key="identifier">14526</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1553</infon><location offset="974" length="8"/><text>glucagon</text></annotation><annotation id="45"><infon key="identifier">16846</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">193</infon><location offset="1014" length="6"/><text>leptin</text></annotation><annotation id="46"><infon key="identifier">12064</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7245</infon><location offset="1022" length="4"/><text>BDNF</text></annotation><annotation id="47"><infon key="identifier">58991</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">9487</infon><location offset="1035" length="7"/><text>ghrelin</text></annotation><annotation id="48"><infon key="identifier">14607</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3043</infon><location offset="1048" length="3"/><text>GIP</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1243" length="22"/><text>glucogenic amino acids</text></annotation><annotation id="50"><infon key="identifier">MESH:D000409</infon><infon key="type">Chemical</infon><location offset="1267" length="7"/><text>alanine</text></annotation><annotation id="51"><infon key="identifier">MESH:D005998</infon><infon key="type">Chemical</infon><location offset="1276" length="7"/><text>glycine</text></annotation><annotation id="52"><infon key="identifier">MESH:D014364</infon><infon key="type">Chemical</infon><location offset="1285" length="10"/><text>tryptophan</text></annotation><annotation id="53"><infon key="identifier">MESH:D011392</infon><infon key="type">Chemical</infon><location offset="1297" length="7"/><text>proline</text></annotation><annotation id="54"><infon key="identifier">MESH:D014633</infon><infon key="type">Chemical</infon><location offset="1309" length="6"/><text>valine</text></annotation><annotation id="55"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1318" length="23"/><text>nitrogenous amino acids</text></annotation><annotation id="56"><infon key="identifier">MESH:D009952</infon><infon key="type">Chemical</infon><location offset="1343" length="9"/><text>ornithine</text></annotation><annotation id="57"><infon key="identifier">MESH:D001216</infon><infon key="type">Chemical</infon><location offset="1354" length="10"/><text>asparagine</text></annotation><annotation id="58"><infon key="identifier">MESH:D005973</infon><infon key="type">Chemical</infon><location offset="1370" length="9"/><text>glutamine</text></annotation><annotation id="59"><infon key="identifier">MESH:D013654</infon><infon key="type">Chemical</infon><location offset="1407" length="7"/><text>taurine</text></annotation><annotation id="60"><infon key="identifier">MESH:D003401</infon><infon key="type">Chemical</infon><location offset="1416" length="8"/><text>creatine</text></annotation><annotation id="61"><infon key="identifier">MESH:D011741</infon><infon key="type">Chemical</infon><location offset="1480" length="21"/><text>pyrimidine nucleoside</text></annotation><annotation id="62"><infon key="identifier">MESH:D014529</infon><infon key="type">Chemical</infon><location offset="1503" length="7"/><text>uridine</text></annotation><annotation id="63"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1513" length="5"/><text>lipid</text></annotation><annotation id="64"><infon key="identifier">MESH:D005990</infon><infon key="type">Chemical</infon><location offset="1531" length="8"/><text>glycerol</text></annotation><annotation id="65"><infon key="identifier">MESH:D007657</infon><infon key="type">Chemical</infon><location offset="1545" length="13"/><text>ketone bodies</text></annotation><annotation id="66"><infon key="identifier">MESH:C016635</infon><infon key="type">Chemical</infon><location offset="1560" length="12"/><text>acetoacetate</text></annotation><annotation id="67"><infon key="identifier">MESH:D000085</infon><infon key="type">Chemical</infon><location offset="1577" length="7"/><text>acetate</text></annotation><annotation id="68"><infon key="identifier">MESH:D018129</infon><infon key="type">Chemical</infon><location offset="1799" length="30"/><text>phosphatidylinositol phosphate</text></annotation><annotation id="69"><infon key="identifier">MESH:D020404</infon><infon key="type">Chemical</infon><location offset="1834" length="19"/><text>glycerophospholipid</text></annotation><annotation id="70"><infon key="identifier">MESH:C564765</infon><infon key="type">Disease</infon><location offset="1902" length="10"/><text>inactivity</text></annotation><annotation id="71"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1967" length="24"/><text>glucose sensing hormones</text></annotation><annotation id="72"><infon key="identifier">MESH:D020404</infon><infon key="type">Chemical</infon><location offset="2009" length="19"/><text>glycerophospholipid</text></annotation><annotation id="73"><infon key="identifier">MESH:D008659</infon><infon key="type">Disease</infon><location offset="2079" length="18"/><text>metabolic diseases</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D020404</infon><infon key="role2">Disease|MESH:C564765</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9845</infon><infon key="role1">Chemical|MESH:D020404</infon><infon key="role2">Disease|MESH:D008659</infon><infon key="type">Association</infon><node refid="1" role="36,37"/></relation></document>
<document><id>37909744</id><passage><infon key="journal">mBio;2023Nov01 0204323. doi:10.1128/mbio.02043-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Felczak MM, Bernard MP, TerAvest MA, </infon><offset>0</offset><text>Respiration is essential for aerobic growth of Zymomonas mobilis ZM4.</text></passage><passage><infon key="type">abstract</infon><offset>70</offset><text>Zymomonas mobilis is an alpha-proteobacterium that is a promising platform for industrial scale production of biofuels due to its efficient ethanol fermentation and low biomass generation. Z. mobilis is aerotolerant and encodes a complete respiratory electron transport chain, but the benefit of respiration for growth in oxic conditions has never been confirmed, despite decades of research. Growth and ethanol production of wild-type Z. mobilis is poor in oxic conditions indicating that it does not benefit from oxidative phosphorylation. Additionally, in previous studies, aerobic growth improved significantly when respiratory genes were disrupted (ndh) or acquired point mutations (cydA and cydB), even if respiration was significantly reduced by these changes. Here, we obtained clean deletions of respiratory genes ndh and cydAB, individually and in combination, and showed, for the first time, that deletion of cydAB completely inhibited O2 respiration and dramatically reduced growth in oxic conditions. Both respiration and aerobic growth were restored by expressing a heterologous, water-forming NADH oxidase, noxE. Oxygen can have many negative effects, including formation of reactive oxygen species (ROS) or directly inactivating oxygen sensitive enzymes. Our results suggest that the effect of molecular oxygen on enzymes had a greater negative impact on Z. mobilis than formation of ROS. This result shows that the main role of the electron transport chain in Z. mobilis is reducing the intracellular concentration of molecular oxygen, helping to explain why it is beneficial for Z. mobilis to use electron transport chain complexes that have little capacity to contribute to oxidative phosphorylation. IMPORTANCE A key to producing next-generation biofuels is to engineer microbes that efficiently convert non-food materials into drop-in fuels, and to engineer microbes effectively, we must understand their metabolism thoroughly. Zymomonas mobilis is a bacterium that is a promising candidate biofuel producer, but its metabolism remains poorly understood, especially its metabolism when exposed to oxygen. Although Z. mobilis respires with oxygen, its aerobic growth is poor, and disruption of genes related to respiration counterintuitively improves aerobic growth. This unusual result has sparked decades of research and debate regarding the function of respiration in Z. mobilis. Here, we used a new set of mutants to determine that respiration is essential for aerobic growth and likely protects the cells from damage caused by oxygen. We conclude that the respiratory pathway of Z. mobilis should not be deleted from chassis strains for industrial production because this would yield a strain that is intolerant of oxygen, which is more difficult to manage in industrial settings.</text><annotation id="15"><infon key="identifier">MESH:D000431</infon><infon key="type">Chemical</infon><location offset="210" length="7"/><text>ethanol</text></annotation><annotation id="16"><infon key="identifier">MESH:D000431</infon><infon key="type">Chemical</infon><location offset="474" length="7"/><text>ethanol</text></annotation><annotation id="17"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1017" length="2"/><text>O2</text></annotation><annotation id="18"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1198" length="6"/><text>Oxygen</text></annotation><annotation id="19"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="1260" length="23"/><text>reactive oxygen species</text></annotation><annotation id="20"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="1285" length="3"/><text>ROS</text></annotation><annotation id="21"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1315" length="6"/><text>oxygen</text></annotation><annotation id="22"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1390" length="6"/><text>oxygen</text></annotation><annotation id="23"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="1470" length="3"/><text>ROS</text></annotation><annotation id="24"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1615" length="6"/><text>oxygen</text></annotation><annotation id="25"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="2188" length="6"/><text>oxygen</text></annotation><annotation id="26"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="2230" length="6"/><text>oxygen</text></annotation><annotation id="27"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="2622" length="6"/><text>oxygen</text></annotation><annotation id="28"><infon key="type">Disease</infon><location offset="2712" length="7"/><text>chassis</text></annotation><annotation id="29"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="2810" length="6"/><text>oxygen</text></annotation></passage><relation id="R1"><infon key="score">0.9953</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Chemical|MESH:D017382</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="3,4"/></relation></document>
<document><id>37910099</id><passage><infon key="type">title</infon><offset>0</offset><text>Increased modal damping of undamped single and multiscale acoustic black hole panels.</text></passage><passage><infon key="type">abstract</infon><offset>86</offset><text>The acoustic black hole (ABH) effect has been shown to increase damping of structures by focusing energy into a tapered-thickness region with added damping material. This paper illustrates that enhanced damping can be achieved without the use of damping material. Three panels were designed with different ABH grid patterns and parameters and compared to a baseline panel. Increased damping is shown to exist for two of the three ABH panels even though no damping material was applied. The panel modes which exhibited increased damping were local to the ABH grid while global modes did not exhibit increased damping.</text></passage></document>
<document><id>37910800</id><passage><infon key="journal">Breastfeed Med;2023Nov01. doi:10.1089/bfm.2023.0197</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Delgado D, Stellwagen L, McCune S, Sejane K, Bode L, </infon><offset>0</offset><text>Experience of Induced Lactation in a Transgender Woman: Analysis of Human Milk and a Suggested Protocol.</text></passage><passage><infon key="type">abstract</infon><offset>105</offset><text>Background: A growing number of diverse familial structures wish to colactate their infant. For transgender and gender diverse (TGD) individuals, chestfeeding or breastfeeding may be within their goals of parenthood. There is limited evidence on how to induce lactation for a nongestational parent on gender affirming estrogen treatment. Case Presentation: We report the case of a transgender woman who successfully underwent lactation induction following a protocol using the galactogue domperidone plus use of a breast pump. The patient had modifications to her hormone therapy with estrogen and progesterone while remaining on antiandrogen therapy with spironolactone. A description of the protocol, medications, laboratory monitoring, human milk analysis including macronutrients, oligosaccharides, and hormones is presented. Discussion: This is the fourth case to date known in the literature of a transgender woman with successful lactation induction, and the third case to remain on antiandrogen therapy during this process. Our report is the second to demonstrate comparable macronutrients, and the first to report on human milk oligosaccharides and hormones in induced milk compared with term human milk of a gestational parent. Conclusions: The opportunity to chestfeed or breastfeed an infant can be profound for many parents. Further research is needed to meet the needs of TGD individuals who wish to induce lactation as part of their parental goals.</text><annotation id="5"><infon key="identifier">MESH:D004294</infon><infon key="type">Chemical</infon><location offset="593" length="11"/><text>domperidone</text></annotation><annotation id="6"><infon key="identifier">MESH:D011374</infon><infon key="type">Chemical</infon><location offset="703" length="12"/><text>progesterone</text></annotation><annotation id="7"><infon key="identifier">MESH:D013148</infon><infon key="type">Chemical</infon><location offset="761" length="14"/><text>spironolactone</text></annotation><annotation id="8"><infon key="identifier">MESH:D009844</infon><infon key="type">Chemical</infon><location offset="890" length="16"/><text>oligosaccharides</text></annotation><annotation id="9"><infon key="identifier">MESH:D009844</infon><infon key="type">Chemical</infon><location offset="1242" length="16"/><text>oligosaccharides</text></annotation></passage></document>
<document><id>37911151</id><passage><infon key="journal">Int Dent J (Phila);1893Aug; 14 (8) 570</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109732</infon><infon key="type">title</infon><infon key="authors">Lord B, </infon><offset>0</offset><text>A Few Thoughts on the Combination of Filling-Materials.</text></passage><passage><infon key="type">abstract</infon><offset>56</offset></passage></document>
<document><id>37911501</id><passage><infon key="journal">Int Dent J (Phila);1890Oct; 11 (10) 659</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110224</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37912201</id><passage><infon key="journal">Int Dent J (Phila);1897Oct; 18 (10) 660</infon><infon key="year">1897</infon><infon key="article-id_pmc">PMC10128715</infon><infon key="type">title</infon><offset>0</offset><text>The New York Institute of Stomatology.</text></passage><passage><infon key="type">abstract</infon><offset>39</offset></passage></document>
<document><id>37912901</id><passage><infon key="journal">Int Dent J (Phila);1901May; 22 (5) 355</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153978</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37913251</id><passage><infon key="journal">Int Dent J (Phila);1905Apr; 26 (4) 228</infon><infon key="year">1905</infon><infon key="article-id_pmc">PMC10168743</infon><infon key="type">title</infon><infon key="authors">Goslee HJ, </infon><offset>0</offset><text>The Rationale of Pulp Extirpation.</text></passage><passage><infon key="type">abstract</infon><offset>35</offset></passage></document>
<document><id>37913602</id><passage><infon key="journal">Tissue Cell;2023Oct26; 85 102260. doi:10.1016/j.tice.2023.102260</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhao Y, Liu X, Liu X, Zhang J, Zhang Y, Wen Y, Yang G, </infon><offset>0</offset><text>Salvianolic acid B exerts protective effects against Abeta-induced neuroinflammation through the inhibition of NLRP3 inflammasome activation and switching of M1/M2 polarization.</text><annotation id="3"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="0" length="18"/><text>Salvianolic acid B</text></annotation><annotation id="4"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="67" length="17"/><text>neuroinflammation</text></annotation><annotation id="5"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="111" length="5"/><text>NLRP3</text></annotation></passage><passage><infon key="type">abstract</infon><offset>178</offset><text>BACKGROUND: Salvianolic acid B (SalB) is a bioactive extract of Salvia miltiorrhiza with the ability to ameliorate amyloid beta (Abeta)-induced neuronal degeneration and neuroinflammation in Alzheimer's disease (AD). However, the underlying mechanisms of this action have not been elucidated. Herein, we aimed to investigate whether the neuroprotective effect of SalB is attributable to the modulation of microglial polarization and NLRP3 inflammasome-mediated neuroinflammation. METHODS: Based on the TMT-labeled proteomics analysis, immunofluorescence, western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were employed to investigate the effects of SalB on neuroinflammation in Abeta1-42-stimulated BV2 microglia cells. RESULTS: At the proteomic level, a total of 6631 proteins were quantified, and of these, 104 were significantly influenced under Abeta1-42 treatment. The expression of 36 Abeta1-42-induced differentially expressed proteins were significantly recovered by SalB treatment (13 upregulated and 23 downregulated). NLRP3 was significantly recovered and was identified as one of the hub proteins. Consistent with the result of the proteomic analysis, western blot and qRT-PCR demonstrated that SalB reduced Abeta1-42-induced NLRP3 upregulation at both the protein and mRNA levels. In addition, SalB significantly blocked M1 microglia polarization, enhanced M2 microglial polarization, and inhibited the production of caspase-1 and interleukin-1beta in BV2 microglia cells. CONCLUSION: our study demonstrated, for the first time, that the anti-inflammatory effects of SalB were mediated by the regulation of NLRP3 activation and promotion of microglial M2 polarization, indicating the potential of SalB as a novel therapeutic candidate for AD.</text><annotation id="32"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="190" length="18"/><text>Salvianolic acid B</text></annotation><annotation id="33"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="210" length="4"/><text>SalB</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="231" length="7"/><text>extract</text></annotation><annotation id="35"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="322" length="21"/><text>neuronal degeneration</text></annotation><annotation id="36"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="348" length="17"/><text>neuroinflammation</text></annotation><annotation id="37"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="369" length="19"/><text>Alzheimer's disease</text></annotation><annotation id="38"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="390" length="2"/><text>AD</text></annotation><annotation id="39"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="541" length="4"/><text>SalB</text></annotation><annotation id="40"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="611" length="5"/><text>NLRP3</text></annotation><annotation id="41"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="639" length="17"/><text>neuroinflammation</text></annotation><annotation id="42"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="865" length="4"/><text>SalB</text></annotation><annotation id="43"><infon key="identifier">MESH:D000090862</infon><infon key="type">Disease</infon><location offset="873" length="17"/><text>neuroinflammation</text></annotation><annotation id="44"><infon key="identifier">CVCL:0182</infon><infon key="type">CellLine</infon><location offset="915" length="3"/><text>BV2</text></annotation><annotation id="45"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="1191" length="4"/><text>SalB</text></annotation><annotation id="46"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="1245" length="5"/><text>NLRP3</text></annotation><annotation id="47"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="1423" length="4"/><text>SalB</text></annotation><annotation id="48"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="1454" length="5"/><text>NLRP3</text></annotation><annotation id="49"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="1523" length="4"/><text>SalB</text></annotation><annotation id="50"><infon key="identifier">12362</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133272</infon><location offset="1646" length="9"/><text>caspase-1</text></annotation><annotation id="51"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1660" length="17"/><text>interleukin-1beta</text></annotation><annotation id="52"><infon key="identifier">CVCL:0182</infon><infon key="type">CellLine</infon><location offset="1681" length="3"/><text>BV2</text></annotation><annotation id="53"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1772" length="12"/><text>inflammatory</text></annotation><annotation id="54"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="1796" length="4"/><text>SalB</text></annotation><annotation id="55"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="1836" length="5"/><text>NLRP3</text></annotation><annotation id="56"><infon key="identifier">MESH:C076944</infon><infon key="type">Chemical</infon><location offset="1926" length="4"/><text>SalB</text></annotation><annotation id="57"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="1968" length="2"/><text>AD</text></annotation></passage><relation id="R1"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C076944</infon><infon key="role2">Disease|MESH:D009410</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="3,6"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:C076944</infon><infon key="role2">Gene|216799</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,2"/></relation><relation id="R3"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D000090862</infon><infon key="role2">Gene|216799</infon><infon key="type">Association</infon><node refid="2" role="1,2"/></relation><relation id="R4"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:C076944</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="25,24"/></relation><relation id="R5"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C076944</infon><infon key="role2">Gene|16176</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="20,22"/></relation><relation id="R6"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C076944</infon><infon key="role2">Gene|12362</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="20,21"/></relation><relation id="R7"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C076944</infon><infon key="role2">Disease|MESH:D000090862</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="0,1"/></relation><relation id="R8"><infon key="score">0.9956</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|216799</infon><infon key="type">Association</infon><node refid="7" role="24,26"/></relation><relation id="R9"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:C076944</infon><infon key="role2">Disease|MESH:D000544</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="3,8"/></relation></document>
<document><id>37913952</id><passage><infon key="journal">J Am Acad Dermatol;2023Oct30. doi:10.1016/j.jaad.2023.10.049</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Elston DM, </infon><offset>0</offset><text>Dermatology Images: Lupus erythematosus.</text><annotation id="1"><infon key="identifier">MESH:D008180</infon><infon key="type">Disease</infon><location offset="20" length="19"/><text>Lupus erythematosus</text></annotation></passage><passage><infon key="type">abstract</infon><offset>41</offset></passage></document>
<document><id>37914302</id><passage><infon key="journal">BMJ Open;2023Nov01; 13 (11) 074417. doi:10.1136/bmjopen-2023-074417</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yakoub N, Reinelt T, Natalucci G, </infon><offset>0</offset><text>Behavioural outcomes of children born with intrauterine growth restriction: protocol for a systematic review and meta-analysis.</text><annotation id="1"><infon key="identifier">MESH:D005317</infon><infon key="type">Disease</infon><location offset="43" length="31"/><text>intrauterine growth restriction</text></annotation></passage><passage><infon key="type">abstract</infon><offset>128</offset><text>INTRODUCTION: Intrauterine growth restriction (IUGR) is a pregnancy condition, which is associated with poor perinatal outcomes and long-term neurodevelopmental impairment. Several studies also investigated the impact of IUGR on child behaviour (eg, internalising and externalising behaviour, social competencies). However, so far, no systematic review or meta-analysis has been conducted that summarises these effects while considering relevant third variables such as type of IUGR diagnosis and control group, or concurrent cognitive abilities. The objective of this study is to summarise the current evidence regarding the relationship between IUGR and behavioural outcomes from early childhood to young adulthood. Additionally, to explore how third variables such as type of control group, or cognitive abilities, relate to this association. METHODS: Search strategy: The following electronic databases will be searched-Web of Science, Medline Ovid, PsycInfo, Cochrane Library, Scopus and Embase. INCLUSION CRITERIA: observational (eg, cohort studies and case-control studies) and intervention studies (if standard care is used and norm values are reported for the control group) will be included if they quantitatively compare children with and without IUGR from the age of 2 to 18 years. The main outcomes are internalising and externalising behaviour, and social competencies. ETHICS AND DISSEMINATION: No ethics approval was necessary for this protocol. Dissemination of findings will be done by publishing the results in peer-reviewed journals. The results of this systematic review will provide guidance for practice and counselling for clinicians and therapists facing patients affected by IUGR and their families. PROSPERO REGISTRATION NUMBER: CRD42022347467.</text><annotation id="12"><infon key="identifier">MESH:D005317</infon><infon key="type">Disease</infon><location offset="142" length="31"/><text>Intrauterine growth restriction</text></annotation><annotation id="13"><infon key="identifier">MESH:D005317</infon><infon key="type">Disease</infon><location offset="175" length="4"/><text>IUGR</text></annotation><annotation id="14"><infon key="identifier">MESH:D020763</infon><infon key="type">Disease</infon><location offset="196" length="9"/><text>condition</text></annotation><annotation id="15"><infon key="identifier">MESH:D009422</infon><infon key="type">Disease</infon><location offset="270" length="29"/><text>neurodevelopmental impairment</text></annotation><annotation id="16"><infon key="identifier">MESH:D005317</infon><infon key="type">Disease</infon><location offset="349" length="4"/><text>IUGR</text></annotation><annotation id="17"><infon key="identifier">MESH:D005317</infon><infon key="type">Disease</infon><location offset="606" length="4"/><text>IUGR</text></annotation><annotation id="18"><infon key="identifier">MESH:D005317</infon><infon key="type">Disease</infon><location offset="775" length="4"/><text>IUGR</text></annotation><annotation id="19"><infon key="identifier">MESH:D005317</infon><infon key="type">Disease</infon><location offset="1386" length="4"/><text>IUGR</text></annotation><annotation id="20"><infon key="identifier">MESH:D009103</infon><infon key="type">Disease</infon><location offset="1512" length="24"/><text>ETHICS AND DISSEMINATION</text></annotation><annotation id="21"><infon key="identifier">MESH:D005317</infon><infon key="type">Disease</infon><location offset="1829" length="4"/><text>IUGR</text></annotation></passage></document>
<document><id>37914652</id><passage><infon key="journal">Curr Probl Diagn Radiol;2023Oct20. doi:10.1067/j.cpradiol.2023.10.008</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sevenster M, Hergaarden K, Hertgers O, Nguyen D, Wijn V, Vlachomitrou AS, Vosbergen S, Lamb HJ, </infon><offset>0</offset><text>Design and perceived value of a novel solution for asynchronous communication in radiology.</text></passage><passage><infon key="type">abstract</infon><offset>92</offset><text>RATIONALE AND OBJECTIVES: Communication with and within the Radiology Department is typically initiated over phone, face-to-face or general-purpose chat, causing frequent interruptions, additional mental workload, workflow inefficiencies and diagnostic errors. We developed and evaluated a new communication solution that aims to reduce avoidable interruptions caused by technologist-radiologist communication. MATERIALS AND METHODS: Following an iterative design process with future end users, a scalable web-based software solution, RadConnect, was developed enabling a chat-based communication workflow between a technologist and a radiologist. As a first experimental implementation, technologists can send categorized tickets to a radiology section account. Radiologists receive the tickets in a worklist that is prioritized by urgency. Consented radiologists and technologists performed scripted tasks in 2 hr sessions and completed a structured questionnaire on perceived value and comparison to standard communication modes. RESULTS: Of 17 participants from three academic European institutes, 65% (11/17) believed they would use RadConnect frequently; 53% (9/17) believed that it reduces phone calls >80%; and 88% (15/17) believed it adds value compared to general-purpose enterprise chat applications. DISCUSSION: Participants recognized the value of RadConnect especially its categorized tickets, prioritized worklist and role-based interaction model. Inter-institute differences in perceived value of RadConnect may have been caused by technologist-radiologist proximity and communication alternatives in the institutions. CONCLUSION: Chat-based role-based communication might be a viable mode of communication between technologists and radiologists to reduce avoidable interruptions. Tailoring the chat solution to the needs of and tightly integrated with the radiology workflow is valued by future end users after exposure to the tool in a simulated environment.</text></passage></document>
<document><id>37915354</id><passage><infon key="journal">Plast Surg (Oakv);2023Nov; 31 (4) 319. doi:10.1177/22925503231208495</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10617448</infon><infon key="type">title</infon><infon key="authors">Arneja JS, Gilardino MS, </infon><offset>0</offset><text>Quiet Quitting: Why Is It Worse in Healthcare and What Do We Do About It?</text></passage><passage><infon key="type">abstract</infon><offset>74</offset></passage></document>
<document><id>37916054</id><passage><infon key="journal">J Obstet Gynaecol India;2023Oct; 73 (5) 374. doi:10.1007/s13224-023-01873-6</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10616057</infon><infon key="type">title</infon><infon key="authors">Chawla S, Sharma R, </infon><offset>0</offset><text>Retained Products of Conception (RPOC): Diagnosis, Complication &amp; Management.</text><annotation id="2"><infon key="identifier">MESH:D007787</infon><infon key="type">Disease</infon><location offset="0" length="31"/><text>Retained Products of Conception</text></annotation><annotation id="3"><infon key="identifier">MESH:D007787</infon><infon key="type">Disease</infon><location offset="33" length="4"/><text>RPOC</text></annotation></passage><passage><infon key="type">abstract</infon><offset>78</offset><text>Introduction: Retained products of conception (RPOC) generally result after first half of pregnancy termination and also may occur after vaginal or cesarean delivery. It frequently presents with irregular or continuous vaginal bleeding, lower abdominal and pelvic pain, and discharge per vaginum due to infection; it can also cause late complications like formation of intrauterine adhesions and subfertility. The diagnosis of the RPOC along with the symptoms is generally supported by ultrasonography with or without colour Doppler. The patient also undergoes uterine vasculature assessment to diagnose arteriovenous malformation (AVM). The management of RPOC has been conventionally done with blind dilation and suction curettage (D and C); however, expectant management, uterine artery embolization, and hysteroscopic resection of RPOC are safe and efficient alternatives. Materials and methods: In this review, we analyse the current available evidence regarding the clinical presentation, diagnosis and treatment of RPOC comparing the sensitivity, specificity, outcomes, pros and cons of various methods. Conclusion: RPOC is a common complication associated with early and late complications. The judicious use of antibiotics along with interventional radiology and hysteroscopy forms the backbone for the treatment of this condition.</text><annotation id="17"><infon key="identifier">MESH:D007787</infon><infon key="type">Disease</infon><location offset="92" length="31"/><text>Retained products of conception</text></annotation><annotation id="18"><infon key="identifier">MESH:D007787</infon><infon key="type">Disease</infon><location offset="125" length="4"/><text>RPOC</text></annotation><annotation id="19"><infon key="identifier">MESH:D014592</infon><infon key="type">Disease</infon><location offset="297" length="16"/><text>vaginal bleeding</text></annotation><annotation id="20"><infon key="identifier">MESH:D015746</infon><infon key="type">Disease</infon><location offset="321" length="25"/><text>abdominal and pelvic pain</text></annotation><annotation id="21"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="381" length="9"/><text>infection</text></annotation><annotation id="22"><infon key="identifier">MESH:D000267</infon><infon key="type">Disease</infon><location offset="447" length="22"/><text>intrauterine adhesions</text></annotation><annotation id="23"><infon key="identifier">MESH:D007787</infon><infon key="type">Disease</infon><location offset="509" length="4"/><text>RPOC</text></annotation><annotation id="24"><infon key="identifier">MESH:D001165</infon><infon key="type">Disease</infon><location offset="682" length="26"/><text>arteriovenous malformation</text></annotation><annotation id="25"><infon key="identifier">MESH:D001165</infon><infon key="type">Disease</infon><location offset="710" length="3"/><text>AVM</text></annotation><annotation id="26"><infon key="identifier">MESH:D007787</infon><infon key="type">Disease</infon><location offset="734" length="4"/><text>RPOC</text></annotation><annotation id="27"><infon key="identifier">MESH:D007787</infon><infon key="type">Disease</infon><location offset="912" length="4"/><text>RPOC</text></annotation><annotation id="28"><infon key="identifier">MESH:D007787</infon><infon key="type">Disease</infon><location offset="1099" length="4"/><text>RPOC</text></annotation><annotation id="29"><infon key="identifier">MESH:D007787</infon><infon key="type">Disease</infon><location offset="1200" length="4"/><text>RPOC</text></annotation></passage></document>
<document><id>37916404</id><passage><infon key="journal">Ann Surg;2023Nov02. doi:10.1097/SLA.0000000000006148</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ladner DP, Goldstein AM, Billiar TR, Cameron AM, Carpizo DR, Chu DI, Coopersmith CM, DeMatteo RP, Feng SH, Gallagher KA, Gillanders WE, Lal BK, Lipshutz GS, Liu A, Maier RV, Mittendorf EA, Morris AM, Sicklick JK, Velazquez OC, Whitson BA, Wilke LG, Yoon SS, Zeiger MA, Farmer DL, Hwang ES, ASA Task Force for Research Sustainability, </infon><offset>0</offset><text>Transforming the Future of Surgeon-Scientists.</text></passage><passage><infon key="type">abstract</infon><offset>47</offset><text>OBJECTIVE: To create a blueprint for surgical department leaders, academic institutions, and funding agencies to optimally support surgeon-scientists. SUMMARY BACKGROUND DATA: Scientific contributions by surgeons have been transformative across many medical disciplines. Surgeon-scientists provide a distinct approach and mindset toward key scientific questions. However, lack of institutional support, pressure for increased clinical productivity and growing administrative burden are major challenges for the surgeon-scientist, as is the time-consuming nature of surgical training and practice. METHODS: An American Surgical Association (ASA) Research Sustainability Task Force was created to outline a blueprint for sustainable science in surgery. Leaders from top NIH-sponsored departments of surgery engaged in video and in-person meetings between January and April 2023. A SWOT analysis was performed, and workgroups focused on the roles of surgeons, the department and institutions, and funding agencies. RESULTS: Taskforce recommendations: (1) SURGEONS: Growth mindset: identifying research focus, long-term planning, patience/tenacity, team science, collaborations with disparate experts; Skill set: align skills and research, fill critical skill gaps, develop team leadership skills; DEPARTMENT OF SURGERY (DOS): (2) MENTORSHIP: Chair: mentor - mentee matching / regular meetings / accountability, review of junior faculty progress, mentorship training requirement, recognition of mentorship (e.g., RVU equivalent, awards; Mentor: dedicated time, relevant scientific expertise, extramural funding, experience and/or trained as mentor, trusted advisor; Mentee: enthusiastic / eager, proactive, open to feedback, clear about goals; (3) FINANCIAL SUSTAINABILITY: diversification of research portfolio, identification of matching funding sources, departmental resource awards (e.g., T- / P-grants), leveraging of institutional resources, negotiation of formalized / formulaic funds flow investment from AMC towards science, philanthropy; (4) STRUCTURAL / STRATEGIC SUPPORT: Structural: grants administrative support, biostats / bioinformatics support, clinical trial and research support, regulatory support, shared departmental lab space / equipment; Strategic: hiring diverse surgeon-scientist/scientists faculty across DOS, strategic faculty retention / recruitment, philanthropy, career development support, progress tracking, grant writing support, DOS-wide research meetings, regular DOS strategic research planning; (5) COMMUNITY AND CULTURE: Community: right mix of faculty, connection surgeon with broad scientific community; Culture: building research infrastructure, financial support for research, projecting importance of research (awards, grand rounds, shoutouts); (6) THE ROLE OF INSTITUTIONS: Foundation: research space co-location, flexible start-up packages, courses / mock study section, awards, diverse institutional mentorship teams; Nurture: institutional infrastructure, funding (e.g., endowed chairs), promotion friendly towards surgeon-scientists, surgeon-scientists in institutional leadership positions; Expectations: RVU target relief, salary gap funding, competitive starting salaries, longitudinal salary strategy; (7) THE ROLE OF FUNDING AGENCIES: change surgeon research training paradigm, offer alternate awards to K-awards, increasing salary cap to reflect market reality, time extension for surgeon early-stage investigator (ESI) status, surgeon representation on study section, focused award strategies for professional societies/foundations. CONCLUSIONS: Authentic recommitment from surgeon leaders with intentional and ambitious actions from institutions, corporations, funders, and society is essential in order to reap the essential benefits of surgeon-scientists towards advancements of science.</text><annotation id="1"><infon key="identifier">MESH:D000267</infon><infon key="type">Disease</infon><location offset="1352" length="10"/><text>OF SURGERY</text></annotation></passage></document>
<document><id>37916760</id><passage><infon key="journal">J Dent Educ;2023Nov02. doi:10.1002/jdd.13411</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Stewart B, Saad AH, Salinitri FD, Mayberry ME, </infon><offset>0</offset><text>Playing in the sandbox together: Incorporating student pharmacists into dental practice.</text></passage><passage><infon key="type">abstract</infon><offset>89</offset></passage></document>
<document><id>37917112</id><passage><infon key="journal">J Neurotrauma;2023Nov02. doi:10.1089/neu.2022.0383</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Maki S, Furuya T, Inoue T, Yunde A, Miura M, Shiratani Y, Nagashima Y, Maruyama J, Shiga Y, Inage K, Eguchi Y, Orita S, Otori S, </infon><offset>0</offset><text>Machine learning web application for predicting functional outcomes in patients with traumatic spinal cord injury following inpatient rehabilitation.</text><annotation id="1"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="85" length="28"/><text>traumatic spinal cord injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>150</offset><text>Accurately predicting functional outcomes in patients with spinal cord injury (SCI) helps clinicians set realistic functional recovery goals and improve the home environment after discharge. The present study aimed to develop and validate machine learning (ML) models to predict functional outcomes in patients with SCI and deploy the models within a web application. The study included data from the Japan Association of Rehabilitation Database from January 1, 1991 to December 31, 2015. Patients with SCI who were admitted to an SCI center or were transferred to a participating postacute rehabilitation hospital after receiving acute treatment were enrolled in this database. The primary outcome was functional ambulation at discharge from the rehabilitation hospital. The secondary outcome was the total motor Functional Independence Measure (FIM) score at discharge. We used binary classification models to predict whether functional ambulation was achieved, as well as regression models to predict total motor FIM scores at discharge. In the training dataset (70% random sample), using demographic characteristics and neurological and functional status as predictors, we built prediction performance matrices of multiple ML models and selected the best one for each outcome. We validated each model's predictive performance in the test dataset (the remaining 30%). Among the 4181 patients, 3827 were included in the prediction model for the total motor FIM score. The mean (SD) age was 50.4 (18.7) years, and 3211 (83.9%) patients were male. There were 3122 patients included in the prediction model for functional ambulation. The CatBoost Classifier and regressor models showed the best performances in the training dataset. On the test dataset, the CatBoost Classifier had an area under the receiver operating characteristic curve of 0.8452 and an accuracy of 0.7663 for predicting functional ambulation. Likewise, the CatBoost Regressor performed well, with an R2 of 0.7746, a mean absolute error of 9.4895, and a root mean square error of 13.5312 for predicting the total motor FIM score. The final models were deployed in a web application to provide functional predictions. The application can be found at http://www.ortho.m.chiba-u.jp/general/4560. In conclusion, our prediction models developed using ML successfully predicted functional outcomes in patients with SCI and were deployed in an open-access web application.</text><annotation id="8"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="209" length="18"/><text>spinal cord injury</text></annotation><annotation id="9"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="229" length="3"/><text>SCI</text></annotation><annotation id="10"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="466" length="3"/><text>SCI</text></annotation><annotation id="11"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="653" length="3"/><text>SCI</text></annotation><annotation id="12"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="681" length="3"/><text>SCI</text></annotation><annotation id="13"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="2528" length="3"/><text>SCI</text></annotation></passage></document>
<document><id>37917462</id><passage><infon key="journal">Rehabil Psychol;2023Nov02. doi:10.1037/rep0000527</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tjokrowijoto P, Kneebone I, Baker C, Andrew NE, Stolwyk RJ, </infon><offset>0</offset><text>Mental health support after stroke: A qualitative exploration of lived experience.</text><annotation id="2"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="0" length="13"/><text>Mental health</text></annotation><annotation id="3"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="28" length="6"/><text>stroke</text></annotation></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>PURPOSE: Unmanaged mental health problems following a stroke can be detrimental to recovery. We aimed to explore the lived experience of (a) poststroke mental health difficulties, (b) help-seeking for mental health, including factors that influenced treatment access and utilization, and (c) receiving treatment and support. RESEARCH METHOD: Individual semistructured interviews were conducted in 2022 with 13 participants (62% female, age at stroke 35-76 years) who had experienced mental health difficulties following their stroke. Data were analyzed using reflexive thematic analysis with a critical realist approach. RESULTS: Six themes were identified. Mental health challenges poststroke were diverse in nature. Attitudes and previous experiences relating to mental health influenced the inclination to seek help. Participants valued an individualized approach to the provision and timing of psychoeducation. Accessibility of services was impacted by financial and transportation barriers, as well as availability of services and appropriately trained clinicians. Participation in support groups was a positive experience for most participants. Lived experience of mental health treatment ranged from positive to negative, and participants conveyed helpful and unhelpful aspects. CONCLUSIONS: Findings highlight the importance of early screening and psychoeducation provision for poststroke mental health difficulties, alongside accessible community-based mental health support services throughout the stroke recovery journey. Having varied options for mental health support and treatment may aid stroke survivors in finding an approach that personally works for them. Additionally, it may be helpful to train clinicians to tailor mental health treatment to accommodate stroke-related impairments (e.g., cognitive, sensorimotor). (PsycInfo Database Record (c) 2023 APA, all rights reserved).</text><annotation id="21"><infon key="identifier">MESH:D000076082</infon><infon key="type">Disease</infon><location offset="102" length="22"/><text>mental health problems</text></annotation><annotation id="22"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="137" length="6"/><text>stroke</text></annotation><annotation id="23"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="235" length="26"/><text>mental health difficulties</text></annotation><annotation id="24"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="284" length="13"/><text>mental health</text></annotation><annotation id="25"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="526" length="6"/><text>stroke</text></annotation><annotation id="26"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="566" length="26"/><text>mental health difficulties</text></annotation><annotation id="27"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="609" length="6"/><text>stroke</text></annotation><annotation id="28"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="741" length="13"/><text>Mental health</text></annotation><annotation id="29"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="848" length="13"/><text>mental health</text></annotation><annotation id="30"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="1254" length="13"/><text>mental health</text></annotation><annotation id="31"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="1480" length="26"/><text>mental health difficulties</text></annotation><annotation id="32"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="1545" length="13"/><text>mental health</text></annotation><annotation id="33"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="1591" length="6"/><text>stroke</text></annotation><annotation id="34"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="1642" length="13"/><text>mental health</text></annotation><annotation id="35"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="1686" length="6"/><text>stroke</text></annotation><annotation id="36"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="1820" length="13"/><text>mental health</text></annotation><annotation id="37"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="1859" length="26"/><text>stroke-related impairments</text></annotation></passage></document>
<document><id>37917813</id><passage><infon key="journal">Am J Sports Med;2023Nov; 51 (13) 54. doi:10.1177/03635465231193405</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tamura S, Kaizu Y, Miyata K, </infon><offset>0</offset><text>The Minimal Clinically Important Difference Changes Greatly Based on the Different Calculation Methods: Letter to the Editor.</text></passage><passage><infon key="type">abstract</infon><offset>126</offset></passage></document>
<document><id>37918164</id><passage><infon key="journal">Food Chem;2023Oct30; 437 (Pt 1) 137900. doi:10.1016/j.foodchem.2023.137900</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tian W, Wang S, Li X, Zhou M, Wu Y, Zhang J, Chen X, </infon><offset>0</offset><text>An automatic and smart platform for rapid detection of cadmium and lead simultaneously in rice using triple-amplified chemiluminescence immunoassay.</text><annotation id="1"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="55" length="7"/><text>cadmium</text></annotation></passage><passage><infon key="type">abstract</infon><offset>149</offset><text>Rapid detection of trace ions is urgently needed for large-scale screening to ensure food safety. This study developed an innovative and automatic strategy, based on a smart-designed platform for rapid detection of cadmium and lead in rice. As bridge antibody, the antigen was conjugated with goat anti-mouse immunoglobulin G labeled alkaline phosphatase. Meanwhile, a biotin-streptavidin system was introduced to micromagnetic particles, thus providing a triple-amplified chemiluminescence immunoassay with high sensitivity, accuracy and specificity. The limits of detection for cadmium and lead were 0.06 and 1.00 ng mL-1, respectively, within 30 min. The recoveries ranged from 89.81 to 114.92 %, with relative standard deviations less than 9.2 %. The results obtained agreed with those of inductively coupled plasma-mass spectrometry and certified reference materials. Additionally, the auto-operation avoided human errors as well as being convenient, fast, automatic and high-throughput. Therefore, this smart platform can be applied for large-scale Cd2+ and Pb2+ screening.</text><annotation id="6"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="364" length="7"/><text>cadmium</text></annotation><annotation id="7"><infon key="identifier">MESH:D001710</infon><infon key="type">Chemical</infon><location offset="518" length="6"/><text>biotin</text></annotation><annotation id="8"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="729" length="7"/><text>cadmium</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1213" length="4"/><text>Pb2+</text></annotation></passage></document>
<document><id>37918514</id><passage><infon key="journal">J Insect Physiol;2023Oct31 104582. doi:10.1016/j.jinsphys.2023.104582</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mustard JA, Dobb R, Wright GA, </infon><offset>0</offset><text>Chronic nicotine exposure influences learning and memory in the honey bee.</text><annotation id="1"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="8" length="8"/><text>nicotine</text></annotation></passage><passage><infon key="type">abstract</infon><offset>75</offset><text>In insects, nicotine activates nicotinic acetylcholine receptors, which are expressed throughout the central nervous system. However, little work has been done to investigate the effects of chronic nicotine treatment on learning or other behaviors in non-herbivorous insects. To examine the effects of long term nicotine consumption on learning and memory, honey bees were fed nicotine containing solutions over four days. Bees were able to detect nicotine at 0.1 mM in sucrose solutions, and in a no choice assay, bees reduced food intake when nicotine was 1 mM or higher. Treatment with a low dose of nicotine decreased the proportion of bees able to form an associative memory when bees were conditioned with either a massed or spaced appetitive olfactory training paradigm. On the other hand, higher doses of nicotine increased memory retention and the proportion of bees responding to the odor during 10 min and 24 h recall tests. The reduction in nicotine containing food consumed may also impact response levels during learning and recall tests. These data suggest that long term exposure to nicotine has complex effects on learning and memory.</text><annotation id="13"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="87" length="8"/><text>nicotine</text></annotation><annotation id="14"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="273" length="8"/><text>nicotine</text></annotation><annotation id="15"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="387" length="8"/><text>nicotine</text></annotation><annotation id="16"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="452" length="8"/><text>nicotine</text></annotation><annotation id="17"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="523" length="8"/><text>nicotine</text></annotation><annotation id="18"><infon key="identifier">MESH:D013395</infon><infon key="type">Chemical</infon><location offset="545" length="7"/><text>sucrose</text></annotation><annotation id="19"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="620" length="8"/><text>nicotine</text></annotation><annotation id="20"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="678" length="8"/><text>nicotine</text></annotation><annotation id="21"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="888" length="8"/><text>nicotine</text></annotation><annotation id="22"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="1028" length="8"/><text>nicotine</text></annotation><annotation id="23"><infon key="identifier">MESH:D009538</infon><infon key="type">Chemical</infon><location offset="1174" length="8"/><text>nicotine</text></annotation></passage></document>
<document><id>37918864</id><passage><infon key="journal">J Nucl Med;2023Nov02. doi:10.2967/jnumed.123.266380</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Viering O, G&amp;#xfc;nther T, Holzleitner N, Dierks A, Wienand G, Pfob CH, Bundschuh RA, Wester HJ, Enke JS, Kircher M, Lapa C, </infon><offset>0</offset><text>CCK2 Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [68Ga]Ga-DOTA-CCK-66.</text><annotation id="3"><infon key="identifier">887</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7258</infon><location offset="0" length="13"/><text>CCK2 Receptor</text></annotation><annotation id="4"><infon key="identifier">MESH:C536914</infon><infon key="type">Disease</infon><location offset="33" length="24"/><text>Medullary Thyroid Cancer</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="64" length="20"/><text>[68Ga]Ga-DOTA-CCK-66</text></annotation></passage><passage><infon key="type">abstract</infon><offset>86</offset></passage><relation id="R1"><infon key="score">0.9961</infon><infon key="role1">Disease|MESH:C536914</infon><infon key="role2">Gene|887</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation></document>
<document><id>37919214</id><passage><infon key="journal">J Pediatr Urol;2023Oct24. doi:10.1016/j.jpurol.2023.10.019</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">D&amp;#xf6;nmez M&amp;#x130;, Baydilli N, 't Hoen LA, O'Kelly F, Sforza S, Lammers R, Bindi E, Paraboschi I, Haid B, Quiroz Madarriaga Y, Banuelos Marco B, </infon><offset>0</offset><text>Response to letter to the editor re undescended testis: A roundtable discussion based on clinical scenarios - Part 1.</text><annotation id="1"><infon key="identifier">MESH:D003456</infon><infon key="type">Disease</infon><location offset="36" length="18"/><text>undescended testis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>118</offset></passage></document>
<document><id>37919564</id><passage><infon key="journal">MMW Fortschr Med;2023Nov; 165 (19) 10. doi:10.1007/s15006-023-3111-9</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Patzer KH, </infon><offset>0</offset><text>Immer mehr Arztinnen und Arzte aktiv in puncto Klimaschutz.</text></passage><passage><infon key="type">abstract</infon><offset>60</offset></passage></document>
<document><id>37919914</id><passage><infon key="journal">Ann Coloproctol;2023Oct; 39 (5) 373. doi:10.3393/ac.2023.00647.0092</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kang DH, </infon><offset>0</offset><text>Low anterior resection syndrome: is it predictable?</text><annotation id="1"><infon key="identifier">MESH:D000094123</infon><infon key="type">Disease</infon><location offset="0" length="31"/><text>Low anterior resection syndrome</text></annotation></passage><passage><infon key="type">abstract</infon><offset>52</offset></passage></document>
<document><id>37920964</id><passage><infon key="journal">WIREs Mech Dis;2023Nov03 1633. doi:10.1002/wsbm.1633</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bachari A, Nassar N, Schanknecht E, Telukutla S, Piva TJ, Mantri N, </infon><offset>0</offset><text>Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment.</text><annotation id="2"><infon key="identifier">MESH:D002186</infon><infon key="type">Chemical</infon><location offset="47" length="12"/><text>cannabinoids</text></annotation><annotation id="3"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="97" length="8"/><text>melanoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>Melanoma is one of the leading fatal forms of cancer, yet from a treatment perspective, we have minimal control over its reoccurrence and resistance to current pharmacotherapies. The endocannabinoid system (ECS) has recently been accepted as a multifaceted homeostatic regulator, influencing various physiological processes across different biological compartments, including the skin. This review presents an overview of the pathophysiology of melanoma, current pharmacotherapy used for treatment, and the challenges associated with the different pharmacological approaches. Furthermore, it highlights the utility of cannabinoids as an additive remedy for melanoma by restoring the balance between downregulated immunomodulatory pathways and elevated inflammatory cytokines during chronic skin conditions as one of the suggested critical approaches in treating this immunogenic tumor. This article is categorized under: Cancer > Molecular and Cellular Physiology.</text><annotation id="13"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="117" length="8"/><text>Melanoma</text></annotation><annotation id="14"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="163" length="6"/><text>cancer</text></annotation><annotation id="15"><infon key="identifier">MESH:D063388</infon><infon key="type">Chemical</infon><location offset="300" length="15"/><text>endocannabinoid</text></annotation><annotation id="16"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="562" length="8"/><text>melanoma</text></annotation><annotation id="17"><infon key="identifier">MESH:D002186</infon><infon key="type">Chemical</infon><location offset="735" length="12"/><text>cannabinoids</text></annotation><annotation id="18"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="774" length="8"/><text>melanoma</text></annotation><annotation id="19"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="869" length="12"/><text>inflammatory</text></annotation><annotation id="20"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="996" length="5"/><text>tumor</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1038" length="6"/><text>Cancer</text></annotation></passage><relation id="R1"><infon key="score">0.9971</infon><infon key="role1">Chemical|MESH:D002186</infon><infon key="role2">Disease|MESH:D008545</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.9236</infon><infon key="role1">Chemical|MESH:D002186</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="6,8"/></relation></document>
<document><id>37921314</id><passage><infon key="journal">Vet Rec;2023Nov04; 193 (9) . doi:10.1002/vetr.3663</infon><infon key="year">2023</infon><infon key="type">title</infon><offset>0</offset><text>Policy fellowship for SRUC professor.</text></passage><passage><infon key="type">abstract</infon><offset>38</offset></passage></document>
<document><id>37921664</id><passage><infon key="journal">Am J Physiol Heart Circ Physiol;2023Nov03. doi:10.1152/ajpheart.00437.2023</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chen YC, Zheng G, Donner DG, Wright DK, Greenwood JP, Marwick TH, McMullen JR, </infon><offset>0</offset><text>Cardiovascular Magnetic Resonance Imaging for Sequential Assessment of Cardiac Fibrosis in Mice: Technical Advancements and Reverse Translation.</text><annotation id="1"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="71" length="16"/><text>Cardiac Fibrosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>145</offset><text>Cardiovascular magnetic resonance (CMR) imaging has become an essential technique for the assessment of cardiac function and morphology, and is now routinely used to monitor disease progression and intervention efficacy in the clinic. Cardiac fibrosis is a common characteristic of numerous cardiovascular diseases and often precedes cardiac dysfunction and heart failure. Hence, the detection of cardiac fibrosis is important for both early diagnosis and the provision of guidance for interventions/therapies. Experimental mouse models with genetically and/or surgically induced disease have been widely used to understand mechanisms underlying cardiac fibrosis, and to assess new treatment strategies. Improving the appropriate applications of CMR to mouse studies of cardiac fibrosis has the potential to generate new knowledge, and more accurately examine the safety and efficacy of anti-fibrotic therapies. In this review, we provide 1) a brief overview of different types of cardiac fibrosis, 2) general background on magnetic resonance imaging (MRI), 3) a summary of different CMR techniques used in mice for the assessment of cardiac fibrosis including experimental and technical considerations (contrast agents and pulse sequences), and 4) provide an overview of mouse studies that have serially monitored cardiac fibrosis during disease progression and/or therapeutic interventions. Clinically established CMR protocols have advanced mouse CMR for the detection of cardiac fibrosis, and there is hope that discovery studies in mice will identify new anti-fibrotic therapies for patients; highlighting the value of both reverse translation and bench-to-bedside research.</text><annotation id="13"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="380" length="16"/><text>Cardiac fibrosis</text></annotation><annotation id="14"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="436" length="23"/><text>cardiovascular diseases</text></annotation><annotation id="15"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="479" length="19"/><text>cardiac dysfunction</text></annotation><annotation id="16"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="503" length="13"/><text>heart failure</text></annotation><annotation id="17"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="542" length="16"/><text>cardiac fibrosis</text></annotation><annotation id="18"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="791" length="16"/><text>cardiac fibrosis</text></annotation><annotation id="19"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="915" length="16"/><text>cardiac fibrosis</text></annotation><annotation id="20"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="1126" length="16"/><text>cardiac fibrosis</text></annotation><annotation id="21"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="1279" length="16"/><text>cardiac fibrosis</text></annotation><annotation id="22"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="1460" length="16"/><text>cardiac fibrosis</text></annotation><annotation id="23"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="1620" length="16"/><text>cardiac fibrosis</text></annotation></passage></document>
<document><id>37889495</id><passage><infon key="type">title</infon><offset>0</offset><text>Letter to the editor: Positive effects of cognitive-behavioral therapy targeting severe fatigue following COVID-19 are sustained up to one year after treatment.</text><annotation id="2"><infon key="identifier">MESH:D005221</infon><infon key="type">Disease</infon><location offset="88" length="7"/><text>fatigue</text></annotation><annotation id="3"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="106" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>161</offset></passage></document>
<document><id>37889845</id><passage><infon key="type">title</infon><offset>0</offset><text>Trends and components of thyroid status evaluation in commercially insured adults in the US, 2006-2020.</text></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>BACKGROUND: Thyroid stimulating hormone (TSH) is one of the most ordered laboratory tests. OBJECTIVE: Determine trends of TSH testing rates and components of thyroid function testing. DESIGN: Retrospective analysis. PARTICIPANTS: Adults 18-64 years old without evidence of thyroid disease with at least 365 days of continuous enrollment between 2006 and 2020 in the IBM MarketScan Claims Database. MAIN MEASURES: Trends of TSH tests/1,000 eligible patient-months stratified by age, sex, and region and composition of thyroid function testing. KEY RESULTS: Among 67,353,280 patients meeting eligibility criteria, we identified 25,606,518 TSH tests and 15,138,211 patients with ? 1 TSH test. Patients contributing an episode of TSH testing were most commonly 45-54 years old (29.8%) and female (63.6%).TSH testing rates remained consistent throughout the study period with 11.4 and 11.7 TSH tests/1,000 person-months in the first and last study months, respectively (mean 12.2 TSH tests/1,000 person-months). TSH testing rates dropped sharply in the spring of 2020 (4.2 TSH tests/1,000 person-months).Females showed a nearly twofold higher rate of TSH testing compared with males (16.1 TSH tests/1,000 person-months vs. 8.6 TSH tests/1,000 person-months). TSH testing rates increased with age (8.2 TSH tests/1,000 person-months among individuals 18-34 years vs. 15.4 TSH tests/1,000 person-months among individuals 55-64 years old). No difference in TSH testing rates was noted between regions.Thyroid function testing episodes included only TSH in most cases (70.8%). CONCLUSION: TSH testing rates among commercially insured individuals without known thyroid disease appears stable over time, with higher frequency in females and with increasing age.</text><annotation id="2"><infon key="identifier">MESH:D013959</infon><infon key="type">Disease</infon><location offset="377" length="15"/><text>thyroid disease</text></annotation><annotation id="3"><infon key="identifier">MESH:D013959</infon><infon key="type">Disease</infon><location offset="1754" length="15"/><text>thyroid disease</text></annotation></passage></document>
<document><id>37890197</id><passage><infon key="type">title</infon><offset>0</offset><text>Microsurgical disconnection of a T12/L1 ventral intradural perimedullary arteriovenous fistula (type IV) via instrumented trans-pedicular approach.</text><annotation id="1"><infon key="identifier">MESH:D001164</infon><infon key="type">Disease</infon><location offset="73" length="30"/><text>arteriovenous fistula (type IV</text></annotation></passage><passage><infon key="type">abstract</infon><offset>148</offset><text>CASE DESCRIPTION: We present a case of microsurgical disconnection of a PMAVF supplied by the artery of Adamkiewicz with fistulation at the ventral spinal cord.</text><annotation id="4"><infon key="type">Disease</infon><location offset="220" length="5"/><text>PMAVF</text></annotation><annotation id="5"><infon key="type">Disease</infon><location offset="269" length="11"/><text>fistulation</text></annotation></passage></document>
<document><id>37890547</id><passage><infon key="type">title</infon><offset>0</offset><text>Cardiovascular Impact of Near Complete Estrogen Deprivation in Premenopausal Women with Breast Cancer: The CROWN Study.</text><annotation id="1"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="88" length="13"/><text>Breast Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>120</offset><text>Survival with operable breast cancer has improved markedly in recent decades, however, treatment-related cardiovascular toxicities threaten to offset these gains. Ovarian function suppression paired with aromatase inhibition, for premenopausal women with hormone receptor (HR)-positive breast cancer, is a newer widely adopted therapy with the potential for significant long-term cardiovascular toxicity. Abrupt estrogen deprivation for non-cancer reasons is associated with accelerated coronary artery disease. Women with breast cancer treated with aromatase inhibition in addition to ovarian function suppression experience a dual hit with regards to estrogen exposure. The CaRdiac Outcomes With Near-complete estrogen deprivation (CROWN) study seeks to understand the early, subclinical natural history of cardiovascular compromise in young women undergoing near-complete estrogen deprivation (NCED) therapy. It is critical to understand the early subclinical development of cardiovascular disease to identify a window for therapeutic intervention before overt cardiovascular events occur. This three-site regional study (Atrium Health Wake Forest, Duke, and Virginia Commonwealth University) uses serial stress cardiac magnetic resonance (CMR) imaging and cardiac computed tomography angiography (CCTA) obtained during the initial two years of NCED therapy to study myocardial prefusion reserve (MPR), large cardiovascular vessel changes, left ventricular function, and other cardiovascular parameters. The CROWN cohort will consist of 90 premenopausal women with breast cancer, 67 with HR-positive disease receiving NCED and 23 comparators with HR-negative disease. Participants will undergo three annual CMR scans and two CCTA scans during the two-year study period. After initial activation hurdles, accrual has been brisk, and the study is expected to complete accrual in December 2024. Efforts are in place to encourage participant retention with the study primary outcome, change in MPR between the two groups, to be reported in 2026-2027. The results of this study will enable premenopausal women with breast cancer to balance the health burdens of cancer at a young age and treatment-related cardiovascular morbidity. Finally, the tools developed here can be utilized to study cardiovascular risk across a range of cancer types and cancer therapies with the ultimate goals of both developing generalizable risk stratification tools as well as validating interventions which prevent overt cardiovascular compromise.</text><annotation id="27"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="143" length="13"/><text>breast cancer</text></annotation><annotation id="28"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="225" length="25"/><text>cardiovascular toxicities</text></annotation><annotation id="29"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="283" length="28"/><text>Ovarian function suppression</text></annotation><annotation id="30"><infon key="identifier">1588</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30955</infon><location offset="324" length="9"/><text>aromatase</text></annotation><annotation id="31"><infon key="identifier">3164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1612</infon><location offset="375" length="16"/><text>hormone receptor</text></annotation><annotation id="32"><infon key="identifier">3164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1612</infon><location offset="393" length="2"/><text>HR</text></annotation><annotation id="33"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="406" length="13"/><text>breast cancer</text></annotation><annotation id="34"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="500" length="23"/><text>cardiovascular toxicity</text></annotation><annotation id="35"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="561" length="6"/><text>cancer</text></annotation><annotation id="36"><infon key="identifier">MESH:D003324</infon><infon key="type">Disease</infon><location offset="607" length="23"/><text>coronary artery disease</text></annotation><annotation id="37"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="643" length="13"/><text>breast cancer</text></annotation><annotation id="38"><infon key="identifier">1588</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30955</infon><location offset="670" length="9"/><text>aromatase</text></annotation><annotation id="39"><infon key="identifier">MESH:D010051</infon><infon key="type">Disease</infon><location offset="706" length="28"/><text>ovarian function suppression</text></annotation><annotation id="40"><infon key="identifier">MESH:D056828</infon><infon key="type">Disease</infon><location offset="832" length="8"/><text>estrogen</text></annotation><annotation id="41"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="929" length="25"/><text>cardiovascular compromise</text></annotation><annotation id="42"><infon key="identifier">MESH:D056828</infon><infon key="type">Disease</infon><location offset="995" length="8"/><text>estrogen</text></annotation><annotation id="43"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="1098" length="22"/><text>cardiovascular disease</text></annotation><annotation id="44"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1688" length="13"/><text>breast cancer</text></annotation><annotation id="45"><infon key="identifier">3164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1612</infon><location offset="1711" length="2"/><text>HR</text></annotation><annotation id="46"><infon key="identifier">3164</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1612</infon><location offset="1770" length="2"/><text>HR</text></annotation><annotation id="47"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="2233" length="13"/><text>breast cancer</text></annotation><annotation id="48"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="2280" length="6"/><text>cancer</text></annotation><annotation id="49"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="2447" length="6"/><text>cancer</text></annotation><annotation id="50"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="2464" length="6"/><text>cancer</text></annotation><annotation id="51"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="2620" length="25"/><text>cardiovascular compromise</text></annotation></passage><relation id="R1"><infon key="score">0.9957</infon><infon key="role1">Disease|MESH:D002318</infon><infon key="role2">Gene|3164</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="8,5"/></relation><relation id="R2"><infon key="score">0.98</infon><infon key="role1">Disease|MESH:D010051</infon><infon key="role2">Gene|3164</infon><infon key="type">Association</infon><node refid="1" role="3,5"/></relation><relation id="R3"><infon key="score">0.9989</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|1588</infon><infon key="type">Association</infon><node refid="2" role="7,4"/></relation><relation id="R4"><infon key="score">0.9618</infon><infon key="role1">Gene|1588</infon><infon key="role2">Gene|3164</infon><infon key="type">Association</infon><node refid="3" role="4,5"/></relation><relation id="R5"><infon key="score">0.8289</infon><infon key="role1">Disease|MESH:D002318</infon><infon key="role2">Gene|1588</infon><infon key="type">Association</infon><node refid="4" role="8,4"/></relation><relation id="R6"><infon key="score">0.9668</infon><infon key="role1">Disease|MESH:D010051</infon><infon key="role2">Gene|1588</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="3,4"/></relation><relation id="R7"><infon key="score">0.9532</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|3164</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="7,5"/></relation></document>
<document><id>37890897</id><passage><infon key="type">title</infon><offset>0</offset><text>The ethical considerations of an emergency referral.</text></passage><passage><infon key="type">abstract</infon><offset>53</offset></passage></document>
<document><id>37897208</id><passage><infon key="journal">Clin Transplant;2023Oct28 15171. doi:10.1111/ctr.15171</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Koc &amp;#xd6;M, Aslan D, Kramer M, Verbeek J, Van Malenstein H, van der Merwe S, Monbaliu D, Vos R, Verleden GM, Pirenne J, Nevens F, </infon><offset>0</offset><text>Outcomes of liver transplantation for hepatopulmonary syndrome in patients with concomitant respiratory disease.</text><annotation id="2"><infon key="identifier">MESH:D020065</infon><infon key="type">Disease</infon><location offset="38" length="24"/><text>hepatopulmonary syndrome</text></annotation><annotation id="3"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="92" length="19"/><text>respiratory disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>BACKGROUND &amp; AIMS: Concomitant respiratory disease is a common finding in patients with hepatopulmonary syndrome (HPS). Among patients who underwent liver transplantation (LT) for HPS, we compared characteristics and outcome of patients with versus without concomitant respiratory disease. METHODS: This single center retrospective observational study included patients with HPS who underwent LT between 1999 and 2020. RESULTS: During the study period, 32 patients with HPS received a LT; nine (28%) with concomitant respiratory disease of whom one required a combined lung-liver transplantation. Patients with concomitant respiratory disease had higher PaCO2 (38 vs. 33 mm Hg, p = .031). The 30-day postoperative mortality was comparable, but the estimated cumulative probability of resolution of oxygen therapy after LT in HPS patients with versus those without concomitant respiratory disease was lower: 63% versus 91% at 12 months and 63% versus 100% at 18 months (HR 95% CI .140-.995, p = .040). In addition to the presence of concomitant respiratory disease (p = .040), history of smoking (p = .012), and high baseline 99mTcMAA shunt fraction (>=20%) (p = .050) were significantly associated with persistent need of oxygen therapy. The 5-year estimated cumulative probability of mortality in patients with concomitant respiratory disease was worse: 50% versus 23% (HR 95% CI .416-6.867, p = .463). CONCLUSIONS: The presence of a concomitant respiratory disease did not increase the short-term postoperative mortality after LT in patients with HPS. However, it resulted in a longer need for oxygen therapy.</text><annotation id="22"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="144" length="19"/><text>respiratory disease</text></annotation><annotation id="23"><infon key="identifier">MESH:D020065</infon><infon key="type">Disease</infon><location offset="201" length="24"/><text>hepatopulmonary syndrome</text></annotation><annotation id="24"><infon key="identifier">MESH:D020065</infon><infon key="type">Disease</infon><location offset="227" length="3"/><text>HPS</text></annotation><annotation id="25"><infon key="identifier">MESH:D020065</infon><infon key="type">Disease</infon><location offset="293" length="3"/><text>HPS</text></annotation><annotation id="26"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="382" length="19"/><text>respiratory disease</text></annotation><annotation id="27"><infon key="identifier">MESH:D020065</infon><infon key="type">Disease</infon><location offset="488" length="3"/><text>HPS</text></annotation><annotation id="28"><infon key="identifier">MESH:D020065</infon><infon key="type">Disease</infon><location offset="583" length="3"/><text>HPS</text></annotation><annotation id="29"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="630" length="19"/><text>respiratory disease</text></annotation><annotation id="30"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="736" length="19"/><text>respiratory disease</text></annotation><annotation id="31"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="911" length="6"/><text>oxygen</text></annotation><annotation id="32"><infon key="identifier">MESH:D020065</infon><infon key="type">Disease</infon><location offset="938" length="3"/><text>HPS</text></annotation><annotation id="33"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="989" length="19"/><text>respiratory disease</text></annotation><annotation id="34"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="1157" length="19"/><text>respiratory disease</text></annotation><annotation id="35"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1335" length="6"/><text>oxygen</text></annotation><annotation id="36"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="1437" length="19"/><text>respiratory disease</text></annotation><annotation id="37"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="1560" length="19"/><text>respiratory disease</text></annotation><annotation id="38"><infon key="identifier">MESH:D020065</infon><infon key="type">Disease</infon><location offset="1662" length="3"/><text>HPS</text></annotation><annotation id="39"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1709" length="6"/><text>oxygen</text></annotation></passage><relation id="R1"><infon key="score">0.9221</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Disease|MESH:D012140</infon><infon key="type">Association</infon><node refid="0" role="11,13"/></relation><relation id="R2"><infon key="score">0.6764</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Disease|MESH:D020065</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="11,12"/></relation></document>
<document><id>37897559</id><passage><infon key="journal">Int J Biometeorol;2023Oct28. doi:10.1007/s00484-023-02568-3</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Biswas A, Deo C, Sharma D, Matin A, Tiwari AK, </infon><offset>0</offset><text>Production performance, haematological parameters, serum biochemistry, and expression of HSP-70 in broiler chickens fed dietary ascorbic acid during heat stress.</text><annotation id="2"><infon key="identifier">423504</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68564</infon><location offset="89" length="6"/><text>HSP-70</text></annotation><annotation id="3"><infon key="identifier">MESH:D001205</infon><infon key="type">Chemical</infon><location offset="128" length="13"/><text>ascorbic acid</text></annotation></passage><passage><infon key="type">abstract</infon><offset>162</offset><text>An experiment was carried out to assess the efficacy of supplemental ascorbic acid (AA) on broiler chicken production performance, blood haematological profile, biochemical profile, and carcass traits under heat stress conditions. A total of 192-day-old broiler chicks were divided into four groups, each with six replicates of eight each (4 x 6 x 8). Four corn-based dietary treatments were formulated: T1 (control diet), T2 (T1 + AA at 200 mg/kg), T3 (T1 + AA at 400 mg/kg), and T4 (T1 + AA at 600 mg/kg) for a period of 42 days. Despite the high temperature and humidity, the 600 mg AA supplemental groups (T4) gained significantly (P &lt;= 0.05) more body weight and had a higher feed intake and better feed conversion ratio (FCR) than the control group (T1). After 28 days of feeding the three AA-supplemented diets, antibody titres (humoral immune response) were significantly higher (P &lt;= 0.05). The response to intradermally injected phyto-haemagglutinin (PHA-P), an index of the in vivo cell-mediated immune response, was found to be increased (P &lt;= 0.05) in the 400 and 600 mg AA-supplemented groups after 35 days. Higher levels of AA (T4) supplementation significantly (P &lt;= 0.05) improved haematological values such as haemoglobin (Hb), total erythrocyte count (TEC), total leukocyte count (TLC), and differential leukocyte count (DLC), heterophil:lymphocyte (H:L) in comparison to the control group (T1). The supplemented group improved the serum biochemical profile of the birds, with an increase (P &lt;= 0.05) in total serum protein, albumin, and globulin and a decrease in serum cholesterol and corticosterone levels in the T4 group compared to the control group. Heat shock protein-70 (HSP-70) was gradually elevated after increasing the ascorbic acid concentration (P &lt;= 0.05) at 14 and 21 days. As a result, it can be concluded that supplementing ascorbic acid at 600 mg/kg is beneficial for improving the performance, immunity, and blood haematological biochemical profile and upregulating the HSP-70 gene of broiler chickens under heat stress conditions.</text><annotation id="13"><infon key="identifier">MESH:D001205</infon><infon key="type">Chemical</infon><location offset="231" length="13"/><text>ascorbic acid</text></annotation><annotation id="14"><infon key="identifier">396197</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">405</infon><location offset="1706" length="7"/><text>albumin</text></annotation><annotation id="15"><infon key="identifier">MESH:D002784</infon><infon key="type">Chemical</infon><location offset="1752" length="11"/><text>cholesterol</text></annotation><annotation id="16"><infon key="identifier">MESH:D003345</infon><infon key="type">Chemical</infon><location offset="1768" length="14"/><text>corticosterone</text></annotation><annotation id="17"><infon key="identifier">423504</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68564</infon><location offset="1837" length="21"/><text>Heat shock protein-70</text></annotation><annotation id="18"><infon key="identifier">423504</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68564</infon><location offset="1860" length="6"/><text>HSP-70</text></annotation><annotation id="19"><infon key="identifier">MESH:D001205</infon><infon key="type">Chemical</infon><location offset="1912" length="13"/><text>ascorbic acid</text></annotation><annotation id="20"><infon key="identifier">MESH:D001205</infon><infon key="type">Chemical</infon><location offset="2023" length="13"/><text>ascorbic acid</text></annotation><annotation id="21"><infon key="identifier">423504</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68564</infon><location offset="2171" length="6"/><text>HSP-70</text></annotation></passage><relation id="R1"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D001205</infon><infon key="role2">Gene|423504</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="1,0"/></relation></document>
<document><id>37897909</id><passage><infon key="journal">Biochem Biophys Res Commun;2023Oct21; 684 149138. doi:10.1016/j.bbrc.2023.149138</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tang Z, Feng J, Rowthu SR, Zou C, Peng H, Huang C, He Y, </infon><offset>0</offset><text>Uncovering the anti-biofilm activity of Ilicicolin B against Staphylococcus aureus.</text><annotation id="2"><infon key="type">Disease</infon><location offset="20" length="7"/><text>biofilm</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="40" length="12"/><text>Ilicicolin B</text></annotation></passage><passage><infon key="type">abstract</infon><offset>84</offset><text>The formation of bacterial biofilms reduces the entry of antibiotics into bacteria and helps bacteria tolerate otherwise lethal concentrations of antimicrobials, leading to antibiotic resistance. Therefore, clearing bacterial biofilm is an effective strategy to tackle drug resistance. Currently, there are no approved antibiotics for inhibiting bacterial biofilm formation. We found that Ilicicolin B had excellent antibacterial activity against MRSA without obvious hemolytic activity. More importantly, Ilicicolin B effectively inhibited the biofilm formation in a concentration-dependent manner by crystal violet colorimetric assay and fluorescence microscopy analysis. Exposure of Staphylococcus aureus to Ilicicolin B for 24 h reduced the protein and polysaccharide components in EPS, suggesting that Ilicicolin B disintegrated the biofilms by dissociating the EPS in a matrix. In addition, Ilicicolin B demonstrated strong antibacterial effects in a murine abscess model of S. aureus. Our findings suggest that Ilicicolin B has the potential to treat S. aureus infection by inhibiting biofilm formation.</text><annotation id="21"><infon key="type">Disease</infon><location offset="310" length="7"/><text>biofilm</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="440" length="7"/><text>biofilm</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="473" length="12"/><text>Ilicicolin B</text></annotation><annotation id="24"><infon key="type">Disease</infon><location offset="531" length="4"/><text>MRSA</text></annotation><annotation id="25"><infon key="identifier">MESH:D006461</infon><infon key="type">Disease</infon><location offset="552" length="9"/><text>hemolytic</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="590" length="12"/><text>Ilicicolin B</text></annotation><annotation id="27"><infon key="type">Disease</infon><location offset="629" length="7"/><text>biofilm</text></annotation><annotation id="28"><infon key="identifier">MESH:D005840</infon><infon key="type">Chemical</infon><location offset="686" length="14"/><text>crystal violet</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="795" length="12"/><text>Ilicicolin B</text></annotation><annotation id="30"><infon key="identifier">MESH:D011134</infon><infon key="type">Chemical</infon><location offset="841" length="14"/><text>polysaccharide</text></annotation><annotation id="31"><infon key="identifier">MESH:C100219</infon><infon key="type">Chemical</infon><location offset="870" length="3"/><text>EPS</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="891" length="12"/><text>Ilicicolin B</text></annotation><annotation id="33"><infon key="identifier">MESH:C100219</infon><infon key="type">Chemical</infon><location offset="951" length="3"/><text>EPS</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="981" length="12"/><text>Ilicicolin B</text></annotation><annotation id="35"><infon key="identifier">MESH:D000038</infon><infon key="type">Disease</infon><location offset="1048" length="7"/><text>abscess</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1102" length="12"/><text>Ilicicolin B</text></annotation><annotation id="37"><infon key="type">Disease</infon><location offset="1176" length="7"/><text>biofilm</text></annotation></passage></document>
<document><id>37898262</id><passage><infon key="journal">Photodiagnosis Photodyn Ther;2023Oct26 103858. doi:10.1016/j.pdpdt.2023.103858</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gusm&amp;#xe3;o LA, Rodero CF, Pironi AM, Chorilli M, Perussi JR, </infon><offset>0</offset><text>Hypericin supramolecular assembles: a way to increase the skin availability and photodynamic efficiency in tumor cells.</text><annotation id="2"><infon key="identifier">MESH:C004965</infon><infon key="type">Chemical</infon><location offset="0" length="9"/><text>Hypericin</text></annotation><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="107" length="5"/><text>tumor</text></annotation></passage><passage><infon key="type">abstract</infon><offset>120</offset><text>Cyclodextrins (CDs) are molecules approved by the FDA and show promise in increasing the solubility of hydrophobic molecules and making them more available to the skin. These CDs have been used to form complexes with some photosensitizers for Photodynamic Therapy (PDT), such as Hypericin (HY). HY is a lipophilic photosensitizer known for its exceptional fluorescence and singlet oxygen quantum yield generation of over 20% under 590 nm irradiation. In this study, we found a six-fold increase in the release of HY in vitro after complexation with beta-CD. The beta-CDHY assembly also demonstrated better skin retention, which is crucial for the topical application of this photosensitizer. Furthermore, the beta-CD complexation led to a significant increase in the phototoxicity of HY at three different light doses (3, 6, and 10 J cm-2) due to its improved water solubility and higher in vitro accumulation (approximately two times compared with free HY) in HeLa and Vero cell lines.</text><annotation id="20"><infon key="identifier">MESH:D003505</infon><infon key="type">Chemical</infon><location offset="120" length="13"/><text>Cyclodextrins</text></annotation><annotation id="21"><infon key="identifier">MESH:D003505</infon><infon key="type">Chemical</infon><location offset="135" length="3"/><text>CDs</text></annotation><annotation id="22"><infon key="identifier">MESH:D003505</infon><infon key="type">Chemical</infon><location offset="295" length="3"/><text>CDs</text></annotation><annotation id="23"><infon key="identifier">MESH:C004965</infon><infon key="type">Chemical</infon><location offset="399" length="9"/><text>Hypericin</text></annotation><annotation id="24"><infon key="identifier">MESH:C004965</infon><infon key="type">Chemical</infon><location offset="410" length="2"/><text>HY</text></annotation><annotation id="25"><infon key="identifier">MESH:C004965</infon><infon key="type">Chemical</infon><location offset="415" length="2"/><text>HY</text></annotation><annotation id="26"><infon key="identifier">MESH:D026082</infon><infon key="type">Chemical</infon><location offset="493" length="14"/><text>singlet oxygen</text></annotation><annotation id="27"><infon key="identifier">MESH:C004965</infon><infon key="type">Chemical</infon><location offset="633" length="2"/><text>HY</text></annotation><annotation id="28"><infon key="identifier">MESH:C031215</infon><infon key="type">Chemical</infon><location offset="669" length="7"/><text>beta-CD</text></annotation><annotation id="29"><infon key="identifier">MESH:C031215</infon><infon key="type">Chemical</infon><location offset="829" length="7"/><text>beta-CD</text></annotation><annotation id="30"><infon key="identifier">MESH:D017484</infon><infon key="type">Disease</infon><location offset="887" length="13"/><text>phototoxicity</text></annotation><annotation id="31"><infon key="identifier">MESH:C004965</infon><infon key="type">Chemical</infon><location offset="904" length="2"/><text>HY</text></annotation><annotation id="32"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="980" length="5"/><text>water</text></annotation><annotation id="33"><infon key="identifier">MESH:C004965</infon><infon key="type">Chemical</infon><location offset="1074" length="2"/><text>HY</text></annotation><annotation id="34"><infon key="identifier">CVCL:0030</infon><infon key="type">CellLine</infon><location offset="1081" length="4"/><text>HeLa</text></annotation><annotation id="35"><infon key="identifier">CVCL:0059</infon><infon key="type">CellLine</infon><location offset="1090" length="4"/><text>Vero</text></annotation></passage><relation id="R1"><infon key="score">0.9865</infon><infon key="role1">Chemical|MESH:C004965</infon><infon key="role2">Chemical|MESH:C031215</infon><infon key="type">Association</infon><node refid="0" role="9,10"/></relation><relation id="R2"><infon key="score">0.2854</infon><infon key="role1">Chemical|MESH:C004965</infon><infon key="role2">Chemical|MESH:D003505</infon><infon key="type">Cotreatment</infon><node refid="1" role="5,4"/></relation><relation id="R3"><infon key="score">0.9954</infon><infon key="role1">Chemical|MESH:C004965</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Association</infon><node refid="2" role="0,1"/></relation><relation id="R4"><infon key="score">0.9971</infon><infon key="role1">Chemical|MESH:C004965</infon><infon key="role2">Chemical|MESH:D026082</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="7,8"/></relation><relation id="R5"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:C031215</infon><infon key="role2">Disease|MESH:D017484</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="11,12"/></relation></document>
<document><id>37898962</id><passage><infon key="journal">Aging Clin Exp Res;2023Oct29. doi:10.1007/s40520-023-02576-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">9827130</infon><infon key="type">title</infon><infon key="authors">Mao M, Liu R, Dong Y, Wang C, Ren Y, Tian N, Tang S, Hou T, Cong L, Wang Y, Du Y, Qiu C, </infon><offset>0</offset><text>Resting heart rate, cognitive function, and inflammation in older adults: a population-based study.</text><annotation id="2"><infon key="identifier">MESH:D003291</infon><infon key="type">Disease</infon><location offset="30" length="8"/><text>function</text></annotation><annotation id="3"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="44" length="12"/><text>inflammation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>BACKGROUND: Emerging evidence has linked elevated resting heart rate (RHR) with poor cognitive function in older adults, but the mechanisms underlying their association are poorly understood. METHODS: This population-based cross-sectional study included 4510 dementia-free participants (age >= 65 years; 56.9% females; 38.3% no formal education) in the baseline examination of the Multidomain Interventions to Delay Dementia and Disability in Rural China study. Of these, 1,386 had data on serum proinflammatory cytokines and adhesion molecules. RHR was measured using 12-lead electrocardiograph. We used the Mini-Mental State Examination (MMSE) and a neuropsychological test battery to assess cognitive function. Data were analyzed using the general linear and restricted cubic splines models. RESULTS: People with high RHR were more likely to have cardiometabolic diseases and worse cognitive function (p &lt; 0.05). There was an inverted J-shaped association of RHR with MMSE and attention scores. Having RHR >= 80 bpm (vs. 60-69 bpm) was significantly associated with the multivariable-adjusted beta coefficients of - 0.58 [95% confidence interval (CI), - 1.00, - 0.16] for MMSE score and - 0.08 (- 0.15, - 0.01) for attention score. In the serum biomarker subsample, RHR was linearly associated with serum interleukin-6 (IL-6) (beta coefficient = 0.19; 95%CI 0.14, 0.24), IL-8 (0.08; 0.02, 0.13), IL-10 (0.09; 0.04, 0.15), tumor necrosis factor-alpha (0.06; 0.01, 0.11), monocyte chemotactic protein-1 (0.09; 0.04, 0.15), intercellular adhesion molecule-1 (0.16; 0.11, 0.22), and vascular cell adhesion molecule-1 (0.11; 0.06, 0.16). CONCLUSIONS: There is an inverted J-shaped association of RHR with attention and global cognition. Poor cognitive function and high RHR may be linked through systemic low-grade inflammation and endothelial injury.</text><annotation id="21"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="180" length="23"/><text>poor cognitive function</text></annotation><annotation id="22"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="359" length="8"/><text>dementia</text></annotation><annotation id="23"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="516" length="23"/><text>Dementia and Disability</text></annotation><annotation id="24"><infon key="identifier">MESH:D003291</infon><infon key="type">Disease</infon><location offset="804" length="8"/><text>function</text></annotation><annotation id="25"><infon key="identifier">MESH:D024821</infon><infon key="type">Disease</infon><location offset="950" length="24"/><text>cardiometabolic diseases</text></annotation><annotation id="26"><infon key="identifier">MESH:D003291</infon><infon key="type">Disease</infon><location offset="995" length="8"/><text>function</text></annotation><annotation id="27"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1408" length="13"/><text>interleukin-6</text></annotation><annotation id="28"><infon key="identifier">3569</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1423" length="4"/><text>IL-6</text></annotation><annotation id="29"><infon key="identifier">3576</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">47937</infon><location offset="1474" length="4"/><text>IL-8</text></annotation><annotation id="30"><infon key="identifier">3586</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">478</infon><location offset="1499" length="5"/><text>IL-10</text></annotation><annotation id="31"><infon key="identifier">7124</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="1525" length="27"/><text>tumor necrosis factor-alpha</text></annotation><annotation id="32"><infon key="identifier">6347</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2245</infon><location offset="1573" length="30"/><text>monocyte chemotactic protein-1</text></annotation><annotation id="33"><infon key="identifier">3383</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">168</infon><location offset="1624" length="33"/><text>intercellular adhesion molecule-1</text></annotation><annotation id="34"><infon key="identifier">7412</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">838</infon><location offset="1682" length="33"/><text>vascular cell adhesion molecule-1</text></annotation><annotation id="35"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="1835" length="23"/><text>Poor cognitive function</text></annotation><annotation id="36"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1913" length="12"/><text>inflammation</text></annotation><annotation id="37"><infon key="identifier">MESH:D057772</infon><infon key="type">Disease</infon><location offset="1930" length="18"/><text>endothelial injury</text></annotation></passage></document>
<document><id>37899312</id><passage><infon key="journal">Zhonghua Bing Li Xue Za Zhi;2023Nov08; 52 (11) 1083. doi:10.3760/cma.j.cn112151-20230513-00333</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xie HK, Wu CY, </infon><offset>0</offset><text>[Discussion on several issues concerning minimally invasive adenocarcinoma of the lung].</text><annotation id="1"><infon key="identifier">MESH:D000077192</infon><infon key="type">Disease</infon><location offset="60" length="26"/><text>adenocarcinoma of the lung</text></annotation></passage><passage><infon key="type">abstract</infon><offset>89</offset></passage></document>
<document><id>37899664</id><passage><infon key="journal">J Gerontol Soc Work;2023Nov-Dec; 66 (8) 983. doi:10.1080/01634372.2023.2274703</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bonifas RP, </infon><offset>0</offset><text>Introducing Issue 66(8).</text></passage><passage><infon key="type">abstract</infon><offset>25</offset></passage></document>
<document><id>37901065</id><passage><infon key="journal">Int J Transgend Health;2023; 24 (4) 361. doi:10.1080/26895269.2023.2257062</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10601500</infon><infon key="type">title</infon><infon key="authors">Stolk THR, van den Boogaard E, Huirne JAF, van Mello NM, </infon><offset>0</offset><text>Fertility counseling guide for transgender and gender diverse people.</text></passage><passage><infon key="type">abstract</infon><offset>70</offset></passage></document>
<document><id>37902115</id><passage><infon key="journal">Mol Ecol;2023Oct30. doi:10.1111/mec.17184</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang Y, Wang J, He Y, Qu M, Zhu W, Xue Y, Li J, </infon><offset>0</offset><text>Interkingdom ecological networks between plants and fungi drive soil multifunctionality across arid inland river basin.</text></passage><passage><infon key="type">abstract</infon><offset>120</offset><text>Despite the known collective contribution of above- (plants) and below-ground (soil fungi) biodiversity on multiple soil functions, how the associations among plant and fungal communities regulate soil multifunctionality (SMF) differentially remains unknown. Here, plant communities were investigated at 81 plots across a typical arid inland river basin, within which associated soil fungal communities and seven soil functions (nutrients storage and biological activity) were measured in surface (0-15 cm) and subsurface soil (15-30 cm). We evaluated the relative importance of species richness and biotic associations (reflected by network complexity) on SMF. Our results demonstrated that plant species richness and plant-fungus network complexity promoted SMF in surface and subsurface soil. SMF in two soil layers was mainly determined by plant-fungus network complexity, mean groundwater depth and soil variables, among which plant-fungus network complexity played a crucial role. Plant-fungus network complexity had stronger effects on SMF in surface soil than in subsurface soil. We present evidence that plant-fungus network complexity surpassed plant-fungal species richness in determining SMF in surface and subsurface soil. Moreover, plant-fungal species richness could not directly affect SMF. Greater plant-fungal species richness indirectly promoted SMF since they ensured greater plant-fungal associations. Collectively, we concluded that interkingdom networks between plants and fungi drive SMF even in different soil layers. Our findings enhanced our knowledge of the underlying mechanisms that above- and below-ground associations promote SMF in arid inland river basins. Future study should place more emphasis on the associations among plant and microbial communities in protecting soil functions under global changes.</text></passage></document>
<document><id>37902465</id><passage><infon key="journal">J Interpers Violence;2023Oct30 8862605231207624. doi:10.1177/08862605231207624</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li Y, Rhee H, Bullock LFC, McCaw B, Bloom T, </infon><offset>0</offset><text>Self-Compassion, Health, and Empowerment: A Pilot Randomized Controlled Trial for Chinese Immigrant Women Experiencing Intimate Partner Violence.</text><annotation id="1"><infon key="identifier">MESH:C563733</infon><infon key="type">Disease</infon><location offset="119" length="25"/><text>Intimate Partner Violence</text></annotation></passage><passage><infon key="type">abstract</infon><offset>146</offset><text>Chinese immigrant survivors of men's violence experience both significant mental health impacts from abuse and barriers to formal services. Therefore, we examined the preliminary efficacy of an innovative mobile-based empowerment-based intervention (self-compassion, health, and empowerment; SHE) that specifically focuses on abused Chinese immigrant women in the US. This pilot study used a two-arm randomized controlled design with repeated measures. A convenience sample (N = 50) of Chinese immigrant women who experienced past year intimate partner violence (IPV) were recruited online and randomly assigned to the intervention or control group (25 per group). We assessed IPV exposure, safety behaviors, depressive symptoms, anxiety symptoms, post-traumatic stress disorder (PTSD) symptoms, and self-compassion at baseline, post-intervention, and 8-week follow-up. Of 95 eligible participants, 50 (52.6%) agreed to participate and completed baseline data collection; intervention completion rate was 64%. We found a significant group and time interaction for self-judgment (a self-compassion component), with a significant reduction seen in the intervention group compared to the control group. Despite no other significant group differences observed over time, the intervention group showed consistent trends toward improvements in most outcome measures, including specific types of IPV (i.e., negotiation, psychological aggression, and sexual coercion), depressive and PTSD symptoms, self-compassion, and certain components of self-compassion (i.e., isolation and over-identification) when compared to the control group. Our findings suggest that the SHE intervention shows promise in improving the mental health well-being of Chinese immigrant survivors. However, a fully powered randomized controlled trial is warranted to determine its efficacy. Our intervention has the potential to be translated in the Chinese immigrant populations with the necessary organizational support.</text><annotation id="17"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="220" length="13"/><text>mental health</text></annotation><annotation id="18"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="247" length="5"/><text>abuse</text></annotation><annotation id="19"><infon key="identifier">MESH:C563733</infon><infon key="type">Disease</infon><location offset="682" length="25"/><text>intimate partner violence</text></annotation><annotation id="20"><infon key="identifier">MESH:C563733</infon><infon key="type">Disease</infon><location offset="709" length="3"/><text>IPV</text></annotation><annotation id="21"><infon key="identifier">MESH:C563733</infon><infon key="type">Disease</infon><location offset="823" length="3"/><text>IPV</text></annotation><annotation id="22"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="855" length="19"/><text>depressive symptoms</text></annotation><annotation id="23"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="876" length="7"/><text>anxiety</text></annotation><annotation id="24"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="894" length="30"/><text>post-traumatic stress disorder</text></annotation><annotation id="25"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="926" length="4"/><text>PTSD</text></annotation><annotation id="26"><infon key="identifier">MESH:C563733</infon><infon key="type">Disease</infon><location offset="1535" length="3"/><text>IPV</text></annotation><annotation id="27"><infon key="identifier">MESH:D010554</infon><infon key="type">Disease</infon><location offset="1573" length="10"/><text>aggression</text></annotation><annotation id="28"><infon key="identifier">MESH:D050035</infon><infon key="type">Disease</infon><location offset="1589" length="15"/><text>sexual coercion</text></annotation><annotation id="29"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1607" length="10"/><text>depressive</text></annotation><annotation id="30"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="1622" length="4"/><text>PTSD</text></annotation><annotation id="31"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="1852" length="13"/><text>mental health</text></annotation></passage></document>
<document><id>37902815</id><passage><infon key="journal">J Med Internet Res;2023Oct30; 25 49400. doi:10.2196/49400</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Luo T, Zhou J, Yang J, Xie Y, Wei Y, Mai H, Lu D, Yang Y, Cui P, Ye L, Liang H, Huang J, </infon><offset>0</offset><text>Early Warning and Prediction of Scarlet Fever in China Using the Baidu Search Index and Autoregressive Integrated Moving Average With Explanatory Variable (ARIMAX) Model: Time Series Analysis.</text><annotation id="1"><infon key="identifier">MESH:D012541</infon><infon key="type">Disease</infon><location offset="32" length="13"/><text>Scarlet Fever</text></annotation></passage><passage><infon key="type">abstract</infon><offset>193</offset><text>BACKGROUND: Internet-derived data and the autoregressive integrated moving average (ARIMA) and ARIMA with explanatory variable (ARIMAX) models are extensively used for infectious disease surveillance. However, the effectiveness of the Baidu search index (BSI) in predicting the incidence of scarlet fever remains uncertain. OBJECTIVE: Our objective was to investigate whether a low-cost BSI monitoring system could potentially function as a valuable complement to traditional scarlet fever surveillance in China. METHODS: ARIMA and ARIMAX models were developed to predict the incidence of scarlet fever in China using data from the National Health Commission of the People's Republic of China between January 2011 and August 2022. The procedures included establishing a keyword database, keyword selection and filtering through Spearman rank correlation and cross-correlation analyses, construction of the scarlet fever comprehensive search index (CSI), modeling with the training sets, predicting with the testing sets, and comparing the prediction performances. RESULTS: The average monthly incidence of scarlet fever was 4462.17 (SD 3011.75) cases, and annual incidence exhibited an upward trend until 2019. The keyword database contained 52 keywords, but only 6 highly relevant ones were selected for modeling. A high Spearman rank correlation was observed between the scarlet fever reported cases and the scarlet fever CSI (rs=0.881). We developed the ARIMA(4,0,0)(0,1,2)(12) model, and the ARIMA(4,0,0)(0,1,2)(12) + CSI (Lag=0) and ARIMAX(1,0,2)(2,0,0)(12) models were combined with the BSI. The 3 models had a good fit and passed the residuals Ljung-Box test. The ARIMA(4,0,0)(0,1,2)(12), ARIMA(4,0,0)(0,1,2)(12) + CSI (Lag=0), and ARIMAX(1,0,2)(2,0,0)(12) models demonstrated favorable predictive capabilities, with mean absolute errors of 1692.16 (95% CI 584.88-2799.44), 1067.89 (95% CI 402.02-1733.76), and 639.75 (95% CI 188.12-1091.38), respectively; root mean squared errors of 2036.92 (95% CI 929.64-3144.20), 1224.92 (95% CI 559.04-1890.79), and 830.80 (95% CI 379.17-1282.43), respectively; and mean absolute percentage errors of 4.33% (95% CI 0.54%-8.13%), 3.36% (95% CI -0.24% to 6.96%), and 2.16% (95% CI -0.69% to 5.00%), respectively. The ARIMAX models outperformed the ARIMA models and had better prediction performances with smaller values. CONCLUSIONS: This study demonstrated that the BSI can be used for the early warning and prediction of scarlet fever, serving as a valuable supplement to traditional surveillance systems.</text><annotation id="11"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="361" length="18"/><text>infectious disease</text></annotation><annotation id="12"><infon key="identifier">MESH:D012541</infon><infon key="type">Disease</infon><location offset="484" length="13"/><text>scarlet fever</text></annotation><annotation id="13"><infon key="identifier">MESH:D012541</infon><infon key="type">Disease</infon><location offset="669" length="13"/><text>scarlet fever</text></annotation><annotation id="14"><infon key="identifier">MESH:D012541</infon><infon key="type">Disease</infon><location offset="782" length="13"/><text>scarlet fever</text></annotation><annotation id="15"><infon key="identifier">MESH:D012541</infon><infon key="type">Disease</infon><location offset="1099" length="13"/><text>scarlet fever</text></annotation><annotation id="16"><infon key="identifier">MESH:D012541</infon><infon key="type">Disease</infon><location offset="1299" length="13"/><text>scarlet fever</text></annotation><annotation id="17"><infon key="identifier">MESH:D012541</infon><infon key="type">Disease</infon><location offset="1566" length="13"/><text>scarlet fever</text></annotation><annotation id="18"><infon key="identifier">MESH:D012541</infon><infon key="type">Disease</infon><location offset="1603" length="13"/><text>scarlet fever</text></annotation><annotation id="19"><infon key="identifier">MESH:D012541</infon><infon key="type">Disease</infon><location offset="2660" length="13"/><text>scarlet fever</text></annotation></passage></document>
<document><id>37903168</id><passage><infon key="journal">Mil Psychol;2023Nov-Dec; 35 (6) 529. doi:10.1080/08995605.2022.2131189</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10617378</infon><infon key="type">title</infon><infon key="authors">Danahy MP, Paxton Willing MM, Tate LL, Shuping E, Riggs DS, </infon><offset>0</offset><text>Associations between psychological and respiratory distress in post-deployment Veterans.</text><annotation id="2"><infon key="identifier">MESH:D000067073</infon><infon key="type">Disease</infon><location offset="21" length="13"/><text>psychological</text></annotation><annotation id="3"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="39" length="20"/><text>respiratory distress</text></annotation></passage><passage><infon key="type">abstract</infon><offset>89</offset><text>Since September 11, 2001, over 2.7 million United States service members have deployed to South-West Asia and the Middle East and have been exposed to environmental hazards and psychological trauma. Many of these service members have returned with medical and psychological illnesses, some of which have proved complex and resistant to treatment. One notable constellation of symptoms is post-deployment respiratory illness, which has become a focus of research and policy efforts. The present study sought to examine the impact of post-deployment psychological distress on respiratory symptom severity. Data were obtained from the Veterans Affairs Airborne Hazards and Open Burn Pit Registry (AHOBPR) health surveillance database (N =107,403). Psychological factors were compared against common organic and environmental predictors of post-deployment respiratory distress. Psychological distress following deployment was a stronger predictor of 12-month shortness of breath severity than general respiratory pathology or level of exposure to environmental hazards, controlling for gender, age, race, and tobacco use. Additionally, psychological distress was a better predictor of shortness of breath severity than documented respiratory illnesses including asthma, chronic obstructive pulmonary disease, and chronic bronchitis. Implications and directions for future research are discussed, as well as potential alterations to existing treatment and health surveillance paradigms.</text><annotation id="21"><infon key="identifier">MESH:D000067073</infon><infon key="type">Disease</infon><location offset="266" length="20"/><text>psychological trauma</text></annotation><annotation id="22"><infon key="identifier">MESH:D000067073</infon><infon key="type">Disease</infon><location offset="349" length="23"/><text>psychological illnesses</text></annotation><annotation id="23"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="493" length="19"/><text>respiratory illness</text></annotation><annotation id="24"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="637" length="22"/><text>psychological distress</text></annotation><annotation id="25"><infon key="identifier">MESH:D012818</infon><infon key="type">Disease</infon><location offset="663" length="19"/><text>respiratory symptom</text></annotation><annotation id="26"><infon key="identifier">MESH:D002056</infon><infon key="type">Disease</infon><location offset="764" length="4"/><text>Burn</text></annotation><annotation id="27"><infon key="identifier">MESH:D000067073</infon><infon key="type">Disease</infon><location offset="834" length="13"/><text>Psychological</text></annotation><annotation id="28"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="941" length="20"/><text>respiratory distress</text></annotation><annotation id="29"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="963" length="22"/><text>Psychological distress</text></annotation><annotation id="30"><infon key="identifier">MESH:D004417</infon><infon key="type">Disease</infon><location offset="1044" length="19"/><text>shortness of breath</text></annotation><annotation id="31"><infon key="identifier">MESH:D012131</infon><infon key="type">Disease</infon><location offset="1086" length="21"/><text>respiratory pathology</text></annotation><annotation id="32"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1221" length="22"/><text>psychological distress</text></annotation><annotation id="33"><infon key="identifier">MESH:D004417</infon><infon key="type">Disease</infon><location offset="1270" length="19"/><text>shortness of breath</text></annotation><annotation id="34"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="1315" length="21"/><text>respiratory illnesses</text></annotation><annotation id="35"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="1347" length="6"/><text>asthma</text></annotation><annotation id="36"><infon key="identifier">MESH:D029424</infon><infon key="type">Disease</infon><location offset="1355" length="37"/><text>chronic obstructive pulmonary disease</text></annotation><annotation id="37"><infon key="identifier">MESH:D029481</infon><infon key="type">Disease</infon><location offset="1398" length="18"/><text>chronic bronchitis</text></annotation></passage></document>
<document><id>37903544</id><passage><infon key="type">title</infon><offset>0</offset><text>Combination cancer imaging and phototherapy mediated by membrane-wrapped nanoparticles.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="12" length="6"/><text>cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>88</offset><text>Cancer is a devastating health problem with inadequate treatment options. Many conventional treatments for solid-tumor cancers lack tumor specificity, which results in low efficacy and off-target damage to healthy tissues. Nanoparticle (NP)-mediated photothermal therapy (PTT) is a promising minimally invasive treatment for solid-tumor cancers that has entered clinical trials. Traditionally, NPs used for PTT are coated with passivating agents and/or targeting ligands, but alternative coatings are being explored to enhance tumor specific delivery. In particular, cell-derived membranes have emerged as promising coatings that improve the biointerfacing of photoactive NPs, which reduces their immune recognition, prolongs their systemic circulation and increases their tumor accumulation, allowing for more effective PTT. To maximize treatment success, membrane-wrapped nanoparticles (MWNPs) that enable dual tumor imaging and PTT are being explored. These multifunctional theranostic NPs can be used to enhance tumor detection and/or ensure a sufficient quantity of NPs that have arrived in the tumor prior to laser irradiation. This review summarizes the current state-of-the-art in engineering MWNPs for combination cancer imaging and PTT and discusses considerations for the path toward clinical translation.</text><annotation id="12"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="88" length="6"/><text>Cancer</text></annotation><annotation id="13"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="195" length="19"/><text>solid-tumor cancers</text></annotation><annotation id="14"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="220" length="5"/><text>tumor</text></annotation><annotation id="15"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="413" length="19"/><text>solid-tumor cancers</text></annotation><annotation id="16"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="615" length="5"/><text>tumor</text></annotation><annotation id="17"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="861" length="5"/><text>tumor</text></annotation><annotation id="18"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1001" length="5"/><text>tumor</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1104" length="5"/><text>tumor</text></annotation><annotation id="20"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1188" length="5"/><text>tumor</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1311" length="6"/><text>cancer</text></annotation></passage></document>
<document><id>37903895</id><passage><infon key="type">title</infon><offset>0</offset><text>Co-carriage of Plasmid NDM and Chromosomal KPC in Klebsiella pneumoniae ST255 Human Wound Isolate in Brazil.</text></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>Multidrug-resistant K. pneumoniae is one of the main causes of hospital-acquired infections worldwide and frequently carries antimicrobial resistance genes in moving elements. In this study, we described a K. pneumoniae clinical isolate carrying simultaneous chromosomal blaKPC, and plasmid-mediated blaNDM and blaOXA-9. The isolate is multidrug-resistant and belongs to ST 225. While blaKPC were identified in the chromosome, the blaNDM was mediated by IncFII(K) plasmid and the blaOXA-9, in a IncFIB(K) plasmid. The blaKPC context was composed by Tn4401 transposon and two insertion sequences ISKpn6 and ISKpn7. The co-production of diverse ss-lactamases brings an alert about a new adaptive profile of K. pneumoniae strains and their dissemination in the hospital-acquired infectious.</text><annotation id="4"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="190" length="10"/><text>infections</text></annotation><annotation id="5"><infon key="identifier">15334410</infon><infon key="type">Gene</infon><location offset="420" length="8"/><text>blaOXA-9</text></annotation><annotation id="6"><infon key="type">Disease</infon><location offset="540" length="6"/><text>blaNDM</text></annotation><annotation id="7"><infon key="identifier">15334410</infon><infon key="type">Gene</infon><location offset="589" length="8"/><text>blaOXA-9</text></annotation></passage></document>
<document><id>37904595</id><passage><infon key="journal">J Exp Bot;2023Oct31. doi:10.1093/jxb/erad430</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang C, Liu H, Wang J, Li Y, Liu D, Ye Y, Huang R, Li S, Chen L, Chen J, Yao M, Ma C, </infon><offset>0</offset><text>A Key Mutation in Magnesium Chelatase I Subunit Leads to a Chlorophyll-deficient Mutant of Tea (Camellia sinensis).</text><annotation id="1"><infon key="identifier">MESH:D002734</infon><infon key="type">Chemical</infon><location offset="59" length="11"/><text>Chlorophyll</text></annotation></passage><passage><infon key="type">abstract</infon><offset>116</offset><text>Tea (Camellia sinensis) is an a highly important beverage crop renowned for its unique flavour and health benefits. Chlorotic mutants of tea, known worldwide for their umami taste and economic value, have gained global popularity. However, the genetic basis of this chlorosis trait remains unclear. In this study, we identified a major-effect quantitative trait locus (QTL), qChl-3, responsible for the chlorosis trait in tea leaves, linked to a nonsynonymous polymorphism (G1199A) in the magnesium-chelatase I subunit (CsCHLI). Homozygous CsCHLIA plants exhibited an albino phenotype due to defects in magnesium protoporphyrin IX and chlorophylls in leaves. Biochemical assays revealed that CsCHLI mutations did not affect subcellular localization or interactions with CsCHLIG and CsCHLD. However, combining CsCHLIA with CsCHLIG significantly reduced ATPase activity. RNA-seq analysis tentatively indicated that CsCHLI inhibited photosynthesis and enhanced photoinhibition that in turn promoted protein degradation and increased the amino acid levels in chlorotic leaves. RT-qPCR and enzyme activity assays confirmed the crucial role of asparagine synthetase and arginase in asparagine and arginine accumulation, with levels increasing over 90-fold in chlorotic leaves. Therefore, this study provides insights into the genetic mechanism underlying tea chlorosis and the relationship between chlorophyll biosynthesis and amino acid metabolism.</text><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="232" length="9"/><text>Chlorotic</text></annotation><annotation id="15"><infon key="identifier">MESH:D000747</infon><infon key="type">Disease</infon><location offset="382" length="9"/><text>chlorosis</text></annotation><annotation id="16"><infon key="identifier">MESH:D000747</infon><infon key="type">Disease</infon><location offset="519" length="9"/><text>chlorosis</text></annotation><annotation id="17"><infon key="identifier">tmVar:c|SUB|G|1199|A;HGVS:c.1199G>A;VariantGroup:0</infon><infon key="type">DNAMutation</infon><location offset="590" length="6"/><text>G1199A</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="719" length="27"/><text>magnesium protoporphyrin IX</text></annotation><annotation id="19"><infon key="identifier">MESH:D002734</infon><infon key="type">Chemical</infon><location offset="751" length="12"/><text>chlorophylls</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1171" length="9"/><text>chlorotic</text></annotation><annotation id="21"><infon key="identifier">MESH:D001216</infon><infon key="type">Chemical</infon><location offset="1292" length="10"/><text>asparagine</text></annotation><annotation id="22"><infon key="identifier">MESH:D001120</infon><infon key="type">Chemical</infon><location offset="1307" length="8"/><text>arginine</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1369" length="9"/><text>chlorotic</text></annotation><annotation id="24"><infon key="identifier">MESH:D000747</infon><infon key="type">Disease</infon><location offset="1465" length="13"/><text>tea chlorosis</text></annotation><annotation id="25"><infon key="identifier">MESH:D002734</infon><infon key="type">Chemical</infon><location offset="1508" length="11"/><text>chlorophyll</text></annotation></passage><relation id="R1"><infon key="score">0.9525</infon><infon key="role1">DNAMutation|HGVS:c.1199G>A</infon><infon key="role2">Disease|MESH:D000747</infon><infon key="type">Association</infon><node refid="0" role="3,4"/></relation></document>
<document><id>37904945</id><passage><infon key="journal">bioRxiv;2023Oct17. doi:10.1101/2023.10.12.562113</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614795</infon><infon key="type">title</infon><infon key="authors">Robson ES, Ioannidis NM, </infon><offset>0</offset><text>GUANinE v0.9: Benchmark Datasets for Genomic AI Sequence-to-Function Models.</text></passage><passage><infon key="type">abstract</infon><offset>77</offset><text>Computational genomics increasingly relies on machine learning methods for genome interpretation, and the recent adoption of neural sequence-to-function models highlights the need for rigorous model specification and controlled evaluation, problems familiar to other fields of AI. Research strategies that have greatly benefited other fields - including benchmarking, auditing, and algorithmic fairness - are also needed to advance the field of genomic AI and to facilitate model development. Here we propose a genomic AI benchmark, GUANinE , for evaluating model generalization across a number of distinct genomic tasks. Compared to existing task formulations in computational genomics, GUANinE is large-scale, de-noised, and suitable for evaluating pretrained models. GUANinE v0.9 primarily focuses on functional genomics tasks such as functional element annotation and gene expression prediction, but also draws upon connections to evolutionary biology through sequence conservation tasks. The current GUANinE tasks provide insight into the performance of existing genomic AI models and non-neural baselines, with opportunities to be refined, revisited, and broadened as the field matures. Finally, the GUANinE benchmark allows us to evaluate new self-supervised T5 models and explore the tradeoffs between tokenization and model performance, while showcasing the potential for self-supervision to complement existing pretraining procedures.</text></passage></document>
<document><id>37905646</id><passage><infon key="journal">In Vivo;2023Nov-Dec; 37 (6) 2452. doi:10.21873/invivo.13351</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10621411</infon><infon key="type">title</infon><infon key="authors">Liao CH, Tsai CL, Chang SY, Lin YH, Wang YC, Huang WC, Mong MC, Yang YC, Wu WT, Chen JC, Tsai CW, Bau DT, Chang WS, </infon><offset>0</offset><text>Impacts of Matrix Metalloproteinase 9 Genotypes on Renal Cell Carcinoma.</text><annotation id="2"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="11" length="26"/><text>Matrix Metalloproteinase 9</text></annotation><annotation id="3"><infon key="identifier">MESH:D002292</infon><infon key="type">Disease</infon><location offset="51" length="20"/><text>Renal Cell Carcinoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>73</offset><text>BACKGROUND/AIM: The expression of matrix metalloproteinase 9 (MMP9) is elevated in various renal diseases, including renal cell carcinoma. However, the role of MMP9 genotype in this context remains unclear. This study aimed to investigate the association between MMP9 promoter rs3918242 genotypes and the risk of renal cell carcinoma. MATERIALS AND METHODS: The MMP9 rs3918242 genotypes of 118 patients with renal cell carcinoma and 590 healthy subjects were determined using the polymerase chain reaction-restriction fragment length polymorphism method. RESULTS: The results indicated that individuals carrying the CT or TT genotype of MMP9 rs3918242 did not exhibit an increased risk of renal cell carcinoma compared to wild-type CC carriers (odds ratio=1.20 and 2.68, 95% confidence interval=0.75-1.92 and 0.89-8.03; p=0.5270 and 0.1420, respectively). However, individuals with the CT and TT genotypes had a higher prevalence of renal cell carcinoma than those with the CC genotype when they also had hypertension (p=0.0010), diabetes (p=0.0010), or a family history of cancer (p&lt;0.00001). No correlation was observed between MMP9 rs3918242 genotypic distribution and age (60 years or younger vs. older than 60 years) or sex (both p>0.05). Additionally, no correlation was found between MMP9 rs3918242 genotype and the risk of renal cell carcinoma in individuals with smoking or alcohol consumption habits. CONCLUSION: Carrying the T allele for MMP9 rs3918242 may predict a higher risk of renal cell carcinoma among individuals diagnosed with hypertension, diabetes, or with a family history of cancer.</text><annotation id="34"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="107" length="26"/><text>matrix metalloproteinase 9</text></annotation><annotation id="35"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="135" length="4"/><text>MMP9</text></annotation><annotation id="36"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="164" length="14"/><text>renal diseases</text></annotation><annotation id="37"><infon key="identifier">MESH:D002292</infon><infon key="type">Disease</infon><location offset="190" length="20"/><text>renal cell carcinoma</text></annotation><annotation id="38"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="233" length="4"/><text>MMP9</text></annotation><annotation id="39"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="336" length="4"/><text>MMP9</text></annotation><annotation id="40"><infon key="identifier">tmVar:rs3918242;VariantGroup:0;CorrespondingGene:4318;RS#:3918242;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="350" length="9"/><text>rs3918242</text></annotation><annotation id="41"><infon key="identifier">MESH:D002292</infon><infon key="type">Disease</infon><location offset="386" length="20"/><text>renal cell carcinoma</text></annotation><annotation id="42"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="435" length="4"/><text>MMP9</text></annotation><annotation id="43"><infon key="identifier">tmVar:rs3918242;VariantGroup:0;CorrespondingGene:4318;RS#:3918242;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="440" length="9"/><text>rs3918242</text></annotation><annotation id="44"><infon key="identifier">MESH:D002292</infon><infon key="type">Disease</infon><location offset="481" length="20"/><text>renal cell carcinoma</text></annotation><annotation id="45"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="710" length="4"/><text>MMP9</text></annotation><annotation id="46"><infon key="identifier">tmVar:rs3918242;VariantGroup:0;CorrespondingGene:4318;RS#:3918242;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="715" length="9"/><text>rs3918242</text></annotation><annotation id="47"><infon key="identifier">MESH:D002292</infon><infon key="type">Disease</infon><location offset="762" length="20"/><text>renal cell carcinoma</text></annotation><annotation id="48"><infon key="identifier">MESH:D002292</infon><infon key="type">Disease</infon><location offset="1006" length="20"/><text>renal cell carcinoma</text></annotation><annotation id="49"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="1078" length="12"/><text>hypertension</text></annotation><annotation id="50"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1103" length="8"/><text>diabetes</text></annotation><annotation id="51"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1147" length="6"/><text>cancer</text></annotation><annotation id="52"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="1203" length="4"/><text>MMP9</text></annotation><annotation id="53"><infon key="identifier">tmVar:rs3918242;VariantGroup:0;CorrespondingGene:4318;RS#:3918242;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1208" length="9"/><text>rs3918242</text></annotation><annotation id="54"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="1364" length="4"/><text>MMP9</text></annotation><annotation id="55"><infon key="identifier">tmVar:rs3918242;VariantGroup:0;CorrespondingGene:4318;RS#:3918242;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1369" length="9"/><text>rs3918242</text></annotation><annotation id="56"><infon key="identifier">MESH:D002292</infon><infon key="type">Disease</infon><location offset="1404" length="20"/><text>renal cell carcinoma</text></annotation><annotation id="57"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1456" length="7"/><text>alcohol</text></annotation><annotation id="58"><infon key="identifier">4318</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3659</infon><location offset="1522" length="4"/><text>MMP9</text></annotation><annotation id="59"><infon key="identifier">tmVar:rs3918242;VariantGroup:0;CorrespondingGene:4318;RS#:3918242;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1527" length="9"/><text>rs3918242</text></annotation><annotation id="60"><infon key="identifier">MESH:D002292</infon><infon key="type">Disease</infon><location offset="1566" length="20"/><text>renal cell carcinoma</text></annotation><annotation id="61"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="1620" length="12"/><text>hypertension</text></annotation><annotation id="62"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1634" length="8"/><text>diabetes</text></annotation><annotation id="63"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1672" length="6"/><text>cancer</text></annotation></passage><relation id="R1"><infon key="score">0.9908</infon><infon key="role1">Disease|MESH:D003920</infon><infon key="role2">SNP|RS#:3918242;CorrespondingGene:4318</infon><infon key="type">Association</infon><node refid="0" role="30,27"/></relation><relation id="R2"><infon key="score">0.9886</infon><infon key="role1">Disease|MESH:D006973</infon><infon key="role2">SNP|RS#:3918242;CorrespondingGene:4318</infon><infon key="type">Association</infon><node refid="1" role="29,27"/></relation><relation id="R3"><infon key="score">0.9964</infon><infon key="role1">Disease|MESH:D002292</infon><infon key="role2">Gene|4318</infon><infon key="type">Association</infon><node refid="2" role="1,0"/></relation><relation id="R4"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D006973</infon><infon key="role2">Gene|4318</infon><infon key="type">Association</infon><node refid="3" role="29,26"/></relation><relation id="R5"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D003920</infon><infon key="role2">Gene|4318</infon><infon key="type">Association</infon><node refid="4" role="30,26"/></relation><relation id="R6"><infon key="score">0.9822</infon><infon key="role1">Disease|MESH:D007674</infon><infon key="role2">Gene|4318</infon><infon key="type">Association</infon><node refid="5" role="4,2"/></relation><relation id="R7"><infon key="score">0.9908</infon><infon key="role1">Disease|MESH:D003920</infon><infon key="role2">Gene|4318</infon><infon key="type">Association</infon></relation><relation id="R8"><infon key="score">0.9886</infon><infon key="role1">Disease|MESH:D006973</infon><infon key="role2">Gene|4318</infon><infon key="type">Association</infon></relation></document>
<document><id>37906348</id><passage><infon key="journal">Qual Life Res;2023Oct31. doi:10.1007/s11136-023-03525-8</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Alemu WG, Due C, Muir-Cochrane E, Mwanri L, Azale T, Ziersch A, </infon><offset>0</offset><text>Quality of life among people living with mental illness and predictors in Africa: a systematic review and meta-analysis.</text><annotation id="1"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="41" length="14"/><text>mental illness</text></annotation></passage><passage><infon key="type">abstract</infon><offset>121</offset><text>INTRODUCTION: Quality of life (QoL) of patients with mental illness has been examined internationally but to a lesser extent in developing countries, including countries in Africa. Improving QoL is vital to reducing disability among people with mental illness. Therefore, this systematic review and meta-analysis aimed to assess the prevalence of QoL and associated factors among people living with mental illness in Africa. METHODS: Using the PICOT approach, Scopus, MEDLINE, PsycINFO, CINAHL, Embase, the Web of Science, and Google Scholar were searched. A structured search was undertaken, comprising terms associated with mental health, mental illness, QoL, and a list of all African countries. The Joanna Briggs Institute Quality Appraisal Checklist is used to evaluate research quality. Subgroup analysis with Country, domains of QoL, and diagnosis was tested using a random-effect model, and bias was assessed using a funnel plot and an inspection of Egger's regression test. A p value, OR, and 95% CI were used to demonstrate an association. RESULTS: The pooled prevalence of poor QoL was 45.93% (36.04%, 55.83%), I2 = 98.6%, p &lt; 0.001). Subgroup analysis showed that Ethiopia (48.09%; 95% CI = 33.73, 62.44), Egypt (43.51%; 95% CI = 21.84, 65.18), and Nigeria (43.49%; 95% CI = 12.25, 74.74) had the highest mean poor QoL prevalence of the countries. The pooled prevalence of poor QoL by diagnosis was as follows: bipolar disorder (69.63%; 95% CI = 47.48, 91.77), Schizophrenia (48.53%; 95% CI = 29.97, 67.11), group of mental illnesses (40.32%; 95% CI = 23.98, 56.66), and depressive disorders (38.90%; 95% CI = 22.98, 54.81). Being illiterate (3.63; 95% CI = 2.35, 4.91), having a comorbid medical illness (4.7; 95% CI = 2.75, 6.66), having a low monthly income (3.62; 95% CI = 1.96, 5.27), having positive symptoms (0.32; 95% CI = 0.19, 0.55), and having negative symptoms (0.26; 95% CI = 0.16, 0.43) were predictors of QoL. Thus, some factors are significantly associated with pooled effect estimates of QoL. CONCLUSIONS: The current systematic review and meta-analysis showed that almost half of patients with mental illness had poor QoL. Being illiterate, having a comorbid medical condition, having a low monthly income, having positive symptoms, and having negative symptoms of mental illness were independent predictors of poor QoL. This systematic review and meta-analysis emphasize that poor QoL of people with mental illness in Africa needs attention to reduce its negative consequences.</text><annotation id="13"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="174" length="14"/><text>mental illness</text></annotation><annotation id="14"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="366" length="14"/><text>mental illness</text></annotation><annotation id="15"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="520" length="14"/><text>mental illness</text></annotation><annotation id="16"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="762" length="14"/><text>mental illness</text></annotation><annotation id="17"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="1544" length="16"/><text>bipolar disorder</text></annotation><annotation id="18"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="1594" length="13"/><text>Schizophrenia</text></annotation><annotation id="19"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1650" length="16"/><text>mental illnesses</text></annotation><annotation id="20"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1704" length="20"/><text>depressive disorders</text></annotation><annotation id="21"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="2245" length="14"/><text>mental illness</text></annotation><annotation id="22"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="2416" length="14"/><text>mental illness</text></annotation><annotation id="23"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="2552" length="14"/><text>mental illness</text></annotation></passage></document>
<document><id>37906722</id><passage><infon key="journal">JCO Clin Cancer Inform;2023Sep; 7 2300096. doi:10.1200/CCI.23.00096</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Narayan VM, Siolas D, Meadows ES, Turzhitsky V, Sillah A, Imai K, McMurry AJ, Li H, </infon><offset>0</offset><text>Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.</text><annotation id="2"><infon key="identifier">MESH:D009361</infon><infon key="type">Disease</infon><location offset="134" length="9"/><text>-Invasive</text></annotation><annotation id="3"><infon key="identifier">MESH:D001749</infon><infon key="type">Disease</infon><location offset="144" length="14"/><text>Bladder Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>160</offset><text>PURPOSE: Treatment of non-muscle-invasive bladder cancer (NMIBC) is guided by risk stratification using clinical and pathologic criteria. This study aimed to develop a natural language processing (NLP) model for identifying patients with high-risk NMIBC retrospectively from unstructured electronic medical records (EMRs) and to apply the model to describe patient and tumor characteristics. METHODS: We used three independent EMR-derived data sets including adult patients with a bladder cancer diagnosis in 2011-2020 for NLP model development and training (n = 140), validation (n = 697), and application for the retrospective cohort analysis (n = 4,402). Deep learning methods were used to train NLP recognition of medical chart terminology to identify seven high-risk NMIBC criteria; model performance was assessed using the F1 score, weighted across features. An algorithm was then used to classify each patient as high-risk NMIBC (yes/no). Manually reviewed records served as the gold standard. RESULTS: The F1 scores after model training were >0.7 for all but one uncommon feature (prostatic urethral involvement). The highest area under the receiver operating curves (AUC) was observed for Ta (0.897) and T1 (0.897); the lowest AUC was for carcinoma in situ (CIS; 0.617). For high-risk NMIBC classification, positive predictive value was 79.4%, negative predictive value was 93.2%, and false-positive rate was 8.9%. Sensitivity and specificity were 83.7% and 91.1%, respectively. Of 748 patients manually confirmed as having high-risk NMIBC, 196 (26%) had CIS (of whom 19% also had T1 and 23% also had Ta disease); 552 tumors (74%) had no associated CIS. CONCLUSION: The NLP model, combined with a rule-based algorithm, identified high-risk NMIBC with good performance and will enable future work to study real-world treatment patterns and clinical outcomes for high-risk NMIBC.</text><annotation id="24"><infon key="identifier">MESH:D001749</infon><infon key="type">Disease</infon><location offset="202" length="14"/><text>bladder cancer</text></annotation><annotation id="25"><infon key="identifier">MESH:D000093284</infon><infon key="type">Disease</infon><location offset="218" length="5"/><text>NMIBC</text></annotation><annotation id="26"><infon key="identifier">MESH:D000093284</infon><infon key="type">Disease</infon><location offset="408" length="5"/><text>NMIBC</text></annotation><annotation id="27"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="529" length="5"/><text>tumor</text></annotation><annotation id="28"><infon key="identifier">MESH:D001749</infon><infon key="type">Disease</infon><location offset="641" length="14"/><text>bladder cancer</text></annotation><annotation id="29"><infon key="identifier">MESH:D000093284</infon><infon key="type">Disease</infon><location offset="932" length="5"/><text>NMIBC</text></annotation><annotation id="30"><infon key="identifier">MESH:D000093284</infon><infon key="type">Disease</infon><location offset="1090" length="5"/><text>NMIBC</text></annotation><annotation id="31"><infon key="identifier">MESH:D011472</infon><infon key="type">Disease</infon><location offset="1249" length="30"/><text>prostatic urethral involvement</text></annotation><annotation id="32"><infon key="identifier">MESH:C538397</infon><infon key="type">Disease</infon><location offset="1373" length="2"/><text>T1</text></annotation><annotation id="33"><infon key="identifier">MESH:D002278</infon><infon key="type">Disease</infon><location offset="1408" length="17"/><text>carcinoma in situ</text></annotation><annotation id="34"><infon key="identifier">MESH:D002278</infon><infon key="type">Disease</infon><location offset="1427" length="3"/><text>CIS</text></annotation><annotation id="35"><infon key="identifier">MESH:D000093284</infon><infon key="type">Disease</infon><location offset="1454" length="5"/><text>NMIBC</text></annotation><annotation id="36"><infon key="identifier">MESH:D000093284</infon><infon key="type">Disease</infon><location offset="1703" length="5"/><text>NMIBC</text></annotation><annotation id="37"><infon key="identifier">MESH:D002278</infon><infon key="type">Disease</infon><location offset="1724" length="3"/><text>CIS</text></annotation><annotation id="38"><infon key="identifier">MESH:C538397</infon><infon key="type">Disease</infon><location offset="1750" length="2"/><text>T1</text></annotation><annotation id="39"><infon key="identifier">MESH:D004194</infon><infon key="type">Disease</infon><location offset="1770" length="10"/><text>Ta disease</text></annotation><annotation id="40"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1787" length="6"/><text>tumors</text></annotation><annotation id="41"><infon key="identifier">MESH:D002278</infon><infon key="type">Disease</infon><location offset="1818" length="3"/><text>CIS</text></annotation><annotation id="42"><infon key="identifier">MESH:D000093284</infon><infon key="type">Disease</infon><location offset="1909" length="5"/><text>NMIBC</text></annotation><annotation id="43"><infon key="identifier">MESH:D000093284</infon><infon key="type">Disease</infon><location offset="2040" length="5"/><text>NMIBC</text></annotation></passage></document>
<document><id>37907088</id><passage><infon key="journal">Org Lett;2023Oct31. doi:10.1021/acs.orglett.3c03459</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Dong Y, Ji P, Zhang Y, Wang C, Meng X, Wang W, </infon><offset>0</offset><text>Correction to "Organophotoredox-Catalyzed Formation of Alkyl-Aryl and -Alkyl C-S/Se Bonds from Coupling of Redox-Active Esters with Thio/Selenosulfonates".</text><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="61" length="8"/><text>Aryl and</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="71" length="9"/><text>Alkyl C-S</text></annotation><annotation id="6"><infon key="identifier">MESH:D012643</infon><infon key="type">Chemical</infon><location offset="81" length="2"/><text>Se</text></annotation><annotation id="7"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="132" length="21"/><text>Thio/Selenosulfonates</text></annotation></passage><passage><infon key="type">abstract</infon><offset>156</offset></passage></document>
<document><id>37907438</id><passage><infon key="journal">Cleve Clin J Med;2022Sep01; 89 (9) 485. doi:10.3949/ccjm.89a.21099</infon><infon key="year">2022</infon><infon key="type">title</infon><infon key="authors">Poetzscher IK, Klebanov N, Das S, </infon><offset>0</offset><text>Widespread skin-thickening and hyperpigmentation.</text><annotation id="2"><infon key="identifier">MESH:D013585</infon><infon key="type">Disease</infon><location offset="11" length="15"/><text>skin-thickening</text></annotation><annotation id="3"><infon key="identifier">MESH:D017495</infon><infon key="type">Disease</infon><location offset="31" length="17"/><text>hyperpigmentation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>50</offset></passage></document>
<document><id>37907788</id><passage><infon key="journal">Nature;2023Oct31. doi:10.1038/d41586-023-03343-5</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">You X, </infon><offset>0</offset><text>Blood-sucking fish had flesh-eating ancestors.</text></passage><passage><infon key="type">abstract</infon><offset>47</offset></passage></document>
<document><id>37908138</id><passage><infon key="journal">Child Dev;2023Oct31. doi:10.1111/cdev.14025</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chen S, Benner A, Kim SY, </infon><offset>0</offset><text>Peer-based discrimination and adolescent emotional and sleep health: A daily examination of direct and buffering associations.</text><annotation id="4"><infon key="identifier">MESH:D010468</infon><infon key="type">Disease</infon><location offset="11" length="14"/><text>discrimination</text></annotation><annotation id="5"><infon key="type">Disease</infon><location offset="26" length="3"/><text>and</text></annotation><annotation id="6"><infon key="type">Disease</infon><location offset="51" length="3"/><text>and</text></annotation><annotation id="7"><infon key="type">Disease</infon><location offset="99" length="3"/><text>and</text></annotation></passage><passage><infon key="type">abstract</infon><offset>127</offset><text>Using 10-day daily diary data collected in 2019 from 10th grade students in southern U.S. (N = 161, 57% Latina/x/o, 21% Biracial, 10% Asian, 9% White, 4% Black; 55% female, Mage  = 15.51), this study examined various forms of peer-based discrimination in adolescents' everyday lives. Results showed that personally experienced discrimination, peer racial teasing, and vicarious discrimination were frequent and impactful events. Results also provided strong evidence for the protective role of psychological resilience and some evidence for the protective-reactive roles of peer support and school climate in moderating the link between peer-based discrimination and daily well-being. The findings highlight the necessity to eliminate peer-based discrimination and shed light on interventions to reduce the harmful effects of peer-based discrimination on adolescents' daily well-being.</text><annotation id="20"><infon key="identifier">MESH:D010468</infon><infon key="type">Disease</infon><location offset="364" length="14"/><text>discrimination</text></annotation><annotation id="21"><infon key="identifier">MESH:D010468</infon><infon key="type">Disease</infon><location offset="454" length="14"/><text>discrimination</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="491" length="3"/><text>and</text></annotation><annotation id="23"><infon key="identifier">MESH:D010468</infon><infon key="type">Disease</infon><location offset="505" length="14"/><text>discrimination</text></annotation><annotation id="24"><infon key="type">Disease</infon><location offset="534" length="3"/><text>and</text></annotation><annotation id="25"><infon key="type">Disease</infon><location offset="646" length="3"/><text>and</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="714" length="3"/><text>and</text></annotation><annotation id="27"><infon key="identifier">MESH:D010468</infon><infon key="type">Disease</infon><location offset="775" length="14"/><text>discrimination</text></annotation><annotation id="28"><infon key="type">Disease</infon><location offset="790" length="3"/><text>and</text></annotation><annotation id="29"><infon key="identifier">MESH:D010468</infon><infon key="type">Disease</infon><location offset="873" length="14"/><text>discrimination</text></annotation><annotation id="30"><infon key="type">Disease</infon><location offset="888" length="3"/><text>and</text></annotation><annotation id="31"><infon key="identifier">MESH:D010468</infon><infon key="type">Disease</infon><location offset="964" length="14"/><text>discrimination</text></annotation></passage></document>
<document><id>37909190</id><passage><infon key="journal">Eurasian J Med;2023Oct; 55 (3) 199. doi:10.5152/eurasianjmed.2023.22283</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Abu&amp;#x15f;o&amp;#x11f;lu G, Durmu&amp;#x15f; M&amp;#x130;, Karakurt S, </infon><offset>0</offset><text>7,8-Dihydroxy Flavone Induces Apoptosis via Upregulation of Caspase-3 in Human Hepatocarcinoma Cell.</text><annotation id="3"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="0" length="21"/><text>7,8-Dihydroxy Flavone</text></annotation><annotation id="4"><infon key="identifier">836</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37912</infon><location offset="60" length="9"/><text>Caspase-3</text></annotation><annotation id="5"><infon key="type">Disease</infon><location offset="79" length="15"/><text>Hepatocarcinoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>101</offset><text>OBJECTIVE: 7,8-Dihydroxyflavone, a tyrosine kinase receptor agonist, is a flavonoid that has recently gained the attention of researchers due to its anticancer properties. Nevertheless, molecular pathways of 7,8-dihydroxyflavone for hepatocarcinoma are uncertain. Our aim was to identify the impact of 7,8-dihydroxyflavone on human hepatocarcinoma. MATERIAL AND METHODS: Human hepatocarcinoma cell line-7 cells were used as human hepatocarcinoma cells, and 7,8-dihydroxyflavone was applied to the cells at various doses. The cytotoxic and apoptotic effects of 7,8-dihydroxyflavone were determined with Alamar Blue and flow cytometry. The properties of 7,8-dihydroxyflavone on the mRNA expressions related with Bcl-2, Bax, cleaved-caspase-3 genes, and protein expressions were determined via quantitative real-time polymerase chain reaction and western blot analysis, respectively. RESULTS: 7,8-Dihydroxyflavone-enhanced cell death in human hepatocarcinoma cell line-7 via the overexpression of cleaved-caspase-3 (P=.003) and decreased Bcl-2 (P=.038) protein levels. Furthermore, cleavedcaspase-3 mRNA overexpression (P=.001) markedly led to 7,8-dihydroxyflavone-induced apoptosis. CONCLUSION: 7,8-Dihydroxyflavone could promote apoptotic cell death by modulating caspase pathways and suppressing antiapoptotic protein. These characteristics may mediate to clinical practice of 7,8-dihydroxyflavone for prevention and therapy of hepatocarcinoma.</text><annotation id="29"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="112" length="20"/><text>7,8-Dihydroxyflavone</text></annotation><annotation id="30"><infon key="identifier">MESH:D005419</infon><infon key="type">Chemical</infon><location offset="175" length="9"/><text>flavonoid</text></annotation><annotation id="31"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="309" length="20"/><text>7,8-dihydroxyflavone</text></annotation><annotation id="32"><infon key="type">Disease</infon><location offset="334" length="15"/><text>hepatocarcinoma</text></annotation><annotation id="33"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="403" length="20"/><text>7,8-dihydroxyflavone</text></annotation><annotation id="34"><infon key="type">Disease</infon><location offset="433" length="15"/><text>hepatocarcinoma</text></annotation><annotation id="35"><infon key="identifier">MESH:C537955</infon><infon key="type">Disease</infon><location offset="478" length="27"/><text>hepatocarcinoma cell line-7</text></annotation><annotation id="36"><infon key="type">Disease</infon><location offset="531" length="15"/><text>hepatocarcinoma</text></annotation><annotation id="37"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="558" length="20"/><text>7,8-dihydroxyflavone</text></annotation><annotation id="38"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="661" length="20"/><text>7,8-dihydroxyflavone</text></annotation><annotation id="39"><infon key="identifier">MESH:C005843</infon><infon key="type">Chemical</infon><location offset="703" length="11"/><text>Alamar Blue</text></annotation><annotation id="40"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="753" length="20"/><text>7,8-dihydroxyflavone</text></annotation><annotation id="41"><infon key="identifier">596</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">527</infon><location offset="811" length="5"/><text>Bcl-2</text></annotation><annotation id="42"><infon key="identifier">581</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7242</infon><location offset="818" length="3"/><text>Bax</text></annotation><annotation id="43"><infon key="identifier">836</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37912</infon><location offset="831" length="9"/><text>caspase-3</text></annotation><annotation id="44"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="991" length="20"/><text>7,8-Dihydroxyflavone</text></annotation><annotation id="45"><infon key="identifier">MESH:C537955</infon><infon key="type">Disease</infon><location offset="1041" length="27"/><text>hepatocarcinoma cell line-7</text></annotation><annotation id="46"><infon key="identifier">836</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37912</infon><location offset="1103" length="9"/><text>caspase-3</text></annotation><annotation id="47"><infon key="identifier">596</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">527</infon><location offset="1136" length="5"/><text>Bcl-2</text></annotation><annotation id="48"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="1242" length="20"/><text>7,8-dihydroxyflavone</text></annotation><annotation id="49"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="1294" length="20"/><text>7,8-Dihydroxyflavone</text></annotation><annotation id="50"><infon key="identifier">MESH:C485383</infon><infon key="type">Chemical</infon><location offset="1478" length="20"/><text>7,8-dihydroxyflavone</text></annotation><annotation id="51"><infon key="type">Disease</infon><location offset="1529" length="15"/><text>hepatocarcinoma</text></annotation></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:C485383</infon><infon key="role2">Gene|596</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="14,15"/></relation><relation id="R2"><infon key="score">0.9224</infon><infon key="role1">Disease|MESH:C537955</infon><infon key="role2">Gene|596</infon><infon key="type">Association</infon><node refid="1" role="19,21"/></relation><relation id="R3"><infon key="score">0.4639</infon><infon key="role1">Chemical|MESH:C485383</infon><infon key="role2">Disease|MESH:C537955</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="11,9"/></relation><relation id="R4"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:C485383</infon><infon key="role2">Gene|836</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="0,1"/></relation><relation id="R5"><infon key="score">0.702</infon><infon key="role1">Disease|MESH:C537955</infon><infon key="role2">Gene|836</infon><infon key="type">Association</infon><node refid="4" role="19,20"/></relation></document>
<document><id>37909544</id><passage><infon key="journal">An Acad Bras Cienc;2023; 95 (3) 20220919. doi:10.1590/0001-3765202320220919</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nunes PIG, Viana AFSC, Sasahara GL, Santos SMD, Alves APNN, Silveira ER, Santos FA, </infon><offset>0</offset><text>N-Methyl-(2S,4R)-trans-4-hydroxy-L-proline isolated Sideroxylon obtusifolium attenuates TPA-induced irritant contact dermatitis in mice.</text><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="42"/><text>N-Methyl-(2S,4R)-trans-4-hydroxy-L-proline</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="52" length="24"/><text>Sideroxylon obtusifolium</text></annotation><annotation id="6"><infon key="identifier">MESH:D013755</infon><infon key="type">Chemical</infon><location offset="88" length="3"/><text>TPA</text></annotation><annotation id="7"><infon key="identifier">MESH:D003877</infon><infon key="type">Disease</infon><location offset="109" length="18"/><text>contact dermatitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>137</offset><text>Dermatitis is defined as a set of inflammatory diseases that affect the skin, with varied causes. Among the different types of dermatitis, contact dermatitis is the most prevalent. Although the current therapy is often effective, it is associated with adverse effects and the possibility of drug tolerance. N-Methyl-(2S, 4R)-trans-4-hydroxy-L-proline is a L-proline amino acid derivative found in the leaves of Sideroxylon obtusifolium, a species traditionally used to treat inflammatory diseases. The aim of this study was to investigate the topical anti-inflammatory effect of N-methyl-(2S, 4R)-trans-4-hydroxy-L-proline (NMP) in 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced irritant contact dermatitis in mice. Topically administered NMP, at doses of 0.03 - 0.50 mg/ear, reduced TPA-induced ear edema and neutrophil migration, as evidenced by low tissue myeloperoxidase activity and verified by histological examination. In addition, NMP (0.06 mg/ear) reduced tissue levels of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, INF-gamma and MCP-1) and of the anti-inflammatory cytokine IL-10, and reduced gene expression of TNF-alpha, IL-6 and IL-1beta increased by TPA. The data suggest that N-methyl-(2S, 4R)-trans-4-hydroxy-L-proline acts as a topical anti-inflammatory agent that decreases the expression of inflammatory cytokines, making it useful for the treatment of skin inflammation. Further investigations are necessary for its development as a therapeutic agent.</text><annotation id="41"><infon key="identifier">MESH:D003872</infon><infon key="type">Disease</infon><location offset="137" length="10"/><text>Dermatitis</text></annotation><annotation id="42"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="171" length="21"/><text>inflammatory diseases</text></annotation><annotation id="43"><infon key="identifier">MESH:D003872</infon><infon key="type">Disease</infon><location offset="264" length="10"/><text>dermatitis</text></annotation><annotation id="44"><infon key="identifier">MESH:D003877</infon><infon key="type">Disease</infon><location offset="276" length="18"/><text>contact dermatitis</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="444" length="43"/><text>N-Methyl-(2S, 4R)-trans-4-hydroxy-L-proline</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="493" length="20"/><text>L-proline amino acid</text></annotation><annotation id="47"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="612" length="21"/><text>inflammatory diseases</text></annotation><annotation id="48"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="693" length="12"/><text>inflammatory</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="716" length="43"/><text>N-methyl-(2S, 4R)-trans-4-hydroxy-L-proline</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="761" length="3"/><text>NMP</text></annotation><annotation id="51"><infon key="identifier">MESH:D013755</infon><infon key="type">Chemical</infon><location offset="769" length="36"/><text>12-O-tetradecanoylphorbol-13-acetate</text></annotation><annotation id="52"><infon key="identifier">MESH:D013755</infon><infon key="type">Chemical</infon><location offset="807" length="3"/><text>TPA</text></annotation><annotation id="53"><infon key="identifier">MESH:D003877</infon><infon key="type">Disease</infon><location offset="829" length="18"/><text>contact dermatitis</text></annotation><annotation id="54"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="880" length="3"/><text>NMP</text></annotation><annotation id="55"><infon key="identifier">MESH:D013755</infon><infon key="type">Chemical</infon><location offset="925" length="3"/><text>TPA</text></annotation><annotation id="56"><infon key="identifier">MESH:D004427</infon><infon key="type">Disease</infon><location offset="937" length="9"/><text>ear edema</text></annotation><annotation id="57"><infon key="identifier">17523</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55450</infon><location offset="1000" length="15"/><text>myeloperoxidase</text></annotation><annotation id="58"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1080" length="3"/><text>NMP</text></annotation><annotation id="59"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1127" length="12"/><text>inflammatory</text></annotation><annotation id="60"><infon key="identifier">21926</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="1151" length="9"/><text>TNF-alpha</text></annotation><annotation id="61"><infon key="identifier">16193</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1162" length="4"/><text>IL-6</text></annotation><annotation id="62"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1168" length="8"/><text>IL-1beta</text></annotation><annotation id="63"><infon key="identifier">17224</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">137209</infon><location offset="1192" length="5"/><text>MCP-1</text></annotation><annotation id="64"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1215" length="12"/><text>inflammatory</text></annotation><annotation id="65"><infon key="identifier">16153</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">478</infon><location offset="1237" length="5"/><text>IL-10</text></annotation><annotation id="66"><infon key="identifier">21926</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">496</infon><location offset="1275" length="9"/><text>TNF-alpha</text></annotation><annotation id="67"><infon key="identifier">16193</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1286" length="4"/><text>IL-6</text></annotation><annotation id="68"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1295" length="8"/><text>IL-1beta</text></annotation><annotation id="69"><infon key="identifier">MESH:D013755</infon><infon key="type">Chemical</infon><location offset="1317" length="3"/><text>TPA</text></annotation><annotation id="70"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1344" length="43"/><text>N-methyl-(2S, 4R)-trans-4-hydroxy-L-proline</text></annotation><annotation id="71"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1411" length="12"/><text>inflammatory</text></annotation><annotation id="72"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1463" length="12"/><text>inflammatory</text></annotation><annotation id="73"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1525" length="17"/><text>skin inflammation</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D013755</infon><infon key="role2">Gene|16193</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="32,24"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D013755</infon><infon key="role2">Disease|MESH:D004427</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="18,19"/></relation><relation id="R3"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D013755</infon><infon key="role2">Disease|MESH:D003877</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="2,3"/></relation><relation id="R4"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D013755</infon><infon key="role2">Gene|21926</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="32,23"/></relation><relation id="R5"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D013755</infon><infon key="role2">Gene|16176</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="32,25"/></relation><relation id="R6"><infon key="score">0.9874</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|17224</infon><infon key="type">Association</infon><node refid="5" role="22,26"/></relation></document>
<document><id>37909899</id><passage><infon key="journal">Chaos;2023Nov01; 33 (11) . doi:10.1063/5.0159982</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Dolmatova AV, Tyulkina IV, Goldobin DS, </infon><offset>0</offset><text>Circular cumulant reductions for macroscopic dynamics of oscillator populations with non-Gaussian noise.</text></passage><passage><infon key="type">abstract</infon><offset>105</offset><text>We employ the circular cumulant approach to construct a low dimensional description of the macroscopic dynamics of populations of phase oscillators (elements) subject to non-Gaussian white noise. Two-cumulant reduction equations for alpha-stable noises are derived. The implementation of the approach is demonstrated for the case of the Kuramoto ensemble with non-Gaussian noise. The results of direct numerical simulation of the ensemble of N=1500 oscillators and the "exact" numerical solution for the fractional Fokker-Planck equation in the Fourier space are found to be in good agreement with the analytical solutions for two feasible circular cumulant model reductions. We also illustrate that the two-cumulant model reduction is useful for studying the bifurcations of chimera states in hierarchical populations of coupled noisy phase oscillators.</text></passage></document>
<document><id>37910252</id><passage><infon key="journal">Odontology;2023Nov01. doi:10.1007/s10266-023-00865-2</infon><infon key="year">2023</infon><infon key="article-id_pmc">6206815</infon><infon key="type">title</infon><infon key="authors">Imai T, Kubota S, Nishimoto A, Katsura-Fuchihata S, Uzawa N, </infon><offset>0</offset><text>Risk factors for impacted lower third molar root perforation through the undercut-shaped lingual plate: preoperative insights from panoramic radiography.</text><annotation id="1"><infon key="identifier">MESH:D057112</infon><infon key="type">Disease</infon><location offset="49" length="11"/><text>perforation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>154</offset><text>This study aimed to identify risk factors associated with perforation of the undercut (U)-shaped lingual plate (LP) by the lower third molar (LM3) root using panoramic radiography (PAN). We retrospectively examined 468 impacted LM3s from 468 individuals, categorizing LM3-LP associations and LP morphology in the coronal section of cone-beam computed tomography as perforation or nonperforation and U-type or non-U-type, respectively. The outcome was the combination of perforation and U-type, and study variables included patient demographics (age and sex) and PAN-associated features (Winter's classification, Pell-Gregory classification, and two major Rood signs). Multivariate logistic regression methods were used for analysis. Perforated and U-type LPs were observed in 205 (43.8%) and 212 (45.3%) cases, respectively. The double-positive outcome was observed in 126 LM3s (26.9%). In the multivariate model, age >= 26 years [odds ratio (OR), 2.66; p = 0.002], men (OR, 2.01; p = 0.002), mesioangular (OR, 2.74; p = 0.038) and horizontal impaction (OR, 3.05; p = 0.019), and root darkening (OR, 1.73; p = 0.039) were independently associated with the risk. Class III impaction (OR, 0.35; p = 0.021) and interruption of the white line (OR, 0.55; p = 0.017) were negatively correlated with the risk. In conclusion, this study highlights the importance of identifying the higher probability of U-type LP perforation by the LM3 root in men aged over their midtwenties with Class I/II impaction and mesioangularly or horizontally impacted LM3s, along with root darkening and no interruption of the white line on PAN.</text><annotation id="12"><infon key="identifier">MESH:D057112</infon><infon key="type">Disease</infon><location offset="212" length="11"/><text>perforation</text></annotation><annotation id="13"><infon key="type">Disease</infon><location offset="382" length="4"/><text>LM3s</text></annotation><annotation id="14"><infon key="identifier">MESH:D057112</infon><infon key="type">Disease</infon><location offset="519" length="11"/><text>perforation</text></annotation><annotation id="15"><infon key="identifier">MESH:D057112</infon><infon key="type">Disease</infon><location offset="624" length="11"/><text>perforation</text></annotation><annotation id="16"><infon key="type">Disease</infon><location offset="809" length="4"/><text>Rood</text></annotation><annotation id="17"><infon key="identifier">MESH:D057112</infon><infon key="type">Disease</infon><location offset="887" length="10"/><text>Perforated</text></annotation><annotation id="18"><infon key="identifier">MESH:C563617</infon><infon key="type">Disease</infon><location offset="904" length="8"/><text>type LPs</text></annotation><annotation id="19"><infon key="type">Disease</infon><location offset="1027" length="4"/><text>LM3s</text></annotation><annotation id="20"><infon key="identifier">MESH:D000072042</infon><infon key="type">Disease</infon><location offset="1557" length="14"/><text>LP perforation</text></annotation><annotation id="21"><infon key="type">Disease</infon><location offset="1693" length="4"/><text>LM3s</text></annotation></passage></document>
<document><id>37910602</id><passage><infon key="journal">Sci Transl Med;2023Nov; 15 (720) 3049. doi:10.1126/scitranslmed.adg3049</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li J, Liu J, Zhou Z, Wu R, Chen X, Yu C, Stockwell B, Kroemer G, Kang R, Tang D, </infon><offset>0</offset><text>Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer.</text><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="0" length="5"/><text>Tumor</text></annotation><annotation id="4"><infon key="identifier">625249</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">134384</infon><location offset="15" length="4"/><text>GPX4</text></annotation><annotation id="5"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="108" length="17"/><text>pancreatic cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>127</offset><text>Lipid peroxidation-dependent ferroptosis has become an emerging strategy for tumor therapy. However, current strategies not only selectively induce ferroptosis in malignant cells but also trigger ferroptosis in immune cells simultaneously, which can compromise anti-tumor immunity. Here, we used In-Cell Western assays combined with an unbiased drug screening to identify the compound N6F11 as a ferroptosis inducer that triggered the degradation of glutathione peroxidase 4 (GPX4), a key ferroptosis repressor, specifically in cancer cells. N6F11 did not cause the degradation of GPX4 in immune cells, including dendritic, T, natural killer, and neutrophil cells. Mechanistically, N6F11 bound to the RING domain of E3 ubiquitin ligase tripartite motif containing 25 (TRIM25) in cancer cells to trigger TRIM25-mediated K48-linked ubiquitination of GPX4, resulting in its proteasomal degradation. Functionally, N6F11 treatment caused ferroptotic cancer cell death that initiated HMGB1-dependent antitumor immunity mediated by CD8+ T cells. N6F11 also sensitized immune checkpoint blockade that targeted CD274/PD-L1 in advanced cancer models, including genetically engineered mouse models of pancreatic cancer driven by KRAS and TP53 mutations. These findings may establish a safe and efficient strategy to boost ferroptosis-driven antitumor immunity.</text><annotation id="28"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="127" length="5"/><text>Lipid</text></annotation><annotation id="29"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="204" length="5"/><text>tumor</text></annotation><annotation id="30"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="393" length="5"/><text>tumor</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="512" length="5"/><text>N6F11</text></annotation><annotation id="32"><infon key="identifier">625249</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">134384</infon><location offset="577" length="24"/><text>glutathione peroxidase 4</text></annotation><annotation id="33"><infon key="identifier">625249</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">134384</infon><location offset="603" length="4"/><text>GPX4</text></annotation><annotation id="34"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="655" length="6"/><text>cancer</text></annotation><annotation id="35"><infon key="identifier">625249</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">134384</infon><location offset="708" length="4"/><text>GPX4</text></annotation><annotation id="36"><infon key="identifier">68350</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11576</infon><location offset="843" length="19"/><text>E3 ubiquitin ligase</text></annotation><annotation id="37"><infon key="identifier">217069</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48325</infon><location offset="863" length="30"/><text>tripartite motif containing 25</text></annotation><annotation id="38"><infon key="identifier">217069</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48325</infon><location offset="895" length="6"/><text>TRIM25</text></annotation><annotation id="39"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="906" length="6"/><text>cancer</text></annotation><annotation id="40"><infon key="identifier">217069</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48325</infon><location offset="930" length="6"/><text>TRIM25</text></annotation><annotation id="41"><infon key="identifier">625249</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">134384</infon><location offset="975" length="4"/><text>GPX4</text></annotation><annotation id="42"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1072" length="6"/><text>cancer</text></annotation><annotation id="43"><infon key="identifier">15289</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">135819</infon><location offset="1105" length="5"/><text>HMGB1</text></annotation><annotation id="44"><infon key="identifier">60533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1229" length="5"/><text>CD274</text></annotation><annotation id="45"><infon key="identifier">60533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="1235" length="5"/><text>PD-L1</text></annotation><annotation id="46"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1253" length="6"/><text>cancer</text></annotation><annotation id="47"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="1317" length="17"/><text>pancreatic cancer</text></annotation><annotation id="48"><infon key="identifier">16653</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37990</infon><location offset="1345" length="4"/><text>KRAS</text></annotation><annotation id="49"><infon key="identifier">22059</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">460</infon><location offset="1354" length="4"/><text>TP53</text></annotation></passage><relation id="R1"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|625249</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D008055</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Association</infon><node refid="1" role="3,4"/></relation><relation id="R3"><infon key="score">0.9987</infon><infon key="role1">Disease|MESH:D010190</infon><infon key="role2">Gene|16653</infon><infon key="type">Association</infon><node refid="2" role="22,23"/></relation><relation id="R4"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D010190</infon><infon key="role2">Gene|625249</infon><infon key="type">Association</infon><node refid="3" role="2,1"/></relation><relation id="R5"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|217069</infon><infon key="type">Association</infon><node refid="4" role="14,12"/></relation><relation id="R6"><infon key="score">0.9991</infon><infon key="role1">Disease|MESH:D010190</infon><infon key="role2">Gene|60533</infon><infon key="type">Association</infon><node refid="5" role="22,19"/></relation><relation id="R7"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D010190</infon><infon key="role2">Gene|22059</infon><infon key="type">Association</infon><node refid="6" role="22,24"/></relation><relation id="R8"><infon key="score">0.9954</infon><infon key="role1">Gene|217069</infon><infon key="role2">Gene|625249</infon><infon key="type">Association</infon><node refid="7" role="12,16"/></relation></document>
<document><id>37911304</id><passage><infon key="journal">Int Dent J (Phila);1891Oct; 12 (10) 739</infon><infon key="year">1891</infon><infon key="article-id_pmc">PMC10109953</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37913054</id><passage><infon key="journal">Int Dent J (Phila);1902Jul; 23 (7) 531</infon><infon key="year">1902</infon><infon key="article-id_pmc">PMC10156373</infon><infon key="type">title</infon><offset>0</offset><text>Dr. Benjamin Lord.</text></passage><passage><infon key="type">abstract</infon><offset>19</offset></passage></document>
<document><id>37913405</id><passage><infon key="journal">Int Dent J (Phila);1904May; 25 (5) 397</infon><infon key="year">1904</infon><infon key="article-id_pmc">PMC10168957</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37913755</id><passage><infon key="journal">Brain Behav Evol;2023Nov01. doi:10.1159/000534936</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Womack MC, Hoke KL, </infon><offset>0</offset><text>Convergent anuran middle ear loss lacks a universal, adaptive explanation.</text><annotation id="1"><infon key="identifier">MESH:D010033</infon><infon key="type">Disease</infon><location offset="18" length="15"/><text>middle ear loss</text></annotation></passage><passage><infon key="type">abstract</infon><offset>75</offset><text>Shared selection pressures often explain convergent trait loss, yet anurans (frogs and toads) have lost their middle ears at least 38 times with no obvious shared selection pressures unifying 'earless' taxa. Anuran tympanic middle ear loss is especially perplexing because acoustic communication is dominant within Anura and tympanic middle ears enhance airborne hearing in most tetrapods. Here we examine whether particular geographic ranges, microhabitats, activity patterns, or aspects of acoustic communication are associated with anuran tympanic middle ear loss. Although we find modest differences between the geographic ranges of eared and earless species and increased diurnality in earless species, we find no universal adaptive explanation for the many instances of anuran tympanic middle ear loss. The puzzling lack of shared selection pressures motivates discussion of alternative hypotheses, including genetic or developmental constraints, and the possibility that tympanic middle ear loss is maladaptive.</text><annotation id="6"><infon key="identifier">MESH:D010033</infon><infon key="type">Disease</infon><location offset="290" length="24"/><text>tympanic middle ear loss</text></annotation><annotation id="7"><infon key="identifier">MESH:D010033</infon><infon key="type">Disease</infon><location offset="617" length="24"/><text>tympanic middle ear loss</text></annotation><annotation id="8"><infon key="identifier">MESH:D010033</infon><infon key="type">Disease</infon><location offset="858" length="24"/><text>tympanic middle ear loss</text></annotation><annotation id="9"><infon key="identifier">MESH:D010033</infon><infon key="type">Disease</infon><location offset="1053" length="24"/><text>tympanic middle ear loss</text></annotation></passage></document>
<document><id>37914105</id><passage><infon key="journal">J Clin Epidemiol;2023Oct30. doi:10.1016/j.jclinepi.2023.10.017</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hirt J, Ewald H, Briel M, Schandelmaier S, </infon><offset>0</offset><text>Searching a methods topic: practical challenges and implications for search design.</text></passage><passage><infon key="type">abstract</infon><offset>84</offset><text>Performing a systematic search of a methods topic (e.g., "risk of bias", "subgroup analysis") in biomedical databases such as MEDLINE or Embase can be challenging. In this commentary, we address common search-related challenges, including inconsistent terminology for methods and suboptimal indexing. We suggest that reviewers addressing methods topics, compared to clinical topics, may start with specific, methods-oriented journals; invest extra time to scrutinize index terms and identify alternative terms; try citation search and machine learning assisted screening; and anticipate lower sensitivity and precision.</text></passage></document>
<document><id>37914455</id><passage><infon key="journal">J Med Vasc;2023Sep; 48 (3-4) 105. doi:10.1016/j.jdmv.2023.10.002</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lebreton O, Fels A, Compagnon A, Lazareth I, Ghaffari P, Chatellier G, Emmerich J, Michon-Pasturel U, Priollet P, Yannoutsos A, </infon><offset>0</offset><text>Amputation-free survival in the long-term follow-up and gender-related characteristics in patients revascularized for critical limb ischemia.</text><annotation id="1"><infon key="identifier">MESH:D000089802</infon><infon key="type">Disease</infon><location offset="118" length="22"/><text>critical limb ischemia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>142</offset><text>OBJECTIVE: Patients with Critical Limb Ischemia (CLI) present a high risk of cardiovascular events and death. Revascularization is the cornerstone of therapy to relieve ischemic pain and prevent limb loss. Literature data suggest that women tend to present with worse outcomes after revascularization. The aim of the present study is to determine amputation-free survival in a long-term follow-up in women and men following endovascular revascularization procedure for CLI. METHODS: From November 2013 to December 2020, 357 consecutive patients were retrospectively included. Clinical and biological parameters were recorded at baseline before endovascular revascularization. During follow-up until February 2023, overall survival and amputation-free survival (freedom from major amputation) were analysed using the Kaplan-Meier method. Univariate and multivariate analyses were performed to study the parameters associated with amputation-free survival. A P&lt;0.05 was considered as statistically significant. RESULTS: A total of 357 consecutive patients were included, 189 men and 168 women with CLI, with a mean age of 78.6+-12 years. Treated hypertension (79%), diabetes mellitus (48%), coronary artery disease (39%) and protein malnutrition (61%) were the most prevalent comorbidities. Women were older than men with a mean age of 82.4+-11.4 years (versus 75.4+-11 years in men) and presented more frequently with protein malnutrition (70% of women). Prevalence of diabetes, tobacco use and history of coronary heart disease were significantly higher in men. During the 10-year follow-up period, 241 patients had died (68%) and 38 (11%) underwent major amputation, of whom 22 patients were still alive on February 2023. Median survival was 35.5 months [IQR: 29.5; 43] in the overall population, 38.5 [32; 50.4] months in women and 33.5 months [24.7; 43.5] in men. No gender-related differences were noted according to peri-procedural complications, survival probability and amputation-free survival. In multivariate analysis for amputation-free survival, age, previous coronary heart disease, C-reactive protein level, left ventricular ejection fraction (LVEF)&lt;60% and albumin level&lt;35g/L were correlated with poor outcome. In particular, protein malnutrition, as a treatable risk factor, appears significantly correlated with poor outcome in both men and women (HR=2.50 [1.16;5.38], P=0.0196 in men; HR=1.77 [1.00;3.13], P=0.049 in women). CONCLUSION: The present results highlight that mortality in patients after endovascular revascularization remains high with a mortality rate of 28% at 1 year, 40% at 2 years and 51% at 3 years. Women represented a distinct population, almost 10-year older than their male counterparts, with more prevalent protein malnutrition. However, no gender-related difference was noted according to amputation-free survival on the long-term follow-up. Associated risk factors are mainly age, a history of coronary heart disease, pre-procedural inflammatory syndrome and protein malnutrition. Correction of malnutrition could have the potential to improve functional and general long-term prognosis in patients with CLI together with optimal medical and interventional management.</text><annotation id="27"><infon key="identifier">MESH:D000089802</infon><infon key="type">Disease</infon><location offset="167" length="22"/><text>Critical Limb Ischemia</text></annotation><annotation id="28"><infon key="identifier">MESH:D000089802</infon><infon key="type">Disease</infon><location offset="191" length="3"/><text>CLI</text></annotation><annotation id="29"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="245" length="5"/><text>death</text></annotation><annotation id="30"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="311" length="13"/><text>ischemic pain</text></annotation><annotation id="31"><infon key="identifier">MESH:D001259</infon><infon key="type">Disease</infon><location offset="337" length="9"/><text>limb loss</text></annotation><annotation id="32"><infon key="identifier">MESH:D000089802</infon><infon key="type">Disease</infon><location offset="611" length="3"/><text>CLI</text></annotation><annotation id="33"><infon key="identifier">MESH:D000089802</infon><infon key="type">Disease</infon><location offset="1238" length="3"/><text>CLI</text></annotation><annotation id="34"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="1286" length="12"/><text>hypertension</text></annotation><annotation id="35"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1306" length="17"/><text>diabetes mellitus</text></annotation><annotation id="36"><infon key="identifier">MESH:D003324</infon><infon key="type">Disease</infon><location offset="1331" length="23"/><text>coronary artery disease</text></annotation><annotation id="37"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="1365" length="20"/><text>protein malnutrition</text></annotation><annotation id="38"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="1559" length="20"/><text>protein malnutrition</text></annotation><annotation id="39"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1610" length="8"/><text>diabetes</text></annotation><annotation id="40"><infon key="identifier">MESH:D003327</infon><infon key="type">Disease</infon><location offset="1647" length="22"/><text>coronary heart disease</text></annotation><annotation id="41"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1758" length="4"/><text>died</text></annotation><annotation id="42"><infon key="identifier">MESH:D003327</infon><infon key="type">Disease</infon><location offset="2214" length="22"/><text>coronary heart disease</text></annotation><annotation id="43"><infon key="identifier">1401</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">128039</infon><location offset="2238" length="18"/><text>C-reactive protein</text></annotation><annotation id="44"><infon key="identifier">213</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">405</infon><location offset="2314" length="7"/><text>albumin</text></annotation><annotation id="45"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="2384" length="20"/><text>protein malnutrition</text></annotation><annotation id="46"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="2892" length="20"/><text>protein malnutrition</text></annotation><annotation id="47"><infon key="identifier">MESH:D003327</infon><infon key="type">Disease</infon><location offset="3081" length="22"/><text>coronary heart disease</text></annotation><annotation id="48"><infon key="identifier">MESH:D018746</infon><infon key="type">Disease</infon><location offset="3120" length="21"/><text>inflammatory syndrome</text></annotation><annotation id="49"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="3146" length="20"/><text>protein malnutrition</text></annotation><annotation id="50"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="3182" length="12"/><text>malnutrition</text></annotation><annotation id="51"><infon key="identifier">MESH:D000089802</infon><infon key="type">Disease</infon><location offset="3291" length="3"/><text>CLI</text></annotation></passage><relation id="R1"><infon key="score">0.5004</infon><infon key="role1">Disease|MESH:D000089802</infon><infon key="role2">Gene|1401</infon><infon key="type">Association</infon><node refid="0" role="25,17"/></relation></document>
<document><id>37915155</id><passage><infon key="journal">Acta Med Indones;2023Jul; 55 (3) 255</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sukmawan R, Akip HM, Wulandari P, Bobians ET, Koencoro BAS, Danny SS, Ambari AM, Raharjo SB, Widyantoro B, Adiarto S, </infon><offset>0</offset><text>Gender Differences of Gly972Arg Polymorphism of the IRS-1 Gene Related to Cardiovascular Disease Risk Factors Among Indonesians.</text><annotation id="3"><infon key="identifier">tmVar:p|SUB|G|972|R;HGVS:p.G972R;VariantGroup:0;CorrespondingGene:3667;RS#:1801278;CorrespondingSpecies:9606;CA#:128619</infon><infon key="type">ProteinMutation</infon><location offset="22" length="9"/><text>Gly972Arg</text></annotation><annotation id="4"><infon key="identifier">3667</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4049</infon><location offset="52" length="5"/><text>IRS-1</text></annotation><annotation id="5"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="74" length="22"/><text>Cardiovascular Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>BACKGROUND: Cardiovascular disease is driven by traditional risk factors, sex, and genetic differences. The Asian population, specifically Indonesians, has been known at high risk of insulin resistance and endothelial dysfunction. A possible genetic risk factor related to cardiovascular diseases is Gly972Arg polymorphism of insulin receptor substrate 1 (IRS-1) gene, as this impairs endothelial function. To date, whether there is a gender difference in Gly972Arg polymorphism of the IRS-1 gene in Indonesians is unknown. This study aimed to to define whether there is a gender difference in Gly972Arg polymorphism of the IRS-1 gene in Indonesians. METHODS: We studied adults living in two areas (rural and urban) in Indonesia. We collected demographic and clinical data from the study subjects. Gly972Arg polymorphism of the IRS-1 gene (rs1801278) was detected using TaqMan real-time polymerase chain reaction. RESULTS: A total of 378 subjects were recruited. The wild-type allele (CC) was found in 86 (22.8%) subjects, heterozygous mutant allele (CT) in 245 (64.8%), and homozygous mutant allele in 47 (12.4%). The proportion of subjects with T alleles was significantly higher among women than men (54.6% vs. 45.4%, odds ratio: 1.89; p = 0.01). Subjects with T allele more often have hypertension (odds ratio: 1.69, p = 0.058). CONCLUSION: There were a higher proportion of women than men carrying the T allele of Gly972Arg polymorphism among Indonesians. Individuals with the T allele appeared to show a greater prevalence of hypertension. These results may explain a possible mechanism of the high prevalence of metabolic syndrome in Indonesia, especially in women.</text><annotation id="24"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="141" length="22"/><text>Cardiovascular disease</text></annotation><annotation id="25"><infon key="identifier">MESH:D007333</infon><infon key="type">Disease</infon><location offset="312" length="18"/><text>insulin resistance</text></annotation><annotation id="26"><infon key="identifier">MESH:D014652</infon><infon key="type">Disease</infon><location offset="335" length="23"/><text>endothelial dysfunction</text></annotation><annotation id="27"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="402" length="23"/><text>cardiovascular diseases</text></annotation><annotation id="28"><infon key="identifier">tmVar:p|SUB|G|972|R;HGVS:p.G972R;VariantGroup:0;CorrespondingGene:3667;RS#:1801278;CorrespondingSpecies:9606;CA#:128619</infon><infon key="type">ProteinMutation</infon><location offset="429" length="9"/><text>Gly972Arg</text></annotation><annotation id="29"><infon key="identifier">3667</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4049</infon><location offset="455" length="28"/><text>insulin receptor substrate 1</text></annotation><annotation id="30"><infon key="identifier">3667</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4049</infon><location offset="485" length="5"/><text>IRS-1</text></annotation><annotation id="31"><infon key="identifier">tmVar:p|SUB|G|972|R;HGVS:p.G972R;VariantGroup:0;CorrespondingGene:3667;RS#:1801278;CorrespondingSpecies:9606;CA#:128619</infon><infon key="type">ProteinMutation</infon><location offset="585" length="9"/><text>Gly972Arg</text></annotation><annotation id="32"><infon key="identifier">3667</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4049</infon><location offset="615" length="5"/><text>IRS-1</text></annotation><annotation id="33"><infon key="identifier">tmVar:p|SUB|G|972|R;HGVS:p.G972R;VariantGroup:0;CorrespondingGene:3667;RS#:1801278;CorrespondingSpecies:9606;CA#:128619</infon><infon key="type">ProteinMutation</infon><location offset="723" length="9"/><text>Gly972Arg</text></annotation><annotation id="34"><infon key="identifier">3667</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4049</infon><location offset="753" length="5"/><text>IRS-1</text></annotation><annotation id="35"><infon key="identifier">tmVar:p|SUB|G|972|R;HGVS:p.G972R;VariantGroup:0;CorrespondingGene:3667;RS#:1801278;CorrespondingSpecies:9606;CA#:128619</infon><infon key="type">ProteinMutation</infon><location offset="927" length="9"/><text>Gly972Arg</text></annotation><annotation id="36"><infon key="identifier">3667</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4049</infon><location offset="957" length="5"/><text>IRS-1</text></annotation><annotation id="37"><infon key="identifier">tmVar:rs1801278;VariantGroup:0;CorrespondingGene:3667;RS#:1801278;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="969" length="9"/><text>rs1801278</text></annotation><annotation id="38"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="1418" length="12"/><text>hypertension</text></annotation><annotation id="39"><infon key="identifier">tmVar:p|SUB|G|972|R;HGVS:p.G972R;VariantGroup:0;CorrespondingGene:3667;RS#:1801278;CorrespondingSpecies:9606;CA#:128619</infon><infon key="type">ProteinMutation</infon><location offset="1548" length="9"/><text>Gly972Arg</text></annotation><annotation id="40"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="1661" length="12"/><text>hypertension</text></annotation><annotation id="41"><infon key="identifier">MESH:D024821</infon><infon key="type">Disease</infon><location offset="1748" length="18"/><text>metabolic syndrome</text></annotation></passage><relation id="R1"><infon key="score">0.975</infon><infon key="role1">Disease|MESH:D024821</infon><infon key="role2">ProteinMutation|RS#:1801278;HGVS:p.G972R;CorrespondingGene:3667</infon><infon key="type">Association</infon><node refid="0" role="20,18"/></relation><relation id="R2"><infon key="score">0.7058</infon><infon key="role1">Disease|MESH:D002318</infon><infon key="role2">ProteinMutation|RS#:1801278;HGVS:p.G972R;CorrespondingGene:3667</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="2,0"/></relation><relation id="R3"><infon key="score">0.517</infon><infon key="role1">Disease|MESH:D006973</infon><infon key="role2">ProteinMutation|RS#:1801278;HGVS:p.G972R;CorrespondingGene:3667</infon><infon key="type">Association</infon><node refid="2" role="17,18"/></relation><relation id="R4"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D002318</infon><infon key="role2">Gene|3667</infon><infon key="type">Association</infon><node refid="3" role="2,1"/></relation><relation id="R5"><infon key="score">0.6842</infon><infon key="role1">Disease|MESH:D024821</infon><infon key="role2">Gene|3667</infon><infon key="type">Association</infon><node refid="4" role="20,15"/></relation><relation id="R6"><infon key="score">0.999</infon><infon key="role1">Disease|MESH:D006973</infon><infon key="role2">Gene|3667</infon><infon key="type">Association</infon><node refid="5" role="17,15"/></relation><relation id="R7"><infon key="score">0.967</infon><infon key="role1">Disease|MESH:D002318</infon><infon key="role2">SNP|RS#:1801278;CorrespondingGene:3667</infon><infon key="type">Association</infon><node refid="6" role="6,16"/></relation><relation id="R8"><infon key="score">0.568</infon><infon key="role1">Disease|MESH:D006973</infon><infon key="role2">SNP|RS#:1801278;CorrespondingGene:3667</infon><infon key="type">Positive_Correlation</infon><node refid="7" role="17,16"/></relation><relation id="R9"><infon key="score">0.975</infon><infon key="role1">Disease|MESH:D024821</infon><infon key="role2">Gene|3667</infon><infon key="type">Association</infon></relation><relation id="R10"><infon key="score">0.7058</infon><infon key="role1">Disease|MESH:D002318</infon><infon key="role2">Gene|3667</infon><infon key="type">Association</infon></relation><relation id="R11"><infon key="score">0.517</infon><infon key="role1">Disease|MESH:D006973</infon><infon key="role2">Gene|3667</infon><infon key="type">Association</infon></relation></document>
<document><id>37916561</id><passage><infon key="journal">Khirurgiia (Mosk);2023 (10) 78. doi:10.17116/hirurgia202310178</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chkhikvadze VD, Chaptykova SY, Bolotina NA, </infon><offset>0</offset><text>[Features of surgical treatment of central tracheal and bronchial carcinoid].</text><annotation id="1"><infon key="identifier">MESH:D002276</infon><infon key="type">Disease</infon><location offset="43" length="32"/><text>tracheal and bronchial carcinoid</text></annotation></passage><passage><infon key="type">abstract</infon><offset>78</offset><text>OBJECTIVE: To analyze features of surgical treatment of central tracheal and bronchial carcinoid. MATERIAL AND METHODS: A retrospective analysis included 115 patients with carcinoid tracheal and bronchial tumors who have been examined and treated from 1974 to the present. The majority of patients (97, 84.3%) had central form of carcinoid of the trachea, bronchi and lungs. Of these, 95 (97.9%) ones underwent surgical treatment. RESULTS: We used pre- and intraoperative diagnostics including bronchotomy. This approach provided organ-sparing surgery with resection and reconstruction of the bronchi and trachea in 71 (74.7%) patients including complete preservation of lung function in 20 (21.1%) cases and lobectomy/segmentectomy with resection and reconstruction of the bronchi in 51 (53.7%) cases. Two patients underwent pneumonectomy with wedge-shaped and marginal resection and reconstruction of tracheal bifurcation. Postoperative complications developed in 4 (4.2%) patients, and 2 (2.1%) ones died. Overall 5-year survival after radical surgeries was 89.2% (100% in typical carcinoid and 78.0% in atypical carcinoid).</text><annotation id="9"><infon key="identifier">MESH:D002276</infon><infon key="type">Disease</infon><location offset="142" length="32"/><text>tracheal and bronchial carcinoid</text></annotation><annotation id="10"><infon key="identifier">MESH:D002276</infon><infon key="type">Disease</infon><location offset="250" length="39"/><text>carcinoid tracheal and bronchial tumors</text></annotation><annotation id="11"><infon key="identifier">MESH:D002276</infon><infon key="type">Disease</infon><location offset="408" length="9"/><text>carcinoid</text></annotation><annotation id="12"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="1003" length="27"/><text>Postoperative complications</text></annotation><annotation id="13"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1081" length="4"/><text>died</text></annotation><annotation id="14"><infon key="identifier">MESH:D002276</infon><infon key="type">Disease</infon><location offset="1162" length="9"/><text>carcinoid</text></annotation><annotation id="15"><infon key="identifier">MESH:D002276</infon><infon key="type">Disease</infon><location offset="1194" length="9"/><text>carcinoid</text></annotation></passage></document>
<document><id>37916915</id><passage><infon key="type">title</infon><offset>0</offset><text>A cascaded convolutional neural networks for stroke detection imaging.</text><annotation id="1"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="45" length="6"/><text>stroke</text></annotation></passage><passage><infon key="type">abstract</infon><offset>71</offset><text>In recent years, electrical impedance tomography has widely been used in stroke detection. To improve the prediction accuracy and anti-noise ability of the system, the inverse problem of electrical impedance tomography needs to be solved, for which cascade convolutional neural networks are used. The proposed network is divided into two parts so that the advantages can be compounded when parts of a network are cascaded together. To get high-resolution imaging, an optimized network based on encoding and decoding is designed in the first part. The second part is composed of a residual module, which is used to extract the characteristics of voltage information and ensure that no information is lost. The anti-noise performance of the network is better than other networks. In physical experiments, it is also proved that the algorithm can roughly restore the location of the object in the field.</text><annotation id="3"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="144" length="6"/><text>stroke</text></annotation></passage></document>
<document><id>37917265</id><passage><infon key="journal">Environ Sci Pollut Res Int;2023Nov02. doi:10.1007/s11356-023-30593-7</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sandil S, Z&amp;#xe1;ray G, Endr&amp;#xe9;di A, F&amp;#xfc;zy A, Tak&amp;#xe1;cs T, &amp;#xd3;v&amp;#xe1;ri M, Dobosy P, </infon><offset>0</offset><text>Arsenic uptake and accumulation in bean and lettuce plants at different developmental stages.</text><annotation id="1"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="0" length="7"/><text>Arsenic</text></annotation></passage><passage><infon key="type">abstract</infon><offset>94</offset><text>The pattern of arsenic (As) uptake at different developmental stages in plants and its consequent influence on the growth of plants was investigated in bean and lettuce. Further, the human health risk from the consumption of these As-laced vegetables was determined. The irrigation water was contaminated with As at concentrations of 0.1, 0.25, and 0.5 mg/L. The As concentration in the plant parts (root, stem, leaves, and flower/fruit) was determined in bean at the young, flowering, and fruiting stages and lettuce at the young and mature stages. At the different growth stages, As had an impact on the biomass of bean and lettuce plant parts, but none of the biomass changes were significant (p>0.05). The increase in As concentration of the irrigation water elevated the As concentration of plant parts of both plants at all growth stages, with the exception of the bean fruit. The As concentration in the developmental stages was in the order: lettuce (young>mature) and bean (fruiting>young>flowering). In lettuce, the transfer factor was higher at the young stage (0.09-0.19, in the control and 0.1 mg/L As treatment), while in bean, it was highest at the flowering stage (0.09-0.41, in all treatments). In the edible part, lettuce possessed substantially elevated As concentrations (0.30, 0.61, and 1.21 mg/kg DW) compared to bean (0.008, 0.005, and 0.022 mg/kg DW) at As treatments of 0.1, 0.25, and 0.5 mg/L, respectively, and posed significant health risks at all applied As concentrations.</text><annotation id="15"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="109" length="7"/><text>arsenic</text></annotation><annotation id="16"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="118" length="2"/><text>As</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="325" length="19"/><text>As-laced vegetables</text></annotation><annotation id="18"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="404" length="2"/><text>As</text></annotation><annotation id="19"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="457" length="2"/><text>As</text></annotation><annotation id="20"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="676" length="2"/><text>As</text></annotation><annotation id="21"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="816" length="2"/><text>As</text></annotation><annotation id="22"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="870" length="2"/><text>As</text></annotation><annotation id="23"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="981" length="2"/><text>As</text></annotation><annotation id="24"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1206" length="2"/><text>As</text></annotation><annotation id="25"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1367" length="2"/><text>As</text></annotation><annotation id="26"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1472" length="2"/><text>As</text></annotation><annotation id="27"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1578" length="2"/><text>As</text></annotation></passage></document>
<document><id>37917967</id><passage><infon key="type">title</infon><offset>0</offset><text>Synergistic Role of Water and Oxygen Leads to Degradation in Formamidinium-Based Halide Perovskites.</text><annotation id="4"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="20" length="5"/><text>Water</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30" length="12"/><text>Oxygen Leads</text></annotation><annotation id="6"><infon key="identifier">MESH:C077922</infon><infon key="type">Chemical</infon><location offset="61" length="13"/><text>Formamidinium</text></annotation><annotation id="7"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="81" length="6"/><text>Halide</text></annotation></passage><passage><infon key="type">abstract</infon><offset>101</offset><text>Mixed-cation metal halide perovskites have shown remarkable progress in photovoltaic applications with high power conversion efficiencies. However, to achieve large-scale deployment of this technology, efficiencies must be complemented by long-term durability. The latter is limited by external factors, such as exposure to humidity and air, which lead to the rapid degradation of the perovskite materials and devices. In this work, we study the mechanisms causing Cs and formamidinium (FA)-based halide perovskite phase transformations and stabilization during moisture and air exposure. We use in situ X-ray scattering, X-ray photoelectron spectroscopy, and first-principles calculations to study these chemical interactions and their effects on structure. We unravel a surface reaction pathway involving the dissolution of FAI by water and iodide oxidation by oxygen, driving the Cs/FA ratio into thermodynamically unstable regions, leading to undesirable phase transformations. This work demonstrates the interplay of bulk phase transformations with surface chemical reactions, providing a detailed understanding of the degradation mechanism and strategies for designing durable and efficient perovskite materials.</text><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="114" length="24"/><text>metal halide perovskites</text></annotation><annotation id="18"><infon key="identifier">MESH:C059910</infon><infon key="type">Chemical</infon><location offset="486" length="10"/><text>perovskite</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="566" length="49"/><text>Cs and formamidinium (FA)-based halide perovskite</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="927" length="3"/><text>FAI</text></annotation><annotation id="21"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="934" length="5"/><text>water</text></annotation><annotation id="22"><infon key="identifier">MESH:D007454</infon><infon key="type">Chemical</infon><location offset="944" length="6"/><text>iodide</text></annotation><annotation id="23"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="964" length="6"/><text>oxygen</text></annotation><annotation id="24"><infon key="identifier">MESH:D002586</infon><infon key="type">Chemical</infon><location offset="984" length="2"/><text>Cs</text></annotation><annotation id="25"><infon key="identifier">MESH:C059910</infon><infon key="type">Chemical</infon><location offset="1298" length="10"/><text>perovskite</text></annotation></passage><relation id="R1"><infon key="score">0.9965</infon><infon key="role1">Chemical|MESH:D007454</infon><infon key="role2">Chemical|MESH:D010100</infon><infon key="type">Association</infon><node refid="0" role="9,10"/></relation><relation id="R2"><infon key="score">0.7479</infon><infon key="role1">Chemical|MESH:C077922</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="1" role="2,0"/></relation></document>
<document><id>37918317</id><passage><infon key="journal">Domest Anim Endocrinol;2023Oct04; 86 106820. doi:10.1016/j.domaniend.2023.106820</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Katarzy&amp;#x144;ska-Banasik D, Kowalik K, Sechman A, </infon><offset>0</offset><text>Influence of silver nanoparticles on mRNA expression of thyroid hormone-related genes in the thyroid gland and liver of laying hens.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="13" length="20"/><text>silver nanoparticles</text></annotation></passage><passage><infon key="type">abstract</infon><offset>133</offset><text>The widespread use of silver nanoparticles (AgNPs) in consumer products and animal husbandry raises the need to study their impact on living organisms. This study was conducted on Hy-Line Brown hens at the age of 25 weeks with an average weight of 1.58 kg. Hens for 2 weeks received a solution of 50 nm AgNPs at a concentration of 100 pm (experimental group; n = 6) or a solution in which the nanoparticles were suspended (control group; n = 6). Thyroid hormones (thyroxine - T4, triiodothyronine - T3) were evaluated in the blood plasma and expression profiles of genes involved in thyroid hormone (TH) synthesis (TSHR, NIS, TPO, TG), metabolism (DIO1, DIO2, DIO3) and transport (MCT8, MCT10, LAT1) were determined in the chicken thyroid gland. Furthermore, iodothyronine deiodinase, TH transporter and TH receptor (THRA, THRB) mRNA expressions were evaluated in the livers isolated from the same chickens. AgNPs did not affect serum T4 levels but elevated serum T3 concentration. The results showed that AgNPs increased DIO3 mRNA in the thyroid gland. In turn, in the liver AgNPs administration significantly upregulated DIO2 and downregulated MCT10 mRNA levels. These results indicate that exposure to AgNPs leads to a tissue-specific alternative expression of genes engaged in TH metabolism. Moreover, the mRNA expression of DIO2 in the liver showed a positive correlation with plasma T3 levels. In conclusion, AgNPs may have an impact on TH metabolism by affecting deiodinases and TH transporter MCT10 mRNA expression.</text><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="155" length="20"/><text>silver nanoparticles</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="177" length="5"/><text>AgNPs</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="436" length="5"/><text>AgNPs</text></annotation><annotation id="28"><infon key="identifier">MESH:D013974</infon><infon key="type">Chemical</infon><location offset="597" length="9"/><text>thyroxine</text></annotation><annotation id="29"><infon key="identifier">MESH:D014284</infon><infon key="type">Chemical</infon><location offset="613" length="16"/><text>triiodothyronine</text></annotation><annotation id="30"><infon key="identifier">MESH:D014284</infon><infon key="type">Chemical</infon><location offset="632" length="2"/><text>T3</text></annotation><annotation id="31"><infon key="identifier">428900</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">315</infon><location offset="748" length="4"/><text>TSHR</text></annotation><annotation id="32"><infon key="identifier">776120</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">461</infon><location offset="759" length="3"/><text>TPO</text></annotation><annotation id="33"><infon key="identifier">395940</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">620</infon><location offset="781" length="4"/><text>DIO1</text></annotation><annotation id="34"><infon key="identifier">373903</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">621</infon><location offset="787" length="4"/><text>DIO2</text></annotation><annotation id="35"><infon key="identifier">395939</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1044</infon><location offset="793" length="4"/><text>DIO3</text></annotation><annotation id="36"><infon key="identifier">396251</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37747</infon><location offset="950" length="4"/><text>THRA</text></annotation><annotation id="37"><infon key="identifier">396431</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">36025</infon><location offset="956" length="4"/><text>THRB</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1041" length="5"/><text>AgNPs</text></annotation><annotation id="39"><infon key="identifier">MESH:D014284</infon><infon key="type">Chemical</infon><location offset="1097" length="2"/><text>T3</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1139" length="5"/><text>AgNPs</text></annotation><annotation id="41"><infon key="identifier">395939</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1044</infon><location offset="1155" length="4"/><text>DIO3</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1209" length="5"/><text>AgNPs</text></annotation><annotation id="43"><infon key="identifier">373903</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">621</infon><location offset="1256" length="4"/><text>DIO2</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1338" length="5"/><text>AgNPs</text></annotation><annotation id="45"><infon key="identifier">373903</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">621</infon><location offset="1462" length="4"/><text>DIO2</text></annotation><annotation id="46"><infon key="identifier">MESH:D014284</infon><infon key="type">Chemical</infon><location offset="1522" length="2"/><text>T3</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1548" length="5"/><text>AgNPs</text></annotation></passage><relation id="R1"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:D014284</infon><infon key="role2">Gene|373903</infon><infon key="type">Association</infon><node refid="0" role="6,11"/></relation></document>
<document><id>37918667</id><passage><infon key="type">title</infon><offset>0</offset><text>If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary.</text></passage><passage><infon key="type">abstract</infon><offset>87</offset></passage></document>
<document><id>37919017</id><passage><infon key="journal">J Sport Health Sci;2023Nov; 12 (6) 651. doi:10.1016/j.jshs.2023.09.003</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gao Z, Trinh L, </infon><offset>0</offset><text>Exercise and oncology: The role of physical activity in disease prevention and health promotion.</text></passage><passage><infon key="type">abstract</infon><offset>97</offset></passage></document>
<document><id>37919367</id><passage><infon key="journal">Nat Biomed Eng;2023Nov02. doi:10.1038/s41551-023-01120-3</infon><infon key="year">2023</infon><infon key="article-id_pmc">5938574</infon><infon key="type">title</infon><infon key="authors">Anaya J, Sidhom JW, Mahmood F, Baras AS, </infon><offset>0</offset><text>Multiple-instance learning of somatic mutations for the classification of tumour type and the prediction of microsatellite status.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="74" length="6"/><text>tumour</text></annotation></passage><passage><infon key="type">abstract</infon><offset>131</offset><text>Large-scale genomic data are well suited to analysis by deep learning algorithms. However, for many genomic datasets, labels are at the level of the sample rather than for individual genomic measures. Machine learning models leveraging these datasets generate predictions by using statically encoded measures that are then aggregated at the sample level. Here we show that a single weakly supervised end-to-end multiple-instance-learning model with multi-headed attention can be trained to encode and aggregate the local sequence context or genomic position of somatic mutations, hence allowing for the modelling of the importance of individual measures for sample-level classification and thus providing enhanced explainability. The model solves synthetic tasks that conventional models fail at, and achieves best-in-class performance for the classification of tumour type and for predicting microsatellite status. By improving the performance of tasks that require aggregate information from genomic datasets, multiple-instance deep learning may generate biological insight.</text><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="993" length="6"/><text>tumour</text></annotation></passage></document>
<document><id>37919717</id><passage><infon key="type">title</infon><offset>0</offset><text>High-precision detection and navigation surgery of colorectal cancer micrometastases.</text><annotation id="1"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="51" length="17"/><text>colorectal cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>86</offset><text>Surgical resection is an effective treatment for colorectal cancer (CRC) patients, whereas occult metastases hinder the curative effect. Currently, there is no effective method to achieve intraoperatively diagnosis of tumor-positive lymph nodes (LNs). Herein, we adopt a near-infrared-II (NIR-II) organic donor-pi-acceptor-pi-donor probe FE-2PEG, which exhibits bright fluorescence over 1100 nm, excellent photostability, blood circulation time, and biocompatibility, to achieve high-performance bioimaging with improved temporal and spatial resolution. Importantly, the FE-2PEG shows efficient passive enrichment in orthotopic CRC, metastatic mesenteric LNs, and peritoneal metastases by enhanced permeability and retention effect. Under NIR-II fluorescence-guided surgery (FGS), the peritoneal micrometastases were resected with a sensitivity of 94.51%, specificity of 86.59%, positive predictive value (PPV) of 96.57%, and negative predictive value of 79.78%. The PPV still achieves 96.07% even for micrometastases less than 3 mm. Pathological staining and NIR-II microscopy imaging proved that FE-2PEG could successfully delineate the boundary between the tumor and normal tissues. Dual-color NIR-II imaging strategy with FE-2PEG (1100 ~ 1300 nm) and PbS@CdS quantum dots (> 1500 nm) successfully protects both blood supply and normal tissues during surgery. The NIR-II-based FGS provides a promising prospect for precise intraoperative diagnosis and minimally invasive surgery of CRC.</text><annotation id="16"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="135" length="17"/><text>colorectal cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="154" length="3"/><text>CRC</text></annotation><annotation id="18"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="184" length="10"/><text>metastases</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="304" length="5"/><text>tumor</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="424" length="7"/><text>FE-2PEG</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="657" length="7"/><text>FE-2PEG</text></annotation><annotation id="22"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="714" length="3"/><text>CRC</text></annotation><annotation id="23"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="750" length="21"/><text>peritoneal metastases</text></annotation><annotation id="24"><infon key="identifier">MESH:D061206</infon><infon key="type">Disease</infon><location offset="871" length="26"/><text>peritoneal micrometastases</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1184" length="7"/><text>FE-2PEG</text></annotation><annotation id="26"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1246" length="5"/><text>tumor</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1312" length="7"/><text>FE-2PEG</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1341" length="20"/><text>PbS@CdS quantum dots</text></annotation><annotation id="29"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="1571" length="3"/><text>CRC</text></annotation></passage></document>
<document><id>37920067</id><passage><infon key="journal">BJPsych Open;2023Nov03; 9 (6) 208. doi:10.1192/bjo.2023.600</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wolpe N, Fernandez-Egea E, </infon><offset>0</offset><text>[The structural stability of negative symptoms over time].</text></passage><passage><infon key="type">abstract</infon><offset>59</offset><text>Negative symptoms remain poorly understood and treated despite their huge impact on patients' lives and clinical outcomes. This is partly because of ongoing debates about the clinical constructs underlying negative symptoms. A longitudinal analysis of the structure of negative symptoms presented in BJPsych Open reports striking temporal stability of symptom structure, which behaves as a few independent domains. This further underscores the need to address specific symptom domains when considering interventions or pathophysiology studies.</text></passage></document>
<document><id>37921117</id><passage><infon key="journal">Chemistry;2023Nov03 202302178. doi:10.1002/chem.202302178</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Das SK, Odelius M, Banerjee A, </infon><offset>0</offset><text>Simulating non-adiabatic dynamics of photoexcited phenyl azide: Investigating electronic and structural relaxation en route to the formation of phenyl nitrene.</text><annotation id="2"><infon key="identifier">MESH:C014747</infon><infon key="type">Chemical</infon><location offset="50" length="12"/><text>phenyl azide</text></annotation><annotation id="3"><infon key="identifier">MESH:C017621</infon><infon key="type">Chemical</infon><location offset="144" length="14"/><text>phenyl nitrene</text></annotation></passage><passage><infon key="type">abstract</infon><offset>160</offset><text>Excited state molecular dynamics simulations of the photoexcited phenyl azide have been performed. The semi-classical surface hopping approximation has enabled an unconstrained analysis of the electronic and nuclear degrees of freedom which contribute to the molecular dissociation of phenyl azide into phenyl nitrene and molecular nitrogen. The significance of the second singlet excited state in leading the photodissociation has been established through electronic structure calculations, based on multiconfigurational schemes, and state population dynamics. The investigations on the structural dynamics have revealed the N - N bond separation to be accompanied by synchronous changes in the azide N - N - N bond angle. The 100 fs simulation results in a nitrene fragment that is electronically excited in the singlet manifold.</text><annotation id="10"><infon key="identifier">MESH:C014747</infon><infon key="type">Chemical</infon><location offset="225" length="12"/><text>phenyl azide</text></annotation><annotation id="11"><infon key="identifier">MESH:C014747</infon><infon key="type">Chemical</infon><location offset="445" length="12"/><text>phenyl azide</text></annotation><annotation id="12"><infon key="identifier">MESH:C017621</infon><infon key="type">Chemical</infon><location offset="463" length="14"/><text>phenyl nitrene</text></annotation><annotation id="13"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="492" length="8"/><text>nitrogen</text></annotation><annotation id="14"><infon key="identifier">MESH:D001386</infon><infon key="type">Chemical</infon><location offset="856" length="5"/><text>azide</text></annotation><annotation id="15"><infon key="identifier">MESH:C017621</infon><infon key="type">Chemical</infon><location offset="919" length="7"/><text>nitrene</text></annotation></passage><relation id="R1"><infon key="score">0.9215</infon><infon key="role1">Chemical|MESH:C014747</infon><infon key="role2">Chemical|MESH:C017621</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.9284</infon><infon key="role1">Chemical|MESH:C014747</infon><infon key="role2">Chemical|MESH:D009584</infon><infon key="type">Association</infon><node refid="1" role="3,5"/></relation></document>
<document><id>37921467</id><passage><infon key="journal">Biotechnol Bioeng;2023Nov03. doi:10.1002/bit.28597</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xu F, Zhang W, Wang Y, Tian X, Chu J, </infon><offset>0</offset><text>Enhancing and Monitoring Spore Production in Clostridium butyricum Using pH-based Regulation Strategy and a Robust Soft Sensor Based on Back-propagation Neural Networks.</text></passage><passage><infon key="type">abstract</infon><offset>170</offset><text>Clostridium butyricum (C. butyricum) is a probiotic that forms anaerobic spores and plays a crucial role in regulating gut microbiota. However, the total viable cell count and spore yield of C. butyricum in industrial production are comparatively low. To this end, we investigated the metabolic characteristics of the strain and proposed three distinct pH regulation strategies for enhancing spore production. In addition, precise measurement of fermentation parameters such as substrate concentration, total viable cell count, and spore concentration is crucial for successful industrial probiotics production. Nevertheless, online measurement of these intricate parameters in the fermentation of C. butyricum poses a considerable challenge owing to the complex, nonlinear, multivariate, and strongly coupled characteristics of the production process. Therefore, we analyzed the capacitance and conductivity acquired from a viable cell sensor as the core parameters for the fermentation process. Subsequently, a robust soft sensor was developed using a seven-input back-propagation neural network model with input variables of fermentation time, capacitance, conductivity, pH, initial total sugar concentration, ammonium ion concentration, and calcium ion concentration. The model enables the online monitoring of total viable biomass count, substrate concentrations, and spore yield, and can be extended to similar fermentation processes with pH changes as a characteristic feature. This article is protected by copyright. All rights reserved.</text><annotation id="3"><infon key="identifier">MESH:D000073893</infon><infon key="type">Chemical</infon><location offset="1362" length="5"/><text>sugar</text></annotation><annotation id="4"><infon key="identifier">MESH:D064751</infon><infon key="type">Chemical</infon><location offset="1383" length="12"/><text>ammonium ion</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1415" length="11"/><text>calcium ion</text></annotation></passage></document>
<document><id>37921817</id><passage><infon key="journal">Dermatol Online J;2023Aug15; 29 (4) . doi:10.5070/D329461906</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Johanis M, Cheema KS, Young PA, Narala S, Saleem A, Novoa RA, Bae GH, </infon><offset>0</offset><text>Cutaneous larva migrans in the northeastern US.</text><annotation id="1"><infon key="identifier">MESH:D007815</infon><infon key="type">Disease</infon><location offset="0" length="23"/><text>Cutaneous larva migrans</text></annotation></passage><passage><infon key="type">abstract</infon><offset>48</offset><text>Cutaneous larva migrans (CLM) is a dermo-epidermal parasitic infection with a disproportionate incidence in developing countries, particularly in, and near tropical areas. It is characterized by erythematous, twisting, and linear plaques that can migrate to adjacent skin. Herein, we present an otherwise healthy 45-year-old woman who acquired a pruritic, erythematous, and serpiginous rash localized to her right medial ankle during a trip to New England. Oral ivermectin, the preferred first-line treatment for cutaneous larva migrans, was administered in combination with triamcinolone. This was followed by removal of the papular area via punch biopsy; treatment was successful with a one-week recovery. Although cutaneous larva migrans has traditionally been considered a tropical disease, clinicians should be cognizant of its expanding geographic spread.</text><annotation id="11"><infon key="identifier">MESH:D007815</infon><infon key="type">Disease</infon><location offset="48" length="23"/><text>Cutaneous larva migrans</text></annotation><annotation id="12"><infon key="identifier">MESH:D007815</infon><infon key="type">Disease</infon><location offset="73" length="3"/><text>CLM</text></annotation><annotation id="13"><infon key="identifier">MESH:D010272</infon><infon key="type">Disease</infon><location offset="83" length="35"/><text>dermo-epidermal parasitic infection</text></annotation><annotation id="14"><infon key="identifier">MESH:D005076</infon><infon key="type">Disease</infon><location offset="434" length="4"/><text>rash</text></annotation><annotation id="15"><infon key="identifier">MESH:D007559</infon><infon key="type">Chemical</infon><location offset="510" length="10"/><text>ivermectin</text></annotation><annotation id="16"><infon key="identifier">MESH:D007815</infon><infon key="type">Disease</infon><location offset="561" length="23"/><text>cutaneous larva migrans</text></annotation><annotation id="17"><infon key="identifier">MESH:D014221</infon><infon key="type">Chemical</infon><location offset="623" length="13"/><text>triamcinolone</text></annotation><annotation id="18"><infon key="identifier">MESH:D007815</infon><infon key="type">Disease</infon><location offset="765" length="23"/><text>cutaneous larva migrans</text></annotation><annotation id="19"><infon key="identifier">MESH:D015493</infon><infon key="type">Disease</infon><location offset="825" length="16"/><text>tropical disease</text></annotation></passage><relation id="R1"><infon key="score">0.871</infon><infon key="role1">Chemical|MESH:D007559</infon><infon key="role2">Chemical|MESH:D014221</infon><infon key="type">Cotreatment</infon><node refid="0" role="5,7"/></relation><relation id="R2"><infon key="score">0.9602</infon><infon key="role1">Chemical|MESH:D014221</infon><infon key="role2">Disease|MESH:D007815</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="7,6"/></relation><relation id="R3"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:D007559</infon><infon key="role2">Disease|MESH:D007815</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="5,6"/></relation><relation id="R4"><infon key="score">0.9424</infon><infon key="role1">Chemical|MESH:D007559</infon><infon key="role2">Disease|MESH:D005076</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="5,4"/></relation></document>
<document><id>37889609</id><passage><infon key="journal">ACS Appl Mater Interfaces;2023Oct27. doi:10.1021/acsami.3c12690</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gu M, Wang J, Song Z, Li C, Wang W, Wang A, Huang Y, </infon><offset>0</offset><text>Multifunctional Asymmetric Separator Constructed by Polyacrylonitrile-Derived Nanofibers for Lithium-Sulfur Batteries.</text><annotation id="2"><infon key="identifier">MESH:C010504</infon><infon key="type">Chemical</infon><location offset="52" length="17"/><text>Polyacrylonitrile</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="93" length="14"/><text>Lithium-Sulfur</text></annotation></passage><passage><infon key="type">abstract</infon><offset>119</offset><text>Lithium-sulfur (Li-S) batteries hold great promise as next-generation high-energy storage devices owing to the high theoretical specific capacity of sulfur, but polysulfide shuttling and lithium dendrite growth remain key challenges limiting cycling life. In this work, we propose a polyacrylonitrile-derived asymmetric (PDA) separator to enhance Li-S battery performance by accelerating sulfur redox kinetics and guiding lithium plating and stripping. A PDA separator was constructed from two layers: the cathode-facing side consists of polyacrylonitrile nanofibers carbonized at 800  C and doped with titanium nitride, which can achieve rapid polysulfide conversion via electrocatalysis to suppress their shuttling; the anode-facing side consists of polyacrylonitrile oxidized at 280  C, on which the abundant electronegative groups guide uniform lithium ion plating and stripping. Li-S batteries assembled with the PDA separator exhibited enhanced rate performance, cycling stability, and sulfur utilization, retaining 426 mA h g-1 capacity at 1 C over 1000 cycles and 632 mA h g-1 at 4 C over 200 cycles. Attractively, the PDA separator showed high thermal stability, which could mitigate the risk of internal short circuits and thermal runaway. This work demonstrates an original path to addressing the most critical issues with Li-S batteries.</text><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="119" length="14"/><text>Lithium-sulfur</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="135" length="4"/><text>Li-S</text></annotation><annotation id="23"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="268" length="6"/><text>sulfur</text></annotation><annotation id="24"><infon key="identifier">MESH:C032915</infon><infon key="type">Chemical</infon><location offset="280" length="11"/><text>polysulfide</text></annotation><annotation id="25"><infon key="identifier">MESH:D008094</infon><infon key="type">Chemical</infon><location offset="306" length="7"/><text>lithium</text></annotation><annotation id="26"><infon key="identifier">MESH:C010504</infon><infon key="type">Chemical</infon><location offset="402" length="17"/><text>polyacrylonitrile</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="466" length="4"/><text>Li-S</text></annotation><annotation id="28"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="507" length="6"/><text>sulfur</text></annotation><annotation id="29"><infon key="identifier">MESH:D008094</infon><infon key="type">Chemical</infon><location offset="541" length="7"/><text>lithium</text></annotation><annotation id="30"><infon key="identifier">MESH:C010504</infon><infon key="type">Chemical</infon><location offset="657" length="17"/><text>polyacrylonitrile</text></annotation><annotation id="31"><infon key="identifier">MESH:C041500</infon><infon key="type">Chemical</infon><location offset="722" length="16"/><text>titanium nitride</text></annotation><annotation id="32"><infon key="identifier">MESH:C032915</infon><infon key="type">Chemical</infon><location offset="764" length="11"/><text>polysulfide</text></annotation><annotation id="33"><infon key="identifier">MESH:C010504</infon><infon key="type">Chemical</infon><location offset="871" length="17"/><text>polyacrylonitrile</text></annotation><annotation id="34"><infon key="identifier">MESH:D008094</infon><infon key="type">Chemical</infon><location offset="968" length="7"/><text>lithium</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1003" length="4"/><text>Li-S</text></annotation><annotation id="36"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="1111" length="6"/><text>sulfur</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1453" length="4"/><text>Li-S</text></annotation></passage><relation id="R1"><infon key="score">0.5818</infon><infon key="role1">Chemical|MESH:C010504</infon><infon key="role2">Chemical|MESH:C032915</infon><infon key="type">Association</infon><node refid="0" role="11,13"/></relation><relation id="R2"><infon key="score">0.9144</infon><infon key="role1">Chemical|MESH:C010504</infon><infon key="role2">Chemical|MESH:C041500</infon><infon key="type">Association</infon><node refid="1" role="11,12"/></relation><relation id="R3"><infon key="score">0.9847</infon><infon key="role1">Chemical|MESH:C032915</infon><infon key="role2">Chemical|MESH:C041500</infon><infon key="type">Association</infon><node refid="2" role="13,12"/></relation></document>
<document><id>37889960</id><passage><infon key="journal">Dis Colon Rectum;2023Oct26. doi:10.1097/DCR.0000000000003139</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Vailati BB, Cerd&amp;#xe1;n-Santacruz C, S&amp;#xe3;o Juli&amp;#xe3;o GP, Corbi L, Perez RO, </infon><offset>0</offset><text>Local Recurrence in Rectal Cancer: Small Absolute Numbers in a BIG Problem.</text><annotation id="2"><infon key="identifier">MESH:D012008</infon><infon key="type">Disease</infon><location offset="6" length="10"/><text>Recurrence</text></annotation><annotation id="3"><infon key="identifier">MESH:D012004</infon><infon key="type">Disease</infon><location offset="20" length="13"/><text>Rectal Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>76</offset></passage></document>
<document><id>37890311</id><passage><infon key="journal">Int J Biol Macromol;2023Oct25; 253 (Pt 8) 127683. doi:10.1016/j.ijbiomac.2023.127683</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liu Z, Zhao M, Zhang Z, Li C, Xia G, Shi H, Liu Z, </infon><offset>0</offset><text>Chitosan-based edible film incorporated with wampee (Clausena lansium) seed essential oil: Preparation, characterization and biological activities.</text><annotation id="2"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="0" length="8"/><text>Chitosan</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="45" length="44"/><text>wampee (Clausena lansium) seed essential oil</text></annotation></passage><passage><infon key="type">abstract</infon><offset>148</offset><text>Chitosan (Ch)-based edible composite films were prepared by incorporating blending wampee seed essential oil (WSEO) into a Ch matrix, using the incorporation ratio as a variable. The physical, mechanical properties, structure morphology and rheological properties were determined using tensile strength (TS), elongation at break (EB), water vapor permeability (WVP) tests together with Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM) observations and apparent viscosity and shear rate. In addition, the antimicrobial, antioxidant activities were investigated by the DPPH &amp; ABTS radicals scavenging and inhibition zone assays, respectively. Compared with Ch, the incorporation of WSEO significantly decreased (P &lt; 0.05) the TS, EB, and WVP values, especially when the WSEO ratio reached 1.0 % or higher. Meanwhile, the films exhibited greatly improved visible light barrier performance after WSEO incorporation. Both FTIR spectroscopy and SEM observations reflected the crosslinking between WSEO and Ch. Meanwhile, the composite films demonstrated smaller particle size and weaker rheological viscosities, which enhanced the antimicrobial and antioxidant capabilities when compared with those of Ch. Therefore, this study suggested that WSEO incorporated with Ch is an effective ingredient for the preparation of edible films with enhanced physicochemical and biological properties.</text><annotation id="21"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="148" length="8"/><text>Chitosan</text></annotation><annotation id="22"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="158" length="2"/><text>Ch</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="231" length="25"/><text>wampee seed essential oil</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="258" length="4"/><text>WSEO</text></annotation><annotation id="25"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="271" length="2"/><text>Ch</text></annotation><annotation id="26"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="483" length="5"/><text>water</text></annotation><annotation id="27"><infon key="identifier">MESH:C004931</infon><infon key="type">Chemical</infon><location offset="749" length="4"/><text>DPPH</text></annotation><annotation id="28"><infon key="identifier">MESH:C002502</infon><infon key="type">Chemical</infon><location offset="756" length="4"/><text>ABTS</text></annotation><annotation id="29"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="837" length="2"/><text>Ch</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="862" length="4"/><text>WSEO</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="950" length="4"/><text>WSEO</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1074" length="4"/><text>WSEO</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1173" length="4"/><text>WSEO</text></annotation><annotation id="34"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="1182" length="2"/><text>Ch</text></annotation><annotation id="35"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="1378" length="2"/><text>Ch</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1419" length="4"/><text>WSEO</text></annotation><annotation id="37"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="1442" length="2"/><text>Ch</text></annotation></passage></document>
<document><id>37890661</id><passage><infon key="journal">J Thorac Cardiovasc Surg;2023Oct25. doi:10.1016/j.jtcvs.2023.10.043</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Galloway AC, Dorsey MP, </infon><offset>0</offset><text>Commentary: Incremental Improvement is Better Than No Improvement!</text></passage><passage><infon key="type">abstract</infon><offset>67</offset></passage></document>
<document><id>37891012</id><passage><infon key="journal">Oral Dis;2023Oct27. doi:10.1111/odi.14749</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Porter SR, Ukwas A, </infon><offset>0</offset><text>Cachexia and head and neck squamous cell carcinoma: A scoping review.</text><annotation id="2"><infon key="identifier">MESH:D002100</infon><infon key="type">Disease</infon><location offset="0" length="8"/><text>Cachexia</text></annotation><annotation id="3"><infon key="identifier">MESH:D000077195</infon><infon key="type">Disease</infon><location offset="13" length="37"/><text>head and neck squamous cell carcinoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>70</offset><text>OBJECTIVE: The objective of this paper was to provide an understanding of cachexia in relation to oral squamous cell carcinoma relevant to oral health care. The paper is a scoping review of aspects of the clinical presentation, aetiology and management of cachexia in relation to oral health and oral health care. METHODS: A combined search of MEDLINE and EMBASE databases (via OVID) was conducted using the terms ([Head and Neck] OR [Oral Squamous Cell Carcinoma]) AND (Cachexia). Duplicates were removed and results were subsequently limited to studies published between 2000 and 2023, humans and English language. After screening and full-text assessment a total number of 87 studies were included in the review. RESULTS: It is evident that cachexia is a not uncommon feature of patients with advanced malignancy of the head and neck driven by a multitude of mechanisms, induced by the tumour itself, that lead to reduced nutritional intake, increased metabolism and loss of adipose and skeletal tissue. CONCLUSION: While a variety of nutritional, physical, psychological and pharmacological interventions may improve quality and duration of life, ultimately the diagnosis of cachexia in relation to head and neck cancer remains an indicator of poor life expectancy.</text><annotation id="15"><infon key="identifier">MESH:D002100</infon><infon key="type">Disease</infon><location offset="144" length="8"/><text>cachexia</text></annotation><annotation id="16"><infon key="identifier">MESH:D000077195</infon><infon key="type">Disease</infon><location offset="168" length="28"/><text>oral squamous cell carcinoma</text></annotation><annotation id="17"><infon key="identifier">MESH:D002100</infon><infon key="type">Disease</infon><location offset="326" length="8"/><text>cachexia</text></annotation><annotation id="18"><infon key="identifier">MESH:D006258</infon><infon key="type">Disease</infon><location offset="486" length="13"/><text>Head and Neck</text></annotation><annotation id="19"><infon key="identifier">MESH:D000077195</infon><infon key="type">Disease</infon><location offset="505" length="28"/><text>Oral Squamous Cell Carcinoma</text></annotation><annotation id="20"><infon key="identifier">MESH:D002100</infon><infon key="type">Disease</infon><location offset="541" length="8"/><text>Cachexia</text></annotation><annotation id="21"><infon key="identifier">MESH:D002100</infon><infon key="type">Disease</infon><location offset="814" length="8"/><text>cachexia</text></annotation><annotation id="22"><infon key="identifier">MESH:D006258</infon><infon key="type">Disease</infon><location offset="875" length="31"/><text>malignancy of the head and neck</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="959" length="6"/><text>tumour</text></annotation><annotation id="24"><infon key="identifier">MESH:D002100</infon><infon key="type">Disease</infon><location offset="1249" length="8"/><text>cachexia</text></annotation><annotation id="25"><infon key="identifier">MESH:D006258</infon><infon key="type">Disease</infon><location offset="1273" length="20"/><text>head and neck cancer</text></annotation></passage></document>
<document><id>37891363</id><passage><infon key="journal">AAPS PharmSciTech;2023Oct27; 24 (8) 219. doi:10.1208/s12249-023-02680-y</infon><infon key="year">2023</infon><infon key="article-id_pmc">9864382</infon><infon key="type">title</infon><infon key="authors">Bharti K, Deepika D, Kumar M, Jha A, ManjitAkhileshTiwari V, Kumar V, Mishra B, </infon><offset>0</offset><text>Development and Evaluation of Amorphous Solid Dispersion of Riluzole with PBPK Model to Simulate the Pharmacokinetic Profile.</text><annotation id="1"><infon key="identifier">MESH:D019782</infon><infon key="type">Chemical</infon><location offset="60" length="8"/><text>Riluzole</text></annotation></passage><passage><infon key="type">abstract</infon><offset>126</offset><text>In the current work, screening of polymers viz. polyacrylic acid (PAA), polyvinyl pyrrolidone vinyl acetate (PVP VA), and hydroxypropyl methyl cellulose acetate succinate (HPMC AS) based on drug-polymer interaction and wetting property was done for the production of a stable amorphous solid dispersion (ASD) of a poorly water-soluble drug Riluzole (RLZ). PAA showed maximum interaction and wetting property hence, was selected for further studies. Solid state characterization studies confirmed the formation of ASD with PAA. Saturation solubility, dissolution profile, and in vivo pharmacokinetic data of the ASD formulation were generated in rats against its marketed tablet Rilutor. The RLZ:PAA ASD showed exponential enhancement in the dissolution of RLZ. Predicted and observed pharmacokinetic data in rats showed enhanced area under curve (AUC) and Cmax in plasma and brain with respect to Rilutor. Furthermore, a physiologically based pharmacokinetic (PBPK) model of rats for Rilutor and RLZ ASD was developed and then extrapolated to humans where physiological parameters were changed along with a biochemical parameter. The partition coefficient was kept similar in both species. The model was used to predict different exposure scenarios, and the simulated data was compared with observed data points. The PBPK model simulated Cmax and AUC was within two times the experimental data for plasma and brain. The Cmax and AUC in the brain increased with ASD compared to Rilutor for humans showing its potential in improving its biopharmaceutical performance and hence enhanced therapeutic efficacy. The model can predict the RLZ concentration in multiple compartments including plasma and liver.</text><annotation id="24"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="160" length="8"/><text>polymers</text></annotation><annotation id="25"><infon key="identifier">MESH:C006903</infon><infon key="type">Chemical</infon><location offset="174" length="16"/><text>polyacrylic acid</text></annotation><annotation id="26"><infon key="identifier">MESH:C006903</infon><infon key="type">Chemical</infon><location offset="192" length="3"/><text>PAA</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="198" length="35"/><text>polyvinyl pyrrolidone vinyl acetate</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="235" length="6"/><text>PVP VA</text></annotation><annotation id="29"><infon key="identifier">MESH:C048331</infon><infon key="type">Chemical</infon><location offset="248" length="48"/><text>hydroxypropyl methyl cellulose acetate succinate</text></annotation><annotation id="30"><infon key="identifier">MESH:C048331</infon><infon key="type">Chemical</infon><location offset="298" length="7"/><text>HPMC AS</text></annotation><annotation id="31"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="321" length="7"/><text>polymer</text></annotation><annotation id="32"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="447" length="5"/><text>water</text></annotation><annotation id="33"><infon key="identifier">MESH:D019782</infon><infon key="type">Chemical</infon><location offset="466" length="8"/><text>Riluzole</text></annotation><annotation id="34"><infon key="identifier">MESH:D019782</infon><infon key="type">Chemical</infon><location offset="476" length="3"/><text>RLZ</text></annotation><annotation id="35"><infon key="identifier">MESH:C006903</infon><infon key="type">Chemical</infon><location offset="482" length="3"/><text>PAA</text></annotation><annotation id="36"><infon key="identifier">MESH:C006903</infon><infon key="type">Chemical</infon><location offset="648" length="3"/><text>PAA</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="804" length="7"/><text>Rilutor</text></annotation><annotation id="38"><infon key="identifier">MESH:D019782</infon><infon key="type">Chemical</infon><location offset="817" length="3"/><text>RLZ</text></annotation><annotation id="39"><infon key="identifier">MESH:C006903</infon><infon key="type">Chemical</infon><location offset="821" length="3"/><text>PAA</text></annotation><annotation id="40"><infon key="identifier">MESH:D019782</infon><infon key="type">Chemical</infon><location offset="882" length="3"/><text>RLZ</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1023" length="7"/><text>Rilutor</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1110" length="7"/><text>Rilutor</text></annotation><annotation id="43"><infon key="identifier">MESH:D019782</infon><infon key="type">Chemical</infon><location offset="1122" length="3"/><text>RLZ</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1603" length="7"/><text>Rilutor</text></annotation><annotation id="45"><infon key="identifier">MESH:D019782</infon><infon key="type">Chemical</infon><location offset="1758" length="3"/><text>RLZ</text></annotation></passage><relation id="R1"><infon key="score">0.5683</infon><infon key="role1">Chemical|MESH:C048331</infon><infon key="role2">Chemical|MESH:D019782</infon><infon key="type">Association</infon><node refid="0" role="6,10"/></relation><relation id="R2"><infon key="score">0.4709</infon><infon key="role1">Chemical|MESH:C006903</infon><infon key="role2">Chemical|MESH:D019782</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="2,10"/></relation></document>
<document><id>37891714</id><passage><infon key="journal">Am J Health Promot;2023Oct27 8901171231211158. doi:10.1177/08901171231211158</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lee K, Zhao S, </infon><offset>0</offset><text>Do Household Headship and Gender Affect Diet Quality under the Supplemental Nutrition Assistance Program (SNAP)?</text></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>PURPOSE: Examine whether the association between Supplemental Nutrition Assistance Program (SNAP) participation and diet quality is different by gender and household headship. DESIGN: Quantitative, cross-sectional. SETTING: The 2007-2018 waves of the National Health and Nutrition Examination Survey (NHANES). SUBJECTS: 6180 individuals aged 20 to 65 with household annual income below 130% of the poverty level. MEASURES: The outcome of diet quality was measured using the 2015 Healthy Eating Index (HEI) based on dietary intake from 24-hour diet recall. The exposures were self-reported participation in SNAP and socio-demographic variables. ANALYSIS: Ordinary Least Square (OLS) regression models. RESULTS: The study found that female household heads had higher average total HEI scores relative to their male and non-head counterparts (beta = 1.81, 95% CI: -.27, 3.88). However, for SNAP participants, female household heads had lower average total HEI scores (beta = -3.67, 95% CI: -7.36, .11). CONCLUSION: Female household heads are more likely to experience difficulty in maintaining diet quality relative to their counterparts. The study suggests that intra-household effort allocation may play an important role in differentiating and maintaining diet quality.</text></passage></document>
<document><id>37897322</id><passage><infon key="journal">Adv Sci (Weinh);2023Oct28 2304294. doi:10.1002/advs.202304294</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cheng J, Huang H, Chen Y, Wu R, </infon><offset>0</offset><text>Nanomedicine for Diagnosis and Treatment of Atherosclerosis.</text><annotation id="1"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="44" length="15"/><text>Atherosclerosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>61</offset><text>With the changing disease spectrum, atherosclerosis has become increasingly prevalent worldwide and the associated diseases have emerged as the leading cause of death. Due to their fascinating physical, chemical, and biological characteristics, nanomaterials are regarded as a promising tool to tackle enormous challenges in medicine. The emerging discipline of nanomedicine has filled a huge application gap in the atherosclerotic field, ushering a new generation of diagnosis and treatment strategies. Herein, based on the essential pathogenic contributors of atherogenesis, as well as the distinct composition/structural characteristics, synthesis strategies, and surface design of nanoplatforms, the three major application branches (nanodiagnosis, nanotherapy, and nanotheranostic) of nanomedicine in atherosclerosis are elaborated. Then, state-of-art studies containing a sequence of representative and significant achievements are summarized in detail with an emphasis on the intrinsic interaction/relationship between nanomedicines and atherosclerosis. Particularly, attention is paid to the biosafety of nanomedicines, which aims to pave the way for future clinical translation of this burgeoning field. Finally, this comprehensive review is concluded by proposing unresolved key scientific issues and sharing the vision and expectation for the future, fully elucidating the closed loop from atherogenesis to the application paradigm of nanomedicines for advancing the early achievement of clinical applications.</text><annotation id="9"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="97" length="15"/><text>atherosclerosis</text></annotation><annotation id="10"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="222" length="5"/><text>death</text></annotation><annotation id="11"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="477" length="15"/><text>atherosclerotic</text></annotation><annotation id="12"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="623" length="13"/><text>atherogenesis</text></annotation><annotation id="13"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="867" length="15"/><text>atherosclerosis</text></annotation><annotation id="14"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1105" length="15"/><text>atherosclerosis</text></annotation><annotation id="15"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1462" length="13"/><text>atherogenesis</text></annotation></passage></document>
<document><id>37897673</id><passage><infon key="journal">J Bone Miner Metab;2023Oct28. doi:10.1007/s00774-023-01470-7</infon><infon key="year">2023</infon><infon key="article-id_pmc">9072485</infon><infon key="type">title</infon><infon key="authors">Ri K, Fukasawa T, Masuda S, Tanaka S, Takeuchi M, Yoshida S, Kawakami K, </infon><offset>0</offset><text>Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis.</text><annotation id="3"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="36" length="7"/><text>calcium</text></annotation><annotation id="4"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="62" length="12"/><text>eldecalcitol</text></annotation><annotation id="5"><infon key="identifier">MESH:D010024</infon><infon key="type">Disease</infon><location offset="100" length="12"/><text>osteoporosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>INTRODUCTION: Eldecalcitol (ELD) is an active vitamin D3 analog (AVD) commonly used to treat osteoporosis in Japan. Although routine monitoring of serum calcium levels during ELD therapy is recommended, little is known about the actual frequency and determinants of monitoring. MATERIALS AND METHODS: This was a descriptive cohort study using a Japanese electronic medical records database. We identified osteoporosis patients who initiated treatment with ELD or other AVDs (alfacalcidol and calcitriol) between April 1, 2011 and September 10, 2021. The index date for cohort entry was the first prescription date of ELD or other AVDs. The frequency of serum calcium monitoring was evaluated every 6 months. Determinants of serum calcium monitoring were identified using multivariable logistic regression models. We also calculated the incidence of hypercalcemia and the frequency of serum calcium monitoring within 6 months before hypercalcemia. RESULTS: We identified 12,671 ELD users and 7867 other AVD users. Within 6 months after cohort entry, 45.9% of ELD users and 58.7% of other AVD users underwent serum calcium monitoring. Female sex, no use of systemic corticosteroids, moderate-to-good renal function, treatment in smaller hospitals, and treatment in orthopedic surgery departments were associated with a lower likelihood of receiving serum calcium monitoring during ELD therapy. The incidence of hypercalcemia among ELD users was 6.36 per 100 person-years, with 20.6% of cases not receiving serum calcium monitoring before hypercalcemia. CONCLUSION: Our findings suggest that serum calcium monitoring is not given adequate attention during ELD therapy in routine clinical practice.</text><annotation id="38"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="128" length="12"/><text>Eldecalcitol</text></annotation><annotation id="39"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="142" length="3"/><text>ELD</text></annotation><annotation id="40"><infon key="identifier">MESH:D002762</infon><infon key="type">Chemical</infon><location offset="160" length="10"/><text>vitamin D3</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="179" length="3"/><text>AVD</text></annotation><annotation id="42"><infon key="identifier">MESH:D010024</infon><infon key="type">Disease</infon><location offset="207" length="12"/><text>osteoporosis</text></annotation><annotation id="43"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="267" length="7"/><text>calcium</text></annotation><annotation id="44"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="289" length="3"/><text>ELD</text></annotation><annotation id="45"><infon key="identifier">MESH:D010024</infon><infon key="type">Disease</infon><location offset="519" length="12"/><text>osteoporosis</text></annotation><annotation id="46"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="570" length="3"/><text>ELD</text></annotation><annotation id="47"><infon key="type">Disease</infon><location offset="583" length="4"/><text>AVDs</text></annotation><annotation id="48"><infon key="identifier">MESH:C008088</infon><infon key="type">Chemical</infon><location offset="589" length="12"/><text>alfacalcidol</text></annotation><annotation id="49"><infon key="identifier">MESH:D002117</infon><infon key="type">Chemical</infon><location offset="606" length="10"/><text>calcitriol</text></annotation><annotation id="50"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="731" length="3"/><text>ELD</text></annotation><annotation id="51"><infon key="type">Disease</infon><location offset="744" length="4"/><text>AVDs</text></annotation><annotation id="52"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="773" length="7"/><text>calcium</text></annotation><annotation id="53"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="844" length="7"/><text>calcium</text></annotation><annotation id="54"><infon key="identifier">MESH:D006934</infon><infon key="type">Disease</infon><location offset="963" length="13"/><text>hypercalcemia</text></annotation><annotation id="55"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="1004" length="7"/><text>calcium</text></annotation><annotation id="56"><infon key="identifier">MESH:D006934</infon><infon key="type">Disease</infon><location offset="1046" length="13"/><text>hypercalcemia</text></annotation><annotation id="57"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="1091" length="3"/><text>ELD</text></annotation><annotation id="58"><infon key="identifier">MESH:C564005</infon><infon key="type">Disease</infon><location offset="1116" length="3"/><text>AVD</text></annotation><annotation id="59"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="1172" length="3"/><text>ELD</text></annotation><annotation id="60"><infon key="identifier">MESH:C564005</infon><infon key="type">Disease</infon><location offset="1201" length="3"/><text>AVD</text></annotation><annotation id="61"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="1227" length="7"/><text>calcium</text></annotation><annotation id="62"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="1467" length="7"/><text>calcium</text></annotation><annotation id="63"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="1493" length="3"/><text>ELD</text></annotation><annotation id="64"><infon key="identifier">MESH:D006934</infon><infon key="type">Disease</infon><location offset="1523" length="13"/><text>hypercalcemia</text></annotation><annotation id="65"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="1543" length="3"/><text>ELD</text></annotation><annotation id="66"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="1624" length="7"/><text>calcium</text></annotation><annotation id="67"><infon key="identifier">MESH:D006934</infon><infon key="type">Disease</infon><location offset="1650" length="13"/><text>hypercalcemia</text></annotation><annotation id="68"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="1709" length="7"/><text>calcium</text></annotation><annotation id="69"><infon key="identifier">MESH:C547512</infon><infon key="type">Chemical</infon><location offset="1767" length="3"/><text>ELD</text></annotation></passage><relation id="R1"><infon key="score">0.9974</infon><infon key="role1">Chemical|MESH:C008088</infon><infon key="role2">Disease|MESH:D010024</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="13,10"/></relation><relation id="R2"><infon key="score">0.9745</infon><infon key="role1">Chemical|MESH:C547512</infon><infon key="role2">Chemical|MESH:D002118</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.9982</infon><infon key="role1">Chemical|MESH:C547512</infon><infon key="role2">Disease|MESH:D010024</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="1,2"/></relation><relation id="R4"><infon key="score">0.3968</infon><infon key="role1">Chemical|MESH:D002118</infon><infon key="role2">Disease|MESH:D006934</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="20,19"/></relation><relation id="R5"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C547512</infon><infon key="role2">Disease|MESH:D006934</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="30,29"/></relation><relation id="R6"><infon key="score">0.997</infon><infon key="role1">Chemical|MESH:D002117</infon><infon key="role2">Disease|MESH:D010024</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="14,10"/></relation></document>
<document><id>37898023</id><passage><infon key="journal">Biomaterials;2023Nov; 302 122356. doi:10.1016/j.biomaterials.2023.122356</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li M, Li D, Jiang Y, He P, Li Y, Wu Y, Lei W, de Bruijn JD, Cannon RD, Mei L, Zhang H, Ji P, Zhang H, Yuan H, </infon><offset>0</offset><text>The genetic background determines material-induced bone formation through the macrophage-osteoclast axis.</text><annotation id="1"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="56" length="9"/><text>formation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>106</offset><text>Osteoinductive materials are characterized by their ability to induce bone formation in ectopic sites. Thus, osteoinductive materials hold promising potential for repairing bone defects. However, the mechanism of material-induced bone formation remains unknown, which limits the design of highly potent osteoinductive materials. Here, we demonstrated a genetic background link among macrophage polarization, osteoclastogenesis and material-induced bone formation. The intramuscular implantation of an osteoinductive material in FVB/NCrl (FVB) mice resulted in more M2 macrophages at week 1, more osteoclasts at week 2 and increased bone formation after week 4 compared with the results obtained in C57BL/6JOlaHsd (C57) mice. Similarly, in vitro, with a greater potential to form M2 macrophages, monocytes derived from FVB mice formed more osteoclasts than those derived from C57 mice. A transcriptomic analysis identified Csf1, Cxcr4 and Tgfbr2 as the main genes controlling macrophage-osteoclast coupling, which were further confirmed by related inhibitors. With such coupling, macrophage polarization and osteoclast formation of monocytes in vitro successfully predicted in vivo bone formation in four other mouse strains. Considering material-induced bone formation as an example of acquired heterotopic bone formation, the current findings shed a light on precision medicine for both bone regeneration and the treatment of pathological heterotopic bone formation.</text><annotation id="16"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="181" length="9"/><text>formation</text></annotation><annotation id="17"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="279" length="12"/><text>bone defects</text></annotation><annotation id="18"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="341" length="9"/><text>formation</text></annotation><annotation id="19"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="559" length="9"/><text>formation</text></annotation><annotation id="20"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="743" length="9"/><text>formation</text></annotation><annotation id="21"><infon key="identifier">CVCL:5985</infon><infon key="type">CellLine</infon><location offset="809" length="9"/><text>/6JOlaHsd</text></annotation><annotation id="22"><infon key="identifier">12977</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7282</infon><location offset="1028" length="4"/><text>Csf1</text></annotation><annotation id="23"><infon key="identifier">12767</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20739</infon><location offset="1034" length="5"/><text>Cxcr4</text></annotation><annotation id="24"><infon key="identifier">21813</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2435</infon><location offset="1044" length="6"/><text>Tgfbr2</text></annotation><annotation id="25"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="1224" length="9"/><text>formation</text></annotation><annotation id="26"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="1292" length="9"/><text>formation</text></annotation><annotation id="27"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="1365" length="9"/><text>formation</text></annotation><annotation id="28"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="1401" length="26"/><text>heterotopic bone formation</text></annotation><annotation id="29"><infon key="identifier">MESH:D058426</infon><infon key="type">Disease</infon><location offset="1546" length="26"/><text>heterotopic bone formation</text></annotation></passage></document>
<document><id>37898376</id><passage><infon key="journal">Biochim Biophys Acta Mol Cell Res;2023Oct26 119615. doi:10.1016/j.bbamcr.2023.119615</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Curcio R, Frattaruolo L, Marra F, Pesole G, Vozza A, Cappello AR, Fiorillo M, Lauria G, Ahmed A, Fiermonte G, Capobianco L, Dolce V, </infon><offset>0</offset><text>Two functionally different mitochondrial phosphate carriers support Drosophila melanogaster OXPHOS throughout distinct developmental stages.</text><annotation id="1"><infon key="identifier">MESH:D010710</infon><infon key="type">Chemical</infon><location offset="41" length="9"/><text>phosphate</text></annotation></passage><passage><infon key="type">abstract</infon><offset>141</offset></passage></document>
<document><id>37898726</id><passage><infon key="journal">Bone Marrow Transplant;2023Oct28. doi:10.1038/s41409-023-02128-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">7773521</infon><infon key="type">title</infon><infon key="authors">Hollaender N, Glimm E, Gauvin J, Stefanelli T, Zeiser R, </infon><offset>0</offset><text>A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study.</text><annotation id="3"><infon key="identifier">MESH:D000092122</infon><infon key="type">Disease</infon><location offset="64" length="33"/><text>chronic graft versus host disease</text></annotation><annotation id="4"><infon key="identifier">MESH:D000092122</infon><infon key="type">Disease</infon><location offset="99" length="5"/><text>cGvHD</text></annotation><annotation id="5"><infon key="identifier">CVCL:C6V6</infon><infon key="type">CellLine</infon><location offset="165" length="6"/><text>REACH3</text></annotation></passage><passage><infon key="type">abstract</infon><offset>179</offset><text>Overall response rate (ORR) is commonly used as key endpoint to assess treatment efficacy of chronic graft versus host disease (cGvHD), either as ORR at week 24 or as best overall response rate (BOR) at any time point up to week 24 or beyond. Both endpoints as well as duration of response (DOR) were previously reported for the REACH3 study, a phase 3 open-label, randomized study comparing ruxolitinib (RUX) versus best available therapy (BAT). The comparison between RUX and BAT was performed on ORR and BOR using all randomized patients, while DOR was derived for the subgroup of responders only. Here we illustrate the application of the probability of being in response (PBR), a graphical method presenting simultaneously the time to first response and subsequent failure using all randomized patients. In REACH3, PBR showed an earlier time to first response, a higher probability of being in response and a longer duration of response for RUX compared to BAT. PBR is a clinically easily interpretable measurement and can serve as a novel efficacy endpoint to assess treatments for chronic graft versus host disease.</text><annotation id="15"><infon key="identifier">MESH:D000092122</infon><infon key="type">Disease</infon><location offset="272" length="33"/><text>chronic graft versus host disease</text></annotation><annotation id="16"><infon key="identifier">MESH:D000092122</infon><infon key="type">Disease</infon><location offset="307" length="5"/><text>cGvHD</text></annotation><annotation id="17"><infon key="identifier">CVCL:C6V6</infon><infon key="type">CellLine</infon><location offset="508" length="6"/><text>REACH3</text></annotation><annotation id="18"><infon key="identifier">MESH:C540383</infon><infon key="type">Chemical</infon><location offset="571" length="11"/><text>ruxolitinib</text></annotation><annotation id="19"><infon key="identifier">MESH:C540383</infon><infon key="type">Chemical</infon><location offset="584" length="3"/><text>RUX</text></annotation><annotation id="20"><infon key="identifier">MESH:C540383</infon><infon key="type">Chemical</infon><location offset="649" length="3"/><text>RUX</text></annotation><annotation id="21"><infon key="identifier">CVCL:C6V6</infon><infon key="type">CellLine</infon><location offset="991" length="6"/><text>REACH3</text></annotation><annotation id="22"><infon key="identifier">MESH:C540383</infon><infon key="type">Chemical</infon><location offset="1125" length="3"/><text>RUX</text></annotation><annotation id="23"><infon key="identifier">MESH:D000092122</infon><infon key="type">Disease</infon><location offset="1267" length="33"/><text>chronic graft versus host disease</text></annotation></passage><relation id="R1"><infon key="score">0.9981</infon><infon key="role1">Chemical|MESH:C540383</infon><infon key="role2">Disease|MESH:D000092122</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="6,3"/></relation></document>
<document><id>37902229</id><passage><infon key="journal">Photochem Photobiol;2023Oct30. doi:10.1111/php.13877</infon><infon key="year">2023</infon><infon key="type">title</infon><offset>0</offset><text>Correction to "Characteristics of an Impaired PDT Response".</text></passage><passage><infon key="type">abstract</infon><offset>61</offset></passage></document>
<document><id>37902579</id><passage><infon key="journal">Biomater Sci;2023Oct30. doi:10.1039/d3bm01170d</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Raza F, Zafar H, Jiang L, Su J, Yuan W, Qiu M, Paiva-Santos AC, </infon><offset>0</offset><text>Progress of cell membrane-derived biomimetic nanovesicles for cancer phototherapy.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="62" length="6"/><text>cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>In recent years, considerable attention has been given to phototherapy, including photothermal and photodynamic therapy to kill tumor cells by producing heat or reactive oxygen species (ROS). It has the high merits of noninvasiveness and limited drug resistance. To fully utilize this therapy, an extraordinary nanovehicle is required to target phototherapeutic agents in the tumor cells. Nanovesicles embody an ideal strategy for drug delivery applications. Cell membrane-derived biomimetic nanovesicles represent a developing type of nanocarrier. Combining this technique with cancer phototherapy could enable a novel strategy. Herein, efforts are made to describe a comprehensive overview of cell membrane-derived biomimetic nanovesicles for cancer phototherapy. The description in this review is mainly based on representative examples of exosome-derived biomimetic nanomedicine research, ranging from their comparison with traditional nanocarriers to extensive applications in cancer phototherapy. Additionally, the challenges and future prospectives for translating these for clinical application are discussed.</text><annotation id="9"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="211" length="5"/><text>tumor</text></annotation><annotation id="10"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="244" length="23"/><text>reactive oxygen species</text></annotation><annotation id="11"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="269" length="3"/><text>ROS</text></annotation><annotation id="12"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="459" length="5"/><text>tumor</text></annotation><annotation id="13"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="662" length="6"/><text>cancer</text></annotation><annotation id="14"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="828" length="6"/><text>cancer</text></annotation><annotation id="15"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1065" length="6"/><text>cancer</text></annotation></passage><relation id="R1"><infon key="score">0.9874</infon><infon key="role1">Chemical|MESH:D017382</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="2,1"/></relation></document>
<document><id>37902929</id><passage><infon key="journal">Head Neck Pathol;2023Oct30. doi:10.1007/s12105-023-01588-0</infon><infon key="year">2023</infon><infon key="article-id_pmc">4245411</infon><infon key="type">title</infon><infon key="authors">Kirschnick LB, Schuch LF, Gondak R, Rivero ERC, Gomes APN, Etges A, Tarquinio SBC, Mesquita RA, Caldeira PC, da Costa AAS, Mendon&amp;#xe7;a EF, Dos Santos JN, Smit C, Robinson L, Tager EMJR, Mosqueda-Taylor A, Pontes HAR, de Andrade BAB, Fonseca TC, Abrah&amp;#xe3;o AC, Agostini M, Roma&amp;#xf1;ach MJ, Alves FA, Jaguar GC, de Mendon&amp;#xe7;a NF, Pinto MBR, da Silva LC, Lopes MA, Vargas PA, van Heerden W, Abreu LG, Martins MD, Vasconcelos ACU, </infon><offset>0</offset><text>Clinicopathological Features of Metastasis to the Oral and Maxillofacial Region-Multicenter Study.</text><annotation id="1"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="32" length="10"/><text>Metastasis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>99</offset><text>BACKGROUND: This study aimed to investigate the clinicopathological features of metastases in the oral and maxillofacial regions. METHODS: In this retrospective study, biopsy records were obtained from referral centers for oral and maxillofacial diagnosis in Brazil, Guatemala, Mexico, and South Africa. RESULTS: A total of 120 cases were evaluated. Of these, 53.78% affected female patients, with a mean age of 57.64 years. Intraosseous lesions were more frequent, particularly in the posterior region of the mandible (49.58%). Clinically, most cases presented with symptomatic swelling, with an average evolution time of 25 months. The clinical diagnostic hypothesis in most instances was that of a malignant lesion. Breast cancer was the most common primary tumor location in females, while lung origin was most common in males. In most cases, the primary cancer was an adenocarcinoma (44.73%). The follow-up period was available for 29 cases, and out of these, 20 had died due to the disease. CONCLUSION: Although this is a rare condition, clinicians should be aware that any oral lesions have the possibility of being metastatic, particularly in individuals with a previous history of cancer. The findings from this study could assist clinicians in prompt diagnosing these lesions and subsequent conducting oncologic assessments and treatment.</text><annotation id="13"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="179" length="10"/><text>metastases</text></annotation><annotation id="14"><infon key="identifier">MESH:C564648</infon><infon key="type">Disease</infon><location offset="524" length="20"/><text>Intraosseous lesions</text></annotation><annotation id="15"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="678" length="8"/><text>swelling</text></annotation><annotation id="16"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="818" length="13"/><text>Breast cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="860" length="5"/><text>tumor</text></annotation><annotation id="18"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="958" length="6"/><text>cancer</text></annotation><annotation id="19"><infon key="identifier">MESH:D000230</infon><infon key="type">Disease</infon><location offset="972" length="14"/><text>adenocarcinoma</text></annotation><annotation id="20"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1071" length="4"/><text>died</text></annotation><annotation id="21"><infon key="identifier">MESH:D009059</infon><infon key="type">Disease</infon><location offset="1179" length="12"/><text>oral lesions</text></annotation><annotation id="22"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1289" length="6"/><text>cancer</text></annotation><annotation id="23"><infon key="identifier">MESH:D000072716</infon><infon key="type">Disease</infon><location offset="1411" length="9"/><text>oncologic</text></annotation></passage></document>
<document><id>37903307</id><passage><infon key="journal">Retin Cases Brief Rep;2023Nov01; 17 (6) 714. doi:10.1097/ICB.0000000000001269</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bello NR, Pisuchpen P, de Guimar&amp;#xe3;es TAC, Capasso JE, Levin AV, </infon><offset>0</offset><text>TWO CASES OF CRB1-RELATED RETINAL DYSTROPHY ASSOCIATED WITH RETINAL MASSES.</text><annotation id="3"><infon key="identifier">23418</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8092</infon><location offset="13" length="4"/><text>CRB1</text></annotation><annotation id="4"><infon key="identifier">MESH:D058499</infon><infon key="type">Disease</infon><location offset="26" length="17"/><text>RETINAL DYSTROPHY</text></annotation><annotation id="5"><infon key="identifier">MESH:D012164</infon><infon key="type">Disease</infon><location offset="60" length="14"/><text>RETINAL MASSES</text></annotation></passage><passage><infon key="type">abstract</infon><offset>76</offset><text>BACKGROUND/PURPOSE: Mutations in CRB1 are associated with variable severity in expression leading to apparent phenotypic diversity. We present two retinal findings. METHODS: We present two unrelated children with CRB1-related retinal dystrophy with a solitary mass visualized on fundoscopy. Both underwent a complete ophthalmologic examination including visual acuity assessment, optical coherence tomography, intravenous fluorescein angiography, and fundus autofluorescence. RESULTS: In one child, a gliotic mass was observed on the superior temporal vessel away from disk. On optical coherence tomography, the mass appeared to be located in the superficial retina and contained discrete internal moth-eaten optically empty spaces as previously reported in the astrocytic hamartomas of tuberous sclerosis. Fundus autofluorescence showed speckled hyperautofluorescence of the lesion. In the other child, there was a calcified mass within the nerve fiber layer just temporal to the optic nerve. On optical coherence tomography, this mass appeared irregular in shape, encapsulated, and had a heterogeneous disorganized interior with hyperreflective areas. CONCLUSION: In this report, we detail two presentations of CRB1-related retinal dystrophy: retinal astrocytic hamartoma and another form of superficial retinal hamartoma. We believe this may represent a manifestation of CRB1 mutations. Recognition of this finding may prevent unnecessary evaluation for tumor cause in patients with CRB1-related retinal dystrophy.</text><annotation id="20"><infon key="identifier">23418</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8092</infon><location offset="109" length="4"/><text>CRB1</text></annotation><annotation id="21"><infon key="identifier">23418</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8092</infon><location offset="289" length="4"/><text>CRB1</text></annotation><annotation id="22"><infon key="identifier">MESH:D058499</infon><infon key="type">Disease</infon><location offset="302" length="17"/><text>retinal dystrophy</text></annotation><annotation id="23"><infon key="identifier">MESH:D019793</infon><infon key="type">Chemical</infon><location offset="498" length="11"/><text>fluorescein</text></annotation><annotation id="24"><infon key="identifier">MESH:D006222</infon><infon key="type">Disease</infon><location offset="838" length="21"/><text>astrocytic hamartomas</text></annotation><annotation id="25"><infon key="identifier">MESH:D014402</infon><infon key="type">Disease</infon><location offset="863" length="18"/><text>tuberous sclerosis</text></annotation><annotation id="26"><infon key="identifier">23418</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8092</infon><location offset="1289" length="4"/><text>CRB1</text></annotation><annotation id="27"><infon key="identifier">MESH:D058499</infon><infon key="type">Disease</infon><location offset="1302" length="17"/><text>retinal dystrophy</text></annotation><annotation id="28"><infon key="identifier">MESH:D012173</infon><infon key="type">Disease</infon><location offset="1321" length="28"/><text>retinal astrocytic hamartoma</text></annotation><annotation id="29"><infon key="identifier">MESH:D012173</infon><infon key="type">Disease</infon><location offset="1382" length="17"/><text>retinal hamartoma</text></annotation><annotation id="30"><infon key="identifier">23418</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8092</infon><location offset="1450" length="4"/><text>CRB1</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1533" length="5"/><text>tumor</text></annotation><annotation id="32"><infon key="identifier">23418</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8092</infon><location offset="1562" length="4"/><text>CRB1</text></annotation><annotation id="33"><infon key="identifier">MESH:D058499</infon><infon key="type">Disease</infon><location offset="1575" length="17"/><text>retinal dystrophy</text></annotation></passage><relation id="R1"><infon key="score">0.9989</infon><infon key="role1">Disease|MESH:D012173</infon><infon key="role2">Gene|23418</infon><infon key="type">Association</infon><node refid="0" role="11,9"/></relation><relation id="R2"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D058499</infon><infon key="role2">Gene|23418</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D012164</infon><infon key="role2">Gene|23418</infon><infon key="type">Association</infon><node refid="2" role="2,0"/></relation></document>
<document><id>37903658</id><passage><infon key="journal">Neurosci Biobehav Rev;2023Oct28 105442. doi:10.1016/j.neubiorev.2023.105442</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Neves L, Correia AI, Castro SL, Martins D, Lima CF, </infon><offset>0</offset><text>Corrigendum to "Does music training enhance auditory and linguistic processing? A systematic review and meta-analysis of behavioral and brain evidence" [Neurosci. Biobehav. Rev. 140 (2022) 104777].</text></passage><passage><infon key="type">abstract</infon><offset>198</offset></passage></document>
<document><id>37904009</id><passage><infon key="journal">Mol Biol Rep;2023Oct30. doi:10.1007/s11033-023-08798-3</infon><infon key="year">2023</infon><infon key="article-id_pmc">4121655</infon><infon key="type">title</infon><infon key="authors">Wang H, Liu F, Xue J, Liu Y, Gao W, Yang S, Mi Y, Zhang X, Gao S, Geng C, </infon><offset>0</offset><text>The investigation of circRNA profiling reveals the regulatory role of the hsa_circ_0000375/miR-7706 pathway in breast cancer.</text><annotation id="2"><infon key="identifier">102465803</infon><infon key="type">Gene</infon><location offset="91" length="8"/><text>miR-7706</text></annotation><annotation id="3"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="111" length="13"/><text>breast cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>126</offset><text>BACKGROUND: Circular RNAs (circRNAs) take an effect on tumorigenesis and progression. However, circRNAs have not been systematically identified in breast cancer (BC) as crucial regulators in multitudinous biological processes. This study is conducted to explore novel circRNAs in BC and the corresponding mechanisms of their action. METHODS: The circRNA expression profile and RNA-sequencing data about BC were respectively downloaded from public database. Differentially expressed circRNAs, miRNAs, and mRNAs were identified by fold change filtering. The competing endogenous RNAs (ceRNAs) network was established based on the relationship between circular RNAs, miRNAs and mRNAs. GO and KEGG enrichment analysis of the overlapped genes were carried out to predict the potential functions and mechanisms of circRNAs in BC. The CytoHubba plugin in Cytoscape was applied to identify the hub genes from the PPI regulatory network. Kaplan-Meier plotter was used to perform survival analysis of these hub genes further. Real-time PCR was performed to test the expression of circRNA in BC tissues. Cell function studies including transwell analysis and CCK-8 analysis were used to investigate circRNAs' biological functions. RESULTS: A total of seven circRNAs exhibiting differential expression were identified in this study. After the intersection between the predicted target miRNA and the down-regulated differential miRNAs (DEmiRNAs), circRNA-miRNA interactions involving 3 circRNAs and 4 miRNAs were identified. Venn diagram was utilized to intersect the predicted target genes of the 4 miRNAs and the down-regulated differential genes in BC, and 149 overlapped genes were screened out ulteriorly. Additionally, we built a protein-protein interaction (PPI) network and selected six hub genes. Moreover, the survival data of BC patients suggested that low expression of ADIPOQ, LPL and LEP were significantly correlated with poor prognosis. Results from real-time PCR indicated that hsa_circ_0000375 was significantly down-regulated in breast cancer tissues. Functional in vitro experiments showed that over-expression of hsa_circ_0000375 can restrain proliferation, migration and invasion abilities of breast cancer cells. Further verification indicated that hsa_circ_0000375 exerted its anti-oncogene effect via sponge of miR-7706. CONCLUSIONS: This study constructed and analyzed a circRNA-associated ceRNA regulatory network and uncovered that hsa_circ_0000375 exerted its anti-oncogene effect via sponge of miR-7706.</text><annotation id="20"><infon key="identifier">MESH:D063646</infon><infon key="type">Disease</infon><location offset="181" length="13"/><text>tumorigenesis</text></annotation><annotation id="21"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="273" length="13"/><text>breast cancer</text></annotation><annotation id="22"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="288" length="2"/><text>BC</text></annotation><annotation id="23"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="406" length="2"/><text>BC</text></annotation><annotation id="24"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="529" length="2"/><text>BC</text></annotation><annotation id="25"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="946" length="2"/><text>BC</text></annotation><annotation id="26"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1207" length="2"/><text>BC</text></annotation><annotation id="27"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1765" length="2"/><text>BC</text></annotation><annotation id="28"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="1950" length="2"/><text>BC</text></annotation><annotation id="29"><infon key="identifier">9370</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3525</infon><location offset="1995" length="6"/><text>ADIPOQ</text></annotation><annotation id="30"><infon key="identifier">4023</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">200</infon><location offset="2003" length="3"/><text>LPL</text></annotation><annotation id="31"><infon key="identifier">3952</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">193</infon><location offset="2011" length="3"/><text>LEP</text></annotation><annotation id="32"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="2161" length="13"/><text>breast cancer</text></annotation><annotation id="33"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="2328" length="13"/><text>breast cancer</text></annotation><annotation id="34"><infon key="identifier">102465803</infon><infon key="type">Gene</infon><location offset="2449" length="8"/><text>miR-7706</text></annotation><annotation id="35"><infon key="identifier">102465803</infon><infon key="type">Gene</infon><location offset="2637" length="8"/><text>miR-7706</text></annotation></passage><relation id="R1"><infon key="score">0.9574</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|3952</infon><infon key="type">Association</infon><node refid="0" role="10,13"/></relation><relation id="R2"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|102465803</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.9983</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|9370</infon><infon key="type">Association</infon><node refid="2" role="10,11"/></relation><relation id="R4"><infon key="score">0.9583</infon><infon key="role1">Disease|MESH:D001943</infon><infon key="role2">Gene|4023</infon><infon key="type">Association</infon><node refid="3" role="10,12"/></relation></document>
<document><id>37905059</id><passage><infon key="journal">medRxiv;2023Oct16. doi:10.1101/2023.10.16.23297100</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10615013</infon><infon key="type">title</infon><infon key="authors">Hou X, Heckman MG, Fiesel FC, Koga S, Soto-Beasley AI, Watzlawik JO, Zhao J, Valentino RR, Johnson PW, White LJ, Quicksall ZS, Reddy JS, Bras J, Guerreiro R, Zhao N, Bu G, Dickson DW, Ross OA, Springer W, </infon><offset>0</offset><text>Genome-wide association study identifies APOE and ZMIZ1 variants as mitophagy modifiers in Lewy body disease.</text><annotation id="3"><infon key="identifier">328365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">10667</infon><location offset="50" length="5"/><text>ZMIZ1</text></annotation><annotation id="4"><infon key="type">Disease</infon><location offset="68" length="9"/><text>mitophagy</text></annotation><annotation id="5"><infon key="identifier">MESH:D020961</infon><infon key="type">Disease</infon><location offset="91" length="17"/><text>Lewy body disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>110</offset><text>The PINK1-PRKN pathway mediates a critical quality control to maintain mitochondrial health and function. Together the kinase-ligase pair identifies and decorate damaged mitochondria with phosphorylated ubiquitin (p-S65-Ub). This selective label serves as the mitophagy tag and facilitates their degradation via autophagy-lysosome system. While complete loss of PINK1 or PRKN function causes early-onset Parkinson disease, much broader mitophagy impairments are emerging across neurodegenerative disorders. We previously found age- and disease-dependent accumulation of p-S65-Ub signal in the hippocampus of autopsy brains with Lewy body disease (LBD). However, the contribution of genetic variation to mitochondrial damage and p-S65-Ub levels remains unknown in LBD cases. To identify novel regulators of PINK1-PRKN mitophagy in LBD, we performed an unbiased genome-wide association study of hippocampal p-S65-Ub level with 1,012 autopsy confirmed LBD samples. Using an established, mostly automated workflow, hippocampal sections were immunostained for p-S65-Ub, scanned, and quantified with unbiased algorithms. Functional validation of the significant hit was performed in animal model and human induced pluripotent stem cells (hiPSCs). We identified a strong association with p-S65-Ub for APOE4 (rs429358; beta : 0.50, 95% CI: 0.41 to 0.69; p =8.67x10 -25 ) and a genome-wide significant association for ZMIZ1 (rs6480922; beta : -0.33, 95% CI: -0.45 to -0.22; p =1.42x10 -8 ). The increased p-S65-Ub levels in APOE4 -carrier may be mediated by both co-pathology-dependent and -independent mechanisms, which was confirmed in Apoe-targeted replacement mice and hiPSC-derived astrocytes. Intriguingly, ZMIZ1 rs6480922 also significantly associated with increased brain weight and reduced neuropathological burden indicating a potential role as a resilience factor. Our findings nominate novel mitophagy regulators in LBD brain ( ZMIZ1 locus) and highlight a strong association of APOE4 with mitophagy alteration. With APOE4 being the strongest known risk factor for clinical Alzheimer's disease and dementia with Lewy bodies, our findings suggest a common mechanistic link underscoring the importance of mitochondrial quality control.</text><annotation id="38"><infon key="identifier">68943</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">32672</infon><location offset="114" length="5"/><text>PINK1</text></annotation><annotation id="39"><infon key="identifier">5071</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3355</infon><location offset="120" length="4"/><text>PRKN</text></annotation><annotation id="40"><infon key="type">Disease</infon><location offset="370" length="9"/><text>mitophagy</text></annotation><annotation id="41"><infon key="identifier">68943</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">32672</infon><location offset="472" length="5"/><text>PINK1</text></annotation><annotation id="42"><infon key="identifier">50873</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3355</infon><location offset="481" length="4"/><text>PRKN</text></annotation><annotation id="43"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="514" length="17"/><text>Parkinson disease</text></annotation><annotation id="44"><infon key="type">Disease</infon><location offset="546" length="9"/><text>mitophagy</text></annotation><annotation id="45"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="588" length="27"/><text>neurodegenerative disorders</text></annotation><annotation id="46"><infon key="identifier">MESH:D020961</infon><infon key="type">Disease</infon><location offset="738" length="17"/><text>Lewy body disease</text></annotation><annotation id="47"><infon key="identifier">MESH:D020961</infon><infon key="type">Disease</infon><location offset="757" length="3"/><text>LBD</text></annotation><annotation id="48"><infon key="identifier">MESH:D028361</infon><infon key="type">Disease</infon><location offset="813" length="20"/><text>mitochondrial damage</text></annotation><annotation id="49"><infon key="identifier">MESH:D020961</infon><infon key="type">Disease</infon><location offset="873" length="3"/><text>LBD</text></annotation><annotation id="50"><infon key="identifier">68943</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">32672</infon><location offset="916" length="5"/><text>PINK1</text></annotation><annotation id="51"><infon key="identifier">50873</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3355</infon><location offset="922" length="4"/><text>PRKN</text></annotation><annotation id="52"><infon key="type">Disease</infon><location offset="927" length="9"/><text>mitophagy</text></annotation><annotation id="53"><infon key="identifier">MESH:D020961</infon><infon key="type">Disease</infon><location offset="940" length="3"/><text>LBD</text></annotation><annotation id="54"><infon key="identifier">MESH:D020961</infon><infon key="type">Disease</infon><location offset="1059" length="3"/><text>LBD</text></annotation><annotation id="55"><infon key="identifier">348</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30951</infon><location offset="1404" length="5"/><text>APOE4</text></annotation><annotation id="56"><infon key="identifier">tmVar:rs429358;VariantGroup:0;CorrespondingGene:348;RS#:429358;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1411" length="8"/><text>rs429358</text></annotation><annotation id="57"><infon key="identifier">328365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">10667</infon><location offset="1519" length="5"/><text>ZMIZ1</text></annotation><annotation id="58"><infon key="identifier">tmVar:rs6480922;VariantGroup:1;OriginalGene:328365;CorrespondingGene:57178;RS#:6480922;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="1526" length="9"/><text>rs6480922</text></annotation><annotation id="59"><infon key="identifier">348</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30951</infon><location offset="1625" length="5"/><text>APOE4</text></annotation><annotation id="60"><infon key="identifier">328365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">10667</infon><location offset="1814" length="5"/><text>ZMIZ1</text></annotation><annotation id="61"><infon key="identifier">tmVar:rs6480922;VariantGroup:1;OriginalGene:328365;CorrespondingGene:57178;RS#:6480922;CorrespondingSpecies:10090</infon><infon key="type">SNP</infon><location offset="1820" length="9"/><text>rs6480922</text></annotation><annotation id="62"><infon key="type">Disease</infon><location offset="2005" length="9"/><text>mitophagy</text></annotation><annotation id="63"><infon key="identifier">MESH:D020961</infon><infon key="type">Disease</infon><location offset="2029" length="3"/><text>LBD</text></annotation><annotation id="64"><infon key="identifier">328365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">10667</infon><location offset="2041" length="5"/><text>ZMIZ1</text></annotation><annotation id="65"><infon key="identifier">348</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30951</infon><location offset="2092" length="5"/><text>APOE4</text></annotation><annotation id="66"><infon key="type">Disease</infon><location offset="2103" length="9"/><text>mitophagy</text></annotation><annotation id="67"><infon key="identifier">348</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">30951</infon><location offset="2130" length="5"/><text>APOE4</text></annotation><annotation id="68"><infon key="identifier">MESH:D000544</infon><infon key="type">Disease</infon><location offset="2187" length="19"/><text>Alzheimer's disease</text></annotation><annotation id="69"><infon key="identifier">MESH:D020961</infon><infon key="type">Disease</infon><location offset="2211" length="25"/><text>dementia with Lewy bodies</text></annotation></passage><relation id="R1"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D020961</infon><infon key="role2">Gene|50873</infon><infon key="type">Association</infon><node refid="0" role="18,16"/></relation><relation id="R2"><infon key="score">0.9791</infon><infon key="role1">Gene|5071</infon><infon key="role2">Gene|68943</infon><infon key="type">Association</infon><node refid="1" role="4,3"/></relation><relation id="R3"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D020961</infon><infon key="role2">Gene|68943</infon><infon key="type">Association</infon><node refid="2" role="18,15"/></relation><relation id="R4"><infon key="score">0.9983</infon><infon key="role1">Disease|MESH:D010300</infon><infon key="role2">Gene|68943</infon><infon key="type">Association</infon><node refid="3" role="8,6"/></relation><relation id="R5"><infon key="score">0.9984</infon><infon key="role1">Disease|MESH:D010300</infon><infon key="role2">Gene|50873</infon><infon key="type">Association</infon><node refid="4" role="8,7"/></relation><relation id="R6"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D020961</infon><infon key="role2">Gene|328365</infon><infon key="type">Association</infon><node refid="5" role="2,0"/></relation></document>
<document><id>37905409</id><passage><infon key="journal">Proc Nutr Soc;2023Oct31 1. doi:10.1017/S0029665123004809</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Woodside JV, Lindberg L, Nugent AP, </infon><offset>0</offset><text>Harnessing the power on our plates: sustainable dietary patterns for public and planetary health.</text></passage><passage><infon key="type">abstract</infon><offset>98</offset></passage></document>
<document><id>37905760</id><passage><infon key="journal">Zhongguo Dang Dai Er Ke Za Zhi;2023Oct15; 25 (10) 1034. doi:10.7499/j.issn.1008-8830.2305114</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10621052</infon><infon key="type">title</infon><infon key="authors">Wang RY, Chen H, Huang ZX, Chen Y, Zhong JM, </infon><offset>0</offset><text>[Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a retrospective analysis].</text><annotation id="1"><infon key="identifier">MESH:D009157</infon><infon key="type">Disease</infon><location offset="84" length="24"/><text>ocular myasthenia gravis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>137</offset><text>OBJECTIVES: To investigate the clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis (OMG). METHODS: A retrospective analysis was conducted on 130 children with OMG who were treated in the Department of Neurology, Jiangxi Children's Hospital, from February 2018 to February 2023. According to the treatment regimen, they were divided into four groups: glucocorticoid (GC) group (n=29), mycophenolate mofetil (MMF) group (GC+MMF; n=33), methotrexate (MTX) group (GC+MTX; n=30), and tacrolimus (FK506) group (GC+FK506; n=38). Treatment outcomes and adverse reactions were compared among the groups. RESULTS: After 3 months of treatment, the FK506 group had significantly lower scores of Myasthenia Gravis Quantitative Scale and Myasthenia Gravis-Specific Activities of Daily Living than the other three groups (P&lt;0.05). After 3 months of treatment, the FK506 group had a significantly lower dose of prednisone than the GC group, and after 6 and 9 months of treatment, the MMF, MTX, and FK506 groups had a significantly lower dose of prednisone than the GC group (P&lt;0.05). After 12 months of treatment, the MMF, MTX, and FK506 groups had a significantly lower incidence rate of GC-related adverse reactions than the GC group (P&lt;0.05). CONCLUSIONS: For children with OMG, the addition of various immunosuppressants can reduce the dosage of GC and adverse reactions. Among them, FK506 shows superior efficacy compared to other immunosuppressants in the early treatment of OMG.</text><annotation id="29"><infon key="identifier">MESH:D009157</infon><infon key="type">Disease</infon><location offset="251" length="24"/><text>ocular myasthenia gravis</text></annotation><annotation id="30"><infon key="identifier">MESH:D009157</infon><infon key="type">Disease</infon><location offset="277" length="3"/><text>OMG</text></annotation><annotation id="31"><infon key="identifier">MESH:D009157</infon><infon key="type">Disease</infon><location offset="352" length="3"/><text>OMG</text></annotation><annotation id="32"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="577" length="21"/><text>mycophenolate mofetil</text></annotation><annotation id="33"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="600" length="3"/><text>MMF</text></annotation><annotation id="34"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="615" length="3"/><text>MMF</text></annotation><annotation id="35"><infon key="identifier">MESH:D008727</infon><infon key="type">Chemical</infon><location offset="627" length="12"/><text>methotrexate</text></annotation><annotation id="36"><infon key="identifier">MESH:D008727</infon><infon key="type">Chemical</infon><location offset="641" length="3"/><text>MTX</text></annotation><annotation id="37"><infon key="identifier">MESH:D008727</infon><infon key="type">Chemical</infon><location offset="656" length="3"/><text>MTX</text></annotation><annotation id="38"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="672" length="10"/><text>tacrolimus</text></annotation><annotation id="39"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="684" length="5"/><text>FK506</text></annotation><annotation id="40"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="701" length="5"/><text>FK506</text></annotation><annotation id="41"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="830" length="5"/><text>FK506</text></annotation><annotation id="42"><infon key="identifier">MESH:D020294</infon><infon key="type">Disease</infon><location offset="876" length="10"/><text>Myasthenia</text></annotation><annotation id="43"><infon key="identifier">MESH:D020294</infon><infon key="type">Disease</infon><location offset="917" length="10"/><text>Myasthenia</text></annotation><annotation id="44"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="1042" length="5"/><text>FK506</text></annotation><annotation id="45"><infon key="identifier">MESH:D011241</infon><infon key="type">Chemical</infon><location offset="1088" length="10"/><text>prednisone</text></annotation><annotation id="46"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="1161" length="3"/><text>MMF</text></annotation><annotation id="47"><infon key="identifier">MESH:D008727</infon><infon key="type">Chemical</infon><location offset="1166" length="3"/><text>MTX</text></annotation><annotation id="48"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="1175" length="5"/><text>FK506</text></annotation><annotation id="49"><infon key="identifier">MESH:D011241</infon><infon key="type">Chemical</infon><location offset="1222" length="10"/><text>prednisone</text></annotation><annotation id="50"><infon key="identifier">MESH:D009173</infon><infon key="type">Chemical</infon><location offset="1295" length="3"/><text>MMF</text></annotation><annotation id="51"><infon key="identifier">MESH:D008727</infon><infon key="type">Chemical</infon><location offset="1300" length="3"/><text>MTX</text></annotation><annotation id="52"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="1309" length="5"/><text>FK506</text></annotation><annotation id="53"><infon key="identifier">MESH:D009157</infon><infon key="type">Disease</infon><location offset="1454" length="3"/><text>OMG</text></annotation><annotation id="54"><infon key="identifier">MESH:D016559</infon><infon key="type">Chemical</infon><location offset="1565" length="5"/><text>FK506</text></annotation><annotation id="55"><infon key="identifier">MESH:D009157</infon><infon key="type">Disease</infon><location offset="1658" length="3"/><text>OMG</text></annotation></passage><relation id="R1"><infon key="score">0.7464</infon><infon key="role1">Chemical|MESH:D009173</infon><infon key="role2">Chemical|MESH:D011241</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="18,17"/></relation><relation id="R2"><infon key="score">0.9773</infon><infon key="role1">Chemical|MESH:D011241</infon><infon key="role2">Chemical|MESH:D016559</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="17,16"/></relation><relation id="R3"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:D016559</infon><infon key="role2">Disease|MESH:D009157</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="26,27"/></relation><relation id="R4"><infon key="score">0.9247</infon><infon key="role1">Chemical|MESH:D008727</infon><infon key="role2">Chemical|MESH:D011241</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="19,17"/></relation><relation id="R5"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D016559</infon><infon key="role2">Disease|MESH:D020294</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="13,14"/></relation></document>
<document><id>37906111</id><passage><infon key="journal">J Basic Microbiol;2023Oct31. doi:10.1002/jobm.202300225</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Solomon S, Babu DT, Gopalakrishnan S, Augustine D, Kachiprath B, Kesavan D, Sarasan M, Philip R, </infon><offset>0</offset><text>Marine actinomycete Streptomyces variabilis S26 as a biocontrol agent for vibriosis in shrimp larval rearing systems.</text><annotation id="1"><infon key="identifier">MESH:D014735</infon><infon key="type">Disease</infon><location offset="74" length="9"/><text>vibriosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>118</offset><text>Indiscriminate use of antibiotics has led to the emergence of antibiotic-resistant microbes and the loss of natural flora in aquaculture systems necessitating the ban of many of these chemotherapeutants in aquaculture. Actinobacteria play a profound role in the biogeochemical cycling in the marine environment and represent the principal source of secondary metabolites with antimicrobial property. In the present study, 98 marine-derived actinomycete isolates were screened for antimicrobial activity against the common aquatic pathogens. A potent actinomycete isolate S26, identified as Streptomyces variabilis based on 16 S ribosomal RNA (rRNA) gene sequencing was then checked for the production of antibiotic in five different fermentation media and the one which showed maximum production was chosen for further study. Optimization of the fermentation medium for secondary metabolite production was carried out by response surface methodology (RSM) using DESIGN EXPERT. The analysis of variance (ANOVA) of the quadratic regression model demonstrated that the model was highly significant for the response concerned that is, antimicrobial activity as evident from the Fisher's F- test with a very low probability value [(P model>F) = 0.0001]. Of the 10 different solutions suggested by the software, the most suitable composition was found to be starch, 1.38%; soy powder, 0.88%; ammonium sulfate, 0.16% and salinity, 27.76%. S. variabilis S26 cultured in the optimized production medium was applied in the Penaeus monodon larval rearing system and the total Vibrio count and survival rate were estimated. S. variabilis S26 treatment showed a significant reduction in vibrios and conferred better protection to P. monodon in culture system compared with control.</text><annotation id="5"><infon key="identifier">CVCL:B0UB</infon><infon key="type">CellLine</infon><location offset="689" length="3"/><text>S26</text></annotation><annotation id="6"><infon key="identifier">MESH:D013213</infon><infon key="type">Chemical</infon><location offset="1470" length="6"/><text>starch</text></annotation><annotation id="7"><infon key="identifier">MESH:D000645</infon><infon key="type">Chemical</infon><location offset="1504" length="16"/><text>ammonium sulfate</text></annotation></passage></document>
<document><id>37906462</id><passage><infon key="journal">Water Sci Technol;2023Oct; 88 (8) 2121. doi:10.2166/wst.2023.306</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Devipriya B, Mohanan S, Surenjan A, </infon><offset>0</offset><text>CFD modelling of an immobilised photocatalytic reactor for phenol degradation.</text><annotation id="1"><infon key="identifier">MESH:D019800</infon><infon key="type">Chemical</infon><location offset="59" length="6"/><text>phenol</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Photocatalysis is an advanced oxidation process, which has been gaining attention as a sustainable technology for tackling pollution. Optimum design, fabrication and scaling up of novel photocatalytic reactors are faced with problems such as fabrication cost and numerous experimental trials for optimisation. Computational fluid dynamics (CFD), a computer simulation technique can ease the process of scaling up photocatalytic reactors. The current study focuses on CFD modelling of a serpentine flow path photocatalytic reactor with curved baffles for phenol degradation. The investigation compared different reactor configurations to finalise the optimum design with maximum removal efficiency. Initially, a simple cuboidal reactor was chosen with an efficiency of 27%. However, with a serpentine flow path being introduced, the reactor displayed an improved efficiency of 42%. The addition of baffles improved flow homogeneity and degradation efficiency. The investigation showed that serpentine flow increased the residence time and fluid mixing, while the curved baffles prevented flow channelisation, which enhanced the degradation efficiency. Efficiencies corresponding to different baffle types and geometry were also compared and the final reactor design chosen was a horizontal curved baffled serpentine flow reactor with a flow rate of 0.3 L/s and improved efficiency of 43.1% for a residence time of 18.44 s.</text><annotation id="7"><infon key="identifier">MESH:C009244</infon><infon key="type">Chemical</infon><location offset="565" length="10"/><text>serpentine</text></annotation><annotation id="8"><infon key="identifier">MESH:D019800</infon><infon key="type">Chemical</infon><location offset="633" length="6"/><text>phenol</text></annotation><annotation id="9"><infon key="identifier">MESH:C009244</infon><infon key="type">Chemical</infon><location offset="868" length="10"/><text>serpentine</text></annotation><annotation id="10"><infon key="identifier">MESH:C009244</infon><infon key="type">Chemical</infon><location offset="1068" length="10"/><text>serpentine</text></annotation><annotation id="11"><infon key="identifier">MESH:C009244</infon><infon key="type">Chemical</infon><location offset="1383" length="10"/><text>serpentine</text></annotation></passage></document>
<document><id>37906836</id><passage><infon key="journal">Langmuir;2023Oct31. doi:10.1021/acs.langmuir.3c02555</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zheng J, Li J, Fu Q, Zhang L, Zhu X, Liao Q, </infon><offset>0</offset><text>Boosting Carbon Dioxide Reduction in a Photocatalytic Fuel Cell with a Bubbling Fluidized Cathode: Dual Function of Titanium Carbide.</text><annotation id="2"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="9" length="14"/><text>Carbon Dioxide</text></annotation><annotation id="3"><infon key="identifier">MESH:C096521</infon><infon key="type">Chemical</infon><location offset="116" length="16"/><text>Titanium Carbide</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>Photoelectrochemical reduction of carbon dioxide (CO2) is a promising avenue to realize resourceful utilization of carbon dioxide and mitigate the energy shortage. Herein, a photocatalytic fuel cell with a bubbling fluidized cathode (PFC-BFC) is proposed to increase the performance of the photocatalytic CO2 reduction reaction (CO2RR). Titanium carbide (Ti3C2) is first used as a fluidized cathode catalyst with the dual features of superior capacitance and high CO2RR catalytic activity. Compared with the conventional PFC system, the as-proposed PFC-BFC system exhibits a higher gas production performance. Particularly, the generation rate and Faraday efficiency for CH4 production reach to 37.2 mumol g-1 h-1 and 72%, which are 10.9 and 6.5 times higher than that of the conventional PFC system, respectively. The bubbling fluidized cathode allows a rapid electron transfer between catalysts and the current collector and an efficient diffusion of catalysts in the whole solution, thus remarkably increasing the effective reaction area of the CO2RR. In addition, the fluidized reaction mechanism of charging/discharging-coupled CO2RR is investigated. Significantly, a magnified PFC-BFC system is designed and exhibits a similar gas generation rate compared to that of the small-scale system, indicating a good potential of scaling up in the industry applications. These results demonstrated that the proposed PFC-BFC system can maximize the utilization of catalyst active sites and enhance the reaction kinetics, providing an alternative design for the application of CO2RR.</text><annotation id="21"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="168" length="14"/><text>carbon dioxide</text></annotation><annotation id="22"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="184" length="3"/><text>CO2</text></annotation><annotation id="23"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="249" length="14"/><text>carbon dioxide</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="368" length="3"/><text>PFC</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="372" length="3"/><text>BFC</text></annotation><annotation id="26"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="439" length="3"/><text>CO2</text></annotation><annotation id="27"><infon key="identifier">MESH:C096521</infon><infon key="type">Chemical</infon><location offset="471" length="16"/><text>Titanium carbide</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="489" length="5"/><text>Ti3C2</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="655" length="3"/><text>PFC</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="683" length="3"/><text>PFC</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="687" length="3"/><text>BFC</text></annotation><annotation id="32"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="805" length="3"/><text>CH4</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="923" length="3"/><text>PFC</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1317" length="3"/><text>PFC</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1321" length="3"/><text>BFC</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1548" length="3"/><text>PFC</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1552" length="3"/><text>BFC</text></annotation></passage><relation id="R1"><infon key="score">0.4882</infon><infon key="role1">Chemical|MESH:C096521</infon><infon key="role2">Chemical|MESH:D002245</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation></document>
<document><id>37907202</id><passage><infon key="journal">Adv Mater;2023Oct31 2309223. doi:10.1002/adma.202309223</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhao Z, Alshareef HN, </infon><offset>0</offset><text>Sustainable Dual-Ion Batteries Beyond Li.</text></passage><passage><infon key="type">abstract</infon><offset>42</offset><text>The limitations of resources used in current Li-ion batteries render them unsuitable for grid energy storage systems, prompting the search for low-cost and resource-abundant alternatives. "Beyond-Li cation" batteries have emerged as promising contenders; however, they confront noteworthy challenges due to the scarcity of suitable host materials for these cations. In contrast, anions, the other crucial component in electrolytes, demonstrate reversible intercalation capacity in specific materials like graphite. The convergence of anion and cation storage has given rise to a new battery technology known as dual-ion batteries (DIBs). This comprehensive review presents the current status, advancements, and future prospects of sustainable DIBs beyond Li. Notably, most DIBs exhibit similar cathode reaction mechanisms involving anion intercalation, while the distinguishing factor lies in the cation types functioning at the anode. Accordingly, this review is organized into sections by various cation types, including Na-, K-, Mg-, Zn-, Ca-, Al-, NH4 + -, and proton-based DIBs. Moreover, a perspective on these novel DIBs is presented, along with proposed protocols for investigating DIBs and promising future research directions. We envision that this review will inspire fresh concepts, ideas, and research directions, while raising important questions to further tailor and understand sustainable DIBs, ultimately facilitating their practical realization. This article is protected by copyright. All rights reserved.</text><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="87" length="16"/><text>Li-ion batteries</text></annotation><annotation id="7"><infon key="identifier">MESH:D006108</infon><infon key="type">Chemical</infon><location offset="547" length="8"/><text>graphite</text></annotation><annotation id="8"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1074" length="2"/><text>Mg</text></annotation><annotation id="9"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="1079" length="2"/><text>Zn</text></annotation><annotation id="10"><infon key="identifier">MESH:D000535</infon><infon key="type">Chemical</infon><location offset="1089" length="2"/><text>Al</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1094" length="5"/><text>NH4 +</text></annotation></passage></document>
<document><id>37909305</id><passage><infon key="journal">Med Teach;2023Nov01 1. doi:10.1080/0142159X.2023.2276978</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Abbasi K, Ali P, Barbour V, Benfield T, Bibbins-Domingo K, Erhabor GE, Hancocks S, Horton R, Laybourn-Langton L, Mash R, Sahni P, Sharief WM, Yonga P, Zielinski C, </infon><offset>0</offset><text>Time to treat the climate and nature crisis as one indivisible global health emergency.</text></passage><passage><infon key="type">abstract</infon><offset>88</offset></passage></document>
<document><id>37909659</id><passage><infon key="journal">Mol Ecol;2023Nov01. doi:10.1111/mec.17189</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Quiroga MV, Stegen JC, Mataloni G, Cowan D, Lebre PH, Valverde A, </infon><offset>0</offset><text>Microdiverse bacterial clades prevail across Antarctic wetlands.</text></passage><passage><infon key="type">abstract</infon><offset>65</offset><text>Antarctica's extreme environmental conditions impose selection pressures on microbial communities. Indeed, a previous study revealed that bacterial assemblages at the Cierva Point Wetland Complex (CPWC) are shaped by strong homogeneous selection. Yet which bacterial phylogenetic clades are shaped by selection processes and their ecological strategies to thrive in such extreme conditions remain unknown. Here, we applied the phyloscore and feature-level betaNTI indexes coupled with phylofactorization to successfully detect bacterial monophyletic clades subjected to homogeneous (HoS) and heterogenous (HeS) selection. Remarkably, only the HoS clades showed high relative abundance across all samples and signs of putative microdiversity. The majority of the amplicon sequence variants (ASVs) within each HoS clade clustered into a unique 97% sequence similarity operational taxonomic unit (OTU) and inhabited a specific environment (lotic, lentic or terrestrial). Our findings suggest the existence of microdiversification leading to sub-taxa niche differentiation, with putative distinct ecotypes (consisting of groups of ASVs) adapted to a specific environment. We hypothesize that HoS clades thriving in the CPWC have phylogenetically conserved traits that accelerate their rate of evolution, enabling them to adapt to strong spatio-temporally variable selection pressures. Variable selection appears to operate within clades to cause very rapid microdiversification without losing key traits that lead to high abundance. Variable and homogeneous selection, therefore, operate simultaneously but on different aspects of organismal ecology. The result is an overall signal of homogeneous selection due to rapid within-clade microdiversification caused by variable selection. It is unknown whether other systems experience this dynamic, and we encourage future work evaluating the transferability of our results.</text></passage></document>
<document><id>37910015</id><passage><infon key="journal">J Med Microbiol;2023Nov; 72 (11) . doi:10.1099/jmm.0.001772</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Pourhajibagher M, Azimi Mohammadabadi M, Ghafari HA, Hodjat M, Bahador A, </infon><offset>0</offset><text>Evaluation of anti-biofilm effect of antimicrobial sonodynamic therapy-based periodontal ligament stem cell-derived exosome-loaded kojic acid on Enterococcus faecalis biofilm.</text><annotation id="3"><infon key="type">Disease</infon><location offset="19" length="7"/><text>biofilm</text></annotation><annotation id="4"><infon key="identifier">MESH:C011890</infon><infon key="type">Chemical</infon><location offset="131" length="10"/><text>kojic acid</text></annotation><annotation id="5"><infon key="type">Disease</infon><location offset="167" length="7"/><text>biofilm</text></annotation></passage><passage><infon key="type">abstract</infon><offset>176</offset><text>Introduction. Antimicrobial sonodynamic therapy (aSDT) is an approach that uses ultrasound waves (UWs) and a sonosensitizer to generate reactive oxygen species (ROS) to damage microbial cells in biofilms. Using nano-carriers, such as exosomes (Exos), to deliver the sonosensitizer can potentially enhance the effectiveness of aSDT.Hypothesis/Gap Statement. aSDT can downregulate the expression of gelE and sprE genes, increasing the production of endogenous ROS and degradation of pre-formed Enterococcus faecalis biofilms.Aim. This study investigated the anti-biofilm effect of aSDT-based periodontal ligament stem cell-derived exosome-loaded kojic acid (KA@PDL-Exo) on pre-formed E. faecalis biofilms in root canals.Methodology. Following the isolation and characterization of PDL-Exo, KA@PDL-Exo was prepared and confirmed. The minimal biofilm inhibitory concentration (MBIC) of KA, PDL-Exo, KA@PDL-Exo and sodium hypochlorite (NaOCl) was determined, and their anti-biofilm effects were assessed with and without UWs. The binding affinity of KA with GelE and SprE proteins was evaluated using in silico molecular docking. Additionally, the study measured the generation of endogenous ROS and evaluated changes in the gene expression levels of gelE and sprE.Results. The results revealed a dose-dependent decrease in the viability of E. faecalis cells within biofilms. KA@PDL-Exo was the most effective, with an MBIC of 62.5 microg ml-1, while NaOCl, KA and PDL-Exo had MBIC values of 125, 250 and 500 microg ml-1, respectively. The use of KA@PDL-Exo-mediated aSDT resulted in a significant reduction of the E. faecalis biofilm (3.22+-0.36 log10 c.f.u. ml-1; P&lt;0.05). The molecular docking analysis revealed docking scores of -5.3 and -5.2 kcal mol-1 for GelE-KA an SprE-KA, respectively. The findings observed the most significant reduction in gene expression of gelE and sprE in the KA@PDL-Exo group, with a decrease of 7.9- and 9.3-fold, respectively, compared to the control group (P&lt;0.05).Conclusion. The KA@PDL-Exo-mediated aSDT was able to significantly reduce the E. faecalis load in pre-formed biofilms, decrease the expression of gelE and srpE mRNA, and increase the generation of endogenous ROS. These findings imply that KA@PDL-Exo-mediated aSDT could be a promising anti-biofilm strategy that requires additional in vitro and in vivo investigations.</text><annotation id="30"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="312" length="23"/><text>reactive oxygen species</text></annotation><annotation id="31"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="337" length="3"/><text>ROS</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="502" length="15"/><text>aSDT.Hypothesis</text></annotation><annotation id="33"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="634" length="3"/><text>ROS</text></annotation><annotation id="34"><infon key="type">Disease</infon><location offset="737" length="7"/><text>biofilm</text></annotation><annotation id="35"><infon key="identifier">MESH:C011890</infon><infon key="type">Chemical</infon><location offset="820" length="10"/><text>kojic acid</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="832" length="10"/><text>KA@PDL-Exo</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="964" length="10"/><text>KA@PDL-Exo</text></annotation><annotation id="38"><infon key="type">Disease</infon><location offset="1015" length="7"/><text>biofilm</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1071" length="10"/><text>KA@PDL-Exo</text></annotation><annotation id="40"><infon key="identifier">MESH:D012973</infon><infon key="type">Chemical</infon><location offset="1086" length="19"/><text>sodium hypochlorite</text></annotation><annotation id="41"><infon key="identifier">MESH:D012973</infon><infon key="type">Chemical</infon><location offset="1107" length="5"/><text>NaOCl</text></annotation><annotation id="42"><infon key="type">Disease</infon><location offset="1145" length="7"/><text>biofilm</text></annotation><annotation id="43"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="1363" length="3"/><text>ROS</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1547" length="10"/><text>KA@PDL-Exo</text></annotation><annotation id="45"><infon key="identifier">MESH:D012973</infon><infon key="type">Chemical</infon><location offset="1622" length="5"/><text>NaOCl</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1636" length="3"/><text>PDL</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1718" length="10"/><text>KA@PDL-Exo</text></annotation><annotation id="48"><infon key="type">Disease</infon><location offset="1798" length="7"/><text>biofilm</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2063" length="10"/><text>KA@PDL-Exo</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2188" length="10"/><text>KA@PDL-Exo</text></annotation><annotation id="51"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="2380" length="3"/><text>ROS</text></annotation><annotation id="52"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2411" length="10"/><text>KA@PDL-Exo</text></annotation><annotation id="53"><infon key="type">Disease</infon><location offset="2462" length="7"/><text>biofilm</text></annotation></passage></document>
<document><id>37910366</id><passage><infon key="journal">Environ Sci Pollut Res Int;2023Nov01. doi:10.1007/s11356-023-30275-4</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hashemizadeh A, Ashraf RU, Khan I, Zaidi SAH, </infon><offset>0</offset><text>Digital financial inclusion, environmental quality, and economic development: the contributions of financial development and investments in OECD countries.</text></passage><passage><infon key="type">abstract</infon><offset>156</offset><text>Economic development has long acknowledged the significance of financial innovation and technological advancement. Communication technology increases the availability of information, generates new modes of communication, restructures production processes, and enhances the efficacy of a wide range of economic operations. This study investigates the effects of digital financial inclusion and information and communication technology (ICT) on economic growth in 38 OECD nations between 2004 and 2020, with a focus on the contributions of financial development and investments in non-financial assets. To this end, advanced econometric methodologies are employed to conduct an exhaustive empirical analysis utilizing second-generation panel unit root and cointegration techniques. The results demonstrate a positive correlation between digital financial inclusion, information and communication technology, population growth, and non-financial investments in OECD nations. It is recommended that OECD policymakers promote digital financial inclusion by utilizing cost-effective digital technologies to reach currently financially excluded and underserved populations. This can be achieved through a variety of formal financial services that are tailored to their needs and responsibly delivered at a cost that is affordable to customers and sustainable for providers. Moreover, policymakers are recommended to promote information and communication technologies that strengthen the means for implementing Sustainable Development Goals through international cooperation and coordination, technology transfer, capacity building, strengthening multi-stakeholder partnerships, and data monitoring and accountability. Finally, a detailed conclusion is provided to discuss the research limitations and future directions.</text></passage></document>
<document><id>37910717</id><passage><infon key="journal">Opt Lett;2023Nov01; 48 (21) 5619. doi:10.1364/OL.501824</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rupp M, Goth K, Eichhorn M, Kieleck C, </infon><offset>0</offset><text>High average power Q-switched Ho3+:YAG laser with a single-line emission at 2122 nm.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30" length="8"/><text>Ho3+:YAG</text></annotation></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>We present an efficient Q-switched dual-crystal Ho3+:YAG laser resonator achieving an output power of 56 W at an incident pump power of 100.7 W with a slope efficiency of 64.4%. The setup was pump power limited. Notably, by carefully tuning multiple etalons placed within the cavity, we achieved a single-line spectral emission at 2122 nm. This deviates from the typical emission wavelengths of 2090 nm or 2096 nm for Ho3+:YAG at comparable output powers in Q-switched operation. The laser exhibited very good beam quality, approaching diffraction-limited performance with an excellent M2- &lt; 1.2. At the maximum output power, a pulse FWHM of 100 ns was measured.</text><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="133" length="8"/><text>Ho3+:YAG</text></annotation><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="503" length="8"/><text>Ho3+:YAG</text></annotation></passage></document>
<document><id>37911068</id><passage><infon key="journal">Int Dent J (Phila);1893Feb; 14 (2) 152</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109617</infon><infon key="type">title</infon><infon key="authors">Peirce CN, </infon><offset>0</offset><text>New Mode of Using Nitrate of Silver.</text><annotation id="2"><infon key="identifier">MESH:D009566</infon><infon key="type">Chemical</infon><location offset="18" length="7"/><text>Nitrate</text></annotation><annotation id="3"><infon key="identifier">MESH:D012834</infon><infon key="type">Chemical</infon><location offset="29" length="6"/><text>Silver</text></annotation></passage><passage><infon key="type">abstract</infon><offset>37</offset></passage></document>
<document><id>37911418</id><passage><infon key="journal">Int Dent J (Phila);1890Apr; 11 (4) 255</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110116</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37912118</id><passage><infon key="journal">Int Dent J (Phila);1896Dec; 17 (12) 806</infon><infon key="year">1896</infon><infon key="article-id_pmc">PMC10124503</infon><infon key="type">title</infon><offset>0</offset><text>American Academy of Dental Science.</text></passage><passage><infon key="type">abstract</infon><offset>36</offset></passage></document>
<document><id>37912818</id><passage><infon key="journal">Int Dent J (Phila);1901Apr; 22 (4) 218</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153872</infon><infon key="type">title</infon><infon key="authors">Bogue EA, </infon><offset>0</offset><text>Impressions of the International Dental Congress.</text></passage><passage><infon key="type">abstract</infon><offset>50</offset></passage></document>
<document><id>37913168</id><passage><infon key="journal">Int Dent J (Phila);1903Aug; 24 (8) 596</infon><infon key="year">1903</infon><infon key="article-id_pmc">PMC10162255</infon><infon key="type">title</infon><infon key="authors">Fletcher MH, </infon><offset>0</offset><text>Tolerance of the Tissues to Foreign Bodies, with Special Reference to the Pulp and Gums.</text></passage><passage><infon key="type">abstract</infon><offset>89</offset></passage></document>
<document><id>37913519</id><passage><infon key="journal">N Engl J Med;2023Nov02; 389 (18) 1727. doi:10.1056/NEJMc2310656</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Whelan TJ, Parpia S, Levine MN, </infon><offset>0</offset><text>Omitting Radiotherapy in Luminal A Breast Cancer. Reply.</text><annotation id="1"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="25" length="23"/><text>Luminal A Breast Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>57</offset></passage></document>
<document><id>37913869</id><passage><infon key="journal">J Infect Chemother;2023Oct30. doi:10.1016/j.jiac.2023.10.011</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Samborska M, Wzi&amp;#x105;tek A, M&amp;#x142;ynarczyk &amp;#x141;, Dey S, Varghese N, Derwich K, </infon><offset>0</offset><text>Fusarium oxysporum disseminated infection in a teenage patient with a relapse of acute lymphoblastic leukemia - Case report and review of the literature.</text><annotation id="2"><infon key="identifier">MESH:D000072742</infon><infon key="type">Disease</infon><location offset="19" length="22"/><text>disseminated infection</text></annotation><annotation id="3"><infon key="identifier">MESH:D054198</infon><infon key="type">Disease</infon><location offset="81" length="28"/><text>acute lymphoblastic leukemia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>154</offset><text>Infections are still a significant cause of mortality in children with hematologic malignancies. Fusariosis is a relatively rare and opportunistic infection, which may present dangerous course and a poor prognosis. Below, we describe the fatal course of a 15-years old patient with a combined bone marrow and testicular relapse of ALL and multisystemic Fusariosis oxysporum infection with fulminant evolution. Despite aggressive therapy, which included multiagent antifungal treatment and surgical debridement, patient succumbed to the disease. The review of the literature was conducted and the need for early detection of fusarium symptoms was emphasized. The case encourages further research in the prevention and treatment of the illness.</text><annotation id="9"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="154" length="10"/><text>Infections</text></annotation><annotation id="10"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="225" length="24"/><text>hematologic malignancies</text></annotation><annotation id="11"><infon key="identifier">MESH:D060585</infon><infon key="type">Disease</infon><location offset="251" length="10"/><text>Fusariosis</text></annotation><annotation id="12"><infon key="identifier">MESH:D009894</infon><infon key="type">Disease</infon><location offset="287" length="23"/><text>opportunistic infection</text></annotation><annotation id="13"><infon key="identifier">MESH:D060585</infon><infon key="type">Disease</infon><location offset="778" length="8"/><text>fusarium</text></annotation></passage></document>
<document><id>37914219</id><passage><infon key="journal">J Rheumatol;2023Nov01. doi:10.3899/jrheum.2023-0202</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Inanc N, Jousse-Joulin S, Abacar K, Cim&amp;#x15f;it &amp;#xc7;, Cim&amp;#x15f;it C, D'Agostino MA, Naredo E, Hocevar A, Finzel S, Pineda C, Keen H, Iagnocco A, Hanova P, Schmidt WA, Mumcu G, Terslev L, Bruyn GA, </infon><offset>0</offset><text>The novel OMERACT Ultrasound Scoring System for salivary glands changes in patients with Sjogren's syndrome is associated with MRI and salivary flow rates.</text><annotation id="1"><infon key="identifier">MESH:D012859</infon><infon key="type">Disease</infon><location offset="89" length="18"/><text>Sjogren's syndrome</text></annotation></passage><passage><infon key="type">abstract</infon><offset>156</offset><text>OBJECTIVE: To assess the construct validity of the novel OMERACT ultrasound (US) semiquantitative scoring system for morphological lesions in major salivary glands by comparing with MRI and unstimulated whole salivary flow rates (U-WSFRs) in patients with primary Sjogren's syndrome (pSS). METHODS: Nine sonographers applied the OMERACT 0-3 grayscale scoring system for parotid (PGs) and submandibular glands (SMGs) in 11 patients with pSS who also had MRIs performed. These were evaluated by two radiologists using a semiquantitative 0-3 scoring system for morphological lesions. The agreement between ultrasound and MRI and the association between U-WSFRs and imaging structural lesions was determined. A score >= 2 for both ultrasound and MRI was defined as gland pathology. RESULTS: The prevalence of US morphological lesions in 11 patients with a score >=2 was 58% for PGs and 76% for the SMGs, while 46% and 41% for the PGs and SMGs, respectively, for MRI. Agreement between OMERACT US scores and MRI scores were 73-91% (Median :82) in right and 73-91% (Median :91) in left PGs, 55-91% (Median :55) in right SMG and 55-82% (Median :55) in left SMG. When relations between the presence of hyposalivation and >= 2 score of US were examined, agreement were 91-100% (Median :83) in both PGs and 55-91% (Median :67) in both SMGs. CONCLUSION: There is moderate to strong agreement between the OMERACT US and MRI scores for major salivary glands in patients with pSS. Similar agreement ratios were observed between the higher OMERACT US scores and presence of hyposalivation.</text><annotation id="8"><infon key="identifier">MESH:D012859</infon><infon key="type">Disease</infon><location offset="412" length="26"/><text>primary Sjogren's syndrome</text></annotation><annotation id="9"><infon key="identifier">MESH:D012859</infon><infon key="type">Disease</infon><location offset="440" length="3"/><text>pSS</text></annotation><annotation id="10"><infon key="identifier">MESH:D012859</infon><infon key="type">Disease</infon><location offset="592" length="3"/><text>pSS</text></annotation><annotation id="11"><infon key="identifier">MESH:D014987</infon><infon key="type">Disease</infon><location offset="1350" length="14"/><text>hyposalivation</text></annotation><annotation id="12"><infon key="identifier">MESH:D012859</infon><infon key="type">Disease</infon><location offset="1618" length="3"/><text>pSS</text></annotation><annotation id="13"><infon key="identifier">MESH:D014987</infon><infon key="type">Disease</infon><location offset="1715" length="14"/><text>hyposalivation</text></annotation></passage></document>
<document><id>37914569</id><passage><infon key="journal">Urol Oncol;2023Oct30. doi:10.1016/j.urolonc.2023.08.019</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li Y, Shi X, Jia E, Qin S, Yu F, </infon><offset>0</offset><text>Extracellular vesicle biomarkers for prostate cancer diagnosis: A systematic review and meta-analysis.</text><annotation id="1"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="37" length="15"/><text>prostate cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>103</offset><text>Extracellular vesicle (EV) biomarkers have promising diagnostic and screening capabilities for several cancers, and growing evidence indicates that EV biomarkers can be used as diagnostic markers for prostate cancer (CaP). However, data on the diagnostic accuracy of EV biomarkers for CaP diagnosis are conflicting. We performed a systematic review and meta-analysis, aimed to summarize the diagnostic performance of EV biomarkers for CaP. We systematically searched PubMed, Medline, and Web of Science from inception to 12 September 2022 for studies that assessed the diagnostic accuracy of EV biomarkers for CaP. We summarized the pooled sensitivity and specificity calculated using a random-effects model. We identified 19 studies involving 976 CaP patients and 676 noncancerous controls; one study conducted independent validation tests. Ten studies emphasized EV RNAs, 6 on EV proteins, and 9 on biomarker panels. MiR-141, miR-221, and PSMA were the most frequently reported RNAs and proteins for CaP diagnosis. For individual RNAs and proteins, the pooled sensitivity and specificity were 70% (95% CI: 68%-71%), 79% (95% CI: 77%-80%), 85% (95% CI: 81%-87%), and 83% (95% CI: 80%-86%), respectively. The pooled sensitivity and specificity of the EV panels were 84% (95% CI: 82%-86%) and 86% (95% CI: 84%-88%), respectively. The studies may have been somewhat limited by the EV isolation and detection techniques. EV biomarkers showed promising diagnostic capability for CaP. Addressing deficiencies in EV isolation and detection techniques has important implications for the application of these novel noninvasive biomarkers in clinical practice.</text><annotation id="14"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="206" length="7"/><text>cancers</text></annotation><annotation id="15"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="303" length="15"/><text>prostate cancer</text></annotation><annotation id="16"><infon key="identifier">MESH:C579969</infon><infon key="type">Disease</infon><location offset="320" length="3"/><text>CaP</text></annotation><annotation id="17"><infon key="identifier">MESH:C579969</infon><infon key="type">Disease</infon><location offset="388" length="3"/><text>CaP</text></annotation><annotation id="18"><infon key="identifier">MESH:C579969</infon><infon key="type">Disease</infon><location offset="538" length="4"/><text>CaP.</text></annotation><annotation id="19"><infon key="identifier">MESH:C579969</infon><infon key="type">Disease</infon><location offset="713" length="4"/><text>CaP.</text></annotation><annotation id="20"><infon key="identifier">MESH:C579969</infon><infon key="type">Disease</infon><location offset="851" length="3"/><text>CaP</text></annotation><annotation id="21"><infon key="identifier">406933</infon><infon key="type">Gene</infon><location offset="1022" length="7"/><text>MiR-141</text></annotation><annotation id="22"><infon key="identifier">407006</infon><infon key="type">Gene</infon><location offset="1031" length="7"/><text>miR-221</text></annotation><annotation id="23"><infon key="identifier">2346</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136782</infon><location offset="1044" length="4"/><text>PSMA</text></annotation><annotation id="24"><infon key="identifier">MESH:C579969</infon><infon key="type">Disease</infon><location offset="1105" length="3"/><text>CaP</text></annotation><annotation id="25"><infon key="identifier">MESH:C579969</infon><infon key="type">Disease</infon><location offset="1578" length="4"/><text>CaP.</text></annotation></passage><relation id="R1"><infon key="score">0.9982</infon><infon key="role1">Disease|MESH:C579969</infon><infon key="role2">Gene|407006</infon><infon key="type">Association</infon><node refid="0" role="11,9"/></relation><relation id="R2"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:C579969</infon><infon key="role2">Gene|2346</infon><infon key="type">Association</infon><node refid="1" role="11,10"/></relation><relation id="R3"><infon key="score">0.9971</infon><infon key="role1">Disease|MESH:C579969</infon><infon key="role2">Gene|406933</infon><infon key="type">Association</infon><node refid="2" role="11,8"/></relation></document>
<document><id>37914919</id><passage><infon key="journal">Intern Emerg Med;2023Nov01. doi:10.1007/s11739-023-03457-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">8874413</infon><infon key="type">title</infon><infon key="authors">de Boisriou I, Ellouze S, Kassasseya C, Feral-Pierssens AL, Gerlier C, Chauvin A, Beaune S, Dubreucq E, Pereira L, Chocron R, Khellaf M, Mariotte &amp;#xc9;, Zafrani L, Peyrony O, </infon><offset>0</offset><text>Misdiagnosis of thrombotic microangiopathy in the emergency department: a multicenter retrospective study.</text><annotation id="2"><infon key="identifier">MESH:D057049</infon><infon key="type">Disease</infon><location offset="16" length="26"/><text>thrombotic microangiopathy</text></annotation><annotation id="3"><infon key="identifier">MESH:D004630</infon><infon key="type">Disease</infon><location offset="50" length="20"/><text>emergency department</text></annotation></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>To estimate the rate of inappropriate diagnosis in patients who visited the ED with thrombotic microangiopathy (TMA) and to assess the factors and outcomes associated with emergency department (ED) misdiagnosis. Retrospective multicenter study of adult patients admitted to the intensive care unit (ICU) for TMA from 2012 to 2021 who had previously attended the ED for a reason related to TMA. Patient characteristics and outcomes were compared in a univariate analysis based on whether a TMA diagnosis was mentioned in the ED or not. Forty patients were included. The diagnosis of TMA was not mentioned in the ED in 16 patients (40%). Patients for whom the diagnosis was mentioned in the ED had more frequently a request for schistocytes research, and therefore had more often objectified schistocytes. They also had more frequently a troponin dosage in the ED (even if the difference was not significant), an ECG performed or interpreted, and were admitted more quickly in the ICU (0 [0-0] vs 2 [0-2] days; P = 0.002). Hemoglobin levels decreased significantly in both groups, and creatinine levels increased significantly in the misdiagnosis group between ED arrival and ICU admission. In patients with a final diagnosis of TTP, the time to platelets durable recovery was shorter for those in whom the diagnosis was mentioned in the ED without reaching statistical significance (7 [5-11] vs 14 [5-21] days; P = 0.3).</text><annotation id="13"><infon key="identifier">MESH:D057049</infon><infon key="type">Disease</infon><location offset="191" length="26"/><text>thrombotic microangiopathy</text></annotation><annotation id="14"><infon key="identifier">MESH:D057049</infon><infon key="type">Disease</infon><location offset="219" length="3"/><text>TMA</text></annotation><annotation id="15"><infon key="identifier">MESH:D004630</infon><infon key="type">Disease</infon><location offset="279" length="20"/><text>emergency department</text></annotation><annotation id="16"><infon key="identifier">MESH:D057049</infon><infon key="type">Disease</infon><location offset="415" length="3"/><text>TMA</text></annotation><annotation id="17"><infon key="identifier">MESH:D057049</infon><infon key="type">Disease</infon><location offset="496" length="3"/><text>TMA</text></annotation><annotation id="18"><infon key="identifier">MESH:D057049</infon><infon key="type">Disease</infon><location offset="596" length="3"/><text>TMA</text></annotation><annotation id="19"><infon key="identifier">MESH:D057049</infon><infon key="type">Disease</infon><location offset="689" length="3"/><text>TMA</text></annotation><annotation id="20"><infon key="identifier">MESH:D003404</infon><infon key="type">Chemical</infon><location offset="1190" length="10"/><text>creatinine</text></annotation><annotation id="21"><infon key="identifier">MESH:D011697</infon><infon key="type">Disease</infon><location offset="1334" length="3"/><text>TTP</text></annotation></passage></document>
<document><id>37915271</id><passage><infon key="journal">Turk Arch Pediatr;2023Nov; 58 (6) 631. doi:10.5152/TurkArchPediatr.2023.23101</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Y&amp;#x131;rg&amp;#x131;n K, G&amp;#xfc;r E, Erener-Ercan T, Can G, </infon><offset>0</offset><text>Vaccination Status in Children with Chronic Diseases: Are They Up-to-Date for Mandatory and Specific Vaccines?</text><annotation id="1"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="36" length="16"/><text>Chronic Diseases</text></annotation></passage><passage><infon key="type">abstract</infon><offset>111</offset><text>OBJECTIVE: The aim of this study is to investigate the immunization coverage for mandatory and specific vaccines in a group of children with chronic diseases. MATERIALS AND METHODS: Children with chronic diseases aged 6 months to 18 years who were followed up by outpatient subspecialty clinics of a tertiary hospital were enrolled. Children who were up-to-date and who were under-vaccinated were compared with respect to demographic characteristics, parental educational status, healthcare providers' attitudes toward vaccination, age at the time of diagnosis, and duration of follow-up. RESULTS: A total of 366 patients with variable chronic diseases were enrolled. Of these, 84.7% were up-to-date for the mandatory vaccines. This rate was 99.5% for the primary series of diphtheria-tetanus-acellular pertussis and 98.9% for the first dose of measles-mumps-rubella vaccines. Vaccination coverage for specific vaccines was low (13.9% for influenza and 55% for conjugated pneumococcal vaccine). Being older at the time of diagnosis increased the likelihood of being up-to-date for mandatory vaccines by 1.1 times, while being followed up from multiple subspecialty outpatient clinics and attendance to private doctors' clinics for vaccination increased the likelihood of being up-to-date for specific vaccines by 19.1 and 6.4 times, respectively. CONCLUSION: In this study, immunization coverage for mandatory vaccines was comparable to that of the general population. However, vaccination coverage was low for specific vaccines. Therefore, efforts of prioritization of pediatric immunizations and raising awareness among healthcare providers about the impact of medical recommendations for specific vaccines among children with chronic diseases can help to improve vaccination rates.</text><annotation id="13"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="252" length="16"/><text>chronic diseases</text></annotation><annotation id="14"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="307" length="16"/><text>chronic diseases</text></annotation><annotation id="15"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="747" length="16"/><text>chronic diseases</text></annotation><annotation id="16"><infon key="identifier">MESH:D004165</infon><infon key="type">Disease</infon><location offset="885" length="10"/><text>diphtheria</text></annotation><annotation id="17"><infon key="identifier">MESH:D013746</infon><infon key="type">Disease</infon><location offset="896" length="7"/><text>tetanus</text></annotation><annotation id="18"><infon key="identifier">MESH:D014917</infon><infon key="type">Disease</infon><location offset="914" length="9"/><text>pertussis</text></annotation><annotation id="19"><infon key="identifier">MESH:D008457</infon><infon key="type">Disease</infon><location offset="956" length="7"/><text>measles</text></annotation><annotation id="20"><infon key="identifier">MESH:D009107</infon><infon key="type">Disease</infon><location offset="964" length="5"/><text>mumps</text></annotation><annotation id="21"><infon key="identifier">MESH:D012409</infon><infon key="type">Disease</infon><location offset="970" length="7"/><text>rubella</text></annotation><annotation id="22"><infon key="identifier">MESH:D007251</infon><infon key="type">Disease</infon><location offset="1050" length="9"/><text>influenza</text></annotation><annotation id="23"><infon key="identifier">MESH:D002908</infon><infon key="type">Disease</infon><location offset="1840" length="16"/><text>chronic diseases</text></annotation></passage></document>
<document><id>37916321</id><passage><infon key="journal">Eur Rev Med Pharmacol Sci;2023Oct; 27 (20) 9540. doi:10.26355/eurrev_202310_34127</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Shalabi KM, AlSharif ZA, Alrowaishd SA, Al Ali RE, </infon><offset>0</offset><text>Relationship between body mass index and health-related physical fitness: a cross-sectional study.</text></passage><passage><infon key="type">abstract</infon><offset>99</offset><text>OBJECTIVE: Physical fitness is seen to be a sign of overall health and happiness. The purpose of this study was to investigate the association between female Saudi student's body mass index (BMI) and health-related physical fitness. SUBJECTS AND METHODS: 48 participants (mean age=19.60 years) were chosen for this cross-sectional study design, and their BMI, health-related physical fitness and physical fitness testing were all analyzed (cardiovascular endurance, muscular endurance, muscular strength, flexibility, and body composition). RESULTS: The physical activity score (total-MET)-minutes/week was 1,533.88. 18.8% of the participants were underweight, 52.1% were normal weight, 27.1% were overweight, and 2.1% were obese, as per BMI. The correlation between total-MET and other physical parameters revealed a statistically significant negative correlation with muscle strength (Rho=-0.293, p=0.043), BMI (Rho=-0.562, p=0.0001), waist circumference (Rho=-0.524, p=0.0001), and fat mass index (FMI) (Rho=-0.589, p=0.0001). The relationship between BMI and physical measurements was positively correlated with waist circumference (Rho=0.877, p&lt;0.0001), fat mass index (Rho=0.944, p&lt;0.0001), muscular strength (Rho=0.501, p&lt;0.0001), and curls per minute (Rho=0.510, p&lt;0.0001) in statistically significant ways. When total-MET was compared to BMI, age, waist circumference, fat mass index (FMI), and muscular strength, the regression was statistically significant (F=3.954, p=0.005). Age, waist size, activity level, fat mass index, muscular strength, and curls per minute all had a significant connection with BMI (F=106.26, p=0.0001). CONCLUSIONS: Physical exercise may be related to changes in BMI. Physicians and other stakeholders putting forth strategies to increase physical activity and control weight may find the data useful.</text><annotation id="3"><infon key="identifier">MESH:D013851</infon><infon key="type">Disease</infon><location offset="747" length="11"/><text>underweight</text></annotation><annotation id="4"><infon key="identifier">MESH:D050177</infon><infon key="type">Disease</infon><location offset="797" length="10"/><text>overweight</text></annotation><annotation id="5"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="823" length="5"/><text>obese</text></annotation></passage></document>
<document><id>37916675</id><passage><infon key="journal">J Magn Reson Imaging;2023Nov02. doi:10.1002/jmri.29107</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yeung K, M&amp;#xf3;zes FE, Grist JT, </infon><offset>0</offset><text>Editorial for "Oscillating Gradient Diffusion-Weighted MRI for Risk Stratification of Uterine Endometrial Cancer".</text><annotation id="1"><infon key="identifier">MESH:D016889</infon><infon key="type">Disease</infon><location offset="86" length="26"/><text>Uterine Endometrial Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>115</offset></passage></document>
<document><id>37917379</id><passage><infon key="journal">Acta Neurochir (Wien);2023Nov02. doi:10.1007/s00701-023-05859-1</infon><infon key="year">2023</infon><infon key="article-id_pmc">6019721</infon><infon key="type">title</infon><infon key="authors">Tatebayashi K, Shirakawa M, Abe S, Fujita M, Yoshimura S, </infon><offset>0</offset><text>Vascular Ehlers-Danlos syndrome with a Novel missense COL3A1 gene mutation present with bilateral spontaneous carotid-cavernous fistula: a case report.</text><annotation id="3"><infon key="identifier">MESH:D004535</infon><infon key="type">Disease</infon><location offset="9" length="22"/><text>Ehlers-Danlos syndrome</text></annotation><annotation id="4"><infon key="identifier">1281</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55433</infon><location offset="54" length="6"/><text>COL3A1</text></annotation><annotation id="5"><infon key="identifier">MESH:D020216</infon><infon key="type">Disease</infon><location offset="110" length="25"/><text>carotid-cavernous fistula</text></annotation></passage><passage><infon key="type">abstract</infon><offset>152</offset><text>This report describes a unique case of vascular Ehlers-Danlos syndrome (vEDS) characterized by multiple spontaneous direct carotid-cavernous sinus fistulas (CCF). The patient initially presented with ocular symptoms and was effectively treated with transarterial coil embolization. Five years later, the patient developed recurrent contralateral CCF that required complex endovascular techniques. Genetic testing identified a novel mutation in the COL3A1 gene, confirming the diagnosis of vEDS. This case report provides a near-term perspective on the identification of structural abnormalities in the COL3A1 protein to ensure the safety of endovascular therapy for patients with vEDS.</text><annotation id="15"><infon key="identifier">MESH:D004535</infon><infon key="type">Disease</infon><location offset="200" length="22"/><text>Ehlers-Danlos syndrome</text></annotation><annotation id="16"><infon key="identifier">MESH:D000094623</infon><infon key="type">Disease</infon><location offset="224" length="4"/><text>vEDS</text></annotation><annotation id="17"><infon key="identifier">MESH:D020216</infon><infon key="type">Disease</infon><location offset="275" length="32"/><text>carotid-cavernous sinus fistulas</text></annotation><annotation id="18"><infon key="identifier">MESH:D020216</infon><infon key="type">Disease</infon><location offset="309" length="3"/><text>CCF</text></annotation><annotation id="19"><infon key="identifier">MESH:D020216</infon><infon key="type">Disease</infon><location offset="498" length="3"/><text>CCF</text></annotation><annotation id="20"><infon key="identifier">1281</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55433</infon><location offset="600" length="6"/><text>COL3A1</text></annotation><annotation id="21"><infon key="identifier">MESH:D000094623</infon><infon key="type">Disease</infon><location offset="641" length="4"/><text>vEDS</text></annotation><annotation id="22"><infon key="identifier">1281</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55433</infon><location offset="754" length="6"/><text>COL3A1</text></annotation><annotation id="23"><infon key="identifier">MESH:D000094623</infon><infon key="type">Disease</infon><location offset="832" length="4"/><text>vEDS</text></annotation></passage><relation id="R1"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D000094623</infon><infon key="role2">Gene|1281</infon><infon key="type">Association</infon><node refid="0" role="9,8"/></relation><relation id="R2"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D004535</infon><infon key="role2">Gene|1281</infon><infon key="type">Association</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D020216</infon><infon key="role2">Gene|1281</infon><infon key="type">Association</infon><node refid="2" role="2,1"/></relation></document>
<document><id>37917730</id><passage><infon key="journal">PLoS One;2023; 18 (11) 0289696. doi:10.1371/journal.pone.0289696</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sanini Belin CH, Nunes LM, Ficagna CR, Neves RO, Moreira PR, Bernardi JR, </infon><offset>0</offset><text>Adherence to different complementary feeding methods in the first year of life: A randomized clinical trial.</text></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>BACKGROUND: Infant-guided methods, such as Baby-Led Introduction to SolidS (BLISS), encourage children to feed themselves from the same food consumed by their family since the beginning of the introduction of complementary foods, in opposition to the Parent-Led Weaning (PLW) method, which proposes foods mashed with a fork and given by parents. Adherence to child-guided methods is low due to a lack of confidence in the children's ability to feed themselves. This study aimed to assess adherence to three methods of food introduction: PLW, BLISS, or mixed (PLW and BLISS) at seven, nine, and 12 months of age. METHODS: A randomized clinical trial was conducted with mother-infant pairs undergoing intervention at 5.5 months of age. Data were presented in absolute numbers and percentages and analyzed using the Chi-Square test. RESULTS: The sample was constituted of 139 mother-infant pairs: 45 (32%) used PLW, 48 (35%) used BLISS, and 46 (33%) used the mixed method. Adherence to the method at seven, nine, and 12 months of age children was 34.1% (n = 45), 28.5% (n = 37), and 34.1% (n = 46), respectively. The mixed method presented significantly higher adherence results: 69.0% (n = 29) at seven months, 55.8% (n = 24) at nine months, and 78.6% (n = 33) at 12 months (p&lt;0.001). Among the sample that unfollowed the proposed method, those who used PLW and BLISS migrated mostly to the mixed method at 12 months, 60.0% (n = 27) and 72.9% (n = 35) of them, respectively, because of the feeding mode and 97.8% (n = 44) and 100.0% (n = 48) because of food consistency. CONCLUSION: Complementary feeding in a mixed method presented higher adherence at seven, nine, and 12 months of age of children, which shows the feasibility of this approach to guide families in the introduction of complementary feeding.</text></passage></document>
<document><id>37918081</id><passage><infon key="journal">J Clin Anesth;2023Oct30; 92 111310. doi:10.1016/j.jclinane.2023.111310</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jelacic S, Bowdle A, Bussey L, Nguyen S, Ocol JM, Togashi K, </infon><offset>0</offset><text>Should respiratory therapists routinely monitor neuromuscular blockade in the intensive care unit?</text><annotation id="1"><infon key="identifier">MESH:D020879</infon><infon key="type">Disease</infon><location offset="48" length="22"/><text>neuromuscular blockade</text></annotation></passage><passage><infon key="type">abstract</infon><offset>99</offset></passage></document>
<document><id>37918431</id><passage><infon key="journal">Dtsch Med Wochenschr;2023Nov; 148 (22) 1456. doi:10.1055/a-1971-3381</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">van der Giet M, </infon><offset>0</offset><text>[SGLT2 inhibitors for heart and kidney].</text><annotation id="1"><infon key="identifier">6524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="1" length="5"/><text>SGLT2</text></annotation></passage><passage><infon key="type">abstract</infon><offset>41</offset><text>Sodium-glucose co-transporter 2 (SGLT2) inhibitors can block glucose reabsorption in the proximal tubule and thus play an important role in glycemic control in diabetes mellitus. In addition to glucosuric effects, surprisingly very extensive other positive effects were observed in chronic renal dysfunction and strong cardioprotective effects in heart failure. In the meantime, numerous mechanisms have been identified apart from the pure sugar-influencing effect of the SGLT2 inhibitors, which can have a direct positive influence heart and kidneys.In recent years there has been an extensive clinical study program, which has dealt with the effects of SGLT2 inhibitors on the progression of diabetic and non-diabetic chronic renal failure. It could be shown that patients with albuminuria have a significant benefit from the use of SGLT2 inhibitors. Therefore, the progression of renal dysfunction is slowed down significantly, while at the same time, positive cardiovascular endpoints could be influenced. Numerous studies have also been conducted in patients with and without diabetes or with heart failure, with and without, preserved ejection fraction. Impressive protection was also shown here, with the benefit of using SGLT2 inhibitors to reduce heart failure worsening.In a short period of 10 years, the use of SGLT2 inhibitors was established as an essential therapy for cardio-renal indications to inhibit the progression of renal failure as well as to protect against heart failure apart from pure diabetes therapy. In numerous guidelines (ESC heart failure, KDGIO diabetes, ESH hypertension), the early use of SGLT2 inhibitors is now recommended for protection against cardio-renal events and is an important first-line addition to the previously established therapies. Apart from diabetes therapy, it offers patients completely new options in cardio-renal protection.</text><annotation id="29"><infon key="identifier">6524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="41" length="31"/><text>Sodium-glucose co-transporter 2</text></annotation><annotation id="30"><infon key="identifier">6524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="74" length="5"/><text>SGLT2</text></annotation><annotation id="31"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="102" length="7"/><text>glucose</text></annotation><annotation id="32"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="201" length="17"/><text>diabetes mellitus</text></annotation><annotation id="33"><infon key="type">Disease</infon><location offset="235" length="10"/><text>glucosuric</text></annotation><annotation id="34"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="323" length="25"/><text>chronic renal dysfunction</text></annotation><annotation id="35"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="388" length="13"/><text>heart failure</text></annotation><annotation id="36"><infon key="identifier">MESH:D000073893</infon><infon key="type">Chemical</infon><location offset="481" length="5"/><text>sugar</text></annotation><annotation id="37"><infon key="identifier">6524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="513" length="5"/><text>SGLT2</text></annotation><annotation id="38"><infon key="identifier">6524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="696" length="5"/><text>SGLT2</text></annotation><annotation id="39"><infon key="identifier">MESH:D007676</infon><infon key="type">Disease</infon><location offset="735" length="47"/><text>diabetic and non-diabetic chronic renal failure</text></annotation><annotation id="40"><infon key="identifier">MESH:D000419</infon><infon key="type">Disease</infon><location offset="821" length="11"/><text>albuminuria</text></annotation><annotation id="41"><infon key="identifier">6524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="876" length="5"/><text>SGLT2</text></annotation><annotation id="42"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="924" length="17"/><text>renal dysfunction</text></annotation><annotation id="43"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1122" length="8"/><text>diabetes</text></annotation><annotation id="44"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1139" length="13"/><text>heart failure</text></annotation><annotation id="45"><infon key="identifier">6524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="1270" length="5"/><text>SGLT2</text></annotation><annotation id="46"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1297" length="13"/><text>heart failure</text></annotation><annotation id="47"><infon key="identifier">6524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="1363" length="5"/><text>SGLT2</text></annotation><annotation id="48"><infon key="identifier">MESH:D051437</infon><infon key="type">Disease</infon><location offset="1479" length="13"/><text>renal failure</text></annotation><annotation id="49"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1523" length="13"/><text>heart failure</text></annotation><annotation id="50"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1553" length="8"/><text>diabetes</text></annotation><annotation id="51"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1599" length="13"/><text>heart failure</text></annotation><annotation id="52"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1620" length="8"/><text>diabetes</text></annotation><annotation id="53"><infon key="identifier">MESH:D006973</infon><infon key="type">Disease</infon><location offset="1634" length="12"/><text>hypertension</text></annotation><annotation id="54"><infon key="identifier">6524</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2289</infon><location offset="1666" length="5"/><text>SGLT2</text></annotation><annotation id="55"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1837" length="8"/><text>diabetes</text></annotation></passage><relation id="R1"><infon key="score">0.5552</infon><infon key="role1">Disease|MESH:D000419</infon><infon key="role2">Gene|6524</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="15,17"/></relation><relation id="R2"><infon key="score">0.4851</infon><infon key="role1">Chemical|MESH:D005947</infon><infon key="role2">Gene|6524</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="4,2"/></relation><relation id="R3"><infon key="score">0.9962</infon><infon key="role1">Disease|MESH:D003920</infon><infon key="role2">Gene|6524</infon><infon key="type">Association</infon><node refid="2" role="5,2"/></relation><relation id="R4"><infon key="score">0.839</infon><infon key="role1">Disease|MESH:D006333</infon><infon key="role2">Gene|6524</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="23,22"/></relation><relation id="R5"><infon key="score">0.9761</infon><infon key="role1">Disease|MESH:D051437</infon><infon key="role2">Gene|6524</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="26,22"/></relation></document>
<document><id>37918781</id><passage><infon key="journal">Rev Esp Med Nucl Imagen Mol (Engl Ed);2023Oct31. doi:10.1016/j.remnie.2023.10.005</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ma L, Chen X, Chen J, Liu M, Fu Z, </infon><offset>0</offset><text>Synchronous inflammatory pseudotumor-like follicular dendritic cell sarcoma of spleen and primary lung cancer: a diagnostic challenge in 18F-FDG PET/CT.</text><annotation id="4"><infon key="identifier">MESH:D006104</infon><infon key="type">Disease</infon><location offset="12" length="24"/><text>inflammatory pseudotumor</text></annotation><annotation id="5"><infon key="identifier">MESH:D012509</infon><infon key="type">Disease</infon><location offset="68" length="7"/><text>sarcoma</text></annotation><annotation id="6"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="90" length="19"/><text>primary lung cancer</text></annotation><annotation id="7"><infon key="identifier">MESH:D019788</infon><infon key="type">Chemical</infon><location offset="137" length="7"/><text>18F-FDG</text></annotation></passage><passage><infon key="type">abstract</infon><offset>153</offset></passage></document>
<document><id>37919131</id><passage><infon key="journal">J Prosthet Dent;2023Oct31. doi:10.1016/j.prosdent.2023.09.037</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhu J, Xu Y, Li M, Huang C, </infon><offset>0</offset><text>Instrumental and visual evaluation of the color adjustment potential of a recently introduced single-shade composite resin versus multishade composite resins.</text><annotation id="2"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="107" length="15"/><text>composite resin</text></annotation><annotation id="3"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="141" length="16"/><text>composite resins</text></annotation></passage><passage><infon key="type">abstract</infon><offset>159</offset><text>STATEMENT OF PROBLEM: Single-shade composite resins simplify the process of shade selection by providing a narrow range of color but the ability to simulate all shades. However, evidence is limited for the color shifting ability of a newly developed single-shade composite resin. PURPOSE: The purpose of this in vitro study was to evaluate the instrumental color adjustment potential (CAP-I) and visual color adjustment potential (CAP-V) of a recently introduced single-shade composite resin compared with conventional multishade composite resins against different background colors. MATERIAL AND METHODS: Four multishade composite resins (Spectrum TPH3, Beautifil II, Clearfil AP-X, and Gradia Direct) and a single-shade composite resin (Charisma Diamond One) were tested. Four base shades (A1, A2, A3, and A3.5) of the same composite resin (Filtek Z350XT) were selected as different background colors. Dual specimens (an outer base material with an inner hole filled with inner test material) and single specimens of all test and base materials were prepared (n=6 per group). Spectral reflectance values were obtained by using a spectroradiometer. The color difference (DeltaE00) and relative translucency parameter (RTP) were calculated by using the CIEDE2000 and RTPCIEDE2000 formula. Visual scoring of color matching was performed by independent observers. The CAP-I and CAP-V values were calculated according to DeltaE00 and visual scoring. Analysis of variance (ANOVA) was used for statistical analysis (alpha=.05). RESULTS: CAP-I and CAP-V were significantly affected by composite resin type, background color, and their interaction (P&lt;.001). Positive CAP-I and CAP-V values were found for the majority of test materials. Charisma Diamond One exhibited the highest CAP-I value under all background colors, the highest CAP-V value under most background colors, and the significantly highest RTP value (P&lt;.001). CONCLUSIONS: The color adjustment potential was dependent on the material type and background color. Charisma Diamond One exhibited the highest color adjustment potential and the most pronounced color shifting ability.</text><annotation id="20"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="194" length="16"/><text>composite resins</text></annotation><annotation id="21"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="422" length="15"/><text>composite resin</text></annotation><annotation id="22"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="635" length="15"/><text>composite resin</text></annotation><annotation id="23"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="689" length="16"/><text>composite resins</text></annotation><annotation id="24"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="781" length="16"/><text>composite resins</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="799" length="13"/><text>Spectrum TPH3</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="814" length="12"/><text>Beautifil II</text></annotation><annotation id="27"><infon key="identifier">MESH:C112828</infon><infon key="type">Chemical</infon><location offset="828" length="13"/><text>Clearfil AP-X</text></annotation><annotation id="28"><infon key="identifier">MESH:C470230</infon><infon key="type">Chemical</infon><location offset="847" length="13"/><text>Gradia Direct</text></annotation><annotation id="29"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="881" length="15"/><text>composite resin</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="898" length="20"/><text>Charisma Diamond One</text></annotation><annotation id="31"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="985" length="15"/><text>composite resin</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1002" length="13"/><text>Filtek Z350XT</text></annotation><annotation id="33"><infon key="identifier">MESH:D003188</infon><infon key="type">Chemical</infon><location offset="1738" length="15"/><text>composite resin</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1889" length="20"/><text>Charisma Diamond One</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2178" length="20"/><text>Charisma Diamond One</text></annotation></passage></document>
<document><id>37919481</id><passage><infon key="journal">Sci Rep;2023Nov02; 13 (1) 18896. doi:10.1038/s41598-023-46441-0</infon><infon key="year">2023</infon><infon key="article-id_pmc">8075005</infon><infon key="type">title</infon><infon key="authors">Izaddoost N, Amiri-Farahani L, Haghani S, Bordbar A, Shojaii A, Pezaro S, </infon><offset>0</offset><text>The effect of orally consumed Lactuca sativa syrup on human milk volume and weight gain in the preterm infant: a randomized controlled clinical trial.</text><annotation id="1"><infon key="identifier">MESH:D015430</infon><infon key="type">Disease</infon><location offset="76" length="11"/><text>weight gain</text></annotation></passage><passage><infon key="type">abstract</infon><offset>151</offset><text>Human milk feeding can support premature infants to thrive. Yet those with premature infants can be challenged in human milk production. Considering this, and the use of potentially harmful human milk enhancers, the present study was conducted with the aim of determining the effect of orally consumed Lactuca sativa (L. sativa) syrup (lettuce extract) on human milk volume and subsequent weight gain in the preterm infant. Extracts from lettuce and other plants such as silymarin are already evidenced to be safe for use during lactation and have other therapeutic effects in humans. Yet this is the first study of its kind. This parallel randomized clinical trial included lactating participants with their preterm infants who were born at &lt; 32 weeks' gestation and admitted to an intensive care unit. Convenience sampling was used to recruit participants. Eligible participants were allocated to groups randomly: intervention (n = 47), placebo (n = 46), and control (n = 47). The intervention group received one tablespoon of Lactuca sativa (L. sativa) syrup, and the placebo group received one tablespoon of placebo syrup 3 times a day for 1 week. Those in the control group did not receive any herbal or chemical milk-enhancing compounds. Routine care was provided to all three groups. Participants recorded their milk volume for 7 days in a daily information recorder form. Infant weight was measured prior to the intervention, and on the third, fifth and seventh days of the intervention period. There was a statistically significant difference observed in the adjusted mean volume of milk on the fourth and fifth days between the intervention, placebo, and control groups (P &lt; 0.05). The adjusted mean milk volume of those in the intervention group on the first day was significantly higher than those in the control group and those in the placebo group. On the second day, the adjusted mean milk volume of those in the intervention group was higher than in those from the control group; and on the fourth day it was higher than in those from both the control and placebo groups; on the fifth day it was higher than in those in the placebo group; on the sixth day it was higher than in those in the control group and on the seventh day it was higher than in those in the control group (P &lt; 0.05). There was no statistically significant difference in terms of the mean changes (with or without adjustment) in the weight of preterm infants between any of the groups. Lactuca sativa (L. sativa) syrup increases the volume of human milk production and no specific side effects have been reported in its use. Therefore, Lactuca sativa syrup can be recommended for use as one of the compounds that increase human milk volume.</text><annotation id="12"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="192" length="7"/><text>infants</text></annotation><annotation id="13"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="236" length="7"/><text>infants</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="453" length="32"/><text>Lactuca sativa (L. sativa) syrup</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="487" length="15"/><text>lettuce extract</text></annotation><annotation id="16"><infon key="identifier">MESH:D015430</infon><infon key="type">Disease</infon><location offset="540" length="11"/><text>weight gain</text></annotation><annotation id="17"><infon key="identifier">MESH:D012838</infon><infon key="type">Chemical</infon><location offset="622" length="9"/><text>silymarin</text></annotation><annotation id="18"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="868" length="7"/><text>infants</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1180" length="32"/><text>Lactuca sativa (L. sativa) syrup</text></annotation><annotation id="20"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="2589" length="7"/><text>infants</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2624" length="32"/><text>Lactuca sativa (L. sativa) syrup</text></annotation></passage></document>
<document><id>37919831</id><passage><infon key="journal">Cladistics;2023Nov02. doi:10.1111/cla.12561</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cruaud A, Rasplus JY, Zhang J, Burks R, Delvare G, Fusu L, Gumovsky A, Huber JT, Jan&amp;#x161;ta P, Mitroiu MD, Noyes JS, van Noort S, Baker A, B&amp;#xf6;hmov&amp;#xe1; J, Baur H, Blaimer BB, Brady SG, Buben&amp;#xed;kov&amp;#xe1; K, Chartois M, Copeland RS, Dale-Skey Papilloud N, Dal Molin A, Dominguez C, Gebiola M, Guerrieri E, Kresslein RL, Krogmann L, Lemmon E, Murray EA, Nidelet S, Nieves-Aldrey JL, Perry RK, Peters RS, Polaszek A, Saun&amp;#xe9; L, Torr&amp;#xe9;ns J, Triapitsyn S, Tselikh EV, Yoder M, Lemmon AR, Woolley JB, Heraty JM, </infon><offset>0</offset><text>The Chalcidoidea bush of life: evolutionary history of a massive radiation of minute wasps.</text></passage><passage><infon key="type">abstract</infon><offset>92</offset><text>Chalcidoidea are mostly parasitoid wasps that include as many as 500 000 estimated species. Capturing phylogenetic signal from such a massive radiation can be daunting. Chalcidoidea is an excellent example of a hyperdiverse group that has remained recalcitrant to phylogenetic resolution. We combined 1007 exons obtained with Anchored Hybrid Enrichment with 1048 ultra-conserved elements (UCEs) for 433 taxa including all extant families, >95% of all subfamilies, and 356 genera chosen to represent the vast diversity of the superfamily. Going back and forth between the molecular results and our collective knowledge of morphology and biology, we detected bias in the analyses that was driven by the saturation of nucleotide data. Our final results are based on a concatenated analysis of the least saturated exons and UCE datasets (2054 loci, 284 106 sites). Our analyses support an expected sister relationship with Mymarommatoidea. Seven previously recognized families were not monophyletic, so support for a new classification is discussed. Natural history in some cases would appear to be more informative than morphology, as illustrated by the elucidation of a clade of plant gall associates and a clade of taxa with planidial first-instar larvae. The phylogeny suggests a transition from smaller soft-bodied wasps to larger and more heavily sclerotized wasps, with egg parasitism as potentially ancestral for the entire superfamily. Deep divergences in Chalcidoidea coincide with an increase in insect families in the fossil record, and an early shift to phytophagy corresponds with the beginning of the "Angiosperm Terrestrial Revolution". Our dating analyses suggest a middle Jurassic origin of 174 Ma (167.3-180.5 Ma) and a crown age of 162.2 Ma (153.9-169.8 Ma) for Chalcidoidea. During the Cretaceous, Chalcidoidea may have undergone a rapid radiation in southern Gondwana with subsequent dispersals to the Northern Hemisphere. This scenario is discussed with regard to knowledge about the host taxa of chalcid wasps, their fossil record and Earth's palaeogeographic history.</text></passage></document>
<document><id>37920881</id><passage><infon key="journal">Vox Sang;2023Nov03. doi:10.1111/vox.13548</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rom&amp;#xf3;n I, Arroyo JL, </infon><offset>0</offset><text>A norm for all seasons: Application of the ISO 14001 standard to manage the environmental impacts of transfusion.</text></passage><passage><infon key="type">abstract</infon><offset>114</offset></passage></document>
<document><id>37921231</id><passage><infon key="journal">ANZ J Surg;2023Nov03. doi:10.1111/ans.18758</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Machado P, Fuzzard S, Hamilton S, Jackett L, Fox C, </infon><offset>0</offset><text>An ear-piercing melanoma in situ.</text><annotation id="1"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="16" length="8"/><text>melanoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>34</offset></passage></document>
<document><id>37921581</id><passage><infon key="journal">New Phytol;2023Nov03. doi:10.1111/nph.19366</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Parra-Nunez P, Fern&amp;#xe1;ndez-Jim&amp;#xe9;nez N, Pachon-Penalba M, Sanchez-Moran E, Pradillo M, Santos JL, </infon><offset>0</offset><text>Synthetically induced Arabidopsis thaliana autotetraploids provide insights into the analysis of meiotic mutants with altered crossover frequency.</text></passage><passage><infon key="type">abstract</infon><offset>147</offset><text>Mutations affecting crossover (CO) frequency and distribution lead to the presence of univalents during meiosis, giving rise to aneuploid gametes and sterility. These mutations may have a different effect after chromosome doubling. The combination of altered ploidy and mutations could be potentially useful to gain new insights into the mechanisms and regulation of meiotic recombination; however, studies using autopolyploid meiotic mutants are scarce. Here, we have analyzed the cytogenetic consequences in colchicine-induced autotetraploids (colchiploids) from different Arabidopsis mutants with an altered CO frequency. We have found that there are three types of mutants: mutants in which chiasma frequency is doubled after chromosome duplication (zip4, mus81), as in the control; mutants in which polyploidy leads to a higher-than-expected increase in chiasma frequency (asy1, mer3, hei10, and mlh3); and mutants in which the rise in chiasma frequency produced by the presence of two extrachromosomal sets is less than doubled (msh5, fancm). In addition, the proportion of class I/class II COs varies after chromosome duplication in the control. The results obtained reveal the potential of colchiploid meiotic mutants for better understanding of the function of key proteins during plant meiosis. This is especially relevant considering that most crops are polyploids.</text><annotation id="8"><infon key="identifier">MESH:D003078</infon><infon key="type">Chemical</infon><location offset="657" length="10"/><text>colchicine</text></annotation><annotation id="9"><infon key="identifier">829211</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">116443</infon><location offset="907" length="5"/><text>mus81</text></annotation><annotation id="10"><infon key="identifier">843058</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">135472</infon><location offset="1025" length="4"/><text>asy1</text></annotation><annotation id="11"><infon key="identifier">822395</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">87103</infon><location offset="1031" length="4"/><text>mer3</text></annotation><annotation id="12"><infon key="identifier">841784</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">92730</infon><location offset="1037" length="5"/><text>hei10</text></annotation><annotation id="13"><infon key="identifier">829704</infon><infon key="type">Gene</infon><location offset="1048" length="4"/><text>mlh3</text></annotation><annotation id="14"><infon key="identifier">821593</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8415</infon><location offset="1182" length="4"/><text>msh5</text></annotation><annotation id="15"><infon key="identifier">840448</infon><infon key="type">Gene</infon><location offset="1188" length="5"/><text>fancm</text></annotation></passage></document>
<document><id>37855161</id><passage><infon key="journal">Catheter Cardiovasc Interv;2023Oct19. doi:10.1002/ccd.30861</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Al Mawed M, Vlachojannis M, Pula A, Gielen S, </infon><offset>0</offset><text>Delayed coronary perforation four days after percutaneous coronary intervention with subsequent cardiac tamponade: A case report.</text><annotation id="2"><infon key="identifier">MESH:D003323</infon><infon key="type">Disease</infon><location offset="8" length="20"/><text>coronary perforation</text></annotation><annotation id="3"><infon key="identifier">MESH:D002305</infon><infon key="type">Disease</infon><location offset="96" length="17"/><text>cardiac tamponade</text></annotation></passage><passage><infon key="type">abstract</infon><offset>130</offset><text>Coronary artery perforation (CAP) is a rare but lethal complication of percutaneous coronary interventions (PCIs), and its incidence has been increasing with advances in PCI techniques. Delayed CAP presents a highly challenging complication, as it occurs 30 min-9 days after intervention, making subsequent diagnosis and treatment difficult. We present the case of a 63-year-old male patient who underwent PCI for an obtuse marginalis II because of posterior wall myocardial infarction. Following 4 days of uneventful postoperative stay, the patient developed angina pectoris and hypotension 4 h after reinitiation of anticoagulant therapy with edoxaban. Angiography revealed distal vessel perforation from a side branch of the obtuse marginalis II. The vessel was occluded using autologous fat embolization via a microcatheter, resulting in complete sealing of the perforation. After discharge, 4 weeks after the infarction, the patient started rehabilitation therapy. Distal vessel perforations are typically caused by wire damage. In our case, we also suspected distal wire perforation, which was initially not recognized possibly due to distal occlusion through the thrombotic material. The temporal correlation between the re-initiation of anticoagulant therapy and the occurrence of cardiac tamponade suggests that the thrombotic material was resolved due to the former. The management of delayed CAP does not differ from that of CAP; thus, this rare complication should be considered even days after PCI as it could prove lethal if not recognized early.</text><annotation id="20"><infon key="identifier">MESH:D003324</infon><infon key="type">Disease</infon><location offset="130" length="27"/><text>Coronary artery perforation</text></annotation><annotation id="21"><infon key="identifier">MESH:D003324</infon><infon key="type">Disease</infon><location offset="159" length="3"/><text>CAP</text></annotation><annotation id="22"><infon key="identifier">MESH:D003324</infon><infon key="type">Disease</infon><location offset="324" length="3"/><text>CAP</text></annotation><annotation id="23"><infon key="identifier">MESH:C537730</infon><infon key="type">Disease</infon><location offset="547" length="20"/><text>obtuse marginalis II</text></annotation><annotation id="24"><infon key="identifier">MESH:D009203</infon><infon key="type">Disease</infon><location offset="594" length="21"/><text>myocardial infarction</text></annotation><annotation id="25"><infon key="identifier">MESH:D000787</infon><infon key="type">Disease</infon><location offset="690" length="15"/><text>angina pectoris</text></annotation><annotation id="26"><infon key="identifier">MESH:D007022</infon><infon key="type">Disease</infon><location offset="710" length="11"/><text>hypotension</text></annotation><annotation id="27"><infon key="identifier">MESH:C552171</infon><infon key="type">Chemical</infon><location offset="775" length="8"/><text>edoxaban</text></annotation><annotation id="28"><infon key="identifier">MESH:C537730</infon><infon key="type">Disease</infon><location offset="858" length="20"/><text>obtuse marginalis II</text></annotation><annotation id="29"><infon key="identifier">MESH:D007238</infon><infon key="type">Disease</infon><location offset="1044" length="10"/><text>infarction</text></annotation><annotation id="30"><infon key="identifier">MESH:D057112</infon><infon key="type">Disease</infon><location offset="1107" length="19"/><text>vessel perforations</text></annotation><annotation id="31"><infon key="identifier">MESH:D013927</infon><infon key="type">Disease</infon><location offset="1300" length="10"/><text>thrombotic</text></annotation><annotation id="32"><infon key="identifier">MESH:D002305</infon><infon key="type">Disease</infon><location offset="1419" length="17"/><text>cardiac tamponade</text></annotation><annotation id="33"><infon key="identifier">MESH:D013927</infon><infon key="type">Disease</infon><location offset="1455" length="10"/><text>thrombotic</text></annotation><annotation id="34"><infon key="identifier">MESH:D003324</infon><infon key="type">Disease</infon><location offset="1533" length="3"/><text>CAP</text></annotation><annotation id="35"><infon key="identifier">MESH:D003324</infon><infon key="type">Disease</infon><location offset="1566" length="3"/><text>CAP</text></annotation></passage><relation id="R1"><infon key="score">0.9612</infon><infon key="role1">Chemical|MESH:C552171</infon><infon key="role2">Disease|MESH:D000787</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="9,7"/></relation><relation id="R2"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C552171</infon><infon key="role2">Disease|MESH:D007022</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="9,8"/></relation></document>
<document><id>37855515</id><passage><infon key="journal">Appl Opt;2023Oct01; 62 (28) 7463. doi:10.1364/AO.491623</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhao J, Li Y, Pu T, Zheng J, Zhou H, Wang X, Wu G, Zhou H, Liu J, </infon><offset>0</offset><text>Experimental demonstration of the quantum noise randomized cipher based on cascaded phase shift keying without a high-level digital-to-analog converter.</text></passage><passage><infon key="type">abstract</infon><offset>153</offset><text>To break the dependence on a high-speed and high-resolution digital-to-analog converter (DAC) in the traditional quantum noise randomized cipher (QNRC), a practical DAC-free modulation scheme based on cascaded phase-shift keying (PSK) is proposed and demonstrated by a proof-of-concept experiment. By employing seven cascaded phase modulators (PMs) driven by designed electrical voltage signals, a 128 PSK-QNRC system is achieved with a transmission rate of 10 Gbaud/s and a transmission distance more than 50 km, which eliminates the need for a DAC on the transmitter side. The bit error rate (BER) performance of the proposed scheme is compared to that of a traditional scheme based on an arbitrary waveform generator (AWG) with a sampling rate of 25 GSa/s. The results show that compared to a traditional scheme, the power penalties of the proposed scheme are -1.8d B, 0.9 dB, and 1 dB, respectively, at the rates of 10, 5, and 2.5 Gbps. In other words, the BER performance of the proposed scheme is close to the traditional scheme at a low transmission rate, but better than that of the traditional scheme at a high transmission rate, where the sampling rate of the DAC is not high enough to generate a complete waveform. This work greatly enhances the security of a QNRC system.</text></passage></document>
<document><id>37855868</id><passage><infon key="journal">Avian Pathol;2023Oct19 1. doi:10.1080/03079457.2023.2272617</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sun Y, Wang Y, Wang L, Zou M, Peng X, </infon><offset>0</offset><text>STAT5-Mediated Transcription of miR-33-5p in Mycoplasma gallisepticum-Infected DF-1 Cells.</text><annotation id="2"><infon key="identifier">395556</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55718</infon><location offset="0" length="5"/><text>STAT5</text></annotation><annotation id="3"><infon key="identifier">CVCL:XF08</infon><infon key="type">CellLine</infon><location offset="79" length="4"/><text>DF-1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>91</offset><text>Mycoplasma gallisepticum (MG) represents the primary causative agent of chronic respiratory disease (CRD) in chickens. CRD is prevalent ailment in the global poultry industry, resulting in substantial economic losses. In our previous work, we reported that miR-33-5p inhibits MG-induced apoptosis, inflammatory factors production, and MG replication by specifically targeting JNK1 in chickens. Nevertheless, the regulatory mechanisms governing miR-33-5p expression during MG infection remain poorly understood. Therefore, the objective of this study is to explore the regulation of miR-33-5p gene expression during MG infection. In this study, we observed an upregulation in the expression of pri-miR-33-5p and pre-miR-33-5p following MG infection, suggesting that their regulation takes place at the transcriptional level. Moreover, we characterized the transcriptional regulatory region of miR-33-5p and discovered the presence of a binding motif for STAT5, a recognized transcription factor responsible for gene expression regulation. Luciferase reporter assays and mutational analyses unequivocally showed that STAT5 binds to the miR-33-5p promoter element, thereby modulating miR-33-5p transcription in response to MG infection. Ultimately, the overexpression of STAT5 led to an elevation in miR-33-5p expression while concurrently suppressingJNK1 expression. Our findings elucidate that STAT5 governs the up-regulation of miR-33-5p during MG infection. This research offers a comprehensive comprehension of MG pathogenesis and the exploration of therapeutic approaches for MG-induced CRD.</text><annotation id="19"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="163" length="27"/><text>chronic respiratory disease</text></annotation><annotation id="20"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="192" length="3"/><text>CRD</text></annotation><annotation id="21"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="210" length="3"/><text>CRD</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="227" length="7"/><text>ailment</text></annotation><annotation id="23"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="389" length="12"/><text>inflammatory</text></annotation><annotation id="24"><infon key="identifier">MESH:D009175</infon><infon key="type">Disease</infon><location offset="563" length="12"/><text>MG infection</text></annotation><annotation id="25"><infon key="identifier">MESH:D009175</infon><infon key="type">Disease</infon><location offset="706" length="12"/><text>MG infection</text></annotation><annotation id="26"><infon key="identifier">MESH:D009175</infon><infon key="type">Disease</infon><location offset="826" length="12"/><text>MG infection</text></annotation><annotation id="27"><infon key="identifier">395556</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55718</infon><location offset="1044" length="5"/><text>STAT5</text></annotation><annotation id="28"><infon key="identifier">395556</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55718</infon><location offset="1206" length="5"/><text>STAT5</text></annotation><annotation id="29"><infon key="identifier">MESH:D009175</infon><infon key="type">Disease</infon><location offset="1311" length="12"/><text>MG infection</text></annotation><annotation id="30"><infon key="identifier">395556</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55718</infon><location offset="1359" length="5"/><text>STAT5</text></annotation><annotation id="31"><infon key="identifier">395556</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55718</infon><location offset="1484" length="5"/><text>STAT5</text></annotation><annotation id="32"><infon key="identifier">MESH:D009175</infon><infon key="type">Disease</infon><location offset="1536" length="12"/><text>MG infection</text></annotation><annotation id="33"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="1681" length="3"/><text>CRD</text></annotation></passage><relation id="R1"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D009175</infon><infon key="role2">Gene|395556</infon><infon key="type">Association</infon><node refid="0" role="12,11"/></relation></document>
<document><id>37856218</id><passage><infon key="journal">Dalton Trans;2023Oct19. doi:10.1039/d3dt02269b</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xie S, Liu F, Abdiryim T, Liu X, Jamal R, Song Y, Niyaz M, Liu Y, Zhang H, Tang X, </infon><offset>0</offset><text>PEDOT-embellished Ti3C2Tx nanosheet supported Pt-Pd bimetallic nanoparticles as efficient and stable methanol oxidation electrocatalysts.</text><annotation id="5"><infon key="identifier">MESH:C121383</infon><infon key="type">Chemical</infon><location offset="0" length="5"/><text>PEDOT</text></annotation><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="18" length="7"/><text>Ti3C2Tx</text></annotation><annotation id="7"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="46" length="2"/><text>Pt</text></annotation><annotation id="8"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="49" length="2"/><text>Pd</text></annotation><annotation id="9"><infon key="identifier">MESH:D000432</infon><infon key="type">Chemical</infon><location offset="101" length="8"/><text>methanol</text></annotation></passage><passage><infon key="type">abstract</infon><offset>138</offset><text>Exploiting high-efficiency and durable electrocatalysts toward the methanol oxidation reaction (MOR) is crucial for the advancement of direct methanol fuel cells (DMFCs). Herein, we demonstrate the loading of platinum-palladium bimetallic nanoparticles (Pt-Pd NPs) onto poly(3,4-ethylenedioxythiophene) (PEDOT)-embellished titanium carbide (Ti3C2Tx) nanosheets as the electrocatalyst (Ti3C2Tx/PEDOT/Pt-Pd) via a facile and rapid chemical reduction-assisted one-pot hydrothermal process. The structural and morphological analyses of Ti3C2Tx/PEDOT/Pt-Pd indicate that the three-dimensional (3D) hybrid structure formed between PEDOT and Ti3C2Tx provides a sizable active surface and more active sites, which enhances the homogeneous dispersion of the Pt-Pd NPs and facilitates mass transfer. The Schottky junctions formed between PEDOT and Pt-Pd NPs contribute to charge transfer. The electronic effects and synergistic interactions between the support and catalyst favor the electrocatalytic activity of the catalyst. The electrochemical test results reveal that the Ti3C2Tx/PEDOT/Pt-Pd catalyst has prominent electrocatalytic capability for the MOR. Compared with Ti3C2Tx/Pt-Pd and commercial Pt/C catalysts, the Ti3C2Tx/PEDOT/Pt-Pd catalyst has a larger electrochemical activity surface area (ECSA = 122 m2 g-1) and higher mass activity (MA = 1445.4 mA mg-1), as well as better CO tolerance and more reliable long-term durability (a peak current density retention of 71% after 5200 s).</text><annotation id="49"><infon key="identifier">MESH:D000432</infon><infon key="type">Chemical</infon><location offset="205" length="8"/><text>methanol</text></annotation><annotation id="50"><infon key="identifier">MESH:D000432</infon><infon key="type">Chemical</infon><location offset="280" length="8"/><text>methanol</text></annotation><annotation id="51"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="347" length="8"/><text>platinum</text></annotation><annotation id="52"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="356" length="9"/><text>palladium</text></annotation><annotation id="53"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="392" length="2"/><text>Pt</text></annotation><annotation id="54"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="395" length="2"/><text>Pd</text></annotation><annotation id="55"><infon key="identifier">MESH:C121383</infon><infon key="type">Chemical</infon><location offset="408" length="32"/><text>poly(3,4-ethylenedioxythiophene)</text></annotation><annotation id="56"><infon key="identifier">MESH:C121383</infon><infon key="type">Chemical</infon><location offset="442" length="5"/><text>PEDOT</text></annotation><annotation id="57"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="449" length="28"/><text>embellished titanium carbide</text></annotation><annotation id="58"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="479" length="7"/><text>Ti3C2Tx</text></annotation><annotation id="59"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="523" length="7"/><text>Ti3C2Tx</text></annotation><annotation id="60"><infon key="identifier">MESH:C121383</infon><infon key="type">Chemical</infon><location offset="531" length="5"/><text>PEDOT</text></annotation><annotation id="61"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="537" length="2"/><text>Pt</text></annotation><annotation id="62"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="540" length="2"/><text>Pd</text></annotation><annotation id="63"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="670" length="7"/><text>Ti3C2Tx</text></annotation><annotation id="64"><infon key="identifier">MESH:C121383</infon><infon key="type">Chemical</infon><location offset="678" length="5"/><text>PEDOT</text></annotation><annotation id="65"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="684" length="2"/><text>Pt</text></annotation><annotation id="66"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="687" length="2"/><text>Pd</text></annotation><annotation id="67"><infon key="identifier">MESH:C121383</infon><infon key="type">Chemical</infon><location offset="763" length="5"/><text>PEDOT</text></annotation><annotation id="68"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="773" length="7"/><text>Ti3C2Tx</text></annotation><annotation id="69"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="887" length="2"/><text>Pt</text></annotation><annotation id="70"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="890" length="2"/><text>Pd</text></annotation><annotation id="71"><infon key="identifier">MESH:C121383</infon><infon key="type">Chemical</infon><location offset="966" length="5"/><text>PEDOT</text></annotation><annotation id="72"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="976" length="2"/><text>Pt</text></annotation><annotation id="73"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="979" length="2"/><text>Pd</text></annotation><annotation id="74"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1204" length="7"/><text>Ti3C2Tx</text></annotation><annotation id="75"><infon key="identifier">MESH:C121383</infon><infon key="type">Chemical</infon><location offset="1212" length="5"/><text>PEDOT</text></annotation><annotation id="76"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="1218" length="2"/><text>Pt</text></annotation><annotation id="77"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="1221" length="2"/><text>Pd</text></annotation><annotation id="78"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1302" length="7"/><text>Ti3C2Tx</text></annotation><annotation id="79"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="1310" length="2"/><text>Pt</text></annotation><annotation id="80"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="1313" length="2"/><text>Pd</text></annotation><annotation id="81"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="1331" length="2"/><text>Pt</text></annotation><annotation id="82"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1334" length="1"/><text>C</text></annotation><annotation id="83"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1351" length="7"/><text>Ti3C2Tx</text></annotation><annotation id="84"><infon key="identifier">MESH:C121383</infon><infon key="type">Chemical</infon><location offset="1359" length="5"/><text>PEDOT</text></annotation><annotation id="85"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="1365" length="2"/><text>Pt</text></annotation><annotation id="86"><infon key="identifier">MESH:D010165</infon><infon key="type">Chemical</infon><location offset="1368" length="2"/><text>Pd</text></annotation><annotation id="87"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="1517" length="2"/><text>CO</text></annotation></passage><relation id="R1"><infon key="score">0.7432</infon><infon key="role1">Chemical|MESH:C121383</infon><infon key="role2">Chemical|MESH:D000432</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,4"/></relation><relation id="R2"><infon key="score">0.6604</infon><infon key="role1">Chemical|MESH:D000432</infon><infon key="role2">Chemical|MESH:D010165</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="4,3"/></relation><relation id="R3"><infon key="score">0.7155</infon><infon key="role1">Chemical|MESH:C121383</infon><infon key="role2">Chemical|MESH:D010165</infon><infon key="type">Association</infon><node refid="2" role="0,3"/></relation><relation id="R4"><infon key="score">0.3612</infon><infon key="role1">Chemical|MESH:D010165</infon><infon key="role2">Chemical|MESH:D010984</infon><infon key="type">Comparison</infon><node refid="3" role="3,2"/></relation><relation id="R5"><infon key="score">0.668</infon><infon key="role1">Chemical|MESH:D000432</infon><infon key="role2">Chemical|MESH:D010984</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="4,2"/></relation><relation id="R6"><infon key="score">0.3141</infon><infon key="role1">Chemical|MESH:C121383</infon><infon key="role2">Chemical|MESH:D010984</infon><infon key="type">Cotreatment</infon><node refid="5" role="0,2"/></relation></document>
<document><id>37856573</id><passage><infon key="journal">J Bone Joint Surg Am;2023Oct19. doi:10.2106/JBJS.22.01175</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Han G, Zhou S, Qiu W, Fan Z, Yue L, Li W, Wang W, Sun Z, Li W, </infon><offset>0</offset><text>Role of the Paraspinal Muscles in the Sagittal Imbalance Cascade: The Effects of Their Endurance and of Their Morphology on Sagittal Spinopelvic Alignment.</text><annotation id="1"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="38" length="18"/><text>Sagittal Imbalance</text></annotation></passage><passage><infon key="type">abstract</infon><offset>156</offset><text>BACKGROUND: The role of paraspinal muscle degeneration in the cascade of sagittal imbalance is still unclear. This study aimed to compare paraspinal muscle degeneration in the 4 stages of sagittal imbalance: sagittal balance (SB), compensated sagittal balance (CSB), decompensated sagittal imbalance (DSI), and sagittal imbalance with failure of pelvic compensation (SI-FPC). In addition, it aimed to compare the effects paraspinal muscle endurance and morphology on sagittal spinopelvic alignment in patients with lumbar spinal stenosis. METHODS: A cross-sectional study of 219 patients hospitalized with lumbar spinal stenosis was performed. The isometric paraspinal extensor endurance test and evaluation of atrophy and fat infiltration of the paraspinal extensor muscles and psoas major on magnetic resonance imaging were performed at baseline. Spinopelvic parameters including lumbar lordosis, pelvic tilt, sacral slope, pelvic incidence, and the sagittal vertical axis were measured. RESULTS: The patients with lumbar spinal stenosis were divided into 67 with SB, 85 with CSB, 49 with DSI, and 17 with SI-FPC. There were significant differences in paraspinal muscle endurance and morphology among the 4 groups. Furthermore, the SI-FPC group had poorer paraspinal muscle endurance than either the SB or the CSB group. In multiple linear regression analysis, paraspinal muscle endurance and the relative functional cross-sectional area of the paraspinal extensor muscles were the independent predictors of the sagittal vertical axis, and the relative functional cross-sectional area of the psoas major was the independent predictor of relative pelvic version. CONCLUSIONS: This study indicated that paraspinal muscle degeneration is not only an initiating factor in pelvic retroversion but also a risk factor for progression from a compensated to a decompensated stage. Specifically, the impairment of muscle endurance in the CSB stage may be the reason why patients experience failure of pelvic compensation. In addition, paraspinal muscle endurance and muscle morphology (relative functional cross-sectional area of the paraspinal extensor muscles and psoas major) had different clinical consequences. LEVEL OF EVIDENCE: Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.</text><annotation id="23"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="180" length="30"/><text>paraspinal muscle degeneration</text></annotation><annotation id="24"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="229" length="18"/><text>sagittal imbalance</text></annotation><annotation id="25"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="294" length="30"/><text>paraspinal muscle degeneration</text></annotation><annotation id="26"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="344" length="18"/><text>sagittal imbalance</text></annotation><annotation id="27"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="437" length="18"/><text>sagittal imbalance</text></annotation><annotation id="28"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="457" length="3"/><text>DSI</text></annotation><annotation id="29"><infon key="identifier">MESH:D003398</infon><infon key="type">Disease</infon><location offset="467" length="18"/><text>sagittal imbalance</text></annotation><annotation id="30"><infon key="identifier">MESH:D034161</infon><infon key="type">Disease</infon><location offset="499" length="9"/><text>of pelvic</text></annotation><annotation id="31"><infon key="identifier">MESH:D011125</infon><infon key="type">Disease</infon><location offset="525" length="4"/><text>-FPC</text></annotation><annotation id="32"><infon key="identifier">MESH:C563613</infon><infon key="type">Disease</infon><location offset="671" length="22"/><text>lumbar spinal stenosis</text></annotation><annotation id="33"><infon key="identifier">MESH:C563613</infon><infon key="type">Disease</infon><location offset="762" length="22"/><text>lumbar spinal stenosis</text></annotation><annotation id="34"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="867" length="7"/><text>atrophy</text></annotation><annotation id="35"><infon key="identifier">MESH:D004620</infon><infon key="type">Disease</infon><location offset="879" length="3"/><text>fat</text></annotation><annotation id="36"><infon key="identifier">MESH:C563613</infon><infon key="type">Disease</infon><location offset="1173" length="22"/><text>lumbar spinal stenosis</text></annotation><annotation id="37"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1247" length="3"/><text>DSI</text></annotation><annotation id="38"><infon key="identifier">MESH:D011125</infon><infon key="type">Disease</infon><location offset="1267" length="3"/><text>FPC</text></annotation><annotation id="39"><infon key="identifier">MESH:D011125</infon><infon key="type">Disease</infon><location offset="1393" length="3"/><text>FPC</text></annotation><annotation id="40"><infon key="identifier">MESH:D009410</infon><infon key="type">Disease</infon><location offset="1859" length="30"/><text>paraspinal muscle degeneration</text></annotation><annotation id="41"><infon key="identifier">MESH:D060751</infon><infon key="type">Disease</infon><location offset="1926" length="19"/><text>pelvic retroversion</text></annotation><annotation id="42"><infon key="identifier">MESH:D009135</infon><infon key="type">Disease</infon><location offset="2048" length="30"/><text>impairment of muscle endurance</text></annotation><annotation id="43"><infon key="identifier">MESH:D034161</infon><infon key="type">Disease</infon><location offset="2146" length="9"/><text>of pelvic</text></annotation></passage></document>
<document><id>37856952</id><passage><infon key="journal">Ann Diagn Pathol;2023Oct05; 67 152215. doi:10.1016/j.anndiagpath.2023.152215</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Donati M, Nosek D, Olivares S, Lemahieu J, Loontiens S, Mansour B, Gerami P, Kazakov DV, </infon><offset>0</offset><text>Spitz tumor with RAF1 fusion: A report of 3 cases.</text><annotation id="2"><infon key="identifier">MESH:D018332</infon><infon key="type">Disease</infon><location offset="0" length="11"/><text>Spitz tumor</text></annotation><annotation id="3"><infon key="identifier">5894</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48145</infon><location offset="17" length="4"/><text>RAF1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>51</offset><text>Spitz tumors are melanocytic neoplasms morphologically characterized by spindled and/or epithelioid cells and specific stromal and epidermal changes associated with mutually exclusive fusion kinases involving ALK, ROS1, NTRK1, NTRK2, NTRK3, MET and RET, BRAF and MAP3K8 genes or, less commonly, HRAS mutation. RAF1 fusions have been recently detected in cutaneous melanocytic neoplasms, including conventional melanoma, congenital nevus and BAP-1 inactivated tumors. We report herewith three Spitz neoplasms with a RAF1 fusion, including a previously reported CTDSPL::RAF1 fusion and two novel PPAP2B::RAF1 and ATP2B4::RAF1 fusions. Two cases were classified as Spitz nevus, while the remaining neoplasm was classified as Spitz melanoma at the time of the diagnosis, given 9p21 homozygous deletion and positive sentinel lymph node biopsy. We suggest that RAF1 fused melanocytic neoplasms can represent a novel subgroup of Spitz tumors, with a RAF1 fusion representing an oncogenic driver.</text><annotation id="35"><infon key="identifier">MESH:D018332</infon><infon key="type">Disease</infon><location offset="51" length="12"/><text>Spitz tumors</text></annotation><annotation id="36"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="68" length="21"/><text>melanocytic neoplasms</text></annotation><annotation id="37"><infon key="identifier">238</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68387</infon><location offset="260" length="3"/><text>ALK</text></annotation><annotation id="38"><infon key="identifier">6098</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2207</infon><location offset="265" length="4"/><text>ROS1</text></annotation><annotation id="39"><infon key="identifier">4914</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1898</infon><location offset="271" length="5"/><text>NTRK1</text></annotation><annotation id="40"><infon key="identifier">4915</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4504</infon><location offset="278" length="5"/><text>NTRK2</text></annotation><annotation id="41"><infon key="identifier">4916</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49183</infon><location offset="285" length="5"/><text>NTRK3</text></annotation><annotation id="42"><infon key="identifier">79811</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11696</infon><location offset="292" length="3"/><text>MET</text></annotation><annotation id="43"><infon key="identifier">5979</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7517</infon><location offset="300" length="3"/><text>RET</text></annotation><annotation id="44"><infon key="identifier">673</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3197</infon><location offset="305" length="4"/><text>BRAF</text></annotation><annotation id="45"><infon key="identifier">1326</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3812</infon><location offset="314" length="6"/><text>MAP3K8</text></annotation><annotation id="46"><infon key="identifier">3265</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55890</infon><location offset="346" length="4"/><text>HRAS</text></annotation><annotation id="47"><infon key="identifier">5894</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48145</infon><location offset="361" length="4"/><text>RAF1</text></annotation><annotation id="48"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="405" length="31"/><text>cutaneous melanocytic neoplasms</text></annotation><annotation id="49"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="448" length="21"/><text>conventional melanoma</text></annotation><annotation id="50"><infon key="identifier">MESH:D009506</infon><infon key="type">Disease</infon><location offset="471" length="16"/><text>congenital nevus</text></annotation><annotation id="51"><infon key="identifier">8314</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3421</infon><location offset="492" length="5"/><text>BAP-1</text></annotation><annotation id="52"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="510" length="6"/><text>tumors</text></annotation><annotation id="53"><infon key="identifier">MESH:D018332</infon><infon key="type">Disease</infon><location offset="543" length="15"/><text>Spitz neoplasms</text></annotation><annotation id="54"><infon key="identifier">5894</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48145</infon><location offset="566" length="4"/><text>RAF1</text></annotation><annotation id="55"><infon key="type">Disease</infon><location offset="611" length="12"/><text>CTDSPL::RAF1</text></annotation><annotation id="56"><infon key="identifier">8613;5894</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">15410;48145</infon><location offset="645" length="12"/><text>PPAP2B::RAF1</text></annotation><annotation id="57"><infon key="identifier">5894</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48145</infon><location offset="662" length="12"/><text>ATP2B4::RAF1</text></annotation><annotation id="58"><infon key="identifier">MESH:D018332</infon><infon key="type">Disease</infon><location offset="713" length="11"/><text>Spitz nevus</text></annotation><annotation id="59"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="746" length="8"/><text>neoplasm</text></annotation><annotation id="60"><infon key="identifier">MESH:D008545</infon><infon key="type">Disease</infon><location offset="773" length="14"/><text>Spitz melanoma</text></annotation><annotation id="61"><infon key="identifier">9</infon><infon key="type">Chromosome</infon><location offset="824" length="4"/><text>9p21</text></annotation><annotation id="62"><infon key="identifier">5894</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48145</infon><location offset="906" length="4"/><text>RAF1</text></annotation><annotation id="63"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="917" length="21"/><text>melanocytic neoplasms</text></annotation><annotation id="64"><infon key="identifier">MESH:D018332</infon><infon key="type">Disease</infon><location offset="973" length="12"/><text>Spitz tumors</text></annotation><annotation id="65"><infon key="identifier">5894</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">48145</infon><location offset="994" length="4"/><text>RAF1</text></annotation></passage><relation id="R1"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|5894</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.9817</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|3265</infon><infon key="type">Association</infon><node refid="1" role="2,13"/></relation><relation id="R3"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D008545</infon><infon key="role2">Gene|5894</infon><infon key="type">Association</infon><node refid="2" role="16,14"/></relation><relation id="R4"><infon key="score">0.9864</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|4916</infon><infon key="type">Association</infon><node refid="3" role="2,8"/></relation><relation id="R5"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|5894</infon><infon key="type">Association</infon><node refid="4" role="15,14"/></relation><relation id="R6"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|238</infon><infon key="type">Association</infon><node refid="5" role="2,4"/></relation><relation id="R7"><infon key="score">0.9944</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|1326</infon><infon key="type">Association</infon><node refid="6" role="2,12"/></relation><relation id="R8"><infon key="score">0.9979</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|4914</infon><infon key="type">Association</infon><node refid="7" role="2,6"/></relation><relation id="R9"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|8613</infon><infon key="type">Association</infon><node refid="8" role="20,24"/></relation><relation id="R10"><infon key="score">0.9967</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|4915</infon><infon key="type">Association</infon><node refid="9" role="2,7"/></relation><relation id="R11"><infon key="score">0.9984</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|673</infon><infon key="type">Association</infon><node refid="10" role="2,11"/></relation><relation id="R12"><infon key="score">0.9946</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|5979</infon><infon key="type">Association</infon><node refid="11" role="2,10"/></relation><relation id="R13"><infon key="score">0.9981</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|6098</infon><infon key="type">Association</infon><node refid="12" role="2,5"/></relation><relation id="R14"><infon key="score">0.9778</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|8314</infon><infon key="type">Association</infon><node refid="13" role="15,18"/></relation><relation id="R15"><infon key="score">0.9603</infon><infon key="role1">Disease|MESH:D018332</infon><infon key="role2">Gene|79811</infon><infon key="type">Association</infon><node refid="14" role="2,9"/></relation></document>
<document><id>37857302</id><passage><infon key="journal">Environ Sci Technol;2023Oct31; 57 (43) 16512. doi:10.1021/acs.est.3c03107</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wu F, Yang L, Wang X, Yuan W, Lin CJ, Feng X, </infon><offset>0</offset><text>Mercury Accumulation and Sequestration in a Deglaciated Forest Chronosequence: Insights from Particulate and Mineral-Associated Forms of Organic Matter.</text><annotation id="2"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="0" length="7"/><text>Mercury</text></annotation><annotation id="3"><infon key="identifier">MESH:D008903</infon><infon key="type">Chemical</infon><location offset="109" length="7"/><text>Mineral</text></annotation></passage><passage><infon key="type">abstract</infon><offset>153</offset><text>Understanding mercury (Hg) complexation with soil organic matter is important in assessing atmospheric Hg accumulation and sequestration processes in forest ecosystems. Separating soil organic matter into particulate organic matter (POM) and mineral-associated organic matter (MAOM) can help in the understanding of Hg dynamics and cycling due to their very different chemical constituents and associated formation and functioning mechanisms. The concentration of Hg, carbon, and nitrogen contents and isotopic signatures of POM and MAOM in a deglaciated forest chronosequence were determined to construct the processes of Hg accumulation and sequestration. The results show that Hg in POM and MAOM are mainly derived from atmospheric Hg0 deposition. Hg concentration in MAOM is up to 76% higher than that in POM of broadleaf forests and up to 60% higher than that in POM of coniferous forests. Hg accumulation and sequestration in organic soil vary with the vegetation succession. Variations of delta202Hg and Delta199Hg are controlled by source mixing in the broadleaf forest and by Hg sequestration processes in the coniferous forest. Accumulation of atmospheric Hg and subsequent microbial reduction enrich heavier Hg isotopes in MAOM compared to POM due to the specific chemical constituents and nutritional role of MAOM.</text><annotation id="29"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="167" length="7"/><text>mercury</text></annotation><annotation id="30"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="176" length="2"/><text>Hg</text></annotation><annotation id="31"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="256" length="2"/><text>Hg</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="358" length="26"/><text>particulate organic matter</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="386" length="3"/><text>POM</text></annotation><annotation id="34"><infon key="identifier">MESH:D008903</infon><infon key="type">Chemical</infon><location offset="395" length="7"/><text>mineral</text></annotation><annotation id="35"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="469" length="2"/><text>Hg</text></annotation><annotation id="36"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="617" length="2"/><text>Hg</text></annotation><annotation id="37"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="621" length="6"/><text>carbon</text></annotation><annotation id="38"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="633" length="8"/><text>nitrogen</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="678" length="3"/><text>POM</text></annotation><annotation id="40"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="776" length="2"/><text>Hg</text></annotation><annotation id="41"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="833" length="2"/><text>Hg</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="839" length="3"/><text>POM</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="888" length="3"/><text>Hg0</text></annotation><annotation id="44"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="904" length="2"/><text>Hg</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="962" length="3"/><text>POM</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1021" length="3"/><text>POM</text></annotation><annotation id="47"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="1048" length="2"/><text>Hg</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1149" length="10"/><text>delta202Hg</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1164" length="10"/><text>Delta199Hg</text></annotation><annotation id="50"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="1238" length="2"/><text>Hg</text></annotation><annotation id="51"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="1319" length="2"/><text>Hg</text></annotation><annotation id="52"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="1372" length="2"/><text>Hg</text></annotation><annotation id="53"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1404" length="3"/><text>POM</text></annotation></passage></document>
<document><id>37858004</id><passage><infon key="journal">Behav Res Methods;2023Oct19. doi:10.3758/s13428-023-02253-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">2386493</infon><infon key="type">title</infon><infon key="authors">Wiedermann W, Zhang B, Shi D, </infon><offset>0</offset><text>Detecting heterogeneity in the causal direction of dependence: A model-based recursive partitioning approach.</text></passage><passage><infon key="type">abstract</infon><offset>110</offset><text>Methods of causal discovery and direction of dependence to evaluate causal properties of variable relations have experienced rapid development. The majority of causal discovery methods, however, relies on the assumption of causal effect homogeneity, that is, the identified causal structure is expected to hold for the entire population. Because causal mechanisms can vary across subpopulations, we propose combining methods of model-based recursive partitioning and non-Gaussian causal discovery to identify such subpopulations. The resulting algorithm can discover subpopulations with potentially varying magnitude and causal direction of effects under mild parameter inequality assumptions. Feasibility conditions are described and results from synthetic data experiments are presented suggesting that large effects and large sample sizes are beneficial for detecting causally competing subgroups with acceptable statistical performance. In a real-world data example, the extraction of meaningful subgroups that differ in the causal mechanism underlying the development of numerical cognition is illustrated. Potential extensions and recommendations for best practice applications are discussed.</text></passage></document>
<document><id>37858356</id><passage><infon key="journal">Radiologia (Engl Ed);2023Oct; 65 Suppl 2 74. doi:10.1016/j.rxeng.2023.09.005</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jover-S&amp;#xe1;nchez JJ, Crist&amp;#xf3;bal-Velasco L, Benza-Villarejo E, Maldonado-Morillo AA, </infon><offset>0</offset><text>Tarsal tunnel ganglion cyst: intraneural or extraneural site?</text><annotation id="2"><infon key="identifier">MESH:D045888</infon><infon key="type">Disease</infon><location offset="0" length="27"/><text>Tarsal tunnel ganglion cyst</text></annotation><annotation id="3"><infon key="type">Disease</infon><location offset="29" length="11"/><text>intraneural</text></annotation></passage><passage><infon key="type">abstract</infon><offset>62</offset><text>Intraneural ganglion cysts are very uncommon lesions, whose diagnosis has increased since the articular theory and the description of the MRI findings were established. We present a case report of a 59-year-old man with symptoms of tarsal tunnel syndrome. Foot and ankle MRI demonstrated the presence of an intraneural cystic lesion in the posterior tibial neve and its connection with the subtalar joint through an articular branch. The identification of the specific radiological signs like the &lt;&lt;signet ring sign>> allowed establishing an adequate preoperative diagnosis, differentiating it from an extraneural lesion and facilitating the articular disconnection of the nerve branch during surgery.</text><annotation id="10"><infon key="type">Disease</infon><location offset="62" length="11"/><text>Intraneural</text></annotation><annotation id="11"><infon key="identifier">MESH:D045888</infon><infon key="type">Disease</infon><location offset="74" length="14"/><text>ganglion cysts</text></annotation><annotation id="12"><infon key="identifier">MESH:D013641</infon><infon key="type">Disease</infon><location offset="294" length="22"/><text>tarsal tunnel syndrome</text></annotation><annotation id="13"><infon key="type">Disease</infon><location offset="369" length="11"/><text>intraneural</text></annotation><annotation id="14"><infon key="identifier">MESH:D052177</infon><infon key="type">Disease</infon><location offset="381" length="13"/><text>cystic lesion</text></annotation><annotation id="15"><infon key="identifier">MESH:D009059</infon><infon key="type">Disease</infon><location offset="664" length="18"/><text>extraneural lesion</text></annotation></passage></document>
<document><id>37858706</id><passage><infon key="journal">J Mol Biol;2023Oct17 168315. doi:10.1016/j.jmb.2023.168315</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gao Z, Wang M, Smith A, Boyes J, </infon><offset>0</offset><text>YY1 Binding to Regulatory Elements that Lack Enhancer Activity Promotes Locus Folding and Gene Activation.</text><annotation id="1"><infon key="identifier">22632</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2556</infon><location offset="0" length="3"/><text>YY1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>Enhancers activate their cognate promoters over huge distances but how enhancer/promoter interactions become established is not completely understood. There is strong evidence that cohesin-mediated loop extrusion is involved but this does not appear to be a universal mechanism. Here, we identify an element within the mouse immunoglobulin lambda (Iglambda) light chain locus, HSClambda1, that has characteristics of active regulatory elements but lacks intrinsic enhancer or promoter activity. Remarkably, knock-out of the YY1 binding site from HSClambda1 reduces Iglambda transcription significantly and disrupts enhancer/promoter interactions, even though these elements are >10 kb from HSClambda1. Genome-wide analyses of mouse embryonic stem cells identified 2671 similar YY1-bound, putative genome organizing elements that lie within CTCF/cohesin loop boundaries but that lack intrinsic enhancer activity. We suggest that such elements play a fundamental role in locus folding and in facilitating enhancer/promoter interactions.</text><annotation id="5"><infon key="identifier">22632</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2556</infon><location offset="631" length="3"/><text>YY1</text></annotation><annotation id="6"><infon key="identifier">22632</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2556</infon><location offset="884" length="3"/><text>YY1</text></annotation><annotation id="7"><infon key="identifier">13018</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4786</infon><location offset="947" length="4"/><text>CTCF</text></annotation></passage><relation id="R1"><infon key="score">0.6677</infon><infon key="role1">Gene|13018</infon><infon key="role2">Gene|22632</infon><infon key="type">Association</infon><node refid="0" role="3,2"/></relation></document>
<document><id>37859074</id><passage><infon key="journal">Opt Express;2023Sep25; 31 (20) 32799. doi:10.1364/OE.499177</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wu Y, Pan C, Lu C, Zhang Y, Zhang L, Huang Z, </infon><offset>0</offset><text>Hybrid waveguide based augmented reality display system with extra large field of view and 2D exit pupil expansion.</text></passage><passage><infon key="type">abstract</infon><offset>116</offset><text>For a waveguide display device, the field of view (FOV) is a key parameter for evaluating its optical performance. To address this issue, we propose a hybrid waveguide system, which is composed of two projectors, two in-couplers, two half-mirror arrays and an out-coupler. We use two projectors to generate the left and right parts of the output image separately, which can increase the upper limit of the FOV significantly. Unlike conventional waveguide-based system, we use half-mirror arrays instead of folding gratings to realize 2D exit pupil expansion. By doing so, the total internal reflection condition can always be met during the pupil expansion process. To solve the difficulty in designing collimating optical system with large FOV, we propose a method of tilting the projection system. The hybrid waveguide system can realize a FOV of 88 (H) x 53 (V).</text></passage></document>
<document><id>37859427</id><passage><infon key="journal">Ann Palliat Med;2023Sep; 12 (5) 1117. doi:10.21037/apm-23-532</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Simone CB, </infon><offset>0</offset><text>The most downloaded articles published in Annals of Palliative Medicine in 2022.</text></passage><passage><infon key="type">abstract</infon><offset>81</offset></passage></document>
<document><id>37860834</id><passage><infon key="journal">Turk J Gastroenterol;2023Oct20. doi:10.5152/tjg.2023.23309</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lee J, Park JS, Jeong S, Lee DH, Lim JH, Cho SG, Il Kwon C, Hyun JJ, Choe JW, Cho JH, Ill Jang S, </infon><offset>0</offset><text>Prognostic Impact of Minimal Pelvic Fluid in Locally Advanced Pancreatic Cancer: A Multicenter Retrospective Study.</text><annotation id="1"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="53" length="26"/><text>Advanced Pancreatic Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>116</offset><text>BACKGROUND/AIMS: Minimal pelvic fluid (MPF) is occasionally encountered on computed tomography (CT) scans during the initial staging of newly diagnosed pancreatic cancer. However, its clinical relevance has scarcely been studied. This study intends to explore the incidence of minimal pelvic fluid and its relevance in terms of survival in locally advanced pancreatic cancer (LAPC) patients. MATERIALS AND METHODS: The medical records of patients with LAPC at 4 tertiary referral institutions were retrospectively reviewed from January 2005 to December 2015. Minimal pelvic fluid was defined as a fluid collection volume in the pelvic cavity of &lt;100 mL as determined by abdominal CT. The association between the presence of MPF and patient survival was evaluated. RESULTS: A total of 59 patients (male:female, 33:26; median age, 68 years; range 46-82 years) with LAPC were enrolled. Of the 59 patients, 22.0% (n = 13) had MPF, and 78.0% (n = 46) had no pelvic fluid (NPF). Baseline clinical characteristics in the 2 groups, including extent of the tumor stage, extent of spread to the lymph nodes stage, and pattern of treatments, were not significantly different. However, median overall survival was significantly less in the MPF group [9.7 months, (95% CI, 5.9-13.5)] than in the NPF group as determined by the log-rank test [16.9 months, (95% CI, 9.3-24.5)] (P = .002), and univariate and multivariate analyses showed that the presence of MPF independently predicted a poor prognosis. CONCLUSION: The presence of MPF was found to be significantly associated with reduced survival and an independent poor prognostic biomarker in LAPC patients.</text><annotation id="9"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="268" length="17"/><text>pancreatic cancer</text></annotation><annotation id="10"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="464" length="26"/><text>advanced pancreatic cancer</text></annotation><annotation id="11"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="492" length="4"/><text>LAPC</text></annotation><annotation id="12"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="568" length="4"/><text>LAPC</text></annotation><annotation id="13"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="979" length="4"/><text>LAPC</text></annotation><annotation id="14"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1164" length="5"/><text>tumor</text></annotation><annotation id="15"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="1748" length="4"/><text>LAPC</text></annotation></passage></document>
<document><id>37861196</id><passage><infon key="journal">Curr Opin Crit Care;2023Dec01; 29 (6) 542. doi:10.1097/MCC.0000000000001105</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kashani KB, Koyner JL, </infon><offset>0</offset><text>Digital health utilities in acute kidney injury management.</text><annotation id="1"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="28" length="19"/><text>acute kidney injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>60</offset><text>PURPOSE OF REVIEW: Acute kidney injury (AKI) is a highly prevalent clinical syndrome that substantially impacts patient outcomes. It is accepted by the clinical communities that the management of AKI is time-sensitive. Unfortunately, despite growing proof of its preventability, AKI management remains suboptimal in community, acute care, and postacute care settings. Digital health solutions comprise various tools and models to improve care processes and patient outcomes in multiple medical fields. AKI development, progression, recovery, or lack thereof, offers tremendous opportunities for developing, validating, and implementing digital health solutions in multiple settings. This article will review the definitions and components of digital health, the characteristics of AKI that allow digital health solutions to be considered, and the opportunities and threats in implementing these solutions. RECENT FINDINGS: Over the past two decades, the academic output related to the use of digital health solutions in AKI has exponentially grown. While this indicates the growing interest in the topic, most topics are primarily related to clinical decision support by detecting AKI within hospitals or using artificial intelligence or machine learning technologies to predict AKI within acute care settings. However, recently, projects to assess the impact of digital health solutions in more complex scenarios, for example, managing nephrotoxins among adults of pediatric patients who already have AKI, is increasing. Depending on the type of patients, chosen digital health solution intervention, comparator groups, and selected outcomes, some of these studies showed benefits, while some did not indicate additional gain in care processes or clinical outcomes. SUMMARY: Careful needs assessment, selection of the correct digital health solution, and appropriate clinical validation of the benefits while avoiding additional health disparities are moral, professional, and ethical obligations for all individuals using these healthcare tools, including clinicians, data scientists, and administrators.</text><annotation id="12"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="79" length="19"/><text>Acute kidney injury</text></annotation><annotation id="13"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="100" length="3"/><text>AKI</text></annotation><annotation id="14"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="256" length="3"/><text>AKI</text></annotation><annotation id="15"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="339" length="3"/><text>AKI</text></annotation><annotation id="16"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="562" length="3"/><text>AKI</text></annotation><annotation id="17"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="841" length="3"/><text>AKI</text></annotation><annotation id="18"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="1080" length="3"/><text>AKI</text></annotation><annotation id="19"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="1241" length="3"/><text>AKI</text></annotation><annotation id="20"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="1339" length="3"/><text>AKI</text></annotation><annotation id="21"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="1562" length="3"/><text>AKI</text></annotation></passage></document>
<document><id>37861904</id><passage><infon key="journal">Bull Exp Biol Med;2023Sep; 175 (5) 667. doi:10.1007/s10517-023-05923-x</infon><infon key="year">2023</infon><infon key="article-id_pmc">7653219</infon><infon key="type">title</infon><infon key="authors">Bgatova NP, Savchenko SV, Lamanov AN, Ergazina MZ, Adilova MT, Letyagin AY, </infon><offset>0</offset><text>Ultrastructural Reorganization of Endotheliocytes of Pulmonary Blood Capillaries in COVID-19.</text><annotation id="1"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="84" length="8"/><text>COVID-19</text></annotation></passage><passage><infon key="type">abstract</infon><offset>94</offset><text>The ultrastructural organization endotheliocytes of pulmonary blood capillaries in COVID-19 was studied on autopsy material using electron microscopy. Swelling of the cytoplasm and mitochondria with destruction of the cristae, dilation of the Golgi complex cisternae, a decrease in the volume density of the luminal and basal caveolae and free transport vesicles, an increase of the rough endoplasmic reticulum, as well as the presence of elements of coronavirus replication (reticulovesicular structures, zippered endoplasmic reticulum, electron-dense particles in the Golgi cisternae, and vacuoles with viral particles) were revealed. Further studies of the intracellular mechanisms used by the virus to replicate could help to develop antiviral drugs for the treatment of the new coronavirus infection.</text><annotation id="4"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="177" length="8"/><text>COVID-19</text></annotation><annotation id="5"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="873" length="25"/><text>new coronavirus infection</text></annotation></passage></document>
<document><id>37862255</id><passage><infon key="journal">Sante Ment Que;2023Spring; 48 (1) 95</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Touchette E, Servot S, Davidson-Urbain W, Pennestri MH, Godbout R, Montplaisir J, </infon><offset>0</offset><text>[Assessments of sleepiness in adolescents: A key tool for better intervene in mental health].</text><annotation id="1"><infon key="identifier">MESH:D000077260</infon><infon key="type">Disease</infon><location offset="16" length="10"/><text>sleepiness</text></annotation></passage><passage><infon key="type">abstract</infon><offset>94</offset><text>Objectives Daytime sleepiness in adolescents has negative impacts on physical, cognitive, and emotional health, with direct or indirect consequences on their mental health. This review aims to describe specialized tools assessing daytime sleepiness in adolescents so that mental health professionals can screen for a variety of sleep disorders, from the rarest ones, such as narcolepsy, to the most common ones, such as sleep-wake cycle delay in adolescents. Method Articles were selected in Medline (https://pubmed.ncbi.nlm.nih.gov/) and targeted adolescents aged between 13 and 18 or the keyword "adolescent*". The keywords used were: "sleepiness test" AND "questionnaire*". Only articles in French or English and published until January 9, 2023 were included. A total of 277 scientific articles were screened. Final sample included a total of 35 articles describing sleepiness measurement tools in adolescents. Results Among the 35 articles, a total of seven daytime sleepiness measurement tools in adolescents were identified. Four of them were subjective: 1) the Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD), 2) the Pediatric Daytime Sleepiness Scale (PDSS), 3) the Cleveland Adolescent Sleepiness Questionnaire (CASQ) and 4) the French Sleepiness Scale for Adolescents (FSSA). These self-reported questionnaires are less expensive and they can be used easily by mental health professionals as opposed to objective tools. Three objective tools have been identified: 1) the multiple sleep latency test (MSLT), 2) the maintenance of wakefulness test or called the "Maintenance Wakefulness Test" (MWT) and 3) the pupillographic sleepiness test (PST). Conclusion Given that adolescents end-of the-day sleep pressure, often resulting in a greater opportunity to light exposure, they are more at risk for daytime sleepiness and consequently to mental health challenges. Mental health professionals should therefore systematically screen for daytime sleepiness in adolescents using subjective tools. There are reliable and validated tools that are translated into French, such as the FSSA and the ESS-CHAD to measure daytime sleepiness in adolescents and lifestyles problems associated with sleep loss When daytime sleepiness suggests the presence of medical-based sleep disorders, such as narcolepsy, restless sleep disorders or sleep apnea, it is important to pursue an investigation with objective tools (nocturnal polysomnography, MLST and MWT) in collaboration with the adolescent's physician.</text><annotation id="24"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="105" length="18"/><text>Daytime sleepiness</text></annotation><annotation id="25"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="324" length="18"/><text>daytime sleepiness</text></annotation><annotation id="26"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="422" length="15"/><text>sleep disorders</text></annotation><annotation id="27"><infon key="identifier">MESH:D009290</infon><infon key="type">Disease</infon><location offset="469" length="10"/><text>narcolepsy</text></annotation><annotation id="28"><infon key="identifier">MESH:D020178</infon><infon key="type">Disease</infon><location offset="514" length="22"/><text>sleep-wake cycle delay</text></annotation><annotation id="29"><infon key="identifier">MESH:D000077260</infon><infon key="type">Disease</infon><location offset="732" length="10"/><text>sleepiness</text></annotation><annotation id="30"><infon key="identifier">MESH:D000077260</infon><infon key="type">Disease</infon><location offset="963" length="10"/><text>sleepiness</text></annotation><annotation id="31"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="1056" length="18"/><text>daytime sleepiness</text></annotation><annotation id="32"><infon key="identifier">MESH:D000077260</infon><infon key="type">Disease</infon><location offset="1170" length="10"/><text>Sleepiness</text></annotation><annotation id="33"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="1245" length="18"/><text>Daytime Sleepiness</text></annotation><annotation id="34"><infon key="identifier">MESH:D000077260</infon><infon key="type">Disease</infon><location offset="1306" length="10"/><text>Sleepiness</text></annotation><annotation id="35"><infon key="identifier">MESH:D000077260</infon><infon key="type">Disease</infon><location offset="1356" length="10"/><text>Sleepiness</text></annotation><annotation id="36"><infon key="identifier">MESH:D000077260</infon><infon key="type">Disease</infon><location offset="1744" length="10"/><text>sleepiness</text></annotation><annotation id="37"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="1918" length="18"/><text>daytime sleepiness</text></annotation><annotation id="38"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="2054" length="18"/><text>daytime sleepiness</text></annotation><annotation id="39"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="2229" length="18"/><text>daytime sleepiness</text></annotation><annotation id="40"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="2303" length="10"/><text>sleep loss</text></annotation><annotation id="41"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="2319" length="18"/><text>daytime sleepiness</text></annotation><annotation id="42"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="2377" length="15"/><text>sleep disorders</text></annotation><annotation id="43"><infon key="identifier">MESH:D009290</infon><infon key="type">Disease</infon><location offset="2402" length="10"/><text>narcolepsy</text></annotation><annotation id="44"><infon key="identifier">MESH:C000715309</infon><infon key="type">Disease</infon><location offset="2414" length="24"/><text>restless sleep disorders</text></annotation><annotation id="45"><infon key="identifier">MESH:D012891</infon><infon key="type">Disease</infon><location offset="2442" length="11"/><text>sleep apnea</text></annotation></passage></document>
<document><id>37862605</id><passage><infon key="journal">Nano Lett;2023Oct20. doi:10.1021/acs.nanolett.3c02833</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fan Y, Xue X, Yang F, Zhao J, Xiong X, Sun J, Wang W, Shi J, Zhou J, Zhang Z, </infon><offset>0</offset><text>Reconstruction of the Near-Field Electric Field by SNOM Measurement.</text></passage><passage><infon key="type">abstract</infon><offset>69</offset><text>Scanning near-field optical microscope (SNOM) with nanoscale spatial resolution has been a powerful tool in studying the plasmonic properties of nano materials/structures. However, the quantification of the SNOM measurement remains a major challenge in the field due to the lack of reliable methodologies. We employed the point-dipole model to describe the tip-surface interaction upon laser illumination and theoretically derived the quantitative relationship between the measured results and the actual near-field electric field strength. Thus, we can experimentally reconstruct the near-field electric field through this theoretically calculated relationship. We also developed an experimental technique together with FEM simulation to get the above relationship experimentally and reconstruct the near-field electric field from the measurement by SNOM.</text></passage></document>
<document><id>37862956</id><passage><infon key="journal">J Crit Care;2023Oct18; 79 154448. doi:10.1016/j.jcrc.2023.154448</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xu Y, Peng F, Wang S, Yu H, </infon><offset>0</offset><text>Lower versus higher oxygen targets after resuscitation from out-of-hospital cardiac arrest: A systematic review and meta-analysis of randomized controlled trials.</text><annotation id="2"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="20" length="6"/><text>oxygen</text></annotation><annotation id="3"><infon key="identifier">MESH:D006323</infon><infon key="type">Disease</infon><location offset="76" length="14"/><text>cardiac arrest</text></annotation></passage><passage><infon key="type">abstract</infon><offset>163</offset><text>PURPOSE: To update the existing evidence and gain further insight into effects of lower versus higher oxygen targets on the outcomes in patients resuscitated from out-of-hospital cardiac arrest (OHCA). METHODS: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing lower versus higher oxygen targets on the outcomes among adults resuscitated from OHCA. The primary outcome was short-term survival (in hospital or within 30 days). Subgroup analyses were performed according to timing of study interventions. RESULTS: Seven RCTs with 1454 patients were finally included. The short-term survival did not differ between the two groups with a relative risk (RR) of 0.98 (95% CI, 0.86 to 1.11). There were no significant differences in survival at longest follow-up (RR, 1.01; 95% CI, 0.91 to 1.14), favorable neurological outcome (RR, 1.00; 95% CI, 0.91 to 1.11), length of intensive care unit stay (mean difference, -4.94 h; 95% CI, -14.83 to 4.96 h), or risk of re-arrest (RR, 0.68; 95% CI, 0.21 to 2.19). The quality of evidence ranged from moderate to very low. CONCLUSION: Current evidence suggests that targeting a lower or higher oxygen therapy in patients after resuscitation from OHCA results in similar short-term survival and other clinical outcomes.</text><annotation id="11"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="265" length="6"/><text>oxygen</text></annotation><annotation id="12"><infon key="identifier">MESH:D006323</infon><infon key="type">Disease</infon><location offset="342" length="14"/><text>cardiac arrest</text></annotation><annotation id="13"><infon key="identifier">MESH:D058687</infon><infon key="type">Disease</infon><location offset="358" length="4"/><text>OHCA</text></annotation><annotation id="14"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="494" length="6"/><text>oxygen</text></annotation><annotation id="15"><infon key="identifier">MESH:D058687</infon><infon key="type">Disease</infon><location offset="556" length="4"/><text>OHCA</text></annotation><annotation id="16"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1341" length="6"/><text>oxygen</text></annotation><annotation id="17"><infon key="identifier">MESH:D058687</infon><infon key="type">Disease</infon><location offset="1393" length="4"/><text>OHCA</text></annotation></passage><relation id="R1"><infon key="score">0.9916</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Disease|MESH:D058687</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="2,4"/></relation><relation id="R2"><infon key="score">0.8881</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Disease|MESH:D006323</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,1"/></relation></document>
<document><id>37863306</id><passage><infon key="journal">Exp Neurol;2023Oct18; 370 114576. doi:10.1016/j.expneurol.2023.114576</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lee JY, Park CS, Seo KJ, Kim IY, Han S, Youn I, Yune TY, </infon><offset>0</offset><text>IL-6/JAK2/STAT3 axis mediates neuropathic pain by regulating astrocyte and microglia activation after spinal cord injury.</text><annotation id="5"><infon key="identifier">24498</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="0" length="4"/><text>IL-6</text></annotation><annotation id="6"><infon key="identifier">24514</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21033</infon><location offset="5" length="4"/><text>JAK2</text></annotation><annotation id="7"><infon key="identifier">25125</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="10" length="5"/><text>STAT3</text></annotation><annotation id="8"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="30" length="16"/><text>neuropathic pain</text></annotation><annotation id="9"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="102" length="18"/><text>spinal cord injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>After spinal cord injury (SCI), the control of activated glial cells such as microglia and astrocytes has emerged as a promising strategy for neuropathic pain management. However, signaling mechanism involved in glial activation in the process of neuropathic pain development and maintenance after SCI is not well elucidated. In this study, we investigated the potential role and mechanism of the JAK2/STAT3 pathway associated with glial cell activation in chronic neuropathic pain development and maintenance after SCI. One month after contusive SCI, the activation of JAK2/STAT3 pathway was markedly upregulated in both microglia and astrocyte in nociceptive processing regions of the lumbar spinal cord. In addition, both mechanical allodynia and thermal hyperalgesia was significantly inhibited by a JAK2 inhibitor, AG490. In particular, AG490 treatment inhibited both microglial and astrocyte activation in the lumbar (L) 4-5 dorsal horn and significantly decreased levels of p-p38MAPK, p-ERK and p-JNK, which are known to be activated in microglia (p-p38MAPK and p-ERK) and astrocyte (p-JNK). Experiments using primary cell cultures also revealed that the JAK2/STAT3 pathway promoted microglia and astrocyte activation after lipopolysaccharide stimulation. Furthermore, JAK2/STAT3 signaling and pain behaviors were significantly attenuated when the rats were treated with anti-IL-6 antibody. Finally, minocycline, a tetracycline antibiotic, inhibited IL-6/JAK2/STAT3 signaling pathway in activated glial cells and restored nociceptive thresholds and the hyperresponsiveness of dorsal neurons. These results suggest an important role of the IL-6/JAK2/STAT3 pathway in the activation of microglia and astrocytes and in the maintenance of chronic below-level pain after SCI.</text><annotation id="48"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="128" length="18"/><text>spinal cord injury</text></annotation><annotation id="49"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="148" length="3"/><text>SCI</text></annotation><annotation id="50"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="264" length="16"/><text>neuropathic pain</text></annotation><annotation id="51"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="369" length="16"/><text>neuropathic pain</text></annotation><annotation id="52"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="420" length="3"/><text>SCI</text></annotation><annotation id="53"><infon key="identifier">24514</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21033</infon><location offset="519" length="4"/><text>JAK2</text></annotation><annotation id="54"><infon key="identifier">25125</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="524" length="5"/><text>STAT3</text></annotation><annotation id="55"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="587" length="16"/><text>neuropathic pain</text></annotation><annotation id="56"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="638" length="3"/><text>SCI</text></annotation><annotation id="57"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="669" length="3"/><text>SCI</text></annotation><annotation id="58"><infon key="identifier">24514</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21033</infon><location offset="692" length="4"/><text>JAK2</text></annotation><annotation id="59"><infon key="identifier">25125</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="697" length="5"/><text>STAT3</text></annotation><annotation id="60"><infon key="identifier">MESH:D006930</infon><infon key="type">Disease</infon><location offset="847" length="20"/><text>mechanical allodynia</text></annotation><annotation id="61"><infon key="identifier">MESH:D006930</infon><infon key="type">Disease</infon><location offset="872" length="20"/><text>thermal hyperalgesia</text></annotation><annotation id="62"><infon key="identifier">24514</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21033</infon><location offset="926" length="4"/><text>JAK2</text></annotation><annotation id="63"><infon key="identifier">MESH:C095512</infon><infon key="type">Chemical</infon><location offset="942" length="5"/><text>AG490</text></annotation><annotation id="64"><infon key="identifier">MESH:C095512</infon><infon key="type">Chemical</infon><location offset="964" length="5"/><text>AG490</text></annotation><annotation id="65"><infon key="identifier">24338</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20936</infon><location offset="1116" length="3"/><text>ERK</text></annotation><annotation id="66"><infon key="identifier">116554</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56760</infon><location offset="1126" length="3"/><text>JNK</text></annotation><annotation id="67"><infon key="identifier">24338</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20936</infon><location offset="1193" length="3"/><text>ERK</text></annotation><annotation id="68"><infon key="identifier">116554</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56760</infon><location offset="1215" length="3"/><text>JNK</text></annotation><annotation id="69"><infon key="identifier">24514</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21033</infon><location offset="1284" length="4"/><text>JAK2</text></annotation><annotation id="70"><infon key="identifier">25125</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="1289" length="5"/><text>STAT3</text></annotation><annotation id="71"><infon key="identifier">MESH:D008070</infon><infon key="type">Chemical</infon><location offset="1353" length="18"/><text>lipopolysaccharide</text></annotation><annotation id="72"><infon key="identifier">24514</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21033</infon><location offset="1398" length="4"/><text>JAK2</text></annotation><annotation id="73"><infon key="identifier">25125</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="1403" length="5"/><text>STAT3</text></annotation><annotation id="74"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1423" length="4"/><text>pain</text></annotation><annotation id="75"><infon key="identifier">24498</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1505" length="4"/><text>IL-6</text></annotation><annotation id="76"><infon key="identifier">MESH:D008911</infon><infon key="type">Chemical</infon><location offset="1529" length="11"/><text>minocycline</text></annotation><annotation id="77"><infon key="identifier">MESH:D013752</infon><infon key="type">Chemical</infon><location offset="1544" length="12"/><text>tetracycline</text></annotation><annotation id="78"><infon key="identifier">24498</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1579" length="4"/><text>IL-6</text></annotation><annotation id="79"><infon key="identifier">24514</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21033</infon><location offset="1584" length="4"/><text>JAK2</text></annotation><annotation id="80"><infon key="identifier">25125</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="1589" length="5"/><text>STAT3</text></annotation><annotation id="81"><infon key="identifier">24498</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1768" length="4"/><text>IL-6</text></annotation><annotation id="82"><infon key="identifier">24514</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21033</infon><location offset="1773" length="4"/><text>JAK2</text></annotation><annotation id="83"><infon key="identifier">25125</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7960</infon><location offset="1778" length="5"/><text>STAT3</text></annotation><annotation id="84"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1884" length="4"/><text>pain</text></annotation><annotation id="85"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1895" length="3"/><text>SCI</text></annotation></passage><relation id="R1"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D009437</infon><infon key="role2">Gene|24514</infon><infon key="type">Association</infon><node refid="0" role="3,1"/></relation><relation id="R2"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D009437</infon><infon key="role2">Gene|25125</infon><infon key="type">Association</infon><node refid="1" role="3,2"/></relation><relation id="R3"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D010146</infon><infon key="role2">Gene|24498</infon><infon key="type">Association</infon><node refid="2" role="31,32"/></relation><relation id="R4"><infon key="score">0.9789</infon><infon key="role1">Disease|MESH:D010146</infon><infon key="role2">Gene|24514</infon><infon key="type">Association</infon><node refid="3" role="31,29"/></relation><relation id="R5"><infon key="score">0.9932</infon><infon key="role1">Disease|MESH:D013119</infon><infon key="role2">Gene|24498</infon><infon key="type">Association</infon><node refid="4" role="4,0"/></relation><relation id="R6"><infon key="score">0.9992</infon><infon key="role1">Gene|24498</infon><infon key="role2">Gene|25125</infon><infon key="type">Association</infon><node refid="5" role="0,2"/></relation><relation id="R7"><infon key="score">0.9357</infon><infon key="role1">Disease|MESH:D006930</infon><infon key="role2">Gene|24514</infon><infon key="type">Association</infon><node refid="6" role="17,19"/></relation><relation id="R8"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:D008911</infon><infon key="role2">Gene|24514</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="33,36"/></relation><relation id="R9"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D008070</infon><infon key="role2">Gene|24514</infon><infon key="type">Association</infon><node refid="8" role="28,26"/></relation><relation id="R10"><infon key="score">0.9915</infon><infon key="role1">Disease|MESH:D013119</infon><infon key="role2">Gene|24514</infon><infon key="type">Association</infon><node refid="9" role="4,1"/></relation><relation id="R11"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C095512</infon><infon key="role2">Gene|24338</infon><infon key="type">Negative_Correlation</infon><node refid="10" role="21,22"/></relation><relation id="R12"><infon key="score">0.9978</infon><infon key="role1">Gene|24514</infon><infon key="role2">Gene|25125</infon><infon key="type">Association</infon><node refid="11" role="1,2"/></relation><relation id="R13"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D008911</infon><infon key="role2">Gene|24498</infon><infon key="type">Negative_Correlation</infon><node refid="12" role="33,35"/></relation><relation id="R14"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:C095512</infon><infon key="role2">Gene|116554</infon><infon key="type">Negative_Correlation</infon><node refid="13" role="21,23"/></relation><relation id="R15"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D010146</infon><infon key="role2">Gene|25125</infon><infon key="type">Association</infon><node refid="14" role="31,30"/></relation><relation id="R16"><infon key="score">0.9967</infon><infon key="role1">Gene|24498</infon><infon key="role2">Gene|24514</infon><infon key="type">Association</infon><node refid="15" role="0,1"/></relation><relation id="R17"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:C095512</infon><infon key="role2">Gene|24514</infon><infon key="type">Negative_Correlation</infon><node refid="16" role="20,19"/></relation><relation id="R18"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D008911</infon><infon key="role2">Gene|25125</infon><infon key="type">Negative_Correlation</infon><node refid="17" role="33,37"/></relation><relation id="R19"><infon key="score">0.9981</infon><infon key="role1">Chemical|MESH:D008070</infon><infon key="role2">Gene|25125</infon><infon key="type">Association</infon><node refid="18" role="28,27"/></relation><relation id="R20"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D009437</infon><infon key="role2">Gene|24498</infon><infon key="type">Association</infon><node refid="19" role="3,0"/></relation><relation id="R21"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D013119</infon><infon key="role2">Gene|25125</infon><infon key="type">Association</infon><node refid="20" role="4,2"/></relation><relation id="R22"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:C095512</infon><infon key="role2">Disease|MESH:D006930</infon><infon key="type">Negative_Correlation</infon><node refid="21" role="20,17"/></relation></document>
<document><id>37863657</id><passage><infon key="journal">eNeuro;2023Oct20. doi:10.1523/ENEURO.0282-23.2023</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Imani E, Radkani S, Hashemi A, Harati A, Pourreza H, Moazami Goudarzi M, </infon><offset>0</offset><text>Distributed coding of evidence accumulation across the mouse brain using microcircuits with a diversity of timescales.</text></passage><passage><infon key="type">abstract</infon><offset>119</offset><text>The gradual accumulation of noisy evidence for or against options is the main step in the perceptual decision-making process. Using brain-wide electrophysiological recording in mice (Steinmetz et al., 2019), we examined neural correlates of evidence accumulation across brain areas. We demonstrated that the neurons with Drift-Diffusion-Model-like firing rate activity (i.e., evidence-sensitive ramping firing rate) were distributed across the brain. Exploring the underlying neural mechanism of evidence accumulation for the DDM-like neurons revealed different accumulation mechanisms (i.e. single and race) both within and across the brain areas. Our findings support the hypothesis that evidence accumulation is happening through multiple integration mechanisms in the brain. We further explored the timescale of the integration process in the single and race accumulator models. The results demonstrated that the accumulator microcircuits within each brain area had distinct properties in terms of their integration timescale, which were organized hierarchically across the brain. These findings support the existence of evidence accumulation over multiple timescales. Besides the variability of integration timescale across the brain, a heterogeneity of timescales was observed within each brain area as well. We demonstrated that this variability reflected the diversity of microcircuit parameters, such that accumulators with longer integration timescales had higher recurrent excitation strength.Significance StatementIn this paper we characterized the perceptual decision-making process across the mouse brain. Our findings shed more light on the decision-making process by analyzing the brain-wide electrophysiological recording dataset. This paper contains a comprehensive analysis to characterize different aspects of the evidence accumulation process, including the distribution of accumulator-like neurons, the timescale of information integration, accumulation architecture, and the relationship between accumulators' timescale and their integration circuit properties.</text><annotation id="1"><infon key="type">Disease</infon><location offset="645" length="3"/><text>DDM</text></annotation></passage></document>
<document><id>37864358</id><passage><infon key="journal">J Adv Nurs;2023Oct20. doi:10.1111/jan.15908</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Grabenweger R, V&amp;#xf6;lz D, Bumes E, Weck C, Best M, Paal P, </infon><offset>0</offset><text>Vignettes as a novel research tool in spiritual care: A methods paper.</text></passage><passage><infon key="type">abstract</infon><offset>71</offset><text>AIMS: To discuss the construction and use of vignettes as a novel approach in spiritual care research and education. DESIGN: Methods paper. METHODS: In this methods paper, the authors introduce the use of vignettes in spiritual care research and provide insight into the construction of vignettes. The vignette presented was part of a study of neurosurgical nurses' attitudes and responses to the spiritual needs of neuro-oncology patients. The development process, consisting of four steps, is explained in this paper. RESULTS: Using a vignette to explore nurses' attitudes towards spiritual care is an innovative way to understand what behaviours nurses consider appropriate in situations where the patient is seeking meaning and connection. Transparent description of the development process is crucial to ensure reproducibility. CONCLUSION: The use of theoretically constructed and validated vignettes in spiritual care research is new. Vignettes used in surveys have the potential to elicit nurses' responses to patients' search for meaning and connectedness. IMPLICATIONS: In order to investigate nurses' attitudes and behaviours towards patients' spiritual needs, carefully constructed and validated vignettes are valuable research tools. IMPACT: Vignettes have proven to be a valuable research tool in the social and health sciences. So far, their use as a survey instrument in spiritual care research has not been investigated. Therefore, this method paper introduces vignettes as a novel approach to spiritual care research. Our findings contribute to the further development of vignettes in nursing science, as there are similarities with case development and simulation training in nursing education. REPORTING METHOD: Reporting guideline is not applicable. PATIENT OR PUBLIC CONTRIBUTION: No patient or public contribution.</text><annotation id="1"><infon key="type">Disease</infon><location offset="1859" length="12"/><text>CONTRIBUTION</text></annotation></passage></document>
<document><id>37864708</id><passage><infon key="journal">Appl Biochem Biotechnol;2023Oct21. doi:10.1007/s12010-023-04718-0</infon><infon key="year">2023</infon><infon key="article-id_pmc">3128575</infon><infon key="type">title</infon><infon key="authors">Pu D, Chen H, Fu W, Cui Y, Shu K, </infon><offset>0</offset><text>Combining E-ice-COLD-PCR and Pyrosequencing with Di-Base Addition (PDBA) Enables Sensitive Detection of Low-Abundance Mutations.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="10" length="5"/><text>E-ice</text></annotation></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>Detecting low-abundance mutations is of particular interest in the fields of biology and medical science. However, most currently available molecular assays have limited sensitivity for the detection of low-abundance mutations. Here, we established a platform for detecting low-level DNA mutations with high sensitivity and accuracy by combining enhanced-ice-COLD-PCR (E-ice-COLD-PCR) and pyrosequencing with di-base addition (PDBA). The PDBA assay was performed by selectively adding one di-base (AG, CT, AC, GT, AT, or GC) instead of one base (A, T, C, or G) into the reaction at a time during sequencing primer extension and thus enabling to increase the sequencing intensity. A specific E-ice-COLD-PCR/PDBA assay was developed for the detection of the most frequent BRAF V600E mutation to verify the feasibility of our method. E-ice-COLD-PCR/PDBA assay permitted the reliable detection of down to 0.007% of mutant alleles in a wild-type background. Furthermore, it required only a small amount of starting material (20 pg) to sensitively detect and identify low-abundance mutations, thus increasing the screening capabilities in limited DNA material. The E-ice-COLD-PCR/PDBA assay was applied in the current study to clinical formalin-fixed paraffin-embedded (FFPE) and plasma samples, and it enabled the detection of BRAF V600E mutations in samples that appeared as a wild type using PCR/conventional pyrosequencing (CP) and E-ice-COLD-PCR/CP. E-ice-COLD-PCR/PDBA assay is a rapid, cost-effective, and highly sensitive method that could improve the detection of low-abundance mutations in routine clinical use.</text><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="498" length="5"/><text>E-ice</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="820" length="5"/><text>E-ice</text></annotation><annotation id="16"><infon key="identifier">673</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3197</infon><location offset="899" length="4"/><text>BRAF</text></annotation><annotation id="17"><infon key="identifier">tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:0;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:9606;CA#:123643</infon><infon key="type">ProteinMutation</infon><location offset="904" length="5"/><text>V600E</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="960" length="5"/><text>E-ice</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1288" length="5"/><text>E-ice</text></annotation><annotation id="20"><infon key="identifier">MESH:D005557</infon><infon key="type">Chemical</infon><location offset="1359" length="8"/><text>formalin</text></annotation><annotation id="21"><infon key="identifier">MESH:D010232</infon><infon key="type">Chemical</infon><location offset="1374" length="8"/><text>paraffin</text></annotation><annotation id="22"><infon key="identifier">673</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3197</infon><location offset="1451" length="4"/><text>BRAF</text></annotation><annotation id="23"><infon key="identifier">tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:0;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:9606;CA#:123643</infon><infon key="type">ProteinMutation</infon><location offset="1456" length="5"/><text>V600E</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1559" length="5"/><text>E-ice</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1578" length="5"/><text>E-ice</text></annotation></passage><relation id="R1"><infon key="score">0.7649</infon><infon key="role1">Chemical|MESH:D005557</infon><infon key="role2">Chemical|MESH:D010232</infon><infon key="type">Association</infon><node refid="0" role="7,8"/></relation></document>
<document><id>37865058</id><passage><infon key="journal">Comput Methods Programs Biomed;2023Oct12; 243 107857. doi:10.1016/j.cmpb.2023.107857</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lv T, Hong X, Liu Y, Miao K, Sun H, Li L, Deng C, Jiang C, Pan X, </infon><offset>0</offset><text>AI-powered interpretable imaging phenotypes noninvasively characterize tumor microenvironment associated with diverse molecular signatures and survival in breast cancer.</text><annotation id="2"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="71" length="5"/><text>tumor</text></annotation><annotation id="3"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="155" length="13"/><text>breast cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>170</offset><text>BACKGROUND AND OBJECTIVES: Tumor microenvironment (TME) is a determining factor in decision-making and personalized treatment for breast cancer, which is highly intra-tumor heterogeneous (ITH). However, the noninvasive imaging phenotypes of TME are poorly understood, even invasive genotypes have been largely known in breast cancer. METHODS: Here, we develop an artificial intelligence (AI)-driven approach for noninvasively characterizing TME by integrating the predictive power of deep learning with the explainability of human-interpretable imaging phenotypes (IMPs) derived from 4D dynamic imaging (DCE-MRI) of 342 breast tumors linked to genomic and clinical data, which connect cancer phenotypes to genotypes. An unsupervised dual-attention deep graph clustering model (DGCLM) is developed to divide bulk tumor into multiple spatially segregated and phenotypically consistent subclusters. The IMPs ranging from spatial heterogeneity to kinetic heterogeneity are leveraged to capture architecture, interaction, and proximity between intratumoral subclusters. RESULTS: We demonstrate that our IMPs correlate with well-known markers of TME and also can predict distinct molecular signatures, including expression of hormone receptor, epithelial growth factor receptor and immune checkpoint proteins, with the performance of accuracy, reliability and transparency superior to recent state-of-the-art radiomics and 'black-box' deep learning methods. Moreover, prognostic value is confirmed by survival analysis accounting for IMPs. CONCLUSIONS: Our approach provides an interpretable, quantitative, and comprehensive perspective to characterize TME in a noninvasive and clinically relevant manner.</text><annotation id="11"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="197" length="5"/><text>Tumor</text></annotation><annotation id="12"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="300" length="13"/><text>breast cancer</text></annotation><annotation id="13"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="331" length="11"/><text>intra-tumor</text></annotation><annotation id="14"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="489" length="13"/><text>breast cancer</text></annotation><annotation id="15"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="790" length="13"/><text>breast tumors</text></annotation><annotation id="16"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="855" length="6"/><text>cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="982" length="5"/><text>tumor</text></annotation></passage></document>
<document><id>37866108</id><passage><infon key="journal">Ecotoxicol Environ Saf;2023Oct20; 267 115620. doi:10.1016/j.ecoenv.2023.115620</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhen Z, Cai R, Salam M, Hu J, Yang B, Liu M, Li H, Tang B, </infon><offset>0</offset><text>The competitive advantage of Microcystis aeruginosa over Scenedesmus obliquus weakened by exposure to polylactic acid microplastics.</text><annotation id="2"><infon key="identifier">MESH:C033616</infon><infon key="type">Chemical</infon><location offset="102" length="15"/><text>polylactic acid</text></annotation><annotation id="3"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="118" length="13"/><text>microplastics</text></annotation></passage><passage><infon key="type">abstract</infon><offset>133</offset><text>Aquatic ecosystems are heavily affected by microplastics (MPs), and its impacts on aquatic life have received extensive attention. However, it is still unclear how biodegradable MPs influence the growth and competition of phytoplankton. In this study, the response of growth dynamics, alternation in algal cell morphology and toxin-producing capability, and changes in the extracellular process of Microcystis aeruginosa (M. aeruginosa) and Scenedesmus obliquus (S. obliquus) were systematically studied in monoculture and co-culture conditions with and without the presence of polylactic acid MPs (PLA-MPs). The results indicated that although the loss of cell integrity was observed, PLA-MPs addition (50 mg/L) caused a 1.40- and 1.36-fold increase in cell densities of M. aeruginosa and S. obliquus in monoculture systems, respectively. This suggests the PLA-MPs more favored the growth of M. aeruginosa. This effect was manifested in co-culture conditions, because the degradation of PLA-MPs provided additional inorganic carbon in the experimental systems and benefited the growth of both M. aeruginosa and S. obliquus. Meanwhile, the synthesis of microcystins from the toxic M. aeruginosa was substantially reduced upon PLA-MPs exposure, which reduced the competitive advantage of M. aeruginosa over S. obliquus. Thus; the cell density of M. aeruginosa and S. obliquus showed 1.15- and 1.88-folds increasing compared to that without PLA-MPs addition. This interaction between PLA-MPs and algae weakened the competitive advantage of M. aeruginosa over S. obliquus, but their competitive outcomes remained unchanged. The results provided new insights into understanding the potential ecological risks of biodegradable plastics in aquatic ecosystems.</text><annotation id="17"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="176" length="13"/><text>microplastics</text></annotation><annotation id="18"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="191" length="3"/><text>MPs</text></annotation><annotation id="19"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="311" length="3"/><text>MPs</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="711" length="19"/><text>polylactic acid MPs</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="732" length="7"/><text>PLA-MPs</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="819" length="7"/><text>PLA-MPs</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="991" length="7"/><text>PLA-MPs</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1121" length="7"/><text>PLA-MPs</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1149" length="16"/><text>inorganic carbon</text></annotation><annotation id="26"><infon key="identifier">MESH:D052998</infon><infon key="type">Chemical</infon><location offset="1286" length="12"/><text>microcystins</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1359" length="7"/><text>PLA-MPs</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1572" length="7"/><text>PLA-MPs</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1615" length="7"/><text>PLA-MPs</text></annotation></passage></document>
<document><id>37866459</id><passage><infon key="journal">Exp Cell Res;2023Oct21; 433 (2) 113825. doi:10.1016/j.yexcr.2023.113825</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lenz LS, Torgo D, Buss JH, Pereira LC, Bueno M, Filippi-Chiela EC, Lenz G, </infon><offset>0</offset><text>Mitochondrial response of glioma cells to temozolomide.</text><annotation id="2"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="26" length="6"/><text>glioma</text></annotation><annotation id="3"><infon key="identifier">MESH:D000077204</infon><infon key="type">Chemical</infon><location offset="42" length="12"/><text>temozolomide</text></annotation></passage><passage><infon key="type">abstract</infon><offset>56</offset><text>Metabolic adaptations are central for carcinogenesis and response to therapy, but little is known about the contribution of mitochondrial dynamics to the response of glioma cells to the standard treatment with temozolomide (TMZ). Glioma cells responded to TMZ with mitochondrial mass increased and the production of round structures of dysfunctional mitochondria. At single-cell level, asymmetric mitosis contributed to the heterogeneity of mitochondrial levels. It affected the fitness of cells in control and treated condition, indicating that the mitochondrial levels are relevant for glioma cell fitness in the presence of TMZ.</text><annotation id="12"><infon key="identifier">MESH:D063646</infon><infon key="type">Disease</infon><location offset="94" length="14"/><text>carcinogenesis</text></annotation><annotation id="13"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="222" length="6"/><text>glioma</text></annotation><annotation id="14"><infon key="identifier">MESH:D000077204</infon><infon key="type">Chemical</infon><location offset="266" length="12"/><text>temozolomide</text></annotation><annotation id="15"><infon key="identifier">MESH:D000077204</infon><infon key="type">Chemical</infon><location offset="280" length="3"/><text>TMZ</text></annotation><annotation id="16"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="286" length="6"/><text>Glioma</text></annotation><annotation id="17"><infon key="identifier">MESH:D000077204</infon><infon key="type">Chemical</infon><location offset="312" length="3"/><text>TMZ</text></annotation><annotation id="18"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="644" length="6"/><text>glioma</text></annotation><annotation id="19"><infon key="identifier">MESH:D000077204</infon><infon key="type">Chemical</infon><location offset="683" length="3"/><text>TMZ</text></annotation></passage><relation id="R1"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:D000077204</infon><infon key="role2">Disease|MESH:D005910</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="1,0"/></relation></document>
<document><id>37866809</id><passage><infon key="journal">Life Sci;2023Oct20 122188. doi:10.1016/j.lfs.2023.122188</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Xia H, Guo J, Shen J, Jiang S, Han S, Li L, </infon><offset>0</offset><text>Butyrate ameliorated the intestinal barrier dysfunction and attenuated acute pancreatitis in mice fed with ketogenic diet.</text><annotation id="2"><infon key="identifier">MESH:D002087</infon><infon key="type">Chemical</infon><location offset="0" length="8"/><text>Butyrate</text></annotation><annotation id="3"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="71" length="18"/><text>acute pancreatitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>123</offset><text>Butyrate, a short-chain fatty acid (SCFA), has demonstrated significant efficacy in preventing colitis-associated inflammation. Acute pancreatitis is an acute gastrointestinal disorder characterized by increased systemic inflammation, bacterial translocation, and disrupted intestinal barrier. However, the effects and mechanisms of butyrate in attenuating acute pancreatitis remain unclear. In this study, we established two mouse models of acute pancreatitis induced by cerulein (Cer) and taurocholate (TA), which were further exacerbated by a ketogenic diet (KD). The results suggested that butyrate supplementation effectively reduced mortality rates, systemic inflammation, and intestinal barrier disruption caused by Cer- and TA-induced acute pancreatitis in mice fed a KD. Furthermore, we observed a significant reduction in gut microbiota diversity as well as overgrowth of Lachnospirales and Erysipelotrichales along with depletion of SCFAs in mice fed a KD, and these alterations were reversed by butyrate supplement. To evaluate the role of microbiota and butyrate supplement, we conducted germ-depletion trials by antibiotics. The results showed that while systemic inflammation was attenuated in mice with TA-induced pancreatitis following antibiotic treatment, the reduction in mortality remained inconclusive (p = 0.055). Importantly, the key differential change between antibiotic treatment and butyrate supplementation was found to be related to intestinal barrier dysfunction and repairment. These results suggest that butyrate plays a central role in mitigating acute pancreatitis through amelioration of intestinal barrier dysfunction.</text><annotation id="33"><infon key="identifier">MESH:D002087</infon><infon key="type">Chemical</infon><location offset="123" length="8"/><text>Butyrate</text></annotation><annotation id="34"><infon key="identifier">MESH:D005232</infon><infon key="type">Chemical</infon><location offset="135" length="22"/><text>short-chain fatty acid</text></annotation><annotation id="35"><infon key="identifier">MESH:D005232</infon><infon key="type">Chemical</infon><location offset="159" length="4"/><text>SCFA</text></annotation><annotation id="36"><infon key="identifier">MESH:D003092</infon><infon key="type">Disease</infon><location offset="218" length="7"/><text>colitis</text></annotation><annotation id="37"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="237" length="12"/><text>inflammation</text></annotation><annotation id="38"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="251" length="18"/><text>Acute pancreatitis</text></annotation><annotation id="39"><infon key="identifier">MESH:D005767</infon><infon key="type">Disease</infon><location offset="282" length="25"/><text>gastrointestinal disorder</text></annotation><annotation id="40"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="344" length="12"/><text>inflammation</text></annotation><annotation id="41"><infon key="identifier">MESH:D002087</infon><infon key="type">Chemical</infon><location offset="456" length="8"/><text>butyrate</text></annotation><annotation id="42"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="480" length="18"/><text>acute pancreatitis</text></annotation><annotation id="43"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="565" length="18"/><text>acute pancreatitis</text></annotation><annotation id="44"><infon key="identifier">MESH:D002108</infon><infon key="type">Chemical</infon><location offset="595" length="8"/><text>cerulein</text></annotation><annotation id="45"><infon key="identifier">MESH:D002108</infon><infon key="type">Chemical</infon><location offset="605" length="3"/><text>Cer</text></annotation><annotation id="46"><infon key="identifier">MESH:D013656</infon><infon key="type">Chemical</infon><location offset="614" length="12"/><text>taurocholate</text></annotation><annotation id="47"><infon key="identifier">MESH:D013656</infon><infon key="type">Chemical</infon><location offset="628" length="2"/><text>TA</text></annotation><annotation id="48"><infon key="identifier">MESH:D002087</infon><infon key="type">Chemical</infon><location offset="717" length="8"/><text>butyrate</text></annotation><annotation id="49"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="788" length="12"/><text>inflammation</text></annotation><annotation id="50"><infon key="identifier">MESH:D002108</infon><infon key="type">Chemical</infon><location offset="846" length="3"/><text>Cer</text></annotation><annotation id="51"><infon key="identifier">MESH:D013656</infon><infon key="type">Chemical</infon><location offset="855" length="2"/><text>TA</text></annotation><annotation id="52"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="866" length="18"/><text>acute pancreatitis</text></annotation><annotation id="53"><infon key="identifier">MESH:D005232</infon><infon key="type">Chemical</infon><location offset="1067" length="5"/><text>SCFAs</text></annotation><annotation id="54"><infon key="identifier">MESH:D002087</infon><infon key="type">Chemical</infon><location offset="1130" length="8"/><text>butyrate</text></annotation><annotation id="55"><infon key="identifier">MESH:D002087</infon><infon key="type">Chemical</infon><location offset="1190" length="8"/><text>butyrate</text></annotation><annotation id="56"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1301" length="12"/><text>inflammation</text></annotation><annotation id="57"><infon key="identifier">MESH:D013656</infon><infon key="type">Chemical</infon><location offset="1342" length="2"/><text>TA</text></annotation><annotation id="58"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="1353" length="12"/><text>pancreatitis</text></annotation><annotation id="59"><infon key="identifier">MESH:D002087</infon><infon key="type">Chemical</infon><location offset="1534" length="8"/><text>butyrate</text></annotation><annotation id="60"><infon key="identifier">MESH:D002087</infon><infon key="type">Chemical</infon><location offset="1660" length="8"/><text>butyrate</text></annotation><annotation id="61"><infon key="identifier">MESH:D010195</infon><infon key="type">Disease</infon><location offset="1704" length="18"/><text>acute pancreatitis</text></annotation></passage><relation id="R1"><infon key="score">0.9981</infon><infon key="role1">Chemical|MESH:D005232</infon><infon key="role2">Disease|MESH:D003092</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="3,5"/></relation><relation id="R2"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D002087</infon><infon key="role2">Disease|MESH:D010195</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,1"/></relation><relation id="R3"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D002087</infon><infon key="role2">Disease|MESH:D003092</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="2,5"/></relation><relation id="R4"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D002108</infon><infon key="role2">Disease|MESH:D010195</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="13,12"/></relation><relation id="R5"><infon key="score">0.9941</infon><infon key="role1">Chemical|MESH:D005232</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="3,6"/></relation><relation id="R6"><infon key="score">0.9978</infon><infon key="role1">Chemical|MESH:D002087</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="2,6"/></relation><relation id="R7"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D013656</infon><infon key="role2">Disease|MESH:D010195</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="15,12"/></relation></document>
<document><id>37867171</id><passage><infon key="journal">Environ Sci Pollut Res Int;2023Oct23. doi:10.1007/s11356-023-30314-0</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liu Q, Chen Y, Chen Z, Xie Y, Yu H, Yuan S, Guo Y, Cheng Y, Qian H, Yao W, </infon><offset>0</offset><text>Rapid magnetization and removal of microplastics from environment and food based on magnetic metal-organic framework Fe3O4@SiO2@MIL-53(Al).</text><annotation id="4"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="35" length="13"/><text>microplastics</text></annotation><annotation id="5"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="93" length="23"/><text>metal-organic framework</text></annotation><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="117" length="17"/><text>Fe3O4@SiO2@MIL-53</text></annotation><annotation id="7"><infon key="identifier">MESH:D000535</infon><infon key="type">Chemical</infon><location offset="135" length="2"/><text>Al</text></annotation></passage><passage><infon key="type">abstract</infon><offset>140</offset><text>Microplastics (MPs) are now not only emerging as pollutants in the environment, but their current state of contamination in food is also a cause for concern. It is necessary to focus how to control, reduce, and even remove MPs. In this study, a magnetic metal-organic framework (MOF) material, Fe3O4@SiO2@MIL-53(Al), was synthesized and applied to simulate the magnetization and removal of four types of MPs. Fe3O4@SiO2@MIL-53(Al) was characterized by various means to demonstrate its successful synthesis as a core-shell nanomaterial. The conditions of the method were optimized by examining the effect of time, the mass ratio of material to MPs, temperature, and pH on the removal effect. The removal rates of four MPs were 54.10-94.17%, and the maximum adsorption capacities of Fe3O4@SiO2@MIL-53(Al) that can be adsorbed were 10511.45-44390.24 mg g-1. Notably, the material can effectively magnetize and remove MPs from liquid food containing alcohol with highest efficiency of 97.10 +- 1.21%. Potential adsorption mechanisms were analyzed using kinetic, isothermal, and thermodynamic models, and electrostatic attraction and hydrogen bonding were found to play a dominant role in the adsorption process. In addition, not only can Fe3O4@SiO2@MIL-53(Al) be reused up to five times to maintain high removal rates, but it can also be used in food systems. Therefore, Fe3O4@SiO2@MIL-53(Al) not only has the advantages of ease of use and stability, but also can efficiently and quickly magnetize and remove many common MPs in more complex matrices such as food.</text><annotation id="30"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="140" length="13"/><text>Microplastics</text></annotation><annotation id="31"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="155" length="3"/><text>MPs</text></annotation><annotation id="32"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="363" length="3"/><text>MPs</text></annotation><annotation id="33"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="394" length="23"/><text>metal-organic framework</text></annotation><annotation id="34"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="419" length="3"/><text>MOF</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="434" length="17"/><text>Fe3O4@SiO2@MIL-53</text></annotation><annotation id="36"><infon key="identifier">MESH:D000535</infon><infon key="type">Chemical</infon><location offset="452" length="2"/><text>Al</text></annotation><annotation id="37"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="544" length="3"/><text>MPs</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="549" length="17"/><text>Fe3O4@SiO2@MIL-53</text></annotation><annotation id="39"><infon key="identifier">MESH:D000535</infon><infon key="type">Chemical</infon><location offset="567" length="2"/><text>Al</text></annotation><annotation id="40"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="783" length="3"/><text>MPs</text></annotation><annotation id="41"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="857" length="3"/><text>MPs</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="921" length="17"/><text>Fe3O4@SiO2@MIL-53</text></annotation><annotation id="43"><infon key="identifier">MESH:D000535</infon><infon key="type">Chemical</infon><location offset="939" length="2"/><text>Al</text></annotation><annotation id="44"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="1054" length="3"/><text>MPs</text></annotation><annotation id="45"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1086" length="7"/><text>alcohol</text></annotation><annotation id="46"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="1269" length="8"/><text>hydrogen</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1374" length="17"/><text>Fe3O4@SiO2@MIL-53</text></annotation><annotation id="48"><infon key="identifier">MESH:D000535</infon><infon key="type">Chemical</infon><location offset="1392" length="2"/><text>Al</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1507" length="17"/><text>Fe3O4@SiO2@MIL-53</text></annotation><annotation id="50"><infon key="identifier">MESH:D000535</infon><infon key="type">Chemical</infon><location offset="1525" length="2"/><text>Al</text></annotation><annotation id="51"><infon key="identifier">MESH:D000080545</infon><infon key="type">Chemical</infon><location offset="1657" length="3"/><text>MPs</text></annotation></passage><relation id="R1"><infon key="score">0.4352</infon><infon key="role1">Chemical|MESH:D000073396</infon><infon key="role2">Chemical|MESH:D000080545</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9946</infon><infon key="role1">Chemical|MESH:D000080545</infon><infon key="role2">Chemical|MESH:D000535</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="0,3"/></relation></document>
<document><id>37869973</id><passage><infon key="journal">Br J Nutr;2023Oct23 1. doi:10.1017/S0007114523002258</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Damasceno YO, Leit&amp;#xe3;o CVFS, de Oliveira GM, Andrade FAB, Pereira AB, Viza RS, Correia RC, Campos HO, Drummond LR, Leite LHR, Coimbra CC, </infon><offset>0</offset><text>Plant-based diets benefit aerobic performance and do not compromise strength/power performance: A systematic review and meta-analysis.</text></passage><passage><infon key="type">abstract</infon><offset>135</offset><text>Plant-based diets have emerged as athletic performance enhancers for various types of exercise. Therefore, the present study evaluated the effectiveness of plant-based diets on aerobic and strength/power performances, as well as on body mass index (BMI) of physically active individuals. This systematic review and meta-analysis was conducted and reported according to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. A systematic search of electronic databases, including PubMed, Web of Science and SPORTDiscus, was performed. On the basis of the search and inclusion criteria, four and six studies evaluating the effects of plant-based diets on aerobic and strength/power performances in humans were respectively included in the systematic review and meta-analysis. Plant-based diets had a moderate but positive effect on aerobic performance (0.55; 95% CI: 0.29 to 0.81), and no effect on strength/power performance (-0.30; 95% CI: -0.67 to 0.07). The altogether analyses of both aerobic and strength/power exercises revealed that athletic performance was unchanged (0.01; 95% CI: -0.21 to 0.22) in athletes that adopted plant-based diets. However, a small negative effect on BMI (-0.27; 95% CI: -0.40 to -0.15) was induced by these diets. The results indicate that plant-based diets have the potential to exclusively assist aerobic performance. On the other hand, these diets do not jeopardize strength/power performance. Overall, the predicted effects of plant-based diets on physical performance are impactless, even though the BMI of their adherents is reduced.</text></passage></document>
<document><id>37870324</id><passage><infon key="journal">Health Care Women Int;2023Oct23 1. doi:10.1080/07399332.2023.2267007</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Trehan A, Sehgal SS, </infon><offset>0</offset><text>Effect of social media on body image of pregnant and postpartum women in India.</text></passage><passage><infon key="type">abstract</infon><offset>80</offset><text>In the present times, there is a high influence caused by social media platforms in case of body image issues faced by an individual. Pregnancy is a stage for women where they go through several mental and physical changes. Realizing the inseparable role played by social media in this aspect, it is an attempt here to determine the effect caused by social media on the body image of pregnant women as well for those in their post-partum stages. The PRISMA method is used by the authors to arrive at 55 research papers from the Scopus databases that are systematically reviewed. The authors' review reveals that social media can have both negative and positive effects on women's perception of body image during pregnancy and the postpartum period.</text></passage></document>
<document><id>37870674</id><passage><infon key="journal">Probiotics Antimicrob Proteins;2023Oct23. doi:10.1007/s12602-023-10175-2</infon><infon key="year">2023</infon><infon key="article-id_pmc">7913060</infon><infon key="type">title</infon><infon key="authors">Zhang Y, Jiang Y, Zhao J, Mo Q, Wang C, Wang D, Li M, </infon><offset>0</offset><text>Weizmannia coagulans Extracellular Proteins Reduce Skin Acne by Inhibiting Pathogenic Bacteria and Regulating TLR2/TRAF6-Mediated NF-kappaB and MAPKs Signaling Pathways.</text><annotation id="1"><infon key="identifier">MESH:D000152</infon><infon key="type">Disease</infon><location offset="56" length="4"/><text>Acne</text></annotation></passage><passage><infon key="type">abstract</infon><offset>170</offset><text>As a probiotic, Weizmannia coagulans (W. coagulans) is often used in food and medicine to regulate intestinal flora and exert anti-inflammatory effects. In this study, the anti-acne efficacy and mechanism of extracellular proteins (YTCY-EPs) from W. coagulans YTCY strain are analyzed. The main components of YTCY-EPs, extracted and separated from the fermentation broth, are peptides ranging from 1.51 to 11.44 kDa, accounting for about 80%. Among the peptides identified by LC/MS-MS, YTCY_A-F possess the properties of antimicrobial peptides, while YTCY_1-4 possess antioxidative properties. These peptides have a strong effect on Cutibacterium acnes (C. acnes) and significantly inhibit Staphylococcus aureus. The inhibition rate of biofilm adhesion of YT-EPs to C. acnes reached 50% under the MIC. It was found that YTCY-EPs possess strong antioxidant and anti-inflammatory properties. It can effectively reduce active oxygen nearly 3 times and can reduce the downstream TLR2/NF-kappaB and MAPKs/AP-1 pathways by regulating the nuclear translocation of NF-kappaB and AP-1 in vitro. The transcriptional expression of inflammatory cytokines, inflammatory chemokines, and matrix metalloproteinase genes is also regulated, thereby slowing the recruitment of inflammatory cells and the development of inflammation, and increasing keratinocyte mobility. In addition, the expression levels of inflammatory factors and matrix metalloproteinases in the rabbit ears with acne problems that were tested with YTCY-EPs were significantly reduced, and it was obviously observed that the rabbit ear inflammation, acne, and keratinization problems were repaired. The results of this study prove that YTCY-EPs can be used as a potential anti-acne raw material in cosmetics.</text><annotation id="20"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="301" length="12"/><text>inflammatory</text></annotation><annotation id="21"><infon key="identifier">MESH:D000152</infon><infon key="type">Disease</infon><location offset="347" length="4"/><text>acne</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="402" length="8"/><text>YTCY-EPs</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="479" length="8"/><text>YTCY-EPs</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="990" length="8"/><text>YTCY-EPs</text></annotation><annotation id="25"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1035" length="12"/><text>inflammatory</text></annotation><annotation id="26"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1093" length="6"/><text>oxygen</text></annotation><annotation id="27"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1290" length="12"/><text>inflammatory</text></annotation><annotation id="28"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1314" length="12"/><text>inflammatory</text></annotation><annotation id="29"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1428" length="12"/><text>inflammatory</text></annotation><annotation id="30"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1470" length="12"/><text>inflammation</text></annotation><annotation id="31"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1560" length="12"/><text>inflammatory</text></annotation><annotation id="32"><infon key="identifier">MESH:D000152</infon><infon key="type">Disease</infon><location offset="1635" length="4"/><text>acne</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1671" length="8"/><text>YTCY-EPs</text></annotation><annotation id="34"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1758" length="12"/><text>inflammation</text></annotation><annotation id="35"><infon key="identifier">MESH:D000152</infon><infon key="type">Disease</infon><location offset="1772" length="4"/><text>acne</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1858" length="8"/><text>YTCY-EPs</text></annotation><annotation id="37"><infon key="identifier">MESH:D000152</infon><infon key="type">Disease</infon><location offset="1899" length="4"/><text>acne</text></annotation></passage></document>
<document><id>37871027</id><passage><infon key="journal">Plast Reconstr Surg;2023Nov01; 152 (5) 1125. doi:10.1097/PRS.0000000000010883</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Levin LS, </infon><offset>0</offset><text>Discussion: Secondary Surgery after Lower Extremity Free Flap Reconstruction.</text></passage><passage><infon key="type">abstract</infon><offset>78</offset></passage></document>
<document><id>37871387</id><passage><infon key="journal">Accid Anal Prev;2023Oct21; 194 107342. doi:10.1016/j.aap.2023.107342</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Han Z, Zhang D, Fan L, Zhang J, Zhang M, </infon><offset>0</offset><text>A Dynamic Bayesian Network model to evaluate the availability of machinery systems in Maritime Autonomous Surface Ships.</text></passage><passage><infon key="type">abstract</infon><offset>121</offset><text>With their complex structure, multiple failure modes and lack of maintenance crew, the safety problem of Maritime Autonomous Surface Ships' (MASS) machinery systems are becoming an important research topic. The present study presents an availability model for ship machinery systems incorporating a maintenance strategy based on Dynamic Bayesian Networks (DBN). First, the availability of conventional ship machinery systems is evaluated and used as a benchmark based on the configuration and planned maintenance strategy. Secondly, the availability of MASS machinery systems is compared to the benchmark, before the introduction of any changes to the ship's configuration and planned maintenance strategy. Finally, the availability improvement strategies, including redundant designs and planned maintenance strategies at port, are proposed based on sensitivity analysis and planned maintenance cost minimization. To exemplify the model's application, a case study of a cooling water system is explored. Based on a sensitivity analysis using the model, it is possible to decide which components need to be redundant. Different redundancy designs and corresponding planned maintenance strategies can be adopted to meet the availability demand. It is also shown that redundancy and enhanced detection capabilities reduce much of the planned maintenance cost. This framework can be used in the early design stages to determine whether the MASS machinery systems' availability is at least equivalent to that of conventional ships, and has certain reference significance for redundant configuration designs and MASS planned maintenance strategy schedule.</text></passage></document>
<document><id>37871737</id><passage><infon key="journal">Environ Pollut;2023Oct21; 340 (Pt 2) 122785. doi:10.1016/j.envpol.2023.122785</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Barreira J, Ara&amp;#xfa;jo DF, Rodrigues BQA, Tonh&amp;#xe1; MS, Mendes RA, Souto-Oliveira CE, Babinski M, Knoery J, Sanders CJ, Garnier J, Machado W, </infon><offset>0</offset><text>Copper isotopes as a tool to trace contamination in mangroves from an urbanized watershed.</text><annotation id="1"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="0" length="6"/><text>Copper</text></annotation></passage><passage><infon key="type">abstract</infon><offset>91</offset><text>This study investigates the chronology of copper (Cu) contamination and its stable isotopes within an emblematic Brazilian mangrove impacted by multiple urban and industrial Cu sources, deforestation, and eutrophication. In particular, it tests Cu isotopes as tracers of anthropogenic inputs into an anthropized watershed impacted by multiple sources. To do so, we used multi-isotopic approaches (delta65Cu, delta13C, and delta15N), elemental analyses (Al, Ca, Fe, P, Cu, C, and N), and selective and sequential extractions in a210Pb-dated sediment core. This geochemical "toolbox" allowed identifying two main stages of Cu evolution in the sediment core. In the first stage, before 1965, Cu isotope fingerprints responded to landscape changes, indicating a shift from marine to geogenic dominance due to the remobilization and erosion of terrestrial materials. In the second stage, after 1965, the sediment geochemical profile showed increased Cu total concentrations with a higher bioavailability (as reflected by sequential extraction data) accompanying changes in Cu isotope signatures towards anthropogenic values. The findings evidence that local industrial sources, possibly combined with diffuse urban sources, export Cu into downstream mangroves with a distinguishable isotope signature compared to natural values. This study demonstrates the applicability of Cu isotopes as new environmental forensic tools to trace anthropogenic sources in mangrove sediments. Incorporated into a robust geochemical toolbox that combines inorganic and organic proxies for sedimentary materials, this new tool provides a comprehensive understanding of Cu dynamics in mangrove ecosystems, shedding light on the historical and current sources of Cu.</text><annotation id="23"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="133" length="6"/><text>copper</text></annotation><annotation id="24"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="141" length="2"/><text>Cu</text></annotation><annotation id="25"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="265" length="2"/><text>Cu</text></annotation><annotation id="26"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="336" length="2"/><text>Cu</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="488" length="9"/><text>delta65Cu</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="499" length="8"/><text>delta13C</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="513" length="8"/><text>delta15N</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="544" length="2"/><text>Al</text></annotation><annotation id="31"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="552" length="2"/><text>Fe</text></annotation><annotation id="32"><infon key="identifier">MESH:D010758</infon><infon key="type">Chemical</infon><location offset="556" length="1"/><text>P</text></annotation><annotation id="33"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="559" length="2"/><text>Cu</text></annotation><annotation id="34"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="563" length="1"/><text>C</text></annotation><annotation id="35"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="570" length="1"/><text>N</text></annotation><annotation id="36"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="712" length="2"/><text>Cu</text></annotation><annotation id="37"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="780" length="2"/><text>Cu</text></annotation><annotation id="38"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="1036" length="2"/><text>Cu</text></annotation><annotation id="39"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="1159" length="2"/><text>Cu</text></annotation><annotation id="40"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="1317" length="2"/><text>Cu</text></annotation><annotation id="41"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="1460" length="2"/><text>Cu</text></annotation><annotation id="42"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="1736" length="2"/><text>Cu</text></annotation><annotation id="43"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="1828" length="2"/><text>Cu</text></annotation></passage></document>
<document><id>37872087</id><passage><infon key="journal">Zhonghua Gan Zang Bing Za Zhi;2023Sep20; 31 (9) 921. doi:10.3760/cma.j.cn501113-20221111-00560</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang TY, Sun X, Yao YH, Jin Q, Gan DN, Ye YA, Li XK, </infon><offset>0</offset><text>[Update points for the 2022 edition of the European Association for the Study of Liver Diseases Clinical Practice Guidelines for the Management of Hepatic Encephalopathy and comparison with China's 2018 edition guidelines].</text><annotation id="2"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="81" length="14"/><text>Liver Diseases</text></annotation><annotation id="3"><infon key="identifier">MESH:D006501</infon><infon key="type">Disease</infon><location offset="147" length="22"/><text>Hepatic Encephalopathy</text></annotation></passage><passage><infon key="type">abstract</infon><offset>224</offset><text>The European Association for the Study of Liver Diseases issued the "Clinical Practice Guidelines for the Management of Hepatic Encephalopathy" in 2022, which included recommendations for clinical diagnosis, assessment, treatment, management, and prevention. The Society's "Hepatic Encephalopathy Clinical Practice Guidelines in Chronic Liver Disease," which was last published in 2014, and the "Guidelines for the Diagnosis and Treatment of Hepatic Encephalopathy in Cirrhosis," which the Chinese Society of Hepatology, Chinese Medical Association, released in 2018, have certain differences and updates in terms of comparison to terminology, grading and classification, diagnosis, clinical evaluation and treatment, management, and prevention. Herein, the updated points of this guideline and the differences between it and our nation's guidelines are summarized in order to refine and understand the guiding role of the new version of the guideline for the clinical treatment of hepatic encephalopathy and provide aid for standardizing clinical diagnosis and treatment.</text><annotation id="11"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="266" length="14"/><text>Liver Diseases</text></annotation><annotation id="12"><infon key="identifier">MESH:D006501</infon><infon key="type">Disease</infon><location offset="344" length="22"/><text>Hepatic Encephalopathy</text></annotation><annotation id="13"><infon key="identifier">MESH:D006501</infon><infon key="type">Disease</infon><location offset="498" length="22"/><text>Hepatic Encephalopathy</text></annotation><annotation id="14"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="553" length="21"/><text>Chronic Liver Disease</text></annotation><annotation id="15"><infon key="identifier">MESH:D006501</infon><infon key="type">Disease</infon><location offset="666" length="22"/><text>Hepatic Encephalopathy</text></annotation><annotation id="16"><infon key="identifier">MESH:D005355</infon><infon key="type">Disease</infon><location offset="692" length="9"/><text>Cirrhosis</text></annotation><annotation id="17"><infon key="identifier">MESH:D006501</infon><infon key="type">Disease</infon><location offset="1206" length="22"/><text>hepatic encephalopathy</text></annotation></passage></document>
<document><id>37872437</id><passage><infon key="journal">Arch Orthop Trauma Surg;2023Oct24. doi:10.1007/s00402-023-05066-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">5994632</infon><infon key="type">title</infon><infon key="authors">Spranz D, Skrobek D, Randoll J, Kinkel S, Merle C, Walker T, Renkawitz T, Reiner T, </infon><offset>0</offset><text>Femoral revision in total hip arthroplasty using a cementless modular stem: clinical and radiological results with a 8-year follow-up.</text><annotation id="1"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="26" length="3"/><text>hip</text></annotation></passage><passage><infon key="type">abstract</infon><offset>135</offset><text>INTRODUCTION: Modular femoral components allow for patient-specific restoration of hip joint geometry and the reconstruction of extensive bone defects in revision total hip arthroplasty (THA); however, potential problems of modular implants such as taper corrosion and the risk of implant fracture continue to be of concern. The aim of the present study was to evaluate the clinical and radiological results of a cementless modular revision stem following revision surgery due to aseptic loosening and periprosthetic fracture and to assess patient-reported outcome measures (PROMs) in these patients at mid-term follow-up. MATERIALS AND METHODS: In this study, a consecutive cohort of 75 patients who underwent primary revision THA at our institution using a modular cementless stem design (MRP-TITAN stem) was retrospectively evaluated at a mean follow-up of 7.7 years. Kaplan-Meier survivorship analyses were performed with revision of the femoral component for any reason as the end point. The Harris-Hip Score, the UCLA Activity Score, the Forgotten Joint Score and the SF-12 Score were used for clinical assessment. We used the Wilcoxon signed rank test to compare pre- and postoperative clinical scores. RESULTS: Overall stem survival with the endpoint stem re-revision for any reason was 85.4% at a mean follow-up of 7.7 years (range 2.4-14 years). Stem survival was 89.5% in the aseptic loosening group and 78.3% in the periprosthetic fracture group with no statistically significant difference between both groups (p = 0.107). One patient had to be revised due to taper fracture. PROMs improved significantly up to the latest follow-up, and radiographic evaluation showed full osseointegration of all stems in this cohort. CONCLUSIONS: Revision THA using a modular cementless titanium revision stem demonstrated adequate clinical and radiological results at mid- to long-term follow-up in this cohort. Cementless revision stems are a useful treatment option to restore the anatomy, especially in deformed hips and in complex revision hip arthroplasty. However, there are some significant disadvantages related to an increased risk of mechanical failure such as corrosion/fretting damage and implant fracture. Future high-quality prospective studies with longer follow-up are necessary to confirm the supposed advantages.</text><annotation id="16"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="218" length="3"/><text>hip</text></annotation><annotation id="17"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="273" length="12"/><text>bone defects</text></annotation><annotation id="18"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="304" length="3"/><text>hip</text></annotation><annotation id="19"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="424" length="8"/><text>fracture</text></annotation><annotation id="20"><infon key="identifier">MESH:D011475</infon><infon key="type">Disease</infon><location offset="615" length="17"/><text>aseptic loosening</text></annotation><annotation id="21"><infon key="identifier">MESH:D057068</infon><infon key="type">Disease</infon><location offset="637" length="23"/><text>periprosthetic fracture</text></annotation><annotation id="22"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="1139" length="3"/><text>Hip</text></annotation><annotation id="23"><infon key="identifier">MESH:D011475</infon><infon key="type">Disease</infon><location offset="1522" length="17"/><text>aseptic loosening</text></annotation><annotation id="24"><infon key="identifier">MESH:D057068</infon><infon key="type">Disease</infon><location offset="1563" length="23"/><text>periprosthetic fracture</text></annotation><annotation id="25"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="1714" length="8"/><text>fracture</text></annotation><annotation id="26"><infon key="identifier">MESH:D014025</infon><infon key="type">Chemical</infon><location offset="1920" length="8"/><text>titanium</text></annotation><annotation id="27"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="2149" length="4"/><text>hips</text></annotation><annotation id="28"><infon key="identifier">MESH:D025981</infon><infon key="type">Disease</infon><location offset="2178" length="3"/><text>hip</text></annotation><annotation id="29"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="2343" length="8"/><text>fracture</text></annotation></passage></document>
<document><id>37872787</id><passage><infon key="journal">Mater Horiz;2023Oct24. doi:10.1039/d3mh01133j</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Du Z, Luong HM, Sabury S, Therdkatanyuphong P, Chae S, Welton C, Jones AL, Zhang J, Peng Z, Zhu Z, Nanayakkara S, Coropceanu V, Choi DG, Xiao S, Yi A, Kim HJ, Bredas JL, Ade H, Reddy GNM, Marder SR, Reynolds JR, Nguyen TQ, </infon><offset>0</offset><text>Additive-free molecular acceptor organic solar cells processed from a biorenewable solvent approaching 15% efficiency.</text></passage><passage><infon key="type">abstract</infon><offset>119</offset><text>We report on the use of molecular acceptors (MAs) and donor polymers processed with a biomass-derived solvent (2-methyltetrahydrofuran, 2-MeTHF) to facilitate bulk heterojunction (BHJ) organic photovoltaics (OPVs) with power conversion efficiency (PCE) approaching 15%. Our approach makes use of two newly designed donor polymers with an opened ring unit in their structures along with three molecular acceptors (MAs) where the backbone and sidechain were engineered to enhance the processability of BHJ OPVs using 2-MeTHF, as evaluated by an analysis of donor-acceptor (D-A) miscibility and interaction parameters. To understand the differences in the PCE values that ranged from 9-15% as a function of composition, the surface, bulk, and interfacial BHJ morphologies were characterized at different length scales using atomic force microscopy, grazing-incidence wide-angle X-ray scattering, resonant soft X-ray scattering, X-ray photoelectron spectroscopy, and 2D solid-state nuclear magnetic resonance spectroscopy. Our results indicate that the favorable D-A intermixing that occurs in the best performing BHJ film with an average domain size of ~25 nm, high domain purity, uniform distribution and enhanced local packing interactions - facilitates charge generation and extraction while limiting the trap-assisted recombination process in the device, leading to high effective mobility and good performance.</text><annotation id="5"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="179" length="8"/><text>polymers</text></annotation><annotation id="6"><infon key="identifier">MESH:C550584</infon><infon key="type">Chemical</infon><location offset="230" length="23"/><text>2-methyltetrahydrofuran</text></annotation><annotation id="7"><infon key="identifier">MESH:C587233</infon><infon key="type">Chemical</infon><location offset="255" length="7"/><text>2-MeTHF</text></annotation><annotation id="8"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="440" length="8"/><text>polymers</text></annotation><annotation id="9"><infon key="identifier">MESH:C587233</infon><infon key="type">Chemical</infon><location offset="634" length="7"/><text>2-MeTHF</text></annotation></passage><relation id="R1"><infon key="score">0.9968</infon><infon key="role1">Chemical|MESH:C550584</infon><infon key="role2">Chemical|MESH:D011108</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9961</infon><infon key="role1">Chemical|MESH:C587233</infon><infon key="role2">Chemical|MESH:D011108</infon><infon key="type">Association</infon><node refid="1" role="2,0"/></relation></document>
<document><id>37873139</id><passage><infon key="journal">bioRxiv;2023Oct11. doi:10.1101/2023.10.10.561756</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10592734</infon><infon key="type">title</infon><infon key="authors">Simmons CR, Buchberger A, Henry SJW, Novacek A, Fahmi NE, MacCulloch T, Stephanopoulos N, Yan H, </infon><offset>0</offset><text>Site-specific arrangement and structure determination of minor groove binding molecules in self-assembled three-dimensional DNA crystals.</text></passage><passage><infon key="type">abstract</infon><offset>138</offset><text>The structural analysis of guest molecules in rationally designed and self-assembling DNA crystals has proven elusive since its conception. Oligonucleotide frameworks provide an especially attractive route towards studying DNA-binding molecules by using three-dimensional lattices with defined sequence and structure. In this work, we site-specifically position a suite of minor groove binding molecules, and solve their structures via x-ray crystallography, as a proof-of-principle towards scaffolding larger guest species. Two crystal motifs were used to precisely immobilize the molecules DAPI, Hoechst, and netropsin at defined positions in the lattice, allowing us to control occupancy within the crystal. We also solved the structure of a three-ring imidazole-pyrrole-pyrrole polyamide molecule, which sequence-specifically packs in an anti-parallel dimeric arrangement within the minor groove. Finally, we engineered a crystal designed to position both netropsin and the polyamide at two distinct locations within the same lattice. Our work elucidates the design principles for the spatial arrangement of functional guests within lattices and opens new potential opportunities for the use of DNA crystals to display and structurally characterize small molecules, peptides, and ultimately proteins of unknown structure.</text><annotation id="7"><infon key="identifier">MESH:D009841</infon><infon key="type">Chemical</infon><location offset="278" length="15"/><text>Oligonucleotide</text></annotation><annotation id="8"><infon key="identifier">MESH:C007293</infon><infon key="type">Chemical</infon><location offset="730" length="4"/><text>DAPI</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="736" length="7"/><text>Hoechst</text></annotation><annotation id="10"><infon key="identifier">MESH:D009429</infon><infon key="type">Chemical</infon><location offset="749" length="9"/><text>netropsin</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="894" length="35"/><text>imidazole-pyrrole-pyrrole polyamide</text></annotation><annotation id="12"><infon key="identifier">MESH:D009429</infon><infon key="type">Chemical</infon><location offset="1098" length="9"/><text>netropsin</text></annotation><annotation id="13"><infon key="identifier">MESH:D009757</infon><infon key="type">Chemical</infon><location offset="1116" length="9"/><text>polyamide</text></annotation></passage></document>
<document><id>37873841</id><passage><infon key="journal">Clocks Sleep;2023Oct16; 5 (4) 604. doi:10.3390/clockssleep5040040</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Matsumoto Y, Hino A, Kumadaki K, Itani O, Otsuka Y, Kaneita Y, </infon><offset>0</offset><text>Relationship between Telework Jetlag and Perceived Psychological Distress among Japanese Hybrid Workers.</text><annotation id="2"><infon key="type">Disease</infon><location offset="30" length="6"/><text>Jetlag</text></annotation><annotation id="3"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="51" length="22"/><text>Psychological Distress</text></annotation></passage><passage><infon key="type">abstract</infon><offset>105</offset><text>Social jetlag is associated with physical and mental health problems. With the increased popularity of telework, we investigated a specific form of social jetlag that we termed "telework jetlag". This study aimed to clarify the relationship between telework jetlag-the difference in sleep and wake-up times between in-office and telework days-and mental health problems among Japanese hybrid workers. A cross-sectional study was conducted with 1789 participants from October to December 2021 using an online-based questionnaire. Telework jetlag, defined as the difference in the midsleep point between in-office and telework days, was investigated using two groups according to telework jetlag-those lagging &lt;1 h versus >=1 h. We used the six-item Kessler Scale as a nonspecific psychological distress scale for the outcome. Telework jetlag was significantly associated with psychological distress, and the >=1 h group had a higher risk (odds ratio: 1.80) of developing high psychological distress (HPD) than the &lt;1 h group in the multivariate analysis. Since most teleworkers are forced to have a hybrid work style that mixes going to work and teleworking, telework jetlag must be addressed to maintain the health of teleworkers.</text><annotation id="18"><infon key="type">Disease</infon><location offset="112" length="6"/><text>jetlag</text></annotation><annotation id="19"><infon key="identifier">MESH:D000076082</infon><infon key="type">Disease</infon><location offset="151" length="22"/><text>mental health problems</text></annotation><annotation id="20"><infon key="type">Disease</infon><location offset="260" length="6"/><text>jetlag</text></annotation><annotation id="21"><infon key="type">Disease</infon><location offset="292" length="6"/><text>jetlag</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="363" length="6"/><text>jetlag</text></annotation><annotation id="23"><infon key="identifier">MESH:D000076082</infon><infon key="type">Disease</infon><location offset="452" length="22"/><text>mental health problems</text></annotation><annotation id="24"><infon key="type">Disease</infon><location offset="643" length="6"/><text>jetlag</text></annotation><annotation id="25"><infon key="type">Disease</infon><location offset="792" length="6"/><text>jetlag</text></annotation><annotation id="26"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="884" length="22"/><text>psychological distress</text></annotation><annotation id="27"><infon key="type">Disease</infon><location offset="939" length="6"/><text>jetlag</text></annotation><annotation id="28"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="980" length="22"/><text>psychological distress</text></annotation><annotation id="29"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1080" length="22"/><text>psychological distress</text></annotation><annotation id="30"><infon key="identifier">MESH:D012128</infon><infon key="type">Disease</infon><location offset="1104" length="3"/><text>HPD</text></annotation><annotation id="31"><infon key="type">Disease</infon><location offset="1272" length="6"/><text>jetlag</text></annotation></passage></document>
<document><id>37874192</id><passage><infon key="journal">Acta Neurobiol Exp (Wars);2023Sep29; 83 (3) 255. doi:10.55782/ane-2023-2430</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Dalkiran B, Acikgoz B, Aksu I, Kiray A, Kiray M, </infon><offset>0</offset><text>The effects of bee venom on behavior and the role of leptin in rats.</text><annotation id="1"><infon key="identifier">25608</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">193</infon><location offset="53" length="6"/><text>leptin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>69</offset><text>The aim of this study is to evaluate the dose-dependent effect of bee venom (BV) on behavioral functions in rats and the physiological role of leptin in the prefrontal cortex, hippocampus, and amygdala tissues. Adult Sprague-Dawley male rats were used in the experiments. The rats were divided into three groups of control, 0.1 mg/kg BV, and 0.5 mg/kg BV. The rats were injected with BV subcutaneously for 15 consecutive days. The open field test (OFT), the elevated plus maze test (EPM), and the forced swimming test (FST) were performed as behavioral assessments. Animals were sacrificed, and brain regions were removed. Leptin levels were measured in various brain regions by ELISA. In the OFT, the total distance and speed for the 0.1 mg/kg BV group increased compared to controls and the 0.5 mg/kg BV group. In the EPM, the 0.1 mg/kg BV group remained in the open arm for a significantly longer period of time compared to the other groups. In the FST, the 0.5 mg/kg BV group was more mobile than the other groups. Leptin levels in the prefrontal cortex were significantly higher in the 0.1 mg/kg BV group compared to the control and 0.5 mg/kg groups. There were no significant differences between groups in hippocampus and amygdala leptin levels. The results of the study show that BV has a positive effect on behavioral parameters. BV may have a positive effect on anxiety- and depression-like behaviors by increasing leptin levels in the prefrontal cortex.</text><annotation id="9"><infon key="identifier">25608</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">193</infon><location offset="212" length="6"/><text>leptin</text></annotation><annotation id="10"><infon key="identifier">25608</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">193</infon><location offset="692" length="6"/><text>Leptin</text></annotation><annotation id="11"><infon key="identifier">25608</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">193</infon><location offset="1088" length="6"/><text>Leptin</text></annotation><annotation id="12"><infon key="identifier">25608</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">193</infon><location offset="1306" length="6"/><text>leptin</text></annotation><annotation id="13"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="1440" length="7"/><text>anxiety</text></annotation><annotation id="14"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1453" length="10"/><text>depression</text></annotation><annotation id="15"><infon key="identifier">25608</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">193</infon><location offset="1493" length="6"/><text>leptin</text></annotation></passage></document>
<document><id>37874543</id><passage><infon key="journal">Ir Med J;2023Oct19; 116 (9) 863</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">McKeown C, Kalu C, DeTavernier MC, </infon><offset>0</offset><text>Heterotopic pregnancy following spontaneous conception.</text></passage><passage><infon key="type">abstract</infon><offset>56</offset></passage></document>
<document><id>37874904</id><passage><infon key="journal">Inflamm Bowel Dis;2023Oct24. doi:10.1093/ibd/izad238</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cook L, Wong MQ, Rees WD, Schick A, Lisko DJ, Lunken GR, Wang X, Peters H, Oliveira L, Lau T, Mah R, Bressler B, Levings MK, Steiner TS, </infon><offset>0</offset><text>Dysregulated Immunity to Clostridioides difficile in IBD Patients Without a History of Recognized Infection.</text><annotation id="2"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="53" length="3"/><text>IBD</text></annotation><annotation id="3"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="98" length="9"/><text>Infection</text></annotation></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>BACKGROUND &amp; AIMS: Clostridioides difficile is a toxin-secreting bacteria that is an urgent antimicrobial resistance threat, with approximately 25% of patients developing recurrent infections. Inflammatory bowel disease (IBD) patients are at increased risk of severe, recurrent C. difficile infection. METHODS: To investigate a role for C. difficile infection in IBD pathogenesis, we collected peripheral blood and stool from 20 each of ulcerative colitis patients, Crohn's disease patients, and healthy control subjects. We used a flow cytometric activation induced marker assay to quantify C. difficile toxin-specific CD4+ T cells and 16S ribosomal RNA sequencing to study microbiome diversity. RESULTS: We found IBD patients had significantly increased levels of C. difficile toxin B-specific CD4+ T cells, but not immunoglobulin G or immunoglobulin A, compared with healthy control subjects. Within antigen-specific CD4+ T cells, T helper type 17 cells and cells expressing the gut homing receptor integrin beta7 were reduced compared with healthy control subjects, similar to our previous study of non-IBD patients with recurrent C. difficile infection. Stool microbiome analysis revealed that gut homing, toxin-specific CD4+ T cells negatively associated with microbial diversity and, along with T helper type 17 cells, positively associated with bacteria enriched in healthy control subjects. CONCLUSIONS: These data suggest that IBD patients, potentially due to underlying intestinal dysbiosis, experience undiagnosed C. difficile infections that result in impaired toxin-specific immunity. This may contribute to the development of inflammatory T cell responses toward commensal bacteria and provide a rationale for C. difficile testing in IBD patients.</text><annotation id="21"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="290" length="10"/><text>infections</text></annotation><annotation id="22"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="302" length="26"/><text>Inflammatory bowel disease</text></annotation><annotation id="23"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="330" length="3"/><text>IBD</text></annotation><annotation id="24"><infon key="identifier">MESH:D003015</infon><infon key="type">Disease</infon><location offset="387" length="22"/><text>C. difficile infection</text></annotation><annotation id="25"><infon key="identifier">MESH:D003015</infon><infon key="type">Disease</infon><location offset="446" length="22"/><text>C. difficile infection</text></annotation><annotation id="26"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="472" length="3"/><text>IBD</text></annotation><annotation id="27"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="546" length="18"/><text>ulcerative colitis</text></annotation><annotation id="28"><infon key="identifier">MESH:D003424</infon><infon key="type">Disease</infon><location offset="575" length="15"/><text>Crohn's disease</text></annotation><annotation id="29"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="824" length="3"/><text>IBD</text></annotation><annotation id="30"><infon key="identifier">3695</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20247</infon><location offset="1111" length="14"/><text>integrin beta7</text></annotation><annotation id="31"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="1216" length="3"/><text>IBD</text></annotation><annotation id="32"><infon key="identifier">MESH:D003015</infon><infon key="type">Disease</infon><location offset="1244" length="22"/><text>C. difficile infection</text></annotation><annotation id="33"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="1546" length="3"/><text>IBD</text></annotation><annotation id="34"><infon key="identifier">MESH:D064806</infon><infon key="type">Disease</infon><location offset="1601" length="9"/><text>dysbiosis</text></annotation><annotation id="35"><infon key="identifier">MESH:D003015</infon><infon key="type">Disease</infon><location offset="1635" length="23"/><text>C. difficile infections</text></annotation><annotation id="36"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1750" length="12"/><text>inflammatory</text></annotation><annotation id="37"><infon key="identifier">MESH:D015212</infon><infon key="type">Disease</infon><location offset="1858" length="3"/><text>IBD</text></annotation></passage></document>
<document><id>37875265</id><passage><infon key="journal">Int J Hyperthermia;2023; 40 (1) 2272067. doi:10.1080/02656736.2023.2272067</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10624165</infon><infon key="type">title</infon><infon key="authors">Carlton H, Weber M, Peters M, Arepally N, Lad YS, Jaswal A, Ivkov R, Attaluri A, Goodwill P, </infon><offset>0</offset><text>HYPER: pre-clinical device for spatially-confined magnetic particle hyperthermia.</text></passage><passage><infon key="type">abstract</infon><offset>82</offset><text>PURPOSE: Magnetic particle hyperthermia is an approved cancer treatment that harnesses thermal energy generated by magnetic nanoparticles when they are exposed to an alternating magnetic field (AMF). Thermal stress is either directly cytotoxic or increases the susceptibility of cancer cells to standard therapies, such as radiation. As with other thermal therapies, the challenge with nanoparticle hyperthermia is controlling energy delivery. Here, we describe the design and implementation of a prototype pre-clinical device, called HYPER, that achieves spatially confined nanoparticle heating within a user-selected volume and location. DESIGN: Spatial control of nanoparticle heating was achieved by placing an AMF generating coil (340 kHz, 0-15 mT), between two opposing permanent magnets. The relative positions between the magnets determined the magnetic field gradient (0.7 T/m-2.3 T/m), which in turn governed the volume of the field free region (FFR) between them (0.8-35 cm3). Both the gradient value and position of the FFR within the AMF ([-14, 14]x, [-18, 18]y, [-30, 30]z) mm are values selected by the user via the graphical user interface (GUI). The software then controls linear actuators that move the static magnets to adjust the position of the FFR in 3D space based on user input. Within the FFR, the nanoparticles generate hysteresis heating; however, outside the FFR where the static field is non-negligible, the nanoparticles are unable to generate hysteresis loss power. VERIFICATION: We verified the performance of the HYPER to design specifications by independently heating two nanoparticle-rich areas of a phantom placed within the volume occupied by the AMF heating coil.</text><annotation id="2"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="137" length="6"/><text>cancer</text></annotation><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="361" length="6"/><text>cancer</text></annotation></passage></document>
<document><id>37875616</id><passage><infon key="journal">Cardiovasc Intervent Radiol;2023Oct24. doi:10.1007/s00270-023-03571-2</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Higashino N, Sonomura T, Ikoma A, Tamai K, Fukuda K, Kawai N, Minamiguchi H, </infon><offset>0</offset><text>Balloon-Assisted Arterial Embolization of Pseudoaneurysms Using NBCA-Lipiodol-Iopamidol Mixture in Two Clinical Cases.</text><annotation id="2"><infon key="identifier">MESH:D017541</infon><infon key="type">Disease</infon><location offset="42" length="15"/><text>Pseudoaneurysms</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="64" length="23"/><text>NBCA-Lipiodol-Iopamidol</text></annotation></passage><passage><infon key="type">abstract</infon><offset>119</offset></passage></document>
<document><id>37876327</id><passage><infon key="journal">Histopathology;2023Oct25. doi:10.1111/his.15079</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Maguire J, Harvey H, Jones A, Law R, Bashir M, O'Brien O, Sargent J, Grant C, Flavin R, </infon><offset>0</offset><text>Clinical boundaries in adult cases of large B cell lymphoma with IRF4 rearrangement.</text><annotation id="2"><infon key="identifier">MESH:D016393</infon><infon key="type">Disease</infon><location offset="38" length="21"/><text>large B cell lymphoma</text></annotation><annotation id="3"><infon key="identifier">3662</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1842</infon><location offset="65" length="4"/><text>IRF4</text></annotation></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>AIMS: Large B-cell lymphoma with IRF4 rearrangement (LBCL-IRF4) is a recently described entity included in the revised 4th edition of the WHO Classification of Haematolymphoid Tumours (2017). Here we highlight the difficulties in classification of those cases which arise in adult patients with unusual clinical features. RESULTS: We present three cases with morphological and immunohistochemical features consistent with large B-cell lymphoma arising in adult patients, which were found to have isolated IRF4 rearrangements on FISH analysis. Each patient presented with advanced-stage disease and had a history of immunosuppression; clinical features that are not typical of LBCL-IRF4 and which make the distinction from DLBCL, not otherwise specified (NOS) challenging. CONCLUSION: We propose that the clinical boundaries of LBCL-IRF4 arising in adult patients need further delineation to allow distinction from true cases of DLBCL, NOS.</text><annotation id="19"><infon key="identifier">MESH:D016393</infon><infon key="type">Disease</infon><location offset="91" length="21"/><text>Large B-cell lymphoma</text></annotation><annotation id="20"><infon key="identifier">3662</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1842</infon><location offset="118" length="4"/><text>IRF4</text></annotation><annotation id="21"><infon key="type">Disease</infon><location offset="138" length="4"/><text>LBCL</text></annotation><annotation id="22"><infon key="identifier">3662</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1842</infon><location offset="143" length="4"/><text>IRF4</text></annotation><annotation id="23"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="245" length="23"/><text>Haematolymphoid Tumours</text></annotation><annotation id="24"><infon key="identifier">MESH:D016393</infon><infon key="type">Disease</infon><location offset="507" length="21"/><text>large B-cell lymphoma</text></annotation><annotation id="25"><infon key="identifier">3662</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1842</infon><location offset="590" length="4"/><text>IRF4</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="761" length="4"/><text>LBCL</text></annotation><annotation id="27"><infon key="identifier">3662</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1842</infon><location offset="766" length="4"/><text>IRF4</text></annotation><annotation id="28"><infon key="identifier">MESH:C536665</infon><infon key="type">Disease</infon><location offset="807" length="30"/><text>DLBCL, not otherwise specified</text></annotation><annotation id="29"><infon key="identifier">MESH:C536665</infon><infon key="type">Disease</infon><location offset="839" length="3"/><text>NOS</text></annotation><annotation id="30"><infon key="type">Disease</infon><location offset="912" length="4"/><text>LBCL</text></annotation><annotation id="31"><infon key="identifier">3662</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1842</infon><location offset="917" length="4"/><text>IRF4</text></annotation><annotation id="32"><infon key="type">Disease</infon><location offset="1013" length="5"/><text>DLBCL</text></annotation><annotation id="33"><infon key="identifier">MESH:C536665</infon><infon key="type">Disease</infon><location offset="1020" length="3"/><text>NOS</text></annotation></passage><relation id="R1"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D016393</infon><infon key="role2">Gene|3662</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation></document>
<document><id>37877393</id><passage><infon key="journal">Sheng Wu Gong Cheng Xue Bao;2023Oct25; 39 (10) 4098. doi:10.13345/j.cjb.230092</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yang Y, Liu Y, Chen M, Li S, Lu X, He Y, Zhang K, Zou Q, </infon><offset>0</offset><text>[Rapamycin mediated caspase 9 homodimerization to safeguard human pluripotent stem cell therapy].</text><annotation id="2"><infon key="identifier">MESH:D020123</infon><infon key="type">Chemical</infon><location offset="1" length="9"/><text>Rapamycin</text></annotation><annotation id="3"><infon key="identifier">842</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31024</infon><location offset="20" length="9"/><text>caspase 9</text></annotation></passage><passage><infon key="type">abstract</infon><offset>98</offset><text>Human induced pluripotent stem cells (hiPSCs) are promising in regenerative medicine. However, the pluripotent stem cells (PSCs) may form clumps of cancerous tissue, which is a major safety concern in PSCs therapies. Rapamycin is a safe and widely used immunosuppressive pharmaceutical that acts through heterodimerization of the FKBP12 and FRB fragment. Here, we aimed to insert a rapamycin inducible caspase 9 (riC9) gene in a safe harbor AAVS1 site to safeguard hiPSCs therapy by drug induced homodimerization. The donor vector containing an EF1alpha promoter, a FRB-FKBP-Caspase 9 (CARD domain) fusion protein and a puromycin resistant gene was constructed and co-transfected with sgRNA/Cas9 vector into hiPSCs. After one to two weeks screening with puromycin, single clones were collected for genotype and phenotype analysis. Finally, rapamycin was used to induce the homodimerization of caspase 9 to activate the apoptosis of the engineered cells. After transfection of hiPSCs followed by puromycin screening, five cell clones were collected. Genome amplification and sequencing showed that the donor DNA has been precisely knocked out at the endogenous AAVS1 site. The engineered hiPSCs showed normal pluripotency and proliferative capacity. Rapamycin induced caspase 9 activation, which led to the apoptosis of all engineered hiPSCs and its differentiated cells with different sensitivity to drugs. In conclusion, we generated a rapamycin-controllable hiPSCs survival by homodimerization of caspase 9 to turn on cell apoptosis. It provides a new strategy to guarantee the safety of the hiPSCs therapy.</text><annotation id="20"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="246" length="9"/><text>cancerous</text></annotation><annotation id="21"><infon key="identifier">MESH:D020123</infon><infon key="type">Chemical</infon><location offset="315" length="9"/><text>Rapamycin</text></annotation><annotation id="22"><infon key="identifier">2282</infon><infon key="type">Gene</infon><location offset="428" length="6"/><text>FKBP12</text></annotation><annotation id="23"><infon key="identifier">MESH:D020123</infon><infon key="type">Chemical</infon><location offset="480" length="9"/><text>rapamycin</text></annotation><annotation id="24"><infon key="identifier">842</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31024</infon><location offset="500" length="9"/><text>caspase 9</text></annotation><annotation id="25"><infon key="identifier">1917</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">121568</infon><location offset="643" length="8"/><text>EF1alpha</text></annotation><annotation id="26"><infon key="identifier">842</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31024</infon><location offset="673" length="9"/><text>Caspase 9</text></annotation><annotation id="27"><infon key="identifier">MESH:D011691</infon><infon key="type">Chemical</infon><location offset="718" length="9"/><text>puromycin</text></annotation><annotation id="28"><infon key="identifier">MESH:D011691</infon><infon key="type">Chemical</infon><location offset="852" length="9"/><text>puromycin</text></annotation><annotation id="29"><infon key="identifier">MESH:D020123</infon><infon key="type">Chemical</infon><location offset="938" length="9"/><text>rapamycin</text></annotation><annotation id="30"><infon key="identifier">842</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31024</infon><location offset="991" length="9"/><text>caspase 9</text></annotation><annotation id="31"><infon key="identifier">MESH:D011691</infon><infon key="type">Chemical</infon><location offset="1093" length="9"/><text>puromycin</text></annotation><annotation id="32"><infon key="identifier">MESH:D020123</infon><infon key="type">Chemical</infon><location offset="1347" length="9"/><text>Rapamycin</text></annotation><annotation id="33"><infon key="identifier">842</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31024</infon><location offset="1365" length="9"/><text>caspase 9</text></annotation><annotation id="34"><infon key="identifier">MESH:D020123</infon><infon key="type">Chemical</infon><location offset="1535" length="9"/><text>rapamycin</text></annotation><annotation id="35"><infon key="identifier">842</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31024</infon><location offset="1597" length="9"/><text>caspase 9</text></annotation></passage><relation id="R1"><infon key="score">0.6938</infon><infon key="role1">Chemical|MESH:D020123</infon><infon key="role2">Gene|2282</infon><infon key="type">Association</infon><node refid="0" role="3,4"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D020123</infon><infon key="role2">Gene|842</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="0,1"/></relation></document>
<document><id>37877744</id><passage><infon key="journal">Int J Occup Med Environ Health;2023Oct23. doi:10.13075/ijomeh.1896.02224</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sygit-Kowalkowska E, Orlak K, Stolarski M, </infon><offset>0</offset><text>Work for the Prison Service: selected health consequences - investigating the role of personal resources, job demands, work stress, and burnout.</text><annotation id="2"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="124" length="6"/><text>stress</text></annotation><annotation id="3"><infon key="identifier">MESH:D002055</infon><infon key="type">Disease</infon><location offset="136" length="7"/><text>burnout</text></annotation></passage><passage><infon key="type">abstract</infon><offset>145</offset><text>OBJECTIVES: The specific job demands of the Prison Service (PS) may affect the health of officers. The job demands-resources model (JD-R) model was used to design a survey of the consequences of working subject to particular job demands. The aim was to gain an insight into the relationship between job demands, personal resources, occupational stress and burnout and selected health consequence indicators (such as behaviors associated with the consumption of alcohol, stress symptoms). MATERIAL AND METHODS: A total of 1732 PS officers in Poland were surveyed. The following tools were used as part of the survey: the Copenhagen Psychosocial Questionnaire (COPSOQ II), the Multidimensional Inventory for Assessing Coping Responses (COPE), the Alcohol Use Disorders Identification Test (AUDIT) and a form with a respondent's particulars. Path analysis using partial least squares structural equation modelling (PLS-SEM) was performed. RESULTS: The assumed hypotheses were partially confirmed by the results. Out of 4 job demands categories only work pace turned out not to be a significant predictor of burnout and stress. For alcohol related behaviors, stress level was the only significant predictor, both as a direct and indirect effect taking into account job demands. It transpired that support from superiors rather than support from colleagues or self-efficacy was a significant moderator in the emotional demands - stress relationship. Limitations of the study and perspectives for its continuation are also presented herein. CONCLUSIONS: Based on the obtained results it may be concluded that job demands and support from superiors do have an impact on stress in the PS group. This is also consistent with available reports in literature. At the same time stress is a significant predictor of alcohol related behaviors. Coping through the use of psychoactive substances was not a significant factor in statistical analyses and it has still not been subject to sufficient scientific analysis. Int J Occup Med Environ Health. 2023;36(6).</text><annotation id="18"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="490" length="6"/><text>stress</text></annotation><annotation id="19"><infon key="identifier">MESH:D002055</infon><infon key="type">Disease</infon><location offset="501" length="7"/><text>burnout</text></annotation><annotation id="20"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="606" length="7"/><text>alcohol</text></annotation><annotation id="21"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="615" length="6"/><text>stress</text></annotation><annotation id="22"><infon key="identifier">MESH:D000437</infon><infon key="type">Disease</infon><location offset="890" length="21"/><text>Alcohol Use Disorders</text></annotation><annotation id="23"><infon key="identifier">MESH:D002055</infon><infon key="type">Disease</infon><location offset="1249" length="7"/><text>burnout</text></annotation><annotation id="24"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="1261" length="6"/><text>stress</text></annotation><annotation id="25"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1273" length="7"/><text>alcohol</text></annotation><annotation id="26"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="1300" length="6"/><text>stress</text></annotation><annotation id="27"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="1569" length="6"/><text>stress</text></annotation><annotation id="28"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="1808" length="6"/><text>stress</text></annotation><annotation id="29"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="1911" length="6"/><text>stress</text></annotation><annotation id="30"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1948" length="7"/><text>alcohol</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2001" length="23"/><text>psychoactive substances</text></annotation></passage><relation id="R1"><infon key="score">0.9923</infon><infon key="role1">Chemical|MESH:D000438</infon><infon key="role2">Disease|MESH:D000079225</infon><infon key="type">Association</infon><node refid="0" role="4,2"/></relation></document>
<document><id>37878094</id><passage><infon key="journal">Rev Med Suisse;2023Oct25; 19 (847) 1963. doi:10.53738/REVMED.2023.19.847.1963</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Aubert C&amp;#xc9;, Gabutti L, Genn&amp;#xe9; D, Reny JL, </infon><offset>0</offset><text>Smarter Medicine : donnons-nous les moyens avec les bons soutiens!</text></passage><passage><infon key="type">abstract</infon><offset>67</offset></passage></document>
<document><id>37878444</id><passage><infon key="journal">IEEE Trans Vis Comput Graph;2023Oct25; PP. doi:10.1109/TVCG.2023.3327387</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang Y, Qian Y, Qi X, Cao N, Wang D, </infon><offset>0</offset><text>InnovationInsights: A Visual Analytics Approach for Understanding the Dual Frontiers of Science and Technology.</text></passage><passage><infon key="type">abstract</infon><offset>112</offset><text>Science has long been viewed as a key driver of economic growth and rising standards of living. Knowledge about how scientific advances support marketplace inventions is therefore essential for understanding the role of science in propelling real-world applications and technological progress. The increasing availability of large-scale datasets tracing scientific publications and patented inventions and the complex interactions among them offers us new opportunities to explore the evolving dual frontiers of science and technology at an unprecedented level of scale and detail. However, we lack suitable visual analytics approaches to analyze such complex interactions effectively. Here we introduce InnovationInsights, an interactive visual analysis system for researchers, research institutions, and policymakers to explore the complex linkages between science and technology, and to identify critical innovations, inventors, and potential partners. The system first identifies important associations between scientific papers and patented inventions through a set of statistical measures introduced by our experts from the field of the Science of Science. A series of visualization views are then used to present these associations in the data context. In particular, we introduce the Interplay Graph to visualize patterns and insights derived from the data, helping users effectively navigate citation relationships between papers and patents. This visualization thereby helps them identify the origins of technical inventions and the impact of scientific research. We evaluate the system through two case studies with experts followed by expert interviews. We further engage a premier research institution to test-run the system, helping its institution leaders to extract new insights for innovation. Through both the case studies and the engagement project, we find that our system not only meets our original goals of design, allowing users to better identify the sources of technical inventions and to understand the broad impact of scientific research; it also goes beyond these purposes to enable an array of new applications for researchers and research institutions, ranging from identifying untapped innovation potential within an institution to forging new collaboration opportunities between science and industry.</text></passage></document>
<document><id>37878803</id><passage><infon key="journal">Eur J Cardiothorac Surg;2023Oct25. doi:10.1093/ejcts/ezad352</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Keeling WB, Binongo J, Wei J, Leshnower B, Farrington W, Halkos ME, </infon><offset>0</offset><text>National Trends in Emergency Coronary Artery Bypass Grafting.</text></passage><passage><infon key="type">abstract</infon><offset>62</offset><text>BACKGROUND: Emergency CABG is often omitted from current research, and volumes as well as outcomes are unknown. The purpose of this research is to examine national trends in emergency CABG. METHODS: The STS national adult cardiac surgical database was queried from 2005-2017 for patients who underwent emergency and emergency salvage isolated CABG procedures, and 92607 patients were included for analysis. Generalized linear mixed models were used to assess time trends, taking into account the clustering effect of region. RESULTS: Over the study period, volumes of emergency and emergency salvage CABG declined from 7991 cases/year to 6916 cases/year. Emergency and emergency salvage cases accounted for approximately 4.9% of all CABG procedures performed nationwide in 2005 and 4.1% in 2017. Predicted risk of mortality declined in the entire patient cohort over time from 12% to 8% (p &lt; 0.0001). Rates of important postoperative morbidities also declined including prolonged intubation, re-exploration for haemorrhage, and postoperative pneumonia (p &lt; 0.001). Observed to expected (O/E) mortality rates rose over the study period from 0.81 to 1.06 as overall PROM declined from 9.3% to 7.6%. Emergency salvage CABG rates also declined over the course of the study from 358 cases/year to 323 cases/year. The O/E ratios for mortality increased for emergency salvage CABG during the study from 1.16 to 1.66, and emergency salvage mortality rates averaged 46.5%. CONCLUSIONS: The volume of patients undergoing emergency and emergency salvage CABG in the US has declined. Increases in mortality are largely driven by emergency salvage cases, and the predicted risk of mortality algorithm may not accurately reflect the risk involved for these patients.</text><annotation id="3"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="982" length="25"/><text>postoperative morbidities</text></annotation><annotation id="4"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="1073" length="11"/><text>haemorrhage</text></annotation><annotation id="5"><infon key="identifier">MESH:D011014</infon><infon key="type">Disease</infon><location offset="1090" length="23"/><text>postoperative pneumonia</text></annotation></passage></document>
<document><id>37879154</id><passage><infon key="journal">Atherosclerosis;2023Oct10; 385 117331. doi:10.1016/j.atherosclerosis.2023.117331</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cauwenberghs N, Verheyen A, Sabov&amp;#x10d;ik F, Ntalianis E, Vanassche T, Brguljan J, Kuznetsova T, </infon><offset>0</offset><text>Serum proteomic profiling of carotid arteriopathy: A population outcome study.</text><annotation id="1"><infon key="identifier">MESH:D020212</infon><infon key="type">Disease</infon><location offset="29" length="20"/><text>carotid arteriopathy</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>BACKGROUND AND AIMS: Circulating proteins reflecting subclinical vascular disease may improve prediction of atherosclerotic cardiovascular disease (ASCVD). We applied feature selection and unsupervised clustering on proteomic data to identify proteins associated with carotid arteriopathy and construct a protein-based classifier for ASCVD event prediction. METHODS: 491 community-dwelling participants (mean age, 58 +- 11 years; 51 % women) underwent carotid ultrasonography and proteomic profiling (CVD II panel, Olink Proteomics). ASCVD outcome was collected (median follow-up time: 10.2 years). We applied partial least squares (PLS) to identify proteins linked to carotid intima-media thickness (cIMT). Next, we assessed the association between future ASCVD events and protein-based phenogroups derived by unsupervised clustering (Gaussian Mixture modelling) based on proteins selected in PLS. RESULTS: PLS identified 19 proteins as important, which were all associated with cIMT in multivariable-adjusted linear regression. 8 of the 19 proteins were excluded from the clustering analysis because of high collinearity. Based on the 11 remaining proteins, the clustering algorithm subdivided the cohort into two phenogroups. Compared to the first phenogroup (n = 177), participants in the second phenogroup (n = 314) presented: i) a more unfavorable lipid profile with higher total cholesterol and triglycerides and lower HDL cholesterol (p &lt;= 0.014); ii) higher cIMT (p = 0.0020); and iii) a significantly higher risk for future ASCVD events (multivariable-adjusted hazard ratio (95 % CI) versus phenogroup 1: 2.05 (1.26-3.52); p = 0.0093). The protein-based phenogrouping supplemented ACC/AHA 10-year ASCVD risk scoring for prediction of a first ASCVD event. CONCLUSIONS: Focused protein-based phenogrouping identified individuals at high risk for future ASCVD and may complement current risk stratification strategies.</text><annotation id="18"><infon key="identifier">MESH:D014652</infon><infon key="type">Disease</infon><location offset="144" length="16"/><text>vascular disease</text></annotation><annotation id="19"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="187" length="38"/><text>atherosclerotic cardiovascular disease</text></annotation><annotation id="20"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="227" length="5"/><text>ASCVD</text></annotation><annotation id="21"><infon key="identifier">MESH:D020212</infon><infon key="type">Disease</infon><location offset="347" length="20"/><text>carotid arteriopathy</text></annotation><annotation id="22"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="413" length="5"/><text>ASCVD</text></annotation><annotation id="23"><infon key="type">Disease</infon><location offset="580" length="3"/><text>CVD</text></annotation><annotation id="24"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="613" length="5"/><text>ASCVD</text></annotation><annotation id="25"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="836" length="5"/><text>ASCVD</text></annotation><annotation id="26"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1433" length="5"/><text>lipid</text></annotation><annotation id="27"><infon key="identifier">MESH:D002784</infon><infon key="type">Chemical</infon><location offset="1465" length="11"/><text>cholesterol</text></annotation><annotation id="28"><infon key="identifier">MESH:D014280</infon><infon key="type">Chemical</infon><location offset="1481" length="13"/><text>triglycerides</text></annotation><annotation id="29"><infon key="identifier">MESH:D002784</infon><infon key="type">Chemical</infon><location offset="1509" length="11"/><text>cholesterol</text></annotation><annotation id="30"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1613" length="5"/><text>ASCVD</text></annotation><annotation id="31"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1786" length="5"/><text>ASCVD</text></annotation><annotation id="32"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1831" length="5"/><text>ASCVD</text></annotation><annotation id="33"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1940" length="5"/><text>ASCVD</text></annotation></passage><relation id="R1"><infon key="score">0.7563</infon><infon key="role1">Chemical|MESH:D014280</infon><infon key="role2">Disease|MESH:D050197</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="11,13"/></relation></document>
<document><id>37879506</id><passage><infon key="journal">J Ethnopharmacol;2023Oct23; 319 (Pt 3) 117346. doi:10.1016/j.jep.2023.117346</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liu YC, Wang JW, Li J, Guo Y, Han FJ, Lu WH, Wu Q, </infon><offset>0</offset><text>Mechanism of cryptotanshinone to improve endocrine and metabolic functions in the endometrium of PCOS rats.</text><annotation id="2"><infon key="identifier">MESH:C037886</infon><infon key="type">Chemical</infon><location offset="13" length="16"/><text>cryptotanshinone</text></annotation><annotation id="3"><infon key="identifier">MESH:D011085</infon><infon key="type">Disease</infon><location offset="97" length="4"/><text>PCOS</text></annotation></passage><passage><infon key="type">abstract</infon><offset>108</offset><text>ETHNOPHARMACOLOGICAL RELEVANCE: Cryptotanshinone is the main bioactive component of Salvia miltiorrhiza, with various mechanisms of action, including antioxidant, anti-inflammatory, cardiovascular protection, neuroprotection, and hepatoprotection. Salvia miltiorrhiza is used clinically by gynecologists in China. AIM OF THE STUDY: Polycystic ovary syndrome (PCOS) has a significant impact on women's quality of life, leading to infertility and reproductive disorders. Hence, this study aims to assess the pharmacological activity of cryptotanshinone in the treatment of PCOS and investigate its therapeutic mechanism. MATERIALS AND METHODS: Human chorionic gonadotropin (HCG) combined with insulin is used to simulate a PCOS-like rat model and attempt to discover the abnormal changes that occur and the means by which the pathway acts in this model. RESULTS: The transcriptome sequencing method is used to identify 292 differential genes that undergo significant changes, of which 219 were upregulated and 73 were downregulated. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of the signaling pathways reveals that differential expressed genes are significantly enriched in 23 typical pathways. Estrogen signaling pathways are screened in the cryptotanshinone and model groups, and significant differential changes in Fos, ALOX12, and AQP8 are found. This suggests that these signaling pathways and molecules may be the main signaling targets for regulating the differences in endometrial tissue. CONCLUSION: These results indicate that cryptotanshinone has targets for regulating the proliferation of endometrial tissue via estrogen signaling pathways in PCOS-like rats, providing an experimental basis for the clinical application of cryptotanshinone in the treatment of PCOS.</text><annotation id="21"><infon key="identifier">MESH:C037886</infon><infon key="type">Chemical</infon><location offset="140" length="16"/><text>Cryptotanshinone</text></annotation><annotation id="22"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="276" length="12"/><text>inflammatory</text></annotation><annotation id="23"><infon key="identifier">MESH:D011085</infon><infon key="type">Disease</infon><location offset="440" length="25"/><text>Polycystic ovary syndrome</text></annotation><annotation id="24"><infon key="identifier">MESH:D011085</infon><infon key="type">Disease</infon><location offset="467" length="4"/><text>PCOS</text></annotation><annotation id="25"><infon key="identifier">MESH:D007246</infon><infon key="type">Disease</infon><location offset="537" length="11"/><text>infertility</text></annotation><annotation id="26"><infon key="identifier">MESH:D060737</infon><infon key="type">Disease</infon><location offset="553" length="22"/><text>reproductive disorders</text></annotation><annotation id="27"><infon key="identifier">MESH:C037886</infon><infon key="type">Chemical</infon><location offset="642" length="16"/><text>cryptotanshinone</text></annotation><annotation id="28"><infon key="identifier">MESH:D011085</infon><infon key="type">Disease</infon><location offset="679" length="4"/><text>PCOS</text></annotation><annotation id="29"><infon key="identifier">MESH:D011085</infon><infon key="type">Disease</infon><location offset="829" length="4"/><text>PCOS</text></annotation><annotation id="30"><infon key="identifier">MESH:C037886</infon><infon key="type">Chemical</infon><location offset="1373" length="16"/><text>cryptotanshinone</text></annotation><annotation id="31"><infon key="identifier">314322</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3844</infon><location offset="1448" length="3"/><text>Fos</text></annotation><annotation id="32"><infon key="identifier">287454</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">560</infon><location offset="1453" length="6"/><text>ALOX12</text></annotation><annotation id="33"><infon key="identifier">29172</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68166</infon><location offset="1465" length="4"/><text>AQP8</text></annotation><annotation id="34"><infon key="identifier">MESH:C037886</infon><infon key="type">Chemical</infon><location offset="1667" length="16"/><text>cryptotanshinone</text></annotation><annotation id="35"><infon key="identifier">MESH:D011085</infon><infon key="type">Disease</infon><location offset="1786" length="4"/><text>PCOS</text></annotation><annotation id="36"><infon key="identifier">MESH:C037886</infon><infon key="type">Chemical</infon><location offset="1866" length="16"/><text>cryptotanshinone</text></annotation><annotation id="37"><infon key="identifier">MESH:D011085</infon><infon key="type">Disease</infon><location offset="1903" length="4"/><text>PCOS</text></annotation></passage><relation id="R1"><infon key="score">0.9994</infon><infon key="role1">Chemical|MESH:C037886</infon><infon key="role2">Gene|314322</infon><infon key="type">Association</infon><node refid="0" role="11,12"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:C037886</infon><infon key="role2">Gene|29172</infon><infon key="type">Association</infon><node refid="1" role="11,14"/></relation><relation id="R3"><infon key="score">0.997</infon><infon key="role1">Chemical|MESH:C037886</infon><infon key="role2">Disease|MESH:D011085</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="0,1"/></relation><relation id="R4"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:C037886</infon><infon key="role2">Gene|287454</infon><infon key="type">Association</infon><node refid="3" role="11,13"/></relation><relation id="R5"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:C037886</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="2,3"/></relation></document>
<document><id>37879856</id><passage><infon key="journal">Br J Sports Med;2023Oct25. doi:10.1136/bjsports-2023-107766</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zielinski C, authorship group listed below, </infon><offset>0</offset><text>Time to treat the climate and nature crisis as one indivisible global health emergency.</text></passage><passage><infon key="type">abstract</infon><offset>88</offset></passage></document>
<document><id>37880558</id><passage><infon key="journal">Med Biol Eng Comput;2023Oct25. doi:10.1007/s11517-023-02939-3</infon><infon key="year">2023</infon><infon key="article-id_pmc">3262268</infon><infon key="type">title</infon><infon key="authors">P&amp;#xe9;rez-Pacheco A, Ram&amp;#xed;rez-Chavarr&amp;#xed;a RG, Quispe-Siccha RM, Col&amp;#xed;n-Garc&amp;#xed;a MP, </infon><offset>0</offset><text>Dynamic modeling of photoacoustic sensor data to classify human blood samples.</text></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>The photoacoustic effect is an attractive tool for diagnosis in several biomedical applications. Analyzing photoacoustic signals, however, is challenging to provide qualitative results in an automated way. In this work, we introduce a dynamic modeling scheme of photoacoustic sensor data to classify blood samples according to their physiological status. Thirty-five whole human blood samples were studied with a state-space model estimated by a subspace method. Furthermore, the samples are classified using the model parameters and the linear discriminant analysis algorithm. The classification performance is compared with time- and frequency-domain features and an autoregressive-moving-average model. As a result, the proposed analysis can predict five blood classes: healthy women and men, microcytic and macrocytic anemia, and leukemia. Our findings indicate that the proposed method outperforms conventional signal processing techniques to analyze photoacoustic data for medical diagnosis. Hence, the method is a promising tool in point-of-care devices to detect hematological diseases in clinical scenarios.</text><annotation id="3"><infon key="identifier">MESH:D000748</infon><infon key="type">Disease</infon><location offset="875" length="32"/><text>microcytic and macrocytic anemia</text></annotation><annotation id="4"><infon key="identifier">MESH:D007938</infon><infon key="type">Disease</infon><location offset="913" length="8"/><text>leukemia</text></annotation><annotation id="5"><infon key="identifier">MESH:D006402</infon><infon key="type">Disease</infon><location offset="1150" length="22"/><text>hematological diseases</text></annotation></passage></document>
<document><id>37880908</id><passage><infon key="journal">Colorectal Dis;2023Oct25. doi:10.1111/codi.16771</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">MacLeod C, Foxton A, Wilson P, Treweek S, Watson AJM, </infon><offset>0</offset><text>Associations between patient factors and successful colon capsule endoscopy - A prospective cohort study.</text></passage><passage><infon key="type">abstract</infon><offset>106</offset><text>AIM: To establish patient factors associated with a successful colon capsule endoscopy (CCE) test. METHOD: This prospective cohort study used data collected from patients who underwent CCE as part of the ScotCap evaluation prior to April 2020. A CCE was defined as successful if the capsule visualized the whole colon and rectum (complete test) with sufficient bowel cleansing to permit assessment of the colonic mucosa (adequate bowel preparation). Factors from patients in symptomatic and surveillance groups were analysed for associations with a successful test, complete test, adequate bowel preparation and requirement for further procedure using univariate, multivariate logistic, least absolute shrinkage and selection operator regression. RESULTS: Data from 263 symptomatic and 137 surveillance patients were analysed. There was an association between a symptomatic patient's age and a successful test (OR = 0.97, 95% CI: 0.95-0.99), adequate bowel preparation (OR = 0.97, 95% CI: 0.94-1.00) and further procedure requirement (OR = 1.04, 95% CI: 1.02-1.06). An association was found, for symptomatic patients, between a faecal immunochemical test result in the range 10-399 mug/g and a further procedure (OR = 2.32, 95% CI: 1.23-4.48). In patients undergoing surveillance for previous colorectal cancer (OR = 0.42, 95% CI: 0.18-0.97), had previous bowel resection surgery (OR = 0.43, 95% CI: 0.19-0.98) or took a beta blocker medication (OR = 0.32, 95% CI: 0.11-0.88), an association was found with further procedure requirement. CONCLUSIONS: Among symptomatic patients, younger age was associated with obtaining a successful CCE test. Clinicians could consider patient selection based on these results to improve the rate of successful testing in clinical practice.</text><annotation id="1"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="1399" length="17"/><text>colorectal cancer</text></annotation></passage></document>
<document><id>37881960</id><passage><infon key="journal">Chin Med J (Engl);2023Oct25. doi:10.1097/CM9.0000000000002879</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wan Z, Dai B, Zhu X, Huang Y, Zhu B, </infon><offset>0</offset><text>HIV-associated dyslipidemia: Pathogenesis and its management.</text><annotation id="2"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="0" length="4"/><text>HIV-</text></annotation><annotation id="3"><infon key="identifier">MESH:D050171</infon><infon key="type">Disease</infon><location offset="15" length="12"/><text>dyslipidemia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>62</offset></passage></document>
<document><id>37882381</id><passage><infon key="journal">Am J Nurs;2023Nov01; 123 (11) 9. doi:10.1097/01.NAJ.0000995276.03176.f0</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lundgren BS, </infon><offset>0</offset><text>Assessing Movement-Evoked Pain.</text><annotation id="1"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="26" length="4"/><text>Pain</text></annotation></passage><passage><infon key="type">abstract</infon><offset>32</offset></passage></document>
<document><id>37882742</id><passage><infon key="journal">Bioinformatics;2023Oct26. doi:10.1093/bioinformatics/btad656</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rohde PD, Fourie S&amp;#xf8;rensen I, S&amp;#xf8;rensen P, </infon><offset>0</offset><text>Expanded utility of the R package, qgg, with applications within genomic medicine.</text></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>SUMMARY: Here we present an expanded utility of the R package qgg for genetic analyses of complex traits and diseases. One of the major updates of the package is, that it now includes Bayesian Linear Regression (BLR) modeling procedures, which provide a unified framework for mapping of genetic variants, estimation of heritability and genomic prediction from either individual level data or from genome-wide association study (GWAS) summary data. With this release, the qgg package now provides a wealth of the commonly used methods in analysis of complex traits and diseases, without the need to switch between software and data formats. AVAILABILITY AND IMPLEMENTATION: The methodologies are implemented in the publicly available R software package, qgg, using fast and memory efficient algorithms in C ++ and is available on CRAN or as a developer version at our GitHub page (https://github.com/psoerensen/qgg). Notes on the implemented statistical genetic models, tutorials and example scripts are available at our GitHub page https://psoerensen.github.io/qgg/.</text></passage></document>
<document><id>37883821</id><passage><infon key="journal">Cognition;2023Oct24; 242 105635. doi:10.1016/j.cognition.2023.105635</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Barthel M, Tomasello R, Liu M, </infon><offset>0</offset><text>Conditionals in context: Brain signatures of prediction in discourse processing.</text></passage><passage><infon key="type">abstract</infon><offset>81</offset><text>Comprehenders are known to generate expectations about upcoming linguistic input at the sentence and discourse level. However, most previous studies on prediction focused mainly on word-induced brain activity rather than examining neural activity preceding a critical stimulus in discourse processing, where prediction actually takes place. In this EEG study, participants were presented with multiple sentences resembling a discourse including conditional sentences with either only if or if, which are characterized by different semantics, triggering stronger or weaker predictions about the possible continuation of the presented discourses, respectively. Results revealed that discourses including only if, as compared to discourses with bare if, triggered an increased predictive neural activity before the expected critical word, resembling the readiness potential. Moreover, word-induced P300 brain responses were found to be enhanced by unpredictable discourse continuations and reduced in predictable discourse continuations. Intriguingly, brain responses preceding and following the critical word were found to be correlated, which yields evidence for predictive activity modulating word-induced processing on the discourse level. These findings shed light on the predictive nature of neural processes at the discourse level, critically advancing our understanding of the functional interconnection between discourse understanding and prediction processes in brain and mind.</text></passage></document>
<document><id>37884174</id><passage><infon key="journal">Top Companion Anim Med;2023Oct24 100826. doi:10.1016/j.tcam.2023.100826</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Almeida KC, Pinto-Ferreira F, Navarro IT, Souza KL, Balbino LS, Bernardes JC, Bahia Dos Santos DL, Falbo MK, </infon><offset>0</offset><text>Occurrence of zoonotic enteric parasites in fecal samples from dogs in shelters, parks, squares and public roads, and the dog guardians' perception of zoonoses as for the risk to public health in the city of Guarapuava, Parana, Brazil.</text><annotation id="2"><infon key="identifier">MESH:D004751</infon><infon key="type">Disease</infon><location offset="23" length="17"/><text>enteric parasites</text></annotation><annotation id="3"><infon key="identifier">MESH:D015047</infon><infon key="type">Disease</infon><location offset="151" length="8"/><text>zoonoses</text></annotation></passage><passage><infon key="type">abstract</infon><offset>236</offset><text>The aim of this study was to determine the occurrence of zoonotic enteroparasites in the feces of dogs from public shelters, squares, parks, and public roads in the city of Guarapuava, Parana, Brazil, and to evaluate the perception of dog guardians regarding zoonoses and their risk to public health. Fecal samples were collected, coproparasitological examinations were performed to detect zoonotic enteroparasites, and polymerase chain reaction (PCR) was used to identify Giardia spp. and Cryptosporidium spp. Questionnaires were given to guardians who walked their dogs in parks, squares, and public roads, as to assess their perception of zoonoses. A total of 333 samples were collected, of these 75, 123, and 135 of them were from public shelters, squares and parks, and public roads, respectively. One or more parasites were identified in 166 (50%) samples, of which 58/75 (77%) were from public shelters, 50/123 (41%) from squares and parks, and 58/135 (43%) from public roads. The parasites detected included Ancylostoma spp., Giardia spp., Trichuris spp., Toxocara spp., and Cystoisospora spp., with Ancylostoma spp. having the highest occurrence. PCR was performed on 161 samples for convenience due to financial limitations, because only a portion of the study was funded by the municipal government, of which 15.6% were positive for Giardia spp., and all were negative for Cryptosporidium spp. In total, 246 guardians were interviewed, of which 36% said they did not collect their animals' feces during walks, 20% did not use anti-helminthics on their dogs, and 23% did not know which diseases could be transmitted by feces. Therefore, we conclude that there is a high infection rate of parasites with zoonotic potential in public places, showing the need to raise awareness among guardians about the diseases transmitted by dog feces, correct vermifugation and the importance of collecting feces in public places.</text><annotation id="8"><infon key="identifier">MESH:D015047</infon><infon key="type">Disease</infon><location offset="495" length="8"/><text>zoonoses</text></annotation><annotation id="9"><infon key="identifier">MESH:D015047</infon><infon key="type">Disease</infon><location offset="878" length="8"/><text>zoonoses</text></annotation><annotation id="10"><infon key="identifier">MESH:D014257</infon><infon key="type">Disease</infon><location offset="1284" length="9"/><text>Trichuris</text></annotation><annotation id="11"><infon key="identifier">MESH:C538433</infon><infon key="type">Disease</infon><location offset="1344" length="15"/><text>Ancylostoma spp</text></annotation></passage></document>
<document><id>37885938</id><passage><infon key="journal">Indian J Thorac Cardiovasc Surg;2023Nov; 39 (6) 626. doi:10.1007/s12055-023-01550-3</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10597970</infon><infon key="type">title</infon><infon key="authors">Patel R, Katewa A, Haranal M, Saxena S, Patel P, Patel K, </infon><offset>0</offset><text>Double outlet left atrium: successful management of a rare entity.</text><annotation id="1"><infon key="identifier">MESH:D003310</infon><infon key="type">Disease</infon><location offset="0" length="25"/><text>Double outlet left atrium</text></annotation></passage><passage><infon key="type">abstract</infon><offset>67</offset><text>Double-outlet left atrium is an extremely rare congenital ventriculo-atrial mal-alignment anomaly, wherein, the left atrium drains into both ventricles, through either a common atrioventricular valve or two separate atrioventricular valves. The only egress from the right atrium is through an inter-atrial communication. We present a 16-month-old male, diagnosed to have double outlet left atrium and describe its surgical management.</text><annotation id="5"><infon key="identifier">MESH:D003310</infon><infon key="type">Disease</infon><location offset="67" length="25"/><text>Double-outlet left atrium</text></annotation><annotation id="6"><infon key="identifier">MESH:C535326</infon><infon key="type">Disease</infon><location offset="125" length="39"/><text>ventriculo-atrial mal-alignment anomaly</text></annotation><annotation id="7"><infon key="identifier">MESH:D003310</infon><infon key="type">Disease</infon><location offset="438" length="25"/><text>double outlet left atrium</text></annotation></passage></document>
<document><id>37886288</id><passage><infon key="journal">Med Sci Educ;2023Oct; 33 (5) 1215. doi:10.1007/s40670-023-01882-0</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10597941</infon><infon key="type">title</infon><infon key="authors">Gilkar SA, Jaan I, Arawa S, Nyiem MP, Bashir M, </infon><offset>0</offset><text>Buzz Session as an Active Learning Method in Medical Undergraduate Physiology Teaching-An Institutional-Based Study.</text></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>Background: In the current era of medical teaching, multiple active teaching-learning strategies are being explored due to drawbacks of conventional didactic learning methodology which are applicable to a typical classroom setting. Our attempt was to introduce short interactive buzz sessions in the midst of a lecture and assess the perception of students and faculty towards the use of these buzz sessions as an active learning method in physiology. Aim and Objectives: To introduce buzz sessions as a teaching-learning tool in undergraduate medical teaching and to assess the student and faculty perception of this teaching method. Methodology: This prospective, non-randomized, interventional study was carried out in the Department of Physiology, GMC Srinagar. The participants were 180 students of MBBS 1st Phase and 08 faculty members of the Physiology Department. Both the students and faculty were sensitized about the buzz sessions. Ten lectures of 1 h each were chosen from the Endocrine System, and taught by incorporating the buzz session in the lecture. The study was approved by the Institutional Ethical Committee. Results: Both the students and the faculty favoured incorporating buzz sessions during the lectures as this teaching method makes the class interesting and interactive and helps to enhance communication, reasoning skills, and collaborative learning among the students. Conclusions: The study concludes that learning physiology using buzz sessions is liked and preferred by both students and faculty, and hence the need for buzz sessions in current medical teaching.</text></passage></document>
<document><id>37889090</id><passage><infon key="journal">Cell Adh Migr;2023Dec; 17 (1) 1. doi:10.1080/19336918.2023.2271260</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Guan L, Fan P, Wang Y, Liu X, Liu R, Ma W, Bai H, </infon><offset>0</offset><text>Lymphangiogenic responses of lymphatic endothelial cells to steady direct-current electric fields.</text></passage><passage><infon key="type">abstract</infon><offset>99</offset><text>Lymphangiogenesis plays pivotal roles in diverse physiological and pathological conditions. Steady direct-current electric fields (DC EFs) induce vascular endothelial behaviors related to angiogenesis have been observed. This study investigated the effects of DC EFs on the lymphangiogenic response of lymphatic endothelial cells (LECs). We demonstrated that EFs stimulation induced directional migration, reorientation, and elongation of human LECs in culture. These lymphangiogenic responses required VEGF receptor 3 (VEGFR-3) activation and were mediated through the PI3K-Akt, Erk1/2, and p38 MAPK signaling pathways in relation to the reorganization of the actin cytoskeleton. Our results indicate that endogenous EFs may play a role in lymphangiogenesis in vivo, and VEGFR-3 signaling activation may be involved in the cellular function of LECs driven by EFs.</text><annotation id="10"><infon key="identifier">10278</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4284</infon><location offset="233" length="3"/><text>EFs</text></annotation><annotation id="11"><infon key="identifier">10278</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4284</infon><location offset="362" length="3"/><text>EFs</text></annotation><annotation id="12"><infon key="identifier">10278</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4284</infon><location offset="458" length="3"/><text>EFs</text></annotation><annotation id="13"><infon key="identifier">2324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7321</infon><location offset="602" length="15"/><text>VEGF receptor 3</text></annotation><annotation id="14"><infon key="identifier">2324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7321</infon><location offset="619" length="7"/><text>VEGFR-3</text></annotation><annotation id="15"><infon key="identifier">207</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3785</infon><location offset="674" length="3"/><text>Akt</text></annotation><annotation id="16"><infon key="identifier">5595;5594</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55682;37670</infon><location offset="679" length="6"/><text>Erk1/2</text></annotation><annotation id="17"><infon key="identifier">10278</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4284</infon><location offset="817" length="3"/><text>EFs</text></annotation><annotation id="18"><infon key="identifier">2324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7321</infon><location offset="871" length="7"/><text>VEGFR-3</text></annotation><annotation id="19"><infon key="identifier">10278</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4284</infon><location offset="959" length="3"/><text>EFs</text></annotation></passage><relation id="R1"><infon key="score">0.9926</infon><infon key="role1">Gene|10278</infon><infon key="role2">Gene|2324</infon><infon key="type">Association</infon><node refid="0" role="8,9"/></relation></document>
<document><id>37889441</id><passage><infon key="journal">J Neurooncol;2023Oct27. doi:10.1007/s11060-023-04466-5</infon><infon key="year">2023</infon><infon key="article-id_pmc">5560102</infon><infon key="type">title</infon><infon key="authors">Crompton D, Koffler D, Fekrmandi F, Lehrer EJ, Sheehan JP, Trifiletti DM, </infon><offset>0</offset><text>Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors.</text><annotation id="1"><infon key="identifier">MESH:D001932</infon><infon key="type">Disease</infon><location offset="77" length="12"/><text>brain tumors</text></annotation></passage><passage><infon key="type">abstract</infon><offset>91</offset><text>PURPOSE: Stereotactic radiosurgery (SRS) is a method of delivering conformal radiation, which allows minimal radiation damage to surrounding healthy tissues. Adjuvant radiation therapy has been shown to improve local control in a variety of intracranial neoplasms, such as brain metastases, gliomas, and benign tumors (i.e., meningioma, vestibular schwannoma, etc.). For brain metastases, adjuvant SRS specifically has demonstrated positive oncologic outcomes as well as preserving cognitive function when compared to conventional whole brain radiation therapy. However, as compared with neoadjuvant SRS, larger post-operative volumes and greater target volume uncertainty may come with an increased risk of local failure and treatment-related complications, such as radiation necrosis. In addition to its role in brain metastases, neoadjuvant SRS for high grade gliomas may enable dose escalation and increase immunogenic effects and serve a purpose in benign tumors for which one cannot achieve a gross total resection (GTR). Finally, although neoadjuvant SRS has historically been delivered with photon therapy, there are high LET radiation modalities such as carbon-ion therapy which may allow radiation damage to tissue and should be further studied if done in the neoadjuvant setting. In this review we discuss the evolving role of neoadjuvant radiosurgery in the treatment for brain metastases, gliomas, and benign etiologies. We also offer perspective on the evolving role of high LET radiation such as carbon-ion therapy. METHODS: PubMed was systemically reviewed using the search terms "neoadjuvant radiosurgery", "brain metastasis", and "glioma". ' Clinicaltrials.gov ' was also reviewed to include ongoing phase III trials. RESULTS: This comprehensive review describes the evolving role for neoadjuvant SRS in the treatment for brain metastases, gliomas, and benign etiologies. We also discuss the potential role for high LET radiation in this setting such as carbon-ion radiotherapy. CONCLUSION: Early clinical data is very promising for neoadjuvant SRS in the setting of brain metastases. There are three ongoing phase III trials that will be more definitive in evaluating the potential benefits. While there is less data available for neoadjuvant SRS for gliomas, there remains a potential role, particularly to enable dose escalation and increase immunogenic effects.</text><annotation id="24"><infon key="identifier">MESH:D001932</infon><infon key="type">Disease</infon><location offset="332" length="22"/><text>intracranial neoplasms</text></annotation><annotation id="25"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="370" length="10"/><text>metastases</text></annotation><annotation id="26"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="382" length="7"/><text>gliomas</text></annotation><annotation id="27"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="395" length="13"/><text>benign tumors</text></annotation><annotation id="28"><infon key="identifier">MESH:D008579</infon><infon key="type">Disease</infon><location offset="416" length="10"/><text>meningioma</text></annotation><annotation id="29"><infon key="identifier">MESH:D009464</infon><infon key="type">Disease</infon><location offset="428" length="21"/><text>vestibular schwannoma</text></annotation><annotation id="30"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="468" length="10"/><text>metastases</text></annotation><annotation id="31"><infon key="identifier">MESH:D011832</infon><infon key="type">Disease</infon><location offset="858" length="18"/><text>radiation necrosis</text></annotation><annotation id="32"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="911" length="10"/><text>metastases</text></annotation><annotation id="33"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="954" length="7"/><text>gliomas</text></annotation><annotation id="34"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1045" length="13"/><text>benign tumors</text></annotation><annotation id="35"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1254" length="6"/><text>carbon</text></annotation><annotation id="36"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="1481" length="10"/><text>metastases</text></annotation><annotation id="37"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="1493" length="7"/><text>gliomas</text></annotation><annotation id="38"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1602" length="6"/><text>carbon</text></annotation><annotation id="39"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="1716" length="16"/><text>brain metastasis</text></annotation><annotation id="40"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="1740" length="6"/><text>glioma</text></annotation><annotation id="41"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="1937" length="10"/><text>metastases</text></annotation><annotation id="42"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="1949" length="7"/><text>gliomas</text></annotation><annotation id="43"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="2063" length="6"/><text>carbon</text></annotation><annotation id="44"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="2182" length="10"/><text>metastases</text></annotation><annotation id="45"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="2361" length="7"/><text>gliomas</text></annotation></passage></document>
<document><id>37890115</id><passage><infon key="journal">Photobiomodul Photomed Laser Surg;2023Oct27. doi:10.1089/photob.2023.0021</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Agbele AT, Dehpour AR, Jafari RM, Mahdavi SRM, Elyasi A, Seyedi M, Bagheri M, Ala M, Roudsari BA, Hejazi SM, </infon><offset>0</offset><text>Development and Application of Prototype System Based on Light-Emitting Diode Arrays (660 nm) with a Top Hat Beam Profile in Order to Optimize Photobiomodulation Protocols for Treatment of Radiation-Induced Oral Mucositis in Rats.</text><annotation id="1"><infon key="identifier">MESH:D013280</infon><infon key="type">Disease</infon><location offset="207" length="14"/><text>Oral Mucositis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>231</offset><text>Background: Oral mucositis (OM) is a common adverse effect of radiation to the head and neck. Recent research has shown that extra oral photobiomodulation (EO-PBM) reduces the severity of OM. However, appropriate EO-PBM therapy parameters for OM severity reduction have not been documented. Objective: This work aims to optimize EO-PBM radiation parameters for lowering the severity of radiation-induced OM in rats by establishing a photobiomodulation (PBM) treatment system based on light-emitting diode arrays with top-hat beam profile. Methods: The 36 rats are separated into 2 control groups and 4 groups receiving PBM treatment. The PBM groups are exposed to irradiance between 4 and 24 J/cm2 at 660 nm. The cheek pouch mucosa is removed after scarification for biochemical and histological examination. Student's t-test, and one-way analysis of variance (ANOVA) followed by Tukey's Multiple were applied to compare the statistical significance of differences between control groups and PBM treatment groups. Results: Statistical analysis reveals that PBM irradiation at 12 J/cm2 (200 sec) with a flatness of 0.8 and a diameter of 3 cm substantially decreased the level of inflammatory cytokines compared with the positive control group. Conclusion: Our results indicate that the designed treatment PBM system is capable of delivering the optical parameters necessary for therapeutic treatment.</text><annotation id="10"><infon key="identifier">MESH:D013280</infon><infon key="type">Disease</infon><location offset="243" length="14"/><text>Oral mucositis</text></annotation><annotation id="11"><infon key="identifier">MESH:D013280</infon><infon key="type">Disease</infon><location offset="259" length="2"/><text>OM</text></annotation><annotation id="12"><infon key="identifier">MESH:D065606</infon><infon key="type">Disease</infon><location offset="283" length="6"/><text>effect</text></annotation><annotation id="13"><infon key="identifier">MESH:D006258</infon><infon key="type">Disease</infon><location offset="293" length="30"/><text>radiation to the head and neck</text></annotation><annotation id="14"><infon key="identifier">MESH:D013280</infon><infon key="type">Disease</infon><location offset="419" length="2"/><text>OM</text></annotation><annotation id="15"><infon key="identifier">MESH:D013280</infon><infon key="type">Disease</infon><location offset="474" length="2"/><text>OM</text></annotation><annotation id="16"><infon key="identifier">MESH:D013280</infon><infon key="type">Disease</infon><location offset="635" length="2"/><text>OM</text></annotation><annotation id="17"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1409" length="12"/><text>inflammatory</text></annotation></passage></document>
<document><id>37890465</id><passage><infon key="journal">Adv Sci (Weinh);2023Oct27 2303799. doi:10.1002/advs.202303799</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liu F, Liu Z, Cheng W, Zhao Q, Zhang X, Zhang H, Yu M, Xu H, Gao Y, Jiang Q, Shi G, Wang L, Gu S, Wang J, Cao N, Chen Z, </infon><offset>0</offset><text>The PERK Branch of the Unfolded Protein Response Safeguards Protein Homeostasis and Mesendoderm Specification of Human Pluripotent Stem Cells.</text><annotation id="1"><infon key="identifier">9451</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3557</infon><location offset="4" length="4"/><text>PERK</text></annotation></passage><passage><infon key="type">abstract</infon><offset>143</offset><text>Cardiac development involves large-scale rearrangements of the proteome. How the developing cardiac cells maintain the integrity of the proteome during the rapid lineage transition remains unclear. Here it is shown that proteotoxic stress visualized by the misfolded and/or aggregated proteins appears during early cardiac differentiation of human pluripotent stem cells and is resolved by activation of the PERK branch of unfolded protein response (UPR). PERK depletion increases misfolded and/or aggregated protein accumulation, leading to pluripotency exit defect and impaired mesendoderm specification of human pluripotent stem cells. Mechanistically, it is found that PERK safeguards mesendoderm specification through its conserved downstream effector ATF4, which subsequently activates a novel transcriptional target WARS1, to cope with the differentiation-induced proteotoxic stress. The results indicate that protein quality control represents a previously unrecognized core component of the cardiogenic regulatory network. Broadly, these findings provide a framework for understanding how UPR is integrated into the developmental program by activating the PERK-ATF4-WARS1 axis.</text><annotation id="8"><infon key="identifier">9451</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3557</infon><location offset="551" length="4"/><text>PERK</text></annotation><annotation id="9"><infon key="identifier">9451</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3557</infon><location offset="599" length="4"/><text>PERK</text></annotation><annotation id="10"><infon key="identifier">9451</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3557</infon><location offset="816" length="4"/><text>PERK</text></annotation><annotation id="11"><infon key="identifier">468</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1266</infon><location offset="900" length="4"/><text>ATF4</text></annotation><annotation id="12"><infon key="identifier">9451</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3557</infon><location offset="1308" length="4"/><text>PERK</text></annotation><annotation id="13"><infon key="identifier">468</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1266</infon><location offset="1313" length="4"/><text>ATF4</text></annotation></passage><relation id="R1"><infon key="score">0.879</infon><infon key="role1">Gene|468</infon><infon key="role2">Gene|9451</infon><infon key="type">Association</infon><node refid="0" role="4,3"/></relation></document>
<document><id>37890815</id><passage><infon key="journal">Acta Biomater;2023Oct25. doi:10.1016/j.actbio.2023.10.024</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yao Z, Qi C, Zhang F, Yao H, Wang C, Cao X, Zhao C, Wang Z, Qi M, Yao C, Wang X, Xia H, </infon><offset>0</offset><text>Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.</text><annotation id="3"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="7" length="7"/><text>Cu2MoS4</text></annotation><annotation id="4"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="82" length="5"/><text>tumor</text></annotation><annotation id="5"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="134" length="17"/><text>pancreatic cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>153</offset><text>Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease that responds poorly to single-drug immunotherapy with PD-L1 (CD274) inhibitors. Here, we prepared mesoporous nanomaterials Cu2MoS4 (CMS)/PEG loaded with PD-L1 inhibitor BMS-1 and CXCR4 inhibitor Plerixafor to form the nanodrug CMS/PEG-B-P. In vitro experiments, CMS/PEG-B-P have a more substantial inhibitory effect on the expression of PD-L1 and CXCR4 as well as to promote the apoptosis of pancreatic cancer cells KPC and suppressed KPC cell proliferation were detected by flow cytometry, qPCR and Western blotting (WB). Promotes the release of the cytotoxic substance reactive oxygen species (ROS) and the production of the immunogenic cell death (ICD) marker calreticulin (CRT) in KPC cells. CMS/PEG-B-P was also detected to have a certain activating effect on mouse immune cells, dendritic cells (mDC) and macrophage RAW264.7. Subcutaneous tumorigenicity experiments in C57BL/6 mice verified that CMS/PEG-B-P had an inhibitory effect on the growth of tumors and remodeling of the tumor immune microenvironment, including infiltration of CD4+ and CD8+ T cells and polarization of macrophages, as well as reduction of immunosuppressive cells. Meanwhile, CMS/PEG-B-P was found to have different effects on the release of cytokines in the tumor immune microenvironment, including The levels of immunostimulatory cytokines INF-gamma and IL-12 are increased and the levels of immunosuppressive cytokines IL-6, IL-10 and IFN-alpha are decreased. In conclusion, nanomaterial-loaded immune checkpoint inhibitor therapies can enhance the immune response and reduce side effects, a combination that shows great potential as a new immunotherapeutic approach. STATEMENT OF SIGNIFICANCE: Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease that has a low response to single-drug immunotherapy with PD-L1 (CD274) inhibitors. We preared PEG-modified mesoporous nanomaterials Cu2MoS4 (CMS) loaded with PD-L1 inhibitor BMS-1 and CXCR4 inhibitor Plerixafor to form the nanodrug CMS/PEG-B-P. Our study demonstrated that Nanomaterial-loaded immune checkpoint inhibitor therapies can enhance the immune response and reduce side effects, a combination that shows great potential as a new immunotherapeutic approach.</text><annotation id="57"><infon key="identifier">MESH:D021441</infon><infon key="type">Disease</infon><location offset="153" length="32"/><text>Pancreatic ductal adenocarcinoma</text></annotation><annotation id="58"><infon key="identifier">MESH:D021441</infon><infon key="type">Disease</infon><location offset="187" length="4"/><text>PDAC</text></annotation><annotation id="59"><infon key="identifier">60533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="267" length="5"/><text>PD-L1</text></annotation><annotation id="60"><infon key="identifier">60533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="274" length="5"/><text>CD274</text></annotation><annotation id="61"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="336" length="7"/><text>Cu2MoS4</text></annotation><annotation id="62"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="345" length="3"/><text>CMS</text></annotation><annotation id="63"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="350" length="3"/><text>PEG</text></annotation><annotation id="64"><infon key="identifier">60533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="366" length="5"/><text>PD-L1</text></annotation><annotation id="65"><infon key="identifier">12767</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20739</infon><location offset="392" length="5"/><text>CXCR4</text></annotation><annotation id="66"><infon key="identifier">MESH:C088327</infon><infon key="type">Chemical</infon><location offset="408" length="10"/><text>Plerixafor</text></annotation><annotation id="67"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="440" length="3"/><text>CMS</text></annotation><annotation id="68"><infon key="identifier">MESH:C000716357</infon><infon key="type">Chemical</infon><location offset="444" length="8"/><text>PEG-B-P.</text></annotation><annotation id="69"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="475" length="3"/><text>CMS</text></annotation><annotation id="70"><infon key="identifier">MESH:C000716357</infon><infon key="type">Chemical</infon><location offset="479" length="7"/><text>PEG-B-P</text></annotation><annotation id="71"><infon key="identifier">60533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="550" length="5"/><text>PD-L1</text></annotation><annotation id="72"><infon key="identifier">12767</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20739</infon><location offset="560" length="5"/><text>CXCR4</text></annotation><annotation id="73"><infon key="identifier">MESH:D010190</infon><infon key="type">Disease</infon><location offset="605" length="17"/><text>pancreatic cancer</text></annotation><annotation id="74"><infon key="identifier">MESH:C565455</infon><infon key="type">Disease</infon><location offset="629" length="3"/><text>KPC</text></annotation><annotation id="75"><infon key="identifier">MESH:C565455</infon><infon key="type">Disease</infon><location offset="648" length="3"/><text>KPC</text></annotation><annotation id="76"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="784" length="23"/><text>reactive oxygen species</text></annotation><annotation id="77"><infon key="identifier">MESH:D017382</infon><infon key="type">Chemical</infon><location offset="809" length="3"/><text>ROS</text></annotation><annotation id="78"><infon key="identifier">12317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37911</infon><location offset="876" length="12"/><text>calreticulin</text></annotation><annotation id="79"><infon key="identifier">12317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37911</infon><location offset="890" length="3"/><text>CRT</text></annotation><annotation id="80"><infon key="identifier">CVCL:A9ZK</infon><infon key="type">CellLine</infon><location offset="898" length="3"/><text>KPC</text></annotation><annotation id="81"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="909" length="3"/><text>CMS</text></annotation><annotation id="82"><infon key="identifier">MESH:C000716357</infon><infon key="type">Chemical</infon><location offset="913" length="7"/><text>PEG-B-P</text></annotation><annotation id="83"><infon key="identifier">CVCL:0493</infon><infon key="type">CellLine</infon><location offset="1035" length="8"/><text>RAW264.7</text></annotation><annotation id="84"><infon key="identifier">CVCL:C0MU</infon><infon key="type">CellLine</infon><location offset="1088" length="7"/><text>C57BL/6</text></annotation><annotation id="85"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="1115" length="3"/><text>CMS</text></annotation><annotation id="86"><infon key="identifier">MESH:C000716357</infon><infon key="type">Chemical</infon><location offset="1119" length="7"/><text>PEG-B-P</text></annotation><annotation id="87"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1169" length="6"/><text>tumors</text></annotation><annotation id="88"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1198" length="5"/><text>tumor</text></annotation><annotation id="89"><infon key="identifier">12504</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">513</infon><location offset="1255" length="3"/><text>CD4</text></annotation><annotation id="90"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="1370" length="3"/><text>CMS</text></annotation><annotation id="91"><infon key="identifier">MESH:C000716357</infon><infon key="type">Chemical</infon><location offset="1374" length="7"/><text>PEG-B-P</text></annotation><annotation id="92"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1453" length="5"/><text>tumor</text></annotation><annotation id="93"><infon key="identifier">16193</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">502</infon><location offset="1616" length="4"/><text>IL-6</text></annotation><annotation id="94"><infon key="identifier">16153</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">478</infon><location offset="1622" length="5"/><text>IL-10</text></annotation><annotation id="95"><infon key="identifier">111654</infon><infon key="type">Gene</infon><location offset="1632" length="9"/><text>IFN-alpha</text></annotation><annotation id="96"><infon key="identifier">MESH:D021441</infon><infon key="type">Disease</infon><location offset="1892" length="32"/><text>Pancreatic ductal adenocarcinoma</text></annotation><annotation id="97"><infon key="identifier">MESH:D021441</infon><infon key="type">Disease</infon><location offset="1926" length="4"/><text>PDAC</text></annotation><annotation id="98"><infon key="identifier">60533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="2009" length="5"/><text>PD-L1</text></annotation><annotation id="99"><infon key="identifier">60533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="2016" length="5"/><text>CD274</text></annotation><annotation id="100"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2046" length="3"/><text>PEG</text></annotation><annotation id="101"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="2084" length="7"/><text>Cu2MoS4</text></annotation><annotation id="102"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="2093" length="3"/><text>CMS</text></annotation><annotation id="103"><infon key="identifier">60533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8560</infon><location offset="2110" length="5"/><text>PD-L1</text></annotation><annotation id="104"><infon key="identifier">12767</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20739</infon><location offset="2136" length="5"/><text>CXCR4</text></annotation><annotation id="105"><infon key="identifier">MESH:C088327</infon><infon key="type">Chemical</infon><location offset="2152" length="10"/><text>Plerixafor</text></annotation><annotation id="106"><infon key="identifier">MESH:C000707327</infon><infon key="type">Chemical</infon><location offset="2184" length="3"/><text>CMS</text></annotation><annotation id="107"><infon key="identifier">MESH:C000716357</infon><infon key="type">Chemical</infon><location offset="2188" length="8"/><text>PEG-B-P.</text></annotation></passage><relation id="R1"><infon key="score">0.877</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.9947</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Gene|16193</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="36,39"/></relation><relation id="R3"><infon key="score">0.5579</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Chemical|MESH:C000716357</infon><infon key="type">Cotreatment</infon><node refid="2" role="7,14"/></relation><relation id="R4"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C088327</infon><infon key="role2">Gene|12767</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="12,11"/></relation><relation id="R5"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Gene|12767</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="7,11"/></relation><relation id="R6"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Gene|12767</infon><infon key="type">Negative_Correlation</infon><node refid="5" role="14,11"/></relation><relation id="R7"><infon key="score">0.9971</infon><infon key="role1">Disease|MESH:D010190</infon><infon key="role2">Gene|60533</infon><infon key="type">Association</infon><node refid="6" role="19,17"/></relation><relation id="R8"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="32,33"/></relation><relation id="R9"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Gene|16193</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="37,39"/></relation><relation id="R10"><infon key="score">0.9902</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Gene|12317</infon><infon key="type">Positive_Correlation</infon><node refid="9" role="15,24"/></relation><relation id="R11"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Gene|60533</infon><infon key="type">Negative_Correlation</infon><node refid="10" role="14,10"/></relation><relation id="R12"><infon key="score">0.9956</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Gene|60533</infon><infon key="type">Negative_Correlation</infon><node refid="11" role="7,10"/></relation><relation id="R13"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Gene|16153</infon><infon key="type">Negative_Correlation</infon><node refid="12" role="37,40"/></relation><relation id="R14"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Gene|16153</infon><infon key="type">Negative_Correlation</infon><node refid="13" role="36,40"/></relation><relation id="R15"><infon key="score">0.801</infon><infon key="role1">Disease|MESH:D021441</infon><infon key="role2">Gene|60533</infon><infon key="type">Negative_Correlation</infon><node refid="14" role="3,5"/></relation><relation id="R16"><infon key="score">0.9977</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Chemical|MESH:D017382</infon><infon key="type">Positive_Correlation</infon><node refid="15" role="16,22"/></relation><relation id="R17"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Disease|MESH:C565455</infon><infon key="type">Negative_Correlation</infon><node refid="16" role="15,20"/></relation><relation id="R18"><infon key="score">0.9983</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Gene|12317</infon><infon key="type">Positive_Correlation</infon><node refid="17" role="16,24"/></relation><relation id="R19"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Gene|111654</infon><infon key="type">Negative_Correlation</infon><node refid="18" role="36,41"/></relation><relation id="R20"><infon key="score">0.6212</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Disease|MESH:D010190</infon><infon key="type">Negative_Correlation</infon><node refid="19" role="16,19"/></relation><relation id="R21"><infon key="score">0.4585</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Chemical|MESH:C088327</infon><infon key="type">Cotreatment</infon><node refid="20" role="7,12"/></relation><relation id="R22"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Gene|111654</infon><infon key="type">Negative_Correlation</infon><node refid="21" role="37,41"/></relation><relation id="R23"><infon key="score">0.9978</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Chemical|MESH:D017382</infon><infon key="type">Positive_Correlation</infon><node refid="22" role="15,22"/></relation><relation id="R24"><infon key="score">0.9917</infon><infon key="role1">Chemical|MESH:C000716357</infon><infon key="role2">Disease|MESH:C565455</infon><infon key="type">Negative_Correlation</infon><node refid="23" role="16,20"/></relation><relation id="R25"><infon key="score">0.9336</infon><infon key="role1">Chemical|MESH:C000707327</infon><infon key="role2">Disease|MESH:D010190</infon><infon key="type">Negative_Correlation</infon><node refid="24" role="0,2"/></relation><relation id="R26"><infon key="score">0.5427</infon><infon key="role1">Chemical|MESH:D017382</infon><infon key="role2">Disease|MESH:D010190</infon><infon key="type">Negative_Correlation</infon><node refid="25" role="22,19"/></relation></document>
<document><id>37897126</id><passage><infon key="journal">Biotechnol J;2023Oct27 2300318. doi:10.1002/biot.202300318</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Romann P, Schneider S, Tobler D, Jordan M, Perilleux A, Souquet J, Herwig C, Bielser JM, Villiger TK, </infon><offset>0</offset><text>Raman-controlled pyruvate feeding to control metabolic activity and product quality in continuous biomanufacturing.</text><annotation id="1"><infon key="identifier">MESH:D019289</infon><infon key="type">Chemical</infon><location offset="17" length="8"/><text>pyruvate</text></annotation></passage><passage><infon key="type">abstract</infon><offset>116</offset><text>BACKGROUND: Despite technological advances ensuring stable cell culture perfusion operation over prolonged time, reaching a cellular steady-state metabolism remains a challenge for certain manufacturing cell lines. This study investigated the stabilization of a steady-state perfusion process producing a bispecific antibody with drifting product quality attributes, caused by shifting metabolic activity in the cell culture. MAIN METHODS: A novel on-demand pyruvate feeding strategy was developed, leveraging lactate as an indicator for tricarboxylic acid (TCA) cycle saturation. Real-time lactate monitoring was achieved through in-line Raman spectroscopy, enabling accurate control at predefined target setpoints. MAJOR RESULTS: The implemented feedback control strategy resulted in a 3-fold reduction of ammonium accumulation and stabilized product quality profiles. Stable and flat glycosylation profiles were achieved with standard deviations below 0.2% for high mannose and fucosylation. Whereas galactosylation and sialylation were stabilized in a similar manner, varying lactate setpoints might allow for fine tuning of these glycan forms. IMPLICATION: The Raman-controlled pyruvate feeding strategy represents a valuable tool for continuous manufacturing, stabilizing metabolic activity and preventing product quality drifting in perfusion cell cultures. Additionally, this approach effectively reduced high mannose, helping to mitigate increases associated with process intensification, such as extended culture durations or elevated culture densities. This article is protected by copyright. All rights reserved.</text><annotation id="13"><infon key="identifier">MESH:D019289</infon><infon key="type">Chemical</infon><location offset="574" length="8"/><text>pyruvate</text></annotation><annotation id="14"><infon key="identifier">MESH:D019344</infon><infon key="type">Chemical</infon><location offset="626" length="7"/><text>lactate</text></annotation><annotation id="15"><infon key="identifier">MESH:D014233</infon><infon key="type">Chemical</infon><location offset="654" length="18"/><text>tricarboxylic acid</text></annotation><annotation id="16"><infon key="identifier">MESH:D014233</infon><infon key="type">Chemical</infon><location offset="674" length="3"/><text>TCA</text></annotation><annotation id="17"><infon key="identifier">MESH:D019344</infon><infon key="type">Chemical</infon><location offset="707" length="7"/><text>lactate</text></annotation><annotation id="18"><infon key="identifier">MESH:D064751</infon><infon key="type">Chemical</infon><location offset="924" length="8"/><text>ammonium</text></annotation><annotation id="19"><infon key="identifier">MESH:D008358</infon><infon key="type">Chemical</infon><location offset="1085" length="7"/><text>mannose</text></annotation><annotation id="20"><infon key="identifier">MESH:D019344</infon><infon key="type">Chemical</infon><location offset="1196" length="7"/><text>lactate</text></annotation><annotation id="21"><infon key="identifier">MESH:D011134</infon><infon key="type">Chemical</infon><location offset="1251" length="6"/><text>glycan</text></annotation><annotation id="22"><infon key="identifier">MESH:D019289</infon><infon key="type">Chemical</infon><location offset="1299" length="8"/><text>pyruvate</text></annotation><annotation id="23"><infon key="identifier">MESH:D008358</infon><infon key="type">Chemical</infon><location offset="1534" length="7"/><text>mannose</text></annotation></passage><relation id="R1"><infon key="score">0.9681</infon><infon key="role1">Chemical|MESH:D008358</infon><infon key="role2">Chemical|MESH:D019289</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="11,10"/></relation><relation id="R2"><infon key="score">0.9962</infon><infon key="role1">Chemical|MESH:D011134</infon><infon key="role2">Chemical|MESH:D019344</infon><infon key="type">Association</infon><node refid="1" role="9,8"/></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Chemical|MESH:D014233</infon><infon key="role2">Chemical|MESH:D019344</infon><infon key="type">Association</infon><node refid="2" role="3,2"/></relation></document>
<document><id>37897477</id><passage><infon key="journal">J Perianesth Nurs;2023Oct25. doi:10.1016/j.jopan.2023.07.022</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Akire SC, Bayraktar N, </infon><offset>0</offset><text>Outcomes of Pain Management Among Postoperative Patients: A Cross-sectional Study.</text><annotation id="1"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="12" length="4"/><text>Pain</text></annotation></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>PURPOSE: Postoperative pain management has always been a significant challenge for both hospital staff and surgical patients. Determination of pain management outcomes among surgically treated patients may help develop pain management strategies, improve health services that would yield better outcomes, and increase patient satisfaction. This study aimed to assess the outcomes of pain management among postoperative patients. DESIGN: The study was a descriptive cross-sectional study. METHODS: The research was performed on postoperative patients at two university hospitals in North Cyprus from July to September 2019. The study sample consisted of 90 patients from both hospitals. The Turkish Version of the revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R-TR) was used for data collection. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to report the present study. FINDINGS: This study showed that the overall mean for pain severity and the worst pain experienced by patients after 24 hours was slightly higher than medium. Examination of interference of the pain with functions demonstrated that patients experienced problems with physical activities and sleeping. The most experienced side effects were nausea and drowsiness, and the most common emotions were anxiety and helplessness during the postsurgery period. The satisfaction rate of the patients with postoperative pain management was relatively high. CONCLUSIONS: A holistic approach with evidence-based practices is crucial for adequate postoperative pain management. The recommendations include the development of individual pain outcome strategies to improve overall satisfaction with pain management among postoperative patients.</text><annotation id="16"><infon key="identifier">MESH:D010149</infon><infon key="type">Disease</infon><location offset="92" length="18"/><text>Postoperative pain</text></annotation><annotation id="17"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="226" length="4"/><text>pain</text></annotation><annotation id="18"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="302" length="4"/><text>pain</text></annotation><annotation id="19"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="466" length="4"/><text>pain</text></annotation><annotation id="20"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="813" length="4"/><text>Pain</text></annotation><annotation id="21"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1085" length="4"/><text>pain</text></annotation><annotation id="22"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1113" length="4"/><text>pain</text></annotation><annotation id="23"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1225" length="4"/><text>pain</text></annotation><annotation id="24"><infon key="identifier">MESH:D009325</infon><infon key="type">Disease</infon><location offset="1371" length="6"/><text>nausea</text></annotation><annotation id="25"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="1428" length="7"/><text>anxiety</text></annotation><annotation id="26"><infon key="identifier">MESH:D010149</infon><infon key="type">Disease</infon><location offset="1527" length="18"/><text>postoperative pain</text></annotation><annotation id="27"><infon key="identifier">MESH:D010149</infon><infon key="type">Disease</infon><location offset="1665" length="18"/><text>postoperative pain</text></annotation><annotation id="28"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1754" length="4"/><text>pain</text></annotation><annotation id="29"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1815" length="4"/><text>pain</text></annotation></passage></document>
<document><id>37897827</id><passage><infon key="journal">Food Chem;2023Oct21; 437 (Pt 1) 137827. doi:10.1016/j.foodchem.2023.137827</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kang M, Yao Y, Yuan B, Zhang S, Oderinde O, Zhang Z, </infon><offset>0</offset><text>A sensitive bimetallic copper/bismuth metal-organic frameworks-based aptasensors for zearalenone detection in foodstuffs.</text><annotation id="3"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="23" length="6"/><text>copper</text></annotation><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30" length="32"/><text>bismuth metal-organic frameworks</text></annotation><annotation id="5"><infon key="identifier">MESH:D015025</infon><infon key="type">Chemical</infon><location offset="85" length="11"/><text>zearalenone</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>Electrochemical aptasensors have emerged as promising platforms for effectivelydetection of various target analytes. Here, we developed a sensitive and selective electrochemical aptasensor for zearalenone (ZEN) determination based on a bimetallic organic framework (CuBi-BPDC). The results of HR-TEM, FE-SEM, XPS, etc. indicate the CuBi-BPDC possessing mixed nodes of Cu(II) and Bi(III) and multilayered nanosheets bearing nanoparticles. Due to its improved electrochemical activity and strong affinity for aptamers, the CuBi-BPDC-based aptasensor obtains a low limit of detection of 0.19 fg mL-1 (IUPAC S/N = 3) in a wide range of 1 fg mL-1-10 ng mL-1 via EIS and 0.73 fg mL-1 from 0 fg mL-1 to 1 x 107 fg mL-1 via DPV for ZEN detection, respectively. Moreover, the excellent selectivity allows this aptasensor to specifically identify ZEN from other interfering substances in raw milk and rice, indicating the potential applicability of the CuBi-BPDC-based aptasensor in sensitive and selective detection of ZEN.</text><annotation id="19"><infon key="identifier">MESH:D015025</infon><infon key="type">Chemical</infon><location offset="315" length="11"/><text>zearalenone</text></annotation><annotation id="20"><infon key="identifier">MESH:D015025</infon><infon key="type">Chemical</infon><location offset="328" length="3"/><text>ZEN</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="358" length="28"/><text>bimetallic organic framework</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="388" length="9"/><text>CuBi-BPDC</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="454" length="9"/><text>CuBi-BPDC</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="490" length="6"/><text>Cu(II)</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="501" length="7"/><text>Bi(III)</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="643" length="9"/><text>CuBi-BPDC</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="838" length="3"/><text>DPV</text></annotation><annotation id="28"><infon key="identifier">MESH:D015025</infon><infon key="type">Chemical</infon><location offset="846" length="3"/><text>ZEN</text></annotation><annotation id="29"><infon key="identifier">MESH:D015025</infon><infon key="type">Chemical</infon><location offset="959" length="3"/><text>ZEN</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1065" length="9"/><text>CuBi-BPDC</text></annotation><annotation id="31"><infon key="identifier">MESH:D015025</infon><infon key="type">Chemical</infon><location offset="1132" length="3"/><text>ZEN</text></annotation></passage><relation id="R1"><infon key="score">0.9199</infon><infon key="role1">Chemical|MESH:D003300</infon><infon key="role2">Chemical|MESH:D015025</infon><infon key="type">Association</infon><node refid="0" role="0,2"/></relation></document>
<document><id>37898180</id><passage><infon key="journal">Neurosci Lett;2023Oct26 137537. doi:10.1016/j.neulet.2023.137537</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yamaguchi K, Yazawa T, </infon><offset>0</offset><text>Development of the human medullary arcuate nucleus from mid-gestation to the perinatal period: A morphometric study.</text></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>INTRODUCTION: Development of the human medullary arcuate nucleus (AN) has not been sufficiently investigated. The present study provides morphometric data by examining the brains from preterm and perinatal infants. MATERIALS AND METHODS: Nine brains were obtained from infants aged 21-43 postmenstrual weeks (PW). Serial celloidin sections were cut and stained using the Kluver-Barrera method. After microscopic observations, morphometric parameters [AN volume, numerical density (Nv) and total number (Nt) of neurons, and neuronal profile area (PA)] were analyzed. RESULTS: The AN was found as a pair of neuronal masses on the ventral medullary surface at 21 PW. Caudally, it was ventrolateral to the pyramidal tract (PT), and rostrally, medial to the PT. In the middle, it was diminished in size or interrupted. The AN neurons were gradually enlarged with age, showing multiplicity in size and shape. The following findings had a marked asymmetry and individual variability: (1) complete or partial inclusion of the AN in the PT; (2) connection between the rostral AN and the pontine nuclei; (3) coexistence of pyknotic neurons. The AN volume increased exponentially with age, while the Nv decreased exponentially. The Nt changed along two phases (decrease-increase) after mid-gestation. The mean PA increased linearly with age. Asymmetry and/or individual variability were demonstrated in the AN volume, Nt, and mean PA. CONCLUSIONS: Asymmetry and individual variability in the AN morphology are present in fetal period. The AN may undergo neuron death and neuroblasts production in tandem after mid-gestation.</text></passage></document>
<document><id>37898530</id><passage><infon key="journal">Lancet;2023Oct28; 402 (10412) 1527. doi:10.1016/S0140-6736(23)01068-1</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Bellomo R, Ronco C, Kellum J, Reis T, Forni L, Rational Evaluation of Nomenclature and Agreement based on Logic (RENAL) Group, </infon><offset>0</offset><text>How renal is the kidney?</text></passage><passage><infon key="type">abstract</infon><offset>25</offset></passage></document>
<document><id>37898880</id><passage><infon key="journal">Environ Sci Technol;2023Oct29. doi:10.1021/acs.est.3c05041</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hicks E, Rogers NMK, Hendren CO, Kuehn MJ, Wiesner MR, </infon><offset>0</offset><text>Extracellular Vesicles and Bacteriophages: New Directions in Environmental Biocolloid Research.</text></passage><passage><infon key="type">abstract</infon><offset>96</offset><text>There is a long-standing appreciation among environmental engineers and scientists regarding the importance of biologically derived colloidal particles and their environmental fate. This interest has been recently renewed in considering bacteriophages and extracellular vesicles, which are each poised to offer engineers unique insights into fundamental aspects of environmental microbiology and novel approaches for engineering applications, including advances in wastewater treatment and sustainable agricultural practices. Challenges persist due to our limited understanding of interactions between these nanoscale particles with unique surface properties and their local environments. This review considers these biological particles through the lens of colloid science with attention given to their environmental impact and surface properties. We discuss methods developed for the study of inert (nonbiological) particle-particle interactions and the potential to use these to advance our understanding of the environmental fate and transport of extracellular vesicles and bacteriophages.</text></passage></document>
<document><id>37899230</id><passage><infon key="journal">Uirusu;2022; 72 (1) 55. doi:10.2222/jsv.72.55</infon><infon key="year">2022</infon><infon key="type">title</infon><infon key="authors">Kanai Y, Nouda R, Kobayashi T, </infon><offset>0</offset><text>[Reverse genetics systems for Reoviridae viruses].</text></passage><passage><infon key="type">abstract</infon><offset>51</offset></passage></document>
<document><id>37899581</id><passage><infon key="journal">J Aging Health;2023Oct29 8982643231207517. doi:10.1177/08982643231207517</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Guti&amp;#xe9;rrez &amp;#xc1;, L&amp;#xf3;pez-Anuarbe M, Webster NJ, Mahmoudi E, </infon><offset>0</offset><text>Rural-Urban Health Care Cost Differences Among Latinx Adults With and Without Dementia in the United States.</text><annotation id="1"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="78" length="8"/><text>Dementia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>OBJECTIVES: To compare rural-urban health care costs among Latinx adults ages 51+ and examine variations by dementia status. METHODS: Data are from the Health and Retirement Study (2006-2018 waves; n = 15,567). We inflation-adjusted all health care costs using the 2021 consumer price index. Geographic context and dementia status were the main exposure variables. We applied multivariate two-part generalized linear models and adjusted for sociodemographic and health characteristics. RESULTS: Rural residents had higher total health care costs, regardless of dementia status. Total health care costs were $850 higher in rural ($2,640) compared to urban ($1,789) areas (p &lt; .001). Out-of-pocket costs were $870 higher in rural ($2,677) compared to urban ($1,806) areas (p &lt; .001). Dementia status was not an effect modifier. DISCUSSION: Health care costs are disproportionately higher among Latinx rural, relative to urban, residents. Addressing health care costs among Latinx rural residents is a public health priority.</text><annotation id="6"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="217" length="8"/><text>dementia</text></annotation><annotation id="7"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="424" length="8"/><text>dementia</text></annotation><annotation id="8"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="670" length="8"/><text>dementia</text></annotation><annotation id="9"><infon key="identifier">MESH:D003704</infon><infon key="type">Disease</infon><location offset="891" length="8"/><text>Dementia</text></annotation></passage></document>
<document><id>37900633</id><passage><infon key="journal">Indian J Surg Oncol;2023Sep; 14 (3) 579. doi:10.1007/s13193-020-01174-8</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10611663</infon><infon key="type">title</infon><infon key="authors">Nair LM, Nair RP, Radhakrishnan B, James FV, </infon><offset>0</offset><text>Malignant Peripheral Nerve Sheath Tumour of Uterine Cervix-a Case Report and Review of Literature.</text><annotation id="1"><infon key="identifier">MESH:D010524</infon><infon key="type">Disease</infon><location offset="0" length="58"/><text>Malignant Peripheral Nerve Sheath Tumour of Uterine Cervix</text></annotation></passage><passage><infon key="type">abstract</infon><offset>99</offset><text>Malignant peripheral nerve sheath tumour (MPNST) is a rare variety of sarcoma occurring in the uterine cervix. Only 16 cases have been reported in literature till date. There is no clear consensus on the treatment due to the rarity of the disease. This is primarily managed by surgery. Here, we present a case of MPNST of the cervix who was treated with preoperative radiotherapy followed by radical hysterectomy and bilateral salpingo-oophorectomy.</text><annotation id="6"><infon key="identifier">MESH:D010524</infon><infon key="type">Disease</infon><location offset="99" length="40"/><text>Malignant peripheral nerve sheath tumour</text></annotation><annotation id="7"><infon key="identifier">MESH:D010524</infon><infon key="type">Disease</infon><location offset="141" length="5"/><text>MPNST</text></annotation><annotation id="8"><infon key="identifier">MESH:D012509</infon><infon key="type">Disease</infon><location offset="169" length="7"/><text>sarcoma</text></annotation><annotation id="9"><infon key="identifier">MESH:D010524</infon><infon key="type">Disease</infon><location offset="412" length="19"/><text>MPNST of the cervix</text></annotation></passage></document>
<document><id>37902033</id><passage><infon key="journal">Turk Kardiyol Dern Ars;2023Oct30. doi:10.5543/tkda.2023.87922</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cengiz El&amp;#xe7;io&amp;#x11f;lu B, Aytekin S, </infon><offset>0</offset><text>Assessment of Bi-Atrial Mechanical Function in Patients with Isolated Atrial Septal Aneurysm.</text><annotation id="2"><infon key="identifier">MESH:D041781</infon><infon key="type">Disease</infon><location offset="17" length="26"/><text>Atrial Mechanical Function</text></annotation><annotation id="3"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="70" length="22"/><text>Atrial Septal Aneurysm</text></annotation></passage><passage><infon key="type">abstract</infon><offset>94</offset><text>OBJECTIVE: Atrial mechanical dysfunction may be an alternative mechanism underlying the increased risk of systemic embolism in patients with atrial septal aneurysm (ASA). This study aimed to evaluate left atrial (LA) and right atrial (RA) function using two-dimensional speckle tracking echocardiography (2D STE) in patients with isolated ASA. METHODS: Fifty-four patients with ASA (mean age 50.3 +- 12.48, 37% male) and 48 healthy individuals of similar age and gender (mean age 48.3 +- 10.84, 39.6% male) were included in the study. To assess atrial mechanical function, measurements of left and right atrial reservoir strain (RS), peak contraction strain (PCS), and conduit strain (CS) were conducted using 2D STE, in addition to conventional evaluation with transthoracic echocardiography. RESULTS: LA RS and PCS values were significantly lower in the ASA group than in the controls (37.52 +- 2.89 vs. 40.16 +- 2.68%, P &lt; 0.001 and 17.29 +- 2.5 vs. 19.18 +- 2.23%, P &lt; 0.001, respectively). Similarly, RA RS and RA PCS were significantly lower in patients with ASA (36.97 +- 2.19 vs. 39.77 +- 2.36%, P &lt; 0.001 and 16.78 +- 2.10 vs. 18.54 +- 2.43%, P &lt; 0.001, respectively). A multivariate regression analysis revealed a strong independent association between ASA and the measures LA RS, LA PCS, RA RS, and RA PCS. CONCLUSION: Our findings indicate that bi-atrial function are diminished in patients with isolated ASA. This may be a possible cause for the increased risk of arterial embolism in this patient group, aside from atrial arrhythmias and patent foramen ovale. Validating these results with larger studies may influence the treatment and follow-up strategies for patients with isolated ASA.</text><annotation id="19"><infon key="identifier">MESH:D041781</infon><infon key="type">Disease</infon><location offset="105" length="29"/><text>Atrial mechanical dysfunction</text></annotation><annotation id="20"><infon key="identifier">MESH:D004617</infon><infon key="type">Disease</infon><location offset="200" length="17"/><text>systemic embolism</text></annotation><annotation id="21"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="235" length="22"/><text>atrial septal aneurysm</text></annotation><annotation id="22"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="259" length="3"/><text>ASA</text></annotation><annotation id="23"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="433" length="3"/><text>ASA</text></annotation><annotation id="24"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="472" length="3"/><text>ASA</text></annotation><annotation id="25"><infon key="identifier">MESH:D041781</infon><infon key="type">Disease</infon><location offset="639" length="26"/><text>atrial mechanical function</text></annotation><annotation id="26"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="950" length="3"/><text>ASA</text></annotation><annotation id="27"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="1159" length="3"/><text>ASA</text></annotation><annotation id="28"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="1357" length="3"/><text>ASA</text></annotation><annotation id="29"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="1511" length="3"/><text>ASA</text></annotation><annotation id="30"><infon key="identifier">MESH:D004617</infon><infon key="type">Disease</infon><location offset="1571" length="17"/><text>arterial embolism</text></annotation><annotation id="31"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="1623" length="18"/><text>atrial arrhythmias</text></annotation><annotation id="32"><infon key="identifier">MESH:D054092</infon><infon key="type">Disease</infon><location offset="1646" length="20"/><text>patent foramen ovale</text></annotation><annotation id="33"><infon key="identifier">MESH:D006344</infon><infon key="type">Disease</infon><location offset="1793" length="3"/><text>ASA</text></annotation></passage></document>
<document><id>37902383</id><passage><infon key="journal">Int J Offender Ther Comp Criminol;2023Oct30 306624. doi:10.1177/0306624X231206518</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Usigbe J, Macey E, Klemme P, Williams M, Turman JE, </infon><offset>0</offset><text>Applying a Maternal Standards of Care Audit Tool and Quality Improvement Process to Improve Healthcare for Pregnant Women in Prison.</text></passage><passage><infon key="type">abstract</infon><offset>133</offset><text>Women are the fastest growing prison population, but little is known about the quality of maternal care for pregnant women in prison. In partnership with the Indiana Department of Correction (IDOC) Transitional Healthcare Team (THT), we developed a maternal standard of care (MSOC) audit tool to identify existing strengths and weaknesses and recommend evidence-based strategies for improvement. After creating the MSOC audit tool, we used it to audit 52 charts and conducted interviews of IDOC staff regarding maternal health care processes. Identified strengths include prenatal care, screening/treatment for sexually transmitted diseases and substance use disorders, contraception use, and health education. Mental and nutritional health care are areas of weakness. Staff motivation and community partnerships facilitate positive change, but a "punitive" culture, lack of resources, and communication challenges are barriers to change. Developing accountability tools and processes to promote maternal standards of care holds the potential to increase the health and wellbeing of mothers and their babies and improve re-integration into society.</text><annotation id="3"><infon key="identifier">MESH:D012749</infon><infon key="type">Disease</infon><location offset="744" length="29"/><text>sexually transmitted diseases</text></annotation><annotation id="4"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="778" length="23"/><text>substance use disorders</text></annotation><annotation id="5"><infon key="identifier">MESH:D018908</infon><infon key="type">Disease</infon><location offset="892" length="8"/><text>weakness</text></annotation></passage></document>
<document><id>37902733</id><passage><infon key="journal">JAMA Neurol;2023Oct30. doi:10.1001/jamaneurol.2023.3931</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10616765</infon><infon key="type">title</infon><infon key="authors">Bernstein RA, Kamel H, Granger CB, Piccini JP, Katz JM, Sethi PP, Pouliot E, Franco N, Ziegler PD, Schwamm LH, STROKE AF Investigators, </infon><offset>0</offset><text>Atrial Fibrillation In Patients With Stroke Attributed to Large- or Small-Vessel Disease: 3-Year Results From the STROKE AF Randomized Clinical Trial.</text><annotation id="5"><infon key="identifier">MESH:D001281</infon><infon key="type">Disease</infon><location offset="0" length="19"/><text>Atrial Fibrillation</text></annotation><annotation id="6"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="37" length="6"/><text>Stroke</text></annotation><annotation id="7"><infon key="identifier">MESH:D059345</infon><infon key="type">Disease</infon><location offset="63" length="25"/><text>- or Small-Vessel Disease</text></annotation><annotation id="8"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="114" length="6"/><text>STROKE</text></annotation><annotation id="9"><infon key="type">Disease</infon><location offset="121" length="2"/><text>AF</text></annotation></passage><passage><infon key="type">abstract</infon><offset>151</offset><text>Importance: The STROKE AF study found that in patients with prior ischemic stroke attributed to large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD), 12% developed AF over 1 year when monitored with an insertable cardiac monitor (ICM). The occurrence over subsequent years is unknown. Objectives: To compare the rates of AF detection through 3 years of follow-up between an ICM vs site-specific usual care in patients with prior ischemic stroke attributed to LAD or SVD. Design, Setting, and Participants: This multicenter, randomized (1:1) clinical trial took place at 33 sites in the US with enrollment between April 2016 and July 2019 and 3-year follow-up through July 2022. Eligible patients were aged 60 years or older, or aged 50 to 59 years with at least 1 additional stroke risk factor and had an index ischemic stroke attributed to LAD or SVD within 10 days prior to ICM insertion. Of the 496 patients enrolled, 492 were randomized and 4 were excluded. Interventions: ICM monitoring vs site-specific usual care. Main Outcomes and Measures: The prespecified long-term outcome of the trial was AF detection through study follow-up (up to 3 years). AF was defined as an episode lasting more than 30 seconds, adjudicated by an expert committee. Results: In total, 492 patients were randomized and included in the analyses (median [IQR] age, 66 [60-74] years; 307 men [62.4%] and 185 women [37.6%]), of whom 314 completed 3-year follow-up (63.8%). The incidence rate of AF at 3 years was 21.7% (46 patients) in the ICM group vs 2.4% (5 patients) in the control group (hazard ratio, 10.0; 95% CI, 4.0-25.2; P &lt; .001). Conclusions and Relevance: Patients with ischemic stroke attributed to LAD or SVD face an increasing risk of AF over time and most of the AF occurrences are not reliably detected by standard medical monitoring methods. One year of negative monitoring should not reassure clinicians that patients who have experienced stroke will not develop AF over the next 2 years. Trial Registration: ClinicalTrials.gov Identifier: NCT02700945.</text><annotation id="36"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="167" length="6"/><text>STROKE</text></annotation><annotation id="37"><infon key="type">Disease</infon><location offset="174" length="2"/><text>AF</text></annotation><annotation id="38"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="217" length="15"/><text>ischemic stroke</text></annotation><annotation id="39"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="247" length="36"/><text>large-artery atherosclerotic disease</text></annotation><annotation id="40"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="285" length="3"/><text>LAD</text></annotation><annotation id="41"><infon key="identifier">MESH:D059345</infon><infon key="type">Disease</infon><location offset="293" length="30"/><text>small-vessel occlusive disease</text></annotation><annotation id="42"><infon key="identifier">MESH:D059345</infon><infon key="type">Disease</infon><location offset="325" length="3"/><text>SVD</text></annotation><annotation id="43"><infon key="type">Disease</infon><location offset="345" length="2"/><text>AF</text></annotation><annotation id="44"><infon key="type">Disease</infon><location offset="502" length="2"/><text>AF</text></annotation><annotation id="45"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="610" length="15"/><text>ischemic stroke</text></annotation><annotation id="46"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="640" length="3"/><text>LAD</text></annotation><annotation id="47"><infon key="identifier">MESH:D059345</infon><infon key="type">Disease</infon><location offset="647" length="3"/><text>SVD</text></annotation><annotation id="48"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="956" length="6"/><text>stroke</text></annotation><annotation id="49"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="992" length="15"/><text>ischemic stroke</text></annotation><annotation id="50"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1022" length="3"/><text>LAD</text></annotation><annotation id="51"><infon key="identifier">MESH:D059345</infon><infon key="type">Disease</infon><location offset="1029" length="3"/><text>SVD</text></annotation><annotation id="52"><infon key="type">Disease</infon><location offset="1282" length="2"/><text>AF</text></annotation><annotation id="53"><infon key="type">Disease</infon><location offset="1336" length="2"/><text>AF</text></annotation><annotation id="54"><infon key="type">Disease</infon><location offset="1655" length="2"/><text>AF</text></annotation><annotation id="55"><infon key="identifier">MESH:D002544</infon><infon key="type">Disease</infon><location offset="1843" length="15"/><text>ischemic stroke</text></annotation><annotation id="56"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1873" length="3"/><text>LAD</text></annotation><annotation id="57"><infon key="identifier">MESH:D059345</infon><infon key="type">Disease</infon><location offset="1880" length="3"/><text>SVD</text></annotation><annotation id="58"><infon key="type">Disease</infon><location offset="1911" length="2"/><text>AF</text></annotation><annotation id="59"><infon key="type">Disease</infon><location offset="1940" length="2"/><text>AF</text></annotation><annotation id="60"><infon key="identifier">MESH:D020521</infon><infon key="type">Disease</infon><location offset="2119" length="6"/><text>stroke</text></annotation><annotation id="61"><infon key="type">Disease</infon><location offset="2143" length="2"/><text>AF</text></annotation></passage></document>
<document><id>37903461</id><passage><infon key="journal">Mol Plant Microbe Interact;2023Oct30. doi:10.1094/MPMI-04-23-0051-R</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cabre L, Jing L, Makechemu M, Heluin K, El Khamlichi S, Leprince J, Kiefer-Meyer MC, Pluchon S, Mollet JC, Zipfel C, Nguema-Ona E, </infon><offset>0</offset><text>Additive and specific effects of elicitor treatments on the metabolic profile of Arabidopsis thaliana.</text></passage><passage><infon key="type">abstract</infon><offset>103</offset><text>Several elicitors of plant defense have been identified and numerous efforts to use them in the field have been made. Exogenous elicitor treatments mimic the in-planta activation of pattern-triggered immunity (PTI), which relies on the perception of pathogen-associated molecular patterns (PAMPs) such as bacterial flg22 or fungal chitins. Early transcriptional responses to distinct PAMPs are mostly overlapping, regardless of the elicitor being used. However, it remains poorly known if the same patterns are observed for metabolites and proteins produced later during PTI. In addition, little is known about the impact of a combination of elicitors on PTI and the level of induced resistance to pathogens. Here, we monitored Arabidopsis thaliana resistance to the bacterial pathogen Pseudomonas syringae pv. tomato DC3000 (Pto DC3000) following application of flg22 and chitosan elicitors, used individually or in combination. A slight, but not statistically significant increase in induced resistance was observed when the elicitors were applied together when compared to individual treatments. We investigated the effect of these treatments on the metabolome by using an untargeted analysis. We found that the combination of flg22 and chitosan impacted a higher number of metabolites and deregulated specific metabolic pathways, than the elicitors individually. These results contribute to a better understanding of plant responses to elicitors, which might help better rationalize their use in the field.</text><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="418" length="5"/><text>flg22</text></annotation><annotation id="5"><infon key="identifier">MESH:D002686</infon><infon key="type">Chemical</infon><location offset="434" length="7"/><text>chitins</text></annotation><annotation id="6"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="976" length="8"/><text>chitosan</text></annotation><annotation id="7"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="1343" length="8"/><text>chitosan</text></annotation></passage></document>
<document><id>37904513</id><passage><infon key="journal">ACS Appl Bio Mater;2023Oct30. doi:10.1021/acsabm.3c00389</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Janipour Z, Najafi H, Abolmaali SS, Heidari R, Azarpira N, &amp;#xd6;zy&amp;#x131;lmaz ED, Tamaddon AM, </infon><offset>0</offset><text>Simvastatin-Releasing Nanofibrous Peptide Hydrogels for Accelerated Healing of Diabetic Wounds.</text><annotation id="3"><infon key="identifier">MESH:D019821</infon><infon key="type">Chemical</infon><location offset="0" length="11"/><text>Simvastatin</text></annotation><annotation id="4"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="34" length="7"/><text>Peptide</text></annotation><annotation id="5"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="79" length="15"/><text>Diabetic Wounds</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset><text>Wound healing is one of the major global health concerns in diabetic patients. Simvastatin (SMV) is a poorly soluble oral cholesterol-lowering drug that may aid diabetic wound healing. In the current study, a thixotropic peptide hydrogel of Fmoc-diphenylalanine (FmocFF) containing SMV was designed to accelerate skin wound healing effectively and safely in diabetic mice. FmocFF hydrogels were prepared at various concentrations by using the solvent-triggering technique and characterized by spectroscopic methods such as attenuated total reflection Fourier transform infrared (FT-IR) spectroscopy and fluorimetry. Mechanical behaviors were explored by oscillatory rheology. In model mice, the regenerative potential of the FmocFF-SMV hydrogel was evaluated in terms of wound contraction and closure, tissue regeneration, acute and chronic inflammation, granulation, and re-epithelization. The results showed that FmocFF-SMV hydrogels had an entangled nanofibrous microstructure and shear-thinning characteristics. FmocFF-SMV demonstrated a sustained drug release over 7 days. Compared to the unloaded FmocFF hydrogel, treatment with FmocFF-SMV led to superior diabetic wound recovery and reduced inflammation. Therefore, the utilization of the sustained-release FmocFF-SMV hydrogel formulation could become an attractive choice for topical wound therapy in diabetes patients.</text><annotation id="27"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="156" length="8"/><text>diabetic</text></annotation><annotation id="28"><infon key="identifier">MESH:D019821</infon><infon key="type">Chemical</infon><location offset="175" length="11"/><text>Simvastatin</text></annotation><annotation id="29"><infon key="identifier">MESH:D019821</infon><infon key="type">Chemical</infon><location offset="188" length="3"/><text>SMV</text></annotation><annotation id="30"><infon key="identifier">MESH:D002784</infon><infon key="type">Chemical</infon><location offset="218" length="11"/><text>cholesterol</text></annotation><annotation id="31"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="257" length="8"/><text>diabetic</text></annotation><annotation id="32"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="317" length="7"/><text>peptide</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="337" length="20"/><text>Fmoc-diphenylalanine</text></annotation><annotation id="34"><infon key="identifier">MESH:C000609769</infon><infon key="type">Chemical</infon><location offset="359" length="6"/><text>FmocFF</text></annotation><annotation id="35"><infon key="identifier">MESH:D019821</infon><infon key="type">Chemical</infon><location offset="378" length="3"/><text>SMV</text></annotation><annotation id="36"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="454" length="8"/><text>diabetic</text></annotation><annotation id="37"><infon key="identifier">MESH:C000609769</infon><infon key="type">Chemical</infon><location offset="469" length="6"/><text>FmocFF</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="821" length="19"/><text>FmocFF-SMV hydrogel</text></annotation><annotation id="39"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="919" length="30"/><text>acute and chronic inflammation</text></annotation><annotation id="40"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1011" length="10"/><text>FmocFF-SMV</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1112" length="10"/><text>FmocFF-SMV</text></annotation><annotation id="42"><infon key="identifier">MESH:C000609769</infon><infon key="type">Chemical</infon><location offset="1199" length="6"/><text>FmocFF</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1231" length="10"/><text>FmocFF-SMV</text></annotation><annotation id="44"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1258" length="8"/><text>diabetic</text></annotation><annotation id="45"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1294" length="12"/><text>inflammation</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1360" length="19"/><text>FmocFF-SMV hydrogel</text></annotation><annotation id="47"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1455" length="8"/><text>diabetes</text></annotation></passage><relation id="R1"><infon key="score">0.9871</infon><infon key="role1">Chemical|MESH:D019821</infon><infon key="role2">Disease|MESH:D003920</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.9662</infon><infon key="role1">Chemical|MESH:D002784</infon><infon key="role2">Chemical|MESH:D019821</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="6,4"/></relation></document>
<document><id>37905564</id><passage><infon key="journal">J Asian Nat Prod Res;2023Oct31 1. doi:10.1080/10286020.2023.2273814</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wu Q, Hu RX, Han YR, Zhu Q, Zhang WJ, Chen J, Zhang F, Zhang CL, Cao ZY, </infon><offset>0</offset><text>Four new alkaloids from the roots of Dactylicapnos scandens.</text><annotation id="1"><infon key="identifier">MESH:D000470</infon><infon key="type">Chemical</infon><location offset="9" length="9"/><text>alkaloids</text></annotation></passage><passage><infon key="type">abstract</infon><offset>61</offset><text>Four new alkaloids (1 - 4), together with five known ones (5 - 9), were isolated from the bulbs of Dactylicapnos scandens. The structures were determined by analysis of their spectroscopic data and quantum-chemical calculations. All the isolates were tested for their ability to modulate neuronal Ca2+ mobilization in primary cultured neocortical neurons. Compound 8 inhibited spontaneous Ca2+ oscillations at low micromolar concentrations.</text><annotation id="6"><infon key="identifier">MESH:D000470</infon><infon key="type">Chemical</infon><location offset="70" length="9"/><text>alkaloids</text></annotation><annotation id="7"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="358" length="4"/><text>Ca2+</text></annotation><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="417" length="10"/><text>Compound 8</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="450" length="4"/><text>Ca2+</text></annotation></passage></document>
<document><id>37905914</id><passage><infon key="journal">Microbiol Spectr;2023Oct31 0261223. doi:10.1128/spectrum.02612-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tian B, Chen Z, Yu Y, Yang Y, Fang A, Bi C, Qu Z, Fu Y, Mehmood MA, Zhou C, Jiang D, </infon><offset>0</offset><text>Transcriptional plasticity of schizotrophic Sclerotinia sclerotiorum responds to symptomatic rapeseed and endophytic wheat hosts.</text></passage><passage><infon key="type">abstract</infon><offset>130</offset><text>Sclerotinia sclerotiorum, a widespread pathogen of dicotyledons, is also a reciprocal endophytic fungus in monocot plants. However, it is unclear how it responds to two distinct plants. Comparative transcriptomic analyses uncovered a network rewiring, with 14.1% up-differentially expressed genes overlapping upon colonizing the endophytic host wheat and a symptomatic host rapeseed. The divergent transcript of genes originating from host-specific induction is central to infection and colonization, including genes related to appressorium, oxalic acid, carbohydrate-active enzymes, and effector-like proteins. We confirmed that appressorium is required for S. sclerotiorum during colonization in symptomatic hosts but not in endophytic wheat via the observation of the infection process of DeltaSs-caf1, a compound appressorium formation-defective mutant with hypovirulence to symptomatic hosts. SS1G_10617 and SS1G_13809 are components of the starch degradation pathways. DeltaSS1G_10617 displayed lower virulence on symptomatic host plants and abnormal endophytic growth on wheat, and DeltaSS1G_13809 only showed an abnormal symbiotic relationship with wheat, implying that starch may be the major carbon source for S. sclerotiorum in the symbiosis with wheat. Our results herein suggest that S. sclerotiorum modulates biphasic colonization via a divergent transcriptional landscape. This study contributes to a better understanding of schizotrophic fungi and provides new clues for cultivating disease-resistant varieties and adjusting reasonable farming strategies. IMPORTANCE The broad host range of fungi with differential fungal responses leads to either a pathogenic or an endophytic lifestyle in various host plants. Yet, the molecular basis of schizotrophic fungal responses to different plant hosts remains unexplored. Here, we observed a general increase in the gene expression of S. sclerotiorum associated with pathogenicity in symptomatic rapeseed, including small protein secretion, appressorial formation, and oxalic acid toxin production. Conversely, in wheat, many carbohydrate metabolism and transport-associated genes were induced, indicating a general increase in processes associated with carbohydrate acquisition. Appressorium is required for S. sclerotiorum during colonization in symptomatic hosts but not in endophytic wheat. These findings provide new clues for understanding schizotrophic fungi, fungal evolution, and the emergence pathways of new plant diseases.</text><annotation id="12"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="603" length="9"/><text>infection</text></annotation><annotation id="13"><infon key="identifier">MESH:D019815</infon><infon key="type">Chemical</infon><location offset="672" length="11"/><text>oxalic acid</text></annotation><annotation id="14"><infon key="identifier">MESH:D002241</infon><infon key="type">Chemical</infon><location offset="685" length="12"/><text>carbohydrate</text></annotation><annotation id="15"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="901" length="9"/><text>infection</text></annotation><annotation id="16"><infon key="identifier">CVCL:W100</infon><infon key="type">CellLine</infon><location offset="922" length="12"/><text>DeltaSs-caf1</text></annotation><annotation id="17"><infon key="identifier">MESH:D013213</infon><infon key="type">Chemical</infon><location offset="1076" length="6"/><text>starch</text></annotation><annotation id="18"><infon key="identifier">MESH:D013213</infon><infon key="type">Chemical</infon><location offset="1308" length="6"/><text>starch</text></annotation><annotation id="19"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1332" length="6"/><text>carbon</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2159" length="17"/><text>oxalic acid toxin</text></annotation><annotation id="21"><infon key="identifier">MESH:D002241</infon><infon key="type">Chemical</infon><location offset="2216" length="12"/><text>carbohydrate</text></annotation><annotation id="22"><infon key="identifier">MESH:D002241</infon><infon key="type">Chemical</infon><location offset="2344" length="12"/><text>carbohydrate</text></annotation><annotation id="23"><infon key="identifier">MESH:D010939</infon><infon key="type">Disease</infon><location offset="2609" length="14"/><text>plant diseases</text></annotation></passage><relation id="R1"><infon key="score">0.8755</infon><infon key="role1">Chemical|MESH:D019815</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.7029</infon><infon key="role1">Chemical|MESH:D002241</infon><infon key="role2">Disease|MESH:D007239</infon><infon key="type">Association</infon><node refid="1" role="2,0"/></relation><relation id="R3"><infon key="score">0.4189</infon><infon key="role1">Chemical|MESH:D002244</infon><infon key="role2">Chemical|MESH:D013213</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="7,6"/></relation></document>
<document><id>37906266</id><passage><infon key="journal">Pathologie (Heidelb);2023Oct31. doi:10.1007/s00292-023-01253-x</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Braunschweig T, Schierle K, </infon><offset>0</offset><text>[Report of the History and Ethics of Pathology Working Group of the German Society for Pathology].</text></passage><passage><infon key="type">abstract</infon><offset>99</offset></passage></document>
<document><id>37907006</id><passage><infon key="journal">J Colloid Interface Sci;2023Oct27; 654 (Pt B) 1272. doi:10.1016/j.jcis.2023.10.120</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Song Z, Zhou X, Sun L, Zhang Q, Li Y, Ren X, Zhang H, Zhang L, </infon><offset>0</offset><text>Enhancing electron interaction between Pt and support for superior electrochemical performance through atomic layer deposition of tungsten oxide.</text><annotation id="2"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="39" length="2"/><text>Pt</text></annotation><annotation id="3"><infon key="identifier">MESH:C511604</infon><infon key="type">Chemical</infon><location offset="130" length="14"/><text>tungsten oxide</text></annotation></passage><passage><infon key="type">abstract</infon><offset>146</offset><text>The stabilization of platinum (Pt) catalysts through strong metal-support interactions is crucial for their successful implementation in fuel cell applications. Tungsten oxide (WO3) has demonstrated excellent CO tolerance and has been recognized as a promising substrate for anchoring and stabilizing Pt nanoparticles (NPs). However, the limited specific surface area of conventional tungsten oxide restricts its effectiveness in dispersing noble metal NPs. In this study, we present a pioneering approach by employing atomic layer deposition (ALD) to create a WO3 interlayer between Pt NPs and a carbon substrate. Using nitrogen-doped carbon nanotubes (NCNT) as the foundation, WO3 nanoparticles (2-5 nm) were selectively synthesized, followed by the subsequent deposition of Pt NPs using a bottom-up approach. The Pt-WO3-NCNT catalyst, with a WO3 bridge layer effectively inserted between the active site and carbon support, has displayed a notable augmentation in electrocatalytic activity and notable stability when compared to commercial Pt catalysts in oxygen reduction reaction (ORR). The detailed microstructure and the enhanced electrochemical reaction mechanism of Pt-WO3-NCNT catalyst has been investigated by X-ray adsorption spectrum and density functional theory (DFT) calculations. This work presents an innovative approach for enhancing the stability of Pt catalysts through the utilization of the ALD technique.</text><annotation id="30"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="167" length="8"/><text>platinum</text></annotation><annotation id="31"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="177" length="2"/><text>Pt</text></annotation><annotation id="32"><infon key="identifier">MESH:C511604</infon><infon key="type">Chemical</infon><location offset="307" length="14"/><text>Tungsten oxide</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="323" length="3"/><text>WO3</text></annotation><annotation id="34"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="355" length="2"/><text>CO</text></annotation><annotation id="35"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="447" length="2"/><text>Pt</text></annotation><annotation id="36"><infon key="identifier">MESH:C511604</infon><infon key="type">Chemical</infon><location offset="530" length="14"/><text>tungsten oxide</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="587" length="11"/><text>noble metal</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="707" length="3"/><text>WO3</text></annotation><annotation id="39"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="730" length="2"/><text>Pt</text></annotation><annotation id="40"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="743" length="6"/><text>carbon</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="767" length="31"/><text>nitrogen-doped carbon nanotubes</text></annotation><annotation id="42"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="800" length="4"/><text>NCNT</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="825" length="3"/><text>WO3</text></annotation><annotation id="44"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="923" length="2"/><text>Pt</text></annotation><annotation id="45"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="962" length="2"/><text>Pt</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="965" length="3"/><text>WO3</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="969" length="4"/><text>NCNT</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="991" length="3"/><text>WO3</text></annotation><annotation id="49"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1057" length="6"/><text>carbon</text></annotation><annotation id="50"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="1189" length="2"/><text>Pt</text></annotation><annotation id="51"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="1205" length="6"/><text>oxygen</text></annotation><annotation id="52"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="1321" length="2"/><text>Pt</text></annotation><annotation id="53"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1324" length="3"/><text>WO3</text></annotation><annotation id="54"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1328" length="4"/><text>NCNT</text></annotation><annotation id="55"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="1516" length="2"/><text>Pt</text></annotation></passage></document>
<document><id>37907356</id><passage><infon key="journal">J Wound Care;2023Nov02; 32 (11) 693. doi:10.12968/jowc.2023.32.11.693</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fletcher J, </infon><offset>0</offset><text>Can you help us to make Every Contact Count and eliminate avoidable pressure?</text></passage><passage><infon key="type">abstract</infon><offset>78</offset></passage></document>
<document><id>37908056</id><passage><infon key="journal">Chem Biodivers;2023Oct31 202300429. doi:10.1002/cbdv.202300429</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Dos Santos GS, Teixeira MVS, Clementino LDC, Gama-Filho PA, Pereira LM, Teixeira TR, Furtado NAJC, Yatsuda AP, da Silva Graminha MA, Colepicolo-Neto P, Edrada-Ebel R, Debonsi HM, </infon><offset>0</offset><text>Annotation of GC-MS Data of Antimicrobial Constituents in the Antarctic Seaweed Phaeurus antarcticus by Molecular Networking.</text></passage><passage><infon key="type">abstract</infon><offset>126</offset><text>Phaeurus antarcticus is a member of the Desmarestiaceae family endemic to the Antarctic Peninsula. Reports addressing its chemical composition and biological activities are scarce. Herein, bioactive non-polar compounds of P. antarcticus against pathogenic bacteria, Leishmania amazonensis and Neospora caninum parasites were targeted through GC-MS Molecular Networking and multivariate analysis (OPLS-DA). The effects on horseradish peroxidase (HRP) were also evaluated. P. antarcticus exhibited selective bacteriostatic and bactericidal activities against Staphylococcus aureus with MIC and MBC values from 6.25 - 100 microg.mL-1. Fractions HX-FC and HX-FD were the most active against L. amazonensis with EC50   ranging from 18.5 - 62.3 microg.mL-1. Additionally, fractions HX-FC and HX-FD showed potent inhibition of N. caninum at EC50 values of 2.8 and 6.3 microg.mL-1, respectively. All fractions inhibited HRP activity, indicating possible interactions with Heme proteins. It was possible to annotate compounds from tree mains clusters, containing terpenoids, steroids, fatty acids, and alcohols by correlating the spectral data of the GC-MS analysis with Molecular Networking and the OPLS-DA results.</text><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="768" length="5"/><text>HX-FC</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="778" length="5"/><text>HX-FD</text></annotation><annotation id="10"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="902" length="5"/><text>HX-FC</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="912" length="5"/><text>HX-FD</text></annotation><annotation id="12"><infon key="identifier">MESH:D013729</infon><infon key="type">Chemical</infon><location offset="1180" length="10"/><text>terpenoids</text></annotation><annotation id="13"><infon key="identifier">MESH:D013256</infon><infon key="type">Chemical</infon><location offset="1192" length="8"/><text>steroids</text></annotation><annotation id="14"><infon key="identifier">MESH:D005227</infon><infon key="type">Chemical</infon><location offset="1202" length="11"/><text>fatty acids</text></annotation><annotation id="15"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="1219" length="8"/><text>alcohols</text></annotation></passage></document>
<document><id>37909107</id><passage><infon key="journal">Pediatrics;2023Nov01. doi:10.1542/peds.2023-062420</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Muentner L, Shlafer RJ, Heard-Garris N, Jackson DB, </infon><offset>0</offset><text>Parental Incarceration in the United States: 2016-2021.</text></passage><passage><infon key="type">abstract</infon><offset>56</offset><text>BACKGROUND AND OBJECTIVES: Parental incarceration (PI) is both an adverse childhood experience (ACE) and an influencer of pediatric health. Despite evidence that rural America sees the highest incarceration rates and substantial inequities in pediatric health care access and services, it is unclear how the prevalence of PI and associated sociodemographic factors vary across urban, suburban, and rural regions of the United States. METHODS: This study used data from the National Survey of Children's Health (2016-2021; N = 145 281). Based on proximity and population, households were categorized as urban, suburban, or rural. Caregivers reported on household income, race/ethnicity, and living arrangements as well as children's exposure to ACEs, including PI. Chi-squared and t-tests compared the prevalence of PI across communities and assessed regional differences in ACEs and sociodemographic characteristics in the context of PI. RESULTS: PI was most common in rural (12%) versus urban (8%) and suburban (6%) areas. ACEs were more prevalent among PI children compared with non-PI peers across regions, with slight differences between PI children across locales. Within all regions, PI was highest for Black, Latinx, Native, and multiracial children; those in poverty; and those in nonparent caregiver placements. However, these prevalences were consistently highest among rural children. CONCLUSIONS: This study points to high rates of adversity and concern racial, economic, and residential disparities for PI children, particularly those in rural communities. Evidence from this study can be used as a foundation for future prevention and intervention pediatric health responses that address inequities and unmet needs for rural populations.</text><annotation id="3"><infon key="type">Disease</infon><location offset="800" length="4"/><text>ACEs</text></annotation><annotation id="4"><infon key="type">Disease</infon><location offset="930" length="4"/><text>ACEs</text></annotation><annotation id="5"><infon key="type">Disease</infon><location offset="1080" length="4"/><text>ACEs</text></annotation></passage></document>
<document><id>37909462</id><passage><infon key="journal">Expert Opin Emerg Drugs;2023Nov01 1. doi:10.1080/14728214.2023.2278677</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wagner MJ, Daniel CP, Plaisance CJ, Borne GE, Ahmadzadeh S, Shekoohi S, Kaye AD, </infon><offset>0</offset><text>Apomorphine for Parkinson's disease: pharmacologic and clinical considerations.</text><annotation id="2"><infon key="identifier">MESH:D001058</infon><infon key="type">Chemical</infon><location offset="0" length="11"/><text>Apomorphine</text></annotation><annotation id="3"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="16" length="19"/><text>Parkinson's disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>80</offset><text>INTRODUCTION: In Parkinson's disease, dopamine depletion in the basal ganglia leads to symptoms including bradykinesia, gait abnormalities, and cognitive impairment. Even with treatment, the disease course leads to decreases in the amount of dopamine produced and released into the synapse. As dopamine production falls and the treatment course is insufficient to match the metabolic supply and demand, acute 'off' periods develop that cause reemergence of symptoms. Apomorphine is used to reverse these 'off' periods and restore function in patients with Parkinson's. This review will provide clinicians a concise article to read to learn more about apomorphine and its appropriate utilization. AREAS COVERED: The research discussed is focused on the history, pharmacokinetics, and mechanism of action of Apomorphine. Its utilization as a treatment for Parkinson's Disease and its comparison to currently utilized drugs is also discussed in this review. We focused on articles published on PubMed and Google Scholar within the last 10 years, but in some instances had to go as far back as 1951 to include early articles published about apomorphine. EXPERT OPINION: The expert opinion section focuses on the ways in which apomorphine could be administered in the future to better promote utilization and increase tolerability.</text><annotation id="18"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="97" length="19"/><text>Parkinson's disease</text></annotation><annotation id="19"><infon key="identifier">MESH:D004298</infon><infon key="type">Chemical</infon><location offset="118" length="8"/><text>dopamine</text></annotation><annotation id="20"><infon key="identifier">MESH:D018476</infon><infon key="type">Disease</infon><location offset="186" length="12"/><text>bradykinesia</text></annotation><annotation id="21"><infon key="identifier">MESH:D020233</infon><infon key="type">Disease</infon><location offset="200" length="18"/><text>gait abnormalities</text></annotation><annotation id="22"><infon key="identifier">MESH:D003072</infon><infon key="type">Disease</infon><location offset="224" length="20"/><text>cognitive impairment</text></annotation><annotation id="23"><infon key="identifier">MESH:D004298</infon><infon key="type">Chemical</infon><location offset="322" length="8"/><text>dopamine</text></annotation><annotation id="24"><infon key="identifier">MESH:D004298</infon><infon key="type">Chemical</infon><location offset="374" length="8"/><text>dopamine</text></annotation><annotation id="25"><infon key="identifier">MESH:D001058</infon><infon key="type">Chemical</infon><location offset="547" length="11"/><text>Apomorphine</text></annotation><annotation id="26"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="636" length="11"/><text>Parkinson's</text></annotation><annotation id="27"><infon key="identifier">MESH:D001058</infon><infon key="type">Chemical</infon><location offset="731" length="11"/><text>apomorphine</text></annotation><annotation id="28"><infon key="identifier">MESH:D001058</infon><infon key="type">Chemical</infon><location offset="886" length="11"/><text>Apomorphine</text></annotation><annotation id="29"><infon key="identifier">MESH:D010300</infon><infon key="type">Disease</infon><location offset="934" length="19"/><text>Parkinson's Disease</text></annotation><annotation id="30"><infon key="identifier">MESH:D001058</infon><infon key="type">Chemical</infon><location offset="1217" length="11"/><text>apomorphine</text></annotation><annotation id="31"><infon key="identifier">MESH:D001058</infon><infon key="type">Chemical</infon><location offset="1302" length="11"/><text>apomorphine</text></annotation></passage><relation id="R1"><infon key="score">0.9796</infon><infon key="role1">Chemical|MESH:D004298</infon><infon key="role2">Disease|MESH:D003072</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="3,6"/></relation><relation id="R2"><infon key="score">0.9765</infon><infon key="role1">Chemical|MESH:D004298</infon><infon key="role2">Disease|MESH:D020233</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="3,5"/></relation><relation id="R3"><infon key="score">0.9978</infon><infon key="role1">Chemical|MESH:D001058</infon><infon key="role2">Disease|MESH:D010300</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="0,1"/></relation><relation id="R4"><infon key="score">0.9874</infon><infon key="role1">Chemical|MESH:D004298</infon><infon key="role2">Disease|MESH:D018476</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="3,4"/></relation><relation id="R5"><infon key="score">0.9739</infon><infon key="role1">Chemical|MESH:D004298</infon><infon key="role2">Disease|MESH:D010300</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="3,2"/></relation></document>
<document><id>37909815</id><passage><infon key="journal">J Pediatr Endocrinol Metab;2006Apr01; 19 (4) 545. doi:10.1515/jpem-2006-190414</infon><infon key="year">2006</infon><infon key="type">title</infon><infon key="authors">Sacco M, Di Giorgio G, </infon><offset>0</offset><text>Recurrent Intracranial Hypertension Induced by Growth Hormone Therapy.</text><annotation id="2"><infon key="identifier">MESH:D019586</infon><infon key="type">Disease</infon><location offset="10" length="25"/><text>Intracranial Hypertension</text></annotation><annotation id="3"><infon key="identifier">MESH:D013006</infon><infon key="type">Chemical</infon><location offset="47" length="14"/><text>Growth Hormone</text></annotation></passage><passage><infon key="type">abstract</infon><offset>71</offset></passage><relation id="R1"><infon key="score">0.9954</infon><infon key="role1">Chemical|MESH:D013006</infon><infon key="role2">Disease|MESH:D019586</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="1,0"/></relation></document>
<document><id>37910170</id><passage><infon key="journal">Int J Syst Evol Microbiol;2023Nov; 73 (11) . doi:10.1099/ijsem.0.006122</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang M, Song Q, Sang J, Li Z, </infon><offset>0</offset><text>Paenibacillus spongiae sp. nov. isolated from deep-water marine sponge Theonella swinhoei.</text></passage><passage><infon key="type">abstract</infon><offset>91</offset><text>A novel bacterial strain, designated as PHS-Z3T, was isolated from a marine sponge belonging to the genus Theonella on the Puerto Galera Deep Monkey, Philippines. Cells of PHS-Z3T were Gram-stain-positive, motile, oxidase- and catalase-positive, white-pigmented, spore-forming, short rods that could grow at 10-40  C (optimum, 20  C), pH 6.0-9.5 (optimum, pH 7.5) and with 2-16 % (w/v) NaCl (optimum, 7 %). The 16S rRNA gene sequence of PHS-Z3T showed 97.9 %, 96.7 %, and 96.2 % identities to Paenibacillus mendelii C/2T, Paenibacillus oenotherae DT7-4T and Paenibacillus aurantiacus RC11T, respectively. The results of phylogenetic analysis based on 16S rRNA gene sequences indicated that PHS-Z3T formed an independent cluster with Paenibacillus mendelii C/2T. The total genome of PHS-Z3T was approximately 7 613 364 bp in size with a DNA G+C content of 51.6 %. The average nucleotide identity (ANI) and digital DNA-DNA hybridization (dDDH) values between PHS-Z3T and other type strains of species of the genus Paenibacillus were 68.0-81.4 % [ANI by blast (ANIb)], 83.0-88.0 % [ANI by MUMmer (ANIm)] and 12.7-32.1 % (dDDH). The dDDH and ANI values were below the standard cut-off criteria for delineation of bacterial species. The percentage of conserved proteins (POCP) values between the genome of PHS-Z3T and those of members of the genus Paenibacillus were 39.7-75.7 %, while the average amino acid identity (AAI) values were 55.9-83.7 %. The sole respiratory quinone in the strain was MK-7, and the predominant fatty acids were anteiso-C15 : 0 and C16 : 0. The major polar lipids of PHS-Z3T consisted of diphosphatidylglycerol, phospholipid and phosphatidylglycerol. The characteristic amino acid in the cell wall of PHS-Z3T was diamino heptanoic acid (meso-DAP). On the basis of the molecular, physiological, biochemical and chemotaxonomic features, strain PHS-Z3T represents a novel species of the genus Paenibacillus, for which the name Paenibacillus spongiae sp. nov. is proposed, with the type strain PHS-Z3T (=MCCC 1K07848T=KCTC 43443T).</text><annotation id="16"><infon key="identifier">847</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55514</infon><location offset="318" length="8"/><text>catalase</text></annotation><annotation id="17"><infon key="identifier">MESH:D012965</infon><infon key="type">Chemical</infon><location offset="477" length="4"/><text>NaCl</text></annotation><annotation id="18"><infon key="identifier">CVCL:6277</infon><infon key="type">CellLine</infon><location offset="1048" length="7"/><text>PHS-Z3T</text></annotation><annotation id="19"><infon key="identifier">MESH:C004532</infon><infon key="type">Chemical</infon><location offset="1556" length="7"/><text>quinone</text></annotation><annotation id="20"><infon key="identifier">MESH:C062629</infon><infon key="type">Chemical</infon><location offset="1582" length="4"/><text>MK-7</text></annotation><annotation id="21"><infon key="identifier">MESH:D005227</infon><infon key="type">Chemical</infon><location offset="1608" length="11"/><text>fatty acids</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1625" length="15"/><text>anteiso-C15 : 0</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1645" length="7"/><text>C16 : 0</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1664" length="12"/><text>polar lipids</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1680" length="7"/><text>PHS-Z3T</text></annotation><annotation id="26"><infon key="identifier">MESH:D002308</infon><infon key="type">Chemical</infon><location offset="1701" length="22"/><text>diphosphatidylglycerol</text></annotation><annotation id="27"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="1725" length="12"/><text>phospholipid</text></annotation><annotation id="28"><infon key="identifier">MESH:D010715</infon><infon key="type">Chemical</infon><location offset="1742" length="20"/><text>phosphatidylglycerol</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1814" length="7"/><text>PHS-Z3T</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1826" length="22"/><text>diamino heptanoic acid</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1850" length="8"/><text>meso-DAP</text></annotation></passage><relation id="R1"><infon key="score">0.9563</infon><infon key="role1">Chemical|MESH:D002308</infon><infon key="role2">Chemical|MESH:D010743</infon><infon key="type">Association</infon><node refid="0" role="10,11"/></relation><relation id="R2"><infon key="score">0.9095</infon><infon key="role1">Chemical|MESH:D002308</infon><infon key="role2">Chemical|MESH:D010715</infon><infon key="type">Association</infon><node refid="1" role="10,12"/></relation><relation id="R3"><infon key="score">0.9797</infon><infon key="role1">Chemical|MESH:D010715</infon><infon key="role2">Chemical|MESH:D010743</infon><infon key="type">Association</infon><node refid="2" role="12,11"/></relation></document>
<document><id>37911222</id><passage><infon key="journal">Int Dent J (Phila);1891Jan; 12 (1) 10</infon><infon key="year">1891</infon><infon key="article-id_pmc">PMC10109821</infon><infon key="type">title</infon><infon key="authors">Brackett CA, </infon><offset>0</offset><text>Concerning Third Molars.</text></passage><passage><infon key="type">abstract</infon><offset>25</offset></passage></document>
<document><id>37912272</id><passage><infon key="journal">Int Dent J (Phila);1897Aug; 18 (8) 540</infon><infon key="year">1897</infon><infon key="article-id_pmc">PMC10128814</infon><infon key="type">title</infon><infon key="authors">Peirce CN, </infon><offset>0</offset><text>Reply of Dr. C. N. Peirce.</text></passage><passage><infon key="type">abstract</infon><offset>27</offset></passage></document>
<document><id>37912972</id><passage><infon key="journal">Int Dent J (Phila);1902Sep; 23 (9) 644</infon><infon key="year">1902</infon><infon key="article-id_pmc">PMC10156267</infon><infon key="type">title</infon><infon key="authors">Genese D, </infon><offset>0</offset><text>Stomatitis from a Dental Stand-Point.</text><annotation id="1"><infon key="identifier">MESH:D013280</infon><infon key="type">Disease</infon><location offset="0" length="10"/><text>Stomatitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>38</offset></passage></document>
<document><id>37913323</id><passage><infon key="journal">Int Dent J (Phila);1905Sep; 26 (9) 629</infon><infon key="year">1905</infon><infon key="article-id_pmc">PMC10168841</infon><infon key="type">title</infon><infon key="authors">Snow GB, </infon><offset>0</offset><text>Teeth Receding in Vulcanization.</text></passage><passage><infon key="type">abstract</infon><offset>33</offset></passage></document>
<document><id>37913673</id><passage><infon key="journal">Vet Microbiol;2023Oct13; 287 109889. doi:10.1016/j.vetmic.2023.109889</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhou P, Liu D, Zhang Q, Wu W, Chen D, Luo R, </infon><offset>0</offset><text>Antiviral effects of duck type I and type III interferons against Duck Tembusu virus in vitro and in vivo.</text></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>Duck Tembusu Virus (DTMUV) is a newly emerging avian flavivirus that causes substantial economic losses to the duck industry in Asia by causing severe egg drop syndrome and fatal encephalitis in domestic ducks. During viral replication, host cells recognize the RNA structures produced by DTMUV, which triggers the production of interferons (IFNs) to inhibit viral replication. However, the function of duck type I and type III IFNs in inhibiting DTMUV infection remains largely unknown. In this study, we expressed and purified recombinant duck IFN-beta (duIFN-beta) and IFN-lambda (duIFN-lambda) in Escherichia coli and evaluated their antiviral activity against vesicular stomatitis virus (VSV). Furthermore, we found that both duIFN-beta and duIFN-lambda activated the ISRE promoter and induced the expression of ZAP, OAS, and RNaseL in duck embryo fibroblasts (DEFs). Notably, duIFN-beta showed faster and more potent induction of ISGs in vitro and in vivo compared to duIFN-lambda. Moreover, both duIFN-beta and duIFN-lambda showed high potential to inhibit DTMUV infection in DEFs, with duIFN-beta demonstrating better antiviral efficacy than duIFN-lambda against DTMUV in ducks. In conclusion, our results revealed that both duIFN-beta and duIFN-lambda can induce ISGs production and exhibit significant antiviral activity against DTMUV in vitro and in vivo, providing new insights for the development of antiviral therapeutic strategies in ducks.</text><annotation id="3"><infon key="identifier">MESH:D021181</infon><infon key="type">Disease</infon><location offset="258" length="17"/><text>egg drop syndrome</text></annotation><annotation id="4"><infon key="identifier">MESH:D004660</infon><infon key="type">Disease</infon><location offset="286" length="12"/><text>encephalitis</text></annotation><annotation id="5"><infon key="identifier">101800595</infon><infon key="type">Gene</infon><location offset="938" length="6"/><text>RNaseL</text></annotation></passage></document>
<document><id>37914023</id><passage><infon key="journal">J Invest Dermatol;2023Oct21. doi:10.1016/j.jid.2023.09.282</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fukunaga K, Tsukagoshi E, Kurata M, Mizukawa Y, Nihara H, Morita E, Watanabe Y, Yamaguchi Y, Watanabe H, Nakajima S, Nomura T, Kabashima K, Tohyama M, Azukizawa H, Asada H, Hasegawa A, Hama N, Ozeki T, Mashimo Y, Sekine A, Matsunaga K, Tanaka Y, Nakamura R, Abe R, Mushiroda T, Saito Y, </infon><offset>0</offset><text>Differential effects of HLA-B*15:11 and HLA-A*31:01 on carbamazepine-induced cutaneous adverse reactions.</text><annotation id="2"><infon key="identifier">MESH:D002220</infon><infon key="type">Chemical</infon><location offset="55" length="13"/><text>carbamazepine</text></annotation><annotation id="3"><infon key="identifier">MESH:D013262</infon><infon key="type">Disease</infon><location offset="77" length="27"/><text>cutaneous adverse reactions</text></annotation></passage><passage><infon key="type">abstract</infon><offset>106</offset><text>BRIEF SUMMARY: HLA-B*15:11 and HLA-A*31:01 would be used as biomarkers in predicting the risk of CBZ-induced cADRs in the populations where allele frequency of HLA-B*15:02 is extremely rare.</text><annotation id="6"><infon key="identifier">MESH:D002220</infon><infon key="type">Chemical</infon><location offset="203" length="3"/><text>CBZ</text></annotation><annotation id="7"><infon key="type">Disease</infon><location offset="215" length="5"/><text>cADRs</text></annotation></passage><relation id="R1"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D002220</infon><infon key="role2">Disease|MESH:D013262</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="0,1"/></relation></document>
<document><id>37914373</id><passage><infon key="journal">Hinyokika Kiyo;2023Oct; 69 (10) 279. doi:10.14989/ActaUrolJap_69_10_279</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Toyota T, Yoshikawa T, Tanaka T, Hashimoto K, Kobayashi K, Masumori N, </infon><offset>0</offset><text>[Evaluation of the Effects of Long-Term Indwelling Ureteral Stents on Preserving Renal Parenchyma and Function in Patients with Ureteral Stenosis].</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="51" length="15"/><text>Ureteral Stents</text></annotation><annotation id="3"><infon key="identifier">MESH:D014515</infon><infon key="type">Disease</infon><location offset="128" length="17"/><text>Ureteral Stenosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>148</offset><text>Although ureteral stenting is a common conservative treatment for ureteral stricture, it is unclear whether a long-term indwelling ureteral stent protects the kidney against parenchymal atrophy and functional deterioration. In this study, we evaluated the changes in renal parenchymal thickness (RPT) and estimated the glomerular filtration rates (eGFR) in patients with indwelling ureteral stents for one year or more. As a control, we also evaluated changes in RPT associated with indwelling percutaneous nephrostomy (PNS) for one year or more. Polymer ureteral stents were used and replaced every three months. RPT was measured using computed tomography (CT). Totally, 69 renal units in 55 patients with baseline and follow up CT scans available were enrolled. The median follow-up period was 29 months. The etiologies of ureteral obstruction were malignant and benign disease in 27 and 28, respectively. RPT was reduced obviously in most cases. At 1 year, the median reduction rate of RPT was 17.3% in unilateral cases, which was significantly higher than that in the healthy contralateral kidney. There was a strong correlation between eGFR and total RPT including the contralateral kidney. The reduction rate of RPT in kidneys with ureteral stents including bilateral cases was also significantly higher than that in 39 renal units of 35 patients with PNS. The results of this study suggest that the long-term efficacy of indwelling ureteral stents in preserving renal function is limited. Regular imaging may be essential to evaluate the residual renal function.</text><annotation id="12"><infon key="identifier">MESH:D003251</infon><infon key="type">Disease</infon><location offset="214" length="18"/><text>ureteral stricture</text></annotation><annotation id="13"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="334" length="7"/><text>atrophy</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="530" length="15"/><text>ureteral stents</text></annotation><annotation id="15"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="695" length="7"/><text>Polymer</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="703" length="15"/><text>ureteral stents</text></annotation><annotation id="17"><infon key="identifier">MESH:D014517</infon><infon key="type">Disease</infon><location offset="973" length="20"/><text>ureteral obstruction</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1386" length="15"/><text>ureteral stents</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1587" length="15"/><text>ureteral stents</text></annotation></passage></document>
<document><id>37915425</id><passage><infon key="journal">Symbiosis;2022May; 87 (1) 45. doi:10.1007/s13199-022-00853-0</infon><infon key="year">2022</infon><infon key="article-id_pmc">PMC10619970</infon><infon key="type">title</infon><infon key="authors">Weinstein SB, Stephens WZ, Greenhalgh R, Round JL, Dearing MD, </infon><offset>0</offset><text>Wild herbivorous mammals (genus Neotoma) host a diverse but transient assemblage of fungi.</text></passage><passage><infon key="type">abstract</infon><offset>91</offset><text>Fungi are often overlooked in microbiome research and, as a result, little is known about the mammalian mycobiome. Although frequently detected in vertebrate guts and known to contribute to digestion in some herbivores, whether these eukaryotes are a persistent part of the mammalian gut microbiome remains contentious. To address this question, we sampled fungi from wild woodrats (Neotoma spp.) collected from 25 populations across the southwestern United States. For each animal, we collected a fecal sample in the wild, and then re-sampled the same individual after a month in captivity on a controlled diet. We characterized and quantified fungi using three techniques: ITS metabarcoding, shotgun metagenomics and qPCR. Wild individuals contained diverse fungal assemblages dominated by plant pathogens, widespread molds, and coprophilous taxa primarily in Ascomycota and Mucoromycota. Fungal abundance, diversity and composition differed between individuals, and was primarily influenced by animal geographic origin. Fungal abundance and diversity significantly declined in captivity, indicating that most fungi in wild hosts came from diet and environmental exposure. While this suggests that these mammals lack a persistent gut mycobiome, natural fungal exposure may still impact fungal dispersal and animal health.</text></passage></document>
<document><id>37915775</id><passage><infon key="journal">Can Vet J;2023Nov; 64 (11) 1044</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10581353</infon><infon key="type">title</infon><infon key="authors">Giraldo AF, Carballo R, Serrenho RC, Tran V, Valverde A, Renaud DL, Gomez DE, </infon><offset>0</offset><text>Association of the type of metabolic acidosis and non-survival of horses with colitis.</text><annotation id="2"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="27" length="18"/><text>metabolic acidosis</text></annotation><annotation id="3"><infon key="identifier">MESH:D003092</infon><infon key="type">Disease</infon><location offset="78" length="7"/><text>colitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>87</offset><text>Background: Metabolic acidosis (MA) is the most common acid-base disorder reported in horses with colitis but its association with survival is yet to be determined. Objective: Investigate the types of MA in horses with colitis to determine effects of various anions on fatality rates. Animals and procedures: We studied 158 horses with colitis. Horses were classified into 4 groups depending on the anion contributing to MA: i) no MA, ii) lactic acidosis (LA), iii) unmeasured strong ion (USI) acidosis, and iv) hyperchloremic acidosis (HA). Results: Sixty percent (95/158) of horses had no MA, 22% (34/158) had LA, 12% (19/158) had HA, and 6% (10/158) had USI acidosis. The fatality rate of horses without MA was 20% (20/95), whereas the rates for those with LA, USI, and HA were 53% (18/34), 30% (3/10), and 16% (3/19), respectively. Horses with LA were more likely to die or be euthanized than horses without MA (OR: 4.2, 95% CI: 1.83 to 9.72, P &lt; 0.001) and HA (OR: 5.9, 95% CI: 1.47 to 24.4, P &lt; 0.01). Conclusion and clinical relevance: Lactic acidosis was the most common type of MA in horses with colitis, and it was associated with non-survival.</text><annotation id="34"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="99" length="18"/><text>Metabolic acidosis</text></annotation><annotation id="35"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="119" length="2"/><text>MA</text></annotation><annotation id="36"><infon key="identifier">MESH:D000137</infon><infon key="type">Disease</infon><location offset="142" length="18"/><text>acid-base disorder</text></annotation><annotation id="37"><infon key="identifier">MESH:D003092</infon><infon key="type">Disease</infon><location offset="185" length="7"/><text>colitis</text></annotation><annotation id="38"><infon key="identifier">MESH:D003092</infon><infon key="type">Disease</infon><location offset="306" length="7"/><text>colitis</text></annotation><annotation id="39"><infon key="identifier">MESH:D003092</infon><infon key="type">Disease</infon><location offset="423" length="7"/><text>colitis</text></annotation><annotation id="40"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="508" length="2"/><text>MA</text></annotation><annotation id="41"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="518" length="2"/><text>MA</text></annotation><annotation id="42"><infon key="identifier">MESH:D000140</infon><infon key="type">Disease</infon><location offset="526" length="15"/><text>lactic acidosis</text></annotation><annotation id="43"><infon key="identifier">MESH:D000140</infon><infon key="type">Disease</infon><location offset="543" length="2"/><text>LA</text></annotation><annotation id="44"><infon key="type">Disease</infon><location offset="576" length="3"/><text>USI</text></annotation><annotation id="45"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="581" length="8"/><text>acidosis</text></annotation><annotation id="46"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="599" length="23"/><text>hyperchloremic acidosis</text></annotation><annotation id="47"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="624" length="2"/><text>HA</text></annotation><annotation id="48"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="678" length="2"/><text>MA</text></annotation><annotation id="49"><infon key="identifier">MESH:D000140</infon><infon key="type">Disease</infon><location offset="699" length="2"/><text>LA</text></annotation><annotation id="50"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="720" length="2"/><text>HA</text></annotation><annotation id="51"><infon key="type">Disease</infon><location offset="744" length="3"/><text>USI</text></annotation><annotation id="52"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="748" length="8"/><text>acidosis</text></annotation><annotation id="53"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="794" length="2"/><text>MA</text></annotation><annotation id="54"><infon key="identifier">MESH:D000140</infon><infon key="type">Disease</infon><location offset="847" length="2"/><text>LA</text></annotation><annotation id="55"><infon key="type">Disease</infon><location offset="851" length="3"/><text>USI</text></annotation><annotation id="56"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="860" length="2"/><text>HA</text></annotation><annotation id="57"><infon key="identifier">MESH:D000140</infon><infon key="type">Disease</infon><location offset="935" length="2"/><text>LA</text></annotation><annotation id="58"><infon key="type">Disease</infon><location offset="958" length="3"/><text>die</text></annotation><annotation id="59"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="999" length="2"/><text>MA</text></annotation><annotation id="60"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="1049" length="2"/><text>HA</text></annotation><annotation id="61"><infon key="identifier">MESH:D000140</infon><infon key="type">Disease</infon><location offset="1130" length="15"/><text>Lactic acidosis</text></annotation><annotation id="62"><infon key="identifier">MESH:D000138</infon><infon key="type">Disease</infon><location offset="1174" length="2"/><text>MA</text></annotation><annotation id="63"><infon key="identifier">MESH:D003092</infon><infon key="type">Disease</infon><location offset="1192" length="7"/><text>colitis</text></annotation></passage></document>
<document><id>37916478</id><passage><infon key="journal">Aust J Rural Health;2023Nov02. doi:10.1111/ajr.13057</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Russell DJ, Zhao Y, Mathew S, Fitts MS, Johnson R, Reeve DM, Honan B, Niclasen P, Liddle Z, Green D, Wakerman J, </infon><offset>0</offset><text>The efficiency, timeliness, health outcomes and cost-effectiveness of a new aeromedical retrieval model in Central Australia: A pre- and post-implementation observational study.</text></passage><passage><infon key="type">abstract</infon><offset>178</offset><text>OBJECTIVE: To assess timeliness, efficiency, health outcomes and cost-effectiveness of the 2018 redesigned Central Australian aeromedical retrieval model. DESIGN: Pre- and postimplementation observational study of all patients receiving telehealth consultations from remote medical practitioners (RMPs) or Medical Retrieval and Consultation Centre (MRaCC) physicians between 1/1/2015 and 29/2/2020. Descriptive and inferential statistics measuring system efficiency, timeliness, health outcomes and incremental cost-effectiveness. FINDINGS: There were 9%-10% reductions in rates of total aeromedical retrievals, emergency department admissions and hospitalisations postimplementation, all p-values &lt; 0.001. Usage rates for total hospital bed days and ICU hours were 17% lower (both p &lt; 0.001). After adjusting for periodicity (12% fewer retrievals on weekends), each postimplementation year, there were 0.7 fewer retrievals/day (p = 0.002). The mean time from initial consultation to aeromedical departure declined by 18 minutes post-implementation (115 vs. 97 min, p = 0.007). The hazard of death within 365 days was nonsignificant (0.912, 95% CI 0.743-1.120). Postimplementation, it cost $302 more per hospital admission and $3051 more per year of life saved, with a 75% probability of cost-effectiveness. These costs excluded estimated savings of $744,528/year in reduced hospitalisations and the substantial social and out-of-pocket costs to patients and their families associated with temporary relocation to Alice Springs. CONCLUSION: Central Australia's new critical care consultant-led aeromedical retrieval model is more efficient, is dispatched faster and is more cost-effective. These findings are highly relevant to other remote regions in Australia and internationally that have comparable GP-led retrieval services.</text><annotation id="1"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1270" length="5"/><text>death</text></annotation></passage></document>
<document><id>37916831</id><passage><infon key="journal">Cancer;2023Nov02. doi:10.1002/cncr.35075</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wilson BE, Hanna TP, Booth CM, </infon><offset>0</offset><text>Efficacy-effectiveness gaps in oncology: Looking beyond survival.</text></passage><passage><infon key="type">abstract</infon><offset>66</offset><text>The efficacy-effectiveness (EE) gap describes the differences in survival seen in clinical trials and routine clinical practice, where patients in real-world practice often have inferior outcomes compared to trial populations. However, EE gaps may exist beyond survival outcomes, including gaps in quality of life, toxicity, cost-effectiveness, and patient time, and these EE gaps should also influence patient and clinician treatment decisions. Failure to clearly acknowledge these EE gaps may cause patients, clinicians, and health care systems to have unrealistic expectations of the benefits of therapy across a range of important clinical and economic domains. In this commentary, the authors review the evidence supporting the existence of EE gaps in quality of life, time toxicity, cost and toxicities, and urge for further research into this important topic.</text><annotation id="3"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="381" length="8"/><text>toxicity</text></annotation><annotation id="4"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="845" length="8"/><text>toxicity</text></annotation><annotation id="5"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="864" length="10"/><text>toxicities</text></annotation></passage></document>
<document><id>37917183</id><passage><infon key="journal">JCI Insight;2023Nov02. doi:10.1172/jci.insight.172062</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Corano-Scheri K, Lavine JA, Tedeschi TR, Thomson BR, Fawzi AA, </infon><offset>0</offset><text>Single cell transcriptomic analysis of proliferative diabetic retinopathy fibrovascular membranes reveals AEBP1 as fibrogenesis modulator.</text><annotation id="3"><infon key="identifier">OMIM:603933</infon><infon key="type">Disease</infon><location offset="39" length="34"/><text>proliferative diabetic retinopathy</text></annotation><annotation id="4"><infon key="identifier">165</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">878</infon><location offset="106" length="5"/><text>AEBP1</text></annotation><annotation id="5"><infon key="type">Disease</infon><location offset="115" length="12"/><text>fibrogenesis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>139</offset><text>The management of preretinal fibrovascular membranes, a devastating complication of advanced diabetic retinopathy (DR), remains challenging. We characterized the molecular profile of cell populations in these fibrovascular membranes to identify new therapeutic targets. Preretinal fibrovascular membranes were surgically removed from patients and submitted for single cell RNA (scRNA) sequencing. Differential gene expression was implemented to define the transcriptomic profile of these cells and revealed the presence of endothelial, inflammatory, and stromal cells. Endothelial cell re-clustering identified subclusters characterized by non-canonical trascriptomic profile, and active angiogenesis. Deeper investigation of the inflammatory cells showed a subcluster of macrophages expressing pro-angiogenic cytokines, presumably contributing to angiogenesis. The stromal cell cluster included a pericyte-myofibroblast transdifferentiating subcluster, indicating the involvement of pericytes in fibrogenesis. Differentially expressed gene analysis showed that Adipocyte Enhancer-binding Protein 1, AEBP1, was significantly upregulated in myofibroblast clusters, suggesting that this molecule may have a potential role in transformation. Cell culture experiments with human retinal pericytes (HRP) in high glucose condition confirmed the molecular transformation of pericytes towards myofibroblastic lineage. siAEBP1 transfection in HRP reduced the expression of profibrotic markers in high glucose.In conclusion, AEBP1 signaling modulates pericyte-myofibroblast transformation, suggesting that targeting AEBP1 could prevent scar tissue formation in advanced DR.</text><annotation id="20"><infon key="identifier">MESH:D019773</infon><infon key="type">Disease</infon><location offset="157" length="34"/><text>preretinal fibrovascular membranes</text></annotation><annotation id="21"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="232" length="20"/><text>diabetic retinopathy</text></annotation><annotation id="22"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="254" length="2"/><text>DR</text></annotation><annotation id="23"><infon key="identifier">MESH:D019773</infon><infon key="type">Disease</infon><location offset="409" length="34"/><text>Preretinal fibrovascular membranes</text></annotation><annotation id="24"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="675" length="12"/><text>inflammatory</text></annotation><annotation id="25"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="869" length="12"/><text>inflammatory</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="1136" length="12"/><text>fibrogenesis</text></annotation><annotation id="27"><infon key="identifier">165</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">878</infon><location offset="1201" length="36"/><text>Adipocyte Enhancer-binding Protein 1</text></annotation><annotation id="28"><infon key="identifier">165</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">878</infon><location offset="1239" length="5"/><text>AEBP1</text></annotation><annotation id="29"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1446" length="7"/><text>glucose</text></annotation><annotation id="30"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1631" length="7"/><text>glucose</text></annotation><annotation id="31"><infon key="identifier">165</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">878</infon><location offset="1654" length="5"/><text>AEBP1</text></annotation><annotation id="32"><infon key="identifier">165</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">878</infon><location offset="1745" length="5"/><text>AEBP1</text></annotation><annotation id="33"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="1799" length="2"/><text>DR</text></annotation></passage><relation id="R1"><infon key="score">0.9988</infon><infon key="role1">Disease|MESH:D003930</infon><infon key="role2">Gene|165</infon><infon key="type">Association</infon><node refid="0" role="16,14"/></relation></document>
<document><id>37917533</id><passage><infon key="journal">J Women Aging;2023Nov02 1. doi:10.1080/08952841.2023.2276640</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Davis HA, Lindley LC, Mu&amp;#xf1;oz S, </infon><offset>0</offset><text>East Tennessee older women's perceptions of Medicare, Medicaid, and related health policies.</text></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>Older women face unique challenges regarding health disparities. This study aims to provide an understanding of older women's perceptions and situated experiences regarding the gendered health disparities they face, which are characterized by the policies related to older women's health and the geopolitical and social norms in which they live. The purpose of this project is to provide policy and decision-makers with insights and a better understanding of older women's experiences and perceptions of the policies that impact their health and healthcare. The data for this study was collected through semi-structured interviews with twelve women in Appalachian East Tennessee. Areas examined include: the women's perceived impact of federal, state, and local policies on the participants, particularly of Medicare and Medicaid; the role of social norming and health narratives, particularly stigmatization, discrimination, and health marginalization of older women; and the role of place and place-based drivers on these areas. This study sought to determine if these factors impact the participants' awareness or lack of awareness of policies related to older women. Findings showed that older women in East Tennessee lacked knowledge of health policies, that older women perceive systemic and individual discrimination in policymaking, clinical care, and health research, and that they perceive that place-based drivers have impacted their access to healthcare. These findings have implications for policymaking and intervention design in co-production with older women in order to mitigate older women's health disparities.</text></passage></document>
<document><id>37917885</id><passage><infon key="journal">J Appl Clin Med Phys;2023Nov02 14189. doi:10.1002/acm2.14189</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Torizuka D, Uto M, Mizowaki T, </infon><offset>0</offset><text>Dosimetric impact of adding non-coplanar arcs for scalp-avoidance whole-brain irradiation with volumetric-modulated arc radiotherapy on scalp dose reduction in pediatric patients with medulloblastomas.</text><annotation id="1"><infon key="identifier">MESH:D008527</infon><infon key="type">Disease</infon><location offset="184" length="16"/><text>medulloblastomas</text></annotation></passage><passage><infon key="type">abstract</infon><offset>202</offset><text>PURPOSE: We performed scalp-avoidance whole-brain irradiation with volumetric-modulated arc therapy (SAWB-VMAT) as a component of craniospinal irradiation. In SAWB-VMAT with two coplanar arcs, radiation oncologists and medical physicists sometimes experience difficulty in reducing the dose to the scalp to below the cut-off equivalent dose in 2 Gy per fraction (assuming alpha/beta = 2) to 50% (EQD50%scalp ). To investigate the advantage of adding coplanar or non-coplanar arcs in reducing the dose to the scalp in SAWB-VMAT, we conducted a planning study to compare the EQD50%scalp , the dose to other organs at risk (OARs), and target coverage in VMAT with two coplanar arcs (Co2arcVMAT), VMAT with three coplanar arcs (Co3arcVMAT), and VMAT with two coplanar and two non-coplanar arcs (NcVMAT). METHODS: Co2arcVMAT, Co3arcVMAT, and NcVMAT plans were created for 10 pediatric patients with medulloblastoma. The planned target volume (PTV) included the regions of the whole brain, cervical spinal cord, cerebrospinal fluid space, and intervertebral foramen. The EQD50%scalp was evaluated separately for four areas (top, back, left, and right) in each case. The prescribed dose for the PTV was 35.2 Gy in 22 fractions. RESULTS: The median EQD50%scalp of the top area was 21.9 , 22.1 , and 18.3 Gy for Co2arcVMAT, Co3arcVMAT, and NcVMAT, respectively. The EQD50%scalp of the top area was significantly reduced in NcVMAT compared to those in Co2arcVMAT and Co3arcVMAT (p &lt; 0.05). The median EQD50%scalp of the top area for NcVMAT was &lt; 19.9 Gy, which is the cut-off dose for severe permanent alopecia. There were no significant differences in EQD50%scalp in the three other areas, the dose to other OARs, or the dose coverage of PTV among the three techniques. CONCLUSION: NcVMAT could reduce the EQD50%scalp of the top area below the cut-off dose of 19.9 Gy. NcVMAT appears to be a promising treatment technique for SAWB-VMAT.</text><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="993" length="6"/><text>NcVMAT</text></annotation><annotation id="12"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1039" length="6"/><text>NcVMAT</text></annotation><annotation id="13"><infon key="identifier">MESH:D008527</infon><infon key="type">Disease</infon><location offset="1096" length="15"/><text>medulloblastoma</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1533" length="6"/><text>NcVMAT</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1616" length="6"/><text>NcVMAT</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1725" length="6"/><text>NcVMAT</text></annotation><annotation id="17"><infon key="identifier">MESH:D003638</infon><infon key="type">Disease</infon><location offset="1784" length="18"/><text>permanent alopecia</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1975" length="6"/><text>NcVMAT</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2062" length="6"/><text>NcVMAT</text></annotation></passage></document>
<document><id>37918235</id><passage><infon key="journal">J Environ Manage;2023Oct31; 349 119334. doi:10.1016/j.jenvman.2023.119334</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wu S, Peng X, Sun X, Dong Z, Zhou A, Zhang L, Wang R, </infon><offset>0</offset><text>One-step processing of waste dredged slurry into planting soil by targeted pretreatment and vacuum filtration.</text></passage><passage><infon key="type">abstract</infon><offset>111</offset><text>A novel method, targeted pretreatment and vacuum filtration (TP-VF), is introduced and validated in this study. TP-VF offers a one-step solution for efficiently dewatering dredged slurry (DS) characterized by heavy metal contamination, high salinity, and excessive moisture content. This innovative approach combines targeted pretreatment (TP) and vacuum filtration (VF) to transform DS into the viable planting soil. TP encompasses a dual optimization strategy that enhances both slurry dewatering efficiency and the quality of the resultant planting soil (cake). By employing flocculation pretreatment, TP increases the size of flocs and enlarges cake pores, leading to improvements in dewatering efficiency and infiltration rates. Additionally, targeted pretreatment results in the discharge of approximately 90% of heavy metal ions and most salts with the filtrate. Remarkably, the addition of chelating agents and freshwater as part of the pretreatment process positively impacts soil quality without compromising floc size or dewatering efficiency. Comparatively, TP-VF demonstrates a substantial reduction of 35.81% in operational costs when contrasted with the traditional two-step process, concurrently diminishing the potential for secondary environmental pollution. This study highlights TP-VF as a promising advancement in sustainable slurry management, addressing pressing environmental challenges while optimizing resource utilization.</text><annotation id="3"><infon key="identifier">MESH:D000075322</infon><infon key="type">Disease</infon><location offset="320" length="11"/><text>heavy metal</text></annotation><annotation id="4"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="930" length="11"/><text>heavy metal</text></annotation><annotation id="5"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="956" length="5"/><text>salts</text></annotation></passage></document>
<document><id>37918585</id><passage><infon key="journal">Int J Biol Macromol;2023Oct31 127697. doi:10.1016/j.ijbiomac.2023.127697</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kumar AM, Rajesh T, Obot IB, Bin Sharfan II, Abdulhamid MA, </infon><offset>0</offset><text>Water-soluble chitosan salt as ecofriendly corrosion inhibitor for N80 pipeline steel in artificial sea water: Experimental and theoretical approach.</text><annotation id="5"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="0" length="5"/><text>Water</text></annotation><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="14" length="13"/><text>chitosan salt</text></annotation><annotation id="7"><infon key="type">Disease</infon><location offset="43" length="9"/><text>corrosion</text></annotation><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="67" length="18"/><text>N80 pipeline steel</text></annotation><annotation id="9"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="104" length="5"/><text>water</text></annotation></passage><passage><infon key="type">abstract</infon><offset>150</offset><text>Chitosan, as a proficient biopolymer, has enormous potential as an ecofriendly corrosion inhibitor (CI), but their limited solubility restricts practical applications. Herein, an eco-friendly and water-soluble chitosan salt (CS) was utilized as a green CI on N80 pipeline steel in artificial sea water. Several structural and surface analytical tools were engaged in describing the characteristics of novel CS polymer. The corrosion inhibition efficiencies of CS on steel at different concentrations were investigated through gravimetric, conventional and advanced electrochemical techniques along with the surface analyses. Tafel polarization tests specified that CS performed as mixed-type CI with prevalent anodic inhibition characteristics. At a concentration of 1000 ppm, CS provided an inhibition efficiency (IE) of 96.68 %, following physiochemical adsorptions of CS on N80 surface validated by fitting Langmuir adsorption isotherm. However, the reductions in the values of IE at high temperature specified that the CS is the temperature dependent CIs. Scanning electrochemical microscopic evaluation confirmed the formation of thin CS inhibitors films with high electrochemical stability on N80 steel in saline. The performed surface characterizations on inhibited surfaces validated the adsorption of CS on the N80 surface by forming thin inhibitor film to obstruct metal corrosion. The theoretical simulation studies using molecular dynamics and density functional theory corroborated the experimentally obtained results.</text><annotation id="32"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="150" length="8"/><text>Chitosan</text></annotation><annotation id="33"><infon key="type">Disease</infon><location offset="229" length="9"/><text>corrosion</text></annotation><annotation id="34"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="346" length="5"/><text>water</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="360" length="13"/><text>chitosan salt</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="375" length="2"/><text>CS</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="409" length="18"/><text>N80 pipeline steel</text></annotation><annotation id="38"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="446" length="5"/><text>water</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="557" length="10"/><text>CS polymer</text></annotation><annotation id="40"><infon key="type">Disease</infon><location offset="573" length="9"/><text>corrosion</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="610" length="2"/><text>CS</text></annotation><annotation id="42"><infon key="identifier">MESH:D013232</infon><infon key="type">Chemical</infon><location offset="616" length="5"/><text>steel</text></annotation><annotation id="43"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="815" length="2"/><text>CS</text></annotation><annotation id="44"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="927" length="2"/><text>CS</text></annotation><annotation id="45"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1021" length="2"/><text>CS</text></annotation><annotation id="46"><infon key="identifier">CVCL:N033</infon><infon key="type">CellLine</infon><location offset="1027" length="3"/><text>N80</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1173" length="2"/><text>CS</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1290" length="2"/><text>CS</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1349" length="9"/><text>N80 steel</text></annotation><annotation id="50"><infon key="identifier">MESH:D012965</infon><infon key="type">Chemical</infon><location offset="1362" length="6"/><text>saline</text></annotation><annotation id="51"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1460" length="2"/><text>CS</text></annotation><annotation id="52"><infon key="identifier">CVCL:N033</infon><infon key="type">CellLine</infon><location offset="1470" length="3"/><text>N80</text></annotation><annotation id="53"><infon key="type">Disease</infon><location offset="1531" length="9"/><text>corrosion</text></annotation></passage></document>
<document><id>37918935</id><passage><infon key="journal">BMJ Open;2023Nov02; 13 (11) 076614. doi:10.1136/bmjopen-2023-076614</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sousa-Pinto B, Vieira RJ, Brozek J, Cardoso-Fernandes A, Louren&amp;#xe7;o-Silva N, Ferreira-da-Silva R, Ferreira A, Gil-Mata S, Bedbrook A, Klimek L, Fonseca JA, Zuberbier T, Sch&amp;#xfc;nemann HJ, Bousquet J, </infon><offset>0</offset><text>Intranasal antihistamines and corticosteroids in the treatment of allergic rhinitis: a systematic review and meta-analysis protocol.</text><annotation id="1"><infon key="identifier">MESH:D065631</infon><infon key="type">Disease</infon><location offset="66" length="17"/><text>allergic rhinitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>133</offset><text>INTRODUCTION: Intranasal antihistamines and corticosteroids are some of the most frequently used drug classes in the treatment of allergic rhinitis. However, there is uncertainty as to whether effectiveness differences may exist among different intranasal specific medications. This systematic review aims to analyse and synthesise all evidence from randomised controlled trials (RCTs) on the effectiveness of intranasal antihistamines and corticosteroids in rhinitis nasal and ocular symptoms and in rhinoconjunctivitis-related quality-of-life. METHODS AND ANALYSIS: We will search four electronic bibliographic databases and three clinical trials databases for RCTs (1) assessing patients >=12 years old with seasonal or perennial allergic rhinitis and (2) comparing the use of intranasal antihistamines or corticosteroids versus placebo. Assessed outcomes will include the Total Nasal Symptom Score (TNSS), the Total Ocular Symptom Score (TOSS) and the Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ). We will assess the methodological quality of included primary studies by using the Cochrane risk-of-bias tool. Certainty in the body of evidence for the analysed outcomes will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. We will perform a random-effects meta-analysis for each assessed medication and outcome, presenting results as pooled mean differences and standardised mean differences. Heterogeneity will be explored by sensitivity and subgroup analyses, considering (1) the risk of bias, (2) the follow-up period and (3) the drug dose. ETHICS AND DISSEMINATION: Ethical considerations will not be required. Results will be disseminated in a peer-review journal. PROSPERO REGISTRATION NUMBER: CRD42023416573.</text><annotation id="9"><infon key="identifier">MESH:D065631</infon><infon key="type">Disease</infon><location offset="263" length="17"/><text>allergic rhinitis</text></annotation><annotation id="10"><infon key="identifier">MESH:D012220</infon><infon key="type">Disease</infon><location offset="592" length="8"/><text>rhinitis</text></annotation><annotation id="11"><infon key="identifier">MESH:D009668</infon><infon key="type">Disease</infon><location offset="601" length="25"/><text>nasal and ocular symptoms</text></annotation><annotation id="12"><infon key="identifier">OMIM:613207</infon><infon key="type">Disease</infon><location offset="634" length="19"/><text>rhinoconjunctivitis</text></annotation><annotation id="13"><infon key="identifier">MESH:D012221</infon><infon key="type">Disease</infon><location offset="844" length="39"/><text>seasonal or perennial allergic rhinitis</text></annotation><annotation id="14"><infon key="identifier">OMIM:613207</infon><infon key="type">Disease</infon><location offset="1089" length="19"/><text>Rhinoconjunctivitis</text></annotation><annotation id="15"><infon key="identifier">MESH:D009103</infon><infon key="type">Disease</infon><location offset="1750" length="24"/><text>ETHICS AND DISSEMINATION</text></annotation></passage></document>
<document><id>37919285</id><passage><infon key="journal">Nat Commun;2023Nov02; 14 (1) 7012. doi:10.1038/s41467-023-42781-7</infon><infon key="year">2023</infon><infon key="article-id_pmc">5947976</infon><infon key="type">title</infon><infon key="authors">Zhu W, Song R, Huang J, Wang QW, Cao Y, Zhai R, Bian Q, Shao Z, Jing H, Zhu L, Hou Y, Gao YH, Li S, Zheng F, Zhang P, Pan M, Liu J, Qu G, Gu Y, Zhang H, Dong Q, Huang Y, Yuan X, He J, Li G, Qian T, Chen G, Li SC, Pan M, Xue QK, </infon><offset>0</offset><text>Intrinsic surface p-wave superconductivity in layered AuSn4.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="54" length="5"/><text>AuSn4</text></annotation></passage><passage><infon key="type">abstract</infon><offset>61</offset><text>The search for topological superconductivity (TSC) is currently an exciting pursuit, since non-trivial topological superconducting phases could host exotic Majorana modes. However, the difficulty in fabricating proximity-induced TSC heterostructures, the sensitivity to disorder and stringent topological restrictions of intrinsic TSC place serious limitations and formidable challenges on the materials and related applications. Here, we report a new type of intrinsic TSC, namely intrinsic surface topological superconductivity (IS-TSC) and demonstrate it in layered AuSn4 with Tc of 2.4 K. Different in-plane and out-of-plane upper critical fields reflect a two-dimensional (2D) character of superconductivity. The two-fold symmetric angular dependences of both magneto-transport and the zero-bias conductance peak (ZBCP) in point-contact spectroscopy (PCS) in the superconducting regime indicate an unconventional pairing symmetry of AuSn4. The superconducting gap and surface multi-bands with Rashba splitting at the Fermi level (EF), in conjunction with first-principle calculations, strongly suggest that 2D unconventional SC in AuSn4 originates from the mixture of p-wave surface and s-wave bulk contributions, which leads to a two-fold symmetric superconductivity. Our results provide an exciting paradigm to realize TSC via Rashba effect on surface superconducting bands in layered materials.</text><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="630" length="5"/><text>AuSn4</text></annotation><annotation id="7"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="999" length="5"/><text>AuSn4</text></annotation><annotation id="8"><infon key="identifier">MESH:D006450</infon><infon key="type">Disease</infon><location offset="1191" length="2"/><text>SC</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1197" length="5"/><text>AuSn4</text></annotation></passage></document>
<document><id>37919635</id><passage><infon key="journal">Matern Child Health J;2023Nov02. doi:10.1007/s10995-023-03822-1</infon><infon key="year">2023</infon><infon key="article-id_pmc">8549161</infon><infon key="type">title</infon><infon key="authors">Johnson EK, Rosoklija I, Walton RF, Matoka DJ, Seager CM, Holl JL, </infon><offset>0</offset><text>Physician Perspectives on Performing Newborn Circumcisions: Barriers and Opportunities.</text></passage><passage><infon key="type">abstract</infon><offset>88</offset><text>OBJECTIVE: Over half of infant boys born in the United States undergo newborn circumcision. However, available data indicate that boys who are publicly insured, or Black/African American, have less access to desired newborn circumcision, thus concentrating riskier, more costly operative circumcision among these populations. This study ascertains perinatal physician perspectives about barriers and facilitators to providing newborn circumcisions, with a goal of informing future strategies to ensure more equitable access. METHODS: Qualitative interviews about newborn circumcision care were conducted from April-June 2020 at eleven Chicago-Area hospitals. Physicians that provide perinatal care (pediatricians, family medicine physicians, and obstetricians) participated in qualitative interviews about newborn circumcision. Inductive and deductive qualitative coding was performed to identify themes related to barriers and facilitators of newborn circumcision care. RESULTS: The 23 participating physicians (78% female, 74% white, median 16 years since medical school graduation [range 5-38 years], 52% hospital leadership role, 78% currently perform circumcisions) reported multiple barriers including difficulty with procedural logistics and inconsistent clinician availability and training; corresponding suggestions for operational improvements were also provided. Regarding newborn circumcision insurance coverage and reimbursement, physicians reported limited knowledge, but noted that some insurance reimbursement policies financially disincentivize clinicians and hospitals from offering inpatient newborn circumcision. CONCLUSIONS: Physicians identified logistical/operational, and reimbursement-related barriers to providing newborn circumcision for desirous families. Future studies and advocacy work should focus on developing clinical strategies and healthcare policies to ensure equitable access, and incentivize clinicians/hospitals to perform newborn circumcisions.</text></passage></document>
<document><id>37919985</id><passage><infon key="journal">Math Biosci Eng;2023Jul28; 20 (9) 15672. doi:10.3934/mbe.2023699</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yang K, Duan P, Yu H, </infon><offset>0</offset><text>An improved genetic algorithm for solving the helicopter routing problem with time window in post-disaster rescue.</text></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>The vehicle routing problem (VRP) is a highly significant and extensively studied issue in post-disaster rescue. In recent years, there has been widespread utilization of helicopters for post-disaster rescue. However, efficiently dispatching helicopters to reach rescue sites in post-disaster rescue is a challenge. To address this issue, this study models the issue of dispatching helicopters as a specific variant of the VRP with time window (VRPTW). Considering that the VRPTW is an NP-hard problem, the genetic algorithm (GA) as one of the prominent evolutionary algorithms with robust optimization capabilities, is a good candidate to deal with this issue. In this study, an improved GA with a local search strategy and global search strategy is proposed. To begin, a cooperative initialization strategy is proposed to generate an initial population with high quality and diversity. Subsequently, a local search strategy is presented to improve the exploitation ability. Additionally, a global search strategy is embedded to enhance the global search performance. Finally, 56 instances extended from Solomon instances are utilized for conducting simulation tests. The simulation results indicate that the average relative percentage increase (RPI) of the distance travelled by helicopters as obtained by the proposed algorithm is 0.178, 0.027, 0.075 and 0.041 times smaller than the average RPIs obtained by the tabu search algorithm, ant colony optimization algorithm, hybrid GA and simulated annealing algorithm, respectively. Simulation results reveal that the proposed algorithm is more efficient and effective for solving the VRPTW to reduce the driving distance of the helicopters in post-disaster rescue.</text></passage></document>
<document><id>37921035</id><passage><infon key="journal">Transfusion;2023Nov03. doi:10.1111/trf.17575</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Moslemi C, Saekmose SG, Larsen R, Bay JT, Brodersen T, Didriksen M, Hjalgrim H, Banasik K, Nielsen KR, Bruun MT, Dowsett J, Dinh KM, Mikkelsen S, Mikkelsen C, Hansen TF, Ullum H, Erikstrup C, Brunak S, Krogfelt KA, Storry JR, Ostrowski SR, Olsson ML, Pedersen OB, </infon><offset>0</offset><text>Genetic prediction of 33 blood group phenotypes using an existing genotype dataset.</text></passage><passage><infon key="type">abstract</infon><offset>84</offset><text>BACKGROUND: Accurate blood type data are essential for blood bank management, but due to costs, few of 43 blood group systems are routinely determined in Danish blood banks. However, a more comprehensive dataset of blood types is useful in scenarios such as rare blood type allocation. We aimed to investigate the viability and accuracy of predicting blood types by leveraging an existing dataset of imputed genotypes for two cohorts of approximately 90,000 each (Danish Blood Donor Study and Copenhagen Biobank) and present a more comprehensive overview of blood types for our Danish donor cohort. STUDY DESIGN AND METHODS: Blood types were predicted from genome array data using known variant determinants. Prediction accuracy was confirmed by comparing with preexisting serological blood types. The Vel blood group was used to test the viability of using genetic prediction to narrow down the list of candidate donors with rare blood types. RESULTS: Predicted phenotypes showed a high balanced accuracy >99.5% in most cases: A, B, C/c, Coa /Cob , Doa /Dob , E/e, Jka /Jkb , Kna /Knb , Kpa /Kpb , M/N, S/s, Sda , Se, and Yta /Ytb , while some performed slightly worse: Fya /Fyb , K/k, Lua /Lub , and Vel ~99%-98% and CW and P1 ~96%. Genetic prediction identified 70 potential Vel negatives in our cohort, 64 of whom were confirmed correct using polymerase chain reaction (negative predictive value: 91.5%). DISCUSSION: High genetic prediction accuracy in most blood groups demonstrated the viability of generating blood types using preexisting genotype data at no cost and successfully narrowed the pool of potential individuals with the rare Vel-negative phenotype from 180,000 to 70.</text><annotation id="3"><infon key="identifier">326625</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12680</infon><location offset="1128" length="3"/><text>Cob</text></annotation><annotation id="4"><infon key="identifier">3112</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1602</infon><location offset="1139" length="3"/><text>Dob</text></annotation><annotation id="5"><infon key="identifier">2533</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22664</infon><location offset="1260" length="3"/><text>Fyb</text></annotation></passage></document>
<document><id>37921385</id><passage><infon key="journal">Rev Esp Salud Publica;2023Feb02; 97 1</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Capit&amp;#xe1;n-Moyano L, Arias-Fern&amp;#xe1;ndez M, Bennasar-Veny M, Y&amp;#xe1;&amp;#xf1;ez AM, Castro-S&amp;#xe1;nchez E, </infon><offset>0</offset><text>[(In)seguridad alimentaria en adolescentes: del paternalismo a la justicia social.]</text><annotation id="1"><infon key="type">Disease</infon><location offset="15" length="11"/><text>alimentaria</text></annotation></passage><passage><infon key="type">abstract</infon><offset>84</offset></passage></document>
<document><id>37921735</id><passage><infon key="journal">J Thorac Cardiovasc Surg;2023Nov01. doi:10.1016/j.jtcvs.2023.10.004</infon><infon key="year">2023</infon><infon key="type">title</infon><offset>0</offset><text>Discussion to: Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study.</text><annotation id="2"><infon key="identifier">MESH:C537153</infon><infon key="type">Disease</infon><location offset="45" length="4"/><text>N2-3</text></annotation><annotation id="3"><infon key="identifier">MESH:D000077277</infon><infon key="type">Disease</infon><location offset="50" length="34"/><text>esophageal squamous cell carcinoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>163</offset></passage></document>
<document><id>37889989</id><passage><infon key="journal">JBJS Case Connect;2023Oct01; 13 (4) . doi:10.2106/JBJS.CC.23.00348</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tummala SV, Lin E, Mujahed T, Beauchamp CP, Blair JE, Goulding KA, </infon><offset>0</offset><text>Rare Bipolaris Species Fungal Periprosthetic Hip Infection in an Immunocompetent Host: A Case Report.</text><annotation id="2"><infon key="identifier">MESH:D009181</infon><infon key="type">Disease</infon><location offset="23" length="6"/><text>Fungal</text></annotation><annotation id="3"><infon key="identifier">MESH:D057068</infon><infon key="type">Disease</infon><location offset="30" length="28"/><text>Periprosthetic Hip Infection</text></annotation></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>CASE: We present a case report of a 64-year-old man who developed a rare Bipolaris species fungal periprosthetic joint infection (PJI) after revision arthroplasty for complications associated with a metal-on-metal total hip arthroplasty. The patient underwent a 2-stage debridement with antibiotic bead placement and implant retention, along with chronic antifungal suppression. At the 2-year follow-up, the patient remained asymptomatic. CONCLUSION: Fungal PJI with filamentous fungi such as Bipolaris species is a rare clinical entity. This case report highlights the clinical presentation and management of this rare condition.</text><annotation id="11"><infon key="identifier">MESH:D009181</infon><infon key="type">Disease</infon><location offset="193" length="6"/><text>fungal</text></annotation><annotation id="12"><infon key="identifier">MESH:D057068</infon><infon key="type">Disease</infon><location offset="200" length="30"/><text>periprosthetic joint infection</text></annotation><annotation id="13"><infon key="identifier">MESH:D057068</infon><infon key="type">Disease</infon><location offset="232" length="3"/><text>PJI</text></annotation><annotation id="14"><infon key="type">Disease</infon><location offset="252" length="12"/><text>arthroplasty</text></annotation><annotation id="15"><infon key="type">Disease</infon><location offset="326" length="12"/><text>arthroplasty</text></annotation><annotation id="16"><infon key="identifier">MESH:D009181</infon><infon key="type">Disease</infon><location offset="553" length="6"/><text>Fungal</text></annotation><annotation id="17"><infon key="identifier">MESH:D057068</infon><infon key="type">Disease</infon><location offset="560" length="3"/><text>PJI</text></annotation></passage></document>
<document><id>37890340</id><passage><infon key="journal">Phys Ther Sport;2023Oct20; 64 133. doi:10.1016/j.ptsp.2023.10.002</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nurse CA, Lewis CL, Shefelbine SJ, </infon><offset>0</offset><text>Frontal plane pelvic kinematics during high velocity running: Association with hamstring injury history.</text><annotation id="1"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="79" length="16"/><text>hamstring injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>105</offset><text>INTRODUCTION: Hamstring injuries are the most prevalent non-contact soft tissue injury in sports, with a larger portion of injuries being recurrent. The sagittal plane running kinematics correlated to hamstring injury history has been well documented. However, analysis of frontal plane kinematics allows for observation of stability and symmetry. This study aimed to examine the frontal plane running kinematics of elite collegiate level sprinters, with and without previous hamstring injury, compared to healthy counterparts. METHODS: Thirty-nine participants performed three 50-m sprints, with three inertial measurement unit sensors placed on the pelvis: one on each iliac crest and one on the sacrum. Participants were classified based on sex, competitive status, and injury history. To investigate differences based on group classification, the data were used to analyze mediolateral motion (relative magnitude of mediolateral acceleration) and asymmetry (difference in acceleration between right and left iliac crests) during each stance phase throughout the run. RESULTS: Injured sprinters displayed significantly greater mediolateral motion and asymmetry during stances than healthy counterparts. CONCLUSIONS: This study demonstrates that frontal plane running stance dynamics are different in athletes with previous hamstring injury than healthy athletes. These athletes may benefit from rehabilitation strategies targeting postural control and stability during dynamic tasks.</text><annotation id="9"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="119" length="18"/><text>Hamstring injuries</text></annotation><annotation id="10"><infon key="identifier">MESH:D017695</infon><infon key="type">Disease</infon><location offset="173" length="18"/><text>soft tissue injury</text></annotation><annotation id="11"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="228" length="8"/><text>injuries</text></annotation><annotation id="12"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="306" length="16"/><text>hamstring injury</text></annotation><annotation id="13"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="581" length="16"/><text>hamstring injury</text></annotation><annotation id="14"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="878" length="6"/><text>injury</text></annotation><annotation id="15"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1431" length="16"/><text>hamstring injury</text></annotation></passage></document>
<document><id>37890690</id><passage><infon key="journal">Am J Ophthalmol;2023Oct25. doi:10.1016/j.ajo.2023.10.016</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang YX, Wang Q, Jonas R, Jonas JB, </infon><offset>0</offset><text>Prevalence and Associations of Peripheral Arterial Disease in China. The Beijing Eye Study.</text><annotation id="1"><infon key="identifier">MESH:D058729</infon><infon key="type">Disease</infon><location offset="31" length="27"/><text>Peripheral Arterial Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>92</offset><text>PURPOSE: To explore the prevalence and associations of peripheral arterial disease (PAD) in China DESIGN: Population-based incidence estimate and cross-sectional study METHODS: The participants (n=3468) of the Beijing Eye Study underwent a detailed ophthalmological and systemic examination including assessment of the ankle-brachial index (ABI). PAD was defined by an ABI of less than 0.9. RESULTS: Blood pressure measurements of both arms and ankles were available for 1078 (31.1%) individuals. An ABI (mean:1.09+-0.11;median:1.10;range:0.25,1.36) of &lt;0.9 and &lt;0.95 was found in 32/1078 participants (3.0%;95%CI:2.0,4.0) and 70/1078 individuals (6.5%;95%CI:5.0,8.0), respectively. Higher PAD prevalence (multivariable analysis) was associated with older age (odds ratio (OR):1.08;95%CI:1.02,1.15;P=0.009), lower level of education (OR:0.62;95%CI:0.43,0.90;P=0.01), lower quality of life (OR:0.67;95%CI:1.11,2.32), higher glucose serum concentration (OR:1.36;95%CI:1.09,1.58;P=0.006), lower estimated glomerular filtration rate (OR:0.98;95%CI:0.96,0.99;P=0.04), and higher prevalence of retinal vein occlusions (OR7.30;95%CI:1.63,32.6;P=0.009). PAD prevalence was not associated with the prevalence of glaucoma (P=0.53) (open-angle glaucoma:P=0.42; angle-closure glaucoma:P=0.57) and age-related macular degeneration (any AMD:P=0.39; early AMD:P=0.31; intermediate AMD:P=0.92; late AMD:P=0.99), prevalence (P=0.26) and stage (P=0.07) of diabetic retinopathy, prevalence (P=0.38) and degree (P=0.68) of nuclear cataract, prevalence (P=0.39) and degree (P=0.72) of cortical cataract, prevalence of subcapsular cataract (P=0.86), prevalence of pseudoexfoliation (P=0.65), intraocular pressure (P=0.50), axial length (P=0.56), and peripapillary retinal nerve fiber layer thickness (P=0.68). CONCLUSIONS: The PAD prevalence (3.0%;95%CI:2.0,4.0) was relatively low in this cohort from rural and urban Beijing, with older age, lower educational level, lower quality of life, higher glucose serum concentration, lower estimated glomerular filtration rate, and higher prevalence of retinal vein occlusions as main associated factors.</text><annotation id="24"><infon key="identifier">MESH:D058729</infon><infon key="type">Disease</infon><location offset="147" length="27"/><text>peripheral arterial disease</text></annotation><annotation id="25"><infon key="identifier">MESH:D058729</infon><infon key="type">Disease</infon><location offset="176" length="3"/><text>PAD</text></annotation><annotation id="26"><infon key="identifier">MESH:D058729</infon><infon key="type">Disease</infon><location offset="439" length="3"/><text>PAD</text></annotation><annotation id="27"><infon key="identifier">MESH:D058729</infon><infon key="type">Disease</infon><location offset="782" length="3"/><text>PAD</text></annotation><annotation id="28"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1015" length="7"/><text>glucose</text></annotation><annotation id="29"><infon key="identifier">MESH:D012170</infon><infon key="type">Disease</infon><location offset="1180" length="23"/><text>retinal vein occlusions</text></annotation><annotation id="30"><infon key="identifier">MESH:D058729</infon><infon key="type">Disease</infon><location offset="1238" length="3"/><text>PAD</text></annotation><annotation id="31"><infon key="identifier">MESH:D005901</infon><infon key="type">Disease</infon><location offset="1295" length="8"/><text>glaucoma</text></annotation><annotation id="32"><infon key="identifier">MESH:D005902</infon><infon key="type">Disease</infon><location offset="1314" length="19"/><text>open-angle glaucoma</text></annotation><annotation id="33"><infon key="identifier">MESH:D015812</infon><infon key="type">Disease</infon><location offset="1342" length="22"/><text>angle-closure glaucoma</text></annotation><annotation id="34"><infon key="identifier">MESH:D008268</infon><infon key="type">Disease</infon><location offset="1377" length="32"/><text>age-related macular degeneration</text></annotation><annotation id="35"><infon key="identifier">MESH:D006009</infon><infon key="type">Disease</infon><location offset="1415" length="3"/><text>AMD</text></annotation><annotation id="36"><infon key="identifier">MESH:D006009</infon><infon key="type">Disease</infon><location offset="1433" length="3"/><text>AMD</text></annotation><annotation id="37"><infon key="identifier">MESH:D006009</infon><infon key="type">Disease</infon><location offset="1458" length="3"/><text>AMD</text></annotation><annotation id="38"><infon key="identifier">MESH:D006009</infon><infon key="type">Disease</infon><location offset="1475" length="3"/><text>AMD</text></annotation><annotation id="39"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="1530" length="20"/><text>diabetic retinopathy</text></annotation><annotation id="40"><infon key="identifier">MESH:D002386</infon><infon key="type">Disease</infon><location offset="1603" length="8"/><text>cataract</text></annotation><annotation id="41"><infon key="identifier">MESH:D002386</infon><infon key="type">Disease</infon><location offset="1665" length="8"/><text>cataract</text></annotation><annotation id="42"><infon key="identifier">MESH:D002386</infon><infon key="type">Disease</infon><location offset="1701" length="8"/><text>cataract</text></annotation><annotation id="43"><infon key="identifier">MESH:D058729</infon><infon key="type">Disease</infon><location offset="1897" length="3"/><text>PAD</text></annotation><annotation id="44"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="2068" length="7"/><text>glucose</text></annotation><annotation id="45"><infon key="identifier">MESH:D012170</infon><infon key="type">Disease</infon><location offset="2166" length="23"/><text>retinal vein occlusions</text></annotation></passage></document>
<document><id>37891041</id><passage><infon key="journal">J Prosthet Dent;2023Oct25. doi:10.1016/j.prosdent.2023.09.020</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Abdelaziz MS, Ayad MW, Tella EAESAEM, </infon><offset>0</offset><text>Fabrication of a reverse-engineered custom scan body as a digital solution for recording implant position: A dental technique.</text></passage><passage><infon key="type">abstract</infon><offset>127</offset><text>A technique for the reverse engineering of the implant-abutment connection to fabricate a custom scan body is described. The implant-abutment connection was designed using the exocad software program, the scan body with screw channel was designed with the Blender software program, and the file was either 3-dimensionally printed in definitive tooth-colored resin with ceramic filler material or milled in polyetheretherketone (PEEK). This technique offers an accurate, cost-effective digital solution for implant optical scanning that can replace prefabricated scan bodies that may not be available for all implants. (J Prosthet Dent xxxx;xxx:xxx-xxx).</text><annotation id="2"><infon key="identifier">MESH:C063834</infon><infon key="type">Chemical</infon><location offset="533" length="20"/><text>polyetheretherketone</text></annotation><annotation id="3"><infon key="identifier">MESH:C063834</infon><infon key="type">Chemical</infon><location offset="555" length="4"/><text>PEEK</text></annotation></passage></document>
<document><id>37891392</id><passage><infon key="journal">AAPS PharmSciTech;2023Oct27; 24 (8) 217. doi:10.1208/s12249-023-02673-x</infon><infon key="year">2023</infon><infon key="article-id_pmc">9229693</infon><infon key="type">title</infon><infon key="authors">Biswas A, Choudhury AD, Bisen AC, Agrawal S, Sanap SN, Verma SK, Mishra A, Kumar S, Bhatta RS, </infon><offset>0</offset><text>Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.</text></passage><passage><infon key="type">abstract</infon><offset>98</offset><text>The eye, an intricate organ comprising physical and physiological barriers, poses a significant challenge for ophthalmic physicians seeking to treat serious ocular diseases affecting the posterior segment, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR). Despite extensive efforts, the delivery of therapeutic drugs to the rear part of the eye remains an unresolved issue. This comprehensive review delves into conventional and innovative formulation strategies for drug delivery to the posterior segment of the eye. By utilizing alternative nanoformulation approaches such as liposomes, nanoparticles, and microneedle patches, researchers and clinicians can overcome the limitations of conventional eye drops and achieve more effective drug delivery to the posterior segment of the eye. These innovative strategies offer improved drug penetration, prolonged residence time, and controlled release, enhancing therapeutic outcomes for ocular diseases. Moreover, this article explores recently approved delivery systems that leverage diverse polymer technologies, such as chitosan and hyaluronic acid, to regulate drug-controlled release over an extended period. By offering a comprehensive understanding of the available formulation strategies, this review aims to empower researchers and clinicians in their pursuit of developing highly effective treatments for posterior-segment ocular diseases.</text><annotation id="10"><infon key="identifier">MESH:D005128</infon><infon key="type">Disease</infon><location offset="255" length="15"/><text>ocular diseases</text></annotation><annotation id="11"><infon key="identifier">MESH:D008268</infon><infon key="type">Disease</infon><location offset="312" length="32"/><text>age-related macular degeneration</text></annotation><annotation id="12"><infon key="identifier">MESH:D008268</infon><infon key="type">Disease</infon><location offset="346" length="3"/><text>AMD</text></annotation><annotation id="13"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="355" length="20"/><text>diabetic retinopathy</text></annotation><annotation id="14"><infon key="identifier">MESH:D003930</infon><infon key="type">Disease</infon><location offset="377" length="2"/><text>DR</text></annotation><annotation id="15"><infon key="identifier">MESH:D005128</infon><infon key="type">Disease</infon><location offset="1061" length="15"/><text>ocular diseases</text></annotation><annotation id="16"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="1167" length="7"/><text>polymer</text></annotation><annotation id="17"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="1197" length="8"/><text>chitosan</text></annotation><annotation id="18"><infon key="identifier">MESH:D006820</infon><infon key="type">Chemical</infon><location offset="1210" length="15"/><text>hyaluronic acid</text></annotation><annotation id="19"><infon key="identifier">MESH:C537775</infon><infon key="type">Disease</infon><location offset="1489" length="33"/><text>posterior-segment ocular diseases</text></annotation></passage></document>
<document><id>37897351</id><passage><infon key="journal">Eur Heart J;2023Oct28. doi:10.1093/eurheartj/ehad693</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Persson J, Ivert T, Omerovic E, </infon><offset>0</offset><text>Observational studies are needed to complete the body of evidence for left main coronary artery disease revascularization strategies.</text><annotation id="1"><infon key="identifier">MESH:D003324</infon><infon key="type">Disease</infon><location offset="80" length="23"/><text>coronary artery disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>134</offset></passage></document>
<document><id>37898052</id><passage><infon key="journal">Curr Opin Microbiol;2023Oct25; 76 102397. doi:10.1016/j.mib.2023.102397</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Reguera-Gomez M, Dores MR, Martinez LR, </infon><offset>0</offset><text>Innovative and potential treatments for fungal central nervous system infections.</text><annotation id="1"><infon key="identifier">MESH:D020314</infon><infon key="type">Disease</infon><location offset="40" length="40"/><text>fungal central nervous system infections</text></annotation></passage><passage><infon key="type">abstract</infon><offset>82</offset><text>Fungal infections of the central nervous system (FI-CNS) are a problematic and important medical challenge considering that those most affected are immunocompromised. Individuals with systemic cryptococcosis (67-84%), candidiasis (3-64%), blastomycosis (40%), coccidioidomycosis (25%), histoplasmosis (5-20%), mucormycosis (12%), and aspergillosis (4-6%) are highly susceptible to develop CNS involvement, which often results in high mortality (15-100%) depending on the mycosis and the affected immunosuppressed population. Current antifungal drugs are limited, prone to resistance, present host toxicity, and show reduced brain penetration, making FI-CNS very difficult to treat. Given these limitations and the rise in FI-CNS, there is a need for innovative strategies for therapeutic development and treatments to manage FI-CNS in at-risk populations. Here, we discuss standards of care, antifungal drug candidates, and novel molecular targets in the blood-brain barrier, which is a protective structure that regulates movement of particles in and out of the brain, to prevent and combat FI-CNS.</text><annotation id="18"><infon key="identifier">MESH:D020314</infon><infon key="type">Disease</infon><location offset="82" length="47"/><text>Fungal infections of the central nervous system</text></annotation><annotation id="19"><infon key="identifier">MESH:D002494</infon><infon key="type">Disease</infon><location offset="131" length="6"/><text>FI-CNS</text></annotation><annotation id="20"><infon key="identifier">MESH:D003453</infon><infon key="type">Disease</infon><location offset="266" length="23"/><text>systemic cryptococcosis</text></annotation><annotation id="21"><infon key="identifier">MESH:D002177</infon><infon key="type">Disease</infon><location offset="300" length="11"/><text>candidiasis</text></annotation><annotation id="22"><infon key="identifier">MESH:D001759</infon><infon key="type">Disease</infon><location offset="321" length="13"/><text>blastomycosis</text></annotation><annotation id="23"><infon key="identifier">MESH:D003047</infon><infon key="type">Disease</infon><location offset="342" length="18"/><text>coccidioidomycosis</text></annotation><annotation id="24"><infon key="identifier">MESH:D006660</infon><infon key="type">Disease</infon><location offset="368" length="14"/><text>histoplasmosis</text></annotation><annotation id="25"><infon key="identifier">MESH:D009091</infon><infon key="type">Disease</infon><location offset="392" length="12"/><text>mucormycosis</text></annotation><annotation id="26"><infon key="identifier">MESH:D001228</infon><infon key="type">Disease</infon><location offset="416" length="13"/><text>aspergillosis</text></annotation><annotation id="27"><infon key="identifier">MESH:D002494</infon><infon key="type">Disease</infon><location offset="471" length="15"/><text>CNS involvement</text></annotation><annotation id="28"><infon key="identifier">MESH:D015821</infon><infon key="type">Disease</infon><location offset="553" length="7"/><text>mycosis</text></annotation><annotation id="29"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="679" length="8"/><text>toxicity</text></annotation><annotation id="30"><infon key="identifier">MESH:D002494</infon><infon key="type">Disease</infon><location offset="732" length="6"/><text>FI-CNS</text></annotation><annotation id="31"><infon key="identifier">MESH:D002494</infon><infon key="type">Disease</infon><location offset="804" length="6"/><text>FI-CNS</text></annotation><annotation id="32"><infon key="identifier">MESH:D002494</infon><infon key="type">Disease</infon><location offset="907" length="6"/><text>FI-CNS</text></annotation><annotation id="33"><infon key="identifier">MESH:D002494</infon><infon key="type">Disease</infon><location offset="1174" length="6"/><text>FI-CNS</text></annotation></passage></document>
<document><id>37898405</id><passage><infon key="journal">J Lipid Res;2023Oct26 100467. doi:10.1016/j.jlr.2023.100467</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yang Y, Jung H, Konrad RJ, Fong LG, Young SG, </infon><offset>0</offset><text>Imaging the ANGPTL3/8-mediated regulation of lipoprotein lipase in the heart.</text><annotation id="2"><infon key="identifier">27329;55908</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8499;83285</infon><location offset="12" length="9"/><text>ANGPTL3/8</text></annotation><annotation id="3"><infon key="identifier">4023</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">200</infon><location offset="45" length="18"/><text>lipoprotein lipase</text></annotation></passage><passage><infon key="type">abstract</infon><offset>78</offset></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Gene|4023</infon><infon key="role2">Gene|55908</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Gene|27329</infon><infon key="role2">Gene|4023</infon><infon key="type">Association</infon><node refid="1" role="0,1"/></relation></document>
<document><id>37899105</id><passage><infon key="journal">Ying Yong Sheng Tai Xue Bao;2023Sep; 34 (9) 2398. doi:10.13287/j.1001-9332.202309.014</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhao YQ, Lian YC, Xu WW, Han GL, Zhao Y, </infon><offset>0</offset><text>Effects of fine substance content in soil substrate on the formation of artificial cyanobacteria crusts.</text></passage><passage><infon key="type">abstract</infon><offset>105</offset><text>The use of artificial cyanobacteria crusts is one of the effective methods to prevention and control of desertification. Soil fine substance is one of the important factors limiting the colonization and growth of artificial cyanobacteria crusts. We compared the growth of artificial cyanobacterial crusts with different fine substance contents by setting the volume ratios of fine substance to quicksand as 0:1, 1:1, 2:1, 4:1 and 1:0. The results showed that the cover of artificial cyanobacteria crusts increased gradually with the increases of fine substance contents, while the contents of chlorophyll a and extracellular polysaccharide firstly increased and then decreased slightly. The optimum growth of artificial cyanobacterial crusts was achieved under the treatment of 4:1 ratio. Under such treatment after 60 days of incubation, artificial cyanobacteria crusts cover was 70%, and the contents of chlorophyll a, loosely bound exopolysaccharide (LB-EPS), tightly bound exopolysaccharide (TB-EPS), and glycocalyx exopolysaccharide (G-EPS) were 17.5, 70.0, 175.0, and 200.0 mug cm-2, respectively. Increasing the amount of cyanobacteria under the condition of low fine substance content could promote the formation and growth of artificial cyanobacterial crusts (0.5 g of cyanobacteria per petri dish was the optimal). It could provide a new idea for the large-scale culture of artificial cyanobacterial crusts inoculum.</text><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="698" length="13"/><text>chlorophyll a</text></annotation><annotation id="10"><infon key="identifier">MESH:D011134</infon><infon key="type">Chemical</infon><location offset="730" length="14"/><text>polysaccharide</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1011" length="13"/><text>chlorophyll a</text></annotation><annotation id="12"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1040" length="17"/><text>exopolysaccharide</text></annotation><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1059" length="6"/><text>LB-EPS</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1082" length="17"/><text>exopolysaccharide</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1101" length="6"/><text>TB-EPS</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1125" length="17"/><text>exopolysaccharide</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1144" length="5"/><text>G-EPS</text></annotation></passage></document>
<document><id>37901908</id><passage><infon key="journal">Chem Commun (Camb);2023Oct30. doi:10.1039/d3cc04159j</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang L, Xu Y, Wei W, </infon><offset>0</offset><text>Water-soluble organic macrocycles based on dye chromophores and their applications.</text><annotation id="1"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="0" length="5"/><text>Water</text></annotation></passage><passage><infon key="type">abstract</infon><offset>84</offset><text>Traditional water-soluble organic macrocyclic receptors generally lack photofunctionality, thus monitoring the drug delivery and the phototheranostic applications of these host-guest macrocyclic systems has been greatly restricted. To address this issue, incorporating pi-conjugated dye chromophores as building blocks into macrocyclic molecules is a straightforward and promising strategy. This approach not only imparts intrinsic optical features to the macrocycles themselves but also enhances the host-guest binding ability due to the large planar structures of the dyes. In this feature article, we focus on recent advances in water-soluble macrocyclic compounds based on organic dye chromophores, such as naphthalimide (NDI), perylene diimides (PDI), azobenzene (azo), tetraphenylethylene (TPE) and anthracene, and provide an overview of their various applications including molecular recognition, drug release, biological imaging, photothermal therapy, etc. We hope that this article could be helpful and instructive for the design of water-soluble dye-based macrocycles and the further development of their biomedical applications, particularly in combination with drug therapy and phototheranostics.</text><annotation id="13"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="96" length="5"/><text>water</text></annotation><annotation id="14"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="716" length="5"/><text>water</text></annotation><annotation id="15"><infon key="identifier">MESH:D053644</infon><infon key="type">Chemical</infon><location offset="795" length="13"/><text>naphthalimide</text></annotation><annotation id="16"><infon key="identifier">MESH:C521332</infon><infon key="type">Chemical</infon><location offset="816" length="17"/><text>perylene diimides</text></annotation><annotation id="17"><infon key="identifier">MESH:C521332</infon><infon key="type">Chemical</infon><location offset="835" length="3"/><text>PDI</text></annotation><annotation id="18"><infon key="identifier">MESH:C009850</infon><infon key="type">Chemical</infon><location offset="841" length="10"/><text>azobenzene</text></annotation><annotation id="19"><infon key="identifier">MESH:C009850</infon><infon key="type">Chemical</infon><location offset="853" length="3"/><text>azo</text></annotation><annotation id="20"><infon key="identifier">MESH:C000617116</infon><infon key="type">Chemical</infon><location offset="859" length="19"/><text>tetraphenylethylene</text></annotation><annotation id="21"><infon key="identifier">MESH:C000617116</infon><infon key="type">Chemical</infon><location offset="880" length="3"/><text>TPE</text></annotation><annotation id="22"><infon key="identifier">MESH:C034020</infon><infon key="type">Chemical</infon><location offset="889" length="10"/><text>anthracene</text></annotation><annotation id="23"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1126" length="5"/><text>water</text></annotation></passage><relation id="R1"><infon key="score">0.5196</infon><infon key="role1">Chemical|MESH:C000617116</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="0" role="8,2"/></relation></document>
<document><id>37902258</id><passage><infon key="journal">Cancer Med;2023Oct30. doi:10.1002/cam4.6641</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Agapito I, Ng DQ, Milam J, Ziogas A, Anton-Culver H, Chan A, </infon><offset>0</offset><text>Neuropsychiatric complications and associated management in adolescent and young adult cancer survivors: An All of Us study.</text><annotation id="2"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="0" length="30"/><text>Neuropsychiatric complications</text></annotation><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="87" length="6"/><text>cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>125</offset><text>BACKGROUND: About 4.5% of new cancer cases affect adolescent and young adult aged between 15 and 39 years in the United States (US). However, the effect of neuropsychiatric conditions on long-term adolescent and young adult cancer (AYAC) survivors has not been formally investigated. Thus, the impact and management of late neuropsychiatric complications in AYAC survivors compared to non-cancer-matched controls (NCMC) in the US were evaluated using the All of Us (AoU) Research Program. METHODS: Participants in the AoU Controlled Tier Dataset (v6) diagnosed with cancer between ages 15 and 39 were identified from electronic health records and surveys. AYAC survivors were matched with NCMC using the optimal pair-matching algorithm at a 1:4 ratio. Data on past diagnoses, current follow-up care, and treatment patterns of neuropsychiatric complications were collected. RESULTS: Analysis was performed on 788 AYAC survivors and 3152 NCMC. AYAC survivors, with an average of 8.8 years since their first cancer diagnosis, were more likely than NCMC to receive a diagnosis of neuropathy, memory loss and epilepsy (p  &lt; 0.001). Survivors also had a higher rate of follow-up care and treatment utilization for these neurological conditions compared to NCMC (p  &lt; 0.05). Treatment utilization was highest among survivors receiving care for epilepsy (88%), and lower for neuropathy (70%), memory loss (61%), and chronic fatigue (59%). CONCLUSIONS: This large study reveals that AYAC survivors, on average 9 years after their cancer diagnosis, require more frequent follow-up care for neurological complications compared to non-cancer individuals. However, the management of neuropathy, memory loss, and chronic fatigue is hindered by a lack of mechanism-based effective therapies.</text><annotation id="26"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="155" length="6"/><text>cancer</text></annotation><annotation id="27"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="281" length="27"/><text>neuropsychiatric conditions</text></annotation><annotation id="28"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="349" length="6"/><text>cancer</text></annotation><annotation id="29"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="449" length="30"/><text>neuropsychiatric complications</text></annotation><annotation id="30"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="514" length="6"/><text>cancer</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="691" length="6"/><text>cancer</text></annotation><annotation id="32"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="951" length="30"/><text>neuropsychiatric complications</text></annotation><annotation id="33"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1130" length="6"/><text>cancer</text></annotation><annotation id="34"><infon key="identifier">MESH:D009422</infon><infon key="type">Disease</infon><location offset="1201" length="10"/><text>neuropathy</text></annotation><annotation id="35"><infon key="identifier">MESH:D008569</infon><infon key="type">Disease</infon><location offset="1213" length="11"/><text>memory loss</text></annotation><annotation id="36"><infon key="identifier">MESH:D004827</infon><infon key="type">Disease</infon><location offset="1229" length="8"/><text>epilepsy</text></annotation><annotation id="37"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="1339" length="23"/><text>neurological conditions</text></annotation><annotation id="38"><infon key="identifier">MESH:D004827</infon><infon key="type">Disease</infon><location offset="1462" length="8"/><text>epilepsy</text></annotation><annotation id="39"><infon key="identifier">MESH:D009422</infon><infon key="type">Disease</infon><location offset="1492" length="10"/><text>neuropathy</text></annotation><annotation id="40"><infon key="identifier">MESH:D008569</infon><infon key="type">Disease</infon><location offset="1510" length="11"/><text>memory loss</text></annotation><annotation id="41"><infon key="identifier">MESH:D015673</infon><infon key="type">Disease</infon><location offset="1533" length="15"/><text>chronic fatigue</text></annotation><annotation id="42"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1646" length="6"/><text>cancer</text></annotation><annotation id="43"><infon key="identifier">MESH:D002493</infon><infon key="type">Disease</infon><location offset="1705" length="26"/><text>neurological complications</text></annotation><annotation id="44"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1748" length="6"/><text>cancer</text></annotation><annotation id="45"><infon key="identifier">MESH:D009422</infon><infon key="type">Disease</infon><location offset="1795" length="10"/><text>neuropathy</text></annotation><annotation id="46"><infon key="identifier">MESH:D008569</infon><infon key="type">Disease</infon><location offset="1807" length="11"/><text>memory loss</text></annotation><annotation id="47"><infon key="identifier">MESH:D015673</infon><infon key="type">Disease</infon><location offset="1824" length="15"/><text>chronic fatigue</text></annotation></passage></document>
<document><id>37902608</id><passage><infon key="journal">Future Microbiol;2023Oct30. doi:10.2217/fmb-2023-0199</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yu KC, Patkar A, </infon><offset>0</offset><text>Hospital-onset bacteremia: clinical and regulatory ramifications.</text><annotation id="1"><infon key="identifier">MESH:D016470</infon><infon key="type">Disease</infon><location offset="15" length="10"/><text>bacteremia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>66</offset><text>Tweetable abstract Read the commentary by @Kalvin_Yu_MD and Anuprita Patkar, PhD on the higher risk mortality, LOS and cost of hospital-onset bacteremia (HOB), and the implications of a regulatory HOB quality metric for patient care, clinical workflows and hospital administration #PatientSafety #QualityMetric.</text><annotation id="5"><infon key="identifier">MESH:D016470</infon><infon key="type">Disease</infon><location offset="208" length="10"/><text>bacteremia</text></annotation><annotation id="6"><infon key="identifier">MESH:D016470</infon><infon key="type">Disease</infon><location offset="220" length="3"/><text>HOB</text></annotation><annotation id="7"><infon key="identifier">MESH:D016470</infon><infon key="type">Disease</infon><location offset="263" length="3"/><text>HOB</text></annotation></passage></document>
<document><id>37902960</id><passage><infon key="journal">J Integr Complement Med;2023Oct30. doi:10.1089/jicm.2023.29124.editorial</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cramer H, </infon><offset>0</offset><text>The World Health Organization Traditional Medicine Strategy: Enhancing Healthcare Access, Health Equity, and Health Choices Worldwide.</text></passage><passage><infon key="type">abstract</infon><offset>135</offset></passage></document>
<document><id>37903336</id><passage><infon key="journal">Cornea;2023Oct30. doi:10.1097/ICO.0000000000003405</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ali M, Dun C, Cho K, Soiberman U, Woreta F, Makary MA, Jhanji V, Srikumaran D, </infon><offset>0</offset><text>Infectious Keratitis After Keratoplasty in the United States: Analysis of a National Medicare Claims Data Set.</text><annotation id="1"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="0" length="20"/><text>Infectious Keratitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>111</offset><text>PURPOSE: The aim of this study was to assess the incidence, trends, and risk factors of infectious keratitis (IK) and subsequent repeat keratoplasty after penetrating keratoplasty (PK) and endothelial keratoplasty (EK). METHODS: Using a retrospective cohort study design, IK cases within 6 months of keratoplasty were identified using billing codes among 100% Medicare beneficiaries aged 65 years and older who underwent either PK or EK between 2011 and 2020. Multivariable logistic regression models were used to evaluate factors associated with postkeratoplasty IK. RESULTS: We identified 115,588 keratoplasties, of which 20.0% (n = 23,144) were PK and 80.0% (n = 92,444) were EK. IK developed within 6 months with a rate of 3.32% (n = 769) post-PK and 0.72% (n = 666) post-EK. Overall rates of IK decreased from 16.05 to 9.61 per 1000 keratoplasties between 2011 and 2020 (P &lt; 0.001). The median interval between keratoplasty and diagnosis of IK was 73 days (interquartile range: 29-114 days) for PK and 74 days (interquartile range: 38-116 days) for EK. After IK, 22.9% (n = 176) and 23.8% (n = 159) eyes underwent repeat keratoplasty within 1 year for PK and EK, respectively. The occurrence of IK after PK was associated with age 85 years and older [odds ratio (OR): 1.38; 95% confidence interval (CI): 1.13-1.68] relative to patients aged 65 to 74 years. The occurrence of IK after EK was also associated with age 85 years and older (OR: 1.44; 95% CI: 1.14-1.82) relative to patients aged 65 to 74 years. CONCLUSIONS: IK was 4 times more common after PK than EK and the complication was associated with older age. Our findings may help corneal surgeons in counseling patients at higher risk and guiding their postoperative care.</text><annotation id="13"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="199" length="20"/><text>infectious keratitis</text></annotation><annotation id="14"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="221" length="2"/><text>IK</text></annotation><annotation id="15"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="383" length="2"/><text>IK</text></annotation><annotation id="16"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="675" length="2"/><text>IK</text></annotation><annotation id="17"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="794" length="2"/><text>IK</text></annotation><annotation id="18"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="908" length="2"/><text>IK</text></annotation><annotation id="19"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="1057" length="2"/><text>IK</text></annotation><annotation id="20"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="1175" length="2"/><text>IK</text></annotation><annotation id="21"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="1311" length="2"/><text>IK</text></annotation><annotation id="22"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="1491" length="2"/><text>IK</text></annotation><annotation id="23"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="1636" length="2"/><text>IK</text></annotation></passage></document>
<document><id>37903687</id><passage><infon key="journal">J Voice;2023Oct28. doi:10.1016/j.jvoice.2023.09.003</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Botti C, Chiari F, Burato A, Molinari G, Presutti L, Molteni G, Fernandez IJ, </infon><offset>0</offset><text>Features Associated With High Risk of Recurrence in Saccular Laryngeal Cysts: A Systematic Review and Qualitative Synthesis.</text><annotation id="1"><infon key="identifier">MESH:D000783</infon><infon key="type">Disease</infon><location offset="52" length="24"/><text>Saccular Laryngeal Cysts</text></annotation></passage><passage><infon key="type">abstract</infon><offset>125</offset><text>INTRODUCTION: Saccular cysts are rare benign anomalies of the larynx (1.5% of laryngeal anomalies) determined by dilatation of the laryngeal saccule. They can be congenital or acquired. Clinical manifestation depends on the site of the cyst and the age of the patient. Children frequently have stridor and dyspnea, while adults usually complain of dysphonia.The therapeutic approach can be surgical or nonsurgical (needle aspiration or drainage).However, guidelines on the management of this disease are lacking in the literature.This systematic literature review was conducted through an interferential analysis with the aim of detecting the association between clinical, diagnostic, and operative factors and the recurrence of saccular cysts. MATERIALS AND METHODS: This systematic literature review was evolved following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist statement Papers published up to August 2023 containing relevant clinical data were searched in Embase/PubMed, Web of Science, Scopus, and Cochrane database. Full texts lacking information on the patient's data, clinical, radiological, and/or histological diagnosis of saccular cysts of the larynx were excluded. Articles with follow-up inferior to 6 months and not reporting any treatment of the cyst were excluded, too. Data concerning signs and symptoms, cyst characteristics, and the type of treatment were described, and the risk of recurrence was studied in association with these features. A qualitative synthesis of the results was performed. RESULTS: Ninety-eight articles were screened. One hundred two patients were involved in the analysis. The articles with low or intermediate risk of bias were 22 (8 case reports and 14 case series) and they were included in the statistical analysis. Median age was 25 years (range 0-81). Saccular cysts were congenital (46/102, 45%) of cases acquired (56/102, 55%). Relying on the available data, all patients were symptomatic, with stridor as the main symptom (59%). Surgical approach was performed in 85% of cases, while drainage or needle aspiration of the cyst was the treatment of choice in the remaining 25% of cases. Twenty-four percent of patients had recurrence of the disease within 3 months. Median age at recurrence was 9 years. Cysts characteristics, preoperative management, and type of treatment were associated with an increased risk of disease recurrence (P &lt; 0.05). CONCLUSIONS: Saccular cysts are rare congenital or acquired laryngeal diseases. Data regarding their management and factors associated with the risk of recurrence are still limited. Congenital cysts treated conservatively have a higher risk of recurrence than acquired cysts treated by open surgical techniques or by microlaryngoscopy. A better knowledge of factors associated with a higher risk of recurrence could help choose the best treatment.</text><annotation id="21"><infon key="identifier">MESH:D000783</infon><infon key="type">Disease</infon><location offset="139" length="14"/><text>Saccular cysts</text></annotation><annotation id="22"><infon key="identifier">MESH:D007818</infon><infon key="type">Disease</infon><location offset="163" length="30"/><text>benign anomalies of the larynx</text></annotation><annotation id="23"><infon key="identifier">MESH:D007827</infon><infon key="type">Disease</infon><location offset="203" length="19"/><text>laryngeal anomalies</text></annotation><annotation id="24"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="361" length="4"/><text>cyst</text></annotation><annotation id="25"><infon key="identifier">MESH:D012135</infon><infon key="type">Disease</infon><location offset="419" length="7"/><text>stridor</text></annotation><annotation id="26"><infon key="identifier">MESH:D004417</infon><infon key="type">Disease</infon><location offset="431" length="7"/><text>dyspnea</text></annotation><annotation id="27"><infon key="identifier">MESH:D055154</infon><infon key="type">Disease</infon><location offset="473" length="9"/><text>dysphonia</text></annotation><annotation id="28"><infon key="identifier">MESH:D000783</infon><infon key="type">Disease</infon><location offset="854" length="14"/><text>saccular cysts</text></annotation><annotation id="29"><infon key="identifier">MESH:D007818</infon><infon key="type">Disease</infon><location offset="1313" length="28"/><text>saccular cysts of the larynx</text></annotation><annotation id="30"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="1441" length="4"/><text>cyst</text></annotation><annotation id="31"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="1502" length="4"/><text>cyst</text></annotation><annotation id="32"><infon key="identifier">MESH:D000783</infon><infon key="type">Disease</infon><location offset="1982" length="14"/><text>Saccular cysts</text></annotation><annotation id="33"><infon key="identifier">MESH:D012135</infon><infon key="type">Disease</infon><location offset="2127" length="7"/><text>stridor</text></annotation><annotation id="34"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="2254" length="4"/><text>cyst</text></annotation><annotation id="35"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="2435" length="5"/><text>Cysts</text></annotation><annotation id="36"><infon key="identifier">MESH:D000783</infon><infon key="type">Disease</infon><location offset="2591" length="14"/><text>Saccular cysts</text></annotation><annotation id="37"><infon key="identifier">MESH:D007818</infon><infon key="type">Disease</infon><location offset="2638" length="18"/><text>laryngeal diseases</text></annotation><annotation id="38"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="2760" length="16"/><text>Congenital cysts</text></annotation><annotation id="39"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="2847" length="5"/><text>cysts</text></annotation></passage></document>
<document><id>37904038</id><passage><infon key="journal">Hernia;2023Oct30. doi:10.1007/s10029-023-02901-0</infon><infon key="year">2023</infon><infon key="article-id_pmc">1448928</infon><infon key="type">title</infon><infon key="authors">Krueger CM, Patrzyk M, Hipp J, Adam U, K&amp;#xf6;ckerling F, Riediger H, </infon><offset>0</offset><text>Incisional hernia repair following pancreatic surgery-open vs laparoscopic approach.</text><annotation id="1"><infon key="identifier">MESH:D000069290</infon><infon key="type">Disease</infon><location offset="0" length="17"/><text>Incisional hernia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>INTRODUCTION: For pancreatic procedures, transverse and midline or combined approaches are used. Having an increased morbidity after pancreatic surgery, these patients have an increased risk of developing an incisional hernia. In the following, we will analyze how the results of incisional hernia surgery after pancreatic surgery are presented in the Herniamed Registry. METHODS: Hospitals and surgeons from Germany, Austria and Switzerland can voluntarily enter all routinely performed hernia operations prospectively into the Herniamed Registry. All patients sign a special informed consent declaration that they agree to the documentation of their treatment in the Herniamed Registry. Perioperative complications (intraoperative complications, postoperative complications, complication-related reoperations and general complications) are recorded up to 30 days after surgery. After 1, 5, and 10 years, patients and primary care physicians are contacted and asked about any pain at rest, pain on exertion, chronic pain requiring treatment or recurrence. This retrospective analysis of prospectively collected data compares the outcomes of minimally invasive vs open techniques in incisional hernia repair after pancreatic surgery. RESULTS: Relative to the total number of all incisional hernia patients in the Herniamed Registry, the proportion after pancreatic surgery with 1-year follow-up was 0.64% (n = 461) patients. 95% of previous pancreatic surgeries were open. Minimally invasive incisional hernia repair was performed in 17.1% and open repair in 82.9% of cases. 23.2% of the defects were larger than 10 cm and 32.8% were located laterally or were a combination of lateral and medial defects. Among the few differences between the collectives, a significantly higher rate of defect closure (58.1% vs 25.3%; p &lt; 0.001) and drainage (72.8% vs 13.9%; p &lt; 0.001) was found in the open repairs, and larger meshes were seen in the minimally invasive procedures (340.6 cm2 vs 259.6 cm2; p &lt; 0.001). No difference deemed a risk factor for chronic postoperative pain was seen in the rate of preoperative pain between the open and minimally invasive procedures (Appendix Table 4) No significant differences were found in either the perioperative complications or at 1-year follow-up. CONCLUSIONS: Incisional hernias after complex pancreatic surgery can be repaired safely and with a low recurrence rate in both open and minimally invasive techniques.</text><annotation id="18"><infon key="identifier">MESH:D000069290</infon><infon key="type">Disease</infon><location offset="293" length="17"/><text>incisional hernia</text></annotation><annotation id="19"><infon key="identifier">MESH:D000069290</infon><infon key="type">Disease</infon><location offset="365" length="17"/><text>incisional hernia</text></annotation><annotation id="20"><infon key="type">Disease</infon><location offset="437" length="9"/><text>Herniamed</text></annotation><annotation id="21"><infon key="identifier">MESH:D006547</infon><infon key="type">Disease</infon><location offset="573" length="6"/><text>hernia</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="614" length="9"/><text>Herniamed</text></annotation><annotation id="23"><infon key="type">Disease</infon><location offset="754" length="9"/><text>Herniamed</text></annotation><annotation id="24"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1062" length="4"/><text>pain</text></annotation><annotation id="25"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1076" length="4"/><text>pain</text></annotation><annotation id="26"><infon key="identifier">MESH:D059350</infon><infon key="type">Disease</infon><location offset="1094" length="12"/><text>chronic pain</text></annotation><annotation id="27"><infon key="identifier">MESH:D000069290</infon><infon key="type">Disease</infon><location offset="1268" length="17"/><text>incisional hernia</text></annotation><annotation id="28"><infon key="identifier">MESH:D000069290</infon><infon key="type">Disease</infon><location offset="1364" length="17"/><text>incisional hernia</text></annotation><annotation id="29"><infon key="type">Disease</infon><location offset="1398" length="9"/><text>Herniamed</text></annotation><annotation id="30"><infon key="identifier">MESH:D000069290</infon><infon key="type">Disease</infon><location offset="1577" length="17"/><text>incisional hernia</text></annotation><annotation id="31"><infon key="identifier">MESH:D010149</infon><infon key="type">Disease</infon><location offset="2128" length="26"/><text>chronic postoperative pain</text></annotation><annotation id="32"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="2192" length="4"/><text>pain</text></annotation><annotation id="33"><infon key="identifier">MESH:D006547</infon><infon key="type">Disease</infon><location offset="2395" length="7"/><text>hernias</text></annotation></passage></document>
<document><id>37905088</id><passage><infon key="journal">bioRxiv;2023Oct22. doi:10.1101/2023.10.19.563175</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614976</infon><infon key="type">title</infon><infon key="authors">Kim K, Wann J, Kim HG, So J, Rosen ED, Roh HC, </infon><offset>0</offset><text>Uncoupling protein 1-driven Cre ( Ucp1-Cre ) is expressed in the epithelial cells of mammary glands and various non-adipose tissues.</text><annotation id="2"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="0" length="20"/><text>Uncoupling protein 1</text></annotation><annotation id="3"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="34" length="4"/><text>Ucp1</text></annotation></passage><passage><infon key="type">abstract</infon><offset>133</offset><text>Objective: Uncoupling protein 1 (UCP1), a mitochondrial protein responsible for nonshivering thermogenesis in adipose tissue, serves as a distinct marker for thermogenic brown and beige adipocytes. Ucp1-Cre mice are thus widely used to genetically manipulate these thermogenic adipocytes. However, evidence suggests that UCP1 may also be expressed in non-adipocyte cell types. In this study, we investigated the presence of UCP1 expression in different mouse tissues that have not been previously reported. Methods: We employed Ucp1-Cre mice crossed with Cre-inducible transgenic reporter Nuclear tagging and Translating Ribosome Affinity Purification (NuTRAP) mice, to investigate Ucp1 - Cre expression in various tissues of adult female mice and developing embryos. Tamoxifen-inducible Ucp1-CreERT2 mice crossed with NuTRAP mice were used to assess active UCP1 expression. Immunostaining, RNA analysis, and single-cell/nucleus RNA-seq (sc/snRNA-seq) data analysis were performed to determine the expression of endogenous UCP1 and Ucp1-Cre -driven reporter expression. We also investigated the impact of UCP1 deficiency on mammary gland development and function using Ucp1 -knockout (KO) mice. Results: Ucp1-Cre expression was observed in the mammary glands within the inguinal white adipose tissue of female Ucp1-Cre ; NuTRAP mice. However, endogenous Ucp1 was not actively expressed as Ucp1-CreERT2 failed to induce the reporter expression in the mammary glands. Ucp1-Cre was activated during embryonic development in various tissues, including mammary glands, as well as in the brain, kidneys, eyes, and ears, specifically in epithelial cells in these organs. While sc/snRNA-seq data suggest potential expression of UCP1 in mammary epithelial cells in adult mice and humans, Ucp1 -KO female mice displayed normal mammary gland development and function. Conclusions: Our findings reveal widespread Ucp1-Cre expression in various non-adipose tissue types, starting during early development. These results highlight the importance of exercising caution when interpreting data and devising experiments involving Ucp1-Cre mice.</text><annotation id="30"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="144" length="20"/><text>Uncoupling protein 1</text></annotation><annotation id="31"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="166" length="4"/><text>UCP1</text></annotation><annotation id="32"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="331" length="4"/><text>Ucp1</text></annotation><annotation id="33"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="454" length="4"/><text>UCP1</text></annotation><annotation id="34"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="557" length="4"/><text>UCP1</text></annotation><annotation id="35"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="661" length="4"/><text>Ucp1</text></annotation><annotation id="36"><infon key="identifier">CVCL:IM23</infon><infon key="type">CellLine</infon><location offset="786" length="6"/><text>NuTRAP</text></annotation><annotation id="37"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="815" length="4"/><text>Ucp1</text></annotation><annotation id="38"><infon key="identifier">MESH:D013629</infon><infon key="type">Chemical</infon><location offset="901" length="9"/><text>Tamoxifen</text></annotation><annotation id="39"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="921" length="4"/><text>Ucp1</text></annotation><annotation id="40"><infon key="identifier">CVCL:IM23</infon><infon key="type">CellLine</infon><location offset="952" length="6"/><text>NuTRAP</text></annotation><annotation id="41"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="991" length="4"/><text>UCP1</text></annotation><annotation id="42"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1156" length="4"/><text>UCP1</text></annotation><annotation id="43"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1165" length="4"/><text>Ucp1</text></annotation><annotation id="44"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1238" length="4"/><text>UCP1</text></annotation><annotation id="45"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1302" length="4"/><text>Ucp1</text></annotation><annotation id="46"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1337" length="4"/><text>Ucp1</text></annotation><annotation id="47"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1443" length="4"/><text>Ucp1</text></annotation><annotation id="48"><infon key="identifier">CVCL:IM23</infon><infon key="type">CellLine</infon><location offset="1454" length="6"/><text>NuTRAP</text></annotation><annotation id="49"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1487" length="4"/><text>Ucp1</text></annotation><annotation id="50"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1522" length="4"/><text>Ucp1</text></annotation><annotation id="51"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1599" length="4"/><text>Ucp1</text></annotation><annotation id="52"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1853" length="4"/><text>UCP1</text></annotation><annotation id="53"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="1912" length="4"/><text>Ucp1</text></annotation><annotation id="54"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="2034" length="4"/><text>Ucp1</text></annotation><annotation id="55"><infon key="identifier">22227</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22524</infon><location offset="2245" length="4"/><text>Ucp1</text></annotation></passage><relation id="R1"><infon key="score">0.9893</infon><infon key="role1">Chemical|MESH:D013629</infon><infon key="role2">Gene|22227</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="10,11"/></relation></document>
<document><id>37905438</id><passage><infon key="journal">J Enzyme Inhib Med Chem;2023Dec; 38 (1) 2274798. doi:10.1080/14756366.2023.2274798</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sanna C, Fais A, Era B, Delogu GL, Sanna E, Dazzi L, Rosa A, Marengo A, Rubiolo P, De Agostini A, Floris S, Pintus F, </infon><offset>0</offset><text>Promising inhibition of diabetes-related enzymes and antioxidant properties of Ptilostemon casabonae leaves extract.</text><annotation id="2"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="24" length="8"/><text>diabetes</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="79" length="36"/><text>Ptilostemon casabonae leaves extract</text></annotation></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>Type 2 diabetes (T2D) is a progressive metabolic disorder of glucose metabolism. One of the therapeutic approaches for the treatment of T2D is reducing postprandial hyperglycaemia through inhibition of the digestive enzymes alpha-glucosidase and alpha-amylase. In this context, aimed at identifying natural products endowed with anti-T2D potential, we focused on Ptilostemon casabonae (L.) Greuter, a species belonging to Asteraceae family. Enzymatic inhibition, antioxidant activity, phenolic composition and cellular assays were performed. This study revealed that the P. casabonae hydroalcoholic extract exerts a potent inhibitory activity against alpha-glucosidase. This activity is supported by an antioxidant effect, preventing ROS formation in a stressed cellular system. HPLC-PDA-MS/MS analysis, revealed a complex polyphenolic fraction. Among the tested pure compounds, 1,5-dicaffeoylquinic acid, apigenin and rutin displayed good alpha-glucosidase inhibitory activity. Our study suggested new potential of P. casabonae encouraging us to further testing the possible therapeutic potential of this extract.</text><annotation id="21"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="117" length="15"/><text>Type 2 diabetes</text></annotation><annotation id="22"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="134" length="3"/><text>T2D</text></annotation><annotation id="23"><infon key="identifier">MESH:D008659</infon><infon key="type">Disease</infon><location offset="156" length="18"/><text>metabolic disorder</text></annotation><annotation id="24"><infon key="identifier">MESH:D018149</infon><infon key="type">Disease</infon><location offset="178" length="7"/><text>glucose</text></annotation><annotation id="25"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="253" length="3"/><text>T2D</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="282" length="14"/><text>hyperglycaemia</text></annotation><annotation id="27"><infon key="identifier">6476</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37424</infon><location offset="341" length="17"/><text>alpha-glucosidase</text></annotation><annotation id="28"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="451" length="3"/><text>T2D</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="602" length="8"/><text>phenolic</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="688" length="35"/><text>P. casabonae hydroalcoholic extract</text></annotation><annotation id="31"><infon key="identifier">6476</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37424</infon><location offset="768" length="17"/><text>alpha-glucosidase</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="851" length="3"/><text>ROS</text></annotation><annotation id="33"><infon key="identifier">MESH:C100257</infon><infon key="type">Chemical</infon><location offset="996" length="25"/><text>1,5-dicaffeoylquinic acid</text></annotation><annotation id="34"><infon key="identifier">MESH:D047310</infon><infon key="type">Chemical</infon><location offset="1023" length="8"/><text>apigenin</text></annotation><annotation id="35"><infon key="identifier">MESH:D012431</infon><infon key="type">Chemical</infon><location offset="1036" length="5"/><text>rutin</text></annotation><annotation id="36"><infon key="identifier">6476</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37424</infon><location offset="1057" length="17"/><text>alpha-glucosidase</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1133" length="12"/><text>P. casabonae</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D047310</infon><infon key="role2">Gene|6476</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="15,17"/></relation><relation id="R2"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D012431</infon><infon key="role2">Gene|6476</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="16,17"/></relation><relation id="R3"><infon key="score">0.9861</infon><infon key="role1">Disease|MESH:D003924</infon><infon key="role2">Gene|6476</infon><infon key="type">Association</infon><node refid="2" role="6,8"/></relation><relation id="R4"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:C100257</infon><infon key="role2">Gene|6476</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="14,17"/></relation></document>
<document><id>37905789</id><passage><infon key="journal">Acupunct Med;2023Oct31 9645284231207865. doi:10.1177/09645284231207865</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Moro MZ, de Oliveira Vidal EI, Pinheiro M&amp;#xf3;dolo NS, Bono Fukushima F, Moreira de Barros GA, </infon><offset>0</offset><text>Dry needling, trigger point electroacupuncture and motor point electroacupuncture for the treatment of myofascial pain syndrome involving the trapezius: a randomised clinical trial.</text><annotation id="1"><infon key="identifier">MESH:D009209</infon><infon key="type">Disease</infon><location offset="103" length="48"/><text>myofascial pain syndrome involving the trapezius</text></annotation></passage><passage><infon key="type">abstract</infon><offset>182</offset><text>OBJECTIVE: The objective of this study was to compare trigger point (TrP) dry needling, TrP electroacupuncture and motor point electroacupuncture of the trapezius muscle for the treatment of myofascial pain syndrome (MPS). METHODS: This randomised clinical trial included 90 patients divided into three groups. Group 1 was treated with dry needling of TrPs, group 2 with intramuscular electrical stimulation of TrPs, and group 3 with electroacupuncture of motor points and/or the spinal accessory nerve. Each group received seven treatment sessions. The outcomes were the pain score measured by visual analogue scale (VAS) and quality of life evaluated by the 12-item short form (SF-12) health questionnaire. We compared the pain outcome over serial time points using growth curve analysis methods. RESULTS: Participants in the three groups experienced significant improvements in pain scores over time. The average pain level of participants in group 3 across the repeated assessments was 0.98 units lower than in group 1 (mean difference (95% confidence interval (CI) = 1.74-0.23)), p = 0.012). There were no significant differences in pain scores between participants in groups 1 and 2, and there were no significant differences in quality of life across the three groups at the end of the treatment period. CONCLUSION: Our results provide evidence that electrical stimulation of motor points and/or of the spinal accessory nerve may be superior in terms of pain relief (but not quality of life) to dry needling and possibly electrical stimulation of trigger points for the management of MPS involving the trapezius. TRIAL REGISTRATION NUMBER: TRIAL-RBR-43R7RF (Brazilian Clinical Trials Registry).</text><annotation id="11"><infon key="identifier">MESH:D009209</infon><infon key="type">Disease</infon><location offset="373" length="24"/><text>myofascial pain syndrome</text></annotation><annotation id="12"><infon key="identifier">MESH:D009209</infon><infon key="type">Disease</infon><location offset="399" length="3"/><text>MPS</text></annotation><annotation id="13"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="754" length="4"/><text>pain</text></annotation><annotation id="14"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="907" length="4"/><text>pain</text></annotation><annotation id="15"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1063" length="4"/><text>pain</text></annotation><annotation id="16"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1098" length="4"/><text>pain</text></annotation><annotation id="17"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1320" length="4"/><text>pain</text></annotation><annotation id="18"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1643" length="4"/><text>pain</text></annotation><annotation id="19"><infon key="identifier">MESH:D009209</infon><infon key="type">Disease</infon><location offset="1773" length="3"/><text>MPS</text></annotation></passage></document>
<document><id>37906141</id><passage><infon key="journal">Zhonghua Yi Xue Yi Chuan Xue Za Zhi;2023Nov10; 40 (11) 1356. doi:10.3760/cma.j.cn511374-20200720-00530</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ma Q, Che L, Kong X, </infon><offset>0</offset><text>[Genetic testing and prenatal diagnosis for two Chinese pedigrees affected with Alport syndrome due to variants of COL4A5 gene].</text><annotation id="2"><infon key="identifier">MESH:D009394</infon><infon key="type">Disease</infon><location offset="80" length="15"/><text>Alport syndrome</text></annotation><annotation id="3"><infon key="identifier">1287</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133559</infon><location offset="115" length="6"/><text>COL4A5</text></annotation></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>OBJECTIVE: To analysis variants of COL4A5 gene in two Chinese pedigrees affected with Alport syndrome (AS) and provide prenatal diagnosis for them. METHODS: Two unrelated ethnic Han Chinese pedigrees who had visited the First Affiliated Hospital of Zhengzhou University respectively in September 2018 and January 2020 were selected as the study subjects. Clinical data were collected, and genomic DNA was extracted from peripheral venous blood and amniotic fluid samples for genetic testing. Following next generation sequencing, candidate variants of the COL4A5 gene were verified by Sanger sequencing and bioinformatic analysis. The gender of the fetuses was determined by the presence of sex-determining region on Y (SRY). RESULTS: Genetic testing revealed that the proband and a fetus from pedigree 1 had both harbored a c.2723G>A (p.Gly908Glu) variant in exon 32 of the COL4A5 gene, whilst the proband and a fetus from pedigree 2 had both harbored a c.3817G>A (p.Gly1273Asp) variant in exon 44 of the COL4A5 gene. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), both variants were classified as likely pathogenic (PP2+PM2_Supporting). Following exclusion of maternal contamination, PCR amplification of the SRY region indicated that both fetuses were males. CONCLUSION: The c.2723G>A (p.Gly908Glu) and c.3817G>A (p.Gly1273Asp) variants of the COL4A5 gene probably underlay the AS in the two pedigrees. Detection of the SRY region can reliably identify the fetal sex, which is conducive to the prenatal diagnosis. Above results have also enriched the mutational spectrum of the COL4A5 gene and provided a reference for correlating the genotype and phenotype of the AS.</text><annotation id="19"><infon key="identifier">1287</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133559</infon><location offset="164" length="6"/><text>COL4A5</text></annotation><annotation id="20"><infon key="identifier">MESH:D009394</infon><infon key="type">Disease</infon><location offset="215" length="15"/><text>Alport syndrome</text></annotation><annotation id="21"><infon key="identifier">1287</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133559</infon><location offset="685" length="6"/><text>COL4A5</text></annotation><annotation id="22"><infon key="identifier">tmVar:c|SUB|G|2723|A;HGVS:c.2723G>A;VariantGroup:0;CorrespondingGene:1287;RS#:878853089;CorrespondingSpecies:9606;CA#:10581392</infon><infon key="type">DNAMutation</infon><location offset="954" length="9"/><text>c.2723G>A</text></annotation><annotation id="23"><infon key="identifier">tmVar:p|SUB|G|908|E;HGVS:p.G908E;VariantGroup:0;CorrespondingGene:1287;RS#:878853089;CorrespondingSpecies:9606;CA#:10581392</infon><infon key="type">ProteinMutation</infon><location offset="965" length="11"/><text>p.Gly908Glu</text></annotation><annotation id="24"><infon key="identifier">1287</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133559</infon><location offset="1004" length="6"/><text>COL4A5</text></annotation><annotation id="25"><infon key="identifier">tmVar:c|SUB|G|3817|A;HGVS:c.3817G>A;VariantGroup:1;CorrespondingGene:1287;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="1084" length="9"/><text>c.3817G>A</text></annotation><annotation id="26"><infon key="identifier">tmVar:p|SUB|G|1273|D;HGVS:p.G1273D;VariantGroup:1;CorrespondingGene:1287;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="1095" length="12"/><text>p.Gly1273Asp</text></annotation><annotation id="27"><infon key="identifier">1287</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133559</infon><location offset="1135" length="6"/><text>COL4A5</text></annotation><annotation id="28"><infon key="identifier">tmVar:c|SUB|G|2723|A;HGVS:c.2723G>A;VariantGroup:0;CorrespondingGene:1287;RS#:878853089;CorrespondingSpecies:9606;CA#:10581392</infon><infon key="type">DNAMutation</infon><location offset="1451" length="9"/><text>c.2723G>A</text></annotation><annotation id="29"><infon key="identifier">tmVar:p|SUB|G|908|E;HGVS:p.G908E;VariantGroup:0;CorrespondingGene:1287;RS#:878853089;CorrespondingSpecies:9606;CA#:10581392</infon><infon key="type">ProteinMutation</infon><location offset="1462" length="11"/><text>p.Gly908Glu</text></annotation><annotation id="30"><infon key="identifier">tmVar:c|SUB|G|3817|A;HGVS:c.3817G>A;VariantGroup:1;CorrespondingGene:1287;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="1479" length="9"/><text>c.3817G>A</text></annotation><annotation id="31"><infon key="identifier">tmVar:p|SUB|G|1273|D;HGVS:p.G1273D;VariantGroup:1;CorrespondingGene:1287;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="1490" length="12"/><text>p.Gly1273Asp</text></annotation><annotation id="32"><infon key="identifier">1287</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133559</infon><location offset="1520" length="6"/><text>COL4A5</text></annotation><annotation id="33"><infon key="identifier">1287</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133559</infon><location offset="1754" length="6"/><text>COL4A5</text></annotation></passage><relation id="R1"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D009394</infon><infon key="role2">Gene|1287</infon><infon key="type">Association</infon><node refid="0" role="0,1"/></relation><relation id="R2"><infon key="score">0.5579</infon><infon key="role1">Disease|MESH:D009394</infon><infon key="role2">ProteinMutation|HGVS:c.3817G>A;CorrespondingGene:1287</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="3,9"/></relation><relation id="R3"><infon key="score">0.5579</infon><infon key="role1">Disease|MESH:D009394</infon><infon key="role2">Gene|1287</infon><infon key="type">Association</infon></relation></document>
<document><id>37906491</id><passage><infon key="journal">IEEE Trans Neural Netw Learn Syst;2023Oct31; PP. doi:10.1109/TNNLS.2023.3326397</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang L, Xie L, Jiang Y, Li Z, Liu X, Su H, </infon><offset>0</offset><text>Optimal Control for Constrained Discrete-Time Nonlinear Systems Based on Safe Reinforcement Learning.</text></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>The state and input constraints of nonlinear systems could greatly impede the realization of their optimal control when using reinforcement learning (RL)-based approaches since the commonly used quadratic utility functions cannot meet the requirements of solving constrained optimization problems. This article develops a novel optimal control approach for constrained discrete-time (DT) nonlinear systems based on safe RL. Specifically, a barrier function (BF) is introduced and incorporated with the value function to help transform a constrained optimization problem into an unconstrained one. Meanwhile, the minimum of such an optimization problem can be guaranteed to occur at the origin. Then a constrained policy iteration (PI) algorithm is developed to realize the optimal control of the nonlinear system and to enable the state and input constraints to be satisfied. The constrained optimal control policy and its corresponding value function are derived through the implementation of two neural networks (NNs). Performance analysis shows that the proposed control approach still retains the convergence and optimality properties of the traditional PI algorithm. Simulation results of three examples reveal its effectiveness.</text></passage></document>
<document><id>37906865</id><passage><infon key="journal">Andes Pediatr;2023Jan; 94 (1) 9. doi:10.32641/andespediatr.v94i1.4203</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rojas Henr&amp;#xed;quez M, Hern&amp;#xe1;ndez G&amp;#xf3;mez A, Balut Oyarzun F, Pereira Hern&amp;#xe1;ndez V, Jim&amp;#xe9;nez Perfetti A, </infon><offset>0</offset><text>[Restless sleep disorder a new entity to considered in children].</text><annotation id="1"><infon key="identifier">MESH:C000715309</infon><infon key="type">Disease</infon><location offset="1" length="23"/><text>Restless sleep disorder</text></annotation></passage><passage><infon key="type">abstract</infon><offset>66</offset><text>Restless sleep disorder (RSD) is a condition recently described by a group of sleep experts who developed diagnostic and polysomnographic criteria after conducting a comprehensive review of the available literature where poor sleep or restless sleep is a symptom alone or that accompanies other disorders. This group defined RSD as a condition characterized by parental complaints of frequent jerking movements during sleep, position changes, and sleep disruption that cause significant impairment during the day. Diagnostic criteria include the presence of symptoms for at least 3 months, 3 times a week, and at least 5 movements per hour on polysomnography. Changes in behavior during the day, such as drowsiness, irritability, and hyperactivity that are not explained by a medical, pharmacological, or behavioral condition, should be considered. Its estimated prevalence is 7.7% of children referred for sleep problems. Children often have ferritin levels below 50 microg/l, a point in common with restless legs syndrome. Treatment consists of iron supplements, which have shown benefits in these children. To establish the diagnosis, secondary symptoms of medical origin or other sleep disorders such as restless legs syndrome or periodic limb movement disorder must be ruled out. The objective of this report is to review the current recommendations on this entity, describe the clinical, pathophysiological, and polysomnographic keys, in order to highlight the need to publicize this condition and expand studies in age groups other than those already defined and to generate treatment guidelines.</text><annotation id="17"><infon key="identifier">MESH:C000715309</infon><infon key="type">Disease</infon><location offset="66" length="23"/><text>Restless sleep disorder</text></annotation><annotation id="18"><infon key="identifier">MESH:C000715309</infon><infon key="type">Disease</infon><location offset="91" length="3"/><text>RSD</text></annotation><annotation id="19"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="287" length="10"/><text>poor sleep</text></annotation><annotation id="20"><infon key="identifier">MESH:C000715309</infon><infon key="type">Disease</infon><location offset="301" length="14"/><text>restless sleep</text></annotation><annotation id="21"><infon key="identifier">MESH:C000715309</infon><infon key="type">Disease</infon><location offset="391" length="3"/><text>RSD</text></annotation><annotation id="22"><infon key="identifier">MESH:D009404</infon><infon key="type">Disease</infon><location offset="450" length="26"/><text>frequent jerking movements</text></annotation><annotation id="23"><infon key="identifier">MESH:D019958</infon><infon key="type">Disease</infon><location offset="513" length="16"/><text>sleep disruption</text></annotation><annotation id="24"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="782" length="12"/><text>irritability</text></annotation><annotation id="25"><infon key="identifier">MESH:D006948</infon><infon key="type">Disease</infon><location offset="800" length="13"/><text>hyperactivity</text></annotation><annotation id="26"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="973" length="14"/><text>sleep problems</text></annotation><annotation id="27"><infon key="identifier">MESH:D012148</infon><infon key="type">Disease</infon><location offset="1067" length="22"/><text>restless legs syndrome</text></annotation><annotation id="28"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1113" length="4"/><text>iron</text></annotation><annotation id="29"><infon key="identifier">MESH:D012893</infon><infon key="type">Disease</infon><location offset="1250" length="15"/><text>sleep disorders</text></annotation><annotation id="30"><infon key="identifier">MESH:D012148</infon><infon key="type">Disease</infon><location offset="1274" length="22"/><text>restless legs syndrome</text></annotation><annotation id="31"><infon key="identifier">MESH:D020189</infon><infon key="type">Disease</infon><location offset="1300" length="31"/><text>periodic limb movement disorder</text></annotation></passage><relation id="R1"><infon key="score">0.8787</infon><infon key="role1">Chemical|MESH:D007501</infon><infon key="role2">Disease|MESH:D012148</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="12,11"/></relation></document>
<document><id>37909690</id><passage><infon key="journal">Laryngoscope;2023Nov01. doi:10.1002/lary.31123</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yosefof E, Boldes T, Dan D, Robenshtok E, Strenov Y, Bachar G, Shpitzer T, Mizrachi A, </infon><offset>0</offset><text>Salivary Gland Secretory Carcinoma; Review of 13 Years World-Wide Experience and Meta-Analysis.</text><annotation id="1"><infon key="identifier">MESH:D012468</infon><infon key="type">Disease</infon><location offset="0" length="34"/><text>Salivary Gland Secretory Carcinoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset><text>OBJECTIVES: Secretory Carcinoma is a malignant salivary gland tumor, initially described in 2010. This rare tumor is associated with the translocation t(12;15) (p13;q25), resulting in the fusion gene ETV6-NTRK3. Since this tumor is quite rare, most publications describe only small cohorts of patients. We aimed to investigate the clinical, pathological, and prognostic features of this newly defined malignant entity. DATA SOURCES: Pubmed, Google Scholar, and Web of Science databases. REVIEW METHODS: All published articles between 2010 and 2023 were reviewed. Search terms included the terms "Mammary Analogue Secretory Carcinoma" and "Secretory Carcinoma". All articles published in English reporting on Secretory Carcinoma of salivary glands were retrieved. RESULTS: One-hundred and 12 retrospective articles reporting a total of 674 patients were included, with 52% males and a mean age of 44.9 +- 18.9. The event rate for patients with advanced-stage disease (Stage 3/4) at presentation was 24.1% (95% CI 17.6%-31.9%, I2  = 9.2%), 14.6% for regional metastases (95% CI 10.5%-20%, I2  = 12%), and the event rate of distant metastasis was 8.4% (95% CI 5.5%-12.7%, I2  = 4.2%). Adjuvant radiotherapy was administered for 30.3% of patients (95% CI 24.1%-37.2%, I2  = 21.5%). The recurrence rate was 19% (95% CI 15.1%-23.8%, I2  = 5%). Survival outcomes showed a 17.2% death of disease rate for Secretory Carcinoma patients (95% CI 13.5%-21.8%, I2  = 7.3%). CONCLUSIONS: Secretory Carcinoma is a rare and relatively newly defined entity arising in the parotid gland most commonly. Characterized as a low-grade tumor, the majority of patients are diagnosed at an early stage, without regional or distant disease, and the prognosis is relatively good. LEVEL OF EVIDENCE: N/A Laryngoscope, 2023.</text><annotation id="17"><infon key="identifier">MESH:C537535</infon><infon key="type">Disease</infon><location offset="108" length="19"/><text>Secretory Carcinoma</text></annotation><annotation id="18"><infon key="identifier">MESH:D012468</infon><infon key="type">Disease</infon><location offset="143" length="20"/><text>salivary gland tumor</text></annotation><annotation id="19"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="204" length="5"/><text>tumor</text></annotation><annotation id="20"><infon key="identifier">2120</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37560</infon><location offset="296" length="4"/><text>ETV6</text></annotation><annotation id="21"><infon key="identifier">4916</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49183</infon><location offset="301" length="5"/><text>NTRK3</text></annotation><annotation id="22"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="319" length="5"/><text>tumor</text></annotation><annotation id="23"><infon key="identifier">MESH:C537535</infon><infon key="type">Disease</infon><location offset="709" length="19"/><text>Secretory Carcinoma</text></annotation><annotation id="24"><infon key="identifier">MESH:C537535</infon><infon key="type">Disease</infon><location offset="735" length="19"/><text>Secretory Carcinoma</text></annotation><annotation id="25"><infon key="identifier">MESH:D012468</infon><infon key="type">Disease</infon><location offset="804" length="38"/><text>Secretory Carcinoma of salivary glands</text></annotation><annotation id="26"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="1153" length="10"/><text>metastases</text></annotation><annotation id="27"><infon key="identifier">MESH:D009362</infon><infon key="type">Disease</infon><location offset="1225" length="10"/><text>metastasis</text></annotation><annotation id="28"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1467" length="5"/><text>death</text></annotation><annotation id="29"><infon key="identifier">MESH:C537535</infon><infon key="type">Disease</infon><location offset="1493" length="19"/><text>Secretory Carcinoma</text></annotation><annotation id="30"><infon key="identifier">MESH:C537535</infon><infon key="type">Disease</infon><location offset="1569" length="19"/><text>Secretory Carcinoma</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1708" length="5"/><text>tumor</text></annotation></passage><relation id="R1"><infon key="score">0.6568</infon><infon key="role1">Gene|2120</infon><infon key="role2">Gene|4916</infon><infon key="type">Association</infon><node refid="0" role="4,5"/></relation><relation id="R2"><infon key="score">0.6084</infon><infon key="role1">Disease|MESH:C537535</infon><infon key="role2">Gene|2120</infon><infon key="type">Association</infon><node refid="1" role="1,4"/></relation></document>
<document><id>37910044</id><passage><infon key="journal">Clin Cancer Res;2023Nov01. doi:10.1158/1078-0432.CCR-23-1872</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X, Clavel A, Reyes-Gonz&amp;#xe1;lez JM, Dyomin V, Diaz L, Zhang L, Abbas S, Sun M, Hsieh CM, Ho M, Shern JF, Gulley JL, Hinrichs CS, </infon><offset>0</offset><text>Cooperative armoring of CAR and TCR T-cells by T cell-restricted IL-15 and IL-21 universally enhances solid tumor efficacy.</text><annotation id="5"><infon key="identifier">12355</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="24" length="3"/><text>CAR</text></annotation><annotation id="6"><infon key="identifier">328483</infon><infon key="type">Gene</infon><location offset="32" length="3"/><text>TCR</text></annotation><annotation id="7"><infon key="identifier">16168</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">487</infon><location offset="65" length="5"/><text>IL-15</text></annotation><annotation id="8"><infon key="identifier">60505</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11032</infon><location offset="75" length="5"/><text>IL-21</text></annotation><annotation id="9"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="102" length="11"/><text>solid tumor</text></annotation></passage><passage><infon key="type">abstract</infon><offset>124</offset><text>PURPOSE: Chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies are effective in a subset of patients with solid tumors, but new approaches are needed to universally improve patient outcomes. Here, we developed a technology to leverage the cooperative effects of IL-15 and IL-21, two common cytokine-receptor gamma chain family members with distinct, pleiotropic effects on T-cells and other lymphocytes, to enhance the efficacy of adoptive T-cells. EXPERIMENTAL DESIGN: We designed vectors that induce the constitutive expression of either membrane-tethered IL-15, IL-21, or IL-15/IL-21. We used clinically relevant preclinical models of transgenic CARs and TCRs against pediatric and adult solid tumors to determine the effect of the membrane-tethered cytokines on engineered T-cells for human administration. RESULTS: We found that self-delivery of these cytokines by CAR or TCR T-cells prevents functional exhaustion by repeated stimulation and limits the emergence of dysfunctional natural killer (NK)-like T-cells. Across different preclinical murine solid tumor models, we observed enhanced regression with each individual cytokine but the greatest anti-tumor efficacy when T-cells were armored with both. CONCLUSION: The co-expression of membrane-tethered IL-15 and IL-21 represents a technology to enhance the resilience and function of engineered T-cells against solid tumors and could be applicable to multiple therapy platforms and diseases.</text><annotation id="29"><infon key="identifier">9970</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="133" length="25"/><text>Chimeric antigen receptor</text></annotation><annotation id="30"><infon key="identifier">9970</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="160" length="3"/><text>CAR</text></annotation><annotation id="31"><infon key="identifier">6962</infon><infon key="type">Gene</infon><location offset="169" length="15"/><text>T-cell receptor</text></annotation><annotation id="32"><infon key="identifier">6962</infon><infon key="type">Gene</infon><location offset="186" length="3"/><text>TCR</text></annotation><annotation id="33"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="251" length="12"/><text>solid tumors</text></annotation><annotation id="34"><infon key="identifier">16168</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">487</infon><location offset="407" length="5"/><text>IL-15</text></annotation><annotation id="35"><infon key="identifier">59067</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11032</infon><location offset="417" length="5"/><text>IL-21</text></annotation><annotation id="36"><infon key="identifier">16168</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">487</infon><location offset="703" length="5"/><text>IL-15</text></annotation><annotation id="37"><infon key="identifier">60505</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11032</infon><location offset="710" length="5"/><text>IL-21</text></annotation><annotation id="38"><infon key="identifier">16168</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">487</infon><location offset="720" length="5"/><text>IL-15</text></annotation><annotation id="39"><infon key="identifier">60505</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11032</infon><location offset="726" length="5"/><text>IL-21</text></annotation><annotation id="40"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="836" length="12"/><text>solid tumors</text></annotation><annotation id="41"><infon key="identifier">12355</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3759</infon><location offset="1015" length="3"/><text>CAR</text></annotation><annotation id="42"><infon key="identifier">328483</infon><infon key="type">Gene</infon><location offset="1022" length="3"/><text>TCR</text></annotation><annotation id="43"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1201" length="11"/><text>solid tumor</text></annotation><annotation id="44"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1305" length="5"/><text>tumor</text></annotation><annotation id="45"><infon key="identifier">16168</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">487</infon><location offset="1408" length="5"/><text>IL-15</text></annotation><annotation id="46"><infon key="identifier">59067</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11032</infon><location offset="1418" length="5"/><text>IL-21</text></annotation><annotation id="47"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1517" length="12"/><text>solid tumors</text></annotation></passage><relation id="R1"><infon key="score">0.795</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|9970</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="9,5"/></relation><relation id="R2"><infon key="score">0.9852</infon><infon key="role1">Gene|328483</infon><infon key="role2">Gene|60505</infon><infon key="type">Association</infon><node refid="1" role="1,3"/></relation><relation id="R3"><infon key="score">0.9965</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|60505</infon><infon key="type">Association</infon><node refid="2" role="4,3"/></relation><relation id="R4"><infon key="score">0.9398</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|12355</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="4,0"/></relation><relation id="R5"><infon key="score">0.9963</infon><infon key="role1">Gene|12355</infon><infon key="role2">Gene|60505</infon><infon key="type">Association</infon><node refid="4" role="0,3"/></relation><relation id="R6"><infon key="score">0.995</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|6962</infon><infon key="type">Association</infon><node refid="5" role="9,7"/></relation><relation id="R7"><infon key="score">0.998</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|16168</infon><infon key="type">Association</infon><node refid="6" role="4,2"/></relation><relation id="R8"><infon key="score">0.9297</infon><infon key="role1">Gene|16168</infon><infon key="role2">Gene|328483</infon><infon key="type">Association</infon><node refid="7" role="2,1"/></relation><relation id="R9"><infon key="score">0.9969</infon><infon key="role1">Gene|12355</infon><infon key="role2">Gene|16168</infon><infon key="type">Association</infon><node refid="8" role="0,2"/></relation><relation id="R10"><infon key="score">0.4605</infon><infon key="role1">Gene|16168</infon><infon key="role2">Gene|59067</infon><infon key="type">Bind</infon><node refid="9" role="10,11"/></relation><relation id="R11"><infon key="score">0.9459</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|328483</infon><infon key="type">Association</infon><node refid="10" role="4,1"/></relation><relation id="R12"><infon key="score">0.9498</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|59067</infon><infon key="type">Association</infon><node refid="11" role="23,22"/></relation></document>
<document><id>37910395</id><passage><infon key="journal">Scand J Prim Health Care;2023Nov01 1. doi:10.1080/02813432.2023.2277756</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chin KZ, Marklund B, Kyl&amp;#xe9;n S, Dalemo S, </infon><offset>0</offset><text>Extended prenatal and postnatal home visits in a vulnerable area in Sweden-a pilot study.</text></passage><passage><infon key="type">abstract</infon><offset>90</offset><text>OBJECTIVE: Despite close to all-embracing access to child healthcare, health divides exist among children in Sweden. Home visits to families with new-born babies are a cost-effective way to identify and strengthen vulnerable families. An extended postnatal home visiting programme has been implemented in a disadvantaged suburb in Stockholm with positive results. DESIGN: Longitudinal, prospective study and register study from medical records. SETTING: A vulnerable rural area in Sweden. INTERVENTION: A parent advisor from the social services and a midwife performed an extended home visiting programme during the end of pregnancy to mothers of children born between 1 May 2018 and 31 May 2019. During these children's first 15 months, three additional home visits were made by a parent advisor and a child healthcare nurse. The aim of the study is to evaluate the effect of the intervention on the health of the children and the mothers. SUBJECTS: All firstborn children at the study site (N = 30 study, N = 55 control group). MAIN OUTCOME MEASURES: The proportion participating in visits to the child and maternal healthcare services, children being breastfed and receiving childhood vaccinations. RESULTS: There were fewer absentees in the study group during routine check-up visits (93 vs. 84%). More mothers in the study group attended the check-up with the midwives (90 vs. 80%). More children in the study group were breastfed (90 vs. 67%) and received all vaccinations (100 vs. 96%). CONCLUSION: Supplementing the extended home visiting programme with a visit at the end of pregnancy seems to contribute to fewer absentees at routine visits for both mothers and children; furthermore, more children were breastfed and vaccinated compared with the control group.</text></passage></document>
<document><id>37910746</id><passage><infon key="journal">Opt Lett;2023Nov01; 48 (21) 5735. doi:10.1364/OL.502932</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Yu Q, Yuan J, Liu Z, He R, Liang S, Zhang Y, Zhang Z, </infon><offset>0</offset><text>Discrete dynamics of light in an anti-parity-time symmetric photonic lattice in atomic vapors.</text></passage><passage><infon key="type">abstract</infon><offset>95</offset><text>We demonstrate the realization of an anti-parity-time (PT)-symmetric photonic lattice in a coherent three-level Lambda-type 85Rb atomic system both experimentally and theoretically. Such an instantaneously reconfigurable anti-PT-symmetric photonic lattice is "written" by two one-dimensional coupling fields, which are arranged alternately along the x direction and can modulate the refractive index of the atomic vapor in a spatially periodical manner via controllable atomic coherence. By properly adjusting the relevant atomic parameters, the phase shift between two adjacent lattice channels occurs in the constructed non-Hermitian photonic system. Such a readily reconfigurable anti-PT-symmetric photonic lattice may open the door for demonstrating the discrete characteristics of the optical waves in periodic anti-PT-symmetric photonic systems.</text></passage></document>
<document><id>37911097</id><passage><infon key="journal">Int Dent J (Phila);1893May; 14 (5) 386</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109657</infon><infon key="type">title</infon><offset>0</offset><text>Our Recent Dead.</text></passage><passage><infon key="type">abstract</infon><offset>17</offset></passage></document>
<document><id>37911447</id><passage><infon key="journal">Int Dent J (Phila);1890Aug; 11 (8) 499</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110152</infon><infon key="type">title</infon><offset>0</offset><text>American Academy of Dental Science: Address of Professor F. W. Putnam before the American Academy of Dental Science at the Peabody Museum of Archaeology and Ethnology, Cambridge, January 8, 1890.</text></passage><passage><infon key="type">abstract</infon><offset>196</offset></passage></document>
<document><id>37912147</id><passage><infon key="journal">Int Dent J (Phila);1897Nov; 18 (11) 740</infon><infon key="year">1897</infon><infon key="article-id_pmc">PMC10128637</infon><infon key="type">title</infon><offset>0</offset><text>American Dental Association.</text></passage><passage><infon key="type">abstract</infon><offset>29</offset></passage></document>
<document><id>37912847</id><passage><infon key="journal">Int Dent J (Phila);1901Feb; 22 (2) 93</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153905</infon><infon key="type">title</infon><offset>0</offset><text>Spinal Anaesthesia.</text></passage><passage><infon key="type">abstract</infon><offset>20</offset></passage></document>
<document><id>37913197</id><passage><infon key="journal">Int Dent J (Phila);1903Oct; 24 (10) 811</infon><infon key="year">1903</infon><infon key="article-id_pmc">PMC10162291</infon><infon key="type">title</infon><offset>0</offset><text>Resolution on Interchange of License.</text></passage><passage><infon key="type">abstract</infon><offset>38</offset></passage></document>
<document><id>37913548</id><passage><infon key="journal">Inorg Chem;2023Nov01. doi:10.1021/acs.inorgchem.3c02526</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li Y, Singh R, Sinha A, Lisensky GC, Haukka M, Nilsson J, Yiga S, Demeshko S, Gross SJ, Dechert S, Gonzalez A, Farias G, Wendt OF, Meyer F, Nordlander E, </infon><offset>0</offset><text>Nonheme FeIV O Complexes Supported by Four Pentadentate Ligands: Reactivity toward H- and O- Atom Transfer Processes.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="8" length="6"/><text>FeIV O</text></annotation></passage><passage><infon key="type">abstract</infon><offset>118</offset><text>Four new pentadentate N5-donor ligands, [N-(1-methyl-2-imidazolyl)methyl-N-(2-pyridyl)-methyl-N-(bis-2-pyridylmethyl)-amine] (L1), [N-bis(1-methyl-2-imidazolyl)methyl-N-(bis-2-pyridylmethyl)amine] (L2), (N-(isoquinolin-3-ylmethyl)-1,1-di(pyridin-2-yl)-N-(pyridin-2-ylmethyl)methanamine (L3), and N,N-bis(isoquinolin-3-ylmethyl)-1,1-di(pyridin-2-yl)methanamine (L4), have been synthesized based on the N4Py ligand framework, where one or two pyridyl arms of the N4Py parent are replaced by (N-methyl)imidazolyl or N-(isoquinolin-3-ylmethyl) moieties. Using these four pentadentate ligands, the mononuclear complexes [FeII(CH3CN)(L1)]2+ (1a), [FeII(CH3CN)(L2)]2+ (2a), [FeII(CH3CN)(L3)]2+ (3a), and [FeII(CH3CN)(L4)]2+ (4a) have been synthesized and characterized. The half-wave potentials (E1/2) of the complexes become more positive in the order: 2a &lt; 1a &lt; 4a &lt;= 3a &lt;= [Fe(N4Py)(CH3CN)]2+. The order of redox potentials correlates well with the Fe-Namine distances observed by crystallography, which are 2a > 1a >= 4a > 3a >= [Fe(N4Py)(CH3CN)]2+. The corresponding ferryl complexes [FeIV(O)(L1)]2+ (1b), [FeIV(O)(L2)]2+ (2b), [FeIV(O)(L3)]2+ (3b), and [FeIV(O)(L4)]2+ (4b) were prepared by the reaction of the ferrous complexes with isopropyl 2-iodoxybenzoate (IBX ester) in acetonitrile. The greenish complexes 3b and 4b were also isolated in the solid state by the reaction of the ferrous complexes in CH3CN with ceric ammonium nitrate in water. Mossbauer spectroscopy and magnetic measurements (using superconducting quantum interference device) show that the four complexes 1b, 2b, 3b, and 4b are low-spin (S = 1) FeIV O complexes. UV/vis spectra of the four FeIV O complexes in acetonitrile show typical long-wavelength absorptions of around 700 nm, which are expected for FeIV O complexes with N4Py-type ligands. The wavelengths of these absorptions decrease in the following order: 721 nm (2b) > 706 nm (1b) > 696 nm (4b) > 695 nm (3b) = 695 nm ([FeIV(O) (N4Py)]2+), indicating that the replacement of the pyridyl arms with (N-methyl) imidazolyl moieties makes L1 and L2 exert weaker ligand fields than the parent N4Py ligand, while the ligand field strengths of L3 and L4 are similar to the N4Py parent despite the replacement of the pyridyl arms with N-(isoquinolin-3-ylmethyl) moieties. Consequently, complexes 1b and 2b tend to be less stable than the parent [FeIV(O)(N4Py)]2+ complex: the half-life sequence at room temperature is 1.67 h (2b) &lt; 16 h (1b) &lt; 45 h (4b) &lt; 63 h (3b)   60 h ([FeIV(O)(N4Py)]2+). Compared to the parent complex, 1b and 2b exhibit enhanced reactivity in both the oxidation of thioanisole in the oxygen atom transfer (OAT) reaction and the oxygenation of C-H bonds of aromatic and aliphatic substrates, presumed to occur via an oxygen rebound process. Furthermore, the second-order rate constants for hydrogen atom transfer (HAT) reactions affected by the ferryl complexes can be directly related to the C-H bond dissociation energies of a range of substrates that have been studied. Using either IBX ester or H2O2 as an oxidant, all four new FeII complexes display good performance in catalytic reactions involving both HAT and OAT reactions.</text><annotation id="60"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="158" length="84"/><text>[N-(1-methyl-2-imidazolyl)methyl-N-(2-pyridyl)-methyl-N-(bis-2-pyridylmethyl)-amine]</text></annotation><annotation id="61"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="249" length="65"/><text>[N-bis(1-methyl-2-imidazolyl)methyl-N-(bis-2-pyridylmethyl)amine]</text></annotation><annotation id="62"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="316" length="2"/><text>L2</text></annotation><annotation id="63"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="321" length="82"/><text>(N-(isoquinolin-3-ylmethyl)-1,1-di(pyridin-2-yl)-N-(pyridin-2-ylmethyl)methanamine</text></annotation><annotation id="64"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="414" length="63"/><text>N,N-bis(isoquinolin-3-ylmethyl)-1,1-di(pyridin-2-yl)methanamine</text></annotation><annotation id="65"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="519" length="4"/><text>N4Py</text></annotation><annotation id="66"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="579" length="4"/><text>N4Py</text></annotation><annotation id="67"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="631" length="26"/><text>N-(isoquinolin-3-ylmethyl)</text></annotation><annotation id="68"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="733" length="17"/><text>[FeII(CH3CN)(L1)]</text></annotation><annotation id="69"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="759" length="15"/><text>[FeII(CH3CN)(L2</text></annotation><annotation id="70"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="785" length="15"/><text>[FeII(CH3CN)(L3</text></annotation><annotation id="71"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="815" length="15"/><text>[FeII(CH3CN)(L4</text></annotation><annotation id="72"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="987" length="19"/><text>[Fe(N4Py)(CH3CN)]2+</text></annotation><annotation id="73"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1063" length="2"/><text>Fe</text></annotation><annotation id="74"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1144" length="19"/><text>[Fe(N4Py)(CH3CN)]2+</text></annotation><annotation id="75"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1183" length="16"/><text>ferryl complexes</text></annotation><annotation id="76"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1201" length="7"/><text>FeIV(O)</text></annotation><annotation id="77"><infon key="identifier">MESH:D000077543</infon><infon key="type">Chemical</infon><location offset="1209" length="2"/><text>L1</text></annotation><annotation id="78"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1223" length="7"/><text>FeIV(O)</text></annotation><annotation id="79"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1231" length="2"/><text>L2</text></annotation><annotation id="80"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1239" length="2"/><text>2b</text></annotation><annotation id="81"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1245" length="7"/><text>FeIV(O)</text></annotation><annotation id="82"><infon key="identifier">MESH:C010200</infon><infon key="type">Chemical</infon><location offset="1253" length="2"/><text>L3</text></annotation><annotation id="83"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1271" length="11"/><text>FeIV(O)(L4)</text></annotation><annotation id="84"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1328" length="17"/><text>ferrous complexes</text></annotation><annotation id="85"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1351" length="26"/><text>isopropyl 2-iodoxybenzoate</text></annotation><annotation id="86"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1379" length="9"/><text>IBX ester</text></annotation><annotation id="87"><infon key="identifier">MESH:C032159</infon><infon key="type">Chemical</infon><location offset="1393" length="12"/><text>acetonitrile</text></annotation><annotation id="88"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1501" length="17"/><text>ferrous complexes</text></annotation><annotation id="89"><infon key="identifier">MESH:C032159</infon><infon key="type">Chemical</infon><location offset="1522" length="5"/><text>CH3CN</text></annotation><annotation id="90"><infon key="identifier">MESH:C004653</infon><infon key="type">Chemical</infon><location offset="1533" length="22"/><text>ceric ammonium nitrate</text></annotation><annotation id="91"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1559" length="5"/><text>water</text></annotation><annotation id="92"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1700" length="2"/><text>2b</text></annotation><annotation id="93"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="1729" length="1"/><text>S</text></annotation><annotation id="94"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1736" length="6"/><text>FeIV O</text></annotation><annotation id="95"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1781" length="6"/><text>FeIV O</text></annotation><annotation id="96"><infon key="identifier">MESH:C032159</infon><infon key="type">Chemical</infon><location offset="1801" length="12"/><text>acetonitrile</text></annotation><annotation id="97"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1896" length="6"/><text>FeIV O</text></annotation><annotation id="98"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1918" length="4"/><text>N4Py</text></annotation><annotation id="99"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2015" length="2"/><text>2b</text></annotation><annotation id="100"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2071" length="18"/><text>[FeIV(O) (N4Py)]2+</text></annotation><annotation id="101"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2193" length="2"/><text>L2</text></annotation><annotation id="102"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2239" length="4"/><text>N4Py</text></annotation><annotation id="103"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2317" length="4"/><text>N4Py</text></annotation><annotation id="104"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2378" length="26"/><text>N-(isoquinolin-3-ylmethyl)</text></annotation><annotation id="105"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2446" length="2"/><text>2b</text></annotation><annotation id="106"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2488" length="25"/><text>[FeIV(O)(N4Py)]2+ complex</text></annotation><annotation id="107"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2569" length="2"/><text>2b</text></annotation><annotation id="108"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2617" length="17"/><text>[FeIV(O)(N4Py)]2+</text></annotation><annotation id="109"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2676" length="2"/><text>2b</text></annotation><annotation id="110"><infon key="identifier">MESH:C093850</infon><infon key="type">Chemical</infon><location offset="2732" length="11"/><text>thioanisole</text></annotation><annotation id="111"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="2751" length="6"/><text>oxygen</text></annotation><annotation id="112"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="2883" length="6"/><text>oxygen</text></annotation><annotation id="113"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="2956" length="8"/><text>hydrogen</text></annotation><annotation id="114"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="3011" length="16"/><text>ferryl complexes</text></annotation><annotation id="115"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="3152" length="9"/><text>IBX ester</text></annotation><annotation id="116"><infon key="identifier">MESH:D006861</infon><infon key="type">Chemical</infon><location offset="3165" length="4"/><text>H2O2</text></annotation><annotation id="117"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="3198" length="4"/><text>FeII</text></annotation></passage><relation id="R1"><infon key="score">0.9831</infon><infon key="role1">Chemical|MESH:C032159</infon><infon key="role2">Chemical|MESH:C093850</infon><infon key="type">Association</infon><node refid="0" role="41,57"/></relation><relation id="R2"><infon key="score">0.9973</infon><infon key="role1">Chemical|MESH:D006859</infon><infon key="role2">Chemical|MESH:D010100</infon><infon key="type">Association</infon><node refid="1" role="60,58"/></relation><relation id="R3"><infon key="score">0.9972</infon><infon key="role1">Chemical|MESH:C032159</infon><infon key="role2">Chemical|MESH:D006861</infon><infon key="type">Association</infon><node refid="2" role="41,63"/></relation><relation id="R4"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D006861</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="3" role="63,35"/></relation><relation id="R5"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C004653</infon><infon key="role2">Chemical|MESH:C032159</infon><infon key="type">Association</infon><node refid="4" role="34,33"/></relation><relation id="R6"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:C093850</infon><infon key="role2">Chemical|MESH:D010100</infon><infon key="type">Association</infon><node refid="5" role="57,58"/></relation><relation id="R7"><infon key="score">0.9905</infon><infon key="role1">Chemical|MESH:C032159</infon><infon key="role2">Chemical|MESH:D013455</infon><infon key="type">Association</infon><node refid="6" role="33,38"/></relation><relation id="R8"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:C004653</infon><infon key="role2">Chemical|MESH:D010100</infon><infon key="type">Association</infon><node refid="7" role="34,58"/></relation><relation id="R9"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:C004653</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="8" role="34,35"/></relation><relation id="R10"><infon key="score">0.9969</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Chemical|MESH:D013455</infon><infon key="type">Association</infon><node refid="9" role="58,38"/></relation><relation id="R11"><infon key="score">0.9974</infon><infon key="role1">Chemical|MESH:D006859</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="10" role="60,35"/></relation><relation id="R12"><infon key="score">0.9994</infon><infon key="role1">Chemical|MESH:C004653</infon><infon key="role2">Chemical|MESH:D006861</infon><infon key="type">Association</infon><node refid="11" role="34,63"/></relation><relation id="R13"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:C004653</infon><infon key="role2">Chemical|MESH:D013455</infon><infon key="type">Association</infon><node refid="12" role="34,38"/></relation><relation id="R14"><infon key="score">0.9935</infon><infon key="role1">Chemical|MESH:C093850</infon><infon key="role2">Chemical|MESH:D013455</infon><infon key="type">Association</infon><node refid="13" role="57,38"/></relation><relation id="R15"><infon key="score">0.997</infon><infon key="role1">Chemical|MESH:C032159</infon><infon key="role2">Chemical|MESH:D006859</infon><infon key="type">Association</infon><node refid="14" role="41,60"/></relation><relation id="R16"><infon key="score">0.995</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="15" role="58,35"/></relation><relation id="R17"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:C093850</infon><infon key="role2">Chemical|MESH:D006861</infon><infon key="type">Association</infon><node refid="16" role="57,63"/></relation><relation id="R18"><infon key="score">0.9922</infon><infon key="role1">Chemical|MESH:D006859</infon><infon key="role2">Chemical|MESH:D006861</infon><infon key="type">Association</infon><node refid="17" role="60,63"/></relation><relation id="R19"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D006861</infon><infon key="role2">Chemical|MESH:D013455</infon><infon key="type">Association</infon><node refid="18" role="63,38"/></relation><relation id="R20"><infon key="score">0.9946</infon><infon key="role1">Chemical|MESH:C004653</infon><infon key="role2">Chemical|MESH:C093850</infon><infon key="type">Association</infon><node refid="19" role="34,57"/></relation><relation id="R21"><infon key="score">0.9994</infon><infon key="role1">Chemical|MESH:C004653</infon><infon key="role2">Chemical|MESH:D006859</infon><infon key="type">Association</infon><node refid="20" role="34,60"/></relation><relation id="R22"><infon key="score">0.976</infon><infon key="role1">Chemical|MESH:C032159</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="21" role="33,35"/></relation><relation id="R23"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:D006861</infon><infon key="role2">Chemical|MESH:D010100</infon><infon key="type">Association</infon><node refid="22" role="63,58"/></relation><relation id="R24"><infon key="score">0.9957</infon><infon key="role1">Chemical|MESH:D013455</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="23" role="38,35"/></relation><relation id="R25"><infon key="score">0.9988</infon><infon key="role1">Chemical|MESH:C093850</infon><infon key="role2">Chemical|MESH:D006859</infon><infon key="type">Association</infon><node refid="24" role="57,60"/></relation><relation id="R26"><infon key="score">0.9981</infon><infon key="role1">Chemical|MESH:D006859</infon><infon key="role2">Chemical|MESH:D013455</infon><infon key="type">Association</infon><node refid="25" role="60,38"/></relation><relation id="R27"><infon key="score">0.9924</infon><infon key="role1">Chemical|MESH:C032159</infon><infon key="role2">Chemical|MESH:D010100</infon><infon key="type">Association</infon><node refid="26" role="41,58"/></relation><relation id="R28"><infon key="score">0.9926</infon><infon key="role1">Chemical|MESH:C093850</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="27" role="57,35"/></relation></document>
<document><id>37913898</id><passage><infon key="journal">Food Chem Toxicol;2023Oct30 114133. doi:10.1016/j.fct.2023.114133</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Api AM, Belsito D, Botelho D, Bruze M, Burton GA, Cancellieri MA, Chon H, Dagli ML, Dekant W, Deodhar C, Fryer AD, Jones L, Joshi K, Kumar M, Lapczynski A, Lavelle M, Lee I, Liebler DC, Moustakas H, Muldoon J, Penning TM, Ritacco G, Romine J, Sadekar N, Schultz TW, Selechnik D, Siddiqi F, Sipes IG, Sullivan G, Thakkar Y, Tokura Y, </infon><offset>0</offset><text>RIFM fragrance ingredient safety assessment, dihydronootkatone, CAS Registry Number 20489-53-6.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="25"/><text>RIFM fragrance ingredient</text></annotation><annotation id="3"><infon key="identifier">MESH:C484717</infon><infon key="type">Chemical</infon><location offset="45" length="17"/><text>dihydronootkatone</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset></passage></document>
<document><id>37914248</id><passage><infon key="journal">Rinsho Ketsueki;2023; 64 (10) 1326. doi:10.11406/rinketsu.64.1326</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kawashima I, Kirito K, </infon><offset>0</offset><text>[Chronic neutrophilic leukemia/chronic eosinophilic leukemia].</text><annotation id="2"><infon key="identifier">MESH:D015467</infon><infon key="type">Disease</infon><location offset="1" length="29"/><text>Chronic neutrophilic leukemia</text></annotation><annotation id="3"><infon key="identifier">MESH:C580364</infon><infon key="type">Disease</infon><location offset="31" length="29"/><text>chronic eosinophilic leukemia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>63</offset><text>Chronic neutrophilic leukemia (CNL) is a clonal disorder that is characterized by increasing mature neutrophils. Colony stimulating factor 3 receptor (CSF3R) T618I mutation was frequently identified in patients with CNL and is defined as a molecular marker of the disease. Ruxolitinib, a JAK2 inhibitor, provided a promising therapeutic effect in a phase II study. In particular, ruxolitinib was more efficient for patients with CSF3R mutation. Allogeneic stem cell transplantation (Allo-SCT) may be a curative treatment for CNL. On the other hand, further studies are needed to define the optimal method of transplantation, source of donor, conditioning therapy, and timing of transplantation. Chronic eosinophilic leukemia (CEL) is a clonal disorder that is characterized by increasing eosinophils. In the World Health Organization Classification 5th edition, diagnostic criteria for CEL are renewed. Because the new criteria will be more specific for CEL than criteria in the older edition, "not otherwise specified (NOS) " is removed from the name of the disease. Anti-CD52 antibody, alemtuzumab, or anti-IL-5 antibody, mepolizumab, are promising drugs to control symptoms that are associated with hypereosinophilic syndrome. Allo-SCT is anticipated as a curative treatment for CEL, but the evidence of Allo-SCT for CEL is still limited. Further study is required to define the treatment strategy.</text><annotation id="28"><infon key="identifier">MESH:D015467</infon><infon key="type">Disease</infon><location offset="63" length="29"/><text>Chronic neutrophilic leukemia</text></annotation><annotation id="29"><infon key="identifier">MESH:D015467</infon><infon key="type">Disease</infon><location offset="94" length="3"/><text>CNL</text></annotation><annotation id="30"><infon key="identifier">MESH:D009358</infon><infon key="type">Disease</infon><location offset="111" length="8"/><text>disorder</text></annotation><annotation id="31"><infon key="identifier">1441</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">601</infon><location offset="176" length="36"/><text>Colony stimulating factor 3 receptor</text></annotation><annotation id="32"><infon key="identifier">1441</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">601</infon><location offset="214" length="5"/><text>CSF3R</text></annotation><annotation id="33"><infon key="identifier">tmVar:p|SUB|T|618|I;HGVS:p.T618I;VariantGroup:0;CorrespondingGene:1441;RS#:796065343;CorrespondingSpecies:9606;CA#:204418</infon><infon key="type">ProteinMutation</infon><location offset="221" length="5"/><text>T618I</text></annotation><annotation id="34"><infon key="identifier">MESH:D015467</infon><infon key="type">Disease</infon><location offset="279" length="3"/><text>CNL</text></annotation><annotation id="35"><infon key="identifier">MESH:C540383</infon><infon key="type">Chemical</infon><location offset="336" length="11"/><text>Ruxolitinib</text></annotation><annotation id="36"><infon key="identifier">3717</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21033</infon><location offset="351" length="4"/><text>JAK2</text></annotation><annotation id="37"><infon key="identifier">MESH:C540383</infon><infon key="type">Chemical</infon><location offset="443" length="11"/><text>ruxolitinib</text></annotation><annotation id="38"><infon key="identifier">1441</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">601</infon><location offset="492" length="5"/><text>CSF3R</text></annotation><annotation id="39"><infon key="identifier">MESH:D015467</infon><infon key="type">Disease</infon><location offset="588" length="3"/><text>CNL</text></annotation><annotation id="40"><infon key="identifier">MESH:C580364</infon><infon key="type">Disease</infon><location offset="758" length="29"/><text>Chronic eosinophilic leukemia</text></annotation><annotation id="41"><infon key="identifier">MESH:C580364</infon><infon key="type">Disease</infon><location offset="789" length="3"/><text>CEL</text></annotation><annotation id="42"><infon key="identifier">MESH:D009358</infon><infon key="type">Disease</infon><location offset="806" length="8"/><text>disorder</text></annotation><annotation id="43"><infon key="identifier">MESH:C580364</infon><infon key="type">Disease</infon><location offset="949" length="3"/><text>CEL</text></annotation><annotation id="44"><infon key="identifier">MESH:C580364</infon><infon key="type">Disease</infon><location offset="1017" length="3"/><text>CEL</text></annotation><annotation id="45"><infon key="identifier">1043</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">88652</infon><location offset="1136" length="4"/><text>CD52</text></annotation><annotation id="46"><infon key="identifier">MESH:D000074323</infon><infon key="type">Chemical</infon><location offset="1151" length="11"/><text>alemtuzumab</text></annotation><annotation id="47"><infon key="identifier">3567</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">679</infon><location offset="1172" length="4"/><text>IL-5</text></annotation><annotation id="48"><infon key="identifier">MESH:C434107</infon><infon key="type">Chemical</infon><location offset="1187" length="11"/><text>mepolizumab</text></annotation><annotation id="49"><infon key="identifier">MESH:D017681</infon><infon key="type">Disease</infon><location offset="1265" length="26"/><text>hypereosinophilic syndrome</text></annotation><annotation id="50"><infon key="identifier">MESH:C580364</infon><infon key="type">Disease</infon><location offset="1345" length="3"/><text>CEL</text></annotation><annotation id="51"><infon key="identifier">MESH:C580364</infon><infon key="type">Disease</infon><location offset="1383" length="3"/><text>CEL</text></annotation></passage><relation id="R1"><infon key="score">0.9962</infon><infon key="role1">Disease|MESH:D017681</infon><infon key="role2">Gene|1043</infon><infon key="type">Association</infon><node refid="0" role="23,19"/></relation><relation id="R2"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:C434107</infon><infon key="role2">Disease|MESH:D017681</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="22,23"/></relation><relation id="R3"><infon key="score">0.6213</infon><infon key="role1">Disease|MESH:D015467</infon><infon key="role2">ProteinMutation|RS#:796065343;HGVS:p.T618I;CorrespondingGene:1441</infon><infon key="type">Association</infon><node refid="2" role="8,7"/></relation><relation id="R4"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:C434107</infon><infon key="role2">Gene|3567</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="22,21"/></relation><relation id="R5"><infon key="score">0.9617</infon><infon key="role1">Disease|MESH:D017681</infon><infon key="role2">Gene|3567</infon><infon key="type">Association</infon><node refid="4" role="23,21"/></relation><relation id="R6"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D015467</infon><infon key="role2">Gene|1441</infon><infon key="type">Association</infon><node refid="5" role="8,5"/></relation><relation id="R7"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:C540383</infon><infon key="role2">Gene|3717</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="9,10"/></relation><relation id="R8"><infon key="score">0.9974</infon><infon key="role1">Chemical|MESH:D000074323</infon><infon key="role2">Gene|1043</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="20,19"/></relation><relation id="R9"><infon key="score">0.5147</infon><infon key="role1">Chemical|MESH:C540383</infon><infon key="role2">Disease|MESH:D015467</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="9,8"/></relation><relation id="R10"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D000074323</infon><infon key="role2">Disease|MESH:D017681</infon><infon key="type">Negative_Correlation</infon><node refid="9" role="20,23"/></relation><relation id="R11"><infon key="score">0.9752</infon><infon key="role1">Chemical|MESH:C540383</infon><infon key="role2">Gene|1441</infon><infon key="type">Negative_Correlation</infon><node refid="10" role="11,12"/></relation><relation id="R12"><infon key="score">0.6213</infon><infon key="role1">Disease|MESH:D015467</infon><infon key="role2">Gene|1441</infon><infon key="type">Association</infon></relation></document>
<document><id>37914598</id><passage><infon key="journal">Trends Pharmacol Sci;2023Oct30. doi:10.1016/j.tips.2023.09.012</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Simon IA, Bj&amp;#xf8;rn-Yoshimoto WE, Harps&amp;#xf8;e K, Iliadis S, Svensson B, Jensen AA, Gloriam DE, </infon><offset>0</offset><text>Ligand selectivity hotspots in serotonin GPCRs.</text></passage><passage><infon key="type">abstract</infon><offset>48</offset><text>Serotonin is a neurotransmitter regulating numerous physiological processes also modulated by drugs, for example, schizophrenia, depression, migraine, and obesity. However, these drugs typically have adverse effects caused by promiscuous binding across 12 serotonin and more than 20 homologous receptors. Recently, structures of the entire serotonin receptor family uncovered molecular ligand recognition. Here, we present a map of 19 'selectivity hotspots', that is, nonconserved binding site residues governing selectivity via favorable target interactions or repulsive 'off-target' contacts. Furthermore, we review functional rationale from observed ligand-binding affinities and mutagenesis effects. Unifying knowledge underlying specific probes and drugs is critical toward the functional characterization of different receptors and alleviation of adverse effects.</text><annotation id="6"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="48" length="9"/><text>Serotonin</text></annotation><annotation id="7"><infon key="identifier">MESH:D012559</infon><infon key="type">Disease</infon><location offset="162" length="13"/><text>schizophrenia</text></annotation><annotation id="8"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="177" length="10"/><text>depression</text></annotation><annotation id="9"><infon key="identifier">MESH:D008881</infon><infon key="type">Disease</infon><location offset="189" length="8"/><text>migraine</text></annotation><annotation id="10"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="203" length="7"/><text>obesity</text></annotation><annotation id="11"><infon key="identifier">MESH:D012701</infon><infon key="type">Chemical</infon><location offset="304" length="9"/><text>serotonin</text></annotation></passage><relation id="R1"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D012701</infon><infon key="role2">Disease|MESH:D003866</infon><infon key="type">Association</infon><node refid="0" role="0,2"/></relation><relation id="R2"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D012701</infon><infon key="role2">Disease|MESH:D009765</infon><infon key="type">Association</infon><node refid="1" role="0,4"/></relation><relation id="R3"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D012701</infon><infon key="role2">Disease|MESH:D012559</infon><infon key="type">Association</infon><node refid="2" role="0,1"/></relation><relation id="R4"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D012701</infon><infon key="role2">Disease|MESH:D008881</infon><infon key="type">Association</infon><node refid="3" role="0,3"/></relation></document>
<document><id>37914948</id><passage><infon key="journal">Nature;2023Nov; 623 (7985) 9. doi:10.1038/d41586-023-03332-8</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">T&amp;#xfc;rk V, </infon><offset>0</offset><text>Protect the 'right to science' for people and the planet.</text></passage><passage><infon key="type">abstract</infon><offset>58</offset></passage></document>
<document><id>37915300</id><passage><infon key="journal">J Appl Clin Med Phys;2023Nov01 14195. doi:10.1002/acm2.14195</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Guo HL, Wu WW, Huan Y, Zhang HW, </infon><offset>0</offset><text>SGRT-based stereotactic body radiotherapy for lung cancer setup accuracy and margin of the PTV.</text><annotation id="1"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="46" length="11"/><text>lung cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset><text>OBJECTIVE: Surface-guided radiation therapy (SGRT, AlignRT) was used to analyze motion during stereotactic body radiotherapy (SBRT) in lung cancer patients and to explore the margin of the planning target volume (PTV). METHODS: The residual errors of the AlignRT were evaluated based on grayscale cone-beam computed tomography registration results before each treatment. AlignRT log file was used to analyze the correlation between the frequency and longest duration of errors larger than 2 mm and lasting longer than 2 s and maximum error with age and treatment duration. The displacement value at the end of treatment, the average displacement value, and the 95% probability density displacement interval were defined as intrafraction errors, and PTV1, PTV2, PTV3 were calculated by Van Herk formula or Z score analysis. Organ dosimetric differences were compared after the experience-based margin was replaced with PTV3. RESULTS: The interfraction residual errors were Vrt0 , 0.06 +- 0.18 cm; Lng0 , -0.03 +- 0.19 cm; Lat0 , 0.02 +- 0.15 cm; Pitch0 , 0.23 +- 0.7 ; Roll0 , 0.1 +- 0.69 ; Rtn0 , -0.02 +- 0.79 . The frequency, longest duration and maximum error in vertical direction were correlated with treatment duration (r = 0.404, 0.353, 0.283, p &lt; 0.05, respectively). In the longitudinal direction, the frequency was correlated with age and treatment duration (r = 0.376, 0.283, p &lt; 0.05, respectively), maximum error was correlated with age (r = 0.4, P &lt; 0.05). Vertical, longitudinal, lateral margins of PTV1, PTV2, PTV3 were 2 mm, 4 mm, 2 mm; 2 mm, 2 mm, 2 mm, 3 mm, 5 mm, 3 mm, respectively. After replacing the original PTV, mean lung dose (MLD), 2-cm3 chest wall dose (CD), lung V20 decreased by 0.2 Gy, 2.1 Gy, 0.5%, respectively (p &lt; 0.05). CONCLUSION: AlignRT can be used for interfraction setup and monitoring intrafraction motion. It is more reasonable to use upper and lower limits of the 95% probability density interval as an intrafraction error.</text><annotation id="3"><infon key="identifier">MESH:D008175</infon><infon key="type">Disease</infon><location offset="231" length="11"/><text>lung cancer</text></annotation></passage></document>
<document><id>37916350</id><passage><infon key="journal">Eur Rev Med Pharmacol Sci;2023Oct; 27 (20) 9838. doi:10.26355/eurrev_202310_34160</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tocoglu AG, Dogan B, Tuzun S, Akcay EU, Altas AE, Ayhan LT, Yilmaz S, Genc AC, Gonullu E, Tamer A, </infon><offset>0</offset><text>The relationship between Salusin-alpha, Salusin-beta, and Klotho levels with subclinical atherosclerosis in ankylosing spondylitis.</text><annotation id="4"><infon key="identifier">27433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">25260</infon><location offset="40" length="12"/><text>Salusin-beta</text></annotation><annotation id="5"><infon key="identifier">9365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68415</infon><location offset="58" length="6"/><text>Klotho</text></annotation><annotation id="6"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="77" length="27"/><text>subclinical atherosclerosis</text></annotation><annotation id="7"><infon key="identifier">MESH:D013167</infon><infon key="type">Disease</infon><location offset="108" length="22"/><text>ankylosing spondylitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>132</offset><text>OBJECTIVE: Subclinical atherosclerosis (SA) is often observed in ankylosing spondylitis (AS) patients; Salusin-alpha (Sal-alpha), Salusin-beta (Sal-beta), and Klotho hormones are thought to be associated with atherosclerosis. This study aims to evaluate the relationship between Sal-alpha, Sal-beta, and Klotho levels with SA in AS. PATIENTS AND METHODS: The study included patients older than 18 years who applied between August 1, 2019, and September 1, 2019. Patients with AS were included in the AS group, and patients without a known disease were included in the healthy group. Epicardial adipose tissue thickness (EATT) and carotid intima-media thickness (CIMT) measurements were used to assess SA. RESULTS: The study group included 38 (40.9%) patients diagnosed with AS, and the control group included 55 (59.1%) participants. CIMT and EATT levels were higher in the AS group than in the healthy group [0.37 (0.17) vs. 0.54+-0.18, p&lt;0.001; 0.44+-0.11 vs. 0.54 (0.18), p=0.004, respectively]. There was no significant difference in Sal-alpha, Sal-beta, and Klotho levels between the AS and healthy groups (p>0.05). Furthermore, there was no observed relationship between EATT or CIMT and Klotho, Sal-alpha, or Sal-beta in either group (p>0.05). CONCLUSIONS: Although SA level was higher in AS patients, there was no relationship between SA and Sal-alpha, Sal-beta, and Klotho levels.</text><annotation id="22"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="143" length="27"/><text>Subclinical atherosclerosis</text></annotation><annotation id="23"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="172" length="2"/><text>SA</text></annotation><annotation id="24"><infon key="identifier">MESH:D013167</infon><infon key="type">Disease</infon><location offset="197" length="22"/><text>ankylosing spondylitis</text></annotation><annotation id="25"><infon key="identifier">27433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">25260</infon><location offset="262" length="12"/><text>Salusin-beta</text></annotation><annotation id="26"><infon key="identifier">9365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68415</infon><location offset="291" length="6"/><text>Klotho</text></annotation><annotation id="27"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="341" length="15"/><text>atherosclerosis</text></annotation><annotation id="28"><infon key="identifier">9365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68415</infon><location offset="436" length="6"/><text>Klotho</text></annotation><annotation id="29"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="455" length="2"/><text>SA</text></annotation><annotation id="30"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="833" length="2"/><text>SA</text></annotation><annotation id="31"><infon key="identifier">9365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68415</infon><location offset="1195" length="6"/><text>Klotho</text></annotation><annotation id="32"><infon key="identifier">9365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68415</infon><location offset="1326" length="6"/><text>Klotho</text></annotation><annotation id="33"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1405" length="2"/><text>SA</text></annotation><annotation id="34"><infon key="identifier">MESH:D050197</infon><infon key="type">Disease</infon><location offset="1475" length="2"/><text>SA</text></annotation><annotation id="35"><infon key="identifier">9365</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68415</infon><location offset="1507" length="6"/><text>Klotho</text></annotation></passage><relation id="R1"><infon key="score">0.9989</infon><infon key="role1">Disease|MESH:D050197</infon><infon key="role2">Gene|9365</infon><infon key="type">Association</infon><node refid="0" role="2,1"/></relation><relation id="R2"><infon key="score">0.7732</infon><infon key="role1">Disease|MESH:D050197</infon><infon key="role2">Gene|27433</infon><infon key="type">Association</infon><node refid="1" role="2,0"/></relation></document>
<document><id>37916705</id><passage><infon key="journal">Anal Methods;2023Nov02. doi:10.1039/d3ay01282d</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tikkisetty K, Filewood T, Yan J, Kwok H, Brunswick P, Cody R, Shang D, </infon><offset>0</offset><text>Method development for forensic oil identification by direct analysis in real time time-of-flight mass spectrometry.</text><annotation id="1"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="32" length="3"/><text>oil</text></annotation></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>The current well-established chromatography and mass spectrometry based oil spill identification procedures, such as those outlined by the European Committee for Standardization, are highly reliable as methods, highly defensible in the court of law, and widely applicable to the majority of oil spill situations. Nevertheless, the methodology is time consuming and labour intensive, which may not be ideal when dealing with an emergency oil spill situation. In this study, direct analysis in real time time-of-flight mass spectrometry (DART/TOFMS) was used to successfully develop an efficient oil identification method. To confirm the accuracy of this method spilled oil samples were tested from five previous years of blind round robin testing organized by the oil spill identification network of experts (OSINET) under the Bonn Agreement. Heatmap inspection, principal component analysis and finally discriminant analysis of principal components were used to arrive at final predictions regarding the identities of the spilled oil samples. The results were compared with the results of previous gas chromatography flame ionization detection (GC/FID) and gas chromatography triple quadrupole mass spectrometry (GC/MS/MS) analyses of the same oils. While taking only about a tenth of the time, the DART/TOFMS analysis produced results similar to those of classical GC/FID and GC/MS/MS (EI+) procedures. The ability of DART/TOFMS to display this level of validity exemplifies its potential to be a new tool for supplementing classical analyses for oil spill forensics.</text><annotation id="11"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="189" length="3"/><text>oil</text></annotation><annotation id="12"><infon key="type">Disease</infon><location offset="408" length="3"/><text>oil</text></annotation><annotation id="13"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="554" length="3"/><text>oil</text></annotation><annotation id="14"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="711" length="3"/><text>oil</text></annotation><annotation id="15"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="785" length="3"/><text>oil</text></annotation><annotation id="16"><infon key="type">Disease</infon><location offset="880" length="3"/><text>oil</text></annotation><annotation id="17"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="1147" length="3"/><text>oil</text></annotation><annotation id="18"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="1361" length="4"/><text>oils</text></annotation><annotation id="19"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="1665" length="3"/><text>oil</text></annotation></passage></document>
<document><id>37917408</id><passage><infon key="journal">Arch Orthop Trauma Surg;2023Nov02. doi:10.1007/s00402-023-05064-w</infon><infon key="year">2023</infon><infon key="article-id_pmc">9297055</infon><infon key="type">title</infon><infon key="authors">Arshad Z, Haq II, Bhatia M, </infon><offset>0</offset><text>Learning curve of total ankle arthroplasty: a systematic review.</text><annotation id="1"><infon key="type">Disease</infon><location offset="30" length="12"/><text>arthroplasty</text></annotation></passage><passage><infon key="type">abstract</infon><offset>65</offset><text>INTRODUCTION: Together with ankle arthrodesis, total ankle arthroplasty is now accepted as a first-line intervention in the management of end-stage arthritis of the ankle. The evidence regarding how outcomes are affected by surgeon experience is inconsistent; we performed a systematic review to evaluate the effect of a learning curve in total ankle arthroplasty outcomes. METHODS: An electronic database search was performed in PubMed, Embase, ISI Web of Science and Cochrane trials. Two reviewers independently conducted a two-stage title/abstract and full text screening. English-language original research studies comparing patient-reported outcome measures (PROMs), complication/revision rates, operative time, length of stay or radiation exposure according to surgeon experience were included. Quality assessment was performed using the methodological index for non-randomised studies. RESULTS: All but one included study report either improved PROMs, reduced complication/revision rate, reduced hospital stay length/operative time or reduced radiation exposure with increasing surgeon experience. However, the majority of these findings lack statistical significance. Two studies assessing the plateau of the learning curve report a wide range of plateau thresholds between 9 and 39 cases. CONCLUSION: This review finds a largely non-significant trend towards improvements in PROMs, complication, and revision rates with improved surgeon experience. The lack of statistical significance in a number of studies may be partially explained by methodological flaws, with more suitably designed studies reporting significant improvements. Future research into the effect of advancements in implant design and insertion guides is required to further characterise the magnitude of the learning curve and guide both mitigation and learning strategies.</text><annotation id="8"><infon key="type">Disease</infon><location offset="124" length="12"/><text>arthroplasty</text></annotation><annotation id="9"><infon key="identifier">MESH:D007676</infon><infon key="type">Disease</infon><location offset="203" length="32"/><text>end-stage arthritis of the ankle</text></annotation><annotation id="10"><infon key="type">Disease</infon><location offset="416" length="12"/><text>arthroplasty</text></annotation><annotation id="11"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="737" length="12"/><text>complication</text></annotation><annotation id="12"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="1032" length="12"/><text>complication</text></annotation><annotation id="13"><infon key="identifier">MESH:D008107</infon><infon key="type">Disease</infon><location offset="1456" length="12"/><text>complication</text></annotation></passage></document>
<document><id>37917759</id><passage><infon key="journal">PLoS One;2023; 18 (11) 0293797. doi:10.1371/journal.pone.0293797</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Picauly I, Adi AAAM, Meiyetriani E, Mading M, Weraman P, Nashriyah SF, Hidayat AT, Boeky DLA, Lobo V, Saleh A, Peni JA, </infon><offset>0</offset><text>Path analysis model for preventing stunting in dryland area island East Nusa Tenggara Province, Indonesia.</text><annotation id="1"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="35" length="8"/><text>stunting</text></annotation></passage><passage><infon key="type">abstract</infon><offset>107</offset><text>BACKGROUND: The problem of stunting is still a fundamental problem in Indonesia's human development. East Nusa Tenggara Province is an archipelago dryland area where in 2007-2021 it has contributed to the highest number of stunting children prevalence in Indonesia. This study aims to determine the relationship of variables in individual, household and district level with the prevalence of stunting. METHODS: This type of research is observational study with a cross sectional design. This study used individual secondary data from the Indonesian Nutritional Status Survey in 2021 consisting of 7,835 toddlers and National Social Economics Survey 2021. RESULTS: This research found that both specific &amp; sensitive intervention programs had an influence in accelerating the decline in stunting prevalence (higher score on Z Score). Results also revealed the positive influence of the food access variable on nutritional intake. The results of the path analysis test showed that sensitive intervention program variables have a positive effect on food access variable and environmental variable (environmental sanitation) such as the habit of open defecation and healthcare. There was significant relationship on disease history, environment and intake to Height for Age (HAZ) score. CONCLUSIONS: In conclusion, direct and indirect factors have important roles to prevent stunting. Sensitive and specific intervention program, food access, macro determinants and environment are the indirect indicators which contribute significantly to the stunting. The risk of children under five years old experiencing malnourished nutritional status increases with a history of infectious disease (diarrhea, ARI, worms). The risk of children under five years experiencing malnourished nutritional status decreases with adequate nutritional intake. It is hoped that there will be a special model of stunting control interventions at the individual level and at the family, household and district level that are integrated and of high quality through multisectoral cooperation in the dryland areas of the islands of East Nusa Tenggara Province.</text><annotation id="15"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="134" length="8"/><text>stunting</text></annotation><annotation id="16"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="330" length="8"/><text>stunting</text></annotation><annotation id="17"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="499" length="8"/><text>stunting</text></annotation><annotation id="18"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="892" length="8"/><text>stunting</text></annotation><annotation id="19"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="1477" length="8"/><text>stunting</text></annotation><annotation id="20"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="1646" length="8"/><text>stunting</text></annotation><annotation id="21"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="1711" length="31"/><text>malnourished nutritional status</text></annotation><annotation id="22"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="1771" length="18"/><text>infectious disease</text></annotation><annotation id="23"><infon key="identifier">MESH:D003967</infon><infon key="type">Disease</infon><location offset="1791" length="8"/><text>diarrhea</text></annotation><annotation id="24"><infon key="type">Disease</infon><location offset="1801" length="3"/><text>ARI</text></annotation><annotation id="25"><infon key="identifier">MESH:D017189</infon><infon key="type">Disease</infon><location offset="1806" length="5"/><text>worms</text></annotation><annotation id="26"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="1865" length="31"/><text>malnourished nutritional status</text></annotation><annotation id="27"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="1991" length="8"/><text>stunting</text></annotation></passage></document>
<document><id>37918110</id><passage><infon key="journal">Am J Vet Res;2023Oct13; 84 (11) . doi:10.2460/ajvr.23.08.0195</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Fang Y, Zhang W, Rowland B, Constable P, </infon><offset>0</offset><text>Surveillance, prevention fight infectious disease.</text><annotation id="1"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="31" length="18"/><text>infectious disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>51</offset></passage></document>
<document><id>37918460</id><passage><infon key="journal">Biol Psychiatry;2023Oct31. doi:10.1016/j.biopsych.2023.10.015</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Miller AB, Jenness J, Elton A, Pelletier-Baldelli A, Patel K, Bonar A, Martin S, Dichter G, Giletta M, Slavich GM, Rudolph KD, Hastings P, Nock M, Prinstein MJ, Sheridan M, </infon><offset>0</offset><text>Neural markers of emotion reactivity and regulation before and after a targeted social rejection: Differences among girls with and without suicidal ideation and behavior histories.</text><annotation id="1"><infon key="identifier">MESH:D001072</infon><infon key="type">Disease</infon><location offset="139" length="17"/><text>suicidal ideation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>181</offset><text>BACKGROUND: Suicidal thoughts and behaviors (STBs) are common among adolescent girls and increase risk for suicide death. Emotion regulation difficulties are linked with STBs, particularly in response to targeted social rejection. However, neural correlates of this link have not been investigated and may identify novel targets for interventions. Here, we examine neural correlates of emotion regulation before and after an experimentally delivered targeted social rejection in girls with and without STBs (i.e., Controls). METHOD: Girls (n=138; ages 9-15, Mage=11.6, SD=1.79) completed a functional neuroimaging emotion regulation task. In the middle of the emotion regulation task, participants were socially rejected by an unfamiliar confederate whom the participants had elected to meet. Participants completed a multi-method STB assessment. RESULTS: Prior to rejection, girls with a history of STBs versus Controls showed greater activation when passively viewing negative stimuli in the right superior frontal gyrus, and girls with suicidal behavior (SB) versus without showed less activation in the right frontal pole during emotion regulation attempts. Following the rejection, girls with STBs versus Controls showed greater activation in the right inferior frontal gyrus during emotion regulation. CONCLUSIONS: Prior to social rejection, girls with versus without SB may not activate brain regions implicated in emotion regulation, suggesting a vulnerability to poor regulation at their baseline emotional state. After a social rejection, girls with any STB history showed altered activation in a brain region strongly associated with inhibition and emotion regulation success, possibly reflecting increased effort at inhibiting emotional responses during regulation following stress exposure.</text><annotation id="22"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="193" length="31"/><text>Suicidal thoughts and behaviors</text></annotation><annotation id="23"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="226" length="4"/><text>STBs</text></annotation><annotation id="24"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="288" length="13"/><text>suicide death</text></annotation><annotation id="25"><infon key="identifier">MESH:C564833</infon><infon key="type">Disease</infon><location offset="303" length="18"/><text>Emotion regulation</text></annotation><annotation id="26"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="351" length="4"/><text>STBs</text></annotation><annotation id="27"><infon key="identifier">MESH:C564833</infon><infon key="type">Disease</infon><location offset="567" length="18"/><text>emotion regulation</text></annotation><annotation id="28"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="683" length="4"/><text>STBs</text></annotation><annotation id="29"><infon key="identifier">MESH:C564833</infon><infon key="type">Disease</infon><location offset="795" length="18"/><text>emotion regulation</text></annotation><annotation id="30"><infon key="identifier">MESH:C564833</infon><infon key="type">Disease</infon><location offset="841" length="18"/><text>emotion regulation</text></annotation><annotation id="31"><infon key="type">Disease</infon><location offset="1012" length="3"/><text>STB</text></annotation><annotation id="32"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1081" length="4"/><text>STBs</text></annotation><annotation id="33"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1220" length="17"/><text>suicidal behavior</text></annotation><annotation id="34"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1239" length="2"/><text>SB</text></annotation><annotation id="35"><infon key="identifier">MESH:C564833</infon><infon key="type">Disease</infon><location offset="1314" length="18"/><text>emotion regulation</text></annotation><annotation id="36"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1379" length="4"/><text>STBs</text></annotation><annotation id="37"><infon key="identifier">MESH:C564833</infon><infon key="type">Disease</infon><location offset="1469" length="18"/><text>emotion regulation</text></annotation><annotation id="38"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1555" length="2"/><text>SB</text></annotation><annotation id="39"><infon key="identifier">MESH:C564833</infon><infon key="type">Disease</infon><location offset="1603" length="18"/><text>emotion regulation</text></annotation><annotation id="40"><infon key="type">Disease</infon><location offset="1745" length="3"/><text>STB</text></annotation><annotation id="41"><infon key="identifier">MESH:C564833</infon><infon key="type">Disease</infon><location offset="1841" length="18"/><text>emotion regulation</text></annotation></passage></document>
<document><id>37918810</id><passage><infon key="journal">J Pediatr (Rio J);2023Oct30. doi:10.1016/j.jped.2023.08.009</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Weffort VRS, Lamounier JA, </infon><offset>0</offset><text>Hidden hunger - a narrative review.</text><annotation id="1"><infon key="type">Disease</infon><location offset="0" length="13"/><text>Hidden hunger</text></annotation></passage><passage><infon key="type">abstract</infon><offset>36</offset><text>OBJECTIVE: Malnutrition is characterized by situations of undernutrition and obesity resulting from the lack of micronutrients with the greatest impact on children. The objective of this review was to highlight inadequate food consumption, food security, and nutritional inadequacy leading to hidden hunger and the prevention and treatment of the main micronutrient deficiencies in Brazil. DATA SOURCE: Literature review carried out through a bibliographic survey in PubMed (National Library of Medicine, United States), Lilacs (Latin American and Caribbean Literature in Health Sciences), and SciELO (Scientific Electronic Library Online) databases. The search used the terms Occult hunger, (hidden hunger), and Child, in articles published between 2013 and 2023 in Portuguese, English and Spanish. The search was performed on 06/25/2023. DATA SYNTHESIS: The lack of micronutrients can occur insidiously and without clinical manifestations, being called hidden hunger. The prevention of nutritional deficiencies is part of the recommended actions in childcare, with healthy eating. Studies were cited related to macro and micronutrient intake deficiencies, both national and international, and strategies to improve micronutrient intake, including routine supplementation of iron, and vitamins D and A. The diagnosis, prevention, and treatment of the main deficiencies in Brazil (iron, vitamin A, vitamin D, zinc), currently adopted, concluded the topic. CONCLUSION: Zero hunger and zero obesity must be part of the same policy, together with a nutritional education program.</text><annotation id="19"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="47" length="12"/><text>Malnutrition</text></annotation><annotation id="20"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="94" length="14"/><text>undernutrition</text></annotation><annotation id="21"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="113" length="7"/><text>obesity</text></annotation><annotation id="22"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="295" length="22"/><text>nutritional inadequacy</text></annotation><annotation id="23"><infon key="type">Disease</infon><location offset="329" length="13"/><text>hidden hunger</text></annotation><annotation id="24"><infon key="identifier">MESH:D007153</infon><infon key="type">Disease</infon><location offset="388" length="26"/><text>micronutrient deficiencies</text></annotation><annotation id="25"><infon key="type">Disease</infon><location offset="720" length="6"/><text>hunger</text></annotation><annotation id="26"><infon key="type">Disease</infon><location offset="729" length="13"/><text>hidden hunger</text></annotation><annotation id="27"><infon key="type">Disease</infon><location offset="991" length="13"/><text>hidden hunger</text></annotation><annotation id="28"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="1024" length="24"/><text>nutritional deficiencies</text></annotation><annotation id="29"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1312" length="4"/><text>iron</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1322" length="17"/><text>vitamins D and A.</text></annotation><annotation id="31"><infon key="identifier">MESH:D007501</infon><infon key="type">Chemical</infon><location offset="1417" length="4"/><text>iron</text></annotation><annotation id="32"><infon key="identifier">MESH:D014801</infon><infon key="type">Chemical</infon><location offset="1423" length="9"/><text>vitamin A</text></annotation><annotation id="33"><infon key="identifier">MESH:D014807</infon><infon key="type">Chemical</infon><location offset="1434" length="9"/><text>vitamin D</text></annotation><annotation id="34"><infon key="type">Disease</infon><location offset="1504" length="11"/><text>Zero hunger</text></annotation><annotation id="35"><infon key="identifier">MESH:D009765</infon><infon key="type">Disease</infon><location offset="1525" length="7"/><text>obesity</text></annotation></passage></document>
<document><id>37919160</id><passage><infon key="journal">Sci Bull (Beijing);2023Oct28. doi:10.1016/j.scib.2023.10.026</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Qin L, Li Y, Wang S, </infon><offset>0</offset><text>Safety concerns of preserved food-does nitrite cause disease?</text><annotation id="1"><infon key="identifier">MESH:D009573</infon><infon key="type">Chemical</infon><location offset="39" length="7"/><text>nitrite</text></annotation></passage><passage><infon key="type">abstract</infon><offset>62</offset></passage></document>
<document><id>37919510</id><passage><infon key="journal">Environ Sci Pollut Res Int;2023Nov03. doi:10.1007/s11356-023-30755-7</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gao S, Sun P, Zhao X, Chang K, Chen W, </infon><offset>0</offset><text>Waterborne copper exposure decreases fish growth and survival by promoting gills and liver impairments in largemouth bass (Micropterus salmoides).</text><annotation id="2"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="11" length="6"/><text>copper</text></annotation><annotation id="3"><infon key="identifier">MESH:D017093</infon><infon key="type">Disease</infon><location offset="85" length="17"/><text>liver impairments</text></annotation></passage><passage><infon key="type">abstract</infon><offset>147</offset><text>The study aimed to investigate the effect of Cu exposure (0, 51.3, 164, 513, 1,640, and 5,130 mug/L) on fish growth performance, histology, oxidative stress, inflammation, and apoptosis in largemouth bass (Micropterus salmoides) juveniles. 270 fish (2.69 +- 0.02 g) were randomly divided into 6 groups of tanks for 4 weeks with each group comprising three replicate tanks. The results showed that fish exposed to 1,640 and 5,130 mug/L Cu exhibited a significant reduction in fish growth and survival rate (P &lt; 0.05). Compared to the control, the fish at and above 513 mug/L Cu demonstrated histopathological damages in the gills and liver, such as shorter primary and secondary lamellae, smaller hepatocyte nuclei, and an increase in the number of necrotic cells in the liver. Compared to the control, fish at and above 1,640 mug/L Cu had a significantly higher malondialdehyde content and lower activity levels of total superoxide dismutase, glutathione peroxidase, and catalase in the gills and liver (P &lt; 0.05). Furthermore, high concentrations of Cu (1,640 and 5,130 mug/L) significantly increased hepatic inflammation by upregulating interleukin-1beta and tumor necrosis factor alpha expression and hepatic apoptosis by increasing cysteinyl aspartate specific protease 3 (caspase-3) and caspase-9 expression (P &lt; 0.05). Pearson correlation analysis showed that fish growth and survival positively correlated with histological and antioxidant defense parameters, and negatively correlated with oxidative stress parameters, hepatic inflammation, and hepatic apoptosis. Taken together, these results suggest that high levels of waterborne Cu can induce growth retardation and mortality by damaging the liver and gill health.</text><annotation id="20"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="192" length="2"/><text>Cu</text></annotation><annotation id="21"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="305" length="12"/><text>inflammation</text></annotation><annotation id="22"><infon key="identifier">MESH:D065703</infon><infon key="type">Disease</infon><location offset="323" length="9"/><text>apoptosis</text></annotation><annotation id="23"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="582" length="2"/><text>Cu</text></annotation><annotation id="24"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="721" length="2"/><text>Cu</text></annotation><annotation id="25"><infon key="identifier">MESH:D020263</infon><infon key="type">Disease</infon><location offset="737" length="25"/><text>histopathological damages</text></annotation><annotation id="26"><infon key="identifier">MESH:D002292</infon><infon key="type">Disease</infon><location offset="895" length="14"/><text>necrotic cells</text></annotation><annotation id="27"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="979" length="2"/><text>Cu</text></annotation><annotation id="28"><infon key="identifier">MESH:D008315</infon><infon key="type">Chemical</infon><location offset="1009" length="15"/><text>malondialdehyde</text></annotation><annotation id="29"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="1198" length="2"/><text>Cu</text></annotation><annotation id="30"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1249" length="20"/><text>hepatic inflammation</text></annotation><annotation id="31"><infon key="identifier">MESH:D065703</infon><infon key="type">Disease</infon><location offset="1359" length="9"/><text>apoptosis</text></annotation><annotation id="32"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1674" length="20"/><text>hepatic inflammation</text></annotation><annotation id="33"><infon key="identifier">MESH:D065703</infon><infon key="type">Disease</infon><location offset="1708" length="9"/><text>apoptosis</text></annotation><annotation id="34"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="1788" length="2"/><text>Cu</text></annotation><annotation id="35"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="1802" length="18"/><text>growth retardation</text></annotation></passage><relation id="R1"><infon key="score">0.9969</infon><infon key="role1">Chemical|MESH:D003300</infon><infon key="role2">Disease|MESH:D020263</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="6,7"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D003300</infon><infon key="role2">Disease|MESH:D002292</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="6,8"/></relation><relation id="R3"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D003300</infon><infon key="role2">Disease|MESH:D017093</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="0,1"/></relation><relation id="R4"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:D003300</infon><infon key="role2">Chemical|MESH:D008315</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="9,10"/></relation><relation id="R5"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:D003300</infon><infon key="role2">Disease|MESH:D006130</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="16,17"/></relation><relation id="R6"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:D003300</infon><infon key="role2">Disease|MESH:D065703</infon><infon key="type">Positive_Correlation</infon><node refid="5" role="2,4"/></relation><relation id="R7"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:D003300</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="2,3"/></relation></document>
<document><id>37919860</id><passage><infon key="journal">Small;2023Nov02 2306508. doi:10.1002/smll.202306508</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Huang L, Du M, Sun D, He M, Liu Z, Wu R, Jiang Y, Qi L, Wang J, Zhu C, Li Y, Liu L, Feng G, Zhang L, </infon><offset>0</offset><text>Propelling Multi-Modal Therapeutics of PEEK Implants through the Power of NO evolving Covalent Organic Frameworks (COFs).</text><annotation id="1"><infon key="identifier">MESH:C063834</infon><infon key="type">Chemical</infon><location offset="39" length="4"/><text>PEEK</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>The design and fabrication of NO-evolving core-shell nanoparticles (denoted as NC@Fe), comprised of BNN6-laden COF@Fe3 O4 nanoparticles, are reported. This innovation extends to the modification of 3D printed polyetheretherketone scaffolds with NC@Fe, establishing a pioneering approach to multi-modal bone therapy tailored to address complications such as device-associated infections and osteomyelitis. This work stands out prominently from previous research, particularly those relying on the use of antibiotics, by introducing a bone implant capable of simultaneous NO gas therapy and photothermal therapy (PPT). Under NIR laser irradiation, the Fe3 O4 NP core (photothermal conversion agent) within NC@Fe absorbs photoenergy and initiates electron transfer to the loaded NO donor (BNN6), resulting in controlled NO release. The additional heat generated through photothermal conversion further propels the NC@Fe nanoparticles, amplifying the therapeutic reach. The combined effect of NO release and PPT enhances the efficacy in eradicating bacteria over a more extensive area around the implant, presenting a distinctive solution to conventional challenges. Thorough in vitro and in vivo investigations validate the robust potential of the scaffold in infection control, osteogenesis, and angiogenesis, emphasizing the timeliness of this unique solution in managing complicated bone related infectious diseases.</text><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="201" length="5"/><text>NC@Fe</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="222" length="4"/><text>BNN6</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="233" length="10"/><text>COF@Fe3 O4</text></annotation><annotation id="20"><infon key="identifier">MESH:C063834</infon><infon key="type">Chemical</infon><location offset="331" length="20"/><text>polyetheretherketone</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="367" length="5"/><text>NC@Fe</text></annotation><annotation id="22"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="497" length="10"/><text>infections</text></annotation><annotation id="23"><infon key="identifier">MESH:D010019</infon><infon key="type">Disease</infon><location offset="512" length="13"/><text>osteomyelitis</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="733" length="3"/><text>PPT</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="772" length="6"/><text>Fe3 O4</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="826" length="5"/><text>NC@Fe</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="908" length="4"/><text>BNN6</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1033" length="5"/><text>NC@Fe</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1126" length="3"/><text>PPT</text></annotation><annotation id="30"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1379" length="9"/><text>infection</text></annotation><annotation id="31"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="1518" length="19"/><text>infectious diseases</text></annotation></passage><relation id="R1"><infon key="score">0.8158</infon><infon key="role1">Chemical|MESH:C063834</infon><infon key="role2">Disease|MESH:D010019</infon><infon key="type">Association</infon><node refid="0" role="6,9"/></relation></document>
<document><id>37920910</id><passage><infon key="journal">Acad Med;2023Oct17. doi:10.1097/ACM.0000000000005474</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Steen K, VanDenBerg KR, Servoss J, Subramanian S, Grieb TA, </infon><offset>0</offset><text>A Research Operations, Management, and Strategy Fellowship for Life Sciences PhD Graduates.</text></passage><passage><infon key="type">abstract</infon><offset>92</offset><text>PROBLEM: With less than 25% of PhD-trained scientists in the United States securing a tenure-track faculty position following training, nonacademic careers have become common. As the academic research enterprise has increased, business-oriented careers have emerged. The Research Operations, Management, and Strategy (ROMS) Fellowship was developed to increase awareness of and prepare life sciences PhD graduates for business-focused careers. APPROACH: The ROMS Fellowship was developed from March through December 2018 by the University of Michigan Medical School. Launched in 2019 and based on real-world experiences, the 2-year ROMS Fellowship combines immersion rotations and project work to develop an understanding of foundational infrastructure across the full spectrum of research. OUTCOMES: From 2019 to 2022, there were 4 ROMS Fellowship recruitment cycles, with a mean of 7 applicants per cycle and 2 fellows selected each year. Of the 8 fellows recruited, 5 (62.5%) joined directly from PhD training, whereas 3 (37.5%) had 2 to 6 years of postdoctoral training. Fellows have worked with 26 departments on 44 rotation projects and 30 impact projects and self-reported significant skill development in communicating with diverse stakeholders, strategic thinking, using new tools and resources, developing and scoping a project plan, and managing and leading a project. To date, 4 fellows have completed the program and were hired immediately into full-time positions at the University of Michigan Medical School. NEXT STEPS: Early feedback indicates that the program has been well received and effective. Previously, program refinement was directed by qualitative input from fellows and unit directors. However, for future cohorts, assessment tools will be implemented to capture qualitative and quantitative data to measure acquired skills and how program components contribute to professional development and career placement. A longitudinal follow-up will also be conducted with program alumni to track longer-term outcomes and career pathways.</text></passage></document>
<document><id>37921260</id><passage><infon key="journal">J Cardiovasc Electrophysiol;2023Nov03. doi:10.1111/jce.16109</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gupte T, Liang JJ, Latchamsetty R, Crawford T, Jongnarangsin K, Bogun F, Ghannam M, </infon><offset>0</offset><text>Long-term outcomes of patients with ventricular arrhythmias and negative programmed ventricular stimulation followed with implantable loop recorders: Impact of delayed-enhancement cardiac magnetic resonance imaging.</text><annotation id="1"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="36" length="23"/><text>ventricular arrhythmias</text></annotation></passage><passage><infon key="type">abstract</infon><offset>216</offset><text>BACKGROUND: Programed ventricular stimulation (PVS) is a risk stratification tool in patients at risk for adverse arrhythmia outcomes. Patients with negative PVS may yet be at risk for adverse arrhythmia-related events, particularly in the presence of symptomatic ventricular arrhythmias (VA). OBJECTIVE: To investigate the long-term outcomes of real-world patients with symptomatic VA without indication for device therapy and negative PVS, and to examine the role of cardiac scaring on arrhythmia recurrence. METHODS: Patients with symptomatic VA, and late gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMR), and negative PVS testing were included. All patients underwent placement of implantable cardiac monitors (ICM). Survival analysis was performed to investigate the impact of LGE-CMR findings on survival free from adverse arrhythmic events. RESULTS: Seventy-eight patients were included (age 60 +- 14 years, women n = 36 (46%), ejection fraction 57 +- 9%, cardiomyopathy n = 26 (33%), mitral valve prolapse [MVP] n = 9 (12%), positive LGE-CMR scar n = 49 (62%), history of syncope n = 23 (29%)) including patients with primarily premature ventricular contractions (n = 21) or nonsustained VA (n = 57). Patients were followed for 1.6 +- 1.5 years during which 14 patients (18%) experienced VA requiring treatment (n = 14) or syncope due to bradycardia (n = 2). Four/9 patients (44%) with MVP experienced VA (n = 3) or syncope (n = 1). Baseline characteristics between those with and without adverse events were similar (p > 0.05); however, the presence of cardiac scar on LGE-CMR was independently associated with an increased risk of adverse events (hazard ratio: 5.6 95% confidence interval: [1.2-27], p = 0.03, log-rank p = 0.03). CONCLUSIONS: In a real-world cohort with long-term follow-up, adverse arrhythmic outcomes occurred in 18% of patients with symptomatic VA despite negative PVS, and this risk was significantly greater in patients with positive DE-CMR scar. Long term-monitoring, including the use of ICM, may be appropriate in these patients.</text><annotation id="26"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="330" length="10"/><text>arrhythmia</text></annotation><annotation id="27"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="409" length="10"/><text>arrhythmia</text></annotation><annotation id="28"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="480" length="23"/><text>ventricular arrhythmias</text></annotation><annotation id="29"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="505" length="2"/><text>VA</text></annotation><annotation id="30"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="599" length="2"/><text>VA</text></annotation><annotation id="31"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="704" length="10"/><text>arrhythmia</text></annotation><annotation id="32"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="762" length="2"/><text>VA</text></annotation><annotation id="33"><infon key="identifier">MESH:D005682</infon><infon key="type">Chemical</infon><location offset="775" length="10"/><text>gadolinium</text></annotation><annotation id="34"><infon key="identifier">OMIM:212500</infon><infon key="type">Disease</infon><location offset="1064" length="10"/><text>arrhythmic</text></annotation><annotation id="35"><infon key="identifier">MESH:D009202</infon><infon key="type">Disease</infon><location offset="1198" length="14"/><text>cardiomyopathy</text></annotation><annotation id="36"><infon key="identifier">MESH:D008945</infon><infon key="type">Disease</infon><location offset="1227" length="21"/><text>mitral valve prolapse</text></annotation><annotation id="37"><infon key="identifier">MESH:D008945</infon><infon key="type">Disease</infon><location offset="1250" length="3"/><text>MVP</text></annotation><annotation id="38"><infon key="identifier">MESH:D013575</infon><infon key="type">Disease</infon><location offset="1315" length="7"/><text>syncope</text></annotation><annotation id="39"><infon key="identifier">MESH:D018879</infon><infon key="type">Disease</infon><location offset="1371" length="34"/><text>premature ventricular contractions</text></annotation><annotation id="40"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="1431" length="2"/><text>VA</text></annotation><annotation id="41"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="1531" length="2"/><text>VA</text></annotation><annotation id="42"><infon key="identifier">MESH:D013575</infon><infon key="type">Disease</infon><location offset="1566" length="7"/><text>syncope</text></annotation><annotation id="43"><infon key="identifier">MESH:D001919</infon><infon key="type">Disease</infon><location offset="1581" length="11"/><text>bradycardia</text></annotation><annotation id="44"><infon key="identifier">MESH:D008945</infon><infon key="type">Disease</infon><location offset="1629" length="3"/><text>MVP</text></annotation><annotation id="45"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="1645" length="2"/><text>VA</text></annotation><annotation id="46"><infon key="identifier">MESH:D013575</infon><infon key="type">Disease</infon><location offset="1659" length="7"/><text>syncope</text></annotation><annotation id="47"><infon key="identifier">MESH:D002921</infon><infon key="type">Disease</infon><location offset="1797" length="12"/><text>cardiac scar</text></annotation><annotation id="48"><infon key="identifier">OMIM:212500</infon><infon key="type">Disease</infon><location offset="2045" length="10"/><text>arrhythmic</text></annotation><annotation id="49"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="2110" length="2"/><text>VA</text></annotation></passage></document>
<document><id>37921610</id><passage><infon key="journal">Rev Med Virol;2023Nov03 2488. doi:10.1002/rmv.2488</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Al-Eitan L, Mihyar A, Zhang L, Bisht P, Jaenisch R, </infon><offset>0</offset><text>Genomic and biological variation in bat IFNs: An antiviral treatment approach.</text></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Bat-borne viruses have attracted considerable research, especially in relation to the Covid-19 pandemic. Although bats can carry multiple zoonotic viruses that are lethal to many mammalian species, they appear to be asymptomatic to viral infection despite the high viral loads contained in their bodies. There are several differences between bats and other mammals. One of the major differences between bats and other mammals is the bats' ability to fly, which is believed to have induced evolutionary changes. It may have also favoured them as suitable hosts for viruses. This is related to their tolerance to viral infection. Innate immunity is the first line of defence against viral infection, but bats have metamorphosed the type of responses induced by innate immunity factors such as interferons. The expression patterns of interferons differ, as do those of interferon-related genes such as interferon regulatory factors and interferon-stimulated genes that contribute to the antiviral response of infected cells. In addition, the signalling pathways related to viral infection and immune responses have been subject to evolutionary changes, including mutations compared to their homologues in other mammals and gene selection. This article discusses the differences in the interferon-mediated antiviral response in bats compared to that of other mammals and how these differences are correlated to viral tolerance in bats. The effect of bat interferons related genes on human antiviral response against bat-borne viruses is also discussed.</text><annotation id="5"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="165" length="8"/><text>Covid-19</text></annotation><annotation id="6"><infon key="identifier">MESH:D014777</infon><infon key="type">Disease</infon><location offset="311" length="15"/><text>viral infection</text></annotation><annotation id="7"><infon key="identifier">MESH:D014777</infon><infon key="type">Disease</infon><location offset="690" length="15"/><text>viral infection</text></annotation><annotation id="8"><infon key="identifier">MESH:D014777</infon><infon key="type">Disease</infon><location offset="760" length="15"/><text>viral infection</text></annotation><annotation id="9"><infon key="identifier">MESH:D014777</infon><infon key="type">Disease</infon><location offset="1149" length="15"/><text>viral infection</text></annotation></passage></document>
<document><id>37889616</id><passage><infon key="journal">J Adolesc Young Adult Oncol;2023Oct27. doi:10.1089/jayao.2023.0091</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Schwartz-Attias I, David T, Amromin T, Bar-Yosef M, Bartov Y, Ben Yaakov O, Bernstein L, Broitman M, Cohen A, Cohen O, Eisenberg L, Eshel N, Gindi Amsalem N, Gorelik N, Gerbi S, Raz H, Naamneh N, Nemtsov S, Pintel D, Sztrigler K, Goldberg S, Melnikov S, </infon><offset>0</offset><text>Recommendations from the Professional Advisory Committee on Nursing Practice When Caring for Adolescents and Young Adults with Cancer in Israel.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="127" length="6"/><text>Cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>145</offset></passage></document>
<document><id>37890318</id><passage><infon key="journal">Mar Pollut Bull;2023Oct25; 197 115618. doi:10.1016/j.marpolbul.2023.115618</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Aljahdali MO, Alhassan AB, </infon><offset>0</offset><text>The use of marine sponge species as a bioindicator to monitor metal pollution in Red Sea, Saudi Arabia.</text><annotation id="2"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="33" length="2"/><text>as</text></annotation><annotation id="3"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="62" length="5"/><text>metal</text></annotation></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>The existing data on trace elements of benthic sea organisms is scarce. Yet, the pressing issue of environmental contamination has spurred a surge in the use of organisms as biomonitors. In this study, sediment cores were sampled with the sponges, and metal concentrations were determined in both samples using ICP-MS. The mean concentrations of metals in benthic sediments and sponge species analyzed in this study differed significantly (Sediment > Phorbas species > Negombata magnifica > Callyspongia species &gt; Amphimedon chloros). This could be due to the varying capacity of each sponge species to accumulate a particular metal by different means. Negombata magnifica and Phorbas species appear to be indicators, accumulators, or hyper-accumulators of Cu and Mn, while Callyspongia species is an indicator, accumulator, or hyper-accumulator of Cu only due to bioconcentration factor > 1 for the aforementioned metals. Concentrations of Cu and As in sediment were below the Effects Range Median but above the Effects Range Low threshold, hence the need to give more attention to these metals. This research provides a baseline dataset for designing monitoring strategies on this ecosystem and using sponge species for biomonitoring.</text><annotation id="11"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="275" length="2"/><text>as</text></annotation><annotation id="12"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="356" length="5"/><text>metal</text></annotation><annotation id="13"><infon key="identifier">MESH:D008670</infon><infon key="type">Chemical</infon><location offset="731" length="5"/><text>metal</text></annotation><annotation id="14"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="861" length="2"/><text>Cu</text></annotation><annotation id="15"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="953" length="2"/><text>Cu</text></annotation><annotation id="16"><infon key="identifier">MESH:D003300</infon><infon key="type">Chemical</infon><location offset="1045" length="2"/><text>Cu</text></annotation><annotation id="17"><infon key="identifier">MESH:D001151</infon><infon key="type">Chemical</infon><location offset="1052" length="2"/><text>As</text></annotation></passage></document>
<document><id>37890668</id><passage><infon key="journal">J Lipid Res;2023Oct25 100464. doi:10.1016/j.jlr.2023.100464</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">H&amp;#xfc;lsmeier AJ, Toelle SP, Bellstedt P, Wentzel C, Bahr A, Kolokotronis K, Hornemann T, </infon><offset>0</offset><text>The atypical sphingolipid SPB 18:1(14Z);O2 is a biomarker for DEGS1 related hypomyelinating leukodystrophy.</text><annotation id="6"><infon key="identifier">MESH:D013107</infon><infon key="type">Chemical</infon><location offset="13" length="12"/><text>sphingolipid</text></annotation><annotation id="7"><infon key="identifier">6439</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">456</infon><location offset="26" length="3"/><text>SPB</text></annotation><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="35" length="4"/><text>14Z)</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="40" length="2"/><text>O2</text></annotation><annotation id="10"><infon key="identifier">8560</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55770</infon><location offset="62" length="5"/><text>DEGS1</text></annotation><annotation id="11"><infon key="identifier">MESH:C536319</infon><infon key="type">Disease</infon><location offset="76" length="30"/><text>hypomyelinating leukodystrophy</text></annotation></passage><passage><infon key="type">abstract</infon><offset>108</offset><text>Sphingolipids (SL) represent a structurally diverse class of lipids that are central to cellular physiology and neuronal development and function. Defects in the sphingolipid metabolism are typically associated with nervous system disorders. The C4-dihydroceramide desaturase (DEGS1) catalyzes the conversion of dihydroceramide to ceramide, the final step in the SL de-novo synthesis. Loss of function mutations in DEGS1 cause a hypomyelinating leukodystrophy, which is associated with increased plasma dihydrosphingolipids (dhSL) and with the formation of an atypical SPB 18:1(14Z);O2 metabolite. Here, we characterize two novel DEGS1 variants of unknown significance (VUS), provide a structural model with a predicted substrate binding site and propose a regulatory link between DEGS1 and fatty acid desaturase 3 (FADS3). Both VUS involve single amino acid substitutions near the C-terminus within conserved regions of the enzyme. Patient 1 (p.R311K variant) shows severe progressive tetraspasticity, intellectual disability, and epilepsy in combination with brain magnetic resonance imaging (MRI) findings, typical for DEGS1-related leukodystrophy. Patient 2 (p.G270E variant) presents with delayed psychomotor development, oculomotor apraxia, and a normal brain MRI. Plasma from the p.R311K carrier showed a significantly elevated dhSL species and the presence of SPB 18:1(14Z);O2, while the plasma SL profile for the p.G270E variant was not altered. This suggests the p.R331K variant is pathogenic, while the p.G270E appears benign. As an increase in dihydroSL species is also seen in other pathological disorders of the SL metabolism, the SPB 18:1(14Z);O2 seems to be a more specific biomarker to discriminate between pathogenic and benign DEGS1 variants.</text><annotation id="56"><infon key="identifier">MESH:D013107</infon><infon key="type">Chemical</infon><location offset="108" length="13"/><text>Sphingolipids</text></annotation><annotation id="57"><infon key="identifier">MESH:D013107</infon><infon key="type">Chemical</infon><location offset="123" length="2"/><text>SL</text></annotation><annotation id="58"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="169" length="6"/><text>lipids</text></annotation><annotation id="59"><infon key="identifier">MESH:D013107</infon><infon key="type">Chemical</infon><location offset="270" length="12"/><text>sphingolipid</text></annotation><annotation id="60"><infon key="identifier">MESH:D009422</infon><infon key="type">Disease</infon><location offset="324" length="24"/><text>nervous system disorders</text></annotation><annotation id="61"><infon key="identifier">8560</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55770</infon><location offset="385" length="5"/><text>DEGS1</text></annotation><annotation id="62"><infon key="identifier">MESH:C109343</infon><infon key="type">Chemical</infon><location offset="420" length="15"/><text>dihydroceramide</text></annotation><annotation id="63"><infon key="identifier">MESH:D002518</infon><infon key="type">Chemical</infon><location offset="439" length="8"/><text>ceramide</text></annotation><annotation id="64"><infon key="identifier">MESH:D013107</infon><infon key="type">Chemical</infon><location offset="471" length="2"/><text>SL</text></annotation><annotation id="65"><infon key="identifier">8560</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55770</infon><location offset="523" length="5"/><text>DEGS1</text></annotation><annotation id="66"><infon key="identifier">MESH:C536319</infon><infon key="type">Disease</infon><location offset="537" length="30"/><text>hypomyelinating leukodystrophy</text></annotation><annotation id="67"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="611" length="20"/><text>dihydrosphingolipids</text></annotation><annotation id="68"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="633" length="4"/><text>dhSL</text></annotation><annotation id="69"><infon key="identifier">6439</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">456</infon><location offset="677" length="3"/><text>SPB</text></annotation><annotation id="70"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="686" length="4"/><text>14Z)</text></annotation><annotation id="71"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="691" length="2"/><text>O2</text></annotation><annotation id="72"><infon key="identifier">8560</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55770</infon><location offset="738" length="5"/><text>DEGS1</text></annotation><annotation id="73"><infon key="identifier">8560</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55770</infon><location offset="889" length="5"/><text>DEGS1</text></annotation><annotation id="74"><infon key="identifier">3995</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11025</infon><location offset="899" length="23"/><text>fatty acid desaturase 3</text></annotation><annotation id="75"><infon key="identifier">3995</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11025</infon><location offset="924" length="5"/><text>FADS3</text></annotation><annotation id="76"><infon key="identifier">tmVar:p|SUB|R|311|K;HGVS:p.R311K;VariantGroup:0;CorrespondingGene:8560;RS#:1340821791;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="1052" length="7"/><text>p.R311K</text></annotation><annotation id="77"><infon key="identifier">MESH:D008607</infon><infon key="type">Disease</infon><location offset="1111" length="23"/><text>intellectual disability</text></annotation><annotation id="78"><infon key="identifier">MESH:D004827</infon><infon key="type">Disease</infon><location offset="1140" length="8"/><text>epilepsy</text></annotation><annotation id="79"><infon key="identifier">8560</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55770</infon><location offset="1230" length="5"/><text>DEGS1</text></annotation><annotation id="80"><infon key="identifier">MESH:D007966</infon><infon key="type">Disease</infon><location offset="1244" length="14"/><text>leukodystrophy</text></annotation><annotation id="81"><infon key="identifier">tmVar:p|SUB|G|270|E;HGVS:p.G270E;VariantGroup:2;CorrespondingGene:6439;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="1271" length="7"/><text>p.G270E</text></annotation><annotation id="82"><infon key="identifier">MESH:D002658</infon><infon key="type">Disease</infon><location offset="1302" length="31"/><text>delayed psychomotor development</text></annotation><annotation id="83"><infon key="identifier">MESH:C537423</infon><infon key="type">Disease</infon><location offset="1335" length="18"/><text>oculomotor apraxia</text></annotation><annotation id="84"><infon key="identifier">tmVar:p|SUB|R|311|K;HGVS:p.R311K;VariantGroup:0;CorrespondingGene:8560;RS#:1340821791;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="1395" length="7"/><text>p.R311K</text></annotation><annotation id="85"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1443" length="4"/><text>dhSL</text></annotation><annotation id="86"><infon key="identifier">6439</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">456</infon><location offset="1476" length="3"/><text>SPB</text></annotation><annotation id="87"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1485" length="4"/><text>14Z)</text></annotation><annotation id="88"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1490" length="2"/><text>O2</text></annotation><annotation id="89"><infon key="identifier">MESH:D013107</infon><infon key="type">Chemical</infon><location offset="1511" length="2"/><text>SL</text></annotation><annotation id="90"><infon key="identifier">tmVar:p|SUB|G|270|E;HGVS:p.G270E;VariantGroup:2;CorrespondingGene:6439;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="1530" length="7"/><text>p.G270E</text></annotation><annotation id="91"><infon key="identifier">tmVar:p|SUB|R|331|K;HGVS:p.R331K;VariantGroup:1;CorrespondingGene:6439;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="1581" length="7"/><text>p.R331K</text></annotation><annotation id="92"><infon key="identifier">tmVar:p|SUB|G|270|E;HGVS:p.G270E;VariantGroup:2;CorrespondingGene:6439;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="1622" length="7"/><text>p.G270E</text></annotation><annotation id="93"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1664" length="9"/><text>dihydroSL</text></annotation><annotation id="94"><infon key="identifier">MESH:D005598</infon><infon key="type">Disease</infon><location offset="1704" length="22"/><text>pathological disorders</text></annotation><annotation id="95"><infon key="identifier">MESH:D013107</infon><infon key="type">Chemical</infon><location offset="1734" length="2"/><text>SL</text></annotation><annotation id="96"><infon key="identifier">6439</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">456</infon><location offset="1753" length="3"/><text>SPB</text></annotation><annotation id="97"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1762" length="4"/><text>14Z)</text></annotation><annotation id="98"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1767" length="2"/><text>O2</text></annotation><annotation id="99"><infon key="identifier">8560</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55770</infon><location offset="1854" length="5"/><text>DEGS1</text></annotation></passage><relation id="R1"><infon key="score">0.5048</infon><infon key="role1">Disease|MESH:D002658</infon><infon key="role2">ProteinMutation|HGVS:p.G270E;CorrespondingGene:6439</infon><infon key="type">Association</infon><node refid="0" role="34,33"/></relation><relation id="R2"><infon key="score">0.9987</infon><infon key="role1">Gene|3995</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon><node refid="1" role="26,24"/></relation><relation id="R3"><infon key="score">0.8164</infon><infon key="role1">Disease|MESH:D007966</infon><infon key="role2">ProteinMutation|RS#:1340821791;HGVS:p.R311K;CorrespondingGene:8560</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="32,28"/></relation><relation id="R4"><infon key="score">0.4773</infon><infon key="role1">Disease|MESH:C537423</infon><infon key="role2">ProteinMutation|HGVS:p.G270E;CorrespondingGene:6439</infon><infon key="type">Association</infon><node refid="3" role="35,33"/></relation><relation id="R5"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:C536319</infon><infon key="role2">Gene|6439</infon><infon key="type">Association</infon><node refid="4" role="6,2"/></relation><relation id="R6"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D008607</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon><node refid="5" role="29,31"/></relation><relation id="R7"><infon key="score">0.7296</infon><infon key="role1">Chemical|MESH:C109343</infon><infon key="role2">Chemical|MESH:D002518</infon><infon key="type">Association</infon><node refid="6" role="13,14"/></relation><relation id="R8"><infon key="score">0.9996</infon><infon key="role1">Gene|6439</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon><node refid="7" role="2,5"/></relation><relation id="R9"><infon key="score">0.6784</infon><infon key="role1">Disease|MESH:D004827</infon><infon key="role2">ProteinMutation|RS#:1340821791;HGVS:p.R311K;CorrespondingGene:8560</infon><infon key="type">Positive_Correlation</infon><node refid="8" role="30,28"/></relation><relation id="R10"><infon key="score">0.9995</infon><infon key="role1">Chemical|MESH:D013107</infon><infon key="role2">Disease|MESH:C536319</infon><infon key="type">Association</infon><node refid="9" role="0,6"/></relation><relation id="R11"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:C109343</infon><infon key="role2">Chemical|MESH:D013107</infon><infon key="type">Association</infon><node refid="10" role="13,15"/></relation><relation id="R12"><infon key="score">0.9996</infon><infon key="role1">Chemical|MESH:D013107</infon><infon key="role2">Disease|MESH:D009422</infon><infon key="type">Association</infon><node refid="11" role="10,11"/></relation><relation id="R13"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D013107</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon><node refid="12" role="0,5"/></relation><relation id="R14"><infon key="score">0.9805</infon><infon key="role1">Disease|MESH:D002658</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon><node refid="13" role="34,31"/></relation><relation id="R15"><infon key="score">0.5183</infon><infon key="role1">Chemical|MESH:C109343</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon><node refid="14" role="13,12"/></relation><relation id="R16"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:C536319</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon><node refid="15" role="6,5"/></relation><relation id="R17"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D004827</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon><node refid="16" role="30,31"/></relation><relation id="R18"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D007966</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon><node refid="17" role="32,31"/></relation><relation id="R19"><infon key="score">0.5492</infon><infon key="role1">Disease|MESH:D002658</infon><infon key="role2">ProteinMutation|RS#:1340821791;HGVS:p.R311K;CorrespondingGene:8560</infon><infon key="type">Association</infon><node refid="18" role="34,33"/></relation><relation id="R20"><infon key="score">0.5048</infon><infon key="role1">Disease|MESH:D002658</infon><infon key="role2">Gene|6439</infon><infon key="type">Association</infon></relation><relation id="R21"><infon key="score">0.8164</infon><infon key="role1">Disease|MESH:D007966</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon></relation><relation id="R22"><infon key="score">0.4773</infon><infon key="role1">Disease|MESH:C537423</infon><infon key="role2">Gene|6439</infon><infon key="type">Association</infon></relation><relation id="R23"><infon key="score">0.6784</infon><infon key="role1">Disease|MESH:D004827</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon></relation><relation id="R24"><infon key="score">0.5492</infon><infon key="role1">Disease|MESH:D002658</infon><infon key="role2">Gene|8560</infon><infon key="type">Association</infon></relation></document>
<document><id>37891019</id><passage><infon key="journal">Transplant Proc;2023Oct25. doi:10.1016/j.transproceed.2023.09.014</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mi H, Fang J, Wu S, Mao S, Jiang W, Tong J, Lu C, </infon><offset>0</offset><text>Comparison of Postoperative Hemorrhage Risk After Partial Liver Transplantation Versus Whole Liver Transplantation: A Single-Center Experience.</text><annotation id="1"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="14" length="24"/><text>Postoperative Hemorrhage</text></annotation></passage><passage><infon key="type">abstract</infon><offset>144</offset><text>BACKGROUND: We aimed to identify risk factors associated with reoperation for postoperative intraperitoneal hemorrhage (PIH) after orthotopic liver transplantation and investigate if partial liver transplantation (PLT) increases the risk of PIH. METHODS: We retrospectively analyzed the medical records of 304 consecutive recipients who underwent orthotopic liver transplantation at the Affiliated Lihuili Hospital, Ningbo University, from January 2016 to July 2022. Data were compared between recipients who experienced PIH requiring reoperation and those who did not. Subgroup propensity score matching analysis was performed to assess the impact of PLT on PIH risk. Neither prisoners nor participants who were coerced or paid were used in the study. RESULTS: Among the 304 recipients, 22 (7.2%) underwent reoperation for PIH. Multivariate analysis revealed that the recipient Model for End-Stage Liver Disease (MELD) score (odds ratio = 1.066, 95% CI [1.025-1.109], P = .001) and volume of intraoperative packed red blood cell transfusion (odds ratio = 1.089, 95% CI [1.032-1.481], P = .002) were independent risk factors for PIH. No significant differences were observed in the risk of PIH between PLT and whole liver transplantation. CONCLUSION: Preoperative MELD score and intraoperative packed red blood cell transfusion should be carefully considered to manage the risk of PIH in liver transplantation recipients. Partial liver transplantation, a crucial approach for addressing donor shortages, does not increase the risk of reoperation for PIH in recipients.</text><annotation id="15"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="222" length="40"/><text>postoperative intraperitoneal hemorrhage</text></annotation><annotation id="16"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="264" length="3"/><text>PIH</text></annotation><annotation id="17"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="385" length="3"/><text>PIH</text></annotation><annotation id="18"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="665" length="3"/><text>PIH</text></annotation><annotation id="19"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="803" length="3"/><text>PIH</text></annotation><annotation id="20"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="968" length="3"/><text>PIH</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1023" length="33"/><text>Model for End-Stage Liver Disease</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1058" length="4"/><text>MELD</text></annotation><annotation id="23"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="1273" length="3"/><text>PIH</text></annotation><annotation id="24"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="1334" length="3"/><text>PIH</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1408" length="4"/><text>MELD</text></annotation><annotation id="26"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="1525" length="3"/><text>PIH</text></annotation><annotation id="27"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="1694" length="3"/><text>PIH</text></annotation></passage></document>
<document><id>37891370</id><passage><infon key="journal">Surg Endosc;2023Oct27. doi:10.1007/s00464-023-10497-w</infon><infon key="year">2023</infon><infon key="article-id_pmc">4888907</infon><infon key="type">title</infon><infon key="authors">El Masry MAMA, Attia MS, </infon><offset>0</offset><text>A comparative study between staple line reinforcement during laparoscopic sleeve gastrectomy and no reinforcement: an Egyptian experience.</text></passage><passage><infon key="type">abstract</infon><offset>139</offset><text>BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) has become an increasingly popular bariatric procedure. LSG still conveys some risks, including early staple line complications such as bleeding and leaks. It has been proposed that staple line complications can be reduced by staple line reinforcement (SLR). This study aimed to compare the short-term efficacy and safety of the SLR during LSG by oversewing versus no SLR in an Egyptian cohort over a period of 11 years. PATIENTS AND METHODS: This is a retrospective study that analyzed data from patients undergoing LSG by the same surgeon over a period of 11 years. The patients' early postoperative complications were compared according to performing SLR. RESULTS: The SLR group showed significantly longer surgery time (p = 0.021) and a lower rate of postoperative bleeding (p = 0.027). All leakage cases occurred in the non-SLR group (0.7% vs. 0.0%) without statistical significance (p = 0.212). The two mortality cases occurred in the non-SLR group. The LOS was comparable in the two groups (p = 0.289). CONCLUSION: This study confirms the short-term benefits of SLR by oversewing during LSG in terms of a lower incidence of 30-day morbidity, particularly bleeding, and lower rates of reoperation, with a clinically questionable longer operation time.</text><annotation id="5"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="325" length="8"/><text>bleeding</text></annotation><annotation id="6"><infon key="identifier">MESH:D019559</infon><infon key="type">Disease</infon><location offset="338" length="5"/><text>leaks</text></annotation><annotation id="7"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="777" length="27"/><text>postoperative complications</text></annotation><annotation id="8"><infon key="identifier">MESH:D019106</infon><infon key="type">Disease</infon><location offset="944" length="22"/><text>postoperative bleeding</text></annotation><annotation id="9"><infon key="identifier">MESH:D006470</infon><infon key="type">Disease</infon><location offset="1351" length="8"/><text>bleeding</text></annotation></passage></document>
<document><id>37897329</id><passage><infon key="journal">Chempluschem;2023Oct28 202300521. doi:10.1002/cplu.202300521</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li B, Xu X, Yang Z, Lu J, Han J, </infon><offset>0</offset><text>Recent advances in layered-double-hydroxides (LDHs)-based separation membranes.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="19" length="25"/><text>layered-double-hydroxides</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="46" length="4"/><text>LDHs</text></annotation></passage><passage><infon key="type">abstract</infon><offset>80</offset><text>The use of two-dimensional materials shows great promise for the development of next-generation membrane materials, thanks to their atomic thinness and the ease with which precise nanochannels can be constructed. Among these materials, layered double hydroxides (LDHs) stand out as an important class, possessing many features that make them ideal for constructing high-performance membranes. LDHs offer many advantages, such as their abundant and tunable interlayer anions, which enable the preparation of membranes with adjustable sub-nanometer pore sizes. Additionally, their hydrophilicity and positive charge characteristics afford them unique benefits. LDHs have been found to be effective in gas separation, ion sieving, and nanofiltration. This review provides a summary of the latest progress in using LDHs for membrane separation. It begins by introducing the basic properties of LDHs, followed by the assembly strategy for LDH membranes. Furthermore, the review presents the research status of LDH membranes in various fields in a systematic manner. Lastly, the paper highlights some challenges and future prospects for preparing and applying LDH membranes.</text><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="316" length="25"/><text>layered double hydroxides</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="343" length="4"/><text>LDHs</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="473" length="4"/><text>LDHs</text></annotation><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="739" length="4"/><text>LDHs</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="891" length="4"/><text>LDHs</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="970" length="4"/><text>LDHs</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1014" length="3"/><text>LDH</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1085" length="3"/><text>LDH</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1234" length="3"/><text>LDH</text></annotation></passage></document>
<document><id>37897680</id><passage><infon key="journal">Acta Neurochir (Wien);2023Oct28. doi:10.1007/s00701-023-05823-z</infon><infon key="year">2023</infon><infon key="article-id_pmc">6398292</infon><infon key="type">title</infon><infon key="authors">Huang P, Liu H, Liu Z, Huang L, Lu M, Wang L, Yu Y, Jin X, </infon><offset>0</offset><text>Effectiveness of percutaneous balloon compression (PBC) in improving physical function and quality of life in trigeminal neuralgia: a retrospective study.</text><annotation id="1"><infon key="identifier">MESH:D014277</infon><infon key="type">Disease</infon><location offset="110" length="20"/><text>trigeminal neuralgia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>155</offset><text>OBJECTIVE: To evaluate the effectiveness of percutaneous balloon compression (PBC) in treating trigeminal neuralgia (TN) and determine improvements in quality of life (QoL) and daily functional status. METHODS: Data from primary TN (pTN) patients treated with PBC from December 2018 to April 2021 were retrospectively analyzed. Short-Form 36 (SF-36) Health Survey and Functional Independence Measure (FIM) assessments were used to evaluate patients' QoL and physical function every 6 months after surgery, and facial pain was evaluated every 3 to 6 months post-surgery. RESULTS: A total of 80 pTN patients were enrolled for analysis. The Barrow Neurological Institute (BNI) scores of I-II were achieved in 67 (83.8%) patients immediately after the surgery. The estimated rates of BNI I-II pain relief at one, two, and three years were 94.2%, 87.6%, and 83.2%, respectively. All aspects of the SF-36 questionnaire were significantly improved after the PBC, especially in terms of role physical (RP), bodily pain (BP), and social functioning (SF). Patients' functional outcomes measured by FIM at the 6-month follow-up examination were 108.6 +- 9.9, which was significantly improved compared with the pretreatment scores (90.8 +- 12.7). There was no difference between the severity of facial numbness in FIM and any item of the SF-36 except RP (P = 0.004) at 6 months after surgery. There was also no difference in SF-36 and FIM between patients with or without facial hyperalgesia. CONCLUSIONS: PBC can produce long-term and stable pain relief and significantly improve the patient's QoL and physical function. However, further well-designed, high-level, evidence-based studies are needed to precisely assess the efficacy of PBC for pTN patients.</text><annotation id="15"><infon key="identifier">MESH:D014277</infon><infon key="type">Disease</infon><location offset="250" length="20"/><text>trigeminal neuralgia</text></annotation><annotation id="16"><infon key="identifier">MESH:D014277</infon><infon key="type">Disease</infon><location offset="272" length="2"/><text>TN</text></annotation><annotation id="17"><infon key="identifier">MESH:D014277</infon><infon key="type">Disease</infon><location offset="384" length="2"/><text>TN</text></annotation><annotation id="18"><infon key="identifier">MESH:D014277</infon><infon key="type">Disease</infon><location offset="388" length="3"/><text>pTN</text></annotation><annotation id="19"><infon key="identifier">MESH:D005157</infon><infon key="type">Disease</infon><location offset="665" length="11"/><text>facial pain</text></annotation><annotation id="20"><infon key="identifier">MESH:D014277</infon><infon key="type">Disease</infon><location offset="748" length="3"/><text>pTN</text></annotation><annotation id="21"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="944" length="4"/><text>pain</text></annotation><annotation id="22"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1154" length="11"/><text>bodily pain</text></annotation><annotation id="23"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1167" length="2"/><text>BP</text></annotation><annotation id="24"><infon key="identifier">MESH:D006987</infon><infon key="type">Disease</infon><location offset="1438" length="15"/><text>facial numbness</text></annotation><annotation id="25"><infon key="identifier">MESH:D006930</infon><infon key="type">Disease</infon><location offset="1615" length="19"/><text>facial hyperalgesia</text></annotation><annotation id="26"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="1686" length="4"/><text>pain</text></annotation><annotation id="27"><infon key="identifier">MESH:D014277</infon><infon key="type">Disease</infon><location offset="1887" length="3"/><text>pTN</text></annotation></passage></document>
<document><id>37898030</id><passage><infon key="journal">Clin Neurol Neurosurg;2023Oct24; 235 108021. doi:10.1016/j.clineuro.2023.108021</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhu J, Shi L, Su Y, </infon><offset>0</offset><text>A rs-fMRI study of functional connectivity changes between thalamus and postcentral gyrus in patients with neuropathic pain after brachial plexus avulsion.</text><annotation id="2"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="107" length="16"/><text>neuropathic pain</text></annotation><annotation id="3"><infon key="identifier">MESH:D020516</infon><infon key="type">Disease</infon><location offset="130" length="24"/><text>brachial plexus avulsion</text></annotation></passage><passage><infon key="type">abstract</infon><offset>156</offset><text>BACKGROUND: The neuropathic pain (NPP) after brachial plexus avulsion (BPA) is common and difficult to cure, and thalamus and postcentral gyrus have been accepted to be the key nodes of mechanisms and pathways for pain. However, little attention has been paid on the thalamus-postcentral gyrus functional connectivity changes in NP patients after BPA. METHODS: Eighteen patients with NPP after BPA and twenty age and gender matched healthy controls were enrolled and underwent resting-state functional MRI (rs-fMRI) scans in this study. The Pearson's r-value of functional connection (bilateral thalamus and postcentral gyrus as regions of interest) was generated and examined using two sample t-test. The linear regression analysis was used to select possible related factors, and multiple linear regression of the possible predictors was used to identify the variables that significantly predicted Visual Analogue Score (VAS). RESULTS: The standardized Pearson r-values of the left thalamus-right thalamus, left thalamus-left postcentral gyrus, left thalamus-right postcentral gyrus, right thalamus-left postcentral gyrus and right thalamus-right postcentral gyrus in the control group were 0.759 +- 0.242, 0.358 +- 0.297, 0.383 +- 0.270, 0.317 +- 0.295 and 0.333 +- 0.304, respectively. And the corresponding standardized Pearson r-values in patients group were 0.510 +- 0.224,0.305 +- 0.212,0.281 +- 0.225,0.333 +- 0.193 and 0.333 +- 0.210, respectively. The functional connectivity strength of the left thalamus-right thalamus in control group was significantly higher than that in the patients group (P &lt; 0.05). Linear regression analysis showed that the functional connectivity strength of the left thalamus-right thalamus was negatively correlated with the patients' VAS score (P &lt; 0.05). CONCLUSIONS: NPP patients after BPA had a significant pain-related bilateral thalamus functional connection reorganization, with the purpose to limit the pain signal inputs within the unilateral cerebral hemisphere.</text><annotation id="17"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="172" length="16"/><text>neuropathic pain</text></annotation><annotation id="18"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="190" length="3"/><text>NPP</text></annotation><annotation id="19"><infon key="identifier">MESH:D020516</infon><infon key="type">Disease</infon><location offset="201" length="24"/><text>brachial plexus avulsion</text></annotation><annotation id="20"><infon key="identifier">MESH:D020516</infon><infon key="type">Disease</infon><location offset="227" length="3"/><text>BPA</text></annotation><annotation id="21"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="370" length="4"/><text>pain</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="485" length="2"/><text>NP</text></annotation><annotation id="23"><infon key="identifier">MESH:D020516</infon><infon key="type">Disease</infon><location offset="503" length="3"/><text>BPA</text></annotation><annotation id="24"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="540" length="3"/><text>NPP</text></annotation><annotation id="25"><infon key="identifier">MESH:D020516</infon><infon key="type">Disease</infon><location offset="550" length="3"/><text>BPA</text></annotation><annotation id="26"><infon key="identifier">MESH:D009437</infon><infon key="type">Disease</infon><location offset="1966" length="3"/><text>NPP</text></annotation><annotation id="27"><infon key="identifier">MESH:D020516</infon><infon key="type">Disease</infon><location offset="1985" length="3"/><text>BPA</text></annotation><annotation id="28"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="2007" length="4"/><text>pain</text></annotation><annotation id="29"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="2107" length="4"/><text>pain</text></annotation></passage></document>
<document><id>37898383</id><passage><infon key="journal">Acad Pediatr;2023Oct26. doi:10.1016/j.acap.2023.10.004</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Al-Shoaibi AAA, Iyra P, Raney JH, Ganson KT, Dooley EE, Testa A, Jackson DB, Gabriel KP, Baker FC, Nagata JM, </infon><offset>0</offset><text>Associations between adverse childhood experiences and early adolescent physical activity in the United States.</text></passage><passage><infon key="type">abstract</infon><offset>112</offset><text>OBJECTIVE: To determine the associations between the number of adverse childhood experiences (ACEs) and objectively-measured physical activity (PA) in a population-based, demographically diverse cohort of 9-14-year-olds and to determine which subtypes of ACEs were associated with physical activity levels. METHODS: We analyzed data (n=7,046) from the Adolescent Brain Cognitive Development (ABCD) Study 4.0 release at baseline and year 2 follow-up. ACE (cumulative score and subtypes) and physical activity (average Fitbit daily steps assessed at Year 2) were analyzed using linear regression analyses. Covariates included race/ethnicity, sex, household income, parent education, body mass index, study site, twins/siblings, and data collection period. RESULTS: Adjusted models suggest an inverse association between number of ACEs and Fitbit daily steps, with >=4 (compared to 0) ACEs associated with 526 fewer daily steps (95% CI -882.7, -222.6). Of the ACEs subtypes, emotional abuse (B= -716.8, 95% CI -1408.3, -25.3), physical neglect (B= -373.6, 95% CI -690.4, -56.7), household mental illness (B= -287.7, 95% CI -454.6, -120.7), and household divorce or separation (B= -24.1, 95% CI --482.1, -8.22) were inversely and statistically significant associated with Fitbit daily steps after adjusting for confounders. CONCLUSIONS: Our results suggest that there is an inverse, dose-dependent relationship between cumulative number of ACEs and physical activity as measured by daily steps. This work highlights the importance of screening for ACEs among young people at an early age to help identify those who could benefit from interventions or community programs that support increased physical activity.</text><annotation id="6"><infon key="identifier">MESH:D002658</infon><infon key="type">Disease</infon><location offset="475" length="27"/><text>Brain Cognitive Development</text></annotation><annotation id="7"><infon key="identifier">163</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68176</infon><location offset="562" length="3"/><text>ACE</text></annotation><annotation id="8"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="1084" length="15"/><text>emotional abuse</text></annotation><annotation id="9"><infon key="identifier">MESH:D058069</infon><infon key="type">Disease</infon><location offset="1136" length="16"/><text>physical neglect</text></annotation><annotation id="10"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="1198" length="14"/><text>mental illness</text></annotation><annotation id="11"><infon key="type">Disease</infon><location offset="1263" length="7"/><text>divorce</text></annotation></passage></document>
<document><id>37899083</id><passage><infon key="journal">BMJ Case Rep;2023Oct29; 16 (10) . doi:10.1136/bcr-2023-254724</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10619036</infon><infon key="type">title</infon><infon key="authors">Maupin CM, Herrmann AA, Kashyap B, Rosenbloom MH, </infon><offset>0</offset><text>Abnormal clinical presentation and surgical outcome of an intraventricular cavernoma of the third ventricle.</text><annotation id="1"><infon key="identifier">MESH:C535966</infon><infon key="type">Disease</infon><location offset="58" length="49"/><text>intraventricular cavernoma of the third ventricle</text></annotation></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>We present a unique case of a man presenting with progressive short-term memory deficits over 10+ years who was found to have a large intraventricular cavernoma in the anterior wall of the third ventricle with invasion of medial limbic structures. Identifying intraventricular cavernomas early is crucial to prevent substantial growth and to increase the chance of successful patient outcomes.</text><annotation id="5"><infon key="identifier">MESH:D008569</infon><infon key="type">Disease</infon><location offset="182" length="15"/><text>memory deficits</text></annotation><annotation id="6"><infon key="type">Disease</infon><location offset="260" length="9"/><text>cavernoma</text></annotation><annotation id="7"><infon key="identifier">MESH:D006345</infon><infon key="type">Disease</infon><location offset="369" length="27"/><text>intraventricular cavernomas</text></annotation></passage></document>
<document><id>37902236</id><passage><infon key="journal">Cancer Med;2023Oct30. doi:10.1002/cam4.6638</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang WJ, Huang XY, Lin B, Zheng WC, Ke ZB, Lin XD, Chen JY, Cai H, Lin YZ, Chen YH, Zheng QS, Wei Y, Xue XY, Li XD, Xu N, </infon><offset>0</offset><text>The effect of body mass index on quality of life in modified single stoma cutaneous ureterostomy or ileal conduit after radical cystectomy.</text></passage><passage><infon key="type">abstract</infon><offset>140</offset><text>OBJECTIVE: To explore the influence of postoperative body mass index (BMI) change on postoperative quality of life (QOL) in patients undergoing radical cystectomy (RC) plus modified single stoma cutaneous ureterostomy (MSSCU) or ileal conduit (IC). METHODS: Patients were divided into two groups according to different BMI change patterns: patients experiencing an elevated postoperative BMI level, along with a clinically significant increase in their BMI (an increase of more than 10%) were categorized as Group 1, while patients experiencing a decrease postoperative BMI level, along with a clinically significant reduction in their BMI (a decrease of more than 5%) were categorized as Group 2. Spearman correlation analysis was used to examine the correlations between quality-of-life scores and postoperative clinical parameters. RESULTS: Spearman correlation analysis showed that postoperative BMI, late complications and catheter-free state were significantly associated with postoperative global QoL and symptom scale in MSSCU and postoperative global QoL and physical scale in IC patients. Additionally, postoperative BMI, catheter-free state and the use of adjuvant therapy were associated with bad performance in many scales of QoL like body image, future perspective, social scale, future perspective (MSSCU), and abdominal bloating (IC) (Table 2, p&lt;0.05). Patients in Group 2 with significant weight loss had a better Global QoL, a lower rate of stomal stricture and a higher catheter-free state compared with those in Group 1 in both IC and MSSCU patients. MSSCU patients in Group 2 could achieve a comparable Global QoL as to IC patients in Group 1. CONCLUSION: Controlling the substantial increase in body weight after surgery contributes to improving QoL, reducing the occurrence of stomal stricture, and ensuring a postoperative catheter-free state in BCa patients undergoing MSSCU.</text><annotation id="5"><infon key="identifier">MESH:D000007</infon><infon key="type">Disease</infon><location offset="1466" length="18"/><text>abdominal bloating</text></annotation><annotation id="6"><infon key="identifier">MESH:D015431</infon><infon key="type">Disease</infon><location offset="1546" length="11"/><text>weight loss</text></annotation><annotation id="7"><infon key="identifier">MESH:D003251</infon><infon key="type">Disease</infon><location offset="1599" length="16"/><text>stomal stricture</text></annotation><annotation id="8"><infon key="identifier">MESH:D003251</infon><infon key="type">Disease</infon><location offset="1940" length="16"/><text>stomal stricture</text></annotation><annotation id="9"><infon key="type">Disease</infon><location offset="2010" length="3"/><text>BCa</text></annotation></passage></document>
<document><id>37902586</id><passage><infon key="journal">Mol Pharm;2023Oct30. doi:10.1021/acs.molpharmaceut.3c00683</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Jadhav H, Augustijns P, Tannergren C, </infon><offset>0</offset><text>Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.</text></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>The rate and extent of colon absorption are important determinants of the in vivo performance of extended-release (ER) drug products. The ability to appropriately predict this at different stages of development using mechanistic physiologically based biopharmaceutic modeling (PBBM) is highly desirable. This investigation aimed to evaluate the prediction performance of three different approaches to account for colon absorption in predictions of the in vivo performance of ER drug product variants with different in vitro release profiles. This was done by mechanistic predictions of the absorption and plasma exposure of the ER drug products using GastroPlus and GI-Sim for five drugs with different degrees of colon absorption limitations in humans. Colon absorption was accounted for in the predictions using three different approaches: (1) by an a priori approach using the default colon models, (2) by fitting the colon absorption scaling factors to the observed plasma concentration-time profiles after direct administration to the colon in humans, or (3) from the ER drug product variant with the slowest in vitro release profile. The prediction performance was evaluated based on the percentage prediction error and the average absolute prediction error (AAPE). Two levels of acceptance criteria corresponding to highly accurate (AAPE &lt;= 20%) and accurate (AAPE 20-50%) predictions were defined prior to the evaluation. For the a priori approach, the relative bioavailability (Frel), AUC0-t, and Cmax of the ER drug product variants for the low to medium colon absorption limitation risk drugs was accurately predicted with an AAPE range of 11-53 and 8-59% for GastroPlus and GI-Sim, respectively. However, the prediction performance was poor for the high colon absorption limitation risk drugs. Moreover, accounting for the human regional colon absorption data in the models did not improve the prediction performance. In contrast, using the colon absorption scaling factors derived from the slowest ER variant significantly improved the prediction performance regardless of colon absorption limitation, with a majority of the predictions meeting the high accuracy criteria. For the slowest ER approach, the AAPE ranges were 5-24 and 5-32% for GastroPlus and GI-Sim, respectively, excluding the low permeability drug. In conclusion, the a priori PBBM can be used during candidate selection and early product design to predict the in vivo performance of ER drug products for low to medium colon absorption limitation risk drugs with sufficient accuracy. The results also indicate a limited value in performing human regional absorption studies in which the drug is administered to the colon as a bolus to support PBBM development for ER drug products. Instead, by performing an early streamlined relative bioavailability study with the slowest relevant ER in vitro release profile, a highly accurate PBBM suitable for ER predictions for commercial and regulatory applications can be developed, except for permeability-limited drugs.</text></passage></document>
<document><id>37902936</id><passage><infon key="journal">Sports Med;2023Oct30. doi:10.1007/s40279-023-01954-6</infon><infon key="year">2023</infon><infon key="article-id_pmc">8106311</infon><infon key="type">title</infon><infon key="authors">Raberin A, Burtscher J, Citherlet T, Manferdelli G, Krumm B, Bourdillon N, Antero J, Rasica L, Malatesta D, Brocherie F, Burtscher M, Millet GP, </infon><offset>0</offset><text>Women at Altitude: Sex-Related Physiological Responses to Exercise in Hypoxia.</text><annotation id="1"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="70" length="7"/><text>Hypoxia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>79</offset><text>Sex differences in physiological responses to various stressors, including exercise, have been well documented. However, the specific impact of these differences on exposure to hypoxia, both at rest and during exercise, has remained underexplored. Many studies on the physiological responses to hypoxia have either excluded women or included only a limited number without analyzing sex-related differences. To address this gap, this comprehensive review conducted an extensive literature search to examine changes in physiological functions related to oxygen transport and consumption in hypoxic conditions. The review encompasses various aspects, including ventilatory responses, cardiovascular adjustments, hematological alterations, muscle metabolism shifts, and autonomic function modifications. Furthermore, it delves into the influence of sex hormones, which evolve throughout life, encompassing considerations related to the menstrual cycle and menopause. Among these physiological functions, the ventilatory response to exercise emerges as one of the most sex-sensitive factors that may modify reactions to hypoxia. While no significant sex-based differences were observed in cardiac hemodynamic changes during hypoxia, there is evidence of greater vascular reactivity in women, particularly at rest or when combined with exercise. Consequently, a diffusive mechanism appears to be implicated in sex-related variations in responses to hypoxia. Despite well-established sex disparities in hematological parameters, both acute and chronic hematological responses to hypoxia do not seem to differ significantly between sexes. However, it is important to note that these responses are sensitive to fluctuations in sex hormones, and further investigation is needed to elucidate the impact of the menstrual cycle and menopause on physiological responses to hypoxia.</text><annotation id="11"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="256" length="7"/><text>hypoxia</text></annotation><annotation id="12"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="374" length="7"/><text>hypoxia</text></annotation><annotation id="13"><infon key="identifier">MESH:D010100</infon><infon key="type">Chemical</infon><location offset="631" length="6"/><text>oxygen</text></annotation><annotation id="14"><infon key="identifier">MESH:D002534</infon><infon key="type">Disease</infon><location offset="667" length="7"/><text>hypoxic</text></annotation><annotation id="15"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="1194" length="7"/><text>hypoxia</text></annotation><annotation id="16"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="1298" length="7"/><text>hypoxia</text></annotation><annotation id="17"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="1522" length="7"/><text>hypoxia</text></annotation><annotation id="18"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="1651" length="7"/><text>hypoxia</text></annotation><annotation id="19"><infon key="identifier">MESH:D000860</infon><infon key="type">Disease</infon><location offset="1938" length="7"/><text>hypoxia</text></annotation></passage><relation id="R1"><infon key="score">0.9995</infon><infon key="role1">Chemical|MESH:D010100</infon><infon key="role2">Disease|MESH:D002534</infon><infon key="type">Association</infon><node refid="0" role="3,4"/></relation></document>
<document><id>37903665</id><passage><infon key="journal">Am J Surg;2023Oct21. doi:10.1016/j.amjsurg.2023.10.031</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">James K, Glasswell A, Costa B, </infon><offset>0</offset><text>Single-use negative pressure wound therapy versus conventional dressings for the reduction of surgical site infections in closed surgical incisions: Systematic literature review and meta-analysis.</text><annotation id="1"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="108" length="10"/><text>infections</text></annotation></passage><passage><infon key="type">abstract</infon><offset>197</offset><text>BACKGROUND: To evaluate whether a single-use negative pressure wound therapy (sNPWT) device can reduce the incidence of surgical site infection (SSI) in at-risk patients with closed surgical incisions across a range of surgical specialties, compared with standard care. METHODS: PubMed, Embase, Cochrane Library and ClinicalTrials.gov were searched from the period January 2011 to April 2021. RESULTS: Out of 15,283 articles identified, 19 were included. A statistically significant improvement (p &lt; 0.05) in the composite SSI (odds ratio [OR]: 0.36; 95 % confidence interval [CI]: 0.27-0.49), superficial SSI (OR: 0.30; 95 % CI: 0.17-0.53), and deep SSI (OR: 0.67; 95 % CI: 0.46-0.96) outcomes was observed with the sNPWT device compared with standard care in a pooled analysis of all surgical specialties. CONCLUSION: A -80 mmHg sNPWT device reduces the incidence of composite, superficial, and deep SSIs when compared with standard care across a heterogenous at-risk surgical population containing a variety of surgical specialties.</text><annotation id="8"><infon key="identifier">MESH:D013530</infon><infon key="type">Disease</infon><location offset="317" length="23"/><text>surgical site infection</text></annotation><annotation id="9"><infon key="identifier">MESH:D013530</infon><infon key="type">Disease</infon><location offset="342" length="3"/><text>SSI</text></annotation><annotation id="10"><infon key="identifier">MESH:D013530</infon><infon key="type">Disease</infon><location offset="720" length="3"/><text>SSI</text></annotation><annotation id="11"><infon key="identifier">MESH:D013530</infon><infon key="type">Disease</infon><location offset="803" length="3"/><text>SSI</text></annotation><annotation id="12"><infon key="identifier">MESH:D013530</infon><infon key="type">Disease</infon><location offset="848" length="3"/><text>SSI</text></annotation><annotation id="13"><infon key="type">Disease</infon><location offset="1099" length="4"/><text>SSIs</text></annotation></passage></document>
<document><id>37904016</id><passage><infon key="journal">Acta Psychiatr Scand;2023Oct30. doi:10.1111/acps.13620</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Grover C, Huber J, Brewer M, Basu A, Large M, </infon><offset>0</offset><text>Meta-analysis of clinical risk factors for suicide among people presenting to emergency departments and general hospitals with suicidal thoughts and behaviours.</text><annotation id="3"><infon key="type">Disease</infon><location offset="43" length="7"/><text>suicide</text></annotation><annotation id="4"><infon key="identifier">MESH:D004630</infon><infon key="type">Disease</infon><location offset="78" length="21"/><text>emergency departments</text></annotation><annotation id="5"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="127" length="32"/><text>suicidal thoughts and behaviours</text></annotation></passage><passage><infon key="type">abstract</infon><offset>161</offset><text>BACKGROUND: Suicidal thoughts and behaviours (STB) are a common reason for presentation to emergency departments and general hospitals. A meta-analysis of the strength of clinical risk factors for subsequent suicide might aid understanding of suicidal behaviour and help suicide prevention. METHODS: We conducted a meta-analysis of cohort and controlled studies on clinical risk factors and later suicide among people presenting to emergency departments and general hospitals with STB. Data were extracted from papers meeting inclusion criteria, published in Medline, PsycINFO, and Embase between 1 January 1960 and 10 October 2022 using papers located with the search terms ((suicide*).m_titl AND (emergency* OR accident and emergency OR casualty OR general hospital OR toxicology service).mp) or were indexed in PubMed and had titles located with the search terms (suicide* OR self-harm OR self-harm OR self-injury OR self-injury OR self-poisoning OR self-poisoning OR overdose OR para-suicide OR parasuicide [title/abstract]) AND (Emergency department OR emergency room OR Casualty OR general hospital OR toxicology OR accident and emergency [all fields]). Data about the association between clinical risk factors and suicide extracted from three or more studies were included in a random-effects meta-analysis of the odds of later death by suicide. The study was registered in PROSPERO and conducted according to MOOSE and PRISMA guidelines. RESULTS: Seventy-five studies reported on 741,624 people, of which 19,649 died by suicide (2.65%). Male sex (odds ratio (OR) = 1.99) and age (OR = 2.01) were the most consistently reported risk factors. The strongest associations with subsequent death by suicide related to violent self-harm methods at the hospital presentation, including: unspecified violent method (OR = 4.97), any violent method (OR = 4.57) and the specific violent methods of drowning (OR = 4.32), hanging (OR = 4.26), and use of firearms (OR = 10.08). Patients categorised as higher risk using suicide prediction scales or any other method that combined risk factors had moderately increased odds of suicide (OR = 2.58). Younger age, Black and Hispanic ethnicity, overdose, a diagnosis of adjustment disorder, and the absence of any psychiatric diagnosis were protective against suicide. CONCLUSIONS: Most risk factors for suicide among people who have presented with STB are not strongly associated with later suicide. The strongest risk factors relate to self-harm methods. In the absence of clear indicators of future suicide, all people presenting with suicidality warrant a thorough assessment of their needs, and further research is needed before we can meaningfully categorise people with STB according to suicide risk.</text><annotation id="43"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="173" length="32"/><text>Suicidal thoughts and behaviours</text></annotation><annotation id="44"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="207" length="3"/><text>STB</text></annotation><annotation id="45"><infon key="identifier">MESH:D004630</infon><infon key="type">Disease</infon><location offset="252" length="21"/><text>emergency departments</text></annotation><annotation id="46"><infon key="type">Disease</infon><location offset="369" length="7"/><text>suicide</text></annotation><annotation id="47"><infon key="type">Disease</infon><location offset="432" length="7"/><text>suicide</text></annotation><annotation id="48"><infon key="type">Disease</infon><location offset="558" length="7"/><text>suicide</text></annotation><annotation id="49"><infon key="identifier">MESH:D004630</infon><infon key="type">Disease</infon><location offset="593" length="21"/><text>emergency departments</text></annotation><annotation id="50"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="642" length="3"/><text>STB</text></annotation><annotation id="51"><infon key="type">Disease</infon><location offset="838" length="7"/><text>suicide</text></annotation><annotation id="52"><infon key="type">Disease</infon><location offset="1028" length="7"/><text>suicide</text></annotation><annotation id="53"><infon key="identifier">MESH:D012652</infon><infon key="type">Disease</infon><location offset="1040" length="9"/><text>self-harm</text></annotation><annotation id="54"><infon key="identifier">MESH:D012652</infon><infon key="type">Disease</infon><location offset="1053" length="9"/><text>self-harm</text></annotation><annotation id="55"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1071" length="6"/><text>injury</text></annotation><annotation id="56"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1085" length="7"/><text>-injury</text></annotation><annotation id="57"><infon key="identifier">MESH:D011041</infon><infon key="type">Disease</infon><location offset="1100" length="10"/><text>-poisoning</text></annotation><annotation id="58"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="1132" length="8"/><text>overdose</text></annotation><annotation id="59"><infon key="type">Disease</infon><location offset="1148" length="8"/><text>-suicide</text></annotation><annotation id="60"><infon key="type">Disease</infon><location offset="1160" length="11"/><text>parasuicide</text></annotation><annotation id="61"><infon key="type">Disease</infon><location offset="1382" length="7"/><text>suicide</text></annotation><annotation id="62"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1496" length="16"/><text>death by suicide</text></annotation><annotation id="63"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1681" length="4"/><text>died</text></annotation><annotation id="64"><infon key="type">Disease</infon><location offset="1689" length="7"/><text>suicide</text></annotation><annotation id="65"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1853" length="16"/><text>death by suicide</text></annotation><annotation id="66"><infon key="identifier">MESH:D012652</infon><infon key="type">Disease</infon><location offset="1889" length="9"/><text>self-harm</text></annotation><annotation id="67"><infon key="type">Disease</infon><location offset="2174" length="7"/><text>suicide</text></annotation><annotation id="68"><infon key="type">Disease</infon><location offset="2280" length="7"/><text>suicide</text></annotation><annotation id="69"><infon key="identifier">MESH:D062787</infon><infon key="type">Disease</infon><location offset="2344" length="8"/><text>overdose</text></annotation><annotation id="70"><infon key="identifier">MESH:D000275</infon><infon key="type">Disease</infon><location offset="2369" length="19"/><text>adjustment disorder</text></annotation><annotation id="71"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="2413" length="11"/><text>psychiatric</text></annotation><annotation id="72"><infon key="type">Disease</infon><location offset="2459" length="7"/><text>suicide</text></annotation><annotation id="73"><infon key="type">Disease</infon><location offset="2503" length="7"/><text>suicide</text></annotation><annotation id="74"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="2548" length="3"/><text>STB</text></annotation><annotation id="75"><infon key="type">Disease</infon><location offset="2591" length="7"/><text>suicide</text></annotation><annotation id="76"><infon key="identifier">MESH:D012652</infon><infon key="type">Disease</infon><location offset="2637" length="9"/><text>self-harm</text></annotation><annotation id="77"><infon key="type">Disease</infon><location offset="2701" length="7"/><text>suicide</text></annotation><annotation id="78"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="2876" length="3"/><text>STB</text></annotation><annotation id="79"><infon key="type">Disease</infon><location offset="2893" length="7"/><text>suicide</text></annotation></passage></document>
<document><id>37904716</id><passage><infon key="journal">Nutr Bull;2023Oct31. doi:10.1111/nbu.12648</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Shewry PR, Joy EJM, De La Revilla LS, Hansen A, Brennan J, Lovegrove A, </infon><offset>0</offset><text>Increasing fibre in white flour and bread: Implications for health and processing.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="11" length="5"/><text>fibre</text></annotation></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>Dietary fibre is beneficial for human health, but dietary intakes are below recommended levels in most countries. Cereals are the major source of dietary fibre in Western diets, with bread providing about 20% of the daily intake in the United Kingdom. Despite the promotion of fibre-rich wholegrain products, white bread (which has a lower fibre content) remains dominant in many countries due to cultural preferences. Increasing the fibre content of white bread and other products made from white flour is therefore an attractive strategy for increasing fibre intake. This can be achieved by exploiting genetic variation in wheat without major effects on the processing quality or the consumer acceptability of products. Modelling data for food consumption in the United Kingdom shows that increasing the fibre content of white flour by 50% (from about 4% to 6% dry weight) and in wholegrain by 20% will increase total fibre intake by 1.04 g/day and 1.41 g/day in adult females and males, respectively. Furthermore, in vitro studies indicate that the increased fibre content of white bread should reduce the rate of starch digestion and glucose release in the human gastrointestinal tract.</text><annotation id="16"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="91" length="5"/><text>fibre</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="237" length="5"/><text>fibre</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="360" length="5"/><text>fibre</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="392" length="11"/><text>white bread</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="423" length="5"/><text>fibre</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="517" length="5"/><text>fibre</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="534" length="11"/><text>white bread</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="638" length="5"/><text>fibre</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="889" length="5"/><text>fibre</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1003" length="5"/><text>fibre</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1145" length="5"/><text>fibre</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1162" length="11"/><text>white bread</text></annotation><annotation id="28"><infon key="identifier">MESH:D013213</infon><infon key="type">Chemical</infon><location offset="1200" length="6"/><text>starch</text></annotation><annotation id="29"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="1221" length="7"/><text>glucose</text></annotation></passage></document>
<document><id>37905066</id><passage><infon key="journal">medRxiv;2023Oct18. doi:10.1101/2023.10.17.23297108</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10615019</infon><infon key="type">title</infon><infon key="authors">Jones HS, Anderson RL, Cust H, McClelland RS, Richardson BA, Thirumurthy H, Malama K, Hensen B, Platt L, Rice B, Cowan FM, Imai-Eaton JW, Hargreaves JR, Stevens O, </infon><offset>0</offset><text>HIV incidence among women engaging in sex work in sub-Saharan Africa: a systematic review and meta-analysis.</text><annotation id="1"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="0" length="3"/><text>HIV</text></annotation></passage><passage><infon key="type">abstract</infon><offset>109</offset><text>Introduction: HIV incidence among women in sub-Saharan Africa (SSA) has declined steadily, but it is unknown whether new infections among women who engage in sex work (WESW) have declined at a similar rate. We synthesised estimates of HIV incidence among WESW in SSA and compared these to the wider female population to understand levels and trends in incidence over time. Methods: We searched Medline, Embase, Global Health, Popline, Web of Science, and Google Scholar from January 1990 to October 2022, and grey literature for estimates of HIV incidence among WESW in SSA. We included studies reporting empirical estimates in any SSA country. We calculated incidence rate ratios (IRR) compared to age-district-year matched total female population incidence estimates. We conducted a meta-analysis of IRRs and used a continuous mixed-effects model to estimate changes in IRR over time. Results: From 32 studies between 1985 and 2020, 2,194 new HIV infections were observed in WESW over 51,000 person-years (py). Median HIV incidence was 4.3/100py (IQR 2.8-7.0/100py), declining from a median of 5.96/100py between 1985 and 1995 to a median of 3.2/100py between 2010 and 2020. Incidence among WESW was nine times higher than in matched total population women (RR 8.6, 95%CI: 5.7-12.9), and greater in Western and Central Africa (RR 22.4, 95%CI: 11.3-44.3) than in Eastern and Southern Africa (RR 5.3, 95%CI: 3.7-7.6). Annual changes in log IRRs were minimal (-0.1% 95%CI: -6.9 to +6.8%). Conclusions: Across SSA, HIV incidence among WESW remains disproportionately high compared to the total female population but showed similar rates of decline between 1990 and 2020. Improved surveillance and standardisation of approaches to obtain empirical estimates of sex worker incidence would enable a clearer understanding of whether we are on track to meet global targets for this population and better support data-driven HIV prevention programming.</text><annotation id="9"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="123" length="3"/><text>HIV</text></annotation><annotation id="10"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="230" length="10"/><text>infections</text></annotation><annotation id="11"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="344" length="3"/><text>HIV</text></annotation><annotation id="12"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="651" length="3"/><text>HIV</text></annotation><annotation id="13"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="1054" length="14"/><text>HIV infections</text></annotation><annotation id="14"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="1622" length="3"/><text>HIV</text></annotation><annotation id="15"><infon key="identifier">MESH:D015658</infon><infon key="type">Disease</infon><location offset="2026" length="3"/><text>HIV</text></annotation></passage></document>
<document><id>37905416</id><passage><infon key="journal">J Investig Allergol Clin Immunol;2023Oct30 0. doi:10.18176/jiaci.0958</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Narv&amp;#xe1;ez-Fern&amp;#xe1;ndez E, Pose K, Caballero ML, Rodr&amp;#xed;guez-P&amp;#xe9;rez R, Quirce S, </infon><offset>0</offset><text>Occupational asthma and food allergy due to soybean in a bakery worker.</text><annotation id="2"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="13" length="6"/><text>asthma</text></annotation><annotation id="3"><infon key="identifier">MESH:D005512</infon><infon key="type">Disease</infon><location offset="24" length="12"/><text>food allergy</text></annotation></passage><passage><infon key="type">abstract</infon><offset>72</offset></passage></document>
<document><id>37905767</id><passage><infon key="journal">Zhongguo Dang Dai Er Ke Za Zhi;2023Oct15; 25 (10) 1078. doi:10.7499/j.issn.1008-8830.2304056</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10621051</infon><infon key="type">title</infon><infon key="authors">Li JY, </infon><offset>0</offset><text>[Recent research on the relationship between pulmonary microbiome and asthma endotypes in children].</text><annotation id="1"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="70" length="6"/><text>asthma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>101</offset><text>Bronchial asthma is not considered a singular disease, but rather a collection of syndromes with multiple phenotypes and mechanisms that involve various signaling pathways. It typically emerges during the preschool years, and its etiology is intricate and diverse. In recent years, the advancement of high-throughput sequencing technology has revealed that early alterations in lung microbiota may be associated with asthma incidence and progression. Moreover, significant variations in lung microbiota have been observed among different airway inflammation profiles, known as asthma endotypes. Hence, a comprehensive understanding of the characteristics of lung microbiota in children with asthma can aid in managing disease progression and improving long-term prognosis. Additionally, such insights may spark novel approaches to diagnosing and treating childhood asthma.</text><annotation id="8"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="101" length="16"/><text>Bronchial asthma</text></annotation><annotation id="9"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="518" length="6"/><text>asthma</text></annotation><annotation id="10"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="639" length="19"/><text>airway inflammation</text></annotation><annotation id="11"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="678" length="6"/><text>asthma</text></annotation><annotation id="12"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="792" length="6"/><text>asthma</text></annotation><annotation id="13"><infon key="identifier">MESH:D001249</infon><infon key="type">Disease</infon><location offset="966" length="6"/><text>asthma</text></annotation></passage></document>
<document><id>37906119</id><passage><infon key="journal">Chem Biodivers;2023Oct31 202301302. doi:10.1002/cbdv.202301302</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Shahmoradi A, Ebadi A, Dastan D, </infon><offset>0</offset><text>Ferulago bernardii as a new source of alpha-pinene binds to ctDNA: In silico and in vitro studies.</text><annotation id="1"><infon key="identifier">MESH:C005451</infon><infon key="type">Chemical</infon><location offset="38" length="12"/><text>alpha-pinene</text></annotation></passage><passage><infon key="type">abstract</infon><offset>99</offset><text>Ferulago bernardii Tomk &amp; M. Pimen belongs to Apiaceae family. Various species of the Ferulago genus have antioxidant, anticholinesterase, cytotoxic, and antiproliferative effects. In this study, the essential oil of F. bernardii was extracted using the Clevenger apparatus. The essential oil compounds were identified using GC-MS/FID. The interaction between the essential oil and DNA strands was evaluated through spectrophotometric titration. The molecular mechanism of the interaction between the main components of the essential oil and different DNA strands was assessed using molecular dynamics simulation. Based on the results, 92.03 +- 1.20 % of the essential oil consisted of alpha-pinene. Therefore, the essential oil could serve as a suitable source of alpha-pinene. alpha-pinene is a monoterpene hydrocarbon that has various effects, including anti-inflammatory, antioxidant, antimicrobial, and antitumor properties. The binding constant of the essential oil to DNA strands (Ka) was determined to be 5.40 +- 0.47 x 10-3 M-1. Molecular dynamics simulation demonstrated that alpha-pinene could interact with AT and CG rich DNA strands and indirectly stabilize G-Quadruplex. Given the different applications for alpha-pinene and its high percentage in the essential oil, it is suggested that researchers pay more attention to F. bernardii in the pharmaceutical, cosmetic, and food industries.</text><annotation id="17"><infon key="identifier">MESH:D009822</infon><infon key="type">Chemical</infon><location offset="299" length="13"/><text>essential oil</text></annotation><annotation id="18"><infon key="identifier">MESH:D009822</infon><infon key="type">Chemical</infon><location offset="378" length="13"/><text>essential oil</text></annotation><annotation id="19"><infon key="identifier">MESH:D009822</infon><infon key="type">Chemical</infon><location offset="463" length="13"/><text>essential oil</text></annotation><annotation id="20"><infon key="identifier">MESH:D009822</infon><infon key="type">Chemical</infon><location offset="623" length="13"/><text>essential oil</text></annotation><annotation id="21"><infon key="identifier">MESH:D009822</infon><infon key="type">Chemical</infon><location offset="758" length="13"/><text>essential oil</text></annotation><annotation id="22"><infon key="identifier">MESH:C005451</infon><infon key="type">Chemical</infon><location offset="785" length="12"/><text>alpha-pinene</text></annotation><annotation id="23"><infon key="identifier">MESH:D009822</infon><infon key="type">Chemical</infon><location offset="814" length="13"/><text>essential oil</text></annotation><annotation id="24"><infon key="identifier">MESH:C005451</infon><infon key="type">Chemical</infon><location offset="864" length="12"/><text>alpha-pinene</text></annotation><annotation id="25"><infon key="identifier">MESH:C005451</infon><infon key="type">Chemical</infon><location offset="878" length="12"/><text>alpha-pinene</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="896" length="23"/><text>monoterpene hydrocarbon</text></annotation><annotation id="27"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="961" length="12"/><text>inflammatory</text></annotation><annotation id="28"><infon key="identifier">MESH:D009822</infon><infon key="type">Chemical</infon><location offset="1057" length="13"/><text>essential oil</text></annotation><annotation id="29"><infon key="identifier">MESH:C005451</infon><infon key="type">Chemical</infon><location offset="1185" length="12"/><text>alpha-pinene</text></annotation><annotation id="30"><infon key="identifier">MESH:C005451</infon><infon key="type">Chemical</infon><location offset="1321" length="12"/><text>alpha-pinene</text></annotation><annotation id="31"><infon key="identifier">MESH:D009822</infon><infon key="type">Chemical</infon><location offset="1365" length="13"/><text>essential oil</text></annotation></passage><relation id="R1"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:C005451</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="8,11"/></relation><relation id="R2"><infon key="score">0.9792</infon><infon key="role1">Chemical|MESH:C005451</infon><infon key="role2">Chemical|MESH:D009822</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="6,5"/></relation></document>
<document><id>37906469</id><passage><infon key="journal">J Endovasc Ther;2023Oct31 15266028231208652. doi:10.1177/15266028231208652</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nakai M, Saguchi T, Yunaiyama D, Takara Y, Tanaka T, Okada Y, Saito K, </infon><offset>0</offset><text>Development and Experimental Study of a Polytetrafluoroethylene-Tipped Microcatheter Poorly Adhesive to n-Butyl-2-Cyanoacrylate.</text><annotation id="2"><infon key="identifier">MESH:D011138</infon><infon key="type">Chemical</infon><location offset="40" length="23"/><text>Polytetrafluoroethylene</text></annotation><annotation id="3"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="104" length="23"/><text>n-Butyl-2-Cyanoacrylate</text></annotation></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>PURPOSE: We have developed a new microcatheter (designated "NSX") with an outer layer of polytetrafluoroethylene (PTFE) at its tip. We compared the adhesion of the new NSX microcatheter and a conventional microcatheter with n-butyl-2-cyanoacrylate (NBCA) in vitro and in swine blood vessels. MATERIALS AND METHODS: The 3 cm tip of the NSX microcatheter is composed of PTFE, which can be identified by double platinum markers. The tips of the NSX and conventional microcatheters were inserted into a vascular model filled with porcine blood with no flow, and NBCA mixed with lipiodol (1:2) was injected from the microcatheters. Two minutes after the injection of NBCA, the microcatheter was withdrawn and the degree of its adhesion to NBCA was evaluated by measuring the resistance value (N) during catheter removal with a digital force gauge. These measurements were repeated with 20 catheters of each type. Similarly, 5 injections were performed with both the NSX and conventional microcatheters in swine vessels. The degree of adhesion of the catheter and blood vessel was evaluated by 2 radiologists under X-ray fluoroscopy on a 3-point scale: 1, no adhesion; 2, mild adhesion; 3, strong adhesion. RESULTS: The mean resistance values (N) for the NSX and conventional microcatheters were 0.503+-0.186 and 1.051+-0.367 (N), respectively (p&lt;0.001). The NSX adhered negligibly to the NBCA and was easily removed, whereas the conventional microcatheter adhered strongly to the NBCA in the blood vessels and was difficult to remove from the swine vessels (p=0.008). CONCLUSIONS: The new NSX microcatheter with a PTFE tip exhibits poorer adhesion to NBCA than do conventional microcatheters and allows for safer injection of NBCA than conventional microcatheters, without requiring immediate catheter retrieval. CLINICAL IMPACT: The NSX microcatheter with a PTFE tip adheres less strongly to NBCA than do conventional microcatheters and allows the safe injection of NBCA. The NSX microcatheter has double platinum markers on its tip, which make it easy to distinguish the PTFE-covered region. As the NSX does not adhere firmly to the arterial wall, it is less likely to cause vascular injury during removal of the catheter compared with conventional microcatheters, so there is no need to remove the NSX immediately after injecting NBCA. Even operators unfamiliar with NBCA can use NBCA safely with this new NSX microcatheter without requiring special training or skill.</text><annotation id="35"><infon key="identifier">MESH:D011138</infon><infon key="type">Chemical</infon><location offset="218" length="23"/><text>polytetrafluoroethylene</text></annotation><annotation id="36"><infon key="identifier">MESH:D011138</infon><infon key="type">Chemical</infon><location offset="243" length="4"/><text>PTFE</text></annotation><annotation id="37"><infon key="identifier">MESH:D000267</infon><infon key="type">Disease</infon><location offset="277" length="8"/><text>adhesion</text></annotation><annotation id="38"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="353" length="23"/><text>n-butyl-2-cyanoacrylate</text></annotation><annotation id="39"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="378" length="4"/><text>NBCA</text></annotation><annotation id="40"><infon key="identifier">MESH:D011138</infon><infon key="type">Chemical</infon><location offset="497" length="4"/><text>PTFE</text></annotation><annotation id="41"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="537" length="8"/><text>platinum</text></annotation><annotation id="42"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="687" length="4"/><text>NBCA</text></annotation><annotation id="43"><infon key="identifier">MESH:D004998</infon><infon key="type">Chemical</infon><location offset="703" length="8"/><text>lipiodol</text></annotation><annotation id="44"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="791" length="4"/><text>NBCA</text></annotation><annotation id="45"><infon key="identifier">MESH:D000267</infon><infon key="type">Disease</infon><location offset="851" length="8"/><text>adhesion</text></annotation><annotation id="46"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="863" length="4"/><text>NBCA</text></annotation><annotation id="47"><infon key="identifier">MESH:D000267</infon><infon key="type">Disease</infon><location offset="1158" length="8"/><text>adhesion</text></annotation><annotation id="48"><infon key="identifier">MESH:D000267</infon><infon key="type">Disease</infon><location offset="1282" length="8"/><text>adhesion</text></annotation><annotation id="49"><infon key="identifier">MESH:D000267</infon><infon key="type">Disease</infon><location offset="1300" length="8"/><text>adhesion</text></annotation><annotation id="50"><infon key="identifier">MESH:D000267</infon><infon key="type">Disease</infon><location offset="1320" length="8"/><text>adhesion</text></annotation><annotation id="51"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="1512" length="4"/><text>NBCA</text></annotation><annotation id="52"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="1604" length="4"/><text>NBCA</text></annotation><annotation id="53"><infon key="identifier">MESH:D011138</infon><infon key="type">Chemical</infon><location offset="1738" length="4"/><text>PTFE</text></annotation><annotation id="54"><infon key="identifier">MESH:D000267</infon><infon key="type">Disease</infon><location offset="1763" length="8"/><text>adhesion</text></annotation><annotation id="55"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="1775" length="4"/><text>NBCA</text></annotation><annotation id="56"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="1850" length="4"/><text>NBCA</text></annotation><annotation id="57"><infon key="identifier">MESH:D011138</infon><infon key="type">Chemical</infon><location offset="1983" length="4"/><text>PTFE</text></annotation><annotation id="58"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="2017" length="4"/><text>NBCA</text></annotation><annotation id="59"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="2091" length="4"/><text>NBCA</text></annotation><annotation id="60"><infon key="identifier">MESH:D010984</infon><infon key="type">Chemical</infon><location offset="2130" length="8"/><text>platinum</text></annotation><annotation id="61"><infon key="identifier">MESH:D011138</infon><infon key="type">Chemical</infon><location offset="2197" length="4"/><text>PTFE</text></annotation><annotation id="62"><infon key="identifier">MESH:D057772</infon><infon key="type">Disease</infon><location offset="2301" length="15"/><text>vascular injury</text></annotation><annotation id="63"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="2457" length="4"/><text>NBCA</text></annotation><annotation id="64"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="2494" length="4"/><text>NBCA</text></annotation><annotation id="65"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="2507" length="4"/><text>NBCA</text></annotation></passage><relation id="R1"><infon key="score">0.2392</infon><infon key="role1">Chemical|MESH:D004659</infon><infon key="role2">Chemical|MESH:D004998</infon><infon key="type">Cotreatment</infon><node refid="0" role="9,10"/></relation><relation id="R2"><infon key="score">0.9841</infon><infon key="role1">Chemical|MESH:D004659</infon><infon key="role2">Chemical|MESH:D011138</infon><infon key="type">Association</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.3615</infon><infon key="role1">Chemical|MESH:D004659</infon><infon key="role2">Disease|MESH:D000267</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="5,4"/></relation></document>
<document><id>37906843</id><passage><infon key="journal">Andes Pediatr;2022Aug; 93 (4) 458. doi:10.32641/andespediatr.v93i4.4050</infon><infon key="year">2022</infon><infon key="type">title</infon><infon key="authors">Alarc&amp;#xf3;n Ben&amp;#xed;tez D, de Los Angeles Beyt&amp;#xed;a Reyes M, Escobar RG, N&amp;#xfa;&amp;#xf1;ez Far&amp;#xed;as A, L&amp;#xf3;pez Bohner ME, Avila-Smirnow D, </infon><offset>0</offset><text>[Hypotonic infant].</text><annotation id="1"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="1" length="16"/><text>Hypotonic infant</text></annotation></passage><passage><infon key="type">abstract</infon><offset>20</offset><text>Hypotonia of the newborn or infant is defined as decreased resistance to passive movement and is a frequent diagnostic challenge in pediatric practice. The hypotonic syndrome is a working diagnosis and its etiology must be identified to determine associated morbidities, prognosis, and management. Rapid advances in bioinformatics and molecular genetic testing allow for early accurate diagnoses in the diagnostic process. Therefore, it is necessary to carry out an updated review on this topic. The objective of this non-systematic narrative review is to describe the diagnostic approach to hypotonic syndrome and its main etiologies. A review of the literature from PubMed and Scielo databases was carried out, including relevant articles in English and Spanish published in the last 15 years. We emphasize the value of the clinical examination and history in locating the cause of hypotonia (cen tral or peripheral) as the first step toward the etiological diagnosis. Systemic diseases such as sepsis, hypoxic-ischemic encephalopathy, heart failure, and metabolic and electrolyte abnormalities are still common causes of central hypotonia. Peripheral hypotonia involves disorders of the anterior horn of the spinal cord, peripheral nerve, neuromuscular junction and muscle, of inherited and acquired origin. The use of images of the central nervous system and muscle and genetic panels and exome, constitute the most recent contributions to the diagnosis of hypotonic syndrome. This article propo ses an initial approach based on the main clinical clues leading to a certain diagnosis. Its therapy is supportive, except for some conditions that require specific treatment.</text><annotation id="17"><infon key="identifier">MESH:D009123</infon><infon key="type">Disease</infon><location offset="20" length="9"/><text>Hypotonia</text></annotation><annotation id="18"><infon key="identifier">MESH:D009123</infon><infon key="type">Disease</infon><location offset="176" length="18"/><text>hypotonic syndrome</text></annotation><annotation id="19"><infon key="identifier">MESH:D009123</infon><infon key="type">Disease</infon><location offset="612" length="18"/><text>hypotonic syndrome</text></annotation><annotation id="20"><infon key="identifier">MESH:D009123</infon><infon key="type">Disease</infon><location offset="904" length="9"/><text>hypotonia</text></annotation><annotation id="21"><infon key="type">Disease</infon><location offset="915" length="8"/><text>cen tral</text></annotation><annotation id="22"><infon key="identifier">MESH:D018805</infon><infon key="type">Disease</infon><location offset="1017" length="6"/><text>sepsis</text></annotation><annotation id="23"><infon key="identifier">MESH:D020925</infon><infon key="type">Disease</infon><location offset="1025" length="31"/><text>hypoxic-ischemic encephalopathy</text></annotation><annotation id="24"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="1058" length="13"/><text>heart failure</text></annotation><annotation id="25"><infon key="identifier">MESH:D008659</infon><infon key="type">Disease</infon><location offset="1077" length="39"/><text>metabolic and electrolyte abnormalities</text></annotation><annotation id="26"><infon key="identifier">MESH:D009123</infon><infon key="type">Disease</infon><location offset="1152" length="9"/><text>hypotonia</text></annotation><annotation id="27"><infon key="identifier">MESH:D009123</infon><infon key="type">Disease</infon><location offset="1163" length="20"/><text>Peripheral hypotonia</text></annotation><annotation id="28"><infon key="identifier">MESH:D016472</infon><infon key="type">Disease</infon><location offset="1193" length="49"/><text>disorders of the anterior horn of the spinal cord</text></annotation><annotation id="29"><infon key="identifier">MESH:C537568</infon><infon key="type">Disease</infon><location offset="1255" length="5"/><text>nerve</text></annotation><annotation id="30"><infon key="identifier">MESH:D020511</infon><infon key="type">Disease</infon><location offset="1262" length="22"/><text>neuromuscular junction</text></annotation><annotation id="31"><infon key="identifier">MESH:D009123</infon><infon key="type">Disease</infon><location offset="1481" length="18"/><text>hypotonic syndrome</text></annotation></passage></document>
<document><id>37907209</id><passage><infon key="journal">BMJ;2023Oct31; 383 2422. doi:10.1136/bmj.p2422</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Davies M, </infon><offset>0</offset><text>Caring for the whole person: the consultant neurologist.</text></passage><passage><infon key="type">abstract</infon><offset>57</offset></passage></document>
<document><id>37909312</id><passage><infon key="journal">Dalton Trans;2023Nov01. doi:10.1039/d3dt02474a</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li W, Li X, Robeyns K, Wolff M, Kfoury J, Ol&amp;#xe1;h J, Herchel R, Demeshko S, Meyer F, Garcia Y, </infon><offset>0</offset><text>Spin-state versatility in FeII4L6 supramolecular cages with a pyridyl-hydrazone ligand scaffold modulated by solvents and counter anions.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="26" length="7"/><text>FeII4L6</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="62" length="17"/><text>pyridyl-hydrazone</text></annotation></passage><passage><infon key="type">abstract</infon><offset>138</offset><text>Discrete spin crossover (SCO) tetranuclear cages are a unique class of materials that have potential use in next-generation molecular recognition and sensing. In this work, two new edge-bridged SCO FeII4L6 (L = 2,7-bis(((E)-pyridin-2-ylmethylene)amino)benzo[lmn] [3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone) supramolecular cages with different counter anions: ClO4- (2) and CF3SO3- (3) were constructed via subcomponent self-assembly to investigate both solvent and anion influences on their magnetic properties and compare them to cage 1 with a BF4- anion. Pyridyl-hydrazone bidentate ligand scaffolds were employed to replace the 'classical' imidazole/thiazolyl-imine coordination units to induce SCO behaviour in these cages. 2 and 3 were structurally characterized by single-crystal X-ray diffraction analysis and electrospray ionization time-of-flight mass spectrometry. Magnetic susceptibilities of 1-3 and 1-3 desolvated indicate that the solvents' presence is in favor of the low-spin (LS) state. While different counter anions in 1-3 desolvated affect the spin-state configurations of the four FeII metal centers. According to the 57Fe Mossbauer spectral analysis, the spin-state distributions in 1-3 at 80 K are [2 high-spin (HS)-2LS], [1HS-3LS] and [2HS-2LS], respectively and density functional theory calculations were employed to investigate the reasons. These findings provide insights to regulate the spin-state versatility of SCO FeII cage systems in the solid state.</text><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="336" length="7"/><text>FeII4L6</text></annotation><annotation id="19"><infon key="identifier">MESH:D007930</infon><infon key="type">Chemical</infon><location offset="345" length="1"/><text>L</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="349" length="95"/><text>2,7-bis(((E)-pyridin-2-ylmethylene)amino)benzo[lmn] [3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone</text></annotation><annotation id="21"><infon key="identifier">MESH:C494474</infon><infon key="type">Chemical</infon><location offset="498" length="5"/><text>ClO4-</text></annotation><annotation id="22"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="512" length="11"/><text>CF3SO3- (3)</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="684" length="4"/><text>BF4-</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="696" length="17"/><text>Pyridyl-hydrazone</text></annotation><annotation id="25"><infon key="identifier">MESH:C029899</infon><infon key="type">Chemical</infon><location offset="782" length="9"/><text>imidazole</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="792" length="15"/><text>thiazolyl-imine</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1241" length="4"/><text>FeII</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1278" length="4"/><text>57Fe</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1385" length="3"/><text>1HS</text></annotation><annotation id="30"><infon key="identifier">MESH:D003903</infon><infon key="type">Chemical</infon><location offset="1399" length="3"/><text>2HS</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1585" length="4"/><text>FeII</text></annotation></passage></document>
<document><id>37910022</id><passage><infon key="journal">J Clin Pharmacol;2023Nov01. doi:10.1002/jcph.2381</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cheng L, Liu Z, Yu M, Lin L, Xiong L, Dai Q, </infon><offset>0</offset><text>Hypokalemia and hyponatremia in adult patients receiving voriconazole therapeutic drug monitoring.</text><annotation id="3"><infon key="identifier">MESH:D007008</infon><infon key="type">Disease</infon><location offset="0" length="11"/><text>Hypokalemia</text></annotation><annotation id="4"><infon key="identifier">MESH:D007010</infon><infon key="type">Disease</infon><location offset="16" length="12"/><text>hyponatremia</text></annotation><annotation id="5"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="57" length="12"/><text>voriconazole</text></annotation></passage><passage><infon key="type">abstract</infon><offset>99</offset><text>Hypokalemia and hyponatremia are common but easily ignored adverse events of voriconazole (VCZ) that can lead to serious consequences. We intend to investigate the incidence of VCZ-induced hypokalemia and hyponatremia and their risk factors based on real-world data. A prospective study was conducted. A total of 272 patients with 414 VCZ plasma trough concentrations (C0 ) and VCZ N-oxide concentrations (CN ) were included. The incidence of hypokalemia was 18.0% (48/266). A total of 81.2% (39/48) of patients developed hypokalemia within 14 days, while 56.2% (27/48) of patients developed hypokalemia within 1 week. The proportion of female patients in the hypokalemia group was higher than that in the nonhypokalemia group, as was the proportion of patients receiving intravenous VCZ. In the multivariate analysis, the independent risk factors for hypokalemia were sex, combined use of antibiotics, and VCZ CN /C0 . The incidence of hyponatremia was 7.9% (21/266). The proportion of patients over 47 years of age in the hyponatremia group was 71.4% (15/21). The number of days of VCZ use in the hyponatremia group was greater than that in the nonhyponatremia group. A total of 47.6% (10/21) of patients in the hyponatremia group had supratherapeutic VCZ C0 (>5.0 mug/mL). In conclusion, hypokalemia is more likely to occur in females, patients receiving intravenous VCZ, and patients with combined use of antibiotics. Hyponatremia is more likely to occur in patients older than 47 years who have been using VCZ for a long time and have higher VCZ C0 . This article is protected by copyright. All rights reserved.</text><annotation id="33"><infon key="identifier">MESH:D007008</infon><infon key="type">Disease</infon><location offset="99" length="11"/><text>Hypokalemia</text></annotation><annotation id="34"><infon key="identifier">MESH:D007010</infon><infon key="type">Disease</infon><location offset="115" length="12"/><text>hyponatremia</text></annotation><annotation id="35"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="176" length="12"/><text>voriconazole</text></annotation><annotation id="36"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="190" length="3"/><text>VCZ</text></annotation><annotation id="37"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="276" length="3"/><text>VCZ</text></annotation><annotation id="38"><infon key="identifier">MESH:D007008</infon><infon key="type">Disease</infon><location offset="288" length="11"/><text>hypokalemia</text></annotation><annotation id="39"><infon key="identifier">MESH:D007010</infon><infon key="type">Disease</infon><location offset="304" length="12"/><text>hyponatremia</text></annotation><annotation id="40"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="434" length="3"/><text>VCZ</text></annotation><annotation id="41"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="477" length="11"/><text>VCZ N-oxide</text></annotation><annotation id="42"><infon key="identifier">MESH:D007008</infon><infon key="type">Disease</infon><location offset="542" length="11"/><text>hypokalemia</text></annotation><annotation id="43"><infon key="identifier">MESH:D007008</infon><infon key="type">Disease</infon><location offset="621" length="11"/><text>hypokalemia</text></annotation><annotation id="44"><infon key="identifier">MESH:D007008</infon><infon key="type">Disease</infon><location offset="691" length="11"/><text>hypokalemia</text></annotation><annotation id="45"><infon key="identifier">MESH:D007008</infon><infon key="type">Disease</infon><location offset="759" length="11"/><text>hypokalemia</text></annotation><annotation id="46"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="883" length="3"/><text>VCZ</text></annotation><annotation id="47"><infon key="identifier">MESH:D007008</infon><infon key="type">Disease</infon><location offset="951" length="11"/><text>hypokalemia</text></annotation><annotation id="48"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="1006" length="3"/><text>VCZ</text></annotation><annotation id="49"><infon key="identifier">MESH:D007010</infon><infon key="type">Disease</infon><location offset="1036" length="12"/><text>hyponatremia</text></annotation><annotation id="50"><infon key="identifier">MESH:D007010</infon><infon key="type">Disease</infon><location offset="1123" length="12"/><text>hyponatremia</text></annotation><annotation id="51"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="1183" length="3"/><text>VCZ</text></annotation><annotation id="52"><infon key="identifier">MESH:D007010</infon><infon key="type">Disease</infon><location offset="1198" length="12"/><text>hyponatremia</text></annotation><annotation id="53"><infon key="identifier">MESH:D007010</infon><infon key="type">Disease</infon><location offset="1313" length="12"/><text>hyponatremia</text></annotation><annotation id="54"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="1353" length="3"/><text>VCZ</text></annotation><annotation id="55"><infon key="identifier">MESH:D007008</infon><infon key="type">Disease</infon><location offset="1390" length="11"/><text>hypokalemia</text></annotation><annotation id="56"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="1469" length="3"/><text>VCZ</text></annotation><annotation id="57"><infon key="identifier">MESH:D007010</infon><infon key="type">Disease</infon><location offset="1521" length="12"/><text>Hyponatremia</text></annotation><annotation id="58"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="1610" length="3"/><text>VCZ</text></annotation><annotation id="59"><infon key="identifier">MESH:D065819</infon><infon key="type">Chemical</infon><location offset="1646" length="3"/><text>VCZ</text></annotation></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D065819</infon><infon key="role2">Disease|MESH:D007010</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="2,1"/></relation><relation id="R2"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D065819</infon><infon key="role2">Disease|MESH:D007008</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="2,0"/></relation></document>
<document><id>37910373</id><passage><infon key="journal">Environ Sci Pollut Res Int;2023Nov01. doi:10.1007/s11356-023-30663-w</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li Y, Li X, Ma X, Qiu T, Fu X, Ma Z, Ping H, Li C, </infon><offset>0</offset><text>Livestock wastes from family-operated farms are potential important sources of potentially toxic elements, antibiotics, and estrogens in rural areas in North China.</text></passage><passage><infon key="type">abstract</infon><offset>165</offset><text>The open-air storage and disposal of livestock waste from family-operated livestock farms can be a potential health threat to rural residents. In this study, the occurrence and seasonal distribution of 8 potentially toxic elements, 24 antibiotics, and 4 estrogens were investigated in 44 waste samples from 11 rural farms in North China. The results showed that these micropollutants were ubiquitous in livestock waste, with concentration ranges of 238.9-4555 mg/kg for potentially toxic elements, not detected (ND) to 286,672 mug/kg for antibiotics and ND to 229.5 mug/kg for estrogens. The pollutants in animal wastes showed seasonal variation. Since these wastes are directly applicable to nearby farmland without treatment, the risks those wastes pose to farmland soils were also evaluated. Risk assessment results showed that Zn, Cd, Hg, FF and DC in swine manures were at high risk, while total estrogens in chicken and dairy cattle manures were at high risk. The results will provide important data for the regulation of animal wastes produced by small-scale livestock farms in rural areas of China.</text><annotation id="4"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="996" length="2"/><text>Zn</text></annotation><annotation id="5"><infon key="identifier">MESH:D002104</infon><infon key="type">Chemical</infon><location offset="1000" length="2"/><text>Cd</text></annotation><annotation id="6"><infon key="identifier">MESH:D008628</infon><infon key="type">Chemical</infon><location offset="1004" length="2"/><text>Hg</text></annotation><annotation id="7"><infon key="identifier">MESH:D003841</infon><infon key="type">Chemical</infon><location offset="1015" length="2"/><text>DC</text></annotation></passage></document>
<document><id>37910724</id><passage><infon key="journal">Opt Lett;2023Nov01; 48 (21) 5647. doi:10.1364/OL.505616</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Carlos Basilio-Ortiz J, Moreno I, </infon><offset>0</offset><text>All dielectric reflective metalens based on multilayer meta-atoms.</text></passage><passage><infon key="type">abstract</infon><offset>67</offset><text>While transmission-mode metalenses have been extensively studied, reflection-mode metalenses remain almost unexplored, presenting advantages in terms of improved efficiency and reduced complexity. In this Letter, we investigate a multilayer dielectric metalens operating in reflection mode at visible wavelengths without a metallic layer. Simulations and analysis demonstrate the performance of the metalens, with an 84% reflectivity the metalens proves its efficacy in reflection mode. At a numerical aperture of 0.15, the metalens achieves a 33% focusing efficiency, which is approximately twice that of similar reflective metalenses, facilitating efficient light manipulation and subwavelength resolution. Additionally, the metalens exhibits a well-defined focal spot with a full width at half maximum of 2.03 microm, approaching the diffraction limit.</text></passage></document>
<document><id>37911075</id><passage><infon key="journal">Int Dent J (Phila);1893Feb; 14 (2) 109</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109626</infon><infon key="type">title</infon><offset>0</offset><text>American Dental Association: Second Day.-Evening Session.</text></passage><passage><infon key="type">abstract</infon><offset>58</offset></passage></document>
<document><id>37911425</id><passage><infon key="journal">Int Dent J (Phila);1890Apr; 11 (4) 253</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110125</infon><infon key="type">title</infon><offset>0</offset><text>Domestic Correspondence.</text></passage><passage><infon key="type">abstract</infon><offset>25</offset></passage></document>
<document><id>37912125</id><passage><infon key="journal">Int Dent J (Phila);1896Dec; 17 (12) 788</infon><infon key="year">1896</infon><infon key="article-id_pmc">PMC10124516</infon><infon key="type">title</infon><offset>0</offset><text>American Dental Association: August 5, 1896.-Second Day.-Morning Session.</text><annotation id="1"><infon key="type">Disease</infon><location offset="65" length="7"/><text>Session</text></annotation></passage><passage><infon key="type">abstract</infon><offset>74</offset></passage></document>
<document><id>37912825</id><passage><infon key="journal">Int Dent J (Phila);1901Apr; 22 (4) 264</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153880</infon><infon key="type">title</infon><offset>0</offset><text>Academy of Stomatology.</text></passage><passage><infon key="type">abstract</infon><offset>24</offset></passage></document>
<document><id>37913175</id><passage><infon key="journal">Int Dent J (Phila);1903Aug; 24 (8) 634</infon><infon key="year">1903</infon><infon key="article-id_pmc">PMC10162263</infon><infon key="type">title</infon><offset>0</offset><text>The New York Institute of Stomatology.</text></passage><passage><infon key="type">abstract</infon><offset>39</offset></passage></document>
<document><id>37913526</id><passage><infon key="journal">ACS Appl Mater Interfaces;2023Nov01. doi:10.1021/acsami.3c12139</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chiu NC, Compton D, G&amp;#x142;adysiak A, Simrod S, Khivantsev K, Woo TK, Stadie NP, Stylianou KC, </infon><offset>0</offset><text>Hydrogen Adsorption in Ultramicroporous Metal-Organic Frameworks Featuring Silent Open Metal Sites.</text><annotation id="1"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="0" length="8"/><text>Hydrogen</text></annotation></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>In this study, we utilized an ultramicroporous metal-organic framework (MOF) named [Ni3(pzdc)2(ade)2(H2O)4] 2.18H2O (where H3pzdc represents pyrazole-3,5-dicarboxylic acid and ade represents adenine) for hydrogen (H2) adsorption. Upon activation, [Ni3(pzdc)2(ade)2] was obtained, and in situ carbon monoxide loading by transmission infrared spectroscopy revealed the generation of open Ni(II) sites. The MOF displayed a Brunauer-Emmett-Teller (BET) surface area of 160 m2/g and a pore size of 0.67 nm. Hydrogen adsorption measurements conducted on this MOF at 77 K showed a steep increase in uptake (up to 1.93 mmol/g at 0.04 bar) at low pressure, reaching a H2 uptake saturation at 2.11 mmol/g at ~0.15 bar. The affinity of this MOF for H2 was determined to be 9.7 +- 1.0 kJ/mol. In situ H2 loading experiments supported by molecular simulations confirmed that H2 does not bind to the open Ni(II) sites of [Ni3(pzdc)2(ade)2], and the high affinity of the MOF for H2 is attributed to the interplay of pore size, shape, and functionality.</text><annotation id="26"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="147" length="23"/><text>metal-organic framework</text></annotation><annotation id="27"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="172" length="3"/><text>MOF</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="183" length="32"/><text>[Ni3(pzdc)2(ade)2(H2O)4] 2.18H2O</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="223" length="6"/><text>H3pzdc</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="241" length="30"/><text>pyrazole-3,5-dicarboxylic acid</text></annotation><annotation id="31"><infon key="identifier">MESH:C060154</infon><infon key="type">Chemical</infon><location offset="276" length="3"/><text>ade</text></annotation><annotation id="32"><infon key="identifier">MESH:D000225</infon><infon key="type">Chemical</infon><location offset="291" length="7"/><text>adenine</text></annotation><annotation id="33"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="304" length="8"/><text>hydrogen</text></annotation><annotation id="34"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="314" length="2"/><text>H2</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="348" length="16"/><text>Ni3(pzdc)2(ade)2</text></annotation><annotation id="36"><infon key="identifier">MESH:D002248</infon><infon key="type">Chemical</infon><location offset="392" length="15"/><text>carbon monoxide</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="486" length="6"/><text>Ni(II)</text></annotation><annotation id="38"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="504" length="3"/><text>MOF</text></annotation><annotation id="39"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="602" length="8"/><text>Hydrogen</text></annotation><annotation id="40"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="653" length="3"/><text>MOF</text></annotation><annotation id="41"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="759" length="2"/><text>H2</text></annotation><annotation id="42"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="830" length="3"/><text>MOF</text></annotation><annotation id="43"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="838" length="2"/><text>H2</text></annotation><annotation id="44"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="889" length="2"/><text>H2</text></annotation><annotation id="45"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="962" length="2"/><text>H2</text></annotation><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="991" length="6"/><text>Ni(II)</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1008" length="16"/><text>Ni3(pzdc)2(ade)2</text></annotation><annotation id="48"><infon key="identifier">MESH:D000073396</infon><infon key="type">Chemical</infon><location offset="1056" length="3"/><text>MOF</text></annotation><annotation id="49"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="1064" length="2"/><text>H2</text></annotation></passage><relation id="R1"><infon key="score">0.9637</infon><infon key="role1">Chemical|MESH:D000073396</infon><infon key="role2">Chemical|MESH:D006859</infon><infon key="type">Association</infon><node refid="0" role="1,8"/></relation></document>
<document><id>37913876</id><passage><infon key="journal">Int J Biol Macromol;2023Oct30 127734. doi:10.1016/j.ijbiomac.2023.127734</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sayed IR, Alfassam HE, El-Sayed MI, Abd El-Gaied IM, Allam AA, Abukhadra MR, </infon><offset>0</offset><text>Synthesis and characterization of chitosan hybridized zinc phosphate/hydroxyapatite core shell nanostructure and its potentiality as delivery system of oxaliplatin drug.</text><annotation id="4"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="34" length="8"/><text>chitosan</text></annotation><annotation id="5"><infon key="identifier">MESH:C043952</infon><infon key="type">Chemical</infon><location offset="54" length="14"/><text>zinc phosphate</text></annotation><annotation id="6"><infon key="identifier">MESH:D017886</infon><infon key="type">Chemical</infon><location offset="69" length="14"/><text>hydroxyapatite</text></annotation><annotation id="7"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="152" length="11"/><text>oxaliplatin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>170</offset><text>An advanced form of zinc phosphate/hydroxyapatite nanorods with a core-shell structure (ZPh/HPANRs) was made and then hybridized with chitosan polymeric chains to make a safe biocomposite (CH@ZPh/HPANRs) that improves the delivery structure of traditional oxaliplatin (OXPN) chemotherapy during the treatment of colorectal cancer cells. The qualifications of CH@ZPh/HPANRs in comparison with ZPh/HPANRs as a carrier for OXPN were followed based on loading, release, and cytotoxicity. CH@ZPh/HPANRs composite exhibits a notably higher OXPN loading capacity (321.75 mg/g) than ZPh/HPANRs (127.2 mg/g). The OXPN encapsulation processes into CH@ZPh/HPANRs display the isotherm behavior of the Langmuir model (R2 = 0.99) and the kinetic assumptions of pseudo-first-order kinetics (R2 > 0.89). The steric studies reflect a strong increment in the quantities of the free sites after the chitosan hybridization steps (Nm = 34.6 mg/g) as compared to pure ZPh/HPANRs (Nm = 18.7 mg/g). Also, the capacity of each site was enhanced to be loaded by 10 OXPN molecules (n = 9.3) in a vertical orientation. The OXPN loading energy into CH@ZPh/HPANRs (&lt;40 KJ/mol) reflects physical loading reactions involving van der Waals forces and hydrogen bonding. The OXPN release profiles of CH@ZPh/HPANRs exhibit slow and controlled properties for about 140 h at pH 7.4 and 80 h at pH 5.5. The release kinetics and diffusion exponent (>0.45) signify non-Fickian transport and a complex erosion/diffusion release mechanism. The free CH@ZPh/HPANRs particles display a considerable cytotoxic effect on the HCT-116 cancer cells (9.53 % cell viability), and their OXPN-loaded product shows a strong cytotoxic effect (1.83 % cell viability).</text><annotation id="48"><infon key="identifier">MESH:C043952</infon><infon key="type">Chemical</infon><location offset="190" length="14"/><text>zinc phosphate</text></annotation><annotation id="49"><infon key="identifier">MESH:D017886</infon><infon key="type">Chemical</infon><location offset="205" length="14"/><text>hydroxyapatite</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="258" length="3"/><text>ZPh</text></annotation><annotation id="51"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="262" length="6"/><text>HPANRs</text></annotation><annotation id="52"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="304" length="8"/><text>chitosan</text></annotation><annotation id="53"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="359" length="6"/><text>CH@ZPh</text></annotation><annotation id="54"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="366" length="6"/><text>HPANRs</text></annotation><annotation id="55"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="426" length="11"/><text>oxaliplatin</text></annotation><annotation id="56"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="439" length="4"/><text>OXPN</text></annotation><annotation id="57"><infon key="identifier">MESH:D015179</infon><infon key="type">Disease</infon><location offset="482" length="17"/><text>colorectal cancer</text></annotation><annotation id="58"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="529" length="6"/><text>CH@ZPh</text></annotation><annotation id="59"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="536" length="6"/><text>HPANRs</text></annotation><annotation id="60"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="562" length="3"/><text>ZPh</text></annotation><annotation id="61"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="566" length="6"/><text>HPANRs</text></annotation><annotation id="62"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="590" length="4"/><text>OXPN</text></annotation><annotation id="63"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="640" length="12"/><text>cytotoxicity</text></annotation><annotation id="64"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="661" length="6"/><text>HPANRs</text></annotation><annotation id="65"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="704" length="4"/><text>OXPN</text></annotation><annotation id="66"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="745" length="3"/><text>ZPh</text></annotation><annotation id="67"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="749" length="6"/><text>HPANRs</text></annotation><annotation id="68"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="774" length="4"/><text>OXPN</text></annotation><annotation id="69"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="808" length="6"/><text>CH@ZPh</text></annotation><annotation id="70"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="815" length="6"/><text>HPANRs</text></annotation><annotation id="71"><infon key="identifier">MESH:D048271</infon><infon key="type">Chemical</infon><location offset="1050" length="8"/><text>chitosan</text></annotation><annotation id="72"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1116" length="3"/><text>ZPh</text></annotation><annotation id="73"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1120" length="6"/><text>HPANRs</text></annotation><annotation id="74"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="1209" length="4"/><text>OXPN</text></annotation><annotation id="75"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="1265" length="4"/><text>OXPN</text></annotation><annotation id="76"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1290" length="6"/><text>CH@ZPh</text></annotation><annotation id="77"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1297" length="6"/><text>HPANRs</text></annotation><annotation id="78"><infon key="identifier">MESH:D006859</infon><infon key="type">Chemical</infon><location offset="1388" length="8"/><text>hydrogen</text></annotation><annotation id="79"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="1410" length="4"/><text>OXPN</text></annotation><annotation id="80"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1435" length="6"/><text>CH@ZPh</text></annotation><annotation id="81"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1442" length="6"/><text>HPANRs</text></annotation><annotation id="82"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1676" length="6"/><text>CH@ZPh</text></annotation><annotation id="83"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1683" length="6"/><text>HPANRs</text></annotation><annotation id="84"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1723" length="9"/><text>cytotoxic</text></annotation><annotation id="85"><infon key="identifier">CVCL:0291</infon><infon key="type">CellLine</infon><location offset="1747" length="14"/><text>HCT-116 cancer</text></annotation><annotation id="86"><infon key="identifier">MESH:D000077150</infon><infon key="type">Chemical</infon><location offset="1803" length="4"/><text>OXPN</text></annotation><annotation id="87"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1838" length="9"/><text>cytotoxic</text></annotation></passage><relation id="R1"><infon key="score">0.9982</infon><infon key="role1">Chemical|MESH:D000077150</infon><infon key="role2">Disease|MESH:D015179</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="11,13"/></relation><relation id="R2"><infon key="score">0.6311</infon><infon key="role1">Chemical|MESH:D000077150</infon><infon key="role2">Chemical|MESH:D048271</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="3,0"/></relation><relation id="R3"><infon key="score">0.9688</infon><infon key="role1">Chemical|MESH:D017886</infon><infon key="role2">Chemical|MESH:D048271</infon><infon key="type">Association</infon><node refid="2" role="2,0"/></relation><relation id="R4"><infon key="score">0.9806</infon><infon key="role1">Chemical|MESH:C043952</infon><infon key="role2">Chemical|MESH:D048271</infon><infon key="type">Association</infon><node refid="3" role="1,0"/></relation></document>
<document><id>37914226</id><passage><infon key="journal">BJGP Open;2023Nov01. doi:10.3399/BJGPO.2023.0143</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Faux-Nightingale A, Saunders B, Burton C, Chew-Graham CA, Somayajula G, Twohig H, Welsh V, </infon><offset>0</offset><text>Experiences and care needs of children with long Covid: a qualitative study.</text><annotation id="1"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="44" length="10"/><text>long Covid</text></annotation></passage><passage><infon key="type">abstract</infon><offset>77</offset><text>BACKGROUND: Long Covid, the patient-preferred term, describes symptoms persisting after an acute episode of Covid-19 infection. Symptoms in children and young people (CYP) can affect daily routine, with broader impacts on education, health-related quality of life, and social activities, which may have long term effects on health and wellbeing. AIM: To explore the lived experiences and care needs of CYP with Long Covid from the perspectives of CYP with Long Covid, their parents, and professionals associated with the care of children and families living with Long Covid. DESIGN &amp; SETTING: CYP and their parent/carer were invited for interview following participation in a cohort study, which recruited from a primary care setting. METHOD: Interviews were carried out with four CYP with Long Covid (all female, aged 10-17 years), three interviews included a parent. Two focus groups were conducted, which included seven professionals involved with care of CYP or Long Covid, from a range of disciplines. Interviews and focus groups were transcribed verbatim, and data analysed thematically using constant comparison techniques. RESULTS: The main themes presented are Living with Long Covid; Uncertainty surrounding Long Covid; and Seeking help for symptoms. CONCLUSIONS: Long Covid can severely impact the lives of CYP and their families. CYP and their families need to be listened to by professionals and have any uncertainties acknowledged. It is imperative that agencies working with them understand the condition, its impact, and are able to offer support where needed.</text><annotation id="12"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="89" length="10"/><text>Long Covid</text></annotation><annotation id="13"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="185" length="18"/><text>Covid-19 infection</text></annotation><annotation id="14"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="488" length="10"/><text>Long Covid</text></annotation><annotation id="15"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="533" length="10"/><text>Long Covid</text></annotation><annotation id="16"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="640" length="10"/><text>Long Covid</text></annotation><annotation id="17"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="867" length="10"/><text>Long Covid</text></annotation><annotation id="18"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="1043" length="10"/><text>Long Covid</text></annotation><annotation id="19"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="1259" length="10"/><text>Long Covid</text></annotation><annotation id="20"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="1295" length="10"/><text>Long Covid</text></annotation><annotation id="21"><infon key="identifier">MESH:D000094024</infon><infon key="type">Disease</infon><location offset="1351" length="10"/><text>Long Covid</text></annotation></passage></document>
<document><id>37914576</id><passage><infon key="journal">Trends Cell Biol;2023Oct30. doi:10.1016/j.tcb.2023.10.004</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">den Brave F, Schulte U, Fakler B, Pfanner N, Becker T, </infon><offset>0</offset><text>Mitochondrial complexome and import network.</text></passage><passage><infon key="type">abstract</infon><offset>45</offset><text>Mitochondria perform crucial functions in cellular metabolism, protein and lipid biogenesis, quality control, and signaling. The systematic analysis of protein complexes and interaction networks provided exciting insights into the structural and functional organization of mitochondria. Most mitochondrial proteins do not act as independent units, but are interconnected by stable or dynamic protein-protein interactions. Protein translocases are responsible for importing precursor proteins into mitochondria and form central elements of several protein interaction networks. These networks include molecular chaperones and quality control factors, metabolite channels and respiratory chain complexes, and membrane and organellar contact sites. Protein translocases link the distinct networks into an overarching network, the mitochondrial import network (MitimNet), to coordinate biogenesis, membrane organization and function of mitochondria.</text><annotation id="1"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="120" length="5"/><text>lipid</text></annotation></passage></document>
<document><id>37914926</id><passage><infon key="journal">Acta Diabetol;2023Nov02. doi:10.1007/s00592-023-02201-0</infon><infon key="year">2023</infon><infon key="article-id_pmc">5787541</infon><infon key="type">title</infon><infon key="authors">Demir &amp;#xd6;F, &amp;#x15e;ensoy N&amp;#xd6;, Akp&amp;#x131;nar E, Demir G, </infon><offset>0</offset><text>The stress hyperglycemic ratio can predict the no-reflow phenomenon following saphenous vein graft intervention in patients with acute coronary syndrome.</text><annotation id="3"><infon key="identifier">MESH:D006944</infon><infon key="type">Disease</infon><location offset="11" length="13"/><text>hyperglycemic</text></annotation><annotation id="4"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="47" length="20"/><text>no-reflow phenomenon</text></annotation><annotation id="5"><infon key="identifier">MESH:D054058</infon><infon key="type">Disease</infon><location offset="129" length="23"/><text>acute coronary syndrome</text></annotation></passage><passage><infon key="type">abstract</infon><offset>154</offset><text>AIMS: The no-reflow phenomenon (NRP) is a common complication of saphenous vein graft (SVG) interventions. The aim of this study was to investigate the effect of the stress hyperglycemia ratio (SHR) on the development of NRP in patients with acute coronary syndrome (ACS) undergoing percutaneous SVG intervention. METHODS: The study included 223 patients who presented at our center with ACS, had a history of coronary artery bypass graft and underwent a saphenous graft procedure. The relationship between SHR calculated at the time of presentation from glucose and HbA1c values, and the development of NRP evaluated after the procedure with angiography was determined with univariate and multivariate binary regression analysis. RESULT: The study population was separated into two groups as those who developed and did not develop NRP. Mean age was determined to be significantly higher in the group that did not develop NRP compared to the group with NRP (p: 0.004). Angiographically, the thrombus burden was determined to be significantly higher in the group that developed NRP (p &lt; 0.001). Patients were separated into 3 tertiles according to the SHR level (T1, T2, T3), and the rate of NRP development was determined at a significantly higher rate in the T3 group (p &lt; 0.001). CONCLUSIONS: This study showed that SHR, a parameter that can be easily calculated noninvasively, is an independent predictor of NRP development in ACS patients undergoing saphenous interventions. In addition, high thrombus burden and predilatation before stenting were also found to be factors that increase the likelihood of developing NRP.</text><annotation id="25"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="164" length="20"/><text>no-reflow phenomenon</text></annotation><annotation id="26"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="186" length="3"/><text>NRP</text></annotation><annotation id="27"><infon key="identifier">MESH:D006943</infon><infon key="type">Disease</infon><location offset="327" length="13"/><text>hyperglycemia</text></annotation><annotation id="28"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="375" length="3"/><text>NRP</text></annotation><annotation id="29"><infon key="identifier">MESH:D054058</infon><infon key="type">Disease</infon><location offset="396" length="23"/><text>acute coronary syndrome</text></annotation><annotation id="30"><infon key="identifier">MESH:D054058</infon><infon key="type">Disease</infon><location offset="421" length="3"/><text>ACS</text></annotation><annotation id="31"><infon key="identifier">MESH:D054058</infon><infon key="type">Disease</infon><location offset="542" length="3"/><text>ACS</text></annotation><annotation id="32"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="709" length="7"/><text>glucose</text></annotation><annotation id="33"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="758" length="3"/><text>NRP</text></annotation><annotation id="34"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="987" length="3"/><text>NRP</text></annotation><annotation id="35"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="1077" length="3"/><text>NRP</text></annotation><annotation id="36"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="1108" length="3"/><text>NRP</text></annotation><annotation id="37"><infon key="identifier">MESH:D013927</infon><infon key="type">Disease</infon><location offset="1146" length="8"/><text>thrombus</text></annotation><annotation id="38"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="1232" length="3"/><text>NRP</text></annotation><annotation id="39"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="1346" length="3"/><text>NRP</text></annotation><annotation id="40"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="1566" length="3"/><text>NRP</text></annotation><annotation id="41"><infon key="identifier">MESH:D054058</infon><infon key="type">Disease</infon><location offset="1585" length="3"/><text>ACS</text></annotation><annotation id="42"><infon key="identifier">MESH:D013927</infon><infon key="type">Disease</infon><location offset="1652" length="8"/><text>thrombus</text></annotation><annotation id="43"><infon key="identifier">MESH:D054318</infon><infon key="type">Disease</infon><location offset="1775" length="3"/><text>NRP</text></annotation></passage></document>
<document><id>37915278</id><passage><infon key="journal">Dent Traumatol;2023Nov01. doi:10.1111/edt.12904</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gugliotta Y, Roccia F, Sobrero F, Ramieri G, Volpe F, </infon><offset>0</offset><text>Changing trends in maxillofacial injuries among paediatric, adult and elderly populations: A 22-year statistical analysis of 3424 patients in a tertiary care centre in Northwest Italy.</text><annotation id="1"><infon key="identifier">MESH:D008446</infon><infon key="type">Disease</infon><location offset="19" length="22"/><text>maxillofacial injuries</text></annotation></passage><passage><infon key="type">abstract</infon><offset>185</offset><text>BACKGROUND: This retrospective study analysed the epidemiology of maxillofacial trauma over 22 years to assess whether there have been significant changes in the causes and characteristics of fractures in paediatric, adult and elderly populations. MATERIALS AND METHODS: The following data were collected: age, sex, injury cause and mechanism, fracture site, Facial Injury Severity Scale, associated injuries, time of injury, type of treatment and length of hospital stay. The patients were analysed by age group (children [&lt;=16 years], adults [17-60 years] and elderly [>60 years]) and divided into two time groups (group 1: 2001-2011; group 2: 2012-2022) that were compared to each other. Statistical analyses were performed using SPSS software. RESULTS: Between 01 January 2001 and 31 December 2022, 3535 patients (2690 males and 845 females, mean age 39.3 years) were admitted for facial fractures. The comparison of the two temporal periods showed a decrease in the prevalence of males (p = .02), in road traffic injuries (p &lt; .001), and in fractures of the lower third of the face (p = .005); there were significant increases in the mean age (p &lt; .001), prevalence of the elderly (p = .006) and in fall- and assault-related injuries (p &lt; .001 and p = .03, respectively). Assault injuries increased only in the 17-60 age group (p = .02) while RTA-related fractures decreased in all age groups (p &lt; .05 for all comparisons). Bicycle accidents increased significantly, with a parallel decrease in motor vehicle accidents (both p &lt; .001). Fall-related fractures increased only in 17-60 and >60 age groups (p &lt; .001 and p = .02, respectively). CONCLUSIONS: This study shows significant changing trends in the epidemiology of maxillofacial trauma. While road traffic policies have been effective in the last years, preventive measures for falls in the elderly population and new legislative measures to prevent interpersonal violence should be advocated.</text><annotation id="21"><infon key="identifier">MESH:D008446</infon><infon key="type">Disease</infon><location offset="251" length="20"/><text>maxillofacial trauma</text></annotation><annotation id="22"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="377" length="9"/><text>fractures</text></annotation><annotation id="23"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="501" length="6"/><text>injury</text></annotation><annotation id="24"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="529" length="8"/><text>fracture</text></annotation><annotation id="25"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="551" length="6"/><text>Injury</text></annotation><annotation id="26"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="585" length="8"/><text>injuries</text></annotation><annotation id="27"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="603" length="6"/><text>injury</text></annotation><annotation id="28"><infon key="identifier">MESH:D005153</infon><infon key="type">Disease</infon><location offset="1070" length="16"/><text>facial fractures</text></annotation><annotation id="29"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1190" length="21"/><text>road traffic injuries</text></annotation><annotation id="30"><infon key="identifier">MESH:C536384</infon><infon key="type">Disease</infon><location offset="1231" length="40"/><text>fractures of the lower third of the face</text></annotation><annotation id="31"><infon key="type">Disease</infon><location offset="1399" length="7"/><text>assault</text></annotation><annotation id="32"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1415" length="8"/><text>injuries</text></annotation><annotation id="33"><infon key="identifier">MESH:D014947</infon><infon key="type">Disease</infon><location offset="1462" length="16"/><text>Assault injuries</text></annotation><annotation id="34"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="1545" length="9"/><text>fractures</text></annotation><annotation id="35"><infon key="identifier">MESH:D000081084</infon><infon key="type">Disease</infon><location offset="1614" length="17"/><text>Bicycle accidents</text></annotation><annotation id="36"><infon key="identifier">MESH:C537863</infon><infon key="type">Disease</infon><location offset="1726" length="22"/><text>Fall-related fractures</text></annotation><annotation id="37"><infon key="identifier">MESH:D008446</infon><infon key="type">Disease</infon><location offset="1911" length="20"/><text>maxillofacial trauma</text></annotation><annotation id="38"><infon key="identifier">MESH:C537863</infon><infon key="type">Disease</infon><location offset="2024" length="5"/><text>falls</text></annotation><annotation id="39"><infon key="type">Disease</infon><location offset="2096" length="22"/><text>interpersonal violence</text></annotation></passage></document>
<document><id>37916328</id><passage><infon key="journal">Eur Rev Med Pharmacol Sci;2023Oct; 27 (20) 9628. doi:10.26355/eurrev_202310_34134</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Abu-Nawareg MM, Nassar HM, Sonbul HM, </infon><offset>0</offset><text>Enhancing bond stability: impact of adhesive thinning on resin-dentin bonded interfaces.</text></passage><passage><infon key="type">abstract</infon><offset>89</offset><text>OBJECTIVE: This study aimed to investigate the effect of adhesive thinning on resin-dentin-bonded interfaces created by two simplified adhesives. MATERIALS AND METHODS: Micro-tensile bond strengths and interfacial nanoleakage were evaluated within bonded dentin interfaces formed by Adper Single Bond 2 and Single Bond Universal after 24 hours and 6 months of water storage. The adhesives were subjected to three different techniques: air-thinning, brush-thinning, or application without thinning. Statistical analysis was performed using a multi-level analysis of variance followed by Bonferroni's post-hoc test, at a significance level of 0.05. RESULTS: Adper Single Bond 2 demonstrated the highest immediate microtensile bond strengths (43.5 +- 1.3 MPa) and the lowest immediate nanoleakage (49.8 +- 2.8%) when air-thinning was employed. Single Bond Universal exhibited the lowest nanoleakage (36.4 +- 1.8%) when air-thinning was used, although there was no significant difference in immediate bond strengths between air-thinning and brush-thinning approaches, which both showed higher values compared to the no-thinning approach. After 6 months of storage, a significant decrease in bond strengths and a significant increase in nanoleakage were observed across most groups (p &lt; 0.001). CONCLUSIONS: While all groups displayed varying degrees of instability over a 6-month storage period, air-thinning of simplified etch-and-rinse and self-etch adhesives proved to provide clinically acceptable bonded interfaces. The findings suggest that adhesive thinning techniques can play a vital role in enhancing bond stability and longevity in resin-dentin-bonded interfaces.</text><annotation id="1"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="449" length="5"/><text>water</text></annotation></passage></document>
<document><id>37916682</id><passage><infon key="journal">Food Funct;2023Nov02. doi:10.1039/d3fo03327a</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wei RR, Lin QY, Adu M, Huang HL, Yan ZH, Shao F, Zhong GY, Zhang ZL, Sang ZP, Cao L, Ma QG, </infon><offset>0</offset><text>The sources, properties, extraction, biosynthesis, pharmacology, and application of lycopene.</text><annotation id="1"><infon key="identifier">MESH:D000077276</infon><infon key="type">Chemical</infon><location offset="84" length="8"/><text>lycopene</text></annotation></passage><passage><infon key="type">abstract</infon><offset>94</offset><text>Lycopene is an important pigment with an alkene skeleton from Lycopersicon esculentum, which is also obtained from some red fruits and vegetables. Lycopene is used in the food field with rich functions and serves in the medical field with multiple clinical values because it has dual functions of both medicine and food. It was found that lycopene was mainly isolated by solvent extraction, ultrasonic-assisted extraction, supercritical fluid extraction, high-intensity pulsed electric field-assisted extraction, enzymatic-assisted extraction, and microwave-assisted extraction. Meanwhile, it was also obtained via 2 synthetic pathways: chemical synthesis and biosynthesis. Pharmacological studies revealed that lycopene has anti-oxidant, hypolipidemic, anti-cancer, immunity-enhancing, hepatoprotective, hypoglycemic, cardiovascular-protective, anti-inflammatory, neuroprotective, and osteoporosis-inhibiting effects. The application of lycopene mainly includes food processing, animal breeding, and medical cosmetology fields. It is hoped that this review will provide some useful information and guidance for future study and exploitation of lycopene.</text><annotation id="12"><infon key="identifier">MESH:D000077276</infon><infon key="type">Chemical</infon><location offset="94" length="8"/><text>Lycopene</text></annotation><annotation id="13"><infon key="identifier">MESH:D000475</infon><infon key="type">Chemical</infon><location offset="135" length="6"/><text>alkene</text></annotation><annotation id="14"><infon key="identifier">MESH:D000077276</infon><infon key="type">Chemical</infon><location offset="241" length="8"/><text>Lycopene</text></annotation><annotation id="15"><infon key="identifier">MESH:D000077276</infon><infon key="type">Chemical</infon><location offset="433" length="8"/><text>lycopene</text></annotation><annotation id="16"><infon key="identifier">MESH:D000077276</infon><infon key="type">Chemical</infon><location offset="806" length="8"/><text>lycopene</text></annotation><annotation id="17"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="853" length="6"/><text>cancer</text></annotation><annotation id="18"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="945" length="12"/><text>inflammatory</text></annotation><annotation id="19"><infon key="identifier">MESH:D010024</infon><infon key="type">Disease</infon><location offset="980" length="12"/><text>osteoporosis</text></annotation><annotation id="20"><infon key="identifier">MESH:D000077276</infon><infon key="type">Chemical</infon><location offset="1032" length="8"/><text>lycopene</text></annotation><annotation id="21"><infon key="identifier">MESH:D000077276</infon><infon key="type">Chemical</infon><location offset="1239" length="8"/><text>lycopene</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D000077276</infon><infon key="role2">Disease|MESH:D010024</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="5,8"/></relation><relation id="R2"><infon key="score">0.9985</infon><infon key="role1">Chemical|MESH:D000077276</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="5,6"/></relation><relation id="R3"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:D000077276</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="5,7"/></relation></document>
<document><id>37917036</id><passage><infon key="journal">J Nurs Scholarsh;2023Nov; 55 (6) 1116. doi:10.1111/jnu.12908</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wu WW, Lu FL, Tang CC, Chao FH, Yu TH, </infon><offset>0</offset><text>Pediatric palliative care utilization by decedent children: A nationwide population-based study, 2002-2017.</text><annotation id="1"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="21" length="4"/><text>care</text></annotation></passage><passage><infon key="type">abstract</infon><offset>108</offset><text>PURPOSE: This study aimed (1) to describe how trends in pediatric palliative care (PPC) utilization changed from 2002 to 2017, and (2) to examine factors predicting PPC utilization among decedent children in Taiwan. DESIGN: This retrospective, correlational study retrieved 2002-2017 data from three national claims databases in Taiwan. METHODS: Children aged 1 through 18 years who died between January 2002 and December 2017 were included. Pediatric palliative care utilization was defined as PPC enrollment and PPC duration, with enrollment described by frequency (n) and percentage (%) and duration described by mean and standard deviation (SD). Logistic regression was used to examine the associations of various demographic characteristics with PPC enrollment; generalized linear regression was used to examine associations of the demographic characteristics with PPC duration. FINDINGS: Across the 16-year study period, PPC enrollment increased sharply (15.49 times), while PPC duration decreased smoothly (by 29.41%). Cause of death was a continuous predictor of both PPC enrollment and PPC duration. The children less likely to be enrolled in PPC services were those aged 1 to 6 years, boys, living in poverty, living in rural areas, and diagnosed with life-threatening noncancer diseases. CONCLUSION: This study used nationwide databases to investigate PPC enrollment and PPC duration among a large sample of deceased children from 2002 to 2017. The findings not only delineate trends and predictors of PPC enrollment and PPC duration but also highlight great progress in PPC as well as the areas still understudied and underserved. This information could help the pediatric healthcare system achieve the core value of family-centered care for children with life-threatening diseases and their families. CLINICAL RELEVANCE: Pediatric palliative care should be widely and continuously implemented in routine pediatric clinical practice to enhance quality of life for children and their families at the end of life.</text><annotation id="25"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="185" length="4"/><text>care</text></annotation><annotation id="26"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="191" length="3"/><text>PPC</text></annotation><annotation id="27"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="273" length="3"/><text>PPC</text></annotation><annotation id="28"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="491" length="4"/><text>died</text></annotation><annotation id="29"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="571" length="4"/><text>care</text></annotation><annotation id="30"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="603" length="3"/><text>PPC</text></annotation><annotation id="31"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="622" length="3"/><text>PPC</text></annotation><annotation id="32"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="859" length="3"/><text>PPC</text></annotation><annotation id="33"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="978" length="3"/><text>PPC</text></annotation><annotation id="34"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1035" length="3"/><text>PPC</text></annotation><annotation id="35"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1089" length="3"/><text>PPC</text></annotation><annotation id="36"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="1143" length="5"/><text>death</text></annotation><annotation id="37"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1184" length="3"/><text>PPC</text></annotation><annotation id="38"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1203" length="3"/><text>PPC</text></annotation><annotation id="39"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1260" length="3"/><text>PPC</text></annotation><annotation id="40"><infon key="identifier">MESH:D004194</infon><infon key="type">Disease</infon><location offset="1387" length="18"/><text>noncancer diseases</text></annotation><annotation id="41"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1471" length="3"/><text>PPC</text></annotation><annotation id="42"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1490" length="3"/><text>PPC</text></annotation><annotation id="43"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1621" length="3"/><text>PPC</text></annotation><annotation id="44"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1640" length="3"/><text>PPC</text></annotation><annotation id="45"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1690" length="3"/><text>PPC</text></annotation><annotation id="46"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1853" length="4"/><text>care</text></annotation><annotation id="47"><infon key="identifier">MESH:D003428</infon><infon key="type">Disease</infon><location offset="1963" length="4"/><text>care</text></annotation></passage></document>
<document><id>37917386</id><passage><infon key="journal">Curr HIV/AIDS Rep;2023Nov02. doi:10.1007/s11904-023-00673-x</infon><infon key="year">2023</infon><infon key="article-id_pmc">9352102</infon><infon key="type">title</infon><infon key="authors">Young LE, Nan Y, Jang E, Stevens R, </infon><offset>0</offset><text>Digital Epidemiological Approaches in HIV Research: a Scoping Methodological Review.</text></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>PURPOSE OF REVIEW: The purpose of this scoping review was to summarize literature regarding the use of user-generated digital data collected for non-epidemiological purposes in human immunodeficiency virus (HIV) research. RECENT FINDINGS: Thirty-nine papers were included in the final review. Four types of digital data were used: social media data, web search queries, mobile phone data, and data from global positioning system (GPS) devices. With these data, four HIV epidemiological objectives were pursued, including disease surveillance, behavioral surveillance, assessment of public attention to HIV, and characterization of risk contexts. Approximately one-third used machine learning for classification, prediction, or topic modeling. Less than a quarter discussed the ethics of using user-generated data for epidemiological purposes. User-generated digital data can be used to monitor, predict, and contextualize HIV risk and can help disrupt trajectories of risk closer to onset. However, more attention needs to be paid to digital ethics and the direction of the field in a post-Application Programming Interface (API) world.</text></passage></document>
<document><id>37917737</id><passage><infon key="journal">PLoS One;2023; 18 (11) 0284415. doi:10.1371/journal.pone.0284415</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Armstrong E, Law CS, </infon><offset>0</offset><text>Resilience of Emiliania huxleyi to future changes in subantarctic waters.</text></passage><passage><infon key="type">abstract</infon><offset>74</offset><text>Lower pH and elevated temperature alter phytoplankton growth and biomass in short-term incubations, but longer-term responses and adaptation potential are less well-studied. To determine the future of the coccolithophore Emiliania huxleyi, a mixed genotype culture from subantarctic water was incubated for 720 days under present-day temperature and pH, and also projected future conditions by the year 2100. The future population exhibited a higher growth rate relative to present-day cells transferred to future conditions after 309 days, indicating adaptation or genotype selection; this was reflected by an increase in optimum growth temperature of ~2.5 C by the end of the experiment. Following transfer to opposing conditions in short-term cross-over incubations, cell volume responded rapidly, within eight generations, confirming trait plasticity. The changes in growth rate and cell volume were larger than reported in previous single stressor relationships and incubations, suggesting synergistic or additive effects of combined elevated temperature and lower pH and highlighting the importance of long-term multiple stressor experiments. At the end of the incubation there were no significant differences in cellular composition (particulate organic content and chlorophyll a), or primary production between present-day and future populations. Conversely, two independent methods showed a 50% decrease in both particulate inorganic carbon and calcification rate, consistent with the decrease in cell volume, in the future population. The observed plasticity and adaptive capacity of E. huxleyi indicate resilience to future conditions in subantarctic waters, although changes in cell volume and carbonate may alter grazing loss and cell ballast, so influencing carbon export to the deep ocean.</text><annotation id="5"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1347" length="13"/><text>chlorophyll a</text></annotation><annotation id="6"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1507" length="16"/><text>inorganic carbon</text></annotation><annotation id="7"><infon key="identifier">MESH:D002114</infon><infon key="type">Disease</infon><location offset="1528" length="13"/><text>calcification</text></annotation><annotation id="8"><infon key="identifier">MESH:D002254</infon><infon key="type">Chemical</infon><location offset="1780" length="9"/><text>carbonate</text></annotation><annotation id="9"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1846" length="6"/><text>carbon</text></annotation></passage><relation id="R1"><infon key="score">0.7989</infon><infon key="role1">Chemical|MESH:D002244</infon><infon key="role2">Chemical|MESH:D002254</infon><infon key="type">Association</infon><node refid="0" role="4,3"/></relation></document>
<document><id>37918088</id><passage><infon key="journal">J Vet Cardiol;2023Oct05; 50 23. doi:10.1016/j.jvc.2023.09.004</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Alessandrino K, Tjostheim SS, Flynn KM, Cole C, Aschenbroich S, </infon><offset>0</offset><text>Myocardial plasma cell tumor with intratumoral amyloidosis in a dog.</text><annotation id="2"><infon key="identifier">MESH:D010954</infon><infon key="type">Disease</infon><location offset="0" length="28"/><text>Myocardial plasma cell tumor</text></annotation><annotation id="3"><infon key="identifier">MESH:D000686</infon><infon key="type">Disease</infon><location offset="47" length="11"/><text>amyloidosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>69</offset><text>A 12-year-old mixed breed dog was evaluated for marked hypercalcemia that was identified during assessment for acute polydipsia and polyuria. Physical examination identified a new grade II/VI left apical systolic murmur. A mass involving the left ventricular posterior wall and left atrium was identified by echocardiography, suggesting neoplastic invasion into the myocardium. The patient was euthanized, and post-mortem cardiac evaluation identified an intramyocardial amyloid-producing plasma cell tumor. Multiple myeloma was suspected but could not be confirmed due to the limited post-mortem evaluation. This case is the first report of myocardial amyloidosis in a dog with a myeloma-related disorder (MRD). Dogs with MRD and myocardial involvement may not exhibit clinical signs that localize to the cardiovascular system; therefore, echocardiography should be considered during the staging process.</text><annotation id="16"><infon key="identifier">MESH:D006934</infon><infon key="type">Disease</infon><location offset="124" length="13"/><text>hypercalcemia</text></annotation><annotation id="17"><infon key="identifier">MESH:D059606</infon><infon key="type">Disease</infon><location offset="186" length="10"/><text>polydipsia</text></annotation><annotation id="18"><infon key="identifier">MESH:D011141</infon><infon key="type">Disease</infon><location offset="201" length="8"/><text>polyuria</text></annotation><annotation id="19"><infon key="identifier">MESH:D054160</infon><infon key="type">Disease</infon><location offset="273" length="15"/><text>systolic murmur</text></annotation><annotation id="20"><infon key="identifier">MESH:C000718787</infon><infon key="type">Disease</infon><location offset="540" length="7"/><text>amyloid</text></annotation><annotation id="21"><infon key="identifier">MESH:D010954</infon><infon key="type">Disease</infon><location offset="558" length="17"/><text>plasma cell tumor</text></annotation><annotation id="22"><infon key="identifier">MESH:D009101</infon><infon key="type">Disease</infon><location offset="577" length="16"/><text>Multiple myeloma</text></annotation><annotation id="23"><infon key="identifier">MESH:D000686</infon><infon key="type">Disease</infon><location offset="711" length="22"/><text>myocardial amyloidosis</text></annotation><annotation id="24"><infon key="identifier">MESH:D009101</infon><infon key="type">Disease</infon><location offset="750" length="24"/><text>myeloma-related disorder</text></annotation><annotation id="25"><infon key="identifier">MESH:D009101</infon><infon key="type">Disease</infon><location offset="776" length="3"/><text>MRD</text></annotation><annotation id="26"><infon key="identifier">MESH:D009101</infon><infon key="type">Disease</infon><location offset="792" length="3"/><text>MRD</text></annotation><annotation id="27"><infon key="identifier">MESH:C564676</infon><infon key="type">Disease</infon><location offset="800" length="22"/><text>myocardial involvement</text></annotation></passage></document>
<document><id>37918438</id><passage><infon key="journal">Bone Joint Res;2023Nov03; 12 (11) 691. doi:10.1302/2046-3758.1211.BJR-2023-0101.R1</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Dai Z, Chen Y, He E, Wang H, Guo W, Wu Z, Huang K, Zhao Q, </infon><offset>0</offset><text>Interleukin-19 promotes bone resorption by suppressing osteoprotegerin expression in BMSCs in a lipopolysaccharide-induced bone loss mouse model.</text><annotation id="5"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="0" length="14"/><text>Interleukin-19</text></annotation><annotation id="6"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="24" length="15"/><text>bone resorption</text></annotation><annotation id="7"><infon key="identifier">18383</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1912</infon><location offset="55" length="15"/><text>osteoprotegerin</text></annotation><annotation id="8"><infon key="identifier">MESH:D008070</infon><infon key="type">Chemical</infon><location offset="96" length="18"/><text>lipopolysaccharide</text></annotation><annotation id="9"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="123" length="9"/><text>bone loss</text></annotation></passage><passage><infon key="type">abstract</infon><offset>146</offset><text>Aims: Osteoporosis is characterized by decreased trabecular bone volume, and microarchitectural deterioration in the medullary cavity. Interleukin-19 (IL-19), a member of the IL-10 family, is an anti-inflammatory cytokine produced primarily by macrophages. The aim of our study was to investigate the effect of IL-19 on osteoporosis. Methods: Blood and femoral bone marrow suspension IL-19 levels were first measured in the lipopolysaccharide (LPS)-induced bone loss model. Small interfering RNA (siRNA) was applied to knock down IL-19 for further validation. Thereafter, osteoclast production was stimulated with IL-19 in combination with mouse macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-kappaB ligand (RANKL). The effect of IL-19 was subsequently evaluated using tartrate-resistant acid phosphatase (TRAP) staining and quantitative real-time polymerase chain reaction (RT-qPCR). The effect of IL-19 on osteoprotegerin (OPG) was then assessed using in vitro recombinant IL-19 treatment of primary osteoblasts and MLO-Y4 osteoblast cell line. Finally, transient transfection experiments and chromatin immunoprecipitation (ChIP) experiments were used to examine the exact mechanism of action. Results: In the LPS-induced bone loss mouse model, the levels of IL-19 in peripheral blood serum and femoral bone marrow suspension were significantly increased. The in vivo results indicated that global IL-19 deletion had no significant effect on RANKL content in the serum and bone marrow, but could increase the content of OPG in serum and femoral bone marrow, suggesting that IL-19 inhibits OPG expression in bone marrow mesenchymal stem cells (BMSCs) and thus increases bone resorption. Conclusion: IL-19 promotes bone resorption by suppressing OPG expression in BMSCs in a LPS-induced bone loss mouse model, which highlights the potential benefits and side effects of IL-19 for future clinical applications.</text><annotation id="48"><infon key="identifier">MESH:D010024</infon><infon key="type">Disease</infon><location offset="152" length="12"/><text>Osteoporosis</text></annotation><annotation id="49"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="281" length="14"/><text>Interleukin-19</text></annotation><annotation id="50"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="297" length="5"/><text>IL-19</text></annotation><annotation id="51"><infon key="identifier">16153</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">478</infon><location offset="321" length="5"/><text>IL-10</text></annotation><annotation id="52"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="346" length="12"/><text>inflammatory</text></annotation><annotation id="53"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="457" length="5"/><text>IL-19</text></annotation><annotation id="54"><infon key="identifier">MESH:D010024</infon><infon key="type">Disease</infon><location offset="466" length="12"/><text>osteoporosis</text></annotation><annotation id="55"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="530" length="5"/><text>IL-19</text></annotation><annotation id="56"><infon key="identifier">MESH:D008070</infon><infon key="type">Chemical</infon><location offset="570" length="18"/><text>lipopolysaccharide</text></annotation><annotation id="57"><infon key="identifier">MESH:D008070</infon><infon key="type">Chemical</infon><location offset="590" length="3"/><text>LPS</text></annotation><annotation id="58"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="603" length="9"/><text>bone loss</text></annotation><annotation id="59"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="676" length="5"/><text>IL-19</text></annotation><annotation id="60"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="760" length="5"/><text>IL-19</text></annotation><annotation id="61"><infon key="identifier">21943</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2744</infon><location offset="841" length="50"/><text>receptor activator of nuclear factor-kappaB ligand</text></annotation><annotation id="62"><infon key="identifier">21943</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2744</infon><location offset="893" length="5"/><text>RANKL</text></annotation><annotation id="63"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="915" length="5"/><text>IL-19</text></annotation><annotation id="64"><infon key="identifier">11433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">137203</infon><location offset="954" length="35"/><text>tartrate-resistant acid phosphatase</text></annotation><annotation id="65"><infon key="identifier">11433</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">137203</infon><location offset="991" length="4"/><text>TRAP</text></annotation><annotation id="66"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="1084" length="5"/><text>IL-19</text></annotation><annotation id="67"><infon key="identifier">18383</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1912</infon><location offset="1093" length="15"/><text>osteoprotegerin</text></annotation><annotation id="68"><infon key="identifier">18383</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1912</infon><location offset="1110" length="3"/><text>OPG</text></annotation><annotation id="69"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="1160" length="5"/><text>IL-19</text></annotation><annotation id="70"><infon key="identifier">CVCL:M098</infon><infon key="type">CellLine</infon><location offset="1203" length="6"/><text>MLO-Y4</text></annotation><annotation id="71"><infon key="identifier">MESH:D008070</infon><infon key="type">Chemical</infon><location offset="1397" length="3"/><text>LPS</text></annotation><annotation id="72"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="1409" length="9"/><text>bone loss</text></annotation><annotation id="73"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="1446" length="5"/><text>IL-19</text></annotation><annotation id="74"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="1585" length="5"/><text>IL-19</text></annotation><annotation id="75"><infon key="identifier">21943</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2744</infon><location offset="1629" length="5"/><text>RANKL</text></annotation><annotation id="76"><infon key="identifier">18383</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1912</infon><location offset="1707" length="3"/><text>OPG</text></annotation><annotation id="77"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="1761" length="5"/><text>IL-19</text></annotation><annotation id="78"><infon key="identifier">18383</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1912</infon><location offset="1776" length="3"/><text>OPG</text></annotation><annotation id="79"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="1856" length="15"/><text>bone resorption</text></annotation><annotation id="80"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="1885" length="5"/><text>IL-19</text></annotation><annotation id="81"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="1900" length="15"/><text>bone resorption</text></annotation><annotation id="82"><infon key="identifier">18383</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1912</infon><location offset="1931" length="3"/><text>OPG</text></annotation><annotation id="83"><infon key="identifier">MESH:D008070</infon><infon key="type">Chemical</infon><location offset="1960" length="3"/><text>LPS</text></annotation><annotation id="84"><infon key="identifier">MESH:D001847</infon><infon key="type">Disease</infon><location offset="1972" length="9"/><text>bone loss</text></annotation><annotation id="85"><infon key="identifier">329244</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">17813</infon><location offset="2055" length="5"/><text>IL-19</text></annotation></passage><relation id="R1"><infon key="score">0.8641</infon><infon key="role1">Disease|MESH:D001847</infon><infon key="role2">Gene|18383</infon><infon key="type">Association</infon><node refid="0" role="4,2"/></relation><relation id="R2"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:D008070</infon><infon key="role2">Gene|329244</infon><infon key="type">Association</infon><node refid="1" role="3,0"/></relation><relation id="R3"><infon key="score">0.999</infon><infon key="role1">Disease|MESH:D001862</infon><infon key="role2">Gene|329244</infon><infon key="type">Association</infon><node refid="2" role="1,0"/></relation><relation id="R4"><infon key="score">0.8988</infon><infon key="role1">Gene|21943</infon><infon key="role2">Gene|329244</infon><infon key="type">Association</infon><node refid="3" role="18,17"/></relation><relation id="R5"><infon key="score">0.9923</infon><infon key="role1">Gene|18383</infon><infon key="role2">Gene|329244</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="2,0"/></relation><relation id="R6"><infon key="score">0.9988</infon><infon key="role1">Disease|MESH:D001862</infon><infon key="role2">Gene|18383</infon><infon key="type">Association</infon><node refid="5" role="1,2"/></relation><relation id="R7"><infon key="score">0.9991</infon><infon key="role1">Disease|MESH:D010024</infon><infon key="role2">Gene|329244</infon><infon key="type">Association</infon><node refid="6" role="11,10"/></relation><relation id="R8"><infon key="score">0.9964</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|329244</infon><infon key="type">Negative_Correlation</infon><node refid="7" role="9,6"/></relation><relation id="R9"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D008070</infon><infon key="role2">Disease|MESH:D001847</infon><infon key="type">Positive_Correlation</infon><node refid="8" role="3,4"/></relation></document>
<document><id>37918788</id><passage><infon key="journal">J Glob Antimicrob Resist;2023Oct31. doi:10.1016/j.jgar.2023.10.020</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang L, Qiu Y, Fu Y, Li Y, </infon><offset>0</offset><text>Characterization of a novel blaNDM-1-harbouring transposon coexisting with tmexCD2-toprJ2 in an Aeromonas caviae isolate.</text></passage><passage><infon key="type">abstract</infon><offset>122</offset></passage></document>
<document><id>37919138</id><passage><infon key="journal">Transplant Rev (Orlando);2023Oct26 100803. doi:10.1016/j.trre.2023.100803</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Moorlock G, Asgari E, Callaghan C, Draper H, Dupont P, Gilbert P, Nasralla D, Veitch P, Watson C, O'Neill S, </infon><offset>0</offset><text>The British Transplantation Society guidelines on ethics, law and consent in relation to deceased donors after circulatory death.</text><annotation id="1"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="123" length="5"/><text>death</text></annotation></passage><passage><infon key="type">abstract</infon><offset>130</offset><text>The British Transplantation Society (BTS) 'Guideline on transplantation from deceased donors after circulatory death' has recently been updated and this manuscript summarises the relevant recommendations from chapters specifically related to law, ethics, donor consent and informing the recipient.</text><annotation id="3"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="241" length="5"/><text>death</text></annotation></passage></document>
<document><id>37919488</id><passage><infon key="journal">Indian J Pediatr;2023Nov03. doi:10.1007/s12098-023-04899-w</infon><infon key="year">2023</infon><infon key="article-id_pmc">6477149</infon><infon key="type">title</infon><infon key="authors">Kainth D, Chandra P, Singhal A, Verma A, Sankar MJ, Agarwal R, Thukral A, </infon><offset>0</offset><text>Feeding Outcomes in Preterm Neonates with Antenatal Abnormal Umbilical Artery Doppler Profile: A Retrospective Cohort Study.</text></passage><passage><infon key="type">abstract</infon><offset>125</offset><text>Neonates with absent-or-reversed umbilical artery end-diastolic flow (AREDF) are at an increased risk of feeding problems. In this retrospective study, authors evaluated the incidence of feed intolerance in 213 preterm neonates (January 2017-May 2022) with AREDF. The median (IQR) gestation and birth weight were 32 (30, 33) wk and 1120 (840, 1425) g, respectively. Of 213 neonates, 103 (48.4%; 95% CI 41.5%, 55.3%) neonates developed feed intolerance. Twelve of 213 neonates developed any stage necrotizing enterocolitis (NEC) (5.6%; 95% CI 2.9%, 9.6%) at a median age of 10 d. On multivariate regression, gestation was the only independent predictor of feed intolerance (OR 1.48; 95% CI 1.28, 1.70; for every 1 wk decrease below 36 wk). Almost 50% of preterm neonates with AREDF develop feed intolerance. Alternative feeding strategies warrant exploration to optimise nutrition in these neonates.</text><annotation id="6"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="312" length="16"/><text>feed intolerance</text></annotation><annotation id="7"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="560" length="16"/><text>feed intolerance</text></annotation><annotation id="8"><infon key="identifier">MESH:D020345</infon><infon key="type">Disease</infon><location offset="621" length="25"/><text>necrotizing enterocolitis</text></annotation><annotation id="9"><infon key="identifier">MESH:D020345</infon><infon key="type">Disease</infon><location offset="648" length="3"/><text>NEC</text></annotation><annotation id="10"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="780" length="16"/><text>feed intolerance</text></annotation><annotation id="11"><infon key="identifier">MESH:D001068</infon><infon key="type">Disease</infon><location offset="914" length="16"/><text>feed intolerance</text></annotation></passage></document>
<document><id>37919838</id><passage><infon key="journal">Arch Insect Biochem Physiol;2023Nov02 22060. doi:10.1002/arch.22060</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li SY, Yao Y, Sun L, Ling HN, Jin WD, Lin XL, </infon><offset>0</offset><text>DNA barcodes and morphology reveal new species within the Rheotanytarsus guineensis species group from China (Diptera: Chironomidae).</text></passage><passage><infon key="type">abstract</infon><offset>134</offset><text>The Rheotanytarsus guineensis species group (Diptera: Chironomidae) is a species diverse and taxonomically difficult group. Using DNA barcodes, we found five new species within the R. guineensis species group and reviewed the species group based on adult males from China. Rheotanytarsus guoae Lin &amp; Yao sp. n., Rheotanytarsus miaoae Lin &amp; Yao sp. n., Rheotanytarsus qiangi Lin &amp; Yao sp. n., Rheotanytarsus yueqingensis Lin &amp; Yao sp. n., and Rheotanytarsus yui Lin &amp; Yao sp. n. are all described and figured. A key to known adult males of the R. guineensis species group worldwide is provided for the first time.</text></passage></document>
<document><id>37920188</id><passage><infon key="journal">Afr J Health Sci;2021Aug11; 34 (3) 364</infon><infon key="year">2021</infon><infon key="article-id_pmc">PMC10621471</infon><infon key="type">title</infon><infon key="authors">Kissel A, Gebreyohanns M, Chahrour MH, </infon><offset>0</offset><text>A Brief Survey of Medical Practitioner Knowledge and Attitudes Regarding Autism Spectrum Disorder in Bahir Dar, Ethiopia.</text><annotation id="1"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="73" length="24"/><text>Autism Spectrum Disorder</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>BACKGROUND: Autism spectrum disorder (ASD) continues to climb in prevalence worldwide. Developed nations have focused on aligning their medical and research communities in order to investigate the mechanisms of pathogenesis, diagnosis, and societal impact of this disorder. A simultaneous rise of ASD has impacted developing nations, such as Ethiopia, without a commensurate ability to research the knowledge, beliefs, resources, and training regarding this condition in the country. MATERIALS AND METHODS: We administered a brief survey during a medical conference in Bahir Dar, Ethiopia, to investigate some of the education, information, and experiences with ASD within a small sample of medical and mental health providers in Ethiopia. RESULTS: The data provided insight into the following areas pertaining to ASD in Ethiopia: perceived causes, knowledge, training, and areas of need. CONCLUSIONS: Understanding local beliefs for causes and cures, as well as gaining indigenous opinions regarding what is needed for ASD education and resources in their nation, is the first step towards understanding the impact of this disorder and the approach to its treatment in Ethiopia.</text><annotation id="8"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="134" length="24"/><text>Autism spectrum disorder</text></annotation><annotation id="9"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="160" length="3"/><text>ASD</text></annotation><annotation id="10"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="419" length="3"/><text>ASD</text></annotation><annotation id="11"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="784" length="3"/><text>ASD</text></annotation><annotation id="12"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="936" length="3"/><text>ASD</text></annotation><annotation id="13"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="1142" length="3"/><text>ASD</text></annotation></passage></document>
<document><id>37920888</id><passage><infon key="journal">J Chem Inf Model;2023Nov03. doi:10.1021/acs.jcim.3c01238</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang T, Wang W, Jiang X, Mao J, Zhuo L, Liu M, Fu X, Yao X, </infon><offset>0</offset><text>ML-NPI: Predicting Interactions between Noncoding RNA and Protein Based on Meta-Learning in a Large-Scale Dynamic Graph.</text></passage><passage><infon key="type">abstract</infon><offset>121</offset><text>Deep learning methods can accurately study noncoding RNA protein interactions (NPI), which is of great significance in gene regulation, human disease, and other fields. However, the computational method for predicting NPI in large-scale dynamic ncRNA protein bipartite graphs is rarely discussed, which is an online modeling and prediction problem. In addition, the results published by researchers on the Web site cannot meet real-time needs due to the large amount of basic data and long update cycles. Therefore, we propose a real-time method based on the dynamic ncRNA-protein bipartite graph learning framework, termed ML-GNN, which can model and predict the NPIs in real time. Our proposed method has the following advantages: first, the meta-learning strategy can alleviate the problem of large prediction errors in sparse neighborhood samples; second, dynamic modeling of newly added data can reduce computational pressure and predict NPIs in real-time. In the experiment, we built a dynamic bipartite graph based on 300000 NPIs from the NPInterv4.0 database. The experimental results indicate that our model achieved excellent performance in multiple experiments. The code for the model is available at https://github.com/taowang11/ML-NPI, and the data can be downloaded freely at http://bigdata.ibp.ac.cn/npinter4.</text></passage></document>
<document><id>37921238</id><passage><infon key="journal">Neurourol Urodyn;2023Nov03. doi:10.1002/nau.25319</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gammie A, Arlandis S, Couri BM, Drinnan M, Carolina Ochoa D, Rantell A, de Rijk M, van Steenbergen T, Damaser M, </infon><offset>0</offset><text>Can we use machine learning to improve the interpretation and application of urodynamic data?: International Consultation on Incontinence-Research Society 2023.</text></passage><passage><infon key="type">abstract</infon><offset>161</offset><text>INTRODUCTION: A "Think Tank" at the International Consultation on Incontinence-Research Society meeting held in Bristol, United Kingdom in June 2023 considered the progress and promise of machine learning (ML) applied to urodynamic data. METHODS: Examples of the use of ML applied to data from uroflowmetry, pressure flow studies and imaging were presented. The advantages and limitations of ML were considered. Recommendations made during the subsequent debate for research studies were recorded. RESULTS: ML analysis holds great promise for the kind of data generated in urodynamic studies. To date, ML techniques have not yet achieved sufficient accuracy for routine diagnostic application. Potential approaches that can improve the use of ML were agreed and research questions were proposed. CONCLUSIONS: ML is well suited to the analysis of urodynamic data, but results to date have not achieved clinical utility. It is considered likely that further research can improve the analysis of the large, multifactorial data sets generated by urodynamic clinics, and improve to some extent data pattern recognition that is currently subject to observer error and artefactual noise.</text></passage></document>
<document><id>37921588</id><passage><infon key="journal">J Am Chem Soc;2023Nov03. doi:10.1021/jacs.3c05940</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Samudrala KK, Conley MP, </infon><offset>0</offset><text>A Supported Ziegler-Type Organohafnium Site Metabolizes Polypropylene.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="25" length="13"/><text>Organohafnium</text></annotation><annotation id="3"><infon key="identifier">MESH:D011126</infon><infon key="type">Chemical</infon><location offset="56" length="13"/><text>Polypropylene</text></annotation></passage><passage><infon key="type">abstract</infon><offset>71</offset><text>Cp2Hf(CH3)2 reacts with silica containing strong aluminum Lewis sites to form Cp2Hf-13CH3+ paired with aluminate anions. Solid-state NMR studies show that this reaction also forms neutral organohafnium and hafnium sites lacking methyl groups. Cp2Hf-13CH3+ reacts with isotatic polypropylene (iPP, Mn = 13.3 kDa; D = 2.4; mmmm = 94%; ~110 C3H6/Hf) and H2 to form oils with moderate molecular weights (Mn = 290-1200 Da) in good yields. The aliphatic oils show characteristic 13C{1H} NMR properties consistent with complete loss of diastereoselectivity and formation of regioirregular errors under 1 atm H2. These results show that a Ziegler-Natta-type active site is compatible in a common reaction used to digest waste plastic into smaller aliphatic fragments.</text><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="71" length="11"/><text>Cp2Hf(CH3)2</text></annotation><annotation id="24"><infon key="identifier">MESH:D012822</infon><infon key="type">Chemical</infon><location offset="95" length="6"/><text>silica</text></annotation><annotation id="25"><infon key="identifier">MESH:D000535</infon><infon key="type">Chemical</infon><location offset="120" length="8"/><text>aluminum</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="149" length="12"/><text>Cp2Hf-13CH3+</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="174" length="9"/><text>aluminate</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="259" length="13"/><text>organohafnium</text></annotation><annotation id="29"><infon key="identifier">MESH:D006195</infon><infon key="type">Chemical</infon><location offset="277" length="7"/><text>hafnium</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="314" length="12"/><text>Cp2Hf-13CH3+</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="339" length="22"/><text>isotatic polypropylene</text></annotation><annotation id="32"><infon key="identifier">MESH:C041272</infon><infon key="type">Chemical</infon><location offset="363" length="3"/><text>iPP</text></annotation><annotation id="33"><infon key="identifier">MESH:D003903</infon><infon key="type">Chemical</infon><location offset="383" length="1"/><text>D</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="409" length="4"/><text>C3H6</text></annotation><annotation id="35"><infon key="identifier">MESH:D006195</infon><infon key="type">Chemical</infon><location offset="414" length="2"/><text>Hf</text></annotation><annotation id="36"><infon key="identifier">MESH:D003903</infon><infon key="type">Chemical</infon><location offset="422" length="2"/><text>H2</text></annotation><annotation id="37"><infon key="identifier">MESH:D009821</infon><infon key="type">Chemical</infon><location offset="433" length="4"/><text>oils</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="509" length="14"/><text>aliphatic oils</text></annotation><annotation id="39"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="544" length="6"/><text>13C{1H</text></annotation><annotation id="40"><infon key="identifier">MESH:D003903</infon><infon key="type">Chemical</infon><location offset="672" length="2"/><text>H2</text></annotation><annotation id="41"><infon key="identifier">MESH:D010969</infon><infon key="type">Chemical</infon><location offset="789" length="7"/><text>plastic</text></annotation></passage><relation id="R1"><infon key="score">0.4335</infon><infon key="role1">Chemical|MESH:D003903</infon><infon key="role2">Chemical|MESH:D009821</infon><infon key="type">Association</infon><node refid="0" role="13,17"/></relation></document>
<document><id>37890062</id><passage><infon key="journal">R I Med J (2013);2023Nov01; 106 (10) 34</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Adewusi A, Moore JL, Clark MA, Rosen RK, Barron CE, Goldberg AP, </infon><offset>0</offset><text>Female Caregivers' Perception of their Child's Sexualized Behaviors: A Pilot Study at a Child Protection Clinic.</text></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>This pilot study explored female caregiver's perception of their child's behaviors during sexual abuse evaluations. We compared reports by caregivers with histories of their own child sexual abuse (PCSA) to caregivers with no prior history of child sexual abuse (NPCSA) regarding their 1) child's sexualized behaviors and (2) perceptions of whether their child had been sexually abused. Forty-four caregivers met inclusion criteria. Ninety-five percent of PCSA caregivers versus 21% of NPCSA caregivers reported at least one behavior from the Child Sexual Behavior Inventory. Our findings identified that PCSA caregivers reported more sexualized behaviors for their children overall, potentially contributing to their perception that their child had been sexually abused. This pilot study demonstrated that caregivers were able to tolerate answering questions about their own history of child abuse. Parents should be asked these questions as this may influence perceptions of their child's behaviors and possible sexual abuse.</text><annotation id="8"><infon key="identifier">MESH:D000082002</infon><infon key="type">Disease</infon><location offset="203" length="12"/><text>sexual abuse</text></annotation><annotation id="9"><infon key="type">Disease</infon><location offset="311" length="4"/><text>PCSA</text></annotation><annotation id="10"><infon key="identifier">MESH:D000082002</infon><infon key="type">Disease</infon><location offset="483" length="15"/><text>sexually abused</text></annotation><annotation id="11"><infon key="type">Disease</infon><location offset="569" length="4"/><text>PCSA</text></annotation><annotation id="12"><infon key="type">Disease</infon><location offset="718" length="4"/><text>PCSA</text></annotation><annotation id="13"><infon key="identifier">MESH:D000082002</infon><infon key="type">Disease</infon><location offset="868" length="15"/><text>sexually abused</text></annotation><annotation id="14"><infon key="identifier">MESH:C535569</infon><infon key="type">Disease</infon><location offset="1000" length="11"/><text>child abuse</text></annotation><annotation id="15"><infon key="identifier">MESH:D000082002</infon><infon key="type">Disease</infon><location offset="1127" length="12"/><text>sexual abuse</text></annotation></passage></document>
<document><id>37890412</id><passage><infon key="journal">Indian J Med Microbiol;2023Oct25; 47 100490. doi:10.1016/j.ijmmb.2023.100490</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">KhyatiManchanda V, Pumma P, Chawla R, Garg S, Saxena S, </infon><offset>0</offset><text>Diagnostic performance of saliva RT-PCR test as a diagnostic tool and its utility in the detection of SARS-CoV-2 shedding with different patient characteristics: Prospective observational study.</text></passage><passage><infon key="type">abstract</infon><offset>195</offset><text>BACKGROUND: Salivary shedding of SARS-CoV-2 is a known entity and its role has been established in transmission of the disease. The present study was performed to evaluate the duration of viral shedding in saliva in COVID-19 patients and its variation among symptomatic and asymptomatic patients with or without co-morbidities. METHODS: The present prospective observational study was conducted at the COVID-19 care hospital associated with primary to tertiary care in New Delhi, India. A total of 124 COVID-19 confirmed cases enrolled in two phases (January-March 2021; April-June 2021) who consented for 48hrly saliva and nasopharyngeal swab (NPS) specimens till discharge from the hospital for SARS-CoV-2 detection were included. The specimens obtained were tested for SARS-CoV-2 by Real-Time PCR. RESULTS: The sensitivity and the specificity of RT-PCR on saliva were 81.7 % and 85.0 %, respectively. The sensitivity of saliva-based PCR was comparable in symptomatic and asymptomatic patients (81.6 % vs 82.1 %). The sensitivity of saliva-based PCR markedly increased in the second phase of enrollment as compared to the first phase (92.6 % vs 78.5 %) indicating higher level of salivary shedding by the delta variant of SARS-CoV-2. The sensitivity of PCR on saliva was the highest up to day seven of illness. The median duration of RNA shedding in saliva was comparable among the symptomatic and asymptomatic patients. The severity of the disease was not associated with the duration of SARS-CoV-2 shedding in saliva. CONCLUSIONS: SARS-CoV-2 shedding in saliva continued till seven days in large number of patients including asymptomatic patients. Saliva is non-inferior to NPS specimen in the diagnosis of SARS-CoV-2. Saliva specimen is recommended as a good alternate to NPS for SARS-CoV-2 testing.</text><annotation id="3"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="411" length="8"/><text>COVID-19</text></annotation><annotation id="4"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="597" length="8"/><text>COVID-19</text></annotation><annotation id="5"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="697" length="8"/><text>COVID-19</text></annotation></passage></document>
<document><id>37890762</id><passage><infon key="journal">Food Chem Toxicol;2023Oct25; 182 114108. doi:10.1016/j.fct.2023.114108</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Overdahl KE, Tighe RM, Stapleton HM, Ferguson PL, </infon><offset>0</offset><text>Investigating sensitization activity of azobenzene disperse dyes via the Direct Peptide Reactivity Assay (DPRA).</text><annotation id="1"><infon key="identifier">MESH:C009850</infon><infon key="type">Chemical</infon><location offset="40" length="10"/><text>azobenzene</text></annotation></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>Azobenzene disperse dyes are the fastest-growing category of commercial dyestuffs and have been found in indoor house dust and in children's polyester apparel. Azobenzene disperse dyes are implicated as potentially allergenic; however, little experimental data is available on allergenicity of these dyes. Here, we examine the binding of azobenzene disperse dyes to nucleophilic peptide residues as a proxy for their potential reactivity as electrophilic allergenic sensitizers. The Direct Peptide Reactivity Assay (DPRA) was utilized via both a spectrophotometric method and a high-performance liquid chromatography (HPLC) method. We tested dyes purified from commercial dyestuffs as well as several known transformation products. All dyes were found to react with nucleophilic peptides in a dose-dependent manner with pseudo-first order kinetics (rate constants as high as 0.04 h-1). Rates of binding reactivity were also found to correlate to electrophilic properties of dyes as measured by Hammett constants and electrophilicity indices. Reactivities of polyester shirt extracts were also tested for DPRA activity and the shirt extracts with high measured abundances of azobenzene disperse dyes were observed to induce greater peptide reactivity. Results suggest that azobenzene disperse dyes may function as immune sensitizers, and that clothing containing these dyes may pose risks for skin sensitization.</text><annotation id="10"><infon key="identifier">MESH:C009850</infon><infon key="type">Chemical</infon><location offset="113" length="10"/><text>Azobenzene</text></annotation><annotation id="11"><infon key="identifier">MESH:C009850</infon><infon key="type">Chemical</infon><location offset="273" length="10"/><text>Azobenzene</text></annotation><annotation id="12"><infon key="identifier">MESH:C009850</infon><infon key="type">Chemical</infon><location offset="451" length="10"/><text>azobenzene</text></annotation><annotation id="13"><infon key="identifier">MESH:D010455</infon><infon key="type">Chemical</infon><location offset="892" length="8"/><text>peptides</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1171" length="15"/><text>polyester shirt</text></annotation><annotation id="15"><infon key="identifier">MESH:C009850</infon><infon key="type">Chemical</infon><location offset="1287" length="10"/><text>azobenzene</text></annotation><annotation id="16"><infon key="identifier">MESH:C009850</infon><infon key="type">Chemical</infon><location offset="1385" length="10"/><text>azobenzene</text></annotation><annotation id="17"><infon key="identifier">MESH:D012871</infon><infon key="type">Disease</infon><location offset="1505" length="18"/><text>skin sensitization</text></annotation></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:C009850</infon><infon key="role2">Disease|MESH:D012871</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="7,8"/></relation></document>
<document><id>37891113</id><passage><infon key="journal">Asian J Surg;2023Oct26. doi:10.1016/j.asjsur.2023.10.010</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Huang X, </infon><offset>0</offset><text>The "Hands" teaching method applied to illustrate the surgical approach of rectal cancer surgery.</text><annotation id="1"><infon key="identifier">MESH:D012004</infon><infon key="type">Disease</infon><location offset="75" length="13"/><text>rectal cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>98</offset></passage></document>
<document><id>37897073</id><passage><infon key="journal">Mycoses;2023Oct27. doi:10.1111/myc.13671</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Liu YY, Song Y, Guan MQ, Yang L, Chen RL, Shi Y, Cui Y, Li SS, </infon><offset>0</offset><text>Hyperthermia is a Promising Potential Adjunct to Treating Sporotrichosis: A Refractory Case of HIV Sporotrichosis and In Vitro Experiments on Sporothrix spp.</text><annotation id="3"><infon key="identifier">MESH:D005334</infon><infon key="type">Disease</infon><location offset="0" length="12"/><text>Hyperthermia</text></annotation><annotation id="4"><infon key="identifier">MESH:D013174</infon><infon key="type">Disease</infon><location offset="58" length="14"/><text>Sporotrichosis</text></annotation><annotation id="5"><infon key="identifier">MESH:D013174</infon><infon key="type">Disease</infon><location offset="99" length="14"/><text>Sporotrichosis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>158</offset><text>BACKGROUND: Hyperthermia is a common monotherapy for sporotrichosis, but only in patients with special conditions, such as pregnancy and nursing. However, hyperthermia has not been used more widely for sporotrichosis in clinical practice. PATIENTS/METHODS: An HIV-positive adult male with lymphocutaneous sporotrichosis caused by Sporothrix globosa that did not respond to conventional itraconazole therapy lasting > 2 months received adjunctive therapy with local hyperthermia. To simulate the effects of heat exposure on growth and morphology of Sporothrix spp. in vitro, S. globosa, S. schenckii, and S. brasiliensis were exposed to intermittent heat (42 C) for 1 hour a day for 7 or 28 days and observed under transmission electron microscopy. RESULTS: Itraconazole combined with local hyperthermia significantly improved the lesions, and the patient was successfully cured of sporotrichosis, with no recurrence after 2 years of follow-up. Cultures of Sporothrix spp. treated with 7 days of daily heat exposure in vitro showed obvious decreases in colony diameters, but not numbers, compared with untreated cultures (p &lt; 0.001). After 28 days of heat exposure in vitro, Sporothrix spp. were unable to thrive (p &lt; 0.001), and ultrastructural alterations, including loose cell wall structure, incomplete cell membrane, disrupted vacuoles, and fragmented nuclei, were noticeable. CONCLUSIONS: Our case findings and in vitro experiments on Sporothrix spp., together with a literature review of previous sporotrichosis cases, suggest that hyperthermia has a clinical role as a treatment adjunct. Large-scale clinical trials are required to examine the utility of hyperthermia in various forms of cutaneous sporotrichosis.</text><annotation id="20"><infon key="identifier">MESH:D005334</infon><infon key="type">Disease</infon><location offset="170" length="12"/><text>Hyperthermia</text></annotation><annotation id="21"><infon key="identifier">MESH:D013174</infon><infon key="type">Disease</infon><location offset="211" length="14"/><text>sporotrichosis</text></annotation><annotation id="22"><infon key="identifier">MESH:D005334</infon><infon key="type">Disease</infon><location offset="313" length="12"/><text>hyperthermia</text></annotation><annotation id="23"><infon key="identifier">MESH:D013174</infon><infon key="type">Disease</infon><location offset="360" length="14"/><text>sporotrichosis</text></annotation><annotation id="24"><infon key="identifier">MESH:D013174</infon><infon key="type">Disease</infon><location offset="447" length="30"/><text>lymphocutaneous sporotrichosis</text></annotation><annotation id="25"><infon key="identifier">MESH:D017964</infon><infon key="type">Chemical</infon><location offset="544" length="12"/><text>itraconazole</text></annotation><annotation id="26"><infon key="identifier">MESH:D005334</infon><infon key="type">Disease</infon><location offset="623" length="12"/><text>hyperthermia</text></annotation><annotation id="27"><infon key="identifier">MESH:D017964</infon><infon key="type">Chemical</infon><location offset="915" length="12"/><text>Itraconazole</text></annotation><annotation id="28"><infon key="identifier">MESH:D005334</infon><infon key="type">Disease</infon><location offset="948" length="12"/><text>hyperthermia</text></annotation><annotation id="29"><infon key="identifier">MESH:D013174</infon><infon key="type">Disease</infon><location offset="1039" length="14"/><text>sporotrichosis</text></annotation><annotation id="30"><infon key="identifier">MESH:D013174</infon><infon key="type">Disease</infon><location offset="1661" length="14"/><text>sporotrichosis</text></annotation><annotation id="31"><infon key="identifier">MESH:D005334</infon><infon key="type">Disease</infon><location offset="1696" length="12"/><text>hyperthermia</text></annotation><annotation id="32"><infon key="identifier">MESH:D005334</infon><infon key="type">Disease</infon><location offset="1820" length="12"/><text>hyperthermia</text></annotation><annotation id="33"><infon key="identifier">MESH:D013174</infon><infon key="type">Disease</infon><location offset="1853" length="24"/><text>cutaneous sporotrichosis</text></annotation></passage><relation id="R1"><infon key="score">0.998</infon><infon key="role1">Chemical|MESH:D017964</infon><infon key="role2">Disease|MESH:D013174</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="8,7"/></relation><relation id="R2"><infon key="score">0.7116</infon><infon key="role1">Chemical|MESH:D017964</infon><infon key="role2">Disease|MESH:D005334</infon><infon key="type">Association</infon><node refid="1" role="8,9"/></relation></document>
<document><id>37897424</id><passage><infon key="journal">J Clin Endocrinol Metab;2023Oct28. doi:10.1210/clinem/dgad635</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nemiroff S, Chai R, Fan J, Ramer-Bass I, </infon><offset>0</offset><text>Ectopic Cervical Thymoma in a Patient Diagnosed with Graves Disease: A Systematic Literature Review.</text><annotation id="2"><infon key="identifier">MESH:D013945</infon><infon key="type">Disease</infon><location offset="0" length="24"/><text>Ectopic Cervical Thymoma</text></annotation><annotation id="3"><infon key="identifier">MESH:D006111</infon><infon key="type">Disease</infon><location offset="53" length="14"/><text>Graves Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>101</offset><text>Thymomas are benign thymic epithelial neoplasms, rarely found outside the anterior mediastinum. Although hyperthyroid states have been associated with thymic hyperplasia, only 3 thymoma cases have been previously reported in patients with Graves Disease (GD), all within the anterior mediastinum. Here, we report a case of ectopic cervical thymoma in a 22-year-old female patient previously treated for GD. The patient underwent ultrasonography, computed tomography, inconclusive fine-needle aspiration, and ultimately gross dissection for diagnostic workup and definitive treatment of an anterior neck mass, producing a 2.5 x 2.3 x 1.5 cm entity consistent with Masaoka stage I and Type B2 thymoma per WHO classification. The patient underwent an uncomplicated subsequent clinical course, with no adjuvant radiotherapy administered. After conducting a systematic literature review, we conclude that of the 109 cases of ectopic cervical thymoma reported, this is the first to describe a case of ectopic cervical thymoma in a patient with a past medical history of GD. For GD patients in stable euthyroid remission with the persistent or recurrent presence of an anterior neck mass, the extrathyroidal origin of the mass should always be considered, including the exceptional presence of a cervical ectopic thymoma.</text><annotation id="24"><infon key="identifier">MESH:D013945</infon><infon key="type">Disease</infon><location offset="101" length="8"/><text>Thymomas</text></annotation><annotation id="25"><infon key="identifier">MESH:C536905</infon><infon key="type">Disease</infon><location offset="121" length="27"/><text>thymic epithelial neoplasms</text></annotation><annotation id="26"><infon key="identifier">MESH:D006980</infon><infon key="type">Disease</infon><location offset="206" length="12"/><text>hyperthyroid</text></annotation><annotation id="27"><infon key="identifier">MESH:D013952</infon><infon key="type">Disease</infon><location offset="252" length="18"/><text>thymic hyperplasia</text></annotation><annotation id="28"><infon key="identifier">MESH:D013945</infon><infon key="type">Disease</infon><location offset="279" length="7"/><text>thymoma</text></annotation><annotation id="29"><infon key="identifier">MESH:D006111</infon><infon key="type">Disease</infon><location offset="340" length="14"/><text>Graves Disease</text></annotation><annotation id="30"><infon key="identifier">MESH:D006111</infon><infon key="type">Disease</infon><location offset="356" length="2"/><text>GD</text></annotation><annotation id="31"><infon key="identifier">MESH:D013945</infon><infon key="type">Disease</infon><location offset="424" length="24"/><text>ectopic cervical thymoma</text></annotation><annotation id="32"><infon key="identifier">MESH:D006111</infon><infon key="type">Disease</infon><location offset="504" length="2"/><text>GD</text></annotation><annotation id="33"><infon key="identifier">MESH:C536030</infon><infon key="type">Disease</infon><location offset="704" length="4"/><text>mass</text></annotation><annotation id="34"><infon key="identifier">MESH:D062706</infon><infon key="type">Disease</infon><location offset="764" length="15"/><text>Masaoka stage I</text></annotation><annotation id="35"><infon key="identifier">MESH:C536943</infon><infon key="type">Disease</infon><location offset="789" length="2"/><text>B2</text></annotation><annotation id="36"><infon key="identifier">MESH:D013945</infon><infon key="type">Disease</infon><location offset="792" length="7"/><text>thymoma</text></annotation><annotation id="37"><infon key="identifier">MESH:D013945</infon><infon key="type">Disease</infon><location offset="1021" length="24"/><text>ectopic cervical thymoma</text></annotation><annotation id="38"><infon key="identifier">MESH:D013945</infon><infon key="type">Disease</infon><location offset="1096" length="24"/><text>ectopic cervical thymoma</text></annotation><annotation id="39"><infon key="identifier">MESH:D006111</infon><infon key="type">Disease</infon><location offset="1165" length="2"/><text>GD</text></annotation><annotation id="40"><infon key="identifier">MESH:D006111</infon><infon key="type">Disease</infon><location offset="1173" length="2"/><text>GD</text></annotation><annotation id="41"><infon key="identifier">MESH:C536030</infon><infon key="type">Disease</infon><location offset="1277" length="4"/><text>mass</text></annotation><annotation id="42"><infon key="identifier">MESH:C536030</infon><infon key="type">Disease</infon><location offset="1316" length="4"/><text>mass</text></annotation><annotation id="43"><infon key="identifier">MESH:D013945</infon><infon key="type">Disease</infon><location offset="1399" length="15"/><text>ectopic thymoma</text></annotation></passage></document>
<document><id>37897774</id><passage><infon key="journal">Phys Rev Lett;2023Oct13; 131 (15) 153801. doi:10.1103/PhysRevLett.131.153801</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kim K, Bittner S, Jin Y, Zeng Y, Wang QJ, Cao H, </infon><offset>0</offset><text>Impact of Cavity Geometry on Microlaser Dynamics.</text></passage><passage><infon key="type">abstract</infon><offset>50</offset><text>We experimentally investigate spatiotemporal lasing dynamics in semiconductor microcavities with various geometries, featuring integrable or chaotic ray dynamics. The classical ray dynamics directly impacts the lasing dynamics, which is primarily determined by the local directionality of long-lived ray trajectories. The directionality of optical propagation dictates the characteristic length scales of intensity variations, which play a pivotal role in nonlinear light-matter interactions. While wavelength-scale intensity variations tend to stabilize lasing dynamics, modulation on much longer scales causes spatial filamentation and irregular pulsation. Our results will pave the way to control the lasing dynamics by engineering the cavity geometry and ray dynamical properties.</text></passage></document>
<document><id>37898124</id><passage><infon key="journal">Cell Stem Cell;2023Oct25. doi:10.1016/j.stem.2023.09.014</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cai Y, Xiong M, Xin Z, Liu C, Ren J, Yang X, Lei J, Li W, Liu F, Chu Q, Zhang Y, Yin J, Ye Y, Liu D, Fan Y, Sun S, Jing Y, Zhao Q, Zhao L, Che S, Zheng Y, Yan H, Ma S, Wang S, Izpisua Belmonte JC, Qu J, Zhang W, Liu GH, </infon><offset>0</offset><text>Decoding aging-dependent regenerative decline across tissues at single-cell resolution.</text></passage><passage><infon key="type">abstract</infon><offset>88</offset><text>Regeneration across tissues and organs exhibits significant variation throughout the body and undergoes a progressive decline with age. To decode the relationships between aging and regenerative capacity, we conducted a comprehensive single-cell transcriptome analysis of regeneration in eight tissues from young and aged mice. We employed diverse analytical models to study tissue regeneration and unveiled the intricate cellular and molecular mechanisms underlying the attenuated regenerative processes observed in aged tissues. Specifically, we identified compromised stem cell mobility and inadequate angiogenesis as prominent contributors to this age-associated decline in regenerative capacity. Moreover, we discovered a unique subset of Arg1+ macrophages that were activated in young tissues but suppressed in aged regenerating tissues, suggesting their important role in age-related immune response disparities during regeneration. This study provides a comprehensive single-cell resource for identifying potential targets for interventions aimed at enhancing regenerative outcomes in the aging population.</text><annotation id="1"><infon key="identifier">11846</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">29</infon><location offset="832" length="4"/><text>Arg1</text></annotation></passage></document>
<document><id>37898477</id><passage><infon key="journal">Crit Rev Oncol Hematol;2023Oct26 104192. doi:10.1016/j.critrevonc.2023.104192</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zhang L, Ma J, Liu L, Li G, Li H, Hao Y, Zhang X, Ma X, Chen Y, Wu J, Wang X, Yang S, Xu S, </infon><offset>0</offset><text>Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="20" length="5"/><text>tumor</text></annotation></passage><passage><infon key="type">abstract</infon><offset>80</offset><text>Cancer progression is a dynamic process of continuous evolution, in which genetic diversity and heterogeneity are generated by clonal and subclonal amplification based on random mutations. Traditional cancer treatment strategies have a great challenge, which often leads to treatment failure due to drug resistance. Integrating evolutionary dynamics into treatment regimens may be an effective way to overcome the problem of drug resistance. In particular, a potential treatment is adaptive therapy, which strategy advocates containment strategies that adjust the treatment cycles according to tumor evolution to control the growth of treatment-resistant cells. In this review, we first summarize the shortcomings of traditional tumor treatment methods in evolution and then introduce the theoretical basis and research status of adaptive therapy. By analyzing the limitations of adaptive therapy and exploring possible solutions, we can broaden people's understanding of adaptive therapy and provide new insights and strategies for tumor treatment.</text><annotation id="7"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="80" length="6"/><text>Cancer</text></annotation><annotation id="8"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="281" length="6"/><text>cancer</text></annotation><annotation id="9"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="674" length="5"/><text>tumor</text></annotation><annotation id="10"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="809" length="5"/><text>tumor</text></annotation><annotation id="11"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1113" length="5"/><text>tumor</text></annotation></passage></document>
<document><id>37898827</id><passage><infon key="journal">Cancer;2023Nov15; 129 (22) 3516. doi:10.1002/cncr.35080</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nierengarten MB, </infon><offset>0</offset><text>Targeting metabolic abnormality for advanced prostate cancer: The prodrug Platin-L effectively targets the metabolic abnormality needed to make this cancer sensitive to cisplatin.</text><annotation id="6"><infon key="identifier">MESH:D008659</infon><infon key="type">Disease</infon><location offset="10" length="21"/><text>metabolic abnormality</text></annotation><annotation id="7"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="45" length="15"/><text>prostate cancer</text></annotation><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="74" length="8"/><text>Platin-L</text></annotation><annotation id="9"><infon key="identifier">MESH:D008659</infon><infon key="type">Disease</infon><location offset="107" length="21"/><text>metabolic abnormality</text></annotation><annotation id="10"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="149" length="6"/><text>cancer</text></annotation><annotation id="11"><infon key="identifier">MESH:D002945</infon><infon key="type">Chemical</infon><location offset="169" length="9"/><text>cisplatin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>180</offset></passage><relation id="R1"><infon key="score">0.969</infon><infon key="role1">Chemical|MESH:D002945</infon><infon key="role2">Disease|MESH:D009369</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="5,4"/></relation><relation id="R2"><infon key="score">0.7193</infon><infon key="role1">Chemical|MESH:D002945</infon><infon key="role2">Disease|MESH:D008659</infon><infon key="type">Association</infon><node refid="1" role="5,0"/></relation></document>
<document><id>37899177</id><passage><infon key="journal">Chem Pharm Bull (Tokyo);2023Oct27. doi:10.1248/cpb.c23-00635</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Uchiyama N, Hosoe J, Komatsu T, Sugimoto N, Ishizuki K, Koide T, Murabayashi M, Shinozaki T, Kobayashi K, Fujimine Y, Ofuji K, Shimizu H, Hasebe T, Asai Y, Ena E, Kiyota K, Fujita K, Makino Y, Miura T, Muto Y, Asakura K, Suematsu T, Muto H, Kohama A, Goto T, Yasuda M, Ueda T, Goda Y, </infon><offset>0</offset><text>Quantitative 31P-NMR for the purity determination of the organophosphorus compound brigatinib and its method validation.</text><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="13" length="3"/><text>31P</text></annotation><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="57" length="16"/><text>organophosphorus</text></annotation><annotation id="5"><infon key="identifier">MESH:C000598580</infon><infon key="type">Chemical</infon><location offset="83" length="10"/><text>brigatinib</text></annotation></passage><passage><infon key="type">abstract</infon><offset>121</offset><text>The spectrum of 31P-NMR is fundamentally simpler than that of 1H-NMR; consequently identifying the target signal(s) for quantitation is simpler using quantitative 31P-NMR (31P-qNMR) than using quantitative 1H-NMR (1H-qNMR), which has been already established as an absolute determination method. We have previously reported a 31P-qNMR method for the absolute determination of cyclophosphamide hydrate and sofosbuvir as water-soluble and water-insoluble organophosphorus compounds, respectively. This study introduces the purity determination of brigatinib (BR), an organophosphorus compound with limited water solubility, using 31P-qNMR at multiple laboratories.Phosphonoacetic acid (PAA) and 1,4-BTMSB-d4 were selected as the reference standards (RSs) for 31P-qNMR and 1H-qNMR, respectively. The qNMR solvents were chosen based on the solubilities of BR and the RSs for qNMR. CD3OH was selected as the solvent for 31P-qNMR measurements to prevent the influence of deuterium exchange caused by the presence of exchangeable intramolecular protons of BR and PAA on the quantitative values, while CD3OD was the solvent of choice for the 1H-qNMR measurements to prevent the influence of water signals and the exchangeable intramolecular protons of BR and PAA. The mean purity of BR determined by 31P-qNMR was 97.94 +- 0.69%, which was in agreement with that determined by 1H-qNMR (97.26 +- 0.71%), thus indicating the feasibility of purity determination of BR by 31P-qNMR. Therefore, the findings of this study may provide an effective method that is simpler than conventional 1H-qNMR for the determination of organophosphorus compounds.</text><annotation id="46"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="137" length="3"/><text>31P</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="183" length="2"/><text>1H</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="284" length="3"/><text>31P</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="293" length="3"/><text>31P</text></annotation><annotation id="50"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="327" length="2"/><text>1H</text></annotation><annotation id="51"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="335" length="2"/><text>1H</text></annotation><annotation id="52"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="447" length="3"/><text>31P</text></annotation><annotation id="53"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="497" length="24"/><text>cyclophosphamide hydrate</text></annotation><annotation id="54"><infon key="identifier">MESH:D000069474</infon><infon key="type">Chemical</infon><location offset="526" length="10"/><text>sofosbuvir</text></annotation><annotation id="55"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="540" length="5"/><text>water</text></annotation><annotation id="56"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="558" length="5"/><text>water</text></annotation><annotation id="57"><infon key="identifier">MESH:D009943</infon><infon key="type">Chemical</infon><location offset="574" length="26"/><text>organophosphorus compounds</text></annotation><annotation id="58"><infon key="identifier">MESH:C000598580</infon><infon key="type">Chemical</infon><location offset="666" length="10"/><text>brigatinib</text></annotation><annotation id="59"><infon key="identifier">MESH:C000598580</infon><infon key="type">Chemical</infon><location offset="678" length="2"/><text>BR</text></annotation><annotation id="60"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="686" length="16"/><text>organophosphorus</text></annotation><annotation id="61"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="725" length="5"/><text>water</text></annotation><annotation id="62"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="749" length="3"/><text>31P</text></annotation><annotation id="63"><infon key="identifier">MESH:D010746</infon><infon key="type">Chemical</infon><location offset="783" length="20"/><text>Phosphonoacetic acid</text></annotation><annotation id="64"><infon key="identifier">MESH:D010746</infon><infon key="type">Chemical</infon><location offset="805" length="3"/><text>PAA</text></annotation><annotation id="65"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="814" length="12"/><text>1,4-BTMSB-d4</text></annotation><annotation id="66"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="878" length="3"/><text>31P</text></annotation><annotation id="67"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="891" length="2"/><text>1H</text></annotation><annotation id="68"><infon key="identifier">MESH:C000598580</infon><infon key="type">Chemical</infon><location offset="973" length="2"/><text>BR</text></annotation><annotation id="69"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="998" length="5"/><text>CD3OH</text></annotation><annotation id="70"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1036" length="3"/><text>31P</text></annotation><annotation id="71"><infon key="identifier">MESH:D003903</infon><infon key="type">Chemical</infon><location offset="1086" length="9"/><text>deuterium</text></annotation><annotation id="72"><infon key="identifier">MESH:C000598580</infon><infon key="type">Chemical</infon><location offset="1170" length="2"/><text>BR</text></annotation><annotation id="73"><infon key="identifier">MESH:D010746</infon><infon key="type">Chemical</infon><location offset="1177" length="3"/><text>PAA</text></annotation><annotation id="74"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1215" length="5"/><text>CD3OD</text></annotation><annotation id="75"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1255" length="2"/><text>1H</text></annotation><annotation id="76"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1304" length="5"/><text>water</text></annotation><annotation id="77"><infon key="identifier">MESH:C000598580</infon><infon key="type">Chemical</infon><location offset="1365" length="2"/><text>BR</text></annotation><annotation id="78"><infon key="identifier">MESH:D010746</infon><infon key="type">Chemical</infon><location offset="1372" length="3"/><text>PAA</text></annotation><annotation id="79"><infon key="identifier">MESH:C000598580</infon><infon key="type">Chemical</infon><location offset="1396" length="2"/><text>BR</text></annotation><annotation id="80"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1413" length="3"/><text>31P</text></annotation><annotation id="81"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1489" length="2"/><text>1H</text></annotation><annotation id="82"><infon key="identifier">MESH:C000598580</infon><infon key="type">Chemical</infon><location offset="1574" length="2"/><text>BR</text></annotation><annotation id="83"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1580" length="3"/><text>31P</text></annotation><annotation id="84"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1694" length="2"/><text>1H</text></annotation><annotation id="85"><infon key="identifier">MESH:D009943</infon><infon key="type">Chemical</infon><location offset="1727" length="26"/><text>organophosphorus compounds</text></annotation></passage><relation id="R1"><infon key="score">0.9911</infon><infon key="role1">Chemical|MESH:D000069474</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="0" role="11,12"/></relation><relation id="R2"><infon key="score">0.4391</infon><infon key="role1">Chemical|MESH:D000069474</infon><infon key="role2">Chemical|MESH:D009943</infon><infon key="type">Association</infon><node refid="1" role="11,14"/></relation></document>
<document><id>37899528</id><passage><infon key="journal">J Vasc Access;2023Oct29 11297298231176315. doi:10.1177/11297298231176315</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Pokala NK, Mesick M, Kim SK, Kavali PK, Mani NB, </infon><offset>0</offset><text>Tunneled femoral dialysis catheters and factors affecting their outcome: a single institution experience.</text></passage><passage><infon key="type">abstract</infon><offset>106</offset><text>BACKGROUND: To assess a single-center experience with tunneled femoral dialysis catheter usage and outcomes and to identify any operator-dependent factors related to risk of premature catheter failure. METHODS: Retrospective review of the institutional radiology information system for tunneled femoral dialysis catheter placement from 2010 to 2017 was performed. Patients for whom the catheter was placed for an indication other than dialysis or who were less than 18 years of age at the time of catheter placement were excluded. Premature catheter failure rate, cause of premature failure, catheter patency (in days) and infection rate were assessed. Operator/placement characteristics, including laterality, catheter tip placement, and catheter length were also assessed. RESULTS: A total of 101 patients were included in the study. This included n = 116 catheter placements. Thirty-four percent of patients (n = 40) were lost to follow-up, resulting in n = 61 patients and n = 76 catheters analyzed. Premature catheter failure rate was 48% (n = 36), with low flows being the foremost cause of failure (64%, n = 23). Average primary patency of these catheters was 82.4 days (1-328 days). About 8% of catheters (n = 3) were complicated by infection, resulting in an infection rate of 0.4/1000 catheter days. None of the operator-dependent factors analyzed, including catheter laterality, catheter tip placement, and catheter length, demonstrated a significant association with premature catheter failure. CONCLUSIONS: Institutional primary access patency rates are comparable to or higher than previously published data, while infection rates are similar to or lower than those reported in the literature. None of the operator-dependent factors related to placement was shown to significantly decrease the risk of premature catheter failure. These findings suggest that while femoral dialysis catheters do not function well in the long term relative to internal jugular vein dialysis catheters, prior literature may undervalue their utility and function, particularly given that these catheters are used as a "last resort" for many patients.</text><annotation id="4"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="729" length="9"/><text>infection</text></annotation><annotation id="5"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1347" length="9"/><text>infection</text></annotation><annotation id="6"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1374" length="9"/><text>infection</text></annotation><annotation id="7"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1735" length="9"/><text>infection</text></annotation></passage></document>
<document><id>37901980</id><passage><infon key="journal">G Ital Cardiol (Rome);2023Nov; 24 (11) 893. doi:10.1714/4129.41232</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Berisso MZ, Drago F, Battaglia A, Mariucci E, Mirizzi G, Vignati G, Sarubbi B, a nome dell&amp;#x2019;Area GUCH dell&amp;#x2019;Associazione Italiana di Aritmologia e Cardiostimolazione (AIAC), </infon><offset>0</offset><text>[Management of postoperative arrhythmias in the tetralogy of Fallot: a literature review].</text><annotation id="2"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="29" length="11"/><text>arrhythmias</text></annotation><annotation id="3"><infon key="identifier">MESH:D013771</infon><infon key="type">Disease</infon><location offset="48" length="19"/><text>tetralogy of Fallot</text></annotation></passage><passage><infon key="type">abstract</infon><offset>91</offset><text>Tetralogy of Fallot (ToF) occurs in about 4 births/1000/year and represents about one tenth of all congenital heart diseases. Nowadays 86% of patients reach adulthood with corrective surgery. Before the 1980s, these patients were treated only with "surgical palliation", which consisted in the creation of a systemic to pulmonary artery shunt or a pulmonary valvulotomy, whereas after the introduction of extracorporeal circulation, corrective surgery is performed electively between 3 and 6 months of life. After repair patients during their life may develop hemodynamic lesions, including right ventricular outflow tract dysfunction, and arrhythmias which can occur in over 30% of cases. It is estimated that these patients present a risk of sudden death of 0.2%/year. Therefore, for the prevention and treatment of arrhythmic events, a periodic follow-up in specialized centres for adult congenital heart disease is mandatory, because most often arrhythmias are triggered by the presence of hemodynamic lesions, first of all pulmonary regurgitation.</text><annotation id="14"><infon key="identifier">MESH:D013771</infon><infon key="type">Disease</infon><location offset="91" length="19"/><text>Tetralogy of Fallot</text></annotation><annotation id="15"><infon key="identifier">MESH:D013771</infon><infon key="type">Disease</infon><location offset="112" length="3"/><text>ToF</text></annotation><annotation id="16"><infon key="identifier">MESH:D006330</infon><infon key="type">Disease</infon><location offset="190" length="25"/><text>congenital heart diseases</text></annotation><annotation id="17"><infon key="identifier">MESH:D000092243</infon><infon key="type">Disease</infon><location offset="682" length="43"/><text>right ventricular outflow tract dysfunction</text></annotation><annotation id="18"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="731" length="11"/><text>arrhythmias</text></annotation><annotation id="19"><infon key="identifier">MESH:D003645</infon><infon key="type">Disease</infon><location offset="835" length="12"/><text>sudden death</text></annotation><annotation id="20"><infon key="identifier">OMIM:212500</infon><infon key="type">Disease</infon><location offset="909" length="10"/><text>arrhythmic</text></annotation><annotation id="21"><infon key="identifier">MESH:D006330</infon><infon key="type">Disease</infon><location offset="982" length="24"/><text>congenital heart disease</text></annotation><annotation id="22"><infon key="identifier">MESH:D001145</infon><infon key="type">Disease</infon><location offset="1040" length="11"/><text>arrhythmias</text></annotation><annotation id="23"><infon key="identifier">MESH:D011665</infon><infon key="type">Disease</infon><location offset="1119" length="23"/><text>pulmonary regurgitation</text></annotation></passage></document>
<document><id>37902330</id><passage><infon key="journal">mSphere;2023Oct30 0051723. doi:10.1128/msphere.00517-23</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Benigno V, Carraro N, Sarton-Loh&amp;#xe9;ac G, Romano-Bertrand S, Blanc DS, van der Meer JR, </infon><offset>0</offset><text>Diversity and evolution of an abundant ICEclc family of integrative and conjugative elements in Pseudomonas aeruginosa.</text></passage><passage><infon key="type">abstract</infon><offset>120</offset><text>Integrative and conjugative elements (ICEs) are widespread autonomous mobile DNA elements, containing the genes necessary for their excision, conjugative transfer, and insertion into a new host cell. ICEs can carry additional genes that are non-essential for their transfer but can confer adaptive phenotypes to the host. Our aim here was to better characterize the presence, distribution, and variation of ICEs related to the well-described ICEclc among Pseudomonas aeruginosa clinical isolates within a geographically restrained environment to understand the factors contributing to their evolution. We examined a total of 181 P. aeruginosa genome sequences obtained from patient or hospital environment isolates, most of which were obtained from a single hospital during 20 years of sampling. More than 90% of the isolates carried one or more ICEclc-like elements, with different degrees of conservation to the known ICEclc lifestyle and transfer genes. ICE clones closely matched their host clonal phylogeny, but not exclusively, indicating that both clonal evolution and ICE horizontal transfer are occurring in the hospital environment. ICEs from this singular hospital environment were mainly associated to three clone types found worldwide, suggesting an enrichment of local clones. Variable gene regions among the clinical P. aeruginosa ICEclc-type elements were notably enriched for heavy metal resistance genes, toxin-anti-toxin systems, potential efflux systems and multidrug resistance proteins, a metalloprotease and for a variety of regulatory systems, but not for specific recognizable antibiotic-resistance cassettes. Clonal persistence suggests adaptive benefits of these functional categories, and micro-patterns of gene gain and loss indicate ongoing ICE evolution within the P. aeruginosa hosts. IMPORTANCE Microbial populations swiftly adapt to changing environments through horizontal gene transfer. While the mechanisms of gene transfer are well known, the impact of environmental conditions on the selection of transferred gene functions remains less clear. We investigated ICEs, specifically the ICEclc-type, in Pseudomonas aeruginosa clinical isolates. Our findings revealed co-evolution between ICEs and their hosts, with ICE transfers occurring within strains. Gene functions carried by ICEs are positively selected, including potential virulence factors and heavy metal resistance. Comparison to publicly available P. aeruginosa genomes unveiled widespread antibiotic-resistance determinants within ICEclc clades. Thus, the ubiquitous ICEclc family significantly contributes to P. aeruginosa's adaptation and fitness in diverse environments.</text><annotation id="3"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="1513" length="11"/><text>heavy metal</text></annotation><annotation id="4"><infon key="identifier">MESH:D057129</infon><infon key="type">Disease</infon><location offset="1891" length="3"/><text>ICE</text></annotation><annotation id="5"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="2508" length="11"/><text>heavy metal</text></annotation></passage></document>
<document><id>37902680</id><passage><infon key="journal">Dev Psychol;2023Oct30. doi:10.1037/dev0001650</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Poudel S, Denicola-Prechtl K, Nelson JA, Behboudi MH, Benitez-Barrera C, Castro S, Maguire MJ, </infon><offset>0</offset><text>Rethinking household size and children's language environment.</text></passage><passage><infon key="type">abstract</infon><offset>63</offset><text>The number of U.S. children living in households with extended families has greatly increased in the last 4 decades. This demographic shift calls for a reevaluation of the impact of household size on children's development. Household density (HHD), measured as the ratio of people to bedrooms in a home, has been shown to negatively relate to children's language. Here, we propose that while greater HHD may result in poorer language abilities, more adults in relation to the number of children in the home may have a positive impact on children's language. To test this hypothesis, we studied relations between HHD and adult-to-child ratio with children's vocabulary scores, as well as whether maternal education and household chaos accounted for these associations. Participants included families from a range of socioeconomic and ethnic backgrounds (N = 275; Mage = 10.85; 51% female; 51% Hispanic; annual income range less than $10,000-over $100,000). In general, higher HHD was related to lower child vocabulary scores. Conversely, higher adult-to-child ratio was related to higher child vocabulary and lower household chaos. These patterns were primarily driven by effects in Hispanic families. Our results suggest that a reevaluation of household size is needed, as more adults in the home can be protective for children's language development in larger families, an effect that may vary by culture. (PsycInfo Database Record (c) 2023 APA, all rights reserved).</text></passage></document>
<document><id>37903032</id><passage><infon key="journal">J Phys Chem Lett;2023Oct30 9883. doi:10.1021/acs.jpclett.3c02539</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Miao Y, Zhai M, Zhao Z, Ding X, Xia Z, Wang H, Wang L, Chen C, Cheng M, </infon><offset>0</offset><text>Asymmetric Small Molecule as Interface "Governor" for FAPbI3 Perovskite Solar Cells.</text><annotation id="1"><infon key="identifier">MESH:C059910</infon><infon key="type">Chemical</infon><location offset="61" length="10"/><text>Perovskite</text></annotation></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>Delicate interface modification is necessary for improving the photovoltaic performance of a perovskite solar cell (PSC). Herein, two asymmetric small molecules, termed BTD-DA and BTD-PA are designed and synthesized to govern the perovskite/Spiro-OMeTAD interface. The molecule BTD-PA featuring a donor-acceptor-acceptor (D-A-A') configuration shows a larger molecule dipole and a better effect on defect passivation and energy level regulation through the strong interaction between the pyridine group in BTD-PA and the surficial uncoordinated Pb2+. Consequently, the PSCs based on the BTD-PA treatment harvest a champion power conversion efficiency (PCE) of 24.46% for a 0.09 cm2 active area and 22.46% for the 1 cm2 device. Moreover, the long-term stability of FAPbI3 PSCs is also significantly improved because of the enhanced hydrophobicity and the inhibited phase transition of the FAPbI3 film with BTD-PA treatment. Our research provides a new strategy for interfacial engineering to boost the PCE and stability of the FAPbI3 PSCs.</text><annotation id="16"><infon key="identifier">MESH:C059910</infon><infon key="type">Chemical</infon><location offset="178" length="10"/><text>perovskite</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="254" length="6"/><text>BTD-DA</text></annotation><annotation id="18"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="265" length="6"/><text>BTD-PA</text></annotation><annotation id="19"><infon key="identifier">MESH:C059910</infon><infon key="type">Chemical</infon><location offset="315" length="10"/><text>perovskite</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="326" length="12"/><text>Spiro-OMeTAD</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="363" length="6"/><text>BTD-PA</text></annotation><annotation id="22"><infon key="identifier">MESH:C023666</infon><infon key="type">Chemical</infon><location offset="573" length="8"/><text>pyridine</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="591" length="6"/><text>BTD-PA</text></annotation><annotation id="24"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="630" length="4"/><text>Pb2+</text></annotation><annotation id="25"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="672" length="6"/><text>BTD-PA</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="849" length="6"/><text>FAPbI3</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="973" length="6"/><text>FAPbI3</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="990" length="6"/><text>BTD-PA</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1111" length="6"/><text>FAPbI3</text></annotation></passage></document>
<document><id>37903408</id><passage><infon key="journal">Chaos;2023Oct01; 33 (10) . doi:10.1063/5.0140660</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Char&amp;#xf3; GD, Ghil M, Sciamarella D, </infon><offset>0</offset><text>Random templex encodes topological tipping points in noise-driven chaotic dynamics.</text></passage><passage><infon key="type">abstract</infon><offset>84</offset><text>Random attractors are the time-evolving pullback attractors of deterministically chaotic and stochastically perturbed dynamical systems. These attractors have a structure that changes in time and that has been characterized recently using Branched Manifold Analysis through Homologies cell complexes and their homology groups. This description has been further improved for their deterministic counterparts by endowing the cell complex with a directed graph (digraph), which encodes the order in which the cells in the complex are visited by the flow in phase space. A templex is a mathematical object formed by a cell complex and a digraph; it provides a finer description of deterministically chaotic attractors and permits their accurate classification. In a deterministic framework, the digraph of the templex connects cells within a single complex for all time. Here, we introduce the stochastic version of a templex. In such a random templex, there is one complex per snapshot of the random attractor and the digraph connects the generators or "holes" of successive cell complexes. Tipping points appear in a random templex as drastic changes of its holes in time, through their birth, splitting, merging, or death. This paper introduces random templexes and computes them for the noise-driven Lorenz system's random attractor.</text></passage></document>
<document><id>37904810</id><passage><infon key="journal">Hand Ther;2023Mar; 28 (1) 33. doi:10.1177/17589983231152958</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10584072</infon><infon key="type">title</infon><infon key="authors">Magni N, Olds M, McLaine S, </infon><offset>0</offset><text>Reliability and validity of the K-force grip dynamometer in healthy subjects: do we need to assess it three times?</text></passage><passage><infon key="type">abstract</infon><offset>115</offset><text>Introduction: Digital dynamometers to assess grip strength are becoming more common in research and clinical settings. The aim of the study was to assess validity and reliability of the K-force dynamometer compared to the Jamar dynamometer. We also aimed to assess differences over the course of three measurements. Methods: Twenty-seven healthy participants were included. Three trials with the K-force and Jamar dynamometers were completed. Testing order was randomised. Intraclass correlation coefficients (ICCs) with absolute agreement assessed reliability and validity. Standard error of the measurement (SEM) and minimal detectable change (MDC95) were calculated. Concurrent validity was assessed using Pearson's correlations and ICCs. Differences between the three repetitions were assessed using one-way repeated measures ANOVAs. Results: Both the K-force and the Jamar presented excellent intra-rater reliability with ICCs ranging from 0.96 to 0.97. The SEM ranged from 1.7 to 2 kg and the MDC from 4.7 to 5.7 kg for both dynamometers. The concurrent validity of the K-force was high (r >= 0.89). However, the K-force underestimated the grip strength by 4.5-8.5 kg. There was no change in grip strength with either dynamometer over the course of three trials. Conclusions: The K-force is reliable, but it underestimates grip strength by 4.5-8.5 kg compared to the Jamar dynamometer. K-force can be used to monitor progress over time but cannot be used to compare results against normative data. The use of a single measurement when assessing grip strength is sufficient when assessing healthy subjects.</text></passage></document>
<document><id>37905511</id><passage><infon key="journal">ACS Appl Mater Interfaces;2023Oct31. doi:10.1021/acsami.3c12072</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ganabady K, Contessi Negrini N, Scherba JC, Nitschke BM, Alexander MR, Vining KH, Grunlan MA, Mooney DJ, Celiz AD, </infon><offset>0</offset><text>High-Throughput Screening of Thiol-ene Click Chemistries for Bone Adhesive Polymers.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="29" length="9"/><text>Thiol-ene</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="66" length="17"/><text>Adhesive Polymers</text></annotation></passage><passage><infon key="type">abstract</infon><offset>85</offset><text>Metal surgical pins and screws are employed in millions of orthopedic surgical procedures every year worldwide, but their usability is limited in the case of complex, comminuted fractures or in surgeries on smaller bones. Therefore, replacing such implants with a bone adhesive material has long been considered an attractive option. However, synthesizing a biocompatible bone adhesive with a high bond strength that is simple to apply presents many challenges. To rapidly identify candidate polymers for a biocompatible bone adhesive, we employed a high-throughput screening strategy to assess human mesenchymal stromal cell (hMSC) adhesion toward a library of polymers synthesized via thiol-ene click chemistry. We chose thiol-ene click chemistry because multifunctional monomers can be rapidly cured via ultraviolet (UV) light while minimizing residual monomer, and it provides a scalable manufacturing process for candidate polymers identified from a high-throughput screen. This screening methodology identified a copolymer (1-S2-FT01) composed of the monomers 1,3,5-triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (TATATO) and pentaerythritol tetrakis (3-mercaptopropionate) (PETMP), which supported highest hMSC adhesion across a library of 90 polymers. The identified copolymer (1-S2-FT01) exhibited favorable compressive and tensile properties compared to existing commercial bone adhesives and adhered to bone with adhesion strengths similar to commercially available bone glues such as Histoacryl. Furthermore, this cytocompatible polymer supported osteogenic differentiation of hMSCs and could adhere 3D porous polymer scaffolds to the bone tissue, making this polymer an ideal candidate as an alternative bone adhesive with broad utility in orthopedic surgery.</text><annotation id="23"><infon key="identifier">MESH:D050723</infon><infon key="type">Disease</infon><location offset="263" length="9"/><text>fractures</text></annotation><annotation id="24"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="577" length="8"/><text>polymers</text></annotation><annotation id="25"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="747" length="8"/><text>polymers</text></annotation><annotation id="26"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="772" length="9"/><text>thiol-ene</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="808" length="9"/><text>thiol-ene</text></annotation><annotation id="28"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="1013" length="8"/><text>polymers</text></annotation><annotation id="29"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1104" length="9"/><text>copolymer</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1115" length="9"/><text>1-S2-FT01</text></annotation><annotation id="31"><infon key="identifier">MESH:C480124</infon><infon key="type">Chemical</infon><location offset="1151" length="52"/><text>1,3,5-triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione</text></annotation><annotation id="32"><infon key="identifier">MESH:C480124</infon><infon key="type">Chemical</infon><location offset="1205" length="6"/><text>TATATO</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1217" length="47"/><text>pentaerythritol tetrakis (3-mercaptopropionate)</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1266" length="5"/><text>PETMP</text></annotation><annotation id="35"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="1335" length="8"/><text>polymers</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1360" length="9"/><text>copolymer</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1371" length="9"/><text>1-S2-FT01</text></annotation><annotation id="38"><infon key="identifier">MESH:D004659</infon><infon key="type">Chemical</infon><location offset="1581" length="10"/><text>Histoacryl</text></annotation><annotation id="39"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="1626" length="7"/><text>polymer</text></annotation><annotation id="40"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="1707" length="7"/><text>polymer</text></annotation><annotation id="41"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="1757" length="7"/><text>polymer</text></annotation></passage></document>
<document><id>37905861</id><passage><infon key="journal">Neural Regen Res;2024Jun01; 19 (6) 1195. doi:10.4103/1673-5374.385870</infon><infon key="year">2024</infon><infon key="type">title</infon><infon key="authors">Garland B, Ma L, </infon><offset>0</offset><text>Nuance of inward rectifying potassium (Kir) channel dysfunctions in neurodegenerative diseases.</text><annotation id="2"><infon key="identifier">3805</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">124412</infon><location offset="39" length="3"/><text>Kir</text></annotation><annotation id="3"><infon key="identifier">MESH:D019636</infon><infon key="type">Disease</infon><location offset="68" length="26"/><text>neurodegenerative diseases</text></annotation></passage><passage><infon key="type">abstract</infon><offset>96</offset></passage><relation id="R1"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D019636</infon><infon key="role2">Gene|3805</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation></document>
<document><id>37906213</id><passage><infon key="journal">JMIR Form Res;2023Feb14. doi:10.2196/37653</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Petcu C, Boukhelif I, Davis V, Shamsi H, Al-Assi M, Miladi A, Khaled SM, </infon><offset>0</offset><text>The Design and Implementation of Survey Quality Control System for Qatar's First National Mental Health Survey: A Case Study.</text><annotation id="1"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="90" length="13"/><text>Mental Health</text></annotation></passage><passage><infon key="type">abstract</infon><offset>126</offset><text>BACKGROUND: All World Mental Health (WMH) surveys apply high standards of data quality. Most published quality control procedures for these surveys to date were in relation to face-to-face interviews. However, due to the social restrictions that emerged from the COVID-19 pandemic, telephone interviews are the most effective alternative for conducting complex probability based large-scale surveys. OBJECTIVE: In this paper, we present the quality control system implemented in the World Mental Health Qatar (WMHQ) survey - the first WMH survey conducted during the COVID-19 pandemic in the Middle East. The objective of the quality control process was to acquire high data quality through reduction in random errors and bias in data collection. METHODS: The QC design and procedures in this study were adapted to telephone survey mode in response to the COVID-19 pandemic. We focus on the design of the quality control indicator system and its implementation including investigation process, monitoring interviewers' performance during survey fielding, and applying quality-informed interventions. RESULTS: The study team investigated a total of 11,035 flags triggered during two waves of survey data collection. The most triggered flags were related to short question administration duration and multiple visits to the same survey questions or responses. Live monitoring of the interviews helped in understanding why certain duration-related flags were triggered and interviewing patterns of the interviewers. Corrective and preventive actions were taken against interviewers' behaviors based on the investigation of triggered flags per interviewer and live call monitoring of interviews. While in most cases, the interviewers required refresher training sessions and feedback for improving their performance, several interviewers discontinued work due to low productivity and high number of triggered flags. CONCLUSIONS: The specific QC procedures implemented in the course of the WMHQ survey were essential in successfully meeting the target number of interviews (N=5000). The QC strategies as well as the new indicators customized for the telephone interviews contributed to the flag investigation and verification process. The QC data presented here shed light on the rigorous methods and quality monitoring process in the course of conducting a large-scale national survey on a sensitive topic during the COVID-19 pandemic. CLINICALTRIAL: </text><annotation id="10"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="148" length="13"/><text>Mental Health</text></annotation><annotation id="11"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="163" length="3"/><text>WMH</text></annotation><annotation id="12"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="389" length="8"/><text>COVID-19</text></annotation><annotation id="13"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="615" length="13"/><text>Mental Health</text></annotation><annotation id="14"><infon key="identifier">OMIM:603663</infon><infon key="type">Disease</infon><location offset="661" length="3"/><text>WMH</text></annotation><annotation id="15"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="693" length="8"/><text>COVID-19</text></annotation><annotation id="16"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="982" length="8"/><text>COVID-19</text></annotation><annotation id="17"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="2539" length="8"/><text>COVID-19</text></annotation></passage></document>
<document><id>37906953</id><passage><infon key="journal">Adv Mater;2023Oct31 2305546. doi:10.1002/adma.202305546</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mu&amp;#xf1;oz J, </infon><offset>0</offset><text>Rational Design of Stimuli-Responsive Inorganic 2D Materials via Molecular Engineering: Towards Molecule-Programmable Nanoelectronics.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="48" length="2"/><text>2D</text></annotation></passage><passage><infon key="type">abstract</infon><offset>135</offset><text>The ability of electronic devices to act as switches makes digital information processing possible. Succeeding graphene, emerging Inorganic 2D Materials (i2DMs) have been identified as alternative 2D Materials to harbor a variety of active molecular components to move the current silicon-based semiconductor technology forward to a post-Moore era based on molecule-based information processing components. In this regard, i2DMs benefits not only for their prominent physiochemical properties (e.g., the existence of band gap, contrary to graphene), but also their high surface-to-volume ratio rich in reactive sites (functionalization capability). Nonetheless, since this field is still in an early stage, having knowledge of both i) the different strategies for molecularly functionalizing the current library of i2DMs, and ii) the different types of active molecular components is a sine qua non condition for a rational design of stimuli-responsive i2DMs capable of performing logical binary operations at the molecular level. Consequently, this Review provides a comprehensive tutorial for covalently anchoring ad hoc molecular components -as active units triggered by different external inputs- onto pivotal i2DMs to assess their role in the expanding field of Molecule-Programmable Nanoelectronics for electrically monitoring bistable molecular switches. Limitations, challenges, and future perspectives of this emerging field which crosses materials chemistry with computation are critically discussed. This article is protected by copyright. All rights reserved.</text><annotation id="12"><infon key="identifier">MESH:D006108</infon><infon key="type">Chemical</infon><location offset="246" length="8"/><text>graphene</text></annotation><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="275" length="2"/><text>2D</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="289" length="5"/><text>i2DMs</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="332" length="2"/><text>2D</text></annotation><annotation id="16"><infon key="identifier">MESH:D012825</infon><infon key="type">Chemical</infon><location offset="416" length="7"/><text>silicon</text></annotation><annotation id="17"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="558" length="5"/><text>i2DMs</text></annotation><annotation id="18"><infon key="identifier">MESH:D006108</infon><infon key="type">Chemical</infon><location offset="674" length="8"/><text>graphene</text></annotation><annotation id="19"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="950" length="5"/><text>i2DMs</text></annotation><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1088" length="5"/><text>i2DMs</text></annotation><annotation id="21"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1349" length="5"/><text>i2DMs</text></annotation></passage></document>
<document><id>37909053</id><passage><infon key="journal">AIDS Care;2023Nov01 1. doi:10.1080/09540121.2023.2275041</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Feelemyer J, Des Jarlais DC, Nagot N, Huong DT, Oanh KTH, Khue PM, Thi Giang H, Tuyet Thanh NT, Cleland CM, Arasteh K, Caniglia E, Chen Y, Bart G, Moles JP, Vinh VH, Vallo R, Quillet C, Rapoud D, Le SM, Michel L, Laureillard D, Khan MR, </infon><offset>0</offset><text>Utility of self-report antiretroviral adherence for predicting HIV viral load among persons who inject drugs in Hai Phong Vietnam: assessing differences by methamphetamine use.</text><annotation id="1"><infon key="identifier">MESH:D008694</infon><infon key="type">Chemical</infon><location offset="156" length="15"/><text>methamphetamine</text></annotation></passage><passage><infon key="type">abstract</infon><offset>177</offset><text>ABSTRACTIn resource-limited settings, alternatives to HIV viral load testing may be necessary to monitor the health of people living with HIV. We assessed the utility of self-report antiretroviral therapy (ART) to screen for HIV viral load among persons who inject drugs in Hai Phong Vietnam, and consider differences by recent methamphetamine use. From 2016 to 2018 we recruited PWID through cross sectional surveys and collected self-report ART adherence and HIV viral load to estimate sensitivity, specificity, positive and negative predictive values (PPV, NPV) and likelihood ratios (LR+, LR-) for self-reported ART adherence as a screening test for HIV viral load. We used three HIV viral load thresholds: &lt; 1000, 500 and 250 copies/mL; laboratory-confirmed HIV viral load was the gold standard. Among 792 PWID recruited, PPV remained above 90% regardless of recent methamphetamine use with slightly higher PPV among those not reporting recent methamphetamine use. The results remained consistent across all three HIV viral load thresholds. Our findings suggest that when HIV viral load testing is not possible, self-reported ART adherence may inform decisions about how to prioritize HIV viral load testing among PWID. The high PPV values suggest self-reported high ART adherence indicates likely HIV viral suppression, irrespective of methamphetamine use.</text><annotation id="6"><infon key="identifier">MESH:D008694</infon><infon key="type">Chemical</infon><location offset="505" length="15"/><text>methamphetamine</text></annotation><annotation id="7"><infon key="identifier">MESH:D008694</infon><infon key="type">Chemical</infon><location offset="1048" length="15"/><text>methamphetamine</text></annotation><annotation id="8"><infon key="identifier">MESH:D008694</infon><infon key="type">Chemical</infon><location offset="1126" length="15"/><text>methamphetamine</text></annotation><annotation id="9"><infon key="identifier">MESH:D008694</infon><infon key="type">Chemical</infon><location offset="1519" length="15"/><text>methamphetamine</text></annotation></passage></document>
<document><id>37909407</id><passage><infon key="journal">J Wildl Dis;2023Nov01. doi:10.7589/JWD-D-23-00023</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Reinoso-P&amp;#xe9;rez MT, Dhondt KV, Dulcet H, Katzenstein N, Sydenstricker AV, Dhondt AA, </infon><offset>0</offset><text>Seasonal Variation in Detection of Haemosporidia in a Bird Community: A Comparison of Nested PCR and Microscopy.</text><annotation id="1"><infon key="type">Disease</infon><location offset="35" length="13"/><text>Haemosporidia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>In a 2-yr study on prevalence of Haemosporidia in an avian community in Ithaca, New York, USA, we tested the hypothesis that apparent seasonal variation in prevalence is influenced by the detection protocol. We confirmed a higher detection of Haemosporidia using a molecular diagnosis technique (PCR) than by microscopy; this further increased when the PCR test was triplicated. Microscopic examination and PCR techniques have different specificity and sensitivity and therefore different probabilities of detecting hemoparasites. Birds with chronic infections or sampled during winter often have very low parasitemia, and such infections may be missed by microscopy but detected by PCR. Haemosporidian prevalence was higher during the breeding season than during the nonbreeding season regardless of the method used. Detection of Leucocytozoon spp. infection from blood smears using microscopy was challenging.</text><annotation id="4"><infon key="type">Disease</infon><location offset="356" length="13"/><text>Haemosporidia</text></annotation><annotation id="5"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="963" length="9"/><text>infection</text></annotation></passage></document>
<document><id>37909762</id><passage><infon key="journal">Am J Respir Crit Care Med;2023Nov01; 208 (9) -. doi:10.1164/rccm.208i9xxvi</infon><infon key="year">2023</infon><infon key="type">title</infon><offset>0</offset><text>November 1 Highlight.</text></passage><passage><infon key="type">abstract</infon><offset>22</offset></passage></document>
<document><id>37910117</id><passage><infon key="journal">JAMA Psychiatry;2023Nov01. doi:10.1001/jamapsychiatry.2023.4150</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10620679</infon><infon key="type">title</infon><infon key="authors">Schumer MC, Bertocci MA, Aslam HA, Graur S, Bebko G, Stiffler RS, Skeba AS, Brady TJ, Benjamin OE, Wang Y, Chase HW, Phillips ML, </infon><offset>0</offset><text>Patterns of Neural Network Functional Connectivity Associated With Mania/Hypomania and Depression Risk in 3 Independent Young Adult Samples.</text><annotation id="3"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="67" length="5"/><text>Mania</text></annotation><annotation id="4"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="73" length="9"/><text>Hypomania</text></annotation><annotation id="5"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="87" length="10"/><text>Depression</text></annotation></passage><passage><infon key="type">abstract</infon><offset>141</offset><text>Importance: Mania/hypomania is the pathognomonic feature of bipolar disorder (BD). Established, reliable neural markers denoting mania/hypomania risk to help with early risk detection and diagnosis and guide the targeting of pathophysiologically informed interventions are lacking. Objective: To identify patterns of neural responses associated with lifetime mania/hypomania risk, the specificity of such neural responses to mania/hypomania risk vs depression risk, and the extent of replication of findings in 2 independent test samples. Design, Setting, and Participants: This cross-sectional study included 3 independent samples of young adults aged 18 to 30 years without BD or active substance use disorder within the past 3 months who were recruited from the community through advertising. Of 603 approached, 299 were ultimately included and underwent functional magnetic resonance imaging at the University of Pittsburgh, Pittsburgh, Pennsylvania, from July 2014 to May 2023. Main Outcomes and Measures: Activity and functional connectivity to approach-related emotions were examined using a region-of-interest mask supporting emotion processing and emotional regulation. The Mood Spectrum Self-Report assessed lifetime mania/hypomania risk and depression risk. In the discovery sample, elastic net regression models identified neural variables associated with mania/hypomania and depression risk; multivariable regression models identified the extent to which selected variables were significantly associated with each risk measure. Multivariable regression models then determined whether associations in the discovery sample replicated in both test samples. Results: A total of 299 participants were included. The discovery sample included 114 individuals (mean [SD] age, 21.60 [1.91] years; 80 female and 34 male); test sample 1, 103 individuals (mean [SD] age, 21.57 [2.09] years; 30 male and 73 female); and test sample 2, 82 individuals (mean [SD] age, 23.43 [2.86] years; 48 female, 29 male, and 5 nonbinary). Associations between neuroimaging variables and Mood Spectrum Self-Report measures were consistent across all 3 samples. Bilateral amygdala-left amygdala functional connectivity and bilateral ventrolateral prefrontal cortex-right dorsolateral prefrontal cortex functional connectivity were positively associated with mania/hypomania risk: discovery omnibus chi2 = 1671.7 (P &lt; .001); test sample 1 omnibus chi2 = 1790.6 (P &lt; .001); test sample 2 omnibus chi2 = 632.7 (P &lt; .001). Bilateral amygdala-left amygdala functional connectivity and right caudate activity were positively associated and negatively associated with depression risk, respectively: discovery omnibus chi2 = 2566.2 (P &lt; .001); test sample 1 omnibus chi2 = 2935.9 (P &lt; .001); test sample 2 omnibus chi2 = 1004.5 (P &lt; .001). Conclusions and Relevance: In this study of young adults, greater interamygdala functional connectivity was associated with greater risk of both mania/hypomania and depression. By contrast, greater functional connectivity between ventral attention or salience and central executive networks and greater caudate deactivation were reliably associated with greater risk of mania/hypomania and depression, respectively. These replicated findings indicate promising neural markers distinguishing mania/hypomania-specific risk from depression-specific risk and may provide neural targets to guide and monitor interventions for mania/hypomania and depression in at-risk individuals.</text><annotation id="42"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="153" length="5"/><text>Mania</text></annotation><annotation id="43"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="159" length="9"/><text>hypomania</text></annotation><annotation id="44"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="201" length="16"/><text>bipolar disorder</text></annotation><annotation id="45"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="219" length="2"/><text>BD</text></annotation><annotation id="46"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="270" length="5"/><text>mania</text></annotation><annotation id="47"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="276" length="9"/><text>hypomania</text></annotation><annotation id="48"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="500" length="5"/><text>mania</text></annotation><annotation id="49"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="506" length="9"/><text>hypomania</text></annotation><annotation id="50"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="566" length="5"/><text>mania</text></annotation><annotation id="51"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="572" length="9"/><text>hypomania</text></annotation><annotation id="52"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="590" length="10"/><text>depression</text></annotation><annotation id="53"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="817" length="2"/><text>BD</text></annotation><annotation id="54"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="830" length="22"/><text>substance use disorder</text></annotation><annotation id="55"><infon key="identifier">MESH:D019964</infon><infon key="type">Disease</infon><location offset="1324" length="4"/><text>Mood</text></annotation><annotation id="56"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="1368" length="5"/><text>mania</text></annotation><annotation id="57"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="1374" length="9"/><text>hypomania</text></annotation><annotation id="58"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1393" length="10"/><text>depression</text></annotation><annotation id="59"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="1509" length="5"/><text>mania</text></annotation><annotation id="60"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="1515" length="9"/><text>hypomania</text></annotation><annotation id="61"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1529" length="10"/><text>depression</text></annotation><annotation id="62"><infon key="identifier">MESH:D019964</infon><infon key="type">Disease</infon><location offset="2213" length="4"/><text>Mood</text></annotation><annotation id="63"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="2482" length="5"/><text>mania</text></annotation><annotation id="64"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="2488" length="9"/><text>hypomania</text></annotation><annotation id="65"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="2785" length="10"/><text>depression</text></annotation><annotation id="66"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="3101" length="5"/><text>mania</text></annotation><annotation id="67"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="3107" length="9"/><text>hypomania</text></annotation><annotation id="68"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="3121" length="10"/><text>depression</text></annotation><annotation id="69"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="3326" length="5"/><text>mania</text></annotation><annotation id="70"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="3332" length="9"/><text>hypomania</text></annotation><annotation id="71"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="3346" length="10"/><text>depression</text></annotation><annotation id="72"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="3447" length="5"/><text>mania</text></annotation><annotation id="73"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="3453" length="9"/><text>hypomania</text></annotation><annotation id="74"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="3482" length="10"/><text>depression</text></annotation><annotation id="75"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="3577" length="5"/><text>mania</text></annotation><annotation id="76"><infon key="identifier">MESH:D000087122</infon><infon key="type">Disease</infon><location offset="3583" length="9"/><text>hypomania</text></annotation><annotation id="77"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="3597" length="10"/><text>depression</text></annotation></passage></document>
<document><id>37910818</id><passage><infon key="journal">J Pediatr Hematol Oncol;2023Oct31. doi:10.1097/MPH.0000000000002776</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chalfant V, Riveros C, Bechtel A, Bradfield SM, Stec AA, </infon><offset>0</offset><text>Impact of Social Disparities on 5-Year Survival Rates in Pediatric Hematologic Malignancies.</text><annotation id="1"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="67" length="24"/><text>Hematologic Malignancies</text></annotation></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>BACKGROUND: Socioeconomic disparities exist in pediatric patients with hematologic malignancies, leading to suboptimal survival rates. Social determinants of health impact health outcomes, and in children, they may not only lead to worse survival outcomes but carry over into late effects in adult life. The social deprivation index (SDI) is a composite score using geographic county data to measure social determinants of health. Using the SDI, the purpose of the present study is to stratify survival outcomes in pediatric patients with hematologic malignancies based on area deprivation. METHODS: A retrospective cohort study was performed using the national Surveillance, Epidemiology, and End Results oncology registry in the USA from 1975 to 2016 based on county-level data. Pediatric patients (&lt;=18 y old) with a diagnosis of leukemia or lymphoma based on the International Classification for Oncology, third edition (ICD-O-3) were used for inclusion criteria. Patients were grouped by cancer subtype for leukemia into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia while for lymphoma into non-Hodgkin's lymphoma and Hodgkin's lymphoma. SDI scores were calculated for each patient and divided into quartiles, with Q1 being the lowest area of deprivation and Q4 being the highest, respectively. RESULTS: A total of 38,318 leukemia and lymphoma patients were included. Quartile data demonstrated stratification in survival based on area deprivation for ALL, with no survival differences in the other cancer subtypes. Patients with ALL from the most deprived area had a roughly 3% difference in both overall and cancer-specific morality at 5 years compared with the least deprived area. CONCLUSION: Disparities in pediatric patients with ALL represent a significant area for quality improvement. Social programs may have value in improving survival outcomes and could rely on metrics such as SDI.</text><annotation id="17"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="164" length="24"/><text>hematologic malignancies</text></annotation><annotation id="18"><infon key="identifier">MESH:D019337</infon><infon key="type">Disease</infon><location offset="632" length="24"/><text>hematologic malignancies</text></annotation><annotation id="19"><infon key="identifier">MESH:D007938</infon><infon key="type">Disease</infon><location offset="926" length="8"/><text>leukemia</text></annotation><annotation id="20"><infon key="identifier">MESH:D008223</infon><infon key="type">Disease</infon><location offset="938" length="8"/><text>lymphoma</text></annotation><annotation id="21"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1086" length="6"/><text>cancer</text></annotation><annotation id="22"><infon key="identifier">MESH:D007938</infon><infon key="type">Disease</infon><location offset="1105" length="8"/><text>leukemia</text></annotation><annotation id="23"><infon key="identifier">MESH:D054198</infon><infon key="type">Disease</infon><location offset="1119" length="28"/><text>acute lymphoblastic leukemia</text></annotation><annotation id="24"><infon key="identifier">MESH:D015470</infon><infon key="type">Disease</infon><location offset="1158" length="22"/><text>acute myeloid leukemia</text></annotation><annotation id="25"><infon key="identifier">MESH:D008223</infon><infon key="type">Disease</infon><location offset="1191" length="8"/><text>lymphoma</text></annotation><annotation id="26"><infon key="identifier">MESH:D008228</infon><infon key="type">Disease</infon><location offset="1205" length="22"/><text>non-Hodgkin's lymphoma</text></annotation><annotation id="27"><infon key="identifier">MESH:D006689</infon><infon key="type">Disease</infon><location offset="1232" length="18"/><text>Hodgkin's lymphoma</text></annotation><annotation id="28"><infon key="identifier">MESH:D007938</infon><infon key="type">Disease</infon><location offset="1436" length="8"/><text>leukemia</text></annotation><annotation id="29"><infon key="identifier">MESH:D008223</infon><infon key="type">Disease</infon><location offset="1449" length="8"/><text>lymphoma</text></annotation><annotation id="30"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1613" length="6"/><text>cancer</text></annotation><annotation id="31"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1724" length="6"/><text>cancer</text></annotation></passage></document>
<document><id>37911169</id><passage><infon key="journal">Int Dent J (Phila);1891Apr; 12 (4) 236</infon><infon key="year">1891</infon><infon key="article-id_pmc">PMC10109755</infon><infon key="type">title</infon><offset>0</offset><text>American Academy of Dental Science.</text></passage><passage><infon key="type">abstract</infon><offset>36</offset></passage></document>
<document><id>37912219</id><passage><infon key="journal">Int Dent J (Phila);1897May; 18 (5) 353</infon><infon key="year">1897</infon><infon key="article-id_pmc">PMC10128748</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37912919</id><passage><infon key="journal">Int Dent J (Phila);1902Mar; 23 (3) 221</infon><infon key="year">1902</infon><infon key="article-id_pmc">PMC10156193</infon><infon key="type">title</infon><offset>0</offset><text>The Army Dentist.</text></passage><passage><infon key="type">abstract</infon><offset>18</offset></passage></document>
<document><id>37913270</id><passage><infon key="journal">Int Dent J (Phila);1905Jul; 26 (7) 483</infon><infon key="year">1905</infon><infon key="article-id_pmc">PMC10168769</infon><infon key="type">title</infon><infon key="authors">Bogue EA, </infon><offset>0</offset><text>Correspondence on Orthodontia.</text><annotation id="1"><infon key="type">Disease</infon><location offset="18" length="11"/><text>Orthodontia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>31</offset></passage></document>
<document><id>37913620</id><passage><infon key="journal">J Plast Reconstr Aesthet Surg;2023Oct18; 87 215. doi:10.1016/j.bjps.2023.10.089</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Moses O, Qureshi M, King ICC, </infon><offset>0</offset><text>Letter to the Editor regarding 'Development of a deep learning-based tool to assist wound classification'.</text></passage><passage><infon key="type">abstract</infon><offset>107</offset></passage></document>
<document><id>37913970</id><passage><infon key="journal">Acta Trop;2023Oct30 107056. doi:10.1016/j.actatropica.2023.107056</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Castillo AP, Miranda JVO, Fonseca PLC, Silva SO, Lopes REN, Spanhol VC, Moreira RG, Nicolino RR, Queiroz DC, de Ara&amp;#xfa;jo E Santos LCG, Soares Dos Santos AP, Rivetti HAA, Martins-Duarte ES, de Almeida Vitor RW, Dos Reis JKP, Aguiar RS, da Silveira JAG, </infon><offset>0</offset><text>Evidence of SARS-CoV-2 infection and co-infections in stray cats in Brazil.</text><annotation id="2"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="12" length="20"/><text>SARS-CoV-2 infection</text></annotation><annotation id="3"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="40" length="10"/><text>infections</text></annotation></passage><passage><infon key="type">abstract</infon><offset>76</offset><text>The zoonotic virus SARS-CoV-2, which causes severe acute respiratory syndrome in humans (COVID-19), has been identified in cats. Notably, most positive cases were in cats that had close contact with infected humans, suggesting a role for humans in animal transmission routes. Previous studies have suggested that animals with immune depletion are more susceptible to SARS-CoV-2 infection. To date, there is limited evidence of SARS-CoV-2 infections in stray and free-range cats affected by other pathogens. In this study, we investigated infections caused by SARS-CoV-2, Leishmania spp., Toxoplasma gondii, Mycoplasma spp., Bartonella spp., Feline leukemia virus (FeLV), and Feline immunodeficiency virus (FIV) in stray cats from an urban park in Brazil during the COVID-19 pandemic. From February to September 2021, 78 mixed-breed cats were tested for SARS-CoV-2 and hemopathogens using molecular analysis at Americo Renne Giannetti Municipal Park, Belo Horizonte, Minas Gerais, Brazil. An enzyme-linked immunosorbent assay (ELISA) was used to detect IgG in T. gondii. None of the animals in this study showed any clinical signs of infections. The SARS-CoV-2 virus RNA was detected in 7.7% of cats, and a whole virus genome sequence analysis revealed the SARS-CoV-2 Delta lineage (B.1.617.2). Phylogenetic analysis showed that SARS-CoV-2 isolated from cats was grouped into the sublineage AY.99.2, which matches the epidemiological scenario of COVID-19 in the urban area of our study. Leishmania infantum was detected and sequenced in 9% of cats. The seroprevalence of T. gondii was 23.1%. Hemotropic Mycoplasma spp. was detected in 7.7% of the cats, with Mycoplasma haemofelis and Candidatus Mycoplasma haemominutum being the most common. Bartonella henselae and Bartonella clarridgeiae were detected in 38.5% of the cats, FeLV was detected in 17,9%, and none of the cats studied tested positive for FIV. This study reports, for the first time, the SARS-CoV-2 infection with whole-genome sequencing in stray cats in southeastern Brazil and co-infection with other pathogens, including Bartonella spp. and Feline leukemia virus. Our study observed no correlation between SARS-CoV-2 and the other detected pathogens. Our results emphasize the importance of monitoring SARS-CoV-2 in stray cats to characterize their epidemiological role in SARS-CoV-2 infection and reinforce the importance of zoonotic disease surveillance.</text><annotation id="16"><infon key="identifier">MESH:D045169</infon><infon key="type">Disease</infon><location offset="120" length="36"/><text>severe acute respiratory syndrome in</text></annotation><annotation id="17"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="165" length="8"/><text>COVID-19</text></annotation><annotation id="18"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="443" length="20"/><text>SARS-CoV-2 infection</text></annotation><annotation id="19"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="503" length="21"/><text>SARS-CoV-2 infections</text></annotation><annotation id="20"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="614" length="10"/><text>infections</text></annotation><annotation id="21"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="841" length="8"/><text>COVID-19</text></annotation><annotation id="22"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="1209" length="10"/><text>infections</text></annotation><annotation id="23"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="1521" length="8"/><text>COVID-19</text></annotation><annotation id="24"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="2027" length="20"/><text>SARS-CoV-2 infection</text></annotation><annotation id="25"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="2121" length="9"/><text>infection</text></annotation><annotation id="26"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="2415" length="20"/><text>SARS-CoV-2 infection</text></annotation><annotation id="27"><infon key="identifier">MESH:D015047</infon><infon key="type">Disease</infon><location offset="2468" length="16"/><text>zoonotic disease</text></annotation></passage></document>
<document><id>37914320</id><passage><infon key="journal">Nihon Yakurigaku Zasshi;2023; 158 (6) 448. doi:10.1254/fpj.23072</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tokuyama S, </infon><offset>0</offset><text>[Preface].</text></passage><passage><infon key="type">abstract</infon><offset>11</offset></passage></document>
<document><id>37914670</id><passage><infon key="journal">Hong Kong Med J;2023Nov02. doi:10.12809/hkmj2210277</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chan HMH, Fu H, Chiu KY, </infon><offset>0</offset><text>Tuberculosis of the knee as a great mimicker of inflammatory arthritis: a case report.</text><annotation id="2"><infon key="identifier">MESH:D014376</infon><infon key="type">Disease</infon><location offset="0" length="24"/><text>Tuberculosis of the knee</text></annotation><annotation id="3"><infon key="identifier">MESH:D001168</infon><infon key="type">Disease</infon><location offset="48" length="22"/><text>inflammatory arthritis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>87</offset></passage></document>
<document><id>37916422</id><passage><infon key="journal">Neurourol Urodyn;2023Nov02. doi:10.1002/nau.25323</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hashimoto M, Karnup S, Daugherty SL, Cho KJ, Banno E, Shimizu N, Fujita K, Hirayama A, Uemura H, de Groat WC, Beckel JM, Yoshimura N, </infon><offset>0</offset><text>Sex differences in lower urinary tract function in mice with or without spinal cord injury.</text><annotation id="1"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="72" length="18"/><text>spinal cord injury</text></annotation></passage><passage><infon key="type">abstract</infon><offset>92</offset><text>OBJECTIVES: We examined sex differences of lower urinary tract function and molecular mechanisms in mice with and without spinal cord injury (SCI). METHODS: SCI was induced by Th8-9 spinal cord transection in male and female mice. We evaluated cystometrograms (CMG) and electromyography (EMG) of external urethral sphincter (EUS) at 6 weeks after SCI in spinal intact (SI) and SCI mice. The mRNA levels of Piezo2 and TRPV1 were measured in L6-S1 dorsal root ganglia (DRG). Protein levels of nerve growth factor (NGF) in the bladder mucosa was evaluated using an enzyme-linked immunosorbent assay. RESULTS: Sex differences were found in the EUS behavior during voiding as voiding events in female mice with or without SCI occurred during EUS relaxation periods without EUS bursting activity whereas male mice with or without SCI urinated during EUS bursting activity in EMG recordings. In both sexes, SCI decreased voiding efficiency along with increased tonic EUS activities evident as reduced EUS relaxation time in females and longer active periods of EUS bursting activity in males. mRNA levels of Piezo2 and TRPV1 of DRG in male and female SCI mice were significantly upregulated compared with SI mice. NGF in the bladder mucosa showed a significant increase in male and female SCI mice compared with SI mice. However, there were no significant differences in Piezo2 or TRPV1 levels in DRG or NGF protein levels in the bladder mucosa between male and female SCI mice. CONCLUSIONS: We demonstrated that female and male mice voided during EUS relaxation and EUS bursting activity, respectively. Also, upregulation of TRPV1 and Piezo2 in L6-S1 DRG and NGF in the bladder could be involved in SCI-induced lower urinary tract dysfunction in both sexes of mice.</text><annotation id="32"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="214" length="18"/><text>spinal cord injury</text></annotation><annotation id="33"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="234" length="3"/><text>SCI</text></annotation><annotation id="34"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="249" length="3"/><text>SCI</text></annotation><annotation id="35"><infon key="identifier">CVCL:8306</infon><infon key="type">CellLine</infon><location offset="268" length="5"/><text>Th8-9</text></annotation><annotation id="36"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="274" length="23"/><text>spinal cord transection</text></annotation><annotation id="37"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="439" length="3"/><text>SCI</text></annotation><annotation id="38"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="469" length="3"/><text>SCI</text></annotation><annotation id="39"><infon key="identifier">667742</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49695</infon><location offset="498" length="6"/><text>Piezo2</text></annotation><annotation id="40"><infon key="identifier">193034</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12920</infon><location offset="509" length="5"/><text>TRPV1</text></annotation><annotation id="41"><infon key="identifier">CVCL:XK50</infon><infon key="type">CellLine</infon><location offset="532" length="2"/><text>L6</text></annotation><annotation id="42"><infon key="identifier">18049</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1876</infon><location offset="583" length="19"/><text>nerve growth factor</text></annotation><annotation id="43"><infon key="identifier">18049</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1876</infon><location offset="604" length="3"/><text>NGF</text></annotation><annotation id="44"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="809" length="3"/><text>SCI</text></annotation><annotation id="45"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="916" length="3"/><text>SCI</text></annotation><annotation id="46"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="992" length="3"/><text>SCI</text></annotation><annotation id="47"><infon key="identifier">667742</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49695</infon><location offset="1193" length="6"/><text>Piezo2</text></annotation><annotation id="48"><infon key="identifier">193034</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12920</infon><location offset="1204" length="5"/><text>TRPV1</text></annotation><annotation id="49"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1236" length="3"/><text>SCI</text></annotation><annotation id="50"><infon key="identifier">18049</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1876</infon><location offset="1299" length="3"/><text>NGF</text></annotation><annotation id="51"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1374" length="3"/><text>SCI</text></annotation><annotation id="52"><infon key="identifier">667742</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49695</infon><location offset="1456" length="6"/><text>Piezo2</text></annotation><annotation id="53"><infon key="identifier">193034</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12920</infon><location offset="1466" length="5"/><text>TRPV1</text></annotation><annotation id="54"><infon key="identifier">18049</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1876</infon><location offset="1489" length="3"/><text>NGF</text></annotation><annotation id="55"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1554" length="3"/><text>SCI</text></annotation><annotation id="56"><infon key="identifier">193034</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12920</infon><location offset="1711" length="5"/><text>TRPV1</text></annotation><annotation id="57"><infon key="identifier">667742</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">49695</infon><location offset="1721" length="6"/><text>Piezo2</text></annotation><annotation id="58"><infon key="identifier">CVCL:XK50</infon><infon key="type">CellLine</infon><location offset="1731" length="2"/><text>L6</text></annotation><annotation id="59"><infon key="identifier">18049</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1876</infon><location offset="1745" length="3"/><text>NGF</text></annotation><annotation id="60"><infon key="identifier">MESH:D013119</infon><infon key="type">Disease</infon><location offset="1785" length="3"/><text>SCI</text></annotation><annotation id="61"><infon key="identifier">MESH:D014570</infon><infon key="type">Disease</infon><location offset="1803" length="25"/><text>urinary tract dysfunction</text></annotation></passage><relation id="R1"><infon key="score">0.9989</infon><infon key="role1">Disease|MESH:D014570</infon><infon key="role2">Gene|193034</infon><infon key="type">Association</infon><node refid="0" role="30,25"/></relation><relation id="R2"><infon key="score">0.9986</infon><infon key="role1">Disease|MESH:D013119</infon><infon key="role2">Gene|667742</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="18,16"/></relation><relation id="R3"><infon key="score">0.9991</infon><infon key="role1">Disease|MESH:D013119</infon><infon key="role2">Gene|193034</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="18,17"/></relation><relation id="R4"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D014570</infon><infon key="role2">Gene|667742</infon><infon key="type">Association</infon><node refid="3" role="30,26"/></relation><relation id="R5"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D014570</infon><infon key="role2">Gene|18049</infon><infon key="type">Association</infon><node refid="4" role="30,28"/></relation><relation id="R6"><infon key="score">0.9984</infon><infon key="role1">Disease|MESH:D013119</infon><infon key="role2">Gene|18049</infon><infon key="type">Positive_Correlation</infon><node refid="5" role="20,19"/></relation></document>
<document><id>37916778</id><passage><infon key="journal">Environ Sci Technol;2023Nov02. doi:10.1021/acs.est.3c03742</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zheng S, Song C, Curria MC, Ren ZJ, White CE, </infon><offset>0</offset><text>Ca-Based Layered Double Hydroxides for Environmentally Sustainable Carbon Capture.</text><annotation id="2"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="0" length="8"/><text>Ca-Based</text></annotation><annotation id="3"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="67" length="6"/><text>Carbon</text></annotation></passage><passage><infon key="type">abstract</infon><offset>83</offset><text>The process of carbon dioxide capture typically requires a large amount of energy for the separation of carbon dioxide from other gases, which has been a major barrier to the widespread deployment of carbon capture technologies. Innovation of carbon dioxide adsorbents is herein vital for the attainment of a sustainable carbon capture process. In this study, we investigated the electrified synthesis and rejuvenation of calcium-based layered double hydroxides (Ca-based LDHs) as solid adsorbents for CO2. We discovered that the particle morphology and phase purity of the LDHs, along with the presence of secondary phases, can be controlled by tuning the current density during electrodeposition on a porous carbon substrate. The change in phase composition during carbonation and calcination was investigated to unveil the effect of different intercalated anions on the surface basicity and thermal stability of Ca-based LDHs. By decoupling the adsorption of water and CO2, we showed that the adsorbed water largely promoted CO2 adsorption, most likely through a sequential dissolution and reaction pathway. A carbon capture capacity of 4.3 +- 0.5 mmol/g was measured at 30  C and relative humidity of 40% using 10 vol % CO2 in nitrogen as the feed stream. After CO2 capture occurred, the thermal regeneration step was carried out by directly passing an electric current through the conductive carbon substrate, known as the Joule-heating effect. CO2 was found to start desorbing from the Ca-based LDHs at a temperature as low as 220  C as opposed to the temperature above 700  C required for calcium carbonate that forms as part of the Ca-looping capture process. Finally, we evaluated the cumulative energy demand and environmental impact of the LDH-based capture process using a life cycle assessment. We identified the most environmentally concerning step in the process and concluded that the postcombustion CO2 capture using LDH could be advantageous compared with existing technologies.</text><annotation id="27"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="98" length="14"/><text>carbon dioxide</text></annotation><annotation id="28"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="187" length="14"/><text>carbon dioxide</text></annotation><annotation id="29"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="283" length="6"/><text>carbon</text></annotation><annotation id="30"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="326" length="14"/><text>carbon dioxide</text></annotation><annotation id="31"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="404" length="6"/><text>carbon</text></annotation><annotation id="32"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="505" length="39"/><text>calcium-based layered double hydroxides</text></annotation><annotation id="33"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="546" length="13"/><text>Ca-based LDHs</text></annotation><annotation id="34"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="585" length="3"/><text>CO2</text></annotation><annotation id="35"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="793" length="6"/><text>carbon</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="998" length="13"/><text>Ca-based LDHs</text></annotation><annotation id="37"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1045" length="5"/><text>water</text></annotation><annotation id="38"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1055" length="3"/><text>CO2</text></annotation><annotation id="39"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1088" length="5"/><text>water</text></annotation><annotation id="40"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1111" length="3"/><text>CO2</text></annotation><annotation id="41"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1196" length="6"/><text>carbon</text></annotation><annotation id="42"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1307" length="3"/><text>CO2</text></annotation><annotation id="43"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="1314" length="8"/><text>nitrogen</text></annotation><annotation id="44"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1349" length="3"/><text>CO2</text></annotation><annotation id="45"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1480" length="6"/><text>carbon</text></annotation><annotation id="46"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1533" length="3"/><text>CO2</text></annotation><annotation id="47"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1575" length="13"/><text>Ca-based LDHs</text></annotation><annotation id="48"><infon key="identifier">MESH:D002119</infon><infon key="type">Chemical</infon><location offset="1679" length="17"/><text>calcium carbonate</text></annotation><annotation id="49"><infon key="identifier">MESH:D002245</infon><infon key="type">Chemical</infon><location offset="1999" length="3"/><text>CO2</text></annotation></passage><relation id="R1"><infon key="score">0.9943</infon><infon key="role1">Chemical|MESH:D002245</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="0" role="13,12"/></relation></document>
<document><id>37917130</id><passage><infon key="journal">Chembiochem;2023Nov02 202300732. doi:10.1002/cbic.202300732</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mlotek MD, Dose B, Hertweck C, </infon><offset>0</offset><text>Bacterial Isothiocyanate Biosynthesis by Rhodanese-Catalyzed Sulfur Transfer onto Isonitriles.</text><annotation id="4"><infon key="identifier">MESH:C037152</infon><infon key="type">Chemical</infon><location offset="10" length="14"/><text>Isothiocyanate</text></annotation><annotation id="5"><infon key="identifier">29444967</infon><infon key="type">Gene</infon><location offset="41" length="9"/><text>Rhodanese</text></annotation><annotation id="6"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="61" length="6"/><text>Sulfur</text></annotation><annotation id="7"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="82" length="11"/><text>Isonitriles</text></annotation></passage><passage><infon key="type">abstract</infon><offset>95</offset><text>Natural products bearing isothiocyanate (ITC) groups are an important group of specialized metabolites that play various roles in health, nutrition, and ecology. Whereas ITC biosynthesis via glucosinolates in plants has been studied in detail, there is a gap in understanding the bacterial route to specialized metabolites with such reactive heterocumulene groups, as in the antifungal sinapigladioside from Burkholderia gladioli. Here we propose an alternative ITC pathway by enzymatic sulfur transfer onto isonitriles catalyzed by rhodanese-like enzymes (thiosulfate:cyanide sulfurtransferases). Mining the B. gladioli genome revealed six candidate genes (rhdA-F), which were individually expressed in E. coli. By means of a synthetic probe, the gene products were evaluated for their ability to produce the key ITC intermediate in the sinapigladioside pathway. In vitro biotransformation assays identified RhdE, a prototype single-domain rhodanese, as the most potent ITC synthase. Interestingly, while RhdE also efficiently transforms cyanide into thiocyanate, it shows high specificity for the natural pathway intermediate, indicating that the sinapigladioside pathway has recruited a ubiquitous detoxification enzyme for the formation of a bioactive specialized metabolite. These findings not only elucidate an elusive step in bacterial ITC biosynthesis but also reveals an overlooked function of rhodanese-like enzymes.</text><annotation id="26"><infon key="identifier">MESH:C037152</infon><infon key="type">Chemical</infon><location offset="120" length="14"/><text>isothiocyanate</text></annotation><annotation id="27"><infon key="identifier">MESH:C037152</infon><infon key="type">Chemical</infon><location offset="136" length="3"/><text>ITC</text></annotation><annotation id="28"><infon key="identifier">MESH:C037152</infon><infon key="type">Chemical</infon><location offset="265" length="3"/><text>ITC</text></annotation><annotation id="29"><infon key="identifier">MESH:D005961</infon><infon key="type">Chemical</infon><location offset="286" length="14"/><text>glucosinolates</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="437" length="14"/><text>heterocumulene</text></annotation><annotation id="31"><infon key="identifier">MESH:C000720768</infon><infon key="type">Chemical</infon><location offset="481" length="16"/><text>sinapigladioside</text></annotation><annotation id="32"><infon key="identifier">MESH:C037152</infon><infon key="type">Chemical</infon><location offset="557" length="3"/><text>ITC</text></annotation><annotation id="33"><infon key="identifier">MESH:D013455</infon><infon key="type">Chemical</infon><location offset="582" length="6"/><text>sulfur</text></annotation><annotation id="34"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="603" length="11"/><text>isonitriles</text></annotation><annotation id="35"><infon key="identifier">29444967</infon><infon key="type">Gene</infon><location offset="628" length="9"/><text>rhodanese</text></annotation><annotation id="36"><infon key="identifier">MESH:C037152</infon><infon key="type">Chemical</infon><location offset="909" length="3"/><text>ITC</text></annotation><annotation id="37"><infon key="identifier">MESH:C000720768</infon><infon key="type">Chemical</infon><location offset="933" length="16"/><text>sinapigladioside</text></annotation><annotation id="38"><infon key="identifier">29444967</infon><infon key="type">Gene</infon><location offset="1036" length="9"/><text>rhodanese</text></annotation><annotation id="39"><infon key="identifier">MESH:D003486</infon><infon key="type">Chemical</infon><location offset="1134" length="7"/><text>cyanide</text></annotation><annotation id="40"><infon key="identifier">MESH:C031760</infon><infon key="type">Chemical</infon><location offset="1147" length="11"/><text>thiocyanate</text></annotation><annotation id="41"><infon key="identifier">MESH:C000720768</infon><infon key="type">Chemical</infon><location offset="1244" length="16"/><text>sinapigladioside</text></annotation><annotation id="42"><infon key="identifier">MESH:C037152</infon><infon key="type">Chemical</infon><location offset="1438" length="3"/><text>ITC</text></annotation><annotation id="43"><infon key="identifier">29444967</infon><infon key="type">Gene</infon><location offset="1498" length="9"/><text>rhodanese</text></annotation></passage><relation id="R1"><infon key="score">0.9979</infon><infon key="role1">Chemical|MESH:D013455</infon><infon key="role2">Gene|29444967</infon><infon key="type">Association</infon><node refid="0" role="2,1"/></relation><relation id="R2"><infon key="score">0.3987</infon><infon key="role1">Chemical|MESH:C031760</infon><infon key="role2">Chemical|MESH:D003486</infon><infon key="type">Association</infon><node refid="1" role="18,17"/></relation><relation id="R3"><infon key="score">0.9804</infon><infon key="role1">Chemical|MESH:C037152</infon><infon key="role2">Chemical|MESH:D013455</infon><infon key="type">Association</infon><node refid="2" role="0,2"/></relation><relation id="R4"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:C037152</infon><infon key="role2">Gene|29444967</infon><infon key="type">Association</infon><node refid="3" role="0,1"/></relation></document>
<document><id>37917480</id><passage><infon key="journal">Cultur Divers Ethnic Minor Psychol;2023Nov02. doi:10.1037/cdp0000630</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Eddy Z, Small PA, Padilla-Garcia D, Major B, </infon><offset>0</offset><text>Examining the effects of genetic ancestry information on appraisals of contested racial identities.</text></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>OBJECTIVES: The increasing accessibility of DNA ancestry information may influence perceptions of others' and one's own racial identity. The current work tested whether the presence of genetic testing information influenced Black participants' perceptions of individuals who claim a mismatched racial identity (i.e., a racial identity that differs from their parents), and whether these perceptions are moderated by the amount of corroborating DNA evidence and racial claim of the target. METHOD: Black participants (N = 1,041) were randomly assigned to read about an individual claiming a Black or White mismatched racial identity. The target either had a majority amount (71%) of corroborating genetic information, a minimal amount (29%) or made no mention of genetic information. RESULTS: When a majority percentage of corroborating genetic information was provided, participants evaluated Black-identified targets more favorably than White-identified targets. Additionally, Black-identified targets were evaluated most favorably when they had a majority amount of corroborating genetic information. CONCLUSIONS: Among Black perceivers, a majority amount of corroborating genetic information increased positive evaluations of a mismatched, Black-identified racial claim. (PsycInfo Database Record (c) 2023 APA, all rights reserved).</text></passage></document>
<document><id>37917832</id><passage><infon key="journal">Biomacromolecules;2023Nov02. doi:10.1021/acs.biomac.3c00749</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Lee S, Kim W, Kim G, </infon><offset>0</offset><text>Efficient Myogenic Activities Achieved through Blade-Casting-Assisted Bioprinting of Aligned Myoblasts Laden in Collagen Bioink.</text></passage><passage><infon key="type">abstract</infon><offset>129</offset><text>This study investigated mechanical stimulation combined with three-dimensional (3D) bioprinting as a new approach for introducing biophysical and biological cues for tissue regeneration. A blade-casting method in conjunction with bioprinting was employed to fabricate bioengineered skeletal muscle constructs using a bioink composed of C2C12 myoblasts and collagen type-I. Various printing process parameters were selected and optimized to achieve a highly organized cell alignment within the constructs. The resulting cell-aligned constructs demonstrated remarkable improvement in actin filament alignment and cell proliferation compared with conventionally printed cell-laden constructs. This improvement can be attributed to the synergistic effects of mechanotransduction, facilitating the cellular response to mechanical cues and the alignment of fibrillated collagen, which plays a significant role in modulating cellular functions and promoting muscle tissue regeneration. Furthermore, we assessed the impact of blade casting combined with 3D bioprinting on gene expression. The expression levels of myogenesis-related genes were substantially upregulated, with an approximately 1.6-fold increase compared to the constructs fabricated without the blade-casting technique. The results demonstrated the effectiveness of combining mechanical stimulation through blade casting with 3D bioprinting in promoting aligned cell structures, enhancing cellular functions, and driving muscle tissue regeneration.</text><annotation id="1"><infon key="identifier">CVCL:0188</infon><infon key="type">CellLine</infon><location offset="465" length="15"/><text>C2C12 myoblasts</text></annotation></passage></document>
<document><id>37918182</id><passage><infon key="journal">Biomaterials;2023Oct16; 303 122345. doi:10.1016/j.biomaterials.2023.122345</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang EY, Sarmadi M, Ying B, Jaklenec A, Langer R, </infon><offset>0</offset><text>Recent advances in nano- and micro-scale carrier systems for controlled delivery of vaccines.</text></passage><passage><infon key="type">abstract</infon><offset>94</offset><text>Vaccines provide substantial safety against infectious diseases, saving millions of lives each year. The recent COVID-19 pandemic highlighted the importance of vaccination in providing mass-scale immunization against outbreaks. However, the delivery of vaccines imposes a unique set of challenges due to their large molecular size and low room temperature stability. Advanced biomaterials and delivery systems such as nano- and mciro-scale carriers are becoming critical components for successful vaccine development. In this review, we provide an updated overview of recent advances in the development of nano- and micro-scale carriers for controlled delivery of vaccines, focusing on carriers compatible with nucleic acid-based vaccines and therapeutics that emerged amid the recent pandemic. We start by detailing nano-scale delivery systems, focusing on nanoparticles, then move on to microscale systems including hydrogels, microparticles, and 3D printed microneedle patches. Additionally, we delve into emerging methods that move beyond traditional needle-based applications utilizing innovative delivery systems. Future challenges for clinical translation and manufacturing in this rapidly advancing field are also discussed.</text><annotation id="2"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="138" length="19"/><text>infectious diseases</text></annotation><annotation id="3"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="206" length="8"/><text>COVID-19</text></annotation></passage></document>
<document><id>37918532</id><passage><infon key="journal">Chemosphere;2023Oct31 140603. doi:10.1016/j.chemosphere.2023.140603</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ni X, Song J, Lu D, Tong H, Zhou H, Liu Y, Zhan J, Yi X, </infon><offset>0</offset><text>Effect of bioturbation of the mitten crab on distribution of tire wear particles and their combined effect on sediment ecosystem.</text><annotation id="2"><infon key="type">Disease</infon><location offset="37" length="4"/><text>crab</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="61" length="4"/><text>tire</text></annotation></passage><passage><infon key="type">abstract</infon><offset>130</offset><text>Tire wear particles (TWPs) are a major source of environmental microplastic pollution which gradually settle and accumulate in sediments after entering the aquatic environment, which can affect the behaviors of benthic organisms. Bioturbation of benthic species could affect the fate, impacts and potential risks of TWPs by altering the properties and structure of sediments. Therefore, in this study, the effect of TWPs on the burrowing activity of Chinese mitten crab (Eriocheir sinensis) was investigated. In addition, the effects of crab bioturbation on the distribution of TWPs and their additives were studied. The combined effects of TWPs and crab bioturbation on the microbial communities in the sediments were also explored. The results of this study showed that both TWPs and the leachate significantly inhibited the burrowing activity of crabs. TWPs in the surface layer of sediments were re-distributed by crab bioturbation and enriched mainly in the sediments near the burrow walls. Meanwhile, the heavy metals (i.e., Zn, Ca, Mg, Ba and Al) used as additives during the tire production in the burrow walls significantly increased as the accumulation of TWPs near burrow walls. In this study, TWP exposure decreased the bacterial diversity and abundance, as well as the functional genes related to carbon and nitrogen cycling process, but crab bioturbation increased them in the sediments of burrow walls by constructing a unique habitat. However, after TWPs entering into burrows, they were significantly decreased in the sediments near the burrow walls like the effects of TWPs, suggesting the negative effects of TWPs could play a dominant role in this combined system. Overall, this study is important for evaluating the distribution and effects of TWP pollution in the sediment ecosystem under biological factors such as bioturbation.</text><annotation id="20"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="130" length="4"/><text>Tire</text></annotation><annotation id="21"><infon key="type">Disease</infon><location offset="667" length="4"/><text>crab</text></annotation><annotation id="22"><infon key="type">Disease</infon><location offset="780" length="4"/><text>crab</text></annotation><annotation id="23"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="920" length="8"/><text>leachate</text></annotation><annotation id="24"><infon key="type">Disease</infon><location offset="1048" length="4"/><text>crab</text></annotation><annotation id="25"><infon key="identifier">MESH:D019216</infon><infon key="type">Chemical</infon><location offset="1141" length="12"/><text>heavy metals</text></annotation><annotation id="26"><infon key="identifier">MESH:D015032</infon><infon key="type">Chemical</infon><location offset="1161" length="2"/><text>Zn</text></annotation><annotation id="27"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1169" length="2"/><text>Mg</text></annotation><annotation id="28"><infon key="identifier">MESH:D001464</infon><infon key="type">Chemical</infon><location offset="1173" length="2"/><text>Ba</text></annotation><annotation id="29"><infon key="identifier">MESH:D000535</infon><infon key="type">Chemical</infon><location offset="1180" length="2"/><text>Al</text></annotation><annotation id="30"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1213" length="4"/><text>tire</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1335" length="3"/><text>TWP</text></annotation><annotation id="32"><infon key="identifier">MESH:D002244</infon><infon key="type">Chemical</infon><location offset="1440" length="6"/><text>carbon</text></annotation><annotation id="33"><infon key="identifier">MESH:D009584</infon><infon key="type">Chemical</infon><location offset="1451" length="8"/><text>nitrogen</text></annotation><annotation id="34"><infon key="type">Disease</infon><location offset="1481" length="4"/><text>crab</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1895" length="3"/><text>TWP</text></annotation></passage></document>
<document><id>37918882</id><passage><infon key="journal">BMJ;2023Nov02; 383 2513. doi:10.1136/bmj.p2513</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nolan T, </infon><offset>0</offset><text>Tom Nolan's research reviews-2 November 2023.</text></passage><passage><infon key="type">abstract</infon><offset>46</offset></passage></document>
<document><id>37919232</id><passage><infon key="journal">Angew Chem Int Ed Engl;2023Nov02 202311635. doi:10.1002/anie.202311635</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chen J, Brea R, Fracassi A, Cho C, Wong A, Salvador-Castell M, Sinha S, Budin I, Devaraj NK, </infon><offset>0</offset><text>Rapid Formation of Non-canonical Phospholipid Membranes by Chemoselective Amide-forming Ligations with Hydroxylamines.</text><annotation id="3"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="33" length="12"/><text>Phospholipid</text></annotation><annotation id="4"><infon key="identifier">MESH:D000577</infon><infon key="type">Chemical</infon><location offset="74" length="5"/><text>Amide</text></annotation><annotation id="5"><infon key="identifier">MESH:D006898</infon><infon key="type">Chemical</infon><location offset="103" length="14"/><text>Hydroxylamines</text></annotation></passage><passage><infon key="type">abstract</infon><offset>119</offset><text>There has been increasing interest in methods to generate synthetic lipid membranes as key constituents of artificial cells or to develop new tools for remodeling membranes in living cells. However, the biosynthesis of phospholipids involves elaborate enzymatic pathways that are challenging to reconstitute in vitro. An alternative approach is to use chemical reactions to non-enzymatically generate natural or non-canonical phospholipids de novo. Previous reports have shown that synthetic lipid membranes can be formed in situ using various ligation chemistries, but these methods lack biocompatibility and/or suffer from slow kinetics at physiological pH. Thus, it would be valuable to develop chemoselective strategies for synthesizing phospholipids from water-soluble precursors that are compatible with synthetic or living cells Here, we demonstrate that amide-forming ligations between lipid precursors bearing hydroxylamines and alpha-ketoacids (KAs) or potassium acyltrifluoroborates (KATs) can be used to prepare non-canonical phospholipids at physiological pH conditions. The generated amide-linked phospholipids spontaneously self-assemble into cell-like micron-sized vesicles similar to natural phospholipid membranes. We show that lipid synthesis using KAT ligation proceeds extremely rapidly, and the high selectivity and biocompatibility of the approach facilitates the in situ synthesis of phospholipids and associated membranes in living cells.</text><annotation id="26"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="187" length="5"/><text>lipid</text></annotation><annotation id="27"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="338" length="13"/><text>phospholipids</text></annotation><annotation id="28"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="545" length="13"/><text>phospholipids</text></annotation><annotation id="29"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="611" length="5"/><text>lipid</text></annotation><annotation id="30"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="860" length="13"/><text>phospholipids</text></annotation><annotation id="31"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="879" length="5"/><text>water</text></annotation><annotation id="32"><infon key="identifier">MESH:D000577</infon><infon key="type">Chemical</infon><location offset="981" length="5"/><text>amide</text></annotation><annotation id="33"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1013" length="5"/><text>lipid</text></annotation><annotation id="34"><infon key="identifier">MESH:D006898</infon><infon key="type">Chemical</infon><location offset="1038" length="14"/><text>hydroxylamines</text></annotation><annotation id="35"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1057" length="15"/><text>alpha-ketoacids</text></annotation><annotation id="36"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1074" length="3"/><text>KAs</text></annotation><annotation id="37"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1082" length="30"/><text>potassium acyltrifluoroborates</text></annotation><annotation id="38"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1114" length="4"/><text>KATs</text></annotation><annotation id="39"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="1157" length="13"/><text>phospholipids</text></annotation><annotation id="40"><infon key="identifier">MESH:D000577</infon><infon key="type">Chemical</infon><location offset="1217" length="5"/><text>amide</text></annotation><annotation id="41"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="1230" length="13"/><text>phospholipids</text></annotation><annotation id="42"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="1328" length="12"/><text>phospholipid</text></annotation><annotation id="43"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="1365" length="5"/><text>lipid</text></annotation><annotation id="44"><infon key="identifier">100131187</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7014</infon><location offset="1387" length="3"/><text>KAT</text></annotation><annotation id="45"><infon key="identifier">MESH:D010743</infon><infon key="type">Chemical</infon><location offset="1527" length="13"/><text>phospholipids</text></annotation></passage><relation id="R1"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:D008055</infon><infon key="role2">Gene|100131187</infon><infon key="type">Association</infon><node refid="0" role="20,21"/></relation><relation id="R2"><infon key="score">0.9931</infon><infon key="role1">Chemical|MESH:D010743</infon><infon key="role2">Gene|100131187</infon><infon key="type">Association</infon><node refid="1" role="22,21"/></relation><relation id="R3"><infon key="score">0.9359</infon><infon key="role1">Chemical|MESH:D000577</infon><infon key="role2">Chemical|MESH:D010743</infon><infon key="type">Association</infon><node refid="2" role="1,0"/></relation></document>
<document><id>37919582</id><passage><infon key="journal">MMW Fortschr Med;2023Nov; 165 (19) 35. doi:10.1007/s15006-023-2900-5</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Friedrich U, </infon><offset>0</offset><text>Hausarztliche Streifzuge durch die Alkohollandschaft.</text></passage><passage><infon key="type">abstract</infon><offset>54</offset></passage></document>
<document><id>37919932</id><passage><infon key="journal">J Perioper Pract;2023Nov; 33 (11) 331. doi:10.1177/17504589231203390</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Quick J, </infon><offset>0</offset><text>Interprofessional education.</text></passage><passage><infon key="type">abstract</infon><offset>29</offset></passage></document>
<document><id>37920982</id><passage><infon key="journal">Eur J Ophthalmol;2023Nov03 11206721231212545. doi:10.1177/11206721231212545</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Savastano A, Ferrara S, Sasso P, Savastano MC, Crincoli E, Caporossi T, De Vico U, Vidal Aroca F, Francione G, Sammarco L, Gambini G, Fedeli C, Di Nardo E, Rizzo S, </infon><offset>0</offset><text>Smaller-Incision new-generation implantable miniature telescope: Three-months follow-up study.</text></passage><passage><infon key="type">abstract</infon><offset>95</offset><text>PURPOSE: To evaluate three months follow-up of SING IMT implant in patients affected by late-stage AMD. DESIGN: Prospective cohort study. SUBJECTS: In a total of 80 eyes of 40 patients who underwent the enrollment tests, 11 patients' eyes affected by late-stage AMD matched the inclusion criteria and underwent SING IMT implant from February to June 2022. METHODS: Before surgery, each patient underwent the enrollment examination to verify inclusion and exclusion criteria. MAIN OUTCOME MEASURES: BCVA for distance and for near, IOP, ACD and ECD were evaluated at 1 and 3 months follow up. Also quality of life in doing the activities of daily life was evaluated. RESULTS: BCVA for distance and for near improved from baseline to 3 months follow up (23.91 +- 9.418 ETDRS letters and 59.09 +- 11.58 ETDRS letters respectively (p &lt; 0.001). An endothelial cell loss was shown (p &lt; 0.001), with a rate of cell density reduction around 8.3% (baseline vs 3 months). CONCLUSIONS: SING IMT could be a valid surgical device to improve patients' sight and quality of life which have been deteriorated by late-stage macular degeneration. Further studies with more patients and longer follow up are needed to confirm our results.</text><annotation id="3"><infon key="identifier">MESH:D006009</infon><infon key="type">Disease</infon><location offset="194" length="3"/><text>AMD</text></annotation><annotation id="4"><infon key="identifier">MESH:D006009</infon><infon key="type">Disease</infon><location offset="357" length="3"/><text>AMD</text></annotation><annotation id="5"><infon key="identifier">MESH:D008268</infon><infon key="type">Disease</infon><location offset="1190" length="31"/><text>late-stage macular degeneration</text></annotation></passage></document>
<document><id>37921332</id><passage><infon key="journal">Semin Ophthalmol;2023Nov03 1. doi:10.1080/08820538.2023.2275620</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Huang YT, Lin SC, Huang LY, Rujikajorn K, Chen PJ, Chen JJ, Wu MY, Lin HJ, Wan L, </infon><offset>0</offset><text>Incidence, Risk Factors and Management of Postoperative Complications in Horizontal Strabismus Surgery.</text><annotation id="2"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="42" length="27"/><text>Postoperative Complications</text></annotation><annotation id="3"><infon key="identifier">MESH:D013285</infon><infon key="type">Disease</infon><location offset="84" length="10"/><text>Strabismus</text></annotation></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>OBJECTIVE: To report the incidence, risk factors and management of postoperative complications after horizontal strabismus surgery. DESIGN: Retrospective Cohort study. PARTICIPANTS: The study assessed 1,273 patients with 1,035 cases of exotropia and 238 cases of esotropia, with a minimum 18-month follow-up. METHODS: Retrospective review of strabismus operation patients' medical records included baseline demographics, age at surgery, pre/postoperative visual acuity, and deviation. Complications were categorized as surgical site (infection, scarring, cyst, granuloma, ischemia) and strabismus-related (recurrence, diplopia), with analysis of incidence, risk factors, and management. RESULTS: Among surgical site complications, the incidence of infection, pyogenic granuloma, and anterior segment ischemia were similar between the exotropia (0.3%, 0.3%, 0.2%) and esotropia (0.8%, 0%, 0.4%) groups (p = .221, 0.406, 0.515). In contrast, the esotropia group presented a higher risk of conjunctival inclusion cyst and conjunctival scar than the exotropia group, with incidences of 5.0% vs 2.2% and 6.3% vs 1.3%, respectively (p = .004, &lt;0.001). Regarding strabismus complications, the incidence of early recurrence was not significant between the two groups, with 10.0% in the exotropia group and 10.5% in the esotropia group (p = .553). Older age and poor initial visual acuity were associated with early recurrence (p &lt; .001). The esotropia group had a higher risk of persistent diplopia than the exotropia group, with incidences of 4.2% vs 2.0%, respectively (p = .003). CONCLUSION: Esotropia carries a higher risk of conjunctival inclusion cysts, conjunctival scarring, and persistent diplopia compared to the exotropia group, while both groups exhibit similar rates of early recurrence and other surgical site complications.</text><annotation id="33"><infon key="identifier">MESH:D011183</infon><infon key="type">Disease</infon><location offset="171" length="27"/><text>postoperative complications</text></annotation><annotation id="34"><infon key="identifier">MESH:D013285</infon><infon key="type">Disease</infon><location offset="216" length="10"/><text>strabismus</text></annotation><annotation id="35"><infon key="identifier">MESH:D005099</infon><infon key="type">Disease</infon><location offset="340" length="9"/><text>exotropia</text></annotation><annotation id="36"><infon key="identifier">MESH:D004948</infon><infon key="type">Disease</infon><location offset="367" length="9"/><text>esotropia</text></annotation><annotation id="37"><infon key="identifier">MESH:D013285</infon><infon key="type">Disease</infon><location offset="446" length="10"/><text>strabismus</text></annotation><annotation id="38"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="638" length="9"/><text>infection</text></annotation><annotation id="39"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="659" length="4"/><text>cyst</text></annotation><annotation id="40"><infon key="identifier">MESH:D006099</infon><infon key="type">Disease</infon><location offset="665" length="9"/><text>granuloma</text></annotation><annotation id="41"><infon key="identifier">MESH:D007511</infon><infon key="type">Disease</infon><location offset="676" length="8"/><text>ischemia</text></annotation><annotation id="42"><infon key="identifier">MESH:D013285</infon><infon key="type">Disease</infon><location offset="690" length="10"/><text>strabismus</text></annotation><annotation id="43"><infon key="identifier">MESH:D004172</infon><infon key="type">Disease</infon><location offset="722" length="8"/><text>diplopia</text></annotation><annotation id="44"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="852" length="9"/><text>infection</text></annotation><annotation id="45"><infon key="identifier">MESH:D017789</infon><infon key="type">Disease</infon><location offset="863" length="18"/><text>pyogenic granuloma</text></annotation><annotation id="46"><infon key="identifier">MESH:C537775</infon><infon key="type">Disease</infon><location offset="887" length="25"/><text>anterior segment ischemia</text></annotation><annotation id="47"><infon key="identifier">MESH:D005099</infon><infon key="type">Disease</infon><location offset="938" length="9"/><text>exotropia</text></annotation><annotation id="48"><infon key="identifier">MESH:D004948</infon><infon key="type">Disease</infon><location offset="971" length="9"/><text>esotropia</text></annotation><annotation id="49"><infon key="identifier">MESH:D004948</infon><infon key="type">Disease</infon><location offset="1048" length="9"/><text>esotropia</text></annotation><annotation id="50"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="1104" length="14"/><text>inclusion cyst</text></annotation><annotation id="51"><infon key="identifier">MESH:D005099</infon><infon key="type">Disease</infon><location offset="1150" length="9"/><text>exotropia</text></annotation><annotation id="52"><infon key="identifier">MESH:D013285</infon><infon key="type">Disease</infon><location offset="1260" length="10"/><text>strabismus</text></annotation><annotation id="53"><infon key="identifier">MESH:D005099</infon><infon key="type">Disease</infon><location offset="1382" length="9"/><text>exotropia</text></annotation><annotation id="54"><infon key="identifier">MESH:D004948</infon><infon key="type">Disease</infon><location offset="1415" length="9"/><text>esotropia</text></annotation><annotation id="55"><infon key="identifier">MESH:D004948</infon><infon key="type">Disease</infon><location offset="1538" length="9"/><text>esotropia</text></annotation><annotation id="56"><infon key="identifier">MESH:D004172</infon><infon key="type">Disease</infon><location offset="1586" length="8"/><text>diplopia</text></annotation><annotation id="57"><infon key="identifier">MESH:D005099</infon><infon key="type">Disease</infon><location offset="1604" length="9"/><text>exotropia</text></annotation><annotation id="58"><infon key="identifier">MESH:D004948</infon><infon key="type">Disease</infon><location offset="1691" length="9"/><text>Esotropia</text></annotation><annotation id="59"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="1739" length="15"/><text>inclusion cysts</text></annotation><annotation id="60"><infon key="identifier">MESH:D004172</infon><infon key="type">Disease</infon><location offset="1794" length="8"/><text>diplopia</text></annotation><annotation id="61"><infon key="identifier">MESH:D005099</infon><infon key="type">Disease</infon><location offset="1819" length="9"/><text>exotropia</text></annotation></passage></document>
<document><id>37921682</id><passage><infon key="journal">Am J Ther;2023 Nov-Dec 01; 30 (6) 554. doi:10.1097/MJT.0000000000001485</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Sablaban IM, Stodolak D, Stallworth B, </infon><offset>0</offset><text>Apathy in Anoxic Brain Injury Treated With Bupropion.</text><annotation id="3"><infon key="type">Disease</infon><location offset="0" length="6"/><text>Apathy</text></annotation><annotation id="4"><infon key="identifier">MESH:D002534</infon><infon key="type">Disease</infon><location offset="10" length="19"/><text>Anoxic Brain Injury</text></annotation><annotation id="5"><infon key="identifier">MESH:D016642</infon><infon key="type">Chemical</infon><location offset="43" length="9"/><text>Bupropion</text></annotation></passage><passage><infon key="type">abstract</infon><offset>54</offset></passage><relation id="R1"><infon key="score">0.9894</infon><infon key="role1">Chemical|MESH:D016642</infon><infon key="role2">Disease|MESH:D002534</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="2,1"/></relation></document>
<document><id>37889607</id><passage><infon key="journal">J Phys Chem Lett;2023Oct27 9819. doi:10.1021/acs.jpclett.3c01751</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Golbek TW, Weidner T, </infon><offset>0</offset><text>Peptide Orientation Strongly Affected by the Nanoparticle Size as Revealed by Sum Frequency Scattering Spectroscopy.</text></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>The orientation of proteins at interfaces has a profound effect on the function of proteins. For nanoparticles (NPs) in a biological environment, protein orientation determines the toxicity, function, and identity of the NP. Thus, understanding how proteins orientate at NP surfaces is a critical parameter in controlling NP biochemistry. While planar surfaces are often used to model NP interfaces for protein orientation studies, it has been shown recently that proteins can orient very differently on NP surfaces. This study uses sum frequency scattering vibrational spectroscopy of the model helical leucine-lysine (LK) peptide on NPs of different sizes to determine the cause for the orientation effects. The data show that, for low dielectric constant materials, the orientation of the helical LK peptide is a function of the coulombic forces between peptides across different particle volumes. This finding strongly suggests that flat model systems are only of limited use for determining protein orientation at NP interfaces and that charge interactions should be considered when designing medical NPs or assessing NP biocompatibility.</text><annotation id="2"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="298" length="8"/><text>toxicity</text></annotation><annotation id="3"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="721" length="14"/><text>leucine-lysine</text></annotation></passage></document>
<document><id>37889958</id><passage><infon key="journal">Europace;2023Oct27. doi:10.1093/europace/euad318</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li L, Ding L, Zhou L, Wu L, Zheng L, Zhang Z, Xiong Y, Zhang Z, Yao Y, </infon><offset>0</offset><text>Outcomes of catheter ablation in high-risk patients with Brugada syndrome refusing an ICD implantation.</text><annotation id="1"><infon key="identifier">MESH:D053840</infon><infon key="type">Disease</infon><location offset="57" length="16"/><text>Brugada syndrome</text></annotation></passage><passage><infon key="type">abstract</infon><offset>104</offset><text>AIMS: The aim of this study was to investigate the outcomes of catheter ablation (CA) in preventing arrhythmic events among patients with symptomatic Brugada syndrome (BrS) who declined implantable cardioverter-defibrillator (ICD) implantation. METHODS AND RESULTS: A total of 40 patients with symptomatic BrS were included in the study, of which 18 patients refused ICD implantation and underwent CA, while 22 patients received ICD implantation. The study employed substrate modification (including endocardial and epicardial approaches) and VF-triggering premature ventricular contraction (PVC) ablation strategies. The primary outcomes were a composite endpoint consisting of episodes of ventricular fibrillation (VF) and sudden cardiac death during the follow-up period. The study population had a mean age of 43.8 +- 9.6 years, with 36 (90.0%) of them being male. All patients exhibited the typical type 1 BrS electrocardiogram pattern, and 16 (40.0%) were carriers of an SCN5A mutation. The Shanghai risk scores were comparable between the CA and ICD groups (7.05 +- 0.80 vs. 6.71 +- 0.86, P = 0.351). VF-triggering PVCs were ablated in 3 patients (16.7%), while VF substrates were ablated in 15 patients (83.3%). Epicardial ablation was performed in 12 patients (66.7%). During a median follow-up of 46.2 (17.5-73.7) months, the primary outcomes occurred more frequently in the ICD group compared to the CA group (5.6% vs. 54.5%, Log-rank P = 0.012). CONCLUSION: CA is an effective alternative therapy for improving arrhythmic outcomes in patients with symptomatic BrS who decline ICD implantation. Our findings support the consideration of CA as an alternative treatment option in this population.</text><annotation id="19"><infon key="identifier">OMIM:212500</infon><infon key="type">Disease</infon><location offset="204" length="10"/><text>arrhythmic</text></annotation><annotation id="20"><infon key="identifier">MESH:D053840</infon><infon key="type">Disease</infon><location offset="254" length="16"/><text>Brugada syndrome</text></annotation><annotation id="21"><infon key="identifier">MESH:D053840</infon><infon key="type">Disease</infon><location offset="272" length="3"/><text>BrS</text></annotation><annotation id="22"><infon key="identifier">MESH:D053840</infon><infon key="type">Disease</infon><location offset="410" length="3"/><text>BrS</text></annotation><annotation id="23"><infon key="identifier">MESH:D014693</infon><infon key="type">Disease</infon><location offset="647" length="2"/><text>VF</text></annotation><annotation id="24"><infon key="identifier">MESH:D018879</infon><infon key="type">Disease</infon><location offset="661" length="33"/><text>premature ventricular contraction</text></annotation><annotation id="25"><infon key="identifier">MESH:D018879</infon><infon key="type">Disease</infon><location offset="696" length="3"/><text>PVC</text></annotation><annotation id="26"><infon key="identifier">MESH:D014693</infon><infon key="type">Disease</infon><location offset="795" length="24"/><text>ventricular fibrillation</text></annotation><annotation id="27"><infon key="identifier">MESH:D014693</infon><infon key="type">Disease</infon><location offset="821" length="2"/><text>VF</text></annotation><annotation id="28"><infon key="identifier">MESH:D016757</infon><infon key="type">Disease</infon><location offset="829" length="20"/><text>sudden cardiac death</text></annotation><annotation id="29"><infon key="identifier">MESH:D053840</infon><infon key="type">Disease</infon><location offset="1008" length="10"/><text>type 1 BrS</text></annotation><annotation id="30"><infon key="identifier">6331</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22738</infon><location offset="1081" length="5"/><text>SCN5A</text></annotation><annotation id="31"><infon key="identifier">MESH:D014693</infon><infon key="type">Disease</infon><location offset="1212" length="2"/><text>VF</text></annotation><annotation id="32"><infon key="type">Disease</infon><location offset="1226" length="4"/><text>PVCs</text></annotation><annotation id="33"><infon key="identifier">MESH:D014693</infon><infon key="type">Disease</infon><location offset="1273" length="2"/><text>VF</text></annotation><annotation id="34"><infon key="identifier">OMIM:212500</infon><infon key="type">Disease</infon><location offset="1627" length="10"/><text>arrhythmic</text></annotation><annotation id="35"><infon key="identifier">MESH:D053840</infon><infon key="type">Disease</infon><location offset="1676" length="3"/><text>BrS</text></annotation></passage><relation id="R1"><infon key="score">0.9993</infon><infon key="role1">Disease|MESH:D053840</infon><infon key="role2">Gene|6331</infon><infon key="type">Association</infon><node refid="0" role="11,12"/></relation></document>
<document><id>37890309</id><passage><infon key="journal">Pediatr Neurol;2023Aug29; 149 151. doi:10.1016/j.pediatrneurol.2023.08.020</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ayaz A, Nisar I, Muhammad A, Ahmed K, Chand P, Jehan F, </infon><offset>0</offset><text>Structural Changes in the Brain on Magnetic Resonance Imaging in Malnourished Children: A Scoping Review of the Literature.</text><annotation id="1"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="65" length="12"/><text>Malnourished</text></annotation></passage><passage><infon key="type">abstract</infon><offset>124</offset><text>BACKGROUND: This review was conducted to summarize the current evidence on the structural findings seen in brain magnetic resonance imaging (MRI) in malnourished children and the effect of optimized nutritional supplementation on brain development as studied through MRI. METHODS: A systematic search was carried out in PubMed, Embase, The Cochrane Library, Web of Science (Clarivate Analytics), WHO ICTRP Clinical Trials in Children, and ClinicalTrials.gov using a predefined search criterion for relevant literature from inception to January 2022. The primary outcome of the study was structural changes observed in the brain on MRI. RESULTS: The most common abnormal findings on MRI in malnourished infants were cerebral atrophy and dilated ventricles. Furthermore, a higher proportion of breast milk, calorie, and lipid intake in the diet was significantly associated with increased brain volumes; this also increased the likelihood of normal MRI scores at term. When followed till adolescence, it was observed that these infants had increased neonatal weight gain and a higher intelligence quotient when compared with the group. CONCLUSIONS: In conclusion, most children with moderate/severe malnutrition had abnormal MRI findings, mostly cerebral atrophy with or without ventricular dilatation. Since none of the studies measured the degree of atrophy or ventricular dilatation, it was not possible to assess the effect of the severity of malnutrition on brain atrophy. A universal measurement or scoring system for assessing the degree of brain atrophy is needed to help correlate the severity of malnutrition with the degree of brain atrophy and monitor the effects of nutritional rehabilitation over time.</text><annotation id="18"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="273" length="12"/><text>malnourished</text></annotation><annotation id="19"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="813" length="12"/><text>malnourished</text></annotation><annotation id="20"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="839" length="16"/><text>cerebral atrophy</text></annotation><annotation id="21"><infon key="identifier">MESH:D002311</infon><infon key="type">Disease</infon><location offset="860" length="18"/><text>dilated ventricles</text></annotation><annotation id="22"><infon key="identifier">MESH:D008055</infon><infon key="type">Chemical</infon><location offset="942" length="5"/><text>lipid</text></annotation><annotation id="23"><infon key="identifier">MESH:D015430</infon><infon key="type">Disease</infon><location offset="1181" length="11"/><text>weight gain</text></annotation><annotation id="24"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="1321" length="12"/><text>malnutrition</text></annotation><annotation id="25"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="1368" length="16"/><text>cerebral atrophy</text></annotation><annotation id="26"><infon key="identifier">MESH:C566255</infon><infon key="type">Disease</infon><location offset="1401" length="22"/><text>ventricular dilatation</text></annotation><annotation id="27"><infon key="identifier">MESH:D001284</infon><infon key="type">Disease</infon><location offset="1474" length="7"/><text>atrophy</text></annotation><annotation id="28"><infon key="identifier">MESH:C566255</infon><infon key="type">Disease</infon><location offset="1485" length="22"/><text>ventricular dilatation</text></annotation><annotation id="29"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="1569" length="12"/><text>malnutrition</text></annotation><annotation id="30"><infon key="identifier">MESH:C566985</infon><infon key="type">Disease</infon><location offset="1585" length="13"/><text>brain atrophy</text></annotation><annotation id="31"><infon key="identifier">MESH:C566985</infon><infon key="type">Disease</infon><location offset="1670" length="13"/><text>brain atrophy</text></annotation><annotation id="32"><infon key="identifier">MESH:D044342</infon><infon key="type">Disease</infon><location offset="1728" length="12"/><text>malnutrition</text></annotation><annotation id="33"><infon key="identifier">MESH:C566985</infon><infon key="type">Disease</infon><location offset="1760" length="13"/><text>brain atrophy</text></annotation></passage></document>
<document><id>37890659</id><passage><infon key="journal">J Thorac Cardiovasc Surg;2023Oct25. doi:10.1016/j.jtcvs.2023.10.042</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ad N, Holmes SD, </infon><offset>0</offset><text>Author Reply to Commentary: Surgical Treatment for Atrial Fibrillation: When It Comes to Atrial Fibrillation It Is Not the Great Evidence, It Is the Surgeon.</text><annotation id="2"><infon key="identifier">MESH:D001281</infon><infon key="type">Disease</infon><location offset="51" length="19"/><text>Atrial Fibrillation</text></annotation><annotation id="3"><infon key="identifier">MESH:D001281</infon><infon key="type">Disease</infon><location offset="89" length="19"/><text>Atrial Fibrillation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>158</offset></passage></document>
<document><id>37891010</id><passage><infon key="journal">Oral Dis;2023Oct27. doi:10.1111/odi.14769</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Thomas JT, Joseph B, Sorsa T, Mauramo M, Anil S, Waltimo T, </infon><offset>0</offset><text>Expression of advanced glycation end products and their receptors in diabetic periodontitis patients.</text><annotation id="1"><infon key="identifier">MESH:D010518</infon><infon key="type">Disease</infon><location offset="69" length="22"/><text>diabetic periodontitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>102</offset><text>AIM: The systematic review aimed to compare the levels of advanced glycation end products (AGEs) and RAGE (AGE receptors) expression in diabetic periodontitis patients with non-diabetic periodontitis patients and to identify the relationship of AGE and RAGE levels with periodontal disease severity. MATERIALS AND METHODS: The literature search was carried out according to PRISMA guidelines by two independent researchers using four online databases: PubMed, Scopus, Web of Science Core Collection, and Pro-Quest. Relevant studies published between 2000 and March 2023 were included in this review. The association of diabetes and AGE/RAGE levels on periodontal health, periodontal pocket depth (PPD), and clinical attachment loss (CAL) was studied. RESULTS: Sixteen cross-sectional studies, including 2794 patients (age range 15-75 years), were identified in the final stage. An elevated AGE level was observed among patients with diabetes and chronic periodontal disease compared to the non-diabetic group. Furthermore, the levels of AGE and RAGE are associated with CAL and PPD. Potential confounding factors like genetic and methodological differences were also responsible for AGE and RAGE variation. CONCLUSION: Levels of AGEs and RAGE expressions in diabetic periodontitis patients differ from non-diabetic periodontitis patients. The differences may impact the course and severity of periodontal disease.</text><annotation id="25"><infon key="identifier">177</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">883</infon><location offset="203" length="4"/><text>RAGE</text></annotation><annotation id="26"><infon key="identifier">5973</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2184</infon><location offset="209" length="3"/><text>AGE</text></annotation><annotation id="27"><infon key="identifier">MESH:D010518</infon><infon key="type">Disease</infon><location offset="238" length="22"/><text>diabetic periodontitis</text></annotation><annotation id="28"><infon key="identifier">MESH:D010518</infon><infon key="type">Disease</infon><location offset="279" length="22"/><text>diabetic periodontitis</text></annotation><annotation id="29"><infon key="identifier">5973</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2184</infon><location offset="347" length="3"/><text>AGE</text></annotation><annotation id="30"><infon key="identifier">177</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">883</infon><location offset="355" length="4"/><text>RAGE</text></annotation><annotation id="31"><infon key="identifier">MESH:D010510</infon><infon key="type">Disease</infon><location offset="372" length="19"/><text>periodontal disease</text></annotation><annotation id="32"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="721" length="8"/><text>diabetes</text></annotation><annotation id="33"><infon key="identifier">5973</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2184</infon><location offset="734" length="3"/><text>AGE</text></annotation><annotation id="34"><infon key="identifier">177</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">883</infon><location offset="738" length="4"/><text>RAGE</text></annotation><annotation id="35"><infon key="identifier">5973</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2184</infon><location offset="920" length="3"/><text>age</text></annotation><annotation id="36"><infon key="identifier">5973</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2184</infon><location offset="992" length="3"/><text>AGE</text></annotation><annotation id="37"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1035" length="8"/><text>diabetes</text></annotation><annotation id="38"><infon key="identifier">MESH:D010510</infon><infon key="type">Disease</infon><location offset="1056" length="19"/><text>periodontal disease</text></annotation><annotation id="39"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1096" length="8"/><text>diabetic</text></annotation><annotation id="40"><infon key="identifier">5973</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2184</infon><location offset="1139" length="3"/><text>AGE</text></annotation><annotation id="41"><infon key="identifier">177</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">883</infon><location offset="1147" length="4"/><text>RAGE</text></annotation><annotation id="42"><infon key="identifier">5973</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2184</infon><location offset="1285" length="3"/><text>AGE</text></annotation><annotation id="43"><infon key="identifier">177</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">883</infon><location offset="1293" length="4"/><text>RAGE</text></annotation><annotation id="44"><infon key="identifier">177</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">883</infon><location offset="1340" length="4"/><text>RAGE</text></annotation><annotation id="45"><infon key="identifier">MESH:D010518</infon><infon key="type">Disease</infon><location offset="1360" length="22"/><text>diabetic periodontitis</text></annotation><annotation id="46"><infon key="identifier">MESH:D010518</infon><infon key="type">Disease</infon><location offset="1408" length="22"/><text>diabetic periodontitis</text></annotation><annotation id="47"><infon key="identifier">MESH:D010510</infon><infon key="type">Disease</infon><location offset="1495" length="19"/><text>periodontal disease</text></annotation></passage><relation id="R1"><infon key="score">0.856</infon><infon key="role1">Disease|MESH:D010510</infon><infon key="role2">Gene|177</infon><infon key="type">Association</infon><node refid="0" role="7,1"/></relation><relation id="R2"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D010518</infon><infon key="role2">Gene|177</infon><infon key="type">Association</infon><node refid="1" role="3,1"/></relation><relation id="R3"><infon key="score">0.9353</infon><infon key="role1">Disease|MESH:D010510</infon><infon key="role2">Gene|5973</infon><infon key="type">Association</infon><node refid="2" role="7,2"/></relation><relation id="R4"><infon key="score">0.9989</infon><infon key="role1">Disease|MESH:D003920</infon><infon key="role2">Gene|5973</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="8,9"/></relation></document>
<document><id>37891361</id><passage><infon key="journal">Neurosurg Rev;2023Oct28; 46 (1) 286. doi:10.1007/s10143-023-02169-z</infon><infon key="year">2023</infon><infon key="article-id_pmc">6852930</infon><infon key="type">title</infon><infon key="authors">Harms JWA, Streckert EMS, Kiolbassa NM, Thomas C, Grauer O, Oertel M, Eich HT, Stummer W, Paulus W, Brokinkel B, </infon><offset>0</offset><text>Confounders of intraoperative frozen section pathology during glioma surgery.</text><annotation id="1"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="62" length="6"/><text>glioma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>78</offset><text>Although frozen section pathology (FSP) is commonly performed during surgery for glioma-suspicious lesions, confounders of accuracy are largely unknown. FSP and final diagnosis were compared in 398 surgeries for glioma-suspicious lesions. Diagnostic accuracy, risk factors for diagnostic shift from neoplastic to non-neoplastic tissue and vice versa according to the final diagnosis, and the impact on intraoperative and postoperative decision-making were analyzed. Diagnostic shift occurred in 70 cases (18%), and sensitivity, specificity, and the positive (PPV) and negative (NPV) predictive value of FSP were 82.5%, 77.8%, 99.4%, and 9.3%, respectively. No correlations between shift and patients' age and sex, sample fluorescence or volume, tumor location, correct information on the pathology form, final high- or low-grade histology, or molecular alterations were found (p > .05, each). Shift was more common after irradiation (25% vs 15%; p = .025) or chemotherapy (26% vs 15%; p = .022) than in treatment naive cases and correlated with the type of surgery (p = .002). FSP altered intraoperative decision-making in 25 cases (6%). Postoperative shift led to repeated surgery in 12 patients (3%). In 45 cases, in which FSP and final diagnosis based on the same tissue, shift occurred in only 5 patients (11%), and sensitivity, specificity, PPV, and NPV for FSP were 77.4%, 78.6%, 88.9%, and 61.1%, respectively. No correlations between diagnostic shift and any of the analyzed variables were found (p > .05, each). Although accuracy of FSP during glioma surgery is sufficient, moderate NPV should be considered during intraoperative decision-making. While confounders are sparse, accuracy might be increased by repeated sampling. Diagnostic shift rarely alters postoperative treatment strategy.</text><annotation id="6"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="159" length="6"/><text>glioma</text></annotation><annotation id="7"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="290" length="6"/><text>glioma</text></annotation><annotation id="8"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="823" length="5"/><text>tumor</text></annotation><annotation id="9"><infon key="identifier">MESH:D005910</infon><infon key="type">Disease</infon><location offset="1631" length="6"/><text>glioma</text></annotation></passage></document>
<document><id>37891712</id><passage><infon key="journal">Small Methods;2023Oct27 2301013. doi:10.1002/smtd.202301013</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ran Z, Liu J, Zhuang J, Liu Y, Hu C, </infon><offset>0</offset><text>Multicolor Afterglow from Carbon Dots: Preparation and Mechanism.</text><annotation id="1"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="26" length="11"/><text>Carbon Dots</text></annotation></passage><passage><infon key="type">abstract</infon><offset>66</offset><text>Carbon dots (CDs), as emerging long afterglow luminescent material, have attracted the attention of researchers and become one of the hot topics in long afterglow materials. In recent years, researchers have obtained a series of CDs-based long afterglow materials with different properties utilizing matrix-assisted and self-protective methods. To meet diverse application needs, the development of multicolor CDs-based long afterglow materials is a focus and challenge in this field. Most of the previously reported CDs-based long afterglow materials generally emit blue or green afterglow. Recently, some multicolor systems have been discovered, and the emission range can extend from ultraviolet to near-infrared. However, there is a lack of systematic and in-depth analysis regarding the preparation strategy and luminescence mechanism of multicolor afterglow from CDs-based long afterglow materials. Based on this, this review summarizes the preparation strategies of multicolor afterglow from raw materials and reaction parameters. Then, the luminescence mechanisms of multicolor afterglow are analyzed from seven factors, including carbonization degree, surface state, aggregation degree, temperature dependence, excitation dependence, multi-emission center, and energy transfer. Moreover, the applications of multicolor afterglow from CDs-based long afterglow materials are introduced. Finally, the problems and challenges in this field are discussed, and the future development directions are analyzed.</text><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="66" length="11"/><text>Carbon dots</text></annotation><annotation id="10"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="79" length="3"/><text>CDs</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="295" length="3"/><text>CDs</text></annotation><annotation id="12"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="476" length="3"/><text>CDs</text></annotation><annotation id="13"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="583" length="3"/><text>CDs</text></annotation><annotation id="14"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="935" length="3"/><text>CDs</text></annotation><annotation id="15"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1409" length="3"/><text>CDs</text></annotation></passage></document>
<document><id>37897320</id><passage><infon key="journal">Disabil Rehabil;2023Oct28 1. doi:10.1080/09638288.2023.2274884</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang X, Chen L, Lyu M, Wei N, </infon><offset>0</offset><text>The optimal cut-off values of screening tools for dynapenia: a cross-sectional study.</text><annotation id="1"><infon key="type">Disease</infon><location offset="50" length="9"/><text>dynapenia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>86</offset><text>PURPOSE: This study evaluated whether anthropometric measurements and the five times sit-to-stand test could be used to identify dynapenia. The cut-off values of accurate screening tools for identifying dynapenia were also established. MATERIALS AND METHODS: This was a cross-sectional study conducted on individuals >= 60 years old (N = 529). All participants underwent handgrip strength measurement, anthropometric measurements and the five times sit-to-stand test. The participants whose handgrip strength was &lt; 28 kg for men and &lt; 18 kg for women were considered to have dynapenia. The association between the recorded variables and dynapenia was determined using logistic regression, and cut-off values were established by performing the Receiver Operating Characteristic curve analysis. RESULTS: The prevalence of dynapenia was 35.42% in men and 25.61% in women. For males, both calf circumference (&lt;= 35.2 cm) and the five times sit-to-stand test (>= 14.6 s) could be used as accurate tools for dynapenia. For females, only the five times sit-to-stand test (>= 11.8 s) had sufficient accuracy to be used as a screening tool for dynapenia. CONCLUSIONS: The five times sit-to-stand test was an accurate screening tool for identifying dynapenia. The calf circumference could be only used as a screening tool in males.</text><annotation id="10"><infon key="type">Disease</infon><location offset="215" length="9"/><text>dynapenia</text></annotation><annotation id="11"><infon key="type">Disease</infon><location offset="289" length="9"/><text>dynapenia</text></annotation><annotation id="12"><infon key="type">Disease</infon><location offset="661" length="9"/><text>dynapenia</text></annotation><annotation id="13"><infon key="type">Disease</infon><location offset="723" length="9"/><text>dynapenia</text></annotation><annotation id="14"><infon key="type">Disease</infon><location offset="906" length="9"/><text>dynapenia</text></annotation><annotation id="15"><infon key="type">Disease</infon><location offset="1088" length="9"/><text>dynapenia</text></annotation><annotation id="16"><infon key="type">Disease</infon><location offset="1221" length="9"/><text>dynapenia</text></annotation><annotation id="17"><infon key="type">Disease</infon><location offset="1325" length="9"/><text>dynapenia</text></annotation></passage></document>
<document><id>37897671</id><passage><infon key="journal">J Bone Miner Metab;2023Oct28. doi:10.1007/s00774-023-01471-6</infon><infon key="year">2023</infon><infon key="article-id_pmc">7138213</infon><infon key="type">title</infon><infon key="authors">Harata S, Kasukawa Y, Nozaka K, Tsuchie H, Shoji R, Igarashi S, Kasama F, Oya K, Okamoto K, Miyakoshi N, </infon><offset>0</offset><text>Effects of bisphosphonates and treadmill exercise on bone and kidney in adenine-induced chronic kidney disease rats.</text><annotation id="4"><infon key="identifier">MESH:D004164</infon><infon key="type">Chemical</infon><location offset="11" length="15"/><text>bisphosphonates</text></annotation><annotation id="5"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="62" length="6"/><text>kidney</text></annotation><annotation id="6"><infon key="identifier">MESH:D000225</infon><infon key="type">Chemical</infon><location offset="72" length="7"/><text>adenine</text></annotation><annotation id="7"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="88" length="22"/><text>chronic kidney disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>117</offset><text>INTRODUCTION: The increasing prevalence of osteoporosis and chronic kidney disease (CKD) due to the aging of society has highlighted the need for development of effective treatments for elderly patients. This study examined whether the combination of treadmill exercise therapy and alendronate (ALN) can improve bone mineral density (BMD) and bone strength without worsening renal function in adenine-induced CKD model rats. MATERIALS AND METHODS: 8-week-old male Wistar rats (n = 70) were divided into experimental groups based on the treatment protocol, i.e., non-CKD (control), vehicle only (CKD), ALN only, exercise only, and combined ALN plus exercise. A 0.75% adenine diet was used to induce CKD. Groups were killed at either 20 or 30 weeks of age. Comprehensive assessments included serum and urine biochemistry tests, renal histology, bone histomorphometry, BMD measurement, micro-computed tomography examinations, and biomechanical testing. RESULTS: Blood biochemistry tests, urine analyses and histological evaluations of the kidney demonstrated that ALN treatment did not worsen renal function or kidney fibrosis in moderate-stage CKD model rats. Both ALN and treadmill exercise significantly suppressed bone resorption (p &lt; 0.05-p &lt; 0.01). Moreover, ALN monotherapy and combined ALN and treadmill exercise significantly improved BMD of the lumbar spine and femur, bone microstructure, and trabecular bone strength (p &lt; 0.05-p &lt; 0.01). Treadmill exercise was also shown to decrease cortical porosity at the mid-diaphysis of the femur and improve kidney fibrosis. CONCLUSION: The combination of ALN and treadmill exercise is effective in improving BMD, the microstructure of trabecular and cortical bone, and bone strength, without compromising renal function in adenine-induced CKD model rats.</text><annotation id="30"><infon key="identifier">MESH:D010024</infon><infon key="type">Disease</infon><location offset="160" length="12"/><text>osteoporosis</text></annotation><annotation id="31"><infon key="identifier">MESH:D051436</infon><infon key="type">Disease</infon><location offset="177" length="22"/><text>chronic kidney disease</text></annotation><annotation id="32"><infon key="identifier">MESH:D019386</infon><infon key="type">Chemical</infon><location offset="399" length="11"/><text>alendronate</text></annotation><annotation id="33"><infon key="identifier">MESH:D019386</infon><infon key="type">Chemical</infon><location offset="412" length="3"/><text>ALN</text></annotation><annotation id="34"><infon key="identifier">MESH:D006030</infon><infon key="type">Disease</infon><location offset="492" length="5"/><text>renal</text></annotation><annotation id="35"><infon key="identifier">MESH:D000225</infon><infon key="type">Chemical</infon><location offset="510" length="7"/><text>adenine</text></annotation><annotation id="36"><infon key="identifier">MESH:D019386</infon><infon key="type">Chemical</infon><location offset="718" length="3"/><text>ALN</text></annotation><annotation id="37"><infon key="identifier">MESH:D019386</infon><infon key="type">Chemical</infon><location offset="756" length="3"/><text>ALN</text></annotation><annotation id="38"><infon key="identifier">MESH:D000225</infon><infon key="type">Chemical</infon><location offset="783" length="7"/><text>adenine</text></annotation><annotation id="39"><infon key="identifier">MESH:D006030</infon><infon key="type">Disease</infon><location offset="943" length="5"/><text>renal</text></annotation><annotation id="40"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="1153" length="6"/><text>kidney</text></annotation><annotation id="41"><infon key="identifier">MESH:D019386</infon><infon key="type">Chemical</infon><location offset="1178" length="3"/><text>ALN</text></annotation><annotation id="42"><infon key="identifier">MESH:D006030</infon><infon key="type">Disease</infon><location offset="1207" length="5"/><text>renal</text></annotation><annotation id="43"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="1225" length="15"/><text>kidney fibrosis</text></annotation><annotation id="44"><infon key="identifier">MESH:D019386</infon><infon key="type">Chemical</infon><location offset="1280" length="3"/><text>ALN</text></annotation><annotation id="45"><infon key="identifier">MESH:D001862</infon><infon key="type">Disease</infon><location offset="1332" length="15"/><text>bone resorption</text></annotation><annotation id="46"><infon key="identifier">MESH:D019386</infon><infon key="type">Chemical</infon><location offset="1379" length="3"/><text>ALN</text></annotation><annotation id="47"><infon key="identifier">MESH:D019386</infon><infon key="type">Chemical</infon><location offset="1408" length="3"/><text>ALN</text></annotation><annotation id="48"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="1674" length="15"/><text>kidney fibrosis</text></annotation><annotation id="49"><infon key="identifier">MESH:D019386</infon><infon key="type">Chemical</infon><location offset="1722" length="3"/><text>ALN</text></annotation><annotation id="50"><infon key="identifier">MESH:D006030</infon><infon key="type">Disease</infon><location offset="1872" length="5"/><text>renal</text></annotation><annotation id="51"><infon key="identifier">MESH:D000225</infon><infon key="type">Chemical</infon><location offset="1890" length="7"/><text>adenine</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D019386</infon><infon key="role2">Disease|MESH:D001862</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="18,19"/></relation><relation id="R2"><infon key="score">0.6563</infon><infon key="role1">Chemical|MESH:D000225</infon><infon key="role2">Disease|MESH:D051436</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="2,3"/></relation></document>
<document><id>37898021</id><passage><infon key="journal">Biomaterials;2023Nov; 302 122363. doi:10.1016/j.biomaterials.2023.122363</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Gonzalez G, Nelson AC, Holman AR, Whitehead AJ, LaMontagne E, Lian R, Vatsyayan R, Dayeh SA, Engler AJ, </infon><offset>0</offset><text>Conductive electrospun polymer improves stem cell-derived cardiomyocyte function and maturation.</text><annotation id="1"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="23" length="7"/><text>polymer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>97</offset><text>Despite numerous efforts to generate mature human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs), cells often remain immature, electrically isolated, and may not reflect adult biology. Conductive polymers are attractive candidates to facilitate electrical communication between hPSC-CMs, especially at sub-confluent cell densities or diseased cells lacking cell-cell junctions. Here we electrospun conductive polymers to create a conductive fiber mesh and assess if electrical signal propagation is improved in hPSC-CMs seeded on the mesh network. Matrix characterization indicated fiber structure remained stable over weeks in buffer, scaffold stiffness remained near in vivo cardiac stiffness, and electrical conductivity scaled with conductive polymer concentration. Cells remained adherent and viable on the scaffolds for at least 5 days. Transcriptomic profiling of hPSC-CMs cultured on conductive substrates for 3 days showed upregulation of cardiac and muscle-related genes versus non-conductive fibers. Structural proteins were more organized and calcium handling was improved on conductive substrates, even at sub-confluent cell densities; prolonged culture on conductive scaffolds improved membrane depolarization compared to non-conductive substrates. Taken together, these data suggest that blended, conductive scaffolds are stable, supportive of electrical coupling in hPSC-CMs, and promote maturation, which may improve our ability to model cardiac diseases and develop targeted therapies.</text><annotation id="7"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="291" length="19"/><text>Conductive polymers</text></annotation><annotation id="8"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="504" length="19"/><text>conductive polymers</text></annotation><annotation id="9"><infon key="identifier">MESH:D011108</infon><infon key="type">Chemical</infon><location offset="853" length="7"/><text>polymer</text></annotation><annotation id="10"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="1161" length="7"/><text>calcium</text></annotation><annotation id="11"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="1561" length="16"/><text>cardiac diseases</text></annotation></passage></document>
<document><id>37898374</id><passage><infon key="journal">Transplant Cell Ther;2023Oct26. doi:10.1016/j.jtct.2023.10.014</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Munoz J, Flinn IW, Cohen JB, Sachs J, Exter B, Ranger A, Harris P, Payumo F, Nath R, Hamadani M, Westin JR, Bachanova V, </infon><offset>0</offset><text>Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B-Cell Lymphoma.</text><annotation id="4"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="32" length="7"/><text>ACTR707</text></annotation><annotation id="5"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="60" length="9"/><text>Rituximab</text></annotation><annotation id="6"><infon key="identifier">54474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56837</infon><location offset="110" length="4"/><text>CD20</text></annotation><annotation id="7"><infon key="identifier">MESH:D016393</infon><infon key="type">Disease</infon><location offset="116" length="15"/><text>B-Cell Lymphoma</text></annotation></passage><passage><infon key="type">abstract</infon><offset>133</offset><text>BACKGROUND: The antibody-coupled T-cell receptor (ACTR) platform is an autologous engineered T-cell therapy combining cell-killing ability of T-cells and tumor-targeting ability of co-administered antibodies. Activation of the T-cell product ACTR707 is dependent on engagement of antibody bound to target cells via the CD16 domain of the chimeric receptor (CD16V-CD28-CD3zeta). ACTR707 in combination with the anti-CD20 monoclonal antibody rituximab was evaluated in the ATTCK-20-03 study, a multi-site, single-arm, open-label phase I trial in B-cell NHL. OBJECTIVES: The primary objectives were to evaluate the safety of the combination of ACTR707 and rituximab and determine a recommended phase 2 dose (RP2D). Secondary objectives included evaluation of antitumor activity and ACTR T-cell persistence. STUDY DESIGN: The study design included an ACTR707 cell dose escalation phase and an expansion phase at the RP2D. Escalating dose levels of ACTR707 in combination with rituximab were explored in five dose cohorts with 25 subjects receiving study treatment. METHODS: Subjects received lymphodepleting (LD) chemotherapy (cyclophosphamide 400 mg/m2/day and fludarabine 30 mg/m2/day) for 3 days, followed by rituximab 375 mg/m2 and 24-48 hours later, a single dose of ACTR707. Additional doses of rituximab were administered q3w until either disease progression, unacceptable toxicity, or Investigator decision. Blood samples were collected at various timepoints to assess rituximab levels, cytokines, inflammatory markers and ACTR707 T-cell levels. RESULTS: The overall response rate of ACTR707 plus rituximab was 56% (14/25) across all dose levels. Ten subjects (40.0%) achieved complete response (CR), with the longest duration of 586 days (min-max: 85-586), and 4 subjects (16.0%) experienced partial response (PR) with the longest duration of 130 days (min-max: 44-130). Only one case of cytokine release syndrome (CRS; Grade 2) and no events of neurotoxicity were reported. There were no dose limiting toxicities (DLTs) or events leading to death. ACTR707 plus rituximab resulted in only one adverse event (AE) (neutropenia) leading to study discontinuation of rituximab. CONCLUSIONS: The ATTCK-20-03 trial serves as proof of principle regarding the ACTR approach that could potentially be used with other antibodies targeting other markers in other malignancies. Although the ACTR707 program has been discontinued, these results may support other programs in employing similar novel approaches of antibody-coupled T-cell activation.</text><annotation id="44"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="287" length="5"/><text>tumor</text></annotation><annotation id="45"><infon key="identifier">2214</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">477</infon><location offset="452" length="4"/><text>CD16</text></annotation><annotation id="46"><infon key="identifier">940</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4473</infon><location offset="496" length="4"/><text>CD28</text></annotation><annotation id="47"><infon key="identifier">919</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12818</infon><location offset="501" length="7"/><text>CD3zeta</text></annotation><annotation id="48"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="511" length="7"/><text>ACTR707</text></annotation><annotation id="49"><infon key="identifier">54474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56837</infon><location offset="548" length="4"/><text>CD20</text></annotation><annotation id="50"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="573" length="9"/><text>rituximab</text></annotation><annotation id="51"><infon key="identifier">MESH:D015448</infon><infon key="type">Disease</infon><location offset="677" length="10"/><text>B-cell NHL</text></annotation><annotation id="52"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="774" length="7"/><text>ACTR707</text></annotation><annotation id="53"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="786" length="9"/><text>rituximab</text></annotation><annotation id="54"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="980" length="7"/><text>ACTR707</text></annotation><annotation id="55"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="1105" length="9"/><text>rituximab</text></annotation><annotation id="56"><infon key="identifier">MESH:D003520</infon><infon key="type">Chemical</infon><location offset="1256" length="16"/><text>cyclophosphamide</text></annotation><annotation id="57"><infon key="identifier">MESH:C024352</infon><infon key="type">Chemical</infon><location offset="1291" length="11"/><text>fludarabine</text></annotation><annotation id="58"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="1341" length="9"/><text>rituximab</text></annotation><annotation id="59"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1401" length="7"/><text>ACTR707</text></annotation><annotation id="60"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="1430" length="9"/><text>rituximab</text></annotation><annotation id="61"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="1509" length="8"/><text>toxicity</text></annotation><annotation id="62"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="1606" length="9"/><text>rituximab</text></annotation><annotation id="63"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1635" length="12"/><text>inflammatory</text></annotation><annotation id="64"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1721" length="7"/><text>ACTR707</text></annotation><annotation id="65"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="1734" length="9"/><text>rituximab</text></annotation><annotation id="66"><infon key="identifier">MESH:D000080424</infon><infon key="type">Disease</infon><location offset="2026" length="25"/><text>cytokine release syndrome</text></annotation><annotation id="67"><infon key="identifier">MESH:D000080424</infon><infon key="type">Disease</infon><location offset="2053" length="3"/><text>CRS</text></annotation><annotation id="68"><infon key="identifier">MESH:D020258</infon><infon key="type">Disease</infon><location offset="2084" length="13"/><text>neurotoxicity</text></annotation><annotation id="69"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="2141" length="10"/><text>toxicities</text></annotation><annotation id="70"><infon key="identifier">MESH:D045745</infon><infon key="type">Disease</infon><location offset="2153" length="4"/><text>DLTs</text></annotation><annotation id="71"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="2180" length="5"/><text>death</text></annotation><annotation id="72"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2187" length="7"/><text>ACTR707</text></annotation><annotation id="73"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="2200" length="9"/><text>rituximab</text></annotation><annotation id="74"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="2231" length="13"/><text>adverse event</text></annotation><annotation id="75"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="2246" length="2"/><text>AE</text></annotation><annotation id="76"><infon key="identifier">MESH:D009503</infon><infon key="type">Disease</infon><location offset="2251" length="11"/><text>neutropenia</text></annotation><annotation id="77"><infon key="identifier">MESH:D000069283</infon><infon key="type">Chemical</infon><location offset="2300" length="9"/><text>rituximab</text></annotation><annotation id="78"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="2489" length="12"/><text>malignancies</text></annotation><annotation id="79"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2516" length="7"/><text>ACTR707</text></annotation></passage><relation id="R1"><infon key="score">0.9972</infon><infon key="role1">Chemical|MESH:D000069283</infon><infon key="role2">Gene|54474</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="1,2"/></relation><relation id="R2"><infon key="score">0.9273</infon><infon key="role1">Chemical|MESH:D000069283</infon><infon key="role2">Disease|MESH:D009503</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="35,38"/></relation><relation id="R3"><infon key="score">0.6158</infon><infon key="role1">Chemical|MESH:D003520</infon><infon key="role2">Disease|MESH:D015448</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="18,12"/></relation><relation id="R4"><infon key="score">0.9879</infon><infon key="role1">Chemical|MESH:D000069283</infon><infon key="role2">Disease|MESH:D015448</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="11,12"/></relation><relation id="R5"><infon key="score">0.9968</infon><infon key="role1">Chemical|MESH:D000069283</infon><infon key="role2">Disease|MESH:D016393</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="1,3"/></relation><relation id="R6"><infon key="score">0.9115</infon><infon key="role1">Chemical|MESH:D000069283</infon><infon key="role2">Disease|MESH:D020258</infon><infon key="type">Positive_Correlation</infon><node refid="5" role="27,30"/></relation><relation id="R7"><infon key="score">0.9995</infon><infon key="role1">Disease|MESH:D016393</infon><infon key="role2">Gene|54474</infon><infon key="type">Association</infon><node refid="6" role="3,2"/></relation></document>
<document><id>37898724</id><passage><infon key="journal">Br J Cancer;2023Oct28. doi:10.1038/s41416-023-02472-y</infon><infon key="year">2023</infon><infon key="article-id_pmc">2849765</infon><infon key="type">title</infon><infon key="authors">Feng X, Zhang Y, Vaselkiv JB, Li R, Nguyen PL, Penney KL, Giovannucci EL, Mucci LA, Stopsack KH, </infon><offset>0</offset><text>Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.</text><annotation id="1"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="46" length="15"/><text>prostate cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>116</offset><text>BACKGROUND: Previously suggested modifiable risk factors for prostate cancer could have resulted from detection bias because diagnosis requires a biopsy. We investigated modifiable risk factors for a subsequent cancer diagnosis among men with an initially negative prostate biopsy. METHODS: In total, 10,396 participants of the Health Professionals Follow-up Study with an initial negative prostate biopsy after 1994 were followed for incident prostate cancer until 2017. Potential risk factors were based on previous studies in the general population. Outcomes included localised, advanced, and lethal prostate cancer. RESULTS: With 1851 prostate cancer cases (168 lethal) diagnosed over 23 years of follow-up, the 20-year risk of any prostate cancer diagnosis was 18.5% (95% CI: 17.7-19.3). Higher BMI and lower alcohol intake tended to be associated with lower rates of localised disease. Coffee, lycopene intake and statin use tended to be associated with lower rates of lethal prostate cancer. Results for other risk factors were less precise but compatible with and of similar direction as for men in the overall cohort. CONCLUSIONS: Risk factors for future prostate cancer among men with a negative biopsy were generally consistent with those for the general population, supporting their validity given reduced detection bias, and could be actionable, if confirmed.</text><annotation id="13"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="177" length="15"/><text>prostate cancer</text></annotation><annotation id="14"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="327" length="6"/><text>cancer</text></annotation><annotation id="15"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="560" length="15"/><text>prostate cancer</text></annotation><annotation id="16"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="719" length="15"/><text>prostate cancer</text></annotation><annotation id="17"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="755" length="15"/><text>prostate cancer</text></annotation><annotation id="18"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="852" length="15"/><text>prostate cancer</text></annotation><annotation id="19"><infon key="identifier">MESH:D000438</infon><infon key="type">Chemical</infon><location offset="930" length="7"/><text>alcohol</text></annotation><annotation id="20"><infon key="identifier">MESH:D004194</infon><infon key="type">Disease</infon><location offset="999" length="7"/><text>disease</text></annotation><annotation id="21"><infon key="identifier">MESH:D000077276</infon><infon key="type">Chemical</infon><location offset="1016" length="8"/><text>lycopene</text></annotation><annotation id="22"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="1098" length="15"/><text>prostate cancer</text></annotation><annotation id="23"><infon key="identifier">MESH:D011471</infon><infon key="type">Disease</infon><location offset="1280" length="15"/><text>prostate cancer</text></annotation></passage><relation id="R1"><infon key="score">0.9992</infon><infon key="role1">Chemical|MESH:D000438</infon><infon key="role2">Disease|MESH:D004194</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="7,8"/></relation><relation id="R2"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D000077276</infon><infon key="role2">Disease|MESH:D011471</infon><infon key="type">Negative_Correlation</infon><node refid="1" role="9,10"/></relation></document>
<document><id>37901877</id><passage><infon key="journal">Biomed Rep;2023Dec; 19 (6) 91. doi:10.3892/br.2023.1673</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10603372</infon><infon key="type">title</infon><infon key="authors">Muniandy S, Few LL, Khoo BY, Hassan SA, Yvonne-&amp;#x3a4;ee GB, See Too WC, </infon><offset>0</offset><text>Dysregulated expression of miR-367 in disease development and its prospects as a therapeutic target and diagnostic biomarker (Review).</text><annotation id="1"><infon key="identifier">442912</infon><infon key="type">Gene</infon><location offset="27" length="7"/><text>miR-367</text></annotation></passage><passage><infon key="type">abstract</infon><offset>135</offset><text>MicroRNA (miR)-367 has a wide range of functions in gene regulation and as such plays a critical role in cell proliferation, differentiation and development, making it an essential molecule in various physiological processes. miR-367 belongs to the miR-302/367 cluster and is located in the intronic region of human chromosome 4 on the 4q25 locus. Dysregulation of miR-367 is associated with various disease conditions, including cancer, inflammation and cardiac conditions. Moreover, miR-367 has shown promise both as a tumor suppressor and a potential diagnostic biomarker for breast, gastric and prostate cancer. The elucidation of the essential role of miR-367 in inflammation, development and cardiac diseases emphasizes its versatility in regulating various physiological processes beyond cancer biology. However, further research is necessary to fully understand the complex regulatory mechanisms involving miR-367 in different physiological and pathological contexts. In conclusion, the versatility and significance of miR-367 makes it a promising candidate for further study and in the development of new diagnostic and therapeutic strategies.</text><annotation id="20"><infon key="identifier">442912</infon><infon key="type">Gene</infon><location offset="135" length="18"/><text>MicroRNA (miR)-367</text></annotation><annotation id="21"><infon key="identifier">442912</infon><infon key="type">Gene</infon><location offset="361" length="7"/><text>miR-367</text></annotation><annotation id="22"><infon key="identifier">442912</infon><infon key="type">Gene</infon><location offset="384" length="11"/><text>miR-302/367</text></annotation><annotation id="23"><infon key="identifier">4</infon><infon key="type">Chromosome</infon><location offset="451" length="12"/><text>chromosome 4</text></annotation><annotation id="24"><infon key="identifier">4</infon><infon key="type">Chromosome</infon><location offset="471" length="4"/><text>4q25</text></annotation><annotation id="25"><infon key="identifier">442912</infon><infon key="type">Gene</infon><location offset="500" length="7"/><text>miR-367</text></annotation><annotation id="26"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="565" length="6"/><text>cancer</text></annotation><annotation id="27"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="573" length="12"/><text>inflammation</text></annotation><annotation id="28"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="590" length="18"/><text>cardiac conditions</text></annotation><annotation id="29"><infon key="identifier">442912</infon><infon key="type">Gene</infon><location offset="620" length="7"/><text>miR-367</text></annotation><annotation id="30"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="656" length="5"/><text>tumor</text></annotation><annotation id="31"><infon key="identifier">MESH:C537243</infon><infon key="type">Disease</infon><location offset="714" length="35"/><text>breast, gastric and prostate cancer</text></annotation><annotation id="32"><infon key="identifier">442912</infon><infon key="type">Gene</infon><location offset="792" length="7"/><text>miR-367</text></annotation><annotation id="33"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="803" length="12"/><text>inflammation</text></annotation><annotation id="34"><infon key="identifier">MESH:D006331</infon><infon key="type">Disease</infon><location offset="833" length="16"/><text>cardiac diseases</text></annotation><annotation id="35"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="930" length="6"/><text>cancer</text></annotation><annotation id="36"><infon key="identifier">442912</infon><infon key="type">Gene</infon><location offset="1049" length="7"/><text>miR-367</text></annotation><annotation id="37"><infon key="identifier">442912</infon><infon key="type">Gene</infon><location offset="1162" length="7"/><text>miR-367</text></annotation></passage><relation id="R1"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|442912</infon><infon key="type">Association</infon><node refid="0" role="8,6"/></relation><relation id="R2"><infon key="score">0.9991</infon><infon key="role1">Disease|MESH:D009369</infon><infon key="role2">Gene|442912</infon><infon key="type">Association</infon><node refid="1" role="7,6"/></relation><relation id="R3"><infon key="score">0.9903</infon><infon key="role1">Disease|MESH:C537243</infon><infon key="role2">Gene|442912</infon><infon key="type">Association</infon><node refid="2" role="12,10"/></relation><relation id="R4"><infon key="score">0.9992</infon><infon key="role1">Disease|MESH:D006331</infon><infon key="role2">Gene|442912</infon><infon key="type">Association</infon><node refid="3" role="9,6"/></relation></document>
<document><id>37902227</id><passage><infon key="journal">Psychol Rep;2023Oct30 332941231207957. doi:10.1177/00332941231207957</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Rabbing L, Lau B, Fostervold KI, Blenkinsopp J, Bj&amp;#xf8;rkelo B, </infon><offset>0</offset><text>Enhancing Self-Reported Assessment of Working Conditions in Policing: Revisiting the Psychometric Properties and Applications of the Police Stress Questionnaire.</text><annotation id="1"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="140" length="6"/><text>Stress</text></annotation></passage><passage><infon key="type">abstract</infon><offset>162</offset><text>OBJECTIVES: Policing is recognized as a highly stressful occupation, encompassing stressors not commonly encountered in other fields. In response, police-specific stress scales have been developed and used when studying police work. Despite changes in the composition of police personnel, most studies examining police working conditions focus on sworn police officers (SPO), excluding employees without police education (EWPE). To advance research and practice on stress in the police, align results, and increase the possibilities for comparisons across studies using police-specific measures (PSMs) we conducted a psychometric evaluation of the two scales in the Police Stress Questionnaire (PSQ). We examined whether adding "Not Applicable" to the response scales would reduce vulnerability and make the PSQ more robust. METHOD: Based on a survey with a randomised sample (N = 560) of SPO and EWPE in the Norwegian Police, we tested the original factor structures of the PSQ through Confirmatory Factor Analysis including tests of factor structures from previous studies. RESULTS: For all models, the indicators of fit indicated a poor fit with either our whole or stratified sample. The response choice 'Not Applicable' provided extended information for SPOs and EWPEs on the PSQ. CONCLUSIONS: To promote aligning results and enabling comparisons across studies using the PSQ, we suggest treating the PSQ scales as formative indexes, rather than reflective scales. Adding "Not Applicable" to the response scale offers an influential elaboration of the PSQ with beneficial and extended information. Generalised studies of stress in the police should include the entire population working there.</text><annotation id="6"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="325" length="6"/><text>stress</text></annotation><annotation id="7"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="627" length="6"/><text>stress</text></annotation><annotation id="8"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="835" length="6"/><text>Stress</text></annotation><annotation id="9"><infon key="identifier">MESH:D000079225</infon><infon key="type">Disease</infon><location offset="1788" length="6"/><text>stress</text></annotation></passage></document>
<document><id>37902577</id><passage><infon key="journal">J Intern Med;2023Oct30. doi:10.1111/joim.13737</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Mart&amp;#xed;nez-Montoro JI, Pic&amp;#xf3;n-C&amp;#xe9;sar MJ, Generoso-Pi&amp;#xf1;ar M, Fern&amp;#xe1;ndez-Valero A, L&amp;#xf3;pez-Montalb&amp;#xe1;n &amp;#xc1;, Sim&amp;#xf3;n-Frapolli VJ, Hern&amp;#xe1;ndez-Bayo J, Pinz&amp;#xf3;n-Mart&amp;#xed;n JL, Tinahones FJ, </infon><offset>0</offset><text>Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study.</text><annotation id="1"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="51" length="15"/><text>type 2 diabetes</text></annotation></passage><passage><infon key="type">abstract</infon><offset>89</offset></passage></document>
<document><id>37902927</id><passage><infon key="journal">Inflammopharmacology;2023Oct30. doi:10.1007/s10787-023-01362-2</infon><infon key="year">2023</infon><infon key="article-id_pmc">3751427</infon><infon key="type">title</infon><infon key="authors">Abdel-Razek EA, Mahmoud HM, Azouz AA, </infon><offset>0</offset><text>Management of ulcerative colitis by dichloroacetate: Impact on NFATC1/NLRP3/IL1B signaling based on bioinformatics analysis combined with in vivo experimental verification.</text><annotation id="5"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="14" length="18"/><text>ulcerative colitis</text></annotation><annotation id="6"><infon key="identifier">MESH:D003999</infon><infon key="type">Chemical</infon><location offset="36" length="15"/><text>dichloroacetate</text></annotation><annotation id="7"><infon key="identifier">4772</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">32336</infon><location offset="63" length="6"/><text>NFATC1</text></annotation><annotation id="8"><infon key="identifier">114548</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="70" length="5"/><text>NLRP3</text></annotation><annotation id="9"><infon key="identifier">3553</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="76" length="4"/><text>IL1B</text></annotation></passage><passage><infon key="type">abstract</infon><offset>173</offset><text>The inflammatory response in ulcerative colitis (UC) could be relieved by the conventional immunomodulatory agents; 5-aminosalicylic acid, corticosteroids, or azathioprine. However, the low remission rates and the intolerance to these agents necessitate investigation of gene expression signature in UC that could influence the therapeutic efficacy of drugs, as well as the interference with persistence genes by novel therapeutic option. Three microarray datasets (GSE66407, GSE38713 and GSE14580) from the NCBI-GEO database were utilized. Differentially expressed genes between samples of patients with UC and healthy ones were analyzed using R software. In addition, in vivo study using oxazolone-induced UC in BALB/c mice was carried out to investigate the proposed therapeutic efficacy of dichloroacetate (DCA). The bioinformatics analysis revealed the persistence of NLRP3, NFATC1, and IL1B in UC despite treatment with common therapeutic agents. DCA administration to oxazolone-treated mice showed remarkable interference with those persistence genes. Western blotting analysis for NLRP3, NFATC1, nuclear/total NF-kappaB, and cleaved caspase-1 revealed the ability of DCA to reduce the expression levels of these proteins in oxazolone-treated mice. Additionally, the inflammatory cytokines IL-1beta and IL-13 were reduced in colonic tissue by DCA treatment. The therapeutic efficacy of DCA was further confirmed by the apparent reduction in histopathological scoring, disease activity index, and the normalization of colon length. Therefore, DCA could be suggested as a novel and promising therapeutic option in UC based on its ability to interfere with the persistence of NFATC1/NLRP3/IL1B signaling. That merits further safety/toxicological pre-clinical assessment and update of bioavailability/metabolism data prior to clinical investigation.</text><annotation id="44"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="177" length="12"/><text>inflammatory</text></annotation><annotation id="45"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="202" length="18"/><text>ulcerative colitis</text></annotation><annotation id="46"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="222" length="2"/><text>UC</text></annotation><annotation id="47"><infon key="identifier">MESH:D019804</infon><infon key="type">Chemical</infon><location offset="289" length="21"/><text>5-aminosalicylic acid</text></annotation><annotation id="48"><infon key="identifier">MESH:D001379</infon><infon key="type">Chemical</infon><location offset="332" length="12"/><text>azathioprine</text></annotation><annotation id="49"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="473" length="2"/><text>UC</text></annotation><annotation id="50"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="778" length="2"/><text>UC</text></annotation><annotation id="51"><infon key="identifier">MESH:D010081</infon><infon key="type">Chemical</infon><location offset="863" length="9"/><text>oxazolone</text></annotation><annotation id="52"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="881" length="2"/><text>UC</text></annotation><annotation id="53"><infon key="identifier">CVCL:0184</infon><infon key="type">CellLine</infon><location offset="887" length="6"/><text>BALB/c</text></annotation><annotation id="54"><infon key="identifier">MESH:D003999</infon><infon key="type">Chemical</infon><location offset="967" length="15"/><text>dichloroacetate</text></annotation><annotation id="55"><infon key="identifier">MESH:D003999</infon><infon key="type">Chemical</infon><location offset="984" length="3"/><text>DCA</text></annotation><annotation id="56"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="1046" length="5"/><text>NLRP3</text></annotation><annotation id="57"><infon key="identifier">18018</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">32336</infon><location offset="1053" length="6"/><text>NFATC1</text></annotation><annotation id="58"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1065" length="4"/><text>IL1B</text></annotation><annotation id="59"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="1073" length="2"/><text>UC</text></annotation><annotation id="60"><infon key="identifier">MESH:D003999</infon><infon key="type">Chemical</infon><location offset="1126" length="3"/><text>DCA</text></annotation><annotation id="61"><infon key="identifier">MESH:D010081</infon><infon key="type">Chemical</infon><location offset="1148" length="9"/><text>oxazolone</text></annotation><annotation id="62"><infon key="identifier">216799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="1262" length="5"/><text>NLRP3</text></annotation><annotation id="63"><infon key="identifier">18018</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">32336</infon><location offset="1269" length="6"/><text>NFATC1</text></annotation><annotation id="64"><infon key="identifier">18033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2971</infon><location offset="1291" length="9"/><text>NF-kappaB</text></annotation><annotation id="65"><infon key="identifier">12362</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133272</infon><location offset="1314" length="9"/><text>caspase-1</text></annotation><annotation id="66"><infon key="identifier">MESH:D003999</infon><infon key="type">Chemical</infon><location offset="1348" length="3"/><text>DCA</text></annotation><annotation id="67"><infon key="identifier">MESH:D010081</infon><infon key="type">Chemical</infon><location offset="1405" length="9"/><text>oxazolone</text></annotation><annotation id="68"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="1447" length="12"/><text>inflammatory</text></annotation><annotation id="69"><infon key="identifier">16176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1470" length="8"/><text>IL-1beta</text></annotation><annotation id="70"><infon key="identifier">16163</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1649</infon><location offset="1483" length="5"/><text>IL-13</text></annotation><annotation id="71"><infon key="identifier">MESH:D003999</infon><infon key="type">Chemical</infon><location offset="1523" length="3"/><text>DCA</text></annotation><annotation id="72"><infon key="identifier">MESH:D003999</infon><infon key="type">Chemical</infon><location offset="1566" length="3"/><text>DCA</text></annotation><annotation id="73"><infon key="identifier">MESH:D003999</infon><infon key="type">Chemical</infon><location offset="1722" length="3"/><text>DCA</text></annotation><annotation id="74"><infon key="identifier">MESH:D003093</infon><infon key="type">Disease</infon><location offset="1792" length="2"/><text>UC</text></annotation><annotation id="75"><infon key="identifier">4772</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">32336</infon><location offset="1853" length="6"/><text>NFATC1</text></annotation><annotation id="76"><infon key="identifier">114548</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3600</infon><location offset="1860" length="5"/><text>NLRP3</text></annotation><annotation id="77"><infon key="identifier">3553</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">481</infon><location offset="1866" length="4"/><text>IL1B</text></annotation></passage><relation id="R1"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Gene|18033</infon><infon key="type">Negative_Correlation</infon><node refid="0" role="27,25"/></relation><relation id="R2"><infon key="score">0.9274</infon><infon key="role1">Disease|MESH:D003093</infon><infon key="role2">Gene|114548</infon><infon key="type">Association</infon><node refid="1" role="0,3"/></relation><relation id="R3"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D003093</infon><infon key="role2">Gene|216799</infon><infon key="type">Association</infon><node refid="2" role="20,17"/></relation><relation id="R4"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D001379</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="3" role="9,5"/></relation><relation id="R5"><infon key="score">0.9984</infon><infon key="role1">Chemical|MESH:D001379</infon><infon key="role2">Disease|MESH:D003093</infon><infon key="type">Negative_Correlation</infon><node refid="4" role="9,6"/></relation><relation id="R6"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|16163</infon><infon key="type">Association</infon><node refid="5" role="29,31"/></relation><relation id="R7"><infon key="score">0.9917</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Gene|18018</infon><infon key="type">Negative_Correlation</infon><node refid="6" role="27,24"/></relation><relation id="R8"><infon key="score">0.9988</infon><infon key="role1">Disease|MESH:D007249</infon><infon key="role2">Gene|16176</infon><infon key="type">Association</infon><node refid="7" role="29,30"/></relation><relation id="R9"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D019804</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="8" role="8,5"/></relation><relation id="R10"><infon key="score">0.4911</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Gene|216799</infon><infon key="type">Negative_Correlation</infon><node refid="9" role="27,23"/></relation><relation id="R11"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Disease|MESH:D007249</infon><infon key="type">Negative_Correlation</infon><node refid="10" role="32,29"/></relation><relation id="R12"><infon key="score">0.9595</infon><infon key="role1">Disease|MESH:D003093</infon><infon key="role2">Gene|4772</infon><infon key="type">Association</infon><node refid="11" role="0,2"/></relation><relation id="R13"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Gene|3553</infon><infon key="type">Association</infon><node refid="12" role="1,4"/></relation><relation id="R14"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Gene|12362</infon><infon key="type">Negative_Correlation</infon><node refid="13" role="27,26"/></relation><relation id="R15"><infon key="score">0.9981</infon><infon key="role1">Chemical|MESH:D019804</infon><infon key="role2">Disease|MESH:D003093</infon><infon key="type">Negative_Correlation</infon><node refid="14" role="8,6"/></relation><relation id="R16"><infon key="score">0.9981</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Disease|MESH:D003093</infon><infon key="type">Negative_Correlation</infon><node refid="15" role="1,0"/></relation><relation id="R17"><infon key="score">0.9934</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Chemical|MESH:D010081</infon><infon key="type">Negative_Correlation</infon><node refid="16" role="15,12"/></relation><relation id="R18"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Gene|114548</infon><infon key="type">Association</infon><node refid="17" role="1,3"/></relation><relation id="R19"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Gene|16176</infon><infon key="type">Negative_Correlation</infon><node refid="18" role="32,30"/></relation><relation id="R20"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D003093</infon><infon key="role2">Gene|16176</infon><infon key="type">Association</infon><node refid="19" role="20,19"/></relation><relation id="R21"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Gene|4772</infon><infon key="type">Association</infon><node refid="20" role="1,2"/></relation><relation id="R22"><infon key="score">0.9962</infon><infon key="role1">Chemical|MESH:D010081</infon><infon key="role2">Disease|MESH:D003093</infon><infon key="type">Positive_Correlation</infon><node refid="21" role="12,13"/></relation><relation id="R23"><infon key="score">0.999</infon><infon key="role1">Chemical|MESH:D003999</infon><infon key="role2">Gene|16163</infon><infon key="type">Negative_Correlation</infon><node refid="22" role="32,31"/></relation><relation id="R24"><infon key="score">0.9876</infon><infon key="role1">Disease|MESH:D003093</infon><infon key="role2">Gene|3553</infon><infon key="type">Association</infon><node refid="23" role="0,4"/></relation><relation id="R25"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D003093</infon><infon key="role2">Gene|18018</infon><infon key="type">Association</infon><node refid="24" role="20,18"/></relation></document>
<document><id>37903305</id><passage><infon key="journal">Retin Cases Brief Rep;2023Nov01; 17 (6) 649. doi:10.1097/ICB.0000000000001268</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Chebolu AP, Wallsh JO, Falk N, Bhatnagar P, </infon><offset>0</offset><text>CENTRAL RETINAL ARTERY OCCLUSION AS PRESENTATION OF BARTONELLA ENDOCARDITIS.</text><annotation id="1"><infon key="identifier">MESH:D004696</infon><infon key="type">Disease</infon><location offset="23" length="52"/><text>OCCLUSION AS PRESENTATION OF BARTONELLA ENDOCARDITIS</text></annotation></passage><passage><infon key="type">abstract</infon><offset>77</offset><text>BACKGROUND/PURPOSE: To describe a rare ocular presentation of a systemic illness and the important lifesaving diagnosis made by a complete eye examination. METHODS: The patient was evaluated with a comprehensive ophthalmic examination and followed closely in the outpatient setting with optical coherence tomography, fluorescein angiography, and color fundus photos. RESULTS: A 66-year-old man presented with acute vision loss of the left eye. A complete eye examination revealed that he had a central retinal artery occlusion. Systemic workup revealed that he had a mitral valve vegetation and blood cultures grew Bartonella henselae. His kidney biopsy showed membranoproliferative glomerulonephritis, which is often seen with septic emboli. Furthermore, the patient lacked any ocular inflammatory signs. This constellation of findings was diagnostic for a thromboembolic etiology causing his central retinal artery occlusion. At follow-up, the optical coherence tomography demonstrated inner retinal hyperreflectivity and the fluorescein angiogram showed segmented flow and no neovascularization. On follow-up, the patient had a stable examination with light perception vision and completed antibiotic therapy for bartonella endocarditis. CONCLUSION: The detection of a fatal systemic illness was made promptly with a thorough ocular examination. We highlight the importance of a multidisciplinary approach in making a lifesaving diagnosis.</text><annotation id="14"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="141" length="16"/><text>systemic illness</text></annotation><annotation id="15"><infon key="identifier">MESH:D019793</infon><infon key="type">Chemical</infon><location offset="394" length="11"/><text>fluorescein</text></annotation><annotation id="16"><infon key="identifier">MESH:D014786</infon><infon key="type">Disease</infon><location offset="492" length="11"/><text>vision loss</text></annotation><annotation id="17"><infon key="identifier">MESH:D015356</infon><infon key="type">Disease</infon><location offset="579" length="24"/><text>retinal artery occlusion</text></annotation><annotation id="18"><infon key="identifier">MESH:D008944</infon><infon key="type">Disease</infon><location offset="644" length="23"/><text>mitral valve vegetation</text></annotation><annotation id="19"><infon key="identifier">MESH:D015432</infon><infon key="type">Disease</infon><location offset="738" length="40"/><text>membranoproliferative glomerulonephritis</text></annotation><annotation id="20"><infon key="identifier">MESH:D020766</infon><infon key="type">Disease</infon><location offset="805" length="13"/><text>septic emboli</text></annotation><annotation id="21"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="856" length="19"/><text>ocular inflammatory</text></annotation><annotation id="22"><infon key="identifier">MESH:D013923</infon><infon key="type">Disease</infon><location offset="935" length="14"/><text>thromboembolic</text></annotation><annotation id="23"><infon key="identifier">MESH:D015356</infon><infon key="type">Disease</infon><location offset="979" length="24"/><text>retinal artery occlusion</text></annotation><annotation id="24"><infon key="identifier">MESH:D019793</infon><infon key="type">Chemical</infon><location offset="1105" length="11"/><text>fluorescein</text></annotation><annotation id="25"><infon key="identifier">MESH:D012140</infon><infon key="type">Disease</infon><location offset="1355" length="16"/><text>systemic illness</text></annotation></passage></document>
<document><id>37903656</id><passage><infon key="journal">Eur J Heart Fail;2023Oct; 25 (10) 1719. doi:10.1002/ejhf.3070</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Tomasoni D, Adamo M, Metra M, </infon><offset>0</offset><text>October 2023 at a glance: From prevention to diagnosis, prognosis and treatment of acute decompensation and comorbidities.</text></passage><passage><infon key="type">abstract</infon><offset>123</offset></passage></document>
<document><id>37904007</id><passage><infon key="journal">Psychol Res;2023Oct31. doi:10.1007/s00426-023-01890-0</infon><infon key="year">2023</infon><infon key="article-id_pmc">4663255</infon><infon key="type">title</infon><infon key="authors">Abou Khalil G, Dor&amp;#xe9;-Mazars K, Legrand A, </infon><offset>0</offset><text>Stand up to better pay attention, sit down to better subtract: a new perspective on the advantage of cognitive-motor interactions.</text></passage><passage><infon key="type">abstract</infon><offset>131</offset><text>The Stroop task and subtraction rely on the different cognitive processes and cerebral regions, but both these cognitive functions interact with posture. The study of cognitive-motor interactions falls under the concept of sharing resources, implying that resources for processing are limited. Researchers try to understand this interaction by constructing dual task (DT) paradigms. None have investigated the Stroop and subtraction tasks in three inherently simple postures in two groups of young adults. This study aimed to test whether a given posture benefits a given cognitive function when cognitive and postural tasks are not overly demanding and are underpinned by common cerebral structures. This study presents the results of 60 healthy young adults performing a subtraction task in three postures (sitting, standing, and walking) and 57 healthy young adults performing the Stroop task in the same three postures. Our results showed that performance at the Stroop task, in terms of number of correct answers and interference, are better while standing or even walking compared to sitting while subtraction is better sitting compared to standing and walking. Moreover, static postural parameters did not vary when in DT compared to single task. This means that there was no additional cost on posture when achieving the cognitive activity simultaneously. The absence of impact of the DT on postural parameters in static postures and the changes in the gait pace when walking suggest that cognitive tasks can be achieved in various postures, without being too costly on posture.</text></passage></document>
<document><id>37905057</id><passage><infon key="journal">bioRxiv;2023Oct16. doi:10.1101/2023.06.20.545761</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10614748</infon><infon key="type">title</infon><infon key="authors">Ahn JE, Amrein H, </infon><offset>0</offset><text>Opposing chemosensory functions of closely related gustatory receptors.</text></passage><passage><infon key="type">abstract</infon><offset>72</offset><text>Most animals have functionally distinct populations of taste cells, expressing receptors that are tuned to compounds of different valence. This organizational feature allows for discrimination between chemicals associated with specific taste modalities and facilitates differentiating between unadulterated foods and foods contaminated with toxic substances. In the fruit fly D. melanogaster , primary sensory neurons express taste receptors that are tuned to distinct groups of chemicals, thereby activating neural ensembles that elicit either feeding or avoidance behavior. Members of a family of ligand gated receptor channels, the Gustatory receptors (Grs), play a central role in these behaviors. In general, closely related, evolutionarily conserved Gr proteins are co-expressed in the same type of taste neurons, tuned to chemically related compounds, and therefore triggering the same behavioral response. Here, we report that members of the Gr28 subfamily are expressed in largely non-overlapping sets of taste neurons in Drosophila larvae, detect chemicals of different valence and trigger opposing feeding behaviors. We determined the intrinsic properties of Gr28 neurons by expressing the mammalian Vanilloid Receptor (VR1), which is activated by capsaicin, a chemical to which wildtype Drosophila larvae do not respond. When VR1 is expressed in Gr28a neurons, larvae become attracted to capsaicin, consistent with reports showing that Gr28a itself encodes a receptor for nutritious RNA. In contrast, expression of VR1 in two pairs of Gr28b.c neurons triggers avoidance to capsaicin. Moreover, neuronal inactivation experiments show that the Gr28b.c neurons are necessary for avoidance of several bitter compounds. Lastly, behavioral experiments of Gr28 deficient larvae and live Ca 2+ imaging studies of Gr28b.c neurons revealed that denatonium benzoate, a synthetic bitter compound that shares structural similarities with natural bitter chemicals, is a ligand for a receptor complex containing a Gr28b.c or Gr28b.a subunit. Thus, the Gr28 proteins, which have been evolutionarily conserved over 260 million years in insects, represent the first taste receptor subfamily in which specific members mediate behavior with opposite valence.</text><annotation id="17"><infon key="identifier">7442</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12920</infon><location offset="1303" length="3"/><text>VR1</text></annotation><annotation id="18"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="1331" length="9"/><text>capsaicin</text></annotation><annotation id="19"><infon key="identifier">36420</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1032</infon><location offset="1410" length="3"/><text>VR1</text></annotation><annotation id="20"><infon key="identifier">117348</infon><infon key="type">Gene</infon><location offset="1430" length="5"/><text>Gr28a</text></annotation><annotation id="21"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="1472" length="9"/><text>capsaicin</text></annotation><annotation id="22"><infon key="identifier">117348</infon><infon key="type">Gene</infon><location offset="1520" length="5"/><text>Gr28a</text></annotation><annotation id="23"><infon key="identifier">36420</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1032</infon><location offset="1599" length="3"/><text>VR1</text></annotation><annotation id="24"><infon key="identifier">117496</infon><infon key="type">Gene</infon><location offset="1619" length="7"/><text>Gr28b.c</text></annotation><annotation id="25"><infon key="identifier">MESH:D002211</infon><infon key="type">Chemical</infon><location offset="1657" length="9"/><text>capsaicin</text></annotation><annotation id="26"><infon key="identifier">117496</infon><infon key="type">Gene</infon><location offset="1726" length="7"/><text>Gr28b.c</text></annotation><annotation id="27"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1781" length="16"/><text>bitter compounds</text></annotation><annotation id="28"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1864" length="5"/><text>Ca 2+</text></annotation><annotation id="29"><infon key="identifier">117496</infon><infon key="type">Gene</infon><location offset="1889" length="7"/><text>Gr28b.c</text></annotation><annotation id="30"><infon key="identifier">MESH:C043414</infon><infon key="type">Chemical</infon><location offset="1919" length="19"/><text>denatonium benzoate</text></annotation><annotation id="31"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="2017" length="16"/><text>bitter chemicals</text></annotation><annotation id="32"><infon key="identifier">117496</infon><infon key="type">Gene</infon><location offset="2083" length="7"/><text>Gr28b.c</text></annotation><annotation id="33"><infon key="identifier">117496</infon><infon key="type">Gene</infon><location offset="2094" length="7"/><text>Gr28b.a</text></annotation></passage><relation id="R1"><infon key="score">0.9976</infon><infon key="role1">Gene|117348</infon><infon key="role2">Gene|36420</infon><infon key="type">Association</infon><node refid="0" role="3,2"/></relation><relation id="R2"><infon key="score">0.9993</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|7442</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="1,0"/></relation><relation id="R3"><infon key="score">0.6897</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|117348</infon><infon key="type">Association</infon><node refid="2" role="4,3"/></relation><relation id="R4"><infon key="score">0.9971</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|36420</infon><infon key="type">Association</infon><node refid="3" role="4,2"/></relation><relation id="R5"><infon key="score">0.9986</infon><infon key="role1">Chemical|MESH:D002211</infon><infon key="role2">Gene|117496</infon><infon key="type">Association</infon><node refid="4" role="8,7"/></relation><relation id="R6"><infon key="score">0.996</infon><infon key="role1">Chemical|MESH:C043414</infon><infon key="role2">Gene|117496</infon><infon key="type">Association</infon><node refid="5" role="13,12"/></relation></document>
<document><id>37905407</id><passage><infon key="journal">Psychol Med;2023Oct31 1. doi:10.1017/S0033291723003021</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kennedy KG, Ghugre NR, Roifman I, Qi X, Saul K, McCrindle BW, Macgowan CK, MacIntosh BJ, Goldstein BI, </infon><offset>0</offset><text>Impaired coronary microvascular reactivity in youth with bipolar disorder.</text><annotation id="2"><infon key="identifier">MESH:D003323</infon><infon key="type">Disease</infon><location offset="9" length="22"/><text>coronary microvascular</text></annotation><annotation id="3"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="57" length="16"/><text>bipolar disorder</text></annotation></passage><passage><infon key="type">abstract</infon><offset>75</offset><text>BACKGROUND: Cardiovascular disease (CVD) is excessively prevalent and premature in bipolar disorder (BD), even after controlling for traditional cardiovascular risk factors. The increased risk of CVD in BD may be subserved by microvascular dysfunction. We examined coronary microvascular function in relation to youth BD. METHODS: Participants were 86 youth, ages 13-20 years (n = 39 BD, n = 47 controls). Coronary microvascular reactivity (CMVR) was assessed using quantitative T2 magnetic resonance imaging during a validated breathing-paradigm. Quantitative T2 maps were acquired at baseline, following 60-s of hyperventilation, and every 10-s thereafter during a 40-s breath-hold. Left ventricular structure and function were evaluated based on 12-15 short- and long-axis cardiac-gated cine images. A linear mixed-effects model that controlled for age, sex, and body mass index assessed for between-group differences in CMVR (time-by-group interaction). RESULTS: The breathing-paradigm induced a significant time-related increase in T2 relaxation time for all participants (i.e. CMVR; beta = 0.36, p &lt; 0.001). CMVR was significantly lower in BD v. controls (beta = -0.11, p = 0.002). Post-hoc analyses found lower T2 relaxation time in BD youth after 20-, 30-, and 40 s of breath-holding (d = 0.48, d = 0.72, d = 0.91, respectively; all pFDR &lt; 0.01). Gross left ventricular structure and function (e.g. mass, ejection fraction) were within normal ranges and did not differ between groups. CONCLUSION: Youth with BD showed evidence of subclinically impaired coronary microvascular function, despite normal gross cardiac structure and function. These results converge with prior findings in adults with major depressive disorder and post-traumatic stress disorder. Future studies integrating larger samples, prospective follow-up, and blood-based biomarkers are warranted.</text><annotation id="23"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="87" length="22"/><text>Cardiovascular disease</text></annotation><annotation id="24"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="111" length="3"/><text>CVD</text></annotation><annotation id="25"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="158" length="16"/><text>bipolar disorder</text></annotation><annotation id="26"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="176" length="2"/><text>BD</text></annotation><annotation id="27"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="271" length="3"/><text>CVD</text></annotation><annotation id="28"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="278" length="2"/><text>BD</text></annotation><annotation id="29"><infon key="identifier">MESH:D017566</infon><infon key="type">Disease</infon><location offset="301" length="25"/><text>microvascular dysfunction</text></annotation><annotation id="30"><infon key="identifier">MESH:D003323</infon><infon key="type">Disease</infon><location offset="340" length="22"/><text>coronary microvascular</text></annotation><annotation id="31"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="393" length="2"/><text>BD</text></annotation><annotation id="32"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="459" length="2"/><text>BD</text></annotation><annotation id="33"><infon key="identifier">MESH:D003323</infon><infon key="type">Disease</infon><location offset="481" length="22"/><text>Coronary microvascular</text></annotation><annotation id="34"><infon key="identifier">MESH:D006985</infon><infon key="type">Disease</infon><location offset="689" length="16"/><text>hyperventilation</text></annotation><annotation id="35"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="1221" length="2"/><text>BD</text></annotation><annotation id="36"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="1315" length="2"/><text>BD</text></annotation><annotation id="37"><infon key="identifier">MESH:D001714</infon><infon key="type">Disease</infon><location offset="1591" length="2"/><text>BD</text></annotation><annotation id="38"><infon key="identifier">MESH:D003323</infon><infon key="type">Disease</infon><location offset="1636" length="22"/><text>coronary microvascular</text></annotation><annotation id="39"><infon key="identifier">MESH:D004830</infon><infon key="type">Disease</infon><location offset="1780" length="5"/><text>major</text></annotation><annotation id="40"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1786" length="19"/><text>depressive disorder</text></annotation><annotation id="41"><infon key="identifier">MESH:D013313</infon><infon key="type">Disease</infon><location offset="1810" length="30"/><text>post-traumatic stress disorder</text></annotation></passage></document>
<document><id>37905758</id><passage><infon key="journal">Zhongguo Dang Dai Er Ke Za Zhi;2023Oct15; 25 (10) 1022. doi:10.7499/j.issn.1008-8830.2303100</infon><infon key="year">2023</infon><infon key="article-id_pmc">PMC10621060</infon><infon key="type">title</infon><infon key="authors">Lai CC, Zhang LL, Sun MY, Sun JF, Jiang H, </infon><offset>0</offset><text>[Association between HLA-DRB1 gene polymorphisms and genetic susceptibility of early-onset severe preeclampsia].</text><annotation id="2"><infon key="identifier">3123;3105</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136635;128352</infon><location offset="21" length="8"/><text>HLA-DRB1</text></annotation><annotation id="3"><infon key="identifier">MESH:D011225</infon><infon key="type">Disease</infon><location offset="98" length="12"/><text>preeclampsia</text></annotation></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>OBJECTIVES: To explore the correlation between the single nucleotide polymorphisms (SNP) of rs3135388, rs114293611 and rs142804168 of HLA-DRB1 gene and early-onset severe preeclampsia (sPE). METHODS: Blood samples were collected from 102 early-onset sPE mothers and their neonates (sPE group), as well as 120 normotensive mothers and their neonates (control group). Sanger sequencing was performed to compare the genotype distribution, allele frequencies, and differences in genotype distribution after maternal-infant compatibility between the two groups. RESULTS: Statistically significant differences in genotype distribution at rs114293611 of HLA-DRB1 gene were observed between sPE and control groups in both mothers and neonates (P&lt;0.05). The frequency of the T allele at rs114293611 was higher in the sPE group of neonates than that in the control group (P&lt;0.05), while no significant difference was found between the two groups of mothers (P>0.05). The maternal-infant genotype compatibility analysis showed significant differences in genotype distribution between sPE and control groups (P&lt;0.05). There were no significant differences in genotype distribution and allele frequencies at rs3135388 and rs142804168 of HLA-DRB1 gene between the two groups of mothers and neonates (P>0.05). CONCLUSIONS: The SNP at rs114293611 of HLA-DRB1 gene may be associated with the development of early-onset sPE in mothers. Maternal-infant genotype compatibility abnormality at rs114293611 of HLA-DRB1 gene may be a predisposition factor for the development of sPE.</text><annotation id="27"><infon key="identifier">tmVar:rs3135388;VariantGroup:2;CorrespondingGene:3122;RS#:3135388;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="205" length="9"/><text>rs3135388</text></annotation><annotation id="28"><infon key="identifier">tmVar:rs114293611;VariantGroup:0;CorrespondingGene:3127;RS#:114293611;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="216" length="11"/><text>rs114293611</text></annotation><annotation id="29"><infon key="identifier">tmVar:rs142804168;VariantGroup:1;CorrespondingGene:3127;RS#:142804168;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="232" length="11"/><text>rs142804168</text></annotation><annotation id="30"><infon key="identifier">3123;3105</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136635;128352</infon><location offset="247" length="8"/><text>HLA-DRB1</text></annotation><annotation id="31"><infon key="identifier">MESH:D011225</infon><infon key="type">Disease</infon><location offset="284" length="12"/><text>preeclampsia</text></annotation><annotation id="32"><infon key="identifier">MESH:D045169</infon><infon key="type">Disease</infon><location offset="298" length="3"/><text>sPE</text></annotation><annotation id="33"><infon key="identifier">MESH:D045169</infon><infon key="type">Disease</infon><location offset="363" length="3"/><text>sPE</text></annotation><annotation id="34"><infon key="identifier">MESH:D045169</infon><infon key="type">Disease</infon><location offset="395" length="3"/><text>sPE</text></annotation><annotation id="35"><infon key="identifier">tmVar:rs114293611;VariantGroup:0;CorrespondingGene:3127;RS#:114293611;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="745" length="11"/><text>rs114293611</text></annotation><annotation id="36"><infon key="identifier">3123;3105</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136635;128352</infon><location offset="760" length="8"/><text>HLA-DRB1</text></annotation><annotation id="37"><infon key="identifier">MESH:D045169</infon><infon key="type">Disease</infon><location offset="796" length="3"/><text>sPE</text></annotation><annotation id="38"><infon key="identifier">tmVar:rs114293611;VariantGroup:0;CorrespondingGene:3127;RS#:114293611;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="891" length="11"/><text>rs114293611</text></annotation><annotation id="39"><infon key="identifier">MESH:D045169</infon><infon key="type">Disease</infon><location offset="921" length="3"/><text>sPE</text></annotation><annotation id="40"><infon key="identifier">MESH:D045169</infon><infon key="type">Disease</infon><location offset="1186" length="3"/><text>sPE</text></annotation><annotation id="41"><infon key="identifier">tmVar:rs3135388;VariantGroup:2;CorrespondingGene:3122;RS#:3135388;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1308" length="9"/><text>rs3135388</text></annotation><annotation id="42"><infon key="identifier">tmVar:rs142804168;VariantGroup:1;CorrespondingGene:3127;RS#:142804168;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1322" length="11"/><text>rs142804168</text></annotation><annotation id="43"><infon key="identifier">3123;3105</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136635;128352</infon><location offset="1337" length="8"/><text>HLA-DRB1</text></annotation><annotation id="44"><infon key="identifier">tmVar:rs114293611;VariantGroup:0;CorrespondingGene:3127;RS#:114293611;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1432" length="11"/><text>rs114293611</text></annotation><annotation id="45"><infon key="identifier">3123;3105</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136635;128352</infon><location offset="1447" length="8"/><text>HLA-DRB1</text></annotation><annotation id="46"><infon key="identifier">MESH:D045169</infon><infon key="type">Disease</infon><location offset="1515" length="3"/><text>sPE</text></annotation><annotation id="47"><infon key="identifier">tmVar:rs114293611;VariantGroup:0;CorrespondingGene:3127;RS#:114293611;CorrespondingSpecies:9606</infon><infon key="type">SNP</infon><location offset="1585" length="11"/><text>rs114293611</text></annotation><annotation id="48"><infon key="identifier">3123;3105</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">136635;128352</infon><location offset="1600" length="8"/><text>HLA-DRB1</text></annotation><annotation id="49"><infon key="identifier">MESH:D045169</infon><infon key="type">Disease</infon><location offset="1668" length="3"/><text>sPE</text></annotation></passage><relation id="R1"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D011225</infon><infon key="role2">Gene|3123</infon><infon key="type">Association</infon><node refid="0" role="1,0"/></relation><relation id="R2"><infon key="score">0.9405</infon><infon key="role1">Disease|MESH:D045169</infon><infon key="role2">SNP|RS#:114293611;CorrespondingGene:3127</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="7,3"/></relation><relation id="R3"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D011225</infon><infon key="role2">Gene|3105</infon><infon key="type">Association</infon><node refid="2" role="1,0"/></relation><relation id="R4"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D045169</infon><infon key="role2">Gene|3105</infon><infon key="type">Association</infon><node refid="3" role="7,5"/></relation><relation id="R5"><infon key="score">0.9574</infon><infon key="role1">Disease|MESH:D045169</infon><infon key="role2">SNP|RS#:3135388;CorrespondingGene:3122</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="7,2"/></relation><relation id="R6"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D045169</infon><infon key="role2">Gene|3123</infon><infon key="type">Association</infon><node refid="5" role="7,5"/></relation><relation id="R7"><infon key="score">0.9405</infon><infon key="role1">Disease|MESH:D045169</infon><infon key="role2">Gene|3127</infon><infon key="type">Association</infon></relation><relation id="R8"><infon key="score">0.9574</infon><infon key="role1">Disease|MESH:D045169</infon><infon key="role2">Gene|3122</infon><infon key="type">Association</infon></relation></document>
<document><id>37906109</id><passage><infon key="journal">LGBT Health;2023Oct31. doi:10.1089/lgbt.2023.0032</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">DeSon JJ, Andover MS, </infon><offset>0</offset><text>Microaggressions Toward Sexual and Gender Minority Emerging Adults: An Updated Systematic Review of Psychological Correlates and Outcomes and the Role of Intersectionality.</text></passage><passage><infon key="type">abstract</infon><offset>173</offset><text>Purpose: Quantitative data on the psychological effects of microaggressions toward sexual and gender minority individuals have grown substantially. Sexual orientation-based and transgender and gender-diverse (trans+) identity-based microaggressions have been thematically identified in prior research. In addition, combined lesbian, gay, bisexual, transgender and gender-diverse, queer/questioning, and other non-heterosexual (LGBTQ) microaggressions can be examined intersectionally with other marginalized identities. This systematic review synthesizes research on the relationships among these microaggressions and psychological correlates and outcomes. Methods: Forty-five quantitative studies examining sexual orientation-, trans+ identity-, or intersectional identity-based microaggressions and various psychological outcomes were identified from systematic searches of PsycINFO, PsycARTICLES, MEDLINE, and PubMed databases. Data regarding microaggressions were extracted, synthesized, and grouped by mental health outcome or correlate. Results: Sexual orientation-based microaggressions were risk factors for depression, anxiety, and internalized stigma and were positively associated with psychological distress, traumatic stress symptoms, alcohol use and abuse, cannabis use and problems, suicidal ideation, and suicide attempt. Trans+ identity-based microaggressions were positively associated with depression, suicide attempt, and cannabis use. LGBTQ intersectional identity-based microaggressions concerning race/ethnicity were associated with depression, anxiety, and suicidal ideation. Research on other intersectional identity-based microaggressions is scarce. Conclusion: These findings emphasize the psychological harm inflicted by various microaggressions on LGBTQ late adolescents and early adults. Future work should focus on microaggressions toward individuals with trans+ and intersectional identities and protective factors for these experiences. This review also highlights the distinct need for community-based research on implementing microintervention strategies in family, school, and work environments to mitigate the harmful effects of these microaggressions.</text><annotation id="12"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1289" length="10"/><text>depression</text></annotation><annotation id="13"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="1301" length="7"/><text>anxiety</text></annotation><annotation id="14"><infon key="identifier">MESH:D000068376</infon><infon key="type">Disease</infon><location offset="1394" length="25"/><text>traumatic stress symptoms</text></annotation><annotation id="15"><infon key="identifier">MESH:D000437</infon><infon key="type">Disease</infon><location offset="1421" length="21"/><text>alcohol use and abuse</text></annotation><annotation id="16"><infon key="identifier">MESH:D002189</infon><infon key="type">Disease</infon><location offset="1444" length="8"/><text>cannabis</text></annotation><annotation id="17"><infon key="identifier">MESH:D001072</infon><infon key="type">Disease</infon><location offset="1471" length="17"/><text>suicidal ideation</text></annotation><annotation id="18"><infon key="type">Disease</infon><location offset="1494" length="15"/><text>suicide attempt</text></annotation><annotation id="19"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1582" length="10"/><text>depression</text></annotation><annotation id="20"><infon key="type">Disease</infon><location offset="1594" length="15"/><text>suicide attempt</text></annotation><annotation id="21"><infon key="identifier">MESH:D003866</infon><infon key="type">Disease</infon><location offset="1729" length="10"/><text>depression</text></annotation><annotation id="22"><infon key="identifier">MESH:D001007</infon><infon key="type">Disease</infon><location offset="1741" length="7"/><text>anxiety</text></annotation><annotation id="23"><infon key="identifier">MESH:D001072</infon><infon key="type">Disease</infon><location offset="1754" length="17"/><text>suicidal ideation</text></annotation></passage></document>
<document><id>37906460</id><passage><infon key="journal">Water Sci Technol;2023Oct; 88 (8) 2081. doi:10.2166/wst.2023.325</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wu Z, Yan Z, Zhang Q, Zhu Y, Luo M, Zhou D, </infon><offset>0</offset><text>Review on descaling and anti-scaling technology of heat exchanger in high-salt wastewater thermal desalination.</text><annotation id="1"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="74" length="4"/><text>salt</text></annotation></passage><passage><infon key="type">abstract</infon><offset>112</offset><text>Thermal desalination evaporation of high-salt wastewater has been widely used in industry because of the proposed concept of 'zero liquid discharge'. However, due to the high content of Ca2+ and Mg2+ in high-salt wastewater, the heat exchanger, as the main treatment equipment, suffers from serious scaling problems. This review presents descaling and scale inhibition technologies of high-salt wastewater. The advantages and disadvantages of various technologies are summarized and analyzed to provide theoretical support for the research of descaling and anti-scaling of heat exchangers with high-salt wastewater. In future industrial development, the synergistic application of electromagnetic water treatment technology and scale inhibitors can significantly improve the anti-scaling effect, which can reach over 95% stably. Furthermore, the addition of a physical field can also expand the application range of scale inhibitors.</text><annotation id="9"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="153" length="4"/><text>salt</text></annotation><annotation id="10"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="298" length="4"/><text>Ca2+</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="307" length="4"/><text>Mg2+</text></annotation><annotation id="12"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="320" length="4"/><text>salt</text></annotation><annotation id="13"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="502" length="4"/><text>salt</text></annotation><annotation id="14"><infon key="identifier">MESH:D012492</infon><infon key="type">Chemical</infon><location offset="711" length="4"/><text>salt</text></annotation><annotation id="15"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="809" length="5"/><text>water</text></annotation></passage></document>
<document><id>37906834</id><passage><infon key="journal">Rev Med Chil;2022Jul; 150 (7) 976. doi:10.4067/s0034-98872022000700976</infon><infon key="year">2022</infon><infon key="type">title</infon><infon key="authors">Sanhueza-Parra M, </infon><offset>0</offset><text>[Older adults caring older adults: the effects of an aging population].</text></passage><passage><infon key="type">abstract</infon><offset>72</offset></passage></document>
<document><id>37907200</id><passage><infon key="journal">Am J Perinatol;2023Oct31. doi:10.1055/s-0043-1776344</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Koerner R, Bendixen MM, Monk A, Lamberti MFT, Lorca GL, Neu J, Parker LA, </infon><offset>0</offset><text>A Scoping Review of the Oral Microbiome in Preterm Infants.</text><annotation id="1"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="51" length="7"/><text>Infants</text></annotation></passage><passage><infon key="type">abstract</infon><offset>60</offset><text>The purpose of this scoping review was to examine the oral microbiome composition in preterm infants, sampling and collection methods, as well as exposures associated with oral microbiome composition and health implications. We conducted a scoping review of the literature using the Arskey and O'Malley framework. We identified a total of 13 articles which met our inclusion criteria and purpose of this scoping review. Articles included in this review compared the oral microbiome in preterm infants to term infants, examined alterations to the oral microbiome over time, compared the oral microbiome to different body site microbiomes, and explored associations with clinically relevant covariates and outcomes. Exposures associated with the diversity and composition of the oral microbiome in preterm infants included delivery mode, oral feeding, oropharyngeal care, skin-to-skin care, and antibiotics. Day of life and birth weight were also associated with oral microbiome composition. The oral microbiome may be associated with the composition of the tracheal and gut microbiomes, likely due to their proximity. Alpha and beta diversity findings varied across studies as well as the relative abundance of taxa. This is likely due to the different sampling techniques and timing of collection, as well as the wide range of infant clinical characteristics. Multiple factors may influence the composition of the oral microbiome in preterm infants. However, given the heterogeneity of sampling techniques and results within this review, the evidence is not conclusive on the development as well as short- and long-term implications of the oral microbiome in preterm infants and needs to be explored in future research studies. KEY POINTS:   Day of life is a critical factor in oral microbiome development in preterm infants..   The oral microbiome may be associated with tracheal and gut microbiome colonization..   Future research should examine sampling methodology for examining the oral microbiome..   Future research should explore associations with the oral microbiome and adverse health outcomes..</text><annotation id="9"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="153" length="7"/><text>infants</text></annotation><annotation id="10"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="553" length="7"/><text>infants</text></annotation><annotation id="11"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="569" length="7"/><text>infants</text></annotation><annotation id="12"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="864" length="7"/><text>infants</text></annotation><annotation id="13"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="1501" length="7"/><text>infants</text></annotation><annotation id="14"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="1727" length="7"/><text>infants</text></annotation><annotation id="15"><infon key="identifier">MESH:D063766</infon><infon key="type">Disease</infon><location offset="1877" length="7"/><text>infants</text></annotation></passage></document>
<document><id>37909303</id><passage><infon key="journal">Per Med;2023Nov01. doi:10.2217/pme-2023-0072</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li W, Wen K, Zhu W, Luo S, </infon><offset>0</offset><text>A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment.</text><annotation id="2"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="68" length="10"/><text>toxicities</text></annotation><annotation id="3"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="82" length="6"/><text>cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>Background: This study analyzed real-world data from 2004 to 2023 to evaluate the toxicity profile of tyrosine receptor kinase (TRK) inhibitor therapy. Method: A retrospective analysis of US FDA Adverse Event Reporting System data was conducted to identify adverse events in patients receiving TRK inhibitor therapy. Result: Entrectinib demonstrated toxicities primarily in the cardiovascular and nervous systems, followed by the renal and urinary system. Common adverse effects included dizziness, renal impairment, constipation, heart failure and taste disorders. Larotrectinib induced adverse events mainly in the hepatobiliary and nervous systems, with peripheral neuropathy, myalgia, renal impairment and increased alanine aminotransferase commonly reported. Conclusion: Careful monitoring and supportive care strategies are essential for managing adverse events associated with TRK inhibitor therapy.</text><annotation id="18"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="182" length="8"/><text>toxicity</text></annotation><annotation id="19"><infon key="identifier">4914</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1898</infon><location offset="202" length="24"/><text>tyrosine receptor kinase</text></annotation><annotation id="20"><infon key="identifier">4914</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1898</infon><location offset="228" length="3"/><text>TRK</text></annotation><annotation id="21"><infon key="identifier">MESH:C000607349</infon><infon key="type">Chemical</infon><location offset="425" length="11"/><text>Entrectinib</text></annotation><annotation id="22"><infon key="identifier">MESH:D064420</infon><infon key="type">Disease</infon><location offset="450" length="10"/><text>toxicities</text></annotation><annotation id="23"><infon key="identifier">MESH:D004244</infon><infon key="type">Disease</infon><location offset="588" length="9"/><text>dizziness</text></annotation><annotation id="24"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="599" length="16"/><text>renal impairment</text></annotation><annotation id="25"><infon key="identifier">MESH:D003248</infon><infon key="type">Disease</infon><location offset="617" length="12"/><text>constipation</text></annotation><annotation id="26"><infon key="identifier">MESH:D006333</infon><infon key="type">Disease</infon><location offset="631" length="13"/><text>heart failure</text></annotation><annotation id="27"><infon key="identifier">MESH:D013651</infon><infon key="type">Disease</infon><location offset="649" length="15"/><text>taste disorders</text></annotation><annotation id="28"><infon key="identifier">MESH:C000609083</infon><infon key="type">Chemical</infon><location offset="666" length="13"/><text>Larotrectinib</text></annotation><annotation id="29"><infon key="identifier">MESH:D010523</infon><infon key="type">Disease</infon><location offset="757" length="21"/><text>peripheral neuropathy</text></annotation><annotation id="30"><infon key="identifier">MESH:D063806</infon><infon key="type">Disease</infon><location offset="780" length="7"/><text>myalgia</text></annotation><annotation id="31"><infon key="identifier">MESH:D007674</infon><infon key="type">Disease</infon><location offset="789" length="16"/><text>renal impairment</text></annotation></passage><relation id="R1"><infon key="score">0.7622</infon><infon key="role1">Chemical|MESH:C000607349</infon><infon key="role2">Disease|MESH:D003248</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="5,9"/></relation><relation id="R2"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:C000609083</infon><infon key="role2">Disease|MESH:D010523</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="12,13"/></relation><relation id="R3"><infon key="score">0.8585</infon><infon key="role1">Chemical|MESH:C000607349</infon><infon key="role2">Disease|MESH:D064420</infon><infon key="type">Negative_Correlation</infon><node refid="2" role="5,6"/></relation><relation id="R4"><infon key="score">0.9942</infon><infon key="role1">Chemical|MESH:C000609083</infon><infon key="role2">Disease|MESH:D007674</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="12,15"/></relation><relation id="R5"><infon key="score">0.9674</infon><infon key="role1">Chemical|MESH:C000607349</infon><infon key="role2">Disease|MESH:D006333</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="5,10"/></relation><relation id="R6"><infon key="score">0.9932</infon><infon key="role1">Chemical|MESH:C000607349</infon><infon key="role2">Disease|MESH:D013651</infon><infon key="type">Positive_Correlation</infon><node refid="5" role="5,11"/></relation><relation id="R7"><infon key="score">0.9975</infon><infon key="role1">Chemical|MESH:C000609083</infon><infon key="role2">Disease|MESH:D063806</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="12,14"/></relation><relation id="R8"><infon key="score">0.992</infon><infon key="role1">Chemical|MESH:C000607349</infon><infon key="role2">Disease|MESH:D004244</infon><infon key="type">Positive_Correlation</infon><node refid="7" role="5,7"/></relation></document>
<document><id>37909657</id><passage><infon key="journal">Clin Child Psychol Psychiatry;2023Nov01 13591045231208577. doi:10.1177/13591045231208577</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Cardelle-P&amp;#xe9;rez F, Banacloig-Delgado C, Garc&amp;#xed;a-Garc&amp;#xed;a L, </infon><offset>0</offset><text>Resilience and family quality of life in parents of children with autism spectrum disorders.</text><annotation id="1"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="66" length="25"/><text>autism spectrum disorders</text></annotation></passage><passage><infon key="type">abstract</infon><offset>93</offset><text>INTRODUCTION: Resilience and quality of life (QOL) can involve a positive approach in group interventions for parents of children with autism spectrum disorders (ASD). This study aims to evaluate resilience and family QOL at the start of a psychoeducational group. METHODS: Cross-sectional assessment of resilience and family QOL used the Family Quality of Life Scale (ECVF) and 14-item Resilience Scale (RS-14). RESULTS: The study group showed high levels of resilience. Parents considered the resources/support domain crucial, although satisfaction in this area was comparatively lower. Concerns about low satisfaction with available resources and support were notable. Gender differences were observed but not statistically significant. DISCUSSION: The study's findings support prior research on parental resilience in families of children with ASD. The literature on the QOL for these families presents mixed findings. The importance of parental involvement in service planning is highlighted. CONCLUSIONS: This study emphasizes the importance of resilience in parents of children with ASD, suggesting it as a potential therapeutic target. The findings underscore the need to address the perceived low quality of available resources and support. Further investigation is needed.</text><annotation id="6"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="228" length="25"/><text>autism spectrum disorders</text></annotation><annotation id="7"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="255" length="3"/><text>ASD</text></annotation><annotation id="8"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="941" length="3"/><text>ASD</text></annotation><annotation id="9"><infon key="identifier">MESH:D000067877</infon><infon key="type">Disease</infon><location offset="1183" length="3"/><text>ASD</text></annotation></passage></document>
<document><id>37910364</id><passage><infon key="journal">Environ Sci Pollut Res Int;2023Nov01. doi:10.1007/s11356-023-30584-8</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Khalil RG, Damrah S, Bajaher M, Shawtari FA, </infon><offset>0</offset><text>Unveiling the relationship of ESG, fintech, green finance, innovation and sustainability: case of Gulf countries.</text></passage><passage><infon key="type">abstract</infon><offset>114</offset><text>Technological advancement and innovations not only transformed businesses but also optimize numerous functional areas of financial services. Besides, green finance and fintech are also essential tools to achieve sustainable development agendas. Thus, it is imperative to document the evidence that how conducive such factors are to achieve 2030 sustainable development goals. The study, in this regard, is aimed to scrutinize innovation, green finance, financial technologies, and ESG factors altogether in order to determine their effectiveness on sustainable development in Gulf countries in the time span of 2000-2020. The study opts for methods of moments quantile regression (MMQR) and claim that green finance, green innovation, and fintech helps in achieving sustainable development goals. However, among ESG factors, social and governance role is negative in the sampled economies. Findings are interesting for policy makers and government institutions because it assists them to improve governance evaluation system and classification standards so that countries may no longer experience hindrance when indulging in sustainable development actions.</text></passage></document>
<document><id>37910715</id><passage><infon key="journal">Opt Lett;2023Nov01; 48 (21) 5611. doi:10.1364/OL.494414</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Hong MS, Lim MG, Kim DU, Her MJ, Park YJ, Choi DJ, Jeong Y, Park J, Han S, Chun YH, Eom SC, Oh S, Yu K, Han S, </infon><offset>0</offset><text>Programmable MZI based on a silicon photonic MEMS-tunable delay line.</text></passage><passage><infon key="type">abstract</infon><offset>70</offset><text>We report on a scalable and programmable integrated Mach-Zehnder interferometer (MZI) with a tunable free spectral range (FSR) and extinction ratio (ER). For the tunable path of the MZI, we designed and utilized a tunable delay line having high flexibility based on silicon photonic microelectromechanical systems (MEMS). By utilizing MEMS, the length of the delay line can be geometrically modified. In this way, there is no optical loss penalty other than the waveguide propagation loss as the number of tunable steps increases. Therefore, our device is more scalable in terms of optical loss than the previous approaches based on cascaded MZIs. In addition, the tuning energy required to reconfigure the length is only 8.46 pJ.</text></passage></document>
<document><id>37911066</id><passage><infon key="journal">Int Dent J (Phila);1893Feb; 14 (2) 141</infon><infon key="year">1893</infon><infon key="article-id_pmc">PMC10109615</infon><infon key="type">title</infon><offset>0</offset><text>New Dental School in New York.</text></passage><passage><infon key="type">abstract</infon><offset>31</offset></passage></document>
<document><id>37911416</id><passage><infon key="journal">Int Dent J (Phila);1890Apr; 11 (4) 193</infon><infon key="year">1890</infon><infon key="article-id_pmc">PMC10110113</infon><infon key="type">title</infon><infon key="authors">McCausey GH, </infon><offset>0</offset><text>The Relations of the Tooth-Pulp to the Other Tooth Tissues.</text><annotation id="1"><infon key="identifier">MESH:D003788</infon><infon key="type">Disease</infon><location offset="21" length="10"/><text>Tooth-Pulp</text></annotation></passage><passage><infon key="type">abstract</infon><offset>60</offset></passage></document>
<document><id>37912116</id><passage><infon key="journal">Int Dent J (Phila);1896May; 17 (5) 314</infon><infon key="year">1896</infon><infon key="article-id_pmc">PMC10124500</infon><infon key="type">title</infon><infon key="authors">Darby GDB, </infon><offset>0</offset><text>Academy of Stomatology.</text></passage><passage><infon key="type">abstract</infon><offset>24</offset></passage></document>
<document><id>37912816</id><passage><infon key="journal">Int Dent J (Phila);1901Apr; 22 (4) 274</infon><infon key="year">1901</infon><infon key="article-id_pmc">PMC10153869</infon><infon key="type">title</infon><offset>0</offset><text>The Army Examining Board.</text></passage><passage><infon key="type">abstract</infon><offset>26</offset></passage></document>
<document><id>37913166</id><passage><infon key="journal">Int Dent J (Phila);1903Aug; 24 (8) 647</infon><infon key="year">1903</infon><infon key="article-id_pmc">PMC10162253</infon><infon key="type">title</infon><offset>0</offset><text>Current News.</text></passage><passage><infon key="type">abstract</infon><offset>14</offset></passage></document>
<document><id>37913517</id><passage><infon key="journal">N Engl J Med;2023Nov02; 389 (18) 1726. doi:10.1056/NEJMc2310640</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kooshesh KA, Gustafsson K, Scadden DT, </infon><offset>0</offset><text>Health Consequences of Thymus Removal in Adults. Reply.</text></passage><passage><infon key="type">abstract</infon><offset>56</offset></passage></document>
<document><id>37913867</id><passage><infon key="journal">Orthop Traumatol Surg Res;2023Oct30 103740. doi:10.1016/j.otsr.2023.103740</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Nakamura Y, Ogawa H, Ichikawa K, Sohmiya K, Sengoku M, Shimokawa T, Onishi K, Akiyama H, </infon><offset>0</offset><text>A new magnetic resonance imaging grading system for anterior cruciate ligament myxoid degeneration in osteoarthritis of the knee.</text><annotation id="2"><infon key="identifier">MESH:D000070598</infon><infon key="type">Disease</infon><location offset="52" length="46"/><text>anterior cruciate ligament myxoid degeneration</text></annotation><annotation id="3"><infon key="identifier">MESH:D020370</infon><infon key="type">Disease</infon><location offset="102" length="26"/><text>osteoarthritis of the knee</text></annotation></passage><passage><infon key="type">abstract</infon><offset>130</offset><text>BACKGROUND: This study aimed to investigate association between magnetic resonance imaging (MRI) and histological findings of degenerated anterior cruciate ligament (ACL) in knee osteoarthritis (OA), and based on this result, to develop a new ACL degeneration grading system by MRI that corresponds to histological findings of degenerated ACLs. HYPOTHESIS: MRI signal intensity of the ACL could correspond to histological findings of collagen degeneration. PATIENTS AND METHODS: A collection of 106 ACL specimens from 85 patients who underwent primary total knee arthroplasty were investigated for signal intensity of the ACL and muscle on axial Fat-Saturated Proton Density-Weighted MRI and MRI signal intensity ratio (ACL/muscle) was calculated. The correlation between ACL histological degeneration and MRI ACL/muscle signal intensity ratio was analyzed. The ACL was stratified into 3 grades based on signal intensity relative to muscle intensity (grade 1, low; grade 2, iso; and grade 3, high), and the extent to ACL degeneration in each MRI ACL degeneration grade was evaluated. RESULTS: Collagen degeneration (53.5 +- 24.0%) and myxoid change (25.2 +- 18.8%) in degenerated ACLs significantly correlated with MRI signal intensity ratio of the ACL/muscle (r = 0.62, P &lt; 0.0001; r = 0.67, P &lt; 0.0001). ACLs were assigned to grade 1 (n = 22 [20.8%]), grade 2 (n = 56 [52.8%]), and grade 3 (n = 28 [26.4%]). ACL collagen degeneration was 34.8 +- 18.4% in grade1, 49.3 +- 21.7% in grade 2, and 76.6 +- 12.0% in grade 3. ACL myxoid change was 10.0 +- 11.3% in grade1, 21.3 +- 14.1% in grade 2, and 45.0 +- 15.3% in grade 3. DISCUSSION: The ACL/muscle signal intensity ratio on MRI correlated with the extent to ACL myxoid degeneration. The new MRI ACL degeneration grade is helpful to estimate the extent to ACL myxoid degeneration in knee OA. LEVEL OF PROOF: III; Retrospective cohort study.</text><annotation id="21"><infon key="identifier">MESH:D020370</infon><infon key="type">Disease</infon><location offset="304" length="19"/><text>knee osteoarthritis</text></annotation><annotation id="22"><infon key="identifier">MESH:D010003</infon><infon key="type">Disease</infon><location offset="325" length="2"/><text>OA</text></annotation><annotation id="23"><infon key="identifier">MESH:D000070598</infon><infon key="type">Disease</infon><location offset="373" length="16"/><text>ACL degeneration</text></annotation><annotation id="24"><infon key="type">Disease</infon><location offset="469" length="4"/><text>ACLs</text></annotation><annotation id="25"><infon key="identifier">MESH:D003095</infon><infon key="type">Disease</infon><location offset="564" length="21"/><text>collagen degeneration</text></annotation><annotation id="26"><infon key="identifier">MESH:D000070598</infon><infon key="type">Disease</infon><location offset="902" length="29"/><text>ACL histological degeneration</text></annotation><annotation id="27"><infon key="identifier">MESH:D000070598</infon><infon key="type">Disease</infon><location offset="1147" length="16"/><text>ACL degeneration</text></annotation><annotation id="28"><infon key="identifier">MESH:D000070598</infon><infon key="type">Disease</infon><location offset="1176" length="16"/><text>ACL degeneration</text></annotation><annotation id="29"><infon key="identifier">MESH:D003095</infon><infon key="type">Disease</infon><location offset="1223" length="21"/><text>Collagen degeneration</text></annotation><annotation id="30"><infon key="type">Disease</infon><location offset="1310" length="4"/><text>ACLs</text></annotation><annotation id="31"><infon key="type">Disease</infon><location offset="1436" length="4"/><text>ACLs</text></annotation><annotation id="32"><infon key="identifier">MESH:D000070598</infon><infon key="type">Disease</infon><location offset="1540" length="25"/><text>ACL collagen degeneration</text></annotation><annotation id="33"><infon key="identifier">MESH:D000070598</infon><infon key="type">Disease</infon><location offset="1841" length="23"/><text>ACL myxoid degeneration</text></annotation><annotation id="34"><infon key="identifier">MESH:D000070598</infon><infon key="type">Disease</infon><location offset="1878" length="16"/><text>ACL degeneration</text></annotation><annotation id="35"><infon key="identifier">MESH:D000070598</infon><infon key="type">Disease</infon><location offset="1938" length="23"/><text>ACL myxoid degeneration</text></annotation><annotation id="36"><infon key="identifier">MESH:D020370</infon><infon key="type">Disease</infon><location offset="1965" length="7"/><text>knee OA</text></annotation><annotation id="37"><infon key="identifier">MESH:C564133</infon><infon key="type">Disease</infon><location offset="1974" length="14"/><text>LEVEL OF PROOF</text></annotation></passage></document>
<document><id>37914217</id><passage><infon key="journal">J Rheumatol;2023Nov01. doi:10.3899/jrheum.2023-0402</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Farrer C, Thib S, Eder L, Jerome D, Gakhal N, </infon><offset>0</offset><text>Use of Coordinator role improves access to Rheumatologic Advanced Therapy.</text><annotation id="1"><infon key="identifier">MESH:D012216</infon><infon key="type">Disease</infon><location offset="43" length="13"/><text>Rheumatologic</text></annotation></passage><passage><infon key="type">abstract</infon><offset>75</offset><text>OBJECTIVE: Delays in initiation of advanced therapies, which include biologics and targeted synthetic disease modifying anti-rheumatic drugs, contribute to poor patient outcomes. The objective of this quality improvement project was to identify factors that lead to a delay in the initiation of advanced therapy and to perform plan-do-study-act cycles to decrease time to start advanced therapy. METHODS: A retrospective chart review identified factors involved in delay to start advanced therapy. The primary outcome of the study was the number of days to advanced therapy start as measured by the date of rheumatologist recommendation to the date advanced therapy was initiated by the patient. An Advanced Therapy Coordinator role was created to standardize the workflow, optimize communication, and ensure a safety checklist was instituted. RESULTS: A total of 125 patients were reviewed for the study with 18 excluded. Pre-intervention median wait time was 82.0 (IQR 46.0-80.5) days. Median wait time during the intervention improved to 49.5 (IQR 34.0-69.5)days (April 2021-February 2022) with non-random variation post intervention (Figure 4). Non-random variation was also noted in the latter baseline data (March 2020-March 2021). CONCLUSION: This study demonstrates improved wait time to advanced therapy initiation through the role of an Advanced Therapy Coordinator to facilitate communication pathways.</text></passage></document>
<document><id>37914567</id><passage><infon key="journal">Exp Neurol;2023Oct18 114575. doi:10.1016/j.expneurol.2023.114575</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Wang T, </infon><offset>0</offset><text>Human stem cells hold the key to the study of human neural infectious disorders.</text><annotation id="1"><infon key="identifier">MESH:D003141</infon><infon key="type">Disease</infon><location offset="52" length="27"/><text>neural infectious disorders</text></annotation></passage><passage><infon key="type">abstract</infon><offset>81</offset></passage></document>
<document><id>37914917</id><passage><infon key="journal">Daru;2023Nov02. doi:10.1007/s40199-023-00488-6</infon><infon key="year">2023</infon><infon key="article-id_pmc">6502177</infon><infon key="type">title</infon><infon key="authors">Hosseini MS, Namazi S, </infon><offset>0</offset><text>Immediate hypersensitivity reaction to levetiracetam: a case report study.</text><annotation id="2"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="10" length="16"/><text>hypersensitivity</text></annotation><annotation id="3"><infon key="identifier">MESH:D000077287</infon><infon key="type">Chemical</infon><location offset="39" length="13"/><text>levetiracetam</text></annotation></passage><passage><infon key="type">abstract</infon><offset>75</offset><text>BACKGROUND: Anticonvulsant drugs are one of the most common causes of delayed hypersensitivity reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). These reactions are more prevalent with aromatic anticonvulsant drugs such as phenytoin and carbamazepine. However, immediate hypersensitivity reactions such as urticaria, angioedema, and anaphylaxis with anticonvulsant drugs are rare. We describe a 51-year-old woman who developed spreading skin rashes on her wrists with urticaria and pruritus 24 h after receiving intravenous levetiracetam. CONCLUSION: Clinicians should be aware of immediate hypersensitivity reactions with intravenous levetiracetam.</text><annotation id="23"><infon key="identifier">MESH:D006967</infon><infon key="type">Disease</infon><location offset="153" length="26"/><text>hypersensitivity reactions</text></annotation><annotation id="24"><infon key="identifier">MESH:D063926</infon><infon key="type">Disease</infon><location offset="189" length="53"/><text>drug reaction with eosinophilia and systemic symptoms</text></annotation><annotation id="25"><infon key="identifier">MESH:D063926</infon><infon key="type">Disease</infon><location offset="244" length="5"/><text>DRESS</text></annotation><annotation id="26"><infon key="identifier">MESH:D013262</infon><infon key="type">Disease</infon><location offset="252" length="24"/><text>Stevens-Johnson syndrome</text></annotation><annotation id="27"><infon key="identifier">MESH:D013262</infon><infon key="type">Disease</infon><location offset="278" length="3"/><text>SJS</text></annotation><annotation id="28"><infon key="identifier">MESH:D013262</infon><infon key="type">Disease</infon><location offset="288" length="26"/><text>toxic epidermal necrolysis</text></annotation><annotation id="29"><infon key="identifier">MESH:D013262</infon><infon key="type">Disease</infon><location offset="316" length="3"/><text>TEN</text></annotation><annotation id="30"><infon key="identifier">MESH:D010672</infon><infon key="type">Chemical</infon><location offset="400" length="9"/><text>phenytoin</text></annotation><annotation id="31"><infon key="identifier">MESH:D002220</infon><infon key="type">Chemical</infon><location offset="414" length="13"/><text>carbamazepine</text></annotation><annotation id="32"><infon key="identifier">MESH:D006967</infon><infon key="type">Disease</infon><location offset="448" length="26"/><text>hypersensitivity reactions</text></annotation><annotation id="33"><infon key="identifier">MESH:D014581</infon><infon key="type">Disease</infon><location offset="483" length="9"/><text>urticaria</text></annotation><annotation id="34"><infon key="identifier">MESH:D000799</infon><infon key="type">Disease</infon><location offset="494" length="10"/><text>angioedema</text></annotation><annotation id="35"><infon key="identifier">MESH:D000707</infon><infon key="type">Disease</infon><location offset="510" length="11"/><text>anaphylaxis</text></annotation><annotation id="36"><infon key="identifier">MESH:D005076</infon><infon key="type">Disease</infon><location offset="614" length="11"/><text>skin rashes</text></annotation><annotation id="37"><infon key="identifier">MESH:D014581</infon><infon key="type">Disease</infon><location offset="645" length="9"/><text>urticaria</text></annotation><annotation id="38"><infon key="identifier">MESH:D011537</infon><infon key="type">Disease</infon><location offset="659" length="8"/><text>pruritus</text></annotation><annotation id="39"><infon key="identifier">MESH:D000077287</infon><infon key="type">Chemical</infon><location offset="701" length="13"/><text>levetiracetam</text></annotation><annotation id="40"><infon key="identifier">MESH:D006967</infon><infon key="type">Disease</infon><location offset="768" length="26"/><text>hypersensitivity reactions</text></annotation><annotation id="41"><infon key="identifier">MESH:D000077287</infon><infon key="type">Chemical</infon><location offset="812" length="13"/><text>levetiracetam</text></annotation></passage><relation id="R1"><infon key="score">0.9989</infon><infon key="role1">Chemical|MESH:D000077287</infon><infon key="role2">Disease|MESH:D005076</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="18,15"/></relation><relation id="R2"><infon key="score">0.9991</infon><infon key="role1">Chemical|MESH:D000077287</infon><infon key="role2">Disease|MESH:D014581</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="18,16"/></relation><relation id="R3"><infon key="score">0.9987</infon><infon key="role1">Chemical|MESH:D000077287</infon><infon key="role2">Disease|MESH:D004342</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="1,0"/></relation><relation id="R4"><infon key="score">0.9928</infon><infon key="role1">Chemical|MESH:D010672</infon><infon key="role2">Disease|MESH:D013262</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="9,5"/></relation><relation id="R5"><infon key="score">0.9529</infon><infon key="role1">Chemical|MESH:D002220</infon><infon key="role2">Disease|MESH:D013262</infon><infon key="type">Positive_Correlation</infon><node refid="4" role="10,5"/></relation><relation id="R6"><infon key="score">0.799</infon><infon key="role1">Chemical|MESH:D000077287</infon><infon key="role2">Disease|MESH:D000799</infon><infon key="type">Positive_Correlation</infon><node refid="5" role="18,13"/></relation><relation id="R7"><infon key="score">0.9976</infon><infon key="role1">Chemical|MESH:D000077287</infon><infon key="role2">Disease|MESH:D011537</infon><infon key="type">Positive_Correlation</infon><node refid="6" role="18,17"/></relation></document>
<document><id>37915269</id><passage><infon key="journal">Turk Arch Pediatr;2023Nov; 58 (6) 564. doi:10.5152/TurkArchPediatr.2023.233110</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kasap&amp;#xe7;opur &amp;#xd6;, </infon><offset>0</offset><text>Poverty and Discrimination: Big Enemies of Children All Over the World.</text><annotation id="1"><infon key="type">Disease</infon><location offset="0" length="7"/><text>Poverty</text></annotation></passage><passage><infon key="type">abstract</infon><offset>72</offset></passage></document>
<document><id>37916319</id><passage><infon key="journal">Eur Rev Med Pharmacol Sci;2023Oct; 27 (20) 9521. doi:10.26355/eurrev_202310_34125</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Uysal E, Cine HS, Cetin E, </infon><offset>0</offset><text>The necessity and timing of exercise after lumbar disc herniation surgery.</text><annotation id="1"><infon key="identifier">MESH:C535531</infon><infon key="type">Disease</infon><location offset="43" length="22"/><text>lumbar disc herniation</text></annotation></passage><passage><infon key="type">abstract</infon><offset>75</offset><text>OBJECTIVE: Physical therapy and rehabilitation may improve low back pain and quality of life after lumbar disc herniation. However, there is no agreement on its optimal start time and rehabilitative methods. This study evaluates the effects of early and late rehabilitation on low back pain and quality of life following unilateral microdiscectomy. PATIENTS AND METHODS: A total of 204 patients who underwent surgery for lumbar disc herniation were included and subsequently randomized into five groups: 1. No exercise, 2. The 2nd-week walking group, 3. 1st-month walking group, 4. 2nd-week waist exercise, 5. 1st-month waist exercise. Visual analog scale (VAS) and Oswestry Disability Index (ODI) were assessed at the 1st week, 1st, 3rd, and 6th, and 12th-month follow-up after surgery. RESULTS: 1st-month VAS scores were analyzed, and a significant difference was found between the VAS scores of the 2nd-week walk (3.60+-0.78) and 2nd-week waist exercise (3.38+-0.67) groups and the other groups (p&lt;0.001). 3rd-month VAS results were analyzed, and the VAS scores of the 1st-month walk group (2.67+-0.48) were significantly higher than those of the 2nd-week walk group (1.73+-0.45) (p&lt;0.001). A significant difference was observed between the no-exercise group (2.93+-0.91) and the other groups according to the 12-month VAS scores, with the VAS scores of the no-exercise group being significantly higher than the other groups (p&lt;0.001). There was a significant difference between the ODI scores of both the 2nd-week walk (38+-8.55) and the 2nd-week waist (33.8+-6.61) exercise groups and the other groups according to the 1st-month ODI scores (p&lt;0.001). A significant difference was observed between the no-exercise group (35.2+-8.25) and the other groups according to the 12-month ODI scores, and the ODI scores of the no-exercise group were significantly higher than the other groups (p&lt;0.001). CONCLUSIONS: Regular exercise is highly recommended for long-term pain relief, as well as for achieving a speedy recovery after surgery, which is crucial to maintaining a high quality of life and preventing loss of earning potential. We believe that early implementation of exercises is ideal, but even if initiated later, standard back exercises can still expedite rehabilitation.</text><annotation id="7"><infon key="identifier">MESH:D017116</infon><infon key="type">Disease</infon><location offset="134" length="13"/><text>low back pain</text></annotation><annotation id="8"><infon key="identifier">MESH:C535531</infon><infon key="type">Disease</infon><location offset="174" length="22"/><text>lumbar disc herniation</text></annotation><annotation id="9"><infon key="identifier">MESH:D017116</infon><infon key="type">Disease</infon><location offset="352" length="13"/><text>low back pain</text></annotation><annotation id="10"><infon key="identifier">MESH:C535531</infon><infon key="type">Disease</infon><location offset="496" length="22"/><text>lumbar disc herniation</text></annotation><annotation id="11"><infon key="identifier">MESH:D010146</infon><infon key="type">Disease</infon><location offset="2040" length="4"/><text>pain</text></annotation></passage></document>
<document><id>37916673</id><passage><infon key="journal">Chemistry;2023Nov02 202303037. doi:10.1002/chem.202303037</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Ludwig P, Mayer J, Ahrens L, Rominger F, Ligorio G, Hermerschmidt F, List-Kratochvil EJW, Freudenberg J, Bunz UH, </infon><offset>0</offset><text>Doubly Bridged Anthracenes: Blue Emitters for OLEDs.</text><annotation id="1"><infon key="identifier">MESH:D000873</infon><infon key="type">Chemical</infon><location offset="15" length="11"/><text>Anthracenes</text></annotation></passage><passage><infon key="type">abstract</infon><offset>53</offset><text>The photooxidative stability of a series of doubly bridged anthracenes was evaluated after their preparation via twofold macrocyclization of a bis(resorcinyl)anthracene. Lightfastness correlates with the energy levels of the highest occupied molecular orbital (HOMO), resulting in superior stability of the tetraesters compared to the tetraethers. The lengths and steric demand of the linker only plays a minor role for the ester-based compounds, which can be prepared in reasonable yields and thus tested in proof-of-concept organic light-emitting diodes. Double ester-bridging allows deep blue electro-luminescence, highlighting the importance of the choice of the functional groups used for macrocyclization.</text><annotation id="8"><infon key="identifier">MESH:D000873</infon><infon key="type">Chemical</infon><location offset="112" length="11"/><text>anthracenes</text></annotation><annotation id="9"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="196" length="25"/><text>bis(resorcinyl)anthracene</text></annotation><annotation id="10"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="360" length="11"/><text>tetraesters</text></annotation><annotation id="11"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="388" length="11"/><text>tetraethers</text></annotation><annotation id="12"><infon key="identifier">MESH:D004952</infon><infon key="type">Chemical</infon><location offset="477" length="5"/><text>ester</text></annotation><annotation id="13"><infon key="identifier">MESH:D004952</infon><infon key="type">Chemical</infon><location offset="617" length="5"/><text>ester</text></annotation></passage></document>
<document><id>37917027</id><passage><infon key="journal">Anal Methods;2023Nov02. doi:10.1039/d3ay01389h</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Li X, Tang X, Wang B, Lu Y, Chen H, </infon><offset>0</offset><text>An adaptive extended Gaussian peak derivative reweighted penalised least squares method for baseline correction.</text></passage><passage><infon key="type">abstract</infon><offset>113</offset><text>Baseline drift is an important issue in spectral analysis (e.g., infrared, Raman, and laser-induced spectroscopy). Most common methods for baseline correction perform poorly in high noise, complex baselines, and overlapping peaks. To solve this problem, we proposed an adaptive extended Gaussian peak derivative reweighted penalised least squares (agdPLS) method for removing baseline drift from spectra. The method added extended Gaussian peaks to spectra, added derivative terms for spectral and baseline differences during iterations, and adaptively adjusted penalty coefficients lambda. Experiments with simulated and measured spectra for methane and ethane were carried out to compare the performance of the different methods. agdPLS performed better than the other methods, with more accurate baseline estimation in low- and high-noise situations. Especially when the spectrum contained high noise, complex baselines and overlapping peaks, the agdPLS method performed significantly better than other methods. Moreover, agdPLS was computationally efficient. Results of actual spectral experiments showed that the proposed agdPLS method could be effective for baseline correction of spectra which, in turn, improved qualitative and quantitative spectral performances.</text><annotation id="2"><infon key="identifier">MESH:D008697</infon><infon key="type">Chemical</infon><location offset="756" length="7"/><text>methane</text></annotation><annotation id="3"><infon key="identifier">MESH:D004980</infon><infon key="type">Chemical</infon><location offset="768" length="6"/><text>ethane</text></annotation></passage></document>
<document><id>37917377</id><passage><infon key="journal">BioDrugs;2023Nov02. doi:10.1007/s40259-023-00632-3</infon><infon key="year">2023</infon><infon key="article-id_pmc">4767260</infon><infon key="type">title</infon><infon key="authors">Szwec S, Kap&amp;#x142;ucha Z, Chamberlain JS, Konieczny P, </infon><offset>0</offset><text>Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.</text><annotation id="3"><infon key="identifier">1756</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20856</infon><location offset="0" length="10"/><text>Dystrophin</text></annotation><annotation id="4"><infon key="identifier">7402</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21398</infon><location offset="16" length="8"/><text>Utrophin</text></annotation><annotation id="5"><infon key="identifier">MESH:D020388</infon><infon key="type">Disease</infon><location offset="71" length="27"/><text>Duchenne Muscular Dystrophy</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>Duchenne muscular dystrophy is a devastating disease that leads to progressive muscle loss and premature death. While medical management focuses mostly on symptomatic treatment, decades of research have resulted in first therapeutics able to restore the affected reading frame of dystrophin transcripts or induce synthesis of a truncated dystrophin protein from a vector, with other strategies based on gene therapy and cell signaling in preclinical or clinical development. Nevertheless, recent reports show that potentially therapeutic dystrophins can be immunogenic in patients. This raises the question of whether a dystrophin paralog, utrophin, could be a more suitable therapeutic protein. Here, we compare dystrophin and utrophin amino acid sequences and structures, combining published data with our extended in silico analyses. We then discuss these results in the context of therapeutic approaches for Duchenne muscular dystrophy. Specifically, we focus on strategies based on delivery of micro-dystrophin and micro-utrophin genes with recombinant adeno-associated viral vectors, exon skipping of the mutated dystrophin pre-mRNAs, reading through termination codons with small molecules that mask premature stop codons, dystrophin gene repair by clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (CRISPR/Cas9)-mediated genetic engineering, and increasing utrophin levels. Our analyses highlight the importance of various dystrophin and utrophin domains in Duchenne muscular dystrophy treatment, providing insights into designing novel therapeutic compounds with improved efficacy and decreased immunoreactivity. While the necessary actin and beta-dystroglycan binding sites are present in both proteins, important functional distinctions can be identified in these domains and some other parts of truncated dystrophins might need redesigning due to their potentially immunogenic qualities. Alternatively, therapies based on utrophins might provide a safer and more effective approach.</text><annotation id="24"><infon key="identifier">MESH:D020388</infon><infon key="type">Disease</infon><location offset="122" length="27"/><text>Duchenne muscular dystrophy</text></annotation><annotation id="25"><infon key="identifier">MESH:D009135</infon><infon key="type">Disease</infon><location offset="201" length="11"/><text>muscle loss</text></annotation><annotation id="26"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="217" length="15"/><text>premature death</text></annotation><annotation id="27"><infon key="identifier">1756</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20856</infon><location offset="402" length="10"/><text>dystrophin</text></annotation><annotation id="28"><infon key="identifier">1756</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20856</infon><location offset="460" length="10"/><text>dystrophin</text></annotation><annotation id="29"><infon key="identifier">1756</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20856</infon><location offset="742" length="10"/><text>dystrophin</text></annotation><annotation id="30"><infon key="identifier">7402</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21398</infon><location offset="762" length="8"/><text>utrophin</text></annotation><annotation id="31"><infon key="identifier">1756</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20856</infon><location offset="835" length="10"/><text>dystrophin</text></annotation><annotation id="32"><infon key="identifier">7402</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21398</infon><location offset="850" length="8"/><text>utrophin</text></annotation><annotation id="33"><infon key="identifier">MESH:D020388</infon><infon key="type">Disease</infon><location offset="1034" length="27"/><text>Duchenne muscular dystrophy</text></annotation><annotation id="34"><infon key="identifier">1756</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20856</infon><location offset="1127" length="10"/><text>dystrophin</text></annotation><annotation id="35"><infon key="identifier">7402</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21398</infon><location offset="1147" length="9"/><text>-utrophin</text></annotation><annotation id="36"><infon key="identifier">1756</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20856</infon><location offset="1241" length="10"/><text>dystrophin</text></annotation><annotation id="37"><infon key="identifier">1756</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20856</infon><location offset="1352" length="10"/><text>dystrophin</text></annotation><annotation id="38"><infon key="identifier">7402</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21398</infon><location offset="1532" length="8"/><text>utrophin</text></annotation><annotation id="39"><infon key="identifier">1756</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20856</infon><location offset="1598" length="10"/><text>dystrophin</text></annotation><annotation id="40"><infon key="identifier">7402</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21398</infon><location offset="1613" length="8"/><text>utrophin</text></annotation><annotation id="41"><infon key="identifier">MESH:D020388</infon><infon key="type">Disease</infon><location offset="1633" length="27"/><text>Duchenne muscular dystrophy</text></annotation></passage><relation id="R1"><infon key="score">0.9991</infon><infon key="role1">Disease|MESH:D020388</infon><infon key="role2">Gene|7402</infon><infon key="type">Association</infon><node refid="0" role="2,1"/></relation><relation id="R2"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D020388</infon><infon key="role2">Gene|1756</infon><infon key="type">Association</infon><node refid="1" role="2,0"/></relation></document>
<document><id>37917728</id><passage><infon key="journal">PLoS One;2023; 18 (11) 0292595. doi:10.1371/journal.pone.0292595</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Trout Fryxell RT, Chavez-Lindell T, Butler RA, Odoi A, </infon><offset>0</offset><text>Environmental variables serve as predictors of the invasive Asian longhorned tick (Haemaphysalis longicornis Neumann): An approach for targeted tick surveillance.</text></passage><passage><infon key="type">abstract</infon><offset>163</offset><text>Since the 2017 discovery of established populations of the Asian longhorned tick, (Haemaphysalis longicornis Neumann) in the United States, populations continue to be detected in new areas. For this exotic and invasive species, capable of transmitting a diverse repertoire of pathogens and blood feeding on a variety of host species, there remains a lack of targeted information on how to best prepare for this tick and understand when and where it occurs. To fill this gap, we conducted two years of weekly tick surveillance at four farms in Tennessee (three H. longicornis-infested and one without) to identify environmental factors associated with each questing life stage, to investigate predictors of abundance, and to determine the likelihood of not collecting ticks at different life stages. A total of 46,770 ticks were collected, of which 12,607 H. longicornis and five other tick species were identified. Overall, abundance of H. longicornis were associated with spring and summer seasons, forested environments, relative humidity and barometric pressure, sunny conditions, and in relation with other tick species. The likelihood of not collecting H. longicornis was associated with day length and barometric pressure. Additional associations for different life stages were also identified and included other tick species, climatic variables, and environmental conditions. Here, we demonstrated that environmental variables can be useful to predict the presence of questing H. longicornis and provide ideas on how to use this information to develop a surveillance plan for different southeastern areas with and without infestations.</text></passage></document>
<document><id>37918079</id><passage><infon key="journal">Plant Physiol Biochem;2023Oct26; 204 108146. doi:10.1016/j.plaphy.2023.108146</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Guo J, Jiao Y, Wang Y, Hu W, Jia Y, Huang Z, Yang LT, Chen LS, </infon><offset>0</offset><text>Regulation of magnesium and calcium homeostasis in citrus seedlings under varying magnesium supply.</text><annotation id="3"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="14" length="9"/><text>magnesium</text></annotation><annotation id="4"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="28" length="7"/><text>calcium</text></annotation><annotation id="5"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="82" length="9"/><text>magnesium</text></annotation></passage><passage><infon key="type">abstract</infon><offset>100</offset><text>Magnesium (Mg) and calcium (Ca) are two essential macronutrients in plants; however, the characteristics of Mg and Ca concentrations in organ, subcellular and chemical forms and their relationships in citrus plants, especially under varying Mg supply, are not well understood. In this study, Citrus sinensis seedlings (cv. Xuegan) were cultivated in conditions of Mg deficiency (0 mmol Mg2+ L-1) and Mg sufficiency (2 mmol Mg2+ L-1) to investigate the responses of Mg and Ca homeostasis in different organs and fractions. Compared with Mg sufficiency, Mg deficiency significantly decreased root and shoot growth, with the shoot biomass reduction of branch organs was greater than that of parent organs. In addition to increasing the Ca concentration in the parent stem and lateral root organs, Mg deficiency significantly decreased the concentrations and accumulations of Mg and Ca in citrus seedlings, further altering their distribution in different organs. More than 50% of Ca and Mg were sequestrated in the cell wall and soluble fractions, respectively, with Mg concentration decreasing by 15.4% in roots and 46.9% in leaves under Mg deficiency, while Ca concentration decreased by 27.6% in roots and increased by 23.6% in parent leaves. Approximately 90% of Mg exists in inorganic, water-soluble, and pectate and protein-bound forms, and nearly 90% of Ca exists in water-soluble, pectate and protein-bound, phosphate and oxalate acid forms. Except for the decreased inorganic Mg in roots and water-soluble Mg and Ca in leaves, Mg deficiency increased the proportions of Mg and Ca in all chemical forms. However, Mg deficiency generally increased the Ca/Mg ratio in various organs, subcellular and chemical forms, with negative relationships between Mg concentration and Ca/Mg ratio, and the variations of Mg and Ca were highly separated between Mg supply and organs. In conclusion, our results provide insights into the effects of Mg supply on Mg and Ca homeostasis in citrus plants.</text><annotation id="43"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="100" length="9"/><text>Magnesium</text></annotation><annotation id="44"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="111" length="2"/><text>Mg</text></annotation><annotation id="45"><infon key="identifier">MESH:D002118</infon><infon key="type">Chemical</infon><location offset="119" length="7"/><text>calcium</text></annotation><annotation id="46"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="208" length="2"/><text>Mg</text></annotation><annotation id="47"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="341" length="2"/><text>Mg</text></annotation><annotation id="48"><infon key="identifier">MESH:D008275</infon><infon key="type">Disease</infon><location offset="464" length="13"/><text>Mg deficiency</text></annotation><annotation id="49"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="486" length="4"/><text>Mg2+</text></annotation><annotation id="50"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="500" length="2"/><text>Mg</text></annotation><annotation id="51"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="523" length="4"/><text>Mg2+</text></annotation><annotation id="52"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="565" length="2"/><text>Mg</text></annotation><annotation id="53"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="636" length="2"/><text>Mg</text></annotation><annotation id="54"><infon key="identifier">MESH:D008275</infon><infon key="type">Disease</infon><location offset="652" length="13"/><text>Mg deficiency</text></annotation><annotation id="55"><infon key="identifier">MESH:D008275</infon><infon key="type">Disease</infon><location offset="894" length="13"/><text>Mg deficiency</text></annotation><annotation id="56"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="972" length="2"/><text>Mg</text></annotation><annotation id="57"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1084" length="2"/><text>Mg</text></annotation><annotation id="58"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1164" length="2"/><text>Mg</text></annotation><annotation id="59"><infon key="identifier">MESH:D008275</infon><infon key="type">Disease</infon><location offset="1236" length="13"/><text>Mg deficiency</text></annotation><annotation id="60"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1364" length="2"/><text>Mg</text></annotation><annotation id="61"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1388" length="5"/><text>water</text></annotation><annotation id="62"><infon key="identifier">MESH:C003181</infon><infon key="type">Chemical</infon><location offset="1407" length="7"/><text>pectate</text></annotation><annotation id="63"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1471" length="5"/><text>water</text></annotation><annotation id="64"><infon key="identifier">MESH:C003181</infon><infon key="type">Chemical</infon><location offset="1486" length="7"/><text>pectate</text></annotation><annotation id="65"><infon key="identifier">MESH:D010710</infon><infon key="type">Chemical</infon><location offset="1513" length="9"/><text>phosphate</text></annotation><annotation id="66"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="1527" length="12"/><text>oxalate acid</text></annotation><annotation id="67"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1582" length="2"/><text>Mg</text></annotation><annotation id="68"><infon key="identifier">MESH:D014867</infon><infon key="type">Chemical</infon><location offset="1598" length="5"/><text>water</text></annotation><annotation id="69"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1612" length="2"/><text>Mg</text></annotation><annotation id="70"><infon key="identifier">MESH:D008275</infon><infon key="type">Disease</infon><location offset="1633" length="13"/><text>Mg deficiency</text></annotation><annotation id="71"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1676" length="2"/><text>Mg</text></annotation><annotation id="72"><infon key="identifier">MESH:D008275</infon><infon key="type">Disease</infon><location offset="1718" length="13"/><text>Mg deficiency</text></annotation><annotation id="73"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1759" length="2"/><text>Mg</text></annotation><annotation id="74"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1855" length="2"/><text>Mg</text></annotation><annotation id="75"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1879" length="2"/><text>Mg</text></annotation><annotation id="76"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1911" length="2"/><text>Mg</text></annotation><annotation id="77"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="1951" length="2"/><text>Mg</text></annotation><annotation id="78"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="2037" length="2"/><text>Mg</text></annotation><annotation id="79"><infon key="identifier">MESH:D008274</infon><infon key="type">Chemical</infon><location offset="2050" length="2"/><text>Mg</text></annotation></passage><relation id="R1"><infon key="score">0.573</infon><infon key="role1">Chemical|MESH:D008274</infon><infon key="role2">Disease|MESH:D008275</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="12,10"/></relation><relation id="R2"><infon key="score">0.9485</infon><infon key="role1">Chemical|MESH:D008274</infon><infon key="role2">Chemical|MESH:D014867</infon><infon key="type">Association</infon><node refid="1" role="27,28"/></relation><relation id="R3"><infon key="score">0.4082</infon><infon key="role1">Chemical|MESH:D002118</infon><infon key="role2">Chemical|MESH:D008274</infon><infon key="type">Comparison</infon><node refid="2" role="1,0"/></relation><relation id="R4"><infon key="score">0.9945</infon><infon key="role1">Chemical|MESH:C003181</infon><infon key="role2">Chemical|MESH:D008274</infon><infon key="type">Association</infon><node refid="3" role="29,27"/></relation></document>
<document><id>37918429</id><passage><infon key="journal">Dtsch Med Wochenschr;2023Nov; 148 (22) 1443. doi:10.1055/a-1947-9612</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">J&amp;#xf6;bges S, Meier S, </infon><offset>0</offset><text>[News in intensive care unit communication].</text></passage><passage><infon key="type">abstract</infon><offset>45</offset><text>Current publications on the topic of communication in intensive care units (ITS) are shaped by the experiences of the COVID19 pandemic and the restrictions on personal contact and communication experienced during this time. Virtual, computer-based and telemedical concepts have grown out of this situation with limited contact and communication possibilities with patients and their relatives, but also between the individual service providers in the health system. It can also be assumed that artificial intelligence will increasingly be an issue in communication in intensive care units in the coming years. However, the significance, consequences and risks of the use of these new possibilities remain to be seen.</text><annotation id="1"><infon key="identifier">MESH:D000086382</infon><infon key="type">Disease</infon><location offset="163" length="7"/><text>COVID19</text></annotation></passage></document>
<document><id>37918779</id><passage><infon key="journal">Am J Med;2023Oct31. doi:10.1016/j.amjmed.2023.10.026</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Marvasti TB, Philip R, Parikh H, Hazan E, Liu PJ, Saeed O, Billick M, </infon><offset>0</offset><text>Reviewing your ABCs - Acute Kidney Injury, Bartonella Endocarditis, and C-ANCA Vasculitis.</text><annotation id="3"><infon key="identifier">MESH:D058186</infon><infon key="type">Disease</infon><location offset="22" length="19"/><text>Acute Kidney Injury</text></annotation><annotation id="4"><infon key="identifier">MESH:D004696</infon><infon key="type">Disease</infon><location offset="54" length="12"/><text>Endocarditis</text></annotation><annotation id="5"><infon key="identifier">MESH:D056648</infon><infon key="type">Disease</infon><location offset="72" length="17"/><text>C-ANCA Vasculitis</text></annotation></passage><passage><infon key="type">abstract</infon><offset>91</offset></passage></document>
<document><id>37919129</id><passage><infon key="journal">J Prosthet Dent;2023Oct31. doi:10.1016/j.prosdent.2023.10.012</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Thomkov&amp;#xe1; B, Marci&amp;#xe1;n P, Bor&amp;#xe1;k L, Joukal M, Wolff J, </infon><offset>0</offset><text>Biomechanical performance of dental implants inserted in different mandible locations and at different angles: A finite element study.</text></passage><passage><infon key="type">abstract</infon><offset>135</offset><text>STATEMENT OF PROBLEM: Accurate implant placement is essential for the success of dental implants. This placement influences osseointegration and occlusal forces. The freehand technique, despite its cost-effectiveness and time efficiency, may result in significant angular deviations compared with guided implantation, but the effect of angular deviations on the stress-strain state of peri-implant bone is unclear. PURPOSE: The purpose of this finite element analysis (FEA) study was to examine the effects of angular deviations on stress-strain states in peri-implant bone. MATERIAL AND METHODS: Computational modeling was used to investigate 4 different configurations of dental implant positions, each with 3 angles of insertion. The model was developed using computed tomography images, and typical mastication forces were considered. Strains were analyzed using the mechanostat hypothesis. RESULTS: The location of the implant had a significant impact on bone strain intensity. An angular deviation of +-5 degrees from the planned inclination did not significantly affect cancellous bone strains, which primarily support the implant. However, it had a substantial effect on strains in the cortical bone near the implant. Such deviations also significantly influenced implant stresses, especially when the support from the cortical bone was uneven or poorly localized. CONCLUSIONS: In extreme situations, angular deviations can lead to overstraining the cortical bone, risking implant failure from unfavorable interaction with the implant. Accurate implant placement is essential to mitigate these risks.</text></passage></document>
<document><id>37919479</id><passage><infon key="journal">Lasers Med Sci;2023Nov03; 38 (1) 251. doi:10.1007/s10103-023-03911-1</infon><infon key="year">2023</infon><infon key="article-id_pmc">8164819</infon><infon key="type">title</infon><infon key="authors">Ibarra AMC, Aguiar EMG, Ferreira CBR, Siqueira JM, Corr&amp;#xea;a L, Nunes FD, Franco AL, Cecatto RB, Hamblin MR, Rodrigues MFSD, </infon><offset>0</offset><text>Photodynamic therapy in cancer stem cells - state of the art.</text><annotation id="1"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="24" length="6"/><text>cancer</text></annotation></passage><passage><infon key="type">abstract</infon><offset>62</offset><text>Despite significant efforts to control cancer progression and to improve oncology treatment outcomes, recurrence and tumor resistance are frequently observed in cancer patients. These problems are partly related to the presence of cancer stem cells (CSCs). Photodynamic therapy (PDT) has been developed as a therapeutic approach for solid tumors; however, it remains unclear how this therapy can affect CSCs. In this review, we focus on the effects of PDT on CSCs and the possible changes in the CSC population after PDT exposure. Tumor response to PDT varies according to the photosensitizer and light parameters employed, but most studies have reported the successful elimination of CSCs after PDT. However, some studies have reported that CSCs were more resistant to PDT than non-CSCs due to the increased efflux of photosensitizer molecules and the action of autophagy. Additionally, using different PDT approaches to target the CSCs resulted in increased sensitivity, reduction of sphere formation, invasiveness, stem cell phenotype, and improved response to chemotherapy. Lastly, although mainly limited to in vitro studies, PDT, combined with targeted therapies and/or chemotherapy, could successfully target CSCs in different solid tumors and promote the reduction of stemness, suggesting a promising therapeutic approach requiring evaluation in robust pre-clinical studies.</text><annotation id="9"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="101" length="6"/><text>cancer</text></annotation><annotation id="10"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="179" length="5"/><text>tumor</text></annotation><annotation id="11"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="223" length="6"/><text>cancer</text></annotation><annotation id="12"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="293" length="6"/><text>cancer</text></annotation><annotation id="13"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="401" length="6"/><text>tumors</text></annotation><annotation id="14"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="593" length="5"/><text>Tumor</text></annotation><annotation id="15"><infon key="identifier">MESH:D009369</infon><infon key="type">Disease</infon><location offset="1302" length="6"/><text>tumors</text></annotation></passage></document>
<document><id>37920879</id><passage><infon key="journal">Proteins;2023Nov02. doi:10.1002/prot.26617</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Kryshtafovych A, Schwede T, Topf M, Fidelis K, Moult J, </infon><offset>0</offset><text>Critical assessment of methods of protein structure prediction (CASP)-Round XV.</text></passage><passage><infon key="type">abstract</infon><offset>80</offset><text>Computing protein structure from amino acid sequence information has been a long-standing grand challenge. Critical assessment of structure prediction (CASP) conducts community experiments aimed at advancing solutions to this and related problems. Experiments are conducted every 2 years. The 2020 experiment (CASP14) saw major progress, with the second generation of deep learning methods delivering accuracy comparable with experiment for many single proteins. There is an expectation that these methods will have much wider application in computational structural biology. Here we summarize results from the most recent experiment, CASP15, in 2022, with an emphasis on new deep learning-driven progress. Other papers in this special issue of proteins provide more detailed analysis. For single protein structures, the AlphaFold2 deep learning method is still superior to other approaches, but there are two points of note. First, although AlphaFold2 was the core of all the most successful methods, there was a wide variety of implementation and combination with other methods. Second, using the standard AlphaFold2 protocol and default parameters only produces the highest quality result for about two thirds of the targets, and more extensive sampling is required for the others. The major advance in this CASP is the enormous increase in the accuracy of computed protein complexes, achieved by the use of deep learning methods, although overall these do not fully match the performance for single proteins. Here too, AlphaFold2 based method perform best, and again more extensive sampling than the defaults is often required. Also of note are the encouraging early results on the use of deep learning to compute ensembles of macromolecular structures. Critically for the usability of computed structures, for both single proteins and protein complexes, deep learning derived estimates of both local and global accuracy are of high quality, however the estimates in interface regions are slightly less reliable. CASP15 also included computation of RNA structures for the first time. Here, the classical approaches produced better agreement with experiment than the new deep learning ones, and accuracy is limited. Also, for the first time, CASP included the computation of protein-ligand complexes, an area of special interest for drug design. Here too, classical methods were still superior to deep learning ones. Many new approaches were discussed at the CASP conference, and it is clear methods will continue to advance.</text></passage></document>
<document><id>37921229</id><passage><infon key="journal">Mol Genet Genomic Med;2023Nov03 2306. doi:10.1002/mgg3.2306</infon><infon key="year">2023</infon><infon key="type">title</infon><infon key="authors">Zheng Z, Ding L, Wang M, Zhang Y, Yang Y, Tang M, Xu J, Wang L, Wu J, Li H, </infon><offset>0</offset><text>Hearing characteristics and otoradiological abnormalities in three patients with novel pathogenic variants of KMT2D-related Kabuki syndrome.</text><annotation id="3"><infon key="identifier">MESH:D000014</infon><infon key="type">Disease</infon><location offset="28" length="29"/><text>otoradiological abnormalities</text></annotation><annotation id="4"><infon key="identifier">8085</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">86893</infon><location offset="110" length="5"/><text>KMT2D</text></annotation><annotation id="5"><infon key="identifier">MESH:C537705</infon><infon key="type">Disease</infon><location offset="124" length="15"/><text>Kabuki syndrome</text></annotation></passage><passage><infon key="type">abstract</infon><offset>141</offset><text>BACKGROUND: Kabuki syndrome 1 (KS1; OMIM:147920), which is characterized by distinctive dysmorphic facial features (such as arched eyebrows, long palpebral fissures with eversion of the lower lid, and large protuberant ears), intellectual disability, short stature, and dermatoglyphic and skeletal abnormalities, is brought on by pathogenic variants in KMT2D (OMIM:602113). In this work, three individuals with novel pathogenic KMT2D gene variants had their longitudinal audiological manifestations and ear structural characteristics outlined. METHODS: The longitudinal audiological data from neonatal hearing screening and a battery of several hearing tests were evaluated. The battery of hearing tests included tympanometry, distortion product otoacoustic emission (DPOAE), click-evoked air-conduction auditory brain-stem response (AC-ABR), click-evoked bone-conduction auditory brain-stem response (BC-ABR), narrow band CE-chirp auditory steady-state response (NB CE-chirp ASSR), and pure-tone audiometry (PTA). Phenotype identification and whole exome sequencing (WES) were performed on recruited individuals. RESULTS: All three patients (two females and on male; last evaluations at 14 months, 11 months, and 5.7 years, respectively) failed the newborn hearing screening, and the audiological follow-up data revealed mild to profound fluctuating hearing loss, which was directly influenced by the incidence and severity of otitis media with effusion (OME). When OME occurred, the AC-ABR thresholds increased from 30-75 dBnHL to 45-90 dBnHL. The threshold for the BC-ABR and BC-PTA was between 25 and 50 dBnHL, indicating mild to moderate sensorineural hearing loss (SNHL). The high-resolution computed tomography (HRCT) pictures indicated that all three patients had middle and inner ear abnormalities. Middle ear anomalies showed as diminished mastoid gasification and ossicle dysplasia. Cochlear dysplasia, a dilated vestibule, fusion of the vestibule with the horizontal semicircular canals, and a short and thick horizontal semicircular canal were visible on images of the inner ear. This study recruited three individuals with three novel pathogenic variants (c.5104C>T, c.10205delA, and c.12840delC) of KMT2D who were identified at ages 27 days, 2 months, and 5.5 years. CONCLUSIONS: Hearing characteristics of three individuals with three novel pathogenic variants of KMT2D range from mild to profound fluctuating hearing loss with mild to moderate SNHL. HRCT scans showed that all three individuals had anatomical middle and inner ear abnormalities. KS 1 patients must get clinical therapy for OME, frequent auditory monitoring, and prompt intervention.</text><annotation id="36"><infon key="identifier">MESH:C537705</infon><infon key="type">Disease</infon><location offset="153" length="17"/><text>Kabuki syndrome 1</text></annotation><annotation id="37"><infon key="identifier">MESH:C537705</infon><infon key="type">Disease</infon><location offset="172" length="3"/><text>KS1</text></annotation><annotation id="38"><infon key="type">Disease</infon><location offset="177" length="11"/><text>OMIM:147920</text></annotation><annotation id="39"><infon key="identifier">MESH:C565579</infon><infon key="type">Disease</infon><location offset="229" length="17"/><text>dysmorphic facial</text></annotation><annotation id="40"><infon key="identifier">MESH:D008607</infon><infon key="type">Disease</infon><location offset="367" length="23"/><text>intellectual disability</text></annotation><annotation id="41"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="392" length="13"/><text>short stature</text></annotation><annotation id="42"><infon key="identifier">MESH:C537659</infon><infon key="type">Disease</infon><location offset="411" length="41"/><text>dermatoglyphic and skeletal abnormalities</text></annotation><annotation id="43"><infon key="identifier">8085</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">86893</infon><location offset="494" length="5"/><text>KMT2D</text></annotation><annotation id="44"><infon key="type">Disease</infon><location offset="501" length="11"/><text>OMIM:602113</text></annotation><annotation id="45"><infon key="identifier">8085</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">86893</infon><location offset="569" length="5"/><text>KMT2D</text></annotation><annotation id="46"><infon key="identifier">MESH:D034381</infon><infon key="type">Disease</infon><location offset="1492" length="12"/><text>hearing loss</text></annotation><annotation id="47"><infon key="identifier">MESH:D010034</infon><infon key="type">Disease</infon><location offset="1569" length="26"/><text>otitis media with effusion</text></annotation><annotation id="48"><infon key="identifier">MESH:D010034</infon><infon key="type">Disease</infon><location offset="1597" length="3"/><text>OME</text></annotation><annotation id="49"><infon key="identifier">MESH:D010034</infon><infon key="type">Disease</infon><location offset="1608" length="3"/><text>OME</text></annotation><annotation id="50"><infon key="identifier">MESH:D006319</infon><infon key="type">Disease</infon><location offset="1784" length="26"/><text>sensorineural hearing loss</text></annotation><annotation id="51"><infon key="identifier">MESH:D006319</infon><infon key="type">Disease</infon><location offset="1812" length="4"/><text>SNHL</text></annotation><annotation id="52"><infon key="identifier">MESH:D007759</infon><infon key="type">Disease</infon><location offset="1913" length="34"/><text>middle and inner ear abnormalities</text></annotation><annotation id="53"><infon key="identifier">MESH:C564849</infon><infon key="type">Disease</infon><location offset="1949" length="20"/><text>Middle ear anomalies</text></annotation><annotation id="54"><infon key="identifier">MESH:D008417</infon><infon key="type">Disease</infon><location offset="1980" length="31"/><text>diminished mastoid gasification</text></annotation><annotation id="55"><infon key="identifier">MESH:D015792</infon><infon key="type">Disease</infon><location offset="2016" length="17"/><text>ossicle dysplasia</text></annotation><annotation id="56"><infon key="identifier">MESH:D015834</infon><infon key="type">Disease</infon><location offset="2035" length="18"/><text>Cochlear dysplasia</text></annotation><annotation id="57"><infon key="identifier">tmVar:c|SUB|C|5104|T;HGVS:c.5104C>T;VariantGroup:0;CorrespondingGene:8085;RS#:886043414;CorrespondingSpecies:9606;CA#:10605492</infon><infon key="type">DNAMutation</infon><location offset="2311" length="9"/><text>c.5104C>T</text></annotation><annotation id="58"><infon key="identifier">tmVar:c|DEL|10205|A;HGVS:c.10205delA;VariantGroup:2;CorrespondingGene:8085;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="2322" length="11"/><text>c.10205delA</text></annotation><annotation id="59"><infon key="identifier">tmVar:c|DEL|12840|C;HGVS:c.12840delC;VariantGroup:1;CorrespondingGene:8085;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="2339" length="11"/><text>c.12840delC</text></annotation><annotation id="60"><infon key="identifier">8085</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">86893</infon><location offset="2355" length="5"/><text>KMT2D</text></annotation><annotation id="61"><infon key="identifier">8085</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">86893</infon><location offset="2521" length="5"/><text>KMT2D</text></annotation><annotation id="62"><infon key="identifier">MESH:D034381</infon><infon key="type">Disease</infon><location offset="2567" length="12"/><text>hearing loss</text></annotation><annotation id="63"><infon key="identifier">MESH:D006319</infon><infon key="type">Disease</infon><location offset="2602" length="4"/><text>SNHL</text></annotation><annotation id="64"><infon key="identifier">MESH:D007759</infon><infon key="type">Disease</infon><location offset="2668" length="34"/><text>middle and inner ear abnormalities</text></annotation><annotation id="65"><infon key="identifier">MESH:D010034</infon><infon key="type">Disease</infon><location offset="2748" length="3"/><text>OME</text></annotation></passage><relation id="R1"><infon key="score">0.7532</infon><infon key="role1">DNAMutation|RS#:886043414;HGVS:c.5104C>T;CorrespondingGene:8085</infon><infon key="role2">Disease|MESH:D006319</infon><infon key="type">Positive_Correlation</infon><node refid="0" role="34,26"/></relation><relation id="R2"><infon key="score">0.559</infon><infon key="role1">DNAMutation|RS#:886043414;HGVS:c.5104C>T;CorrespondingGene:8085</infon><infon key="role2">Disease|MESH:D015834</infon><infon key="type">Positive_Correlation</infon><node refid="1" role="25,26"/></relation><relation id="R3"><infon key="score">0.9977</infon><infon key="role1">DNAMutation|RS#:886043414;HGVS:c.5104C>T;CorrespondingGene:8085</infon><infon key="role2">Disease|MESH:C537705</infon><infon key="type">Positive_Correlation</infon><node refid="2" role="4,26"/></relation><relation id="R4"><infon key="score">0.6681</infon><infon key="role1">DNAMutation|HGVS:c.12840delC;CorrespondingGene:8085</infon><infon key="role2">Disease|MESH:D006319</infon><infon key="type">Positive_Correlation</infon><node refid="3" role="34,28"/></relation><relation id="R5"><infon key="score">0.9958</infon><infon key="role1">Disease|MESH:D000014</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon><node refid="4" role="0,2"/></relation><relation id="R6"><infon key="score">0.9858</infon><infon key="role1">Disease|MESH:D010034</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon><node refid="5" role="36,31"/></relation><relation id="R7"><infon key="score">0.9296</infon><infon key="role1">Disease|MESH:D006319</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon><node refid="6" role="34,31"/></relation><relation id="R8"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:C537705</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon><node refid="7" role="3,2"/></relation><relation id="R9"><infon key="score">0.9976</infon><infon key="role1">Disease|MESH:D006130</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon><node refid="8" role="9,12"/></relation><relation id="R10"><infon key="score">0.9977</infon><infon key="role1">DNAMutation|HGVS:c.12840delC;CorrespondingGene:8085</infon><infon key="role2">Disease|MESH:C537705</infon><infon key="type">Positive_Correlation</infon><node refid="9" role="4,28"/></relation><relation id="R11"><infon key="score">0.9986</infon><infon key="role1">Disease|MESH:D008607</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon><node refid="10" role="8,12"/></relation><relation id="R12"><infon key="score">0.9978</infon><infon key="role1">DNAMutation|HGVS:c.10205delA;CorrespondingGene:8085</infon><infon key="role2">Disease|MESH:C537705</infon><infon key="type">Positive_Correlation</infon><node refid="11" role="4,27"/></relation><relation id="R13"><infon key="score">0.5423</infon><infon key="role1">DNAMutation|HGVS:c.10205delA;CorrespondingGene:8085</infon><infon key="role2">Disease|MESH:D006319</infon><infon key="type">Positive_Correlation</infon><node refid="12" role="34,27"/></relation><relation id="R14"><infon key="score">0.9964</infon><infon key="role1">Disease|MESH:C537659</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon><node refid="13" role="10,12"/></relation><relation id="R15"><infon key="score">0.8953</infon><infon key="role1">Disease|MESH:D015834</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon><node refid="14" role="25,30"/></relation><relation id="R16"><infon key="score">0.7532</infon><infon key="role1">Disease|MESH:D006319</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon></relation><relation id="R17"><infon key="score">0.559</infon><infon key="role1">Disease|MESH:D015834</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon></relation><relation id="R18"><infon key="score">0.9977</infon><infon key="role1">Disease|MESH:C537705</infon><infon key="role2">Gene|8085</infon><infon key="type">Association</infon></relation></document>
</collection>
